admission O
date O
: O
[ O
* O
* O
220 O
##0 O
- O
5 O
- O
18 O
* O
* O
] O
discharge O
date O
: O
[ O
* O
* O
220 O
##0 O
- O
5 O
- O
30 O
* O
* O
] O
date O
of O
birth O
: O
[ O
* O
* O
214 O
##0 O
- O
12 O
- O
2 O
* O
* O
] O
sex O
: O
m O
service O
: O
medicine O
all O
##er O
##gies O
: O
patient O
recorded O
as O
having O
no O
known O
all O
##er O
##gies O
to O
drugs O
attending O
: O
[ O
* O
* O
first O
name O
##3 O
( O
l O
##f O
) O
75 O
##9 O
* O
* O
] O
chief O
complaint O
: O
w O
##hee O
##zing O
and O
short O
##ness O
of O
breath O
major O
surgical O
or O
invasive O
procedure O
: O
none O
history O
of O
present O
illness O
: O
59 O
yo O
man O
with O
severe O
as O
##th O
##ma O
who O
originally O
presented O
w O
/ O
3 O
days O
of O
worse O
##ning O
d O
##ys O
##p O
##nea O
c O
/ O
w O
prior O
ex O
##ace O
##rb O
##ations O
, O
now O
transferred O
to O
the O
medicine O
team O
for O
ongoing O
care O
. O
he O
had O
as B-REA
##th I-REA
##ma I-REA
ex I-REA
##ace I-REA
##rb I-REA
##ation I-REA
3 O
w O
##ks O
ago O
requiring O
pre B-DRUG
##dn I-DRUG
##ison I-DRUG
##e I-DRUG
tape B-DOS
##r I-DOS
, I-DOS
which O
he O
completed O
about O
1 O
w O
##k O
ago O
. O
over O
the O
past O
few O
days O
, O
he O
has O
had O
productive O
cough O
and O
p O
##le O
##uri O
##tic O
chest O
pain O
, O
but O
no O
f O
/ O
c O
. O
went O
to O
[ O
* O
* O
location O
( O
un O
) O
* O
* O
] O
h O
##c O
on O
day O
of O
admission O
and O
was O
treated O
w O
/ O
al B-DRUG
##but I-DRUG
##ero I-DRUG
##l I-DRUG
/ I-DRUG
at B-DRUG
##rove I-DRUG
##n I-DRUG
ne B-FOR
##bs I-FOR
and O
so O
##lume O
##dr O
##ol O
, O
but O
symptoms O
were O
un O
##rel O
##ie O
##ved O
, O
prompting O
refer O
##ral O
of O
p O
##t O
to O
the O
[ O
* O
* O
hospital O
##1 O
18 O
* O
* O
] O
ed O
. O
in O
ed O
, O
he O
was O
placed O
on O
continuous O
ne B-DRUG
##bs I-DRUG
and O
given O
pre B-DRUG
##dn I-DRUG
##ison I-DRUG
##e I-DRUG
40 B-STR
mg I-STR
, I-STR
then O
admitted O
to O
the O
[ O
* O
* O
hospital O
unit O
name O
153 O
* O
* O
] O
for O
ongoing O
care O
. O
on O
arrival O
to O
the O
[ O
* O
* O
hospital O
unit O
name O
153 O
* O
* O
] O
, O
a O
##b O
##g O
was O
7 O
. O
29 O
/ O
47 O
/ O
83 O
, O
which O
was O
concerning O
for O
respiratory B-REA
fatigue I-REA
. I-REA
he O
was O
treated O
w O
/ O
he B-DRUG
##lio I-DRUG
##x I-DRUG
and O
eventually O
offered O
bi O
##pa O
##p O
, O
though O
he O
refused O
bi O
##pa O
##p O
treatment O
. O
though O
he O
was O
a O
##fe O
##bri O
##le O
, O
em O
##pi O
##ric O
treatment O
for O
cap B-REA
was O
begun O
w O
/ O
c B-DRUG
##ef I-DRUG
##tri I-DRUG
##ax I-DRUG
##one I-DRUG
and O
a B-DRUG
##zi I-DRUG
##th I-DRUG
##rom I-DRUG
##y I-DRUG
##cin I-DRUG
. I-DRUG
he O
was O
found O
to O
have O
r O
##s O
##v O
infection O
on O
viral O
culture O
, O
which O
is O
a O
likely O
explanation O
for O
his O
current O
as O
##th O
##ma O
ex O
##ace O
##rb O
##ation O
. O
his O
respiratory O
status O
improved O
steadily O
until O
the O
present O
time O
, O
when O
he O
is O
transferred O
to O
the O
medicine O
team O
for O
ongoing O
care O
. O

currently O
, O
the O
p O
##t O
complain O
##s O
of O
ongoing O
d B-REA
##ys I-REA
##p I-REA
##nea I-REA
and I-REA
cough I-REA
that O
are O
moderately O
controlled O
w O
/ O
ne B-FOR
##bul I-FOR
##ized I-FOR
al B-DRUG
##but I-DRUG
##ero I-DRUG
##l I-DRUG
. I-DRUG
he O
complain O
##s O
of O
l B-REA
##umba I-REA
##r I-REA
back I-REA
pain I-REA
that O
is O
partially O
relieved O
by O
per B-DRUG
##co I-DRUG
##ce I-DRUG
##t I-DRUG
. I-DRUG
denies O
any O
fever O
, O
chill O
##s O
, O
a O
##b O
##d O
pain O
, O
nausea O
, O
vomit O
##ing O
, O
di O
##ar O
##r O
##hea O
, O
con O
##st O
##ip O
##ation O
, O
hem O
##ato O
##che O
##zia O
, O
and O
me O
##lena O
. O
past O
medical O
history O
: O
1 O
. O
m B-REA
##rsa I-REA
lung I-REA
a I-REA
##bs I-REA
##cess I-REA
in O
[ O
* O
* O
3 O
- O
14 O
* O
* O
] O
s O
/ O
p O
t O
##x O
with O
line B-DRUG
##zo I-DRUG
##lid I-DRUG
2 O
. O
as O
##th O
##ma O
f O
##ev O
##1 O
35 O
% O
f O
##v O
##c O
50 O
% O
, O
in O
##tub O
##ation O
x O
1 O
3 O
. O
h O
##t O
##n O
4 O
. O
p O
##af O
5 O
. O
h O
/ O
o O
p O
##le O
##ural O
e O
##ff O
##usion O
6 O
. O
cocaine O
abuse O
7 O
. O
chronic O
pain O
8 O
. O
ad O
##m O
[ O
* O
* O
3 O
- O
14 O
* O
* O
] O
for O
s O
##ync O
##ope O
in O
setting O
of O
cocaine O
use O
, O
ruled O
out O
for O
mi O
. O
9 O
. O
negative O
hi O
##v O
[ O
* O
* O
2 O
- O
11 O
* O
* O
] O
10 O
. O
la O
##mine O
##ct O
##omy O
[ O
* O
* O
7 O
- O
15 O
* O
* O
] O
y O
##rs O
ago O
social O
history O
: O
cocaine O
abuse O
, O
last O
used O
6 O
day O
p O
##ta O
. O
lives O
with O
fi O
##ance O
. O
denies O
tobacco O
, O
denies O
any O
i O
##v O
##du O
in O
past O
or O
present O
. O
family O
history O
: O
denies O
ca O
##d O
, O
ca O
, O
d O
##m O
. O
brother O
with O
l O
##ymph O
##oma O
. O
physical O
exam O
: O
vs O
t O
98 O
. O
0 O
, O
b O
##p O
142 O
/ O
80 O
, O
h O
##r O
89 O
, O
r O
##r O
18 O
, O
o O
##2 O
sat O
98 O
% O
4 O
##l O
/ O
m O
g O
##en O
: O
dish O
##eve O
##led O
man O
sitting O
up O
in O
bed O
eating O
dinner O
, O
speaking O
in O
full O
sentences O
in O
na O
##d O
he O
##ent O
: O
an O
##ict O
##eric O
, O
e O
##omi O
, O
per O
##rl O
, O
op O
clear O
w O
/ O
mm O
##m O
, O
no O
j O
##v O
##d O
, O
no O
lad O
c O
##v O
: O
re O
##g O
s O
##1 O
/ O
s O
##2 O
, O
no O
s O
##3 O
/ O
s O
##4 O
/ O
m O
/ O
r O
pu O
##lm O
: O
fair O
air O
movement O
throughout O
; O
di O
##ff O
##use O
ex O
##p O
w O
##hee O
##zing O
w O
/ O
prolonged O
ex O
##p O
phase O
, O
no O
crack O
##les O
a O
##b O
##d O
: O
o O
##bes O
##e O
, O
+ O
b O
##s O
, O
soft O
, O
n O
##t O
, O
n O
##d O
ex O
##t O
: O
warm O
, O
2 O
+ O
d O
##p O
b O
, O
1 O
+ O
pit O
##ting O
ed O
##ema O
to O
the O
mid O
- O
leg O
b O
ne O
##uro O
: O
c O
##n O
2 O
- O
12 O
intact O
, O
alert O
and O
oriented O
x O
3 O
, O
strength O
5 O
/ O
5 O
throughout O
u O
##e O
/ O
le O
b O

per O
##tinent O
results O
: O
[ O
* O
* O
220 O
##0 O
- O
5 O
- O
19 O
* O
* O
] O
04 O
: O
45 O
##am O
urine O
b O
##nz O
##od O
##z O
##p O
- O
ne O
##g O
bar O
##bit O
##r O
- O
ne O
##g O
op O
##iate O
##s O
- O
p O
##os O
cocaine O
- O
p O
##os O
am O
##phe O
##t O
##m O
- O
ne O
##g O
m O
##th O
##don O
##e O
- O
ne O
##g O
[ O
* O
* O
220 O
##0 O
- O
5 O
- O
23 O
* O
* O
] O
05 O
: O
22 O
##am O
blood O
w O
##b O
##c O
- O
11 O
. O
6 O
* O
r O
##b O
##c O
- O
4 O
. O
47 O
* O
h O
##g O
##b O
- O
13 O
. O
6 O
* O
h O
##ct O
- O
40 O
. O
8 O
m O
##c O
##v O
- O
91 O
m O
##ch O
- O
30 O
. O
5 O
m O
##ch O
##c O
- O
33 O
. O
4 O
r O
##d O
##w O
- O
14 O
. O
5 O
p O
##lt O
c O
##t O
- O
245 O
[ O
* O
* O
220 O
##0 O
- O
5 O
- O
23 O
* O
* O
] O
05 O
: O
22 O
##am O
blood O
p O
##lt O
c O
##t O
- O
245 O
[ O
* O
* O
220 O
##0 O
- O
5 O
- O
23 O
* O
* O
] O
05 O
: O
22 O
##am O
blood O
glucose O
- O
83 O
u O
##rea O
##n O
- O
20 O
c O
##rea O
##t O
- O
0 O
. O
9 O
na O
- O
140 O
k O
- O
3 O
. O
8 O
c O
##l O
- O
96 O
h O
##co O
##3 O
- O
37 O
* O
an O
##ga O
##p O
- O
11 O
[ O
* O
* O
220 O
##0 O
- O
5 O
- O
23 O
* O
* O
] O
05 O
: O
22 O
##am O
blood O
calcium O
- O
9 O
. O
7 O
p O
##hos O
- O
2 O
. O
7 O
mg O
- O
2 O
. O
1 O
c O
##x O
##r O
: O
cardiac O
and O
media O
##st O
##inal O
con O
##tour O
##s O
are O
normal O
. O
the O
lungs O
are O
clear O
. O
pulmonary O
v O
##as O
##cula O
##ture O
is O
normal O
. O
the O
o O
##sse O
##ous O
structures O
are O
un O
##rem O
##ark O
##able O
. O
there O
is O
apparent O
g O
##yne O
##com O
##ast O
##ia O
. O
e O
##k O
##g O
: O
sin O
##us O
rhythm O
. O
modest O
low O
amplitude O
lateral O
t O
waves O
- O
are O
non O
##sp O
##ec O
##ific O
and O
may O
be O
within O
normal O
limits O
. O
since O
previous O
tracing O
of O
[ O
* O
* O
220 O
##0 O
- O
3 O
- O
12 O
* O
* O
] O
, O
lateral O
t O
wave O
amplitude O
lower O
. O
rapid O
respiratory O
viral O
anti O
##gen O
test O
( O
final O
[ O
* O
* O
220 O
##0 O
- O
5 O
- O
20 O
* O
* O
] O
) O
: O
positive O
for O
respiratory O
s O
##ync O
##yt O
##ial O
viral O
anti O
##gen O
. O
culture O
confirmation O
pending O
. O
specimen O
screened O
for O
: O
ad O
##eno O
, O
para O
##in O
##fluenza O
1 O
, O
2 O
, O
3 O
in O
##fluenza O
a O
, O
b O
and O
r O
##s O
##v O
. O

brief O
hospital O
course O
: O
1 O
. O
as B-REA
##th I-REA
##ma I-REA
ex I-REA
##ace I-REA
##rb I-REA
##ation I-REA
: I-REA
p O
##t O
' O
s O
nasal O
washing O
##s O
returned O
positive O
for O
r B-REA
##s I-REA
##v I-REA
. I-REA
on O
admission O
he O
had O
marked O
w O
##hee O
##zing O
and O
poor O
air O
movement O
, O
with O
a O
##b O
##g O
of O
[ O
* O
* O
214 O
##2 O
- O
9 O
- O
4 O
* O
* O
] O
/ O
83 O
. O
he O
gradually O
improved O
on O
so B-DRUG
##lume I-DRUG
##dr I-DRUG
##ol I-DRUG
, I-DRUG
continuous O
ne B-DRUG
##bs I-DRUG
, I-DRUG
ad B-DRUG
##va I-DRUG
##ir I-DRUG
, I-DRUG
sing B-DRUG
##ula I-DRUG
##ir I-DRUG
, I-DRUG
he B-DRUG
##lio I-DRUG
##x I-DRUG
, I-DRUG
a B-DRUG
##zi I-DRUG
##th I-DRUG
##ro I-DRUG
( O
5 B-DUR
days I-DUR
) I-DUR
and O
c B-DRUG
##ef I-DRUG
##tri I-DRUG
##ax I-DRUG
##one I-DRUG
. I-DRUG
p O
##t O
did O
not O
require O
in O
##tub O
##ation O
, O
and O
his O
ne B-DRUG
##bs I-DRUG
were O
spaced O
out O
to O
q B-FRE
##4 I-FRE
##hr I-FRE
##s I-FRE
. I-FRE
p O
##t O
' O
s O
breathing O
was O
comfortable O
and O
non O
- O
w O
##hee O
##zy O
by O
h O
##d O
# O
5 O
when O
observed O
from O
the O
door O
, O
however O
, O
p O
##t O
appears O
to O
ex O
##ager O
##ate O
end O
- O
ex O
##pi O
##rator O
##y O
w O
##hee O
##zing O
and O
labour O
##ed O
breathing O
when O
approached O
. O
he O
was O
felt O
to O
have O
a O
component O
of O
ps O
##ych O
##ogenic O
d O
##ys O
##p O
##nea O
overly O
##ing O
his O
as O
##th O
##ma O
ex O
##ace O
##rb O
##ation O
. O
he O
was O
slowly O
t B-DOS
##it I-DOS
##rated I-DOS
down I-DOS
on O
his O
s B-DRUG
##tero I-DRUG
##id I-DRUG
dose O
, O
and O
he O
frequently O
requested O
to O
be O
placed O
on O
higher O
doses O
of O
s B-DRUG
##tero I-DRUG
##ids I-DRUG
despite O
an O
improving O
exam O
and O
vital O
##s O
. O
eventually O
, O
he O
had O
both O
subjective O
##ly O
and O
objective O
##ly O
improved O
to O
the O
point O
where O
he O
was O
to O
##ler O
##ating O
oral B-ROU
s B-DRUG
##tero I-DRUG
##ids I-DRUG
and O
was O
able O
to O
be O
discharged O
home O
on O
a O
tape B-DOS
##r I-DOS
with O
plans O
to O
follow O
- O
up O
with O
his O
out O
##patient O
pu O
##lm O
##ono O
##logist O
. O

2 O
. O
ps O
##ych O
/ O
ne O
##uro O
: O
cocaine O
abuse O
and O
op B-DRUG
##io I-DRUG
##id I-DRUG
dependence B-ADE
. I-ADE
p O
##t O
' O
s O
urine O
to O
##x O
screen O
was O
positive O
for O
cocaine O
and O
op B-DRUG
##io I-DRUG
##ids I-DRUG
. I-DRUG
p O
##t O
was O
requiring O
two B-DOS
per B-DRUG
##co I-DRUG
##ce I-DRUG
##ts I-DRUG
every B-FRE
4 I-FRE
hours I-FRE
for O
low B-REA
back I-REA
pain I-REA
s I-REA
/ I-REA
p I-REA
la I-REA
##mine I-REA
##ct I-REA
##omy I-REA
. I-REA
attempts O
to O
we O
##an O
his O
per B-DRUG
##co I-DRUG
##ce I-DRUG
##ts I-DRUG
were O
made O
in O
effort O
to O
minimize O
suppression O
of O
his O
cough O
. O
however O
, O
p O
##t O
was O
unhappy O
with O
this O
recommendation O
and O
insisted O
on O
his O
usual O
dose O
of O
per B-DRUG
##co I-DRUG
##ce I-DRUG
##ts I-DRUG
, I-DRUG
stating O
that O
the O
w O
##hee O
##zing O
/ O
coughing O
greatly O
ex O
##ace O
##rb O
##ated O
the O
back B-REA
pain I-REA
. I-REA
he O
was O
seen O
by O
the O
addiction O
##s O
consult O
and O
social O
work O
while O
he O
was O
an O
in O
##patient O
; O
their O
discussions O
culminated O
in O
an O
agreement O
that O
m O
##r O
. O
[ O
* O
* O
known O
last O
##name O
* O
* O
] O
would O
seek O
out O
##patient O
counseling O
for O
his O
substance O
abuse O
difficulties O
, O
which O
are O
both O
worse O
##ned O
by O
and O
worse O
##n O
his B-REA
chronic I-REA
pain I-REA
. I-REA
he O
was O
discharged O
on O
a O
brief O
course O
of O
o B-DRUG
##xy I-DRUG
##co I-DRUG
##don I-DRUG
##e I-DRUG
/ I-DRUG
ace I-DRUG
##tam I-DRUG
##ino I-DRUG
##phe I-DRUG
##n I-DRUG
, I-DRUG
with O
the O
understanding O
that O
should O
he O
have O
ongoing O
pain O
medication O
requirements O
, O
he O
would O
need O
to O
finally O
establish O
a O
primary O
care O
physician O
; O
he O
has O
been O
stating O
that O
this O
is O
something O
he O
would O
do O
, O
but O
has O
failed O
to O
do O
so O
for O
months O
. O
he O
was O
provided O
with O
multiple O
names O
and O
numbers O
of O
providers O
in O
his O
area O
, O
and O
he O
informed O
the O
team O
that O
he O
was O
dedicated O
to O
being O
seen O
by O
one O
of O
them O
. O
3 O
. O
h B-REA
##yper I-REA
##tens I-REA
##ion I-REA
: I-REA
p O
##t O
was O
h O
##yper O
##tensive O
on O
admission O
in O
setting O
of O
his O
acute O
as O
##th O
##ma O
ex O
##ace O
##rb O
##ation O
. O
he O
continued O
to O
be O
h O
##yper O
##tensive O
and O
h B-DRUG
##ct I-DRUG
##z I-DRUG
was O
started O
, O
with O
a O
good O
effect O
and O
was O
tolerate O
##d O
well O
. O
his O
electro O
##ly O
##tes O
and O
re O
##nal O
function O
remained O
stable O
on O
this O
new O
medication O
, O
and O
he O
was O
advised O
to O
see O
a O
primary O
care O
doctor O
to O
follow O
both O
this O
and O
his O
numerous O
other O
medical O
issues O
. O
medications O
on O
admission O
: O
sing B-DRUG
##ula I-DRUG
##ir I-DRUG
ad B-DRUG
##va I-DRUG
##ir I-DRUG
fl B-DRUG
##ove I-DRUG
##nt I-DRUG
al B-DRUG
##but I-DRUG
##ero I-DRUG
##l I-DRUG
per B-DRUG
##co I-DRUG
##ce I-DRUG
##t I-DRUG
recent O
pre B-DRUG
##dn I-DRUG
##ison I-DRUG
##e I-DRUG
tape B-DOS
##r I-DOS

discharge O
medications O
: O
1 O
. O
mon B-DRUG
##tel I-DRUG
##uka I-DRUG
##st I-DRUG
sodium I-DRUG
10 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( I-FRE
daily I-FRE
) I-FRE
. I-FRE
[ O
* O
* O
known O
last O
##name O
* O
* O
] O
: O
* O
30 O
tablet O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
0 O
* O
2 O
. O
g B-DRUG
##ua I-DRUG
##ife I-DRUG
##nes I-DRUG
##in I-DRUG
100 B-STR
mg I-STR
/ I-STR
5 I-STR
m I-STR
##l I-STR
liquid B-FOR
si O
##g O
: O
5 B-DOS
- I-DOS
10 I-DOS
m I-DOS
##ls I-DOS
p B-ROU
##o I-ROU
q B-FRE
##4 I-FRE
- I-FRE
6 I-FRE
##h I-FRE
p I-FRE
##rn I-FRE
. I-FRE
[ O
* O
* O
known O
last O
##name O
* O
* O
] O
: O
* O
50 O
m O
##l O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
0 O
* O
3 O
. O
multi B-DRUG
##vi I-DRUG
##tam I-DRUG
##in I-DRUG
capsule B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
cap B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( I-FRE
daily I-FRE
) I-FRE
. I-FRE
4 O
. O
th B-DRUG
##iam I-DRUG
##ine I-DRUG
h I-DRUG
##c I-DRUG
##l I-DRUG
100 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( I-FRE
daily I-FRE
) I-FRE
. I-FRE
[ O
* O
* O
known O
last O
##name O
* O
* O
] O
: O
* O
30 O
tablet O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
0 O
* O
5 O
. O
f B-DRUG
##olic I-DRUG
acid I-DRUG
1 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( I-FRE
daily I-FRE
) I-FRE
. I-FRE
[ O
* O
* O
known O
last O
##name O
* O
* O
] O
: O
* O
30 O
tablet O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
0 O
* O
6 O
. O
h B-DRUG
##ydro I-DRUG
##ch I-DRUG
##lor I-DRUG
##oth I-DRUG
##ia I-DRUG
##zi I-DRUG
##de I-DRUG
25 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( I-FRE
daily I-FRE
) I-FRE
. I-FRE
[ O
* O
* O
known O
last O
##name O
* O
* O
] O
: O
* O
30 O
tablet O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
0 O
* O
7 O
. O
al B-DRUG
##but I-DRUG
##ero I-DRUG
##l I-DRUG
90 B-STR
m I-STR
##c I-STR
##g I-STR
/ I-STR
act I-STR
##uation I-STR
a B-FOR
##ero I-FOR
##sol I-FOR
si O
##g O
: O
1 B-DOS
- I-DOS
2 I-DOS
pu B-FOR
##ffs I-FOR
in B-ROU
##hala I-ROU
##tion I-ROU
q B-FRE
##2 I-FRE
##h I-FRE
( I-FRE
every I-FRE
2 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE
[ O
* O
* O
known O
last O
##name O
* O
* O
] O
: O
* O
1 O
m O
##di O
* O
re O
##fill O
##s O
: O
* O
0 O
* O
8 O
. O
flu B-DRUG
##tica I-DRUG
##son I-DRUG
##e I-DRUG
- I-DRUG
sa I-DRUG
##lm I-DRUG
##eter I-DRUG
##ol I-DRUG
250 B-STR
- I-STR
50 I-STR
m I-STR
##c I-STR
##g I-STR
/ I-STR
dose I-STR
disk B-FOR
with I-FOR
device I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
in O
##hala O
##tion O
in O
##hala O
##tion O
[ O
* O
* O
hospital O
##1 O
* O
* O
] O
( B-FRE
2 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE
[ O
* O
* O
hospital O
##1 O
* O
* O
] O
: O
* O
q O
##s O
1 O
month O
supply O
* O
re O
##fill O
##s O
: O
* O
0 O
* O
9 O
. O
ben B-DRUG
##zon I-DRUG
##ata I-DRUG
##te I-DRUG
100 B-STR
mg I-STR
capsule B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
capsule B-FOR
p B-ROU
##o I-ROU
t B-FRE
##id I-FRE
( I-FRE
3 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE
[ O
* O
* O
hospital O
##1 O
* O
* O
] O
: O
* O
30 O
capsule O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
0 O
* O

10 O
. O
pan B-DRUG
##top I-DRUG
##raz I-DRUG
##ole I-DRUG
sodium I-DRUG
40 B-STR
mg I-STR
tablet B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
p B-ROU
##o I-ROU
q B-FRE
##24 I-FRE
##h I-FRE
( I-FRE
every I-FRE
24 I-FRE
hours I-FRE
) I-FRE
. I-FRE
[ O
* O
* O
hospital O
##1 O
* O
* O
] O
: O
* O
30 O
tablet O
, O
delayed O
release O
( O
e O
. O
c O
. O
) O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
0 O
* O
11 O
. O
do B-DRUG
##cus I-DRUG
##ate I-DRUG
sodium I-DRUG
100 B-STR
mg I-STR
capsule B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
capsule B-FOR
p B-ROU
##o I-ROU
bid B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE
[ O
* O
* O
hospital O
##1 O
* O
* O
] O
: O
* O
60 O
capsule O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
0 O
* O
12 O
. O
se B-DRUG
##nna I-DRUG
8 B-STR
. I-STR
6 I-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
bid B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE
[ O
* O
* O
hospital O
##1 O
* O
* O
] O
: O
* O
30 O
tablet O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
0 O
* O
13 O
. O
l B-DRUG
##isi I-DRUG
##no I-DRUG
##p I-DRUG
##ril I-DRUG
10 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE
[ O
* O
* O
hospital O
##1 O
* O
* O
] O
: O
* O
30 O
tablet O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
0 O
* O
14 O
. O
pre B-DRUG
##dn I-DRUG
##ison I-DRUG
##e I-DRUG
10 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
six B-DOS
( I-DOS
6 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
once B-FRE
a I-FRE
day I-FRE
: I-FRE
for B-DUR
2 I-DUR
days I-DUR
( O
[ O
* O
* O
date O
range O
( O
1 O
) O
252 O
##43 O
* O
* O
] O
) O
, O
then O
5 B-DOS
ta B-FOR
##bs I-FOR
daily B-FRE
for B-DUR
2 I-DUR
days I-DUR
( O
[ O
* O
* O
date O
range O
( O
1 O
) O
252 O
##44 O
* O
* O
] O
) O
, O
then O
4 B-DOS
ta B-FOR
##bs I-FOR
daily B-FRE
for B-DUR
2 I-DUR
days I-DUR
( O
4 O
/ O
26 O
/ O
05 O
- O
4 O
/ O
27 O
) O
, O
then O
3 B-DOS
ta B-FOR
##bs I-FOR
daily B-FRE
for B-DUR
2 I-DUR
days I-DUR
( O
[ O
* O
* O
6 O
- O
5 O
* O
* O
] O
/ O
- O
[ O
* O
* O
6 O
- O
6 O
* O
* O
] O
) O
, O
then O
2 B-DOS
t O
##s O
daily B-FRE
for B-DUR
2 I-DUR
days I-DUR
( O
[ O
* O
* O
date O
range O
( O
1 O
) O
252 O
##45 O
* O
* O
] O
) O
, O
then O
1 B-DOS
ta B-FOR
##b I-FOR
daily B-FRE
for B-DUR
2 I-DUR
days I-DUR
( O
[ O
* O
* O
date O
range O
( O
1 O
) O
252 O
##46 O
* O
* O
] O
) O
. O
[ O
* O
* O
date O
range O
( O
1 O
) O
* O
* O
] O
: O
* O
42 O
tablet O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
0 O
* O
15 O
. O
at B-DRUG
##rove I-DRUG
##nt I-DRUG
18 B-STR
m I-STR
##c I-STR
##g I-STR
/ I-STR
act I-STR
##uation I-STR
a B-FOR
##ero I-FOR
##sol I-FOR
si O
##g O
: O
two B-DOS
( I-DOS
2 I-DOS
) I-DOS
pu B-FOR
##ffs I-FOR
in B-ROU
##hala I-ROU
##tion I-ROU
four B-FRE
times I-FRE
a I-FRE
day I-FRE
. I-FRE
[ O
* O
* O
date O
range O
( O
1 O
) O
* O
* O
] O
: O
* O
1 O
m O
##di O
* O
re O
##fill O
##s O
: O
* O
0 O
* O

16 O
. O
al B-DRUG
##but I-DRUG
##ero I-DRUG
##l I-DRUG
su I-DRUG
##lf I-DRUG
##ate I-DRUG
0 B-STR
. I-STR
08 I-STR
##3 I-STR
% I-STR
solution B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
ne B-FOR
##b I-FOR
in B-ROU
##hala I-ROU
##tion I-ROU
every B-FRE
4 I-FRE
- I-FRE
6 I-FRE
hours I-FRE
as I-FRE
needed I-FRE
. I-FRE
[ O
* O
* O
date O
range O
( O
1 O
) O
* O
* O
] O
: O
* O
q O
##s O
one O
month O
* O
re O
##fill O
##s O
: O
* O
0 O
* O
17 O
. O
one O
touch O
ultra O
lance O
##ts O
use O
as O
directed O
[ O
* O
* O
date O
range O
( O
1 O
) O
* O
* O
] O
: O
90 O
re O
##fill O
##s O
: O
0 O
18 O
. O
one O
touch O
ultra O
test O
strips O
use O
as O
directed O
[ O
* O
* O
date O
range O
( O
1 O
) O
* O
* O
] O
: O
90 O
re O
##fill O
##s O
: O
0 O
19 O
. O
space O
chamber O
use O
as O
directed O
[ O
* O
* O
date O
range O
( O
1 O
) O
* O
* O
] O
: O
1 O
re O
##fill O
##s O
: O
0 O
20 O
. O
per B-DRUG
##co I-DRUG
##ce I-DRUG
##t I-DRUG
5 B-STR
- I-STR
325 I-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
1 B-DOS
- I-DOS
2 I-DOS
tablets B-FOR
p B-ROU
##o I-ROU
every B-FRE
4 I-FRE
- I-FRE
6 I-FRE
hours I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
for B-DUR
5 I-DUR
days I-DUR
. I-DUR
[ O
* O
* O
date O
range O
( O
1 O
) O
* O
* O
] O
: O
* O
30 O
tablet B-FOR
( I-FOR
s O
) O
* O
re O
##fill O
##s O
: O
* O
0 O
* O
discharge O
disposition O
: O
home O
discharge O
diagnosis O
: O
primary O
: O
as O
##th O
##ma O
ex O
##ace O
##rb O
##ation O
secondary O
: O
acute O
br O
##on O
##chi O
##tis O
, O
h O
##yper O
##tens O
##ion O
, O
h O
##yper O
##gly O
##ce O
##mia O
discharge O
condition O
: O
good O
discharge O
instructions O
: O
please O
take O
all O
medications O
as O
prescribed O
. O
you O
have O
been O
started O
on O
l B-DRUG
##isi I-DRUG
##no I-DRUG
##p I-DRUG
##ril I-DRUG
and O
h B-DRUG
##ydro I-DRUG
##ch I-DRUG
##lor I-DRUG
##oth I-DRUG
##ia I-DRUG
##zi I-DRUG
##de I-DRUG
for O
high B-REA
blood I-REA
pressure I-REA
. I-REA
please O
follow O
- O
up O
as O
below O
. O
it O
is O
very O
important O
that O
you O
follow O
- O
up O
with O
a O
new O
primary O
care O
physician O
. O
[ O
* O
* O
name O
##10 O
( O
name O
##is O
) O
35 O
##7 O
* O
* O
] O
check O
your O
blood O
sugar O
##s O
2 O
- O
3 O
times O
a O
day O
before O
meals O
. O
if O
your O
fingers O
##tick O
##s O
are O
persistent O
##ly O
> O
250 O
, O
please O
call O
your O
primary O
care O
physician O
( O
see O
below O
) O

follow O
##up O
instructions O
: O
1 O
) O
pulmonary O
- O
you O
will O
be O
contact O
[ O
* O
* O
name O
( O
ni O
) O
* O
* O
] O
by O
the O
pulmonary O
clinic O
regarding O
an O
appointment O
with O
d O
##r O
. O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
* O
* O
] O
or O
d O
##r O
. O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
57 O
##5 O
* O
* O
] O
. O
if O
you O
have O
not O
heard O
from O
them O
in O
the O
next O
week O
, O
please O
call O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
61 O
##2 O
* O
* O
] O
. O
2 O
) O
primary O
care O
: O
if O
you O
are O
unable O
to O
establish O
a O
new O
primary O
care O
physician O
at O
[ O
* O
* O
name O
##9 O
( O
pre O
) O
* O
* O
] O
care O
( O
1 O
- O
[ O
* O
* O
last O
name O
( O
un O
) O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
un O
) O
252 O
##47 O
* O
* O
] O
, O
east O
[ O
* O
* O
n O
##ume O
##ric O
id O
##ent O
##ifier O
252 O
##48 O
* O
* O
] O
) O
as O
you O
plan O
to O
, O
you O
have O
been O
schedule O
for O
a O
new O
patient O
appointment O
as O
below O
: O
provider O
: O
[ O
* O
* O
first O
name O
##11 O
( O
name O
pattern O
##1 O
) O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##4 O
) O
252 O
##4 O
##9 O
* O
* O
] O
, O
m O
##d O
where O
: O
[ O
* O
* O
hospital O
##6 O
29 O
* O
* O
] O
[ O
* O
* O
hospital O
##3 O
249 O
* O
* O
] O
phone O
: O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
250 O
* O
* O
] O
date O
/ O
time O
: O
[ O
* O
* O
220 O
##0 O
- O
6 O
- O
4 O
* O
* O
] O
1 O
: O
30 O

admission O
date O
: O
[ O
* O
* O
214 O
##9 O
- O
5 O
- O
10 O
* O
* O
] O
discharge O
date O
: O
[ O
* O
* O
214 O
##9 O
- O
5 O
- O
24 O
* O
* O
] O
date O
of O
birth O
: O
[ O
* O
* O
212 O
##3 O
- O
2 O
- O
20 O
* O
* O
] O
sex O
: O
m O
service O
: O
ne O
##uro O
##su O
##rger O
##y O
all O
##er O
##gies O
: O
di B-DRUG
##lant I-DRUG
##in I-DRUG
attending O
: O
[ O
* O
* O
first O
name O
##3 O
( O
l O
##f O
) O
1835 O
* O
* O
] O
chief O
complaint O
: O
headache O
major O
surgical O
or O
invasive O
procedure O
: O
[ O
* O
* O
5 O
- O
14 O
* O
* O
] O
: O
right O
frontal O
b O
##ur O
##r O
hole O
, O
c O
##ys O
##t O
evacuation O
and O
e O
##v O
##d O
placement O
. O
[ O
* O
* O
5 O
- O
23 O
* O
* O
] O
: O
right O
v O
##p O
s O
##hun O
##t O
placement O
history O
of O
present O
illness O
: O
26 O
##m O
who O
presented O
to O
an O
o O
##sh O
with O
one O
year O
of O
progressively O
increasing O
headache O
, O
memory O
problems O
( O
both O
long O
and O
short O
term O
) O
, O
and O
vision O
blur O
##rine O
##ss O
who O
was O
found O
to O
have O
new O
mass O
on O
c O
##t O
scan O
. O
his O
symptoms O
have O
been O
progressively O
increasing O
both O
in O
intensity O
and O
frequency O
as O
his O
headache O
##s O
are O
now O
daily O
. O
past O
medical O
history O
: O
denies O
social O
history O
: O
works O
at O
do O
##min O
##o O
' O
s O
pizza O
restaurant O
as O
a O
manager O
. O
denies O
et O
##oh O
, O
tobacco O
, O
or O
ill O
##icit O
drug O
use O
. O
family O
history O
: O
denies O
any O
history O
of O
stroke O
, O
brain O
cancer O
, O
or O
seizure O
##s O
. O
positive O
family O
history O
for O
ca O
##d O
and O
breast O
cancer O
. O
physical O
exam O
: O
on O
admission O
: O
physical O
examination O
97 O
. O
8 O
88 O
123 O
/ O
70 O
19 O
96 O
% O
r O
##a O
g O
##en O
: O
comfortable O
, O
na O
##d O
. O
he O
##ent O
: O
pupils O
: O
2 O
to O
1 O
. O
5 O
mm O
bi O
##l O
e O
##oms O
intact O
neck O
: O
su O
##pp O
##le O
. O
ex O
##tre O
##m O
: O
warm O
and O
well O
- O
per O
##fused O
. O
ne O
##uro O
: O
mental O
status O
: O
appropriate O
, O
cooperative O
with O
exam O
, O
normal O
affect O
. O
orientation O
: O
a O
##ox O
##3 O
. O
language O
: O
fluent O
. O
naming O
intact O
. O
no O
d O
##ys O
##art O
##hr O
##ia O
or O
para O
##pha O
##si O
##c O
errors O
. O
c O
##rani O
##al O
nerves O
: O
i O
: O
not O
tested O
ii O
: O
pupils O
equally O
round O
and O
reactive O
to O
light O
, O
2 O
to O
1 O
. O
5 O
mm O
bilateral O
##ly O
. O
visual O
fields O
intact O
ii O
##i O
, O
i O
##v O
, O
v O
##i O
: O
extra O
##oc O
##ular O
movements O
intact O
bilateral O
##ly O
without O
n O
##ys O
##tag O
##mus O
or O
dip O
##lop O
##ia O
. O
v O
, O
v O
##ii O
: O
facial O
strength O
and O
sensation O
intact O
and O
symmetric O
. O
v O
##ii O
##i O
: O
hearing O
intact O
to O
voice O
. O
i O
##x O
, O
x O
: O
p O
##ala O
##tal O
elevation O
symmetrical O
. O
[ O
* O
* O
doctor O
first O
name O
81 O
* O
* O
] O
: O
stern O
##oc O
##le O
##ido O
##mas O
##to O
##id O
and O
trap O
##ez O
##ius O
normal O
bilateral O
##ly O
. O
x O
##ii O
: O
tongue O
mid O
##line O
without O
f O
##as O
##ci O
##cula O
##tions O
. O

motor O
: O
normal O
bulk O
and O
tone O
bilateral O
##ly O
. O
no O
abnormal O
movements O
, O
t O
##rem O
##ors O
. O
strength O
full O
power O
[ O
* O
* O
5 O
- O
29 O
* O
* O
] O
throughout O
. O
no O
pro O
##nat O
##or O
drift O
sensation O
: O
intact O
to O
light O
touch O
coordination O
: O
no O
d O
##ys O
##mme O
##tri O
##a O
on O
finger O
- O
nose O
- O
finger O
discharge O
exam O
; O
g O
##en O
- O
pleasant O
, O
stable O
a O
##c O
##rome O
##gal O
##y O
, O
pleasant O
and O
cooperative O
skin O
- O
in O
##cision O
##s O
are O
c O
##lian O
and O
dry O
, O
no O
r O
##ash O
no O
e O
##cc O
##ym O
##osis O
c O
##v O
- O
r O
##rr O
, O
s O
##1 O
and O
s O
##2 O
n O
##l O
pu O
##lm O
- O
c O
##ta O
##b O
no O
w O
/ O
c O
/ O
r O
g O
##i O
- O
soft O
, O
o O
##bes O
##e O
, O
di O
##stal O
um O
##bil O
##ical O
in O
##cision O
c O
/ O
d O
/ O
i O
, O
n O
##t O
/ O
n O
##d O
ex O
##t O
- O
no O
c O
/ O
c O
/ O
e O
ne O
##uro O
- O
a O
##o O
x O
3 O
, O
per O
##rl O
, O
bilateral O
ho O
##mony O
##mous O
hem O
##iano O
##ps O
##ia O
, O
full O
motor O
, O
sensory O
to O
light O
touch O
intact O
, O
no O
pro O
##nat O
##or O
drift O
per O
##tinent O
results O
: O
[ O
* O
* O
214 O
##9 O
- O
5 O
- O
10 O
* O
* O
] O
m O
##ri O
brain O
w O
/ O
& O
w O
/ O
o O
contrast O
: O
findings O
: O
a O
mass O
measuring O
approximately O
5 O
x O
5 O
x O
6 O
cm O
appears O
to O
arise O
from O
the O
sell O
##a O
t O
##ur O
##ci O
##ca O
and O
extend O
into O
the O
su O
##pra O
##sel O
##lar O
c O
##ister O
##n O
. O
the O
mass O
is O
in O
##hom O
##ogen O
##eous O
in O
intensity O
, O
but O
predominantly O
h O
##y O
##point O
##ense O
to O
brain O
on O
the O
short O
t O
##r O
images O
and O
marked O
##ly O
h O
##yper O
##int O
##ense O
on O
fl O
##air O
and O
long O
t O
##r O
spin O
echo O
images O
. O
there O
is O
a O
prominent O
c O
##ys O
##tic O
component O
anterior O
##ly O
, O
extending O
into O
the O
right O
frontal O
lobe O
. O
this O
measures O
approximately O
4 O
x O
5 O
x O
6 O
cm O
. O
the O
mass O
enhance O
##s O
in O
##hom O
##ogen O
##eous O
##ly O
after O
contrast O
administration O
. O
the O
sell O
##a O
t O
##ur O
##ci O
##ca O
is O
marked O
##ly O
enlarged O
. O
the O
mass O
extends O
into O
the O
pre O
##pont O
##ine O
c O
##ister O
##n O
and O
gross O
##ly O
fills O
the O
left O
cavern O
##ous O
sin O
##us O
. O
the O
left O
internal O
car O
##ot O
##id O
artery O
is O
en O
##case O
##d O
in O
its O
cavern O
##ous O
and O
su O
##pra O
##c O
##lino O
##id O
portions O
as O
it O
courses O
through O
the O
mass O
. O
the O
op O
##tic O
ch O
##ias O
##m O
is O
traumatic O
##ally O
elevated O
by O
the O
les O
##ion O
, O
and O
i O
cannot O
identify O
the O
course O
of O
the O
op O
##tic O
nerves O
as O
they O
pass O
over O
this O
les O
##ion O
to O
approach O
the O
op O
##tic O
canals O
. O
this O
les O
##ion O
appears O
most O
likely O
to O
represent O
a O
pit O
##uit O
##ary O
ad O
##eno O
##ma O
. O

the O
mass O
el O
##eva O
##tes O
the O
third O
vent O
##ric O
##le O
and O
causes O
compression O
at O
the O
level O
of O
the O
for O
##ame O
##n O
of O
[ O
* O
* O
last O
name O
( O
un O
) O
204 O
##4 O
* O
* O
] O
. O
this O
apparently O
is O
responsible O
for O
bilateral O
di O
##lat O
##ation O
of O
the O
lateral O
vent O
##ric O
##les O
, O
more O
severe O
on O
the O
right O
than O
left O
. O
conclusion O
: O
massive O
sell O
##ar O
and O
su O
##pra O
##sel O
##lar O
enhancing O
neo O
##p O
##las O
##m O
, O
most O
likely O
a O
pit O
##uit O
##ary O
ad O
##eno O
##ma O
. O
there O
is O
compression O
of O
the O
op O
##tic O
ch O
##ias O
##m O
and O
h O
##ydro O
##ce O
##pha O
##lus O
due O
to O
elevation O
and O
compression O
of O
the O
vent O
##ric O
##ular O
system O
at O
the O
level O
of O
the O
for O
##ame O
##n O
of O
[ O
* O
* O
last O
name O
( O
un O
) O
204 O
##4 O
* O
* O
] O
. O
[ O
* O
* O
214 O
##9 O
- O
5 O
- O
11 O
* O
* O
] O
c O
##ta O
head O
: O
large O
sell O
##ar O
and O
su O
##pra O
##sel O
##lar O
mass O
with O
components O
in O
the O
p O
##ont O
##ine O
c O
##ister O
##n O
, O
cavern O
##ous O
sin O
##us O
, O
su O
##pra O
##sel O
##lar O
c O
##ister O
##n O
, O
and O
in O
##va O
##gin O
##ating O
into O
the O
right O
frontal O
lobe O
. O
the O
appearance O
remains O
consistent O
with O
a O
pit O
##uit O
##ary O
ad O
##eno O
##ma O
. O
there O
is O
en O
##case O
##ment O
of O
the O
left O
internal O
car O
##ot O
##id O
artery O
and O
the O
anterior O
cerebral O
art O
##eries O
bilateral O
##ly O
course O
through O
the O
les O
##ion O
. O
[ O
* O
* O
5 O
- O
14 O
* O
* O
] O
c O
##t O
head O
: O
no O
significant O
change O
in O
large O
su O
##pra O
##sel O
##lar O
mass O
leading O
to O
right O
lateral O
vent O
##ric O
##ular O
di O
##lation O
. O
there O
is O
no O
evidence O
of O
interval O
hem O
##or O
##r O
##hage O
. O
[ O
* O
* O
5 O
- O
14 O
* O
* O
] O
c O
##t O
head O
post O
##op O
: O
in O
comparison O
to O
a O
study O
obtained O
five O
hours O
prior O
, O
there O
is O
notable O
improvement O
in O
right O
lateral O
vent O
##ric O
##ular O
di O
##lat O
##ation O
and O
right O
frontal O
c O
##ys O
##tic O
les O
##ion O
. O
there O
is O
no O
hem O
##or O
##r O
##hage O
along O
the O
course O
of O
the O
right O
vent O
##ric O
##ulos O
##tom O
##y O
cat O
##he O
##ter O
, O
which O
is O
terminating O
in O
the O
third O
vent O
##ric O
##le O
. O
small O
- O
to O
- O
moderate O
p O
##ne O
##um O
##oc O
##ep O
##hal O
##us O
is O
likely O
post O
- O
surgical O
. O
[ O
* O
* O
5 O
- O
15 O
* O
* O
] O
c O
##t O
head O
: O
in O
comparison O
to O
[ O
* O
* O
214 O
##9 O
- O
5 O
- O
14 O
* O
* O
] O
exam O
, O
there O
is O
mild O
improvement O
in O
vent O
##ric O
##ular O
size O
. O
no O
evidence O
of O
acute O
in O
##tra O
##c O
##rani O
##al O
hem O
##or O
##r O
##hage O
. O
small O
- O
to O
- O
moderate O
p O
##ne O
##um O
##oc O
##ep O
##hal O
##us O
per O
##sist O
##s O
, O
likely O
post O
- O
surgical O
. O

[ O
* O
* O
5 O
- O
17 O
* O
* O
] O
c O
##t O
head O
- O
1 O
. O
stable O
size O
of O
the O
vent O
##ric O
##les O
compared O
to O
[ O
* O
* O
214 O
##9 O
- O
5 O
- O
15 O
* O
* O
] O
, O
with O
mild O
di O
##lat O
##ation O
of O
the O
right O
lateral O
vent O
##ric O
##le O
. O
2 O
. O
the O
large O
sell O
##ar O
/ O
su O
##pra O
##sel O
##lar O
mass O
, O
with O
a O
large O
c O
##ys O
##tic O
component O
in O
##dent O
##ing O
the O
right O
frontal O
lobe O
[ O
* O
* O
5 O
- O
23 O
* O
* O
] O
c O
##t O
head O
- O
s O
/ O
p O
r O
v O
##p O
s O
##hun O
##t O
, O
no O
acute O
hem O
##or O
##r O
##hage O
brief O
hospital O
course O
: O
26 O
##m O
who O
was O
admitted O
to O
ne O
##uro O
##su O
##rger O
##y O
for O
a O
right O
frontal O
c O
##ys O
##tic O
les O
##ion O
and O
a O
sell O
##ar O
/ O
su O
##pra O
##sel O
##lar O
mass O
with O
subsequent O
h O
##ydro O
##ce O
##pha O
##lus O
. O
he O
admitted O
to O
the O
i O
##cu O
for O
close O
observation O
given O
his O
imaging O
. O
a O
m O
##ri O
was O
obtained O
on O
[ O
* O
* O
5 O
- O
10 O
* O
* O
] O
to O
better O
evaluate O
the O
lesions O
. O
on O
[ O
* O
* O
5 O
- O
11 O
* O
* O
] O
a O
c O
##ta O
head O
was O
obtained O
for O
surgical O
planning O
. O
end O
##oc O
##rine O
was O
also O
consulted O
given O
the O
sell O
##ar O
/ O
su O
##pra O
##sel O
##lar O
mass O
. O
per O
end O
##oc O
##rine O
request O
, O
labs O
were O
ordered O
and O
a O
co B-DRUG
##rt I-DRUG
##is I-DRUG
##ol I-DRUG
stimulation O
test O
was O
done O
on O
[ O
* O
* O
5 O
- O
12 O
* O
* O
] O
am O
. O
h B-DRUG
##ydro I-DRUG
##cor I-DRUG
##tis I-DRUG
##one I-DRUG
was O
held O
in O
order O
to O
perform O
co O
##rt O
##is O
##ol O
s O
##ti O
##m O
test O
. O
a O
1 B-STR
gram I-STR
di B-DRUG
##lant I-DRUG
##in I-DRUG
b B-DOS
##ol I-DOS
##us I-DOS
was O
given O
for O
a O
serum O
di B-DRUG
##lant I-DRUG
##in I-DRUG
level O
of O
0 O
. O
8 O
. O
overnight O
the O
patient O
became O
very O
a B-REA
##gg I-REA
##itated I-REA
, I-REA
pulling O
out O
his O
i O
##v O
line O
requiring O
at B-DRUG
##iva I-DRUG
##n I-DRUG
. I-DRUG
the O
patient O
got O
out O
of O
bed O
and O
wanted O
to O
leave O
the O
hospital O
" O
against O
medical O
advice O
" O
on O
[ O
* O
* O
5 O
- O
12 O
* O
* O
] O
, O
patient O
was O
seen O
to O
have O
bite O
##mpo O
##ral O
hem O
##iano O
##ps O
##ia O
, O
but O
was O
otherwise O
intact O
on O
examination O
. O
the O
co O
##rt O
##is O
##ol O
s O
##ti O
##m O
tea O
##st O
was O
performed O
and O
the O
co O
##rt O
##is O
##ol O
levels O
at O
30 O
mini O
##tes O
, O
60 O
mini O
##tes O
and O
90 O
mini O
##tes O
were O
. O
2 O
- O
30 O
min O
##s O
, O
21 O
- O
60 O
min O
##s O
, O
22 O
- O
90 O
min O
##s O
. O
ne O
##uro O
- O
op O
##th O
##o O
was O
consulted O
for O
formal O
visual O
field O
testing O
which O
was O
done O
on O
[ O
* O
* O
214 O
##9 O
- O
5 O
- O
13 O
* O
* O
] O
which O
demonstrated O
stable O
bite O
##mpo O
##ral O
hem O
##iano O
##ps O
##ia O
. O
end O
##oc O
##rine O
recommended O
stopping O
the O
h B-DRUG
##ydro I-DRUG
##cor I-DRUG
##tis I-DRUG
##one I-DRUG
and O
decreasing O
the O
de B-DRUG
##ca I-DRUG
##dron I-DRUG
. I-DRUG
ne O
##uro O
and O
r O
##ad O
on O
##cology O
were O
also O
consulted O
. O

on O
[ O
* O
* O
214 O
##9 O
- O
5 O
- O
14 O
* O
* O
] O
, O
patient O
underwent O
am O
as O
##piration O
of O
the O
right O
frontal O
c O
##ys O
##t O
and O
e O
##v O
##d O
placement O
. O
he O
tolerate O
##d O
the O
procedure O
well O
without O
in O
##tra O
##oper O
##ative O
complications O
. O
please O
review O
dictated O
operative O
report O
for O
details O
. O
he O
was O
ex O
##tub O
##ated O
and O
transferred O
to O
the O
i O
##cu O
. O
post O
operative O
head O
c O
##t O
revealed O
no O
hem O
##or O
##r O
##hage O
and O
significant O
de O
##com O
##press O
##ion O
. O
he O
was O
b B-DOS
##ol I-DOS
##used I-DOS
with O
500 B-STR
##m I-STR
##g I-STR
of O
di B-DRUG
##lant I-DRUG
##in I-DRUG
for O
a O
sub O
##ther O
##ap O
##eur O
##ic O
level O
of O
7 O
. O
2 O
and O
his O
dose O
was O
increased O
to O
200 B-STR
##m I-STR
##g I-STR
[ O
* O
* O
hospital O
##1 O
* O
* O
] O
. O
on O
[ O
* O
* O
5 O
- O
15 O
* O
* O
] O
the O
e O
##v O
##d O
was O
clamped O
after O
c O
##t O
head O
demonstrated O
stable O
vent O
##ric O
##ular O
size O
however O
it O
had O
to O
be O
opened O
approximately O
2 O
. O
5 O
##hr O
##s O
after O
c O
##lamp O
##ing O
for O
severe O
headache O
and O
episode O
of O
confusion O
. O
it O
was O
opened O
at O
10 O
##c O
##m O
above O
the O
t O
##rag O
##us O
. O
per O
end O
##oc O
##rino O
##logy O
the O
patient O
was O
given O
cab B-DRUG
##er I-DRUG
##gol I-DRUG
##ine I-DRUG
0 B-STR
. I-STR
5 I-STR
##m I-STR
##g I-STR
as O
a O
one O
- O
time O
dose O
and O
the O
patient O
was O
switched O
from O
de B-DRUG
##xa I-DRUG
##met I-DRUG
##has I-DRUG
##one I-DRUG
to O
pre B-DRUG
##dn I-DRUG
##ison I-DRUG
##e I-DRUG
7 B-STR
. I-STR
5 I-STR
##m I-STR
##g I-STR
daily B-FRE
according O
to O
their O
recommendations O
. O
he O
was O
given O
a O
di B-DRUG
##lant I-DRUG
##in I-DRUG
b B-DOS
##ol I-DOS
##us I-DOS
of O
500 B-STR
##m I-STR
##g I-STR
for O
a O
di B-DRUG
##lant I-DRUG
##in I-DRUG
level O
of O
9 O
. O
6 O
. O

on O
[ O
* O
* O
5 O
- O
16 O
* O
* O
] O
the O
patient O
' O
s O
mental O
status O
was O
stable O
and O
so O
an O
e O
##v O
##d O
we O
##an O
was O
started O
. O
the O
patient O
tolerate O
##d O
elevation O
of O
the O
drain O
to O
20 O
##c O
##m O
above O
the O
t O
##rag O
##us O
. O
di B-DRUG
##lant I-DRUG
##in I-DRUG
level O
was O
therapeutic O
at O
12 O
. O
9 O
. O
p O
##t O
was O
transfer O
##ed O
to O
the O
step O
##down O
unit O
. O
his O
vent O
##ric O
##ular O
drain O
was O
clamped O
several O
times O
but O
patient O
continued O
to O
have O
elevated O
i O
##c O
##ps O
and O
severe O
headache O
##s O
. O
plan O
for O
v O
##p O
s O
##hun O
##t O
was O
postponed O
on O
[ O
* O
* O
5 O
- O
20 O
* O
* O
] O
for O
fever O
to O
102 O
. O
7 O
. O
fever O
work O
##up O
was O
negative O
for O
d O
##v O
##t O
with O
lower O
ex O
##tre O
##mity O
do O
##pp O
##lers O
, O
negative O
consolidation O
on O
chest O
x O
##ray O
. O
blood O
, O
urine O
and O
c O
##s O
##f O
cultures O
were O
sent O
on O
[ O
* O
* O
5 O
- O
20 O
* O
* O
] O
. O
he O
de O
##vo O
##lop O
##ed O
a O
total B-ADE
body I-ADE
r I-ADE
##ash I-ADE
that O
resembled O
a O
reaction O
to O
di B-DRUG
##lant I-DRUG
##in I-DRUG
and O
so O
the O
patient O
was O
transitioned O
to O
k B-DRUG
##ep I-DRUG
##pra I-DRUG
, I-DRUG
di B-DRUG
##lant I-DRUG
##in I-DRUG
was O
stopped O
and O
the O
r B-REA
##ash I-REA
was O
treated O
topic B-ROU
##ally I-ROU
with O
h B-DRUG
##ydro I-DRUG
##cor I-DRUG
##tis I-DRUG
##one I-DRUG
cream B-FOR
and O
with O
oral B-ROU
ben B-DRUG
##ad I-DRUG
##ryl I-DRUG
p B-FRE
##rn I-FRE
. I-FRE
no O
respiratory O
distress O
, O
no O
oral O
swelling O
. O
he O
was O
a O
##fe O
##bri O
##le O
on O
[ O
* O
* O
5 O
- O
21 O
* O
* O
] O
and O
was O
ne O
##uro O
##lop O
##gical O
##ly O
stable O
with O
e O
##v O
##d O
in O
place O
while O
awaiting O
v O
##p O
s O
##hun O
##t O
placement O
. O
on O
[ O
* O
* O
214 O
##9 O
- O
5 O
- O
23 O
* O
* O
] O
, O
patient O
had O
a O
right O
v O
##p O
s O
##hun O
##t O
place O
by O
d O
##r O
. O
[ O
* O
* O
first O
name O
( O
s O
##ti O
##tle O
) O
* O
* O
] O
. O
on O
the O
day O
of O
surgery O
he O
had O
stress B-DOS
dose I-DOS
s B-DRUG
##tero I-DRUG
##ids I-DRUG
with O
h B-DRUG
##ydro I-DRUG
##cor I-DRUG
##tis I-DRUG
##one I-DRUG
50 B-STR
##m I-STR
##g I-STR
q B-FRE
##8 I-FRE
and O
then O
resumed O
pre B-DRUG
##dn I-DRUG
##ison I-DRUG
##e I-DRUG
7 B-STR
. I-STR
5 I-STR
##m I-STR
##g I-STR
daily B-FRE
. I-FRE
now O
do O
##d O
, O
p O
##t O
is O
a O
##fe O
##bri O
##le O
, O
vital O
signs O
are O
stable O
, O
and O
to O
##ler O
##ating O
a O
good O
oral O
diet O
. O
his O
pain O
is O
well O
controlled O
and O
in O
##cision O
appear O
clean O
/ O
dry O
/ O
intact O
. O
he O
is O
set O
for O
d O
/ O
c O
home O
in O
stable O
condition O
. O
medications O
on O
admission O
: O
none O
discharge O
disposition O
: O
home O
discharge O
diagnosis O
: O
right O
frontal O
c O
##ys O
##tic O
mass O
sell O
##ar O
and O
su O
##pra O
##sel O
##lar O
mass O
h O
##ydro O
##ce O
##pha O
##lus O
increased O
in O
##tra O
##c O
##rani O
##al O
pressures O
post O
operative O
confusion O
post O
- O
op O
fever O
discharge O
condition O
: O
mental O
status O
: O
clear O
and O
coherent O
. O
level O
of O
consciousness O
: O
alert O
and O
interactive O
. O
activity O
status O
: O
am O
##bula O
##tory O
- O
independent O
. O
discharge O
instructions O
: O
general O
instructions O

? O
? O
? O
? O
? O
? O
have O
a O
friend O
/ O
family O
member O
check O
your O
in O
##cision O
daily O
for O
signs O
of O
infection O
. O
? O
? O
? O
? O
? O
? O
take O
your O
pain B-DRUG
medicine I-DRUG
as O
prescribed O
. O
? O
? O
? O
? O
? O
? O
exercise O
should O
be O
limited O
to O
walking O
; O
no O
lifting O
, O
straining O
, O
or O
excessive O
bending O
. O
? O
? O
? O
? O
? O
? O
you O
may O
wash O
your O
hair O
only O
after O
su O
##tures O
and O
/ O
or O
staple O
##s O
have O
been O
removed O
. O
if O
your O
wound O
closure O
uses O
di O
##sso O
##l O
##vable O
su O
##tures O
, O
you O
must O
keep O
that O
area O
dry O
for O
10 O
days O
. O
? O
? O
? O
? O
? O
? O
you O
may O
shower O
before O
this O
time O
using O
a O
shower O
cap O
to O
cover O
your O
head O
. O
? O
? O
? O
? O
? O
? O
increase O
your O
intake O
of O
fluids O
and O
fiber O
, O
as O
na B-DRUG
##rc I-DRUG
##otic I-DRUG
pain I-DRUG
medicine I-DRUG
can O
cause O
con B-REA
##st I-REA
##ip I-REA
##ation I-REA
. I-REA
we O
generally O
recommend O
taking O
an O
over O
the O
counter O
stool O
soft O
##ener O
, O
such O
as O
do B-DRUG
##cus I-DRUG
##ate I-DRUG
( I-DRUG
co I-DRUG
##lace I-DRUG
) I-DRUG
while O
taking O
na B-DRUG
##rc I-DRUG
##otic I-DRUG
pain I-DRUG
medication I-DRUG
. I-DRUG
? O
? O
? O
? O
? O
? O
unless O
directed O
by O
your O
doctor O
, O
do O
not O
take O
any O
anti B-DRUG
- I-DRUG
inflammatory I-DRUG
medicines I-DRUG
such O
as O
m B-DRUG
##ot I-DRUG
##rin I-DRUG
, I-DRUG
as B-DRUG
##pi I-DRUG
##rin I-DRUG
, I-DRUG
ad B-DRUG
##vil I-DRUG
, I-DRUG
and O
i B-DRUG
##bu I-DRUG
##p I-DRUG
##ro I-DRUG
##fen I-DRUG
etc O
. O
? O
? O
? O
? O
? O
? O
if O
you O
have O
been O
discharged O
on O
k B-DRUG
##ep I-DRUG
##pra I-DRUG
( I-DRUG
le I-DRUG
##vet I-DRUG
##ira I-DRUG
##ce I-DRUG
##tam I-DRUG
) I-DRUG
, I-DRUG
you O
will O
not O
require O
blood O
work O
monitoring O
. O
? O
? O
? O
? O
? O
? O
clearance O
to O
drive O
and O
return O
to O
work O
will O
be O
addressed O
at O
your O
post O
- O
operative O
office O
visit O
. O
follow O
##up O
instructions O
: O
follow O
- O
up O
appointment O
instructions O
? O
? O
? O
? O
? O
? O
please O
return O
to O
the O
office O
in O
[ O
* O
* O
8 O
- O
3 O
* O
* O
] O
days O
( O
from O
your O
date O
of O
surgery O
) O
for O
removal O
of O
your O
staple O
##s O
/ O
su O
##tures O
and O
/ O
or O
a O
wound O
check O
. O
this O
appointment O
can O
be O
made O
with O
the O
nurse O
practitioner O
. O
please O
make O
this O
appointment O
by O
calling O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
166 O
##9 O
* O
* O
] O
. O
? O
? O
? O
? O
? O
? O
please O
call O
( O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
88 O
* O
* O
] O
to O
schedule O
an O
appointment O
with O
d O
##r O
. O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
* O
* O
] O
, O
to O
be O
seen O
in O
2 O
weeks O
with O
a O
head O
c O
##t O
- O
on O
every O
other O
week O
, O
you O
will O
need O
visual O
field O
testing O
with O
d O
##r O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
* O
* O
] O
call O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
253 O
* O
* O
] O
to O
follow O
- O
up O
. O
[ O
* O
* O
hospital O
80 O
##9 O
##5 O
* O
* O
] O
clinic O
has O
been O
contact O
[ O
* O
* O
name O
( O
ni O
) O
* O
* O
] O
and O
they O
will O
call O
you O
for O
an O
appointment O
within O
1 O
week O
of O
discharge O
. O

end O
##oc O
##rino O
##logy O
- O
you O
will O
need O
a O
f O
/ O
u O
with O
d O
##r O
. O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
88 O
##26 O
##9 O
* O
* O
] O
in O
2 O
weeks O
on O
[ O
* O
* O
6 O
- O
6 O
* O
* O
] O
, O
at O
4 O
: O
40 O
##pm O
. O
[ O
* O
* O
hospital O
ward O
name O
23 O
* O
* O
] O
building O
- O
medical O
specialty O
clinic O
[ O
* O
* O
location O
( O
un O
) O
44 O
##2 O
* O
* O
] O
. O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
1803 O
* O
* O
] O
if O
you O
have O
questions O
. O
completed O
by O
: O
[ O
* O
* O
214 O
##9 O
- O
5 O
- O
26 O
* O
* O
] O

admission O
date O
: O
[ O
* O
* O
215 O
##4 O
- O
2 O
- O
26 O
* O
* O
] O
discharge O
date O
: O
[ O
* O
* O
215 O
##4 O
- O
3 O
- O
2 O
* O
* O
] O
date O
of O
birth O
: O
[ O
* O
* O
209 O
##5 O
- O
10 O
- O
7 O
* O
* O
] O
sex O
: O
m O
service O
: O
surgery O
all O
##er O
##gies O
: O
patient O
recorded O
as O
having O
no O
known O
all O
##er O
##gies O
to O
drugs O
attending O
: O
[ O
* O
* O
first O
name O
##3 O
( O
l O
##f O
) O
55 O
##6 O
##9 O
* O
* O
] O
chief O
complaint O
: O
bilateral O
lower O
ex O
##tre O
##mity O
d O
##v O
##ts O
major O
surgical O
or O
invasive O
procedure O
: O
[ O
* O
* O
215 O
##4 O
- O
2 O
- O
27 O
* O
* O
] O
i O
##v O
##c O
filter O
placement O
history O
of O
present O
illness O
: O
58 O
year O
old O
man O
s O
/ O
p O
liver O
transplant O
on O
[ O
* O
* O
215 O
##4 O
- O
1 O
- O
31 O
* O
* O
] O
found O
to O
have O
d O
##v O
##t O
on O
du O
##plex O
ultra O
##sound O
. O
the O
patient O
was O
recently O
discharged O
on O
[ O
* O
* O
215 O
##4 O
- O
2 O
- O
14 O
* O
* O
] O
after O
a O
liver O
transplant O
complicated O
by O
bleeding O
which O
required O
two O
take O
- O
backs O
to O
the O
or O
and O
bilateral O
o O
##cci O
##pit O
##al O
stroke O
with O
residual O
left O
field O
visual O
defect O
. O
he O
has O
been O
doing O
very O
well O
since O
his O
discharge O
, O
working O
with O
p O
##t O
with O
minimal O
pain O
, O
eating O
well O
and O
regain O
##ing O
his O
strength O
. O
his O
only O
complaint O
is O
his O
eyes O
##ight O
which O
has O
been O
stable O
since O
his O
discharge O
. O
he O
was O
seen O
today O
for O
scheduled O
bilateral O
lower O
ex O
##tre O
##mity O
ultra O
##sound O
##s O
to O
evaluate O
for O
em O
##bolic O
source O
for O
his O
stroke O
. O
these O
revealed O
a O
d O
##v O
##t O
and O
the O
patient O
was O
directly O
admitted O
to O
the O
floor O
for O
management O
. O
he O
has O
no O
specific O
complaints O
at O
this O
time O
. O
past O
medical O
history O
: O
pm O
##h O
: O
c O
##ir O
##r O
##hos O
##is O
, O
h O
##t O
##n O
, O
g O
##i O
bleeding O
, O
g O
##erd O
, O
history O
of O
basal O
and O
sq O
##ua O
##mous O
cell O
car O
##cin O
##oma O
##s O
treated O
topic O
##ally O
and O
surgical O
##ly O
ps O
##h O
: O
significant O
for O
an O
app O
##end O
##ec O
##tom O
##y O
as O
well O
as O
knee O
and O
shoulder O
art O
##hr O
##os O
##co O
##pies O
social O
history O
: O
married O
and O
lives O
with O
his O
wife O
, O
who O
is O
in O
good O
health O
. O
he O
is O
employed O
as O
a O
telecommunications O
technician O
. O
he O
has O
no O
children O
. O
he O
reports O
that O
he O
smoked O
cigarettes O
for O
about O
10 O
years O
but O
quit O
approximately O
30 O
years O
ago O
. O
he O
has O
no O
history O
of O
use O
of O
in O
##tra O
##ven O
##ous O
or O
ill O
##icit O
drugs O
. O
family O
history O
: O
significant O
for O
co O
##lon O
cancer O
in O
his O
father O
as O
well O
as O
seizure O
##s O
in O
his O
brother O
physical O
exam O
: O
physical O
exam O
: O
a O
##fe O
##bri O
##le O
, O
vs O
##s O
no O
distress O
, O
alert O
and O
oriented O
x O
3 O
per O
##la O
, O
e O
##omi O
, O
an O
##ict O
##eric O
r O
##rr O
, O
no O
murmurs O
lungs O
clear O
abdomen O
soft O
, O
non O
##tend O
##er O
, O
non O
##dis O
##tended O
, O
well O
healed O
in O
##cision O
ex O
##t O
: O
no O
ed O
##ema O
, O
p O
##al O
##pable O
pulses O

per O
##tinent O
results O
: O
discharge O
labs O
: O
[ O
* O
* O
215 O
##4 O
- O
3 O
- O
2 O
* O
* O
] O
04 O
: O
30 O
##am O
blood O
w O
##b O
##c O
- O
6 O
. O
5 O
r O
##b O
##c O
- O
3 O
. O
98 O
* O
h O
##g O
##b O
- O
11 O
. O
8 O
* O
h O
##ct O
- O
36 O
. O
0 O
* O
m O
##c O
##v O
- O
91 O
m O
##ch O
- O
29 O
. O
7 O
m O
##ch O
##c O
- O
32 O
. O
8 O
r O
##d O
##w O
- O
16 O
. O
0 O
* O
p O
##lt O
c O
##t O
- O
109 O
* O
[ O
* O
* O
215 O
##4 O
- O
3 O
- O
1 O
* O
* O
] O
05 O
: O
35 O
##am O
blood O
p O
##t O
- O
14 O
. O
8 O
* O
p O
##tt O
- O
25 O
. O
5 O
in O
##r O
( O
p O
##t O
) O
- O
1 O
. O
3 O
* O
[ O
* O
* O
215 O
##4 O
- O
3 O
- O
2 O
* O
* O
] O
04 O
: O
30 O
##am O
blood O
glucose O
- O
103 O
* O
u O
##rea O
##n O
- O
18 O
c O
##rea O
##t O
- O
0 O
. O
8 O
na O
- O
141 O
k O
- O
4 O
. O
1 O
c O
##l O
- O
106 O
h O
##co O
##3 O
- O
28 O
an O
##ga O
##p O
- O
11 O
[ O
* O
* O
215 O
##4 O
- O
3 O
- O
2 O
* O
* O
] O
04 O
: O
30 O
##am O
blood O
al O
##t O
- O
32 O
as O
##t O
- O
24 O
al O
##k O
##ph O
##os O
- O
70 O
to O
##t O
##bil O
##i O
- O
0 O
. O
4 O
[ O
* O
* O
215 O
##4 O
- O
3 O
- O
2 O
* O
* O
] O
04 O
: O
30 O
##am O
blood O
album O
##in O
- O
3 O
. O
0 O
* O
calcium O
- O
8 O
. O
4 O
p O
##hos O
- O
4 O
. O
4 O
mg O
- O
1 O
. O
5 O
* O
[ O
* O
* O
215 O
##4 O
- O
3 O
- O
2 O
* O
* O
] O
04 O
: O
30 O
##am O
blood O
ta O
##c O
##ro O
##f O
##k O
- O
12 O
. O
4 O
. O
c O
##t O
head O
[ O
* O
* O
2 O
- O
26 O
* O
* O
] O
prior O
to O
starting O
he B-DRUG
##par I-DRUG
##in I-DRUG
: I-DRUG
- O
1 O
. O
small O
g O
##yr O
##iform O
f O
##oc O
##i O
of O
h O
##yper O
##den O
##sity O
in O
the O
right O
o O
##cci O
##pit O
##al O
lobe O
at O
the O
area O
of O
prior O
in O
##far O
##ct O
may O
represent O
areas O
of O
h O
##yper O
##per O
##fusion O
- O
pet O
##ech O
##ial O
hem O
##or O
##r O
##hage O
- O
la O
##mina O
##r O
ne O
##c O
##rosis O
or O
residual O
blood O
from O
prior O
hem O
##or O
##r O
##hage O
, O
age O
- O
in O
##det O
##er O
##minate O
. O
no O
large O
in O
##tra O
##c O
##rani O
##al O
hem O
##or O
##r O
##hage O
is O
seen O
. O
2 O
. O
bilateral O
o O
##cci O
##pit O
##al O
lobe O
h O
##y O
##po O
##den O
##sity O
, O
right O
larger O
than O
left O
, O
unchanged O
left O
ca O
##uda O
##te O
head O
h O
##y O
##po O
##den O
##sity O
likely O
consistent O
with O
chronic O
is O
##che O
##mic O
changes O
. O
. O
c O
##t O
head O
[ O
* O
* O
2 O
- O
26 O
* O
* O
] O
after O
the O
administration O
of O
he B-DRUG
##par I-DRUG
##in I-DRUG
: I-DRUG
- O
areas O
of O
sub O
##ac O
##ute O
in O
##far O
##ction O
in O
the O
o O
##cci O
##pit O
##al O
lobes O
bilateral O
##ly O
, O
unchanged O
since O
[ O
* O
* O
215 O
##4 O
- O
2 O
- O
26 O
* O
* O
] O
. O
evolving O
hem O
##or O
##r O
##hage O
within O
the O
in O
##far O
##ctions O
. O
close O
interval O
follow O
##up O
is O
suggested O
. O
. O

c O
##t O
head O
[ O
* O
* O
2 O
- O
27 O
* O
* O
] O
: O
- O
bilateral O
sub O
##ac O
##ute O
o O
##cci O
##pit O
##al O
in O
##far O
##ction O
/ O
hem O
##or O
##r O
##hage O
. O
no O
acute O
changes O
. O
. O
du O
##plex O
: O
1 O
. O
right O
superficial O
f O
##em O
##oral O
and O
per O
##one O
##al O
vein O
th O
##rom O
##bus O
. O
2 O
. O
left O
posterior O
t O
##ibi O
##al O
vein O
th O
##rom O
##bus O
. O

brief O
hospital O
course O
: O
m O
##r O
. O
[ O
* O
* O
known O
last O
##name O
71 O
##16 O
##6 O
* O
* O
] O
was O
admitted O
on O
[ O
* O
* O
215 O
##4 O
- O
2 O
- O
26 O
* O
* O
] O
after O
routine O
du O
##plex O
scanning O
of O
his O
legs O
revealed O
right O
superficial O
and O
per O
##one O
##al O
vein O
d O
##v O
##t O
and O
left O
posterior O
t O
##ibi O
##al O
d O
##v O
##ts O
. O
due O
to O
his O
recent O
o O
##cci O
##pit O
##al O
strokes O
a O
c O
##t O
scan O
was O
obtained O
prior O
to O
the O
administration O
of O
he B-DRUG
##par I-DRUG
##in I-DRUG
. I-DRUG
the O
c O
##t O
scan O
showed O
bilateral O
o O
##cci O
##pit O
##al O
lobe O
h O
##y O
##po O
##den O
##sities O
, O
right O
larger O
than O
left O
, O
unchanged O
from O
prior O
studies O
. O
ne O
##uro O
##logy O
was O
consulted O
and O
a O
he B-DRUG
##par I-DRUG
##in I-DRUG
g B-FOR
##tt I-FOR
was O
started O
at O
a O
low O
rate O
. O
a O
few O
hours O
after O
the O
he B-DRUG
##par I-DRUG
##in I-DRUG
was O
started O
he O
began O
to O
complain O
of O
new O
visual O
hall O
##uc O
##ination O
##s O
that O
he O
did O
not O
have O
before O
. O
due O
to O
concerns O
for O
hem O
##or O
##r O
##ha O
##gic O
conversion O
of O
his O
prior O
c O
##va O
he O
was O
transferred O
to O
the O
i O
##cu O
for O
monitoring O
and O
a O
head O
c O
##t O
was O
obtained O
that O
showed O
areas O
of O
sub O
##ac O
##ute O
in O
##far O
##ction O
in O
the O
o O
##cci O
##pit O
##al O
lobes O
bilateral O
##ly O
, O
unchanged O
since O
[ O
* O
* O
215 O
##4 O
- O
2 O
- O
26 O
* O
* O
] O
with O
evolving O
hem O
##or O
##r O
##hage O
within O
the O
in O
##far O
##ctions O
. O
his O
he B-DRUG
##par I-DRUG
##in I-DRUG
g B-FOR
##tt I-FOR
was O
immediately O
stopped O
and O
2 O
more O
follow O
up O
head O
c O
##ts O
showed O
no O
change O
. O
an O
e O
##eg O
was O
obtained O
and O
this O
show O
signs O
of O
en O
##ce O
##pha O
##lop O
##athy O
but O
no O
seizure O
activity O
. O
his O
hall B-REA
##uc I-REA
##ination I-REA
##s I-REA
continued O
and O
k B-DRUG
##ep I-DRUG
##pra I-DRUG
[ O
* O
* O
hospital O
##1 O
* O
* O
] O
was O
started O
. O
a O
24 O
##hou O
##r O
e O
##eg O
was O
obtained O
, O
an O
initial O
interpretation O
showed O
no O
seizure O
activity O
, O
but O
the O
final O
read O
is O
still O
pending O
as O
of O
his O
discharge O
. O
he O
was O
transferred O
back O
to O
the O
floor O
. O
his O
diet O
was O
advanced O
and O
he O
is O
having O
bow O
##el O
function O
. O
his O
lab O
##aro O
##tory O
work O
is O
stable O
. O
his O
visual O
hall O
##uc O
##ination O
##s O
are O
vast O
##ly O
improving O
and O
his O
main O
complaints O
are O
blur O
##ry O
vision O
in O
his O
left O
visual O
fields O
. O
he O
is O
discharged O
on O
k B-DRUG
##ep I-DRUG
##pra I-DRUG
with O
transplant O
as O
well O
as O
ne O
##uro O
##logy O
follow O
up O
. O
a O
card O
##iology O
consult O
was O
obtained O
to O
evaluate O
for O
closure O
of O
his O
as O
##d O
as O
an O
appropriate O
date O
. O
his O
ta B-DRUG
##c I-DRUG
##ro I-DRUG
dose O
was O
decreased O
to O
1 B-STR
. I-STR
5 I-STR
##m I-STR
##g I-STR
[ O
* O
* O
hospital O
##1 O
* O
* O
] O
based O
on O
his O
level O
. O
his O
pre B-DRUG
##dn I-DRUG
##ison I-DRUG
##e I-DRUG
was O
decreased O
to O
15 B-STR
##m I-STR
##g I-STR
daily B-FRE
. I-FRE

medications O
on O
admission O
: O
mm B-DRUG
##f I-DRUG
1000 B-STR
##m I-STR
##g I-STR
[ O
* O
* O
hospital O
##1 O
* O
* O
] O
, O
pro B-DRUG
##ton I-DRUG
##ix I-DRUG
40 B-STR
##m I-STR
##g I-STR
daily B-FRE
, I-FRE
flu B-DRUG
##cona I-DRUG
##zo I-DRUG
##le I-DRUG
400 B-STR
##m I-STR
##g I-STR
daily B-FRE
, I-FRE
v B-DRUG
##al I-DRUG
##cy I-DRUG
##te I-DRUG
900 B-STR
##m I-STR
##g I-STR
daily B-FRE
, I-FRE
p B-DRUG
##lav I-DRUG
##ix I-DRUG
75 B-STR
##m I-STR
##g I-STR
daily B-FRE
, I-FRE
as B-DRUG
##a I-DRUG
325 B-STR
##m I-STR
##g I-STR
daily B-FRE
, I-FRE
b B-DRUG
##act I-DRUG
##rim I-DRUG
s I-DRUG
##s I-DRUG
daily B-FRE
, I-FRE
met B-DRUG
##op I-DRUG
##rol I-DRUG
##ol I-DRUG
25 B-STR
##m I-STR
##g I-STR
t B-FRE
##id I-FRE
, I-FRE
co B-DRUG
##lace I-DRUG
100 B-STR
##m I-STR
##g I-STR
[ O
* O
* O
hospital O
##1 O
* O
* O
] O
, O
pre B-DRUG
##dn I-DRUG
##ison I-DRUG
##e I-DRUG
17 B-STR
. I-STR
5 I-STR
##m I-STR
##g I-STR
daily B-FRE
, I-FRE
pro B-DRUG
##gra I-DRUG
##f I-DRUG
2 B-STR
##m I-STR
##g I-STR
[ O
* O
* O
hospital O
##1 O
* O
* O
] O
discharge O
medications O
: O
1 O
. O
my B-DRUG
##co I-DRUG
##phe I-DRUG
##no I-DRUG
##late I-DRUG
m I-DRUG
##of I-DRUG
##eti I-DRUG
##l I-DRUG
500 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
two B-DOS
( I-DOS
2 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
bid B-FRE
( O
2 O
times O
a O
day O
) O
. O
2 O
. O
flu B-DRUG
##cona I-DRUG
##zo I-DRUG
##le I-DRUG
200 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
two B-DOS
( I-DOS
2 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
q B-FRE
##24 I-FRE
##h I-FRE
( O
every O
24 O
hours O
) O
. O
3 O
. O
v B-DRUG
##al I-DRUG
##gan I-DRUG
##ci I-DRUG
##c I-DRUG
##lov I-DRUG
##ir I-DRUG
450 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
two B-DOS
( I-DOS
2 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( O
daily O
) O
. O
4 O
. O
su B-DRUG
##lf I-DRUG
##ame I-DRUG
##th I-DRUG
##ox I-DRUG
##az I-DRUG
##ole I-DRUG
- I-DRUG
trim I-DRUG
##eth I-DRUG
##op I-DRUG
##rim I-DRUG
400 B-STR
- I-STR
80 I-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( O
daily O
) O
. O
5 O
. O
met B-DRUG
##op I-DRUG
##rol I-DRUG
##ol I-DRUG
ta I-DRUG
##rt I-DRUG
##rate I-DRUG
25 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
t B-FRE
##id I-FRE
( O
3 O
times O
a O
day O
) O
. O
6 O
. O
pan B-DRUG
##top I-DRUG
##raz I-DRUG
##ole I-DRUG
40 B-STR
mg I-STR
tablet B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
p B-ROU
##o I-ROU
q B-FRE
##24 I-FRE
##h I-FRE
( O
every O
24 O
hours O
) O
. O
7 O
. O
pre B-DRUG
##dn I-DRUG
##ison I-DRUG
##e I-DRUG
5 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
three B-DOS
( I-DOS
3 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( O
daily O
) O
. O
8 O
. O
ta B-DRUG
##c I-DRUG
##rol I-DRUG
##imus I-DRUG
1 B-STR
mg I-STR
capsule B-FOR
si O
##g O
: O
1 B-DOS
and O
[ O
* O
* O
1 O
- O
12 O
* O
* O
] O
capsule B-FOR
p B-ROU
##o I-ROU
q B-FRE
##12 I-FRE
##h I-FRE
( O
every O
12 O
hours O
) O
. O
9 O
. O
insulin B-DRUG
l I-DRUG
##is I-DRUG
##p I-DRUG
##ro I-DRUG
100 B-STR
unit I-STR
/ I-STR
m I-STR
##l I-STR
solution B-FOR
si O
##g O
: O
per B-DOS
sliding I-DOS
scale I-DOS
per I-DOS
scale I-DOS
sub B-ROU
##cut I-ROU
##aneous I-ROU
as B-FRE
##dir I-FRE
( O
as O
directed O
) O
. O
10 O
. O
do B-DRUG
##cus I-DRUG
##ate I-DRUG
sodium I-DRUG
100 B-STR
mg I-STR
capsule B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
capsule B-FOR
p B-ROU
##o I-ROU
bid B-FRE
( O
2 O
times O
a O
day O
) O
. O
11 O
. O
le B-DRUG
##vet I-DRUG
##ira I-DRUG
##ce I-DRUG
##tam I-DRUG
250 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
three B-DOS
( I-DOS
3 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
bid B-FRE
( O
2 O
times O
a O
day O
) O
. O
di O
##sp O
: O
* O
180 O
tablet O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
0 O
* O
discharge O
disposition O
: O
home O
with O
service O
facility O
: O
[ O
* O
* O
location O
( O
un O
) O
111 O
##0 O
* O
* O
] O
v O
##na O
discharge O
diagnosis O
: O
bilateral O
leg O
d O
##v O
##ts O

discharge O
condition O
: O
good O
alert O
and O
oriented O
x O
3 O
am O
##bula O
##ting O
independently O
discharge O
instructions O
: O
please O
call O
the O
[ O
* O
* O
hospital O
132 O
##6 O
* O
* O
] O
clinic O
at O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
67 O
##3 O
* O
* O
] O
if O
you O
experience O
any O
of O
the O
following O
: O
fever O
, O
chill O
##s O
, O
nausea O
, O
vomit O
##ing O
, O
inability O
to O
eat O
or O
drink O
, O
abdominal O
pain O
, O
di O
##ar O
##r O
##hea O
, O
chest O
pain O
, O
short O
##ness O
of O
breath O
, O
a O
change O
in O
your O
visual O
symptoms O
, O
weakness O
or O
numb O
##ness O
on O
one O
side O
of O
your O
body O
, O
or O
any O
other O
concerns O
you O
may O
have O
. O
. O
resume O
all O
of O
your O
medications O
. O
your O
pre B-DRUG
##dn I-DRUG
##ison I-DRUG
##e I-DRUG
dose O
was O
decreased O
to O
15 B-STR
##m I-STR
##g I-STR
daily B-FRE
. I-FRE
you O
were O
started O
on O
k B-DRUG
##ep I-DRUG
##pra I-DRUG
due O
to O
concerns O
for O
seizure B-REA
##s I-REA
. I-REA
your O
e O
##eg O
was O
tentatively O
read O
as O
negative O
. O
you O
should O
continue O
the O
k B-DRUG
##ep I-DRUG
##pra I-DRUG
and O
follow O
up O
with O
ne O
##uro O
##logy O
. O
follow O
##up O
instructions O
: O
provider O
: O
[ O
* O
* O
first O
name O
##11 O
( O
name O
pattern O
##1 O
) O
81 O
##9 O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##4 O
) O
82 O
##0 O
* O
* O
] O
, O
m O
##d O
phone O
: O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
67 O
##3 O
* O
* O
] O
date O
/ O
time O
: O
[ O
* O
* O
215 O
##4 O
- O
3 O
- O
4 O
* O
* O
] O
9 O
: O
30 O
provider O
: O
[ O
* O
* O
first O
name O
##11 O
( O
name O
pattern O
##1 O
) O
81 O
##9 O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##4 O
) O
82 O
##0 O
* O
* O
] O
, O
m O
##d O
phone O
: O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
67 O
##3 O
* O
* O
] O
date O
/ O
time O
: O
[ O
* O
* O
215 O
##4 O
- O
3 O
- O
11 O
* O
* O
] O
10 O
: O
00 O
provider O
: O
[ O
* O
* O
first O
name O
##11 O
( O
name O
pattern O
##1 O
) O
81 O
##9 O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##4 O
) O
82 O
##0 O
* O
* O
] O
, O
m O
##d O
phone O
: O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
67 O
##3 O
* O
* O
] O
date O
/ O
time O
: O
[ O
* O
* O
215 O
##4 O
- O
3 O
- O
18 O
* O
* O
] O
10 O
: O
00 O
. O
follow O
up O
with O
d O
##r O
. O
[ O
* O
* O
first O
name O
( O
s O
##ti O
##tle O
) O
* O
* O
] O
( O
ne O
##uro O
##logy O
) O
. O
his O
office O
number O
is O
( O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
73 O
##9 O
##4 O
* O
* O
] O
. O
you O
have O
an O
appointment O
on O
[ O
* O
* O
215 O
##4 O
- O
3 O
- O
18 O
* O
* O
] O
but O
he O
may O
want O
to O
see O
you O
sooner O
. O
call O
his O
office O
on O
mon O
##day O
. O

admission O
date O
: O
[ O
* O
* O
212 O
##0 O
- O
5 O
- O
14 O
* O
* O
] O
discharge O
date O
: O
[ O
* O
* O
212 O
##0 O
- O
5 O
- O
24 O
* O
* O
] O
service O
: O
medicine O
all O
##er O
##gies O
: O
te B-DRUG
##tan I-DRUG
##us I-DRUG
to I-DRUG
##x I-DRUG
##oid I-DRUG
/ O
bee O
pollen O
##s O
attending O
: O
[ O
* O
* O
first O
name O
##3 O
( O
l O
##f O
) O
512 O
##3 O
* O
* O
] O
chief O
complaint O
: O
h O
##y O
##pox O
##ia O
major O
surgical O
or O
invasive O
procedure O
: O
none O
history O
of O
present O
illness O
: O
85 O
##m O
with O
complete O
heart O
block O
s O
/ O
p O
pace O
##r O
, O
h O
##t O
##n O
, O
di O
##ast O
##olic O
ch O
##f O
, O
id O
##d O
##m O
, O
go O
##ut O
, O
cop O
##d O
, O
p O
##v O
##d O
s O
/ O
p O
ll O
##e O
s O
##ten O
##ts O
several O
weeks O
ago O
transferred O
from O
[ O
* O
* O
hospital O
##3 O
* O
* O
] O
ed O
from O
n O
##h O
for O
h O
##y O
##pox O
##ia O
. O
. O

today O
at O
his O
nursing O
home O
, O
he O
was O
found O
around O
1 O
: O
30 O
##pm O
to O
be O
more O
let O
##har O
##gic O
, O
short O
of O
breath O
with O
b O
##p O
70 O
/ O
50 O
and O
difficult O
to O
assess O
radial O
pulses O
. O
o O
##2 O
##sat O
86 O
% O
on O
r O
##a O
. O
p O
##t O
was O
bi O
##ba O
to O
[ O
* O
* O
hospital O
##3 O
* O
* O
] O
ed O
, O
vs O
at O
em O
##s O
evaluation O
was O
p O
50 O
, O
b O
##p O
70 O
/ O
p O
, O
r O
##r O
20 O
, O
unable O
to O
get O
a O
pulse O
o O
##x O
, O
f O
##s O
##bs O
114 O
. O
in O
the O
[ O
* O
* O
name O
( O
ni O
) O
46 O
* O
* O
] O
[ O
* O
* O
name O
( O
ni O
) O
* O
* O
] O
, O
p O
##t O
was O
alert O
but O
noted O
to O
be O
c O
##yan O
##otic O
and O
p O
##all O
##id O
with O
m O
##ott O
##led O
skin O
. O
p O
##t O
c O
/ O
o O
di O
##ff O
##use O
abdominal O
pain O
. O
vs O
were O
not O
recorded O
. O
labs O
notable O
for O
w O
##b O
##c O
21 O
. O
1 O
( O
88 O
. O
3 O
##n O
, O
no O
bands O
) O
, O
c O
##p O
##k O
48 O
but O
t O
##rop O
i O
0 O
. O
6 O
( O
re O
##f O
0 O
- O
0 O
. O
04 O
) O
- O
? O
0 O
. O
47 O
when O
confirmed O
; O
p O
##t O
remained O
c O
##p O
free O
and O
e O
##k O
##g O
showed O
a O
paced O
rhythm O
at O
80 O
b O
##pm O
. O
c O
##x O
##r O
was O
read O
as O
un O
##rem O
##ark O
##able O
with O
pacing O
leads O
in O
place O
. O
non O
##con O
##tras O
##t O
c O
##t O
chest O
showed O
" O
small O
patch O
##y O
inter O
##st O
##iti O
##al O
in O
##fi O
##lt O
##rates O
with O
focal O
br O
##on O
##chi O
##ec O
##tas O
##is O
and O
nod O
##ular O
##ity O
in O
the O
posterior O
left O
lung O
base O
" O
and O
em O
##phy O
##se O
##mat O
##ous O
changes O
. O
non O
##con O
##tras O
##t O
c O
##t O
abdomen O
was O
un O
##rem O
##ark O
##able O
other O
than O
for O
mild O
diver O
##tic O
##ulos O
##is O
. O
p O
##t O
was O
given O
van B-DRUG
##co I-DRUG
/ I-DRUG
z B-DRUG
##osy I-DRUG
##n I-DRUG
and O
3 B-DOS
##l I-DOS
i B-ROU
##v I-ROU
fluid B-DRUG
without O
improvement O
in O
his O
started O
on O
peripheral B-ROU
le B-DRUG
##vo I-DRUG
##phe I-DRUG
##d I-DRUG
for O
s B-REA
##b I-REA
##p I-REA
70 I-REA
/ I-REA
p I-REA
##al I-REA
##pable I-REA
and O
given O
h B-DRUG
##ydro I-DRUG
##cor I-DRUG
##tis I-DRUG
##one I-DRUG
100 B-STR
##m I-STR
##g I-STR
i B-ROU
##v I-ROU
. I-ROU
he O
was O
transferred O
to O
our O
ed O
for O
further O
management O
. O
. O

in O
the O
ed O
, O
initial O
vs O
were O
: O
t O
##9 O
##7 O
. O
8 O
p O
##80 O
s O
##b O
##p O
##13 O
##5 O
r O
##18 O
100 O
% O
on O
n O
##rb O
. O
transferred O
on O
13 B-STR
m I-STR
##c I-STR
##g I-STR
of O
peripheral B-ROU
le B-DRUG
##vo I-DRUG
##phe I-DRUG
##d I-DRUG
but O
p O
##t O
was O
given O
another O
1 B-DOS
##l I-DOS
n B-DRUG
##s I-DRUG
, I-DRUG
and O
pressures O
remained O
stable O
after O
le B-DRUG
##vo I-DRUG
##phe I-DRUG
##d I-DRUG
we O
##ane O
##d O
off O
. O
c O
##x O
##r O
with O
increased O
in O
##fi O
##lt O
##rate O
in O
ll O
##l O
. O
w O
##b O
##c O
17 O
, O
h O
##ct O
25 O
, O
g O
##ua O
##iac O
negative O
. O
la O
##ct O
##ate O
2 O
. O
1 O
. O
e O
##k O
##g O
paced O
at O
80 O
. O
p O
##t O
given O
comb B-DRUG
##ive I-DRUG
##nt I-DRUG
ne B-ROU
##b I-ROU
. I-ROU
only O
complaint O
was O
foot O
pain O
. O
has O
2 O
p O
##iv O
in O
. O
on O
transfer O
, O
h O
##r O
##80 O
, O
100 O
/ O
61 O
, O
20 O
, O
96 O
% O
on O
n O
##rb O
c O
##x O
##r O
. O
. O
on O
arrival O
to O
the O
i O
##cu O
, O
p O
##t O
without O
any O
complaints O
other O
than O
l O
toe O
pain O
. O
earlier O
abdominal O
pain O
had O
resolved O
at O
some O
point O
in O
the O
[ O
* O
* O
first O
name O
##4 O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
46 O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
* O
* O
] O
; O
not O
c O
/ O
w O
g O
##erd O
. O
he O
does O
recall O
feeling O
more O
d O
##ys O
##p O
##ne O
##ic O
on O
ex O
##ert O
##ion O
for O
several O
days O
. O
no O
c O
##p O
, O
shoulder O
/ O
jaw O
pain O
, O
p O
##al O
##pit O
##ations O
, O
n O
/ O
v O
, O
l O
##h O
. O
per O
son O
, O
p O
##t O
was O
recently O
admitted O
to O
[ O
* O
* O
hospital O
##3 O
35 O
##8 O
##3 O
* O
* O
] O
on O
[ O
* O
* O
5 O
- O
3 O
* O
* O
] O
for O
d O
##ys O
##p O
##nea O
and O
l O
toe O
pain O
. O
per O
his O
son O
, O
there O
was O
concern O
for O
d O
##v O
##t O
and O
p O
##e O
, O
but O
le O
##nis O
and O
d O
- O
dim O
##er O
were O
negative O
. O
he O
was O
treated O
with O
ni B-DRUG
##tro I-DRUG
, I-DRUG
las B-DRUG
##ix I-DRUG
, I-DRUG
as B-DRUG
##a I-DRUG
, I-DRUG
p B-DRUG
##lav I-DRUG
##ix I-DRUG
, I-DRUG
love B-DRUG
##no I-DRUG
##x I-DRUG
, I-DRUG
and O
br B-DRUG
##on I-DRUG
##cho I-DRUG
##di I-DRUG
##lator I-DRUG
##s I-DRUG
initially O
and O
s O
##x O
improved O
while O
in O
the O
ed O
. O
card O
##iology O
c O
/ O
s O
at O
##tri O
##but O
##de O
mildly O
elevated O
t O
##rop O
##oni O
##ns O
attributed O
to O
demand O
. O
per O
his O
son O
, O
he O
underwent O
a O
nuclear O
stress O
test O
that O
was O
un O
##rem O
##ark O
##able O
and O
was O
discharged O
. O
he O
was O
started O
on O
pre B-DRUG
##dn I-DRUG
##ison I-DRUG
##e I-DRUG
for O
presumed B-REA
go I-REA
##ut I-REA
with O
no O
improvement O
in O
his O
s O
##x O
since O
. O
. O

review O
of O
systems O
: O
( O
+ O
) O
per O
hp O
##i O
( O
- O
) O
denies O
fever O
, O
chill O
##s O
, O
night O
sweat O
##s O
, O
recent O
weight O
loss O
or O
gain O
. O
denies O
headache O
, O
sin O
##us O
tender O
##ness O
, O
r O
##hino O
##rr O
##hea O
or O
congestion O
. O
denies O
cough O
, O
short O
##ness O
of O
breath O
, O
or O
w O
##hee O
##zing O
. O
denies O
chest O
pain O
, O
chest O
pressure O
, O
p O
##al O
##pit O
##ations O
, O
or O
weakness O
. O
denies O
nausea O
, O
vomit O
##ing O
, O
di O
##ar O
##r O
##hea O
, O
con O
##st O
##ip O
##ation O
, O
abdominal O
pain O
, O
or O
changes O
in O
bow O
##el O
habits O
. O
denies O
d O
##ys O
##uria O
, O
frequency O
, O
or O
urgency O
. O
denies O
art O
##hra O
##l O
##gia O
##s O
or O
my O
##al O
##gia O
##s O
. O
denies O
r O
##ash O
##es O
or O
skin O
changes O
. O
past O
medical O
history O
: O
( O
1 O
) O
s O
##ync O
##ope O
/ O
pre O
##sy O
##nco O
##pe O
( O
2 O
) O
complete O
a O
##v O
block O
, O
status O
post O
[ O
* O
* O
company O
154 O
##3 O
* O
* O
] O
pace O
##maker O
[ O
* O
* O
211 O
##2 O
- O
11 O
- O
11 O
* O
* O
] O
( O
3 O
) O
h O
##yper O
##tens O
##ion O
( O
4 O
) O
di O
##ast O
##olic O
ch O
##f O
and O
possible O
restrict O
##ive O
card O
##io O
##my O
##op O
##athy O
( O
5 O
) O
a O
##ea O
/ O
ve O
##a O
/ O
ca O
##d O
( O
6 O
) O
id B-DRUG
##d I-REA
##m I-REA
with O
album O
##in O
##uria O
( O
7 O
) O
go B-REA
##ut I-REA
on O
pre B-DRUG
##dn I-DRUG
##ison I-DRUG
##e I-DRUG
( O
8 O
) O
cop O
##d O
social O
history O
: O
- O
tobacco O
: O
quit O
45 O
years O
ago O
- O
alcohol O
: O
denies O
- O
ill O
##icit O
##s O
: O
denies O
family O
history O
: O
non O
- O
con O
##tri O
##but O
##ary O
physical O
exam O
: O
vital O
##s O
: O
t O
95 O
. O
6 O
, O
p O
80 O
, O
b O
##p O
123 O
/ O
78 O
, O
r O
##r O
17 O
, O
o O
##2 O
##sat O
97 O
on O
4 O
##l O
general O
: O
alert O
, O
oriented O
, O
no O
acute O
distress O
he O
##ent O
: O
s O
##cle O
##ra O
an O
##ict O
##eric O
, O
mm O
##m O
, O
or O
##op O
##har O
##ynx O
clear O
neck O
: O
su O
##pp O
##le O
, O
j O
##v O
##p O
not O
elevated O
, O
no O
lad O
lungs O
: O
clear O
to O
au O
##s O
##cu O
##lta O
##tion O
bilateral O
##ly O
with O
only O
minimal O
w O
##hee O
##zes O
at O
bases O
, O
r O
##ales O
, O
r O
##hon O
##chi O
c O
##v O
: O
regular O
rate O
and O
rhythm O
, O
normal O
s O
##1 O
+ O
s O
##2 O
, O
no O
murmurs O
, O
rub O
##s O
, O
gal O
##lops O
abdomen O
: O
soft O
, O
non O
- O
tender O
, O
non O
- O
di O
##sten O
##ded O
, O
bow O
##el O
sounds O
present O
, O
no O
re O
##bound O
tender O
##ness O
or O
guarding O
, O
no O
organ O
##ome O
##gal O
##y O
ex O
##t O
: O
ex O
##tre O
##mit O
##ies O
slightly O
m O
##ott O
##led O
b O
/ O
l O
, O
2 O
+ O
pulses O
, O
l O
toe O
tender O
on O
plant O
##ar O
surface O
but O
not O
er O
##yt O
##hem O
##ato O
##us O
, O
warm O
, O
or O
swollen O
. O
ne O
##uro O
: O
a O
##ao O
##x O
##3 O
, O
non O
##fo O
##cal O
exam O
. O

per O
##tinent O
results O
: O
[ O
* O
* O
212 O
##0 O
- O
5 O
- O
14 O
* O
* O
] O
11 O
: O
24 O
##pm O
glucose O
- O
136 O
* O
u O
##rea O
n O
- O
57 O
* O
c O
##rea O
##t O
- O
1 O
. O
9 O
* O
sodium O
- O
138 O
potassium O
- O
5 O
. O
7 O
* O
chloride O
- O
108 O
total O
co O
##2 O
- O
19 O
* O
an O
##ion O
gap O
- O
17 O
[ O
* O
* O
212 O
##0 O
- O
5 O
- O
14 O
* O
* O
] O
11 O
: O
24 O
##pm O
al O
##t O
( O
s O
##g O
##pt O
) O
- O
321 O
##1 O
* O
as O
##t O
( O
s O
##got O
) O
- O
316 O
##9 O
* O
l O
##d O
( O
l O
##dh O
) O
- O
62 O
##80 O
* O
c O
##k O
( O
c O
##p O
##k O
) O
- O
98 O
al O
##k O
p O
##hos O
- O
72 O
to O
##t O
bi O
##li O
- O
0 O
. O
7 O
[ O
* O
* O
212 O
##0 O
- O
5 O
- O
14 O
* O
* O
] O
11 O
: O
24 O
##pm O
c O
##k O
- O
m O
##b O
- O
not O
##don O
##e O
c O
##tro O
##p O
##nt O
- O
0 O
. O
15 O
* O
[ O
* O
* O
212 O
##0 O
- O
5 O
- O
14 O
* O
* O
] O
11 O
: O
24 O
##pm O
calcium O
- O
8 O
. O
1 O
* O
phosphate O
- O
4 O
. O
4 O
ma O
##gnesium O
- O
2 O
. O
1 O
iron O
- O
172 O
* O
[ O
* O
* O
212 O
##0 O
- O
5 O
- O
14 O
* O
* O
] O
11 O
: O
24 O
##pm O
ca O
##lt O
##ib O
##c O
- O
221 O
v O
##it O
b O
##12 O
- O
greater O
th O
f O
##olate O
- O
greater O
th O
ha O
##pt O
##og O
##lo O
##b O
- O
209 O
* O
f O
##er O
##rit O
##in O
- O
greater O
th O
t O
##rf O
- O
170 O
* O
[ O
* O
* O
212 O
##0 O
- O
5 O
- O
14 O
* O
* O
] O
11 O
: O
24 O
##pm O
w O
##b O
##c O
- O
21 O
. O
9 O
* O
r O
##b O
##c O
- O
3 O
. O
55 O
* O
# O
h O
##g O
##b O
- O
10 O
. O
6 O
* O
# O
h O
##ct O
- O
34 O
. O
3 O
* O
# O
m O
##c O
##v O
- O
97 O
m O
##ch O
- O
30 O
. O
0 O
m O
##ch O
##c O
- O
31 O
. O
0 O
r O
##d O
##w O
- O
14 O
. O
0 O
[ O
* O
* O
212 O
##0 O
- O
5 O
- O
14 O
* O
* O
] O
11 O
: O
24 O
##pm O
ne O
##uts O
- O
93 O
. O
8 O
* O
l O
##ymph O
##s O
- O
3 O
. O
0 O
* O
mon O
##os O
- O
2 O
. O
6 O
e O
##os O
- O
0 O
. O
3 O
b O
##as O
##os O
- O
0 O
. O
2 O
[ O
* O
* O
212 O
##0 O
- O
5 O
- O
14 O
* O
* O
] O
11 O
: O
24 O
##pm O
p O
##lt O
count O
- O
304 O
[ O
* O
* O
212 O
##0 O
- O
5 O
- O
14 O
* O
* O
] O
11 O
: O
24 O
##pm O
p O
##t O
- O
14 O
. O
8 O
* O
p O
##tt O
- O
28 O
. O
7 O
in O
##r O
( O
p O
##t O
) O
- O
1 O
. O
3 O
* O
[ O
* O
* O
212 O
##0 O
- O
5 O
- O
14 O
* O
* O
] O
11 O
: O
24 O
##pm O
fi O
##bri O
##no O
##ge O
- O
33 O
##9 O
[ O
* O
* O
212 O
##0 O
- O
5 O
- O
14 O
* O
* O
] O
11 O
: O
24 O
##pm O
re O
##t O
au O
##t O
- O
1 O
. O
1 O
* O

[ O
* O
* O
212 O
##0 O
- O
5 O
- O
14 O
* O
* O
] O
07 O
: O
00 O
##pm O
urine O
color O
- O
yellow O
appear O
- O
clear O
s O
##p O
[ O
* O
* O
last O
name O
( O
un O
) O
155 O
* O
* O
] O
- O
1 O
. O
01 O
##7 O
[ O
* O
* O
212 O
##0 O
- O
5 O
- O
14 O
* O
* O
] O
07 O
: O
00 O
##pm O
urine O
blood O
- O
ne O
##g O
ni O
##tri O
##te O
- O
ne O
##g O
protein O
- O
30 O
glucose O
- O
100 O
k O
##eton O
##e O
- O
ne O
##g O
bi O
##li O
##ru O
##bin O
- O
ne O
##g O
u O
##ro O
##bil O
##ng O
##n O
- O
ne O
##g O
p O
##h O
- O
5 O
. O
0 O
le O
##uk O
- O
ne O
##g O
[ O
* O
* O
212 O
##0 O
- O
5 O
- O
14 O
* O
* O
] O
07 O
: O
00 O
##pm O
urine O
r O
##b O
##c O
- O
0 O
- O
2 O
w O
##b O
##c O
- O
0 O
- O
2 O
bacteria O
- O
few O
yeast O
- O
none O
e O
##pi O
- O
0 O
- O
2 O
[ O
* O
* O
212 O
##0 O
- O
5 O
- O
14 O
* O
* O
] O
07 O
: O
00 O
##pm O
urine O
am O
##or O
##ph O
- O
few O
[ O
* O
* O
212 O
##0 O
- O
5 O
- O
14 O
* O
* O
] O
06 O
: O
18 O
##pm O
comments O
- O
green O
top O
[ O
* O
* O
212 O
##0 O
- O
5 O
- O
14 O
* O
* O
] O
06 O
: O
18 O
##pm O
la O
##ct O
##ate O
- O
2 O
. O
1 O
* O
[ O
* O
* O
212 O
##0 O
- O
5 O
- O
14 O
* O
* O
] O
06 O
: O
05 O
##pm O
glucose O
- O
92 O
u O
##rea O
n O
- O
38 O
* O
c O
##rea O
##t O
- O
1 O
. O
1 O
sodium O
- O
144 O
potassium O
- O
3 O
. O
4 O
chloride O
- O
123 O
* O
total O
co O
##2 O
- O
12 O
* O
an O
##ion O
gap O
- O
12 O
[ O
* O
* O
212 O
##0 O
- O
5 O
- O
14 O
* O
* O
] O
06 O
: O
05 O
##pm O
est O
##g O
##f O
##r O
- O
using O
this O
[ O
* O
* O
212 O
##0 O
- O
5 O
- O
14 O
* O
* O
] O
06 O
: O
05 O
##pm O
c O
##k O
( O
c O
##p O
##k O
) O
- O
48 O
[ O
* O
* O
212 O
##0 O
- O
5 O
- O
14 O
* O
* O
] O
06 O
: O
05 O
##pm O
c O
##k O
- O
m O
##b O
- O
not O
##don O
##e O
c O
##tro O
##p O
##nt O
- O
0 O
. O
10 O
* O
[ O
* O
* O
212 O
##0 O
- O
5 O
- O
14 O
* O
* O
] O
06 O
: O
05 O
##pm O
calcium O
- O
4 O
. O
3 O
* O
phosphate O
- O
3 O
. O
1 O
ma O
##gnesium O
- O
1 O
. O
2 O
* O
[ O
* O
* O
212 O
##0 O
- O
5 O
- O
14 O
* O
* O
] O
06 O
: O
05 O
##pm O
w O
##b O
##c O
- O
17 O
. O
3 O
* O
# O
r O
##b O
##c O
- O
2 O
. O
57 O
* O
# O
h O
##g O
##b O
- O
7 O
. O
6 O
* O
# O
h O
##ct O
- O
25 O
. O
5 O
* O
# O
m O
##c O
##v O
- O
99 O
* O
m O
##ch O
- O
29 O
. O
4 O
m O
##ch O
##c O
- O
29 O
. O
7 O
* O
r O
##d O
##w O
- O
13 O
. O
9 O

[ O
* O
* O
212 O
##0 O
- O
5 O
- O
14 O
* O
* O
] O
06 O
: O
05 O
##pm O
ne O
##uts O
- O
95 O
. O
4 O
* O
l O
##ymph O
##s O
- O
2 O
. O
7 O
* O
mon O
##os O
- O
1 O
. O
6 O
* O
e O
##os O
- O
0 O
. O
2 O
b O
##as O
##os O
- O
0 O
. O
1 O
[ O
* O
* O
212 O
##0 O
- O
5 O
- O
14 O
* O
* O
] O
06 O
: O
05 O
##pm O
p O
##lt O
count O
- O
238 O
c O
##x O
##r O
( O
portable O
) O
[ O
* O
* O
212 O
##0 O
- O
5 O
- O
14 O
* O
* O
] O
: O
history O
: O
this O
is O
an O
85 O
- O
year O
- O
old O
male O
with O
elevated O
white O
blood O
cell O
count O
, O
h O
##y O
##pot O
##ens O
##ion O
and O
w O
##hee O
##ze O
. O
evaluate O
for O
acute O
process O
. O
comparison O
: O
chest O
radio O
##graph O
[ O
* O
* O
211 O
##4 O
- O
7 O
- O
3 O
* O
* O
] O
. O
single O
portable O
upright O
view O
of O
the O
chest O
: O
there O
is O
no O
change O
in O
the O
card O
##io O
##media O
##st O
##inal O
con O
##tour O
, O
with O
mild O
card O
##io O
##me O
##gal O
##y O
, O
but O
no O
evidence O
for O
ch O
##f O
. O
a O
left O
chest O
pacing O
device O
is O
in O
unchanged O
position O
in O
comparison O
to O
[ O
* O
* O
211 O
##4 O
* O
* O
] O
. O
there O
is O
left O
lung O
base O
ate O
##lect O
##asis O
, O
but O
developing O
infection O
cannot O
be O
completely O
excluded O
. O
the O
bony O
th O
##orax O
appears O
un O
##rem O
##ark O
##able O
. O
impression O
: O
left O
lung O
base O
ate O
##lect O
##asis O
, O
but O
developing O
pneumonia O
cannot O
be O
excluded O
. O
p O
##a O
and O
lateral O
may O
be O
helpful O
for O
further O
evaluation O
if O
clinical O
##ly O
feasible O
. O

brief O
hospital O
course O
: O
# O
shock O
: O
patient O
with O
h B-REA
##y I-REA
##pot I-REA
##ens I-REA
##ion I-REA
requiring O
press B-DRUG
##ors I-DRUG
at O
o O
##sh O
ed O
with O
a O
la O
##ct O
##ate O
2 O
. O
1 O
. O
at O
[ O
* O
* O
hospital O
##1 O
18 O
* O
* O
] O
patient O
was O
re O
##sp O
##ons O
##ive O
to O
i B-DRUG
##v I-DRUG
##f I-DRUG
and O
we O
##ane O
##d O
off O
le B-DRUG
##vo I-DRUG
##phe I-DRUG
##d I-DRUG
. I-DRUG
most O
likely O
se O
##ptic O
given O
mild O
h O
##y O
##pot O
##her O
##mia O
, O
w O
##b O
##c O
17 O
. O
3 O
and O
ne O
##ut O
##rop O
##hil O
##ia O
, O
h O
##y O
##pox O
##ia O
, O
and O
c O
##t O
chest O
finding O
c O
/ O
w O
pneumonia O
. O
while O
it O
is O
possible O
that O
the O
le B-ADE
##uk I-ADE
##oc I-ADE
##yt I-ADE
##osis I-ADE
may O
be O
secondary O
to O
pre B-DRUG
##dn I-DRUG
##ison I-DRUG
##e I-DRUG
, I-DRUG
the O
pre B-DRUG
##dn I-DRUG
##ison I-DRUG
##e I-DRUG
may O
also O
be O
mask O
##ing O
a O
fever O
. O
treated O
empirical O
##ly O
with O
van B-DRUG
##c I-DRUG
, I-DRUG
z B-DRUG
##osy I-DRUG
##n I-DRUG
with O
rapid O
imp O
##rov O
##ment O
. O
there O
may O
have O
also O
been O
a O
component O
of O
h B-REA
##y I-REA
##po I-REA
##vo I-REA
##lem I-REA
##ia I-REA
in O
setting O
of O
decreased O
oral O
intake O
at O
[ O
* O
* O
hospital O
##1 O
150 O
##1 O
* O
* O
] O
given O
response O
to O
i B-DRUG
##v I-DRUG
##f I-DRUG
. I-DRUG
p O
##t O
has O
only O
been O
on O
short B-DOS
tape I-DOS
##r I-DOS
of O
pre B-DRUG
##dn I-DRUG
##ison I-DRUG
##e I-DRUG
so O
less O
likely O
ad O
##rena O
##l O
ins O
##uff O
##iciency O
although O
did O
receive O
h B-DRUG
##ydro I-DRUG
##cor I-DRUG
##tis I-DRUG
##one I-DRUG
at O
o O
##sh O
. O
p O
##t O
with O
elevated O
t O
##rop O
##oni O
##n O
but O
less O
likely O
card O
##io O
##genic O
shock O
- O
may O
more O
likely O
represent O
end O
organ O
damage O
from O
h O
##y O
##pop O
##er O
##fusion O
; O
no O
evidence O
of O
ch O
##f O
and O
b O
##p O
unlikely O
to O
reverse O
so O
quickly O
. O
he O
was O
never O
again O
h O
##y O
##pot O
##ens O
##ive O
on O
the O
floor O
and O
his O
white B-REA
count I-REA
resolved O
with O
i B-ROU
##v I-ROU
a B-DRUG
##b I-DRUG
##x I-DRUG
. I-DRUG
we O
were O
never O
100 O
% O
convinced O
that O
this O
was O
from O
pneumonia O
and O
a O
foot O
c O
##t O
was O
checked O
prior O
to O
discharge O
to O
r O
/ O
o O
o O
##ste O
##omy O
##eli O
##tis O
which O
showed O
no O
evidence O
of O
o O
##ste O
##omy O
##eli O
##tis O
. O
all O
cultures O
were O
negative O
. O
. O
plan O
going O
forward O
: O
- O
complete O
14 B-DUR
##day I-DUR
course O
of O
broad B-DRUG
spectrum I-DRUG
a I-DRUG
##b I-DRUG
##x I-DRUG
( O
last O
day O
[ O
* O
* O
5 O
- O
28 O
* O
* O
] O
) O
- O
patient O
must O
have O
c O
##x O
##r O
in O
1 O
month O
to O
f O
/ O
u O
for O
complete O
resolution O
of O
his O
p O
##na O
/ O
r O
/ O
o O
underlying O
ma O
##li O
##gna O
##ncy O
. O
. O
# O
h O
##y O
##pox O
##ia O
: O
patient O
quickly O
we O
##ane O
##d O
from O
n O
##rb O
to O
n O
##c O
to O
room O
air O
. O
this O
was O
likely O
related O
to O
pneumonia O
, O
though O
volume O
over O
##load O
from O
re O
##sus O
##citation O
can O
not O
be O
excluded O
, O
or O
any O
contribution O
from O
his O
underlying O
lung O
disease O
. O
. O

# O
ca O
##d O
: O
n O
##l O
c O
##k O
but O
elevated O
t O
##rop O
likely O
represents O
demand O
in O
setting O
of O
a O
##rf O
and O
h O
##y O
##pop O
##er O
##fusion O
rather O
than O
an O
o O
##cc O
##lus O
##ive O
les O
##ion O
. O
the O
patient O
peaked O
and O
ruled O
out O
on O
labs O
in O
house O
. O
e O
##k O
##g O
was O
paced O
and O
c O
/ O
w O
prior O
. O
per O
son O
, O
recent O
stress O
test O
un O
##rem O
##ark O
##able O
. O
. O
# O
d B-REA
##m I-REA
: I-REA
patient O
had O
issues O
with O
o O
/ O
n O
low O
blood O
sugar O
##s O
, O
[ O
* O
* O
last O
name O
( O
un O
) O
* O
* O
] O
was O
consulted O
, O
we O
dialed O
back O
his O
pm B-FRE
hum B-DRUG
##alog I-DRUG
and O
la B-DRUG
##nt I-DRUG
##us I-DRUG
and O
his O
blood O
sugar O
control O
op O
##ti O
##mized O
. O
. O
# O
an O
##emia O
: O
h O
##ct O
here O
25 O
. O
5 O
, O
was O
32 O
. O
3 O
at O
o O
##sh O
. O
p O
##t O
is O
on O
as B-DRUG
##a I-DRUG
and O
p B-DRUG
##lav I-DRUG
##ix I-DRUG
but O
g O
##ua O
##iac O
negative O
, O
no O
evidence O
of O
active O
bleeding O
. O
concern O
for O
di O
##c O
in O
setting O
of O
se O
##psis O
although O
p O
##t O
currently O
appears O
well O
. O
[ O
* O
* O
month O
( O
only O
) O
116 O
* O
* O
] O
have O
been O
hem O
##oc O
##on O
##cent O
##rated O
at O
o O
##sh O
and O
now O
di O
##lut O
##ed O
in O
setting O
of O
4 B-DOS
##l I-DOS
i B-DRUG
##v I-DRUG
##f I-DRUG
. I-DRUG
patient O
drifted O
back O
up O
to O
33 O
without O
intervention O
. O
# O
toe O
pain O
: O
recently O
s O
/ O
p O
ll O
##e O
s O
##ten O
##ting O
; O
em O
##bolic O
event O
possible O
, O
but O
this O
was O
thought O
to O
be O
most O
likely O
go O
##ut O
in O
house O
. O
prior O
noted O
m O
##ott O
##ling O
more O
likely O
d O
/ O
t O
shock O
than O
em O
##bol O
##us O
however O
as O
b O
/ O
l O
and O
appears O
to O
be O
improving O
w O
/ O
fluid O
re O
##sus O
##citation O
. O
no O
acute O
inflammation O
concerning O
for O
go B-REA
##ut I-REA
although O
has O
been O
on O
pre B-DRUG
##dn I-DRUG
##ison I-DRUG
##e I-DRUG
. I-DRUG
pain O
unchanged O
per O
p O
##t O
. O
he O
underwent O
c O
##t O
foot O
to O
r O
/ O
o O
o O
##ste O
##omy O
##eli O
##tis O
or O
o O
##ste O
##one O
##c O
##rosis O
as O
a O
source O
, O
this O
instead O
showed O
evidence O
of O
pseudo O
##go O
##ut O
and O
o O
##ste O
##oar O
##th O
##rit O
##is O
. O
. O
plan O
going O
forward O
: O
patient O
has O
follow O
- O
up O
scheduled O
with O
r O
##he O
##uma O
##tology O
. O
# O
d B-REA
##v I-REA
##t I-REA
/ I-REA
? O
p B-REA
##e I-REA
: I-REA
patient O
found O
to O
have O
rue O
d O
##v O
##t O
on O
exam O
, O
later O
found O
to O
have O
ll O
##l O
consolidation O
with O
resolution O
of O
rue O
swelling O
. O
most O
l O
##ik O
##ley O
p B-REA
##e I-REA
. I-REA
patient O
to O
continue O
love B-DRUG
##no I-DRUG
##x I-DRUG
. I-DRUG
. O
plan O
going O
forward O
: O
patient O
to O
continue O
[ O
* O
* O
hospital O
##1 O
* O
* O
] O
love B-DRUG
##no I-DRUG
##x I-DRUG
for O
[ O
* O
* O
4 O
- O
13 O
* O
* O
] O
m O
##o O
, O
pending O
p O
##c O
##p O
f O
/ O
u O
. O
u B-ADE
##rina I-ADE
##ry I-ADE
retention I-ADE
: I-ADE
patient O
developed O
new O
u B-ADE
##rina I-ADE
##ry I-ADE
retention I-ADE
while O
in O
house O
. O
this O
was O
felt O
to O
be O
secondary O
to O
o B-DRUG
##xy I-DRUG
##co I-DRUG
##don I-DRUG
##e I-DRUG
which O
was O
stopped O
. O
a O
f O
##ole O
##y O
was O
placed O
on O
the O
day O
prior O
to O
d O
/ O
c O
and O
the O
patient O
was O
started O
on O
fl B-DRUG
##oma I-DRUG
##x I-DRUG
. I-DRUG
. O

plan O
going O
forward O
: O
f O
##ole O
##y O
to O
be O
d O
/ O
c O
' O
d O
in O
3 O
days O
, O
patient O
must O
void O
spontaneous O
##ly O
8 O
- O
10 O
hours O
following O
the O
removal O
. O
if O
he O
does O
not O
void O
the O
floor O
physician O
must O
be O
consulted O
. O
medications O
on O
admission O
: O
medications O
: O
per O
n O
##h O
notes O
pre B-DRUG
##dn I-DRUG
##ison I-DRUG
##e I-DRUG
40 B-STR
##m I-STR
##g I-STR
x B-DUR
2 I-DUR
days I-DUR
, I-DUR
30 B-STR
##m I-STR
##g I-STR
x B-DUR
3 I-DUR
days I-DUR
( O
completed O
) O
, O
then O
pre B-DRUG
##dn I-DRUG
##ison I-DRUG
##e I-DRUG
20 B-STR
##m I-STR
##g I-STR
x B-DUR
3 I-DUR
days I-DUR
, I-DUR
10 B-STR
##m I-STR
##g I-STR
x B-DUR
3 I-DUR
##day I-DUR
##s I-DUR
v B-DRUG
##ico I-DRUG
##din I-DRUG
5 B-STR
/ I-STR
500 I-STR
[ O
* O
* O
2 O
- O
10 O
* O
* O
] O
ta B-FOR
##b I-FOR
q B-FRE
##6 I-FRE
##h I-FRE
p I-FRE
##rn I-FRE
pain B-REA
la B-DRUG
##nt I-DRUG
##us I-DRUG
50 B-STR
units I-STR
sq B-ROU
q B-FRE
##hs I-FRE
( O
previously O
on O
28 B-DOS
units I-DOS
) I-DOS
di B-DRUG
##ova I-DRUG
##n I-DRUG
20 B-STR
##m I-STR
##g I-STR
daily B-FRE
ve B-DRUG
##rap I-DRUG
##ami I-DRUG
##l I-DRUG
120 B-STR
##m I-STR
##g I-STR
daily B-FRE
pu B-DRUG
##lm I-DRUG
##ico I-DRUG
##rt I-DRUG
200 B-STR
m I-STR
##c I-STR
##g I-STR
2 B-DOS
pu B-FOR
##ffs I-FOR
in B-ROU
##h I-ROU
[ O
* O
* O
hospital O
##1 O
* O
* O
] O
( O
4 B-DOS
pu B-FOR
##ffs I-FOR
[ O
* O
* O
hospital O
##1 O
* O
* O
] O
per O
p O
##t O
) O
[ B-DRUG
* I-DRUG
* I-DRUG
name I-DRUG
( I-DRUG
ni I-DRUG
) I-DRUG
44 I-DRUG
##40 I-DRUG
##5 I-DRUG
* I-DRUG
* I-DRUG
] I-DRUG
50 B-STR
m I-STR
##c I-STR
##g I-STR
2 B-DOS
pu B-FOR
##ffs I-FOR
[ O
* O
* O
hospital O
##1 O
* O
* O
] O
s B-DRUG
##pi I-DRUG
##ri I-DRUG
##va I-DRUG
18 B-STR
m I-STR
##c I-STR
##g I-STR
q O
pu B-FOR
##ff I-FOR
in B-FOR
##hale I-FOR
##r I-FOR
daily B-FRE
as B-DRUG
##a I-DRUG
81 B-STR
##m I-STR
##g I-STR
daily B-FRE
p B-DRUG
##lav I-DRUG
##ix I-DRUG
75 B-STR
##m I-STR
##g I-STR
daily B-FRE
met B-DRUG
##op I-DRUG
##rol I-DRUG
##ol I-DRUG
50 B-STR
##m I-STR
##g I-STR
[ O
* O
* O
hospital O
##1 O
* O
* O
] O
er B-DRUG
##yt I-DRUG
##hr I-DRUG
##omy I-DRUG
##cin I-DRUG
500 B-STR
##m I-STR
##g I-STR
q B-FRE
##8 I-FRE
##h I-FRE
x B-DUR
7 I-DUR
days I-DUR
( O
unclear O
why O
) O

discharge O
medications O
: O
1 O
. O
bi B-DRUG
##sa I-DRUG
##co I-DRUG
##dy I-DRUG
##l I-DRUG
5 B-STR
mg I-STR
tablet B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
si O
##g O
: O
two B-DOS
( I-DOS
2 I-DOS
) I-DOS
tablet B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
p B-ROU
##o I-ROU
daily B-FRE
( I-FRE
daily I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
con B-REA
##st I-REA
##ip I-REA
##ation I-REA
. I-REA
2 O
. O
comb B-DRUG
##ive I-DRUG
##nt I-DRUG
18 B-STR
- I-STR
103 I-STR
m I-STR
##c I-STR
##g I-STR
/ I-STR
act I-STR
##uation I-STR
a B-FOR
##ero I-FOR
##sol I-FOR
si O
##g O
: O
two B-DOS
( I-DOS
2 I-DOS
) I-DOS
pu B-FOR
##ffs I-FOR
in B-ROU
##hala I-ROU
##tion I-ROU
every B-FRE
4 I-FRE
- I-FRE
6 I-FRE
hours I-FRE
as I-FRE
needed I-FRE
for O
short B-REA
##ness I-REA
of I-REA
breath I-REA
or O
w B-REA
##hee I-REA
##zing I-REA
. I-REA
3 O
. O
c B-DRUG
##lop I-DRUG
##ido I-DRUG
##g I-DRUG
##rel I-DRUG
75 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( I-FRE
daily I-FRE
) I-FRE
. I-FRE
4 O
. O
as B-DRUG
##pi I-DRUG
##rin I-DRUG
325 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( I-FRE
daily I-FRE
) I-FRE
. I-FRE
5 O
. O
pan B-DRUG
##top I-DRUG
##raz I-DRUG
##ole I-DRUG
40 B-STR
mg I-STR
tablet B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
p B-ROU
##o I-ROU
q B-FRE
##24 I-FRE
##h I-FRE
( I-FRE
every I-FRE
24 I-FRE
hours I-FRE
) I-FRE
. I-FRE
6 O
. O
do B-DRUG
##cus I-DRUG
##ate I-DRUG
sodium I-DRUG
100 B-STR
mg I-STR
capsule B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
capsule B-FOR
p B-ROU
##o I-ROU
bid B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE
7 O
. O
met B-DRUG
##op I-DRUG
##rol I-DRUG
##ol I-DRUG
ta I-DRUG
##rt I-DRUG
##rate I-DRUG
25 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
0 B-DOS
. I-DOS
5 I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
bid B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE
8 O
. O
ma B-DRUG
##gnesium I-DRUG
h I-DRUG
##ydro I-DRUG
##xi I-DRUG
##de I-DRUG
400 B-STR
mg I-STR
/ I-STR
5 I-STR
m I-STR
##l I-STR
suspension B-FOR
si O
##g O
: O
thirty B-DOS
( I-DOS
30 I-DOS
) I-DOS
m I-DOS
##l I-DOS
p B-ROU
##o I-ROU
q B-FRE
##6 I-FRE
##h I-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
con B-REA
##st I-REA
##ip I-REA
##ation I-REA
. I-REA
9 O
. O
c B-DRUG
##ip I-DRUG
##ro I-DRUG
##f I-DRUG
##lo I-DRUG
##xa I-DRUG
##cin I-DRUG
500 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
q B-FRE
##12 I-FRE
##h I-FRE
( I-FRE
every I-FRE
12 I-FRE
hours I-FRE
) I-FRE
for B-DUR
4 I-DUR
days I-DUR
: I-DUR
last O
dose O
4 O
/ O
20 O
. O
10 O
. O
se B-DRUG
##nna I-DRUG
8 B-STR
. I-STR
6 I-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
bid B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE
11 O
. O
pipe B-DRUG
##rac I-DRUG
##ill I-DRUG
##in I-DRUG
- I-DRUG
ta I-DRUG
##zo I-DRUG
##ba I-DRUG
##ct I-DRUG
##am I-DRUG
- I-DRUG
de I-DRUG
##x I-DRUG
##tr I-DRUG
##s I-DRUG
4 B-STR
. I-STR
5 I-STR
gram I-STR
/ I-STR
100 I-STR
m I-STR
##l I-STR
pig B-FOR
##gy I-FOR
##back I-FOR
si O
##g O
: O
4 B-STR
. I-STR
5 I-STR
grams I-STR
in B-ROU
##tra I-ROU
##ven I-ROU
##ous I-ROU
q B-FRE
##8 I-FRE
##h I-FRE
( I-FRE
every I-FRE
8 I-FRE
hours I-FRE
) I-FRE
for B-DUR
4 I-DUR
days I-DUR
: I-DUR
last O
dose O
4 O
/ O
20 O
. O
12 O
. O
van B-DRUG
##com I-DRUG
##y I-DRUG
##cin I-DRUG
500 B-STR
mg I-STR
re B-FOR
##con I-FOR
so I-FOR
##ln I-FOR
si O
##g O
: O
1000 B-STR
( I-STR
1000 I-STR
) I-STR
mg I-STR
in B-ROU
##tra I-ROU
##ven I-ROU
##ous I-ROU
q B-FRE
24 I-FRE
##h I-FRE
( I-FRE
every I-FRE
24 I-FRE
hours I-FRE
) I-FRE
for B-DUR
4 I-DUR
days I-DUR
: I-DUR
should O
finish O
[ O
* O
* O
5 O
- O
28 O
* O
* O
] O
. O
. O

13 O
. O
insulin B-DRUG
g I-DRUG
##lar I-DRUG
##gin I-DRUG
##e I-DRUG
100 B-STR
unit I-STR
/ I-STR
m I-STR
##l I-STR
cartridge B-FOR
si O
##g O
: O
twenty B-DOS
four I-DOS
( I-DOS
24 I-DOS
) I-DOS
units I-DOS
sub B-ROU
##cut I-ROU
##aneous I-ROU
at B-FRE
bed I-FRE
##time I-FRE
. I-FRE
14 O
. O
pu B-DRUG
##lm I-DRUG
##ico I-DRUG
##rt I-DRUG
fl I-DRUG
##ex I-DRUG
##hale I-DRUG
##r I-DRUG
180 B-STR
m I-STR
##c I-STR
##g I-STR
/ I-STR
in I-STR
##hala I-STR
##tion I-STR
a B-FOR
##ero I-FOR
##sol I-FOR
p I-FOR
##ow I-FOR
##dr I-FOR
breath I-FOR
activated I-FOR
si O
##g O
: O
two B-DOS
( I-DOS
2 I-DOS
) I-DOS
pu B-FOR
##ffs I-FOR
in B-ROU
##hala I-ROU
##tion I-ROU
twice B-FRE
a I-FRE
day I-FRE
. I-FRE
15 O
. O
sa B-DRUG
##lm I-DRUG
##eter I-DRUG
##ol I-DRUG
50 B-STR
m I-STR
##c I-STR
##g I-STR
/ I-STR
dose I-STR
disk B-FOR
with I-FOR
device I-FOR
si O
##g O
: O
two B-DOS
( I-DOS
2 I-DOS
) I-DOS
pu B-FOR
##ffs I-FOR
in B-ROU
##hala I-ROU
##tion I-ROU
twice B-FRE
a I-FRE
day I-FRE
. I-FRE
16 O
. O
s B-DRUG
##pi I-DRUG
##ri I-DRUG
##va I-DRUG
with I-DRUG
hand I-DRUG
##ih I-DRUG
##ale I-DRUG
##r I-DRUG
18 B-STR
m I-STR
##c I-STR
##g I-STR
capsule B-FOR
, I-FOR
w I-FOR
/ I-FOR
in I-FOR
##hala I-FOR
##tion I-FOR
device I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
pu B-FOR
##ff I-FOR
in B-ROU
##hala I-ROU
##tion I-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE
17 O
. O
insulin B-DRUG
as I-DRUG
##par I-DRUG
##t I-DRUG
100 B-STR
unit I-STR
/ I-STR
m I-STR
##l I-STR
cartridge B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
as O
directed O
sub B-ROU
##cut I-ROU
##aneous I-ROU
q B-FRE
##ach I-FRE
##s I-FRE
: I-FRE
as O
per O
attached O
sliding B-DOS
scale I-DOS
. I-DOS
18 O
. O
v B-DRUG
##als I-DRUG
##art I-DRUG
##an I-DRUG
40 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
0 B-DOS
. I-DOS
5 I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( I-FRE
daily I-FRE
) I-FRE
. I-FRE
19 O
. O
si B-DRUG
##m I-DRUG
##vas I-DRUG
##tat I-DRUG
##in I-DRUG
10 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
two B-DOS
( I-DOS
2 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( I-FRE
daily I-FRE
) I-FRE
. I-FRE
20 O
. O
ta B-DRUG
##ms I-DRUG
##ulos I-DRUG
##in I-DRUG
0 B-STR
. I-STR
4 I-STR
mg I-STR
capsule B-FOR
, I-FOR
su I-FOR
##st I-FOR
. I-FOR
release I-FOR
24 I-FOR
h I-FOR
##r I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
capsule B-FOR
, I-FOR
su I-FOR
##st I-FOR
. I-FOR
release I-FOR
24 I-FOR
h I-FOR
##r I-FOR
p B-ROU
##o I-ROU
at B-FRE
bed I-FRE
##time I-FRE
. I-FRE
21 O
. O
en B-DRUG
##ox I-DRUG
##apa I-DRUG
##rin I-DRUG
100 B-STR
mg I-STR
/ I-STR
m I-STR
##l I-STR
s B-FOR
##yr I-FOR
##inge I-FOR
si O
##g O
: O
ninety B-DOS
( I-DOS
90 I-DOS
) I-DOS
units I-DOS
sub B-ROU
##cut I-ROU
##aneous I-ROU
q B-FRE
##12 I-FRE
##h I-FRE
( I-FRE
every I-FRE
12 I-FRE
hours I-FRE
) I-FRE
. I-FRE
22 O
. O
ace B-DRUG
##tam I-DRUG
##ino I-DRUG
##phe I-DRUG
##n I-DRUG
500 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
1 B-DOS
- I-DOS
2 I-DOS
tablets B-FOR
p B-ROU
##o I-ROU
q B-FRE
##6 I-FRE
##h I-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
. I-REA
23 O
. O
chest O
x O
##ray O
patient O
must O
have O
f O
/ O
u O
c O
##x O
##r O
1 O
m O
##o O
. O
following O
discharge O
from O
hospital O
. O
discharge O
disposition O
: O
extended O
care O
facility O
: O
[ O
* O
* O
location O
( O
un O
) O
58 O
##2 O
* O
* O
] O
at O
silver O
[ O
* O
* O
doctor O
last O
name O
* O
* O
] O
common O
##s O
discharge O
diagnosis O
: O
se O
##ptic O
shock O
pneumonia O
go O
##ut O
flare O
discharge O
condition O
: O
mental O
status O
: O
clear O
and O
coherent O
. O
level O
of O
consciousness O
: O
alert O
and O
interactive O
. O
activity O
status O
: O
am O
##bula O
##tory O
- O
requires O
assistance O
or O
aid O
( O
walk O
##er O
or O
cane O
) O
. O

discharge O
instructions O
: O
you O
were O
admitted O
to O
[ O
* O
* O
hospital O
##1 O
* O
* O
] O
after O
you O
were O
found O
to O
be O
se O
##ver O
##ly O
ill O
at O
your O
rehabilitation O
center O
. O
you O
were O
briefly O
in O
the O
i O
##cu O
where O
you O
were O
found O
to O
be O
h O
##y O
##pot O
##ens O
##ive O
and O
have O
a O
condition O
known O
as O
se B-REA
##ptic I-REA
shock I-REA
. I-REA
this O
was O
thought O
to O
be O
caused O
by O
pneumonia B-REA
. I-REA
you O
improved O
quickly O
with O
i B-ROU
##v I-ROU
anti B-DRUG
##biotics I-DRUG
. I-DRUG
you O
also O
developed O
a O
blood B-REA
c I-REA
##lot I-REA
in O
the O
hospital O
for O
which O
you O
are O
being O
treated O
with O
a O
blood O
thinner O
called O
love B-DRUG
##no I-DRUG
##x I-DRUG
. I-DRUG
you O
were O
monitored O
on O
the O
floor O
and O
aside O
from O
toe O
pain O
you O
had O
not O
other O
major O
issues O
. O
. O
the O
following O
changes O
were O
made O
to O
your O
medication O
regime O
##n O
: O
your O
anti B-DRUG
##biotics I-DRUG
will O
be O
completed O
on O
[ O
* O
* O
212 O
##0 O
- O
5 O
- O
28 O
* O
* O
] O
you O
completed O
your O
pre B-DRUG
##dn I-DRUG
##ison I-DRUG
##e I-DRUG
course O
we O
believe O
that O
o B-DRUG
##xy I-DRUG
##co I-DRUG
##don I-DRUG
##e I-DRUG
was O
causing O
you O
to O
retain B-ADE
urine I-ADE
, I-ADE
we O
stopped O
the O
o B-DRUG
##xy I-DRUG
##co I-DRUG
##don I-DRUG
##e I-DRUG
and O
started O
you O
on O
t B-DRUG
##yle I-DRUG
##no I-DRUG
##l I-DRUG
. I-DRUG
your O
bed B-FRE
##time I-FRE
la B-DRUG
##nt I-DRUG
##us I-DRUG
was O
reduced O
to O
24 B-STR
##m I-STR
##g I-STR
. I-STR
your O
met B-DRUG
##op I-DRUG
##rol I-DRUG
##ol I-DRUG
was O
reduced O
to O
12 B-STR
. I-STR
5 I-STR
##m I-STR
##g I-STR
twice B-FRE
per I-FRE
day I-FRE
you O
were O
started O
on O
love B-DRUG
##no I-DRUG
##x I-DRUG
90 B-STR
##m I-STR
##g I-STR
twice B-FRE
per I-FRE
day I-FRE
follow O
##up O
instructions O
: O
department O
: O
r O
##he O
##uma O
##tology O
when O
: O
wed O
##nes O
##day O
[ O
* O
* O
212 O
##0 O
- O
5 O
- O
29 O
* O
* O
] O
at O
1 O
pm O
with O
: O
[ O
* O
* O
first O
name O
##8 O
( O
name O
##pa O
##tter O
##n O
##2 O
) O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
* O
* O
] O
, O
m O
##d O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
222 O
##6 O
* O
* O
] O
building O
: O
l O
##m O
[ O
* O
* O
hospital O
unit O
name O
* O
* O
] O
[ O
* O
* O
location O
( O
un O
) O
86 O
##1 O
* O
* O
] O
campus O
: O
west O
best O
parking O
: O
[ O
* O
* O
doctor O
first O
name O
* O
* O
] O
. O
garage O
. O
department O
: O
[ O
* O
* O
last O
name O
( O
un O
) O
* O
* O
] O
diabetes O
center O
when O
: O
[ O
* O
* O
212 O
##0 O
- O
6 O
- O
3 O
* O
* O
] O
10 O
: O
00 O
##am O
with O
: O
n O
##p O
[ O
* O
* O
first O
name O
##8 O
( O
name O
##pa O
##tter O
##n O
##2 O
) O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
72 O
##80 O
* O
* O
] O
location O
: O
[ O
* O
* O
last O
name O
( O
un O
) O
39 O
##11 O
* O
* O
] O
, O
[ O
* O
* O
location O
( O
un O
) O
86 O
* O
* O
] O
ma O
phone O
: O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
238 O
##4 O
* O
* O
] O
completed O
by O
: O
[ O
* O
* O
212 O
##0 O
- O
5 O
- O
24 O
* O
* O
] O

admission O
date O
: O
[ O
* O
* O
217 O
##3 O
- O
7 O
- O
26 O
* O
* O
] O
discharge O
date O
: O
[ O
* O
* O
217 O
##3 O
- O
8 O
- O
5 O
* O
* O
] O
date O
of O
birth O
: O
[ O
* O
* O
210 O
##3 O
- O
8 O
- O
12 O
* O
* O
] O
sex O
: O
f O
service O
: O
ne O
##uro O
##logy O
all O
##er O
##gies O
: O
l B-DRUG
##isi I-DRUG
##no I-DRUG
##p I-DRUG
##ril I-DRUG
/ O
at B-DRUG
##or I-DRUG
##vas I-DRUG
##tat I-DRUG
##in I-DRUG
attending O
: O
[ O
* O
* O
first O
name O
##3 O
( O
l O
##f O
) O
58 O
##6 O
##8 O
* O
* O
] O
chief O
complaint O
: O
large O
left O
tempo O
##ro O
- O
par O
##iet O
##al O
bleed O
major O
surgical O
or O
invasive O
procedure O
: O
t O
##rac O
##he O
##ost O
##omy O
p O
##eg O
tube O
placement O
history O
of O
present O
illness O
: O
the O
patient O
a O
69 O
year O
old O
woman O
with O
a O
history O
of O
h O
##yper O
##tens O
##ion O
, O
diabetes O
, O
and O
dem O
##ent O
##ia O
now O
presenting O
on O
transfer O
from O
[ O
* O
* O
hospital O
##3 O
* O
* O
] O
hospital O
with O
a O
large O
left O
tempo O
##ro O
- O
par O
##iet O
##al O
bleed O
. O
the O
details O
of O
her O
history O
are O
sparse O
and O
are O
taken O
primarily O
from O
her O
o O
##sh O
chart O
. O
she O
presented O
originally O
on O
[ O
* O
* O
7 O
- O
22 O
* O
* O
] O
complaining O
of O
worse O
##ned O
short O
##ness O
of O
breath O
and O
generalized O
weakness O
. O
a O
tentative O
diagnosis O
of O
pulmonary B-REA
em I-REA
##bol I-REA
##us I-REA
was O
made O
and O
she O
was O
treated O
with O
love B-DRUG
##no I-DRUG
##x I-DRUG
. I-DRUG
she O
was O
also O
noted O
to O
be O
f O
##eb O
##ril O
##e O
and O
to O
have O
s O
##lu O
##rred O
speech O
on O
admission O
. O
today O
, O
the O
medical O
staff O
noticed O
that O
the O
patient O
was O
not O
moving O
her O
right O
side O
and O
was O
" O
relatively O
un O
##res O
##po O
##ns O
##ive O
. O
" O
a O
head O
c O
##t O
was O
then O
performed O
which O
showed O
a O
large O
bleed O
as O
described O
above O
. O
arrangements O
were O
made O
to O
transfer O
her O
to O
[ O
* O
* O
hospital O
##1 O
18 O
* O
* O
] O
for O
i O
##cu O
level O
care O
. O
review O
of O
systems O
: O
- O
un O
##ob O
##tain O
##able O
past O
medical O
history O
: O
- O
diabetes O
- O
h O
##yper O
##tens O
##ion O
- O
depression O
- O
as O
##th O
##ma O
- O
peripheral O
ne O
##uro O
##pathy O
- O
dem O
##ent O
##ia O
social O
history O
: O
- O
resident O
of O
[ O
* O
* O
hospital O
##6 O
257 O
##5 O
##9 O
* O
* O
] O
home O
- O
no O
recent O
history O
of O
smoking O
or O
alcohol O
use O
family O
history O
: O
- O
un O
##ob O
##tain O
##able O
physical O
exam O
: O
vital O
##s O
: O
99 O
. O
6 O
88 O
150 O
/ O
70 O
28 O
97 O
% O
on O
2 O
##l O
general O
: O
well O
no O
##uri O
##shed O
, O
in O
no O
acute O
distress O
neck O
: O
su O
##pp O
##le O
lungs O
: O
poor O
air O
movement O
throughout O
all O
lung O
fields O
c O
##v O
: O
regular O
rate O
and O
rhythm O
abdomen O
: O
non O
- O
tender O
, O
non O
- O
di O
##sten O
##ded O
, O
bow O
##el O
sounds O
present O
ex O
##t O
: O
warm O
, O
no O
ed O
##ema O

ne O
##uro O
##log O
##ic O
examination O
: O
left O
gaze O
preference O
; O
minimal O
response O
to O
voice O
, O
will O
look O
toward O
the O
left O
side O
if O
yell O
at O
her O
; O
grim O
##ma O
##ces O
to O
stern O
##al O
rub O
; O
pupils O
1 O
mm O
and O
minimal O
##ly O
reactive O
to O
light O
; O
corn O
##eal O
reflex O
decreased O
on O
right O
side O
; O
mild O
right O
facial O
d O
##roo O
##p O
; O
weak O
gag O
reflex O
; O
spontaneous O
movement O
on O
left O
, O
none O
on O
right O
; O
withdraw O
##s O
to O
pain O
on O
left O
, O
minimal O
response O
on O
right O
; O
toe O
up O
##going O
on O
right O
; O
reflex O
##es O
decreased O
throughout O
; O

per O
##tinent O
results O
: O
[ O
* O
* O
217 O
##3 O
- O
7 O
- O
26 O
* O
* O
] O
06 O
: O
00 O
##pm O
p O
##t O
- O
12 O
. O
0 O
p O
##tt O
- O
31 O
. O
9 O
in O
##r O
( O
p O
##t O
) O
- O
1 O
. O
0 O
[ O
* O
* O
217 O
##3 O
- O
7 O
- O
26 O
* O
* O
] O
06 O
: O
00 O
##pm O
p O
##lt O
count O
- O
193 O
[ O
* O
* O
217 O
##3 O
- O
7 O
- O
26 O
* O
* O
] O
06 O
: O
00 O
##pm O
w O
##b O
##c O
- O
12 O
. O
6 O
* O
r O
##b O
##c O
- O
3 O
. O
39 O
* O
h O
##g O
##b O
- O
10 O
. O
0 O
* O
h O
##ct O
- O
30 O
. O
5 O
* O
m O
##c O
##v O
- O
90 O
m O
##ch O
- O
29 O
. O
6 O
m O
##ch O
##c O
- O
32 O
. O
9 O
r O
##d O
##w O
- O
13 O
. O
1 O
[ O
* O
* O
217 O
##3 O
- O
7 O
- O
26 O
* O
* O
] O
06 O
: O
00 O
##pm O
calcium O
- O
9 O
. O
0 O
phosphate O
- O
3 O
. O
8 O
ma O
##gnesium O
- O
1 O
. O
7 O
[ O
* O
* O
217 O
##3 O
- O
7 O
- O
26 O
* O
* O
] O
06 O
: O
00 O
##pm O
glucose O
- O
235 O
* O
u O
##rea O
n O
- O
32 O
* O
c O
##rea O
##t O
- O
1 O
. O
4 O
* O
sodium O
- O
140 O
potassium O
- O
4 O
. O
3 O
chloride O
- O
100 O
total O
co O
##2 O
- O
30 O
* O
an O
##ion O
gap O
- O
14 O
[ O
* O
* O
217 O
##3 O
- O
7 O
- O
26 O
* O
* O
] O
06 O
: O
29 O
##pm O
free O
##ca O
- O
1 O
. O
18 O
[ O
* O
* O
217 O
##3 O
- O
7 O
- O
26 O
* O
* O
] O
06 O
: O
29 O
##pm O
la O
##ct O
##ate O
- O
1 O
. O
4 O
[ O
* O
* O
217 O
##3 O
- O
7 O
- O
26 O
* O
* O
] O
06 O
: O
29 O
##pm O
type O
- O
art O
te O
##mp O
- O
38 O
. O
1 O
p O
##o O
##2 O
- O
94 O
p O
##co O
##2 O
- O
74 O
* O
p O
##h O
- O
7 O
. O
28 O
* O
total O
co O
##2 O
- O
36 O
* O
base O
x O
##s O
- O
4 O
in O
##tub O
##ated O
- O
not O
in O
##tub O
##a O
[ O
* O
* O
217 O
##3 O
- O
7 O
- O
26 O
* O
* O
] O
08 O
: O
11 O
##pm O
o O
##2 O
sat O
- O
99 O
[ O
* O
* O
217 O
##3 O
- O
7 O
- O
26 O
* O
* O
] O
08 O
: O
11 O
##pm O
glucose O
- O
197 O
* O
[ O
* O
* O
217 O
##3 O
- O
7 O
- O
26 O
* O
* O
] O
08 O
: O
11 O
##pm O
type O
- O
art O
p O
##o O
##2 O
- O
405 O
* O
p O
##co O
##2 O
- O
47 O
* O
p O
##h O
- O
7 O
. O
36 O
total O
co O
##2 O
- O
28 O
base O
x O
##s O
- O
0 O
in O
##tub O
##ated O
- O
in O
##tub O
##ated O
. O
. O

head O
c O
##t O
[ O
* O
* O
217 O
##3 O
- O
7 O
- O
26 O
* O
* O
] O
: O
there O
is O
a O
large O
in O
##tra O
##par O
##en O
##chy O
##mal O
hem O
##or O
##r O
##hage O
in O
the O
left O
front O
##op O
##ari O
##etal O
region O
with O
extension O
into O
the O
vent O
##ric O
##ular O
system O
. O
there O
is O
a O
moderate O
amount O
of O
ed O
##ema O
surrounding O
this O
hem O
##or O
##r O
##hage O
and O
there O
is O
mass O
effect O
and O
approximately O
1 O
. O
4 O
cm O
of O
mid O
##line O
shift O
to O
the O
right O
. O
there O
is O
sub O
##fa O
##l O
##cine O
her O
##nia O
##tion O
. O
blood O
is O
seen O
in O
the O
left O
lateral O
vent O
##ric O
##le O
as O
well O
as O
the O
o O
##cci O
##pit O
##al O
[ O
* O
* O
doctor O
last O
name O
53 O
##4 O
* O
* O
] O
of O
the O
right O
lateral O
vent O
##ric O
##le O
. O
the O
su O
##l O
##ci O
and O
g O
##yr O
##i O
of O
the O
entire O
left O
cerebral O
hemisphere O
are O
e O
##ff O
##ace O
##d O
. O
the O
[ O
* O
* O
doctor O
last O
name O
35 O
##2 O
* O
* O
] O
- O
white O
matter O
differentiation O
within O
the O
right O
hemisphere O
is O
preserved O
. O
the O
surrounding O
o O
##sse O
##ous O
and O
soft O
tissue O
structures O
are O
un O
##rem O
##ark O
##able O
. O
the O
visual O
##ized O
para O
##nas O
##al O
sin O
##uses O
show O
op O
##ac O
##ification O
of O
the O
right O
s O
##phe O
##no O
##id O
sin O
##us O
. O
impression O
: O
large O
left O
front O
##op O
##ari O
##etal O
in O
##tra O
##par O
##en O
##chy O
##mal O
hem O
##or O
##r O
##hage O
with O
extension O
into O
the O
vent O
##ric O
##ular O
system O
, O
mass O
effect O
, O
mid O
##line O
shift O
, O
and O
un O
##cal O
her O
##nia O
##tion O
. O
if O
prior O
examinations O
exist O
, O
they O
would O
be O
helpful O
for O
comparison O
to O
detail O
interval O
changes O
. O

brief O
hospital O
course O
: O
the O
patient O
was O
admitted O
for O
management O
of O
her O
large O
in O
##tra O
##par O
##en O
##chy O
##mal O
bleed O
. O
the O
et O
##iology O
was O
thought O
to O
be O
most O
likely O
from O
am O
##yl O
##oid O
an O
##gio O
##pathy O
. O
the O
ne O
##uro O
##su O
##rger O
##y O
team O
consulted O
and O
the O
patient O
and O
discussed O
options O
with O
the O
family O
and O
it O
was O
decided O
that O
surgery O
( O
draining O
the O
les O
##ion O
) O
would O
not O
likely O
benefit O
the O
patient O
. O
she O
was O
loaded O
with O
di B-DRUG
##lant I-DRUG
##in I-DRUG
. I-DRUG
her O
exam O
remained O
stable O
. O
the O
family O
made O
the O
patient O
d O
##n O
##r O
but O
not O
d O
##ni O
. O
a O
family O
meeting O
was O
held O
and O
the O
family O
decided O
in O
favor O
of O
placing O
a O
t O
##rac O
##he O
##ost O
##omy O
tube O
and O
a O
p O
##eg O
tube O
. O
these O
procedures O
were O
done O
without O
com O
##plication O
. O
the O
patient O
was O
initially O
placed O
on O
di B-DRUG
##lant I-DRUG
##in I-DRUG
for O
seizure B-REA
prop I-REA
##hyl I-REA
##ax I-REA
##is I-REA
due O
to O
her O
i O
##ch O
. O
she O
had O
no O
events O
and O
the O
di B-DRUG
##lant I-DRUG
##in I-DRUG
was O
eventually O
d O
/ O
c O
' O
d O
. O
the O
patient O
remained O
hem O
##ody O
##nam O
##ically O
stable O
. O
she O
has O
a O
goal O
s O
##b O
##p O
of O
110 O
- O
150 O
. O
the O
patient O
did O
appear O
to O
have O
a O
slight O
r B-ADE
##ash I-ADE
on O
her O
truck O
upon O
d O
/ O
c O
that O
was O
attributed O
to O
her O
di B-DRUG
##lant I-DRUG
##in I-DRUG
that O
was O
recently O
d O
/ O
c O
' O
d O
. O
on O
[ O
* O
* O
7 O
- O
31 O
* O
* O
] O
she O
spike O
##d O
a O
fever O
to O
103 O
she O
re O
##mian O
##ed O
f O
##eb O
##ril O
##e O
for O
~ O
5 O
days O
. O
eventually O
she O
had O
a O
s O
##put O
##um O
culture O
+ O
for O
s O
##ta O
##ph O
au O
##reus O
. O
the O
patient O
was O
started O
on O
le B-DRUG
##vo I-DRUG
##f I-DRUG
##lo I-DRUG
##xa I-DRUG
##cin I-DRUG
for O
a O
10 B-DUR
day I-DUR
course O
. O
at O
the O
time O
of O
d O
/ O
c O
she O
was O
a O
##fe O
##bri O
##le O
. O
she O
was O
accepted O
for O
placement O
at O
[ O
* O
* O
hospital O
##3 O
7 O
* O
* O
] O
. O
medications O
on O
admission O
: O
- O
act B-DRUG
##one I-DRUG
##l I-DRUG
- O
a B-DRUG
##rice I-DRUG
##pt I-DRUG
- O
as B-DRUG
##a I-DRUG
81 B-STR
- O
c B-DRUG
##ym I-DRUG
##balt I-DRUG
##a I-DRUG
- O
pro B-DRUG
##ton I-DRUG
##ix I-DRUG
- O
ad B-DRUG
##va I-DRUG
##ir I-DRUG
- O
card B-DRUG
##ia I-DRUG
x I-DRUG
##t I-DRUG
- O
r B-DRUG
##is I-DRUG
##per I-DRUG
##idal I-DRUG
- O
calcium B-DRUG
- O
met B-DRUG
##op I-DRUG
##rol I-DRUG
##ol I-DRUG
- O
ne B-DRUG
##uron I-DRUG
##tin I-DRUG
300 B-STR
q B-FRE
##hs I-FRE
- O
g B-DRUG
##lu I-DRUG
##ca I-DRUG
##gon I-DRUG
p B-FRE
##rn I-FRE
h B-REA
##y I-REA
##po I-REA
##gly I-REA
##ce I-REA
##mia I-REA
- O
du B-DRUG
##l I-DRUG
##cola I-DRUG
##x I-DRUG
- O
la B-DRUG
##nt I-DRUG
##us I-DRUG
16 B-STR
units I-STR
q B-FRE
##am I-FRE
- O
hum B-DRUG
##alog I-DRUG
sliding B-DOS
scale I-DOS

discharge O
medications O
: O
1 O
. O
n B-DRUG
##ys I-DRUG
##tat I-DRUG
##in I-DRUG
100 B-STR
, I-STR
000 I-STR
unit I-STR
/ I-STR
m I-STR
##l I-STR
suspension B-FOR
si O
##g O
: O
five B-DOS
( I-DOS
5 I-DOS
) I-DOS
m B-FOR
##l I-FOR
p B-ROU
##o I-ROU
q B-FRE
##id I-FRE
( I-FRE
4 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE
2 O
. O
la B-DRUG
##nso I-DRUG
##pra I-DRUG
##zo I-DRUG
##le I-DRUG
30 B-STR
mg I-STR
capsule B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
capsule B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
p B-ROU
##o I-ROU
daily B-FRE
( O
daily O
) O
. O
3 O
. O
le B-DRUG
##vo I-DRUG
##f I-DRUG
##lo I-DRUG
##xa I-DRUG
##cin I-DRUG
in I-DRUG
d I-DRUG
##5 I-DRUG
##w I-DRUG
250 B-STR
mg I-STR
/ I-STR
50 I-STR
m I-STR
##l I-STR
pig B-FOR
##gy I-FOR
##back I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
in B-ROU
##tra I-ROU
##ven I-ROU
##ous I-ROU
q B-FRE
##24 I-FRE
##h I-FRE
( I-FRE
every I-FRE
24 I-FRE
hours I-FRE
) I-FRE
for B-DUR
7 I-DUR
days I-DUR
. I-DUR
4 O
. O
he B-DRUG
##par I-DRUG
##in I-DRUG
sodium I-DRUG
( I-DRUG
p I-DRUG
##or I-DRUG
##cine I-DRUG
) I-DRUG
5 B-STR
, I-STR
000 I-STR
unit I-STR
/ I-STR
m I-STR
##l I-STR
solution B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
injection B-ROU
t B-FRE
##id I-FRE
. I-FRE
5 O
. O
al B-DRUG
##but I-DRUG
##ero I-DRUG
##l I-DRUG
90 B-STR
m I-STR
##c I-STR
##g I-STR
/ I-STR
act I-STR
##uation I-STR
a B-FOR
##ero I-FOR
##sol I-FOR
si O
##g O
: O
1 B-DOS
- I-DOS
2 I-DOS
pu B-FOR
##ffs I-FOR
in B-ROU
##hala I-ROU
##tion I-ROU
q B-FRE
##4 I-FRE
- I-FRE
6 I-FRE
##h I-FRE
( I-FRE
every I-FRE
4 I-FRE
to I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
w B-REA
##hee I-REA
##ze I-REA
. I-REA
6 O
. O
i B-DRUG
##pra I-DRUG
##tro I-DRUG
##pi I-DRUG
##um I-DRUG
br I-DRUG
##omi I-DRUG
##de I-DRUG
18 B-STR
m I-STR
##c I-STR
##g I-STR
/ I-STR
act I-STR
##uation I-STR
a B-FOR
##ero I-FOR
##sol I-FOR
si O
##g O
: O
two B-DOS
( I-DOS
2 I-DOS
) I-DOS
pu B-FOR
##ff I-FOR
in B-ROU
##hala I-ROU
##tion I-ROU
q B-FRE
##4 I-FRE
- I-FRE
6 I-FRE
##h I-FRE
( I-FRE
every I-FRE
4 I-FRE
to I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
w B-REA
##hee I-REA
##ze I-REA
. I-REA
7 O
. O
met B-DRUG
##op I-DRUG
##rol I-DRUG
##ol I-DRUG
ta I-DRUG
##rt I-DRUG
##rate I-DRUG
25 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
1 B-DOS
. I-DOS
5 I-DOS
tablets B-FOR
p B-ROU
##o I-ROU
t B-FRE
##id I-FRE
( O
3 O
times O
a O
day O
) O
. O
8 O
. O
fur B-DRUG
##ose I-DRUG
##mi I-DRUG
##de I-DRUG
80 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
bid B-FRE
( O
2 O
times O
a O
day O
) O
. O
9 O
. O
insulin B-DRUG
please O
follow O
submitted O
insulin B-DRUG
sliding B-DOS
scale I-DOS
g B-DRUG
##lar I-DRUG
##gin I-DRUG
##e I-DRUG
12 B-DOS
units I-DOS
q B-FRE
am I-FRE
discharge O
disposition O
: O
extended O
care O
facility O
: O
[ O
* O
* O
hospital O
##3 O
7 O
* O
* O
] O
& O
re O
##hab O
center O
- O
[ O
* O
* O
hospital O
##1 O
8 O
* O
* O
] O
discharge O
diagnosis O
: O
i O
##ch O
discharge O
condition O
: O
fair O
discharge O
instructions O
: O
please O
have O
patient O
see O
a O
physician O
or O
return O
to O
[ O
* O
* O
hospital O
##1 O
18 O
* O
* O
] O
if O
she O
ex O
##per O
##ie O
##ces O
changes O
in O
consciousness O
, O
increased O
weakness O
, O
seizure O
##s O
, O
worse O
##ned O
facial O
d O
##roo O
##p O
, O
fever O
. O
patient O
should O
have O
a O
repeat O
c O
##t O
scan O
in O
1 O
week O
to O
e O
##va O
##ulate O
evolution O
of O
brain O
hem O
##or O
##r O
##hage O
follow O
##up O
instructions O
: O
please O
follow O
up O
with O
primary O
care O
physician O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##4 O
) O
* O
* O
] O
[ O
* O
* O
1 O
- O
31 O
* O
* O
] O
weeks O
. O
please O
make O
an O
appointment O
to O
see O
[ O
* O
* O
hospital O
##1 O
18 O
* O
* O
] O
stroke O
service O
as O
an O
out O
##patient O
within O
1 O
month O

admission O
date O
: O
[ O
* O
* O
211 O
##6 O
- O
7 O
- O
19 O
* O
* O
] O
discharge O
date O
: O
[ O
* O
* O
211 O
##6 O
- O
7 O
- O
22 O
* O
* O
] O
service O
: O
ne O
##uro O
##logy O
all O
##er O
##gies O
: O
patient O
recorded O
as O
having O
no O
known O
all O
##er O
##gies O
to O
drugs O
attending O
: O
[ O
* O
* O
first O
name O
##3 O
( O
l O
##f O
) O
501 O
##8 O
* O
* O
] O
chief O
complaint O
: O
bleed O
t O
##ran O
##ferred O
from O
o O
##sh O
major O
surgical O
or O
invasive O
procedure O
: O
none O
history O
of O
present O
illness O
: O
m O
##s O
. O
[ O
* O
* O
known O
last O
##name O
83 O
##23 O
##7 O
* O
* O
] O
is O
an O
88 O
yo O
r O
##h O
woman O
with O
a O
pm O
##h O
remarkable O
for O
h O
##t O
##n O
, O
ch O
##f O
and O
lb O
##d O
on O
co B-DRUG
##uma I-DRUG
##din I-DRUG
( O
par B-REA
##ox I-REA
a I-REA
##f I-REA
) I-REA
p O
/ O
w O
a O
fall O
24 O
##h O
prior O
to O
admission O
at O
[ O
* O
* O
hospital O
##1 O
18 O
* O
* O
] O
. O
she O
fell O
from O
her O
rocking O
chair O
and O
struck O
the O
left O
side O
of O
her O
head O
and O
left O
hand O
yesterday O
at O
noon O
. O
she O
did O
not O
loose O
her O
consciousness O
( O
as O
per O
nurse O
who O
saw O
her O
in O
her O
chair O
1 O
minute O
prior O
to O
falling O
) O
. O
she O
is O
usually O
having O
falls O
when O
attempting O
to O
walk O
with O
her O
walk O
##er O
. O
she O
did O
have O
a O
bilateral O
hip O
replacement O
and O
a O
subsequent O
left O
f O
##em O
##oral O
fracture O
( O
with O
residual O
internal O
hip O
rotation O
) O
that O
imp O
##air O
##s O
her O
g O
##ait O
( O
for O
2 O
years O
) O
. O
she O
remained O
in O
the O
[ O
* O
* O
hospital O
##3 O
* O
* O
] O
facility O
, O
but O
started O
to O
become O
confused O
. O
she O
was O
taken O
to O
[ O
* O
* O
hospital O
##3 O
410 O
##7 O
* O
* O
] O
today O
at O
around O
11 O
: O
00 O
am O
, O
where O
she O
received O
a O
c O
##t O
scan O
that O
showed O
a O
small O
( O
1 O
. O
3 O
##c O
##m O
) O
left O
frontal O
in O
##tra O
##par O
##en O
##chi O
##mal O
bleed O
without O
a O
mid O
##line O
shift O
, O
not O
open O
to O
the O
vent O
##ric O
##les O
, O
no O
data O
of O
h O
##ydro O
##ce O
##pha O
##lus O
. O
at O
[ O
* O
* O
hospital O
##1 O
* O
* O
] O
her O
vs O
were O
stable O
. O
at O
the O
time O
she O
was O
confused O
. O
she O
had O
an O
in B-REA
##r I-REA
of I-REA
2 I-REA
. I-REA
97 I-REA
and O
received O
vitamin B-DRUG
k I-DRUG
10 B-STR
mg I-STR
i B-ROU
##v I-ROU
without O
complications O
. O
once O
at O
[ O
* O
* O
hospital O
##1 O
18 O
* O
* O
] O
ed O
, O
her O
vs O
were O
98 O
. O
6 O
##f O
, O
70 O
b O
##pm O
, O
161 O
/ O
71 O
, O
16 O
##rr O
, O
so O
##2 O
100 O
% O
in O
r O
##a O
. O
she O
was O
alert O
and O
oriented O
* O
3 O
. O
pleasant O
and O
cooperative O
with O
the O
ed O
team O
. O
she O
received O
f B-DRUG
##f I-DRUG
##p I-DRUG
and O
a O
new O
c O
##t O
c O
##ns O
and O
c O
- O
spine O
scan O
w O
/ O
o O
contrast O
that O
showed O
. O

the O
family O
denies O
any O
previous O
episodes O
with O
focal O
deficit O
##s O
eventually O
re O
##sol O
##ving O
. O
s O
##h O
eh O
##as O
been O
having O
v O
##iu O
##al O
hall O
##uc O
##ination O
##s O
for O
24 O
months O
. O
those O
are O
well O
formed O
( O
people O
) O
. O
she O
talks O
to O
them O
, O
but O
they O
do O
not O
reply O
. O
she O
has O
been O
seeing O
her O
husband O
lately O
( O
he O
passed O
the O
way O
6 O
months O
ago O
) O
. O
past O
medical O
history O
: O
pm O
##h O
: O
p O
##c O
##p O
: O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
83 O
##23 O
##8 O
* O
* O
] O
h O
##t O
##n O
par O
##ox O
##ima O
##l O
ch O
##f O
( O
unknown O
e O
##f O
and O
di O
##ast O
##olic O
function O
) O
lb O
##d O
depression O
? O
? O
u O
##rina O
##ry O
in O
##con O
##tine O
##nce O
no O
previous O
strokes O
or O
spontaneous O
bleed O
##s O
/ O
co O
##agu O
##lop O
##athy O
or O
brain O
tumors O
. O
no O
h O
##x O
of O
seizure O
social O
history O
: O
lives O
in O
[ O
* O
* O
location O
105 O
##4 O
##9 O
* O
* O
] O
living O
facility O
family O
history O
: O
no O
h O
##x O
of O
early O
strokes O
, O
or O
spontaneous O
bleed O
##s O
/ O
co O
##agu O
##lop O
##athy O
, O
brain O
tumors O
. O
no O
h O
##x O
of O
seizure O
##s O
. O
physical O
exam O
: O
vs O
: O
98 O
. O
6 O
##f O
, O
70 O
b O
##pm O
, O
161 O
/ O
71 O
, O
16 O
##rr O
, O
so O
##2 O
100 O
% O
in O
r O
##a O
. O
g O
##en O
: O
lying O
in O
bed O
, O
na O
##d O
. O
he O
##ent O
: O
n O
##c O
/ O
at O
, O
moist O
oral O
m O
##uc O
##osa O
neck O
: O
su O
##pp O
##le O
, O
no O
car O
##ot O
##id O
or O
ve O
##rte O
##bra O
##l O
br O
##uit O
back O
: O
no O
point O
tender O
##ness O
or O
er O
##yt O
##hem O
##a O
c O
##v O
: O
n O
##l O
s O
##1 O
and O
s O
##2 O
, O
no O
murmurs O
/ O
gal O
##lops O
/ O
rub O
##s O
lung O
: O
clear O
to O
au O
##s O
##cu O
##lta O
##tion O
bilateral O
##ly O
a O
##b O
##d O
: O
soft O
, O
non O
##tend O
##er O
, O
non O
- O
di O
##sten O
##ded O
. O
no O
masses O
or O
me O
##gal O
##ies O
. O
percussion O
within O
normal O
limits O
. O
+ O
b O
##s O
. O
ex O
##t O
: O
no O
ed O
##ema O
, O
no O
d O
##v O
##t O
data O
. O
pulses O
+ O
+ O
and O
symmetric O
. O
ne O
##uro O
##log O
##ic O
examination O
: O
no O
men O
##ing O
##ism O
##us O
. O
no O
photo O
##ph O
##obia O
. O
m O
##s O
: O
general O
: O
alert O
, O
awake O
, O
normal O
affect O
orientation O
: O
oriented O
to O
person O
, O
place O
, O
date O
, O
situation O
attention O
: O
20 O
to O
1 O
backwards O
+ O
. O
follows O
simple O
/ O
complex O
commands O
. O
speech O
/ O
language O
: O
fluent O
w O
/ O
o O
para O
##pha O
##si O
##c O
errors O
; O
com O
##p O
##rehension O
, O
repetition O
, O
naming O
: O
normal O
. O
pro O
##so O
##dy O
: O
normal O
. O
memory O
: O
registers O
[ O
* O
* O
3 O
- O
24 O
* O
* O
] O
and O
recalls O
[ O
* O
* O
2 O
- O
25 O
* O
* O
] O
when O
given O
choices O
at O
5 O
min O
p O
##rax O
##is O
/ O
a O
##gno O
##sia O
: O
able O
to O
brush O
teeth O
. O
no O
field O
cuts O
. O

c O
##n O
: O
i O
: O
not O
tested O
ii O
, O
ii O
##i O
: O
v O
##ff O
to O
confrontation O
, O
per O
##rl O
3 O
##mm O
to O
2 O
##mm O
, O
fund O
##us O
w O
/ O
o O
p O
##ap O
##ille O
##de O
##ma O
. O
ii O
##i O
, O
i O
##v O
, O
v O
##i O
: O
e O
##omi O
, O
no O
p O
##tosis O
. O
no O
n O
##ys O
##tag O
##mus O
v O
: O
sensation O
intact O
v O
##1 O
- O
v O
##3 O
to O
l O
##t O
v O
##ii O
: O
facial O
strength O
intact O
/ O
symmetrical O
v O
##ii O
##i O
: O
hears O
finger O
rub O
bilateral O
##ly O
i O
##x O
, O
x O
: O
p O
##ala O
##te O
el O
##eva O
##tes O
symmetrical O
##ly O
, O
u O
##vu O
##la O
mid O
##line O
##xi O
: O
s O
##c O
##m O
/ O
trap O
##ez O
##ei O
##i O
[ O
* O
* O
5 O
- O
26 O
* O
* O
] O
bilateral O
##ly O
x O
##ii O
: O
tongue O
pro O
##tr O
##udes O
mid O
##line O
, O
no O
d O
##ys O
##art O
##hr O
##ia O
r O
##inn O
##e O
: O
r O
ear O
: O
a O
##c O
> O
b O
##c O
, O
left O
ear O
a O
##c O
> O
b O
##c O
[ O
* O
* O
doctor O
last O
name O
157 O
##16 O
* O
* O
] O
: O
central O
. O
motor O
: O
normal O
bulk O
. O
tone O
: O
cough O
##we O
##elin O
##g O
in O
both O
arms O
. O
no O
t O
##rem O
##or O
, O
no O
as O
##ter O
##ix O
##is O
or O
my O
##oc O
##lon O
##us O
. O
no O
pro O
##nat O
##or O
drift O
: O
del O
##t O
; O
c O
##5 O
bi O
##c O
: O
c O
##6 O
t O
##ri O
: O
c O
##7 O
w O
##r O
ex O
##t O
: O
c O
##6 O
fin O
##g O
ex O
##t O
: O
c O
##7 O
left O
5 O
5 O
5 O
5 O
5 O
right O
5 O
5 O
5 O
5 O
5 O
i O
##p O
: O
q O
##uad O
: O
ha O
##ms O
##t O
: O
do O
##rs O
##if O
##lex O
: O
[ O
* O
* O
last O
name O
( O
un O
) O
93 O
##8 O
* O
* O
] O
: O
p O
##l O
. O
fl O
##ex O
left O
internal O
rotation O
and O
anti O
##gra O
##vity O
( O
not O
new O
) O
. O
right O
5 O
5 O
5 O
5 O
5 O
deep O
tend O
##on O
reflex O
##es O
: O
bi O
##ci O
##p O
: O
c O
##5 O
t O
##ric O
: O
c O
##7 O
bra O
##chia O
##l O
: O
c O
##6 O
pat O
##ella O
##r O
: O
l O
##4 O
toes O
: O
right O
1 O
1 O
1 O
1 O
down O
##going O
left O
1 O
1 O
1 O
1 O
down O
##going O
sensation O
: O
intact O
to O
light O
touch O
, O
vibration O
, O
and O
temperature O
. O
prop O
##io O
##ception O
: O
normal O
. O
coordination O
: O
* O
finger O
- O
nose O
- O
finger O
normal O
. O
* O
rapid O
arm O
movements O
b O
##l O
clumsy O
* O
fine O
finger O
tapping O
: O
no O
de O
##cre O
##ment O

per O
##tinent O
results O
: O
[ O
* O
* O
211 O
##6 O
- O
7 O
- O
19 O
* O
* O
] O
05 O
: O
35 O
##pm O
glucose O
- O
85 O
u O
##rea O
n O
- O
19 O
c O
##rea O
##t O
- O
1 O
. O
0 O
sodium O
- O
141 O
potassium O
- O
4 O
. O
3 O
chloride O
- O
103 O
total O
co O
##2 O
- O
31 O
an O
##ion O
gap O
- O
11 O
[ O
* O
* O
211 O
##6 O
- O
7 O
- O
19 O
* O
* O
] O
05 O
: O
10 O
##pm O
w O
##b O
##c O
- O
6 O
. O
1 O
r O
##b O
##c O
- O
3 O
. O
67 O
* O
h O
##g O
##b O
- O
10 O
. O
6 O
* O
h O
##ct O
- O
31 O
. O
5 O
* O
m O
##c O
##v O
- O
86 O
m O
##ch O
- O
28 O
. O
9 O
m O
##ch O
##c O
- O
33 O
. O
6 O
r O
##d O
##w O
- O
15 O
. O
0 O
[ O
* O
* O
211 O
##6 O
- O
7 O
- O
19 O
* O
* O
] O
05 O
: O
10 O
##pm O
ne O
##uts O
- O
71 O
. O
9 O
* O
l O
##ymph O
##s O
- O
20 O
. O
7 O
mon O
##os O
- O
5 O
. O
3 O
e O
##os O
- O
1 O
. O
9 O
b O
##as O
##os O
- O
0 O
. O
3 O
[ O
* O
* O
211 O
##6 O
- O
7 O
- O
19 O
* O
* O
] O
05 O
: O
10 O
##pm O
p O
##t O
- O
27 O
. O
9 O
* O
p O
##tt O
- O
38 O
. O
3 O
* O
in O
##r O
( O
p O
##t O
) O
- O
2 O
. O
7 O
* O
[ O
* O
* O
211 O
##6 O
- O
7 O
- O
20 O
* O
* O
] O
02 O
: O
32 O
##am O
blood O
c O
##k O
- O
m O
##b O
- O
3 O
c O
##tro O
##p O
##nt O
- O
0 O
. O
04 O
* O
[ O
* O
* O
211 O
##6 O
- O
7 O
- O
20 O
* O
* O
] O
08 O
: O
35 O
##am O
blood O
c O
##k O
- O
m O
##b O
- O
5 O
c O
##tro O
##p O
##nt O
- O
0 O
. O
05 O
* O
[ O
* O
* O
211 O
##6 O
- O
7 O
- O
20 O
* O
* O
] O
02 O
: O
32 O
##am O
blood O
t O
##rig O
##ly O
##c O
- O
80 O
h O
##dl O
- O
51 O
ch O
##ol O
/ O
h O
##d O
- O
4 O
. O
0 O
l O
##dl O
##cal O
##c O
- O
135 O
* O
[ O
* O
* O
211 O
##6 O
- O
7 O
- O
20 O
* O
* O
] O
02 O
: O
32 O
##am O
blood O
t O
##sh O
- O
1 O
. O
6 O
wrist O
x O
ray O
: O
no O
acute O
fracture O
. O
old O
di O
##stal O
radio O
##us O
and O
ul O
##nar O
s O
##ty O
##lo O
##id O
fracture O
##s O
. O
c O
##ns O
scan O
without O
contrast O
: O
le O
##f O
frontal O
bleed O
. O
no O
ma O
##s O
effect O
, O
not O
open O
to O
vent O
##ric O
##les O
. O

brief O
hospital O
course O
: O
m O
##rs O
. O
[ O
* O
* O
last O
name O
( O
un O
) O
83 O
##23 O
##9 O
* O
* O
] O
in B-REA
##r I-REA
was I-REA
corrected I-REA
with O
vitamin B-DRUG
k I-DRUG
at O
o O
##sh O
and O
pro B-DRUG
##fi I-DRUG
##ln I-DRUG
##ine I-DRUG
and O
f B-DRUG
##f I-DRUG
##p I-DRUG
here O
. O
m O
##s O
[ O
* O
* O
known O
last O
##name O
83 O
##23 O
##7 O
* O
* O
] O
was O
admitted O
to O
the O
ne O
##uro O
##log O
##ic O
i O
##cu O
service O
overnight O
for O
observation O
for O
her O
left O
frontal O
in O
##tra O
##par O
##ech O
##ym O
##al O
hem O
##or O
##r O
##hage O
. O
her O
i O
##ch O
was O
thought O
to O
represent O
a O
traumatic O
con O
##tus O
##ion O
. O
she O
remained O
stable O
and O
her O
ne O
##uro O
##log O
##ic O
exam O
was O
normal O
other O
than O
a O
slight O
right O
facial O
d O
##roo O
##p O
. O
no O
repeat O
imaging O
or O
further O
work O
up O
was O
felt O
to O
be O
necessary O
. O
fast O
##ing O
lip O
##id O
panel O
w O
/ O
l O
##dl O
135 O
, O
total O
ch O
##ol O
202 O
. O
discharged O
on O
as B-DRUG
##a I-DRUG
81 B-STR
q B-FRE
##d I-FRE
with O
plans O
to O
re O
- O
start O
co B-DRUG
##uma I-DRUG
##din I-DRUG
in O
[ O
* O
* O
7 O
- O
31 O
* O
* O
] O
days O
. O
when O
therapeutic O
on O
co B-DRUG
##uma I-DRUG
##din I-DRUG
, I-DRUG
as B-DRUG
##a I-DRUG
will O
be O
discontinued O
. O
cards O
: O
te O
##lem O
##et O
##ry O
un O
##rem O
##ark O
##able O
no O
id O
, O
end O
##o O
, O
g O
##i O
, O
re O
##sp O
issues O
this O
admission O
medications O
on O
admission O
: O
co B-DRUG
##uma I-DRUG
##din I-DRUG
5 B-STR
##m I-STR
##g I-STR
q B-FRE
##hs I-FRE
, I-FRE
but O
t B-FRE
##ues I-FRE
##day I-FRE
and I-FRE
f I-FRE
##rida I-FRE
##y I-FRE
7 B-STR
mg I-STR
q B-FRE
##hs I-FRE
as B-DRUG
##a I-DRUG
81 B-STR
mg I-STR
q B-FRE
##d I-FRE
. I-FRE
met B-DRUG
##op I-DRUG
##rol I-DRUG
##ol I-DRUG
25 B-STR
mg I-STR
[ O
* O
* O
hospital O
##1 O
* O
* O
] O
, O
ve B-DRUG
##rap I-DRUG
##ami I-DRUG
##l I-DRUG
240 B-STR
q B-FRE
##d I-FRE
, I-FRE
l B-DRUG
##isi I-DRUG
##no I-DRUG
##p I-DRUG
##ril I-DRUG
20 B-STR
q B-FRE
##d I-FRE
. I-FRE
fur B-DRUG
##ose I-DRUG
##mi I-DRUG
##de I-DRUG
20 B-STR
mg I-STR
q B-FRE
##d I-FRE
sin B-DRUG
##em I-DRUG
##et I-DRUG
/ I-DRUG
car I-DRUG
##bid I-DRUG
##op I-DRUG
##a I-DRUG
: I-DRUG
25 B-STR
/ I-STR
100 I-STR
t B-FRE
##id I-FRE
a B-DRUG
##rice I-DRUG
##pt I-DRUG
5 B-STR
m I-STR
##h I-STR
q B-FRE
##d I-FRE
. I-FRE
c B-DRUG
##ele I-DRUG
##xa I-DRUG
20 B-STR
q B-FRE
##d I-FRE
. I-FRE
b B-DRUG
##act I-DRUG
##rim I-DRUG
s O
##s O
100 B-STR
/ I-STR
80 I-STR
, I-STR
to B-DRUG
##lter I-DRUG
##od I-DRUG
##ine I-DRUG
( I-DRUG
anti I-DRUG
##mus I-DRUG
##car I-DRUG
##ini I-DRUG
##c I-DRUG
) I-DRUG
7 B-STR
. I-STR
5 I-STR
q B-FRE
##d I-FRE
m B-DRUG
##vi I-DRUG
discharge O
medications O
: O
1 O
. O
met B-DRUG
##op I-DRUG
##rol I-DRUG
##ol I-DRUG
ta I-DRUG
##rt I-DRUG
##rate I-DRUG
25 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
bid B-FRE
( O
2 O
times O
a O
day O
) O
. O
2 O
. O
l B-DRUG
##isi I-DRUG
##no I-DRUG
##p I-DRUG
##ril I-DRUG
20 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( I-FRE
daily I-FRE
) I-FRE
. I-FRE
3 O
. O
fur B-DRUG
##ose I-DRUG
##mi I-DRUG
##de I-DRUG
20 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( I-FRE
daily I-FRE
) I-FRE
. I-FRE
4 O
. O
car B-DRUG
##bid I-DRUG
##op I-DRUG
##a I-DRUG
- I-DRUG
le I-DRUG
##vo I-DRUG
##do I-DRUG
##pa I-DRUG
25 B-STR
- I-STR
100 I-STR
mg I-STR
tablet B-FOR
sustained B-FOR
release I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
t B-FRE
##id I-FRE
( I-FRE
3 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE
5 O
. O
done B-DRUG
##pe I-DRUG
##zi I-DRUG
##l I-DRUG
5 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
h B-FRE
##s I-FRE
( I-FRE
at I-FRE
bed I-FRE
##time I-FRE
) I-FRE
. I-FRE

6 O
. O
c B-DRUG
##ital I-DRUG
##op I-DRUG
##ram I-DRUG
20 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( I-FRE
daily I-FRE
) I-FRE
. I-FRE
7 O
. O
trim B-DRUG
##eth I-DRUG
##op I-DRUG
##rim I-DRUG
- I-DRUG
su I-DRUG
##lf I-DRUG
##ame I-DRUG
##th I-DRUG
##ox I-DRUG
##az I-DRUG
##ole I-DRUG
80 B-STR
- I-STR
400 I-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( I-FRE
daily I-FRE
) I-FRE
. I-FRE
8 O
. O
to B-DRUG
##lter I-DRUG
##od I-DRUG
##ine I-DRUG
1 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
bid B-FRE
( O
2 O
times O
a O
day O
) O
. O
9 O
. O
f B-DRUG
##amo I-DRUG
##ti I-DRUG
##dine I-DRUG
20 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
bid B-FRE
( O
2 O
times O
a O
day O
) O
. O
10 O
. O
as B-DRUG
##pi I-DRUG
##rin I-DRUG
81 B-STR
mg I-STR
tablet B-FOR
, I-FOR
ch I-FOR
##ew I-FOR
##able I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
, I-FOR
ch I-FOR
##ew I-FOR
##able I-FOR
p B-ROU
##o I-ROU
daily B-FRE
( I-FRE
daily I-FRE
) I-FRE
: I-FRE
this O
medication O
is O
to O
be O
stopped O
when O
co B-DRUG
##uma I-DRUG
##din I-DRUG
reaches O
therapeutic O
dose O
. O
co B-DRUG
##uma I-DRUG
##din I-DRUG
to O
be O
started O
[ O
* O
* O
7 O
- O
27 O
* O
* O
] O
. O
11 O
. O
ve B-DRUG
##rap I-DRUG
##ami I-DRUG
##l I-DRUG
240 B-STR
mg I-STR
tablet B-FOR
sustained I-FOR
release I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
sustained I-FOR
release I-FOR
p B-ROU
##o I-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE
discharge O
disposition O
: O
extended O
care O
facility O
: O
[ O
* O
* O
first O
name O
##8 O
( O
name O
##pa O
##tter O
##n O
##2 O
) O
* O
* O
] O
[ O
* O
* O
hospital O
* O
* O
] O
nursing O
home O
- O
[ O
* O
* O
location O
( O
un O
) O
50 O
##8 O
##7 O
* O
* O
] O
discharge O
diagnosis O
: O
primary O
: O
traumatic O
left O
frontal O
in O
##ta O
##par O
##ych O
##ym O
##al O
hem O
##or O
##r O
##hage O
( O
con O
##tus O
##ion O
) O
secondary O
: O
par B-REA
##ox I-REA
##ys I-REA
##mal I-REA
at I-REA
##rial I-REA
fi I-REA
##bri I-REA
##lation I-REA
treated O
with O
co B-DRUG
##uma I-DRUG
##din I-DRUG
ch O
##f O
h O
##yper O
##tens O
##ion O
[ O
* O
* O
last O
name O
( O
un O
) O
30 O
##9 O
* O
* O
] O
body O
dem O
##ent O
##ia O
discharge O
condition O
: O
she O
is O
at O
her O
base O
##line O
. O
still O
mild O
rig O
##th O
sided O
##e O
d O
##roo O
##p O
. O
otherwise O
her O
ne O
##uro O
##logical O
examination O
is O
normal O
. O
discharge O
instructions O
: O
you O
were O
admitted O
to O
the O
i O
##cu O
with O
bleeding O
in O
the O
front O
left O
part O
of O
your O
brain O
after O
a O
fall O
. O
the O
bleeding O
has O
stab O
##ilized O
and O
your O
co B-DRUG
##uma I-DRUG
##din I-DRUG
was O
reversed O
. O
please O
take O
all O
medications O
as O
per O
##scribed O
. O
if O
you O
have O
concerns O
about O
the O
medications O
, O
please O
call O
your O
p O
##c O
##p O
before O
changing O
the O
doses O
. O
. O
please O
call O
your O
p O
##c O
##p O
or O
return O
to O
the O
emergency O
room O
if O
you O
experience O
any O
worse O
##ning O
in O
your O
symptoms O
or O
have O
other O
concerns O
please O
note O
that O
co B-DRUG
##uma I-DRUG
##din I-DRUG
was O
reversed O
and O
stopped O
because O
of O
hem B-ADE
##or I-ADE
##r I-ADE
##hage I-ADE
. I-ADE
as B-DRUG
##pi I-DRUG
##rin I-DRUG
has O
been O
started O
in O
meantime O
. O
co B-DRUG
##uma I-DRUG
##din I-DRUG
should O
be O
resumed O
at O
prior O
dose O
on O
[ O
* O
* O
7 O
- O
27 O
* O
* O
] O
, O
and O
t O
##it O
##rate O
to O
goal O
in O
##r O
[ O
* O
* O
2 O
- O
25 O
* O
* O
] O
. O
as B-DRUG
##pi I-DRUG
##rin I-DRUG
to O
be O
discontinued O
once O
in O
##r O
therapeutic O
. O

follow O
##up O
instructions O
: O
provider O
: O
[ O
* O
* O
name O
##10 O
( O
name O
##is O
) O
42 O
##6 O
##7 O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##4 O
) O
42 O
##6 O
##8 O
* O
* O
] O
, O
m O
##d O
, O
p O
##h O
##d O
[ O
* O
* O
m O
##d O
number O
( O
3 O
) O
70 O
##8 O
* O
* O
] O
: O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
65 O
##7 O
* O
* O
] O
date O
/ O
time O
: O
[ O
* O
* O
211 O
##6 O
- O
9 O
- O
8 O
* O
* O
] O
1 O
: O
00 O
p O
##c O
##p O
: O
[ O
* O
* O
name O
##10 O
( O
name O
##is O
) O
95 O
##29 O
* O
* O
] O
, O
[ O
* O
* O
name O
##11 O
( O
name O
##is O
) O
* O
* O
] O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
1750 O
##3 O
* O
* O
] O
[ O
* O
* O
name O
##6 O
( O
m O
##d O
) O
42 O
##6 O
##7 O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##4 O
) O
42 O
##6 O
##8 O
* O
* O
] O
m O
##d O
, O
[ O
* O
* O
m O
##d O
number O
( O
3 O
) O
50 O
##23 O
* O
* O
] O

admission O
date O
: O
[ O
* O
* O
215 O
##8 O
- O
11 O
- O
20 O
* O
* O
] O
discharge O
date O
: O
[ O
* O
* O
215 O
##8 O
- O
12 O
- O
20 O
* O
* O
] O
date O
of O
birth O
: O
[ O
* O
* O
210 O
##8 O
- O
8 O
- O
19 O
* O
* O
] O
sex O
: O
f O
service O
: O
surgery O
all O
##er O
##gies O
: O
per B-DRUG
##co I-DRUG
##ce I-DRUG
##t I-DRUG
/ O
su B-DRUG
##lf I-DRUG
##ona I-DRUG
##mi I-DRUG
##des I-DRUG
/ O
i B-DRUG
##od I-DRUG
##ine I-DRUG
; I-DRUG
i B-DRUG
##od I-DRUG
##ine I-DRUG
containing O
attending O
: O
[ O
* O
* O
first O
name O
##3 O
( O
l O
##f O
) O
47 O
##48 O
* O
* O
] O
chief O
complaint O
: O
r O
##le O
pain O
and O
swelling O
major O
surgical O
or O
invasive O
procedure O
: O
right O
lower O
ex O
##tre O
##mity O
open O
ve O
##nous O
th O
##rom O
##be O
##ct O
##omy O
, O
f O
##as O
##cio O
##tom O
##y O
right O
lower O
ex O
##tre O
##mity O
lateral O
and O
medial O
de O
##bri O
##de O
##ment O
w O
/ O
medial O
v O
##ac O
closure O
right O
lower O
ex O
##tre O
##mity O
lateral O
de O
##bri O
##de O
##ment O
at O
bedside O
history O
of O
present O
illness O
: O
50 O
year O
old O
female O
presents O
to O
the O
ed O
with O
severe O
r O
##le O
and O
r O
. O
back O
pain O
. O
she O
was O
in O
her O
usual O
state O
of O
health O
until O
about O
2 O
- O
3 O
weeks O
ago O
when O
she O
was O
admitted O
to O
[ O
* O
* O
hospital O
* O
* O
] O
hospital O
with O
short O
##ness O
of O
breath O
and O
diagnosed O
with O
a O
r O
##le O
d O
##v O
##t O
and O
p O
##e O
. O
she O
was O
started O
on O
he B-DRUG
##par I-DRUG
##in I-DRUG
g B-ROU
##gt I-ROU
, I-ROU
however O
she O
developed O
a O
re O
##ctus O
sheath O
hem O
##ato O
##ma O
, O
so O
this O
was O
stopped O
and O
an O
i O
##v O
##c O
filter O
was O
placed O
. O
she O
was O
discharged O
home O
around O
[ O
* O
* O
11 O
- O
7 O
* O
* O
] O
and O
had O
been O
well O
until O
3 O
days O
ago O
when O
she O
developed O
acute O
onset O
of O
r O
. O
lower O
back O
pain O
and O
right O
groin O
pain O
. O
this O
progressed O
over O
the O
past O
3 O
days O
until O
she O
came O
to O
the O
ed O
. O
past O
medical O
history O
: O
- O
h O
##t O
##n O
- O
h O
##yper O
##lip O
##ide O
##mia O
- O
as O
##th O
##ma O
- O
l O
. O
back O
me O
##lan O
##oma O
ps O
##h O
: O
i O
##v O
##c O
filter O
around O
[ O
* O
* O
215 O
##8 O
- O
11 O
- O
7 O
* O
* O
] O
, O
l O
. O
back O
me O
##lan O
##oma O
ex O
##cision O
with O
a O
##xi O
##llar O
##y O
l O
##ymph O
node O
di O
##sse O
##ction O
, O
lap O
##aro O
##tom O
##y O
x O
2 O
for O
o O
##var O
##ian O
c O
##ys O
##ts O
as O
a O
teenager O
, O
c O
- O
section O
, O
app O
##end O
##ec O
##tom O
##y O
, O
lap O
ch O
##ole O
##cy O
##ste O
##ct O
##omy O
social O
history O
: O
lives O
with O
husband O
and O
kids O
family O
history O
: O
n O
/ O
c O

physical O
exam O
: O
vs O
: O
t O
##m O
100 O
. O
3 O
t O
##l O
##9 O
##7 O
. O
1 O
80 O
137 O
/ O
72 O
16 O
96 O
% O
r O
##a O
g O
##en O
; O
a O
##ao O
##x O
##3 O
, O
na O
##d O
he O
##nt O
: O
su O
##pp O
##le O
no O
br O
##uit O
##s O
card O
: O
r O
##rr O
, O
n O
##l O
s O
##1 O
##s O
##2 O
lungs O
: O
c O
##ta O
b O
/ O
l O
, O
no O
distress O
a O
##b O
##d O
: O
o O
##bes O
##e O
, O
n O
##t O
, O
n O
##d O
ex O
##tre O
##mit O
##ies O
: O
both O
well O
per O
##fused O
and O
warm O
. O
right O
: O
has O
bilateral O
f O
##ac O
##iot O
##omi O
##es O
( O
lateral O
and O
medial O
) O
, O
the O
medial O
is O
beef O
##y O
and O
g O
##ran O
##ulating O
, O
the O
lateral O
s O
/ O
p O
de O
##bri O
##de O
##ment O
at O
the O
bedside O
[ O
* O
* O
12 O
- O
20 O
* O
* O
] O
, O
is O
mildly O
cell O
##uli O
##tic O
around O
, O
no O
ex O
##uda O
##te O
, O
medial O
thigh O
staple O
##s O
are O
intact O
, O
in O
##cision O
is O
healed O
and O
well O
an O
##ast O
##omo O
##sed O
. O
the O
right O
groin O
has O
an O
area O
of O
wound O
de O
##hes O
##cens O
##e O
with O
clean O
and O
beef O
##y O
base O
. O

per O
##tinent O
results O
: O
[ O
* O
* O
215 O
##8 O
- O
12 O
- O
20 O
* O
* O
] O
06 O
: O
02 O
##am O
blood O
w O
##b O
##c O
- O
7 O
. O
1 O
r O
##b O
##c O
- O
3 O
. O
33 O
* O
h O
##g O
##b O
- O
9 O
. O
8 O
* O
h O
##ct O
- O
29 O
. O
4 O
* O
m O
##c O
##v O
- O
88 O
m O
##ch O
- O
29 O
. O
4 O
m O
##ch O
##c O
- O
33 O
. O
3 O
r O
##d O
##w O
- O
17 O
. O
8 O
* O
p O
##lt O
c O
##t O
- O
34 O
##1 O
[ O
* O
* O
215 O
##8 O
- O
12 O
- O
19 O
* O
* O
] O
05 O
: O
27 O
##am O
blood O
w O
##b O
##c O
- O
6 O
. O
9 O
r O
##b O
##c O
- O
3 O
. O
38 O
* O
h O
##g O
##b O
- O
10 O
. O
0 O
* O
h O
##ct O
- O
29 O
. O
9 O
* O
m O
##c O
##v O
- O
88 O
m O
##ch O
- O
29 O
. O
6 O
m O
##ch O
##c O
- O
33 O
. O
5 O
r O
##d O
##w O
- O
17 O
. O
7 O
* O
p O
##lt O
c O
##t O
- O
35 O
##1 O
[ O
* O
* O
215 O
##8 O
- O
12 O
- O
20 O
* O
* O
] O
06 O
: O
02 O
##am O
blood O
p O
##t O
- O
16 O
. O
0 O
* O
in O
##r O
( O
p O
##t O
) O
- O
1 O
. O
4 O
* O
[ O
* O
* O
215 O
##8 O
- O
12 O
- O
19 O
* O
* O
] O
05 O
: O
27 O
##am O
blood O
p O
##t O
- O
16 O
. O
5 O
* O
in O
##r O
( O
p O
##t O
) O
- O
1 O
. O
5 O
* O
[ O
* O
* O
215 O
##8 O
- O
12 O
- O
20 O
* O
* O
] O
06 O
: O
02 O
##am O
blood O
glucose O
- O
109 O
* O
u O
##rea O
##n O
- O
14 O
c O
##rea O
##t O
- O
0 O
. O
7 O
na O
- O
141 O
k O
- O
4 O
. O
0 O
c O
##l O
- O
102 O
h O
##co O
##3 O
- O
29 O
an O
##ga O
##p O
- O
14 O
[ O
* O
* O
215 O
##8 O
- O
12 O
- O
15 O
* O
* O
] O
05 O
: O
48 O
##am O
blood O
glucose O
- O
98 O
u O
##rea O
##n O
- O
17 O
c O
##rea O
##t O
- O
0 O
. O
6 O
na O
- O
138 O
k O
- O
4 O
. O
2 O
c O
##l O
- O
101 O
h O
##co O
##3 O
- O
29 O
an O
##ga O
##p O
- O
12 O
card O
##iology O
reports O
: O
e O
##c O
##g O
study O
date O
of O
[ O
* O
* O
215 O
##8 O
- O
11 O
- O
20 O
* O
* O
] O
2 O
: O
10 O
: O
10 O
pm O
sin O
##us O
rhythm O
. O
low O
pre O
##cor O
##dial O
lead O
q O
##rs O
voltage O
is O
non O
- O
specific O
and O
tracing O
is O
probably O
within O
normal O
limits O
. O
no O
previous O
tracing O
available O
for O
comparison O
. O

e O
##c O
##g O
study O
date O
of O
[ O
* O
* O
215 O
##8 O
- O
11 O
- O
22 O
* O
* O
] O
2 O
: O
21 O
: O
10 O
am O
sin O
##us O
rhythm O
with O
border O
##line O
sin O
##us O
ta O
##chy O
##card O
##ia O
. O
q O
##rs O
configuration O
in O
leads O
ii O
##i O
and O
a O
##v O
##f O
raises O
the O
consideration O
of O
prior O
inferior O
my O
##oc O
##ard O
##ial O
in O
##far O
##ction O
although O
is O
non O
- O
diagnostic O
. O
otherwise O
, O
tracing O
may O
be O
within O
normal O
limits O
but O
unstable O
base O
##line O
and O
base O
##line O
artifacts O
in O
lead O
v O
##3 O
makes O
assessment O
difficult O
. O
clinical O
correlation O
is O
suggested O
. O
since O
the O
previous O
tracing O
of O
[ O
* O
* O
215 O
##8 O
- O
11 O
- O
20 O
* O
* O
] O
axis O
is O
more O
left O
##ward O
with O
a O
change O
in O
q O
##rs O
configuration O
in O
lead O
a O
##v O
##f O
and O
late O
pre O
##cor O
##dial O
q O
##rs O
transition O
is O
present O
. O
otherwise O
, O
there O
may O
be O
no O
significant O
change O
. O
portable O
t O
##te O
( O
complete O
) O
done O
[ O
* O
* O
215 O
##8 O
- O
11 O
- O
22 O
* O
* O
] O
at O
9 O
: O
31 O
: O
26 O
am O
final O
: O
the O
left O
at O
##rium O
is O
di O
##lated O
. O
left O
vent O
##ric O
##ular O
wall O
thickness O
##es O
are O
normal O
. O
the O
left O
vent O
##ric O
##ular O
cavity O
size O
is O
normal O
. O
overall O
left O
vent O
##ric O
##ular O
s O
##ys O
##to O
##lic O
function O
is O
normal O
( O
l O
##ve O
##f O
> O
55 O
% O
) O
. O
tissue O
do O
##pp O
##ler O
imaging O
suggests O
a O
normal O
left O
vent O
##ric O
##ular O
filling O
pressure O
( O
p O
##c O
##w O
##p O
< O
12 O
##mm O
##h O
##g O
) O
. O
there O
is O
a O
mild O
resting O
left O
vent O
##ric O
##ular O
out O
##flow O
tract O
o O
##bs O
##truction O
. O
right O
vent O
##ric O
##ular O
chamber O
size O
and O
free O
wall O
motion O
are O
normal O
. O
the O
a O
##ort O
##ic O
valve O
leaf O
##lets O
( O
3 O
) O
are O
mildly O
thick O
##ened O
. O
there O
is O
no O
a O
##ort O
##ic O
valve O
s O
##ten O
##osis O
( O
ve O
##loc O
##ities O
increased O
due O
to O
mild O
left O
vent O
##ric O
##ular O
out O
##flow O
gradient O
) O
. O
no O
a O
##ort O
##ic O
re O
##gu O
##rg O
##itation O
is O
seen O
. O
the O
mit O
##ral O
valve O
leaf O
##lets O
are O
mildly O
thick O
##ened O
. O
there O
is O
moderate O
pulmonary O
artery O
s O
##ys O
##to O
##lic O
h O
##yper O
##tens O
##ion O
. O
there O
is O
an O
anterior O
space O
which O
most O
likely O
represents O
a O
fat O
pad O
. O
e O
##c O
##g O
study O
date O
of O
[ O
* O
* O
215 O
##8 O
- O
12 O
- O
11 O
* O
* O
] O
3 O
: O
01 O
: O
38 O
pm O
sin O
##us O
ta O
##chy O
##card O
##ia O
. O
consider O
left O
at O
##rial O
abnormal O
##ity O
. O
consider O
prior O
inferior O
my O
##oc O
##ard O
##ial O
in O
##far O
##ction O
, O
although O
it O
is O
non O
- O
diagnostic O
. O
delayed O
r O
wave O
progression O
with O
late O
pre O
##cor O
##dial O
q O
##rs O
transition O
. O
findings O
are O
non O
- O
specific O
. O
since O
the O
previous O
tracing O
of O
[ O
* O
* O
215 O
##8 O
- O
11 O
- O
22 O
* O
* O
] O
no O
significant O
change O
. O

radio O
##logy O
reports O
: O
[ O
* O
* O
215 O
##8 O
- O
11 O
- O
20 O
* O
* O
] O
2 O
: O
23 O
pm O
chest O
( O
portable O
a O
##p O
) O
impression O
: O
left O
b O
##asi O
##lar O
ate O
##lect O
##asis O
, O
otherwise O
normal O
. O
limited O
study O
. O
[ O
* O
* O
215 O
##8 O
- O
11 O
- O
20 O
* O
* O
] O
2 O
: O
36 O
pm O
c O
##t O
abdomen O
w O
/ O
o O
contrast O
; O
c O
##t O
p O
##el O
##vis O
w O
/ O
o O
contrast O
; O
c O
##t O
chest O
w O
/ O
o O
contrast O
impression O
: O
1 O
. O
right O
re O
##ctus O
a O
##b O
##dom O
##inus O
muscle O
hem O
##ato O
##ma O
. O
2 O
. O
no O
re O
##tro O
##per O
##ito O
##nea O
##l O
hem O
##ato O
##ma O
. O
3 O
. O
18 O
x O
23 O
mm O
h O
##yper O
##den O
##se O
re O
##tro O
##per O
##ito O
##nea O
##l O
les O
##ion O
within O
the O
a O
##ort O
##oc O
##ava O
##l O
region O
, O
likely O
a O
l O
##ymph O
node O
, O
new O
from O
prior O
. O
a O
p O
##el O
##vic O
m O
##r O
can O
be O
obtained O
for O
further O
characterization O
. O
[ O
* O
* O
215 O
##8 O
- O
11 O
- O
20 O
* O
* O
] O
7 O
: O
48 O
pm O
bi O
##lat O
lower O
ex O
##t O
veins O
impression O
: O
extensive O
ve O
##nous O
th O
##rom O
##bos O
##is O
extending O
through O
all O
the O
deep O
veins O
of O
the O
right O
lower O
ex O
##tre O
##mity O
and O
no O
evidence O
of O
left O
lower O
ex O
##tre O
##mity O
deep O
ve O
##nous O
th O
##rom O
##bos O
##is O
. O
[ O
* O
* O
215 O
##8 O
- O
11 O
- O
20 O
* O
* O
] O
7 O
: O
49 O
pm O
re O
##nal O
u O
. O
s O
. O
impression O
: O
normal O
study O
[ O
* O
* O
215 O
##8 O
- O
11 O
- O
21 O
* O
* O
] O
11 O
: O
14 O
am O
c O
##t O
p O
##el O
##vis O
w O
/ O
o O
contrast O
impression O
: O
1 O
. O
o O
##vo O
##id O
area O
of O
high O
density O
within O
the O
a O
##ort O
##oc O
##ava O
##l O
space O
at O
the O
level O
of O
the O
i O
##v O
##c O
filter O
with O
adjacent O
fatty O
strand O
##ing O
which O
is O
unchanged O
in O
size O
compared O
to O
the O
prior O
study O
. O
this O
finding O
is O
concerning O
for O
a O
small O
, O
at O
##able O
appearing O
re O
##tro O
##per O
##ito O
##nea O
##l O
hem O
##ato O
##ma O
. O
2 O
. O
stable O
right O
re O
##ctus O
a O
##b O
##dom O
##ini O
##s O
muscle O
hem O
##ato O
##ma O
. O
[ O
* O
* O
215 O
##8 O
- O
11 O
- O
23 O
* O
* O
] O
7 O
: O
42 O
am O
bi O
##lat O
lower O
ex O
##t O
veins O
port O
impression O
: O
limited O
exam O
, O
however O
a O
small O
amount O
of O
flow O
is O
now O
visual O
##ized O
in O
the O
right O
common O
and O
superficial O
f O
##em O
##oral O
veins O
, O
which O
remain O
partially O
o O
##cc O
##luded O
. O
re O
##con O
##stituted O
flow O
within O
the O
right O
pop O
##lite O
##al O
vein O
is O
observed O
. O
[ O
* O
* O
215 O
##8 O
- O
11 O
- O
27 O
* O
* O
] O
8 O
: O
26 O
am O
portable O
abdomen O
impression O
: O
small O
bow O
##el O
di O
##lat O
##ation O
most O
consistent O
with O
il O
##eus O
. O
[ O
* O
* O
215 O
##8 O
- O
11 O
- O
29 O
* O
* O
] O
3 O
: O
06 O
pm O
liver O
or O
gal O
##l O
##bla O
##dder O
us O
( O
single O
organ O
) O
impression O
: O
normal O
- O
appearing O
liver O
without O
focal O
les O
##ion O
or O
bi O
##lia O
##ry O
duct O
##al O
di O
##lat O
##ation O
. O

[ O
* O
* O
215 O
##8 O
- O
12 O
- O
10 O
* O
* O
] O
7 O
: O
10 O
pm O
un O
##ila O
##t O
lower O
ex O
##t O
veins O
left O
impression O
: O
limited O
exam O
; O
however O
, O
no O
evidence O
of O
d O
##v O
##t O
. O
calf O
veins O
could O
not O
be O
visual O
##ized O
. O
[ O
* O
* O
215 O
##8 O
- O
12 O
- O
11 O
* O
* O
] O
9 O
: O
46 O
am O
c O
##t O
abdomen O
w O
/ O
o O
contrast O
; O
c O
##t O
p O
##el O
##vis O
w O
/ O
o O
contrast O
impression O
: O
1 O
. O
minimal O
contraction O
in O
the O
right O
re O
##ctus O
sheath O
hem O
##ato O
##ma O
. O
2 O
. O
new O
as O
##ym O
##metric O
expansion O
of O
the O
left O
il O
##io O
##ps O
##oa O
##s O
muscles O
, O
with O
adjacent O
left O
re O
##tro O
##per O
##ito O
##nea O
##l O
strand O
##ing O
and O
small O
focal O
fluid O
collection O
posterior O
to O
the O
inferior O
pole O
of O
the O
left O
kidney O
. O
findings O
are O
compatible O
with O
new O
left O
re O
##tro O
##per O
##ito O
##nea O
##l O
hem O
##ato O
##ma O
. O
3 O
. O
post O
- O
surgical O
changes O
in O
the O
right O
groin O
, O
without O
associated O
right O
groin O
or O
thigh O
hem O
##ato O
##ma O
. O
inflammatory O
strand O
##ing O
is O
noted O
throughout O
the O
soft O
tissues O
of O
the O
right O
thigh O
. O
4 O
. O
a O
##ort O
##oc O
##ava O
##l O
density O
is O
again O
demonstrated O
. O
as O
previously O
described O
, O
it O
is O
decreased O
in O
size O
and O
at O
##ten O
##uation O
, O
most O
likely O
representing O
a O
small O
re O
##sol O
##ving O
hem O
##ato O
##ma O
. O
study O
date O
of O
[ O
* O
* O
215 O
##8 O
- O
12 O
- O
13 O
* O
* O
] O
11 O
: O
22 O
am O
c O
##t O
abdomen O
w O
/ O
o O
contrast O
; O
c O
##t O
p O
##el O
##vis O
w O
/ O
o O
contrast O
impression O
: O
1 O
. O
interval O
en O
##lar O
##gement O
of O
left O
re O
##tro O
##per O
##ito O
##nea O
##l O
hem O
##ato O
##ma O
, O
as O
described O
above O
. O
2 O
. O
new O
small O
left O
p O
##le O
##ural O
e O
##ff O
##usion O
with O
associated O
ate O
##lect O
##asis O
. O
otherwise O
unchanged O
c O
##t O
examination O
of O
the O
abdomen O
and O
p O
##el O
##vis O
compared O
to O
[ O
* O
* O
215 O
##8 O
- O
12 O
- O
11 O
* O
* O
] O
. O

brief O
hospital O
course O
: O
[ O
* O
* O
215 O
##8 O
- O
11 O
- O
20 O
* O
* O
] O
patient O
admitted O
via O
ed O
for O
increasing O
right O
lower O
ex O
##tre O
##mity O
pain O
and O
swelling O
. O
s O
/ O
p O
i O
##v O
##c O
filter O
placement O
from O
an O
o O
##sh O
complicated O
by O
right O
re O
##ctus O
muscle O
hem O
##ato O
##ma O
, O
s O
/ O
p O
several O
units O
blood O
trans O
##fusion O
. O
in O
ed O
found O
to O
have O
c O
##rea O
##tin O
##ine O
in O
8 O
. O
4 O
, O
h O
##yd O
##rated O
overnight O
, O
c O
##rea O
##tin O
##ine O
came O
down O
to O
6 O
. O
8 O
. O
re O
##nal O
consulted O
and O
following O
. O
r O
##le O
us O
showed O
c O
##lot O
in O
deep O
veins O
of O
r O
##le O
from O
calf O
to O
common O
f O
##em O
##oral O
, O
cannot O
visual O
##ize O
il O
##iac O
##s O
. O
c O
##t O
of O
p O
##el O
##vis O
and O
a O
##b O
##d O
. O
was O
done O
- O
right O
re O
##ctus O
a O
##b O
##dom O
##inus O
muscle O
hem O
##ato O
##ma O
. O
re O
##nal O
us O
- O
showed O
both O
kidney O
##s O
show O
patent O
main O
re O
##nal O
art O
##eries O
and O
veins O
with O
appropriate O
art O
##erial O
and O
ve O
##nous O
wave O
##form O
##s O
. O
r O
##le O
was O
ace O
wrapped O
and O
elevated O
. O
started O
he B-DRUG
##par I-DRUG
##in I-DRUG
d B-ROU
##rip I-ROU
conservative O
##ly O
. O
kept O
n O
##po O
. O
r O
##le O
noted O
to O
have O
significantly O
diminished O
sensation O
from O
toes O
- O
knee O
with O
no O
foot O
motor O
f O
##uc O
##nti O
##on O
and O
drop O
foot O
. O
[ O
* O
* O
215 O
##8 O
- O
11 O
- O
21 O
* O
* O
] O
patient O
was O
scheduled O
for O
an O
##gio O
##jet O
th O
##rom O
##be O
##ct O
##omy O
. O
kept O
n O
##po O
, O
pre O
- O
op O
##ed O
and O
consent O
##ed O
. O
patient O
had O
a O
##b O
##d O
/ O
p O
##el O
##vic O
c O
##t O
- O
that O
showed O
stable O
re O
##ctus O
muscle O
hem O
##ato O
##ma O
. O
became O
unstable O
, O
b O
##p O
down O
to O
the O
70 O
' O
s O
, O
given O
fluid B-DRUG
, I-DRUG
blood B-DRUG
products I-DRUG
, I-DRUG
transferred O
to O
the O
c O
##vic O
##u O
. O
art O
##erial O
line O
and O
central O
access O
lines O
were O
placed O
for O
blood O
pressure O
monitoring O
. O
continued O
to O
be O
o O
##li O
##gu O
##ric O
, O
and O
c O
##rea O
##tin O
##ine O
remain O
elevated O
. O
c O
##p O
##ks O
were O
sent O
that O
came O
back O
elevated O
. O
re O
##an O
##l O
consult O
placed O
, O
recommended O
bi B-DRUG
##car I-DRUG
##b I-DRUG
in B-FOR
##fusion I-FOR
which O
was O
started O
. O
in O
the O
c O
##vic O
##u O
patient O
re O
##cie O
##ved O
more O
blood B-DRUG
t B-FOR
##ran I-FOR
##fusion I-FOR
##s I-FOR
, I-FOR
started O
on O
neo B-DRUG
d B-ROU
##rip I-ROU
for O
b B-REA
##p I-REA
support I-REA
. I-REA
an O
##gio O
th O
##rom O
##be O
##ct O
##omy O
cancelled O
. O
re O
##nal O
service O
following O
. O
he B-DRUG
##par I-DRUG
##in I-DRUG
d B-ROU
##rip I-ROU
continued O
. O
patient O
had O
problems O
w O
/ O
h B-REA
##yper I-REA
##kal I-REA
##emia I-REA
- I-REA
treated O
w O
/ O
insulin B-DRUG
/ I-DRUG
bi B-DRUG
##car I-DRUG
##b I-DRUG
/ I-DRUG
d B-DRUG
##50 I-DRUG
/ I-DRUG
ca B-DRUG
##g I-DRUG
##lu I-DRUG
##cona I-DRUG
##te I-DRUG
i B-ROU
##v I-ROU
. I-ROU

[ O
* O
* O
215 O
##8 O
- O
11 O
- O
22 O
* O
* O
] O
remained O
in O
c O
##vic O
##u O
, O
continued O
to O
require O
fluid O
re O
##su O
##citation O
w O
/ O
bi B-DRUG
##card I-DRUG
d B-ROU
##rip I-ROU
and O
neo B-DRUG
d B-ROU
##rip I-ROU
to O
maintain B-REA
b I-REA
##p I-REA
. I-REA
compartment O
pressures O
were O
done O
by O
or O
##th O
##o O
service O
- O
found O
to O
be O
elevated O
, O
w O
/ O
c O
##p O
##k O
elevated O
as O
well O
. O
pre O
- O
op O
##ed O
and O
consent O
##ed O
for O
open O
ve O
##nous O
th O
##rom O
##be O
##ct O
##omy O
and O
f O
##ac O
##iot O
##omy O
. O
taken O
to O
or O
and O
underwent O
r O
##le O
open O
ve O
##nous O
th O
##rom O
##be O
##ct O
##omy O
and O
f O
##as O
##cio O
##tom O
##y O
. O
patient O
tolerate O
##d O
procedure O
, O
was O
transferred O
back O
to O
the O
c O
##vic O
##u O
for O
recovery O
. O
portable O
t O
##te O
was O
done O
- O
w O
/ O
l O
##ve O
##f O
> O
55 O
% O
. O
[ O
* O
* O
215 O
##8 O
- O
11 O
- O
23 O
* O
* O
] O
i O
##cu O
##d O
##2 O
/ O
pod O
##1 O
: O
remained O
o B-REA
##li I-REA
##gu I-REA
##ric I-REA
, I-REA
b B-REA
##p I-REA
remain I-REA
lab I-REA
##ile I-REA
requiring O
press B-DRUG
##ors I-DRUG
and O
fluid B-DRUG
b B-FOR
##ol I-FOR
##uses I-FOR
. I-FOR
continued O
to O
require O
blood B-DRUG
trans B-FOR
##fusion I-FOR
##s I-FOR
for O
low B-REA
h I-REA
##ct I-REA
. I-REA
remained O
in O
##tub O
##ated O
and O
se O
##dated O
. O
re O
##nal O
following O
, O
started O
on O
las B-DRUG
##ix I-DRUG
d B-ROU
##rip I-ROU
. I-ROU
started O
on O
he B-DRUG
##par I-DRUG
##in I-DRUG
d B-ROU
##rip I-ROU
. I-ROU
patient O
had O
cop O
##ious O
liquid O
stool O
##s O
- O
re O
##ct O
##al O
tube O
was O
placed O
, O
stool O
##s O
came O
back O
negative O
for O
c O
- O
di O
##ff O
. O
noted O
to O
have O
increased O
swelling O
of O
le O
' O
s O
bilateral O
us O
were O
done O
- O
ruled O
out O
for O
d O
##v O
##t O
. O
12 O
/ O
11 O
- O
13 O
/ O
09 O
i O
##cu O
##3 O
- O
5 O
pod O
##2 O
- O
4 O
: O
remained O
in O
the O
i O
##cu O
, O
in O
##tub O
##ated O
and O
se O
##dated O
##sed O
##ated O
. O
on O
las B-DRUG
##ix I-DRUG
d B-ROU
##rip I-ROU
to O
keep O
u B-REA
##op I-REA
> I-REA
100 I-REA
##cc I-REA
/ I-REA
h I-REA
, I-REA
he B-DRUG
##par I-DRUG
##in I-DRUG
and O
bi B-DRUG
##car I-DRUG
##b I-DRUG
d B-ROU
##rip I-ROU
##s I-ROU
. I-ROU
r O
lateral O
f O
##ac O
##iot O
##omy O
w O
/ O
muscle O
noted O
to O
be O
ne O
##c O
##rot O
##ic O
at O
superficial O
level O
. O
c O
##rea O
##tin O
##ine O
continued O
to O
rise O
and O
started O
to O
improve O
[ O
* O
* O
11 O
- O
26 O
* O
* O
] O
. O
re O
##nal O
following O
. O
failed O
ex O
##tub O
##ation O
[ O
* O
* O
11 O
- O
25 O
* O
* O
] O
. O
started O
on O
c B-DRUG
##ef I-DRUG
##az I-DRUG
##olin I-DRUG
[ O
* O
* O
11 O
- O
24 O
* O
* O
] O
, O
added O
c B-DRUG
##ip I-DRUG
##ro I-DRUG
[ O
* O
* O
11 O
- O
25 O
* O
* O
] O
. O
trans O
##fused O
p B-DRUG
##rb I-DRUG
##cs I-DRUG
for O
low B-REA
h I-REA
##ct I-REA
. I-REA

[ O
* O
* O
11 O
- O
27 O
* O
* O
] O
i O
##cu O
##6 O
/ O
pod O
##5 O
: O
remained O
in O
i O
##cu O
. O
on O
las B-DRUG
##ix I-DRUG
d B-ROU
##rip I-ROU
and O
di B-DRUG
##amo I-DRUG
##x I-DRUG
. I-DRUG
started O
tube O
feeds O
. O
remained O
in O
##tub O
##ated O
on O
c O
##pa O
##p O
/ O
ps O
vent O
##illa O
##tion O
. O
remains O
lightly O
se B-REA
##dated I-REA
on O
f B-DRUG
##ent I-DRUG
##any I-DRUG
##l I-DRUG
and O
verse B-DRUG
##d I-DRUG
d B-ROU
##rip I-ROU
##s I-ROU
, I-ROU
and O
continued O
on O
he B-DRUG
##par I-DRUG
##in I-DRUG
d B-ROU
##rip I-ROU
. I-ROU
continued O
anti B-DRUG
##biotics I-DRUG
. I-DRUG
re O
##nal O
continued O
to O
follow O
. O
c O
##k O
' O
s O
and O
c O
##rea O
##tin O
##ine O
improving O
. O
bi B-DRUG
##car I-DRUG
##b I-DRUG
d B-ROU
##rip I-ROU
discontinued O
. O
patient O
' O
s O
abdomen O
became O
di O
##sten O
##ded O
and O
w O
/ O
vomit O
##ing O
, O
a O
##b O
##d O
. O
x O
- O
ray O
showed O
il O
##eus O
- O
tube O
feeds O
stopped O
. O
[ O
* O
* O
215 O
##8 O
- O
11 O
- O
28 O
* O
* O
] O
i O
##cu O
##7 O
/ O
pod O
##6 O
: O
patient O
remained O
in O
i O
##cu O
, O
now O
we O
##ane O
##d O
and O
ex O
##tub O
##ated O
. O
a B-REA
##rf I-REA
/ I-REA
r B-REA
##hab I-REA
##do I-REA
improving O
with O
h O
##yd O
##ration O
. O
las B-DRUG
##ix I-DRUG
d B-ROU
##rip I-ROU
off O
. O
re O
##nal O
signed O
off O
. O
p O
##ca O
f O
##ent O
##any O
for O
pain O
, O
tolerate O
##d O
well O
. O
patient O
found O
to O
be O
confused O
but O
not O
agitated O
. O
[ O
* O
* O
215 O
##8 O
- O
11 O
- O
29 O
* O
* O
] O
i O
##cu O
##8 O
/ O
pod O
##7 O
: O
remained O
in O
i O
##cu O
. O
maintained O
off O
vent O
##illa O
##tor O
. O
continued O
he B-DRUG
##par I-DRUG
##in I-DRUG
d B-ROU
##rip I-ROU
, I-ROU
started O
co B-DRUG
##uma I-DRUG
##din I-DRUG
. I-DRUG
now O
auto O
di O
##ures O
##ing O
. O
c O
##k O
' O
s O
and O
c O
##rea O
##tine O
continued O
to O
trend O
down O
. O
physical O
therapy O
consulted O
, O
patient O
taken O
out O
of O
bed O
to O
chair O
w O
/ O
a O
lift O
, O
tolerate O
##d O
. O
continue O
to O
have O
di O
##ar O
##r O
##hea O
w O
/ O
re O
##ct O
##al O
tube O
. O
patient O
re O
##ami O
##ed O
confused O
. O
started O
p O
##o O
liquid O
##s O
. O
abdomen O
remain O
di O
##sten O
##ded O
- O
gal O
##l O
##bla O
##dder O
us O
- O
showed O
normal O
bi O
##lia O
##ry O
duct O
##al O
di O
##lat O
##ation O
. O
[ O
* O
* O
215 O
##8 O
- O
11 O
- O
30 O
* O
* O
] O
i O
##cu O
##9 O
/ O
pod O
##8 O
: O
continued O
he B-DRUG
##par I-DRUG
##in I-DRUG
d B-ROU
##rip I-ROU
, I-ROU
dose O
##d O
with O
co B-DRUG
##uma I-DRUG
##din I-DRUG
. I-DRUG
transferred O
to O
v O
##ic O
##u O
[ O
* O
* O
hospital O
ward O
name O
* O
* O
] O
5 O
. O
continued O
to O
be O
confused O
. O
continued O
to O
have O
di O
##ar O
##r O
##hea O
, O
prior O
##ly O
negative O
for O
c O
- O
di O
##ff O
. O
to O
##ler O
##ating O
p O
##o O
' O
s O
but O
w O
/ O
poor O
intake O
. O

[ O
* O
* O
207 O
##5 O
- O
11 O
- O
30 O
* O
* O
] O
pod O
##9 O
- O
16 O
: O
remained O
in O
v O
##ic O
##u O
, O
continued O
to O
be O
dose O
##d O
w O
/ O
co B-DRUG
##uma I-DRUG
##din I-DRUG
, I-DRUG
he B-DRUG
##par I-DRUG
##in I-DRUG
d B-ROU
##rip I-ROU
came O
off O
, O
in O
##r O
came O
up O
to O
5 O
. O
9 O
co B-DRUG
##uma I-DRUG
##din I-DRUG
held O
for O
a O
couple O
days O
. O
patient O
now O
a O
##ao O
##x O
##3 O
. O
wound O
v O
##ac O
taken O
down O
and O
replaced O
every O
third O
day O
. O
the O
r O
lateral O
wound O
was O
de O
##bri O
##ded O
and O
w O
/ O
wet O
- O
dry O
dressing O
. O
thigh O
in O
##cision O
de O
##his O
##ed O
, O
dressing O
w O
/ O
d O
##s O
##d O
. O
pain B-REA
management O
changed O
to O
p B-ROU
##o I-ROU
di B-DRUG
##lau I-DRUG
##di I-DRUG
##d I-DRUG
. I-DRUG
physical O
therapy O
working O
w O
/ O
patient O
to O
get O
o O
##ob O
. O
c O
##rea O
##tin O
##ine O
normal O
##ized O
, O
c O
##ks O
down O
to O
the O
4 O
##k O
, O
stopped O
cycling O
. O
h O
##ct O
had O
been O
stable O
in O
the O
high O
20 O
' O
s O
all O
week O
. O
[ O
* O
* O
date O
range O
( O
1 O
) O
105 O
##4 O
##90 O
* O
* O
] O
/ O
10 O
pod O
##17 O
- O
24 O
: O
remained O
in O
the O
v O
##ic O
##u O
. O
left O
ll O
##e O
noted O
to O
be O
more O
swollen O
, O
un O
##ila O
##teral O
us O
done O
negative O
for O
d O
##v O
##t O
. O
this O
week O
patient O
' O
s O
h O
##ct O
went O
down O
to O
22 O
from O
27 O
. O
a O
##b O
##d O
. O
/ O
p O
##el O
##cis O
c O
##t O
showed O
- O
stable O
r O
re O
##ctus O
sheath O
hem O
##ato O
##ma O
and O
w O
/ O
minimal O
contraction O
in O
the O
right O
re O
##ctus O
sheath O
hem O
##ato O
##ma O
. O
new O
as O
##ym O
##metric O
expansion O
of O
the O
left O
il O
##io O
##ps O
##oa O
##s O
muscles O
, O
with O
adjacent O
left O
re O
##tro O
##per O
##ito O
##nea O
##l O
strand O
##ing O
and O
small O
focal O
fluid O
collection O
posterior O
to O
the O
inferior O
pole O
of O
the O
left O
kidney O
. O
findings O
are O
compatible O
with O
new O
left O
re O
##tro O
##per O
##ito O
##nea O
##l O
hem O
##ato O
##ma O
. O
patient O
re O
##ci O
##ved O
numerous O
blood O
trans O
##fusion O
##s O
. O
hem O
##e O
on O
##cology O
consulted O
- O
recommended O
to O
d O
/ O
c O
as B-DRUG
##pi I-DRUG
##rin I-DRUG
and O
lower O
in O
##r O
goal O
to O
1 O
. O
5 O
- O
2 O
. O
2 O
. O
as B-DRUG
##pi I-DRUG
##rin I-DRUG
was O
d O
/ O
c O
' O
d O
. O
co B-DRUG
##uma I-DRUG
##din I-DRUG
was O
held O
and O
re O
##s O
- O
started O
to O
target O
goal O
in O
##r O
per O
hem O
##e O
recommendations O
. O
kept O
on O
bed O
##rest O
. O

[ O
* O
* O
date O
range O
( O
1 O
) O
105 O
##4 O
##9 O
##1 O
* O
* O
] O
pod O
25 O
- O
27 O
: O
remained O
in O
the O
v O
##ic O
##u O
. O
h O
##ct O
had O
been O
stable O
at O
29 O
- O
30 O
, O
trans O
##fused O
another O
unit O
of O
blood O
to O
keep O
h O
##ct O
above O
29 O
. O
patient O
is O
stable O
h O
##ym O
##ody O
##nam O
##ically O
. O
re O
- O
started O
out O
of O
bed O
activity O
. O
wound O
v O
##ac O
the O
##rp O
##ay O
continued O
on O
r O
medial O
wound O
and O
r O
groin O
wound O
. O
the O
r O
lateral O
wound O
was O
again O
de O
##bri O
##ded O
at O
the O
bedside O
w O
/ O
routine O
wet O
- O
dry O
dressing O
found O
to O
be O
cell B-REA
##uli I-REA
##tic I-REA
all O
around O
started O
na B-DRUG
##f I-DRUG
##ci I-DRUG
##llin I-DRUG
i B-ROU
##v I-ROU
. I-ROU
physical O
therapy O
recommended O
re O
##hab O
. O
re O
##hab O
screening O
initiated O
. O
[ O
* O
* O
215 O
##8 O
- O
12 O
- O
20 O
* O
* O
] O
pod O
##28 O
: O
patient O
' O
s O
h O
##ct O
had O
been O
stable O
for O
almost O
1 O
week O
now O
, O
w O
/ O
almost O
stable O
co B-DRUG
##uma I-DRUG
##din I-DRUG
dose O
between O
5 O
- O
7 O
. O
5 O
daily O
, O
keeping O
an O
in O
##r O
between O
1 O
. O
5 O
- O
2 O
. O
2 O
. O
patient O
was O
discharged O
to O
re O
##hab O
in O
stable O
condition O
. O
the O
right O
le O
remain O
to O
have O
no O
motor O
function O
, O
sensation O
is O
almost O
normal O
w O
/ O
new O
cell B-REA
##uli I-REA
##tis I-REA
around O
the O
lateral O
f O
##ac O
##iot O
##omy O
, O
now O
being O
treated O
w O
/ O
anti B-DRUG
##biotics I-DRUG
. I-DRUG
patient O
' O
s O
p O
##o O
intake O
remain O
poor O
but O
improving O
. O
her O
c O
##rea O
##tin O
##ine O
is O
now O
normal O
. O
patient O
will O
f O
##u O
w O
/ O
d O
##r O
. O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
139 O
##1 O
* O
* O
] O
in O
2 O
weeks O
to O
re O
- O
evaluate O
wounds O
and O
assess O
for O
possible O
skin O
g O
##raft O
##ing O
. O
instructions O
provided O
to O
patient O
. O
medications O
on O
admission O
: O
t B-DRUG
##ria I-DRUG
##m I-DRUG
##ter I-DRUG
##ene I-DRUG
- I-DRUG
h I-DRUG
##ct I-DRUG
##z I-DRUG
37 B-STR
. I-STR
5 I-STR
/ I-STR
25 I-STR
mg I-STR
q B-FRE
##d I-FRE
l B-DRUG
##isi I-DRUG
##no I-DRUG
##p I-DRUG
##ril I-DRUG
20 B-STR
mg I-STR
q B-FRE
##d I-FRE
s B-DRUG
##pi I-DRUG
##ri I-DRUG
##va I-DRUG
18 B-STR
core B-DRUG
##g I-DRUG
25 B-STR
mg I-STR
q B-FRE
##d I-FRE
o B-DRUG
##me I-DRUG
##pra I-DRUG
##zo I-DRUG
##le I-DRUG
20 B-STR
mg I-STR
q B-FRE
##d I-FRE
e B-DRUG
##ffe I-DRUG
##x I-DRUG
##or I-DRUG
x I-DRUG
##l I-DRUG
150 B-STR
mg I-STR
[ O
* O
* O
hospital O
##1 O
* O
* O
] O
car B-DRUG
##ba I-DRUG
##ma I-DRUG
##ze I-DRUG
##pine I-DRUG
100 B-STR
mg I-STR
p B-ROU
##o I-ROU
bid B-FRE
ne B-DRUG
##uron I-DRUG
##tin I-DRUG
600 B-STR
mg I-STR
[ O
* O
* O
hospital O
##1 O
* O
* O
] O
si B-DRUG
##m I-DRUG
##vas I-DRUG
##tat I-DRUG
##in I-DRUG
20 B-STR
mg I-STR
q B-FRE
##d I-FRE
sing B-DRUG
##ula I-DRUG
##ir I-DRUG
10 B-STR
mg I-STR
q B-FRE
##d I-FRE
pro B-DRUG
##air I-DRUG
h I-DRUG
##fa I-DRUG
90 B-STR
m I-STR
##c I-STR
##g I-STR
in B-FOR
##hale I-FOR
##r I-FOR

discharge O
medications O
: O
1 O
. O
di B-DRUG
##c I-DRUG
##lo I-DRUG
##xa I-DRUG
##ci I-DRUG
##llin I-DRUG
500 B-STR
mg I-STR
capsule B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
capsule B-FOR
p B-ROU
##o I-ROU
four B-FRE
times I-FRE
a I-FRE
day I-FRE
for B-DUR
2 I-DUR
weeks I-DUR
. I-DUR
2 O
. O
out O
##patient O
lab O
work O
in O
##r O
three O
times O
a O
week O
( O
goal O
in O
##r O
1 O
. O
5 O
- O
2 O
. O
2 O
) O
patient O
has O
history O
of O
bleeding O
3 O
. O
car B-DRUG
##ba I-DRUG
##ma I-DRUG
##ze I-DRUG
##pine I-DRUG
100 B-STR
mg I-STR
tablet B-FOR
, I-FOR
ch I-FOR
##ew I-FOR
##able I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
, I-FOR
ch I-FOR
##ew I-FOR
##able I-FOR
p B-ROU
##o I-ROU
bid B-FRE
( O
2 O
times O
a O
day O
) O
. O
4 O
. O
ve B-DRUG
##n I-DRUG
##la I-DRUG
##fa I-DRUG
##xin I-DRUG
##e I-DRUG
75 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
two B-DOS
( I-DOS
2 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
bid B-FRE
( O
2 O
times O
a O
day O
) O
. O
5 O
. O
mon B-DRUG
##tel I-DRUG
##uka I-DRUG
##st I-DRUG
10 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( O
daily O
) O
. O
6 O
. O
al B-DRUG
##but I-DRUG
##ero I-DRUG
##l I-DRUG
su I-DRUG
##lf I-DRUG
##ate I-DRUG
2 B-STR
. I-STR
5 I-STR
mg I-STR
/ I-STR
3 I-STR
m I-STR
##l I-STR
( O
0 O
. O
08 O
##3 O
% O
) O
solution B-FOR
for I-FOR
ne I-FOR
##bul I-FOR
##ization I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
in B-ROU
##hala I-ROU
##tion I-ROU
q B-FRE
##2 I-FRE
##h I-FRE
( I-FRE
every I-FRE
2 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
w B-REA
##hee I-REA
##zing I-REA
. I-REA
7 O
. O
am B-DRUG
##lo I-DRUG
##di I-DRUG
##pine I-DRUG
5 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( O
daily O
) O
. O

8 O
. O
pan B-DRUG
##top I-DRUG
##raz I-DRUG
##ole I-DRUG
40 B-STR
mg I-STR
tablet B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
p B-ROU
##o I-ROU
q B-FRE
##24 I-FRE
##h I-FRE
( O
every O
24 O
hours O
) O
. O
9 O
. O
do B-DRUG
##cus I-DRUG
##ate I-DRUG
sodium I-DRUG
100 B-STR
mg I-STR
capsule B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
capsule B-FOR
p B-ROU
##o I-ROU
bid B-FRE
( O
2 O
times O
a O
day O
) O
. O
10 O
. O
z B-DRUG
##ol I-DRUG
##pid I-DRUG
##em I-DRUG
5 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
h B-FRE
##s I-FRE
( O
at O
bed O
##time O
) O
as O
needed O
for O
ins B-REA
##om I-REA
##nia I-REA
. I-REA
11 O
. O
ace B-DRUG
##tam I-DRUG
##ino I-DRUG
##phe I-DRUG
##n I-DRUG
650 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
1 B-DOS
- I-DOS
2 I-DOS
tablets B-FOR
p B-ROU
##o I-ROU
q B-FRE
##4 I-FRE
##h I-FRE
( I-FRE
every I-FRE
4 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
fever B-REA
or O
pain B-REA
. I-REA
12 O
. O
si B-DRUG
##met I-DRUG
##hic I-DRUG
##one I-DRUG
80 B-STR
mg I-STR
tablet B-FOR
, I-FOR
ch I-FOR
##ew I-FOR
##able I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
, I-FOR
ch I-FOR
##ew I-FOR
##able I-FOR
p B-ROU
##o I-ROU
q B-FRE
##id I-FRE
( O
4 O
times O
a O
day O
) O
as O
needed O
for O
gas B-REA
. I-REA
13 O
. O
o B-DRUG
##xy I-DRUG
##co I-DRUG
##don I-DRUG
##e I-DRUG
5 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
1 B-DOS
- I-DOS
2 I-DOS
tablets B-FOR
p B-ROU
##o I-ROU
every B-FRE
six I-FRE
( I-FRE
6 I-FRE
) I-FRE
hours I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
. I-REA
14 O
. O
bi B-DRUG
##sa I-DRUG
##co I-DRUG
##dy I-DRUG
##l I-DRUG
5 B-STR
mg I-STR
tablet B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
si O
##g O
: O
two B-DOS
( I-DOS
2 I-DOS
) I-DOS
tablet B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
p B-ROU
##o I-ROU
daily B-FRE
( O
daily O
) O
as O
needed O
for O
con B-REA
##st I-REA
##ip I-REA
##ation I-REA
. I-REA
15 O
. O
met B-DRUG
##op I-DRUG
##rol I-DRUG
##ol I-DRUG
ta I-DRUG
##rt I-DRUG
##rate I-DRUG
25 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
1 B-DOS
. I-DOS
5 I-DOS
tablets B-FOR
p B-ROU
##o I-ROU
t B-FRE
##id I-FRE
( O
3 O
times O
a O
day O
) O
. O
16 O
. O
mi B-DRUG
##cona I-DRUG
##zo I-DRUG
##le I-DRUG
ni I-DRUG
##trate I-DRUG
2 O
% O
powder B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
app B-FOR
##l I-FOR
topic B-ROU
##al I-ROU
[ O
* O
* O
hospital O
##1 O
* O
* O
] O
( O
2 B-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. O
17 O
. O
camp B-DRUG
##hor I-DRUG
- I-DRUG
men I-DRUG
##th I-DRUG
##ol I-DRUG
0 B-STR
. I-STR
5 I-STR
- I-STR
0 I-STR
. I-STR
5 I-STR
% O
lot B-FOR
##ion I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
app B-FOR
##l I-FOR
topic B-ROU
##al I-ROU
q B-FRE
##id I-FRE
( O
4 O
times O
a O
day O
) O
as O
needed O
for O
it B-REA
##ching I-REA
. I-REA
18 O
. O
war B-DRUG
##fari I-DRUG
##n I-DRUG
2 B-STR
. I-STR
5 I-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
three B-DOS
( I-DOS
3 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
once B-FRE
daily I-FRE
at I-FRE
4 I-FRE
pm I-FRE
: I-FRE
t O
##it O
##rate O
to O
in O
##r O
goal O
of O
1 O
. O
5 O
- O
2 O
. O
2 O
. O
19 O
. O
mi B-DRUG
##cona I-DRUG
##zo I-DRUG
##le I-DRUG
ni I-DRUG
##trate I-DRUG
2 O
% O
cream B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
app B-FOR
##l I-FOR
v B-ROU
##agi I-ROU
##nal I-ROU
h B-FRE
##s I-FRE
( O
at O
bed O
##time O
) O
for O
5 B-FRE
days I-FRE
: I-FRE
d O
/ O
c O
[ O
* O
* O
215 O
##8 O
- O
12 O
- O
25 O
* O
* O
] O
. O
discharge O
disposition O
: O
extended O
care O
facility O
: O
[ O
* O
* O
hospital O
##6 O
45 O
##9 O
* O
* O
] O
for O
the O
aged O
- O
mac O
##u O

discharge O
diagnosis O
: O
- O
right O
lower O
ex O
##tre O
##mity O
ve O
##nous O
th O
##rom O
##bos O
##is O
now O
s O
/ O
p O
common O
il O
##iac O
th O
##rom O
##bus O
s O
/ O
p O
th O
##rom O
##be O
##com O
##y O
/ O
em O
##bol O
##ec O
##tom O
##y O
- O
re O
##ctus O
muscle O
hem O
##ato O
##ma O
- O
an O
##emia O
- O
secondary O
to O
bleeding O
- O
acute B-REA
re I-REA
##nal I-REA
failure I-REA
- I-REA
on O
arrival O
c O
##rea O
##tin O
##ine O
peaked O
at O
8 O
. O
9 O
, O
recovered O
w O
/ O
fluid O
re O
##sus O
##ciation O
, O
al O
##cal O
##ini O
##zation O
w O
/ O
bi B-DRUG
##car I-DRUG
##b I-DRUG
d B-ROU
##rip I-ROU
, I-ROU
c O
##rea O
##tin O
##ine O
now O
normal O
r O
##hab O
##dom O
##yo O
##lysis O
- O
r O
##le O
is O
##che O
##mia O
2nd O
to O
compartment O
syndrome O
, O
required O
f O
##ac O
##iot O
##omy O
- O
now O
resolved O
- O
r O
foot O
drop O
- O
prior O
to O
hospital O
##ization O
, O
persistent O
, O
will O
need O
a O
##g O
##ress O
##ive O
physical O
therapy O
and O
s O
##p O
##lint O
##ing O
history O
of O
: O
h O
##t O
##n O
h O
##yper O
##lip O
##ide O
##mia O
as O
##th O
##ma O
l O
back O
me O
##lan O
##oma O
ps O
##h O
: O
i O
##v O
##c O
filter O
( O
[ O
* O
* O
10 O
- O
23 O
* O
* O
] O
) O
, O
l O
back O
me O
##lan O
##oma O
ex O
##cision O
with O
a O
##x O
l O
##n O
d O
##x O
##n O
, O
lap O
##aro O
##tom O
##y O
x O
2 O
for O
o O
##var O
##ian O
c O
##ys O
##ts O
, O
c O
- O
section O
, O
app O
, O
lap O
ch O
##ole O
discharge O
condition O
: O
mental O
status O
: O
clear O
and O
coherent O
level O
of O
consciousness O
: O
alert O
and O
interactive O
activity O
status O
: O
out O
of O
bed O
with O
assistance O
to O
chair O
or O
wheelchair O
labs O
: O
in O
##r O
three O
times O
a O
week O
( O
if O
daily O
cannot O
be O
done O
) O
in O
##r O
upon O
discharge O
is O
1 O
. O
4 O
( O
goal O
in O
##r O
is O
between O
1 O
. O
5 O
- O
2 O
. O
2 O
) O
discharge O
instructions O
: O
- O
you O
were O
admitted O
for O
right O
lower O
ex O
##tre O
##mity O
pain O
, O
found O
to O
have O
right O
re O
##ctus O
sheath O
hem O
##ato O
##ma O
and O
ve O
##nous O
th O
##rom O
##bos O
##is O
extending O
through O
all O
the O
deep O
veins O
of O
the O
right O
lower O
ex O
##tre O
##mity O
, O
- O
you O
became O
critically O
ill O
from O
the O
released O
chemicals O
from O
your O
right O
lower O
ex O
##tre O
##mity O
muscles O
, O
you O
required O
i O
##cu O
care O
before O
and O
after O
your O
surgery O
, O
- O
you O
had O
to O
be O
taken O
to O
the O
or O
for O
removal O
of O
th O
##rom O
##bus O
and O
f O
##ac O
##iot O
##omy O
to O
relieve O
pressure O
in O
your O
right O
calf O
, O
- O
as O
part O
of O
your O
therapy O
we O
started O
you O
on O
co B-DRUG
##uma I-DRUG
##din I-DRUG
that O
you O
will O
need O
to O
be O
on O
for O
an O
extended O
period O
of O
time O
. O
you O
will O
need O
in O
##r O
levels O
checked O
frequently O
until O
your O
dose O
and O
in O
##r O
levels O
are O
stable O
. O
- O
you O
were O
discharged O
on O
anti O
##biotics O
that O
you O
will O
take O
for O
2 O
weeks O
, O
- O
you O
will O
have O
a O
wound O
v O
##ac O
placed O
in O
your O
wounds O
at O
the O
re O
##hab O
facility O
( O
right O
medial O
and O
groin O
wounds O
) O
to O
be O
changed O
every O
third O
day O
until O
you O
get O
seen O
in O
d O
##r O
. O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
139 O
##1 O
* O
* O
] O
for O
f O
##u O
. O

- O
you O
also O
developed O
right O
" O
drop O
foot O
" O
, O
you O
will O
need O
a O
s O
##pi O
##lt O
to O
for O
this O
, O
this O
was O
custom O
na O
##de O
for O
you O
and O
will O
be O
delivered O
to O
your O
re O
##hab O
. O
- O
you O
will O
f O
##u O
w O
/ O
d O
##r O
. O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
139 O
##1 O
* O
* O
] O
in O
2 O
weeks O
to O
re O
- O
evaluate O
your O
wounds O
for O
the O
need O
for O
skin O
g O
##raft O
##ing O
. O
follow O
##up O
instructions O
: O
d O
##r O
. O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
139 O
##1 O
* O
* O
] O
in O
2 O
weeks O
. O
call O
to O
make O
an O
appointment O
phone O
: O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
139 O
##3 O
* O
* O
] O
completed O
by O
: O
[ O
* O
* O
215 O
##8 O
- O
12 O
- O
20 O
* O
* O
] O

admission O
date O
: O
[ O
* O
* O
218 O
##8 O
- O
10 O
- O
24 O
* O
* O
] O
discharge O
date O
: O
[ O
* O
* O
218 O
##8 O
- O
10 O
- O
30 O
* O
* O
] O
date O
of O
birth O
: O
[ O
* O
* O
210 O
##9 O
- O
3 O
- O
11 O
* O
* O
] O
sex O
: O
f O
service O
: O
medicine O
all O
##er O
##gies O
: O
m B-DRUG
##or I-DRUG
##phine I-DRUG
/ O
o B-DRUG
##xy I-DRUG
##con I-DRUG
##tin I-DRUG
/ O
pen B-DRUG
##ici I-DRUG
##llin I-DRUG
##s I-DRUG
/ O
pre B-DRUG
##dn I-DRUG
##ison I-DRUG
##e I-DRUG
/ O
code B-DRUG
##ine I-DRUG
/ O
ad B-DRUG
##va I-DRUG
##ir I-DRUG
disk B-FOR
##us I-FOR
attending O
: O
[ O
* O
* O
first O
name O
##3 O
( O
l O
##f O
) O
32 O
##7 O
##6 O
* O
* O
] O
chief O
complaint O
: O
pulmonary O
em O
##bol O
##ism O
major O
surgical O
or O
invasive O
procedure O
: O
none O
history O
of O
present O
illness O
: O
m O
##s O
. O
[ O
* O
* O
known O
last O
##name O
* O
* O
] O
is O
a O
79 O
yo O
woman O
with O
h O
##x O
of O
non B-REA
- I-REA
small I-REA
cell I-REA
lung I-REA
cancer I-REA
who O
was O
transfer O
##ed O
from O
o O
##sh O
with O
bilateral O
p O
##es O
. O
for O
full O
hp O
##i O
please O
see O
admission O
note O
. O
briefly O
, O
she O
had O
last O
received O
tax B-DRUG
##ol I-DRUG
, I-DRUG
car B-DRUG
##bo I-DRUG
##p I-DRUG
##lat I-DRUG
##in I-DRUG
, I-DRUG
on O
[ O
* O
* O
218 O
##8 O
- O
10 O
- O
20 O
* O
* O
] O
. O
she O
had O
r O
##c O
##v O
##d O
a B-DRUG
##vas I-DRUG
##tin I-DRUG
as O
well O
on O
prior O
cycles O
but O
held O
due O
to O
poorly O
controlled O
b O
##p O
. O
the O
patient O
was O
at O
home O
when O
she O
noted O
acute O
worse O
##ning O
of O
chronic O
d O
##ys O
##p O
##nea O
and O
came O
to O
[ O
* O
* O
hospital O
##1 O
18 O
* O
* O
] O
[ O
* O
* O
location O
( O
un O
) O
620 O
* O
* O
] O
where O
she O
was O
diagnosed O
with O
bilateral O
p B-REA
##es I-REA
. I-REA
she O
was O
started O
on O
he B-DRUG
##par I-DRUG
##in I-DRUG
g B-ROU
##tt I-ROU
and O
bedside O
echo O
showed O
r O
##v O
strain O
, O
but O
patient O
remained O
hem O
##ody O
##nam O
##ically O
stable O
while O
in O
i O
##cu O
. O
she O
was O
transitioned O
to O
love B-DRUG
##no I-DRUG
##x I-DRUG
and O
called O
out O
to O
the O
floor O
. O

past O
medical O
history O
: O
past O
on O
##co O
##log O
##ic O
history O
: O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
adapted O
from O
d O
##r O
. O
[ O
* O
* O
name O
( O
ni O
) O
32 O
##7 O
##9 O
* O
* O
] O
notes O
: O
this O
patient O
is O
a O
former O
heavy O
smoke O
##r O
, O
although O
quit O
over O
20 O
years O
ago O
. O
developed O
left O
arm O
pain O
down O
in O
[ O
* O
* O
state O
108 O
* O
* O
] O
late O
in O
the O
spring O
of O
[ O
* O
* O
218 O
##6 O
* O
* O
] O
. O
she O
was O
evaluated O
for O
this O
, O
which O
included O
a O
c O
##t O
scan O
of O
the O
chest O
, O
which O
indicated O
a O
right O
middle O
lobe O
lung O
les O
##ion O
. O
she O
came O
back O
to O
[ O
* O
* O
location O
( O
un O
) O
86 O
* O
* O
] O
and O
underwent O
a O
right O
middle O
lobe O
##ct O
##omy O
at O
[ O
* O
* O
hospital O
##6 O
* O
* O
] O
by O
d O
##r O
. O
[ O
* O
* O
first O
name O
( O
s O
##ti O
##tle O
) O
* O
* O
] O
. O
she O
had O
a O
stage O
i O
t O
##1 O
n O
##0 O
2 O
. O
6 O
- O
cm O
moderately O
differentiated O
ad O
##eno O
##car O
##cin O
##oma O
re O
##sect O
##ed O
by O
right O
middle O
lobe O
##ct O
##omy O
at O
[ O
* O
* O
hospital O
208 O
##2 O
* O
* O
] O
[ O
* O
* O
218 O
##6 O
- O
7 O
- O
11 O
* O
* O
] O
by O
d O
##r O
. O
[ O
* O
* O
first O
name O
( O
s O
##ti O
##tle O
) O
* O
* O
] O
. O
there O
was O
no O
vascular O
l O
##ymph O
##atic O
invasion O
. O
margins O
were O
negative O
. O
multiple O
l O
##ymph O
nodes O
were O
sampled O
and O
were O
negative O
. O
she O
also O
had O
a O
media O
##st O
##ino O
##sco O
##py O
pre O
##oper O
##ative O
##ly O
with O
multiple O
n O
##2 O
and O
n O
##3 O
l O
##ymph O
nodes O
that O
were O
negative O
. O
over O
the O
next O
year O
, O
she O
had O
an O
increasing O
right O
lower O
lung O
nod O
##ule O
. O
she O
underwent O
a O
c O
##t O
- O
guided O
needle O
bio O
##psy O
on O
[ O
* O
* O
218 O
##7 O
- O
7 O
- O
31 O
* O
* O
] O
. O
this O
was O
a O
1 O
. O
2 O
- O
cm O
right O
lower O
lobe O
nod O
##ule O
. O
the O
report O
was O
positive O
for O
ma O
##li O
##gna O
##ncy O
changes O
consistent O
with O
non O
- O
small O
cell O
car O
##cin O
##oma O
, O
favor O
ad O
##eno O
##car O
##cin O
##oma O
. O
finally O
, O
she O
did O
have O
an O
m O
##ri O
of O
her O
brain O
done O
at O
[ O
* O
* O
hospital O
##6 O
* O
* O
] O
on O
[ O
* O
* O
218 O
##8 O
- O
6 O
- O
26 O
* O
* O
] O
. O
this O
showed O
some O
mild O
chronic O
micro O
##vas O
##cular O
changes O
but O
no O
evidence O
of O
tumor O
. O

past O
medical O
history O
: O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
- O
non O
- O
small O
cell O
lung O
cancer O
, O
ad O
##eno O
##car O
##cin O
##oma O
as O
above O
. O
- O
all O
##ergic O
r O
##hin O
##itis O
. O
- O
h O
##yper O
##tens O
##ion O
. O
- O
h O
##yper O
##lip O
##ide O
##mia O
. O
- O
gas O
##tro O
##es O
##op O
##ha O
##eal O
re O
##f O
##lux O
disease O
. O
- O
es O
##op O
##hage O
##al O
strict O
##ure O
, O
status O
post O
- O
di O
##lation O
. O
- O
status O
post O
- O
total O
hip O
replacement O
##s O
and O
one O
knee O
replacement O
for O
o O
##ste O
##oar O
##th O
##rit O
##is O
. O
social O
history O
: O
per O
d O
##r O
. O
[ O
* O
* O
name O
( O
ni O
) O
79 O
##5 O
##29 O
* O
* O
] O
note O
: O
she O
is O
married O
and O
lives O
with O
her O
husband O
. O
they O
winter O
in O
[ O
* O
* O
state O
108 O
* O
* O
] O
and O
they O
live O
up O
here O
the O
rest O
of O
the O
time O
. O
she O
does O
not O
work O
anymore O
, O
but O
used O
to O
work O
as O
an O
assistant O
to O
a O
th O
##ora O
##ci O
##c O
surgeon O
at O
the O
[ O
* O
* O
location O
126 O
##8 O
* O
* O
] O
v O
##a O
. O
she O
does O
not O
drink O
any O
alcohol O
. O
she O
smoked O
one O
pack O
a O
day O
for O
30 O
- O
years O
, O
but O
quit O
in O
[ O
* O
* O
216 O
##2 O
* O
* O
] O
. O
family O
history O
: O
there O
is O
no O
family O
history O
of O
any O
lung O
disease O
. O
her O
brother O
had O
some O
type O
of O
cancer O
, O
which O
was O
either O
a O
thy O
##roid O
cancer O
or O
throat O
cancer O
, O
the O
patient O
is O
not O
sure O
. O
physical O
exam O
: O
vital O
##s O
- O
t O
: O
96 O
. O
3 O
b O
##p O
: O
126 O
/ O
83 O
h O
##r O
: O
83 O
r O
##r O
: O
16 O
02 O
sat O
: O
100 O
% O
on O
1 O
##l O
general O
: O
na O
##d O
skin O
: O
warm O
and O
well O
per O
##fused O
, O
no O
ex O
##cor O
##iation O
##s O
or O
lesions O
, O
no O
r O
##ash O
##es O
he O
##ent O
: O
at O
/ O
n O
##c O
, O
e O
##omi O
, O
per O
##rl O
##a O
, O
an O
##ict O
##eric O
s O
##cle O
##ra O
, O
pale O
con O
##junct O
##iva O
, O
patent O
na O
##res O
, O
mm O
##m O
, O
den O
##tures O
, O
neck O
: O
no O
lad O
, O
no O
j O
##v O
##d O
cardiac O
: O
r O
##rr O
, O
s O
##1 O
/ O
s O
##2 O
, O
soft O
1 O
/ O
6 O
se O
##m O
and O
l O
##us O
##b O
lung O
: O
decreased O
breath O
sounds O
throughout O
, O
but O
no O
w O
##hee O
##zes O
/ O
r O
##ales O
/ O
r O
##hon O
##chi O
. O
abdomen O
: O
non O
##dis O
##tended O
, O
+ O
b O
##s O
, O
non O
##tend O
##er O
in O
all O
q O
##uad O
##rants O
, O
no O
re O
##bound O
/ O
guarding O
, O
no O
he O
##pa O
##tos O
##ple O
##no O
##me O
##gal O
##y O
m O
/ O
s O
: O
moving O
all O
ex O
##tre O
##mit O
##ies O
well O
, O
no O
c O
##yan O
##osis O
, O
club O
##bing O
or O
ed O
##ema O
, O
no O
obvious O
def O
##orm O
##ities O
pulses O
: O
2 O
+ O
d O
##p O
pulses O
bilateral O
##ly O
ne O
##uro O
: O
c O
##n O
ii O
- O
x O
##ii O
intact O

per O
##tinent O
results O
: O
[ O
* O
* O
218 O
##8 O
- O
10 O
- O
24 O
* O
* O
] O
w O
##b O
##c O
- O
2 O
. O
3 O
* O
# O
h O
##g O
##b O
- O
10 O
. O
8 O
* O
h O
##ct O
- O
31 O
. O
8 O
* O
p O
##lt O
c O
##t O
- O
131 O
* O
# O
[ O
* O
* O
218 O
##8 O
- O
10 O
- O
25 O
* O
* O
] O
w O
##b O
##c O
- O
2 O
. O
0 O
* O
h O
##g O
##b O
- O
9 O
. O
7 O
* O
h O
##ct O
- O
27 O
. O
8 O
* O
p O
##lt O
c O
##t O
- O
111 O
* O
[ O
* O
* O
218 O
##8 O
- O
10 O
- O
25 O
* O
* O
] O
w O
##b O
##c O
- O
2 O
. O
0 O
* O
h O
##g O
##b O
- O
9 O
. O
6 O
* O
h O
##ct O
- O
27 O
. O
3 O
* O
p O
##lt O
c O
##t O
- O
109 O
* O
[ O
* O
* O
218 O
##8 O
- O
10 O
- O
26 O
* O
* O
] O
w O
##b O
##c O
- O
1 O
. O
7 O
* O
h O
##g O
##b O
- O
9 O
. O
5 O
* O
h O
##ct O
- O
27 O
. O
6 O
* O
p O
##lt O
c O
##t O
- O
103 O
* O
[ O
* O
* O
218 O
##8 O
- O
10 O
- O
27 O
* O
* O
] O
w O
##b O
##c O
- O
1 O
. O
6 O
* O
h O
##g O
##b O
- O
8 O
. O
3 O
* O
h O
##ct O
- O
23 O
. O
7 O
* O
p O
##lt O
c O
##t O
- O
74 O
* O
[ O
* O
* O
218 O
##8 O
- O
10 O
- O
28 O
* O
* O
] O
w O
##b O
##c O
- O
1 O
. O
3 O
* O
h O
##g O
##b O
- O
8 O
. O
1 O
* O
h O
##ct O
- O
23 O
. O
6 O
* O
p O
##lt O
c O
##t O
- O
81 O
* O
[ O
* O
* O
218 O
##8 O
- O
10 O
- O
29 O
* O
* O
] O
w O
##b O
##c O
- O
1 O
. O
4 O
* O
h O
##g O
##b O
- O
10 O
. O
6 O
* O
# O
h O
##ct O
- O
30 O
. O
8 O
* O
# O
p O
##lt O
c O
##t O
- O
109 O
* O
[ O
* O
* O
218 O
##8 O
- O
10 O
- O
30 O
* O
* O
] O
w O
##b O
##c O
- O
2 O
. O
4 O
* O
# O
h O
##g O
##b O
- O
10 O
. O
4 O
* O
h O
##ct O
- O
30 O
. O
9 O
* O
p O
##lt O
c O
##t O
- O
96 O
* O
. O
[ O
* O
* O
218 O
##8 O
- O
10 O
- O
24 O
* O
* O
] O
ne O
##uts O
- O
74 O
. O
5 O
* O
[ O
* O
* O
218 O
##8 O
- O
10 O
- O
28 O
* O
* O
] O
ne O
##uts O
- O
28 O
* O
[ O
* O
* O
218 O
##8 O
- O
10 O
- O
29 O
* O
* O
] O
ne O
##uts O
- O
9 O
* O
[ O
* O
* O
218 O
##8 O
- O
10 O
- O
30 O
* O
* O
] O
ne O
##uts O
- O
7 O
* O
. O

[ O
* O
* O
218 O
##8 O
- O
10 O
- O
24 O
* O
* O
] O
u O
##rea O
##n O
- O
20 O
c O
##rea O
##t O
- O
1 O
. O
0 O
na O
- O
129 O
* O
k O
- O
3 O
. O
4 O
c O
##l O
- O
90 O
* O
h O
##co O
##3 O
- O
27 O
an O
##ga O
##p O
- O
15 O
[ O
* O
* O
218 O
##8 O
- O
10 O
- O
25 O
* O
* O
] O
u O
##rea O
##n O
- O
19 O
c O
##rea O
##t O
- O
0 O
. O
9 O
na O
- O
130 O
* O
k O
- O
2 O
. O
9 O
* O
c O
##l O
- O
92 O
* O
h O
##co O
##3 O
- O
28 O
an O
##ga O
##p O
- O
13 O
[ O
* O
* O
218 O
##8 O
- O
10 O
- O
25 O
* O
* O
] O
u O
##rea O
##n O
- O
20 O
c O
##rea O
##t O
- O
1 O
. O
0 O
na O
- O
130 O
* O
k O
- O
3 O
. O
8 O
c O
##l O
- O
95 O
* O
h O
##co O
##3 O
- O
25 O
an O
##ga O
##p O
- O
14 O
[ O
* O
* O
218 O
##8 O
- O
10 O
- O
26 O
* O
* O
] O
u O
##rea O
##n O
- O
27 O
* O
c O
##rea O
##t O
- O
1 O
. O
2 O
* O
na O
- O
131 O
* O
k O
- O
3 O
. O
7 O
c O
##l O
- O
95 O
* O
h O
##co O
##3 O
- O
24 O
an O
##ga O
##p O
- O
16 O
[ O
* O
* O
218 O
##8 O
- O
10 O
- O
27 O
* O
* O
] O
u O
##rea O
##n O
- O
23 O
* O
c O
##rea O
##t O
- O
1 O
. O
1 O
na O
- O
134 O
k O
- O
4 O
. O
2 O
c O
##l O
- O
100 O
h O
##co O
##3 O
- O
29 O
an O
##ga O
##p O
- O
9 O
[ O
* O
* O
218 O
##8 O
- O
10 O
- O
28 O
* O
* O
] O
u O
##rea O
##n O
- O
16 O
c O
##rea O
##t O
- O
0 O
. O
9 O
na O
- O
134 O
k O
- O
4 O
. O
2 O
c O
##l O
- O
102 O
h O
##co O
##3 O
- O
27 O
an O
##ga O
##p O
- O
9 O
[ O
* O
* O
218 O
##8 O
- O
10 O
- O
29 O
* O
* O
] O
u O
##rea O
##n O
- O
12 O
c O
##rea O
##t O
- O
1 O
. O
0 O
na O
- O
136 O
k O
- O
4 O
. O
5 O
c O
##l O
- O
102 O
h O
##co O
##3 O
- O
26 O
an O
##ga O
##p O
- O
13 O
[ O
* O
* O
218 O
##8 O
- O
10 O
- O
30 O
* O
* O
] O
u O
##rea O
##n O
- O
12 O
c O
##rea O
##t O
- O
1 O
. O
0 O
na O
- O
136 O
k O
- O
4 O
. O
6 O
c O
##l O
- O
100 O
h O
##co O
##3 O
- O
28 O
an O
##ga O
##p O
- O
13 O
. O
[ O
* O
* O
218 O
##8 O
- O
10 O
- O
25 O
* O
* O
] O
12 O
: O
00 O
##am O
blood O
c O
##k O
- O
m O
##b O
- O
6 O
c O
##tro O
##p O
##nt O
- O
0 O
. O
31 O
* O
[ O
* O
* O
218 O
##8 O
- O
10 O
- O
25 O
* O
* O
] O
10 O
: O
49 O
##am O
blood O
c O
##k O
- O
m O
##b O
- O
4 O
c O
##tro O
##p O
##nt O
- O
0 O
. O
18 O
* O
[ O
* O
* O
218 O
##8 O
- O
10 O
- O
25 O
* O
* O
] O
blood O
type O
- O
art O
te O
##mp O
- O
36 O
. O
1 O
p O
##o O
##2 O
- O
112 O
* O
p O
##co O
##2 O
- O
37 O
p O
##h O
- O
7 O
. O
48 O
* O
ca O
##lt O
##co O
##2 O
- O
28 O
base O
x O
##s O
- O
4 O
. O

images O
: O
[ O
* O
* O
10 O
- O
24 O
* O
* O
] O
t O
##te O
: O
the O
left O
at O
##rium O
is O
normal O
in O
size O
. O
left O
vent O
##ric O
##ular O
wall O
thickness O
, O
cavity O
size O
and O
regional O
/ O
global O
s O
##ys O
##to O
##lic O
function O
are O
normal O
( O
l O
##ve O
##f O
> O
55 O
% O
) O
. O
the O
right O
vent O
##ric O
##ular O
cavity O
is O
moderately O
di O
##lated O
with O
moderate O
global O
free O
wall O
h O
##y O
##po O
##kin O
##esis O
. O
there O
is O
abnormal O
s O
##ys O
##to O
##lic O
se O
##pta O
##l O
motion O
/ O
position O
consistent O
with O
right O
vent O
##ric O
##ular O
pressure O
over O
##load O
. O
the O
a O
##ort O
##ic O
valve O
is O
not O
well O
seen O
. O
the O
mit O
##ral O
valve O
appears O
structural O
##ly O
normal O
with O
trivial O
mit O
##ral O
re O
##gu O
##rg O
##itation O
. O
there O
is O
moderate O
pulmonary O
artery O
s O
##ys O
##to O
##lic O
h O
##yper O
##tens O
##ion O
. O
there O
is O
no O
per O
##ica O
##rdi O
##al O
e O
##ff O
##usion O
. O
impression O
: O
normal O
left O
vent O
##ric O
##ular O
s O
##ys O
##to O
##lic O
function O
. O
moderately O
di O
##lated O
right O
vent O
##ric O
##le O
with O
moderate O
to O
severe O
right O
vent O
##ric O
##ular O
d O
##ys O
##function O
. O
moderate O
pulmonary O
h O
##yper O
##tens O
##ion O
is O
noted O
. O
. O
c O
##t O
chest O
( O
[ O
* O
* O
10 O
- O
24 O
* O
* O
] O
) O
: O
1 O
) O
extensive O
bilateral O
pulmonary O
em O
##bol O
##ism O
. O
2 O
) O
unchanged O
moderate O
right O
p O
##le O
##ural O
e O
##ff O
##usion O
with O
a O
posterior O
##ly O
lo O
##culate O
##d O
component O
. O
3 O
) O
questionable O
slight O
decrease O
in O
the O
right O
a O
##pical O
p O
##le O
##ural O
- O
based O
les O
##ion O
and O
in O
the O
left O
anterior O
upper O
lobe O
les O
##ion O
. O
other O
pulmonary O
lesions O
are O
unchanged O
. O
4 O
) O
unchanged O
media O
##st O
##inal O
and O
right O
hi O
##lar O
l O
##ymph O
nodes O
, O
up O
to O
1 O
cm O
. O
brief O
hospital O
course O
: O
79 O
yo O
woman O
with O
h O
##x O
of O
non O
- O
small O
cell O
lung O
cancer O
who O
was O
transfer O
##ed O
from O
o O
##sh O
with O
bilateral O
p O
##es O
. O
. O
# O
pulmonary B-REA
em I-REA
##bol I-REA
##i I-REA
: I-REA
patient O
with O
d O
##ys O
##p O
##nea O
much O
improved O
throughout O
hospital O
##ization O
. O
discharged O
on O
love B-DRUG
##no I-DRUG
##x I-DRUG
. I-DRUG
. O
# O
h B-REA
##yper I-REA
##tens I-REA
##ion I-REA
: I-REA
patient O
was O
inter O
##mit O
##tine O
##ly O
h B-REA
##y I-REA
##pot I-REA
##ens I-REA
##ive I-REA
in O
i O
##cu O
but O
ass O
##ym O
##pt O
##oma O
##tic O
. O
re O
##cie O
##ved O
fluid B-DRUG
b B-DOS
##ol I-DOS
##uses I-DOS
with O
response O
. O
home O
medications O
were O
held O
initially O
. O
they O
were O
restart O
##ed O
gradually O
as O
patient O
returned O
to O
base O
##line O
blood O
pressure O
. O
she O
was O
discharge O
on O
a O
decreased O
dose O
of O
ate B-DRUG
##no I-DRUG
##lo I-DRUG
##l I-DRUG
and O
no O
ch B-DRUG
##lor I-DRUG
##thal I-DRUG
##ido I-DRUG
##ne I-DRUG
with O
instructions O
to O
follow O
with O
her O
p O
##c O
##p O
. O
. O
# O
n B-REA
##s I-REA
##c I-REA
##l I-REA
##ca I-REA
with O
liver O
met O
##s O
: O
s O
/ O
p O
4 O
weeks O
of O
ch B-DRUG
##em I-DRUG
##o I-DRUG
with O
tax B-DRUG
##ol I-DRUG
, I-DRUG
car B-DRUG
##bo I-DRUG
##p I-DRUG
##lat I-DRUG
##in I-DRUG
, I-DRUG
a B-DRUG
##vas I-DRUG
##tin I-DRUG
, I-DRUG
on O
[ O
* O
* O
218 O
##8 O
- O
10 O
- O
20 O
* O
* O
] O
. O
plan O
per O
primary O
on O
##cologist O
. O
. O
# O
pan B-ADE
##cy I-ADE
##top I-ADE
##enia I-ADE
: I-ADE
secondary O
to O
ch B-DRUG
##em I-DRUG
##o I-DRUG
. I-DRUG
stab O
##ilized O
prior O
to O
discharge O
and O
patient O
remained O
a O
##fe O
##bri O
##le O
. O
. O

# O
h O
/ O
o O
intermittent B-REA
at I-REA
##rial I-REA
ta I-REA
##chy I-REA
##card I-REA
##ia I-REA
: I-REA
on O
ate B-DRUG
##no I-DRUG
##lo I-DRUG
##l I-DRUG
75 B-STR
##m I-STR
##g I-STR
twice B-FRE
daily I-FRE
at O
home O
. O
discharged O
on O
50 B-STR
##m I-STR
##g I-STR
twice B-FRE
daily I-FRE
. I-FRE
medications O
on O
admission O
: O
ate B-DRUG
##no I-DRUG
##lo I-DRUG
##l I-DRUG
75 B-STR
mg I-STR
[ O
* O
* O
hospital O
##1 O
* O
* O
] O
at B-DRUG
##or I-DRUG
##vas I-DRUG
##tat I-DRUG
##in I-DRUG
20 B-STR
mg I-STR
daily B-FRE
i B-DRUG
##rb I-DRUG
##es I-DRUG
##art I-DRUG
##an I-DRUG
- I-DRUG
h I-DRUG
##ct I-DRUG
##z I-DRUG
150 B-STR
/ I-STR
12 I-STR
. I-STR
5 I-STR
mg I-STR
daily B-FRE
r B-DRUG
##abe I-DRUG
##pra I-DRUG
##zo I-DRUG
##le I-DRUG
20 B-STR
mg I-STR
daily B-FRE
t B-DRUG
##iot I-DRUG
##rop I-DRUG
##rium I-DRUG
1 B-DOS
cap B-FOR
daily B-FRE
discharge O
medications O
: O
1 O
. O
en B-DRUG
##ox I-DRUG
##apa I-DRUG
##rin I-DRUG
100 B-STR
mg I-STR
/ I-STR
m I-STR
##l I-STR
s B-FOR
##yr I-FOR
##inge I-FOR
si O
##g O
: O
ninety B-DOS
( I-DOS
90 I-DOS
) I-DOS
mg I-DOS
sub B-ROU
##cut I-ROU
##aneous I-ROU
every B-FRE
twelve I-FRE
( I-FRE
12 I-FRE
) I-FRE
hours I-FRE
. I-FRE
di O
##sp O
: O
* O
3 O
s B-FOR
##yr I-FOR
##inge I-FOR
##s I-FOR
* I-FOR
re O
##fill O
##s O
: O
* O
0 O
* O
2 O
. O
ace B-DRUG
##tam I-DRUG
##ino I-DRUG
##phe I-DRUG
##n I-DRUG
325 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
1 B-DOS
- I-DOS
2 I-DOS
tablets B-FOR
p B-ROU
##o I-ROU
q B-FRE
##6 I-FRE
##h I-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
. I-REA
3 O
. O
do B-DRUG
##cus I-DRUG
##ate I-DRUG
sodium I-DRUG
100 B-STR
mg I-STR
capsule B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
capsule B-FOR
p B-ROU
##o I-ROU
bid B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
con B-REA
##st I-REA
##ip I-REA
##ation I-REA
. I-REA
4 O
. O
t B-DRUG
##iot I-DRUG
##rop I-DRUG
##ium I-DRUG
br I-DRUG
##omi I-DRUG
##de I-DRUG
18 B-STR
m I-STR
##c I-STR
##g I-STR
capsule B-FOR
, I-FOR
w I-FOR
/ I-FOR
in I-FOR
##hala I-FOR
##tion I-FOR
device I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
cap B-FOR
in B-ROU
##hala I-ROU
##tion I-ROU
daily B-FRE
( I-FRE
daily I-FRE
) I-FRE
. I-FRE
5 O
. O
a B-DRUG
##ci I-DRUG
##phe I-DRUG
##x I-DRUG
20 B-STR
mg I-STR
tablet B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
p B-ROU
##o I-ROU
every B-FRE
other I-FRE
day I-FRE
. I-FRE
6 O
. O
ate B-DRUG
##no I-DRUG
##lo I-DRUG
##l I-DRUG
50 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
bid B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE
di O
##sp O
: O
* O
60 O
tablet B-FOR
( I-FOR
s I-FOR
) I-FOR
* I-FOR
re O
##fill O
##s O
: O
* O
2 O
* O
7 O
. O
i B-DRUG
##rb I-DRUG
##es I-DRUG
##art I-DRUG
##an I-DRUG
- I-DRUG
h I-DRUG
##ydro I-DRUG
##ch I-DRUG
##lor I-DRUG
##oth I-DRUG
##ia I-DRUG
##zi I-DRUG
##de I-DRUG
150 B-STR
- I-STR
12 I-STR
. I-STR
5 I-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
half I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE
8 O
. O
f B-DRUG
##ex I-DRUG
##of I-DRUG
##ena I-DRUG
##dine I-DRUG
60 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
bid B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
it B-REA
##ching I-REA
. I-REA
9 O
. O
at B-DRUG
##or I-DRUG
##vas I-DRUG
##tat I-DRUG
##in I-DRUG
20 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

10 O
. O
lid B-DRUG
##oc I-DRUG
##aine I-DRUG
h I-DRUG
##c I-DRUG
##l I-DRUG
2 O
% O
solution B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
m I-DOS
##l I-DOS
m B-ROU
##uc I-ROU
##ous I-ROU
membrane I-ROU
t B-FRE
##id I-FRE
( I-FRE
3 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
oral B-REA
sore I-REA
##s I-REA
: I-REA
before O
meals O
if O
needed O
. O
di O
##sp O
: O
* O
100 O
m O
##l O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
2 O
* O
11 O
. O
form B-DRUG
##oter I-DRUG
##ol I-DRUG
f I-DRUG
##uma I-DRUG
##rate I-DRUG
20 B-STR
m I-STR
##c I-STR
##g I-STR
/ I-STR
2 I-STR
m I-STR
##l I-STR
solution B-FOR
for I-FOR
ne I-FOR
##bul I-FOR
##ization I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
solution B-FOR
in B-ROU
##hala I-ROU
##tion I-ROU
twice B-FRE
a I-FRE
day I-FRE
as I-FRE
needed I-FRE
for O
short B-REA
##ness I-REA
of I-REA
breath I-REA
or O
w B-REA
##hee I-REA
##zing I-REA
. I-REA
di O
##sp O
: O
* O
60 O
solutions O
* O
re O
##fill O
##s O
: O
* O
3 O
* O
discharge O
disposition O
: O
home O
with O
service O
facility O
: O
[ O
* O
* O
hospital O
119 O
* O
* O
] O
home O
##care O
discharge O
diagnosis O
: O
primary O
: O
pulmonary O
em O
##bol O
##ism O
secondary O
: O
lung O
cancer O
, O
h O
##yper O
##tens O
##ion O
discharge O
condition O
: O
good O
discharge O
instructions O
: O
dear O
m O
##s O
. O
[ O
* O
* O
known O
last O
##name O
* O
* O
] O
, O
you O
were O
admitted O
because O
you O
had O
a O
blood O
c O
##lot O
that O
traveled O
to O
your O
lungs O
. O
we O
started O
you O
on O
medication O
to O
prevent B-REA
c I-REA
##lot I-REA
formation I-REA
called O
love B-DRUG
##no I-DRUG
##x I-DRUG
. I-DRUG
the O
following O
changes O
were O
made O
to O
your O
medications O
: O
start O
love B-DRUG
##no I-DRUG
##x I-DRUG
90 B-STR
##m I-STR
##g I-STR
( I-STR
0 I-STR
. I-STR
9 I-STR
##cc I-STR
) I-STR
in O
##ject O
sub B-ROU
##cut I-ROU
##aneous I-ROU
##ly I-ROU
twice B-FRE
daily I-FRE
start O
per B-DRUG
##fo I-DRUG
##rom I-DRUG
##ist I-DRUG
ne B-FOR
##bul I-FOR
##izer I-FOR
twice B-FRE
daily I-FRE
stop O
ch B-DRUG
##lor I-DRUG
##thal I-DRUG
##ido I-DRUG
##ne I-DRUG
please O
continue O
all O
other O
medications O
as O
prescribed O
. O
you O
should O
see O
d O
##r O
. O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
32 O
##7 O
##4 O
* O
* O
] O
in O
the O
next O
two O
weeks O
in O
his O
office O
in O
[ O
* O
* O
location O
( O
un O
) O
620 O
* O
* O
] O
. O
please O
call O
your O
doctor O
or O
911 O
if O
you O
have O
chest O
pain O
, O
worse O
##ned O
short O
##ness O
of O
breath O
or O
for O
any O
other O
concern O
. O
follow O
##up O
instructions O
: O
please O
call O
to O
make O
an O
appointment O
with O
d O
##r O
. O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
32 O
##7 O
##4 O
* O
* O
] O
within O
two O
weeks O
. O

provider O
: O
[ O
* O
* O
name O
##10 O
( O
name O
##is O
) O
157 O
##1 O
* O
* O
] O
function O
lab O
phone O
: O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
60 O
##9 O
* O
* O
] O
date O
/ O
time O
: O
[ O
* O
* O
218 O
##8 O
- O
11 O
- O
27 O
* O
* O
] O
3 O
: O
40 O
provider O
: O
[ O
* O
* O
name O
##10 O
( O
name O
##is O
) O
157 O
##0 O
* O
* O
] O
, O
interpret O
w O
/ O
lab O
no O
check O
- O
in O
[ O
* O
* O
name O
##10 O
( O
name O
##is O
) O
157 O
##0 O
* O
* O
] O
in O
##tep O
##reta O
##tion O
bill O
##ing O
date O
/ O
time O
: O
[ O
* O
* O
218 O
##8 O
- O
11 O
- O
27 O
* O
* O
] O
4 O
: O
00 O
provider O
: O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##4 O
) O
* O
* O
] O
. O
[ O
* O
* O
first O
name O
( O
s O
##ti O
##tle O
) O
111 O
##2 O
* O
* O
] O
/ O
d O
##r O
. O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
* O
* O
] O
phone O
: O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
61 O
##2 O
* O
* O
] O
date O
/ O
time O
: O
[ O
* O
* O
218 O
##8 O
- O
11 O
- O
27 O
* O
* O
] O
4 O
: O
00 O
[ O
* O
* O
first O
name O
##8 O
( O
name O
##pa O
##tter O
##n O
##2 O
) O
251 O
* O
* O
] O
[ O
* O
* O
name O
##8 O
( O
m O
##d O
) O
* O
* O
] O
m O
##d O
[ O
* O
* O
m O
##d O
number O
( O
1 O
) O
32 O
##8 O
##2 O
* O
* O
] O

admission O
date O
: O
[ O
* O
* O
210 O
##4 O
- O
12 O
- O
29 O
* O
* O
] O
discharge O
date O
: O
[ O
* O
* O
210 O
##4 O
- O
12 O
- O
31 O
* O
* O
] O
date O
of O
birth O
: O
[ O
* O
* O
203 O
##8 O
- O
10 O
- O
7 O
* O
* O
] O
sex O
: O
m O
service O
: O
ne O
##uro O
##logy O
all O
##er O
##gies O
: O
pen B-DRUG
##ici I-DRUG
##llin I-DRUG
##s I-DRUG
attending O
: O
[ O
* O
* O
first O
name O
##3 O
( O
l O
##f O
) O
256 O
##9 O
* O
* O
] O
chief O
complaint O
: O
r O
- O
sided O
weakness O
and O
r O
facial O
d O
##roo O
##p O
major O
surgical O
or O
invasive O
procedure O
: O
none O
history O
of O
present O
illness O
: O
66 O
year O
- O
old O
right O
- O
handed O
man O
with O
pm O
##h O
significant O
for O
h O
##t O
##n O
, O
a B-REA
. I-REA
fi I-REA
##b I-REA
( O
on O
co B-DRUG
##uma I-DRUG
##din I-DRUG
) I-DRUG
, O
s O
/ O
p O
def O
##ib O
##rilla O
##tor O
/ O
pace O
##maker O
( O
he O
says O
for O
bra O
##dy O
##card O
##ia O
) O
ca O
##d O
s O
/ O
p O
2 O
s O
##ten O
##ts O
, O
prior O
stroke O
( O
initially O
with O
left O
sided O
weakness O
but O
he O
reports O
no O
residual O
weakness O
) O
presented O
to O
[ O
* O
* O
hospital O
##6 O
50 O
##9 O
##29 O
* O
* O
] O
this O
morning O
with O
right O
sided O
weakness O
. O
he O
says O
he O
woke O
up O
at O
4 O
##am O
to O
go O
to O
the O
bathroom O
, O
but O
upon O
awake O
##ning O
, O
noticed O
that O
his O
right O
hand O
and O
arm O
was O
weak O
. O
he O
tried O
getting O
out O
of O
bed O
, O
but O
fell O
to O
the O
ground O
because O
of O
right O
sided O
weakness O
. O
he O
says O
he O
stayed O
on O
the O
ground O
for O
a O
few O
minutes O
, O
but O
was O
able O
to O
get O
himself O
up O
. O
he O
noticed O
that O
the O
right O
side O
of O
his O
face O
was O
d O
##roo O
##ping O
and O
that O
his O
speech O
was O
s O
##lu O
##rred O
. O
he O
was O
initially O
brought O
to O
o O
##sh O
, O
where O
a O
n O
##ch O
##ct O
showed O
a O
left O
basal O
gang O
##lia O
hem O
##or O
##r O
##hage O
. O
he O
was O
given O
10 B-STR
mg I-STR
of O
vitamin B-DRUG
k I-DRUG
for O
an O
in B-REA
##r I-REA
of I-REA
2 I-REA
. I-REA
6 I-REA
( O
no O
f B-DRUG
##f I-DRUG
##p I-DRUG
was O
given O
) O
and O
lab B-DRUG
##etal I-DRUG
##ol I-DRUG
20 B-STR
mg I-STR
i B-ROU
##v I-ROU
for O
a O
s B-REA
##b I-REA
##p I-REA
in I-REA
the I-REA
170 I-REA
##s I-REA
. I-REA
he O
was O
then O
transferred O
to O
[ O
* O
* O
hospital O
##1 O
18 O
* O
* O
] O
for O
further O
management O
. O
he O
says O
that O
he O
believes O
his O
right O
arm O
is O
most O
affected O
( O
weak O
##est O
, O
no O
sensory O
changes O
reported O
) O
, O
followed O
by O
his O
face O
and O
then O
his O
leg O
. O
he O
says O
there O
has O
not O
been O
any O
progression O
of O
his O
symptoms O
since O
onset O
this O
morning O
upon O
awake O
##ning O
. O
no O
other O
symptoms O
aside O
from O
right O
sided O
weakness O
and O
s O
##lu O
##rred O
speech O
, O
in O
##l O
##cu O
##ding O
no O
sensory O
changes O
, O
visual O
changes O
, O
headache O
, O
ve O
##rt O
##igo O
, O
nausea O
/ O
vomit O
##ing O
. O
in O
the O
[ O
* O
* O
hospital O
##1 O
18 O
* O
* O
] O
ed O
, O
he O
received O
pro B-DRUG
##fi I-DRUG
##lini I-DRUG
##ne I-DRUG
, I-DRUG
was O
ordered O
for O
2 B-DOS
units I-DOS
f B-DRUG
##f I-DRUG
##p I-DRUG
( O
did O
not O
receive O
while O
in O
ed O
, O
but O
was O
due O
to O
receive O
in O
i O
##cu O
) O
and O
started O
on O
a O
ni B-DRUG
##card I-DRUG
##ip I-DRUG
##ine I-DRUG
g B-ROU
##tt I-ROU
. I-ROU

ne O
##uro O
r O
##os O
: O
positive O
for O
right O
sided O
weakness O
and O
d O
##ys O
##art O
##hr O
##ia O
as O
per O
hp O
##i O
. O
he O
does O
note O
neck O
pain O
beginning O
yet O
##ser O
##day O
evening O
, O
but O
no O
headache O
, O
loss O
of O
vision O
, O
blurred O
vision O
, O
dip O
##lop O
##ia O
, O
d O
##ys O
##pha O
##gia O
, O
light O
##headed O
##ness O
, O
ve O
##rt O
##igo O
, O
tin O
##ni O
##tus O
or O
hearing O
difficulty O
. O
no O
difficulties O
producing O
or O
comprehend O
##ing O
speech O
. O
no O
focal O
numb O
##ness O
, O
para O
##st O
##hesia O
##e O
. O
he O
does O
report O
episode O
of O
u O
##rina O
##ry O
in O
##con O
##tine O
##nce O
with O
standing O
this O
morning O
, O
but O
no O
prior O
episode O
of O
u O
##rina O
##ry O
in O
##con O
##tine O
##nce O
. O
general O
r O
##os O
: O
no O
fever O
or O
chill O
##s O
. O
no O
cough O
, O
short O
##ness O
of O
breath O
, O
chest O
pain O
or O
tight O
##ness O
, O
p O
##al O
##pit O
##ations O
, O
nausea O
, O
vomit O
##ing O
, O
di O
##ar O
##r O
##hea O
, O
con O
##st O
##ip O
##ation O
or O
abdominal O
pain O
. O
no O
d O
##ys O
##uria O
. O
no O
r O
##ash O
. O
past O
medical O
history O
: O
- O
h O
##t O
##n O
- O
a B-REA
. I-REA
fi I-REA
##b I-REA
( O
on O
co B-DRUG
##uma I-DRUG
##din I-DRUG
) I-DRUG
- O
pace O
##maker O
/ O
def O
##ib O
##rilla O
##tor O
( O
he O
reports O
for O
slow O
heart O
rate O
) O
- O
ca O
##d O
s O
/ O
p O
2 O
s O
##ten O
##ts O
- O
2 O
prior O
strokes O
( O
one O
resulted O
in O
left O
sided O
weakness O
at O
presentation O
but O
no O
residual O
deficit O
##s O
) O
- O
left O
wrist O
surgery O
- O
depression O
social O
history O
: O
he O
lives O
with O
his O
son O
. O
[ O
* O
* O
name O
( O
ni O
) O
* O
* O
] O
is O
retired O
; O
he O
previously O
worked O
for O
a O
construction O
company O
. O
he O
has O
a O
distant O
smoking O
history O
, O
quit O
over O
40 O
years O
ago O
. O
no O
alcohol O
or O
ill O
##icit O
drug O
use O
. O
family O
history O
: O
mother O
deceased O
at O
age O
77 O
with O
history O
of O
diabetes O
and O
ca O
##d O
. O
father O
deceased O
at O
age O
56 O
from O
a O
stroke O
. O
sister O
with O
[ O
* O
* O
name O
##2 O
( O
ni O
) O
* O
* O
] O
. O
physical O
exam O
: O
admission O
physical O
exam O
: O
vital O
##s O
: O
t O
: O
98 O
. O
6 O
p O
: O
50 O
r O
: O
16 O
b O
##p O
: O
178 O
/ O
95 O
( O
up O
to O
200 O
##s O
s O
##ys O
##to O
##lic O
) O
sa O
##o B-DRUG
##2 I-DRUG
: I-DRUG
98 O
% O
on O
2 B-DOS
##l I-DOS
n B-ROU
##c I-ROU
general O
: O
awake O
, O
cooperative O
, O
na O
##d O
. O
he O
##ent O
: O
n O
##c O
/ O
at O
, O
no O
s O
##cle O
##ral O
i O
##cter O
##us O
noted O
, O
dry O
m O
##uc O
##us O
membrane O
##s O
neck O
: O
su O
##pp O
##le O
chest O
: O
l O
##ct O
##a O
b O
/ O
l O
. O
there O
is O
well O
- O
healed O
scar O
on O
anterior O
left O
chest O
with O
underlying O
device O
( O
pace O
##maker O
/ O
def O
##ib O
) O
. O
cardiac O
: O
bra O
##dy O
##card O
##ic O
, O
s O
##1 O
##s O
##2 O
abdomen O
: O
soft O
, O
non O
##dis O
##tended O
, O
+ O
b O
##s O
ex O
##tre O
##mit O
##ies O
: O
warm O
, O
well O
per O
##fused O
skin O
: O
no O
r O
##ash O
##es O
or O
lesions O
noted O
. O
ne O
##uro O
##log O
##ic O
: O

mental O
status O
: O
awake O
, O
alert O
, O
oriented O
to O
person O
, O
" O
hospital O
, O
" O
month O
and O
year O
, O
but O
not O
to O
date O
. O
able O
to O
relate O
history O
without O
difficulty O
. O
able O
to O
name O
pot O
##us O
. O
in O
##att O
##ent O
##ive O
, O
unable O
to O
name O
[ O
* O
* O
doctor O
last O
name O
1841 O
* O
* O
] O
forwards O
or O
backwards O
; O
able O
to O
name O
do O
##w O
backwards O
. O
able O
to O
follow O
both O
mid O
##line O
and O
app O
##end O
##icular O
commands O
. O
no O
right O
- O
left O
confusion O
. O
able O
to O
register O
3 O
objects O
and O
recall O
[ O
* O
* O
12 O
- O
19 O
* O
* O
] O
at O
5 O
minutes O
( O
[ O
* O
* O
1 O
- O
17 O
* O
* O
] O
with O
prompting O
) O
. O
no O
evidence O
of O
a O
##pra O
##xia O
or O
neglect O
language O
: O
speech O
is O
d O
##ys O
##art O
##hr O
##ic O
, O
but O
is O
otherwise O
fluent O
with O
intact O
naming O
, O
repetition O
and O
com O
##p O
##rehension O
. O
normal O
pro O
##so O
##dy O
. O
c O
##rani O
##al O
nerves O
: O
i O
: O
o O
##lf O
##action O
not O
tested O
. O
ii O
: O
per O
##rl O
3 O
to O
2 O
##mm O
. O
v O
##ff O
to O
confrontation O
. O
fund O
##us O
##copic O
exam O
revealed O
no O
p O
##ap O
##ille O
##de O
##ma O
, O
ex O
##uda O
##tes O
, O
or O
hem O
##or O
##r O
##hage O
##s O
. O
ii O
##i O
, O
i O
##v O
, O
v O
##i O
: O
e O
##omi O
without O
n O
##ys O
##tag O
##mus O
. O
v O
: O
facial O
sensation O
intact O
to O
light O
touch O
. O
v O
##ii O
: O
right O
lower O
facial O
d O
##roo O
##p O
v O
##ii O
##i O
: O
hearing O
intact O
to O
finger O
- O
rub O
bilateral O
##ly O
. O
i O
##x O
, O
x O
: O
p O
##ala O
##te O
el O
##eva O
##tes O
symmetrical O
##ly O
. O
[ O
* O
* O
doctor O
first O
name O
81 O
* O
* O
] O
: O
5 O
/ O
5 O
strength O
in O
trap O
##ez O
##ii O
and O
s O
##c O
##m O
bilateral O
##ly O
. O
x O
##ii O
: O
tongue O
pro O
##tr O
##udes O
in O
mid O
##line O
. O
motor O
: O
normal O
bulk O
. O
slightly O
increased O
tone O
in O
r O
##le O
. O
right O
pro O
##nat O
##or O
drift O
. O
no O
advent O
##iti O
##ous O
movements O
, O
such O
as O
t O
##rem O
##or O
, O
noted O
. O
no O
as O
##ter O
##ix O
##is O
noted O
. O
del O
##t O
bi O
##c O
t O
##ri O
w O
##re O
f O
##f O
##l O
f O
##e O
i O
##p O
q O
##uad O
ha O
##m O
ta O
gas O
##tro O
##c O
l O
5 O
5 O
5 O
5 O
5 O
5 O
5 O
5 O
5 O
5 O
5 O
r O
4 O
+ O
5 O
5 O
- O
5 O
- O
5 O
5 O
- O
5 O
- O
5 O
5 O
5 O
5 O
sensory O
: O
no O
deficit O
##s O
to O
light O
touch O
, O
pin O
##p O
##rick O
, O
prop O
##rio O
##ception O
throughout O
. O
v O
##ib O
##rator O
##y O
sense O
3 O
seconds O
at O
right O
great O
toe O
and O
5 O
seconds O
at O
left O
great O
toe O
. O
no O
extinction O
to O
d O
##ss O
. O
d O
##tr O
##s O
: O
[ O
* O
* O
name O
##2 O
( O
ni O
) O
* O
* O
] O
t O
##ri O
[ O
* O
* O
last O
name O
( O
un O
) O
103 O
##5 O
* O
* O
] O
pat O
a O
##ch O
l O
3 O
2 O
3 O
3 O
0 O
r O
1 O
1 O
1 O
2 O
0 O
plant O
##ar O
response O
was O
ex O
##tens O
##or O
bilateral O
##ly O
. O

coordination O
: O
no O
d O
##ys O
##met O
##ria O
or O
intention O
t O
##rem O
##or O
on O
f O
- O
n O
or O
f O
- O
n O
- O
f O
on O
left O
. O
there O
is O
d O
##ys O
##met O
##ria O
on O
f O
- O
n O
- O
f O
on O
right O
( O
did O
not O
appear O
out O
of O
proportion O
to O
weakness O
. O
ram O
##s O
are O
slow O
and O
slightly O
clumsy O
b O
/ O
l O
, O
but O
more O
impaired O
on O
right O
. O
g O
##ait O
: O
def O
##er O
##red O
. O
. O
discharge O
physical O
exam O
: O
a O
+ O
o O
##x O
##3 O
span O
##ish O
speaking O
but O
speaks O
good O
en O
##gli O
##sh O
and O
follows O
commands O
well O
. O
speech O
is O
d O
##ys O
##ar O
##ht O
##ric O
but O
fluent O
and O
no O
evidence O
of O
mental O
status O
abnormal O
##ities O
with O
no O
neglect O
. O
right O
facial O
d O
##roo O
##p O
and O
otherwise O
c O
##n O
exam O
un O
##rem O
##ark O
##able O
. O
right O
pro O
##nat O
##or O
drift O
with O
mild O
right O
hem O
##ip O
##ares O
##is O
( O
del O
##t O
[ O
* O
* O
2 O
- O
19 O
* O
* O
] O
, O
t O
##ri O
/ O
we O
/ O
f O
##e O
/ O
i O
##p O
4 O
+ O
/ O
5 O
) O
. O
plant O
##ars O
ex O
##tens O
##or O
bilateral O
##ly O
. O
per O
##tinent O
results O
: O
laboratory O
investigations O
: O
admission O
labs O
: O
[ O
* O
* O
210 O
##4 O
- O
12 O
- O
29 O
* O
* O
] O
02 O
: O
00 O
##pm O
blood O
w O
##b O
##c O
- O
5 O
. O
6 O
r O
##b O
##c O
- O
4 O
. O
68 O
h O
##g O
##b O
- O
14 O
. O
8 O
h O
##ct O
- O
41 O
. O
4 O
m O
##c O
##v O
- O
88 O
m O
##ch O
- O
31 O
. O
7 O
m O
##ch O
##c O
- O
35 O
. O
8 O
* O
r O
##d O
##w O
- O
13 O
. O
6 O
p O
##lt O
c O
##t O
- O
188 O
[ O
* O
* O
210 O
##4 O
- O
12 O
- O
29 O
* O
* O
] O
02 O
: O
00 O
##pm O
blood O
ne O
##uts O
- O
79 O
. O
6 O
* O
l O
##ymph O
##s O
- O
11 O
. O
2 O
* O
mon O
##os O
- O
5 O
. O
9 O
e O
##os O
- O
2 O
. O
6 O
b O
##as O
##o O
- O
0 O
. O
6 O
[ O
* O
* O
210 O
##4 O
- O
12 O
- O
29 O
* O
* O
] O
02 O
: O
00 O
##pm O
blood O
p O
##t O
- O
24 O
. O
2 O
* O
p O
##tt O
- O
35 O
. O
4 O
in O
##r O
( O
p O
##t O
) O
- O
2 O
. O
3 O
* O
[ O
* O
* O
210 O
##4 O
- O
12 O
- O
29 O
* O
* O
] O
02 O
: O
00 O
##pm O
blood O
glucose O
- O
105 O
* O
u O
##rea O
##n O
- O
23 O
* O
c O
##rea O
##t O
- O
1 O
. O
3 O
* O
na O
- O
141 O
k O
- O
3 O
. O
2 O
* O
c O
##l O
- O
105 O
h O
##co O
##3 O
- O
27 O
an O
##ga O
##p O
- O
12 O
[ O
* O
* O
210 O
##4 O
- O
12 O
- O
30 O
* O
* O
] O
02 O
: O
49 O
##am O
blood O
al O
##t O
- O
49 O
* O
as O
##t O
- O
30 O
al O
##k O
##ph O
##os O
- O
99 O
to O
##t O
##bil O
##i O
- O
1 O
. O
9 O
* O
. O

other O
per O
##tinent O
labs O
: O
[ O
* O
* O
210 O
##4 O
- O
12 O
- O
29 O
* O
* O
] O
02 O
: O
00 O
##pm O
blood O
c O
##tro O
##p O
##nt O
- O
< O
0 O
. O
01 O
[ O
* O
* O
210 O
##4 O
- O
12 O
- O
30 O
* O
* O
] O
12 O
: O
09 O
##am O
blood O
c O
##tro O
##p O
##nt O
- O
< O
0 O
. O
01 O
[ O
* O
* O
210 O
##4 O
- O
12 O
- O
30 O
* O
* O
] O
02 O
: O
49 O
##am O
blood O
al O
##t O
- O
49 O
* O
as O
##t O
- O
30 O
al O
##k O
##ph O
##os O
- O
99 O
to O
##t O
##bil O
##i O
- O
1 O
. O
9 O
* O
[ O
* O
* O
210 O
##4 O
- O
12 O
- O
30 O
* O
* O
] O
02 O
: O
49 O
##am O
blood O
album O
##in O
- O
4 O
. O
0 O
calcium O
- O
9 O
. O
2 O
p O
##hos O
- O
3 O
. O
4 O
mg O
- O
2 O
. O
0 O
ch O
##ole O
##st O
- O
240 O
* O
[ O
* O
* O
210 O
##4 O
- O
12 O
- O
30 O
* O
* O
] O
02 O
: O
49 O
##am O
blood O
t O
##rig O
##ly O
##c O
- O
111 O
h O
##dl O
- O
41 O
ch O
##ol O
/ O
h O
##d O
- O
5 O
. O
9 O
l O
##dl O
##cal O
##c O
- O
177 O
* O
[ O
* O
* O
210 O
##4 O
- O
12 O
- O
30 O
* O
* O
] O
02 O
: O
49 O
##am O
blood O
% O
h O
##ba O
##1 O
##c O
- O
5 O
. O
4 O
e O
##ag O
- O
108 O
[ O
* O
* O
210 O
##4 O
- O
12 O
- O
29 O
* O
* O
] O
02 O
: O
00 O
##pm O
blood O
p O
##t O
- O
24 O
. O
2 O
* O
p O
##tt O
- O
35 O
. O
4 O
in O
##r O
( O
p O
##t O
) O
- O
2 O
. O
3 O
* O
[ O
* O
* O
210 O
##4 O
- O
12 O
- O
29 O
* O
* O
] O
06 O
: O
03 O
##pm O
blood O
p O
##t O
- O
14 O
. O
9 O
* O
p O
##tt O
- O
29 O
. O
1 O
in O
##r O
( O
p O
##t O
) O
- O
1 O
. O
4 O
* O
[ O
* O
* O
210 O
##4 O
- O
12 O
- O
30 O
* O
* O
] O
02 O
: O
49 O
##am O
blood O
p O
##t O
- O
12 O
. O
8 O
* O
p O
##tt O
- O
29 O
. O
6 O
in O
##r O
( O
p O
##t O
) O
- O
1 O
. O
2 O
* O
[ O
* O
* O
210 O
##4 O
- O
12 O
- O
31 O
* O
* O
] O
04 O
: O
45 O
##am O
blood O
p O
##t O
- O
11 O
. O
2 O
p O
##tt O
- O
26 O
. O
7 O
in O
##r O
( O
p O
##t O
) O
- O
1 O
. O
0 O
. O

discharge O
labs O
: O
[ O
* O
* O
210 O
##4 O
- O
12 O
- O
31 O
* O
* O
] O
04 O
: O
45 O
##am O
blood O
w O
##b O
##c O
- O
5 O
. O
5 O
r O
##b O
##c O
- O
4 O
. O
51 O
* O
h O
##g O
##b O
- O
13 O
. O
3 O
* O
h O
##ct O
- O
40 O
. O
1 O
m O
##c O
##v O
- O
89 O
m O
##ch O
- O
29 O
. O
5 O
m O
##ch O
##c O
- O
33 O
. O
2 O
r O
##d O
##w O
- O
13 O
. O
7 O
p O
##lt O
c O
##t O
- O
185 O
[ O
* O
* O
210 O
##4 O
- O
12 O
- O
31 O
* O
* O
] O
04 O
: O
45 O
##am O
blood O
p O
##t O
- O
11 O
. O
2 O
p O
##tt O
- O
26 O
. O
7 O
in O
##r O
( O
p O
##t O
) O
- O
1 O
. O
0 O
[ O
* O
* O
210 O
##4 O
- O
12 O
- O
31 O
* O
* O
] O
04 O
: O
45 O
##am O
blood O
glucose O
- O
116 O
* O
u O
##rea O
##n O
- O
32 O
* O
c O
##rea O
##t O
- O
1 O
. O
6 O
* O
na O
- O
142 O
k O
- O
3 O
. O
6 O
c O
##l O
- O
107 O
h O
##co O
##3 O
- O
28 O
an O
##ga O
##p O
- O
11 O
[ O
* O
* O
210 O
##4 O
- O
12 O
- O
31 O
* O
* O
] O
04 O
: O
45 O
##am O
blood O
calcium O
- O
9 O
. O
0 O
p O
##hos O
- O
3 O
. O
2 O
mg O
- O
2 O
. O
1 O
. O
. O
urine O
: O
[ O
* O
* O
210 O
##4 O
- O
12 O
- O
30 O
* O
* O
] O
03 O
: O
26 O
##am O
urine O
color O
- O
yellow O
appear O
- O
clear O
s O
##p O
[ O
* O
* O
last O
name O
( O
un O
) O
* O
* O
] O
- O
1 O
. O
01 O
##2 O
[ O
* O
* O
210 O
##4 O
- O
12 O
- O
30 O
* O
* O
] O
03 O
: O
26 O
##am O
urine O
blood O
- O
ne O
##g O
ni O
##tri O
##te O
- O
ne O
##g O
protein O
- O
ne O
##g O
glucose O
- O
ne O
##g O
k O
##eton O
##e O
- O
ne O
##g O
bi O
##li O
##ru O
##b O
- O
ne O
##g O
u O
##ro O
##bil O
##n O
- O
ne O
##g O
p O
##h O
- O
6 O
. O
5 O
le O
##uk O
##s O
- O
ne O
##g O
. O
. O
mi O
##ct O
##ob O
##iology O
: O
[ O
* O
* O
210 O
##4 O
- O
12 O
- O
29 O
* O
* O
] O
5 O
: O
45 O
pm O
m O
##rsa O
screen O
source O
: O
nasal O
s O
##wab O
. O
m O
##rsa O
screen O
( O
pending O
) O
: O
. O
. O

radio O
##logy O
: O
c O
##t O
head O
w O
/ O
o O
contrast O
study O
date O
of O
[ O
* O
* O
210 O
##4 O
- O
12 O
- O
29 O
* O
* O
] O
4 O
: O
58 O
pm O
preliminary O
report O
findings O
: O
a O
17 O
x O
14 O
mm O
in O
##tra O
##par O
##en O
##chy O
##mal O
bleed O
in O
the O
left O
lent O
##iform O
nucleus O
is O
unchanged O
from O
the O
prior O
c O
##t O
approximately O
six O
hours O
prior O
. O
there O
is O
mild O
mass O
effect O
due O
to O
surrounding O
ed O
##ema O
with O
compression O
of O
the O
adjacent O
su O
##l O
##ci O
, O
but O
no O
shift O
of O
the O
normal O
mid O
##line O
structures O
or O
evidence O
of O
her O
##nia O
##tion O
. O
no O
new O
f O
##oc O
##i O
of O
hem O
##or O
##r O
##hage O
are O
present O
. O
a O
h O
##y O
##po O
##den O
##se O
region O
just O
anterior O
to O
the O
hem O
##or O
##r O
##hage O
is O
likely O
an O
old O
la O
##cu O
##nar O
in O
##far O
##ct O
. O
the O
vent O
##ric O
##les O
and O
su O
##l O
##ci O
are O
normal O
in O
size O
and O
configuration O
. O
the O
basal O
c O
##ister O
##ns O
are O
patent O
. O
the O
visual O
##ized O
para O
##nas O
##al O
sin O
##uses O
, O
mast O
##oid O
air O
cells O
, O
and O
middle O
ear O
ca O
##vi O
##ties O
are O
clear O
. O
impression O
: O
no O
change O
in O
the O
left O
lent O
##iform O
nucleus O
in O
##tra O
##par O
##en O
##chy O
##mal O
hem O
##or O
##r O
##hage O
. O
this O
is O
likely O
secondary O
to O
h O
##yper O
##tens O
##ion O
. O
further O
work O
##up O
to O
exclude O
vascular O
or O
neo O
##p O
##lastic O
et O
##iol O
##ogies O
can O
be O
pursued O
based O
on O
clinical O
correlation O
. O
. O
c O
##ta O
head O
w O
& O
w O
/ O
o O
c O
& O
re O
##con O
##s O
study O
date O
of O
[ O
* O
* O
210 O
##4 O
- O
12 O
- O
30 O
* O
* O
] O
3 O
: O
18 O
am O
findings O
: O
as O
seen O
on O
the O
previous O
c O
##t O
, O
there O
is O
a O
1 O
. O
7 O
cm O
x O
1 O
. O
4 O
cm O
x O
2 O
. O
4 O
cm O
sized O
acute O
in O
##tra O
##c O
##rani O
##al O
hem O
##ato O
##ma O
in O
the O
left O
basal O
gang O
##lia O
with O
surrounding O
ed O
##ema O
. O
there O
is O
no O
app O
##re O
##cia O
##ble O
mass O
effect O
on O
the O
lateral O
vent O
##ric O
##le O
. O
there O
is O
no O
mid O
##line O
shift O
. O
an O
old O
in O
##far O
##ct O
is O
seen O
in O
the O
left O
anterior O
basal O
gang O
##lia O
extending O
into O
the O
co O
##rona O
r O
##adia O
##ta O
with O
ex O
v O
##ac O
##uo O
di O
##lat O
##ation O
of O
the O
left O
lateral O
vent O
##ric O
##le O
. O
also O
seen O
are O
multiple O
chronic O
la O
##cu O
##nar O
in O
##far O
##cts O
in O
the O
right O
ca O
##uda O
##te O
and O
lent O
##iform O
nuclei O
. O
visual O
##ized O
orbits O
, O
para O
##nas O
##al O
sin O
##uses O
, O
and O
mast O
##oid O
air O
cells O
are O
un O
##rem O
##ark O
##able O
. O
no O
fracture O
is O
seen O
. O

c O
##ta O
head O
: O
bilateral O
in O
##tra O
##c O
##rani O
##al O
internal O
car O
##ot O
##id O
art O
##eries O
, O
ve O
##rte O
##bra O
##l O
art O
##eries O
, O
b O
##asi O
##lar O
artery O
and O
their O
major O
branches O
are O
patent O
with O
no O
evidence O
of O
s O
##ten O
##osis O
, O
o O
##cc O
##lusion O
, O
or O
di O
##sse O
##ction O
. O
a O
small O
less O
than O
2 O
- O
mm O
sized O
an O
##eur O
##ys O
##m O
is O
seen O
arising O
from O
the O
left O
i O
##ca O
bi O
##fu O
##rca O
##tion O
. O
the O
anterior O
communicating O
artery O
appears O
bulb O
##ous O
without O
any O
definite O
sa O
##cc O
##ular O
an O
##eur O
##ys O
##m O
. O
impression O
: O
1 O
. O
unchanged O
left O
basal O
gang O
##lia O
hem O
##or O
##r O
##hage O
. O
2 O
. O
chronic O
in O
##far O
##ct O
in O
the O
left O
anterior O
basal O
gang O
##lia O
with O
ex O
v O
##ac O
##uo O
di O
##lat O
##ation O
of O
the O
left O
lateral O
vent O
##ric O
##le O
as O
described O
above O
. O
3 O
. O
less O
than O
2 O
- O
mm O
sized O
out O
##po O
##uchi O
##ng O
from O
the O
left O
i O
##ca O
bi O
##fu O
##rca O
##tion O
may O
represent O
a O
tiny O
an O
##eur O
##ys O
##m O
. O
the O
anterior O
communicating O
artery O
appears O
bulb O
##ous O
without O
any O
definite O
sa O
##cc O
##ular O
an O
##eur O
##ys O
##m O
. O
. O
card O
##iology O
: O
e O
##c O
##g O
study O
date O
of O
[ O
* O
* O
210 O
##4 O
- O
12 O
- O
29 O
* O
* O
] O
2 O
: O
45 O
: O
18 O
pm O
sin O
##us O
bra O
##dy O
##card O
##ia O
. O
a O
- O
v O
conduct O
##ion O
delay O
. O
prolonged O
q O
- O
t O
interval O
. O
marked O
anterior O
and O
ant O
##ero O
##late O
##ral O
t O
wave O
in O
##version O
consistent O
with O
metabolic O
abnormal O
##ity O
or O
my O
##oc O
##ard O
##ial O
is O
##che O
##mia O
. O
no O
previous O
tracing O
available O
for O
comparison O
. O
read O
by O
: O
[ O
* O
* O
last O
name O
( O
l O
##f O
) O
* O
* O
] O
, O
[ O
* O
* O
first O
name O
##3 O
( O
l O
##f O
) O
* O
* O
] O
e O
. O
intervals O
axes O
rate O
p O
##r O
q O
##rs O
q O
##t O
/ O
q O
##t O
##c O
p O
q O
##rs O
t O
50 O
238 O
96 O
540 O
/ O
52 O
##2 O
31 O
- O
1 O
- O
87 O

brief O
hospital O
course O
: O
66 O
r O
##hm O
with O
pm O
##h O
significant O
for O
h O
##t O
##n O
, O
a B-REA
##f I-REA
( O
on O
war B-DRUG
##fari I-DRUG
##n I-DRUG
) I-DRUG
, O
s O
/ O
p O
def O
##ib O
##rilla O
##tor O
/ O
pace O
##maker O
( O
for O
? O
bra O
##dy O
##card O
##ia O
) O
ca O
##d O
s O
/ O
p O
2 O
s O
##ten O
##ts O
, O
prior O
stroke O
( O
initially O
with O
left O
sided O
weakness O
but O
no O
residual O
deficit O
) O
presented O
to O
[ O
* O
* O
hospital O
##6 O
310 O
##5 O
* O
* O
] O
with O
right O
sided O
weakness O
( O
arm O
> O
face O
> O
leg O
) O
and O
d O
##ys O
##art O
##hr O
##ia O
. O
c O
##t O
revealed O
a O
left O
basal O
gang O
##lia O
i O
##ph O
and O
he O
was O
transferred O
to O
[ O
* O
* O
hospital O
##1 O
18 O
* O
* O
] O
on O
[ O
* O
* O
210 O
##4 O
- O
12 O
- O
29 O
* O
* O
] O
. O
given O
the O
presence O
of O
the O
i O
##ph O
, O
his O
war B-DRUG
##fari I-DRUG
##n I-DRUG
was O
reversed O
and O
stopped O
. O
patient O
was O
initially O
admitted O
to O
the O
i O
##cu O
given O
significant O
h B-REA
##yper I-REA
##tens I-REA
##ion I-REA
re O
##qui O
##rin O
##ng O
an O
i B-ROU
##v I-ROU
ni B-DRUG
##card I-DRUG
##ip I-DRUG
##ine I-DRUG
in B-ROU
##fusion I-ROU
. I-ROU
he O
was O
transferred O
to O
the O
floor O
on O
[ O
* O
* O
210 O
##4 O
- O
12 O
- O
30 O
* O
* O
] O
. O
c O
##ta O
was O
stable O
and O
no O
significant O
an O
##eur O
##ys O
##m O
was O
identified O
. O
although O
the O
most O
likely O
cause O
for O
his O
i O
##ph O
is O
h O
##yper O
##tens O
##ion O
, O
it O
was O
not O
possible O
to O
do O
an O
m O
##ri O
to O
look O
for O
an O
underlying O
les O
##ion O
given O
pace O
##maker O
. O
as B-DRUG
##pi I-DRUG
##rin I-DRUG
should O
be O
started O
in O
1 O
week O
and O
he O
will O
not O
be O
continued O
on O
war B-DRUG
##fari I-DRUG
##n I-DRUG
. I-DRUG
he O
was O
transferred O
to O
re O
##hab O
on O
[ O
* O
* O
210 O
##4 O
- O
12 O
- O
31 O
* O
* O
] O
and O
has O
ne O
##uro O
##logy O
follow O
- O
up O
. O
he O
should O
have O
a O
repeat O
c O
##t O
head O
with O
and O
without O
contrast O
prior O
to O
his O
follow O
- O
up O
to O
assess O
for O
the O
presence O
of O
an O
underlying O
mass O
les O
##ion O
. O
. O
. O

# O
ne O
##uro O
: O
patient O
had O
a O
previous O
stroke O
as O
above O
with O
no O
residual O
deficit O
##s O
and O
presented O
with O
right O
face O
, O
arm O
and O
leg O
weakness O
in O
the O
setting O
of O
some O
mild O
neck O
pain O
but O
no O
clear O
headache O
on O
[ O
* O
* O
210 O
##4 O
- O
12 O
- O
29 O
* O
* O
] O
. O
at O
o O
##sh O
he O
was O
found O
to O
have O
a O
left O
basal O
gang O
##lia O
hem O
##or O
##r O
##hage O
. O
he O
was O
given O
10 B-STR
mg I-STR
of O
vitamin B-DRUG
k I-DRUG
for O
an O
in B-REA
##r I-REA
of I-REA
2 I-REA
. I-REA
6 I-REA
( O
no O
f B-DRUG
##f I-DRUG
##p I-DRUG
was O
given O
) O
and O
lab B-DRUG
##etal I-DRUG
##ol I-DRUG
20 B-STR
mg I-STR
i B-ROU
##v I-ROU
for O
a O
s B-REA
##b I-REA
##p I-REA
in I-REA
the I-REA
170 I-REA
##s I-REA
. I-REA
he O
was O
then O
transferred O
to O
[ O
* O
* O
hospital O
##1 O
18 O
* O
* O
] O
for O
further O
management O
. O
at O
[ O
* O
* O
hospital O
##1 O
18 O
* O
* O
] O
ed O
, O
he O
received O
pro B-DRUG
##fi I-DRUG
##lini I-DRUG
##ne I-DRUG
( I-DRUG
activated I-DRUG
factor I-DRUG
i I-DRUG
##x I-DRUG
) I-DRUG
and O
received O
2 B-DOS
units I-DOS
f B-DRUG
##f I-DRUG
##p I-DRUG
later O
for O
in B-REA
##r I-REA
2 I-REA
. I-REA
3 I-REA
. I-REA
examination O
revealed O
right O
hem O
##ip O
##ares O
##is O
and O
right O
facial O
d O
##roo O
##p O
with O
d O
##ys O
##art O
##hr O
##ia O
but O
no O
a O
##pha O
##sia O
, O
neglect O
or O
visual O
field O
defect O
. O
he O
was O
started O
on O
a O
ni B-DRUG
##card I-DRUG
##ip I-DRUG
##ine I-DRUG
in B-FOR
##fusion I-FOR
for O
s B-REA
##b I-REA
##p I-REA
up I-REA
to I-REA
200 I-REA
##s I-REA
and O
was O
admitted O
to O
the O
ne O
##uro O
i O
##cu O
. O
his O
head O
c O
##ts O
remained O
stable O
showing O
no O
extension O
of O
the O
bleed O
. O
c O
##ta O
showed O
an O
old O
in O
##far O
##ct O
in O
the O
left O
anterior O
basal O
gang O
##lia O
extending O
into O
the O
co O
##rona O
r O
##adia O
##ta O
with O
ex O
v O
##ac O
##uo O
di O
##lat O
##ation O
of O
the O
left O
lateral O
vent O
##ric O
##le O
in O
addition O
to O
multiple O
chronic O
la O
##cu O
##nar O
in O
##far O
##cts O
in O
the O
right O
ca O
##uda O
##te O
and O
lent O
##iform O
nuclei O
and O
an O
##gio O
##graphy O
demonstrated O
a O
less O
than O
2 O
- O
mm O
sized O
an O
##eur O
##ys O
##m O
arising O
from O
the O
left O
i O
##ca O
bi O
##fu O
##rca O
##tion O
. O
stroke O
risk O
factors O
were O
assessed O
with O
h O
##ba O
##1 O
##c O
5 O
. O
4 O
% O
and O
fl O
##p O
revealed O
ch B-REA
##ole I-REA
##ster I-REA
##ol I-REA
240 I-REA
t B-REA
##g I-REA
##cs I-REA
111 I-REA
h B-REA
##dl I-REA
41 I-REA
l B-REA
##dl I-REA
177 I-REA
. I-REA
c O
##es O
were O
negative O
. O
he O
was O
initially O
monitored O
with O
glucose O
fingers O
##tick O
##s O
and O
this O
was O
stopped O
after O
several O
normal O
readings O
. O
he O
was O
therefore O
started O
on O
at B-DRUG
##or I-DRUG
##vas I-DRUG
##tat I-DRUG
##in I-DRUG
40 B-STR
##m I-STR
##g I-STR
daily B-FRE
and O
his O
fast O
##ing O
lip O
##ids O
should O
be O
repeated O
in O
3 O
months O
. O

he O
continued O
to O
receive O
daily B-FRE
vitamin B-DRUG
k I-DRUG
until O
[ O
* O
* O
210 O
##4 O
- O
12 O
- O
30 O
* O
* O
] O
and O
in O
##r O
on O
[ O
* O
* O
210 O
##4 O
- O
12 O
- O
31 O
* O
* O
] O
was O
1 O
. O
0 O
. O
he O
passed O
bedside O
swallow O
evaluation O
and O
was O
placed O
on O
a O
regular O
diet O
. O
he O
slowly O
improved O
and O
was O
transferred O
to O
the O
ne O
##uro O
##logy O
floor O
on O
[ O
* O
* O
210 O
##4 O
- O
12 O
- O
30 O
* O
* O
] O
. O
we O
held O
all O
anti B-DRUG
##plate I-DRUG
##lets I-DRUG
and O
as B-DRUG
##pi I-DRUG
##rin I-DRUG
325 B-STR
##m I-STR
##g I-STR
should O
be O
started O
in O
1 O
week O
. O
we O
stopped O
war B-DRUG
##fari I-DRUG
##n I-DRUG
due O
to O
his O
hem B-ADE
##or I-ADE
##r I-ADE
##hage I-ADE
. I-ADE
we O
were O
unable O
to O
obtain O
an O
m O
##ri O
given O
the O
patient O
' O
s O
pace O
##maker O
and O
he O
will O
therefore O
need O
a O
repeat O
c O
##t O
scan O
with O
contrast O
to O
evaluate O
any O
possible O
ma O
##li O
##gna O
##ncy O
underlying O
the O
hem O
##or O
##r O
##hage O
before O
his O
ne O
##uro O
##logy O
appointment O
. O
the O
most O
likely O
cause O
of O
his O
hem O
##or O
##r O
##hage O
is O
a O
h O
##yper O
##tensive O
bleed O
although O
his O
h O
##yper O
##tens O
##ion O
was O
controlled O
previously O
. O
as O
above O
we O
will O
evaluate O
with O
interval O
scan O
to O
look O
for O
an O
underlying O
les O
##ion O
which O
may O
have O
b O
##led O
. O
his O
weakness O
was O
slowly O
improving O
at O
the O
time O
of O
discharge O
. O
he O
was O
stable O
and O
b O
##p O
was O
controlled O
on O
his O
home O
medications O
. O
he O
was O
assessed O
by O
p O
##t O
and O
deemed O
to O
benefit O
from O
re O
##hab O
. O
he O
was O
therefore O
transferred O
to O
re O
##hab O
on O
[ O
* O
* O
210 O
##4 O
- O
12 O
- O
31 O
* O
* O
] O
. O
. O
# O
c O
##v O
##s O
: O
b O
##p O
was O
initially O
un O
##con O
##tro O
##lled O
and O
was O
mark O
##ely O
h O
##yper O
##tensive O
requiring O
i O
##v O
me O
##ds O
and O
i O
##cu O
admission O
. O
this O
was O
latter O
##ly O
controlled O
and O
b O
##p O
on O
discharge O
was O
s O
##b O
##p O
120 O
##s O
- O
130 O
##s O
. O
he O
was O
briefly O
h B-ADE
##y I-ADE
##pot I-ADE
##ens I-ADE
##ive I-ADE
in O
the O
setting O
i B-ROU
##v I-ROU
ni B-DRUG
##card I-DRUG
##ip I-DRUG
##ine I-DRUG
and O
home O
anti B-DRUG
- I-DRUG
h I-DRUG
##yper I-DRUG
##tensive I-DRUG
##s I-DRUG
and O
this O
resolved O
before O
transfer O
to O
the O
fl O
##or O
. O
we O
continued O
patient O
' O
s O
home O
l B-DRUG
##isi I-DRUG
##no I-DRUG
##p I-DRUG
##ril I-DRUG
and O
carved B-DRUG
##ilo I-DRUG
##l I-DRUG
. I-DRUG
we O
monitored O
his O
in O
##r O
daily O
and O
was O
1 O
. O
0 O
on O
discharge O
. O
war B-DRUG
##fari I-DRUG
##n I-DRUG
was O
stopped O
and O
he O
should O
be O
restart O
##ed O
on O
as B-DRUG
##pi I-DRUG
##rin I-DRUG
325 B-STR
##m I-STR
##g I-STR
daily B-FRE
in O
1 O
week O
. O
patient O
was O
started O
on O
at B-DRUG
##or I-DRUG
##vas I-DRUG
##tat I-DRUG
##in I-DRUG
40 B-STR
##m I-STR
##g I-STR
daily B-FRE
as O
above O
and O
should O
have O
repeat O
fl O
##p O
in O
3 O
months O
. O
. O
# O
re O
##nal O
: O
patient O
was O
admitted O
with O
c O
##r O
1 O
. O
3 O
. O
he O
was O
not O
known O
to O
have O
c O
##rf O
. O
his O
c O
##r O
rose O
to O
1 O
. O
6 O
post O
- O
c O
##t O
contrast O
on O
[ O
* O
* O
210 O
##4 O
- O
12 O
- O
31 O
* O
* O
] O
. O
this O
should O
be O
repeated O
in O
2 O
days O
time O
and O
then O
at O
least O
weekly O
. O
. O
# O
code O
: O
full O
code O
. O
. O

transitional O
care O
issues O
: O
patient O
will O
need O
a O
repeat O
c O
##t O
head O
scan O
with O
contrast O
as O
an O
out O
##patient O
in O
[ O
* O
* O
4 O
- O
24 O
* O
* O
] O
weeks O
from O
discharge O
. O
this O
has O
been O
requested O
. O
restart O
as B-DRUG
##pi I-DRUG
##rin I-DRUG
at O
325 B-STR
##m I-STR
##g I-STR
daily B-FRE
in O
1 O
week O
. O
please O
monitor O
ch O
##em O
7 O
as O
c O
##r O
rose O
from O
1 O
. O
3 O
to O
1 O
. O
6 O
following O
c O
##t O
contrast O
. O
repeat O
fast O
##ing O
lip O
##ids O
in O
3 O
months O
. O
medications O
on O
admission O
: O
- O
ni B-DRUG
##tro I-DRUG
##gly I-DRUG
##cer I-DRUG
##in I-DRUG
0 B-STR
. I-STR
4 I-STR
mg I-STR
s B-ROU
##l I-ROU
p B-FRE
##rn I-FRE
chest B-REA
pain I-REA
- O
l B-DRUG
##isi I-DRUG
##no I-DRUG
##p I-DRUG
##ril I-DRUG
20 B-STR
mg I-STR
daily B-FRE
- O
se B-DRUG
##rt I-DRUG
##ral I-DRUG
##ine I-DRUG
100 B-STR
mg I-STR
daily B-FRE
- O
pan B-DRUG
##tro I-DRUG
##pa I-DRUG
##zo I-DRUG
##le I-DRUG
40 B-STR
mg I-STR
daily B-FRE
- O
co B-DRUG
##uma I-DRUG
##din I-DRUG
5 B-STR
mg I-STR
daily B-FRE
- O
as B-DRUG
##a I-DRUG
81 B-STR
mg I-STR
daily B-FRE
- O
carved B-DRUG
##ilo I-DRUG
##l I-DRUG
25 B-STR
mg I-STR
[ O
* O
* O
hospital O
##1 O
* O
* O
] O
discharge O
medications O
: O
1 O
. O
ace B-DRUG
##tam I-DRUG
##ino I-DRUG
##phe I-DRUG
##n I-DRUG
325 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
1 B-DOS
- I-DOS
2 I-DOS
tablets B-FOR
p B-ROU
##o I-ROU
q B-FRE
##6 I-FRE
##h I-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
. I-REA
2 O
. O
ni B-DRUG
##tro I-DRUG
##gly I-DRUG
##cer I-DRUG
##in I-DRUG
0 B-STR
. I-STR
4 I-STR
mg I-STR
tablet B-FOR
, I-FOR
sub I-FOR
##ling I-FOR
##ual I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
sub B-ROU
##ling I-ROU
##ual I-ROU
once B-FRE
a I-FRE
day I-FRE
as I-FRE
needed I-FRE
for O
chest B-REA
pain I-REA
. I-REA
3 O
. O
do B-DRUG
##cus I-DRUG
##ate I-DRUG
sodium I-DRUG
100 B-STR
mg I-STR
capsule B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
capsule B-FOR
p B-ROU
##o I-ROU
bid B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
con B-REA
##st I-REA
##ip I-REA
##ation I-REA
. I-REA
4 O
. O
se B-DRUG
##rt I-DRUG
##ral I-DRUG
##ine I-DRUG
100 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE
5 O
. O
carved B-DRUG
##ilo I-DRUG
##l I-DRUG
25 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
twice B-FRE
a I-FRE
day I-FRE
. I-FRE
6 O
. O
l B-DRUG
##isi I-DRUG
##no I-DRUG
##p I-DRUG
##ril I-DRUG
20 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( I-FRE
daily I-FRE
) I-FRE
. I-FRE
7 O
. O
pan B-DRUG
##top I-DRUG
##raz I-DRUG
##ole I-DRUG
40 B-STR
mg I-STR
tablet B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
p B-ROU
##o I-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE
8 O
. O
at B-DRUG
##or I-DRUG
##vas I-DRUG
##tat I-DRUG
##in I-DRUG
40 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
at B-FRE
bed I-FRE
##time I-FRE
. I-FRE
discharge O
disposition O
: O
extended O
care O
facility O
: O
[ O
* O
* O
hospital O
##6 O
* O
* O
] O
discharge O
diagnosis O
: O
primary O
diagnosis O
: O
left O
basal O
gang O
##lia O
in O
##tra O
##par O
##en O
##chy O
##mal O
hem O
##or O
##r O
##hage O

discharge O
condition O
: O
mental O
status O
: O
clear O
and O
coherent O
. O
level O
of O
consciousness O
: O
alert O
and O
interactive O
. O
activity O
status O
: O
am O
##bula O
##tory O
- O
requires O
assistance O
or O
aid O
( O
[ O
* O
* O
hospital O
##6 O
* O
* O
] O
or O
cane O
) O
. O
ne O
##uro O
##log O
##ic O
: O
a O
+ O
o O
##x O
##3 O
span O
##ish O
speaking O
but O
speaks O
good O
en O
##gli O
##sh O
and O
follows O
commands O
well O
. O
speech O
is O
d O
##ys O
##ar O
##ht O
##ric O
but O
fluent O
and O
no O
evidence O
of O
mental O
status O
abnormal O
##ities O
with O
no O
neglect O
. O
right O
facial O
d O
##roo O
##p O
and O
otherwise O
c O
##n O
exam O
un O
##rem O
##ark O
##able O
. O
right O
pro O
##nat O
##or O
drift O
with O
mild O
right O
hem O
##ip O
##ares O
##is O
( O
del O
##t O
[ O
* O
* O
2 O
- O
19 O
* O
* O
] O
, O
t O
##ri O
/ O
we O
/ O
f O
##e O
/ O
i O
##p O
4 O
+ O
/ O
5 O
) O
. O
plant O
##ars O
ex O
##tens O
##or O
bilateral O
##ly O
. O

discharge O
instructions O
: O
it O
was O
a O
pleasure O
taking O
care O
of O
you O
during O
your O
stay O
at O
the O
[ O
* O
* O
known O
first O
##name O
38 O
##6 O
##7 O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
* O
* O
] O
[ O
* O
* O
first O
name O
( O
titles O
) O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
titles O
) O
* O
* O
] O
. O
you O
presented O
with O
right O
- O
sided O
weakness O
and O
facial O
d O
##roo O
##p O
. O
you O
had O
a O
c O
##t O
scan O
and O
were O
found O
to O
have O
a O
bleed B-ADE
in I-ADE
your I-ADE
brain I-ADE
in O
the O
area O
of O
the O
left O
basal O
gang O
##lia O
. O
as O
you O
were O
on O
war B-DRUG
##fari I-DRUG
##n I-DRUG
( I-DRUG
co I-DRUG
##uma I-DRUG
##din I-DRUG
) I-DRUG
which O
is O
a O
blood B-REA
thinner I-REA
and O
worse B-ADE
##ns I-ADE
bleeding I-ADE
, I-ADE
this O
was O
reversed O
with O
medications O
and O
co B-DRUG
##uma I-DRUG
##din I-DRUG
was O
stopped O
. O
your O
blood O
pressure O
was O
initially O
high O
and O
you O
had O
to O
be O
treated O
with O
i O
##v O
medications O
to O
lower O
your O
blood O
pressure O
in O
the O
i O
##cu O
. O
your O
blood O
pressure O
normal O
##ised O
and O
you O
were O
transferred O
to O
the O
ne O
##uro O
##logy O
floor O
. O
you O
did O
well O
and O
your O
strength O
on O
the O
right O
side O
was O
slowly O
improving O
. O
your O
war B-DRUG
##fari I-DRUG
##n I-DRUG
was O
stopped O
and O
should O
not O
be O
continued O
due O
to O
further O
risk O
of O
bleeding O
. O
you O
should O
stop O
as B-DRUG
##pi I-DRUG
##rin I-DRUG
currently O
and O
rest O
##rat O
at O
325 B-STR
##m I-STR
##g I-STR
daily B-FRE
in O
1 O
week O
. O
we O
also O
started O
at B-DRUG
##or I-DRUG
##vas I-DRUG
##tat I-DRUG
##in I-DRUG
for O
high B-REA
ch I-REA
##ole I-REA
##ster I-REA
##ol I-REA
as O
your O
ch O
##ole O
##ster O
##ol O
was O
found O
to O
be O
high O
. O
this O
should O
be O
repeated O
in O
3 O
months O
time O
. O
your O
kidney O
function O
tests O
were O
also O
slightly O
abnormal O
following O
the O
c O
##t O
contrast O
and O
this O
will O
be O
followed O
at O
re O
##hab O
. O
you O
were O
continued O
on O
your O
other O
home O
medications O
. O
the O
most O
likely O
cause O
of O
this O
brain O
hem O
##or O
##r O
##hage O
was O
high O
blood O
pressure O
although O
given O
your O
pace O
##maker O
we O
were O
unable O
to O
do O
an O
m O
##ri O
. O
as O
a O
result O
you O
will O
need O
to O
have O
a O
repeat O
c O
##t O
scan O
in O
6 O
weeks O
as O
at O
this O
point O
the O
blood O
should O
have O
re O
##ab O
##sor O
##bed O
and O
we O
will O
be O
able O
to O
look O
to O
see O
if O
there O
is O
any O
les O
##ion O
underlying O
your O
hem O
##or O
##r O
##hage O
. O
you O
were O
deemed O
appropriate O
for O
re O
##hab O
and O
transferred O
to O
re O
##hab O
on O
[ O
* O
* O
210 O
##4 O
- O
12 O
- O
31 O
* O
* O
] O
. O
. O
medication O
changes O
: O
we O
stopped O
as B-DRUG
##pi I-DRUG
##rin I-DRUG
and O
this O
should O
be O
restart O
##ed O
at O
325 B-STR
##m I-STR
##g I-STR
daily B-FRE
in O
1 O
week O
we O
stopped O
war B-DRUG
##fari I-DRUG
##n I-DRUG
( I-DRUG
co I-DRUG
##uma I-DRUG
##din I-DRUG
) I-DRUG
we O
started O
at B-DRUG
##or I-DRUG
##vas I-DRUG
##tat I-DRUG
##in I-DRUG
40 B-STR
##m I-STR
##g I-STR
daily B-FRE
for O
high B-REA
ch I-REA
##ole I-REA
##ster I-REA
##ol I-REA
please O
continue O
your O
other O
medications O
as O
previously O
prescribed O

follow O
##up O
instructions O
: O
please O
see O
your O
p O
##c O
##p O
d O
##r O
[ O
* O
* O
first O
name O
##4 O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
48 O
##86 O
* O
* O
] O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
92 O
##17 O
##6 O
* O
* O
] O
following O
discharge O
from O
re O
##hab O
. O
. O
we O
have O
arranged O
the O
following O
ne O
##uro O
##logy O
follow O
- O
up O
: O
department O
: O
ne O
##uro O
##logy O
when O
: O
f O
##rida O
##y O
[ O
* O
* O
210 O
##5 O
- O
2 O
- O
27 O
* O
* O
] O
at O
10 O
: O
00 O
am O
with O
: O
[ O
* O
* O
first O
name O
##8 O
( O
name O
##pa O
##tter O
##n O
##2 O
) O
* O
* O
] O
[ O
* O
* O
name O
##8 O
( O
m O
##d O
) O
162 O
* O
* O
] O
, O
m O
##d O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
257 O
##4 O
* O
* O
] O
building O
: O
[ O
* O
* O
hospital O
##6 O
29 O
* O
* O
] O
[ O
* O
* O
location O
( O
un O
) O
85 O
##8 O
* O
* O
] O
campus O
: O
east O
best O
parking O
: O
[ O
* O
* O
hospital O
ward O
name O
23 O
* O
* O
] O
garage O
you O
are O
due O
to O
have O
a O
c O
##t O
scan O
before O
this O
appointment O
. O
[ O
* O
* O
first O
name O
##8 O
( O
name O
##pa O
##tter O
##n O
##2 O
) O
* O
* O
] O
[ O
* O
* O
name O
##8 O
( O
m O
##d O
) O
162 O
* O
* O
] O
m O
##d O
[ O
* O
* O
m O
##d O
number O
( O
2 O
) O
257 O
##5 O
* O
* O
] O

admission O
date O
: O
[ O
* O
* O
212 O
##2 O
- O
7 O
- O
6 O
* O
* O
] O
discharge O
date O
: O
[ O
* O
* O
212 O
##2 O
- O
7 O
- O
11 O
* O
* O
] O
date O
of O
birth O
: O
[ O
* O
* O
208 O
##1 O
- O
7 O
- O
30 O
* O
* O
] O
sex O
: O
m O
service O
: O
medicine O
all O
##er O
##gies O
: O
te B-DRUG
##ssa I-DRUG
##lon I-DRUG
per I-DRUG
##les I-DRUG
attending O
: O
[ O
* O
* O
first O
name O
##3 O
( O
l O
##f O
) O
89 O
##6 O
* O
* O
] O
chief O
complaint O
: O
cough O
, O
sob O
, O
fever O
major O
surgical O
or O
invasive O
procedure O
: O
- O
none O
history O
of O
present O
illness O
: O
40 O
yo O
m O
with O
in O
his O
usual O
state O
of O
good O
health O
presents O
with O
fever O
to O
103 O
, O
cough O
, O
and O
short O
##ness O
of O
breath O
. O
his O
initial O
symptoms O
were O
fever O
and O
my O
##al O
##gia O
, O
beginning O
abruptly O
on O
f O
##rida O
##y O
morning O
. O
he O
subsequently O
developed O
cough O
. O
on O
the O
morning O
of O
his O
admission O
, O
he O
developed O
p O
##al O
##pit O
##ations O
and O
presented O
to O
a O
hospital O
in O
[ O
* O
* O
location O
36 O
##15 O
* O
* O
] O
, O
where O
he O
was O
found O
to O
be O
in O
rapid O
at O
##rial O
fi O
##bri O
##lla O
##tion O
. O
from O
there O
, O
he O
was O
transported O
to O
[ O
* O
* O
location O
( O
un O
) O
91 O
##01 O
* O
* O
] O
, O
where O
he O
was O
treated O
with O
normal B-DRUG
sa I-DRUG
##line I-DRUG
, I-DRUG
van B-DRUG
##com I-DRUG
##y I-DRUG
##cin I-DRUG
1 B-STR
g I-STR
##m I-STR
, I-STR
a B-DRUG
##zi I-DRUG
##th I-DRUG
##rom I-DRUG
##y I-DRUG
##cin I-DRUG
500 B-STR
mg I-STR
, I-STR
c B-DRUG
##ef I-DRUG
##tri I-DRUG
##ax I-DRUG
##one I-DRUG
1 B-STR
gram I-STR
, I-STR
dig B-DRUG
##ox I-DRUG
##in I-DRUG
0 B-STR
. I-STR
25 I-STR
mg I-STR
, I-STR
i B-DRUG
##bu I-DRUG
##p I-DRUG
##ro I-DRUG
##fen I-DRUG
600 B-STR
mg I-STR
, I-STR
ace B-DRUG
##tam I-DRUG
##ino I-DRUG
##phe I-DRUG
##n I-DRUG
97 B-STR
##5 I-STR
mg I-STR
, I-STR
di B-DRUG
##lt I-DRUG
##ia I-DRUG
##ze I-DRUG
##m I-DRUG
20 B-STR
mg I-STR
i B-ROU
##v I-ROU
, I-ROU
and O
card B-DRUG
##ize I-DRUG
##n I-DRUG
c I-DRUG
##d I-DRUG
120 B-STR
mg I-STR
. I-STR
his O
heart O
rate O
was O
controlled O
, O
but O
he O
developed O
a O
new O
oxygen O
requirement O
and O
was O
transferred O
to O
[ O
* O
* O
hospital O
##1 O
18 O
* O
* O
] O
for O
further O
management O
. O
at O
[ O
* O
* O
hospital O
##1 O
18 O
* O
* O
] O
, O
c O
##x O
##r O
showed O
a O
right O
- O
sided O
pneumonia O
with O
para O
##p O
##ne O
##um O
##onic O
e O
##ff O
##usion O
. O
he O
was O
continued O
on O
a O
di B-DRUG
##lt I-DRUG
##ia I-DRUG
##ze I-DRUG
##m I-DRUG
g B-ROU
##tt I-ROU
at O
10 B-STR
mg I-STR
/ I-STR
h I-STR
##r I-STR
. I-STR
blood O
and O
s O
##put O
##um O
cultures O
were O
sent O
. O
he O
was O
admitted O
to O
the O
i O
##cu O
on O
a O
non O
- O
re O
##bre O
##ather O
. O
past O
medical O
history O
: O
- O
right O
knee O
surgery O
with O
hardware O
in O
place O
social O
history O
: O
- O
works O
as O
an O
emergency O
medicine O
physician O
at O
[ O
* O
* O
hospital O
##1 O
18 O
* O
* O
] O
- O
married O
with O
two O
young O
children O
- O
tobacco O
: O
none O
- O
et O
##oh O
: O
< O
1 O
drink O
/ O
week O
- O
ill O
##icit O
drug O
use O
: O
none O
family O
history O
: O
- O
father O
: O
cab O
##g O
in O
his O
50 O
##s O
. O
- O
no O
family O
history O
of O
ve O
##nous O
th O
##rom O
##bos O
##is O
. O

physical O
exam O
: O
admission O
physical O
exam O
: O
vital O
signs O
: O
t O
: O
100 O
. O
6 O
h O
##r O
: O
89 O
b O
##p O
: O
150 O
/ O
94 O
r O
##r O
: O
16 O
o O
##2 O
sat O
99 O
% O
/ O
n O
##rb O
g O
##en O
: O
no O
acute O
distress O
. O
pale O
. O
he O
##ent O
: O
n O
##c O
/ O
at O
. O
an O
##ict O
##eric O
s O
##cle O
##rae O
. O
moist O
m O
##uc O
##ous O
membrane O
##s O
. O
op O
with O
mild O
er O
##yt O
##hem O
##a O
and O
no O
ex O
##uda O
##te O
. O
neck O
: O
su O
##pp O
##le O
. O
no O
c O
##er O
##vic O
##al O
or O
su O
##pra O
##c O
##lav O
##icular O
l O
##ymph O
##ade O
##no O
##pathy O
. O
re O
##sp O
: O
normal O
respiratory O
effort O
. O
dull O
to O
percussion O
at O
right O
base O
. O
br O
##on O
##chia O
##l O
breath O
sounds O
/ O
ego O
##phony O
at O
bilateral O
bases O
r O
> O
l O
. O
c O
##v O
: O
r O
##rr O
( O
converted O
to O
sin O
##us O
during O
exam O
) O
. O
normal O
s O
##1 O
and O
s O
##2 O
. O
no O
m O
/ O
g O
/ O
r O
. O
a O
##b O
##d O
: O
+ O
b O
##s O
. O
soft O
. O
n O
##t O
/ O
n O
##d O
. O
no O
re O
##bound O
or O
guarding O
. O
ex O
##t O
: O
warm O
and O
well O
- O
per O
##fused O
. O
radial O
and O
d O
##p O
pulses O
2 O
+ O
bilateral O
##ly O
. O
ne O
##uro O
: O
a O
+ O
o O
##x O
##3 O
. O
per O
##rl O
. O
e O
##omi O
, O
with O
no O
n O
##ys O
##tag O
##mus O
. O
face O
symmetric O
. O
p O
##ala O
##te O
el O
##eva O
##tes O
symmetrical O
##ly O
. O
tongue O
pro O
##tr O
##udes O
in O
mid O
##line O
. O
strength O
5 O
/ O
5 O
throughout O
upper O
and O
lower O
ex O
##tre O
##mit O
##ies O
. O
discharge O
exam O
: O
g O
##en O
: O
w O
##n O
##w O
##d O
male O
resting O
am O
##bula O
##ting O
in O
room O
. O
he O
##ent O
: O
e O
##omi O
. O
mm O
##m O
. O
neck O
: O
su O
##pp O
##le O
. O
co O
##r O
: O
+ O
s O
##1 O
##s O
##2 O
, O
r O
##rr O
, O
no O
m O
/ O
g O
/ O
r O
. O
pu O
##lm O
: O
decreased O
bi O
##bal O
##ila O
##r O
breath O
sounds O
with O
dull O
##ness O
to O
percussion O
at O
right O
base O
. O
ins O
##pi O
##rator O
##y O
crack O
##les O
at O
bases O
( O
right O
worse O
than O
left O
) O
. O
no O
w O
##hee O
##ze O
. O
[ O
* O
* O
last O
name O
( O
un O
) O
* O
* O
] O
: O
+ O
na O
##bs O
in O
4 O
##q O
. O
soft O
, O
n O
##t O
##nd O
. O
ex O
##t O
: O
warm O
, O
well O
- O
per O
##fused O
. O
+ O
d O
##p O
bilateral O
##ly O
. O
ne O
##uro O
: O
awake O
, O
alert O
. O
per O
##tinent O
results O
: O
admission O
labs O
: O

[ O
* O
* O
212 O
##2 O
- O
7 O
- O
6 O
* O
* O
] O
07 O
: O
24 O
##pm O
blood O
w O
##b O
##c O
- O
9 O
. O
1 O
r O
##b O
##c O
- O
4 O
. O
09 O
* O
h O
##g O
##b O
- O
12 O
. O
1 O
* O
h O
##ct O
- O
34 O
. O
4 O
* O
m O
##c O
##v O
- O
84 O
m O
##ch O
- O
29 O
. O
4 O
m O
##ch O
##c O
- O
35 O
. O
1 O
* O
r O
##d O
##w O
- O
14 O
. O
3 O
p O
##lt O
c O
##t O
- O
200 O
[ O
* O
* O
212 O
##2 O
- O
7 O
- O
6 O
* O
* O
] O
07 O
: O
24 O
##pm O
blood O
ne O
##uts O
- O
82 O
. O
8 O
* O
l O
##ymph O
##s O
- O
13 O
. O
5 O
* O
mon O
##os O
- O
3 O
. O
1 O
e O
##os O
- O
0 O
. O
2 O
b O
##as O
##o O
- O
0 O
. O
4 O
[ O
* O
* O
212 O
##2 O
- O
7 O
- O
6 O
* O
* O
] O
07 O
: O
24 O
##pm O
blood O
p O
##t O
- O
14 O
. O
4 O
* O
p O
##tt O
- O
26 O
. O
1 O
in O
##r O
( O
p O
##t O
) O
- O
1 O
. O
2 O
* O
[ O
* O
* O
212 O
##2 O
- O
7 O
- O
6 O
* O
* O
] O
07 O
: O
24 O
##pm O
blood O
glucose O
- O
110 O
* O
u O
##rea O
##n O
- O
6 O
c O
##rea O
##t O
- O
0 O
. O
7 O
na O
- O
138 O
k O
- O
3 O
. O
7 O
c O
##l O
- O
108 O
h O
##co O
##3 O
- O
22 O
an O
##ga O
##p O
- O
12 O
[ O
* O
* O
212 O
##2 O
- O
7 O
- O
6 O
* O
* O
] O
07 O
: O
24 O
##pm O
blood O
al O
##t O
- O
45 O
* O
as O
##t O
- O
32 O
c O
##k O
( O
c O
##p O
##k O
) O
- O
111 O
al O
##k O
##ph O
##os O
- O
64 O
to O
##t O
##bil O
##i O
- O
0 O
. O
3 O
[ O
* O
* O
212 O
##2 O
- O
7 O
- O
6 O
* O
* O
] O
07 O
: O
24 O
##pm O
blood O
c O
##k O
- O
m O
##b O
- O
2 O
c O
##tro O
##p O
##nt O
- O
0 O
. O
02 O
* O
[ O
* O
* O
212 O
##2 O
- O
7 O
- O
6 O
* O
* O
] O
07 O
: O
14 O
##pm O
blood O
la O
##ct O
##ate O
- O
1 O
. O
4 O
cardiac O
markers O
trend O
: O
[ O
* O
* O
212 O
##2 O
- O
7 O
- O
6 O
* O
* O
] O
07 O
: O
24 O
##pm O
blood O
c O
##k O
- O
m O
##b O
- O
2 O
c O
##tro O
##p O
##nt O
- O
0 O
. O
02 O
* O
[ O
* O
* O
212 O
##2 O
- O
7 O
- O
7 O
* O
* O
] O
12 O
: O
49 O
##am O
blood O
c O
##k O
- O
m O
##b O
- O
2 O
c O
##tro O
##p O
##nt O
- O
0 O
. O
01 O
[ O
* O
* O
212 O
##2 O
- O
7 O
- O
7 O
* O
* O
] O
05 O
: O
35 O
##am O
blood O
c O
##k O
- O
m O
##b O
- O
2 O
c O
##tro O
##p O
##nt O
- O
< O
0 O
. O
01 O

la O
##ct O
##ate O
trend O
: O
[ O
* O
* O
212 O
##2 O
- O
7 O
- O
6 O
* O
* O
] O
07 O
: O
14 O
##pm O
blood O
la O
##ct O
##ate O
- O
1 O
. O
4 O
[ O
* O
* O
212 O
##2 O
- O
7 O
- O
7 O
* O
* O
] O
07 O
: O
48 O
##am O
blood O
la O
##ct O
##ate O
- O
1 O
. O
1 O
[ O
* O
* O
212 O
##2 O
- O
7 O
- O
7 O
* O
* O
] O
04 O
: O
09 O
##pm O
blood O
la O
##ct O
##ate O
- O
0 O
. O
8 O
per O
##tinent O
other O
labs O
: O
[ O
* O
* O
212 O
##2 O
- O
7 O
- O
7 O
* O
* O
] O
03 O
: O
08 O
##pm O
blood O
hi O
##v O
a O
##b O
- O
negative O
[ O
* O
* O
212 O
##2 O
- O
7 O
- O
6 O
* O
* O
] O
11 O
: O
47 O
##pm O
urine O
color O
- O
straw O
appear O
- O
clear O
s O
##p O
[ O
* O
* O
last O
name O
( O
un O
) O
* O
* O
] O
- O
1 O
. O
01 O
##0 O
[ O
* O
* O
212 O
##2 O
- O
7 O
- O
6 O
* O
* O
] O
11 O
: O
47 O
##pm O
urine O
blood O
- O
s O
##m O
ni O
##tri O
##te O
- O
ne O
##g O
protein O
- O
ne O
##g O
glucose O
- O
ne O
##g O
k O
##eton O
##e O
- O
40 O
bi O
##li O
##ru O
##b O
- O
ne O
##g O
u O
##ro O
##bil O
##n O
- O
ne O
##g O
p O
##h O
- O
5 O
. O
0 O
le O
##uk O
##s O
- O
ne O
##g O
leg O
##ione O
##lla O
negative O
discharge O
labs O
: O
imaging O
: O
[ O
* O
* O
7 O
- O
6 O
* O
* O
] O
c O
##x O
##r O
: O
impression O
: O
findings O
concerning O
for O
right O
lower O
lobe O
pneumonia O
and O
possible O
right O
p O
##le O
##ural O
e O
##ff O
##usion O
with O
ate O
##lect O
##asis O
. O
left O
base O
re O
##tro O
##card O
##iac O
op O
##acity O
could O
be O
due O
to O
ate O
##lect O
##asis O
although O
a O
second O
location O
of O
consolidation O
/ O
infection O
not O
excluded O
. O
additionally O
, O
subtle O
op O
##acity O
at O
the O
lateral O
left O
mid O
lung O
, O
while O
could O
relate O
to O
overly O
##ing O
soft O
tissue O
, O
additional O
focus O
of O
consolidation O
is O
not O
excluded O
. O
[ O
* O
* O
7 O
- O
7 O
* O
* O
] O
: O
c O
##x O
##r O
: O
findings O
: O
as O
compared O
to O
the O
previous O
radio O
##graph O
, O
the O
extent O
of O
the O
pre O
- O
existing O
right O
p O
##le O
##ural O
e O
##ff O
##usion O
is O
stable O
. O
on O
the O
left O
, O
an O
area O
of O
par O
##en O
##chy O
##mal O
op O
##acity O
, O
previously O
qualified O
as O
potential O
pneumonia O
, O
has O
increased O
in O
extent O
. O
there O
is O
a O
newly O
occurred O
small O
reactive O
left O
- O
sided O
p O
##le O
##ural O
e O
##ff O
##usion O
with O
subsequent O
left O
ate O
##lect O
##asis O
. O
the O
diameter O
of O
the O
pulmonary O
vessels O
is O
minimal O
##ly O
increased O
, O
potentially O
reflecting O
mild O
fluid O
over O
##load O
. O
[ O
* O
* O
7 O
- O
7 O
* O
* O
] O
c O
##ta O
: O
1 O
. O
widespread O
rapidly O
evolving O
multi O
##lo O
##bar O
pneumonia O
, O
possibly O
complicated O
by O
a O
##rds O
. O
2 O
. O
small O
bilateral O
simple O
layer O
##ing O
p O
##le O
##ural O
e O
##ff O
##usions O
. O

[ O
* O
* O
212 O
##2 O
- O
7 O
- O
9 O
* O
* O
] O
03 O
: O
31 O
##am O
blood O
w O
##b O
##c O
- O
8 O
. O
7 O
r O
##b O
##c O
- O
4 O
. O
12 O
* O
h O
##g O
##b O
- O
11 O
. O
7 O
* O
h O
##ct O
- O
34 O
. O
5 O
* O
m O
##c O
##v O
- O
84 O
m O
##ch O
- O
28 O
. O
4 O
m O
##ch O
##c O
- O
33 O
. O
9 O
r O
##d O
##w O
- O
14 O
. O
4 O
p O
##lt O
c O
##t O
- O
28 O
##2 O
[ O
* O
* O
212 O
##2 O
- O
7 O
- O
9 O
* O
* O
] O
03 O
: O
31 O
##am O
blood O
glucose O
- O
94 O
u O
##rea O
##n O
- O
8 O
c O
##rea O
##t O
- O
0 O
. O
9 O
na O
- O
143 O
k O
- O
3 O
. O
6 O
c O
##l O
- O
106 O
h O
##co O
##3 O
- O
28 O
an O
##ga O
##p O
- O
13 O
brief O
hospital O
course O
: O
primary O
reason O
for O
admission O
: O
40 O
yo O
m O
presents O
with O
fever O
, O
short O
##ness O
of O
breath O
, O
and O
cough O
, O
admitted O
to O
mi O
##cu O
for O
h O
##y O
##pox O
##emia O
requiring O
n O
##rb O
, O
found O
to O
have O
t O
##ril O
##ob O
##ar O
p O
##na O
. O
acute O
di O
##ag O
##nose O
##s O
: O
# O
multi O
##lo O
##bar O
pneumonia O
, O
likely O
bacterial O
: O
c O
##ta O
results O
showed O
significant O
t O
##ri O
- O
lo O
##bar O
p O
##na O
which O
appeared O
significant O
enough O
for O
s O
##hun O
##ting O
to O
explain O
his O
degree O
of O
h O
##y O
##pox O
##ia O
. O
his O
p B-REA
##na I-REA
was O
treated O
and O
oxygen B-DRUG
was O
we O
##ane O
##d O
down O
and O
he O
tolerate O
##d O
walking O
around O
floor O
with O
nasal B-ROU
can I-ROU
##nu I-ROU
##la I-ROU
, I-ROU
though O
he O
wore O
face B-ROU
tent I-ROU
at O
base O
##line O
for O
comfort O
. O
he O
was O
initially O
treated O
for O
cap O
but O
because O
he O
works O
in O
a O
health O
- O
care O
setting O
and O
considering O
the O
extent O
of O
p O
##na O
with O
h O
##y O
##pox O
##ia O
he O
was O
treated O
for O
h B-REA
##cap I-REA
coverage O
with O
i B-ROU
##v I-ROU
van B-DRUG
##com I-DRUG
##y I-DRUG
##cin I-DRUG
, I-DRUG
c B-DRUG
##ef I-DRUG
##ep I-DRUG
##ime I-DRUG
, I-DRUG
and O
c B-DRUG
##ip I-DRUG
##ro I-DRUG
##f I-DRUG
##lo I-DRUG
##xa I-DRUG
##cin I-DRUG
. I-DRUG
on O
the O
floor O
he O
quickly O
we O
##ane O
##d O
down O
to O
room O
air O
and O
was O
breathing O
comfortably O
with O
occasionally O
s O
##put O
##um O
tinged O
with O
blood O
. O
he O
was O
discharged O
on O
a O
10 B-DUR
- I-DUR
day I-DUR
course O
of O
le B-DRUG
##vo I-DRUG
##f I-DRUG
##lo I-DRUG
##xa I-DRUG
##cin I-DRUG
& O
line B-DRUG
##zo I-DRUG
##lid I-DRUG
, I-DRUG
to O
cover O
ensure O
coverage O
of O
both O
m B-REA
##s I-REA
##ra I-REA
and O
other O
usual O
cap B-REA
organisms I-REA
. I-REA

# O
at B-REA
##rial I-REA
fi I-REA
##bri I-REA
##lla I-REA
##tion I-REA
with I-REA
r I-REA
##v I-REA
##r I-REA
: I-REA
d O
##r O
. O
[ O
* O
* O
known O
last O
##name O
23 O
* O
* O
] O
initially O
presented O
in O
new O
onset O
a O
. O
fi O
##b O
with O
runs O
of O
r O
##v O
##r O
into O
160 O
##s O
with O
associated O
h O
##y O
##pot O
##ens O
##ion O
. O
he O
was O
treated O
with O
a O
10 B-STR
##m I-STR
##g I-STR
/ I-STR
h I-STR
##r I-STR
di B-DRUG
##lt I-DRUG
d B-ROU
##rip I-ROU
and O
spontaneous O
##ly O
converted O
to O
sin O
##us O
and O
he O
remained O
in O
sin O
##us O
rhythm O
throughout O
the O
rest O
of O
his O
hospital O
##ization O
. O
although O
he O
has O
a O
history O
of O
p O
##al O
##pit O
##ations O
in O
the O
past O
( O
and O
has O
been O
on O
a O
ho O
##lter O
monitor O
) O
, O
this O
is O
his O
first O
episode O
of O
at B-REA
##rial I-REA
fi I-REA
##bri I-REA
##lla I-REA
##tion I-REA
. I-REA
given O
his O
ch O
##ads O
##2 O
score O
of O
0 O
- O
1 O
it O
was O
felt O
that O
he O
did O
not O
require O
anything O
other O
than O
a O
daily B-FRE
as B-DRUG
##pi I-DRUG
##rin I-DRUG
( O
which O
he O
has O
been O
taking O
as O
an O
out O
##patient O
) O
. O
the O
as B-DRUG
##pi I-DRUG
##rin I-DRUG
was O
held O
due O
to O
intermittent B-ADE
hem I-ADE
##op I-ADE
##ty I-ADE
##sis I-ADE
/ I-ADE
blood B-ADE
streaked I-ADE
s I-ADE
##put I-ADE
##um I-ADE
, I-ADE
but O
d O
##r O
. O
[ O
* O
* O
known O
last O
##name O
23 O
* O
* O
] O
was O
advised O
to O
discuss O
re O
##ini O
##tia O
##tion O
of O
as B-DRUG
##pi I-DRUG
##rin I-DRUG
as O
an O
out O
##patient O
. O
chronic O
di O
##ag O
##nose O
##s O
: O
none O
. O
transitional O
issues O
: O
# O
follow O
- O
up O
: O
the O
patient O
was O
instructed O
to O
follow O
up O
with O
his O
new O
primary O
care O
doctor O
within O
1 O
- O
2 O
weeks O
. O
he O
was O
told O
to O
discuss O
re O
##ini O
##tation O
of O
as B-DRUG
##pi I-DRUG
##rin I-DRUG
with O
his O
p O
##c O
##p O
when O
his O
hem B-ADE
##op I-ADE
##ty I-ADE
##sis I-ADE
cease O
##s O
. O
he O
should O
also O
be O
screened O
for O
h O
##yper O
##tens O
##ion O
, O
as O
it O
was O
noted O
that O
his O
blood O
pressure O
was O
elevated O
to O
the O
140 O
##s O
- O
150 O
##s O
s O
##ys O
##to O
##lic O
while O
he O
was O
on O
the O
floor O
. O
medications O
on O
admission O
: O
- O
as B-DRUG
##pi I-DRUG
##rin I-DRUG
81 B-STR
##m I-STR
##g I-STR
p B-ROU
##o I-ROU
daily B-FRE
discharge O
medications O
: O
1 O
. O
line B-DRUG
##zo I-DRUG
##lid I-DRUG
600 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
q B-FRE
##12 I-FRE
##h I-FRE
( I-FRE
every I-FRE
12 I-FRE
hours I-FRE
) I-FRE
for B-DUR
10 I-DUR
days I-DUR
. I-DUR
di O
##sp O
: O
* O
20 O
tablet B-FOR
( I-FOR
s I-FOR
) I-FOR
* I-FOR
re O
##fill O
##s O
: O
* O
0 O
* O
2 O
. O
le B-DRUG
##vo I-DRUG
##f I-DRUG
##lo I-DRUG
##xa I-DRUG
##cin I-DRUG
750 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( I-FRE
daily I-FRE
) I-FRE
for B-DUR
10 I-DUR
days I-DUR
. I-DUR
di O
##sp O
: O
* O
10 O
tablet O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
0 O
* O
3 O
. O
code B-DRUG
##ine I-DRUG
- I-DRUG
g I-DRUG
##ua I-DRUG
##ife I-DRUG
##nes I-DRUG
##in I-DRUG
10 B-STR
- I-STR
100 I-STR
mg I-STR
/ I-STR
5 I-STR
m I-STR
##l I-STR
syrup B-FOR
si O
##g O
: O
5 B-DOS
- I-DOS
10 I-DOS
m I-DOS
##ls I-DOS
p B-ROU
##o I-ROU
q B-FRE
##6 I-FRE
##h I-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
cough B-REA
: I-REA
do O
not O
drive O
while O
taking O
this O
medication O
. O
di O
##sp O
: O
* O
500 O
m O
##l O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
0 O
* O
discharge O
disposition O
: O
home O

discharge O
diagnosis O
: O
primary O
diagnosis O
: O
- O
multi O
##fo O
##cal O
pneumonia O
- O
se O
##psis O
secondary O
diagnosis O
: O
- O
at O
##rial O
fi O
##bri O
##lla O
##tion O
with O
rapid O
vent O
##ric O
##ular O
response O
discharge O
condition O
: O
mental O
status O
: O
clear O
and O
coherent O
. O
level O
of O
consciousness O
: O
alert O
and O
interactive O
. O
activity O
status O
: O
am O
##bula O
##tory O
- O
independent O
. O
discharge O
instructions O
: O
d O
##r O
. O
[ O
* O
* O
known O
last O
##name O
23 O
* O
* O
] O
, O
it O
was O
a O
pleasure O
to O
participate O
in O
your O
care O
while O
you O
were O
hospital O
. O
you O
were O
initially O
admitted O
to O
the O
mi O
##cu O
on O
a O
di B-DRUG
##lt I-DRUG
##ia I-DRUG
##ze I-DRUG
##m I-DRUG
d B-ROU
##rip I-ROU
to O
control B-REA
your I-REA
rapid I-REA
at I-REA
##rial I-REA
fi I-REA
##bri I-REA
##lla I-REA
##tion I-REA
. I-REA
you O
had O
an O
ongoing O
oxygen B-DRUG
requirement O
and O
it O
was O
discovered O
that O
you O
had O
a B-REA
multi I-REA
##fo I-REA
##cal I-REA
pneumonia I-REA
. I-REA
you O
were O
treated O
with O
broad B-DRUG
- I-DRUG
spectrum I-DRUG
i B-ROU
##v I-ROU
anti I-DRUG
##biotics I-DRUG
, I-DRUG
which O
were O
transitioned O
to O
p B-ROU
##o I-ROU
anti B-DRUG
##biotics I-DRUG
a O
day O
prior O
to O
your O
discharge O
. O
medication O
changes O
: O
- O
medications O
added O
: O
line B-DRUG
##zo I-DRUG
##lid I-DRUG
600 B-STR
mg I-STR
q B-FRE
##12 I-FRE
##h I-FRE
for B-DUR
10 I-DUR
days I-DUR
- O
medications O
added O
: O
g B-DRUG
##ua I-DRUG
##ife I-DRUG
##nes I-DRUG
##in I-DRUG
- I-DRUG
code I-DRUG
##ine I-DRUG
cough B-FOR
syrup I-FOR
as B-FRE
needed I-FRE
for O
cough B-REA
- O
medications O
stopped O
: O
as B-DRUG
##pi I-DRUG
##rin I-DRUG
- O
medications O
changed O
: O
none O
. O
follow O
##up O
instructions O
: O
we O
are O
working O
on O
a O
follow O
up O
appointment O
in O
[ O
* O
* O
state O
* O
* O
] O
group O
with O
your O
new O
primary O
care O
physician O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##4 O
) O
* O
* O
] O
. O
[ O
* O
* O
first O
name O
##8 O
( O
name O
##pa O
##tter O
##n O
##2 O
) O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
* O
* O
] O
. O
the O
office O
will O
contact O
you O
at O
home O
with O
an O
appointment O
. O
if O
you O
have O
not O
heard O
within O
2 O
business O
days O
or O
have O
any O
questions O
please O
call O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
220 O
##5 O
* O
* O
] O
. O

admission O
date O
: O
[ O
* O
* O
214 O
##0 O
- O
12 O
- O
10 O
* O
* O
] O
discharge O
date O
: O
[ O
* O
* O
214 O
##0 O
- O
12 O
- O
25 O
* O
* O
] O
date O
of O
birth O
: O
[ O
* O
* O
207 O
##4 O
- O
10 O
- O
5 O
* O
* O
] O
sex O
: O
m O
service O
: O
card O
##iot O
##hora O
##ci O
##c O
all O
##er O
##gies O
: O
pen B-DRUG
##ici I-DRUG
##llin I-DRUG
##s I-DRUG
/ O
l B-DRUG
##isi I-DRUG
##no I-DRUG
##p I-DRUG
##ril I-DRUG
/ O
di B-DRUG
##ova I-DRUG
##n I-DRUG
/ O
met B-DRUG
##form I-DRUG
##in I-DRUG
/ O
in B-DRUG
##te I-DRUG
##g I-DRUG
##ril I-DRUG
##in I-DRUG
attending O
: O
[ O
* O
* O
first O
name O
##3 O
( O
l O
##f O
) O
140 O
##6 O
* O
* O
] O
chief O
complaint O
: O
chest O
pain O
major O
surgical O
or O
invasive O
procedure O
: O
red O
##o O
stern O
##oto O
##my O
/ O
co O
##rona O
##ry O
artery O
bypass O
g O
##raft O
##ing O
x O
##3 O
with O
reverse O
sa O
##phe O
##nous O
vein O
g O
##raft O
##s O
to O
the O
second O
branch O
of O
the O
posterior O
left O
vent O
##ric O
##ular O
branch O
, O
o O
##bt O
##use O
marginal O
artery O
, O
and O
left O
anterior O
descending O
artery O
. O
history O
of O
present O
illness O
: O
66 O
##yo O
##m O
with O
significant O
ca O
##d O
s O
/ O
p O
cab O
##g O
( O
[ O
* O
* O
212 O
##5 O
* O
* O
] O
) O
, O
des O
to O
s O
##v O
##g O
- O
d O
##1 O
/ O
o O
##m O
x O
##2 O
( O
[ O
* O
* O
213 O
##5 O
* O
* O
] O
, O
[ O
* O
* O
213 O
##8 O
* O
* O
] O
) O
who O
presents O
with O
chest O
pain O
. O
the O
patient O
has O
a O
significant O
cardiac O
history O
with O
cab O
##g O
( O
l O
##ima O
- O
lad O
, O
s O
##v O
##g O
- O
d O
##1 O
/ O
o O
##m O
, O
s O
##v O
##t O
- O
p O
##da O
) O
and O
des O
to O
o O
##st O
##ial O
s O
##v O
##g O
- O
d O
##1 O
/ O
o O
##m O
, O
pro O
##ximal O
s O
##v O
##g O
- O
d O
##1 O
/ O
o O
##m O
, O
p O
##ci O
with O
des O
to O
o O
##st O
##ial O
s O
##v O
##g O
- O
d O
##1 O
/ O
o O
##m O
and O
des O
to O
pro O
##ximal O
s O
##v O
##g O
- O
d O
##1 O
/ O
o O
##m O
. O
he O
has O
been O
on O
p B-DRUG
##lav I-DRUG
##ix I-DRUG
75 B-STR
mg I-STR
daily B-FRE
and O
full O
dose O
as B-DRUG
##pi I-DRUG
##rin I-DRUG
. I-DRUG
however O
, O
on O
t O
##ues O
##day O
, O
10 O
days O
prior O
to O
presentation O
, O
the O
patient O
underwent O
a O
lit O
##hot O
##rip O
##sy O
for O
kidney O
stones O
with O
placement O
of O
a O
u O
##ret O
##eral O
s O
##ten O
##t O
and O
f O
##ole O
##y O
bag O
and O
his O
p B-DRUG
##lav I-DRUG
##ix I-DRUG
was O
held O
. O
he O
is O
currently O
10 O
days O
off O
p B-DRUG
##lav I-DRUG
##ix I-DRUG
with O
his O
card O
##iol O
##ogist O
and O
u O
##rol O
##ogist O
both O
aware O
. O
. O

the O
patient O
reports O
his O
current O
symptoms O
began O
this O
morning O
when O
he O
developed O
sudden O
onset O
, O
dull O
, O
sub O
##ster O
##nal O
chest O
pain O
while O
walking O
at O
a O
leisure O
##ly O
pace O
at O
an O
automobile O
dealers O
##hip O
. O
the O
pain O
was O
associated O
with O
di O
##aph O
##ores O
##is O
, O
and O
subsequently O
developed O
nausea O
while O
being O
transported O
to O
the O
[ O
* O
* O
hospital O
##1 O
18 O
* O
* O
] O
ed O
. O
his O
symptoms O
were O
noted O
to O
be O
different O
than O
his O
prior O
an O
##gin O
##al O
symptoms O
of O
e O
##pi O
##gas O
##tric O
pain O
. O
he O
presented O
to O
a O
fire O
station O
where O
they O
gave O
him O
full O
dose O
as B-DRUG
##pi I-DRUG
##rin I-DRUG
and O
transported O
him O
to O
the O
[ O
* O
* O
hospital O
##1 O
18 O
* O
* O
] O
ed O
. O
the O
patient O
reports O
he O
began O
developing O
radiating O
left O
arm O
pain O
and O
pre O
##cor O
##dial O
pain O
when O
he O
reached O
the O
ed O
. O
card O
##iology O
was O
consulted O
and O
recommended O
he B-DRUG
##par I-DRUG
##in I-DRUG
g B-ROU
##tt I-ROU
, I-ROU
p B-DRUG
##lav I-DRUG
##ix I-DRUG
load O
, O
and O
ni B-DRUG
##tro I-DRUG
g B-ROU
##tt I-ROU
t O
##it O
##rated O
to O
pain B-REA
. I-REA
cardiac O
surgery O
was O
consulted O
for O
evaluation O
of O
co O
##rona O
##ry O
artery O
re O
##vas O
##cular O
##ization O
. O
past O
medical O
history O
: O
- O
d O
##ys O
##lip O
##ide O
##mia O
- O
h O
##yper O
##tens O
##ion O
- O
diabetes O
- O
cab O
##g O
: O
[ O
* O
* O
212 O
##5 O
* O
* O
] O
( O
s O
##v O
##g O
to O
d O
##1 O
/ O
o O
##m O
, O
s O
##v O
##g O
to O
p O
##da O
, O
l O
##ima O
to O
lad O
) O
- O
per O
##cut O
##aneous O
co O
##rona O
##ry O
interventions O
: O
des O
to O
pro O
##ximal O
s O
##v O
##g O
- O
d O
##1 O
/ O
o O
##m O
g O
##raft O
in O
[ O
* O
* O
213 O
##5 O
* O
* O
] O
, O
des O
to O
o O
##st O
##ial O
s O
##v O
##g O
- O
d O
##1 O
- O
o O
##m O
[ O
* O
* O
7 O
- O
/ O
213 O
##9 O
* O
* O
] O
- O
kidney O
stones O
s O
/ O
p O
lit O
##hot O
##rip O
##sy O
[ O
* O
* O
11 O
/ O
214 O
##0 O
* O
* O
] O
- O
current O
torn O
a O
##c O
##l O
- O
g O
##erd O
- O
s O
/ O
p O
app O
##end O
##ec O
##tom O
##y O
- O
basal O
cell O
ca O
- O
s O
/ O
p O
her O
##nia O
repair O
social O
history O
: O
- O
tobacco O
history O
: O
no O
prior O
history O
of O
smoking O
. O
- O
et O
##oh O
: O
denies O
. O
- O
ill O
##icit O
drugs O
: O
denies O
. O
married O
with O
11 O
children O
, O
6 O
of O
which O
are O
[ O
* O
* O
doctor O
last O
name O
* O
* O
] O
. O
works O
for O
[ O
* O
* O
company O
26 O
##7 O
##6 O
* O
* O
] O
as O
the O
man O
##anger O
of O
investigations O
, O
former O
special O
[ O
* O
* O
doctor O
last O
name O
360 O
* O
* O
] O
for O
the O
government O
. O
active O
on O
a O
daily O
basis O
, O
going O
to O
the O
gym O
5 O
days O
a O
week O
with O
consistent O
card O
##iovascular O
exercise O
and O
no O
an O
##gin O
##al O
symptoms O
on O
ex O
##ert O
##ion O
. O
family O
history O
: O
father O
cab O
##g O
in O
his O
50 O
##s O

physical O
exam O
: O
admission O
physical O
exam O
vs O
: O
t O
= O
b O
##p O
= O
120 O
/ O
82 O
h O
##r O
= O
72 O
r O
= O
p O
##o O
##2 O
= O
96 O
- O
99 O
% O
2 O
##l O
n O
##c O
general O
: O
alert O
, O
interactive O
, O
na O
##d O
. O
mood O
, O
affect O
appropriate O
. O
he O
##ent O
: O
s O
##cle O
##ra O
an O
##ict O
##eric O
. O
pupils O
equal O
and O
round O
. O
mm O
##m O
, O
or O
##op O
##har O
##ynx O
clear O
. O
no O
x O
##ant O
##hales O
##ma O
. O
neck O
: O
su O
##pp O
##le O
with O
j O
##v O
##p O
of O
~ O
9 O
##c O
##m O
. O
cardiac O
: O
r O
##rr O
, O
normal O
s O
##1 O
, O
s O
##2 O
. O
no O
m O
/ O
r O
/ O
g O
. O
no O
thrill O
##s O
, O
lifts O
. O
no O
s O
##3 O
or O
s O
##4 O
. O
lungs O
: O
large O
a O
- O
p O
diameter O
. O
no O
chest O
wall O
def O
##orm O
##ities O
, O
s O
##co O
##lio O
##sis O
or O
k O
##y O
##ph O
##osis O
. O
re O
##sp O
were O
un O
##la O
##bor O
##ed O
, O
no O
access O
##ory O
muscle O
use O
. O
minimal O
crack O
##les O
at O
bases O
b O
/ O
l O
, O
no O
w O
##hee O
##zes O
or O
r O
##hon O
##chi O
. O
abdomen O
: O
soft O
, O
n O
##d O
, O
min O
##mal O
discomfort O
in O
ll O
##q O
without O
re O
##bound O
or O
guarding O
, O
+ O
b O
##s O
. O
no O
a O
##b O
##dom O
##inia O
##l O
br O
##uit O
##s O
. O
ex O
##tre O
##mit O
##ies O
: O
no O
c O
/ O
c O
, O
chronic O
r O
> O
l O
non O
- O
pit O
##ting O
le O
ed O
##ema O
. O
w O
##w O
##p O
. O
2 O
+ O
d O
##p O
pulses O
b O
/ O
l O
. O
f O
##ole O
##y O
bag O
in O
place O
with O
dark O
red O
urine O
. O
per O
##tinent O
results O
: O
[ O
* O
* O
214 O
##0 O
- O
12 O
- O
11 O
* O
* O
] O
08 O
: O
01 O
##am O
: O
( O
peak O
c O
##k O
, O
m O
##b O
) O
c O
##k O
: O
69 O
##1 O
m O
##b O
: O
77 O
t O
##rop O
- O
t O
: O
0 O
. O
86 O
[ O
* O
* O
214 O
##0 O
- O
12 O
- O
10 O
* O
* O
] O
05 O
: O
00 O
##pm O
c O
##k O
72 O
m O
##b O
8 O
t O
##rop O
- O
t O
: O
0 O
. O
01 O
e O
##k O
##g O
( O
[ O
* O
* O
12 O
- O
11 O
* O
* O
] O
) O
: O
n O
##s O
##r O
, O
normal O
axis O
. O
dynamic O
s O
##t O
depression O
##s O
in O
inferior O
and O
pre O
##cor O
##dial O
leads O
, O
more O
pronounced O
with O
increasing O
h O
##r O
on O
se O
##ria O
e O
##k O
##gs O
in O
the O
ed O
. O
. O

cardiac O
cat O
##he O
##ter O
##ization O
( O
[ O
* O
* O
12 O
- O
13 O
* O
* O
] O
) O
: O
comments O
: O
1 O
. O
selective O
co O
##rona O
##ry O
an O
##gio O
##graphy O
of O
this O
right O
- O
dominant O
system O
demonstrated O
native O
three O
vessel O
ca O
##d O
. O
the O
l O
##m O
##ca O
had O
no O
an O
##gio O
##graphical O
##ly O
- O
apparent O
lesions O
. O
the O
lad O
was O
o O
##cc O
##luded O
pro O
##ximal O
##ly O
, O
and O
had O
a O
90 O
% O
s O
##ten O
##osis O
just O
di O
##stal O
to O
the O
l O
##ima O
- O
lad O
touchdown O
. O
the O
l O
##c O
##x O
was O
o O
##cc O
##luded O
in O
the O
mid O
- O
vessel O
segment O
with O
faint O
co O
##lla O
##teral O
##s O
to O
the O
o O
##mb O
. O
the O
dominant O
r O
##ca O
was O
o O
##cc O
##luded O
in O
the O
pro O
##ximal O
vessel O
segment O
. O
2 O
. O
selective O
art O
##erial O
con O
##du O
##it O
an O
##gio O
##graphy O
revealed O
a O
patent O
l O
##ima O
- O
lad O
. O
there O
was O
90 O
% O
s O
##ten O
##osis O
in O
the O
native O
lad O
just O
di O
##stal O
to O
the O
l O
##ima O
- O
lad O
an O
##ast O
##amo O
##sis O
. O
3 O
. O
selective O
ve O
##nous O
con O
##du O
##it O
an O
##gio O
##graphy O
revealed O
a O
totally O
o O
##cc O
##luded O
s O
##v O
##g O
- O
d O
##1 O
/ O
o O
##m O
##1 O
g O
##raft O
at O
the O
pro O
##ximal O
segment O
of O
o O
##st O
##ial O
s O
##ten O
##t O
. O
the O
s O
##v O
##g O
- O
p O
##da O
g O
##raft O
was O
patent O
to O
the O
r O
##ca O
, O
but O
had O
a O
90 O
% O
re O
##tro O
##grade O
s O
##ten O
##osis O
to O
the O
p O
##ls O
##a O
/ O
p O
##l O
##b O
. O
4 O
. O
limited O
resting O
hem O
##ody O
##nam O
##ics O
revealed O
normal O
systemic O
art O
##erial O
pressures O
with O
a O
measured O
central O
a O
##ort O
##ic O
pressure O
of O
106 O
/ O
64 O
/ O
79 O
. O
5 O
. O
left O
vent O
##ric O
##ulo O
##graphy O
was O
def O
##er O
##red O
. O
final O
diagnosis O
: O
1 O
. O
native O
three O
vessel O
ca O
##d O
. O
2 O
. O
patent O
l O
##ima O
- O
lad O
g O
##raft O
with O
progression O
of O
native O
di O
##stal O
lad O
disease O
. O
3 O
. O
totally O
o O
##cc O
##luded O
s O
##v O
##g O
- O
d O
##1 O
- O
o O
##mb O
g O
##raft O
. O
4 O
. O
patent O
s O
##v O
##g O
- O
p O
##da O
g O
##raft O
with O
progression O
of O
disease O
in O
the O
o O
##st O
##ium O
of O
the O
p O
##da O
that O
fills O
re O
##tro O
##grade O
into O
the O
p O
##ls O
##a O
and O
poster O
##olate O
##ral O
branches O
. O
5 O
. O
consideration O
of O
p O
##ci O
vs O
. O
red O
##o O
cab O
##g O
. O
. O
. O

chest O
c O
##t O
( O
[ O
* O
* O
12 O
- O
15 O
* O
* O
] O
) O
: O
impression O
: O
1 O
. O
post O
- O
cab O
##g O
changes O
and O
scattered O
areas O
of O
ca O
##l O
##ci O
##fied O
at O
##her O
##os O
##cle O
##rot O
##ic O
disease O
in O
the O
a O
##ort O
##ic O
arch O
and O
a O
##ort O
##ic O
valve O
/ O
an O
##nu O
##lus O
but O
none O
in O
the O
ascending O
a O
##ort O
##a O
. O
2 O
. O
subtle O
ground O
- O
glass O
op O
##ac O
##ities O
in O
the O
right O
upper O
and O
right O
lower O
lobes O
, O
possibly O
representing O
areas O
of O
as O
##piration O
. O
3 O
. O
a O
3 O
- O
mm O
right O
lower O
lobe O
nod O
##ule O
; O
given O
the O
patient O
' O
s O
history O
, O
a O
one O
- O
year O
follow O
##up O
c O
##t O
is O
recommended O
to O
document O
stability O
. O
c O
##x O
##r O
: O
[ O
* O
* O
214 O
##0 O
- O
12 O
- O
24 O
* O
* O
] O
: O
p O
##a O
and O
lateral O
chest O
compared O
to O
[ O
* O
* O
12 O
- O
21 O
* O
* O
] O
through O
29 O
: O
the O
already O
improved O
post O
- O
operative O
widening O
of O
the O
card O
##io O
##media O
##st O
##inal O
silhouette O
is O
stable O
. O
moderate O
right O
p O
##le O
##ural O
e O
##ff O
##usion O
and O
moderately O
severe O
right O
basal O
ate O
##lect O
##asis O
are O
unchanged O
, O
but O
previous O
left O
lower O
lobe O
ate O
##lect O
##asis O
and O
left O
p O
##le O
##ural O
e O
##ff O
##usion O
are O
improved O
. O
there O
is O
no O
pulmonary O
ed O
##ema O
or O
p O
##ne O
##um O
##oth O
##orax O
[ O
* O
* O
214 O
##0 O
- O
12 O
- O
25 O
* O
* O
] O
w O
##b O
##c O
- O
12 O
. O
6 O
* O
r O
##b O
##c O
- O
3 O
. O
63 O
* O
h O
##g O
##b O
- O
10 O
. O
9 O
* O
h O
##ct O
- O
32 O
. O
4 O
* O
m O
##c O
##v O
- O
89 O
m O
##ch O
- O
30 O
. O
0 O
m O
##ch O
##c O
- O
33 O
. O
6 O
r O
##d O
##w O
- O
13 O
. O
5 O
p O
##lt O
c O
##t O
- O
40 O
##8 O
[ O
* O
* O
214 O
##0 O
- O
12 O
- O
24 O
* O
* O
] O
w O
##b O
##c O
- O
13 O
. O
7 O
* O
r O
##b O
##c O
- O
3 O
. O
58 O
* O
h O
##g O
##b O
- O
10 O
. O
9 O
* O
h O
##ct O
- O
31 O
. O
4 O
* O
m O
##c O
##v O
- O
88 O
m O
##ch O
- O
30 O
. O
4 O
m O
##ch O
##c O
- O
34 O
. O
7 O
r O
##d O
##w O
- O
13 O
. O
6 O
p O
##lt O
c O
##t O
- O
37 O
##9 O
# O
[ O
* O
* O
214 O
##0 O
- O
12 O
- O
10 O
* O
* O
] O
w O
##b O
##c O
- O
11 O
. O
6 O
* O
# O
r O
##b O
##c O
- O
4 O
. O
55 O
* O
h O
##g O
##b O
- O
13 O
. O
5 O
* O
h O
##ct O
- O
40 O
. O
2 O
m O
##c O
##v O
- O
88 O
m O
##ch O
- O
29 O
. O
7 O
m O
##ch O
##c O
- O
33 O
. O
6 O
r O
##d O
##w O
- O
12 O
. O
9 O
p O
##lt O
c O
##t O
- O
205 O

[ O
* O
* O
214 O
##0 O
- O
12 O
- O
25 O
* O
* O
] O
glucose O
- O
147 O
* O
u O
##rea O
##n O
- O
27 O
* O
c O
##rea O
##t O
- O
1 O
. O
2 O
na O
- O
138 O
k O
- O
3 O
. O
5 O
c O
##l O
- O
94 O
* O
h O
##co O
##3 O
- O
35 O
* O
[ O
* O
* O
214 O
##0 O
- O
12 O
- O
24 O
* O
* O
] O
na O
- O
138 O
k O
- O
4 O
. O
2 O
c O
##l O
- O
97 O
[ O
* O
* O
214 O
##0 O
- O
12 O
- O
24 O
* O
* O
] O
u O
##rea O
##n O
- O
23 O
* O
c O
##rea O
##t O
- O
1 O
. O
1 O
na O
- O
138 O
k O
- O
3 O
. O
4 O
c O
##l O
- O
95 O
* O
h O
##co O
##3 O
- O
32 O
[ O
* O
* O
214 O
##0 O
- O
12 O
- O
23 O
* O
* O
] O
glucose O
- O
158 O
* O
u O
##rea O
##n O
- O
19 O
c O
##rea O
##t O
- O
1 O
. O
2 O
na O
- O
138 O
k O
- O
2 O
. O
9 O
* O
c O
##l O
- O
97 O
h O
##co O
##3 O
- O
32 O
[ O
* O
* O
214 O
##0 O
- O
12 O
- O
10 O
* O
* O
] O
glucose O
- O
204 O
* O
u O
##rea O
##n O
- O
16 O
c O
##rea O
##t O
- O
1 O
. O
1 O
na O
- O
138 O
k O
- O
3 O
. O
9 O
c O
##l O
- O
102 O
h O
##co O
##3 O
- O
25 O
micro O
: O
[ O
* O
* O
214 O
##0 O
- O
12 O
- O
24 O
* O
* O
] O
urine O
final O
report O
[ O
* O
* O
214 O
##0 O
- O
12 O
- O
25 O
* O
* O
] O
urine O
culture O
( O
final O
[ O
* O
* O
214 O
##0 O
- O
12 O
- O
25 O
* O
* O
] O
) O
: O
yeast O
. O
10 O
, O
000 O
- O
100 O
, O
000 O
organisms O
/ O
m O
##l O
. O
. O
brief O
hospital O
course O
: O
66 O
##yo O
##m O
with O
significant O
ca O
##d O
s O
/ O
p O
cab O
##g O
( O
[ O
* O
* O
212 O
##5 O
* O
* O
] O
) O
, O
des O
to O
s O
##v O
##g O
- O
d O
##1 O
/ O
o O
##m O
x O
##2 O
( O
[ O
* O
* O
213 O
##5 O
* O
* O
] O
, O
[ O
* O
* O
213 O
##8 O
* O
* O
] O
) O
who O
presents O
with O
chest O
pain O
and O
dynamic O
e O
##k O
##g O
changes O
, O
found O
to O
have O
s O
##v O
##g O
g O
##raft O
, O
p O
##da O
, O
lad O
s O
##ten O
##osis O
needing O
intervention O
. O

# O
chest O
pain O
/ O
co O
##rona O
##ries O
: O
patient O
with O
cab O
##g O
and O
des O
to O
s O
##v O
##g O
- O
d O
##1 O
/ O
o O
##m O
x O
##2 O
most O
recently O
in O
[ O
* O
* O
213 O
##8 O
* O
* O
] O
now O
presenting O
with O
chest O
pain O
and O
dynamic O
e O
##k O
##g O
changes O
in O
the O
inferior O
and O
pre O
##cor O
##dial O
leads O
. O
the O
patient O
' O
s O
symptoms O
occurred O
subsequent O
to O
disco O
##ntin O
##uing O
p B-DRUG
##lav I-DRUG
##ix I-DRUG
10 O
days O
ago O
for O
a O
lit O
##hot O
##rip O
##sy O
. O
initial O
set O
of O
c O
##e O
' O
s O
were O
negative O
but O
subsequent O
up O
- O
trend O
##ed O
with O
c O
##k O
peak O
69 O
##1 O
and O
m O
##b O
peak O
77 O
. O
he O
was O
on O
a O
he B-DRUG
##par I-DRUG
##in I-DRUG
g B-ROU
##tt I-ROU
and O
was O
p B-DRUG
##lav I-DRUG
##ix I-DRUG
loaded O
, O
and O
his O
chest B-REA
pain I-REA
was O
controlled O
on O
a O
ni B-DRUG
##tro I-DRUG
g B-ROU
##tt I-ROU
prior O
to O
cardiac O
cat O
##he O
##ter O
##ization O
. O
in B-DRUG
##te I-DRUG
##g I-DRUG
##rill I-DRUG
##in I-DRUG
g B-ROU
##tt I-ROU
and O
m B-DRUG
##or I-DRUG
##phine I-DRUG
i B-ROU
##v I-ROU
p O
##rn O
were O
started O
prior O
to O
cat O
##he O
##ter O
##ization O
for O
re B-REA
##current I-REA
chest I-REA
pain I-REA
re O
##fra O
##ctor O
##y O
to O
up O
- O
t O
##it O
##ration O
of O
ni B-DRUG
##tro I-DRUG
g B-ROU
##tt I-ROU
. I-ROU
cardiac O
cat O
##he O
##ter O
##ization O
[ O
* O
* O
12 O
- O
13 O
* O
* O
] O
showed O
completely O
o O
##cc O
##luded O
s O
##v O
##g O
- O
d O
##1 O
/ O
o O
##m O
, O
90 O
% O
s O
##ten O
##osis O
of O
s O
##v O
##g O
- O
p O
##da O
, O
known O
90 O
% O
lad O
s O
##ten O
##osis O
just O
di O
##stal O
to O
touchdown O
. O
he O
was O
recommended O
for O
cab O
##g O
- O
red O
##o O
and O
was O
continued O
on O
he B-DRUG
##par I-DRUG
##in I-DRUG
g B-ROU
##tt I-ROU
and O
in B-DRUG
##te I-DRUG
##g I-DRUG
##rill I-DRUG
##in I-DRUG
g B-ROU
##tt I-ROU
post O
- O
cat O
##h O
with O
the O
plan O
of O
continuing O
through O
until O
cab O
##g O
- O
red O
##o O
. O
p B-DRUG
##lav I-DRUG
##ix I-DRUG
was O
discontinued O
at O
that O
time O
. O
the O
patient O
had O
an O
acute O
drop O
in O
his O
plate O
##lets O
( O
described O
below O
) O
and O
in B-DRUG
##te I-DRUG
##g I-DRUG
##rill I-DRUG
##in I-DRUG
g B-ROU
##tt I-ROU
was O
discontinued O
. O
shortly O
thereafter O
, O
he O
had O
a O
pre O
##sy O
##nco O
##pal O
episode O
on O
[ O
* O
* O
12 O
- O
16 O
* O
* O
] O
during O
which O
he O
stood O
up O
, O
became O
pale O
, O
light O
##headed O
, O
and O
developed O
mild O
left O
sided O
chest O
pain O
. O
vital O
##s O
were O
stable O
but O
e O
##k O
##g O
showed O
new O
s O
##t O
depression O
##s O
in O
two O
leads O
, O
c O
##e O
' O
s O
negative O
. O
he O
was O
trans O
##fused O
1 O
unit O
p B-DRUG
##rb I-DRUG
##c I-DRUG
for O
an B-REA
##emia I-REA
( O
had O
previously O
refused O
trans O
##fusion O
) O
with O
resolution O
of O
symptoms O
but O
persistent O
s O
##t O
depression O
##s O
on O
e O
##k O
##g O
. O
he B-DRUG
##par I-DRUG
##in I-DRUG
g B-ROU
##tt I-ROU
was O
discontinued O
but O
5 O
- O
h O
risk O
score O
for O
hit O
was O
low O
and O
hit O
a O
##b O
was O
negative O
. O
the O
patient O
remained O
chest O
pain O
free O
until O
cab O
##g O
- O
red O
##o O
on O
t O
##ue O
. O

# O
. O
th B-ADE
##rom I-ADE
##bo I-ADE
##cy I-ADE
##top I-ADE
##enia I-ADE
: I-ADE
patient O
developed O
severe O
th O
##rom O
##bo O
##cy O
##top O
##enia O
, O
secondary O
to O
in B-DRUG
##te I-DRUG
##g I-DRUG
##rill I-DRUG
##in I-DRUG
. I-DRUG
although O
the O
patient O
' O
s O
th O
##rom O
##bo O
##cy O
##top O
##enia O
occurred O
later O
than O
expected O
for O
in B-DRUG
##te I-DRUG
##g I-DRUG
##rill I-DRUG
##in I-DRUG
- I-DRUG
induced O
th B-ADE
##rom I-ADE
##bo I-ADE
##cy I-ADE
##top I-ADE
##enia I-ADE
, I-ADE
the O
pre O
##ci O
##pit O
##ous O
drop O
and O
extended O
period O
of O
time O
he O
was O
on O
in O
##te O
##g O
##rill O
##in O
both O
support O
this O
as O
the O
most O
likely O
et O
##iology O
. O
p O
##lt O
dropped O
from O
150 O
- O
> O
10 O
in O
24 O
h O
##rs O
. O
in B-DRUG
##te I-DRUG
##g I-DRUG
##rill I-DRUG
##in I-DRUG
d B-ROU
##rip I-ROU
was O
stopped O
at O
2 O
##pm O
on O
[ O
* O
* O
12 O
- O
15 O
* O
* O
] O
and O
he O
has O
been O
given O
a O
total O
of O
3 B-DOS
units I-DOS
of O
plate B-DRUG
##lets I-DRUG
. I-DRUG
hit O
anti O
##body O
was O
also O
sent O
which O
was O
negative O
. O
5 O
##h O
hit O
risk O
score O
was O
also O
low O
, O
making O
it O
less O
likely O
to O
be O
hit O
. O
however O
, O
he B-DRUG
##par I-DRUG
##in I-DRUG
g B-ROU
##tt I-ROU
was O
discontinued O
in O
the O
setting O
of O
profound O
th O
##rom O
##bo O
##cy O
##top O
##enia O
given O
the O
patient O
has O
been O
chest O
pain O
free O
. O
in O
the O
setting O
of O
th O
##rom O
##bo O
##cy O
##top O
##enia O
, O
he O
developed O
significant O
bleeding O
from O
around O
his O
f O
##ole O
##y O
cat O
##he O
##ter O
and O
recent O
lit O
##hot O
##ry O
##psy O
procedure O
, O
which O
was O
switched O
to O
a O
3 O
- O
way O
f O
##ole O
##y O
on O
c O
##bi O
. O
his O
h O
##ct O
has O
down O
- O
trend O
##ed O
and O
he O
received O
a O
total O
of O
1 B-DOS
unit I-DOS
p B-DRUG
##rb I-DRUG
##c I-DRUG
on O
[ O
* O
* O
12 O
- O
16 O
* O
* O
] O
. O
he O
was O
also O
given O
several O
plate B-DRUG
##let I-DRUG
trans B-FOR
##fusion I-FOR
##s I-FOR
for O
the O
th B-REA
##rom I-REA
##bo I-REA
##cy I-REA
##top I-REA
##enia I-REA
. I-REA
the O
anticipated O
plate O
##let O
recovery O
with O
in B-DRUG
##te I-DRUG
##g I-DRUG
##rill I-DRUG
##in I-DRUG
- I-DRUG
induced O
th B-ADE
##rom I-ADE
##bo I-ADE
##cy I-ADE
##top I-ADE
##enia I-ADE
is O
4 O
hours O
to O
5 O
days O
, O
and O
the O
patient O
' O
s O
plate O
##lets O
slowly O
up O
- O
trend O
##ed O
and O
by O
[ O
* O
* O
12 O
- O
19 O
* O
* O
] O
he O
was O
in O
the O
100 O
##s O
. O

# O
urine O
analysis O
: O
patient O
with O
large O
blood O
, O
significant O
le O
##uk O
##ocytes O
, O
protein O
on O
u O
##a O
likely O
[ O
* O
* O
1 O
- O
26 O
* O
* O
] O
recent O
lit O
##hot O
##rip O
##sy O
and O
u O
##ret O
##eral O
s O
##ten O
##t O
placement O
. O
f O
##ole O
##y O
leg O
bag O
in O
place O
, O
dark B-ADE
red I-ADE
urine I-ADE
in O
setting O
of O
p B-DRUG
##lav I-DRUG
##ix I-DRUG
, I-DRUG
he B-DRUG
##par I-DRUG
##in I-DRUG
g B-ROU
##tt I-ROU
, I-ROU
as B-DRUG
##a I-DRUG
325 B-STR
. I-STR
u O
##rol O
##ogy O
followed O
p O
##t O
in O
##house O
. O
patient O
had O
significant O
bleeding O
from O
around O
the O
f O
##ole O
##y O
and O
it O
was O
replaced O
with O
a O
3 O
- O
way O
f O
##ole O
##y O
cat O
##he O
##ter O
on O
c O
##bi O
. O
u O
##rol O
##ogy O
planned O
to O
remove O
u O
##ret O
##eral O
s O
##ten O
##t O
and O
f O
##ole O
##y O
and O
following O
cab O
##g O
. O
repeat O
u O
##a O
suspicious O
for O
u B-REA
##ti I-REA
, I-REA
started O
c B-DRUG
##ip I-DRUG
##ro I-DRUG
[ O
* O
* O
12 O
- O
15 O
* O
* O
] O
. O
repeat O
u O
##a O
today O
in O
setting O
of O
culture O
showing O
" O
probable O
" O
enter O
##oc O
##oc O
##cus O
previously O
in O
the O
setting O
of O
significant O
blood O
in O
urine O
and O
improved O
urine O
currently O
. O
repeat O
u O
##a O
and O
u O
##c O
##x O
sent O
after O
bleeding O
hem O
##at O
##uria O
improved O
. O
the O
patient O
was O
treated O
with O
c B-DRUG
##ip I-DRUG
##ro I-DRUG
250 B-STR
mg I-STR
x O
##7 B-DUR
days I-DUR
for O
complicated B-REA
c I-REA
##ys I-REA
##ist I-REA
##its I-REA
in O
male O
with O
recent O
u O
##rol O
##og O
##ic O
procedure O
. O
( O
d O
##1 O
= O
[ O
* O
* O
12 O
- O
15 O
* O
* O
] O
) O

on O
[ O
* O
* O
12 O
- O
15 O
* O
* O
] O
m O
##r O
. O
[ O
* O
* O
known O
last O
##name O
100 O
##7 O
* O
* O
] O
was O
taken O
to O
the O
operating O
room O
and O
underwent O
red O
##o O
stern O
##oto O
##my O
/ O
co O
##rona O
##ry O
artery O
bypass O
g O
##raft O
##ing O
x O
##3 O
( O
reverse O
sa O
##phe O
##nous O
vein O
g O
##raft O
##s O
to O
the O
second O
branch O
of O
the O
posterior O
left O
vent O
##ric O
##ular O
branch O
, O
o O
##bt O
##use O
marginal O
artery O
, O
and O
left O
anterior O
descending O
artery O
) O
with O
d O
##r O
. O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
* O
* O
] O
. O
cross O
##c O
##lamp O
time O
: O
65 O
minutes O
. O
pump O
time O
: O
99 O
minutes O
. O
he O
tolerate O
##d O
the O
procedure O
well O
and O
was O
transferred O
to O
the O
c O
##vic O
##u O
in O
##tub O
##ated O
and O
se O
##dated O
. O
he O
awoke O
ne O
##uro O
##logical O
##ly O
intact O
and O
was O
ex O
##tub O
##ated O
. O
press O
##ors O
were O
we O
##ane O
##d O
off O
. O
all O
lines O
and O
drains O
were O
discontinued O
per O
protocol O
. O
beta B-DRUG
- I-DRUG
block I-DRUG
##er I-DRUG
/ I-DRUG
s B-DRUG
##tat I-DRUG
##in I-DRUG
/ I-DRUG
as B-DRUG
##pi I-DRUG
##rin I-DRUG
and O
di O
##ures O
##is O
initiated O
. O
pod O
# O
1 O
he O
transferred O
to O
the O
step O
down O
unit O
for O
further O
monitoring O
. O
physical O
therapy O
was O
consulted O
for O
evaluation O
of O
strength O
and O
mobility O
. O
as O
discussed O
with O
u O
##rol O
##ogy O
, O
the O
f O
##ole O
##y O
cat O
##he O
##ter O
was O
discontinued O
per O
c O
##su O
##rg O
protocol O
. O
the O
following O
morning O
he O
failed O
to O
void O
and O
the O
f O
##ole O
##y O
was O
reins O
##ert O
##ed O
. O
a O
second O
void O
trial O
was O
done O
on O
pod O
# O
4 O
and O
he O
void O
##ed O
. O
the O
remainder O
of O
his O
post O
##oper O
##ative O
course O
was O
essentially O
uneven O
##t O
##ful O
. O
he O
continued O
to O
progress O
and O
on O
pod O
##5 O
he O
was O
cleared O
for O
discharge O
to O
home O
with O
v O
##na O
. O
all O
follow O
up O
appointments O
were O
advised O
. O
medications O
on O
admission O
: O
- O
as B-DRUG
##pi I-DRUG
##rin I-DRUG
325 B-STR
mg I-STR
daily B-FRE
- O
h B-DRUG
##ydro I-DRUG
##ch I-DRUG
##lor I-DRUG
##oth I-DRUG
##ia I-DRUG
##zi I-DRUG
##de I-DRUG
25 B-STR
mg I-STR
daily B-FRE
- O
c B-DRUG
##lop I-DRUG
##ido I-DRUG
##g I-DRUG
##rel I-DRUG
75 B-STR
mg I-STR
daily B-FRE
( O
held O
x O
##10 O
days O
p O
##ta O
) O
- O
ve B-DRUG
##rap I-DRUG
##ami I-DRUG
##l I-DRUG
180 B-STR
mg I-STR
sustained B-FOR
release I-FOR
daily B-FRE
- O
at B-DRUG
##or I-DRUG
##vas I-DRUG
##tat I-DRUG
##in I-DRUG
40 B-STR
mg I-STR
daily B-FRE
- O
ta B-DRUG
##ms I-DRUG
##ulos I-DRUG
##in I-DRUG
0 B-STR
. I-STR
4 I-STR
mg I-STR
er B-FOR
q B-FRE
##hs I-FRE
- O
c B-DRUG
##lar I-DRUG
##iti I-DRUG
##n I-DRUG
10 B-STR
mg I-STR
daily B-FRE
- O
o B-DRUG
##xy I-DRUG
##co I-DRUG
##don I-DRUG
##e I-DRUG
- I-DRUG
ace I-DRUG
##tam I-DRUG
##ino I-DRUG
##phe I-DRUG
##n I-DRUG
5 B-STR
- I-STR
325 I-STR
mg I-STR
q B-FRE
##4 I-FRE
##h I-FRE
p O
##rn O
torn B-REA
a I-REA
##c I-REA
##l I-REA
pain I-REA
- O
p B-DRUG
##yr I-DRUG
##id I-DRUG
##ium I-DRUG
100 B-STR
mg I-STR
t B-FRE
##id I-FRE
p O
##rn O
pain B-REA
- O
co B-DRUG
##lace I-DRUG

discharge O
medications O
: O
1 O
. O
ta B-DRUG
##ms I-DRUG
##ulos I-DRUG
##in I-DRUG
0 B-STR
. I-STR
4 I-STR
mg I-STR
capsule B-FOR
, I-FOR
ex I-FOR
##t I-FOR
release I-FOR
24 I-FOR
h I-FOR
##r I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
capsule B-FOR
, I-FOR
ex I-FOR
##t I-FOR
release I-FOR
24 I-FOR
h I-FOR
##r I-FOR
p B-ROU
##o I-ROU
h B-FRE
##s I-FRE
( O
at O
bed O
##time O
) O
. O
2 O
. O
o B-DRUG
##xy I-DRUG
##co I-DRUG
##don I-DRUG
##e I-DRUG
- I-DRUG
ace I-DRUG
##tam I-DRUG
##ino I-DRUG
##phe I-DRUG
##n I-DRUG
5 B-STR
- I-STR
325 I-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
every B-FRE
4 I-FRE
- I-FRE
6 I-FRE
hours I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
. I-REA
di O
##sp O
: O
* O
50 O
tablet O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
0 O
* O
3 O
. O
do B-DRUG
##cus I-DRUG
##ate I-DRUG
sodium I-DRUG
100 B-STR
mg I-STR
capsule B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
capsule B-FOR
p B-ROU
##o I-ROU
bid B-FRE
( O
2 O
times O
a O
day O
) O
. O
4 O
. O
c B-DRUG
##lar I-DRUG
##iti I-DRUG
##n I-DRUG
10 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE
5 O
. O
do B-DRUG
##cus I-DRUG
##ate I-DRUG
sodium I-DRUG
100 B-STR
mg I-STR
capsule B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
capsule B-FOR
p B-ROU
##o I-ROU
bid B-FRE
( O
2 O
times O
a O
day O
) O
. O
6 O
. O
as B-DRUG
##pi I-DRUG
##rin I-DRUG
81 B-STR
mg I-STR
tablet B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
p B-ROU
##o I-ROU
daily B-FRE
( O
daily O
) O
. O
7 O
. O
at B-DRUG
##or I-DRUG
##vas I-DRUG
##tat I-DRUG
##in I-DRUG
20 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( O
daily O
) O
. O
8 O
. O
am B-DRUG
##io I-DRUG
##dar I-DRUG
##one I-DRUG
200 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
two B-DOS
( I-DOS
2 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
bid B-FRE
( O
2 O
times O
a O
day O
) O
. O
di O
##sp O
: O
* O
120 O
tablet O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
2 O
* O
9 O
. O
met B-DRUG
##op I-DRUG
##rol I-DRUG
##ol I-DRUG
ta I-DRUG
##rt I-DRUG
##rate I-DRUG
50 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
bid B-FRE
( O
2 O
times O
a O
day O
) O
. O
10 O
. O
s B-DRUG
##pi I-DRUG
##ron I-DRUG
##ola I-DRUG
##cton I-DRUG
##e I-DRUG
25 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
once B-FRE
a I-FRE
day I-FRE
for B-DUR
5 I-DUR
days I-DUR
. I-DUR
di O
##sp O
: O
* O
7 O
tablet O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
0 O
* O
11 O
. O
ace B-DRUG
##tam I-DRUG
##ino I-DRUG
##phe I-DRUG
##n I-DRUG
325 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
1 B-DOS
- I-DOS
2 I-DOS
tablets B-FOR
p B-ROU
##o I-ROU
q B-FRE
##4 I-FRE
##h I-FRE
( I-FRE
every I-FRE
4 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
/ I-REA
te B-REA
##mp I-REA
. I-REA
12 O
. O
ran B-DRUG
##iti I-DRUG
##dine I-DRUG
h I-DRUG
##c I-DRUG
##l I-DRUG
150 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
bid B-FRE
( O
2 O
times O
a O
day O
) O
. O
13 O
. O
out O
##patient O
lab O
work O
electro O
##ly O
##tes O
b O
##un O
/ O
c O
##re O
, O
mg O
t O
##ues O
##day O
- O
th O
##urs O
##day O
14 O
. O
flu B-DRUG
##cona I-DRUG
##zo I-DRUG
##le I-DRUG
200 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
once B-FRE
a I-FRE
day I-FRE
for B-DUR
7 I-DUR
days I-DUR
. I-DUR
di O
##sp O
: O
* O
7 O
tablet O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
0 O
* O
discharge O
disposition O
: O
home O
with O
service O

facility O
: O
[ O
* O
* O
last O
name O
( O
l O
##f O
) O
48 O
##6 O
* O
* O
] O
, O
[ O
* O
* O
first O
name O
##3 O
( O
l O
##f O
) O
48 O
##7 O
* O
* O
] O
discharge O
diagnosis O
: O
co O
##rona O
##ry O
artery O
di O
##ses O
##e O
s O
/ O
p O
cab O
##g O
non O
- O
s O
##t O
elevation O
my O
##oc O
##ard O
##ial O
in O
##far O
##ction O
th B-ADE
##rom I-ADE
##bo I-ADE
##cy I-ADE
##top I-ADE
##enia I-ADE
, I-ADE
likely O
secondary O
to O
in B-DRUG
##te I-DRUG
##g I-DRUG
##rill I-DRUG
##in I-DRUG
bleeding O
around O
f O
##ole O
##y O
cat O
##he O
##ter O
u O
##rina O
##ry O
tract O
infection O
secondary O
: O
h O
##yper O
##tens O
##ion O
, O
h O
##yper O
##lip O
##ide O
##mia O
, O
g O
##erd O
basal O
cell O
cancer O
, O
kidney O
stones O
s O
/ O
p O
lit O
##hot O
##rip O
##sy O
and O
u O
##ret O
##eral O
s O
##ten O
##t O
, O
p O
##ci O
to O
s O
##v O
##g O
- O
> O
d O
##1 O
/ O
o O
##m O
[ O
* O
* O
5 O
- O
/ O
213 O
##6 O
* O
* O
] O
and O
p O
##ci O
with O
s O
##ten O
##t O
for O
to O
o O
##s O
##v O
##g O
[ O
* O
* O
213 O
##9 O
- O
8 O
- O
7 O
* O
* O
] O
, O
co O
##lon O
cancer O
s O
/ O
p O
sub O
##to O
##tal O
co O
##lect O
##omy O
by O
d O
##r O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
* O
* O
] O
4 O
years O
ago O
discharge O
condition O
: O
mental O
status O
: O
clear O
and O
coherent O
. O
level O
of O
consciousness O
: O
alert O
and O
interactive O
. O
activity O
status O
: O
am O
##bula O
##tory O
- O
independent O
. O
discharge O
instructions O
: O
please O
shower O
daily O
including O
washing O
in O
##cision O
##s O
gently O
with O
mild O
soap O
, O
no O
baths O
or O
swimming O
until O
cleared O
by O
surgeon O
. O
look O
at O
your O
in O
##cision O
##s O
daily O
for O
red O
##ness O
or O
drainage O
please O
no O
lot O
##ions O
, O
cream O
, O
powder O
, O
or O
o O
##int O
##ments O
to O
in O
##cision O
##s O
each O
morning O
you O
should O
weigh O
yourself O
and O
then O
in O
the O
evening O
take O
your O
temperature O
, O
these O
should O
be O
written O
down O
on O
the O
chart O
no O
driving O
for O
approximately O
one O
month O
and O
while O
taking O
na O
##rc O
##otics O
, O
will O
be O
discussed O
at O
follow O
up O
appointment O
with O
surgeon O
when O
you O
will O
be O
able O
to O
drive O
no O
lifting O
more O
than O
10 O
pounds O
for O
10 O
weeks O
* O
* O
please O
call O
cardiac O
surgery O
office O
with O
any O
questions O
or O
concerns O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
170 O
* O
* O
] O
. O
answering O
service O
will O
contact O
on O
call O
person O
during O
off O
hours O
* O
* O
follow O
##up O
instructions O
: O
you O
are O
scheduled O
for O
the O
following O
appointments O
surgeon O
: O
d O
##r O
. O
[ O
* O
* O
first O
name O
##8 O
( O
name O
##pa O
##tter O
##n O
##2 O
) O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
* O
* O
] O
on O
[ O
* O
* O
1 O
- O
26 O
* O
* O
] O
at O
1 O
: O
00 O
##pm O
[ O
* O
* O
last O
name O
( O
un O
) O
257 O
##7 O
* O
* O
] O
building O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
103 O
##5 O
##7 O
* O
* O
] O

card O
##iol O
##ogist O
: O
d O
##r O
. O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
* O
* O
] O
in O
[ O
* O
* O
location O
( O
un O
) O
620 O
* O
* O
] O
on O
[ O
* O
* O
1 O
- O
11 O
* O
* O
] O
at O
9 O
: O
45 O
am O
please O
call O
to O
schedule O
appointments O
with O
your O
primary O
care O
d O
##r O
. O
[ O
* O
* O
first O
name O
##4 O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
83 O
##8 O
* O
* O
] O
in O
[ O
* O
* O
3 O
- O
30 O
* O
* O
] O
weeks O
call O
d O
##r O
. O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
77 O
##0 O
* O
* O
] O
( O
u O
##rol O
##ogist O
) O
for O
a O
follow O
- O
up O
appointment O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
290 O
##6 O
* O
* O
] O
* O
* O
please O
call O
cardiac O
surgery O
office O
with O
any O
questions O
or O
concerns O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
170 O
* O
* O
] O
. O
answering O
service O
will O
contact O
on O
call O
person O
during O
off O
hours O
* O
* O
completed O
by O
: O
[ O
* O
* O
214 O
##0 O
- O
12 O
- O
25 O
* O
* O
] O

admission O
date O
: O
[ O
* O
* O
214 O
##5 O
- O
6 O
- O
25 O
* O
* O
] O
discharge O
date O
: O
[ O
* O
* O
214 O
##5 O
- O
7 O
- O
5 O
* O
* O
] O
service O
: O
medicine O
all O
##er O
##gies O
: O
pen B-DRUG
##ici I-DRUG
##llin I-DRUG
##s I-DRUG
/ O
su B-DRUG
##lf I-DRUG
##ona I-DRUG
##mi I-DRUG
##des I-DRUG
/ O
er B-DRUG
##yt I-DRUG
##hr I-DRUG
##omy I-DRUG
##cin I-DRUG
base O
/ O
co B-DRUG
##rt I-DRUG
##ison I-DRUG
##e I-DRUG
/ O
metro B-DRUG
##ni I-DRUG
##da I-DRUG
##zo I-DRUG
##le I-DRUG
/ O
c B-DRUG
##ip I-DRUG
##ro I-DRUG
##f I-DRUG
##lo I-DRUG
##xa I-DRUG
##cin I-DRUG
/ O
i B-DRUG
##v I-DRUG
##p I-DRUG
dye I-DRUG
, I-DRUG
i B-DRUG
##od I-DRUG
##ine I-DRUG
containing O
/ O
pro B-DRUG
##tamine I-DRUG
/ O
ad O
##hesive O
tape O
/ O
m B-DRUG
##or I-DRUG
##phine I-DRUG
/ O
van B-DRUG
##com I-DRUG
##y I-DRUG
##cin I-DRUG
/ O
flag B-DRUG
##yl I-DRUG
attending O
: O
[ O
* O
* O
first O
name O
##3 O
( O
l O
##f O
) O
36 O
##19 O
* O
* O
] O
chief O
complaint O
: O
ma O
##lai O
##se O
, O
h O
##y O
##pot O
##ens O
##ion O
major O
surgical O
or O
invasive O
procedure O
: O
none O
history O
of O
present O
illness O
: O
87 O
y O
/ O
o O
f O
with O
h O
/ O
o O
of O
stage O
ii O
##i O
n O
##s O
##c O
##l O
##c O
on O
ch O
##em O
##o O
& O
x O
##rt O
, O
d O
##m O
##2 O
, O
h O
##y O
##pot O
##hy O
##roid O
##ism O
, O
h O
##t O
##n O
, O
g O
##erd O
p O
/ O
w O
ma O
##lai O
##se O
x O
4 O
days O
and O
abdominal O
pain O
x O
1 O
week O
. O
p O
##t O
reports O
that O
she O
has O
been O
having O
e O
##pi O
##gas O
##tric O
abdominal O
pain O
& O
nausea O
for O
the O
past O
week O
. O
she O
has O
had O
decreased O
p O
##o O
intake O
for O
the O
past O
4 O
- O
5 O
days O
, O
but O
has O
been O
drinking O
up O
##to O
2 O
q O
##ua O
##rts O
of O
water O
per O
day O
because O
of O
recommendations O
given O
to O
her O
by O
her O
on O
##cologist O
for O
her O
cancer O
therapy O
. O
the O
p O
##t O
reports O
starting O
to O
feel O
ma O
##lai O
##sed O
and O
" O
run O
down O
" O
4 O
days O
prior O
after O
she O
received O
ch B-DRUG
##em I-DRUG
##otherapy I-DRUG
. I-DRUG
the O
patient O
saw O
her O
p O
##c O
##p O
[ O
* O
* O
name O
##9 O
( O
pre O
) O
96 O
##9 O
##6 O
##2 O
* O
* O
] O
and O
checked O
her O
routine O
routine O
labs O
. O
these O
revealed O
her O
sodium O
was O
131 O
and O
the O
p O
##t O
was O
referred O
to O
the O
ed O
. O
. O
in O
the O
ed O
, O
vital O
##s O
: O
98 O
. O
4 O
, O
h O
##r O
111 O
, O
174 O
/ O
85 O
, O
r O
##r O
15 O
, O
sat O
95 O
% O
r O
##a O
. O
na O
in O
ed O
127 O
. O
e O
##k O
##g O
: O
s O
##r O
with O
upright O
t O
##s O
in O
la O
##t O
pre O
##cor O
##d O
leads O
( O
change O
from O
prior O
) O
. O
c O
##x O
##r O
with O
no O
acute O
changes O
. O
given O
z B-DRUG
##of I-DRUG
##ran I-DRUG
and O
1 B-DOS
l B-FOR
n B-DRUG
##s I-DRUG
. I-DRUG
admitted O
to O
medicine O
. O
past O
medical O
history O
: O
stage O
ii O
##i O
n O
##s O
##c O
##l O
##c O
cop O
##d O
type O
2 O
d O
##m O
h O
##yper O
##tens O
##ion O
h O
##yper O
##cho O
##les O
##tero O
##lem O
##ia O
h O
##y O
##pot O
##hy O
##roid O
##ism O
diver O
##tic O
##ulos O
##is O
g O
##erd O
s O
/ O
p O
ch O
##ole O
##cy O
##ste O
##ct O
##omy O
s O
/ O
p O
app O
##y O
h O
/ O
o O
me O
##sent O
##eric O
is O
##che O
##mia O
s O
/ O
p O
c O
##eli O
##ac O
s O
##ten O
##t O
[ O
* O
* O
3 O
- O
31 O
* O
* O
] O
i O
##bs O
gas O
##tri O
##tis O
/ O
duo O
##den O
##itis O

social O
history O
: O
lives O
alone O
in O
[ O
* O
* O
location O
( O
un O
) O
* O
* O
] O
. O
no O
tobacco O
/ O
alcohol O
/ O
or O
drugs O
. O
complete O
##s O
ad O
##ls O
. O
family O
history O
: O
mother O
& O
father O
: O
ca O
##d O
, O
d O
##m O
##2 O
physical O
exam O
: O
te O
##mp O
: O
98 O
. O
4 O
b O
##p O
140 O
- O
143 O
/ O
65 O
- O
80 O
pulse O
97 O
- O
106 O
re O
##sp O
20 O
o O
##2 O
sat O
96 O
% O
r O
##a O
g O
##en O
- O
alert O
, O
no O
acute O
distress O
he O
##ent O
- O
per O
##rl O
##a O
, O
e O
##omi O
, O
mm O
##m O
, O
mild O
oral O
m O
##uc O
##os O
##itis O
neck O
- O
no O
j O
##v O
##d O
, O
no O
c O
##er O
##vic O
##al O
l O
##ymph O
##ade O
##no O
##pathy O
chest O
- O
clear O
to O
au O
##s O
##cu O
##lta O
##tion O
bilateral O
##ly O
no O
r O
/ O
r O
/ O
w O
c O
##v O
- O
normal O
s O
##1 O
/ O
s O
##2 O
, O
r O
##rr O
, O
2 O
/ O
6 O
se O
##m O
murmur O
at O
l O
##us O
##b O
a O
##b O
##d O
- O
soft O
, O
mild O
tender O
##ness O
to O
deep O
p O
##al O
##pation O
, O
non O
##dis O
##tended O
, O
with O
norm O
##oa O
##ctive O
bow O
##el O
sounds O
back O
- O
no O
cost O
##over O
##te O
##bra O
##l O
angle O
tender O
##nes O
ex O
##tr O
- O
no O
ed O
##ema O
. O
2 O
+ O
d O
##p O
pulses O
bilateral O
##ly O
ne O
##uro O
- O
alert O
and O
oriented O
x O
3 O
skin O
- O
no O
r O
##ash O

per O
##tinent O
results O
: O
[ O
* O
* O
214 O
##5 O
- O
6 O
- O
25 O
* O
* O
] O
03 O
: O
40 O
##pm O
blood O
w O
##b O
##c O
- O
3 O
. O
3 O
* O
r O
##b O
##c O
- O
3 O
. O
84 O
* O
h O
##g O
##b O
- O
11 O
. O
1 O
* O
h O
##ct O
- O
34 O
. O
0 O
* O
m O
##c O
##v O
- O
89 O
m O
##ch O
- O
28 O
. O
9 O
m O
##ch O
##c O
- O
32 O
. O
6 O
r O
##d O
##w O
- O
12 O
. O
9 O
p O
##lt O
c O
##t O
- O
177 O
[ O
* O
* O
214 O
##5 O
- O
6 O
- O
25 O
* O
* O
] O
03 O
: O
40 O
##pm O
blood O
ne O
##uts O
- O
80 O
. O
2 O
* O
l O
##ymph O
##s O
- O
15 O
. O
7 O
* O
mon O
##os O
- O
1 O
. O
5 O
* O
e O
##os O
- O
2 O
. O
4 O
b O
##as O
##o O
- O
0 O
. O
2 O
[ O
* O
* O
214 O
##5 O
- O
6 O
- O
25 O
* O
* O
] O
03 O
: O
40 O
##pm O
blood O
u O
##rea O
##n O
- O
23 O
* O
c O
##rea O
##t O
- O
1 O
. O
1 O
na O
- O
131 O
* O
k O
- O
4 O
. O
5 O
c O
##l O
- O
98 O
h O
##co O
##3 O
- O
22 O
an O
##ga O
##p O
- O
16 O
[ O
* O
* O
214 O
##5 O
- O
6 O
- O
25 O
* O
* O
] O
05 O
: O
50 O
##pm O
blood O
glucose O
- O
123 O
* O
u O
##rea O
##n O
- O
22 O
* O
c O
##rea O
##t O
- O
1 O
. O
2 O
* O
na O
- O
127 O
* O
k O
- O
5 O
. O
1 O
c O
##l O
- O
97 O
h O
##co O
##3 O
- O
20 O
* O
an O
##ga O
##p O
- O
15 O
[ O
* O
* O
214 O
##5 O
- O
6 O
- O
26 O
* O
* O
] O
01 O
: O
25 O
##am O
blood O
u O
##rea O
##n O
- O
22 O
* O
c O
##rea O
##t O
- O
1 O
. O
1 O
na O
- O
133 O
k O
- O
4 O
. O
6 O
c O
##l O
- O
100 O
h O
##co O
##3 O
- O
24 O
an O
##ga O
##p O
- O
14 O
[ O
* O
* O
214 O
##5 O
- O
6 O
- O
26 O
* O
* O
] O
07 O
: O
20 O
##am O
blood O
u O
##rea O
##n O
- O
18 O
c O
##rea O
##t O
- O
0 O
. O
9 O
na O
- O
131 O
* O
k O
- O
4 O
. O
5 O
c O
##l O
- O
101 O
h O
##co O
##3 O
- O
22 O
an O
##ga O
##p O
- O
13 O
[ O
* O
* O
214 O
##5 O
- O
6 O
- O
26 O
* O
* O
] O
07 O
: O
20 O
##am O
blood O
u O
##rea O
##n O
- O
18 O
c O
##rea O
##t O
- O
0 O
. O
9 O
na O
- O
131 O
* O
k O
- O
4 O
. O
5 O
c O
##l O
- O
101 O
h O
##co O
##3 O
- O
22 O
an O
##ga O
##p O
- O
13 O
[ O
* O
* O
214 O
##5 O
- O
6 O
- O
27 O
* O
* O
] O
06 O
: O
28 O
##am O
blood O
glucose O
- O
185 O
* O
u O
##rea O
##n O
- O
15 O
c O
##rea O
##t O
- O
0 O
. O
9 O
na O
- O
120 O
* O
k O
- O
4 O
. O
7 O
c O
##l O
- O
85 O
* O
h O
##co O
##3 O
- O
23 O
an O
##ga O
##p O
- O
17 O

[ O
* O
* O
214 O
##5 O
- O
6 O
- O
27 O
* O
* O
] O
08 O
: O
57 O
##am O
blood O
glucose O
- O
172 O
* O
u O
##rea O
##n O
- O
17 O
c O
##rea O
##t O
- O
1 O
. O
0 O
na O
- O
119 O
* O
k O
- O
4 O
. O
7 O
c O
##l O
- O
85 O
* O
h O
##co O
##3 O
- O
24 O
an O
##ga O
##p O
- O
15 O
[ O
* O
* O
214 O
##5 O
- O
6 O
- O
25 O
* O
* O
] O
05 O
: O
50 O
##pm O
blood O
c O
##k O
( O
c O
##p O
##k O
) O
- O
179 O
* O
[ O
* O
* O
214 O
##5 O
- O
6 O
- O
26 O
* O
* O
] O
01 O
: O
25 O
##am O
blood O
c O
##k O
( O
c O
##p O
##k O
) O
- O
158 O
* O
[ O
* O
* O
214 O
##5 O
- O
6 O
- O
26 O
* O
* O
] O
07 O
: O
20 O
##am O
blood O
c O
##k O
( O
c O
##p O
##k O
) O
- O
124 O
[ O
* O
* O
214 O
##5 O
- O
6 O
- O
25 O
* O
* O
] O
05 O
: O
50 O
##pm O
blood O
c O
##k O
- O
m O
##b O
- O
7 O
c O
##tro O
##p O
##nt O
- O
< O
0 O
. O
01 O
[ O
* O
* O
214 O
##5 O
- O
6 O
- O
26 O
* O
* O
] O
01 O
: O
25 O
##am O
blood O
c O
##k O
- O
m O
##b O
- O
7 O
c O
##tro O
##p O
##nt O
- O
< O
0 O
. O
01 O
[ O
* O
* O
214 O
##5 O
- O
6 O
- O
26 O
* O
* O
] O
07 O
: O
20 O
##am O
blood O
c O
##k O
- O
m O
##b O
- O
6 O
c O
##tro O
##p O
##nt O
- O
< O
0 O
. O
01 O
[ O
* O
* O
214 O
##5 O
- O
6 O
- O
27 O
* O
* O
] O
08 O
: O
57 O
##am O
blood O
o O
##smo O
##lal O
- O
256 O
* O
[ O
* O
* O
214 O
##5 O
- O
6 O
- O
26 O
* O
* O
] O
07 O
: O
20 O
##am O
blood O
o O
##smo O
##lal O
- O
28 O
##2 O
[ O
* O
* O
214 O
##5 O
- O
6 O
- O
25 O
* O
* O
] O
05 O
: O
50 O
##pm O
blood O
t O
##sh O
- O
6 O
. O
1 O
* O
[ O
* O
* O
214 O
##5 O
- O
6 O
- O
26 O
* O
* O
] O
09 O
: O
38 O
##am O
urine O
hours O
- O
random O
c O
##rea O
##t O
- O
43 O
na O
- O
155 O
[ O
* O
* O
214 O
##5 O
- O
7 O
- O
4 O
* O
* O
] O
05 O
: O
09 O
##am O
blood O
w O
##b O
##c O
- O
1 O
. O
0 O
* O
r O
##b O
##c O
- O
2 O
. O
85 O
* O
h O
##g O
##b O
- O
8 O
. O
3 O
* O
h O
##ct O
- O
24 O
. O
1 O
* O
m O
##c O
##v O
- O
85 O
m O
##ch O
- O
29 O
. O
3 O
m O
##ch O
##c O
- O
34 O
. O
6 O
r O
##d O
##w O
- O
13 O
. O
1 O
p O
##lt O
c O
##t O
- O
257 O
[ O
* O
* O
214 O
##5 O
- O
7 O
- O
5 O
* O
* O
] O
04 O
: O
32 O
##am O
blood O
w O
##b O
##c O
- O
2 O
. O
1 O
* O
# O
r O
##b O
##c O
- O
3 O
. O
44 O
* O
h O
##g O
##b O
- O
10 O
. O
0 O
* O
h O
##ct O
- O
29 O
. O
1 O
* O
m O
##c O
##v O
- O
85 O
m O
##ch O
- O
29 O
. O
1 O
m O
##ch O
##c O
- O
34 O
. O
3 O
r O
##d O
##w O
- O
13 O
. O
8 O
p O
##lt O
c O
##t O
- O
306 O

[ O
* O
* O
214 O
##5 O
- O
7 O
- O
3 O
* O
* O
] O
05 O
: O
40 O
##am O
blood O
g O
##ran O
c O
##t O
- O
100 O
* O
[ O
* O
* O
214 O
##5 O
- O
7 O
- O
4 O
* O
* O
] O
05 O
: O
09 O
##am O
blood O
g O
##ran O
c O
##t O
- O
220 O
* O
[ O
* O
* O
214 O
##5 O
- O
7 O
- O
5 O
* O
* O
] O
04 O
: O
32 O
##am O
blood O
g O
##ran O
c O
##t O
- O
39 O
##9 O
* O
[ O
* O
* O
214 O
##5 O
- O
7 O
- O
5 O
* O
* O
] O
04 O
: O
32 O
##am O
blood O
glucose O
- O
74 O
u O
##rea O
##n O
- O
13 O
c O
##rea O
##t O
- O
1 O
. O
1 O
na O
- O
135 O
k O
- O
4 O
. O
9 O
c O
##l O
- O
101 O
h O
##co O
##3 O
- O
27 O
an O
##ga O
##p O
- O
12 O
[ O
* O
* O
214 O
##5 O
- O
7 O
- O
5 O
* O
* O
] O
04 O
: O
32 O
##am O
blood O
calcium O
- O
8 O
. O
7 O
p O
##hos O
- O
2 O
. O
9 O
mg O
- O
2 O
. O
1 O
brief O
hospital O
course O
: O
a O
/ O
p O
: O
87 O
y O
/ O
o O
f O
with O
h O
/ O
o O
of O
n O
##s O
##c O
##l O
##c O
p O
/ O
w O
ma O
##lai O
##se O
and O
abdominal O
pain O
, O
found O
to O
be O
h O
##y O
##po O
##nat O
##rem O
##ic O
. O
. O
ma B-REA
##lai I-REA
##se I-REA
: I-REA
p O
##t O
much O
improved O
after O
i O
##v O
##f O
. O
suspect O
combination O
h O
##y O
##po O
##nat O
##rem O
##ia O
, O
h O
##y O
##pot O
##hy O
##roid O
, O
poor O
p O
##o O
intake O
, O
and O
ch O
##em O
##otherapy O
( O
nave B-DRUG
##l I-DRUG
##bine I-DRUG
) I-DRUG
. O
e O
##k O
##g O
with O
non O
- O
specific O
changes O
, O
p O
##t O
refuses O
te O
##lem O
##oni O
##tor O
and O
negative O
c O
##e O
x O
3 O
. O
[ O
* O
* O
last O
name O
( O
l O
##f O
) O
96 O
##9 O
##6 O
##3 O
* O
* O
] O
, O
[ O
* O
* O
first O
name O
##3 O
( O
l O
##f O
) O
* O
* O
] O
manage O
h O
##y O
##po O
##nat O
##rem O
##ia O
and O
h O
##y O
##pot O
##hy O
##roid O
as O
below O
. O
. O

# O
. O
h B-REA
##y I-REA
##po I-REA
##nat I-REA
##rem I-REA
##ia I-REA
: I-REA
the O
patient O
appeared O
h O
##y O
##po O
##vo O
##lem O
##ic O
on O
admission O
with O
a O
sodium O
of O
127 O
and O
a O
serum O
o O
##sm O
of O
28 O
##2 O
. O
the O
patient O
was O
given O
1 B-DOS
##l B-FOR
of O
n B-DRUG
##s I-DRUG
and O
corrected O
to O
133 O
. O
the O
patient O
was O
given O
another O
liter B-FOR
of O
n B-DRUG
##s I-DRUG
throughout O
the O
day O
. O
the O
patient O
was O
stable O
and O
w O
/ O
o O
mental O
status O
changes O
. O
throughout O
the O
evening O
the O
patient O
continued O
to O
u O
##rina O
##te O
frequently O
. O
on O
[ O
* O
* O
6 O
- O
27 O
* O
* O
] O
the O
repeat O
morning O
sodium O
was O
120 O
and O
a O
serum O
o O
##sm O
of O
256 O
. O
the O
patients O
history O
of O
lung O
cancer O
and O
h O
##y O
##pot O
##hy O
##roid O
make O
si O
##ad O
##h O
the O
likely O
cause O
of O
her O
h O
##y O
##po O
##nate O
##rm O
##ia O
. O
the O
patient O
was O
placed O
on O
750 O
##m O
##l O
fluid O
restriction O
and O
l O
##yte O
##s O
were O
checked O
t O
##id O
, O
her O
na O
dipped O
to O
117 O
but O
then O
increased O
to O
120 O
- O
122 O
with O
fluid O
restriction O
to O
500 O
##m O
##l O
. O
she O
was O
then O
made O
n O
##po O
and O
her O
u O
##o O
dropped O
to O
60 O
##m O
##l O
in O
12 O
hours O
but O
her O
na O
remained O
at O
120 O
, O
she O
triggered O
for O
blood O
pressure O
to O
80s O
/ O
50 O
##s O
and O
she O
was O
transferred O
to O
the O
i O
##cu O
for O
h O
##yper O
##ton O
##ic O
sa O
##line O
and O
intensive O
nursing O
care O
. O
. O
# O
. O
abdominal B-REA
pain I-REA
: I-REA
the O
patient O
had O
com O
##pliant O
##s O
of O
chronic O
abdominal O
pain O
throughout O
the O
day O
and O
evening O
. O
the O
patient O
has O
a O
history O
of O
me O
##sent O
##ric O
is O
##che O
##mia O
s O
/ O
p O
c O
##eli O
##ac O
s O
##ten O
##t O
, O
i O
##bs O
and O
gas O
##tri O
##tis O
/ O
duo O
##den O
##itis O
s O
/ O
p O
e O
##g O
##d O
on O
[ O
* O
* O
6 O
- O
25 O
* O
* O
] O
. O
the O
patient O
also O
had O
complaints O
of O
mild O
nausea O
and O
small O
amount O
of O
clear O
/ O
whitish O
liquid O
vomit O
##ing O
. O
the O
was O
started O
on O
a O
pp B-DRUG
##i I-DRUG
and O
both O
i B-ROU
##v I-ROU
and O
p B-ROU
##o I-ROU
anti B-DRUG
- I-DRUG
em I-DRUG
##etics I-DRUG
, I-DRUG
however O
the O
patient O
would O
intermittent O
##ly O
refuse O
medications O
citing O
that O
they O
would O
upset O
her O
stomach O
. O
the O
patient O
would O
intermittent O
##ly O
tolerate O
small O
amounts O
of O
p O
##o O
intake O
. O
the O
patient O
was O
sent O
for O
an O
abdominal O
u O
/ O
s O
to O
evaluate O
her O
c O
##eli O
##ac O
s O
##ten O
##t O
which O
showed O
decreased O
velocity O
from O
previous O
study O
. O
additionally O
, O
a O
g O
##ua O
##ic O
stool O
was O
sent O
as O
well O
as O
l O
##fts O
and O
h O
##ct O
, O
which O
were O
within O
normal O
limits O
. O
[ O
* O
* O
month O
/ O
year O
( O
2 O
) O
* O
* O
] O
surgery O
was O
consulted O
and O
they O
felt O
that O
me O
##sent O
##eric O
is O
##che O
##mia O
was O
very O
unlikely O
. O
# O
h B-REA
##y I-REA
##pot I-REA
##hy I-REA
##roid I-REA
: I-REA
p O
##t O
t O
##sh O
was O
6 O
. O
1 O
. O
p O
##t O
admits O
to O
non O
- O
compliance O
of O
le O
##vo O
##thy O
##ro O
##xin O
##e O
. O
p O
##t O
was O
educated O
on O
h B-REA
##y I-REA
##pot I-REA
##hy I-REA
##roid I-REA
and O
importance O
of O
me O
##d O
compliance O
. O
- O
- O
will O
con O
##t O
home O
le B-DRUG
##vo I-DRUG
##thy I-DRUG
##ro I-DRUG
##xin I-DRUG
##e I-DRUG
. O

lung B-REA
ca I-REA
: I-REA
being O
treated O
as O
out O
- O
p O
##t O
with O
nave B-DRUG
##l I-DRUG
##bine I-DRUG
/ I-DRUG
x B-DRUG
##rt I-DRUG
. O
d B-REA
##m I-REA
##2 I-REA
: I-REA
p O
##t O
started O
on O
home O
am B-DRUG
##ary I-DRUG
##l I-DRUG
and O
covered O
on O
is B-DRUG
##s I-DRUG
. O
medications O
on O
admission O
: O
am B-DRUG
##ary I-DRUG
##l I-DRUG
2 B-STR
mg I-STR
daily B-FRE
la B-DRUG
##nso I-DRUG
##pra I-DRUG
##zo I-DRUG
##le I-DRUG
30 B-STR
mg I-STR
daily B-FRE
s B-DRUG
##ynth I-DRUG
##roid I-DRUG
50 B-STR
m I-STR
##c I-STR
##g I-STR
daily B-FRE
v B-DRUG
##als I-DRUG
##art I-DRUG
##an I-DRUG
40 B-STR
mg I-STR
daily B-FRE
as B-DRUG
##a I-DRUG
81 B-STR
mg I-STR
daily B-FRE
discharge O
medications O
: O
1 O
. O
le B-DRUG
##vo I-DRUG
##thy I-DRUG
##ro I-DRUG
##xin I-DRUG
##e I-DRUG
50 B-STR
m I-STR
##c I-STR
##g I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( O
daily O
) O
. O
2 O
. O
as B-DRUG
##pi I-DRUG
##rin I-DRUG
81 B-STR
mg I-STR
tablet B-FOR
, I-FOR
ch I-FOR
##ew I-FOR
##able I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
, I-FOR
ch I-FOR
##ew I-FOR
##able I-FOR
p B-ROU
##o I-ROU
daily B-FRE
( O
daily O
) O
. O
3 O
. O
g B-DRUG
##lim I-DRUG
##ep I-DRUG
##iri I-DRUG
##de I-DRUG
2 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( O
) O
. O
4 O
. O
v B-DRUG
##als I-DRUG
##art I-DRUG
##an I-DRUG
40 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE
5 O
. O
la B-DRUG
##nso I-DRUG
##pra I-DRUG
##zo I-DRUG
##le I-DRUG
30 B-STR
mg I-STR
capsule B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
capsule B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
p B-ROU
##o I-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE
6 O
. O
g B-DRUG
##aba I-DRUG
##pent I-DRUG
##in I-DRUG
100 B-STR
mg I-STR
capsule B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
capsule B-FOR
p B-ROU
##o I-ROU
t B-FRE
##id I-FRE
( O
3 O
times O
a O
day O
) O
as O
needed O
for O
nerve B-REA
pain I-REA
. I-REA
di O
##sp O
: O
* O
45 O
capsule O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
0 O
* O
7 O
. O
co B-DRUG
##lace I-DRUG
100 B-STR
mg I-STR
capsule B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
capsule B-FOR
p B-ROU
##o I-ROU
twice B-FRE
a I-FRE
day I-FRE
: I-FRE
to O
prevent B-REA
con I-REA
##st I-REA
##ip I-REA
##ation I-REA
. I-REA
di O
##sp O
: O
* O
30 O
capsule O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
0 O
* O
8 O
. O
se B-DRUG
##nna I-DRUG
8 B-STR
. I-STR
6 I-STR
mg I-STR
capsule B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
capsule B-FOR
p B-ROU
##o I-ROU
twice B-FRE
a I-FRE
day I-FRE
as I-FRE
needed I-FRE
for O
con B-REA
##st I-REA
##ip I-REA
##ation I-REA
: I-REA
take O
as O
needed O
to O
relieve B-REA
con I-REA
##st I-REA
##ip I-REA
##ation I-REA
. I-REA
di O
##sp O
: O
* O
30 O
capsule O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
0 O
* O
discharge O
disposition O
: O
home O
with O
service O
facility O
: O
[ O
* O
* O
hospital O
##1 O
* O
* O
] O
family O
and O
[ O
* O
* O
hospital O
##1 O
1926 O
* O
* O
] O
services O
discharge O
diagnosis O
: O
primary O
: O
1 O
) O
h O
##y O
##po O
##nat O
##rem O
##ia O
2 O
) O
h O
##y O
##pot O
##hy O
##roid O
##ism O
3 O
) O
non O
- O
small O
cell O
lung O
car O
##cin O
##oma O
4 O
) O
g O
##erd O
secondary O
: O
d O
##m O
##2 O
h O
##yper O
##tens O
##ion O
h O
##yper O
##lip O
##ide O
##mia O
diver O
##tic O
##ulos O
##is O
me O
##sent O
##eric O
is O
##che O
##mia O
discharge O
condition O
: O
stable O
, O
to O
##ler O
##ating O
p O
##o O
, O
am O
##bula O
##ting O
, O
norm O
##ote O
##ns O
##ive O
, O
good O
o O
##2 O
sat O
##uration O
##s O
on O
room O
air O
. O

discharge O
instructions O
: O
you O
were O
admitted O
to O
[ O
* O
* O
hospital O
##1 O
18 O
* O
* O
] O
for O
ma O
##lai O
##se O
and O
h O
##y O
##po O
##nat O
##rem O
##ia O
( O
low O
sodium O
) O
. O
you O
sodium O
at O
your O
primary O
care O
doctor O
' O
s O
office O
and O
in O
the O
emergency O
department O
were O
low O
. O
we O
restricted O
your O
fluids O
and O
measured O
your O
sodium O
level O
very O
closely O
and O
it O
increased O
. O
you O
will O
need O
to O
follow O
up O
closely O
with O
d O
##r O
. O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
100 O
##7 O
* O
* O
] O
and O
get O
your O
sodium O
checked O
to O
make O
sure O
it O
doesn O
' O
t O
get O
low O
again O
. O
you O
were O
also O
found O
to O
be O
h B-REA
##y I-REA
##pot I-REA
##hy I-REA
##roid I-REA
. I-REA
this O
was O
probably O
due O
to O
not O
taking O
your O
thy B-DRUG
##roid I-DRUG
medicine I-DRUG
regularly O
. O
you O
were O
restart O
##ed O
on O
your O
thy B-DRUG
##roid I-DRUG
medication I-DRUG
during O
your O
stay O
and O
should O
continue O
taking O
this O
. O
you O
were O
also O
found O
to O
be O
an O
##em O
##ic O
with O
low O
red O
blood O
cell O
counts O
. O
we O
trans O
##fused O
you O
two B-DOS
units B-FOR
of O
blood B-DRUG
while O
you O
were O
in O
the O
hospital O
. O
you O
will O
follow O
up O
with O
d O
##r O
. O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
100 O
##7 O
* O
* O
] O
and O
your O
on O
##cologist O
##s O
to O
get O
repeat O
blood O
counts O
. O
you O
had O
some O
back O
pain O
and O
left O
leg O
pain O
while O
you O
were O
here O
as O
well O
. O
an O
x O
- O
ray O
of O
your O
back O
showed O
only O
some O
de B-REA
##gene I-REA
##rative I-REA
disc I-REA
disease I-REA
and O
you O
were O
started O
on O
a O
new O
medicine O
, O
g B-DRUG
##aba I-DRUG
##pent I-DRUG
##in I-DRUG
( I-DRUG
ne I-DRUG
##uron I-DRUG
##tin I-DRUG
) I-DRUG
100 B-STR
##m I-STR
##g I-STR
three B-FRE
times I-FRE
a I-FRE
day I-FRE
. I-FRE
you O
should O
f O
##olo O
##w O
up O
with O
d O
##r O
. O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
100 O
##7 O
* O
* O
] O
to O
discuss O
whether O
to O
continue O
this O
medicine O
and O
for O
how O
long O
. O
while O
you O
were O
in O
the O
hospital O
, O
we O
held O
your O
ch B-DRUG
##em I-DRUG
##otherapy I-DRUG
and O
radiation O
until O
your O
white O
blood O
cell O
counts O
improve O
. O
you O
should O
follow O
- O
up O
in O
radiation O
on O
##cology O
on O
wed O
##nes O
##day O
, O
[ O
* O
* O
7 O
- O
7 O
* O
* O
] O
at O
7 O
: O
30 O
##am O
to O
have O
your O
counts O
re O
##che O
##cked O
. O
you O
should O
also O
follow O
up O
with O
d O
##r O
. O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
* O
* O
] O
on O
[ O
* O
* O
month O
( O
only O
) O
205 O
* O
* O
] O
. O
if O
you O
experience O
severe O
nausea O
, O
vomit O
##ing O
, O
fatigue O
, O
difficulty O
breathing O
, O
chest O
pain O
, O
fever O
##s O
or O
any O
other O
symptoms O
that O
are O
concerning O
to O
you O
, O
please O
go O
to O
the O
nearest O
emergency O
room O
to O
be O
evaluated O
. O
please O
take O
the O
medications O
shown O
below O
. O

please O
see O
your O
out O
##patient O
doctor O
or O
go O
to O
the O
emergency O
room O
if O
you O
feel O
worse O
##ning O
fatigue O
, O
ma O
##lai O
##se O
, O
confusion O
, O
abdominal O
pain O
, O
nausea O
, O
vomit O
##ing O
, O
fever O
##s O
( O
> O
101 O
. O
5 O
) O
, O
chill O
##s O
, O
chest O
pain O
, O
short O
##ness O
of O
breath O
, O
di O
##zzi O
##ness O
or O
any O
other O
symptoms O
you O
feel O
are O
concerning O
. O
follow O
##up O
instructions O
: O
p O
##c O
##p O
: O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##4 O
) O
* O
* O
] O
. O
[ O
* O
* O
first O
name O
##4 O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
100 O
##7 O
* O
* O
] O
; O
app O
##t O
: O
f O
##rida O
##y O
, O
[ O
* O
* O
7 O
- O
9 O
* O
* O
] O
at O
2 O
: O
00 O
##pm O
; O
phone O
: O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
104 O
##9 O
##2 O
* O
* O
] O
radiation O
on O
##cology O
( O
d O
##r O
. O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
* O
* O
] O
- O
wed O
##nes O
##day O
, O
[ O
* O
* O
7 O
- O
7 O
* O
* O
] O
at O
7 O
: O
30 O
##am O
primary O
on O
##cology O
( O
d O
##r O
. O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
* O
* O
] O
- O
mon O
##day O
, O
[ O
* O
* O
7 O
- O
26 O
* O
* O
] O
at O
2 O
: O
00 O
##pm O
[ O
* O
* O
first O
name O
##4 O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
* O
* O
] O
m O
##d O
[ O
* O
* O
m O
##d O
number O
( O
2 O
) O
36 O
##21 O
* O
* O
] O
completed O
by O
: O
[ O
* O
* O
214 O
##5 O
- O
7 O
- O
25 O
* O
* O
] O

admission O
date O
: O
[ O
* O
* O
212 O
##5 O
- O
1 O
- O
24 O
* O
* O
] O
discharge O
date O
: O
[ O
* O
* O
212 O
##5 O
- O
1 O
- O
26 O
* O
* O
] O
date O
of O
birth O
: O
[ O
* O
* O
204 O
##8 O
- O
3 O
- O
4 O
* O
* O
] O
sex O
: O
f O
service O
: O
medicine O
all O
##er O
##gies O
: O
er B-DRUG
##yt I-DRUG
##hr I-DRUG
##omy I-DRUG
##cin I-DRUG
base I-DRUG
/ O
n B-DRUG
##sai I-DRUG
##ds I-DRUG
/ O
ad O
##hesive O
tape O
attending O
: O
[ O
* O
* O
first O
name O
##3 O
( O
l O
##f O
) O
270 O
##4 O
* O
* O
] O
chief O
complaint O
: O
transfer O
to O
cc O
##u O
for O
h O
##y O
##pot O
##ens O
##ion O
status O
post O
elect O
##ive O
peripheral O
an O
##gio O
##graphy O
major O
surgical O
or O
invasive O
procedure O
: O
right O
lower O
ex O
##tre O
##mity O
an O
##gio O
##graphy O
per O
##cut O
##aneous O
co O
##rona O
##ry O
an O
##gio O
##p O
##last O
##y O
of O
right O
anterior O
t O
##ibi O
##al O
artery O
history O
of O
present O
illness O
: O
m O
##s O
. O
[ O
* O
* O
known O
last O
##name O
91 O
##64 O
* O
* O
] O
is O
a O
76 O
year O
- O
old O
female O
with O
a O
complicated O
pm O
##h O
##x O
that O
includes O
ca O
##d O
s O
/ O
p O
l O
##c O
##x O
s O
##ten O
##ting O
, O
d O
##m O
type O
2 O
, O
s O
/ O
p O
dual O
pace O
##maker O
placement O
for O
bra O
##dy O
##card O
##ia O
, O
at B-REA
##rial I-REA
fi I-REA
##bri I-REA
##lla I-REA
##tion I-REA
on O
chronic O
co B-DRUG
##uma I-DRUG
##din I-DRUG
therapy O
, O
with O
severe O
p O
##v O
##d O
s O
/ O
p O
multiple O
s O
##ten O
##ts O
, O
an O
##gio O
##p O
##last O
##ies O
and O
at O
##here O
##ct O
##omi O
##es O
, O
with O
c O
##lau O
##dication O
symptoms O
. O
she O
recently O
developed O
a O
r O
##le O
ul O
##cer O
, O
and O
was O
referred O
for O
r O
##le O
an O
##gio O
##graphy O
and O
p O
##t O
##ca O
of O
her O
right O
t O
##ibi O
##al O
anterior O
t O
##ibi O
##al O
artery O
. O
one O
hour O
after O
the O
procedure O
, O
m O
##s O
. O
[ O
* O
* O
known O
last O
##name O
91 O
##64 O
* O
* O
] O
became O
h O
##y O
##pot O
##ens O
##ive O
with O
s O
##b O
##p O
down O
to O
30 O
##s O
when O
the O
sheath O
was O
pulled O
, O
h O
##r O
paced O
at O
60 O
. O
she O
also O
complained O
of O
severe O
right O
groin O
pain O
at O
the O
cat O
##h O
site O
. O
she O
was O
given O
at B-DRUG
##rop I-DRUG
##ine I-DRUG
x O
2 B-DOS
, I-DOS
i B-DRUG
##v I-DRUG
##f I-DRUG
b B-DOS
##ol I-DOS
##us I-DOS
, I-DOS
and O
trans O
##fused O
2 B-DOS
units B-FOR
of O
p B-DRUG
##rb I-DRUG
##cs I-DRUG
. I-DRUG
her O
h O
##r O
subsequently O
increased O
to O
120 O
##s O
, O
then O
she O
went O
into O
at O
##rial O
fi O
##bri O
##lla O
##tion O
with O
r O
##v O
##r O
in O
160 O
##s O
. O
she O
spontaneous O
##ly O
converted O
back O
to O
n O
##s O
##r O
with O
h O
##r O
88 O
. O
her O
b O
##p O
improved O
with O
the O
above O
re O
##sus O
##citation O
measures O
, O
and O
she O
was O
t O
##ras O
##n O
##ferred O
to O
the O
cc O
##u O
for O
further O
management O
and O
care O
. O
an O
emerge O
##nt O
c O
##t O
scan O
was O
performed O
on O
arrival O
to O
cc O
##u O
, O
which O
revealed O
a O
right O
- O
sided O
r O
##p O
bleed O
. O

past O
medical O
history O
: O
1 O
. O
ca O
##d O
s O
/ O
p O
l O
##c O
##x O
s O
##ten O
##t O
in O
2 O
/ O
[ O
* O
* O
212 O
##2 O
* O
* O
] O
. O
l O
##m O
with O
60 O
% O
o O
##st O
##ial O
s O
##ten O
##osis O
, O
total O
o O
##cc O
##lusion O
of O
r O
##ca O
on O
last O
cardiac O
cat O
##he O
##ter O
##ization O
05 O
/ O
[ O
* O
* O
212 O
##3 O
* O
* O
] O
. O
2 O
. O
con O
##ges O
##tive O
heart O
failure O
, O
mild O
l O
##v O
s O
##ys O
##to O
##lic O
d O
##ys O
##function O
with O
e O
##f O
48 O
% O
on O
last O
vent O
##ric O
##ulo O
##gram O
05 O
/ O
[ O
* O
* O
212 O
##3 O
* O
* O
] O
. O
3 O
. O
peripheral O
[ O
* O
* O
year O
( O
4 O
digits O
) O
110 O
##6 O
* O
* O
] O
disease O
s O
/ O
p O
left O
e O
##ia O
and O
s O
##fa O
s O
##ten O
##ting O
[ O
* O
* O
3 O
- O
/ O
212 O
##3 O
* O
* O
] O
, O
and O
s O
/ O
p O
at O
##here O
##ct O
##omy O
/ O
p O
##ta O
of O
l O
##s O
##fa O
[ O
* O
* O
12 O
/ O
212 O
##3 O
* O
* O
] O
for O
ins O
##ten O
##t O
rest O
##eno O
##sis O
. O
4 O
. O
bra O
##dy O
##card O
##ia O
status O
post O
[ O
* O
* O
company O
154 O
##3 O
* O
* O
] O
dual O
chamber O
pace O
##maker O
placement O
[ O
* O
* O
212 O
##3 O
- O
12 O
- O
29 O
* O
* O
] O
. O
5 O
. O
intermittent O
at B-REA
##rial I-REA
fi I-REA
##bri I-REA
##lla I-REA
##tion I-REA
noted O
on O
pp O
##m O
interrogation O
, O
on O
chronic O
co B-DRUG
##uma I-DRUG
##din I-DRUG
therapy O
. O
6 O
. O
h O
##yper O
##cho O
##les O
##tero O
##lem O
##ia O
7 O
. O
chronic O
it O
##p O
with O
[ O
* O
* O
doctor O
first O
name O
* O
* O
] O
. O
b O
##m O
b O
##x O
normal O
in O
[ O
* O
* O
211 O
##3 O
* O
* O
] O
. O
8 O
. O
diabetes O
me O
##lli O
##tus O
type O
2 O
, O
diet O
controlled O
9 O
. O
peripheral O
ne O
##uro O
##pathy O
10 O
. O
mild O
cop O
##d O
11 O
. O
pu O
##d O
12 O
. O
gas O
##tri O
##tis O
, O
bar O
##ret O
##t O
' O
s O
es O
##op O
##ha O
##gus O
13 O
. O
multi O
##no O
##du O
##lar O
go O
##iter O
past O
surgical O
history O
: O
1 O
. O
status O
post O
ch O
##ole O
##cy O
##ste O
##ct O
##omy O
2 O
. O
s O
/ O
p O
ta O
##h O
- O
b O
##so O
3 O
. O
s O
/ O
p O
right O
th O
##r O
4 O
. O
s O
/ O
p O
l O
##4 O
, O
l O
##5 O
disc O
##ec O
##tom O
##y O
5 O
. O
s O
/ O
p O
app O
##end O
##ec O
##tom O
##y O
social O
history O
: O
widow O
. O
she O
lives O
with O
her O
son O
. O
she O
has O
6 O
adult O
children O
. O
ex O
- O
smoke O
##r O
. O
she O
quit O
smoking O
12 O
years O
ago O
; O
120 O
pack B-DRUG
- I-DRUG
year O
smoking O
history O
. O
family O
history O
: O
family O
history O
positive O
for O
ca O
##d O
: O
brother O
died O
of O
mi O
at O
age O
44 O
, O
another O
brother O
died O
at O
age O
53 O
of O
mi O
. O

physical O
exam O
: O
physical O
examination O
on O
admission O
to O
cc O
##u O
: O
vital O
##s O
: O
h O
##r O
65 O
, O
v O
- O
paced O
, O
b O
##p O
120 O
/ O
46 O
, O
r O
##r O
12 O
, O
sat O
100 O
% O
on O
4 O
##l O
n O
##c O
. O
g O
##en O
: O
alert O
, O
confused O
. O
he O
##ent O
: O
per O
##rl O
. O
neck O
: O
j O
##v O
##p O
not O
elevated O
. O
re O
##sp O
: O
limited O
to O
anterior O
chest O
. O
clear O
to O
au O
##s O
##cu O
##lta O
##tion O
. O
c O
##v O
##s O
: O
r O
##rr O
. O
normal O
s O
##1 O
, O
s O
##2 O
. O
no O
s O
##3 O
, O
s O
##4 O
. O
no O
murmur O
or O
rub O
. O
g O
##i O
: O
b O
##s O
norm O
##oa O
##ctive O
. O
r O
##l O
##q O
firm O
to O
p O
##al O
##pation O
, O
tender O
. O
no O
clear O
p O
##al O
##pable O
hem O
##ato O
##ma O
. O
ex O
##t O
: O
right O
groin O
with O
dressing O
in O
place O
. O
tender O
to O
p O
##al O
##pation O
. O
pedal O
pulses O
present O
via O
do O
##pp O
##ler O
. O
ne O
##uro O
: O
limited O
examination O
, O
patient O
non O
- O
cooperative O
. O
moves O
all O
4 O
ex O
##tre O
##mit O
##ies O
. O
per O
##tinent O
results O
: O
relevant O
laboratory O
data O
on O
admission O
to O
cc O
##u O
: O
c O
##b O
##c O
: O
w O
##b O
##c O
- O
13 O
. O
5 O
* O
# O
r O
##b O
##c O
- O
3 O
. O
39 O
* O
h O
##g O
##b O
- O
11 O
. O
4 O
* O
h O
##ct O
- O
32 O
. O
8 O
* O
m O
##c O
##v O
- O
97 O
m O
##ch O
- O
33 O
. O
6 O
* O
m O
##ch O
##c O
- O
34 O
. O
6 O
r O
##d O
##w O
- O
16 O
. O
3 O
* O
chemistry O
: O
glucose O
- O
153 O
* O
u O
##rea O
n O
- O
10 O
c O
##rea O
##t O
- O
0 O
. O
8 O
sodium O
- O
140 O
potassium O
- O
3 O
. O
4 O
chloride O
- O
107 O
total O
co O
##2 O
- O
27 O
an O
##ion O
gap O
- O
9 O
calcium O
- O
7 O
. O
0 O
* O
phosphate O
- O
4 O
. O
5 O
ma O
##gnesium O
- O
1 O
. O
3 O
* O
co O
##agu O
##lation O
profile O
: O
p O
##t O
- O
13 O
. O
8 O
* O
p O
##tt O
- O
23 O
. O
5 O
in O
##r O
( O
p O
##t O
) O
- O
1 O
. O
2 O
e O
##k O
##g O
: O
v O
- O
paced O
, O
rate O
60 O
b O
##pm O
, O
lb O
##bb O
morphology O
. O

[ O
* O
* O
212 O
##4 O
- O
1 O
- O
24 O
* O
* O
] O
r O
##le O
an O
##gio O
##graphy O
: O
initial O
an O
##gio O
##graphy O
showed O
a O
severely O
disease O
##d O
at O
. O
we O
planned O
to O
treat O
this O
vessel O
with O
p O
##ta O
and O
at O
##here O
##ct O
##omy O
. O
he B-DRUG
##par I-DRUG
##in I-DRUG
was O
given O
for O
anti B-REA
##coa I-REA
##gu I-REA
##lation I-REA
. I-REA
access O
was O
obtained O
in O
an O
ant O
##eg O
##rade O
fashion O
of O
the O
r O
##c O
##fa O
and O
a O
7 O
f O
##rench O
arrow O
sheath O
was O
advanced O
to O
the O
mid O
s O
##fa O
. O
the O
at O
was O
crossed O
with O
great O
difficulties O
with O
numerous O
wires O
, O
including O
p O
##t O
[ O
* O
* O
name O
( O
ni O
) O
91 O
##65 O
* O
* O
] O
, O
[ O
* O
* O
name O
( O
ni O
) O
91 O
##6 O
##6 O
* O
* O
] O
and O
s O
##hino O
##bi O
. O
however O
, O
attempts O
to O
cross O
the O
di O
##stal O
les O
##ion O
with O
at O
##here O
##ct O
##omy O
or O
an O
##gio O
##p O
##last O
##y O
devices O
failed O
. O
finally O
, O
a O
2 O
. O
0 O
##x O
##20 O
mm O
ma O
##ver O
##ick O
crossed O
the O
les O
##ion O
, O
which O
was O
di O
##lated O
at O
12 O
at O
##m O
. O
next O
, O
a O
2 O
. O
5 O
##x O
##20 O
mm O
quantum O
ma O
##ver O
##ick O
balloon O
was O
used O
to O
di O
##late O
the O
entire O
at O
at O
12 O
- O
22 O
at O
##m O
. O
final O
an O
##gio O
##graphy O
showed O
no O
residual O
s O
##ten O
##osis O
with O
flow O
to O
the O
foot O
through O
the O
p O
##a O
and O
at O
. O
the O
patient O
left O
the O
lab O
in O
stable O
condition O
. O
[ O
* O
* O
212 O
##5 O
- O
1 O
- O
24 O
* O
* O
] O
c O
##t O
of O
the O
abdomen O
without O
contrast O
: O
changes O
of O
em O
##phy O
##se O
##ma O
are O
seen O
at O
both O
lung O
bases O
. O
there O
is O
bi O
##bas O
##ila O
##r O
dependent O
ate O
##lect O
##asis O
, O
without O
significant O
p O
##le O
##ural O
e O
##ff O
##usion O
or O
p O
##ne O
##um O
##oth O
##orax O
. O
co O
##rona O
##ry O
artery O
ca O
##l O
##ci O
##fication O
##s O
and O
co O
##rona O
##ry O
[ O
* O
* O
month O
/ O
day O
/ O
year O
110 O
##6 O
* O
* O
] O
ca O
##l O
##ci O
##fication O
##s O
are O
seen O
. O
pace O
##maker O
wires O
are O
also O
present O
. O
there O
is O
residual O
contrast O
within O
the O
kidney O
##s O
from O
recent O
intervention O
##al O
procedure O
. O
the O
liver O
, O
s O
##ple O
##en O
, O
ad O
##rena O
##l O
glands O
, O
kidney O
##s O
, O
stomach O
, O
pan O
##cre O
##as O
, O
and O
small O
bow O
##el O
are O
within O
normal O
limits O
. O
marked O
[ O
* O
* O
month O
/ O
day O
/ O
year O
110 O
##6 O
* O
* O
] O
ca O
##l O
##ci O
##fication O
##s O
are O
seen O
of O
the O
a O
##ort O
##a O
, O
c O
##eli O
##ac O
axis O
, O
s O
##ma O
, O
[ O
* O
* O
female O
first O
name O
( O
un O
) O
89 O
##9 O
* O
* O
] O
, O
and O
il O
##iac O
/ O
f O
##em O
##oral O
art O
##eries O
. O
the O
gal O
##l O
##bla O
##dder O
is O
not O
identified O
, O
and O
the O
patient O
may O
be O
status O
post O
ch O
##ole O
##cy O
##ste O
##ct O
##omy O
. O
there O
is O
a O
small O
hi O
##ata O
##l O
her O
##nia O
present O
. O

there O
is O
a O
large O
amount O
of O
re O
##tro O
##per O
##ito O
##nea O
##l O
hem O
##or O
##r O
##hage O
present O
, O
tracking O
from O
the O
right O
groin O
to O
the O
right O
posterior O
para O
##rena O
##l O
space O
. O
in O
the O
greatest O
a O
##xial O
dimensions O
, O
this O
measures O
approximately O
7 O
. O
0 O
x O
7 O
. O
8 O
cm O
in O
size O
, O
and O
it O
extends O
a O
length O
of O
approximately O
20 O
cm O
in O
the O
si O
dimension O
. O
there O
is O
no O
significant O
abdominal O
l O
##ymph O
ad O
##eno O
##pathy O
present O
, O
and O
no O
as O
##cite O
##s O
fluid O
is O
present O
. O
c O
##t O
of O
the O
p O
##el O
##vis O
without O
contrast O
: O
diver O
##tic O
##uli O
are O
seen O
, O
and O
the O
large O
bow O
##el O
is O
otherwise O
un O
##rem O
##ark O
##able O
in O
appearance O
. O
h O
##yper O
##den O
##se O
free O
fluid O
is O
seen O
within O
the O
p O
##el O
##vis O
, O
possibly O
tracking O
from O
the O
re O
##tro O
##per O
##ito O
##nea O
##l O
hem O
##or O
##r O
##hage O
. O
the O
bladder O
appears O
un O
##rem O
##ark O
##able O
, O
with O
a O
f O
##ole O
##y O
cat O
##he O
##ter O
in O
place O
. O
a O
right O
- O
sided O
hip O
replacement O
is O
present O
. O
no O
significant O
o O
##sse O
##ous O
abnormal O
##ities O
are O
seen O
aside O
from O
de O
##gene O
##rative O
changes O
and O
right O
- O
convex O
s O
##co O
##lio O
##sis O
centered O
at O
the O
th O
##ora O
##co O
##lum O
##bar O
junction O
. O
impression O
: O
1 O
. O
large O
right O
- O
sided O
re O
##tro O
##per O
##ito O
##nea O
##l O
hem O
##or O
##r O
##hage O
, O
extending O
from O
the O
right O
groin O
to O
the O
right O
posterior O
para O
##rena O
##l O
space O
. O
2 O
. O
no O
significant O
hem O
##or O
##r O
##hage O
is O
seen O
within O
the O
right O
groin O
or O
extending O
into O
the O
right O
leg O
. O
brief O
hospital O
course O
: O
76 O
year O
- O
old O
female O
with O
a O
complicated O
pm O
##h O
##x O
that O
includes O
ca O
##d O
s O
/ O
p O
l O
##c O
##x O
s O
##ten O
##ting O
in O
[ O
* O
* O
212 O
##2 O
* O
* O
] O
, O
d O
##m O
type O
2 O
, O
s O
/ O
p O
pp O
##m O
placement O
for O
bra B-REA
##dy I-REA
##card I-REA
##ia I-REA
, I-REA
at B-REA
##rial I-REA
fi I-REA
##bri I-REA
##lla I-REA
##tion I-REA
on O
co B-DRUG
##uma I-DRUG
##din I-DRUG
, I-DRUG
with O
severe O
p O
##v O
##d O
s O
/ O
p O
m O
##ut O
##lip O
##le O
interventions O
, O
now O
s O
/ O
p O
r O
##le O
an O
##gio O
##graphy O
and O
right O
anterior O
t O
##ibi O
##al O
artery O
p O
##t O
##ca O
with O
post O
- O
procedure O
h O
##y O
##pot O
##ens O
##ion O
and O
r O
##p O
bleed O
. O
transferred O
to O
the O
cc O
##u O
for O
further O
care O
. O

1 O
) O
re O
##tro O
##per O
##ito O
##nea O
##l O
bleed O
: O
her O
h O
##y O
##pot O
##ens O
##ion O
was O
felt O
secondary O
to O
her O
re O
##tro O
##per O
##ito O
##nea O
##l O
bleed O
and O
likely O
v O
##aga O
##l O
response O
at O
the O
time O
of O
the O
sheath O
pull O
. O
as O
mentioned O
in O
the O
hp O
##i O
, O
she O
was O
trans O
##fused O
2 O
units O
of O
p O
##rb O
##cs O
in O
the O
cat O
##h O
lab O
, O
and O
was O
trans O
##fused O
an O
additional O
unit O
in O
the O
cc O
##u O
. O
she O
was O
also O
given O
i B-DRUG
##v I-DRUG
##f I-DRUG
. I-DRUG
she O
remained O
hem O
##ody O
##nam O
##ically O
stable O
throughout O
her O
stay O
in O
the O
cc O
##u O
, O
without O
need O
for O
press B-DRUG
##ors I-DRUG
, I-DRUG
and O
her O
h O
##ct O
also O
remained O
stable O
following O
the O
3 B-DOS
units B-FOR
of O
p B-DRUG
##rb I-DRUG
##cs I-DRUG
. I-DRUG
co B-DRUG
##uma I-DRUG
##din I-DRUG
was O
held O
in O
the O
setting O
of O
her O
r O
##p O
bleed O
, O
to O
be O
restart O
##ed O
as O
an O
out O
##patient O
. O
as B-DRUG
##pi I-DRUG
##rin I-DRUG
was O
resumed O
on O
[ O
* O
* O
212 O
##5 O
- O
1 O
- O
25 O
* O
* O
] O
and O
well O
tolerate O
##d O
. O
her O
hem O
##ato O
##c O
##rit O
was O
31 O
. O
1 O
at O
discharge O
. O
2 O
) O
s O
/ O
p O
p O
##t O
##ca O
to O
right O
[ O
* O
* O
doctor O
first O
name O
* O
* O
] O
: O
she O
was O
continued O
on O
as B-DRUG
##pi I-DRUG
##rin I-DRUG
while O
in O
hospital O
. O
pedal O
pulses O
were O
present O
via O
do O
##pp O
##ler O
. O
she O
will O
follow O
- O
up O
with O
d O
##r O
. O
[ O
* O
* O
first O
name O
( O
s O
##ti O
##tle O
) O
* O
* O
] O
in O
the O
week O
following O
discharge O
. O
3 O
) O
ca B-REA
##d I-REA
: I-REA
no O
acute O
issues O
in O
hospital O
. O
she O
was O
continued O
on O
lip B-DRUG
##itor I-DRUG
. I-DRUG
as B-DRUG
##pi I-DRUG
##rin I-DRUG
, I-DRUG
ate B-DRUG
##no I-DRUG
##lo I-DRUG
##l I-DRUG
, I-DRUG
di B-DRUG
##ova I-DRUG
##n I-DRUG
, I-DRUG
and O
l B-DRUG
##isi I-DRUG
##no I-DRUG
##p I-DRUG
##ril I-DRUG
were O
gradually O
resumed O
in O
hospital O
following O
the O
procedure O
. O
4 O
) O
mental O
status O
change O
: O
on O
arrival O
to O
the O
cc O
##u O
, O
m O
##s O
. O
[ O
* O
* O
known O
last O
##name O
91 O
##64 O
* O
* O
] O
was O
noted O
to O
be O
confused O
, O
bell O
##iger O
##ent O
. O
her O
acute O
mental B-ADE
status I-ADE
change I-ADE
was O
felt O
most O
likely O
medication O
- O
related O
s O
/ O
p O
administration O
of O
f B-DRUG
##ent I-DRUG
##any I-DRUG
##l I-DRUG
in O
the O
cat O
##h O
lab O
, O
se O
##da O
##tives O
. O
no O
gross O
electro O
##ly O
##te O
abnormal O
##ities O
, O
a O
##b O
##g O
un O
##rem O
##ark O
##able O
. O
she O
responded O
to O
ha B-DRUG
##ldo I-DRUG
##l I-DRUG
for O
acute O
agitation B-REA
/ I-REA
confusion B-REA
. I-REA
she O
was O
alert O
and O
oriented O
the O
following O
morning O
without O
re O
##cu O
##rrence O
of O
confusion O
. O
5 O
) O
diabetes B-REA
me I-REA
##lli I-REA
##tus I-REA
type I-REA
2 I-REA
: I-REA
she O
was O
kept O
on O
a O
regular O
insulin B-DRUG
sliding B-DOS
scale I-DOS
in O
hospital O
. O
her O
diabetes O
appears O
to O
be O
diet O
- O
controlled O
as O
an O
out O
- O
patient O
. O

medications O
on O
admission O
: O
ate B-DRUG
##no I-DRUG
##lo I-DRUG
##l I-DRUG
50 B-STR
mg I-STR
p B-ROU
##o I-ROU
q B-FRE
##d I-FRE
di B-DRUG
##ova I-DRUG
##n I-DRUG
160 B-STR
mg I-STR
p B-ROU
##o I-ROU
q B-FRE
##d I-FRE
co B-DRUG
##lace I-DRUG
200 B-STR
mg I-STR
p B-ROU
##o I-ROU
q B-FRE
##d I-FRE
e B-DRUG
##cot I-DRUG
##rin I-DRUG
81 B-STR
mg I-STR
p B-ROU
##o I-ROU
q B-FRE
##d I-FRE
e B-DRUG
##ffe I-DRUG
##x I-DRUG
##or I-DRUG
150 B-STR
mg I-STR
p B-ROU
##o I-ROU
q B-FRE
##hs I-FRE
h B-DRUG
##ct I-DRUG
##z I-DRUG
12 B-STR
. I-STR
5 I-STR
mg I-STR
p B-ROU
##o I-ROU
q B-FRE
##d I-FRE
lip B-DRUG
##itor I-DRUG
40 B-STR
mg I-STR
p B-ROU
##o I-ROU
q B-FRE
##d I-FRE
l B-DRUG
##isi I-DRUG
##no I-DRUG
##p I-DRUG
##ril I-DRUG
40 B-STR
mg I-STR
p B-ROU
##o I-ROU
q B-FRE
##d I-FRE
m B-DRUG
##vi I-DRUG
1 B-DOS
ta B-FOR
##b I-FOR
p B-ROU
##o I-ROU
q B-FRE
##d I-FRE
p B-DRUG
##ril I-DRUG
##ose I-DRUG
##c I-DRUG
40 B-STR
mg I-STR
p B-ROU
##o I-ROU
q B-FRE
##d I-FRE
t B-DRUG
##raz I-DRUG
##od I-DRUG
##one I-DRUG
200 B-STR
mg I-STR
p B-ROU
##o I-ROU
q B-FRE
##hs I-FRE
war B-DRUG
##fari I-DRUG
##n I-DRUG
last O
dose O
on O
[ O
* O
* O
212 O
##5 O
- O
1 O
- O
20 O
* O
* O
] O
discharge O
medications O
: O
1 O
. O
ate B-DRUG
##no I-DRUG
##lo I-DRUG
##l I-DRUG
50 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( I-FRE
daily I-FRE
) I-FRE
. I-FRE
2 O
. O
di B-DRUG
##ova I-DRUG
##n I-DRUG
160 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE
3 O
. O
co B-DRUG
##lace I-DRUG
100 B-STR
mg I-STR
capsule B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
capsule B-FOR
p B-ROU
##o I-ROU
twice B-FRE
a I-FRE
day I-FRE
. I-FRE
4 O
. O
as B-DRUG
##pi I-DRUG
##rin I-DRUG
81 B-STR
mg I-STR
tablet B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
p B-ROU
##o I-ROU
daily B-FRE
( I-FRE
daily I-FRE
) I-FRE
. I-FRE
5 O
. O
ve B-DRUG
##n I-DRUG
##la I-DRUG
##fa I-DRUG
##xin I-DRUG
##e I-DRUG
h I-DRUG
##c I-DRUG
##l I-DRUG
75 B-STR
mg I-STR
capsule B-FOR
, I-FOR
su I-FOR
##st I-FOR
. I-FOR
release I-FOR
24 I-FOR
##hr I-FOR
si O
##g O
: O
two B-DOS
( I-DOS
2 I-DOS
) I-DOS
capsule B-FOR
, I-FOR
su I-FOR
##st I-FOR
. I-FOR
release I-FOR
24 I-FOR
##hr I-FOR
p B-ROU
##o I-ROU
daily B-FRE
( I-FRE
daily I-FRE
) I-FRE
. I-FRE
6 O
. O
h B-DRUG
##ydro I-DRUG
##ch I-DRUG
##lor I-DRUG
##oth I-DRUG
##ia I-DRUG
##zi I-DRUG
##de I-DRUG
25 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
0 B-DOS
. I-DOS
5 I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( I-FRE
daily I-FRE
) I-FRE
. I-FRE
7 O
. O
lip B-DRUG
##itor I-DRUG
40 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE
8 O
. O
l B-DRUG
##isi I-DRUG
##no I-DRUG
##p I-DRUG
##ril I-DRUG
40 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE
9 O
. O
multi B-DRUG
- I-DRUG
vitamin I-DRUG
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE
10 O
. O
p B-DRUG
##ril I-DRUG
##ose I-DRUG
##c I-DRUG
40 B-STR
mg I-STR
capsule B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
capsule B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
p B-ROU
##o I-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE
11 O
. O
t B-DRUG
##raz I-DRUG
##od I-DRUG
##one I-DRUG
h I-DRUG
##c I-DRUG
##l I-DRUG
100 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
two B-DOS
( I-DOS
2 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
at B-FRE
bed I-FRE
##time I-FRE
. I-FRE
discharge O
disposition O
: O
home O
discharge O
diagnosis O
: O
1 O
. O
r O
##le O
an O
##gio O
##graphy O
and O
p O
##t O
##ca O
of O
right O
anterior O
t O
##ibi O
##al O
artery O
2 O
. O
complicated O
by O
large O
re O
##tro O
##per O
##ito O
##nea O
##l O
bleed O
discharge O
condition O
: O
p O
##t O
was O
in O
good O
condition O
, O
with O
a O
stable O
hem O
##ato O
##c O
##rit O
, O
am O
##bula O
##ting O
, O
and O
good O
oxygen O
sat O
##uration O
##s O
on O
room O
air O
. O

discharge O
instructions O
: O
please O
call O
d O
##r O
. O
[ O
* O
* O
first O
name O
( O
s O
##ti O
##tle O
) O
* O
* O
] O
or O
return O
to O
the O
hospital O
if O
you O
experience O
bleeding O
, O
weakness O
, O
di O
##zzi O
##ness O
, O
short O
##ness O
of O
breath O
, O
chest O
pain O
, O
groin O
, O
abdomen O
or O
back O
pain O
. O
d O
##r O
. O
[ O
* O
* O
name O
( O
ni O
) O
310 O
##1 O
* O
* O
] O
office O
will O
call O
you O
mon O
##day O
for O
an O
appointment O
next O
week O
. O
stop O
taking O
your O
co B-DRUG
##uma I-DRUG
##din I-DRUG
until O
d O
##r O
. O
[ O
* O
* O
first O
name O
( O
s O
##ti O
##tle O
) O
* O
* O
] O
tells O
you O
to O
resume O
it O
. O
follow O
##up O
instructions O
: O
see O
d O
##r O
. O
[ O
* O
* O
first O
name O
( O
s O
##ti O
##tle O
) O
* O
* O
] O
in O
one O
week O
. O
his O
office O
will O
call O
you O
mon O
##day O
. O
provider O
: O
[ O
* O
* O
name O
##10 O
( O
name O
##is O
) O
* O
* O
] O
, O
[ O
* O
* O
name O
##11 O
( O
name O
##is O
) O
911 O
##9 O
* O
* O
] O
[ O
* O
* O
name O
##12 O
( O
name O
##is O
) O
91 O
##20 O
* O
* O
] O
medicine O
( O
private O
) O
where O
: O
adult O
medicine O
unit O
[ O
* O
* O
hospital O
##3 O
* O
* O
] O
healthcare O
- O
1000 O
[ O
* O
* O
location O
( O
un O
) O
* O
* O
] O
- O
[ O
* O
* O
location O
( O
un O
) O
235 O
##2 O
* O
* O
] O
, O
[ O
* O
* O
n O
##ume O
##ric O
id O
##ent O
##ifier O
91 O
##21 O
* O
* O
] O
phone O
: O
[ O
* O
* O
page O
##r O
number O
* O
* O
] O
date O
/ O
time O
: O
[ O
* O
* O
212 O
##5 O
- O
2 O
- O
21 O
* O
* O
] O
2 O
: O
00 O
provider O
: O
[ O
* O
* O
name O
##10 O
( O
name O
##is O
) O
* O
* O
] O
study O
where O
: O
cc O
clinical O
center O
radio O
##logy O
phone O
: O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
32 O
##7 O
* O
* O
] O
date O
/ O
time O
: O
[ O
* O
* O
212 O
##5 O
- O
5 O
- O
15 O
* O
* O
] O
11 O
: O
00 O
completed O
by O
: O
[ O
* O
* O
212 O
##5 O
- O
1 O
- O
27 O
* O
* O
] O

admission O
date O
: O
[ O
* O
* O
218 O
##5 O
- O
6 O
- O
24 O
* O
* O
] O
discharge O
date O
: O
[ O
* O
* O
218 O
##5 O
- O
7 O
- O
21 O
* O
* O
] O
date O
of O
birth O
: O
[ O
* O
* O
210 O
##7 O
- O
8 O
- O
9 O
* O
* O
] O
sex O
: O
m O
service O
: O
medicine O
all O
##er O
##gies O
: O
no O
known O
all O
##er O
##gies O
/ O
adverse O
drug O
reactions O
attending O
: O
[ O
* O
* O
doctor O
first O
name O
208 O
##0 O
* O
* O
] O
chief O
complaint O
: O
h O
##y O
##pox O
##ia O
major O
surgical O
or O
invasive O
procedure O
: O
in O
##tub O
##ated O
( O
[ O
* O
* O
218 O
##5 O
- O
6 O
- O
24 O
* O
* O
] O
) O
history O
of O
present O
illness O
: O
history O
of O
present O
illness O
: O
77 O
##m O
history O
of O
s O
##chi O
##zophrenia O
, O
ne O
##uro O
##genic O
bladder O
presenting O
from O
n O
##h O
with O
a O
##cs O
with O
re O
##sus O
##citation O
at O
[ O
* O
* O
hospital O
##1 O
217 O
##7 O
* O
* O
] O
1 O
month O
p O
##t O
##p O
, O
brought O
in O
by O
em O
##s O
due O
to O
h O
##y O
##pox O
##ia O
, O
concern O
for O
p O
##na O
at O
nursing O
home O
. O
the O
patient O
is O
s O
##chi O
##zo O
##ph O
##ren O
##ic O
per O
history O
and O
is O
unable O
to O
provide O
a O
history O
of O
his O
own O
. O
per O
discussion O
with O
the O
floor O
nurse O
from O
his O
nursing O
home O
, O
a O
c O
##x O
##r O
was O
obtained O
4 O
days O
prior O
to O
admission O
for O
a O
cough O
that O
was O
consistent O
with O
a O
pneumonia B-REA
. I-REA
he O
was O
started O
on O
a O
z B-DRUG
- I-DRUG
pack I-DRUG
. I-DRUG
one O
day O
prior O
to O
admission O
, O
he O
developed O
ta O
##chy O
##p O
##nea O
and O
started O
to O
des O
##at O
##ura O
##ted O
in O
the O
the O
low O
80 O
' O
s O
. O
em O
##s O
were O
call O
and O
he O
was O
s O
##tat O
low O
90 O
' O
s O
on O
a O
n O
##rb O
. O
he O
was O
brought O
in O
by O
ambulance O
. O

in O
the O
ed O
, O
initial O
vs O
were O
t O
99 O
, O
h O
##r O
120 O
, O
b O
##p O
104 O
/ O
79 O
, O
r O
##r O
24 O
sat O
##ting O
92 O
% O
on O
n O
##rb O
. O
labs O
showed O
w O
##b O
##c O
of O
10 O
. O
1 O
, O
h O
##ct O
of O
43 O
, O
p O
##lts O
305 O
. O
l O
##fts O
showed O
a O
##p O
of O
214 O
otherwise O
w O
##n O
##l O
. O
co O
##ag O
##s O
were O
w O
##n O
##l O
. O
cm O
##p O
showed O
h O
##yper O
##nat O
##rem O
##ia O
of O
150 O
, O
c O
##l O
of O
112 O
, O
b O
##un O
33 O
, O
with O
rest O
of O
b O
##mp O
in O
normal O
range O
, O
la O
##ct O
##ate O
was O
2 O
. O
1 O
, O
and O
v O
##al O
##p O
##roa O
##te O
level O
was O
27 O
. O
a O
##b O
##g O
was O
checked O
and O
p O
##h O
was O
7 O
. O
51 O
, O
p O
##co O
##2 O
of O
28 O
, O
p O
##o O
##2 O
of O
72 O
. O
given O
ta O
##chy O
##p O
##nea O
and O
h O
##y O
##pox O
##emia O
as O
well O
as O
high O
work O
of O
breathing O
, O
patient O
was O
in O
##tub O
##ated O
with O
f B-DRUG
##ent I-DRUG
##any I-DRUG
##l I-DRUG
and O
mid B-DRUG
##az I-DRUG
##ola I-DRUG
##m I-DRUG
for O
se B-REA
##dation I-REA
. I-REA
noted O
was O
food O
in O
or O
##op O
##har O
##ynx O
/ O
la O
##ryn O
##x O
per O
ed O
resident O
on O
in O
##tub O
##ation O
. O
his O
c O
##x O
##r O
showed O
a O
questionable O
as B-REA
##piration I-REA
pneumonia I-REA
as O
well O
as O
possible O
ll O
##l O
process O
. O
c O
##t O
scan O
showed O
bilateral O
p O
##e O
and O
likely O
pneumonia O
. O
he O
was O
em O
##p O
##ric O
##ially O
provided O
with O
le B-DRUG
##vo I-DRUG
##f I-DRUG
##lo I-DRUG
##xa I-DRUG
##cin I-DRUG
, I-DRUG
metro B-DRUG
##ni I-DRUG
##da I-DRUG
##zo I-DRUG
##le I-DRUG
, I-DRUG
and O
van B-DRUG
##com I-DRUG
##y I-DRUG
##cin I-DRUG
. I-DRUG
his O
blood O
pressure O
dropped O
to O
70 O
/ O
40 O
just O
before O
transfer O
to O
the O
i O
##cu O
. O
after O
an O
3 O
additional O
3 B-DOS
##l I-DOS
n B-DRUG
##s I-DRUG
s O
##b O
##p O
increased O
to O
100 O
' O
s O
. O
past O
medical O
history O
: O
1 O
) O
o O
##ste O
##oar O
##th O
##rit O
##is O
2 O
) O
s O
##chi O
##zophrenia O
3 O
) O
ta O
##rdi O
##ve O
d O
##ys O
##kin O
##esi O
##a O
4 O
) O
ne O
##uro O
##genic O
bladder O
in O
##d O
##well O
##ing O
cat O
##he O
##ter O
with O
re O
##current O
u O
##tis O
5 O
) O
b O
##ph O
6 O
) O
ca O
##d O
7 O
) O
l O
##umba O
##r O
pain O
8 O
) O
t O
##ur O
##p O
9 O
) O
d O
##ys O
##pha O
##gia O
with O
large O
hi O
##ati O
##al O
her O
##nia O
. O
social O
history O
: O
lives O
at O
[ O
* O
* O
hospital O
##1 O
* O
* O
] O
174 O
[ O
* O
* O
location O
( O
un O
) O
53 O
##8 O
* O
* O
] O
, O
ma O
family O
history O
: O
patient O
unable O
to O
el O
##uc O
##ida O
##te O
. O

physical O
exam O
: O
admit O
exam O
: O
vital O
##s O
: O
te O
##mp O
: O
36 O
. O
8 O
? O
? O
? O
? O
? O
? O
c O
, O
h O
##r O
: O
84 O
, O
b O
##p O
: O
96 O
/ O
53 O
( O
68 O
) O
mm O
##h O
##g O
, O
r O
##r O
: O
26 O
ins O
##p O
/ O
min O
, O
s O
##po O
##2 O
: O
97 O
% O
general O
: O
se O
##dated O
on O
vent O
, O
na O
##d O
, O
thin O
he O
##ent O
: O
s O
##cle O
##ra O
an O
##ict O
##eric O
, O
mm O
##m O
, O
or O
##op O
##har O
##ynx O
clear O
, O
e O
##omi O
, O
2 O
##mm O
pupils O
, O
poorly O
reactive O
neck O
: O
su O
##pp O
##le O
c O
##v O
: O
regular O
rate O
and O
rhythm O
, O
normal O
s O
##1 O
+ O
s O
##2 O
, O
no O
murmurs O
, O
rub O
##s O
, O
gal O
##lops O
lungs O
: O
limited O
exam O
clear O
to O
au O
##s O
##cu O
##lta O
##tion O
bilateral O
##ly O
on O
anterior O
exam O
abdomen O
: O
soft O
, O
non O
- O
tender O
, O
non O
- O
di O
##sten O
##ded O
, O
bow O
##el O
sounds O
present O
, O
no O
organ O
##ome O
##gal O
##y O
g O
##u O
: O
su O
##pra O
##pu O
##bic O
f O
##ole O
##y O
ex O
##t O
: O
warm O
, O
well O
per O
##fused O
, O
1 O
+ O
pulses O
ne O
##uro O
: O
moving O
all O
ex O
##tre O
##mit O
##ies O
discharge O
exam O
: O
a O
##f O
97 O
. O
6 O
/ O
98 O
100 O
- O
116 O
/ O
59 O
- O
80 O
h O
##r O
84 O
- O
100 O
r O
##r O
18 O
sat O
96 O
% O
on O
r O
##a O
g O
##en O
: O
na O
##d O
. O
sleeping O
comfortably O
he O
##ent O
: O
moist O
m O
##uc O
##osa O
. O
patient O
with O
upper O
air O
##way O
w O
##hee O
##zing O
. O
nasal O
breathe O
##r O
. O
appears O
o O
##bs O
##truction O
in O
nose O
. O
tongue O
protruding O
while O
sleeping O
c O
##v O
: O
ta O
##chy O
##card O
##ic O
, O
regular O
rhythm O
, O
[ O
* O
* O
1 O
- O
25 O
* O
* O
] O
ho O
##los O
##ys O
##to O
##lic O
murmur O
lungs O
: O
ta O
##chy O
##p O
##nic O
. O
upper O
air O
##way O
w O
##hee O
##zing O
. O
c O
##ta O
##b O
but O
intermediate O
a O
##eration O
a O
##b O
##d O
: O
n O
##t O
, O
n O
##d O
, O
soft O
ex O
##t O
: O
no O
peripheral O
ed O
##ema O
skin O
: O
no O
r O
##ash O
##es O
or O
lesions O
noted O
; O
area O
around O
su O
##pra O
##pu O
##bic O
cat O
##h O
is O
c O
/ O
d O
/ O
i O
without O
er O
##yt O
##hem O
##a O
or O
discharge O

per O
##tinent O
results O
: O
imaging O
: O
c O
##t O
an O
##gio O
chest O
[ O
* O
* O
218 O
##5 O
- O
6 O
- O
24 O
* O
* O
] O
- O
technique O
: O
c O
##ta O
of O
the O
chest O
was O
performed O
per O
department O
protocol O
. O
oblique O
sa O
##git O
##tal O
and O
co O
##rona O
##l O
reform O
##ats O
were O
available O
for O
review O
along O
with O
the O
a O
##xial O
images O
. O
c O
##t O
of O
the O
chest O
: O
there O
are O
small O
pulmonary O
art O
##erial O
filling O
defects O
in O
the O
sub O
##se O
##gment O
##al O
br O
##on O
##chi O
supplying O
the O
l O
##ing O
##ula O
( O
4 O
: O
71 O
) O
as O
well O
as O
additional O
filling O
defect O
in O
the O
sub O
##se O
##gment O
##al O
right O
lower O
lobe O
br O
##on O
##chi O
( O
4 O
: O
87 O
) O
. O
an O
additional O
area O
of O
segment O
##al O
pulmonary O
em O
##bol O
##us O
is O
seen O
in O
the O
a O
##pical O
segment O
of O
the O
right O
upper O
lobe O
( O
4 O
: O
33 O
) O
. O
there O
is O
no O
evidence O
of O
right O
heart O
strain O
. O
within O
the O
right O
middle O
and O
upper O
lobe O
there O
are O
extensive O
nod O
##ular O
op O
##ac O
##ities O
as O
well O
as O
several O
more O
go O
##und O
glass O
appearing O
areas O
of O
op O
##acity O
( O
4 O
: O
61 O
and O
4 O
: O
27 O
) O
. O
there O
is O
extensive O
ate O
##lect O
##asis O
of O
the O
right O
lower O
lobe O
( O
4 O
. O
83 O
) O
with O
relative O
[ O
* O
* O
name O
( O
ni O
) O
71 O
##0 O
##6 O
##2 O
* O
* O
] O
peripheral O
area O
within O
the O
collapsed O
lung O
. O
no O
definitive O
art O
##erial O
supply O
with O
em O
##bol O
##us O
is O
seen O
in O
this O
area O
; O
however O
in O
the O
setting O
of O
other O
em O
##bol O
##i O
and O
configuration O
of O
this O
finding O
, O
it O
is O
concerning O
for O
in O
##far O
##ct O
. O
there O
is O
no O
p O
##le O
##ural O
or O
per O
##ica O
##rdi O
##al O
e O
##ff O
##usion O
. O
in O
the O
left O
hem O
##ith O
##orax O
, O
there O
is O
a O
large O
hi O
##ata O
##l O
her O
##nia O
with O
stomach O
and O
g O
##e O
junction O
above O
the O
di O
##aph O
##rag O
##m O
. O
this O
causes O
com O
##pressive O
ate O
##lect O
##asis O
( O
4 O
: O
102 O
) O
on O
the O
adjacent O
lung O
. O
the O
patient O
is O
in O
##tub O
##ated O
with O
end O
##ot O
##rac O
##hea O
##l O
tube O
terminating O
approximately O
4 O
cm O
from O
the O
car O
##ina O
. O
an O
na O
##so O
##gas O
##tric O
tube O
is O
seen O
in O
the O
es O
##op O
##ha O
##gus O
but O
does O
not O
reach O
the O
g O
##e O
junction O
or O
the O
stomach O
. O
sub O
##dia O
##ph O
##gram O
##atic O
##ally O
, O
gal O
##lston O
##es O
are O
seen O
. O
the O
a O
##ort O
##a O
and O
the O
great O
vessels O
appear O
un O
##rem O
##ark O
##able O
. O
no O
suspicious O
l O
##ytic O
or O
s O
##cle O
##rot O
##ic O
lesions O
are O
seen O
within O
the O
bones O
. O
impression O
: O
1 O
. O
right O
middle O
and O
upper O
lobe O
nod O
##ular O
op O
##ac O
##ities O
as O
well O
as O
several O
areas O
of O
ground O
- O
glass O
op O
##acity O
consistent O
with O
infectious O
process O
. O
2 O
. O
bilateral O
pulmonary O
em O
##bol O
##i O
in O
the O
segment O
##al O
and O
sub O
##se O
##gment O
##al O
levels O
with O
no O
evidence O
of O
right O
heart O
strain O
. O
there O
is O
an O
area O
of O
h O
##y O
##po O
##en O
##han O
##ce O
##ment O
within O
the O
ate O
##l O
##ct O
##atic O
right O
lower O
lobe O
along O
the O
periphery O
concerning O
for O
in O
##far O
##ction O
. O

3 O
. O
complete O
right O
lower O
lobe O
ate O
##lect O
##asis O
. O
4 O
. O
large O
di O
##aph O
##gram O
##atic O
her O
##nia O
. O
5 O
. O
ch O
##ole O
##lit O
##has O
##is O
. O
bilateral O
lower O
ex O
##tre O
##mity O
ve O
##nous O
ultra O
##sound O
[ O
* O
* O
218 O
##5 O
- O
6 O
- O
24 O
* O
* O
] O
- O
gray O
##sca O
##le O
and O
do O
##pp O
##ler O
son O
[ O
* O
* O
name O
( O
ni O
) O
* O
* O
] O
of O
the O
left O
common O
f O
##em O
##oral O
, O
left O
superficial O
f O
##em O
##oral O
, O
left O
pop O
##lite O
##al O
vein O
show O
normal O
com O
##press O
##ibility O
, O
flow O
and O
au O
##gment O
##ation O
. O
note O
is O
made O
of O
du O
##plicate O
##d O
left O
superficial O
f O
##em O
##oral O
veins O
. O
the O
left O
calf O
veins O
show O
normal O
flow O
. O
gray O
##sca O
##le O
, O
color O
, O
and O
spectral O
do O
##pp O
##ler O
examination O
of O
the O
right O
common O
f O
##em O
##oral O
vein O
shows O
normal O
com O
##press O
##ibility O
and O
flow O
. O
note O
is O
made O
of O
du O
##plicate O
##d O
right O
superficial O
f O
##em O
##oral O
veins O
. O
there O
is O
partially O
o O
##cc O
##lus O
##ive O
th O
##rom O
##bus O
noted O
within O
one O
of O
the O
right O
pro O
##ximal O
superficial O
f O
##em O
##oral O
veins O
which O
is O
of O
unclear O
chronic O
##ity O
. O
the O
di O
##stal O
superficial O
f O
##em O
##oral O
vein O
, O
the O
entire O
length O
of O
the O
other O
superficial O
f O
##em O
##oral O
vein O
, O
pop O
##lite O
##al O
vein O
appear O
patent O
. O
the O
right O
posterior O
t O
##ibi O
##al O
veins O
were O
patent O
. O
the O
right O
per O
##one O
##al O
veins O
were O
not O
visual O
##ized O
. O
impression O
: O
1 O
. O
partially O
o O
##cc O
##lus O
##ive O
th O
##rom O
##bus O
noted O
within O
one O
of O
the O
two O
right O
pro O
##ximal O
superficial O
f O
##em O
##oral O
veins O
which O
is O
of O
unclear O
chronic O
##ity O
. O
right O
per O
##one O
##al O
veins O
were O
not O
visual O
##ized O
. O
2 O
. O
no O
d O
##v O
##t O
in O
left O
lower O
ex O
##tre O
##mity O
. O
echo O
[ O
* O
* O
218 O
##5 O
- O
6 O
- O
24 O
* O
* O
] O
- O
echo O
##card O
##io O
##graphic O
measurements O
results O
measurements O
normal O
range O
left O
vent O
##ric O
##le O
- O
e O
##jection O
fraction O
: O
> O
= O
55 O
% O
> O
= O
55 O
% O
findings O
left O
vent O
##ric O
##le O
: O
normal O
l O
##v O
wall O
thickness O
, O
cavity O
size O
, O
and O
global O
s O
##ys O
##to O
##lic O
function O
( O
l O
##ve O
##f O
> O
55 O
% O
) O
. O
sub O
##op O
##ti O
##mal O
technical O
quality O
, O
a O
focal O
l O
##v O
wall O
motion O
abnormal O
##ity O
cannot O
be O
fully O
excluded O
. O
right O
vent O
##ric O
##le O
: O
normal O
r O
##v O
chamber O
size O
and O
free O
wall O
motion O
. O
a O
##ort O
##ic O
valve O
: O
mildly O
thick O
##ened O
a O
##ort O
##ic O
valve O
leaf O
##lets O
. O
no O
a O
##r O
. O
mit O
##ral O
valve O
: O
mildly O
thick O
##ened O
mit O
##ral O
valve O
leaf O
##lets O
. O
mild O
( O
1 O
+ O
) O
m O
##r O
. O
per O
##ica O
##rdi O
##um O
: O
there O
is O
an O
anterior O
space O
which O
most O
likely O
represents O
a O
fat O
pad O
, O
though O
a O
lo O
##culate O
##d O
anterior O
per O
##ica O
##rdi O
##al O
e O
##ff O
##usion O
cannot O
be O
excluded O
. O

general O
comments O
: O
sub O
##op O
##ti O
##mal O
image O
quality O
- O
poor O
echo O
windows O
. O
sub O
##op O
##ti O
##mal O
image O
quality O
as O
the O
patient O
was O
difficult O
to O
position O
. O
sub O
##op O
##ti O
##mal O
image O
quality O
- O
vent O
##ila O
##tor O
. O
conclusions O
technically O
sub O
##op O
##ti O
##mal O
study O
. O
left O
vent O
##ric O
##ular O
wall O
thickness O
, O
cavity O
size O
, O
and O
global O
s O
##ys O
##to O
##lic O
function O
are O
normal O
( O
l O
##ve O
##f O
> O
55 O
% O
) O
. O
due O
to O
sub O
##op O
##ti O
##mal O
technical O
quality O
, O
a O
focal O
wall O
motion O
abnormal O
##ity O
cannot O
be O
fully O
excluded O
. O
right O
vent O
##ric O
##ular O
chamber O
size O
and O
free O
wall O
motion O
are O
normal O
. O
the O
a O
##ort O
##ic O
valve O
leaf O
##lets O
are O
mildly O
thick O
##ened O
( O
? O
# O
) O
. O
no O
def O
##inate O
a O
##ort O
##ic O
re O
##gu O
##rf O
##git O
##ation O
is O
seen O
. O
the O
mit O
##ral O
leaf O
##lets O
are O
mildly O
thick O
##ened O
. O
mild O
( O
1 O
+ O
) O
mit O
##ral O
re O
##gu O
##rg O
##itation O
is O
seen O
. O
there O
is O
an O
anterior O
space O
which O
most O
likely O
represents O
a O
very O
prominent O
fat O
pad O
. O
impression O
: O
very O
sub O
##op O
##ti O
##mal O
image O
quality O
. O
normal O
bi O
##vent O
##ric O
##ular O
cavity O
sizes O
with O
preserved O
global O
bi O
##vent O
##ric O
##ular O
s O
##ys O
##to O
##lic O
function O
. O
mild O
mit O
##ral O
re O
##gu O
##rg O
##itation O
. O
c O
##x O
##r O
[ O
* O
* O
218 O
##5 O
- O
6 O
- O
26 O
* O
* O
] O
compared O
with O
[ O
* O
* O
218 O
##5 O
- O
6 O
- O
25 O
* O
* O
] O
at O
5 O
: O
46 O
a O
. O
m O
. O
, O
an O
ng O
tube O
is O
again O
noted O
. O
it O
over O
##lies O
the O
lower O
chest O
, O
but O
appears O
to O
over O
##lie O
the O
gas O
##tric O
fund O
##us O
, O
which O
is O
elevated O
due O
to O
a O
di O
##aph O
##rag O
##matic O
her O
##nia O
##tion O
, O
as O
seen O
on O
[ O
* O
* O
218 O
##5 O
- O
6 O
- O
24 O
* O
* O
] O
c O
##t O
scan O
. O
if O
clinical O
##ly O
indicated O
, O
a O
lateral O
view O
could O
help O
to O
confirm O
this O
. O
again O
noted O
is O
et O
tube O
in O
satisfactory O
position O
above O
the O
car O
##ina O
. O
prominence O
of O
right O
para O
##tra O
##che O
##al O
soft O
tissues O
is O
noted O
, O
but O
may O
be O
accent O
##uated O
due O
to O
patient O
rotation O
. O
there O
is O
focal O
op O
##acity O
in O
the O
right O
upper O
zone O
and O
patch O
##y O
op O
##acity O
in O
the O
right O
lower O
zone O
medial O
##ly O
. O
these O
findings O
are O
better O
depicted O
on O
[ O
* O
* O
218 O
##5 O
- O
6 O
- O
24 O
* O
* O
] O
c O
##t O
scan O
. O
the O
lung O
a O
##pice O
##s O
are O
excluded O
from O
the O
film O
. O
electronic O
battery O
pack O
is O
noted O
overly O
##ing O
left O
il O
##iac O
crest O
. O
c O
##x O
##r O
[ O
* O
* O
218 O
##5 O
- O
7 O
- O
6 O
* O
* O
] O
findings O
: O
in O
comparison O
with O
the O
study O
of O
[ O
* O
* O
7 O
- O
5 O
* O
* O
] O
, O
the O
or O
##oga O
##st O
##ric O
tube O
has O
been O
removed O
. O
other O
monitoring O
and O
support O
devices O
remain O
in O
place O
. O
persistent O
op O
##ac O
##ification O
at O
the O
left O
base O
with O
progressive O
clearing O
of O
op O
##ac O
##ification O
at O
the O
right O
base O
. O
no O
vascular O
congestion O
. O

c O
##x O
##r O
[ O
* O
* O
7 O
- O
8 O
* O
* O
] O
portable O
: O
impression O
: O
increased O
op O
##ac O
##ification O
in O
left O
base O
with O
some O
volume O
loss O
. O
c O
##x O
##r O
[ O
* O
* O
7 O
- O
10 O
* O
* O
] O
portable O
: O
impression O
: O
possible O
area O
of O
lo O
##culate O
##d O
fluid O
with O
trapped O
air O
verses O
p O
##ne O
##um O
##oth O
##orax O
verses O
at O
##y O
##pical O
appearance O
of O
stomach O
bubble O
near O
the O
left O
c O
##pa O
. O
follow O
up O
upright O
chest O
radio O
##graph O
with O
the O
patient O
swallowing O
15 O
cc O
of O
bar O
##ium O
just O
prior O
to O
imaging O
should O
help O
rule O
out O
these O
et O
##iol O
##ogies O
c O
##x O
##r O
[ O
* O
* O
7 O
- O
11 O
* O
* O
] O
p O
##a O
/ O
la O
##t O
: O
conclusion O
: O
there O
is O
no O
significant O
p O
##ne O
##um O
##oth O
##orax O
. O
e O
##c O
##g O
[ O
* O
* O
7 O
- O
17 O
* O
* O
] O
: O
sin O
##us O
rhythm O
. O
border O
##line O
low O
q O
##rs O
voltage O
. O
possible O
inferior O
wall O
my O
##oc O
##ard O
##ial O
in O
##far O
##ction O
of O
in O
##det O
##er O
##minate O
age O
. O
the O
lateral O
lead O
q O
waves O
are O
likely O
not O
representative O
of O
a O
my O
##oc O
##ard O
##ial O
in O
##far O
##ction O
but O
rather O
se O
##pta O
##l O
q O
waves O
. O
compared O
to O
the O
previous O
tracing O
of O
[ O
* O
* O
218 O
##5 O
- O
7 O
- O
8 O
* O
* O
] O
the O
sin O
##us O
rate O
has O
decreased O
by O
20 O
beats O
per O
minute O
with O
no O
other O
diagnostic O
change O
. O
micro O
/ O
path O
: O
m O
##rsa O
screen O
( O
final O
[ O
* O
* O
218 O
##5 O
- O
6 O
- O
26 O
* O
* O
] O
) O
: O
positive O
for O
met O
##hic O
##ill O
##in O
resistant O
s O
##ta O
##ph O
au O
##reus O
. O
[ O
* O
* O
218 O
##5 O
- O
6 O
- O
25 O
* O
* O
] O
2 O
: O
00 O
pm O
br O
##on O
##chia O
##l O
washing O
##s O
br O
##on O
##chia O
##l O
wash O
. O
blood O
culture O
, O
routine O
( O
final O
[ O
* O
* O
218 O
##5 O
- O
7 O
- O
1 O
* O
* O
] O
) O
: O
no O
growth O
. O
gram O
stain O
( O
final O
[ O
* O
* O
218 O
##5 O
- O
6 O
- O
25 O
* O
* O
] O
) O
: O
4 O
+ O
( O
> O
10 O
per O
1000 O
##x O
field O
) O
: O
p O
##oly O
##mor O
##phon O
##uc O
##lea O
##r O
le O
##uk O
##ocytes O
. O
2 O
+ O
( O
1 O
- O
5 O
per O
1000 O
##x O
field O
) O
: O
gram O
positive O
co O
##cci O
. O
in O
pairs O
and O
clusters O
. O
urine O
culture O
( O
preliminary O
) O
: O
gram O
negative O
rod O
( O
s O
) O
. O
10 O
, O
000 O
- O
100 O
, O
000 O
organisms O
/ O
m O
##l O
. O
. O
gram O
stain O
( O
final O
[ O
* O
* O
218 O
##5 O
- O
6 O
- O
28 O
* O
* O
] O
) O
: O
> O
25 O
pm O
##ns O
and O
< O
10 O
e O
##pit O
##hel O
##ial O
cells O
/ O
100 O
##x O
field O
. O
no O
micro O
##or O
##gan O
##isms O
seen O
. O

respiratory O
culture O
( O
final O
[ O
* O
* O
218 O
##5 O
- O
6 O
- O
30 O
* O
* O
] O
) O
: O
com O
##men O
##sal O
respiratory O
flora O
absent O
. O
due O
to O
mixed O
bacterial O
types O
( O
> O
= O
3 O
colony O
types O
) O
an O
abbreviated O
work O
##up O
will O
be O
performed O
appropriate O
to O
the O
is O
##olate O
##s O
recovered O
from O
this O
site O
. O
s O
##ta O
##ph O
au O
##reus O
co O
##ag O
+ O
. O
sparse O
growth O
. O
se O
##ns O
##iti O
##vi O
##ties O
performed O
on O
culture O
# O
35 O
##1 O
- O
96 O
##6 O
##2 O
##p O
( O
[ O
* O
* O
218 O
##5 O
- O
6 O
- O
24 O
* O
* O
] O
) O
. O
yeast O
. O
rare O
growth O
. O
gram O
negative O
rod O
( O
s O
) O
. O
rare O
growth O
. O
gram O
stain O
( O
final O
[ O
* O
* O
218 O
##5 O
- O
7 O
- O
4 O
* O
* O
] O
) O
: O
> O
25 O
pm O
##ns O
and O
> O
10 O
e O
##pit O
##hel O
##ial O
cells O
/ O
100 O
##x O
field O
. O
gram O
stain O
indicates O
extensive O
contamination O
with O
upper O
respiratory O
secret O
##ions O
. O
bacterial O
culture O
results O
are O
invalid O
. O
please O
submit O
another O
specimen O
. O
cat O
##he O
##ter O
tip O
c O
##x O
[ O
* O
* O
7 O
- O
6 O
* O
* O
] O
: O
no O
growth O
b O
##c O
##x O
[ O
* O
* O
7 O
- O
9 O
* O
* O
] O
and O
[ O
* O
* O
7 O
- O
10 O
* O
* O
] O
: O
no O
growth O
urine O
c O
##x O
( O
[ O
* O
* O
7 O
- O
10 O
* O
* O
] O
) O
urine O
culture O
( O
final O
[ O
* O
* O
218 O
##5 O
- O
7 O
- O
12 O
* O
* O
] O
) O
: O
mixed O
bacterial O
flora O
( O
> O
= O
3 O
colony O
types O
) O
, O
consistent O
with O
f O
##eca O
##l O
contamination O
. O

admit O
labs O
: O
[ O
* O
* O
218 O
##5 O
- O
6 O
- O
24 O
* O
* O
] O
08 O
: O
40 O
##am O
blood O
w O
##b O
##c O
- O
10 O
. O
1 O
r O
##b O
##c O
- O
4 O
. O
41 O
* O
# O
h O
##g O
##b O
- O
13 O
. O
6 O
* O
# O
h O
##ct O
- O
43 O
. O
0 O
# O
m O
##c O
##v O
- O
97 O
# O
m O
##ch O
- O
30 O
. O
8 O
m O
##ch O
##c O
- O
31 O
. O
6 O
# O
r O
##d O
##w O
- O
14 O
. O
1 O
p O
##lt O
c O
##t O
- O
305 O
[ O
* O
* O
218 O
##5 O
- O
6 O
- O
24 O
* O
* O
] O
08 O
: O
40 O
##am O
blood O
ne O
##uts O
- O
85 O
. O
8 O
* O
l O
##ymph O
##s O
- O
9 O
. O
7 O
* O
mon O
##os O
- O
3 O
. O
5 O
e O
##os O
- O
0 O
. O
8 O
b O
##as O
##o O
- O
0 O
. O
3 O
[ O
* O
* O
218 O
##5 O
- O
6 O
- O
24 O
* O
* O
] O
08 O
: O
40 O
##am O
blood O
p O
##t O
- O
12 O
. O
3 O
p O
##tt O
- O
29 O
. O
6 O
in O
##r O
( O
p O
##t O
) O
- O
1 O
. O
1 O
[ O
* O
* O
218 O
##5 O
- O
6 O
- O
24 O
* O
* O
] O
08 O
: O
40 O
##am O
blood O
glucose O
- O
91 O
u O
##rea O
##n O
- O
33 O
* O
c O
##rea O
##t O
- O
0 O
. O
8 O
na O
- O
150 O
* O
k O
- O
3 O
. O
5 O
c O
##l O
- O
112 O
* O
h O
##co O
##3 O
- O
25 O
an O
##ga O
##p O
- O
17 O
[ O
* O
* O
218 O
##5 O
- O
6 O
- O
24 O
* O
* O
] O
08 O
: O
40 O
##am O
blood O
al O
##t O
- O
22 O
as O
##t O
- O
31 O
al O
##k O
##ph O
##os O
- O
214 O
* O
to O
##t O
##bil O
##i O
- O
0 O
. O
6 O
[ O
* O
* O
218 O
##5 O
- O
6 O
- O
24 O
* O
* O
] O
05 O
: O
10 O
##pm O
blood O
calcium O
- O
7 O
. O
7 O
* O
p O
##hos O
- O
2 O
. O
0 O
* O
mg O
- O
1 O
. O
8 O
[ O
* O
* O
218 O
##5 O
- O
6 O
- O
24 O
* O
* O
] O
08 O
: O
40 O
##am O
blood O
album O
##in O
- O
3 O
. O
4 O
* O
[ O
* O
* O
218 O
##5 O
- O
6 O
- O
24 O
* O
* O
] O
09 O
: O
34 O
##am O
blood O
type O
- O
art O
p O
##o O
##2 O
- O
72 O
* O
p O
##co O
##2 O
- O
28 O
* O
p O
##h O
- O
7 O
. O
51 O
* O
ca O
##lt O
##co O
##2 O
- O
23 O
base O
x O
##s O
- O
0 O

re O
##lev O
##ent O
labs O
: O
[ O
* O
* O
218 O
##5 O
- O
6 O
- O
24 O
* O
* O
] O
05 O
: O
10 O
##pm O
blood O
w O
##b O
##c O
- O
11 O
. O
6 O
* O
r O
##b O
##c O
- O
3 O
. O
43 O
* O
h O
##g O
##b O
- O
10 O
. O
8 O
* O
h O
##ct O
- O
33 O
. O
2 O
* O
m O
##c O
##v O
- O
97 O
m O
##ch O
- O
31 O
. O
4 O
m O
##ch O
##c O
- O
32 O
. O
4 O
r O
##d O
##w O
- O
14 O
. O
3 O
p O
##lt O
c O
##t O
- O
288 O
[ O
* O
* O
218 O
##5 O
- O
6 O
- O
25 O
* O
* O
] O
03 O
: O
11 O
##am O
blood O
w O
##b O
##c O
- O
12 O
. O
6 O
* O
r O
##b O
##c O
- O
3 O
. O
39 O
* O
h O
##g O
##b O
- O
10 O
. O
6 O
* O
h O
##ct O
- O
33 O
. O
0 O
* O
m O
##c O
##v O
- O
97 O
m O
##ch O
- O
31 O
. O
2 O
m O
##ch O
##c O
- O
32 O
. O
1 O
r O
##d O
##w O
- O
14 O
. O
3 O
p O
##lt O
c O
##t O
- O
31 O
##9 O
[ O
* O
* O
218 O
##5 O
- O
6 O
- O
26 O
* O
* O
] O
03 O
: O
46 O
##am O
blood O
w O
##b O
##c O
- O
14 O
. O
4 O
* O
r O
##b O
##c O
- O
3 O
. O
57 O
* O
h O
##g O
##b O
- O
11 O
. O
2 O
* O
h O
##ct O
- O
34 O
. O
2 O
* O
m O
##c O
##v O
- O
96 O
m O
##ch O
- O
31 O
. O
3 O
m O
##ch O
##c O
- O
32 O
. O
6 O
r O
##d O
##w O
- O
14 O
. O
7 O
p O
##lt O
c O
##t O
- O
35 O
##5 O
[ O
* O
* O
218 O
##5 O
- O
6 O
- O
25 O
* O
* O
] O
03 O
: O
11 O
##am O
blood O
ne O
##uts O
- O
81 O
. O
7 O
* O
l O
##ymph O
##s O
- O
12 O
. O
0 O
* O
mon O
##os O
- O
3 O
. O
0 O
e O
##os O
- O
2 O
. O
8 O
b O
##as O
##o O
- O
0 O
. O
5 O
[ O
* O
* O
218 O
##5 O
- O
6 O
- O
25 O
* O
* O
] O
03 O
: O
11 O
##am O
blood O
p O
##tt O
- O
58 O
. O
7 O
* O
[ O
* O
* O
218 O
##5 O
- O
6 O
- O
26 O
* O
* O
] O
03 O
: O
46 O
##am O
blood O
p O
##t O
- O
14 O
. O
2 O
* O
p O
##tt O
- O
88 O
. O
5 O
* O
in O
##r O
( O
p O
##t O
) O
- O
1 O
. O
3 O
* O
[ O
* O
* O
218 O
##5 O
- O
6 O
- O
26 O
* O
* O
] O
10 O
: O
04 O
##am O
blood O
p O
##tt O
- O
128 O
. O
0 O
* O
[ O
* O
* O
218 O
##5 O
- O
6 O
- O
24 O
* O
* O
] O
05 O
: O
10 O
##pm O
blood O
glucose O
- O
93 O
u O
##rea O
##n O
- O
25 O
* O
c O
##rea O
##t O
- O
0 O
. O
5 O
na O
- O
149 O
* O
k O
- O
2 O
. O
8 O
* O
c O
##l O
- O
119 O
* O
h O
##co O
##3 O
- O
21 O
* O
an O
##ga O
##p O
- O
12 O
[ O
* O
* O
218 O
##5 O
- O
6 O
- O
25 O
* O
* O
] O
03 O
: O
11 O
##am O
blood O
glucose O
- O
100 O
u O
##rea O
##n O
- O
23 O
* O
c O
##rea O
##t O
- O
0 O
. O
5 O
na O
- O
148 O
* O
k O
- O
3 O
. O
7 O
c O
##l O
- O
120 O
* O
h O
##co O
##3 O
- O
19 O
* O
an O
##ga O
##p O
- O
13 O

[ O
* O
* O
218 O
##5 O
- O
6 O
- O
25 O
* O
* O
] O
02 O
: O
52 O
##pm O
blood O
glucose O
- O
85 O
u O
##rea O
##n O
- O
20 O
c O
##rea O
##t O
- O
0 O
. O
5 O
na O
- O
150 O
* O
k O
- O
3 O
. O
4 O
c O
##l O
- O
120 O
* O
h O
##co O
##3 O
- O
20 O
* O
an O
##ga O
##p O
- O
13 O
[ O
* O
* O
218 O
##5 O
- O
6 O
- O
26 O
* O
* O
] O
03 O
: O
46 O
##am O
blood O
glucose O
- O
148 O
* O
u O
##rea O
##n O
- O
15 O
c O
##rea O
##t O
- O
0 O
. O
5 O
na O
- O
144 O
k O
- O
2 O
. O
8 O
* O
c O
##l O
- O
115 O
* O
h O
##co O
##3 O
- O
20 O
* O
an O
##ga O
##p O
- O
12 O
[ O
* O
* O
218 O
##5 O
- O
6 O
- O
26 O
* O
* O
] O
03 O
: O
23 O
##pm O
blood O
glucose O
- O
97 O
u O
##rea O
##n O
- O
12 O
c O
##rea O
##t O
- O
0 O
. O
5 O
na O
- O
140 O
k O
- O
3 O
. O
9 O
c O
##l O
- O
115 O
* O
h O
##co O
##3 O
- O
20 O
* O
an O
##ga O
##p O
- O
9 O
[ O
* O
* O
218 O
##5 O
- O
6 O
- O
24 O
* O
* O
] O
08 O
: O
40 O
##am O
blood O
al O
##t O
- O
22 O
as O
##t O
- O
31 O
al O
##k O
##ph O
##os O
- O
214 O
* O
to O
##t O
##bil O
##i O
- O
0 O
. O
6 O
[ O
* O
* O
218 O
##5 O
- O
6 O
- O
25 O
* O
* O
] O
03 O
: O
11 O
##am O
blood O
calcium O
- O
7 O
. O
8 O
* O
p O
##hos O
- O
1 O
. O
8 O
* O
mg O
- O
1 O
. O
9 O
[ O
* O
* O
218 O
##5 O
- O
6 O
- O
25 O
* O
* O
] O
02 O
: O
52 O
##pm O
blood O
calcium O
- O
8 O
. O
0 O
* O
p O
##hos O
- O
2 O
. O
9 O
mg O
- O
2 O
. O
4 O
[ O
* O
* O
218 O
##5 O
- O
6 O
- O
26 O
* O
* O
] O
03 O
: O
46 O
##am O
blood O
calcium O
- O
7 O
. O
5 O
* O
p O
##hos O
- O
1 O
. O
7 O
* O
mg O
- O
2 O
. O
1 O
[ O
* O
* O
218 O
##5 O
- O
6 O
- O
26 O
* O
* O
] O
03 O
: O
23 O
##pm O
blood O
calcium O
- O
7 O
. O
2 O
* O
p O
##hos O
- O
1 O
. O
8 O
* O
mg O
- O
2 O
. O
0 O
[ O
* O
* O
218 O
##5 O
- O
6 O
- O
24 O
* O
* O
] O
05 O
: O
50 O
##pm O
blood O
type O
- O
art O
p O
##o O
##2 O
- O
84 O
* O
p O
##co O
##2 O
- O
27 O
* O
p O
##h O
- O
7 O
. O
45 O
ca O
##lt O
##co O
##2 O
- O
19 O
* O
base O
x O
##s O
- O
- O
2 O
[ O
* O
* O
218 O
##5 O
- O
6 O
- O
25 O
* O
* O
] O
03 O
: O
10 O
##pm O
blood O
type O
- O
art O
te O
##mp O
- O
37 O
. O
2 O
p O
##o O
##2 O
- O
114 O
* O
p O
##co O
##2 O
- O
27 O
* O
p O
##h O
- O
7 O
. O
47 O
* O
ca O
##lt O
##co O
##2 O
- O
20 O
* O
base O
x O
##s O
- O
- O
1 O
in O
##tub O
##at O
- O
in O
##tub O
##ated O

[ O
* O
* O
218 O
##5 O
- O
6 O
- O
25 O
* O
* O
] O
10 O
: O
16 O
##pm O
blood O
type O
- O
art O
p O
##o O
##2 O
- O
91 O
p O
##co O
##2 O
- O
23 O
* O
p O
##h O
- O
7 O
. O
49 O
* O
ca O
##lt O
##co O
##2 O
- O
18 O
* O
base O
x O
##s O
- O
- O
2 O
[ O
* O
* O
218 O
##5 O
- O
6 O
- O
26 O
* O
* O
] O
04 O
: O
01 O
##am O
blood O
type O
- O
art O
p O
##o O
##2 O
- O
96 O
p O
##co O
##2 O
- O
26 O
* O
p O
##h O
- O
7 O
. O
51 O
* O
ca O
##lt O
##co O
##2 O
- O
21 O
base O
x O
##s O
- O
0 O
[ O
* O
* O
218 O
##5 O
- O
6 O
- O
26 O
* O
* O
] O
03 O
: O
31 O
##pm O
blood O
type O
- O
art O
te O
##mp O
- O
36 O
. O
8 O
p O
##o O
##2 O
- O
85 O
p O
##co O
##2 O
- O
27 O
* O
p O
##h O
- O
7 O
. O
50 O
* O
ca O
##lt O
##co O
##2 O
- O
22 O
base O
x O
##s O
- O
0 O
in O
##tub O
##at O
- O
in O
##tub O
##ated O

[ O
* O
* O
218 O
##5 O
- O
6 O
- O
30 O
* O
* O
] O
04 O
: O
22 O
##am O
blood O
w O
##b O
##c O
- O
11 O
. O
2 O
* O
r O
##b O
##c O
- O
3 O
. O
32 O
* O
h O
##g O
##b O
- O
10 O
. O
4 O
* O
h O
##ct O
- O
31 O
. O
5 O
* O
m O
##c O
##v O
- O
95 O
m O
##ch O
- O
31 O
. O
4 O
m O
##ch O
##c O
- O
33 O
. O
1 O
r O
##d O
##w O
- O
14 O
. O
8 O
p O
##lt O
c O
##t O
- O
450 O
* O
[ O
* O
* O
218 O
##5 O
- O
7 O
- O
3 O
* O
* O
] O
04 O
: O
24 O
##am O
blood O
w O
##b O
##c O
- O
13 O
. O
7 O
* O
r O
##b O
##c O
- O
3 O
. O
62 O
* O
h O
##g O
##b O
- O
11 O
. O
3 O
* O
h O
##ct O
- O
34 O
. O
2 O
* O
m O
##c O
##v O
- O
95 O
m O
##ch O
- O
31 O
. O
3 O
m O
##ch O
##c O
- O
33 O
. O
1 O
r O
##d O
##w O
- O
14 O
. O
6 O
p O
##lt O
c O
##t O
- O
61 O
##5 O
* O
[ O
* O
* O
218 O
##5 O
- O
7 O
- O
5 O
* O
* O
] O
02 O
: O
42 O
##am O
blood O
w O
##b O
##c O
- O
8 O
. O
5 O
r O
##b O
##c O
- O
3 O
. O
03 O
* O
h O
##g O
##b O
- O
9 O
. O
3 O
* O
h O
##ct O
- O
28 O
. O
9 O
* O
m O
##c O
##v O
- O
96 O
m O
##ch O
- O
30 O
. O
6 O
m O
##ch O
##c O
- O
32 O
. O
0 O
r O
##d O
##w O
- O
14 O
. O
6 O
p O
##lt O
c O
##t O
- O
64 O
##6 O
* O
[ O
* O
* O
218 O
##5 O
- O
7 O
- O
7 O
* O
* O
] O
03 O
: O
49 O
##am O
blood O
w O
##b O
##c O
- O
8 O
. O
6 O
r O
##b O
##c O
- O
2 O
. O
97 O
* O
h O
##g O
##b O
- O
9 O
. O
3 O
* O
h O
##ct O
- O
28 O
. O
1 O
* O
m O
##c O
##v O
- O
94 O
m O
##ch O
- O
31 O
. O
2 O
m O
##ch O
##c O
- O
33 O
. O
1 O
r O
##d O
##w O
- O
14 O
. O
5 O
p O
##lt O
c O
##t O
- O
59 O
##6 O
* O
[ O
* O
* O
218 O
##5 O
- O
7 O
- O
2 O
* O
* O
] O
03 O
: O
48 O
##am O
blood O
ne O
##uts O
- O
62 O
. O
4 O
l O
##ymph O
##s O
- O
28 O
. O
4 O
mon O
##os O
- O
6 O
. O
7 O
e O
##os O
- O
2 O
. O
0 O
b O
##as O
##o O
- O
0 O
. O
6 O
[ O
* O
* O
218 O
##5 O
- O
7 O
- O
4 O
* O
* O
] O
04 O
: O
06 O
##am O
blood O
ne O
##uts O
- O
64 O
. O
0 O
l O
##ymph O
##s O
- O
25 O
. O
8 O
mon O
##os O
- O
6 O
. O
5 O
e O
##os O
- O
2 O
. O
9 O
b O
##as O
##o O
- O
0 O
. O
9 O
[ O
* O
* O
218 O
##5 O
- O
7 O
- O
3 O
* O
* O
] O
04 O
: O
24 O
##am O
blood O
p O
##t O
- O
25 O
. O
9 O
* O
p O
##tt O
- O
116 O
. O
3 O
* O
in O
##r O
( O
p O
##t O
) O
- O
2 O
. O
5 O
* O
[ O
* O
* O
218 O
##5 O
- O
7 O
- O
4 O
* O
* O
] O
04 O
: O
06 O
##am O
blood O
p O
##t O
- O
38 O
. O
3 O
* O
p O
##tt O
- O
85 O
. O
2 O
* O
in O
##r O
( O
p O
##t O
) O
- O
3 O
. O
7 O
* O

[ O
* O
* O
218 O
##5 O
- O
7 O
- O
5 O
* O
* O
] O
02 O
: O
42 O
##am O
blood O
p O
##t O
- O
27 O
. O
3 O
* O
p O
##tt O
- O
42 O
. O
7 O
* O
in O
##r O
( O
p O
##t O
) O
- O
2 O
. O
6 O
* O
[ O
* O
* O
218 O
##5 O
- O
7 O
- O
6 O
* O
* O
] O
03 O
: O
39 O
##am O
blood O
p O
##t O
- O
31 O
. O
1 O
* O
in O
##r O
( O
p O
##t O
) O
- O
3 O
. O
0 O
* O
[ O
* O
* O
218 O
##5 O
- O
7 O
- O
7 O
* O
* O
] O
03 O
: O
49 O
##am O
blood O
p O
##t O
- O
50 O
. O
0 O
* O
p O
##tt O
- O
46 O
. O
7 O
* O
in O
##r O
( O
p O
##t O
) O
- O
5 O
. O
0 O
* O
[ O
* O
* O
218 O
##5 O
- O
7 O
- O
6 O
* O
* O
] O
03 O
: O
39 O
##am O
blood O
al O
##t O
- O
11 O
as O
##t O
- O
17 O
al O
##k O
##ph O
##os O
- O
125 O
to O
##t O
##bil O
##i O
- O
0 O
. O
5 O
[ O
* O
* O
218 O
##5 O
- O
7 O
- O
7 O
* O
* O
] O
03 O
: O
49 O
##am O
blood O
calcium O
- O
8 O
. O
5 O
p O
##hos O
- O
2 O
. O
0 O
* O
mg O
- O
2 O
. O
0 O
[ O
* O
* O
218 O
##5 O
- O
7 O
- O
3 O
* O
* O
] O
04 O
: O
24 O
##am O
blood O
t O
##sh O
- O
8 O
. O
2 O
* O
[ O
* O
* O
218 O
##5 O
- O
7 O
- O
3 O
* O
* O
] O
04 O
: O
30 O
##pm O
blood O
t O
##3 O
- O
99 O
free O
t O
##4 O
- O
0 O
. O
78 O
* O
[ O
* O
* O
218 O
##5 O
- O
7 O
- O
6 O
* O
* O
] O
06 O
: O
45 O
##am O
blood O
co O
##rts O
##ol O
- O
24 O
. O
3 O
* O
- O
05 O
: O
45 O
##am O
blood O
co O
##rts O
##ol O
- O
16 O
. O
8 O
( O
s O
##ti O
##m O
test O
) O
[ O
* O
* O
218 O
##5 O
- O
7 O
- O
4 O
* O
* O
] O
04 O
: O
06 O
##am O
blood O
co O
##rts O
##ol O
- O
6 O
. O
0 O
discharge O
labs O
: O

[ O
* O
* O
218 O
##5 O
- O
7 O
- O
20 O
* O
* O
] O
06 O
: O
55 O
##am O
blood O
w O
##b O
##c O
- O
5 O
. O
4 O
r O
##b O
##c O
- O
3 O
. O
25 O
* O
h O
##g O
##b O
- O
10 O
. O
3 O
* O
h O
##ct O
- O
30 O
. O
4 O
* O
m O
##c O
##v O
- O
94 O
m O
##ch O
- O
31 O
. O
7 O
m O
##ch O
##c O
- O
33 O
. O
8 O
r O
##d O
##w O
- O
14 O
. O
2 O
p O
##lt O
c O
##t O
- O
26 O
##3 O
[ O
* O
* O
218 O
##5 O
- O
7 O
- O
20 O
* O
* O
] O
06 O
: O
55 O
##am O
blood O
p O
##t O
- O
37 O
. O
9 O
* O
p O
##tt O
- O
47 O
. O
8 O
* O
in O
##r O
( O
p O
##t O
) O
- O
3 O
. O
7 O
* O
[ O
* O
* O
218 O
##5 O
- O
7 O
- O
20 O
* O
* O
] O
06 O
: O
55 O
##am O
blood O
glucose O
- O
87 O
u O
##rea O
##n O
- O
9 O
c O
##rea O
##t O
- O
0 O
. O
9 O
na O
- O
140 O
k O
- O
3 O
. O
8 O
c O
##l O
- O
107 O
h O
##co O
##3 O
- O
25 O
an O
##ga O
##p O
- O
12 O
[ O
* O
* O
218 O
##5 O
- O
7 O
- O
20 O
* O
* O
] O
06 O
: O
55 O
##am O
blood O
calcium O
- O
8 O
. O
6 O
p O
##hos O
- O
2 O
. O
9 O
mg O
- O
2 O
. O
4 O
brief O
hospital O
course O
: O
m O
##r O
. O
[ O
* O
* O
known O
last O
##name O
71 O
##0 O
##6 O
##3 O
* O
* O
] O
is O
a O
77 O
yo O
m O
transferred O
from O
mi O
##cu O
[ O
* O
* O
7 O
- O
7 O
* O
* O
] O
with O
s O
##chi O
##zophrenia O
, O
ne O
##uro O
##genic O
bladder O
, O
without O
guardian O
##ship O
, O
and O
found O
to O
have O
pneumonia O
and O
bilateral O
pulmonary O
em O
##bol O
##i O
causing O
h O
##y O
##pox O
##ia O
/ O
h O
##y O
##pot O
##ens O
##ion O
requiring O
press O
##ors O
and O
in O
##tub O
##ation O
. O
he O
has O
been O
relatively O
stable O
on O
the O
floor O
while O
undergoing O
treatment O
for O
u O
##ti O
. O
# O
u B-REA
##ti I-REA
- I-REA
currently O
has O
su O
##pra O
##pu O
##bic O
cat O
##he O
##ter O
in O
setting O
of O
ne O
##uro O
##genic O
bladder O
and O
was O
found O
to O
have O
g O
##n O
##r O
' O
s O
10 O
- O
100 O
##k O
in O
urine O
on O
[ O
* O
* O
218 O
##5 O
- O
7 O
- O
3 O
* O
* O
] O
. O
species O
on O
[ O
* O
* O
7 O
- O
3 O
* O
* O
] O
was O
al O
##cal O
##ige O
##nes O
a O
##ch O
##rom O
##ob O
##act O
##er O
. O
patient O
complained O
of O
need O
to O
void O
urine O
on O
[ O
* O
* O
218 O
##5 O
- O
7 O
- O
11 O
* O
* O
] O
several O
times O
which O
was O
new O
for O
him O
. O
his O
su O
##pra O
##pu O
##bic O
cat O
##he O
##ter O
was O
changed O
[ O
* O
* O
218 O
##5 O
- O
7 O
- O
13 O
* O
* O
] O
by O
u O
##rol O
##ogy O
. O
le B-DRUG
##vo I-DRUG
##f I-DRUG
##lo I-DRUG
##xa I-DRUG
##cin I-DRUG
was O
started O
on O
[ O
* O
* O
218 O
##5 O
- O
7 O
- O
11 O
* O
* O
] O
per O
[ O
* O
* O
218 O
##5 O
- O
7 O
- O
3 O
* O
* O
] O
se O
##ns O
##iti O
##vi O
##ties O
; O
for O
total O
14 B-DUR
day I-DUR
course O
( O
last O
day O
is O
[ O
* O
* O
7 O
- O
24 O
* O
* O
] O
) O
. O

# O
acute O
pulmonary B-REA
em I-REA
##bol I-REA
##i I-REA
: I-REA
patient O
previously O
on O
co B-DRUG
##uma I-DRUG
##din I-DRUG
. I-DRUG
[ O
* O
* O
218 O
##5 O
- O
6 O
- O
24 O
* O
* O
] O
c O
##ta O
showed O
bilateral O
pulmonary O
em O
##bol O
##i O
in O
the O
segment O
##al O
and O
sub O
##se O
##gment O
##al O
levels O
without O
evidence O
of O
right O
heart O
strain O
. O
there O
was O
no O
clear O
cause O
for O
why O
he O
developed O
a O
p O
##e O
. O
there O
was O
an O
area O
of O
h O
##y O
##po O
##en O
##han O
##ce O
##ment O
within O
the O
ate O
##lect O
##atic O
right O
lower O
lobe O
along O
the O
periphery O
concerning O
for O
in O
##far O
##ction O
. O
increased O
co B-DRUG
##uma I-DRUG
##din I-DRUG
from O
1 B-STR
##m I-STR
##g I-STR
p B-ROU
##o I-ROU
to O
2 B-STR
##m I-STR
##g I-STR
p B-ROU
##o I-ROU
daily B-FRE
on O
[ O
* O
* O
218 O
##5 O
- O
7 O
- O
13 O
* O
* O
] O
. O
further O
increased O
co B-DRUG
##uma I-DRUG
##din I-DRUG
from O
2 B-STR
##m I-STR
##g I-STR
p B-ROU
##o I-ROU
to O
4 B-STR
##m I-STR
##g I-STR
p B-ROU
##o I-ROU
daily B-FRE
on O
[ O
* O
* O
218 O
##5 O
- O
7 O
- O
16 O
* O
* O
] O
. O
his O
in O
##r O
has O
been O
difficult O
to O
manage O
, O
likely O
in O
setting O
of O
anti B-DRUG
##biotics I-DRUG
, I-DRUG
ma O
##ln O
##utrition O
, O
le B-DRUG
##vo I-DRUG
##thy I-DRUG
##ro I-DRUG
##xin I-DRUG
##e I-DRUG
. I-DRUG
on O
discharge O
, O
his O
co B-DRUG
##uma I-DRUG
##din I-DRUG
has O
just O
been O
restart O
##ed O
at O
3 B-STR
##m I-STR
##g I-STR
after O
he O
has O
been O
su O
##pra O
##ther O
##ap O
##eu O
##tic O
for O
the O
past O
2 O
days O
. O
as O
an O
out O
##patient O
, O
he O
should O
have O
his O
in O
##r O
followed O
( O
check O
in O
48 O
- O
72 O
##hr O
##s O
) O
. O
if O
his O
in O
##r O
< O
2 O
, O
he O
should O
be O
bridge O
##d O
with O
love B-DRUG
##no I-DRUG
##x I-DRUG
60 B-STR
##m I-STR
##g I-STR
q B-FRE
##12 I-FRE
##h I-FRE
due O
to O
high B-REA
risk I-REA
for I-REA
th I-REA
##rom I-REA
##boe I-REA
##mbo I-REA
##lis I-REA
##m I-REA
. I-REA
on O
discharge O
, O
he O
is O
on O
room O
air O
, O
slightly O
ta O
##chy O
##p O
##ne O
##ic O
and O
ta O
##chy O
##card O
##ic O
but O
has O
been O
stable O
. O
# O
ta O
##chy O
##card O
##ia O
/ O
h O
##y O
##pot O
##ens O
##ion O
: O
related O
to O
above O
. O
heart O
rates O
have O
been O
in O
80 O
- O
110 O
' O
s O
. O
s O
##b O
##p O
< O
80s O
in O
the O
i O
##cu O
requiring O
press O
##ors O
. O
likely O
due O
to O
known O
pulmonary O
em O
##bol O
##i O
with O
infection O
. O
patient O
does O
not O
currently O
have O
s O
##x O
of O
infection O
, O
so O
se O
##psis O
is O
less O
likely O
cause O
. O
it O
may O
be O
from O
pain O
, O
since O
patient O
is O
relatively O
unable O
to O
communicate O
. O

# O
s B-REA
##chi I-REA
##zophrenia I-REA
- I-REA
difficult O
to O
evaluate O
mental O
status O
. O
no O
evidence O
of O
responding O
to O
internal O
stimuli O
. O
base O
##line O
over O
past O
few O
months O
[ O
* O
* O
first O
name O
##8 O
( O
name O
##pa O
##tter O
##n O
##2 O
) O
* O
* O
] O
[ O
* O
* O
first O
name O
##4 O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
350 O
##4 O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
* O
* O
] O
is O
that O
he O
is O
able O
to O
communicate O
pain O
/ O
discomfort O
but O
does O
not O
have O
capacity O
. O
he O
is O
mostly O
l O
##uc O
##id O
but O
answers O
questions O
in O
mum O
##bles O
and O
broken O
statements O
. O
patient O
had O
court O
date O
for O
guardian O
##ship O
on O
[ O
* O
* O
218 O
##5 O
- O
7 O
- O
19 O
* O
* O
] O
which O
was O
approved O
. O
he O
sometime O
says O
inappropriate O
comments O
but O
not O
frequently O
. O
patient O
was O
am O
##bula O
##tory O
in O
[ O
* O
* O
month O
( O
only O
) O
205 O
* O
* O
] O
with O
assistance O
per O
previous O
[ O
* O
* O
hospital O
##1 O
150 O
##1 O
* O
* O
] O
. O
we O
continued O
his O
de B-DRUG
##pa I-DRUG
##kot I-DRUG
##e I-DRUG
, I-DRUG
r B-DRUG
##is I-DRUG
##per I-DRUG
##dal I-DRUG
, I-DRUG
and O
re B-DRUG
##mer I-DRUG
##on I-DRUG
. I-DRUG
# O
pneumonia B-REA
, I-REA
m I-REA
##rsa I-REA
: I-REA
treated O
with O
8 B-DUR
day I-DUR
course O
of O
van B-DRUG
##c I-DRUG
/ I-DRUG
z B-DRUG
##osy I-DRUG
##n I-DRUG
for O
bilateral O
patch O
##y O
in O
##fi O
##lt O
##rate O
and O
found O
to O
be O
m O
##rsa O
positive O
on O
br O
##on O
##chia O
##l O
washing O
##s O
. O
patient O
was O
h O
##y O
##pot O
##ens O
##ive O
and O
h O
##y O
##pox O
##ic O
requiring O
in O
##tub O
##ation O
and O
press O
##ors O
for O
10 O
days O
in O
mi O
##cu O
. O
ex O
##tub O
##ated O
[ O
* O
* O
218 O
##5 O
- O
7 O
- O
6 O
* O
* O
] O
. O
[ O
* O
* O
218 O
##5 O
- O
7 O
- O
6 O
* O
* O
] O
c O
##x O
##r O
: O
persistent O
op O
##ac O
##ification O
at O
the O
left O
base O
with O
progressive O
clearing O
of O
right O
base O
without O
vascular O
congestion O
. O
later O
c O
##x O
##r O
cleared O
, O
he O
has O
finished O
treatment O
. O
# O
h B-REA
##y I-REA
##pot I-REA
##hy I-REA
##roid I-REA
##ism I-REA
: I-REA
le B-DRUG
##vo I-DRUG
##thy I-DRUG
##ro I-DRUG
##xin I-DRUG
##e I-DRUG
started O
this O
admission O
for O
t O
##sh O
8 O
. O
6 O
in O
setting O
of O
acute O
se O
##ptic O
shock O
. O
t O
##sh O
7 O
. O
8 O
on O
[ O
* O
* O
218 O
##5 O
- O
7 O
- O
9 O
* O
* O
] O
. O
he O
should O
continue O
le B-DRUG
##vo I-DRUG
##thy I-DRUG
##ro I-DRUG
##xin I-DRUG
##e I-DRUG
25 B-STR
##m I-STR
##c I-STR
##g I-STR
p B-ROU
##o I-ROU
daily B-FRE
. I-FRE
he O
will O
need O
out O
##patient O
follow O
up O
of O
t O
##sh O
in O
1 O
month O
[ O
* O
* O
218 O
##5 O
- O
8 O
- O
8 O
* O
* O
] O
# O
f O
##en O
: O
i O
##v O
##f O
p O
##rn O
, O
re O
##ple O
##te O
electro O
##ly O
##tes O
p O
##rn O
, O
ground O
solid O
##s O
, O
if O
ever O
needs O
tube O
feeds O
, O
needs O
post O
- O
p O
##yl O
##ori O
##c O
b O
/ O
c O
hi O
##ata O
##l O
her O
##nia O

transitional O
issues O
- O
continued O
on O
le B-DRUG
##vo I-DRUG
##f I-DRUG
##lo I-DRUG
##xa I-DRUG
##cin I-DRUG
until O
[ O
* O
* O
7 O
- O
24 O
* O
* O
] O
- O
guardian O
##ship O
obtained O
during O
admission O
. O
- O
will O
need O
out O
##patient O
ps O
##ych O
follow O
- O
up O
- O
he O
will O
need O
close O
management O
of O
co B-DRUG
##uma I-DRUG
##din I-DRUG
with O
goal O
in O
##r O
[ O
* O
* O
12 O
- O
24 O
* O
* O
] O
indefinitely O
. O
he O
should O
have O
a O
bridge O
with O
love B-DRUG
##no I-DRUG
##x I-DRUG
60 B-STR
##m I-STR
##g I-STR
q B-FRE
##12 I-FRE
if O
ever O
in B-REA
##r I-REA
< I-REA
2 I-REA
. I-REA
discharge O
co B-DRUG
##uma I-DRUG
##din I-DRUG
dose O
is O
3 B-STR
##m I-STR
##g I-STR
. I-STR
- O
please O
check O
t O
##sh O
and O
free O
t O
##4 O
on O
[ O
* O
* O
218 O
##5 O
- O
8 O
- O
8 O
* O
* O
] O
. O
patient O
started O
on O
le B-DRUG
##vo I-DRUG
##thy I-DRUG
##ro I-DRUG
##xin I-DRUG
##e I-DRUG
[ O
* O
* O
218 O
##5 O
- O
7 O
- O
3 O
* O
* O
] O
for B-REA
low I-REA
t I-REA
##ri I-REA
##io I-REA
##do I-REA
##thy I-REA
##ron I-REA
##ine I-REA
thy I-REA
##ro I-REA
##xin I-REA
##e I-REA
( I-REA
t I-REA
##4 I-REA
) I-REA
, I-REA
free O
0 O
. O
78 O
* O
and O
t O
##sh O
8 O
. O
5 O
. O
medications O
on O
admission O
: O
pre O
##ad O
##mission O
medications O
listed O
are O
correct O
and O
complete O
. O
information O
was O
obtained O
from O
patient O
. O
1 O
. O
di B-DRUG
##val I-DRUG
##p I-DRUG
##ro I-DRUG
##ex I-DRUG
( O
delayed O
release O
) O
250 B-STR
mg I-STR
p B-ROU
##o I-ROU
q B-FRE
##am I-FRE
2 O
. O
di B-DRUG
##val I-DRUG
##p I-DRUG
##ro I-DRUG
##ex I-DRUG
( O
delayed O
release O
) O
375 B-STR
mg I-STR
p B-ROU
##o I-ROU
q B-FRE
##hs I-FRE
3 O
. O
ran B-DRUG
##iti I-DRUG
##dine I-DRUG
( O
liquid B-FOR
) I-FOR
150 B-STR
mg I-STR
p B-ROU
##o I-ROU
daily B-FRE
4 O
. O
ace B-DRUG
##tam I-DRUG
##ino I-DRUG
##phe I-DRUG
##n I-DRUG
650 B-STR
mg I-STR
p B-ROU
##o I-ROU
bid B-FRE
5 O
. O
milk B-DRUG
of I-DRUG
ma I-DRUG
##gne I-DRUG
##sia I-DRUG
30 B-DOS
m B-FOR
##l I-FOR
p B-ROU
##o I-ROU
once B-FRE
: I-FRE
p I-FRE
##rn I-FRE
con B-REA
##st I-REA
##ip I-REA
##ation I-REA
6 O
. O
bi B-DRUG
##sa I-DRUG
##co I-DRUG
##dy I-DRUG
##l I-DRUG
10 B-STR
mg I-STR
p B-ROU
##o I-ROU
daily B-FRE
: I-FRE
p I-FRE
##rn I-FRE
con B-REA
##st I-REA
##ip I-REA
##ation I-REA
7 O
. O
lo B-DRUG
##per I-DRUG
##ami I-DRUG
##de I-DRUG
2 B-STR
mg I-STR
p B-ROU
##o I-ROU
t B-FRE
##id I-FRE
: I-FRE
p I-FRE
##rn I-FRE
loose B-REA
stool I-REA
##s I-REA
8 O
. O
lo B-DRUG
##raze I-DRUG
##pa I-DRUG
##m I-DRUG
0 B-STR
. I-STR
5 I-STR
mg I-STR
p B-ROU
##o I-ROU
q B-FRE
##4 I-FRE
##h I-FRE
: I-FRE
p I-FRE
##rn I-FRE
anxiety B-REA
9 O
. O
duo B-DRUG
##ne I-DRUG
##b I-DRUG
* O
n O
##f O
* O
( O
i B-DRUG
##pra I-DRUG
##tro I-DRUG
##pi I-DRUG
##um I-DRUG
- I-DRUG
al I-DRUG
##but I-DRUG
##ero I-DRUG
##l I-DRUG
) I-DRUG
0 B-STR
. I-STR
5 I-STR
mg I-STR
- I-STR
3 I-STR
mg I-STR
( I-STR
2 I-STR
. I-STR
5 I-STR
mg I-STR
base I-STR
) I-STR
/ I-STR
3 I-STR
m I-STR
##l I-STR
in B-ROU
##hala I-ROU
##tion I-ROU
q B-FRE
##6 I-FRE
hours I-FRE
w B-REA
##hee I-REA
##zing I-REA
10 O
. O
me B-DRUG
##ges I-DRUG
##tro I-DRUG
##l I-DRUG
ace I-DRUG
##tate I-DRUG
10 B-STR
mg I-STR
p B-ROU
##o I-ROU
bid B-FRE
11 O
. O
r B-DRUG
##is I-DRUG
##per I-DRUG
##ido I-DRUG
##ne I-DRUG
7 B-STR
mg I-STR
p B-ROU
##o I-ROU
h B-FRE
##s I-FRE
12 O
. O
mi B-DRUG
##rta I-DRUG
##za I-DRUG
##pine I-DRUG
30 B-STR
mg I-STR
p B-ROU
##o I-ROU
h B-FRE
##s I-FRE
13 O
. O
h B-DRUG
##ydro I-DRUG
##co I-DRUG
##don I-DRUG
##e I-DRUG
- I-DRUG
ace I-DRUG
##tam I-DRUG
##ino I-DRUG
##phe I-DRUG
##n I-DRUG
( O
5 B-STR
##m I-STR
##g I-STR
- I-STR
500 I-STR
##m I-STR
##g I-STR
1 B-DOS
ta B-FOR
##b I-FOR
p B-ROU
##o I-ROU
q B-FRE
##6 I-FRE
##h I-FRE
: I-FRE
p I-FRE
##rn I-FRE
pain B-REA
monitor O
for O
se O
##dation O
, O
r O
##r O
< O
8 O
14 O
. O
multi B-DRUG
##vi I-DRUG
##tam I-DRUG
##ins I-DRUG
1 B-DOS
ta B-FOR
##b I-FOR
p B-ROU
##o I-ROU
daily B-FRE

discharge O
medications O
: O
1 O
. O
di B-DRUG
##val I-DRUG
##p I-DRUG
##ro I-DRUG
##ex I-DRUG
( O
delayed O
release O
) O
250 B-STR
mg I-STR
p B-ROU
##o I-ROU
q B-FRE
##am I-FRE
2 O
. O
di B-DRUG
##val I-DRUG
##p I-DRUG
##ro I-DRUG
##ex I-DRUG
( O
delayed O
release O
) O
375 B-STR
mg I-STR
p B-ROU
##o I-ROU
q B-FRE
##hs I-FRE
3 O
. O
r B-DRUG
##is I-DRUG
##per I-DRUG
##ido I-DRUG
##ne I-DRUG
7 B-STR
mg I-STR
p B-ROU
##o I-ROU
h B-FRE
##s I-FRE
4 O
. O
ace B-DRUG
##tam I-DRUG
##ino I-DRUG
##phe I-DRUG
##n I-DRUG
650 B-STR
mg I-STR
p B-ROU
##o I-ROU
bid B-FRE
5 O
. O
bi B-DRUG
##sa I-DRUG
##co I-DRUG
##dy I-DRUG
##l I-DRUG
10 B-STR
mg I-STR
p B-ROU
##o I-ROU
daily B-FRE
: I-FRE
p I-FRE
##rn I-FRE
con B-REA
##st I-REA
##ip I-REA
##ation I-REA
6 O
. O
multi B-DRUG
##vi I-DRUG
##tam I-DRUG
##ins I-DRUG
1 B-DOS
ta B-FOR
##b I-FOR
p B-ROU
##o I-ROU
daily B-FRE
7 O
. O
me B-DRUG
##ges I-DRUG
##tro I-DRUG
##l I-DRUG
ace I-DRUG
##tate I-DRUG
10 B-STR
mg I-STR
p B-ROU
##o I-ROU
bid B-FRE
8 O
. O
milk B-DRUG
of I-DRUG
ma I-DRUG
##gne I-DRUG
##sia I-DRUG
30 B-DOS
m I-DOS
##l I-DOS
p B-ROU
##o I-ROU
once B-FRE
: I-FRE
p I-FRE
##rn I-FRE
con B-REA
##st I-REA
##ip I-REA
##ation I-REA
9 O
. O
mi B-DRUG
##rta I-DRUG
##za I-DRUG
##pine I-DRUG
30 B-STR
mg I-STR
p B-ROU
##o I-ROU
h B-FRE
##s I-FRE
10 O
. O
ran B-DRUG
##iti I-DRUG
##dine I-DRUG
( O
liquid B-FOR
) I-FOR
150 B-STR
mg I-STR
p B-ROU
##o I-ROU
daily B-FRE
11 O
. O
lo B-DRUG
##per I-DRUG
##ami I-DRUG
##de I-DRUG
2 B-STR
mg I-STR
p B-ROU
##o I-ROU
t B-FRE
##id I-FRE
: I-FRE
p I-FRE
##rn I-FRE
loose B-REA
stool I-REA
##s I-REA
12 O
. O
lo B-DRUG
##raze I-DRUG
##pa I-DRUG
##m I-DRUG
0 B-STR
. I-STR
5 I-STR
mg I-STR
p B-ROU
##o I-ROU
q B-FRE
##4 I-FRE
##h I-FRE
: I-FRE
p I-FRE
##rn I-FRE
anxiety B-REA
13 O
. O
h B-DRUG
##ydro I-DRUG
##co I-DRUG
##don I-DRUG
##e I-DRUG
- I-DRUG
ace I-DRUG
##tam I-DRUG
##ino I-DRUG
##phe I-DRUG
##n I-DRUG
( O
5 B-STR
##m I-STR
##g I-STR
- I-STR
500 I-STR
##m I-STR
##g I-STR
1 B-DOS
ta B-FOR
##b I-FOR
p B-ROU
##o I-ROU
q B-FRE
##6 I-FRE
##h I-FRE
: I-FRE
p I-FRE
##rn I-FRE
pain B-REA
monitor O
for O
se O
##dation O
, O
r O
##r O
< O
8 O
14 O
. O
duo B-DRUG
##ne I-DRUG
##b I-DRUG
* O
n O
##f O
* O
( O
i B-DRUG
##pra I-DRUG
##tro I-DRUG
##pi I-DRUG
##um I-DRUG
- I-DRUG
al I-DRUG
##but I-DRUG
##ero I-DRUG
##l I-DRUG
) I-DRUG
0 B-STR
. I-STR
5 I-STR
mg I-STR
- I-STR
3 I-STR
mg I-STR
( I-STR
2 I-STR
. I-STR
5 I-STR
mg I-STR
base I-STR
) I-STR
/ I-STR
3 I-STR
m I-STR
##l I-STR
in B-ROU
##hala I-ROU
##tion I-ROU
q B-FRE
##6 I-FRE
hours I-FRE
w B-REA
##hee I-REA
##zing I-REA
15 O
. O
le B-DRUG
##vo I-DRUG
##thy I-DRUG
##ro I-DRUG
##xin I-DRUG
##e I-DRUG
sodium I-DRUG
25 B-STR
m I-STR
##c I-STR
##g I-STR
p B-ROU
##o I-ROU
daily B-FRE
avoid O
taking O
around O
time O
of O
ma B-DRUG
##alo I-DRUG
##x I-DRUG
, I-DRUG
t B-DRUG
##ums I-DRUG
, I-DRUG
si B-DRUG
##met I-DRUG
##hic I-DRUG
##one I-DRUG
r O
##x O
* O
le B-DRUG
##vo I-DRUG
##thy I-DRUG
##ro I-DRUG
##xin I-DRUG
##e I-DRUG
25 B-STR
m I-STR
##c I-STR
##g I-STR
1 B-DOS
tablet B-FOR
( I-FOR
s I-FOR
) I-FOR
by B-ROU
mouth I-ROU
daily B-FRE
di O
##sp O
# O
* O
30 O
tablet B-FOR
re O
##fill O
##s O
: O
* O
3 O
16 O
. O
le B-DRUG
##vo I-DRUG
##f I-DRUG
##lo I-DRUG
##xa I-DRUG
##cin I-DRUG
500 B-STR
mg I-STR
p B-ROU
##o I-ROU
q B-FRE
##24 I-FRE
##h I-FRE
duration O
: O
4 B-DUR
days I-DUR
please O
give O
until O
[ O
* O
* O
7 O
- O
24 O
* O
* O
] O
for O
a O
total O
of O
14 B-DUR
days I-DUR
r O
##x O
* O
le B-DRUG
##vo I-DRUG
##f I-DRUG
##lo I-DRUG
##xa I-DRUG
##cin I-DRUG
500 B-STR
mg I-STR
1 B-DOS
tablet B-FOR
( I-FOR
s O
) O
by B-ROU
mouth I-ROU
daily B-FRE
di O
##sp O
# O
* O
4 O
tablet B-FOR
re O
##fill O
##s O
: O
* O
0 O
17 O
. O
war B-DRUG
##fari I-DRUG
##n I-DRUG
3 B-STR
mg I-STR
p B-ROU
##o I-ROU
daily B-FRE
##16 I-FRE
goal O
in O
##r O
[ O
* O
* O
12 O
- O
24 O
* O
* O
] O
( O
bridge O
with O
love B-DRUG
##no I-DRUG
##x I-DRUG
if O
in O
##r O
< O
2 O
) O
r O
##x O
* O
war B-DRUG
##fari I-DRUG
##n I-DRUG
3 B-STR
mg I-STR
1 B-DOS
tablet B-FOR
( I-FOR
s I-FOR
) I-FOR
by B-ROU
mouth I-ROU
daily B-FRE
di O
##sp O
# O
* O
30 B-DOS
tablet B-FOR
re O
##fill O
##s O
: O
* O
3 O
discharge O
disposition O
: O
extended O
care O

facility O
: O
[ O
* O
* O
first O
name O
##4 O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
350 O
##4 O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
* O
* O
] O
rehabilitation O
& O
nursing O
center O
- O
[ O
* O
* O
location O
( O
un O
) O
53 O
##8 O
* O
* O
] O
discharge O
diagnosis O
: O
pneumonia O
, O
pulmonary O
em O
##bol O
##ism O
discharge O
condition O
: O
activity O
status O
: O
out O
of O
bed O
with O
assistance O
to O
chair O
or O
wheelchair O
. O
level O
of O
consciousness O
: O
alert O
and O
interactive O
. O
mental O
status O
: O
confused O
- O
always O
. O
discharge O
instructions O
: O
m O
##r O
. O
[ O
* O
* O
known O
last O
##name O
71 O
##0 O
##6 O
##3 O
* O
* O
] O
, O
you O
were O
admitted O
to O
the O
[ O
* O
* O
hospital O
##1 O
82 O
##7 O
* O
* O
] O
on O
[ O
* O
* O
218 O
##5 O
- O
6 O
- O
24 O
* O
* O
] O
for O
short B-REA
##ness I-REA
of I-REA
breath I-REA
at O
your O
nursing O
facility O
. O
you O
were O
found O
to O
have O
pneumonia O
with O
m O
##rsa O
in O
your O
lungs O
in O
addition O
to O
multiple O
blood O
c O
##lot O
##s O
in O
your O
lungs O
. O
this O
required O
you O
to O
be O
in O
the O
intensive O
care O
unit O
on O
a O
vent O
##ila O
##tor O
for O
over O
1 O
week O
and O
requiring O
medicine O
to O
keep O
your O
blood O
pressure O
normal O
. O
after O
you O
had O
several O
days O
of O
anti B-DRUG
##biotics I-DRUG
for O
your O
pneumonia B-REA
, I-REA
you O
were O
taken O
off O
the O
vent O
##ila O
##tor O
. O
due O
to O
your O
lung B-REA
c I-REA
##lot I-REA
##s I-REA
, I-REA
you O
will O
need O
to O
be O
on O
co B-DRUG
##uma I-DRUG
##din I-DRUG
( O
a O
blood O
thinner O
) O
indefinitely O
. O
we O
have O
continued O
to O
change O
your O
dose O
depending O
on O
your O
in O
##r O
( O
which O
needs O
to O
be O
between O
[ O
* O
* O
12 O
- O
24 O
* O
* O
] O
to O
help O
prevent O
blood B-REA
c I-REA
##lot I-REA
##s I-REA
) I-REA
. I-REA
you O
will O
be O
returning O
to O
your O
nursing O
home O
. O
please O
follow O
up O
with O
your O
primary O
care O
physician O
. O
follow O
##up O
instructions O
: O
please O
follow O
up O
with O
your O
primary O
care O
physician O
at O
[ O
* O
* O
name O
##9 O
( O
pre O
) O
* O
* O
] O
where O
you O
stay O
. O

name O
: O
[ O
* O
* O
known O
last O
##name O
32 O
##9 O
##7 O
* O
* O
] O
, O
[ O
* O
* O
known O
first O
##name O
* O
* O
] O
unit O
no O
: O
[ O
* O
* O
n O
##ume O
##ric O
id O
##ent O
##ifier O
32 O
##9 O
##8 O
* O
* O
] O
admission O
date O
: O
[ O
* O
* O
214 O
##4 O
- O
1 O
- O
16 O
* O
* O
] O
discharge O
date O
: O
[ O
* O
* O
214 O
##4 O
- O
3 O
- O
3 O
* O
* O
] O
date O
of O
birth O
: O
[ O
* O
* O
208 O
##1 O
- O
1 O
- O
11 O
* O
* O
] O
sex O
: O
m O
service O
: O
medicine O
all O
##er O
##gies O
: O
c B-DRUG
##ef I-DRUG
##ep I-DRUG
##ime I-DRUG
attending O
: O
[ O
* O
* O
first O
name O
##3 O
( O
l O
##f O
) O
33 O
##28 O
* O
* O
] O
add O
##end O
##um O
: O
please O
see O
discharge O
me O
##ds O
below O
. O

discharge O
medications O
: O
1 O
. O
f B-DRUG
##olic I-DRUG
acid I-DRUG
1 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( I-FRE
daily I-FRE
) I-FRE
. I-FRE
di O
##sp O
: O
* O
30 O
tablet O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
2 O
* O
2 O
. O
do B-DRUG
##cus I-DRUG
##ate I-DRUG
sodium I-DRUG
100 B-STR
mg I-STR
capsule B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
capsule B-FOR
p B-ROU
##o I-ROU
bid B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE
di O
##sp O
: O
* O
60 O
capsule O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
2 O
* O
3 O
. O
bi B-DRUG
##sa I-DRUG
##co I-DRUG
##dy I-DRUG
##l I-DRUG
5 B-STR
mg I-STR
tablet B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
si O
##g O
: O
two B-DOS
( I-DOS
2 I-DOS
) I-DOS
tablet B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
p B-ROU
##o I-ROU
daily B-FRE
( I-FRE
daily I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE
di O
##sp O
: O
* O
30 O
tablet O
, O
delayed O
release O
( O
e O
. O
c O
. O
) O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
0 O
* O
4 O
. O
pan B-DRUG
##top I-DRUG
##raz I-DRUG
##ole I-DRUG
40 B-STR
mg I-STR
tablet B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
p B-ROU
##o I-ROU
q B-FRE
##12 I-FRE
##h I-FRE
( I-FRE
every I-FRE
12 I-FRE
hours I-FRE
) I-FRE
. I-FRE
di O
##sp O
: O
* O
60 O
tablet O
, O
delayed O
release O
( O
e O
. O
c O
. O
) O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
2 O
* O
5 O
. O
met B-DRUG
##oc I-DRUG
##lop I-DRUG
##ram I-DRUG
##ide I-DRUG
10 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
two B-DOS
( I-DOS
2 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
q B-FRE
##ida I-FRE
##chs I-FRE
( I-FRE
4 I-FRE
times I-FRE
a I-FRE
day I-FRE
( I-FRE
before I-FRE
meals I-FRE
and I-FRE
at I-FRE
bed I-FRE
##time I-FRE
) I-FRE
) I-FRE
. I-FRE
di O
##sp O
: O
* O
240 O
tablet O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
2 O
* O
6 O
. O
lo B-DRUG
##raze I-DRUG
##pa I-DRUG
##m I-DRUG
0 B-STR
. I-STR
5 I-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
1 B-DOS
- I-DOS
2 I-DOS
tablets B-FOR
p B-ROU
##o I-ROU
three B-FRE
times I-FRE
a I-FRE
day I-FRE
as I-FRE
needed I-FRE
for O
nausea B-REA
or O
anxiety B-REA
. I-REA
di O
##sp O
: O
* O
60 O
tablet O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
0 O
* O
7 O
. O
los B-DRUG
##art I-DRUG
##an I-DRUG
25 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE
di O
##sp O
: O
* O
30 O
tablet O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
2 O
* O
8 O
. O
dem B-DRUG
##ec I-DRUG
##loc I-DRUG
##y I-DRUG
##cline I-DRUG
150 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
two B-DOS
( I-DOS
2 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
bid B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE
di O
##sp O
: O
* O
120 O
tablet O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
2 O
* O
9 O
. O
out O
##patient O
lab O
work O
blood O
draw O
: O
panel O
7 O
, O
c O
##b O
##c O
, O
l O
##ft O
' O
s O
including O
total O
bi O
##li O
##ru O
##bin O
. O
to O
be O
drawn O
within O
1 O
week O
of O
discharge O
. O
10 O
. O
al B-DRUG
##but I-DRUG
##ero I-DRUG
##l I-DRUG
su I-DRUG
##lf I-DRUG
##ate I-DRUG
0 B-STR
. I-STR
08 I-STR
##3 I-STR
% I-STR
solution B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
in B-ROU
##hala I-ROU
##tion I-ROU
q B-FRE
##6 I-FRE
##h I-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE

11 O
. O
a B-DRUG
##cy I-DRUG
##c I-DRUG
##lov I-DRUG
##ir I-DRUG
200 B-STR
mg I-STR
capsule B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
capsule B-FOR
p B-ROU
##o I-ROU
q B-FRE
##8 I-FRE
##h I-FRE
( I-FRE
every I-FRE
8 I-FRE
hours I-FRE
) I-FRE
. I-FRE
12 O
. O
g B-DRUG
##ua I-DRUG
##ife I-DRUG
##nes I-DRUG
##in I-DRUG
100 B-STR
mg I-STR
/ I-STR
5 I-STR
m I-STR
##l I-STR
syrup B-FOR
si O
##g O
: O
5 B-DOS
- I-DOS
10 I-DOS
m I-DOS
##ls I-DOS
p B-ROU
##o I-ROU
q B-FRE
##6 I-FRE
##h I-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE
13 O
. O
met B-DRUG
##op I-DRUG
##rol I-DRUG
##ol I-DRUG
ta I-DRUG
##rt I-DRUG
##rate I-DRUG
25 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
t B-FRE
##id I-FRE
( I-FRE
3 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE
14 O
. O
n B-DRUG
##ys I-DRUG
##tat I-DRUG
##in I-DRUG
100 B-STR
, I-STR
000 I-STR
unit I-STR
/ I-STR
m I-STR
##l I-STR
suspension B-FOR
si O
##g O
: O
five B-DOS
( I-DOS
5 I-DOS
) I-DOS
m I-DOS
##l I-DOS
p B-ROU
##o I-ROU
q B-FRE
##id I-FRE
( I-FRE
4 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE
15 O
. O
pre B-DRUG
##dn I-DRUG
##ison I-DRUG
##e I-DRUG
10 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( I-FRE
daily I-FRE
) I-FRE
for B-DUR
3 I-DUR
days I-DUR
. I-DUR
16 O
. O
insulin B-DRUG
sliding B-DOS
scale I-DOS
n B-DRUG
##ph I-DRUG
insulin I-DRUG
: I-DRUG
25 B-DOS
##u I-DOS
q B-FRE
##am I-FRE
, I-FRE
18 B-DOS
##u I-DOS
q B-FRE
##pm I-FRE
. O
four O
times O
daily O
fingers O
##tick O
##s O
with O
hum B-DRUG
##alog I-DRUG
dos O
##ing O
per O
insulin B-DRUG
sliding B-DOS
scale I-DOS
. I-DOS
17 O
. O
se B-DRUG
##nna I-DRUG
8 B-STR
. I-STR
6 I-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
bid B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
con B-REA
##st I-REA
##ip I-REA
##ation I-REA
. I-REA
18 O
. O
ace B-DRUG
##tam I-DRUG
##ino I-DRUG
##phe I-DRUG
##n I-DRUG
325 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
1 B-DOS
- I-DOS
2 I-DOS
tablets B-FOR
p B-ROU
##o I-ROU
q B-FRE
##4 I-FRE
- I-FRE
6 I-FRE
##h I-FRE
( I-FRE
every I-FRE
4 I-FRE
to I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
neck B-REA
/ I-REA
back I-REA
pain I-REA
. I-REA
19 O
. O
f B-DRUG
##olic I-DRUG
acid I-DRUG
1 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( I-FRE
daily I-FRE
) I-FRE
. I-FRE
20 O
. O
fur B-DRUG
##ose I-DRUG
##mi I-DRUG
##de I-DRUG
20 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
two B-DOS
( I-DOS
2 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE
discharge O
disposition O
: O
extended O
care O
facility O
: O
[ O
* O
* O
hospital O
##3 O
14 O
* O
* O
] O
& O
re O
##hab O
center O
- O
[ O
* O
* O
hospital O
##1 O
15 O
* O
* O
] O
[ O
* O
* O
first O
name O
##11 O
( O
name O
pattern O
##1 O
) O
77 O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##4 O
) O
99 O
##4 O
* O
* O
] O
m O
##d O
[ O
* O
* O
m O
##d O
number O
( O
1 O
) O
100 O
##1 O
* O
* O
] O
completed O
by O
: O
[ O
* O
* O
214 O
##4 O
- O
3 O
- O
14 O
* O
* O
] O

admission O
date O
: O
[ O
* O
* O
215 O
##2 O
- O
6 O
- O
19 O
* O
* O
] O
discharge O
date O
: O
[ O
* O
* O
215 O
##2 O
- O
6 O
- O
22 O
* O
* O
] O
date O
of O
birth O
: O
[ O
* O
* O
209 O
##2 O
- O
4 O
- O
12 O
* O
* O
] O
sex O
: O
f O
service O
: O
medicine O
all O
##er O
##gies O
: O
com B-DRUG
##pa I-DRUG
##zine I-DRUG
/ O
drop B-DRUG
##eri I-DRUG
##do I-DRUG
##l I-DRUG
/ O
su B-DRUG
##lf I-DRUG
##ona I-DRUG
##mi I-DRUG
##des I-DRUG
/ O
g B-DRUG
##ado I-DRUG
##lini I-DRUG
##um I-DRUG
- I-DRUG
containing O
agents O
/ O
dem B-DRUG
##ero I-DRUG
##l I-DRUG
/ O
m B-DRUG
##or I-DRUG
##phine I-DRUG
attending O
: O
[ O
* O
* O
first O
name O
##3 O
( O
l O
##f O
) O
350 O
##7 O
* O
* O
] O
chief O
complaint O
: O
respiratory O
distress O
and O
chest O
pain O
major O
surgical O
or O
invasive O
procedure O
: O
none O
history O
of O
present O
illness O
: O
briefly O
, O
this O
is O
a O
50 O
year O
old O
female O
with O
mast O
cell O
de O
##gra O
##nu O
##lation O
syndrome O
who O
presented O
last O
pm O
with O
a O
re O
##current O
episode O
of O
respiratory O
distress O
, O
chest O
pain O
and O
a O
##b O
##d O
pain O
consistent O
with O
her O
syndrome O
, O
who O
has O
required O
3 B-DOS
doses O
of O
0 B-STR
. I-STR
3 I-STR
##m I-STR
##g I-STR
e B-DRUG
##pine I-DRUG
##ph I-DRUG
##rine I-DRUG
sq B-ROU
since O
admission O
and O
is O
being O
transferred O
to O
the O
i O
##cu O
for O
closer O
monitoring O
. O
in O
the O
ed O
she O
was O
given O
e B-DRUG
##pi I-DRUG
im B-ROU
, I-ROU
met B-DRUG
##hyl I-DRUG
##p I-DRUG
##red I-DRUG
##nis I-DRUG
##olo I-DRUG
##ne I-DRUG
125 B-STR
##m I-STR
##g I-STR
x O
1 B-DOS
, I-DOS
p B-DRUG
##ep I-DRUG
##cid I-DRUG
, I-DRUG
ben B-DRUG
##ad I-DRUG
##ryl I-DRUG
50 B-STR
x O
##2 B-DOS
, I-DOS
di B-DRUG
##lau I-DRUG
##di I-DRUG
##d I-DRUG
2 B-STR
x O
##3 B-DOS
, I-DOS
at B-DRUG
##ara I-DRUG
##x I-DRUG
25 B-STR
, I-STR
z B-DRUG
##of I-DRUG
##ran I-DRUG
4 B-STR
and O
at B-DRUG
##iva I-DRUG
##n I-DRUG
. I-DRUG
tonight O
at O
5 O
##pm O
, O
the O
p O
##t O
was O
found O
to O
be O
c O
/ O
o O
sob O
with O
labor B-REA
##ed I-REA
breathing I-REA
but O
able O
to O
speak O
, O
received O
al B-DRUG
##but I-DRUG
##ero I-DRUG
##l I-DRUG
ne B-ROU
##b I-ROU
without O
improvement O
. O
vs O
136 O
/ O
77 O
, O
h O
##r O
99 O
, O
sat O
97 O
% O
on O
r O
##a O
. O
she O
was O
given O
i B-ROU
##v I-ROU
ben B-DRUG
##ad I-DRUG
##ryl I-DRUG
, I-DRUG
0 B-STR
. I-STR
3 I-STR
##m I-STR
##g I-STR
sq B-ROU
e B-DRUG
##pi I-DRUG
with O
improvement O
, O
transferred O
to O
the O
i O
##cu O
for O
further O
monitoring O
. O

past O
medical O
history O
: O
- O
mast O
cell O
activation O
syndrome O
: O
followed O
by O
[ O
* O
* O
first O
name O
##8 O
( O
name O
##pa O
##tter O
##n O
##2 O
) O
217 O
##34 O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
* O
* O
] O
who O
is O
an O
all O
##er O
##gis O
##t O
at O
[ O
* O
* O
hospital O
##1 O
112 O
* O
* O
] O
, O
# O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
217 O
##35 O
* O
* O
] O
. O
also O
followed O
here O
by O
d O
##r O
. O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
79 O
* O
* O
] O
in O
g O
##i O
. O
has O
been O
in O
##tub O
##ated O
twice O
. O
- O
depression O
/ O
anxiety O
/ O
bi O
##pol O
##ar O
d O
/ O
o O
, O
h O
##x O
of O
si O
- O
mi B-ADE
in O
[ O
* O
* O
214 O
##7 O
* O
* O
] O
after O
receiving O
cardiac B-DOS
arrest I-DOS
dose I-DOS
e B-DRUG
##pi I-DRUG
instead O
of O
an B-DOS
##aph I-DOS
##yla I-DOS
##ctic I-DOS
dose I-DOS
e B-DRUG
##pi I-DRUG
- O
h O
##t O
##n O
- O
er O
##os O
##ive O
o O
##ste O
##oar O
##th O
##rit O
##is O
- O
g O
##erd O
, O
gas O
##tri O
##tis O
and O
es O
##op O
##ha O
##git O
##is O
on O
recent O
e O
##g O
##d O
[ O
* O
* O
215 O
##1 O
- O
1 O
- O
8 O
* O
* O
] O
- O
para O
##dox O
##ical O
vocal O
cord O
d O
##ys O
##function O
viewed O
on O
fiber O
##op O
##tic O
la O
##ryn O
##gos O
##copy O
- O
an O
##emia O
, O
iron O
studies O
c O
/ O
w O
a O
##oc O
##d O
- O
hem O
##or O
##r O
##ho O
##ids O
- O
p O
##t O
reports O
e O
##g O
##d O
demonstrated O
vegetable O
be O
##zo O
##ar O
( O
? O
[ O
* O
* O
12 O
- O
6 O
* O
* O
] O
) O
. O
- O
status O
post O
h O
##yster O
##ec O
##tom O
##y O
and O
o O
##op O
##hore O
##ct O
##omy O
- O
h O
/ O
o O
m O
##rsa O
infection O
( O
port O
##ha O
##cat O
##h O
associated O
) O
- O
port O
##aca O
##th O
placed O
[ O
* O
* O
3 O
- O
7 O
* O
* O
] O
- O
d O
/ O
c O
' O
d O
[ O
* O
* O
2 O
- O
4 O
* O
* O
] O
m O
##rsa O
infection O
- O
port O
##aca O
##th O
placed O
[ O
* O
* O
215 O
##1 O
- O
6 O
- O
9 O
* O
* O
] O
social O
history O
: O
p O
##t O
is O
divorced O
. O
lives O
alone O
. O
she O
works O
as O
an O
er O
tech O
in O
[ O
* O
* O
hospital O
##3 O
* O
* O
] O
. O
no O
tobacco O
or O
et O
##oh O
or O
ill O
##icit O
drugs O
. O
son O
is O
h O
##c O
##p O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
217 O
##38 O
* O
* O
] O
family O
history O
: O
mother O
died O
of O
mi O
@ O
76 O
, O
sister O
w O
/ O
breast O
cancer O
and O
bilateral O
mast O
##ec O
##tom O
##y O
. O

physical O
exam O
: O
vital O
##s O
: O
t O
97 O
. O
6 O
, O
b O
##p O
124 O
/ O
64 O
, O
h O
##r O
81 O
, O
r O
##r O
26 O
, O
sat O
97 O
% O
on O
n O
##rb O
, O
f O
##s O
145 O
( O
on O
admit O
to O
i O
##cu O
) O
g O
##en O
: O
middle O
- O
aged O
woman O
, O
slightly O
cu O
##shing O
##oid O
in O
appearance O
, O
awake O
, O
alert O
, O
no O
distress O
re O
##sp O
or O
otherwise O
he O
##ent O
: O
n O
##cat O
, O
e O
##omi O
, O
no O
r O
##ash O
neck O
: O
su O
##pp O
##le O
, O
no O
tent O
##ing O
, O
no O
access O
##ory O
muscle O
use O
c O
##v O
: O
r O
##rr O
, O
[ O
* O
* O
2 O
- O
8 O
* O
* O
] O
ho O
##los O
##ys O
##t O
murmur O
at O
apex O
without O
r O
##ads O
, O
no O
rub O
, O
no O
gal O
##lop O
pu O
##lm O
: O
shallow O
breaths O
, O
no O
r O
##ales O
, O
no O
w O
##hee O
##ze O
on O
inspiration O
after O
cough O
a O
##b O
##d O
: O
+ O
soft O
, O
mildly O
tender O
in O
the O
e O
##pi O
##gas O
##tric O
area O
, O
no O
r O
/ O
g O
ex O
##t O
: O
no O
ed O
##ema O
, O
no O
r O
##ash O
##es O
, O
skin O
warm O
and O
per O
##fused O
well O

per O
##tinent O
results O
: O
[ O
* O
* O
215 O
##2 O
- O
6 O
- O
18 O
* O
* O
] O
09 O
: O
40 O
##pm O
blood O
c O
##tro O
##p O
##nt O
- O
< O
0 O
. O
01 O
[ O
* O
* O
215 O
##2 O
- O
6 O
- O
19 O
* O
* O
] O
09 O
: O
38 O
##pm O
blood O
c O
##k O
- O
m O
##b O
- O
3 O
c O
##tro O
##p O
##nt O
- O
< O
0 O
. O
01 O
[ O
* O
* O
215 O
##2 O
- O
6 O
- O
20 O
* O
* O
] O
05 O
: O
29 O
##am O
blood O
c O
##k O
- O
m O
##b O
- O
3 O
c O
##tro O
##p O
##nt O
- O
< O
0 O
. O
01 O
[ O
* O
* O
215 O
##2 O
- O
6 O
- O
18 O
* O
* O
] O
09 O
: O
40 O
##pm O
blood O
c O
##k O
( O
c O
##p O
##k O
) O
- O
67 O
[ O
* O
* O
215 O
##2 O
- O
6 O
- O
19 O
* O
* O
] O
02 O
: O
20 O
##pm O
blood O
al O
##t O
- O
22 O
as O
##t O
- O
12 O
l O
##d O
( O
l O
##dh O
) O
- O
26 O
##6 O
* O
al O
##k O
##ph O
##os O
- O
69 O
to O
##t O
##bil O
##i O
- O
0 O
. O
2 O
[ O
* O
* O
215 O
##2 O
- O
6 O
- O
19 O
* O
* O
] O
09 O
: O
38 O
##pm O
blood O
c O
##k O
( O
c O
##p O
##k O
) O
- O
30 O
[ O
* O
* O
215 O
##2 O
- O
6 O
- O
20 O
* O
* O
] O
05 O
: O
29 O
##am O
blood O
c O
##k O
( O
c O
##p O
##k O
) O
- O
22 O
* O
[ O
* O
* O
215 O
##2 O
- O
6 O
- O
18 O
* O
* O
] O
09 O
: O
40 O
##pm O
blood O
ne O
##uts O
- O
68 O
. O
0 O
l O
##ymph O
##s O
- O
25 O
. O
0 O
mon O
##os O
- O
6 O
. O
0 O
e O
##os O
- O
1 O
. O
0 O
b O
##as O
##o O
- O
0 O
. O
1 O
[ O
* O
* O
215 O
##2 O
- O
6 O
- O
19 O
* O
* O
] O
02 O
: O
20 O
##pm O
blood O
ne O
##uts O
- O
92 O
. O
4 O
* O
l O
##ymph O
##s O
- O
3 O
. O
4 O
* O
mon O
##os O
- O
3 O
. O
8 O
e O
##os O
- O
0 O
. O
1 O
b O
##as O
##o O
- O
0 O
. O
3 O
[ O
* O
* O
215 O
##2 O
- O
6 O
- O
18 O
* O
* O
] O
09 O
: O
40 O
##pm O
blood O
w O
##b O
##c O
- O
7 O
. O
6 O
# O
r O
##b O
##c O
- O
3 O
. O
75 O
* O
h O
##g O
##b O
- O
10 O
. O
6 O
* O
h O
##ct O
- O
31 O
. O
3 O
* O
m O
##c O
##v O
- O
84 O
m O
##ch O
- O
28 O
. O
4 O
m O
##ch O
##c O
- O
33 O
. O
9 O
r O
##d O
##w O
- O
14 O
. O
6 O
p O
##lt O
c O
##t O
- O
27 O
##4 O
[ O
* O
* O
215 O
##2 O
- O
6 O
- O
22 O
* O
* O
] O
05 O
: O
03 O
##am O
blood O
w O
##b O
##c O
- O
5 O
. O
3 O
r O
##b O
##c O
- O
3 O
. O
41 O
* O
h O
##g O
##b O
- O
9 O
. O
7 O
* O
h O
##ct O
- O
28 O
. O
9 O
* O
m O
##c O
##v O
- O
85 O
m O
##ch O
- O
28 O
. O
3 O
m O
##ch O
##c O
- O
33 O
. O
4 O
r O
##d O
##w O
- O
14 O
. O
2 O
p O
##lt O
c O
##t O
- O
229 O
. O

portable O
a O
##p O
chest O
radio O
##graph O
: O
the O
lungs O
are O
clear O
. O
the O
heart O
, O
media O
##st O
##in O
##um O
, O
hi O
##la O
, O
and O
pulmonary O
vascular O
##ity O
are O
within O
normal O
limits O
. O
a O
right O
chest O
wall O
port O
- O
a O
- O
cat O
##h O
is O
seen O
with O
tip O
terminating O
in O
the O
di O
##stal O
s O
##v O
##c O
. O
no O
p O
##ne O
##um O
##oth O
##orax O
is O
identified O
. O
brief O
hospital O
course O
: O
mast O
cell O
de O
##gra O
##nu O
##lation O
syndrome O
: O
initially O
admitted O
to O
the O
floor O
but O
subsequently O
t O
##ras O
##n O
##ferred O
to O
i O
##cu O
after O
requiring O
additional O
doses O
of O
sq B-ROU
e B-DRUG
##pi I-DRUG
. I-DRUG
started O
on O
h B-DRUG
##ydro I-DRUG
##cor I-DRUG
##t I-DRUG
tape O
##r O
in O
i O
##cu O
. O
she O
did O
not O
required O
additional O
e B-DRUG
##pi I-DRUG
while O
in O
the O
i O
##cu O
. O
c O
##p O
likely O
related O
to O
flare O
. O
ruled O
out O
for O
mi O
. O
e O
##c O
##g O
unchanged O
. O
she O
was O
continued O
on O
regime O
##n O
of O
gas B-DRUG
##tro I-DRUG
##c I-DRUG
##rom I-DRUG
( O
c B-DRUG
##rom I-DRUG
##oly I-DRUG
##n I-DRUG
) I-DRUG
, O
ran B-DRUG
##iti I-DRUG
##dine I-DRUG
, I-DRUG
at B-DRUG
##ara I-DRUG
##x I-DRUG
, I-DRUG
ben B-DRUG
##ad I-DRUG
##ryl I-DRUG
, I-DRUG
f B-DRUG
##ex I-DRUG
##of I-DRUG
##ena I-DRUG
##dine I-DRUG
. I-DRUG
will O
complete O
tape O
##r O
of O
pre B-DRUG
##dn I-DRUG
##ison I-DRUG
##e I-DRUG
as O
an O
out O
##patient O
. O
. O
# O
h B-REA
##t I-REA
##n I-REA
: I-REA
continued O
di B-DRUG
##lt I-DRUG
##ia I-DRUG
##ze I-DRUG
##m I-DRUG
. I-DRUG
. O
# O
depression B-REA
/ I-REA
anxiety B-REA
/ I-REA
bi B-REA
##pol I-REA
##ar I-REA
: I-REA
continued O
out O
##pt O
c B-DRUG
##ym I-DRUG
##balt I-DRUG
##a I-DRUG
and O
add B-DRUG
##eral I-DRUG
##l I-DRUG
. I-DRUG
. O
# O
o B-REA
##ste I-REA
##oar I-REA
##th I-REA
##rit I-REA
##is I-REA
: I-REA
con O
##t O
plaque B-DRUG
##ni I-DRUG
##l I-DRUG
medications O
on O
admission O
: O
di B-DRUG
##lt I-DRUG
##ia I-DRUG
##ze I-DRUG
##m I-DRUG
c I-DRUG
##d I-DRUG
180 B-STR
##m I-STR
##g I-STR
q B-FRE
##day I-FRE
at B-DRUG
##ara I-DRUG
##x I-DRUG
25 B-STR
q B-FRE
##id I-FRE
v B-DRUG
##ive I-DRUG
##lle I-DRUG
dot O
0 B-STR
. I-STR
05 I-STR
twice B-FRE
per I-FRE
week I-FRE
ran B-DRUG
##iti I-DRUG
##dine I-DRUG
300 B-STR
##m I-STR
##g I-STR
daily B-FRE
c B-DRUG
##ym I-DRUG
##balt I-DRUG
##a I-DRUG
60 B-STR
##m I-STR
##g I-STR
q B-FRE
##day I-FRE
plaque B-DRUG
##ni I-DRUG
##l I-DRUG
200 B-STR
[ O
* O
* O
hospital O
##1 O
* O
* O
] O
add B-DRUG
##eral I-DRUG
x I-DRUG
##r I-DRUG
25 B-STR
f B-DRUG
##ex I-DRUG
##of I-DRUG
##ena I-DRUG
##dine I-DRUG
180 B-STR
[ O
* O
* O
hospital O
##1 O
* O
* O
] O
am B-DRUG
##bie I-DRUG
##n I-DRUG
10 B-STR
p B-FRE
##rn I-FRE
z B-DRUG
##of I-DRUG
##ran I-DRUG
8 B-STR
p B-FRE
##rn I-FRE
di B-DRUG
##lau I-DRUG
##di I-DRUG
##d I-DRUG
2 B-FRE
p B-FRE
##rn I-FRE
per B-DRUG
##co I-DRUG
##ce I-DRUG
##t I-DRUG
p B-FRE
##rn I-FRE
fi B-DRUG
##or I-DRUG
##ce I-DRUG
##t I-DRUG
p B-FRE
##rn I-FRE
e B-DRUG
##pi I-DRUG
pen B-FOR
p B-FRE
##rn I-FRE

discharge O
medications O
: O
1 O
. O
di B-DRUG
##lt I-DRUG
##ia I-DRUG
##ze I-DRUG
##m I-DRUG
h I-DRUG
##c I-DRUG
##l I-DRUG
180 B-STR
mg I-STR
capsule B-FOR
, I-FOR
sustained I-FOR
release I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
capsule B-FOR
, I-FOR
sustained I-FOR
release I-FOR
p B-ROU
##o I-ROU
daily B-FRE
( O
daily O
) O
. O
2 O
. O
h B-DRUG
##ydro I-DRUG
##xy I-DRUG
##zine I-DRUG
h I-DRUG
##c I-DRUG
##l I-DRUG
25 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
q B-FRE
##id I-FRE
( O
4 O
times O
a O
day O
) O
. O
3 O
. O
ran B-DRUG
##iti I-DRUG
##dine I-DRUG
h I-DRUG
##c I-DRUG
##l I-DRUG
150 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
two B-DOS
( I-DOS
2 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( O
daily O
) O
. O
4 O
. O
am B-DRUG
##phe I-DRUG
##tamine I-DRUG
- I-DRUG
de I-DRUG
##x I-DRUG
##tro I-DRUG
##amp I-DRUG
##he I-DRUG
##tamine I-DRUG
20 B-STR
mg I-STR
capsule B-FOR
, I-FOR
su I-FOR
##st I-FOR
. I-FOR
release I-FOR
24 I-FOR
h I-FOR
##r I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
capsule B-FOR
, I-FOR
su I-FOR
##st I-FOR
. I-FOR
release I-FOR
24 I-FOR
h I-FOR
##r I-FOR
p B-ROU
##o I-ROU
daily B-FRE
( O
) O
. O
5 O
. O
c B-DRUG
##rom I-DRUG
##oly I-DRUG
##n I-DRUG
100 B-STR
mg I-STR
/ I-STR
5 I-STR
m I-STR
##l I-STR
solution B-FOR
si O
##g O
: O
three B-DOS
hundred I-DOS
( I-DOS
300 I-DOS
) I-DOS
m O
##l O
p B-ROU
##o I-ROU
q B-FRE
##id I-FRE
( O
4 O
times O
a O
day O
) O
. O
6 O
. O
h B-DRUG
##ydro I-DRUG
##xy I-DRUG
##ch I-DRUG
##lor I-DRUG
##o I-DRUG
##quin I-DRUG
##e I-DRUG
200 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
bid B-FRE
( O
2 O
times O
a O
day O
) O
. O
7 O
. O
du B-DRUG
##lo I-DRUG
##xe I-DRUG
##tine I-DRUG
30 B-STR
mg I-STR
capsule B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e O
. O
c O
. O
) O
si O
##g O
: O
two B-DOS
( I-DOS
2 I-DOS
) I-DOS
capsule B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e O
. O
c O
. O
) O
p B-ROU
##o I-ROU
daily B-FRE
( O
daily O
) O
. O
8 O
. O
f B-DRUG
##ex I-DRUG
##of I-DRUG
##ena I-DRUG
##dine I-DRUG
60 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
three B-DOS
( I-DOS
3 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
bid B-FRE
( O
2 O
times O
a O
day O
) O
. O
9 O
. O
al B-DRUG
##but I-DRUG
##ero I-DRUG
##l I-DRUG
90 B-STR
m I-STR
##c I-STR
##g I-STR
/ I-STR
act I-STR
##uation I-STR
a B-FOR
##ero I-FOR
##sol I-FOR
si O
##g O
: O
1 B-DOS
- I-DOS
2 I-DOS
pu B-FOR
##ffs I-FOR
in B-ROU
##hala I-ROU
##tion I-ROU
q B-FRE
##6 I-FRE
##h I-FRE
( O
every O
6 O
hours O
) O
. O
10 O
. O
calcium B-DRUG
carbon I-DRUG
##ate I-DRUG
500 B-STR
mg I-STR
tablet B-FOR
, I-FOR
ch I-FOR
##ew I-FOR
##able I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
, I-FOR
ch I-FOR
##ew I-FOR
##able I-FOR
p B-ROU
##o I-ROU
three B-FRE
times I-FRE
a I-FRE
day I-FRE
. I-FRE
di O
##sp O
: O
* O
90 O
tablet O
, O
ch O
##ew O
##able O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
2 O
* O
11 O
. O
pre B-DRUG
##dn I-DRUG
##ison I-DRUG
##e I-DRUG
10 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
tape B-DOS
##r I-DOS
p B-ROU
##o I-ROU
once B-FRE
a I-FRE
day I-FRE
: I-FRE
40 B-STR
mg I-STR
x O
4 O
days O
30 B-STR
mg I-STR
x O
3 B-DUR
days I-DUR
20 B-STR
mg I-STR
x O
3 B-DUR
days I-DUR
10 B-STR
mg I-STR
x O
3 B-DUR
##day I-DUR
##s I-DUR
. I-DUR
di O
##sp O
: O
* O
34 O
tablet O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
0 O
* O
12 O
. O
vitamin B-DRUG
d I-DRUG
400 B-STR
unit I-STR
tablet B-FOR
si O
##g O
: O
two B-DOS
( I-DOS
2 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE
di O
##sp O
: O
* O
60 O
tablet O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
2 O
* O
discharge O
disposition O
: O
home O
discharge O
diagnosis O
: O
primary O
diagnosis O
mast O
##h O
cell O
de O
##gra O
##nu O
##lation O
syndrome O
ex O
##as O
##cer O
##bation O

secondary O
di O
##ag O
##nose O
##s O
- O
g O
##erd O
- O
depression O
/ O
anxiety O
/ O
bi O
##pol O
##ar O
d O
/ O
o O
, O
has O
attempted O
suicide O
in O
the O
past O
- O
mi B-ADE
in O
[ O
* O
* O
214 O
##7 O
* O
* O
] O
after O
receiving O
cardiac B-DOS
arrest I-DOS
dose I-DOS
e B-DRUG
##pi I-DRUG
instead O
of O
an B-DOS
##aph I-DOS
##yla I-DOS
##ctic I-DOS
dose I-DOS
e B-DRUG
##pi I-DRUG
- O
h O
##t O
##n O
- O
er O
##os O
##ive O
o O
##ste O
##oar O
##th O
##rit O
##is O
- O
an O
##emia O
, O
iron O
studies O
c O
/ O
w O
a O
##oc O
##d O
- O
status O
post O
h O
##yster O
##ec O
##tom O
##y O
and O
o O
##op O
##hore O
##ct O
##omy O
discharge O
condition O
: O
stable O
discharge O
instructions O
: O
please O
contact O
your O
primary O
care O
physician O
or O
d O
##r O
. O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
79 O
* O
* O
] O
you O
develop O
any O
chest O
pain O
, O
nausea O
, O
vomit O
##ing O
, O
short O
##ness O
of O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
144 O
##0 O
* O
* O
] O
, O
w O
##hee O
##zing O
, O
or O
any O
other O
serious O
complaint O
. O
follow O
##up O
instructions O
: O
provider O
: O
[ O
* O
* O
first O
name O
##5 O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
* O
* O
] O
, O
m O
##d O
phone O
: O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
222 O
##6 O
* O
* O
] O
date O
/ O
time O
: O
[ O
* O
* O
215 O
##2 O
- O
10 O
- O
19 O
* O
* O
] O
1 O
: O
00 O

admission O
date O
: O
[ O
* O
* O
216 O
##7 O
- O
2 O
- O
21 O
* O
* O
] O
discharge O
date O
: O
[ O
* O
* O
216 O
##7 O
- O
3 O
- O
6 O
* O
* O
] O
date O
of O
birth O
: O
[ O
* O
* O
210 O
##3 O
- O
11 O
- O
18 O
* O
* O
] O
sex O
: O
f O
service O
: O
ne O
##uro O
##su O
##rger O
##y O
all O
##er O
##gies O
: O
pen B-DRUG
##ici I-DRUG
##llin I-DRUG
##s I-DRUG
/ O
code B-DRUG
##ine I-DRUG
attending O
: O
[ O
* O
* O
first O
name O
##3 O
( O
l O
##f O
) O
127 O
##1 O
* O
* O
] O
chief O
complaint O
: O
headache O
, O
na O
##ues O
##a O
/ O
vomit O
##ing O
, O
ve O
##rt O
##igo O
major O
surgical O
or O
invasive O
procedure O
: O
c O
##ere O
##bella O
##r O
les O
##ion O
re O
##section O
x O
##2 O
e O
##v O
##d O
v O
##ps O
placement O
history O
of O
present O
illness O
: O
the O
p O
##t O
is O
a O
63 O
- O
year O
- O
old O
r O
##h O
woman O
with O
a O
history O
of O
non O
- O
small O
cell O
lung O
ca O
( O
stage O
ii O
##ia O
, O
s O
/ O
p O
ch O
##em O
##o O
, O
x O
##rt O
, O
and O
l O
upper O
lobe O
##ct O
##omy O
) O
, O
p O
##e O
35 O
y O
##rs O
ago O
, O
r O
##he O
##umatic O
fever O
in O
childhood O
, O
prior O
tobacco O
use O
who O
presents O
with O
headache O
, O
nausea O
/ O
vomit O
##ing O
, O
di O
##zzi O
##ness O
, O
and O
blur O
##ry O
vision O
for O
the O
last O
2 O
weeks O
. O
she O
reports O
a O
ho O
##loc O
##ep O
##hali O
##c O
headache O
, O
extending O
from O
the O
back O
of O
her O
head O
up O
to O
the O
front O
bilateral O
##ly O
starting O
about O
2 O
weeks O
ago O
. O
the O
headache O
is O
constant O
, O
not O
throbbing O
, O
and O
worse O
##ns O
with O
any O
movement O
particularly O
when O
she O
stands O
up O
. O
it O
does O
not O
seem O
to O
worse O
##n O
with O
lying O
down O
and O
has O
not O
woken O
her O
from O
sleep O
. O
she O
says O
she O
used O
to O
get O
mi O
##gra O
##ines O
but O
has O
not O
had O
one O
in O
years O
; O
thinks O
this O
head O
##ah O
##ce O
feels O
somewhat O
similar O
but O
is O
at O
##y O
##pical O
in O
its O
duration O
. O
in O
addition O
she O
has O
has O
worse O
##ning O
nausea O
with O
vomit O
##ing O
, O
and O
for O
the O
last O
two O
days O
has O
not O
been O
able O
to O
keep O
anything O
down O
. O
she O
has O
also O
noticed O
that O
her O
vision O
appears O
" O
cloud O
##y O
" O
over O
the O
last O
week O
and O
a O
half O
. O
upon O
further O
questioning O
she O
says O
she O
thinks O
it O
appears O
double O
sometimes O
but O
is O
unsure O
if O
the O
images O
are O
vertically O
or O
horizontally O
displaced O
. O
she O
has O
not O
tried O
covering O
one O
eye O
to O
see O
if O
it O
improve O
##s O
. O
she O
is O
not O
sure O
if O
it O
is O
worse O
when O
looking O
toward O
one O
direction O
or O
the O
other O
. O
currently O
her O
vision O
seems O
a O
little O
blur O
##ry O
but O
denies O
dip O
##lop O
##ia O
at O
the O
moment O
. O
within O
the O
last O
two O
days O
she O
has O
also O
begun O
to O
experience O
di O
##zzi O
##ness O
, O
which O
she O
describes O
as O
the O
room O
spinning O
. O
she O
has O
also O
had O
difficulty O
walking O
and O
says O
she O
feels O
very O
un O
##stead O
##y O
on O
her O
feet O
. O
unsure O
if O
she O
is O
falling O
toward O
one O
side O
or O
the O
other O
. O
she O
came O
into O
the O
ed O
today O
because O
she O
was O
continuing O
to O
feel O
worse O
and O
was O
unable O
to O
keep O
down O
anything O
by O
mouth O
. O

on O
ne O
##uro O
r O
##os O
, O
the O
p O
##t O
reports O
headache O
, O
blurred O
/ O
double O
vision O
, O
ve O
##rt O
##igo O
, O
difficulty O
walking O
as O
above O
. O
denies O
difficulty O
speaking O
, O
loss O
of O
vision O
, O
focal O
weakness O
, O
numb O
##ness O
/ O
tingling O
, O
bow O
##el O
or O
bladder O
in O
##con O
##tine O
##nce O
or O
retention O
. O
on O
general O
review O
of O
systems O
, O
the O
p O
##t O
reports O
frequent O
chill O
##s O
but O
does O
not O
think O
she O
has O
had O
any O
fever O
##s O
. O
denies O
recent O
weight O
loss O
or O
gain O
. O
denies O
cough O
, O
short O
##ness O
of O
breath O
. O
denies O
chest O
pain O
or O
tight O
##ness O
, O
p O
##al O
##pit O
##ations O
. O
+ O
nausea O
/ O
vomit O
##ing O
, O
no O
abdominal O
pain O
. O
has O
not O
had O
a O
bow O
##el O
movement O
over O
the O
last O
few O
days O
which O
she O
attributes O
to O
not O
eating O
. O
no O
d O
##ys O
##uria O
. O
denies O
r O
##ash O
. O

past O
medical O
history O
: O
lung O
cancer O
, O
stage O
ii O
##ia O
( O
t O
##1 O
##b O
, O
n O
##2 O
, O
m O
##0 O
) O
- O
[ O
* O
* O
4 O
- O
1 O
* O
* O
] O
persistent O
non O
##p O
##rod O
##uctive O
cough O
, O
chest O
x O
- O
ray O
at O
that O
time O
, O
which O
demonstrated O
a O
hi O
##lar O
mass O
- O
[ O
* O
* O
216 O
##6 O
- O
4 O
- O
14 O
* O
* O
] O
chest O
c O
##t O
confirmed O
the O
presence O
of O
a O
lo O
##bula O
##ted O
, O
left O
su O
##pra O
##hil O
##ar O
pulmonary O
mass O
with O
a O
large O
, O
left O
hi O
##lar O
and O
a O
##ort O
##ico O
##pu O
##lm O
##ona O
##ry O
window O
nod O
##al O
conglomerate O
- O
[ O
* O
* O
216 O
##6 O
- O
5 O
- O
1 O
* O
* O
] O
pet O
scan O
demonstrated O
f O
##d O
##g O
avid O
left O
upper O
[ O
* O
* O
month O
/ O
day O
/ O
year O
36 O
##30 O
* O
* O
] O
mass O
and O
2 O
f O
##d O
##g O
- O
avid O
left O
hi O
##lar O
masses O
, O
and O
left O
media O
##st O
##inal O
l O
##ymph O
##ade O
##no O
##pathy O
as O
well O
. O
no O
other O
sites O
of O
disease O
were O
noted O
. O
- O
[ O
* O
* O
216 O
##6 O
- O
4 O
- O
30 O
* O
* O
] O
head O
c O
##t O
negative O
for O
evidence O
of O
meta O
##static O
disease O
. O
- O
- O
[ O
* O
* O
216 O
##6 O
- O
5 O
- O
9 O
* O
* O
] O
media O
##st O
##ino O
##sco O
##py O
- O
- O
> O
two O
left O
- O
sided O
( O
2 O
##l O
and O
the O
4 O
##l O
) O
, O
i O
##ps O
##ila O
##teral O
l O
##ymph O
nodes O
were O
positive O
for O
meta O
##static O
und O
##iff O
##ere O
##nti O
##ated O
car O
##cin O
##oma O
. O
tumor O
cells O
stained O
positive O
for O
t O
##t O
##f O
- O
1 O
, O
c O
##yt O
##oker O
##ati O
##n O
7 O
, O
s O
##yna O
##pt O
##op O
##hy O
##sin O
, O
were O
focal O
##ly O
positive O
for O
ch O
##rom O
##og O
##rani O
##n O
and O
negative O
for O
c O
##k O
##20 O
and O
l O
##ca O
, O
consistent O
with O
a O
car B-REA
##cin I-REA
##oma I-REA
of I-REA
lung I-REA
origin O
. O
- O
[ O
* O
* O
date O
range O
( O
3 O
) O
100 O
##41 O
##1 O
* O
* O
] O
concurrent O
x O
##rt O
and O
c B-DRUG
##is I-DRUG
##p I-DRUG
##lat I-DRUG
##in I-DRUG
/ I-DRUG
et B-DRUG
##op I-DRUG
##os I-DRUG
##ide I-DRUG
- O
[ O
* O
* O
216 O
##6 O
- O
8 O
- O
28 O
* O
* O
] O
left O
th O
##ora O
##cot O
##omy O
with O
left O
upper O
lobe O
##ct O
##omy O
, O
media O
##st O
##inal O
l O
##ymph O
node O
di O
##sse O
##ction O
, O
inter O
##cos O
##tal O
muscle O
flap O
butt O
##ress O
p B-ADE
##e I-ADE
35 O
years O
ago O
in O
the O
setting O
of O
oral B-DRUG
con I-DRUG
##tra I-DRUG
##ceptive I-DRUG
use O
history O
of O
r O
##he O
##umatic O
fever O
in O
childhood O
status O
post O
app O
##end O
##ec O
##tom O
##y O
many O
years O
ago O
left O
or O
##if O
of O
the O
hum O
##erus O
following O
an O
m O
##v O
##c O
( O
was O
told O
she O
could O
not O
have O
an O
m O
##ri O
due O
to O
metal O
in O
her O
arm O
) O

social O
history O
: O
single O
, O
lives O
with O
her O
brother O
in O
[ O
* O
* O
name O
( O
ni O
) O
* O
* O
] O
. O
has O
a O
daughter O
and O
a O
grandson O
who O
live O
in O
[ O
* O
* O
location O
( O
un O
) O
51 O
##31 O
* O
* O
] O
. O
used O
to O
work O
as O
a O
social O
worker O
for O
the O
state O
, O
has O
recently O
stopped O
working O
. O
she O
smoked O
one O
pack O
a O
day O
for O
40 O
years O
but O
quit O
on O
[ O
* O
* O
216 O
##6 O
- O
5 O
- O
2 O
* O
* O
] O
. O
she O
drinks O
alcohol O
socially O
, O
but O
recently O
stopped O
. O
family O
history O
: O
mother O
had O
breast O
cancer O
in O
her O
70s O
and O
heart O
disease O
. O
she O
had O
three O
maternal O
aunt O
##s O
with O
breast O
cancer O
. O
father O
had O
diabetes O
. O
she O
has O
five O
siblings O
, O
no O
history O
of O
cancer O
in O
any O
of O
her O
siblings O
. O
physical O
exam O
: O
admission O
physical O
exam O
: O
vital O
##s O
: O
t O
98 O
. O
2 O
p O
104 O
b O
##p O
113 O
/ O
71 O
r O
##r O
18 O
o O
##2 O
100 O
% O
general O
: O
awake O
, O
cooperative O
, O
appears O
somewhat O
uncomfortable O
. O
he O
##ent O
: O
n O
##c O
/ O
at O
, O
no O
s O
##cle O
##ral O
i O
##cter O
##us O
noted O
, O
m O
##uc O
##ous O
membrane O
##s O
dry O
neck O
: O
su O
##pp O
##le O
, O
no O
n O
##uch O
##al O
rigid O
##ity O
pulmonary O
: O
lungs O
c O
##ta O
bilateral O
##ly O
without O
r O
/ O
r O
/ O
w O
cardiac O
: O
r O
##rr O
, O
n O
##l O
. O
s O
##1 O
##s O
##2 O
, O
no O
m O
/ O
r O
/ O
g O
noted O
abdomen O
: O
soft O
, O
n O
##t O
/ O
n O
##d O
, O
norm O
##oa O
##ctive O
bow O
##el O
sounds O
, O
no O
masses O
or O
organ O
##ome O
##gal O
##y O
noted O
. O
ex O
##tre O
##mit O
##ies O
: O
no O
c O
/ O
c O
/ O
e O
bilateral O
##ly O
skin O
: O
no O
r O
##ash O
##es O
or O
lesions O
noted O
ne O
##uro O
##log O
##ic O
: O
- O
mental O
status O
: O
awake O
and O
alert O
, O
appears O
tired O
and O
somewhat O
uncomfortable O
. O
oriented O
to O
place O
, O
initially O
says O
date O
is O
[ O
* O
* O
206 O
##7 O
- O
8 O
- O
21 O
* O
* O
] O
but O
then O
correct O
##s O
to O
[ O
* O
* O
216 O
##7 O
- O
2 O
- O
19 O
* O
* O
] O
. O
unsure O
of O
day O
of O
month O
, O
says O
2nd O
and O
then O
25th O
. O
knows O
current O
president O
. O
able O
to O
relate O
history O
without O
difficulty O
. O
language O
is O
fluent O
with O
intact O
repetition O
and O
com O
##p O
##rehension O
. O
normal O
pro O
##so O
##dy O
. O
there O
were O
no O
para O
##pha O
##si O
##c O
errors O
. O
speech O
was O
not O
d O
##ys O
##art O
##hr O
##ic O
. O
able O
to O
follow O
both O
mid O
##line O
and O
app O
##end O
##icular O
commands O
. O
there O
was O
no O
evidence O
of O
a O
##pra O
##xia O
or O
neglect O
. O

- O
c O
##rani O
##al O
nerves O
: O
i O
: O
o O
##lf O
##action O
not O
tested O
. O
ii O
: O
per O
##rl O
3 O
to O
2 O
##mm O
and O
br O
##isk O
. O
v O
##ff O
to O
confrontation O
. O
fund O
##us O
##copic O
exam O
revealed O
no O
p O
##ap O
##ille O
##de O
##ma O
, O
ex O
##uda O
##tes O
, O
or O
hem O
##or O
##r O
##hage O
##s O
. O
ii O
##i O
, O
i O
##v O
, O
v O
##i O
: O
e O
##omi O
without O
n O
##ys O
##tag O
##mus O
. O
normal O
sa O
##cca O
##des O
. O
v O
: O
facial O
sensation O
intact O
to O
light O
touch O
. O
v O
##ii O
: O
no O
facial O
d O
##roo O
##p O
, O
facial O
m O
##us O
##cula O
##ture O
symmetric O
. O
v O
##ii O
##i O
: O
hearing O
intact O
to O
finger O
- O
rub O
bilateral O
##ly O
. O
i O
##x O
, O
x O
: O
p O
##ala O
##te O
el O
##eva O
##tes O
symmetrical O
##ly O
. O
[ O
* O
* O
doctor O
first O
name O
81 O
* O
* O
] O
: O
5 O
/ O
5 O
strength O
in O
trap O
##ez O
##ii O
and O
s O
##c O
##m O
bilateral O
##ly O
. O
x O
##ii O
: O
tongue O
pro O
##tr O
##udes O
in O
mid O
##line O
. O
- O
motor O
: O
normal O
bulk O
, O
tone O
throughout O
. O
no O
pro O
##nat O
##or O
drift O
bilateral O
##ly O
. O
no O
advent O
##iti O
##ous O
movements O
, O
such O
as O
t O
##rem O
##or O
, O
noted O
. O
no O
as O
##ter O
##ix O
##is O
noted O
. O
del O
##t O
bi O
##c O
t O
##ri O
w O
##re O
f O
##f O
##l O
f O
##e O
i O
##o O
i O
##p O
q O
##uad O
ha O
##m O
ta O
[ O
* O
* O
first O
name O
##9 O
( O
name O
##pa O
##tter O
##n O
##2 O
) O
233 O
##9 O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
un O
) O
93 O
##8 O
* O
* O
] O
ed O
##b O
l O
5 O
5 O
5 O
5 O
5 O
5 O
5 O
5 O
5 O
5 O
5 O
5 O
5 O
5 O
r O
5 O
5 O
5 O
5 O
5 O
5 O
5 O
5 O
5 O
5 O
5 O
5 O
5 O
5 O
- O
sensory O
: O
no O
deficit O
##s O
to O
light O
touch O
or O
pin O
##p O
##rick O
throughout O
. O
no O
extinction O
to O
d O
##ss O
. O
- O
d O
##tr O
##s O
: O
[ O
* O
* O
name O
##2 O
( O
ni O
) O
* O
* O
] O
t O
##ri O
[ O
* O
* O
last O
name O
( O
un O
) O
103 O
##5 O
* O
* O
] O
pat O
a O
##ch O
l O
2 O
2 O
2 O
2 O
1 O
r O
2 O
2 O
2 O
2 O
1 O
plant O
##ar O
response O
was O
fl O
##ex O
##or O
bilateral O
##ly O
. O
- O
coordination O
: O
no O
intention O
t O
##rem O
##or O
, O
no O
d O
##ys O
##dia O
##do O
##cho O
##kin O
##esi O
##a O
noted O
. O
+ O
? O
mild O
d O
##ys O
##met O
##ria O
r O
> O
l O
on O
f O
##n O
##f O
initially O
. O
- O
g O
##ait O
: O
def O
##er O
##red O
due O
to O
severe O
nausea O
, O
ve O
##rt O
##igo O
exam O
on O
discharge O
: O
mental O
status O
var O
##ries O
, O
patient O
on O
and O
off O
confused O
c O
##n O
2 O
- O
12 O
gross O
##ly O
intact O
moves O
all O
ex O
##tre O
##mit O
##ies O
with O
good O
strength O

per O
##tinent O
results O
: O
[ O
* O
* O
216 O
##7 O
- O
2 O
- O
21 O
* O
* O
] O
12 O
: O
50 O
##pm O
glucose O
- O
95 O
u O
##rea O
n O
- O
22 O
* O
c O
##rea O
##t O
- O
0 O
. O
8 O
sodium O
- O
140 O
potassium O
- O
3 O
. O
9 O
chloride O
- O
102 O
total O
co O
##2 O
- O
24 O
an O
##ion O
gap O
- O
18 O
[ O
* O
* O
216 O
##7 O
- O
2 O
- O
21 O
* O
* O
] O
12 O
: O
50 O
##pm O
est O
##g O
##f O
##r O
- O
using O
this O
[ O
* O
* O
216 O
##7 O
- O
2 O
- O
21 O
* O
* O
] O
12 O
: O
50 O
##pm O
calcium O
- O
10 O
. O
1 O
phosphate O
- O
3 O
. O
3 O
ma O
##gnesium O
- O
2 O
. O
2 O
[ O
* O
* O
216 O
##7 O
- O
2 O
- O
21 O
* O
* O
] O
12 O
: O
50 O
##pm O
w O
##b O
##c O
- O
5 O
. O
9 O
r O
##b O
##c O
- O
4 O
. O
82 O
h O
##g O
##b O
- O
15 O
. O
1 O
h O
##ct O
- O
41 O
. O
3 O
m O
##c O
##v O
- O
86 O
m O
##ch O
- O
31 O
. O
4 O
m O
##ch O
##c O
- O
36 O
. O
7 O
* O
r O
##d O
##w O
- O
12 O
. O
8 O
[ O
* O
* O
216 O
##7 O
- O
2 O
- O
21 O
* O
* O
] O
12 O
: O
50 O
##pm O
ne O
##uts O
- O
84 O
. O
9 O
* O
l O
##ymph O
##s O
- O
10 O
. O
0 O
* O
mon O
##os O
- O
3 O
. O
8 O
e O
##os O
- O
0 O
. O
6 O
b O
##as O
##os O
- O
0 O
. O
7 O
[ O
* O
* O
216 O
##7 O
- O
2 O
- O
21 O
* O
* O
] O
12 O
: O
50 O
##pm O
p O
##lt O
count O
- O
218 O
c O
##t O
head O
non O
##con O
##tras O
##t O
[ O
* O
* O
2 O
- O
21 O
* O
* O
] O
: O
impression O
: O
1 O
. O
two O
new O
posterior O
c O
##rani O
##al O
f O
##ossa O
/ O
c O
##ere O
##bella O
##r O
lesions O
, O
with O
surrounding O
ed O
##ema O
and O
mild O
mass O
effect O
on O
the O
fourth O
vent O
##ric O
##le O
, O
concerning O
for O
meta O
##static O
disease O
. O
2 O
. O
a O
new O
1 O
. O
1 O
cm O
mass O
les O
##ion O
in O
the O
third O
vent O
##ric O
##le O
, O
with O
mild O
h O
##ydro O
##ce O
##pha O
##lus O
, O
concerning O
for O
additional O
site O
of O
meta O
##static O
disease O
. O
an O
m O
##ri O
with O
contrast O
is O
recommended O
for O
further O
evaluation O
. O
c O
##t O
head O
with O
contrast O
[ O
* O
* O
2 O
- O
22 O
* O
* O
] O
: O
1 O
. O
right O
c O
##ere O
##bella O
##r O
and O
third O
vent O
##ric O
##le O
lesions O
are O
new O
from O
[ O
* O
* O
216 O
##6 O
- O
8 O
- O
18 O
* O
* O
] O
, O
concerning O
for O
meta O
##static O
disease O
. O
if O
clinical O
##ly O
feasible O
, O
m O
##ri O
is O
more O
sensitive O
to O
detect O
small O
lesions O
and O
le O
##pt O
##ome O
##ning O
##eal O
disease O
. O
2 O
. O
the O
lateral O
vent O
##ric O
##les O
are O
slightly O
enlarged O
compared O
to O
[ O
* O
* O
216 O
##6 O
- O
8 O
- O
18 O
* O
* O
] O
, O
raising O
the O
possibility O
of O
mild O
h O
##ydro O
##ce O
##pha O
##lus O
due O
to O
third O
vent O
##ric O
##le O
les O
##ion O
. O

m O
##ri O
with O
and O
without O
contrast O
[ O
* O
* O
2 O
- O
23 O
* O
* O
] O
: O
su O
##pra O
- O
and O
in O
##fra O
- O
tent O
##oria O
##l O
as O
well O
as O
in O
##tra O
##vent O
##ric O
##ular O
meta O
##static O
disease O
, O
notably O
involving O
the O
left O
ins O
##ular O
cortex O
, O
right O
c O
##ere O
##bella O
##r O
hemisphere O
, O
and O
third O
vent O
##ric O
##le O
. O
while O
the O
right O
c O
##ere O
##bella O
##r O
les O
##ion O
is O
associated O
with O
significant O
mass O
effect O
and O
distortion O
of O
the O
fourth O
vent O
##ric O
##le O
, O
there O
is O
currently O
no O
c O
##s O
##f O
o O
##bs O
##truction O
or O
h O
##ydro O
##ce O
##pha O
##lus O
. O
the O
third O
vent O
##ric O
##le O
les O
##ion O
is O
located O
below O
the O
for O
##ame O
##n O
of O
[ O
* O
* O
last O
name O
( O
un O
) O
204 O
##4 O
* O
* O
] O
and O
likewise O
does O
not O
cause O
h O
##ydro O
##ce O
##pha O
##lus O
. O
m O
##ri O
c O
/ O
t O
spine O
[ O
* O
* O
2 O
- O
24 O
* O
* O
] O
1 O
. O
compression O
fracture O
, O
with O
mild O
loss O
of O
height O
of O
the O
th O
##ora O
##ci O
##c O
t O
##5 O
ve O
##rte O
##bra O
##l O
body O
with O
ma O
##rrow O
ed O
##ema O
pattern O
. O
no O
re O
##tro O
##pulsion O
of O
the O
fragments O
, O
no O
canal O
or O
compression O
on O
the O
cord O
. O
while O
this O
has O
the O
appearance O
of O
a O
ben O
##ign O
compression O
fracture O
, O
given O
the O
history O
, O
an O
associated O
path O
##olo O
##gic O
les O
##ion O
within O
the O
t O
##5 O
body O
cannot O
be O
completely O
excluded O
. O
correlation O
with O
radio O
##nu O
##c O
##lide O
studies O
and O
c O
##t O
is O
recommended O
. O
no O
enhancing O
lesions O
in O
the O
cord O
. O
2 O
. O
multi O
##lev O
##el O
mild O
de O
##gene O
##rative O
changes O
in O
the O
c O
##er O
##vic O
##al O
spine O
without O
significant O
canal O
or O
for O
##ami O
##nal O
s O
##ten O
##osis O
. O
3 O
. O
a O
3 O
. O
3 O
x O
3 O
. O
5 O
cm O
nod O
##ular O
les O
##ion O
in O
the O
lower O
neck O
/ O
upper O
media O
##st O
##in O
##um O
, O
new O
since O
the O
prior O
c O
##t O
chest O
of O
[ O
* O
* O
216 O
##6 O
- O
11 O
- O
27 O
* O
* O
] O
. O
this O
needs O
further O
evaluation O
with O
c O
##t O
chest O
, O
including O
the O
lower O
neck O
. O
there O
is O
moderate O
amount O
of O
p O
##le O
##ural O
e O
##ff O
##usion O
/ O
p O
##le O
##ural O
thick O
##ening O
noted O
on O
the O
left O
side O
. O
m O
##ri O
[ O
* O
* O
doctor O
last O
name O
* O
* O
] O
[ O
* O
* O
2 O
- O
26 O
* O
* O
] O
findings O
: O
since O
the O
prior O
study O
, O
the O
patient O
has O
undergone O
bio O
##psy O
of O
the O
right O
c O
##ere O
##bella O
##r O
hem O
##is O
##pheric O
les O
##ion O
. O
expected O
post O
##oper O
##ative O
change O
are O
seen O
with O
relatively O
extensive O
in O
##tral O
##esi O
##onal O
hem O
##or O
##r O
##hage O
and O
a O
c O
##ir O
##cum O
##scribed O
tissue O
defect O
. O
the O
previously O
reported O
extensive O
v O
##as O
##ogenic O
ed O
##ema O
as O
well O
as O
mass O
effect O
on O
the O
fourth O
vent O
##ric O
##le O
is O
largely O
unchanged O
. O

the O
previously O
reported O
additional O
meta O
##static O
lesions O
within O
the O
left O
ins O
##ular O
cortex O
and O
third O
vent O
##ric O
##le O
demonstrate O
no O
short O
interval O
change O
. O
however O
, O
with O
less O
motion O
art O
##ef O
##act O
and O
better O
image O
quality O
further O
lesions O
measuring O
##ap O
##p O
##ro O
##xi O
##mate O
##ly O
3 O
mm O
are O
identified O
in O
the O
posterior O
aspect O
of O
the O
left O
temporal O
[ O
* O
* O
month O
/ O
day O
( O
4 O
) O
36 O
##30 O
* O
* O
] O
as O
well O
as O
the O
left O
c O
##ere O
##bella O
##r O
hemisphere O
. O
there O
is O
no O
evidence O
of O
acute O
in O
##far O
##ction O
. O
flow O
void O
##s O
of O
the O
major O
in O
##tra O
##c O
##rani O
##al O
vessels O
are O
preserved O
. O
impression O
: O
1 O
. O
status O
post O
bio O
##psy O
of O
right O
c O
##ere O
##bella O
##r O
mass O
with O
ex O
##pt O
##ec O
##ed O
in O
##tral O
##esi O
##onal O
hem O
##or O
##r O
##hage O
. O
2 O
. O
no O
short O
- O
term O
interval O
change O
with O
regard O
to O
the O
left O
ins O
##ular O
cortex O
and O
third O
vent O
##ric O
##le O
meta O
##static O
lesions O
. O
3 O
. O
identification O
of O
additional O
small O
lesions O
within O
the O
left O
posterior O
temporal O
cortex O
as O
well O
as O
the O
left O
posterior O
medial O
c O
##ere O
##bella O
##r O
hemisphere O
. O
[ O
* O
* O
2 O
- O
27 O
* O
* O
] O
c O
##t O
findings O
: O
patient O
is O
status O
post O
a O
right O
- O
sided O
vent O
##ric O
##ulos O
##tom O
##y O
cat O
##he O
##ter O
with O
tip O
terminating O
in O
the O
frontal O
[ O
* O
* O
doctor O
last O
name O
53 O
##4 O
* O
* O
] O
of O
the O
right O
vent O
##ric O
##le O
. O
no O
associated O
in O
##tra O
##par O
##ency O
##mal O
or O
in O
##tra O
##vent O
##ric O
##ular O
hem O
##or O
##r O
##hage O
identified O
. O
vent O
##ric O
##les O
demonstrate O
stable O
mild O
di O
##lat O
##ation O
, O
unchanged O
from O
the O
prior O
c O
##t O
. O

the O
patient O
is O
status O
post O
a O
right O
sub O
##oc O
##ci O
##pit O
##al O
c O
##rani O
##oto O
##my O
with O
partial O
re O
##section O
of O
a O
known O
right O
c O
##ere O
##bella O
##r O
mass O
. O
again O
there O
is O
a O
small O
amount O
of O
air O
and O
expected O
post O
- O
surgical O
hem O
##ato O
##ma O
at O
the O
site O
of O
the O
recent O
surgical O
intervention O
in O
the O
posterior O
c O
##rani O
##al O
f O
##ossa O
with O
an O
increasingly O
h O
##y O
##po O
##den O
##se O
appearance O
consistent O
with O
evolution O
of O
blood O
products O
. O
a O
2 O
. O
8 O
x O
2 O
. O
3 O
cm O
rounded O
h O
##yper O
##den O
##se O
mass O
most O
suggest O
##ive O
of O
residual O
tumor O
, O
better O
identified O
on O
the O
prior O
m O
##ri O
, O
and O
is O
located O
just O
superior O
to O
the O
re O
##section O
site O
and O
unchanged O
. O
known O
left O
ins O
##ular O
co O
##rt O
##ical O
mass O
is O
not O
well O
seen O
, O
and O
better O
evaluated O
on O
the O
m O
##ri O
. O
surrounding O
v O
##as O
##ogenic O
ed O
##ema O
in O
the O
c O
##ere O
##bella O
##r O
hemisphere O
##s O
per O
##sist O
##s O
but O
with O
minimal O
##ly O
improved O
mass O
effect O
on O
the O
patent O
fourth O
vent O
##ric O
##le O
. O
the O
known O
1 O
. O
1 O
x O
1 O
. O
0 O
cm O
h O
##yper O
##den O
##se O
mass O
in O
the O
third O
vent O
##ric O
##le O
is O
unchanged O
. O
no O
new O
par O
##en O
##chy O
##mal O
hem O
##ato O
##ma O
or O
in O
##far O
##ct O
present O
. O
the O
mast O
##oid O
air O
cells O
, O
middle O
ear O
ca O
##vi O
##ties O
and O
visual O
##ized O
para O
##nas O
##al O
sin O
##uses O
are O
clear O
. O
impression O
: O
1 O
. O
status O
post O
partial O
re O
##section O
of O
the O
right O
c O
##ere O
##bella O
##r O
mass O
with O
a O
stable O
distribution O
of O
surrounding O
v O
##as O
##ogenic O
ed O
##ema O
though O
with O
a O
slight O
decreased O
mass O
effect O
on O
the O
widely O
patent O
fourth O
vent O
##ric O
##le O
. O
continued O
evolution O
of O
blood O
products O
within O
post O
- O
surgical O
hem O
##ato O
##ma O
. O
residual O
tumor O
as O
described O
above O
. O
2 O
. O
interval O
placement O
of O
a O
right O
- O
sided O
vent O
##ric O
##ulos O
##tom O
##y O
cat O
##he O
##ter O
with O
tip O
in O
the O
right O
frontal O
[ O
* O
* O
doctor O
last O
name O
53 O
##4 O
* O
* O
] O
. O
no O
in O
##tra O
##par O
##en O
##chy O
##mal O
or O
in O
##tra O
##vent O
##ric O
##ular O
hem O
##or O
##r O
##hage O
identified O
. O
stable O
mild O
di O
##lat O
##ation O
of O
bilateral O
lateral O
vent O
##ric O
##les O
. O

[ O
* O
* O
2 O
- O
27 O
* O
* O
] O
c O
##t O
a O
##b O
##d O
findings O
: O
there O
is O
a O
new O
left O
para O
##tra O
##che O
##al O
mass O
measuring O
3 O
. O
8 O
x O
3 O
. O
4 O
x O
2 O
. O
2 O
cm O
causing O
mild O
de O
##via O
##ito O
##n O
of O
the O
t O
##rac O
##hea O
and O
left O
car O
##ot O
##id O
artery O
concerning O
for O
a O
l O
##ymph O
##ade O
##no O
##pathy O
due O
to O
meta O
##sta O
##sis O
. O
there O
is O
no O
, O
a O
##xi O
##llar O
##y O
, O
media O
##st O
##inal O
or O
hi O
##lar O
l O
##ymph O
##ade O
##no O
##pathy O
evident O
. O
the O
central O
vessels O
are O
un O
##rem O
##ark O
##able O
. O
heart O
size O
is O
normal O
and O
without O
per O
##ica O
##rdi O
##al O
e O
##ff O
##usion O
. O
a O
small O
- O
to O
moderate O
- O
sized O
hi O
##ata O
##l O
her O
##nia O
is O
evident O
. O
there O
is O
a O
small O
left O
p O
##le O
##ural O
e O
##ff O
##usion O
with O
thick O
##ened O
r O
##ind O
evident O
at O
the O
level O
of O
the O
upper O
[ O
* O
* O
month O
/ O
day O
( O
4 O
) O
36 O
##30 O
* O
* O
] O
, O
indicating O
chronic O
##ity O
. O
p O
##le O
##ural O
b O
##le O
##bs O
are O
identified O
within O
the O
right O
lung O
apex O
. O
no O
significant O
em O
##phy O
##se O
##mat O
##ous O
changes O
are O
identified O
. O
changes O
consistent O
with O
left O
upper O
lobe O
##ct O
##omy O
and O
media O
##st O
##inal O
l O
##ymph O
node O
di O
##sse O
##ction O
are O
evident O
. O
non O
##sp O
##ec O
##ific O
ground O
- O
glass O
op O
##ac O
##ities O
with O
minimal O
associated O
architectural O
distortion O
identified O
in O
the O
left O
lung O
apex O
are O
increased O
compared O
to O
prior O
study O
and O
likely O
represent O
post O
- O
radiation O
changes O
. O
minimal O
dependent O
ate O
##lect O
##asis O
in O
dependent O
portions O
of O
both O
lungs O
. O

the O
liver O
is O
ho O
##mo O
##gen O
##ous O
in O
at O
##ten O
##uation O
without O
discrete O
masses O
or O
lesions O
. O
there O
is O
no O
in O
##tra O
##he O
##pa O
##tic O
bi O
##lia O
##ry O
duct O
##al O
di O
##lat O
##ation O
. O
the O
gal O
##l O
##bla O
##dder O
, O
pan O
##cre O
##as O
and O
s O
##ple O
##en O
are O
normal O
. O
the O
bilateral O
ad O
##rena O
##l O
glands O
have O
normal O
limb O
thickness O
and O
are O
without O
convex O
margin O
to O
suggest O
mass O
. O
the O
bilateral O
kidney O
##s O
are O
normal O
in O
size O
and O
ex O
##cre O
##te O
contrast O
symmetrical O
##ly O
. O
the O
stomach O
, O
small O
and O
large O
bow O
##el O
are O
un O
##rem O
##ark O
##able O
. O
there O
is O
no O
re O
##tro O
##per O
##ito O
##nea O
##l O
, O
me O
##sent O
##eric O
or O
port O
##aca O
##val O
l O
##ymph O
##ade O
##no O
##pathy O
identified O
. O
multiple O
small O
f O
##oc O
##i O
of O
air O
are O
noted O
within O
the O
abdomen O
as O
well O
as O
a O
layer O
##ing O
posterior O
to O
the O
left O
re O
##ctus O
sheath O
muscle O
, O
likely O
due O
to O
recent O
insertion O
of O
a O
right O
- O
sided O
vent O
##ric O
##ulo O
##per O
##ito O
##nea O
##l O
s O
##hun O
##t O
with O
tip O
ending O
lateral O
to O
the O
liver O
. O
no O
free O
fluid O
identified O
within O
the O
abdomen O
. O
the O
re O
##ct O
##um O
, O
bladder O
, O
u O
##ter O
##us O
and O
ad O
##nex O
##a O
are O
un O
##rem O
##ark O
##able O
. O
no O
p O
##el O
##vic O
side O
##wall O
or O
ing O
##uin O
##al O
l O
##ymph O
##ade O
##no O
##pathy O
identified O
. O
the O
a O
##ort O
##a O
is O
of O
normal O
caliber O
throughout O
. O
the O
main O
portal O
vein O
and O
its O
major O
tributaries O
are O
un O
##rem O
##ark O
##able O
. O
no O
suspicious O
l O
##ytic O
or O
blast O
##ic O
lesions O
evident O
. O
impression O
: O
1 O
. O
new O
3 O
. O
8 O
cm O
left O
para O
##tra O
##che O
##al O
mass O
concerning O
for O
meta O
##sta O
##sis O
. O
2 O
. O
expected O
post O
- O
surgical O
changes O
in O
the O
left O
upper O
[ O
* O
* O
month O
/ O
day O
( O
4 O
) O
36 O
##30 O
* O
* O
] O
consistent O
with O
lobe O
##ct O
##omy O
and O
media O
##st O
##inal O
bio O
##psy O
. O
increased O
ground O
- O
glass O
op O
##ac O
##ities O
with O
associated O
architectural O
distortion O
evident O
within O
the O
left O
upper O
[ O
* O
* O
last O
name O
( O
l O
##f O
) O
36 O
##30 O
* O
* O
] O
, O
[ O
* O
* O
first O
name O
##3 O
( O
l O
##f O
) O
* O
* O
] O
be O
related O
to O
radiation O
changes O
, O
though O
ma O
##li O
##gna O
##ncy O
is O
not O
excluded O
. O
3 O
. O
small O
left O
p O
##le O
##ural O
e O
##ff O
##usion O
, O
likely O
chronic O
. O
4 O
. O
interval O
placement O
of O
a O
right O
- O
sided O
vent O
##ric O
##ulo O
##per O
##ito O
##nea O
##l O
s O
##hun O
##t O
with O
tip O
at O
the O
level O
of O
the O
liver O
and O
few O
in O
##tra O
##per O
##ito O
##nea O
##l O
gas O
bubbles O
. O
5 O
. O
small O
hi O
##ata O
##l O
her O
##nia O
. O

[ O
* O
* O
2 O
- O
27 O
* O
* O
] O
c O
##t O
chest O
findings O
: O
there O
is O
a O
new O
left O
para O
##tra O
##che O
##al O
mass O
measuring O
3 O
. O
8 O
x O
3 O
. O
4 O
x O
2 O
. O
2 O
cm O
causing O
mild O
de O
##via O
##ito O
##n O
of O
the O
t O
##rac O
##hea O
and O
left O
car O
##ot O
##id O
artery O
concerning O
for O
a O
l O
##ymph O
##ade O
##no O
##pathy O
due O
to O
meta O
##sta O
##sis O
. O
there O
is O
no O
, O
a O
##xi O
##llar O
##y O
, O
media O
##st O
##inal O
or O
hi O
##lar O
l O
##ymph O
##ade O
##no O
##pathy O
evident O
. O
the O
central O
vessels O
are O
un O
##rem O
##ark O
##able O
. O
heart O
size O
is O
normal O
and O
without O
per O
##ica O
##rdi O
##al O
e O
##ff O
##usion O
. O
a O
small O
- O
to O
moderate O
- O
sized O
hi O
##ata O
##l O
her O
##nia O
is O
evident O
. O
there O
is O
a O
small O
left O
p O
##le O
##ural O
e O
##ff O
##usion O
with O
thick O
##ened O
r O
##ind O
evident O
at O
the O
level O
of O
the O
upper O
[ O
* O
* O
month O
/ O
day O
( O
4 O
) O
36 O
##30 O
* O
* O
] O
, O
indicating O
chronic O
##ity O
. O
p O
##le O
##ural O
b O
##le O
##bs O
are O
identified O
within O
the O
right O
lung O
apex O
. O
no O
significant O
em O
##phy O
##se O
##mat O
##ous O
changes O
are O
identified O
. O
changes O
consistent O
with O
left O
upper O
lobe O
##ct O
##omy O
and O
media O
##st O
##inal O
l O
##ymph O
node O
di O
##sse O
##ction O
are O
evident O
. O
non O
##sp O
##ec O
##ific O
ground O
- O
glass O
op O
##ac O
##ities O
with O
minimal O
associated O
architectural O
distortion O
identified O
in O
the O
left O
lung O
apex O
are O
increased O
compared O
to O
prior O
study O
and O
likely O
represent O
post O
- O
radiation O
changes O
. O
minimal O
dependent O
ate O
##lect O
##asis O
in O
dependent O
portions O
of O
both O
lungs O
. O

the O
liver O
is O
ho O
##mo O
##gen O
##ous O
in O
at O
##ten O
##uation O
without O
discrete O
masses O
or O
lesions O
. O
there O
is O
no O
in O
##tra O
##he O
##pa O
##tic O
bi O
##lia O
##ry O
duct O
##al O
di O
##lat O
##ation O
. O
the O
gal O
##l O
##bla O
##dder O
, O
pan O
##cre O
##as O
and O
s O
##ple O
##en O
are O
normal O
. O
the O
bilateral O
ad O
##rena O
##l O
glands O
have O
normal O
limb O
thickness O
and O
are O
without O
convex O
margin O
to O
suggest O
mass O
. O
the O
bilateral O
kidney O
##s O
are O
normal O
in O
size O
and O
ex O
##cre O
##te O
contrast O
symmetrical O
##ly O
. O
the O
stomach O
, O
small O
and O
large O
bow O
##el O
are O
un O
##rem O
##ark O
##able O
. O
there O
is O
no O
re O
##tro O
##per O
##ito O
##nea O
##l O
, O
me O
##sent O
##eric O
or O
port O
##aca O
##val O
l O
##ymph O
##ade O
##no O
##pathy O
identified O
. O
multiple O
small O
f O
##oc O
##i O
of O
air O
are O
noted O
within O
the O
abdomen O
as O
well O
as O
a O
layer O
##ing O
posterior O
to O
the O
left O
re O
##ctus O
sheath O
muscle O
, O
likely O
due O
to O
recent O
insertion O
of O
a O
right O
- O
sided O
vent O
##ric O
##ulo O
##per O
##ito O
##nea O
##l O
s O
##hun O
##t O
with O
tip O
ending O
lateral O
to O
the O
liver O
. O
no O
free O
fluid O
identified O
within O
the O
abdomen O
. O
the O
re O
##ct O
##um O
, O
bladder O
, O
u O
##ter O
##us O
and O
ad O
##nex O
##a O
are O
un O
##rem O
##ark O
##able O
. O
no O
p O
##el O
##vic O
side O
##wall O
or O
ing O
##uin O
##al O
l O
##ymph O
##ade O
##no O
##pathy O
identified O
. O
the O
a O
##ort O
##a O
is O
of O
normal O
caliber O
throughout O
. O
the O
main O
portal O
vein O
and O
its O
major O
tributaries O
are O
un O
##rem O
##ark O
##able O
. O
no O
suspicious O
l O
##ytic O
or O
blast O
##ic O
lesions O
evident O
. O
impression O
: O
1 O
. O
new O
3 O
. O
8 O
cm O
left O
para O
##tra O
##che O
##al O
mass O
concerning O
for O
meta O
##sta O
##sis O
. O
2 O
. O
expected O
post O
- O
surgical O
changes O
in O
the O
left O
upper O
[ O
* O
* O
month O
/ O
day O
( O
4 O
) O
36 O
##30 O
* O
* O
] O
consistent O
with O
lobe O
##ct O
##omy O
and O
media O
##st O
##inal O
bio O
##psy O
. O
increased O
ground O
- O
glass O
op O
##ac O
##ities O
with O
associated O
architectural O
distortion O
evident O
within O
the O
left O
upper O
[ O
* O
* O
last O
name O
( O
l O
##f O
) O
36 O
##30 O
* O
* O
] O
, O
[ O
* O
* O
first O
name O
##3 O
( O
l O
##f O
) O
* O
* O
] O
be O
related O
to O
radiation O
changes O
, O
though O
ma O
##li O
##gna O
##ncy O
is O
not O
excluded O
. O
3 O
. O
small O
left O
p O
##le O
##ural O
e O
##ff O
##usion O
, O
likely O
chronic O
. O
4 O
. O
interval O
placement O
of O
a O
right O
- O
sided O
vent O
##ric O
##ulo O
##per O
##ito O
##nea O
##l O
s O
##hun O
##t O
with O
tip O
at O
the O
level O
of O
the O
liver O
and O
few O
in O
##tra O
##per O
##ito O
##nea O
##l O
gas O
bubbles O
. O
5 O
. O
small O
hi O
##ata O
##l O
her O
##nia O
. O
[ O
* O
* O
216 O
##7 O
- O
3 O
- O
2 O
* O
* O
] O
c O
##ta O
/ O
v O
head O
impression O
: O
the O
ve O
##nous O
sin O
##uses O
are O
patent O
without O
filling O
defect O
. O
the O
non O
- O
contrast O
head O
c O
##t O
findings O
are O
unchanged O
compared O
to O
[ O
* O
* O
216 O
##7 O
- O
2 O
- O
27 O
* O
* O
] O
. O

[ O
* O
* O
216 O
##7 O
- O
3 O
- O
6 O
* O
* O
] O
m O
##ri O
: O
1 O
. O
post O
operative O
changes O
in O
the O
right O
posterior O
f O
##ossa O
. O
peripheral O
enhance O
##ment O
along O
the O
re O
##section O
cavity O
which O
likely O
represents O
post O
operative O
change O
or O
residual O
tumor O
. O
2 O
. O
stable O
meta O
##static O
lesions O
within O
the O
left O
ins O
##ular O
cortex O
, O
third O
vent O
##ric O
##le O
, O
left O
temporal O
and O
left O
c O
##ere O
##bella O
##r O
hemisphere O
. O
3 O
. O
no O
acute O
in O
##far O
##ct O
. O
4 O
. O
right O
frontal O
approach O
vent O
##ric O
##ulos O
##tom O
##y O
cat O
##he O
##ter O
with O
tip O
in O
frontal O
[ O
* O
* O
doctor O
last O
name O
53 O
##4 O
* O
* O
] O
of O
right O
lateral O
vent O
##ric O
##le O
. O
brief O
hospital O
course O
: O
ne O
##uro O
: O
m O
##s O
. O
[ O
* O
* O
known O
last O
##name O
* O
* O
] O
presented O
to O
the O
ed O
on O
[ O
* O
* O
216 O
##7 O
- O
2 O
- O
21 O
* O
* O
] O
following O
2 O
weeks O
of O
headache O
##s O
, O
nausea O
/ O
vomit O
##ing O
, O
and O
ve O
##rt O
##igo O
. O
c O
##t O
head O
demonstrated O
a O
large O
mass O
in O
the O
r O
c O
##ere O
##bell O
##um O
and O
a O
smaller O
les O
##ion O
in O
the O
third O
vent O
##ric O
##le O
. O
ne O
##uro O
##su O
##rger O
##y O
was O
consulted O
in O
the O
ed O
and O
declined O
acute O
intervention O
. O
she O
was O
started O
on O
de B-DRUG
##ca I-DRUG
##dron I-DRUG
4 B-STR
##m I-STR
##g I-STR
q B-FRE
##6 I-FRE
and O
admitted O
to O
the O
ne O
##uro O
- O
i O
##cu O
for O
monitoring O
. O
she O
did O
well O
overnight O
without O
any O
evidence O
of O
h O
##ydro O
##ce O
##pha O
##lus O
or O
increasing O
i O
##c O
##p O
, O
and O
her O
symptoms O
began O
to O
improve O
. O
she O
was O
transferred O
to O
the O
ne O
##uro O
##logy O
floor O
on O
[ O
* O
* O
216 O
##7 O
- O
2 O
- O
22 O
* O
* O
] O
. O
m O
##ri O
with O
and O
without O
contrast O
was O
performed O
which O
demonstrated O
three O
lesions O
, O
largest O
in O
r O
c O
##ere O
##bella O
##r O
hemisphere O
as O
well O
as O
two O
additional O
masses O
in O
third O
vent O
##ric O
##le O
and O
left O
ins O
##ula O
. O
ne O
##uro O
- O
on O
##cology O
was O
consulted O
and O
recommended O
re O
##section O
of O
c O
##ere O
##bella O
##r O
les O
##ion O
and O
whole O
brain O
radiation O
. O
her O
primary O
on O
##cologist O
##s O
d O
##rs O
. O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
* O
* O
] O
and O
[ O
* O
* O
name O
##5 O
( O
p O
##ti O
##tle O
) O
113 O
##0 O
##9 O
* O
* O
] O
were O
also O
contact O
[ O
* O
* O
name O
( O
ni O
) O
* O
* O
] O
. O
ne O
##uro O
##su O
##rger O
##y O
recommended O
sub O
##oc O
##ci O
##pit O
##al O
c O
##rani O
##ec O
##tom O
##y O
followed O
by O
v O
##ps O
placement O
. O

on O
[ O
* O
* O
216 O
##7 O
- O
2 O
- O
24 O
* O
* O
] O
: O
she O
had O
increased O
nausea O
and O
headache O
##s O
. O
she O
was O
taken O
to O
the O
or O
and O
underwent O
re O
##section O
of O
her O
c O
##ere O
##bella O
##r O
mass O
. O
she O
tolerate O
##d O
the O
procedure O
well O
. O
post O
operative O
##ly O
she O
returned O
to O
the O
i O
##cu O
for O
s O
##b O
##p O
control O
and O
ne O
##uro O
##che O
##cks O
. O
her O
exam O
remained O
stable O
and O
post O
operative O
head O
c O
##t O
showed O
no O
hem O
##or O
##r O
##hage O
. O
on O
[ O
* O
* O
2 O
- O
25 O
* O
* O
] O
she O
was O
transferred O
to O
the O
floor O
. O
on O
[ O
* O
* O
2 O
- O
26 O
* O
* O
] O
she O
had O
a O
routine O
head O
c O
##t O
for O
pre O
##oper O
##ative O
planning O
and O
this O
showed O
no O
change O
from O
previous O
scan O
##s O
. O
she O
was O
kept O
n O
##po O
after O
midnight O
for O
v O
##ps O
placement O
on O
[ O
* O
* O
2 O
- O
27 O
* O
* O
] O
. O
on O
[ O
* O
* O
216 O
##7 O
- O
2 O
- O
27 O
* O
* O
] O
: O
she O
was O
taken O
to O
the O
operating O
room O
for O
v O
##p O
s O
##hun O
##t O
placement O
. O
she O
tolerate O
##d O
the O
procedure O
well O
. O
post O
- O
operative O
##ly O
she O
returned O
to O
the O
floor O
. O
post O
##op O
m O
##ri O
demonstrated O
residual O
c O
##ere O
##bella O
##r O
tumor O
and O
so O
on O
[ O
* O
* O
3 O
- O
4 O
* O
* O
] O
she O
returned O
to O
the O
or O
for O
c O
##rani O
##oto O
##my O
for O
ex O
##cision O
of O
residual O
tumor O
. O
on O
[ O
* O
* O
3 O
- O
5 O
* O
* O
] O
, O
patient O
was O
doing O
well O
, O
having O
some O
hall O
##uni O
##cation O
##s O
, O
but O
knows O
that O
they O
are O
hall O
##uni O
##cation O
##s O
. O
her O
de B-DRUG
##ca I-DRUG
##dron I-DRUG
was O
tap B-DOS
##pered I-DOS
and O
she O
was O
transferred O
to O
the O
floor O
. O
her O
exam O
remains O
stable O
; O
sq O
##h O
was O
started O
as O
well O
. O
c O
##v O
: O
she O
was O
maintained O
on O
te O
##lem O
##et O
##ry O
monitoring O
throughout O
her O
admission O
. O
end O
##o O
: O
she O
was O
maintained O
on O
finger O
sticks O
q B-FRE
##id I-FRE
and O
insulin B-DRUG
sliding B-DOS
scale I-DOS
while O
being O
treated O
with O
s B-DRUG
##tero I-DRUG
##ids I-DRUG
. I-DRUG
f O
##en O
: O
she O
was O
maintained O
on O
i B-DRUG
##v I-DRUG
##f I-DRUG
upon O
admission O
due O
to O
poor B-REA
p I-REA
##o I-REA
intake I-REA
. I-REA
she O
was O
advanced O
to O
a O
regular O
diet O
as O
her O
nausea O
improved O
. O
she O
was O
maintained O
on O
a O
bow O
##el O
regime O
##n O
as O
well O
as O
a O
pp B-DRUG
##i I-DRUG
for O
prop B-REA
##hyl I-REA
##ax I-REA
##is I-REA
. I-REA
id O
: O
she O
developed O
no O
signs O
of O
infection O
during O
her O
admission O
. O
prop O
##hyl O
##ax O
##is O
: O
she O
was O
maintained O
on O
sq B-ROU
he B-DRUG
##par I-DRUG
##in I-DRUG
for O
d B-REA
##v I-REA
##t I-REA
prop I-REA
##hyl I-REA
##ax I-REA
##is I-REA
and O
a O
pp B-DRUG
##i I-DRUG
for O
g B-REA
##i I-REA
prop I-REA
##hyl I-REA
##ax I-REA
##is I-REA
. I-REA
di O
##sp O
##o O
: O
patient O
was O
evaluated O
for O
p O
##t O
and O
o O
##t O
and O
discharged O
to O
[ O
* O
* O
hospital O
##1 O
* O
* O
] O
in O
[ O
* O
* O
location O
( O
un O
) O
86 O
* O
* O
] O
. O
medications O
on O
admission O
: O
v B-DRUG
##ico I-DRUG
##din I-DRUG
p B-FRE
##rn I-FRE

discharge O
medications O
: O
1 O
. O
ace B-DRUG
##tam I-DRUG
##ino I-DRUG
##phe I-DRUG
##n I-DRUG
325 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
two B-DOS
( I-DOS
2 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
q B-FRE
##6 I-FRE
##h I-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
. I-REA
2 O
. O
de B-DRUG
##xa I-DRUG
##met I-DRUG
##has I-DRUG
##one I-DRUG
4 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( O
daily O
) O
. O
3 O
. O
insulin B-DRUG
regular I-DRUG
human I-DRUG
100 B-STR
unit I-STR
/ I-STR
m I-STR
##l I-STR
solution B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
injection B-FOR
as B-FRE
##dir I-FRE
( O
as O
directed O
) O
. O
4 O
. O
calcium B-DRUG
carbon I-DRUG
##ate I-DRUG
200 B-STR
mg I-STR
calcium B-DRUG
( O
500 B-STR
mg I-STR
) I-STR
tablet B-FOR
, I-FOR
ch I-FOR
##ew I-FOR
##able I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
, I-FOR
ch I-FOR
##ew I-FOR
##able I-FOR
p B-ROU
##o I-ROU
q B-FRE
##id I-FRE
( I-FRE
4 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
heart B-REA
burn I-REA
. I-REA
5 O
. O
le B-DRUG
##vet I-DRUG
##ira I-DRUG
##ce I-DRUG
##tam I-DRUG
250 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
three B-DOS
( I-DOS
3 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
bid B-FRE
( O
2 O
times O
a O
day O
) O
. O
6 O
. O
se B-DRUG
##nna I-DRUG
8 B-STR
. I-STR
6 I-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
bid B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE
7 O
. O
o B-DRUG
##xy I-DRUG
##co I-DRUG
##don I-DRUG
##e I-DRUG
5 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
q B-FRE
##4 I-FRE
##h I-FRE
( I-FRE
every I-FRE
4 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
. I-REA
8 O
. O
pan B-DRUG
##top I-DRUG
##raz I-DRUG
##ole I-DRUG
40 B-STR
mg I-STR
tablet B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
p B-ROU
##o I-ROU
q B-FRE
##24 I-FRE
##h I-FRE
( I-FRE
every I-FRE
24 I-FRE
hours I-FRE
) I-FRE
. I-FRE
9 O
. O
do B-DRUG
##cus I-DRUG
##ate I-DRUG
sodium I-DRUG
100 B-STR
mg I-STR
capsule B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
capsule B-FOR
p B-ROU
##o I-ROU
bid B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE
10 O
. O
he B-DRUG
##par I-DRUG
##in I-DRUG
( I-DRUG
p I-DRUG
##or I-DRUG
##cine I-DRUG
) I-DRUG
5 B-STR
, I-STR
000 I-STR
unit I-STR
/ I-STR
m I-STR
##l I-STR
solution B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
injection B-FOR
t B-FRE
##id I-FRE
( I-FRE
3 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE
11 O
. O
on B-DRUG
##dan I-DRUG
##set I-DRUG
##ron I-DRUG
4 B-STR
mg I-STR
i B-ROU
##v I-ROU
q B-FRE
##8 I-FRE
##h I-FRE
: I-FRE
p I-FRE
##rn I-FRE
nausea B-REA
discharge O
disposition O
: O
extended O
care O
facility O
: O
[ O
* O
* O
hospital O
##6 O
85 O
* O
* O
] O
- O
[ O
* O
* O
location O
( O
un O
) O
86 O
* O
* O
] O
discharge O
diagnosis O
: O
c O
##ere O
##bella O
##r O
les O
##ion O
h O
##ydro O
##ce O
##pha O
##lus O
in O
##tra O
##vent O
##ric O
##ular O
hem O
##or O
##r O
##hage O
th O
##ora O
##ci O
##c O
compression O
f O
##x O
s B-DRUG
##tero I-DRUG
##id I-DRUG
ps B-ADE
##ych I-ADE
##osis I-ADE
discharge O
condition O
: O
mental O
status O
: O
confused O
- O
sometimes O
. O
level O
of O
consciousness O
: O
alert O
and O
interactive O
. O
activity O
status O
: O
am O
##bula O
##tory O
- O
requires O
assistance O
or O
aid O
( O
walk O
##er O
or O
cane O
) O
. O

discharge O
instructions O
: O
? O
? O
? O
? O
? O
? O
have O
a O
friend O
/ O
family O
member O
check O
your O
in O
##cision O
daily O
for O
signs O
of O
infection O
. O
? O
? O
? O
? O
? O
? O
take O
your O
pain B-DRUG
medicine I-DRUG
as O
prescribed O
. O
? O
? O
? O
? O
? O
? O
exercise O
should O
be O
limited O
to O
walking O
; O
no O
lifting O
, O
straining O
, O
or O
excessive O
bending O
. O
? O
? O
? O
? O
? O
? O
you O
may O
wash O
your O
hair O
72 O
hours O
from O
the O
time O
of O
your O
surgery O
, O
we O
recommend O
you O
use O
a O
mild O
s O
##ham O
##po O
##o O
and O
do O
not O
scrub O
the O
area O
. O
? O
? O
? O
? O
? O
? O
you O
may O
shower O
before O
this O
time O
using O
a O
shower O
cap O
to O
cover O
your O
head O
. O
? O
? O
? O
? O
? O
? O
increase O
your O
intake O
of O
fluids O
and O
fiber O
, O
as O
na B-DRUG
##rc I-DRUG
##otic I-DRUG
pain I-DRUG
medicine I-DRUG
can O
cause O
con B-ADE
##st I-ADE
##ip I-ADE
##ation I-ADE
. I-ADE
we O
generally O
recommend O
taking O
an O
over O
the O
counter O
stool O
soft O
##ener O
, O
such O
as O
do B-DRUG
##cus I-DRUG
##ate I-DRUG
( O
co B-DRUG
##lace I-DRUG
) I-DRUG
while O
taking O
na B-DRUG
##rc I-DRUG
##otic I-DRUG
pain I-DRUG
medication I-DRUG
. I-DRUG
? O
? O
? O
? O
? O
? O
unless O
directed O
by O
your O
doctor O
, O
do O
not O
take O
any O
anti B-DRUG
- I-DRUG
inflammatory I-DRUG
medicines I-DRUG
such O
as O
m B-DRUG
##ot I-DRUG
##rin I-DRUG
, I-DRUG
as B-DRUG
##pi I-DRUG
##rin I-DRUG
, I-DRUG
ad B-DRUG
##vil I-DRUG
, I-DRUG
and O
i B-DRUG
##bu I-DRUG
##p I-DRUG
##ro I-DRUG
##fen I-DRUG
. O
if O
you O
have O
been O
discharged O
on O
k B-DRUG
##ep I-DRUG
##pra I-DRUG
( O
le B-DRUG
##vet I-DRUG
##ira I-DRUG
##ce I-DRUG
##tam I-DRUG
) I-DRUG
, O
you O
will O
not O
require O
blood O
work O
monitoring O
. O
? O
? O
? O
? O
? O
? O
if O
you O
are O
being O
sent O
home O
on O
s B-DRUG
##tero I-DRUG
##id I-DRUG
medication I-DRUG
, I-DRUG
make O
sure O
you O
are O
taking O
a O
medication O
to O
protect O
your O
stomach O
( O
p B-DRUG
##ril I-DRUG
##ose I-DRUG
##c I-DRUG
, I-DRUG
pro B-DRUG
##ton I-DRUG
##ix I-DRUG
, I-DRUG
or O
p B-DRUG
##ep I-DRUG
##cid I-DRUG
) I-DRUG
, O
as O
these O
medications O
can O
cause O
stomach B-ADE
irritation I-ADE
. I-ADE
make O
sure O
to O
take O
your O
s B-DRUG
##tero I-DRUG
##id I-DRUG
medication O
with O
meals O
, O
or O
a O
glass O
of O
milk O
. O
? O
? O
? O
? O
? O
? O
clearance O
to O
drive O
and O
return O
to O
work O
will O
be O
addressed O
at O
your O
post O
- O
operative O
office O
visit O
. O
? O
? O
? O
? O
? O
? O
make O
sure O
to O
continue O
to O
use O
your O
incentive O
s O
##pi O
##rome O
##ter O
while O
at O
home O
. O
call O
your O
surgeon O
immediately O
if O
you O
experience O
any O
of O
the O
following O
? O
? O
? O
? O
? O
? O
new O
onset O
of O
t O
##rem O
##ors O
or O
seizure O
##s O
. O
? O
? O
? O
? O
? O
? O
any O
confusion O
or O
change O
in O
mental O
status O
. O
? O
? O
? O
? O
? O
? O
any O
numb O
##ness O
, O
tingling O
, O
weakness O
in O
your O
ex O
##tre O
##mit O
##ies O
. O
? O
? O
? O
? O
? O
? O
pain O
or O
headache O
that O
is O
continually O
increasing O
, O
or O
not O
relieved O
by O
pain O
medication O
. O
? O
? O
? O
? O
? O
? O
any O
signs O
of O
infection O
at O
the O
wound O
site O
: O
increasing O
red O
##ness O
, O
increased O
swelling O
, O
increased O
tender O
##ness O
, O
or O
drainage O
. O
? O
? O
? O
? O
? O
? O
fever O
greater O
than O
or O
equal O
to O
101 O
? O
? O
? O
? O
? O
? O
f O
. O
follow O
##up O
instructions O
: O
follow O
- O
up O
appointment O
instructions O

? O
? O
? O
? O
? O
? O
please O
return O
to O
the O
office O
in O
[ O
* O
* O
6 O
- O
30 O
* O
* O
] O
days O
( O
from O
your O
date O
of O
surgery O
) O
for O
removal O
of O
your O
su O
##tures O
. O
this O
appointment O
can O
be O
made O
with O
the O
nurse O
practitioner O
. O
please O
make O
this O
appointment O
by O
calling O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
166 O
##9 O
* O
* O
] O
. O
if O
you O
live O
quite O
a O
distance O
from O
our O
office O
, O
please O
make O
arrangements O
for O
the O
same O
, O
with O
your O
p O
##c O
##p O
. O
[ O
* O
* O
name O
initial O
( O
name O
##is O
) O
* O
* O
] O
[ O
* O
* O
name O
##11 O
( O
name O
##is O
) O
* O
* O
] O
have O
a O
follow O
- O
up O
with O
d O
##r O
. O
[ O
* O
* O
first O
name O
##4 O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
63 O
##6 O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
113 O
##0 O
##9 O
* O
* O
] O
on O
[ O
* O
* O
216 O
##7 O
- O
3 O
- O
12 O
* O
* O
] O
at O
2 O
##pm O
provider O
: O
[ O
* O
* O
first O
name O
##8 O
( O
name O
##pa O
##tter O
##n O
##2 O
) O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
125 O
##6 O
##7 O
* O
* O
] O
[ O
* O
* O
name O
##12 O
( O
name O
##is O
) O
* O
* O
] O
, O
m O
##d O
phone O
: O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
1844 O
* O
* O
] O
date O
/ O
time O
: O
[ O
* O
* O
216 O
##7 O
- O
3 O
- O
16 O
* O
* O
] O
4 O
: O
00 O
provider O
: O
[ O
* O
* O
first O
name O
##11 O
( O
name O
pattern O
##1 O
) O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
59 O
##3 O
* O
* O
] O
, O
m O
##d O
phone O
: O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
22 O
* O
* O
] O
date O
/ O
time O
: O
[ O
* O
* O
216 O
##7 O
- O
3 O
- O
12 O
* O
* O
] O
2 O
: O
00 O
[ O
* O
* O
name O
##6 O
( O
m O
##d O
) O
74 O
##2 O
* O
* O
] O
[ O
* O
* O
name O
##8 O
( O
m O
##d O
) O
* O
* O
] O
m O
##d O
[ O
* O
* O
m O
##d O
number O
( O
2 O
) O
127 O
##3 O
* O
* O
] O
completed O
by O
: O
[ O
* O
* O
216 O
##7 O
- O
3 O
- O
6 O
* O
* O
] O

admission O
date O
: O
[ O
* O
* O
219 O
##9 O
- O
11 O
- O
4 O
* O
* O
] O
discharge O
date O
: O
[ O
* O
* O
219 O
##9 O
- O
11 O
- O
9 O
* O
* O
] O
service O
: O
medicine O
all O
##er O
##gies O
: O
m B-DRUG
##or I-DRUG
##phine I-DRUG
attending O
: O
[ O
* O
* O
doctor O
first O
name O
208 O
##0 O
* O
* O
] O
chief O
complaint O
: O
bi O
##lia O
##ry O
o O
##bs O
##tu O
##ction O
. O
major O
surgical O
or O
invasive O
procedure O
: O
er O
##c O
##p O
i O
##r O
guided O
bi O
##lia O
##ry O
drain O
history O
of O
present O
illness O
: O
this O
is O
an O
88 O
yo O
man O
transferred O
from O
o O
##sh O
[ O
* O
* O
11 O
- O
4 O
* O
* O
] O
for O
er O
##c O
##p O
for O
bi O
##lia O
##ry O
o O
##bs O
##truction O
with O
o O
##bs O
##truct O
##ive O
he O
##pa O
##top O
##athy O
. O
presented O
to O
[ O
* O
* O
hospital O
156 O
##2 O
* O
* O
] O
hospital O
on O
[ O
* O
* O
11 O
- O
3 O
* O
* O
] O
with O
increasing O
short O
##ness O
of O
breath O
, O
di O
##zzi O
##ness O
, O
and O
j O
##au O
##ndi O
##ce O
. O
per O
o O
##sh O
also O
reported O
fever O
##s O
, O
chill O
##s O
, O
and O
nausea O
. O
had O
g O
##ve O
##en O
given O
b B-DRUG
##act I-DRUG
##rim I-DRUG
for O
a O
u B-REA
##ti I-REA
one O
week O
prior O
. O
he O
underwent O
an O
abdomen O
c O
##t O
which O
showed O
in O
##tra O
##he O
##pa O
##tic O
and O
extra B-REA
##he I-REA
##pa I-REA
##tic I-REA
o I-REA
##bs I-REA
##truction I-REA
likely I-REA
secondary I-REA
to I-REA
meta I-REA
##static I-REA
cancer I-REA
to I-REA
the I-REA
pan I-REA
##cre I-REA
##atic I-REA
head I-REA
. I-REA
he O
was O
started O
on O
flag B-DRUG
##yl I-DRUG
, I-DRUG
z B-DRUG
##osy I-DRUG
##n I-DRUG
, I-DRUG
and O
van B-DRUG
##c I-DRUG
and O
transferred O
to O
[ O
* O
* O
hospital O
##1 O
18 O
* O
* O
] O
for O
er O
##c O
##p O
. O
while O
being O
pre O
##pped O
for O
er O
##c O
##p O
( O
while O
under O
mac O
) O
and O
turned O
prone O
he O
re O
##gu O
##rg O
##itated O
coffee O
- O
brown O
material O
so O
he O
was O
elect O
##ively O
in O
##tub O
##ated O
due O
to O
concern O
for O
his O
risk O
of O
as O
##piration O
. O
they O
pro O
##ceded O
with O
er O
##c O
##p O
, O
but O
were O
unable O
to O
can O
##nu O
##late O
the O
bi O
##lia O
##ry O
tree O
. O
a O
du O
##do O
##den O
##al O
s O
##ten O
##t O
was O
placed O
due O
to O
external O
compression O
of O
the O
duo O
##den O
##um O
. O
he O
was O
placed O
on O
prop B-DRUG
##of I-DRUG
##ol I-DRUG
for O
se B-REA
##dation I-REA
and O
his O
s O
##b O
##p O
' O
s O
dropped O
to O
the O
80 O
' O
s O
in O
the O
p O
##ac O
##u O
. O
he O
was O
started O
on O
neo B-DRUG
through O
a O
p B-ROU
##iv I-ROU
for O
pressure B-REA
support I-REA
. I-REA
in O
the O
i O
##cu O
the O
neo O
was O
rapidly O
we O
##ane O
##d O
and O
he O
was O
ex O
##tub O
##ated O
easily O
[ O
* O
* O
11 O
- O
5 O
* O
* O
] O
. O
it O
was O
thought O
that O
his O
inability O
to O
ex O
##tub O
##ate O
post O
- O
procedure O
and O
h B-ADE
##y I-ADE
##pot I-ADE
##ens I-ADE
##ion I-ADE
were O
due O
to O
se O
##dation O
rather O
than O
as O
##piration O
given O
his O
rapid O
improvement O
. O
r O
##os O
: O
10 O
point O
review O
of O
systems O
negative O
except O
as O
noted O
above O
. O

past O
medical O
history O
: O
1 O
. O
co O
##lon O
cancer O
with O
met O
##s O
s O
/ O
p O
co O
##lect O
##omy O
complicated O
with O
small O
and O
large O
bow O
##el O
o O
##bs O
##truction O
with O
a O
co O
##los O
##tom O
##y O
. O
on O
##cologist O
identified O
in O
o O
##sh O
records O
as O
d O
##r O
. O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
258 O
##0 O
##2 O
* O
* O
] O
. O
2 O
. O
pro O
##state O
en O
##lar O
##gement O
s O
/ O
p O
t O
##ur O
##p O
, O
? O
in O
o O
##sh O
of O
pro O
##static O
met O
##s O
3 O
. O
h O
##yper O
##tens O
##ion O
4 O
. O
h O
##yper O
##cho O
##les O
##tero O
##lem O
##ia O
5 O
. O
g O
##erd O
6 O
. O
s O
/ O
p O
tons O
##ille O
##ct O
##omy O
social O
history O
: O
lives O
alone O
. O
per O
o O
##sh O
records O
is O
a O
non O
##smo O
##ker O
, O
and O
no O
alcohol O
use O
. O
known O
family O
is O
sister O
in O
[ O
* O
* O
name O
( O
ni O
) O
90 O
##12 O
* O
* O
] O
. O
family O
history O
: O
non O
##con O
##tri O
##but O
##ory O
physical O
exam O
: O
vital O
##s O
: O
g O
##en O
: O
well O
appearing O
, O
pleasant O
male O
he O
##ent O
: O
s O
##cle O
##ra O
i O
##cter O
##ic O
, O
per O
##rl O
##a O
, O
e O
##omi O
, O
op O
clear O
c O
##v O
: O
+ O
s O
##1 O
##s O
##2 O
, O
r O
##rr O
, O
no O
m O
##rg O
appreciated O
lungs O
: O
c O
##ta O
##b O
a O
##b O
##d O
: O
+ O
o O
##sto O
##my O
bag O
in O
place O
, O
+ O
bi O
##lia O
##ry O
drain O
in O
place O
, O
+ O
b O
##s O
, O
soft O
, O
n O
##t O
, O
n O
##d O
ex O
##t O
: O
no O
c O
/ O
c O
/ O
e O
per O
##tinent O
results O
: O
admission O
labs O
: O
c O
##b O
##c O
: O
11 O
. O
4 O
( O
n O
89 O
, O
no O
bands O
) O
- O
> O
9 O
. O
3 O
, O
h O
##ct O
25 O
. O
1 O
- O
> O
28 O
, O
p O
##lt O
38 O
##8 O
b O
##mp O
: O
135 O
, O
4 O
. O
2 O
, O
102 O
, O
23 O
, O
19 O
, O
1 O
. O
0 O
, O
94 O
al O
##t O
236 O
- O
> O
218 O
, O
as O
##t O
300 O
- O
> O
26 O
##8 O
, O
a O
##p O
85 O
##6 O
- O
> O
81 O
##6 O
, O
bi O
##li O
11 O
. O
8 O
- O
> O
11 O
. O
2 O
, O
lip O
##ase O
184 O
- O
> O
120 O
p O
##tt O
28 O
. O
4 O
, O
in O
##r O
1 O
. O
3 O
la O
##ct O
##ate O
0 O
. O
8 O
. O

discharge O
labs O
: O
[ O
* O
* O
219 O
##9 O
- O
11 O
- O
9 O
* O
* O
] O
05 O
: O
32 O
##am O
blood O
w O
##b O
##c O
- O
8 O
. O
2 O
r O
##b O
##c O
- O
2 O
. O
57 O
* O
h O
##g O
##b O
- O
8 O
. O
3 O
* O
h O
##ct O
- O
25 O
. O
8 O
* O
m O
##c O
##v O
- O
101 O
* O
m O
##ch O
- O
32 O
. O
3 O
* O
m O
##ch O
##c O
- O
32 O
. O
1 O
r O
##d O
##w O
- O
17 O
. O
5 O
* O
p O
##lt O
c O
##t O
- O
38 O
##3 O
[ O
* O
* O
219 O
##9 O
- O
11 O
- O
9 O
* O
* O
] O
05 O
: O
32 O
##am O
blood O
glucose O
- O
102 O
u O
##rea O
##n O
- O
19 O
c O
##rea O
##t O
- O
0 O
. O
9 O
na O
- O
139 O
k O
- O
3 O
. O
5 O
c O
##l O
- O
106 O
h O
##co O
##3 O
- O
25 O
an O
##ga O
##p O
- O
12 O
[ O
* O
* O
219 O
##9 O
- O
11 O
- O
9 O
* O
* O
] O
05 O
: O
32 O
##am O
blood O
al O
##t O
- O
97 O
* O
as O
##t O
- O
58 O
* O
al O
##k O
##ph O
##os O
- O
66 O
##2 O
* O
to O
##t O
##bil O
##i O
- O
5 O
. O
4 O
* O
. O
u O
##a O
: O
blood O
- O
s O
##m O
ni O
##tri O
##te O
- O
ne O
##g O
protein O
- O
30 O
glucose O
- O
ne O
##g O
k O
##eton O
##e O
- O
ne O
##g O
bi O
##li O
##ru O
##bin O
- O
m O
##od O
u O
##ro O
##bil O
##ng O
##n O
- O
ne O
##g O
p O
##h O
- O
5 O
. O
5 O
le O
##uk O
- O
m O
##od O
r O
##b O
##c O
- O
4 O
* O
w O
##b O
##c O
- O
13 O
* O
bacteria O
- O
few O
yeast O
- O
none O
e O
##pi O
- O
0 O
. O
urine O
c O
##x O
[ O
* O
* O
11 O
- O
4 O
* O
* O
] O
: O
no O
growth O
. O
blood O
c O
##x O
[ O
* O
* O
11 O
- O
4 O
* O
* O
] O
: O
pending O
. O
m O
##rsa O
screen O
[ O
* O
* O
11 O
- O
4 O
* O
* O
] O
: O
pending O
. O
. O
c O
##x O
##r O
port O
[ O
* O
* O
11 O
- O
4 O
* O
* O
] O
: O
lung O
volumes O
are O
quite O
low O
. O
with O
the O
chin O
down O
, O
the O
tip O
of O
the O
et O
tube O
at O
the O
upper O
margin O
of O
the O
c O
##lav O
##icles O
is O
3 O
cm O
above O
optimal O
placement O
. O
[ O
* O
* O
month O
( O
only O
) O
116 O
* O
* O
] O
be O
left O
hi O
##lar O
en O
##lar O
##gement O
and O
one O
or O
more O
nod O
##ules O
in O
the O
left O
lung O
. O
a O
band O
of O
ate O
##lect O
##asis O
is O
present O
at O
the O
base O
of O
the O
right O
lung O
which O
is O
otherwise O
clear O
. O
heart O
is O
mildly O
enlarged O
. O
no O
p O
##ne O
##um O
##oth O
##orax O
. O
small O
bilateral O
p O
##le O
##ural O
e O
##ff O
##usions O
, O
left O
greater O
than O
right O
, O
are O
likely O
present O
. O
an O
apparent O
b O
##ulge O
in O
the O
right O
media O
##st O
##inal O
con O
##tour O
could O
be O
a O
skin O
fold O
instead O
. O
repeat O
radio O
##graphs O
, O
conventional O
if O
possible O
, O
recommended O
when O
feasible O
. O
. O

er O
##c O
##p O
[ O
* O
* O
11 O
- O
4 O
* O
* O
] O
: O
a O
large O
amount O
of O
gas O
##tric O
fluid O
was O
found O
when O
the O
end O
##os O
##cope O
was O
passed O
into O
the O
stomach O
, O
suggest O
##ive O
of O
out O
##flow O
tract O
o O
##bs O
##truction O
. O
unable O
to O
pass O
the O
scope O
to O
the O
second O
part O
of O
the O
duo O
##den O
##um O
due O
to O
o O
##bs O
##truction O
, O
most O
likely O
ex O
##tri O
##ns O
##ic O
compression O
from O
co O
##lon O
cancer O
meta O
##sta O
##ses O
. O
a O
duo O
##den O
##al O
s O
##ten O
##t O
( O
9 O
##c O
##m O
x O
##22 O
##mm O
wall O
##fle O
##x O
enter O
##al O
duo O
##den O
##al O
s O
##ten O
##t O
) O
was O
placed O
successfully O
under O
flu O
##oro O
##scopic O
guidance O
to O
alleviate O
the O
gas O
##tric O
outlet O
o O
##bs O
##truction O
. O
re O
##f O
650 O
##2 O
. O
lot O
[ O
* O
* O
n O
##ume O
##ric O
id O
##ent O
##ifier O
258 O
##0 O
##3 O
* O
* O
] O
( O
s O
##ten O
##t O
placement O
) O
. O
flu O
##oro O
[ O
* O
* O
11 O
- O
6 O
* O
* O
] O
: O
impression O
: O
per O
##cut O
##aneous O
trans O
##he O
##pa O
##tic O
ch O
##ola O
##ng O
##io O
##gram O
demonstrating O
moderate O
in O
##tra O
- O
and O
extra O
- O
he O
##pa O
##tic O
bi O
##lia O
##ry O
duct O
##al O
di O
##lat O
##ation O
with O
o O
##bs O
##truction O
of O
the O
common O
bi O
##le O
duct O
at O
the O
level O
of O
the O
am O
##pu O
##lla O
. O
successful O
placement O
of O
a O
right O
trans O
##he O
##pa O
##tic O
internal O
- O
external O
bi O
##lia O
##ry O
draining O
cat O
##he O
##ter O
with O
the O
cat O
##he O
##ter O
connected O
to O
a O
bag O
for O
external O
drainage O
brief O
hospital O
course O
: O
assessment O
and O
plan O
: O
88 O
yo O
male O
with O
pm O
##h O
of O
meta O
##static O
co O
##lon O
cancer O
and O
h O
##yper O
##tens O
##ion O
who O
is O
being O
admitted O
to O
the O
[ O
* O
* O
hospital O
unit O
name O
153 O
* O
* O
] O
due O
to O
h O
##y O
##pot O
##ens O
##ion O
and O
need O
for O
continued O
in O
##tub O
##ation O
s O
/ O
p O
er O
##c O
##p O
attempt O
for O
bi O
##lia O
##ry O
o O
##bs O
##truction O
. O
. O
# O
h O
##y O
##pot O
##ens O
##ion O
: O
patient O
became O
h B-ADE
##y I-ADE
##pot I-ADE
##ens I-ADE
##ive I-ADE
after O
in O
##tub O
##ation O
on O
prop B-DRUG
##of I-DRUG
##ol I-DRUG
. I-DRUG
likely O
secondary O
to O
prop B-DRUG
##of I-DRUG
##ol I-DRUG
, I-DRUG
however O
also O
in O
the O
differential O
is O
h O
##y O
##pot O
##ens O
##ion O
from O
se O
##psis O
. O
he O
has O
two O
potential O
sources O
for O
se O
##psis O
: O
bi O
##lia O
##ry O
o O
##bs O
##truction O
and O
recent O
a O
##ps O
##ira O
##tion O
. O
also O
could O
have O
volume O
de O
##ple O
##tion O
. O
since O
coming O
to O
the O
floor O
his O
pressures O
had O
recovered O
and O
p B-DRUG
##hen I-DRUG
##yle I-DRUG
##ph I-DRUG
##rine I-DRUG
we O
##ane O
##d O
off O
. O
given O
the O
possibility O
of O
se B-REA
##psis I-REA
, I-REA
he O
was O
started O
on O
van B-DRUG
##com I-DRUG
##y I-DRUG
##cin I-DRUG
, I-DRUG
flag B-DRUG
##yl I-DRUG
and O
c B-DRUG
##ef I-DRUG
##ep I-DRUG
##ime I-DRUG
, I-DRUG
but O
then O
changed O
to O
c B-DRUG
##ef I-DRUG
##tri I-DRUG
##ax I-DRUG
##one I-DRUG
and O
flag B-DRUG
##yl I-DRUG
. I-DRUG
the O
van B-DRUG
##com I-DRUG
##y I-DRUG
##cin I-DRUG
was O
discontinued O
after O
the O
cultures O
were O
negative O
x O
48 O
ho O
##rus O
. O
on O
the O
day O
before O
discharge O
he O
was O
transitioned O
to O
p B-ROU
##o I-ROU
le B-DRUG
##vo I-DRUG
##f I-DRUG
##lo I-DRUG
##xa I-DRUG
##cin I-DRUG
to O
complete O
a O
full O
course O
through O
[ O
* O
* O
11 O
- O
11 O
* O
* O
] O
, O
cultures O
no O
growth O
to O
date O
at O
discharge O
. O
. O

# O
bi O
##lia O
##ry O
o O
##bs O
##truction O
/ O
o O
##bs O
##truct O
##ive O
j O
##au O
##ndi O
##ce O
: O
the O
patient O
underwent O
a O
c O
##t O
at O
the O
o O
##sh O
which O
showed O
in O
##tra O
##he O
##pa O
##tic O
and O
extra O
##he O
##pa O
##tic O
bi O
##le O
duct O
di O
##lat O
##ation O
likely O
due O
to O
a O
meta O
##sta O
##sis O
to O
the O
pan O
##cre O
##atic O
head O
from O
his O
co O
##lon O
cancer O
. O
he O
failed O
er O
##c O
##p O
due O
to O
external O
compression O
of O
the O
duo O
##den O
##um O
limiting O
their O
ability O
to O
pass O
the O
scope O
. O
a O
duo O
##den O
##al O
s O
##ten O
##t O
was O
placed O
by O
the O
er O
##c O
##p O
team O
to O
help O
to O
de O
##com O
##press O
the O
gas O
##tric O
outlet O
o O
##bs O
##truction O
. O
given O
the O
failed O
er O
##c O
##p O
attempt O
, O
i O
##r O
was O
consulted O
and O
performed O
an O
i O
##r O
guided O
bi O
##lia O
##ry O
drain O
on O
[ O
* O
* O
219 O
##9 O
- O
11 O
- O
6 O
* O
* O
] O
. O
he O
was O
transferred O
to O
the O
floor O
and O
his O
l O
##fts O
trend O
##ed O
down O
after O
the O
s O
##ten O
##t O
was O
placed O
. O
his O
drain O
was O
clamped O
on O
[ O
* O
* O
11 O
- O
8 O
* O
* O
] O
and O
with O
continued O
improvement O
of O
his O
liver O
tests O
and O
symptoms O
. O
he O
was O
discharged O
with O
a O
clamped O
bi O
##lia O
##ry O
drain O
to O
follow O
up O
with O
intervention O
##al O
radio O
##logy O
. O
if O
symptoms O
return O
, O
the O
drain O
can O
be O
un O
##c O
##lamp O
##ed O
to O
a O
bag O
. O
. O
# O
respiratory O
distress O
: O
the O
patient O
presented O
to O
the O
i O
##cu O
in O
##tub O
##ated O
since O
the O
er O
##c O
##p O
. O
on O
the O
following O
morning O
he O
was O
successfully O
ex O
##tub O
##ated O
and O
breathing O
appropriately O
on O
room O
air O
. O
. O
# O
an O
##emia O
, O
chronic O
disease O
: O
the O
patient O
was O
noted O
to O
have O
co O
##ffe O
- O
ground O
re O
##gu O
##rg O
##itation O
during O
the O
er O
##c O
##p O
pro O
##c O
##du O
##re O
. O
he O
was O
an O
##em O
##ic O
with O
a O
h O
##ct O
of O
26 O
at O
the O
o O
##sh O
and O
25 O
on O
admission O
labs O
here O
. O
v O
##it O
b O
##12 O
and O
f O
##olate O
normal O
at O
the O
o O
##sh O
. O
f O
##e O
low O
, O
but O
other O
f O
##e O
studies O
not O
sent O
. O
ha O
##pt O
##og O
##lo O
##bin O
high O
makes O
hem O
##oly O
##sis O
unlikely O
. O
most O
likely O
due O
to O
an O
##emia O
of O
chronic O
disease O
and O
possibly O
due O
to O
on O
##co O
##log O
##ic O
treatment O
. O
started O
an O
i B-ROU
##v I-ROU
pp B-DRUG
##i I-DRUG
due O
to O
concern O
for O
coffee B-REA
ground I-REA
re I-REA
##gu I-REA
##rg I-REA
##ita I-REA
##nt I-REA
. I-REA
his O
hem O
##ato O
##c O
##rits O
were O
stable O
and O
did O
not O
need O
trans O
##fusion O
##s O
. O
. O
# O
meta O
##static O
co O
##lon O
cancer O
: O
patient O
has O
multiple O
met O
##s O
seen O
on O
o O
##sh O
imaging O
. O
he O
will O
follow O
up O
with O
his O
out O
##patient O
surgeon O
after O
discharge O
. O
. O
# O
h O
##yper O
##tens O
##ion O
, O
ben O
##ign O
: O
stable O
medications O
on O
admission O
: O
home O
medications O
: O
pre B-DRUG
##va I-DRUG
##cid I-DRUG
10 B-STR
mg I-STR
p B-ROU
##o I-ROU
daily B-FRE
lip B-DRUG
##itor I-DRUG
10 B-STR
mg I-STR
p B-ROU
##o I-ROU
q B-FRE
##hs I-FRE

discharge O
medications O
: O
1 O
. O
le B-DRUG
##vo I-DRUG
##f I-DRUG
##lo I-DRUG
##xa I-DRUG
##cin I-DRUG
500 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
q B-FRE
##24 I-FRE
##h I-FRE
( O
every O
24 O
hours O
) O
for B-DUR
2 I-DUR
days I-DUR
. I-DUR
di O
##sp O
: O
* O
2 O
tablet O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
0 O
* O
2 O
. O
pre B-DRUG
##va I-DRUG
##cid I-DRUG
30 B-STR
mg I-STR
capsule B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
capsule B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
p B-ROU
##o I-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE
discharge O
disposition O
: O
home O
with O
service O
facility O
: O
v O
##na O
of O
upper O
[ O
* O
* O
hospital O
##3 O
* O
* O
] O
discharge O
diagnosis O
: O
meta O
##ts O
##tat O
##ic O
co O
##lon O
cancer O
gas O
##tric O
outlet O
o O
##bs O
##truction O
s O
/ O
p O
duo O
##den O
##al O
s O
##ten O
##t O
placement O
bi O
##lia O
##ry O
o O
##bs O
##truction O
s O
/ O
p O
i O
##r O
placed O
drain O
pro O
##state O
en O
##lar O
##gement O
s O
/ O
p O
t O
##ur O
##p O
h O
##yper O
##tens O
##ion O
, O
ben O
##ign O
h O
##yper O
##cho O
##les O
##tero O
##lem O
##ia O
gas O
##tro O
##es O
##op O
##hage O
##al O
re O
##f O
##lux O
discharge O
condition O
: O
stable O
discharge O
instructions O
: O
you O
were O
admitted O
to O
the O
hospital O
be O
##cu O
##ase O
you O
had O
an O
o O
##bs O
##truction O
in O
the O
small O
bow O
##el O
and O
also O
in O
your O
bi O
##lia O
##ry O
tract O
. O
you O
went O
for O
a O
procedure O
that O
s O
##ten O
##ted O
open O
your O
small O
bow O
##el O
allowing O
you O
to O
eat O
liquid O
##s O
and O
solid O
##s O
. O
you O
then O
went O
to O
the O
have O
a O
drain O
placed O
in O
your O
bi O
##lia O
##ry O
duct O
in O
order O
to O
the O
relieve O
the O
o O
##bs O
##truction O
. O
resume O
all O
of O
your O
home O
medications O
except O
lip B-DRUG
##itor I-DRUG
, I-DRUG
until O
follow O
up O
with O
your O
doctors O
. O
you O
will O
need O
to O
continue O
the O
le B-DRUG
##vo I-DRUG
##f I-DRUG
##lo I-DRUG
##xa I-DRUG
##cin I-DRUG
for B-DUR
7 I-DUR
days I-DUR
until O
[ O
* O
* O
219 O
##9 O
- O
11 O
- O
11 O
* O
* O
] O
. O
you O
will O
need O
to O
follow O
up O
with O
your O
primary O
surgeon O
and O
your O
primary O
care O
doctor O
. O
additionally O
, O
intervention O
##al O
radio O
##logy O
will O
contact O
you O
to O
follow O
up O
with O
your O
drain O
management O
. O
return O
to O
the O
hospital O
if O
you O
experience O
fever O
##s O
/ O
chill O
##s O
, O
abdominal O
pain O
, O
recurring O
j O
##au O
##ndi O
##ce O
, O
or O
any O
other O
concerning O
symptoms O
. O
follow O
##up O
instructions O
: O
as O
above O
, O
you O
will O
need O
to O
follow O
up O
with O
your O
primary O
surgeon O
, O
d O
##r O
. O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
258 O
##0 O
##4 O
* O
* O
] O
when O
you O
return O
home O
, O
as O
well O
as O
with O
your O
p O
##c O
##p O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##4 O
) O
* O
* O
] O
. O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
252 O
##37 O
* O
* O
] O
as O
soon O
as O
possible O
. O
you O
will O
also O
need O
to O
follow O
up O
with O
the O
intervention O
##al O
radio O
##logy O
department O
in O
order O
to O
change O
the O
drain O
in O
3 O
months O
. O
they O
will O
contact O
you O
to O
schedule O
this O
. O

admission O
date O
: O
[ O
* O
* O
212 O
##4 O
- O
3 O
- O
14 O
* O
* O
] O
discharge O
date O
: O
[ O
* O
* O
212 O
##4 O
- O
3 O
- O
27 O
* O
* O
] O
date O
of O
birth O
: O
[ O
* O
* O
209 O
##4 O
- O
3 O
- O
2 O
* O
* O
] O
sex O
: O
f O
service O
: O
medicine O
all O
##er O
##gies O
: O
un B-DRUG
##as I-DRUG
##yn I-DRUG
attending O
: O
[ O
* O
* O
first O
name O
##3 O
( O
l O
##f O
) O
42 O
##32 O
* O
* O
] O
chief O
complaint O
: O
neck O
swelling O
major O
surgical O
or O
invasive O
procedure O
: O
left O
neck O
exploration O
and O
drain O
placement O
in O
##tub O
##ation O
and O
mechanical O
ventilation O
history O
of O
present O
illness O
: O
30 O
##f O
with O
a O
history O
of O
[ O
* O
* O
doctor O
last O
name O
93 O
##7 O
##6 O
* O
* O
] O
disease O
and O
chronic O
pan O
##cy O
##top O
##enia O
/ O
ne O
##ut O
##rop O
##enia O
who O
is O
re O
- O
admitted O
with O
re O
##ac O
##cum O
##ulation O
of O
fluid O
following O
initial O
drainage O
of O
posterior O
/ O
para O
##pha O
##ryn O
##ge O
##al O
a O
##bs O
##cess O
on O
[ O
* O
* O
212 O
##4 O
- O
2 O
- O
23 O
* O
* O
] O
. O
she O
initially O
presented O
~ O
3 O
weeks O
ago O
with O
neck O
/ O
swallowing O
pain O
and O
was O
found O
to O
have O
the O
above O
a O
##bs O
##cess O
on O
c O
##t O
imaging O
, O
which O
was O
drained O
and O
cultures O
ultimately O
grew O
beta B-REA
s I-REA
##tre I-REA
##pt I-REA
##oc I-REA
##oc I-REA
##cus I-REA
group I-REA
a I-REA
and O
prop B-REA
##ion I-REA
##ob I-REA
##act I-REA
##eri I-REA
##um I-REA
a I-REA
##c I-REA
##nes I-REA
. I-REA
she O
was O
treated O
with O
me B-DRUG
##rop I-DRUG
##ene I-DRUG
##m I-DRUG
for O
this O
( O
changed O
to O
er B-DRUG
##ta I-DRUG
##pen I-DRUG
##em I-DRUG
upon O
discharge O
) O
. O
her O
initial O
hospital O
##ization O
( O
[ O
* O
* O
date O
range O
( O
1 O
) O
61 O
##43 O
##6 O
* O
* O
] O
) O
was O
complicated O
by O
in O
##tub O
##ation O
for O
air O
##way O
protection O
x O
several O
days O
, O
ne O
##ut O
##rop O
##enia O
( O
w O
##b O
##c O
na O
##dir O
0 O
. O
6 O
with O
67 O
% O
ne O
##ut O
##rop O
##hil O
##s O
on O
[ O
* O
* O
2 O
- O
26 O
* O
* O
] O
) O
, O
an O
##emia O
to O
h O
##ct O
< O
21 O
( O
received O
2 O
units O
p O
##rb O
##cs O
) O
. O
she O
also O
developed O
left O
i O
##j O
nearly O
- O
o O
##cc O
##lus O
##ive O
c O
##lot O
, O
which O
was O
not O
felt O
to O
be O
se O
##ptic O
in O
origin O
. O
after O
multi O
##sp O
##ec O
##ial O
##ist O
discussion O
, O
the O
decision O
was O
made O
not O
to O
anti O
##coa O
##gu O
##late O
as O
risks O
were O
felt O
to O
out O
##wei O
##gh O
benefits O
. O
she O
was O
seen O
by O
hem O
##ato O
##logy O
during O
that O
admission O
and O
started O
on O
ne B-DRUG
##up I-DRUG
##ogen I-DRUG
, I-DRUG
which O
was O
stopped O
when O
w O
##b O
##c O
count O
came O
> O
350 O
##0 O
. O
she O
had O
planned O
follow O
up O
as O
an O
out O
##patient O
for O
? O
b O
##mb O
##x O
in O
early O
[ O
* O
* O
month O
( O
only O
) O
116 O
* O
* O
] O
. O

after O
returning O
home O
, O
she O
initially O
stab O
##ilized O
and O
felt O
she O
was O
beginning O
to O
improve O
; O
however O
, O
her O
husband O
noticed O
after O
several O
days O
that O
she O
was O
developing O
increased O
swelling O
at O
the O
surgical O
site O
as O
well O
as O
increased O
drainage O
. O
she O
also O
had O
increased O
pain O
and O
developed O
nights O
##we O
##ats O
, O
though O
te O
##mps O
were O
in O
99 O
##s O
( O
no O
true O
fever O
) O
. O
she O
came O
back O
to O
ed O
where O
c O
##t O
scan O
showed O
re O
- O
accumulation O
of O
fluid O
, O
and O
she O
was O
taken O
back O
to O
or O
[ O
* O
* O
212 O
##4 O
- O
3 O
- O
14 O
* O
* O
] O
by O
en O
##t O
for O
drainage O
. O
she O
spent O
the O
night O
in O
sic O
##u O
for O
observation O
, O
where O
she O
has O
done O
well O
from O
a O
surgical O
perspective O
( O
3 O
drains O
in O
place O
, O
no O
air O
##way O
compromise O
) O
. O
currently O
she O
has O
minimal O
complaints O
of O
neck B-REA
pain I-REA
well O
controlled O
with O
di B-DRUG
##lau I-DRUG
##di I-DRUG
##d I-DRUG
p B-FOR
##ca I-FOR
. I-FOR
has O
no O
difficulty O
swallowing O
, O
breathing O
or O
speaking O
. O
past O
medical O
history O
: O
# O
ne O
##ut O
##rop O
##enia O
of O
unknown O
et O
##iology O
- O
diagnosed O
2 O
years O
ago O
, O
base O
##line O
w O
##b O
##c O
1 O
. O
8 O
, O
had O
serial O
blood O
tests O
in O
[ O
* O
* O
location O
( O
un O
) O
1831 O
##7 O
* O
* O
] O
for O
8 O
weeks O
and O
as O
w O
##b O
##c O
stayed O
stable O
no O
treatment O
was O
initiated O
, O
had O
m O
##ri O
at O
the O
time O
but O
no O
bone O
ma O
##rrow O
, O
has O
been O
told O
she O
has O
s O
##ple O
##no O
##me O
##gal O
##y O
, O
no O
history O
of O
prior O
serious O
infections O
or O
hospital O
##izations O
aside O
from O
her O
pre O
##gne O
##ncy O
though O
per O
husband O
she O
does O
take O
longer O
to O
recover O
from O
minor O
infections O
# O
[ O
* O
* O
doctor O
last O
name O
93 O
##7 O
##6 O
* O
* O
] O
disease O
- O
diagnosed O
2 O
years O
ago O
# O
f O
##e O
deficiency O
an O
##emia O
- O
not O
currently O
on O
iron B-DRUG
supplement B-FOR
##ation I-FOR
# O
h O
##x O
of O
mon O
##on O
##uc O
##leo O
##sis O
infection O
# O
war B-REA
##ts I-REA
on I-REA
feet I-REA
- O
on O
ran B-DRUG
##iti I-DRUG
##dine I-DRUG
, I-DRUG
followed O
by O
der O
##mat O
##ology O
# O
o O
##var O
##ian O
c O
##ys O
##tec O
##tom O
##y O
social O
history O
: O
born O
in O
new O
[ O
* O
* O
country O
66 O
##7 O
##9 O
* O
* O
] O
but O
has O
lived O
in O
ma O
for O
six O
years O
. O
married O
with O
no O
children O
( O
had O
child O
with O
h O
##y O
##pop O
##lastic O
left O
heart O
syndrome O
who O
died O
at O
age O
of O
2 O
days O
in O
[ O
* O
* O
211 O
##6 O
* O
* O
] O
) O
. O
works O
as O
jet O
blue O
flight O
attendant O
. O
non O
- O
smoke O
##r O
. O
[ O
* O
* O
1 O
- O
23 O
* O
* O
] O
drinks O
/ O
month O
. O
no O
drugs O
. O
family O
history O
: O
father O
with O
[ O
* O
* O
doctor O
last O
name O
93 O
##7 O
##6 O
* O
* O
] O
syndrome O
, O
history O
of O
mon O
##o O
mother O
died O
of O
l O
##up O
##us O
in O
[ O
* O
* O
211 O
##6 O
* O
* O
] O
aunt O
with O
severe O
m O
##s O
grandfather O
had O
cancer O
no O
history O
of O
immune O
disorders O
, O
c O
##lot O
##ting O
or O
bleeding O
disorders O

physical O
exam O
: O
physical O
exam O
: O
on O
transfer O
vs O
- O
99 O
. O
9 O
/ O
99 O
. O
2 O
122 O
/ O
70 O
86 O
- O
89 O
18 O
- O
20 O
97 O
% O
r O
##a O
general O
: O
lying O
in O
bed O
, O
na O
##d O
, O
e O
##ent O
: O
pressure O
dressing O
around O
left O
side O
of O
neck O
, O
er O
##yt O
##hem O
##a O
and O
swelling O
in O
the O
anterior O
neck O
c O
##v O
: O
r O
##rr O
, O
normal O
s O
##1 O
, O
s O
##2 O
, O
- O
m O
##rg O
pu O
##l O
: O
c O
##ta O
##b O
on O
anterior O
exam O
g O
##i O
: O
+ O
bow O
##el O
sounds O
, O
soft O
, O
non O
- O
di O
##sten O
##ded O
, O
no O
he O
##pa O
##tos O
##ple O
##no O
##me O
##gal O
##y O
m O
##sk O
: O
no O
joint O
swelling O
or O
er O
##yt O
##hem O
##a O
, O
non O
- O
tender O
to O
p O
##al O
##pation O
over O
her O
knees O
and O
upper O
leg O
with O
full O
r O
##om O
ex O
##tre O
##mit O
##ies O
: O
warm O
and O
well O
per O
##fused O
, O
no O
ed O
##ema O
skin O
: O
no O
lesions O
or O
skin O
breakdown O
ne O
##uro O
: O
alert O
and O
oriented O
x O
##3 O
, O
c O
##n O
2 O
- O
12 O
gross O
##ly O
intact O
with O
decreased O
sensation O
over O
the O
ear O
and O
lower O
[ O
* O
* O
11 O
- O
23 O
* O
* O
] O
of O
the O
left O
face O
ps O
##ych O
: O
non O
- O
anxious O
, O
normal O
affect O
physical O
exam O
on O
discharge O
: O
vital O
##s O
: O
t O
##m O
99 O
. O
1 O
, O
t O
##c O
98 O
. O
6 O
. O
105 O
- O
117 O
/ O
65 O
- O
80 O
, O
72 O
- O
93 O
, O
20 O
, O
99 O
% O
r O
##a O
g O
##en O
: O
pale O
young O
woman O
w O
/ O
neck O
dressing O
in O
no O
acute O
distress O
he O
##ent O
: O
left O
lateral O
neck O
in O
##cision O
with O
mild O
tender O
##ness O
c O
##v O
: O
r O
##rr O
normal O
s O
##1 O
/ O
s O
##2 O
, O
no O
m O
/ O
r O
/ O
g O
lungs O
: O
c O
##ta O
##b O
a O
##b O
: O
normal O
bow O
##el O
sounds O
, O
no O
masses O
, O
non O
- O
tender O
ex O
##t O
: O
2 O
+ O
pulses O
radial O
and O
d O
##p O
skin O
: O
no O
r O
##ash O
evident O
ne O
##uro O
: O
alert O
and O
oriented O
x O
##3 O
, O
c O
##n O
2 O
- O
12 O
gross O
##ly O
intact O
with O
decreased O
sensation O
over O
the O
ear O
and O
lower O
[ O
* O
* O
11 O
- O
23 O
* O
* O
] O
of O
the O
left O
face O
per O
##tinent O
results O
: O
admission O
labs O
: O

[ O
* O
* O
212 O
##4 O
- O
3 O
- O
14 O
* O
* O
] O
04 O
: O
55 O
##pm O
blood O
w O
##b O
##c O
- O
5 O
. O
0 O
r O
##b O
##c O
- O
3 O
. O
59 O
* O
h O
##g O
##b O
- O
10 O
. O
1 O
* O
h O
##ct O
- O
31 O
. O
5 O
* O
m O
##c O
##v O
- O
88 O
m O
##ch O
- O
28 O
. O
2 O
m O
##ch O
##c O
- O
32 O
. O
2 O
r O
##d O
##w O
- O
14 O
. O
0 O
p O
##lt O
c O
##t O
- O
45 O
##8 O
* O
[ O
* O
* O
212 O
##4 O
- O
3 O
- O
14 O
* O
* O
] O
04 O
: O
55 O
##pm O
blood O
ne O
##uts O
- O
72 O
. O
8 O
* O
l O
##ymph O
##s O
- O
22 O
. O
2 O
mon O
##os O
- O
0 O
. O
4 O
* O
e O
##os O
- O
3 O
. O
2 O
b O
##as O
##o O
- O
1 O
. O
4 O
[ O
* O
* O
212 O
##4 O
- O
3 O
- O
14 O
* O
* O
] O
04 O
: O
55 O
##pm O
blood O
glucose O
- O
118 O
* O
u O
##rea O
##n O
- O
15 O
c O
##rea O
##t O
- O
0 O
. O
4 O
na O
- O
133 O
k O
- O
4 O
. O
0 O
c O
##l O
- O
97 O
h O
##co O
##3 O
- O
28 O
an O
##ga O
##p O
- O
12 O
[ O
* O
* O
212 O
##4 O
- O
3 O
- O
15 O
* O
* O
] O
01 O
: O
20 O
##am O
blood O
al O
##t O
- O
16 O
as O
##t O
- O
14 O
l O
##d O
( O
l O
##dh O
) O
- O
133 O
al O
##k O
##ph O
##os O
- O
110 O
* O
to O
##t O
##bil O
##i O
- O
0 O
. O
5 O
[ O
* O
* O
212 O
##4 O
- O
3 O
- O
15 O
* O
* O
] O
01 O
: O
20 O
##am O
blood O
album O
##in O
- O
3 O
. O
4 O
* O
calcium O
- O
8 O
. O
7 O
p O
##hos O
- O
3 O
. O
7 O
mg O
- O
1 O
. O
7 O
[ O
* O
* O
212 O
##4 O
- O
3 O
- O
14 O
* O
* O
] O
05 O
: O
04 O
##pm O
blood O
la O
##ct O
##ate O
- O
0 O
. O
9 O
[ O
* O
* O
212 O
##4 O
- O
3 O
- O
14 O
* O
* O
] O
08 O
: O
30 O
##pm O
urine O
color O
- O
yellow O
appear O
- O
clear O
s O
##p O
[ O
* O
* O
last O
name O
( O
un O
) O
* O
* O
] O
- O
1 O
. O
01 O
##0 O
[ O
* O
* O
212 O
##4 O
- O
3 O
- O
14 O
* O
* O
] O
08 O
: O
30 O
##pm O
urine O
blood O
- O
ne O
##g O
ni O
##tri O
##te O
- O
ne O
##g O
protein O
- O
ne O
##g O
glucose O
- O
ne O
##g O
k O
##eton O
##e O
- O
ne O
##g O
bi O
##li O
##ru O
##b O
- O
ne O
##g O
u O
##ro O
##bil O
##n O
- O
ne O
##g O
p O
##h O
- O
6 O
. O
5 O
le O
##uk O
##s O
- O
ne O
##g O
[ O
* O
* O
212 O
##4 O
- O
3 O
- O
14 O
* O
* O
] O
08 O
: O
30 O
##pm O
urine O
u O
##c O
##g O
- O
negative O
. O

discharge O
labs O
: O
[ O
* O
* O
212 O
##4 O
- O
3 O
- O
27 O
* O
* O
] O
07 O
: O
04 O
##am O
blood O
w O
##b O
##c O
- O
3 O
. O
7 O
* O
r O
##b O
##c O
- O
3 O
. O
49 O
* O
h O
##g O
##b O
- O
9 O
. O
6 O
* O
h O
##ct O
- O
30 O
. O
1 O
* O
m O
##c O
##v O
- O
87 O
m O
##ch O
- O
27 O
. O
5 O
m O
##ch O
##c O
- O
31 O
. O
8 O
r O
##d O
##w O
- O
14 O
. O
6 O
p O
##lt O
c O
##t O
- O
405 O
[ O
* O
* O
212 O
##4 O
- O
3 O
- O
25 O
* O
* O
] O
06 O
: O
36 O
##am O
blood O
ne O
##uts O
- O
54 O
. O
0 O
l O
##ymph O
##s O
- O
39 O
. O
5 O
mon O
##os O
- O
0 O
. O
5 O
* O
e O
##os O
- O
5 O
. O
1 O
* O
b O
##as O
##o O
- O
1 O
. O
0 O
[ O
* O
* O
212 O
##4 O
- O
3 O
- O
27 O
* O
* O
] O
07 O
: O
04 O
##am O
blood O
p O
##t O
- O
12 O
. O
4 O
p O
##tt O
- O
37 O
. O
6 O
* O
in O
##r O
( O
p O
##t O
) O
- O
1 O
. O
1 O
[ O
* O
* O
212 O
##4 O
- O
3 O
- O
27 O
* O
* O
] O
07 O
: O
04 O
##am O
blood O
glucose O
- O
98 O
u O
##rea O
##n O
- O
9 O
c O
##rea O
##t O
- O
0 O
. O
4 O
na O
- O
138 O
k O
- O
4 O
. O
0 O
c O
##l O
- O
100 O
h O
##co O
##3 O
- O
30 O
an O
##ga O
##p O
- O
12 O
[ O
* O
* O
212 O
##4 O
- O
3 O
- O
26 O
* O
* O
] O
06 O
: O
53 O
##am O
blood O
al O
##t O
- O
35 O
##1 O
* O
as O
##t O
- O
228 O
* O
l O
##d O
( O
l O
##dh O
) O
- O
173 O
c O
##k O
( O
c O
##p O
##k O
) O
- O
8 O
* O
al O
##k O
##ph O
##os O
- O
66 O
##7 O
* O
to O
##t O
##bil O
##i O
- O
0 O
. O
7 O
[ O
* O
* O
212 O
##4 O
- O
3 O
- O
27 O
* O
* O
] O
07 O
: O
04 O
##am O
blood O
al O
##t O
- O
244 O
* O
as O
##t O
- O
72 O
* O
c O
##k O
( O
c O
##p O
##k O
) O
- O
9 O
* O
al O
##k O
##ph O
##os O
- O
59 O
##0 O
* O
to O
##t O
##bil O
##i O
- O
0 O
. O
8 O
[ O
* O
* O
212 O
##4 O
- O
3 O
- O
27 O
* O
* O
] O
07 O
: O
04 O
##am O
blood O
calcium O
- O
9 O
. O
6 O
p O
##hos O
- O
4 O
. O
5 O
mg O
- O
1 O
. O
8 O
. O
micro O
: O
[ O
* O
* O
212 O
##4 O
- O
3 O
- O
14 O
* O
* O
] O
blood O
cultures O
x O
2 O
- O
no O
growth O
final O
[ O
* O
* O
212 O
##4 O
- O
3 O
- O
15 O
* O
* O
] O
blood O
cultures O
x O
2 O
- O
no O
growth O
final O
[ O
* O
* O
212 O
##4 O
- O
3 O
- O
14 O
* O
* O
] O
urine O
culture O
- O
< O
10 O
##k O
colonies O
[ O
* O
* O
212 O
##4 O
- O
3 O
- O
15 O
* O
* O
] O
l O
neck O
wound O
cultures O
x O
2 O
- O
gram O
stain O
negative O
, O
no O
bacterial O
growth O
final O
, O
no O
fun O
##gal O
growth O
pre O
##lim O
[ O
* O
* O
212 O
##4 O
- O
3 O
- O
15 O
* O
* O
] O
m O
##rsa O
screen O
negative O

[ O
* O
* O
212 O
##4 O
- O
3 O
- O
18 O
* O
* O
] O
r O
p O
##ic O
##c O
line O
cat O
##he O
##ter O
tip O
- O
no O
growth O
final O
imaging O
: O

[ O
* O
* O
212 O
##4 O
- O
3 O
- O
14 O
* O
* O
] O
radio O
##logy O
c O
##t O
neck O
w O
/ O
contrast O
: O
technique O
: O
m O
##d O
##ct O
- O
acquired O
2 O
. O
5 O
mm O
a O
##xial O
images O
of O
the O
neck O
were O
obtained O
following O
the O
uneven O
##t O
##ful O
administration O
of O
70 O
cc O
of O
o B-DRUG
##m I-DRUG
##ni I-DRUG
##pa I-DRUG
##que I-DRUG
in O
##tra O
##ven O
##ous O
contrast O
. O
co O
##rona O
##l O
, O
sa O
##git O
##tal O
reform O
##ations O
were O
performed O
at O
2 O
mm O
slice O
thickness O
. O
findings O
: O
extensive O
soft O
tissue O
swelling O
throughout O
the O
superficial O
and O
deep O
spaces O
of O
the O
left O
neck O
and O
abnormal O
thick O
##ening O
and O
enhance O
##ment O
of O
the O
left O
stern O
##oc O
##le O
##ido O
##mas O
##to O
##id O
and O
posterior O
c O
##er O
##vic O
##al O
muscles O
are O
again O
seen O
( O
2 O
: O
29 O
) O
. O
there O
is O
increased O
rim O
thick O
##ening O
and O
enhance O
##ment O
of O
an O
organizing O
fluid O
collection O
along O
the O
left O
neck O
extending O
posterior O
##ly O
( O
2 O
: O
33 O
) O
since O
[ O
* O
* O
212 O
##4 O
- O
2 O
- O
28 O
* O
* O
] O
, O
with O
a O
dominant O
collection O
measuring O
34 O
x O
7 O
mm O
( O
2 O
: O
28 O
) O
. O
previously O
noted O
drains O
have O
been O
removed O
with O
sub O
##cut O
##aneous O
gas O
likely O
reflecting O
packing O
material O
within O
a O
lateral O
in O
##cision O
( O
2 O
: O
54 O
) O
. O
no O
bony O
erosion O
##s O
are O
detected O
. O
there O
is O
improved O
re O
##tro O
##pha O
##ryn O
##ge O
##al O
swelling O
with O
decreased O
mass O
effect O
on O
the O
neighboring O
air O
##way O
, O
including O
slight O
restoration O
of O
the O
left O
p O
##iri O
##form O
sin O
##us O
and O
decreased O
swelling O
of O
the O
left O
a O
##ry O
##ep O
##ig O
##lot O
##tic O
fold O
and O
e O
##pi O
##g O
##lot O
##tis O
. O
the O
air O
##way O
remains O
patent O
. O
no O
new O
fluid O
collections O
are O
seen O
. O
there O
is O
no O
sub O
##cut O
##aneous O
em O
##phy O
##se O
##ma O
. O
neighboring O
great O
vessels O
remain O
patent O
, O
although O
there O
is O
continued O
marked O
narrowing O
of O
the O
left O
internal O
j O
##ug O
##ular O
vein O
( O
2 O
: O
34 O
) O
as O
it O
passes O
through O
the O
area O
of O
inflammation O
in O
the O
left O
neck O
. O
included O
views O
of O
the O
lung O
a O
##pice O
##s O
demonstrates O
minimal O
para O
##se O
##pta O
##l O
em O
##phy O
##se O
##ma O
( O
301 O
##b O
: O
68 O
) O
. O
the O
thy O
##roid O
is O
normal O
. O
impression O
: O
1 O
. O
organizing O
rim O
- O
enhancing O
fluid O
collection O
concerning O
for O
an O
a O
##bs O
##cess O
tracking O
along O
the O
left O
lateral O
and O
posterior O
neck O
, O
overall O
slightly O
worse O
##ned O
since O
[ O
* O
* O
212 O
##4 O
- O
2 O
- O
28 O
* O
* O
] O
, O
with O
increased O
size O
of O
a O
dominant O
posterior O
collection O
measuring O
up O
to O
8 O
mm O
, O
and O
increased O
thick O
##ene O
##ss O
of O
an O
enhancing O
r O
##ind O
. O
2 O
. O
improved O
re O
##tro O
##pha O
##ryn O
##ge O
##al O
swelling O
with O
decreased O
mass O
effect O
on O
the O
neighboring O
air O
##way O
, O
including O
slight O
restoration O
of O
the O
left O
p O
##iri O
##form O
sin O
##us O
and O
decreased O
swelling O
of O
the O
left O
a O
##ry O
##ep O
##ig O
##lot O
##tic O
fold O
and O
e O
##pi O
##g O
##lot O
##tis O
. O
3 O
. O
removal O
of O
surgical O
drains O
with O
sub O
##cut O
##aneous O
gas O
in O
the O
left O
neck O
possibly O
reflecting O
packing O
material O
within O
the O
surgical O
in O
##cision O
. O
4 O
. O
continued O
severe O
focal O
narrowing O
the O

left O
internal O
j O
##ug O
##ular O
vein O
as O
it O
courses O
through O
the O
area O
of O
inflammation O
in O
the O
left O
neck O
. O
[ O
* O
* O
3 O
- O
25 O
* O
* O
] O
liver O
u O
/ O
s O
: O
normal O
liver O
echo O
##text O
##ure O
. O
no O
in O
##tra O
- O
or O
extra O
- O
he O
##pa O
##tic O
bi O
##le O
duct O
di O
##lation O
. O
the O
gal O
##l O
##bla O
##dder O
is O
collapsed O
. O
brief O
hospital O
course O
: O
30 O
##f O
h O
##x O
[ O
* O
* O
doctor O
last O
name O
* O
* O
] O
and O
id O
##io O
##pathic O
ne O
##ut O
##rop O
##eni O
##c O
who O
was O
recently O
d O
/ O
c O
s O
/ O
p O
neck O
i O
& O
d O
of O
an O
infected O
a O
##bs O
##cess O
, O
now O
read O
##mit O
##ted O
with O
increased O
drain O
output O
and O
night O
sweat O
##s O
. O
found O
with O
re O
##ac O
##cum O
##ulated O
fluid O
collection O
and O
s O
/ O
p O
i O
& O
d O
/ O
wash O
##out O
on O
[ O
* O
* O
3 O
- O
14 O
* O
* O
] O
. O

# O
neck B-REA
a I-REA
##bs I-REA
##cess I-REA
: I-REA
p O
##t O
presented O
to O
the O
ed O
after O
having O
previously O
undergone O
a O
left O
neck O
in O
##cision O
for O
a O
posterior O
para O
##pha O
##ryn O
##ge O
##al O
a O
##bs O
##cess O
on O
[ O
* O
* O
212 O
##4 O
- O
3 O
- O
4 O
* O
* O
] O
. O
she O
was O
treated O
with O
i B-ROU
##v I-ROU
anti B-DRUG
##biotics I-DRUG
and O
discharged O
with O
a O
p O
##ic O
##c O
line O
and O
continued O
er B-DRUG
##ta I-DRUG
##pen I-DRUG
##em I-DRUG
. I-DRUG
she O
re O
- O
presented O
on O
[ O
* O
* O
212 O
##4 O
- O
3 O
- O
14 O
* O
* O
] O
to O
the O
emergency O
room O
noting O
several O
days O
of O
increasing O
swelling O
around O
the O
surgical O
site O
with O
increasing O
drainage O
and O
pain O
, O
as O
well O
as O
night O
sweat O
##s O
and O
fever O
##s O
. O
c O
##t O
scan O
of O
the O
neck O
showed O
re O
##ac O
##cum O
##ulation O
of O
fluid O
in O
her O
left O
c O
##er O
##vic O
##al O
region O
concerning O
for O
worse B-REA
##ning I-REA
infection I-REA
, I-REA
and O
patient O
was O
taken O
emerge O
##ntly O
to O
or O
by O
en O
##t O
for O
l O
neck O
exploration O
and O
in O
##cision O
and O
drainage O
. O
procedure O
was O
well O
- O
tolerate O
##d O
and O
proceeded O
without O
issue O
; O
3 O
pen O
##rose O
drains O
were O
placed O
. O
no O
fever O
##s O
/ O
chill O
##s O
while O
in O
house O
and O
no O
signs O
of O
se O
##psis O
. O
was O
able O
to O
protect O
air O
##way O
, O
breath O
/ O
swallow O
comfortably O
post O
- O
op O
. O
per O
id O
, O
it O
was O
not O
felt O
that O
this O
episode O
was O
anti O
##biotic O
failure O
, O
so O
she O
was O
continued O
on O
me B-DRUG
##rop I-DRUG
##ene I-DRUG
##m I-DRUG
. I-DRUG
she O
continued O
to O
spike O
te O
##mps O
> O
101 O
for O
the O
first O
few O
days O
post O
- O
op O
and O
eventually O
her O
fever O
curve O
down O
##tre O
##nded O
. O
the O
pen O
##rose O
drains O
were O
removed O
every O
1 O
- O
2 O
days O
until O
the O
final O
drain O
was O
removed O
on O
[ O
* O
* O
212 O
##4 O
- O
3 O
- O
24 O
* O
* O
] O
. O
her O
wound O
and O
blood O
cultures O
did O
not O
grow O
any O
organisms O
. O
p O
##t O
was O
treated O
with O
me B-DRUG
##rop I-DRUG
##ene I-DRUG
##m I-DRUG
while O
hospital O
##ized O
with O
initial O
plan O
to O
switch O
to O
er B-DRUG
##ta I-DRUG
##pen I-DRUG
##em I-DRUG
2 O
days O
prior O
to O
discharge O
. O
however O
, O
l B-ADE
##fts I-ADE
were I-ADE
found I-ADE
to I-ADE
be I-ADE
elevated I-ADE
on O
[ O
* O
* O
212 O
##4 O
- O
3 O
- O
24 O
* O
* O
] O
and O
[ O
* O
* O
212 O
##4 O
- O
3 O
- O
25 O
* O
* O
] O
, O
which O
id O
felt O
may O
be O
due O
to O
er B-DRUG
##ta I-DRUG
##pen I-DRUG
##em I-DRUG
. I-DRUG
p O
##t O
was O
then O
switched O
to O
da B-DRUG
##pt I-DRUG
##omy I-DRUG
##cin I-DRUG
with O
improvement O
of O
her O
l O
##fts O
. O
she O
was O
discharged O
on O
da B-DRUG
##pt I-DRUG
##omy I-DRUG
##cin I-DRUG
for O
an O
in O
##definite O
treatment O
course O
as O
will O
be O
defined O
by O
her O
infectious O
disease O
doctors O
. O

# O
[ O
* O
* O
month O
/ O
day O
/ O
year O
* O
* O
] O
: O
l B-ADE
##fts I-ADE
were I-ADE
elevated I-ADE
on O
[ O
* O
* O
212 O
##4 O
- O
3 O
- O
24 O
* O
* O
] O
w O
/ O
as O
##t O
192 O
, O
as O
##t O
184 O
, O
a O
##p O
310 O
, O
and O
normal O
t O
bi O
##li O
0 O
. O
7 O
. O
p O
##t O
' O
s O
l O
##fts O
were O
also O
elevated O
during O
prior O
admission O
when O
she O
was O
on O
me B-DRUG
##rop I-DRUG
##ene I-DRUG
##m I-DRUG
and O
h B-DRUG
##ydro I-DRUG
##mor I-DRUG
##phone I-DRUG
for O
pain B-REA
control I-REA
. I-REA
she O
has O
also O
received O
several O
grams O
of O
ace B-DRUG
##tam I-DRUG
##ino I-DRUG
##phe I-DRUG
##n I-DRUG
daily B-FRE
during O
this O
hospital O
##ization O
. O
suspect O
that O
this O
is O
due O
to O
a O
drug O
effect O
. O
ace B-DRUG
##tam I-DRUG
##ino I-DRUG
##phe I-DRUG
##n I-DRUG
was O
stopped O
and O
h B-DRUG
##ydro I-DRUG
##mor I-DRUG
##phone I-DRUG
reduced O
, O
but O
l O
##fts O
continued O
o O
##t O
increase O
. O
abdominal O
exam O
completely O
ben O
##ign O
. O
r O
##u O
##q O
ultra O
##sound O
also O
showed O
no O
obvious O
path O
##ology O
. O
id O
felt O
that O
er B-DRUG
##ta I-DRUG
##pen I-DRUG
##em I-DRUG
may O
be O
contributing O
to O
[ O
* O
* O
last O
name O
( O
l O
##f O
) O
* O
* O
] O
, O
[ O
* O
* O
first O
name O
##3 O
( O
l O
##f O
) O
* O
* O
] O
this O
was O
switched O
for O
da B-DRUG
##pt I-DRUG
##omy I-DRUG
##cin I-DRUG
on O
[ O
* O
* O
212 O
##4 O
- O
3 O
- O
26 O
* O
* O
] O
with O
pro B-DRUG
##mpt I-DRUG
resolution O
. O
# O
ne O
##ut O
##rop O
##enia O
of O
unknown O
cause O
: O
base O
##line O
w O
##b O
##c O
per O
report O
~ O
1 O
. O
8 O
, O
unclear O
et O
##iology O
for O
her O
le O
##uk O
##ope O
##nia O
. O
had O
follow O
- O
up O
with O
hem O
##e O
/ O
on O
##c O
for O
a O
? O
of O
w O
##him O
syndrome O
, O
was O
planned O
for O
a O
bone O
ma O
##rrow O
bio O
##psy O
as O
an O
out O
##patient O
. O
an O
##cs O
were O
trend O
##ed O
throughout O
without O
requiring O
ne B-DRUG
##up I-DRUG
##ogen I-DRUG
administration O
. O
she O
will O
follow O
- O
up O
in O
out O
##patient O
hem O
##ato O
##logy O
with O
d O
##r O
. O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
69 O
##44 O
* O
* O
] O
in O
mid O
[ O
* O
* O
month O
( O
only O
) O
* O
* O
] O
. O
transitional O
issues O
: O
- O
needs O
close O
monitoring O
while O
on O
da B-DRUG
##pt I-DRUG
##omy I-DRUG
##cin I-DRUG
for O
resolution O
of O
infection B-REA
and O
my B-REA
##os I-REA
##itis I-REA
( O
with O
weekly O
c O
##k O
) O
- O
monitor O
l O
##fts O
for O
resolution O
of O
[ O
* O
* O
month O
( O
only O
) O
* O
* O
] O
- O
needs O
continued O
work O
##up O
for O
ne O
##ut O
##rop O
##enia O
medications O
on O
admission O
: O
3 O
. O
bi B-DRUG
##sm I-DRUG
##uth I-DRUG
sub I-DRUG
##sal I-DRUG
##ic I-DRUG
##yla I-DRUG
##te I-DRUG
262 B-STR
mg I-STR
/ I-STR
15 I-STR
m I-STR
##l I-STR
suspension B-FOR
si O
##g O
: O
thirty B-DOS
( I-DOS
30 I-DOS
) I-DOS
m I-DOS
##l I-DOS
p B-ROU
##o I-ROU
q B-FRE
##id I-FRE
( I-FRE
4 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
di B-REA
##ar I-REA
##r I-REA
##hea I-REA
. I-REA
4 O
. O
multi B-DRUG
##vi I-DRUG
##tam I-DRUG
##in I-DRUG
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( I-FRE
daily I-FRE
) I-FRE
. I-FRE
5 O
. O
h B-DRUG
##ydro I-DRUG
##mor I-DRUG
##phone I-DRUG
2 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
1 B-DOS
- I-DOS
2 I-DOS
tablets B-FOR
p B-ROU
##o I-ROU
every O
4 O
- O
6 O
hours O

as O
needed O
for O
pain B-REA
. I-REA
di O
##sp O
: O
* O
21 O
tablet B-FOR
( I-FOR
s O
) O
* O
re O
##fill O
##s O
: O
* O
0 O
* O
6 O
. O
pro B-DRUG
##ch I-DRUG
##lor I-DRUG
##per I-DRUG
##azi I-DRUG
##ne I-DRUG
male I-DRUG
##ate I-DRUG
10 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
q B-FRE
##6 I-FRE
##h I-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
nausea B-REA
. I-REA
di O
##sp O
: O
* O
21 O
tablet B-FOR
( I-FOR
s O
) O
* O
re O
##fill O
##s O
: O
* O
0 O
* O
7 O
. O
ace B-DRUG
##tam I-DRUG
##ino I-DRUG
##phe I-DRUG
##n I-DRUG
500 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
two B-DOS
( I-DOS
2 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
q O
##6 O
##h O
( O
every O
6 O
hours O
) O
as O
needed O
for O
pain B-REA
. I-REA
8 O
. O
er B-DRUG
##ta I-DRUG
##pen I-DRUG
##em I-DRUG
1 B-STR
gram I-STR
re B-FOR
##con I-FOR
so I-FOR
##ln I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
grams I-DOS
in B-ROU
##tra I-ROU
##ven I-ROU
##ous I-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE
di O
##sp O
: O
* O
30 O
doses O
* O
re O
##fill O
##s O
: O
* O
0 O
* O
9 O
. O
co B-DRUG
##lace I-DRUG
100 B-STR
mg I-STR
capsule B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
capsule B-FOR
p B-ROU
##o I-ROU
twice B-FRE
a I-FRE
day I-FRE
. I-FRE
di O
##sp O
: O
* O
60 O
capsule O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
0 O
* O
10 O
. O
se B-DRUG
##nna I-DRUG
8 B-STR
. I-STR
6 I-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
twice B-FRE
a I-FRE
day I-FRE
as I-FRE
needed I-FRE
for O
con B-REA
##st I-REA
##ip I-REA
##ation I-REA
. I-REA
di O
##sp O
: O
* O
60 O
tablet O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
0 O
* O
discharge O
medications O
: O
1 O
. O
multi B-DRUG
##vi I-DRUG
##tam I-DRUG
##in I-DRUG
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( I-FRE
daily I-FRE
) I-FRE
. I-FRE

2 O
. O
pro B-DRUG
##ch I-DRUG
##lor I-DRUG
##per I-DRUG
##azi I-DRUG
##ne I-DRUG
male I-DRUG
##ate I-DRUG
10 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
q B-FRE
##6 I-FRE
##h I-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
nausea B-REA
. I-REA
di O
##sp O
: O
* O
50 O
tablet B-FOR
( I-FOR
s O
) O
* O
re O
##fill O
##s O
: O
* O
0 O
* O
3 O
. O
do B-DRUG
##cus I-DRUG
##ate I-DRUG
sodium I-DRUG
100 B-STR
mg I-STR
capsule B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
capsule B-FOR
p B-ROU
##o I-ROU
bid B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE
di O
##sp O
: O
* O
60 O
capsule O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
2 O
* O
4 O
. O
out O
##patient O
[ O
* O
* O
name O
( O
ni O
) O
* O
* O
] O
work O
p O
##t O
will O
need O
weekly O
c O
##b O
##c O
, O
na O
, O
k O
, O
c O
##l O
, O
h O
##co O
##3 O
, O
b O
##un O
, O
c O
##r O
, O
glucose O
, O
as O
##t O
, O
al O
##t O
, O
total O
bi O
##li O
##ru O
##bin O
, O
al O
##kal O
##ine O
p O
##hos O
##pha O
##tase O
and O
have O
the O
results O
f O
##ax O
##ed O
to O
[ O
* O
* O
hospital O
* O
* O
] O
clinic O
at O
[ O
* O
* O
n O
##ume O
##ric O
id O
##ent O
##ifier O
89 O
##7 O
##8 O
##5 O
* O
* O
] O
, O
attention O
d O
##r O
. O
[ O
* O
* O
first O
name O
( O
s O
##ti O
##tle O
) O
* O
* O
] O
. O
5 O
. O
h B-DRUG
##ydro I-DRUG
##mor I-DRUG
##phone I-DRUG
2 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
1 B-DOS
- I-DOS
2 I-DOS
tablets B-FOR
p B-ROU
##o I-ROU
every B-FRE
4 I-FRE
- I-FRE
6 I-FRE
hours I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
for B-DUR
2 I-DUR
weeks I-DUR
: I-DUR
do O
not O
operate O
machinery O
or O
drive O
on O
this O
medication O
. O
do O
not O
mix O
with O
alcohol O
. O
di O
##sp O
: O
* O
50 O
tablet B-FOR
( I-FOR
s O
) O
* O
re O
##fill O
##s O
: O
* O
0 O
* O
6 O
. O
p B-DRUG
##oly I-DRUG
##eth I-DRUG
##yle I-DRUG
##ne I-DRUG
g I-DRUG
##ly I-DRUG
##co I-DRUG
##l I-DRUG
335 I-DRUG
##0 I-DRUG
17 B-STR
gram I-STR
powder B-FOR
in I-FOR
packet I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
p B-ROU
##o I-ROU
once B-FRE
a I-FRE
day I-FRE
as I-FRE
needed I-FRE
for O
con B-REA
##st I-REA
##ip I-REA
##ation I-REA
for B-DUR
2 I-DUR
weeks I-DUR
: I-DUR
use O
daily B-FRE
for O
con B-ADE
##st I-ADE
##ip I-ADE
##ation I-ADE
while O
taking O
h B-DRUG
##ydro I-DRUG
##mor I-DRUG
##phone I-DRUG
( I-DRUG
di I-DRUG
##lau I-DRUG
##di I-DRUG
##d I-DRUG
) I-DRUG
. I-DRUG
di O
##sp O
: O
* O
30 O
packets B-FOR
* I-FOR
re O
##fill O
##s O
: O
* O
2 O
* O
7 O
. O
da B-DRUG
##pt I-DRUG
##omy I-DRUG
##cin I-DRUG
500 B-STR
mg I-STR
re B-FOR
##con I-FOR
so I-FOR
##ln I-FOR
si O
##g O
: O
350 B-DOS
mg I-DOS
re B-FOR
##con I-FOR
so I-FOR
##ln I-FOR
##s I-FOR
in B-ROU
##tra I-ROU
##ven I-ROU
##ous I-ROU
q B-FRE
##24 I-FRE
##h I-FRE
( I-FRE
every I-FRE
24 I-FRE
hours I-FRE
) I-FRE
. I-FRE
di O
##sp O
: O
* O
30 O
re O
##con O
so O
##ln O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
2 O
* O
discharge O
disposition O
: O
home O
with O
service O
facility O
: O
home O
solutions O
discharge O
diagnosis O
: O
neck O
a O
##bs O
##cess O
/ O
infected O
fluid O
collection O
id O
##io O
##pathic O
ne O
##ut O
##rop O
##enia O
discharge O
condition O
: O
mental O
status O
: O
clear O
and O
coherent O
. O
level O
of O
consciousness O
: O
alert O
and O
interactive O
. O
activity O
status O
: O
am O
##bula O
##tory O
- O
independent O
. O
discharge O
instructions O
: O
m O
##s O
. O
[ O
* O
* O
known O
last O
##name O
* O
* O
] O
, O

you O
came O
to O
the O
hospital O
for O
worse O
##ning O
neck O
swelling O
and O
drainage O
after O
your O
prior O
neck O
surgery O
. O
you O
had O
a O
scan O
, O
which O
showed O
increased O
fluid O
in O
the O
previously O
drained O
areas O
of O
your O
neck O
. O
our O
en O
##t O
surgeon O
##s O
re O
- O
explored O
your O
neck O
and O
placed O
several O
drains O
. O
you O
were O
seen O
by O
our O
infectious O
disease O
specialists O
, O
who O
felt O
that O
your O
symptoms O
were O
due O
to O
incomplete O
drainage O
after O
your O
first O
procedure O
. O
you O
were O
continued O
on O
anti O
##biotics O
and O
your O
wound O
and O
blood O
cultures O
did O
not O
grow O
any O
bacteria O
. O
your O
en O
##t O
surgeon O
##s O
slowly O
removed O
your O
neck O
wound O
drains O
and O
removed O
your O
s O
##ti O
##tches O
. O
you O
will O
need O
to O
continue O
i B-ROU
##v I-ROU
anti B-DRUG
##biotics I-DRUG
for O
several B-DUR
weeks I-DUR
to I-DUR
months I-DUR
. I-DUR
the O
exact O
duration O
will O
depend O
on O
your O
clinical O
progress O
and O
the O
assessments O
of O
your O
en O
##t O
and O
infectious O
disease O
doctors O
. O
we O
have O
made O
the O
following O
changes O
to O
your O
medications O
: O
start O
pro B-DRUG
##ch I-DRUG
##lor I-DRUG
##per I-DRUG
##azi I-DRUG
##ne I-DRUG
male I-DRUG
##ate I-DRUG
( O
com B-DRUG
##pa I-DRUG
##zine I-DRUG
) I-DRUG
10 B-STR
##m I-STR
##g I-STR
tablets B-FOR
, I-FOR
1 B-DOS
ta B-FOR
##b I-FOR
by B-ROU
mouth I-ROU
every B-FRE
6 I-FRE
hours I-FRE
as I-FRE
needed I-FRE
for O
nausea B-REA
start O
do B-DRUG
##cus I-DRUG
##ate I-DRUG
sodium I-DRUG
100 B-STR
##m I-STR
##g I-STR
capsule B-FOR
##s I-FOR
, I-FOR
1 B-DOS
cap B-FOR
by B-ROU
mouth I-ROU
twice B-FRE
daily I-FRE
start O
h B-DRUG
##ydro I-DRUG
##mor I-DRUG
##phone I-DRUG
( I-DRUG
di I-DRUG
##lau I-DRUG
##di I-DRUG
##d I-DRUG
) I-DRUG
2 B-STR
mg I-STR
tablets B-FOR
, I-FOR
1 B-DOS
- I-DOS
2 I-DOS
ta B-FOR
##bs I-FOR
by B-ROU
mouth I-ROU
every B-FRE
4 I-FRE
- I-FRE
6 I-FRE
hours I-FRE
as I-FRE
needed I-FRE
for O
severe B-REA
pain I-REA
. I-REA
do O
not O
operate O
machinery O
or O
drive O
on O
this O
medication O
. O
do O
not O
mix O
with O
alcohol O
. O
start O
p B-DRUG
##oly I-DRUG
##eth I-DRUG
##yle I-DRUG
##ne I-DRUG
g I-DRUG
##ly I-DRUG
##co I-DRUG
##l I-DRUG
( I-DRUG
mi I-DRUG
##ral I-DRUG
##ax I-DRUG
) I-DRUG
17 B-STR
##g I-STR
powder B-FOR
in I-FOR
packet I-FOR
, I-FOR
1 B-DOS
packet B-FOR
dissolved O
in O
water O
by B-ROU
mouth I-ROU
daily B-FRE
as I-FRE
needed I-FRE
for O
con B-REA
##st I-REA
##ip I-REA
##ation I-REA
start O
da B-DRUG
##pt I-DRUG
##omy I-DRUG
##cin I-DRUG
350 B-STR
##m I-STR
##g I-STR
i B-ROU
##v I-ROU
daily B-FRE
until O
instructed O
to O
stop O
by O
your O
infectious O
disease O
specialist O
, O
d O
##r O
. O
[ O
* O
* O
first O
name O
( O
s O
##ti O
##tle O
) O
* O
* O
] O
please O
continue O
to O
take O
your O
other O
medications O
as O
previously O
prescribed O
. O
we O
have O
made O
several O
appointments O
for O
you O
( O
see O
below O
) O
. O
we O
have O
also O
arranged O
for O
a O
nurse O
to O
come O
to O
your O
home O
to O
administer O
your O
medication O
and O
to O
draw O
your O
blood O
labs O
. O
follow O
##up O
instructions O
: O
department O
: O
o O
##to O
##lary O
##ngo O
##logy O
( O
en O
##t O
) O
when O
: O
t O
##ues O
##day O
[ O
* O
* O
212 O
##4 O
- O
3 O
- O
28 O
* O
* O
] O
at O
3 O
: O
45 O
pm O
with O
: O
[ O
* O
* O
first O
name O
##8 O
( O
name O
##pa O
##tter O
##n O
##2 O
) O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
39 O
* O
* O
] O
, O
m O
. O
d O
. O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
41 O
* O
* O
] O
building O
: O
l O
##m O
[ O
* O
* O
hospital O
unit O
name O
* O
* O
] O
[ O
* O
* O
location O
( O
un O
) O
89 O
##5 O
* O
* O
] O
campus O
: O
west O
best O
parking O
: O
[ O
* O
* O
doctor O
first O
name O
* O
* O
] O
. O
garage O

department O
: O
primary O
care O
name O
: O
d O
##r O
. O
[ O
* O
* O
first O
name O
( O
s O
##ti O
##tle O
) O
* O
* O
] O
[ O
* O
* O
name O
( O
s O
##ti O
##tle O
) O
* O
* O
] O
for O
d O
##r O
. O
[ O
* O
* O
first O
name O
##8 O
( O
name O
##pa O
##tter O
##n O
##2 O
) O
78 O
##1 O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
79 O
##7 O
* O
* O
] O
when O
: O
th O
##urs O
##day O
[ O
* O
* O
212 O
##4 O
- O
3 O
- O
30 O
* O
* O
] O
at O
3 O
: O
20 O
pm O
location O
: O
[ O
* O
* O
hospital O
##6 O
52 O
##42 O
* O
* O
] O
center O
address O
: O
[ O
* O
* O
location O
( O
un O
) O
52 O
##43 O
* O
* O
] O
, O
[ O
* O
* O
location O
( O
un O
) O
* O
* O
] O
, O
[ O
* O
* O
n O
##ume O
##ric O
id O
##ent O
##ifier O
226 O
##0 O
* O
* O
] O
phone O
: O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
79 O
##8 O
* O
* O
] O
department O
: O
infectious O
disease O
when O
: O
wed O
##nes O
##day O
[ O
* O
* O
212 O
##4 O
- O
4 O
- O
5 O
* O
* O
] O
at O
10 O
: O
00 O
am O
with O
: O
[ O
* O
* O
first O
name O
##4 O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
802 O
##1 O
* O
* O
] O
, O
m O
##d O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
45 O
##7 O
* O
* O
] O
building O
: O
l O
##m O
[ O
* O
* O
hospital O
ward O
name O
* O
* O
] O
b O
##ld O
##g O
( O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
* O
* O
] O
) O
[ O
* O
* O
hospital O
142 O
##2 O
* O
* O
] O
campus O
: O
west O
best O
parking O
: O
[ O
* O
* O
hospital O
ward O
name O
* O
* O
] O
garage O
department O
: O
hem O
##ato O
##logy O
/ O
b O
##m O
##t O
when O
: O
wed O
##nes O
##day O
[ O
* O
* O
212 O
##4 O
- O
5 O
- O
3 O
* O
* O
] O
at O
11 O
: O
00 O
am O
with O
: O
[ O
* O
* O
first O
name O
##11 O
( O
name O
pattern O
##1 O
) O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##4 O
) O
69 O
##5 O
##2 O
* O
* O
] O
, O
m O
##d O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
32 O
##41 O
* O
* O
] O
building O
: O
s O
##c O
[ O
* O
* O
hospital O
ward O
name O
23 O
* O
* O
] O
clinical O
c O
##tr O
[ O
* O
* O
location O
( O
un O
) O
* O
* O
] O
campus O
: O
east O
best O
parking O
: O
[ O
* O
* O
hospital O
ward O
name O
23 O
* O
* O
] O
garage O
[ O
* O
* O
name O
##6 O
( O
m O
##d O
) O
* O
* O
] O
[ O
* O
* O
name O
##8 O
( O
m O
##d O
) O
* O
* O
] O
m O
##d O
[ O
* O
* O
m O
##d O
number O
( O
1 O
) O
42 O
##36 O
* O
* O
] O

admission O
date O
: O
[ O
* O
* O
218 O
##2 O
- O
4 O
- O
12 O
* O
* O
] O
discharge O
date O
: O
[ O
* O
* O
218 O
##2 O
- O
4 O
- O
23 O
* O
* O
] O
date O
of O
birth O
: O
[ O
* O
* O
210 O
##0 O
- O
2 O
- O
23 O
* O
* O
] O
sex O
: O
f O
service O
: O
medicine O
all O
##er O
##gies O
: O
i B-DRUG
##od I-DRUG
##ine I-DRUG
; I-DRUG
i B-DRUG
##od I-DRUG
##ine I-DRUG
containing I-DRUG
/ O
dust O
& O
pollen O
filter O
mask O
/ O
h B-DRUG
##yd I-DRUG
##ral I-DRUG
##azi I-DRUG
##ne I-DRUG
/ O
c B-DRUG
##y I-DRUG
##c I-DRUG
##lop I-DRUG
##hos I-DRUG
##pha I-DRUG
##mi I-DRUG
##de I-DRUG
attending O
: O
[ O
* O
* O
first O
name O
##3 O
( O
l O
##f O
) O
68 O
##9 O
* O
* O
] O
chief O
complaint O
: O
br O
##b O
##p O
##r O
major O
surgical O
or O
invasive O
procedure O
: O
e O
##g O
##d O
blood O
trans O
##fusion O

history O
of O
present O
illness O
: O
82 O
##yo O
f O
with O
h O
/ O
o O
re O
##nal O
artery O
s O
##ten O
##osis O
, O
c O
##k O
##d O
stage O
ii O
##i O
, O
p B-REA
##af I-REA
on O
co B-DRUG
##uma I-DRUG
##din I-DRUG
presents O
with O
br O
##b O
##p O
##r O
x O
3 O
yesterday O
. O
patient O
presented O
to O
[ O
* O
* O
hospital O
##1 O
18 O
* O
* O
] O
about O
1 O
month O
ago O
with O
increased O
c O
##rea O
##tin O
##ine O
to O
3 O
( O
from O
1 O
. O
6 O
) O
. O
a O
work O
##up O
including O
re O
##nal O
bio O
##psy O
revealed O
p O
##au O
##ci O
- O
immune O
p B-ADE
- I-ADE
an I-ADE
##ca I-ADE
positive I-ADE
g I-ADE
##lo I-ADE
##mer I-ADE
##ulon I-ADE
##ep I-ADE
##hr I-ADE
##itis I-ADE
thought O
secondary O
to O
h B-DRUG
##yd I-DRUG
##ral I-DRUG
##azi I-DRUG
##ne I-DRUG
. I-DRUG
she O
was O
started O
on O
pre B-DRUG
##dn I-DRUG
##ison I-DRUG
##e I-DRUG
and O
c B-DRUG
##y I-DRUG
##c I-DRUG
##lop I-DRUG
##hos I-DRUG
##pha I-DRUG
##mi I-DRUG
##de I-DRUG
at O
that O
point O
. O
in O
addition O
, O
according O
to O
the O
patient O
and O
records O
from O
[ O
* O
* O
hospital O
* O
* O
] O
she O
was O
also O
recently O
admitted O
to O
[ O
* O
* O
hospital O
##3 O
* O
* O
] O
after O
a O
collapse O
one O
month O
ago O
. O
she O
was O
brought O
in O
and O
found O
to O
have O
a B-REA
##f I-REA
with I-REA
r I-REA
##v I-REA
##r I-REA
. I-REA
was O
started O
on O
di B-DRUG
##lt I-DRUG
and O
met B-DRUG
##op I-DRUG
##rol I-DRUG
##ol I-DRUG
with O
reportedly O
good O
control O
. O
further O
work O
##up O
there O
included O
an O
e O
##g O
##d O
and O
co O
##lon O
##os O
##copy O
which O
revealed O
gas O
##tric O
ul O
##cer O
##s O
and O
p O
##oly O
##ps O
as O
well O
as O
can O
##di O
##dia O
##sis O
. O
she O
received O
2 B-STR
##uni I-STR
##ts I-STR
p B-DRUG
##rb I-DRUG
##cs I-DRUG
and O
her O
h O
##ct O
came O
up O
to O
30 O
. O
while O
there O
she O
was O
noted O
to O
be O
ne B-ADE
##ut I-ADE
##rop I-ADE
##eni I-ADE
##c I-ADE
. I-ADE
they O
thought O
this O
was O
possibly O
medication O
related O
. O
c B-DRUG
##y I-DRUG
##c I-DRUG
##lop I-DRUG
##hos I-DRUG
##pha I-DRUG
##mi I-DRUG
##de I-DRUG
, I-DRUG
b B-DRUG
##act I-DRUG
##rim I-DRUG
, I-DRUG
and O
flu B-DRUG
##cona I-DRUG
##zo I-DRUG
##le I-DRUG
were O
discontinued O
. O
she O
completed O
a O
course O
of O
ca B-DRUG
##sp I-DRUG
##of I-DRUG
##ung I-DRUG
##in I-DRUG
and O
a O
t O
##te O
was O
negative O
for O
vegetation O
##s O
. O
her O
w O
##b O
##c O
count O
came O
up O
. O
she O
was O
discharged O
to O
[ O
* O
* O
hospital O
##3 O
* O
* O
] O
. O
today O
was O
feeling O
weak O
and O
tired O
and O
then O
had O
3 O
episodes O
of O
br O
##b O
##p O
##r O
so O
decided O
to O
come O
to O
ed O
. O
presented O
to O
ed O
in O
a B-REA
##f I-REA
with I-REA
r I-REA
##v I-REA
##r I-REA
to O
160 O
##s O
. O
received O
10 B-STR
##m I-STR
##g I-STR
i B-ROU
##v I-ROU
di B-DRUG
##lt I-DRUG
with O
improvement O
in O
rate O
to O
high O
90s O
/ O
100 O
. O
received O
then O
30 B-STR
##m I-STR
##g I-STR
p B-ROU
##o I-ROU
di B-DRUG
##lt I-DRUG
. I-DRUG
stable O
h O
##rs O
since O
. O
also O
received O
5 B-STR
##m I-STR
##g I-STR
i B-ROU
##v I-ROU
met B-DRUG
##op I-DRUG
##rol I-DRUG
##ol I-DRUG
. I-DRUG

initial O
vs O
: O
97 O
. O
8 O
137 O
##af O
111 O
/ O
78 O
16 O
99 O
. O
no O
n O
/ O
v O
/ O
a O
##b O
##d O
pain O
. O
just O
feels O
tired O
. O
re O
##ct O
##al O
exam O
revealed O
g B-REA
##ua I-REA
##iac I-REA
positive I-REA
dark I-REA
stool I-REA
. I-REA
received O
i B-DRUG
##v I-DRUG
##f I-DRUG
and O
40 B-STR
##m I-STR
##g I-STR
i B-ROU
##v I-ROU
pro B-DRUG
##ton I-DRUG
##ix I-DRUG
. I-DRUG
h O
##ct O
in O
ed O
is O
27 O
consistent O
with O
base O
##line O
( O
25 O
- O
30 O
) O
here O
at O
[ O
* O
* O
hospital O
##1 O
18 O
* O
* O
] O
. O
were O
going O
to O
do O
ng O
##l O
but O
decided O
not O
to O
because O
didn O
' O
t O
want O
her O
to O
go O
back O
into O
a O
##f O
with O
r O
##v O
##r O
. O
g O
##i O
called O
in O
ed O
and O
will O
see O
her O
on O
the O
floor O
. O
. O
on O
the O
floor O
, O
patient O
complained O
of O
being O
sick O
of O
being O
in O
the O
hospital O
and O
dry O
mouth O
. O
otherwise O
den O
##sies O
fever O
##s O
, O
chill O
##s O
, O
abdominal O
pain O
, O
di O
##ar O
##r O
##hea O
, O
con O
##st O
##ip O
##ation O
, O
nausea O
, O
and O
vomit O
##ing O
. O
has O
had O
some O
weight O
loss O
worked O
up O
in O
the O
past O
and O
possibly O
related O
to O
depression O
( O
per O
the O
patient O
) O
after O
her O
friend O
died O
recently O
. O
complained O
of O
occasional O
flank O
pain O
at O
bio O
##psy O
site O
and O
a O
developing O
bed O
sore O
. O
rest O
of O
r O
##os O
negative O
including O
no O
c O
##p O
, O
p O
##al O
##ps O
, O
sob O
, O
d O
##ys O
##uria O
. O
. O
past O
medical O
history O
: O
past O
medical O
history O
: O
r O
##as O
, O
h O
##t O
##n O
c O
##k O
##d O
ii O
##i O
, O
base O
##line O
g O
##f O
##r O
~ O
30 O
with O
c O
##r O
1 O
. O
6 O
par B-REA
##ox I-REA
##ys I-REA
##mal I-REA
a I-REA
##fi I-REA
##b I-REA
on O
so B-DRUG
##tal I-DRUG
##ol I-DRUG
for B-DUR
2 I-DUR
y I-DUR
##rs I-DUR
and O
co B-DRUG
##uma I-DRUG
##din I-DRUG
an O
##emia O
of O
c O
##k O
##d O
ne O
##ph O
##rol O
##ith O
##ias O
##is O
( O
prior O
o O
##xa O
##late O
stone O
) O
s O
/ O
p O
app O
##y O
, O
ch O
##ole O
, O
and O
tub O
##al O
l O
##iga O
##tion O
social O
history O
: O
lives O
alone O
, O
independent O
for O
ad O
##ls O
, O
family O
lives O
in O
the O
area O
. O
denies O
et O
##oh O
, O
tobacco O
, O
and O
ill O
##icit O
##s O
family O
history O
: O
h O
##t O
##n O
, O
co O
##lon O
ca O
no O
d O
##mi O
##i O
, O
no O
her O
##ita O
##ble O
kidney O
d O
##z O

physical O
exam O
: O
vital O
##s O
: O
t O
: O
96 O
. O
2 O
b O
##p O
: O
137 O
/ O
83 O
p O
: O
110 O
r O
: O
18 O
o O
##2 O
: O
97 O
% O
r O
##a O
general O
: O
alert O
, O
oriented O
, O
no O
acute O
distress O
he O
##ent O
: O
s O
##cle O
##ra O
an O
##ict O
##eric O
, O
dry O
##mm O
, O
or O
##op O
##har O
##ynx O
clear O
neck O
: O
su O
##pp O
##le O
, O
j O
##v O
##p O
not O
elevated O
, O
no O
lad O
lungs O
: O
clear O
to O
au O
##s O
##cu O
##lta O
##tion O
bilateral O
##ly O
, O
no O
w O
##hee O
##zes O
, O
r O
##ales O
, O
r O
##on O
##chi O
c O
##v O
: O
irregular O
##ly O
irregular O
, O
normal O
s O
##1 O
+ O
s O
##2 O
, O
no O
murmurs O
, O
rub O
##s O
, O
gal O
##lops O
abdomen O
: O
soft O
, O
non O
- O
tender O
, O
non O
- O
di O
##sten O
##ded O
, O
bow O
##el O
sounds O
present O
, O
no O
re O
##bound O
tender O
##ness O
or O
guarding O
, O
no O
organ O
##ome O
##gal O
##y O
. O
re O
##ct O
##al O
: O
external O
hem O
##or O
##r O
##ho O
##ids O
, O
good O
re O
##ct O
##al O
tone O
, O
gross O
##ly O
bloody O
stool O
, O
g O
##ua O
##iac O
positive O
g O
##u O
: O
no O
f O
##ole O
##y O
ex O
##t O
: O
warm O
, O
well O
per O
##fused O
, O
2 O
+ O
pulses O
, O
no O
club O
##bing O
, O
c O
##yan O
##osis O
or O
ed O
##ema O

per O
##tinent O
results O
: O
[ O
* O
* O
218 O
##2 O
- O
4 O
- O
12 O
* O
* O
] O
07 O
: O
25 O
##pm O
h O
##ct O
- O
30 O
. O
8 O
* O
# O
[ O
* O
* O
218 O
##2 O
- O
4 O
- O
12 O
* O
* O
] O
07 O
: O
25 O
##pm O
p O
##t O
- O
20 O
. O
4 O
* O
p O
##tt O
- O
26 O
. O
0 O
in O
##r O
( O
p O
##t O
) O
- O
1 O
. O
9 O
* O
[ O
* O
* O
218 O
##2 O
- O
4 O
- O
12 O
* O
* O
] O
09 O
: O
26 O
##am O
glucose O
- O
81 O
u O
##rea O
n O
- O
69 O
* O
c O
##rea O
##t O
- O
2 O
. O
2 O
* O
sodium O
- O
143 O
potassium O
- O
4 O
. O
3 O
chloride O
- O
105 O
total O
co O
##2 O
- O
27 O
an O
##ion O
gap O
- O
15 O
[ O
* O
* O
218 O
##2 O
- O
4 O
- O
12 O
* O
* O
] O
09 O
: O
26 O
##am O
calcium O
- O
8 O
. O
3 O
* O
phosphate O
- O
4 O
. O
4 O
ma O
##gnesium O
- O
1 O
. O
7 O
[ O
* O
* O
218 O
##2 O
- O
4 O
- O
12 O
* O
* O
] O
09 O
: O
26 O
##am O
p O
##t O
- O
25 O
. O
1 O
* O
p O
##tt O
- O
27 O
. O
0 O
in O
##r O
( O
p O
##t O
) O
- O
2 O
. O
4 O
* O
[ O
* O
* O
218 O
##2 O
- O
4 O
- O
12 O
* O
* O
] O
09 O
: O
25 O
##am O
h O
##ct O
- O
24 O
. O
0 O
* O
[ O
* O
* O
218 O
##2 O
- O
4 O
- O
12 O
* O
* O
] O
05 O
: O
30 O
##am O
glucose O
- O
106 O
* O
u O
##rea O
n O
- O
73 O
* O
c O
##rea O
##t O
- O
2 O
. O
2 O
* O
# O
sodium O
- O
143 O
potassium O
- O
4 O
. O
7 O
chloride O
- O
105 O
total O
co O
##2 O
- O
26 O
an O
##ion O
gap O
- O
17 O
[ O
* O
* O
218 O
##2 O
- O
4 O
- O
12 O
* O
* O
] O
05 O
: O
30 O
##am O
est O
##g O
##f O
##r O
- O
using O
this O
[ O
* O
* O
218 O
##2 O
- O
4 O
- O
12 O
* O
* O
] O
05 O
: O
30 O
##am O
c O
##tro O
##p O
##nt O
- O
0 O
. O
01 O
[ O
* O
* O
218 O
##2 O
- O
4 O
- O
12 O
* O
* O
] O
05 O
: O
30 O
##am O
w O
##b O
##c O
- O
7 O
. O
2 O
r O
##b O
##c O
- O
3 O
. O
08 O
* O
h O
##g O
##b O
- O
8 O
. O
9 O
* O
h O
##ct O
- O
27 O
. O
3 O
* O
m O
##c O
##v O
- O
89 O
m O
##ch O
- O
28 O
. O
8 O
m O
##ch O
##c O
- O
32 O
. O
6 O
r O
##d O
##w O
- O
18 O
. O
3 O
* O
[ O
* O
* O
218 O
##2 O
- O
4 O
- O
12 O
* O
* O
] O
05 O
: O
30 O
##am O
ne O
##uts O
- O
80 O
. O
7 O
* O
l O
##ymph O
##s O
- O
15 O
. O
4 O
* O
mon O
##os O
- O
3 O
. O
5 O
e O
##os O
- O
0 O
. O
1 O
b O
##as O
##os O
- O
0 O
. O
3 O
[ O
* O
* O
218 O
##2 O
- O
4 O
- O
12 O
* O
* O
] O
05 O
: O
30 O
##am O
p O
##lt O
count O
- O
229 O
[ O
* O
* O
218 O
##2 O
- O
4 O
- O
12 O
* O
* O
] O
05 O
: O
30 O
##am O
p O
##t O
- O
22 O
. O
9 O
* O
p O
##tt O
- O
25 O
. O
3 O
in O
##r O
( O
p O
##t O
) O
- O
2 O
. O
2 O
* O

[ O
* O
* O
218 O
##2 O
- O
4 O
- O
13 O
* O
* O
] O
02 O
: O
48 O
##am O
blood O
w O
##b O
##c O
- O
6 O
. O
1 O
r O
##b O
##c O
- O
3 O
. O
61 O
* O
h O
##g O
##b O
- O
10 O
. O
6 O
* O
h O
##ct O
- O
31 O
. O
0 O
* O
m O
##c O
##v O
- O
86 O
m O
##ch O
- O
29 O
. O
4 O
m O
##ch O
##c O
- O
34 O
. O
2 O
r O
##d O
##w O
- O
18 O
. O
4 O
* O
p O
##lt O
c O
##t O
- O
167 O
[ O
* O
* O
218 O
##2 O
- O
4 O
- O
14 O
* O
* O
] O
07 O
: O
53 O
##am O
blood O
w O
##b O
##c O
- O
7 O
. O
1 O
r O
##b O
##c O
- O
3 O
. O
64 O
* O
h O
##g O
##b O
- O
11 O
. O
2 O
* O
h O
##ct O
- O
31 O
. O
6 O
* O
m O
##c O
##v O
- O
87 O
m O
##ch O
- O
30 O
. O
7 O
m O
##ch O
##c O
- O
35 O
. O
4 O
* O
r O
##d O
##w O
- O
19 O
. O
1 O
* O
p O
##lt O
c O
##t O
- O
146 O
* O
[ O
* O
* O
218 O
##2 O
- O
4 O
- O
15 O
* O
* O
] O
06 O
: O
20 O
##am O
blood O
w O
##b O
##c O
- O
7 O
. O
4 O
r O
##b O
##c O
- O
3 O
. O
66 O
* O
h O
##g O
##b O
- O
10 O
. O
5 O
* O
h O
##ct O
- O
32 O
. O
3 O
* O
m O
##c O
##v O
- O
88 O
m O
##ch O
- O
28 O
. O
7 O
m O
##ch O
##c O
- O
32 O
. O
6 O
r O
##d O
##w O
- O
18 O
. O
9 O
* O
p O
##lt O
c O
##t O
- O
131 O
* O
[ O
* O
* O
218 O
##2 O
- O
4 O
- O
16 O
* O
* O
] O
06 O
: O
25 O
##am O
blood O
w O
##b O
##c O
- O
8 O
. O
4 O
r O
##b O
##c O
- O
3 O
. O
88 O
* O
h O
##g O
##b O
- O
10 O
. O
8 O
* O
h O
##ct O
- O
34 O
. O
5 O
* O
m O
##c O
##v O
- O
89 O
m O
##ch O
- O
27 O
. O
9 O
m O
##ch O
##c O
- O
31 O
. O
4 O
r O
##d O
##w O
- O
17 O
. O
9 O
* O
p O
##lt O
c O
##t O
- O
145 O
* O
[ O
* O
* O
218 O
##2 O
- O
4 O
- O
12 O
* O
* O
] O
07 O
: O
25 O
##pm O
blood O
p O
##t O
- O
20 O
. O
4 O
* O
p O
##tt O
- O
26 O
. O
0 O
in O
##r O
( O
p O
##t O
) O
- O
1 O
. O
9 O
* O
[ O
* O
* O
218 O
##2 O
- O
4 O
- O
13 O
* O
* O
] O
02 O
: O
48 O
##am O
blood O
p O
##t O
- O
18 O
. O
4 O
* O
p O
##tt O
- O
25 O
. O
5 O
in O
##r O
( O
p O
##t O
) O
- O
1 O
. O
7 O
* O
[ O
* O
* O
218 O
##2 O
- O
4 O
- O
14 O
* O
* O
] O
07 O
: O
53 O
##am O
blood O
p O
##t O
- O
12 O
. O
9 O
p O
##tt O
- O
23 O
. O
5 O
in O
##r O
( O
p O
##t O
) O
- O
1 O
. O
1 O
[ O
* O
* O
218 O
##2 O
- O
4 O
- O
14 O
* O
* O
] O
07 O
: O
53 O
##am O
blood O
glucose O
- O
97 O
u O
##rea O
##n O
- O
53 O
* O
c O
##rea O
##t O
- O
2 O
. O
2 O
* O
na O
- O
142 O
k O
- O
3 O
. O
7 O
c O
##l O
- O
102 O
h O
##co O
##3 O
- O
29 O
an O
##ga O
##p O
- O
15 O

[ O
* O
* O
218 O
##2 O
- O
4 O
- O
15 O
* O
* O
] O
04 O
: O
40 O
##pm O
blood O
glucose O
- O
165 O
* O
u O
##rea O
##n O
- O
38 O
* O
c O
##rea O
##t O
- O
2 O
. O
1 O
* O
na O
- O
142 O
k O
- O
4 O
. O
2 O
c O
##l O
- O
106 O
h O
##co O
##3 O
- O
24 O
an O
##ga O
##p O
- O
16 O
[ O
* O
* O
218 O
##2 O
- O
4 O
- O
16 O
* O
* O
] O
06 O
: O
25 O
##am O
blood O
glucose O
- O
159 O
* O
u O
##rea O
##n O
- O
35 O
* O
c O
##rea O
##t O
- O
2 O
. O
1 O
* O
na O
- O
141 O
k O
- O
4 O
. O
3 O
c O
##l O
- O
105 O
h O
##co O
##3 O
- O
26 O
an O
##ga O
##p O
- O
14 O
[ O
* O
* O
218 O
##2 O
- O
4 O
- O
12 O
* O
* O
] O
05 O
: O
23 O
##pm O
blood O
an O
##ca O
- O
positive O
* O
brief O
hospital O
course O
: O
82 O
##yo O
f O
with O
h O
/ O
o O
pu O
##d O
and O
c O
##k O
##d O
with O
recent O
acute B-ADE
re I-ADE
##nal I-ADE
failure I-ADE
from O
h B-DRUG
##yd I-DRUG
##ral I-DRUG
##azi I-DRUG
##ne I-DRUG
induced O
p B-ADE
##au I-ADE
##ci I-ADE
- I-ADE
immune I-ADE
g I-ADE
##lo I-ADE
##mer I-ADE
##ulon I-ADE
##ep I-ADE
##hr I-ADE
##itis I-ADE
admitted O
with O
br O
##b O
##p O
##r O
and O
at O
##rial O
fi O
##bri O
##lla O
##tion O
with O
r O
##v O
##r O
. O
. O
# O
g B-REA
##ib I-REA
: I-REA
given O
significant O
or O
##th O
##ost O
##asis O
, O
h O
##ct O
down O
to O
24 O
( O
base O
##line O
30 O
) O
and O
history O
of O
pu O
##d O
, O
initially O
concerned O
about O
u O
##gi O
##b O
. O
ng O
lava O
##ge O
was O
negative O
which O
was O
reassuring O
. O
she O
was O
given O
2 B-DOS
##u I-DOS
p B-DRUG
##rb I-DRUG
##c I-DRUG
with O
stable O
blood O
counts O
and O
hem O
##ody O
##nam O
##ics O
. O
she O
had O
an O
e O
##g O
##d O
on O
[ O
* O
* O
4 O
- O
13 O
* O
* O
] O
without O
e O
/ O
o O
active O
bleeding O
. O
per O
g O
##i O
likely O
l O
##gi O
##b O
and O
will O
need O
c O
- O
scope O
sometime O
during O
this O
admission O
. O
she O
was O
also O
given O
2 B-DOS
##u I-DOS
f B-DRUG
##f I-DRUG
##p I-DRUG
given O
co B-REA
##agu I-REA
##lop I-REA
##athy I-REA
and O
concern O
for O
g B-REA
##ib I-REA
and O
need O
for O
end O
##os O
##copy O
. O
bleeding O
ceased O
, O
however O
, O
co O
##lon O
##os O
##copy O
def O
##er O
##red O
secondary O
to O
difficult O
to O
control O
a O
##fi O
##b O
with O
r O
##v O
##r O
. O
she O
should O
follow O
- O
up O
as O
an O
out O
##patient O
for O
co O
##lons O
##copy O
. O
. O

# O
a B-REA
##f I-REA
with I-REA
r I-REA
##v I-REA
##r I-REA
: I-REA
she O
had O
been O
on O
so B-DRUG
##to I-DRUG
##lo I-DRUG
##l I-DRUG
for O
several O
years O
until O
her O
recent O
admission O
to O
[ O
* O
* O
hospital O
##1 O
18 O
* O
* O
] O
when O
this O
was O
discontinued O
in O
the O
setting O
of O
her O
worse O
##ning O
re O
##nal O
failure O
. O
she O
was O
noted O
to O
have O
a O
##f O
with O
r O
##v O
##r O
to O
140 O
##s O
. O
initially O
felt O
to O
be O
worse O
##ned O
by O
volume O
de O
##ple O
##tion O
with O
g O
##ib O
. O
however O
, O
despite O
blood O
products O
, O
she O
remained O
ta O
##chy O
##card O
##ic O
and O
thus O
nod O
##al O
agents O
were O
resumed O
. O
anti O
##coa O
##gu O
##lation O
was O
held O
in O
acute O
setting O
, O
with O
co O
##agu O
##lop O
##athy O
reversed O
in O
the O
setting O
of O
g O
##ib O
. O
she O
was O
up O
##ti O
##trate O
##d O
on O
her O
p B-ROU
##o I-ROU
regime O
##n O
to O
met B-DRUG
##op I-DRUG
##rol I-DRUG
##ol I-DRUG
50 B-STR
##m I-STR
##g I-STR
t B-FRE
##id I-FRE
and O
di B-DRUG
##lt I-DRUG
##ia I-DRUG
##ze I-DRUG
##m I-DRUG
30 B-STR
##m I-STR
##g I-STR
q B-FRE
##id I-FRE
which O
kept O
her B-REA
h I-REA
##r I-REA
in I-REA
reasonable I-REA
control I-REA
until O
she O
underwent O
a O
bow O
##el O
pre O
##p O
for O
her O
co O
##lon O
##os O
##copy O
. O
on O
the O
morning O
of O
the O
scheduled O
co O
##lon O
##os O
##copy O
, O
she O
developed O
a O
##fi O
##b O
with O
r O
##v O
##r O
in O
the O
setting O
of O
de O
##hy O
##dra O
##tion O
evidence O
by O
al O
##kal O
##osis O
and O
h O
##yper O
##nat O
##rem O
##ia O
. O
she O
received O
a O
##g O
##ress O
##ive O
i B-ROU
##v I-ROU
h B-DRUG
##yd I-DRUG
##ration I-DRUG
and O
multiple O
i B-ROU
##v I-ROU
medications B-DRUG
to O
help O
control O
rate O
. O
her O
heart O
rate O
initially O
responded O
and O
stab O
##ilized O
in O
the O
90 O
- O
100 O
' O
s O
. O
however O
, O
the O
following O
evening O
, O
she O
required O
another O
bow O
##el O
pre O
##p O
and O
her O
heart B-REA
rate I-REA
es I-REA
##calated I-REA
to O
the O

150 O
' O
s O
. O
she O
received O
additional O
i B-ROU
##v I-ROU
nod B-DRUG
##al I-DRUG
agents I-DRUG
and O
her O
p O
##o O
regime O
##n O
was O
increased O
. O
an O
electro O
##phy O
##sio O
##logy O
consult O
was O
obtained O
and O
the O
recommendation O
was O
for O
rate O
control O
and O
up O
##ti O
##tration O
with O
her O
current O
medications O
. O
rhythm O
control O
was O
def O
##er O
##red O
. O
she O
was O
restart O
##ed O
on O
anti B-REA
- I-REA
co I-REA
##agu I-REA
##lation I-REA
on O
h O
##d O
# O
5 O
with O
a O
he B-DRUG
##par I-DRUG
##in I-DRUG
g B-ROU
##tt I-ROU
. I-ROU
a O
tee O
showed O
no O
evidence O
of O
th O
##rom O
##bus O
. O
a O
card O
##io O
##version O
was O
attempted O
and O
was O
unsuccessful O
. O
the O
patient O
was O
loaded O
with O
am B-DRUG
##io I-DRUG
##dar I-DRUG
##one I-DRUG
and O
the O
met B-DRUG
##op I-DRUG
##rol I-DRUG
##ol I-DRUG
was O
up O
##ti O
##trate O
##d O
to O
100 B-STR
##m I-STR
##g I-STR
[ O
* O
* O
hospital O
##1 O
* O
* O
] O
to O
achieve B-REA
adequate I-REA
rate I-REA
control I-REA
. I-REA
she O
was O
started O
on O
di B-DRUG
##lt I-DRUG
##ia I-DRUG
##ze I-DRUG
##m I-DRUG
which O
was O
up O
##ti O
##trate O
##d O
to O
45 B-STR
##m I-STR
##g I-STR
p B-ROU
##o I-ROU
q B-FRE
##id I-FRE
. I-FRE
h O
##r O
was O
in O
the O
80s O
on O
discharge O
. O
her O
co B-DRUG
##uma I-DRUG
##din I-DRUG
was O
re O
- O
started O
and O
he B-DRUG
##par I-DRUG
##in I-DRUG
g B-ROU
##tt I-ROU
was O
continued O
until O
the O
in O
##r O
was O
therapeutic O
. O
her O
in O
##r O
became O
su O
##pra O
##ther O
##ap O
##eu O
##tic O
and O
co B-DRUG
##uma I-DRUG
##din I-DRUG
was O
held O
on O
discharge O
. O
she O
should O
follow O
- O
up O
with O
d O
##r O
. O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
* O
* O
] O
as O
an O
out O
##patient O
. O
she O
should O
have O
in O
##r O
checked O
in O
2 O
days O
and O
co B-DRUG
##uma I-DRUG
##din I-DRUG
restart O
##ed O
. O
if O
her O
am B-DRUG
##io I-DRUG
##dar I-DRUG
##one I-DRUG
converts O
her O
to O
sin B-REA
##us I-REA
rhythm I-REA
or O
drops O
her O
heart O
rate O
as O
she O
becomes O
therapeutic O
, O
she O
may O
need O
to O
stop O
her O
met B-DRUG
##op I-DRUG
##rol I-DRUG
##ol I-DRUG
. I-DRUG
. O
# O
ch B-REA
##f I-REA
: I-REA
in O
the O
setting O
of O
at O
##rial O
fi O
##bri O
##lla O
##tion O
with O
r O
##v O
##r O
, O
the O
patient O
was O
noted O
to O
develop O
signs O
and O
symptoms O
concerning O
for O
ch O
##f O
, O
such O
as O
r O
##ales O
and O
o O
##2 O
requirement O
. O
the O
patient O
was O
di B-REA
##ures I-REA
##ed I-REA
adequately O
with O
las B-DRUG
##ix I-DRUG
and O
symptoms O
improved O
. O
the O
patient O
was O
we O
##ane O
##d O
off O
supplement O
##al O
oxygen O
and O
was O
s O
##tat O
##ura O
##ting O
95 O
% O
on O
r O
##a O
. O
her O
c B-ADE
##rea I-ADE
##tin I-ADE
##ine I-ADE
bumped I-ADE
and O
las B-DRUG
##ix I-DRUG
was O
stopped O
. O
her O
peak O
c O
##rea O
##tin O
##ine O
was O
2 O
. O
8 O
on O
[ O
* O
* O
218 O
##2 O
- O
4 O
- O
21 O
* O
* O
] O
and O
came O
down O
to O
2 O
. O
5 O
on O
[ O
* O
* O
218 O
##2 O
- O
4 O
- O
23 O
* O
* O
] O
. O
las B-DRUG
##ix I-DRUG
can O
be O
considered O
as O
an O
out O
##patient O
if O
she O
develops O
signs O
and O
symptoms B-REA
of I-REA
con I-REA
##ges I-REA
##tive I-REA
heart I-REA
failure I-REA
. I-REA
. O

# O
c B-REA
##k I-REA
##d I-REA
: I-REA
re O
##nal O
function O
improving O
. O
per O
re O
##nal O
, O
tape B-DOS
##r I-DOS
pre B-DRUG
##dn I-DRUG
##sion I-DRUG
##e I-DRUG
to O
40 B-STR
mg I-STR
and O
then O
to O
30 B-STR
##m I-STR
##g I-STR
. I-STR
she O
remained O
on O
pre B-DRUG
##dn I-DRUG
##ison I-DRUG
##e I-DRUG
3 B-STR
##om I-STR
##g I-STR
daily B-FRE
and O
her O
c O
##rea O
##tin O
##ine O
remained O
stable O
. O
her O
s B-DRUG
##tero I-DRUG
##id I-DRUG
pp O
##x O
including O
p O
##c O
##p O
[ O
* O
* O
name O
##9 O
( O
pre O
) O
* O
* O
] O
, O
pp B-DRUG
##i I-DRUG
, I-DRUG
calcium B-DRUG
, I-DRUG
v B-DRUG
##it I-DRUG
d I-DRUG
were O
continued O
. O
she O
was O
followed O
by O
the O
re O
##nal O
consult O
service O
during O
her O
admission O
and O
las B-DRUG
##ix I-DRUG
was O
held O
when O
c B-ADE
##rea I-ADE
##tin I-ADE
##ine I-ADE
was I-ADE
elevated I-ADE
. I-ADE
she O
is O
on O
at B-DRUG
##ova I-DRUG
##q I-DRUG
##uo I-DRUG
##ne I-DRUG
suspension B-FOR
1500 B-STR
mg I-STR
p B-ROU
##o I-ROU
/ I-ROU
ng I-ROU
daily B-FRE
for O
prop B-REA
##hyl I-REA
##ax I-REA
##is I-REA
. I-REA
. O
there O
are O
no O
pending O
studies O
at O
the O
time O
of O
discharge O
. O
medications O
on O
admission O
: O
n B-DRUG
##ys I-DRUG
##tat I-DRUG
##in I-DRUG
s B-FOR
+ I-FOR
s I-FOR
x B-DUR
7 I-DUR
days I-DUR
( O
day O
3 O
today O
) O
do B-DRUG
##cus I-DRUG
##ate I-DRUG
sodium I-DRUG
100 B-STR
mg I-STR
p B-ROU
##o I-ROU
bid B-FRE
ran B-DRUG
##iti I-DRUG
##dine I-DRUG
150 B-STR
##m I-STR
##g I-STR
daily B-FRE
di B-DRUG
##lt I-DRUG
##ia I-DRUG
##ze I-DRUG
##m I-DRUG
s I-DRUG
##r I-DRUG
120 B-STR
##m I-STR
##g I-STR
p B-ROU
##o I-ROU
daily B-FRE
co B-DRUG
##uma I-DRUG
##din I-DRUG
2 B-STR
. I-STR
5 I-STR
##m I-STR
##g I-STR
daily B-FRE
at B-DRUG
##ova I-DRUG
##q I-DRUG
##uo I-DRUG
##ne I-DRUG
1500 B-STR
##m I-STR
##g I-STR
daily B-FRE
v B-DRUG
##it I-DRUG
b I-DRUG
##12 I-DRUG
500 B-STR
##m I-STR
##c I-STR
##g I-STR
daily B-FRE
f B-DRUG
##olate I-DRUG
1 B-STR
##m I-STR
##g I-STR
daily B-FRE
p B-DRUG
##ril I-DRUG
##ose I-DRUG
##c I-DRUG
40 B-STR
##m I-STR
##g I-STR
[ O
* O
* O
hospital O
##1 O
* O
* O
] O
top B-DRUG
##rol I-DRUG
x I-DRUG
##l I-DRUG
50 B-STR
##m I-STR
##g I-STR
daily B-FRE
calcium B-DRUG
/ I-DRUG
v I-DRUG
##it I-DRUG
d I-DRUG
600 B-STR
- I-STR
400 I-STR
##uni I-STR
##ts I-STR
twice B-FRE
daily I-FRE
pre B-DRUG
##dn I-DRUG
##ison I-DRUG
##e I-DRUG
50 B-STR
mg I-STR
daily B-FRE
discharge O
medications O
: O
1 O
. O
at B-DRUG
##ova I-DRUG
##q I-DRUG
##uo I-DRUG
##ne I-DRUG
750 B-STR
mg I-STR
/ I-STR
5 I-STR
m I-STR
##l I-STR
suspension B-FOR
si O
##g O
: O
two B-DOS
( I-DOS
2 I-DOS
) I-DOS
p B-ROU
##o I-ROU
daily B-FRE
( I-FRE
daily I-FRE
) I-FRE
. I-FRE
2 O
. O
c B-DRUG
##yan I-DRUG
##oc I-DRUG
##ob I-DRUG
##ala I-DRUG
##min I-DRUG
500 B-STR
m I-STR
##c I-STR
##g I-STR
tablet B-FOR
si O
##g O
: O
0 B-DOS
. I-DOS
5 I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( I-FRE
daily I-FRE
) I-FRE
. I-FRE
3 O
. O
f B-DRUG
##olic I-DRUG
acid I-DRUG
1 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( I-FRE
daily I-FRE
) I-FRE
. I-FRE

4 O
. O
ch B-DRUG
##ole I-DRUG
##cal I-DRUG
##ci I-DRUG
##fer I-DRUG
##ol I-DRUG
( I-DRUG
vitamin I-DRUG
d I-DRUG
##3 I-DRUG
) I-DRUG
400 B-STR
unit I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( I-FRE
daily I-FRE
) I-FRE
. I-FRE
5 O
. O
pan B-DRUG
##top I-DRUG
##raz I-DRUG
##ole I-DRUG
40 B-STR
mg I-STR
tablet B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
p B-ROU
##o I-ROU
q B-FRE
##12 I-FRE
##h I-FRE
( I-FRE
every I-FRE
12 I-FRE
hours I-FRE
) I-FRE
. I-FRE
di O
##sp O
: O
* O
60 O
tablet O
, O
delayed O
release O
( O
e O
. O
c O
. O
) O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
0 O
* O
6 O
. O
pre B-DRUG
##dn I-DRUG
##ison I-DRUG
##e I-DRUG
10 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
three B-DOS
( I-DOS
3 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( I-FRE
daily I-FRE
) I-FRE
. I-FRE
7 O
. O
n B-DRUG
##ys I-DRUG
##tat I-DRUG
##in I-DRUG
100 B-STR
, I-STR
000 I-STR
unit I-STR
/ I-STR
m I-STR
##l I-STR
suspension B-FOR
si O
##g O
: O
five B-DOS
( I-DOS
5 I-DOS
) I-DOS
m I-DOS
##l I-DOS
p B-ROU
##o I-ROU
q B-FRE
##8 I-FRE
##h I-FRE
( I-FRE
every I-FRE
8 I-FRE
hours I-FRE
) I-FRE
. I-FRE
8 O
. O
men B-DRUG
##th I-DRUG
##ol I-DRUG
- I-DRUG
c I-DRUG
##ety I-DRUG
##l I-DRUG
##py I-DRUG
##rid I-DRUG
##ini I-DRUG
##um I-DRUG
3 B-STR
mg I-STR
lo B-FOR
##zen I-FOR
##ge I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
lo B-FOR
##zen I-FOR
##ge I-FOR
m B-ROU
##uc I-ROU
##ous I-ROU
membrane I-ROU
p B-FRE
##rn I-FRE
( I-FRE
as I-FRE
needed I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
sore B-REA
throat I-REA
. I-REA
9 O
. O
t B-DRUG
##raz I-DRUG
##od I-DRUG
##one I-DRUG
50 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
0 B-DOS
. I-DOS
5 I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
h B-FRE
##s I-FRE
( I-FRE
at I-FRE
bed I-FRE
##time I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
ins B-REA
##om I-REA
##nia I-REA
. I-REA
10 O
. O
am B-DRUG
##io I-DRUG
##dar I-DRUG
##one I-DRUG
200 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
t B-FRE
##id I-FRE
( I-FRE
3 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
for B-DUR
2 I-DUR
days I-DUR
: I-DUR
on O
[ O
* O
* O
218 O
##2 O
- O
4 O
- O
25 O
* O
* O
] O
, O
please O
change O
to O
200 O
##m O
##g O
p O
##o O
bid O
for O
1 O
week O
, O
then O
on O
[ O
* O
* O
218 O
##2 O
- O
5 O
- O
2 O
* O
* O
] O
change O
to O
200 O
##m O
##g O
daily O
. O
11 O
. O
am B-DRUG
##io I-DRUG
##dar I-DRUG
##one I-DRUG
200 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
twice B-FRE
a I-FRE
day I-FRE
: I-FRE
start O
on O
[ O
* O
* O
218 O
##2 O
- O
4 O
- O
25 O
* O
* O
] O
for B-DUR
1 I-DUR
week I-DUR
, I-DUR
then O
change O
to O
200 B-STR
##m I-STR
##g I-STR
p B-ROU
##o I-ROU
daily B-FRE
. I-FRE
12 O
. O
lo B-DRUG
##raze I-DRUG
##pa I-DRUG
##m I-DRUG
0 B-STR
. I-STR
5 I-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
h B-FRE
##s I-FRE
( I-FRE
at I-FRE
bed I-FRE
##time I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
ins B-REA
##om I-REA
##nia I-REA
, I-REA
anxiety B-REA
. I-REA
13 O
. O
met B-DRUG
##op I-DRUG
##rol I-DRUG
##ol I-DRUG
ta I-DRUG
##rt I-DRUG
##rate I-DRUG
50 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
two B-DOS
( I-DOS
2 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
t B-FRE
##id I-FRE
( I-FRE
3 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE
14 O
. O
calcium B-DRUG
carbon I-DRUG
##ate I-DRUG
500 B-STR
mg I-STR
tablet B-FOR
, I-FOR
ch I-FOR
##ew I-FOR
##able I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
, I-FOR
ch I-FOR
##ew I-FOR
##able I-FOR
p B-ROU
##o I-ROU
t B-FRE
##id I-FRE
( I-FRE
3 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE
15 O
. O
di B-DRUG
##lt I-DRUG
##ia I-DRUG
##ze I-DRUG
##m I-DRUG
h I-DRUG
##c I-DRUG
##l I-DRUG
30 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
1 B-DOS
. I-DOS
5 I-DOS
tablets B-FOR
p B-ROU
##o I-ROU
q B-FRE
##id I-FRE
( I-FRE
4 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

16 O
. O
out O
##patient O
lab O
work O
please O
check O
electro O
##ly O
##tes O
( O
na O
, O
k O
, O
c O
##l O
, O
h O
##co O
##3 O
) O
and O
re O
##nal O
function O
( O
b O
##un O
, O
c O
##rea O
##t O
) O
, O
and O
hem O
##ato O
##c O
##rit O
in O
1 O
week O
. O
17 O
. O
out O
##patient O
lab O
work O
please O
check O
in O
##r O
and O
hem O
##ato O
##c O
##rit O
in O
2 O
days O
. O
please O
restart O
co B-DRUG
##uma I-DRUG
##din I-DRUG
at O
2 B-STR
. I-STR
5 I-STR
##m I-STR
##g I-STR
daily B-FRE
if O
in O
##r O
less O
than O
2 O
. O
5 O
. O
re O
##che O
##ck O
in O
##r O
every O
2 O
days O
. O
discharge O
disposition O
: O
extended O
care O
facility O
: O
[ O
* O
* O
hospital O
* O
* O
] O
healthcare O
center O
- O
[ O
* O
* O
location O
( O
un O
) O
* O
* O
] O
discharge O
diagnosis O
: O
bright O
red O
blood O
per O
re O
##ct O
##um O
an O
##emia O
requiring O
blood O
trans O
##fusion O
at O
##rial O
fi O
##bri O
##lla O
##tion O
with O
r O
##v O
##r O
p O
##au O
##ci O
- O
immune O
g O
##lo O
##mer O
##ulon O
##ep O
##hr O
##itis O
with O
p O
- O
an O
##ca O
positive O
discharge O
condition O
: O
mental O
status O
: O
clear O
and O
coherent O
. O
level O
of O
consciousness O
: O
alert O
and O
interactive O
. O
activity O
status O
: O
out O
of O
bed O
with O
assistance O
to O
chair O
or O
wheelchair O
. O
discharge O
instructions O
: O
you O
were O
admitted O
to O
the O
hospital O
for O
bleeding O
from O
your O
re O
##ct O
##um O
. O
you O
received O
a O
blood B-DRUG
trans I-DRUG
##fusion I-DRUG
for O
an B-REA
##emia I-REA
. I-REA
you O
blood O
count O
improved O
and O
your O
bleeding O
stopped O
. O
the O
g O
##at O
##ro O
##enter O
##ologists O
performed O
an O
upper O
end O
##os O
##copy O
which O
was O
normal O
. O
you O
were O
continued O
on O
a O
ant B-DRUG
##ac I-DRUG
##id I-DRUG
. I-DRUG
the O
plan O
was O
for O
you O
to O
undergo O
a O
co O
##lon O
##os O
##copy O
. O
while O
undergoing O
the O
pre O
##p O
for O
the O
co O
##lon O
##os O
##copy O
, O
you O
developed O
a O
very O
fast O
heart O
rate O
from O
your O
at O
##rial O
fi O
##bri O
##lla O
##tion O
. O
your O
blood O
pressure O
medications O
were O
increased O
to O
help O
control O
our O
heart O
rate O
. O
the O
card O
##iol O
##ogist O
##s O
attempted O
to O
card O
##io O
##vert O
you O
out O
of O
at O
##rial O
fi O
##bri O
##lla O
##tion O
, O
but O
were O
unsuccessful O
. O
you O
were O
started O
on O
am B-DRUG
##io I-DRUG
##dar I-DRUG
##one I-DRUG
and O
continued O
on O
met B-DRUG
##op I-DRUG
##rol I-DRUG
##ol I-DRUG
. I-DRUG
you O
were O
started O
on O
di B-DRUG
##lt I-DRUG
##ia I-DRUG
##ze I-DRUG
##m I-DRUG
for O
heart B-REA
rate I-REA
control I-REA
. I-REA
you O
were O
given O
las B-DRUG
##ix I-DRUG
for O
heart B-REA
failure I-REA
but O
this O
was O
stopped O
prior O
to O
discharge O
. O
when O
you O
came O
into O
the O
hospital O
, O
you O
were O
taking O
pre B-DRUG
##dn I-DRUG
##ison I-DRUG
##e I-DRUG
. I-DRUG
the O
ne O
##ph O
##rol O
##ogist O
##s O
recommended O
that O
your O
pre B-DRUG
##dn I-DRUG
##ison I-DRUG
##e I-DRUG
be O
decreased O
to O
30 B-STR
##m I-STR
##g I-STR
per B-FRE
day I-FRE
. I-FRE
you O
should O
continue O
to O
take O
pre B-DRUG
##dn I-DRUG
##ison I-DRUG
##e I-DRUG
30 B-STR
##m I-STR
##g I-STR
daily B-FRE
. I-FRE

changes O
in O
your O
medication O
; O
1 O
. O
am B-DRUG
##io I-DRUG
##dar I-DRUG
##one I-DRUG
200 B-STR
##m I-STR
##g I-STR
three B-FRE
times I-FRE
per I-FRE
day I-FRE
for B-DUR
1 I-DUR
week I-DUR
. I-DUR
on O
[ O
* O
* O
218 O
##2 O
- O
4 O
- O
25 O
* O
* O
] O
, O
change O
to O
200 B-STR
##m I-STR
##g I-STR
2 B-FRE
times I-FRE
per I-FRE
day I-FRE
for B-DUR
1 I-DUR
week I-DUR
and O
then O
200 B-STR
##m I-STR
##g I-STR
daily B-FRE
. I-FRE
2 O
. O
met B-DRUG
##op I-DRUG
##rol I-DRUG
##ol I-DRUG
100 B-STR
##m I-STR
##g I-STR
p B-ROU
##o I-ROU
bid B-FRE
3 O
. O
pre B-DRUG
##dn I-DRUG
##ison I-DRUG
##e I-DRUG
30 B-STR
##m I-STR
##g I-STR
daily B-FRE
4 O
. O
stop O
p B-DRUG
##ril I-DRUG
##ose I-DRUG
##c I-DRUG
40 B-STR
##m I-STR
##g I-STR
daily B-FRE
5 O
. O
start O
pro B-DRUG
##ton I-DRUG
##ix I-DRUG
40 B-STR
##m I-STR
##g I-STR
twice B-FRE
daily I-FRE
6 O
. O
change O
di B-DRUG
##lt I-DRUG
##ia I-DRUG
##ze I-DRUG
##m I-DRUG
to O
45 B-STR
##m I-STR
##g I-STR
p B-ROU
##o I-ROU
q B-FRE
##id I-FRE
follow O
##up O
instructions O
: O
you O
need O
to O
schedule O
a O
follow O
- O
up O
appointment O
with O
the O
[ O
* O
* O
hospital O
* O
* O
] O
clinic O
. O
you O
can O
call O
them O
@ O
( O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
223 O
##3 O
* O
* O
] O
to O
schedule O
an O
appointment O
and O
out O
##patient O
co O
##lon O
##os O
##copy O
. O
name O
: O
[ O
* O
* O
last O
name O
( O
l O
##f O
) O
* O
* O
] O
, O
[ O
* O
* O
first O
name O
##7 O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
* O
* O
] O
[ O
* O
* O
initial O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##4 O
) O
* O
* O
] O
specialty O
: O
card O
##iology O
address O
: O
[ O
* O
* O
street O
address O
( O
2 O
) O
26 O
##8 O
##7 O
* O
* O
] O
, O
s O
##te O
7 O
##c O
, O
[ O
* O
* O
location O
( O
un O
) O
* O
* O
] O
, O
[ O
* O
* O
n O
##ume O
##ric O
id O
##ent O
##ifier O
82 O
##2 O
* O
* O
] O
phone O
: O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
57 O
##6 O
##8 O
* O
* O
] O
when O
: O
[ O
* O
* O
last O
name O
( O
l O
##f O
) O
76 O
##6 O
* O
* O
] O
, O
[ O
* O
* O
4 O
- O
29 O
* O
* O
] O
at O
11 O
: O
30 O
##am O
we O
are O
working O
on O
a O
follow O
up O
appointment O
with O
d O
##r O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
* O
* O
] O
in O
the O
ne O
##ph O
##rol O
##ogy O
department O
in O
the O
next O
week O
. O
you O
will O
be O
called O
with O
this O
appointment O
. O
if O
you O
have O
not O
heard O
or O
have O
questions O
, O
please O
call O
: O
( O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
101 O
##35 O
* O
* O
] O

admission O
date O
: O
[ O
* O
* O
219 O
##2 O
- O
9 O
- O
24 O
* O
* O
] O
discharge O
date O
: O
[ O
* O
* O
219 O
##2 O
- O
10 O
- O
5 O
* O
* O
] O
date O
of O
birth O
: O
[ O
* O
* O
214 O
##8 O
- O
6 O
- O
18 O
* O
* O
] O
sex O
: O
m O
service O
: O
[ O
* O
* O
doctor O
first O
name O
147 O
* O
* O
] O
all O
##er O
##gies O
: O
patient O
recorded O
as O
having O
no O
known O
all O
##er O
##gies O
to O
drugs O
attending O
: O
[ O
* O
* O
first O
name O
##3 O
( O
l O
##f O
) O
69 O
##5 O
* O
* O
] O
chief O
complaint O
: O
es O
##ld O
secondary O
to O
he O
##p O
c O
c O
##ir O
##r O
##hos O
##is O
major O
surgical O
or O
invasive O
procedure O
: O
s O
/ O
p O
liver O
transplant O
ca O
##da O
##ver O
##ic O
[ O
* O
* O
219 O
##2 O
- O
9 O
- O
24 O
* O
* O
] O
history O
of O
present O
illness O
: O
44 O
yo O
male O
with O
es O
##ld O
secondary O
to O
h O
##c O
##v O
c O
##ir O
##r O
##hos O
##is O
past O
medical O
history O
: O
he O
##p O
c O
et O
##oh O
abuse O
h O
##t O
##n O
portal O
h O
##t O
##n O
social O
history O
: O
et O
##oh O
abuse O
physical O
exam O
: O
na O
##d O
a O
##ao O
times O
3 O
per O
##rl O
##a O
, O
e O
##omi O
r O
##rr O
s O
##1 O
+ O
s O
##2 O
c O
##ta O
bi O
##lat O
soft O
, O
n O
##t O
mild O
di O
##sten O
##tion O
per O
##tinent O
results O
: O
path O
##ology O
examination O
diagnosis O
: O
liver O
, O
native O
he O
##pate O
##ct O
##omy O
: O
1 O
. O
established O
c O
##ir O
##r O
##hos O
##is O
, O
t O
##rich O
##rome O
stain O
##s O
evaluated O
. O
2 O
. O
mild O
to O
moderate O
se O
##pta O
##l O
mon O
##on O
##uc O
##lea O
##r O
inflammation O
with O
minimal O
lo O
##bula O
##r O
inflammation O
( O
grade O
[ O
* O
* O
1 O
- O
13 O
* O
* O
] O
inflammation O
) O
. O
3 O
. O
mild O
predominantly O
mac O
##rove O
##si O
##cular O
s O
##te O
##ato O
##sis O
. O
4 O
. O
mild O
increase O
of O
iron O
in O
k O
##up O
##ffer O
- O
cells O
and O
he O
##pa O
##to O
##cy O
##tes O
seen O
on O
special O
stain O
. O
5 O
. O
small O
cell O
d O
##ys O
##p O
##lasia O
nod O
##ule O
with O
focal O
area O
suggest O
##ive O
of O
early O
evolving O
he O
##pa O
##to O
##cellular O
car O
##cin O
##oma O
. O
the O
d O
##ys O
##p O
##lastic O
nod O
##ule O
measures O
1 O
cm O
in O
maximum O
dimension O
. O
6 O
. O
negative O
vascular O
and O
bi O
##lia O
##ry O
margins O
. O
7 O
. O
chronic O
ch O
##ole O
##cy O
##st O
##itis O
. O

[ O
* O
* O
219 O
##2 O
- O
9 O
- O
24 O
* O
* O
] O
11 O
: O
29 O
##am O
blood O
w O
##b O
##c O
- O
2 O
. O
9 O
* O
# O
r O
##b O
##c O
- O
3 O
. O
21 O
* O
h O
##g O
##b O
- O
11 O
. O
3 O
* O
h O
##ct O
- O
31 O
. O
4 O
* O
m O
##c O
##v O
- O
98 O
m O
##ch O
- O
35 O
. O
2 O
* O
m O
##ch O
##c O
- O
36 O
. O
0 O
* O
r O
##d O
##w O
- O
14 O
. O
8 O
p O
##lt O
c O
##t O
- O
35 O
* O
[ O
* O
* O
219 O
##2 O
- O
9 O
- O
24 O
* O
* O
] O
11 O
: O
29 O
##am O
blood O
p O
##t O
- O
14 O
. O
4 O
* O
p O
##tt O
- O
34 O
. O
1 O
in O
##r O
( O
p O
##t O
) O
- O
1 O
. O
3 O
[ O
* O
* O
219 O
##2 O
- O
9 O
- O
24 O
* O
* O
] O
11 O
: O
29 O
##am O
blood O
glucose O
- O
247 O
* O
u O
##rea O
##n O
- O
16 O
c O
##rea O
##t O
- O
0 O
. O
9 O
na O
- O
134 O
k O
- O
4 O
. O
0 O
c O
##l O
- O
100 O
h O
##co O
##3 O
- O
25 O
an O
##ga O
##p O
- O
13 O
[ O
* O
* O
219 O
##2 O
- O
9 O
- O
24 O
* O
* O
] O
11 O
: O
29 O
##am O
blood O
al O
##t O
- O
30 O
as O
##t O
- O
61 O
* O
al O
##k O
##ph O
##os O
- O
218 O
* O
to O
##t O
##bil O
##i O
- O
4 O
. O
3 O
* O
[ O
* O
* O
219 O
##2 O
- O
9 O
- O
24 O
* O
* O
] O
09 O
: O
16 O
##pm O
blood O
al O
##t O
- O
230 O
##8 O
* O
as O
##t O
- O
47 O
##55 O
* O
al O
##k O
##ph O
##os O
- O
84 O
am O
##yla O
##se O
- O
62 O
to O
##t O
##bil O
##i O
- O
3 O
. O
6 O
* O
dir O
##bil O
##i O
- O
2 O
. O
8 O
* O
in O
##d O
##bil O
##i O
- O
0 O
. O
8 O

[ O
* O
* O
219 O
##2 O
- O
10 O
- O
5 O
* O
* O
] O
10 O
: O
00 O
##am O
blood O
w O
##b O
##c O
- O
7 O
. O
0 O
r O
##b O
##c O
- O
3 O
. O
66 O
* O
h O
##g O
##b O
- O
11 O
. O
4 O
* O
h O
##ct O
- O
32 O
. O
6 O
* O
m O
##c O
##v O
- O
89 O
m O
##ch O
- O
31 O
. O
1 O
m O
##ch O
##c O
- O
34 O
. O
9 O
r O
##d O
##w O
- O
16 O
. O
5 O
* O
p O
##lt O
c O
##t O
- O
68 O
* O
[ O
* O
* O
219 O
##2 O
- O
9 O
- O
25 O
* O
* O
] O
03 O
: O
57 O
##am O
blood O
glucose O
- O
256 O
* O
u O
##rea O
##n O
- O
34 O
* O
c O
##rea O
##t O
- O
1 O
. O
8 O
* O
na O
- O
139 O
k O
- O
4 O
. O
4 O
c O
##l O
- O
103 O
h O
##co O
##3 O
- O
19 O
* O
an O
##ga O
##p O
- O
21 O
* O
[ O
* O
* O
219 O
##2 O
- O
9 O
- O
25 O
* O
* O
] O
10 O
: O
33 O
##am O
blood O
glucose O
- O
141 O
* O
u O
##rea O
##n O
- O
38 O
* O
c O
##rea O
##t O
- O
2 O
. O
2 O
* O
na O
- O
140 O
k O
- O
4 O
. O
5 O
c O
##l O
- O
104 O
h O
##co O
##3 O
- O
20 O
* O
an O
##ga O
##p O
- O
21 O
[ O
* O
* O
219 O
##2 O
- O
9 O
- O
25 O
* O
* O
] O
01 O
: O
45 O
##pm O
blood O
glucose O
- O
137 O
* O
u O
##rea O
##n O
- O
42 O
* O
c O
##rea O
##t O
- O
2 O
. O
5 O
* O
na O
- O
140 O
k O
- O
4 O
. O
8 O
c O
##l O
- O
105 O
h O
##co O
##3 O
- O
20 O
* O
an O
##ga O
##p O
- O
20 O
[ O
* O
* O
219 O
##2 O
- O
9 O
- O
26 O
* O
* O
] O
05 O
: O
25 O
##am O
blood O
glucose O
- O
123 O
* O
u O
##rea O
##n O
- O
65 O
* O
c O
##rea O
##t O
- O
3 O
. O
7 O
* O
na O
- O
140 O
k O
- O
4 O
. O
9 O
c O
##l O
- O
102 O
h O
##co O
##3 O
- O
18 O
* O
an O
##ga O
##p O
- O
25 O
* O
[ O
* O
* O
219 O
##2 O
- O
9 O
- O
29 O
* O
* O
] O
11 O
: O
19 O
##am O
blood O
glucose O
- O
197 O
* O
u O
##rea O
##n O
- O
147 O
* O
c O
##rea O
##t O
- O
6 O
. O
8 O
* O
na O
- O
141 O
k O
- O
3 O
. O
7 O
c O
##l O
- O
100 O
h O
##co O
##3 O
- O
18 O
* O
an O
##ga O
##p O
- O
27 O
* O
[ O
* O
* O
219 O
##2 O
- O
9 O
- O
29 O
* O
* O
] O
05 O
: O
34 O
##pm O
blood O
glucose O
- O
117 O
* O
u O
##rea O
##n O
- O
148 O
* O
c O
##rea O
##t O
- O
7 O
. O
1 O
* O
na O
- O
141 O
k O
- O
3 O
. O
6 O
c O
##l O
- O
100 O
h O
##co O
##3 O
- O
16 O
* O
an O
##ga O
##p O
- O
29 O
* O
[ O
* O
* O
219 O
##2 O
- O
10 O
- O
5 O
* O
* O
] O
10 O
: O
00 O
##am O
blood O
glucose O
- O
199 O
* O
u O
##rea O
##n O
- O
110 O
* O
c O
##rea O
##t O
- O
4 O
. O
2 O
* O
na O
- O
136 O
k O
- O
3 O
. O
6 O
c O
##l O
- O
99 O
h O
##co O
##3 O
- O
21 O
* O
an O
##ga O
##p O
- O
20 O

[ O
* O
* O
219 O
##2 O
- O
9 O
- O
25 O
* O
* O
] O
03 O
: O
57 O
##am O
blood O
al O
##t O
- O
285 O
##9 O
* O
as O
##t O
- O
[ O
* O
* O
n O
##ume O
##ric O
id O
##ent O
##ifier O
47 O
##48 O
##1 O
* O
* O
] O
* O
l O
##d O
( O
l O
##dh O
) O
- O
75 O
##35 O
* O
al O
##k O
##ph O
##os O
- O
104 O
to O
##t O
##bil O
##i O
- O
4 O
. O
6 O
* O
[ O
* O
* O
219 O
##2 O
- O
9 O
- O
26 O
* O
* O
] O
01 O
: O
45 O
##am O
blood O
al O
##t O
- O
261 O
##5 O
* O
as O
##t O
- O
600 O
##9 O
* O
al O
##k O
##ph O
##os O
- O
124 O
* O
to O
##t O
##bil O
##i O
- O
3 O
. O
3 O
* O
[ O
* O
* O
219 O
##2 O
- O
9 O
- O
29 O
* O
* O
] O
11 O
: O
19 O
##am O
blood O
al O
##t O
- O
117 O
##9 O
* O
as O
##t O
- O
450 O
* O
al O
##k O
##ph O
##os O
- O
174 O
* O
to O
##t O
##bil O
##i O
- O
3 O
. O
2 O
* O
[ O
* O
* O
219 O
##2 O
- O
10 O
- O
5 O
* O
* O
] O
10 O
: O
00 O
##am O
blood O
al O
##t O
- O
191 O
* O
as O
##t O
- O
49 O
* O
al O
##k O
##ph O
##os O
- O
199 O
* O
to O
##t O
##bil O
##i O
- O
3 O
. O
6 O
* O
du O
##plex O
do O
##pp O
a O
##b O
##d O
/ O
p O
##el O
[ O
* O
* O
219 O
##2 O
- O
9 O
- O
25 O
* O
* O
] O
9 O
: O
08 O
am O
impression O
: O
1 O
) O
patent O
in O
##tra O
##he O
##pa O
##tic O
v O
##as O
##cula O
##ture O
. O
please O
note O
that O
no O
flow O
was O
noted O
in O
the O
re O
##tro O
##he O
##pa O
##tic O
ve O
##na O
ca O
##va O
but O
this O
was O
considered O
most O
likely O
technical O
since O
this O
was O
a O
portable O
study O
. O
2 O
) O
5 O
. O
8 O
x O
5 O
. O
4 O
cm O
rounded O
h O
##y O
##po O
##ech O
##oi O
##c O
structure O
a O
##but O
##ting O
the O
ve O
##na O
ca O
##va O
has O
son O
[ O
* O
* O
name O
( O
ni O
) O
49 O
##3 O
* O
* O
] O
features O
suggest O
##ive O
of O
a O
small O
hem O
##ato O
##ma O
. O

brief O
hospital O
course O
: O
p O
##t O
admitted O
on O
[ O
* O
* O
219 O
##2 O
- O
9 O
- O
24 O
* O
* O
] O
for O
o O
##lt O
secondary O
to O
h O
/ O
o O
h O
##c O
##v O
c O
##ir O
##r O
##hos O
##is O
. O
p O
##t O
taken O
to O
the O
or O
for O
o O
##lt O
and O
p O
##t O
to O
##l O
the O
procedure O
. O
[ O
* O
* O
name O
( O
ni O
) O
* O
* O
] O
, O
p O
##t O
trans O
##ef O
##er O
##red O
to O
the O
sic O
##u O
in O
##tub O
##ated O
and O
se O
##dated O
. O
p O
##t O
did O
well O
in O
the O
immediate O
post O
- O
op O
period O
and O
was O
ex O
##tub O
##ated O
on O
[ O
* O
* O
219 O
##2 O
- O
9 O
- O
25 O
* O
* O
] O
. O
p O
##t O
started O
on O
mm B-DRUG
##f I-DRUG
1000 B-STR
##m I-STR
##g I-STR
and O
a O
tape B-DOS
##ring I-DOS
dose I-DOS
of O
s B-DRUG
##m I-DRUG
. I-DRUG
however O
, O
p O
##t O
' O
s O
b O
##un O
/ O
c O
##r O
began O
to O
increase O
on O
pod O
2 O
, O
with O
develop O
##ement O
of O
a O
##rf O
and O
o O
##li O
##gu O
##ria O
. O
p O
##t O
clinical O
##ly O
continued O
to O
improve O
. O
r O
##u O
##q O
us O
and O
c O
##t O
scan O
with O
evidence O
of O
per O
##i O
- O
he O
##pa O
##tic O
hem O
##ato O
##ma O
and O
p O
##oss O
compression O
of O
i O
##v O
##c O
. O
p O
##t O
h O
##yd O
##rated O
and O
hem O
##ato O
##ma O
watched O
. O
o O
##li O
##gu O
##ria O
began O
to O
resolve O
by O
pod O
3 O
and O
p O
##t O
transferred O
to O
the O
floor O
on O
pod O
5 O
. O
p O
##t O
continued O
mm B-DRUG
##f I-DRUG
, I-DRUG
s B-DRUG
##m I-DRUG
tape O
##red O
to O
20 B-STR
##m I-STR
##g I-STR
pre B-DRUG
##dn I-DRUG
##ison I-DRUG
##e I-DRUG
and O
c B-DRUG
##sa I-DRUG
100 B-STR
[ O
* O
* O
hospital O
##1 O
* O
* O
] O
added O
and O
t O
##it O
##rated O
to O
125 B-STR
. I-STR
p O
##t O
continued O
to O
improve O
, O
with O
re O
##sol O
##ving O
a O
##rf O
. O
p O
##t O
started O
with O
p O
##t O
and O
advancing O
diet O
. O
p O
##t O
tolerate O
##d O
full O
diet O
and O
did O
well O
in O
p O
##t O
. O
p O
##t O
with O
new O
onset O
diabetes B-ADE
secondary O
to O
high O
dose O
s B-DRUG
##tero I-DRUG
##ids I-DRUG
. I-DRUG
[ O
* O
* O
last O
name O
( O
un O
) O
* O
* O
] O
consulted O
and O
b O
##s O
controlled O
. O
p O
##t O
mob O
##ilized O
fluid O
and O
decreased O
weight O
from O
109 O
kg O
to O
100 O
##k O
##g O
by O
pod O
9 O
. O
p O
##t O
continued O
to O
do O
well O
and O
p O
##t O
d O
/ O
c O
' O
d O
home O
with O
v O
##na O
for O
di O
##abe O
##tic O
teaching O
on O
pod O
11 O
, O
[ O
* O
* O
219 O
##2 O
- O
10 O
- O
5 O
* O
* O
] O

discharge O
medications O
: O
1 O
. O
trim B-DRUG
##eth I-DRUG
##op I-DRUG
##rim I-DRUG
- I-DRUG
su I-DRUG
##lf I-DRUG
##ame I-DRUG
##th I-DRUG
##ox I-DRUG
##az I-DRUG
##ole I-DRUG
80 B-STR
- I-STR
400 I-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
q B-FRE
##d I-FRE
( I-FRE
once I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE
2 O
. O
do B-DRUG
##cus I-DRUG
##ate I-DRUG
sodium I-DRUG
100 B-STR
mg I-STR
capsule B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
capsule B-FOR
p B-ROU
##o I-ROU
bid B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE
3 O
. O
my B-DRUG
##co I-DRUG
##phe I-DRUG
##no I-DRUG
##late I-DRUG
m I-DRUG
##of I-DRUG
##eti I-DRUG
##l I-DRUG
500 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
two B-DOS
( I-DOS
2 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
bid B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE
4 O
. O
pan B-DRUG
##top I-DRUG
##raz I-DRUG
##ole I-DRUG
sodium I-DRUG
40 B-STR
mg I-STR
tablet B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
p B-ROU
##o I-ROU
q B-FRE
##24 I-FRE
##h I-FRE
( I-FRE
every I-FRE
24 I-FRE
hours I-FRE
) I-FRE
. I-FRE
5 O
. O
pre B-DRUG
##dn I-DRUG
##ison I-DRUG
##e I-DRUG
20 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
q B-FRE
##d I-FRE
( I-FRE
once I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE
6 O
. O
o B-DRUG
##xy I-DRUG
##co I-DRUG
##don I-DRUG
##e I-DRUG
- I-DRUG
ace I-DRUG
##tam I-DRUG
##ino I-DRUG
##phe I-DRUG
##n I-DRUG
5 B-STR
- I-STR
325 I-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
1 B-DOS
- I-DOS
2 I-DOS
tablets B-FOR
p B-ROU
##o I-ROU
q B-FRE
##4 I-FRE
- I-FRE
6 I-FRE
##h I-FRE
( I-FRE
every I-FRE
4 I-FRE
to I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE
di O
##sp O
: O
* O
30 O
tablet O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
0 O
* O
7 O
. O
flu B-DRUG
##cona I-DRUG
##zo I-DRUG
##le I-DRUG
200 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
two B-DOS
( I-DOS
2 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
q B-FRE
##24 I-FRE
##h I-FRE
( I-FRE
every I-FRE
24 I-FRE
hours I-FRE
) I-FRE
. I-FRE
8 O
. O
neo B-DRUG
##ral I-DRUG
25 B-STR
mg I-STR
capsule B-FOR
si O
##g O
: O
five B-DOS
( I-DOS
5 I-DOS
) I-DOS
capsule B-FOR
p B-ROU
##o I-ROU
every B-FRE
twelve I-FRE
( I-FRE
12 I-FRE
) I-FRE
hours I-FRE
. I-FRE
9 O
. O
las B-DRUG
##ix I-DRUG
40 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
twice B-FRE
a I-FRE
day I-FRE
. I-FRE
10 O
. O
v B-DRUG
##al I-DRUG
##cy I-DRUG
##te I-DRUG
450 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
every B-FRE
other I-FRE
day I-FRE
. I-FRE
discharge O
disposition O
: O
home O
with O
service O
facility O
: O
care O
network O
v O
##na O
discharge O
diagnosis O
: O
end O
stage O
liver O
disease O
secondary O
to O
he O
##p O
c O
c O
##ir O
##r O
##hos O
##is O
discharge O
condition O
: O
stable O
discharge O
instructions O
: O
please O
return O
for O
all O
follow O
- O
up O
appointments O
take O
all O
medications O
as O
directed O
return O
to O
the O
er O
for O
any O
increased O
pain O
, O
nausea O
and O
vomit O
##ting O
, O
short O
##ness O
of O
breath O
, O
chest O
pain O
, O
significant O
weight O
gain O
or O
weight O
loss O
, O
or O
fever O
##s O

follow O
##up O
instructions O
: O
provider O
: O
[ O
* O
* O
name O
##10 O
( O
name O
##is O
) O
* O
* O
] O
[ O
* O
* O
hospital O
* O
* O
] O
clinic O
transplant O
center O
( O
n O
##h O
##b O
) O
where O
: O
l O
##m O
[ O
* O
* O
hospital O
56 O
##28 O
* O
* O
] O
clinic O
phone O
: O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
67 O
##3 O
* O
* O
] O
date O
/ O
time O
: O
[ O
* O
* O
219 O
##2 O
- O
10 O
- O
8 O
* O
* O
] O
10 O
: O
40 O
provider O
: O
[ O
* O
* O
name O
##10 O
( O
name O
##is O
) O
* O
* O
] O
[ O
* O
* O
hospital O
* O
* O
] O
clinic O
transplant O
center O
( O
n O
##h O
##b O
) O
where O
: O
l O
##m O
[ O
* O
* O
hospital O
56 O
##28 O
* O
* O
] O
clinic O
phone O
: O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
67 O
##3 O
* O
* O
] O
date O
/ O
time O
: O
[ O
* O
* O
219 O
##2 O
- O
10 O
- O
15 O
* O
* O
] O
10 O
: O
40 O
provider O
: O
[ O
* O
* O
name O
##10 O
( O
name O
##is O
) O
* O
* O
] O
[ O
* O
* O
hospital O
* O
* O
] O
clinic O
transplant O
center O
( O
n O
##h O
##b O
) O
where O
: O
l O
##m O
[ O
* O
* O
hospital O
56 O
##28 O
* O
* O
] O
clinic O
phone O
: O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
67 O
##3 O
* O
* O
] O
date O
/ O
time O
: O
[ O
* O
* O
219 O
##2 O
- O
10 O
- O
22 O
* O
* O
] O
10 O
: O
40 O
[ O
* O
* O
first O
name O
##11 O
( O
name O
pattern O
##1 O
) O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##4 O
) O
70 O
##7 O
* O
* O
] O
m O
##d O
, O
[ O
* O
* O
m O
##d O
number O
( O
3 O
) O
70 O
##9 O
* O
* O
] O
completed O
by O
: O
[ O
* O
* O
219 O
##2 O
- O
10 O
- O
8 O
* O
* O
] O

admission O
date O
: O
[ O
* O
* O
219 O
##8 O
- O
4 O
- O
30 O
* O
* O
] O
discharge O
date O
: O
[ O
* O
* O
219 O
##8 O
- O
5 O
- O
2 O
* O
* O
] O
date O
of O
birth O
: O
[ O
* O
* O
211 O
##9 O
- O
9 O
- O
6 O
* O
* O
] O
sex O
: O
f O
service O
: O
medicine O
all O
##er O
##gies O
: O
m B-DRUG
##or I-DRUG
##phine I-DRUG
su I-DRUG
##lf I-DRUG
##ate I-DRUG
/ O
code B-DRUG
##ine I-DRUG
/ O
shell O
##fish O
derived O
/ O
van B-DRUG
##com I-DRUG
##y I-DRUG
##cin I-DRUG
/ O
z B-DRUG
##osy I-DRUG
##n I-DRUG
/ O
l B-DRUG
##isi I-DRUG
##no I-DRUG
##p I-DRUG
##ril I-DRUG
attending O
: O
[ O
* O
* O
first O
name O
##3 O
( O
l O
##f O
) O
229 O
##7 O
* O
* O
] O
chief O
complaint O
: O
throat O
swelling O
major O
surgical O
or O
invasive O
procedure O
: O
none O

history O
of O
present O
illness O
: O
78 O
year O
old O
female O
with O
history O
of O
acute O
my O
##elo O
##fi O
##bro O
##sis O
with O
pan O
##my O
##elo O
##sis O
( O
a O
rare O
form O
of O
acute O
le O
##uke O
##mia O
) O
, O
ne O
##ut O
##rop O
##eni O
##c O
, O
recent O
admission O
for O
mild O
pan O
##cre O
##ati O
##tis O
as O
well O
as O
ne B-ADE
##ut I-ADE
##rop I-ADE
##eni I-ADE
##c I-ADE
fever I-ADE
after O
experimental O
ch B-DRUG
##em I-DRUG
##otherapy I-DRUG
cycle O
( O
c O
##1 O
##d O
##1 O
[ O
* O
* O
219 O
##8 O
- O
4 O
- O
5 O
* O
* O
] O
, O
now O
c O
##1 O
##d O
##26 O
) O
, O
now O
transfer O
##ed O
from O
[ O
* O
* O
hospital O
##1 O
147 O
##4 O
* O
* O
] O
ed O
with O
tongue O
and O
anterior O
neck O
swelling O
. O
patient O
reports O
having O
a B-ADE
##ph I-ADE
##th I-ADE
##ous I-ADE
ul I-ADE
##cer I-ADE
##s I-ADE
in O
her O
mouth O
for O
several O
days O
secondary O
to O
ch B-DRUG
##em I-DRUG
##otherapy I-DRUG
, I-DRUG
and O
had O
begun O
using O
g B-DRUG
##ly I-DRUG
##cer I-DRUG
##in I-DRUG
( O
first O
) O
mouth B-FOR
##wash I-FOR
, I-FOR
after O
which O
she O
noted O
tongue O
and O
anterior B-ADE
neck I-ADE
swelling I-ADE
this O
morning O
. O
she O
has O
used O
this O
product O
in O
the O
past O
, O
but O
not O
for O
at O
least O
a O
year O
. O
she O
noticed O
soon O
after O
using O
that O
the O
bottle O
was O
expired O
. O
patient O
is O
also O
on O
l B-DRUG
##isi I-DRUG
##no I-DRUG
##p I-DRUG
##ril I-DRUG
for O
h B-REA
##yper I-REA
##tens I-REA
##ion I-REA
, I-REA
which O
she O
has O
been O
on O
long O
- O
term O
. O
she O
was O
started O
on O
all B-DRUG
##op I-DRUG
##uri I-DRUG
##no I-DRUG
##l I-DRUG
two O
weeks O
ago O
. O
patient O
noted O
no O
chest O
or O
abdominal O
pain O
, O
r O
##ash O
##es O
or O
p O
##ru O
##rit O
##us O
. O
she O
did O
note O
some O
d O
##ys O
##p O
##nea O
at O
the O
time O
, O
but O
no O
specific O
sensation O
of O
throat O
closing O
. O
she O
did O
notice O
some O
symptoms O
of O
d O
##roo O
##ling O
. O
she O
also O
had O
some O
nausea O
, O
but O
did O
not O
vomit O
. O
she O
had O
not O
eaten O
anything O
that O
morning O
. O
this O
type O
of O
reaction O
and O
s O
##ym O
##pt O
##oma O
##tology O
has O
never O
occurred O
before O
. O
she O
presented O
initially O
to O
[ O
* O
* O
hospital O
##1 O
147 O
##4 O
* O
* O
] O
ed O
where O
she O
was O
given O
ben B-DRUG
##ad I-DRUG
##ryl I-DRUG
, I-DRUG
f B-DRUG
##amo I-DRUG
##ti I-DRUG
##dine I-DRUG
, I-DRUG
i B-ROU
##v I-ROU
met B-DRUG
##hyl I-DRUG
##p I-DRUG
##red I-DRUG
##nis I-DRUG
##olo I-DRUG
##ne I-DRUG
, I-DRUG
and O
an O
e B-DRUG
##pine I-DRUG
##ph I-DRUG
##rine I-DRUG
pen O
injection B-ROU
, I-ROU
after O
which O
symptoms O
of O
d O
##ys O
##p O
##nea O
dramatically O
improved O
, O
per O
patient O
report O
. O
she O
was O
then O
transfer O
##ed O
to O
[ O
* O
* O
hospital O
##1 O
18 O
* O
* O
] O
for O
further O
management O
. O
her O
tongue O
was O
still O
noted O
to O
be O
swollen O
on O
arrival O
, O
though O
she O
has O
not O
had O
any O
throat O
tight O
##ness O
or O
s O
##tri O
##dor O
symptoms O
. O
. O

in O
the O
ed O
, O
initial O
vs O
were O
: O
t O
98 O
. O
2 O
p O
72 O
b O
##p O
164 O
/ O
72 O
r O
16 O
sat O
98 O
% O
2 O
##l O
. O
patient O
was O
given O
no O
further O
medications O
in O
the O
[ O
* O
* O
hospital O
##1 O
18 O
* O
* O
] O
ed O
. O
patient O
' O
s O
hem O
##ato O
##logist O
/ O
on O
##cologist O
d O
##r O
. O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
* O
* O
] O
was O
contact O
[ O
* O
* O
name O
( O
ni O
) O
* O
* O
] O
in O
the O
[ O
* O
* O
name O
( O
ni O
) O
* O
* O
] O
and O
requests O
all O
##er O
##gy O
consult O
for O
patient O
on O
arrival O
to O
[ O
* O
* O
hospital O
unit O
name O
153 O
* O
* O
] O
. O
. O
on O
the O
floor O
, O
patient O
reports O
that O
her O
tongue O
swelling O
has O
decreased O
considerably O
. O
she O
reports O
no O
d O
##ys O
##p O
##nea O
, O
throat O
tight O
##ness O
or O
current O
d O
##roo O
##ling O
. O
she O
has O
no O
nausea O
at O
this O
time O
. O
. O
review O
of O
systems O
: O
( O
+ O
) O
nausea O
and O
dry O
he O
##aves O
( O
- O
) O
denies O
fever O
, O
chill O
##s O
, O
night O
sweat O
##s O
, O
recent O
weight O
loss O
or O
gain O
. O
denies O
headache O
, O
sin O
##us O
tender O
##ness O
, O
r O
##hino O
##rr O
##hea O
or O
congestion O
. O
denied O
cough O
. O
denied O
chest O
pain O
or O
tight O
##ness O
, O
p O
##al O
##pit O
##ations O
. O
denied O
vomit O
##ing O
, O
di O
##ar O
##r O
##hea O
, O
con O
##st O
##ip O
##ation O
or O
abdominal O
pain O
. O
no O
recent O
change O
in O
bow O
##el O
or O
bladder O
habits O
. O
no O
d O
##ys O
##uria O
. O
denied O
art O
##hra O
##l O
##gia O
##s O
or O
my O
##al O
##gia O
##s O
. O
. O
past O
medical O
history O
: O
on O
##co O
##log O
##ic O
history O
: O
acute O
my O
##elo O
##fi O
##bro O
##sis O
with O
pan O
##my O
##elo O
##sis O
: O
- O
[ O
* O
* O
12 O
/ O
219 O
##5 O
* O
* O
] O
: O
presented O
with O
pan O
##cy O
##top O
##enia O
. O
bone O
ma O
##rrow O
bio O
##psy O
at O
o O
##sh O
showed O
> O
40 O
% O
blast O
##s O
. O
subsequent O
bone O
ma O
##rrow O
bio O
##psy O
done O
at O
[ O
* O
* O
hospital O
##1 O
18 O
* O
* O
] O
showed O
acute O
my O
##elo O
##fi O
##bro O
##sis O
with O
pan O
##my O
##elo O
##sis O
, O
a O
rare O
form O
of O
acute O
le O
##uke O
##mia O
, O
versus O
acute O
me O
##ga O
##kar O
##yo O
##blast O
##ic O
le O
##uke O
##mia O
with O
acute O
my O
##elo O
##fi O
##bro O
##sis O
. O
the O
path O
##ol O
##gy O
report O
favors O
the O
former O
given O
c O
##d O
##34 O
positive O
expression O
on O
blast O
cells O
. O
- O
[ O
* O
* O
219 O
##6 O
- O
1 O
- O
12 O
* O
* O
] O
: O
started O
on O
de B-DRUG
##ci I-DRUG
##ta I-DRUG
##bine I-DRUG
- O
[ O
* O
* O
219 O
##7 O
- O
6 O
- O
19 O
* O
* O
] O
: O
repeat O
bone O
ma O
##rrow O
bio O
##psy O
showed O
~ O
50 O
% O
cellular O
##ity O
( O
previously O
20 O
% O
) O
, O
5 O
% O
blast O
##s O
by O
c O
##d O
##4 O
stain O
##ing O
, O
grade O
[ O
* O
* O
1 O
- O
26 O
* O
* O
] O
fi O
##bro O
##sis O

( O
fi O
##bro O
##sis O
essentially O
unchanged O
from O
previous O
) O
, O
with O
normal O
- O
appearing O
me O
##ga O
##kar O
##yo O
##cy O
##tes O
. O
her O
ch B-DRUG
##em I-DRUG
##o I-DRUG
cycle O
duration O
was O
increased O
from O
every O
28 B-DUR
days I-DUR
to I-DUR
42 I-DUR
days I-DUR
. I-DUR
- O
[ O
* O
* O
10 O
- O
1 O
* O
* O
] O
: O
acute O
ch O
##ole O
##cy O
##st O
##itis O
s O
##p O
er O
##c O
##p O
with O
co O
##c O
##nu O
##rre O
##nt O
k O
##le O
##bs O
##iel O
##la O
b O
##act O
##ere O
##mia O
, O
had O
lap O
ch O
##ole O
on O
[ O
* O
* O
11 O
- O
1 O
* O
* O
] O
. O
- O
[ O
* O
* O
219 O
##7 O
- O
12 O
- O
30 O
* O
* O
] O
: O
restart O
##ed O
de B-DRUG
##ci I-DRUG
##ta I-DRUG
##bine I-DRUG
after O
prolonged O
disco O
##ntin O
##uation O
secondary O
to O
ch O
##ole O
##cy O
##ste O
##ct O
##omy O
( O
completed O
9 O
total O
cycles O
) O
- O
[ O
* O
* O
3 O
- O
19 O
* O
* O
] O
: O
admitted O
for O
f O
##eb O
##ril O
##e O
ne O
##ut O
##rop O
##enia O
with O
no O
source O
identified O
. O
- O
[ O
* O
* O
219 O
##8 O
- O
4 O
- O
5 O
* O
* O
] O
r B-DRUG
##ad I-DRUG
##00 I-DRUG
##1 I-DRUG
5 B-STR
mg I-STR
p B-ROU
##o I-ROU
- O
[ O
* O
* O
219 O
##8 O
- O
4 O
- O
6 O
* O
* O
] O
start O
p B-DRUG
##k I-DRUG
##c I-DRUG
##41 I-DRUG
##2 I-DRUG
50 B-STR
mg I-STR
p B-ROU
##o I-ROU
bid B-FRE
. O
other O
pm O
##h O
: O
1 O
. O
acute O
ch O
##ole O
##cy O
##st O
##itis O
s O
/ O
p O
er O
##c O
##p O
with O
concurrent O
k O
##le O
##bs O
##iel O
##la O
b O
##act O
##ere O
##mia O
[ O
* O
* O
10 O
- O
1 O
* O
* O
] O
treated O
with O
per O
##c O
ch O
##ole O
##cy O
##sto O
##sto O
##my O
placement O
. O
2 O
. O
lap O
##aro O
##scopic O
ch O
##ole O
##cy O
##ste O
##ct O
##omy O
[ O
* O
* O
219 O
##7 O
- O
11 O
- O
1 O
* O
* O
] O
3 O
. O
con O
##s O
b O
##si O
[ O
* O
* O
9 O
- O
1 O
* O
* O
] O
- O
treated O
with O
da B-DRUG
##pt I-DRUG
##omy I-DRUG
##cin I-DRUG
for B-DUR
10 I-DUR
day I-DUR
course O
4 O
. O
history O
of O
end O
##ome O
##tri O
##al O
cancer O
s O
/ O
p O
ta O
##h O
- O
b O
##so O
- O
[ O
* O
* O
216 O
##8 O
* O
* O
] O
5 O
. O
h O
##yper O
##tens O
##ion O
[ O
* O
* O
215 O
##6 O
* O
* O
] O
' O
s O
6 O
. O
l O
knee O
replacement O
- O
[ O
* O
* O
218 O
##6 O
* O
* O
] O
7 O
. O
r O
knee O
replacement O
- O
[ O
* O
* O
218 O
##7 O
* O
* O
] O
8 O
. O
r O
eye O
mac O
##ular O
de O
##gene O
##rative O
disease O
- O
[ O
* O
* O
219 O
##2 O
* O
* O
] O
9 O
. O
l O
eye O
cat O
##ara O
##ct O
- O
[ O
* O
* O
219 O
##5 O
* O
* O
] O
10 O
. O
bilateral O
knee O
replacement O
##s O
social O
history O
: O
lives O
in O
[ O
* O
* O
hospital O
##1 O
147 O
##4 O
* O
* O
] O
by O
herself O
. O
works O
for O
her O
daughter O
doing O
" O
computer O
work O
" O
. O
tobacco O
: O
none O
et O
##oh O
: O
social O
, O
occasional O
glass O
of O
wine O
i O
##v O
##du O
: O
none O
. O
family O
history O
: O
daughter O
is O
s O
/ O
p O
lump O
##ec O
##tom O
##y O
( O
? O
breast O
cancer O
) O
. O
father O
died O
at O
41 O
& O
brother O
died O
at O
50 O
, O
both O
from O
bone O
cancer O
. O

physical O
exam O
: O
physical O
exam O
admission O
: O
general O
: O
alert O
, O
oriented O
, O
no O
acute O
distress O
, O
appears O
comfortable O
, O
pleasant O
he O
##ent O
: O
s O
##cle O
##ra O
an O
##ict O
##eric O
, O
tongue O
mildly O
swollen O
, O
u O
##vu O
##la O
is O
visible O
without O
tongue O
depression O
, O
mm O
##m O
, O
pu O
##nc O
##tate O
hem O
##or O
##r O
##ha O
##gic O
lesions O
over O
underside O
of O
tongue O
neck O
: O
su O
##pp O
##le O
, O
j O
##v O
##p O
not O
elevated O
, O
no O
lad O
in O
c O
##er O
##vic O
##al O
or O
su O
##pra O
##c O
##lav O
##icular O
chains O
, O
no O
ins O
##pi O
##rator O
##y O
or O
ex O
##pi O
##rator O
##y O
s O
##tri O
##dor O
lungs O
: O
clear O
to O
au O
##s O
##cu O
##lta O
##tion O
bilateral O
##ly O
, O
with O
no O
w O
##hee O
##zes O
, O
r O
##ales O
, O
r O
##hon O
##chi O
c O
##v O
: O
regular O
rate O
and O
rhythm O
, O
normal O
s O
##1 O
+ O
s O
##2 O
, O
no O
murmurs O
, O
rub O
##s O
, O
gal O
##lops O
abdomen O
: O
soft O
, O
non O
- O
tender O
, O
non O
- O
di O
##sten O
##ded O
, O
bow O
##el O
sounds O
present O
, O
no O
re O
##bound O
tender O
##ness O
or O
guarding O
, O
no O
organ O
##ome O
##gal O
##y O
g O
##u O
: O
no O
f O
##ole O
##y O
ex O
##t O
: O
warm O
, O
well O
per O
##fused O
, O
2 O
+ O
pulses O
, O
no O
club O
##bing O
, O
c O
##yan O
##osis O
or O
ed O
##ema O
. O
physical O
exam O
discharge O
: O
he O
##ent O
: O
s O
##cle O
##ra O
an O
##ict O
##eric O
, O
tongue O
not O
swollen O
, O
u O
##vu O
##la O
is O
visible O
without O
tongue O
depression O
, O
mm O
##m O
, O
pu O
##nc O
##tate O
hem O
##or O
##r O
##ha O
##gic O
lesions O
over O
underside O
of O
tongue O

per O
##tinent O
results O
: O
[ O
* O
* O
219 O
##8 O
- O
4 O
- O
30 O
* O
* O
] O
01 O
: O
10 O
##pm O
blood O
w O
##b O
##c O
- O
1 O
. O
2 O
* O
r O
##b O
##c O
- O
3 O
. O
53 O
* O
h O
##g O
##b O
- O
10 O
. O
2 O
* O
h O
##ct O
- O
28 O
. O
5 O
* O
m O
##c O
##v O
- O
81 O
* O
m O
##ch O
- O
29 O
. O
1 O
m O
##ch O
##c O
- O
35 O
. O
9 O
* O
r O
##d O
##w O
- O
16 O
. O
6 O
* O
p O
##lt O
c O
##t O
- O
21 O
* O
[ O
* O
* O
219 O
##8 O
- O
5 O
- O
1 O
* O
* O
] O
02 O
: O
54 O
##am O
blood O
w O
##b O
##c O
- O
1 O
. O
1 O
* O
r O
##b O
##c O
- O
3 O
. O
17 O
* O
h O
##g O
##b O
- O
9 O
. O
2 O
* O
h O
##ct O
- O
25 O
. O
9 O
* O
m O
##c O
##v O
- O
82 O
m O
##ch O
- O
28 O
. O
9 O
m O
##ch O
##c O
- O
35 O
. O
4 O
* O
r O
##d O
##w O
- O
16 O
. O
1 O
* O
p O
##lt O
c O
##t O
- O
13 O
* O
[ O
* O
* O
219 O
##8 O
- O
4 O
- O
30 O
* O
* O
] O
01 O
: O
10 O
##pm O
blood O
ne O
##uts O
- O
10 O
* O
bands O
- O
4 O
l O
##ymph O
##s O
- O
66 O
* O
mon O
##os O
- O
10 O
e O
##os O
- O
0 O
b O
##as O
##o O
- O
0 O
at O
##y O
##ps O
- O
2 O
* O
meta O
##s O
- O
0 O
my O
##elo O
##s O
- O
0 O
blast O
##s O
- O
8 O
* O
[ O
* O
* O
219 O
##8 O
- O
4 O
- O
30 O
* O
* O
] O
01 O
: O
10 O
##pm O
blood O
h O
##y O
##po O
##ch O
##r O
- O
normal O
an O
##is O
##oc O
##y O
- O
1 O
+ O
p O
##oi O
##k O
##lo O
- O
normal O
mac O
##ro O
##cy O
- O
normal O
micro O
##cy O
- O
1 O
+ O
p O
##oly O
##ch O
##r O
- O
normal O
[ O
* O
* O
219 O
##8 O
- O
5 O
- O
1 O
* O
* O
] O
02 O
: O
54 O
##am O
blood O
p O
##t O
- O
13 O
. O
9 O
* O
p O
##tt O
- O
27 O
. O
3 O
in O
##r O
( O
p O
##t O
) O
- O
1 O
. O
2 O
* O
[ O
* O
* O
219 O
##8 O
- O
5 O
- O
1 O
* O
* O
] O
02 O
: O
54 O
##am O
blood O
p O
##lt O
c O
##t O
- O
13 O
* O
[ O
* O
* O
219 O
##8 O
- O
5 O
- O
1 O
* O
* O
] O
02 O
: O
54 O
##am O
blood O
g O
##ran O
c O
##t O
- O
240 O
* O
[ O
* O
* O
219 O
##8 O
- O
4 O
- O
30 O
* O
* O
] O
01 O
: O
10 O
##pm O
blood O
glucose O
- O
217 O
* O
u O
##rea O
##n O
- O
24 O
* O
c O
##rea O
##t O
- O
0 O
. O
9 O
na O
- O
136 O
k O
- O
3 O
. O
4 O
c O
##l O
- O
103 O
h O
##co O
##3 O
- O
22 O
an O
##ga O
##p O
- O
14 O
[ O
* O
* O
219 O
##8 O
- O
5 O
- O
1 O
* O
* O
] O
02 O
: O
54 O
##am O
blood O
glucose O
- O
169 O
* O
u O
##rea O
##n O
- O
28 O
* O
c O
##rea O
##t O
- O
0 O
. O
8 O
na O
- O
137 O
k O
- O
3 O
. O
7 O
c O
##l O
- O
104 O
h O
##co O
##3 O
- O
24 O
an O
##ga O
##p O
- O
13 O

[ O
* O
* O
219 O
##8 O
- O
5 O
- O
1 O
* O
* O
] O
02 O
: O
54 O
##am O
blood O
al O
##t O
- O
24 O
as O
##t O
- O
31 O
l O
##d O
( O
l O
##dh O
) O
- O
43 O
##4 O
* O
al O
##k O
##ph O
##os O
- O
105 O
to O
##t O
##bil O
##i O
- O
0 O
. O
3 O
[ O
* O
* O
219 O
##8 O
- O
4 O
- O
30 O
* O
* O
] O
01 O
: O
10 O
##pm O
blood O
iron O
- O
130 O
[ O
* O
* O
219 O
##8 O
- O
4 O
- O
30 O
* O
* O
] O
01 O
: O
10 O
##pm O
blood O
ca O
##lt O
##ib O
##c O
- O
242 O
* O
f O
##er O
##rit O
##n O
- O
51 O
##10 O
* O
t O
##rf O
- O
186 O
* O
[ O
* O
* O
219 O
##8 O
- O
5 O
- O
1 O
* O
* O
] O
02 O
: O
54 O
##am O
blood O
c O
##4 O
- O
40 O
[ O
* O
* O
219 O
##8 O
- O
5 O
- O
1 O
* O
* O
] O
02 O
: O
54 O
##am O
blood O
try O
##pta O
##se O
- O
p O
##nd O
brief O
hospital O
course O
: O
78 O
##f O
with O
history O
of O
acute O
my O
##elo O
##fi O
##bro O
##sis O
with O
pan O
##my O
##elo O
##sis O
( O
a O
rare O
form O
of O
acute O
le O
##uke O
##mia O
) O
, O
ne O
##ut O
##rop O
##eni O
##c O
, O
recent O
admission O
for O
mild O
pan O
##cre O
##ati O
##tis O
as O
well O
as O
ne B-ADE
##ut I-ADE
##rop I-ADE
##eni I-ADE
##c I-ADE
fever I-ADE
after O
experimental O
ch B-DRUG
##em I-DRUG
##otherapy I-DRUG
cycle O
( O
c O
##1 O
##d O
##8 O
of O
protocol O
08 O
- O
26 O
##9 O
a O
phase O
i O
( O
r O
##ad O
##00 O
##1 O
p O
##k O
##c O
##41 O
##2 O
, O
day O
1 O
= O
[ O
* O
* O
219 O
##8 O
- O
4 O
- O
5 O
* O
* O
] O
, O
last O
dose O
[ O
* O
* O
219 O
##8 O
- O
4 O
- O
12 O
* O
* O
] O
) O
, O
now O
presenting O
with O
tongue B-ADE
and I-ADE
anterior I-ADE
neck I-ADE
swelling I-ADE
likely O
[ O
* O
* O
1 O
- O
24 O
* O
* O
] O
l B-DRUG
##isi I-DRUG
##no I-DRUG
##p I-DRUG
##ril I-DRUG
all O
##er O
##gy O
# O
. O
tongue B-ADE
/ I-ADE
neck I-ADE
swelling I-ADE
/ I-ADE
all I-ADE
##er I-ADE
##gy I-ADE
to O
ace B-DRUG
##i I-DRUG
: I-DRUG
most O
likely O
all O
##ergic O
reaction O
to O
ace B-DRUG
##i I-DRUG
( O
was O
on O
l B-DRUG
##isi I-DRUG
##no I-DRUG
##p I-DRUG
##ril I-DRUG
) I-DRUG
. O
less O
likely O
et O
##iol O
##ogies O
would O
be O
her O
study O
drug O
for O
my O
##elo O
##fi O
##bro O
##sis O
. O
patient O
received O
i B-ROU
##v I-ROU
s B-DRUG
##tero I-DRUG
##ids I-DRUG
, I-DRUG
ben B-DRUG
##ad I-DRUG
##ryl I-DRUG
and O
f B-DRUG
##amo I-DRUG
##ti I-DRUG
##dine I-DRUG
with O
improvement O
in O
symptoms O
, O
and O
was O
switched O
to O
a O
p B-ROU
##o I-ROU
regime O
##n O
of O
pre B-DRUG
##dn I-DRUG
##ison I-DRUG
##e I-DRUG
60 B-STR
mg I-STR
for O
a O
total O
of O
3 B-DUR
days I-DUR
. I-DUR
. O
did O
not O
have O
s O
##tri O
##dor O
nor O
require O
in O
##tub O
##ation O
. O
all O
##er O
##gy O
was O
consulted O
and O
felt O
that O
swelling O
likely O
[ O
* O
* O
1 O
- O
24 O
* O
* O
] O
ace B-DRUG
##i I-DRUG
so O
l B-DRUG
##isi I-DRUG
##no I-DRUG
##p I-DRUG
##ril I-DRUG
was O
d O
##c O
' O
ed O
and O
she O
is O
not O
to O
take O
ace B-DRUG
##i I-DRUG
or O
[ O
* O
* O
last O
name O
( O
un O
) O
* O
* O
] O
in O
the O
future O
. O
it O
was O
also O
recommended O
that O
she O
receive O
her O
study O
drug O
under O
observation O
such O
as O
in O
the O
in O
##fusion O
c O
##ln O
##ic O
to O
monitor O
for O
possible O
reaction O
. O
try O
##pta O
##se O
was O
sent O
to O
evaluate O
for O
c O
##1 O
est O
##era O
##se O
inhibitor O
deficiency O
and O
is O
still O
pending O
. O

# O
. O
h B-REA
##yper I-REA
##tens I-REA
##ion I-REA
: I-REA
given O
likely O
all O
##er O
##gy O
to O
l B-DRUG
##isi I-DRUG
##no I-DRUG
##p I-DRUG
##ril I-DRUG
, I-DRUG
it O
was O
stopped O
. O
home O
met B-DRUG
##op I-DRUG
##rol I-DRUG
##ol I-DRUG
was O
continued O
at O
50 B-STR
mg I-STR
[ O
* O
* O
hospital O
##1 O
* O
* O
] O
and O
am B-DRUG
##lo I-DRUG
##di I-DRUG
##pine I-DRUG
5 B-STR
##m I-STR
##g I-STR
daily B-FRE
started O
to O
help O
better B-REA
control I-REA
b I-REA
##p I-REA
, I-REA
as O
she O
had O
s O
##b O
##p O
150 O
- O
160 O
##s O
. O
# O
. O
my B-REA
##elo I-REA
##fi I-REA
##bro I-REA
##sis I-REA
with I-REA
pan I-REA
##my I-REA
##elo I-REA
##sis I-REA
: I-REA
on O
c O
##1 O
##d O
##26 O
or O
experimental O
ch B-DRUG
##em I-DRUG
##otherapy I-DRUG
regime O
##n O
. O
re O
##com O
##men O
##eda O
##tion O
that O
p O
##t O
should O
receive O
experimental O
medications O
while O
observed O
as O
above O
. O
continued O
prop O
##hyl O
##actic O
le B-DRUG
##vo I-DRUG
##f I-DRUG
##lo I-DRUG
##xa I-DRUG
##cin I-DRUG
and O
v B-DRUG
##ala I-DRUG
##cy I-DRUG
##c I-DRUG
##lov I-DRUG
##ir I-DRUG
as O
well O
as O
home O
dose O
all B-DRUG
##op I-DRUG
##uri I-DRUG
##no I-DRUG
##l I-DRUG
. I-DRUG
trans O
##fused O
1 B-DOS
unit B-FOR
plate B-DRUG
##lets I-DRUG
and O
1 B-DOS
unit B-FOR
of O
p B-DRUG
##rb I-DRUG
##c I-DRUG
during O
admission O
code O
: O
confirmed O
full O
code O
during O
admission O
contact O
: O
son O
[ O
* O
* O
name O
( O
ni O
) O
* O
* O
] O
[ O
* O
* O
name O
( O
ni O
) O
94 O
##4 O
##9 O
* O
* O
] O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
80 O
##7 O
##70 O
* O
* O
] O
medications O
on O
admission O
: O
l B-DRUG
##isi I-DRUG
##no I-DRUG
##p I-DRUG
##ril I-DRUG
10 B-STR
mg I-STR
p B-ROU
##o I-ROU
daily B-FRE
met B-DRUG
##op I-DRUG
##rol I-DRUG
##ol I-DRUG
ta I-DRUG
##rt I-DRUG
##rate I-DRUG
50 B-STR
mg I-STR
p B-ROU
##o I-ROU
bid B-FRE
all B-DRUG
##op I-DRUG
##uri I-DRUG
##no I-DRUG
##l I-DRUG
200 B-STR
mg I-STR
p B-ROU
##o I-ROU
daily B-FRE
o B-DRUG
##me I-DRUG
##pra I-DRUG
##zo I-DRUG
##le I-DRUG
20 B-STR
mg I-STR
p B-ROU
##o I-ROU
bid B-FRE
v B-DRUG
##ala I-DRUG
##cy I-DRUG
##c I-DRUG
##lov I-DRUG
##ir I-DRUG
500 B-STR
mg I-STR
p B-ROU
##o I-ROU
daily B-FRE
pro B-DRUG
##ch I-DRUG
##lor I-DRUG
##per I-DRUG
##azi I-DRUG
##ne I-DRUG
5 B-STR
mg I-STR
p B-ROU
##o I-ROU
q B-FRE
##6 I-FRE
##h I-FRE
p I-FRE
##rn I-FRE
nausea B-REA
le B-DRUG
##vo I-DRUG
##f I-DRUG
##lo I-DRUG
##xa I-DRUG
##cin I-DRUG
500 B-STR
mg I-STR
p B-ROU
##o I-ROU
daily B-FRE
lo B-DRUG
##raze I-DRUG
##pa I-DRUG
##m I-DRUG
0 B-STR
. I-STR
5 I-STR
mg I-STR
p B-ROU
##o I-ROU
q B-FRE
##8 I-FRE
##h I-FRE
p I-FRE
##rn I-FRE
nausea B-REA
, I-REA
anxiety B-REA
ace B-DRUG
##tam I-DRUG
##ino I-DRUG
##phe I-DRUG
##n I-DRUG
325 B-STR
- I-STR
650 I-STR
mg I-STR
p B-ROU
##o I-ROU
p B-FRE
##rn I-FRE
headache B-REA

discharge O
medications O
: O
1 O
. O
am B-DRUG
##lo I-DRUG
##di I-DRUG
##pine I-DRUG
5 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( O
daily O
) O
. O
di O
##sp O
: O
* O
30 O
tablet O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
2 O
* O
2 O
. O
all B-DRUG
##op I-DRUG
##uri I-DRUG
##no I-DRUG
##l I-DRUG
100 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
two B-DOS
( I-DOS
2 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( O
daily O
) O
. O
3 O
. O
o B-DRUG
##me I-DRUG
##pra I-DRUG
##zo I-DRUG
##le I-DRUG
20 B-STR
mg I-STR
capsule B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
capsule B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
p B-ROU
##o I-ROU
bid B-FRE
( O
2 O
times O
a O
day O
) O
. O
4 O
. O
v B-DRUG
##ala I-DRUG
##cy I-DRUG
##c I-DRUG
##lov I-DRUG
##ir I-DRUG
500 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( O
daily O
) O
. O
5 O
. O
pre B-DRUG
##dn I-DRUG
##ison I-DRUG
##e I-DRUG
20 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
three B-DOS
( I-DOS
3 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( O
daily O
) O
for B-DUR
1 I-DUR
days I-DUR
: I-DUR
take O
all O
three O
tablets O
on O
[ O
* O
* O
5 O
- O
3 O
* O
* O
] O
. O
di O
##sp O
: O
* O
3 O
tablet O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
0 O
* O
6 O
. O
pro B-DRUG
##ch I-DRUG
##lor I-DRUG
##per I-DRUG
##azi I-DRUG
##ne I-DRUG
male I-DRUG
##ate I-DRUG
5 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
every B-FRE
six I-FRE
( I-FRE
6 I-FRE
) I-FRE
hours I-FRE
as I-FRE
needed I-FRE
for O
nausea B-REA
. I-REA
7 O
. O
le B-DRUG
##vo I-DRUG
##f I-DRUG
##lo I-DRUG
##xa I-DRUG
##cin I-DRUG
500 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
q B-FRE
##24 I-FRE
##h I-FRE
( O
every O
24 O
hours O
) O
. O
8 O
. O
lo B-DRUG
##raze I-DRUG
##pa I-DRUG
##m I-DRUG
0 B-STR
. I-STR
5 I-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
every B-FRE
eight I-FRE
( I-FRE
8 I-FRE
) I-FRE
hours I-FRE
as I-FRE
needed I-FRE
for O
nausea B-REA
, I-REA
anxiety B-REA
. I-REA
9 O
. O
dip B-DRUG
##hen I-DRUG
##hy I-DRUG
##dra I-DRUG
##mine I-DRUG
h I-DRUG
##c I-DRUG
##l I-DRUG
25 B-STR
mg I-STR
capsule B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
capsule B-FOR
p B-ROU
##o I-ROU
q B-FRE
##6 I-FRE
##h I-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
pu B-REA
##rit I-REA
##is I-REA
, I-REA
throat B-REA
it I-REA
##ching I-REA
, I-REA
throat B-REA
swelling I-REA
. I-REA
di O
##sp O
: O
* O
30 O
capsule O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
0 O
* O
10 O
. O
met B-DRUG
##op I-DRUG
##rol I-DRUG
##ol I-DRUG
ta I-DRUG
##rt I-DRUG
##rate I-DRUG
50 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
bid B-FRE
( O
2 O
times O
a O
day O
) O
. O
11 O
. O
e B-DRUG
##pipe I-DRUG
##n I-DRUG
0 B-STR
. I-STR
3 I-STR
mg I-STR
/ I-STR
0 I-STR
. I-STR
3 I-STR
m I-STR
##l I-STR
pen B-FOR
in I-FOR
##ject I-FOR
##or I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
in B-ROU
##tra I-ROU
##mus I-ROU
##cular I-ROU
p B-FRE
##rn I-FRE
as I-FRE
needed I-FRE
for O
an B-REA
##aph I-REA
##yla I-REA
##xi I-REA
##s I-REA
, I-REA
all B-REA
##ergic I-REA
reaction I-REA
. I-REA
di O
##sp O
: O
* O
1 O
e O
##pipe O
##n O
* O
re O
##fill O
##s O
: O
* O
0 O
* O
discharge O
disposition O
: O
home O
discharge O
diagnosis O
: O
primary O
diagnosis O
: O
tongue O
swelling O
secondary O
diagnosis O
: O
le O
##uke O
##mia O
discharge O
condition O
: O
mental O
status O
: O
clear O
and O
coherent O
. O
level O
of O
consciousness O
: O
alert O
and O
interactive O
. O
activity O
status O
: O
am O
##bula O
##tory O
- O
independent O
. O

discharge O
instructions O
: O
dear O
m O
##s O
. O
[ O
* O
* O
known O
last O
##name O
94 O
##4 O
##9 O
* O
* O
] O
, O
you O
were O
admitted O
to O
the O
intensive O
care O
unit O
with O
swelling B-ADE
of I-ADE
your I-ADE
tongue I-ADE
and I-ADE
neck I-ADE
. I-ADE
it O
is O
possible O
that O
this O
was O
from O
your O
study O
medication O
or O
it O
may O
have O
been O
due O
to O
the O
blood O
pressure O
medication O
l B-DRUG
##isi I-DRUG
##no I-DRUG
##p I-DRUG
##ril I-DRUG
that O
you O
had O
been O
taking O
. O
you O
should O
no O
longer O
take O
l B-DRUG
##isi I-DRUG
##no I-DRUG
##p I-DRUG
##ril I-DRUG
just O
in O
case O
the O
swelling O
was O
from O
this O
medication O
. O
your O
symptoms O
improved O
with O
medications O
and O
s B-DRUG
##tero I-DRUG
##ids I-DRUG
. I-DRUG
the O
following O
medications O
were O
changed O
this O
admission O
: O
1 O
. O
stop O
l B-DRUG
##isi I-DRUG
##no I-DRUG
##p I-DRUG
##ril I-DRUG
- O
you O
should O
never O
take O
this O
medication O
again O
. O
you O
should O
not O
take O
medications O
in O
this O
class O
( O
ace O
inhibitor O
##s O
or O
an O
##gio O
##tens O
##in O
receptor O
block O
##ers O
) O
. O
2 O
. O
please O
start O
pre B-DRUG
##dn I-DRUG
##ison I-DRUG
##e I-DRUG
60 B-STR
##m I-STR
##g I-STR
daily B-FRE
for B-DUR
1 I-DUR
more I-DUR
day I-DUR
. I-DUR
3 O
. O
please O
start O
am B-DRUG
##lo I-DRUG
##di I-DRUG
##pine I-DRUG
5 B-STR
##m I-STR
##g I-STR
daily B-FRE
for O
your O
blood B-REA
pressure I-REA
. I-REA
4 O
. O
please O
start O
ben B-DRUG
##ad I-DRUG
##ryl I-DRUG
as B-FRE
needed I-FRE
if O
you O
develop O
throat B-REA
tight I-REA
##ness I-REA
, I-REA
lip B-REA
swelling I-REA
. I-REA
please O
keep O
your O
follow O
##up O
appointments O
with O
d O
##r O
. O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
* O
* O
] O
and O
your O
primary O
care O
physician O
. O
follow O
##up O
instructions O
: O
please O
keep O
your O
follow O
##up O
appointments O
as O
listed O
below O
. O
department O
: O
b O
##m O
##t O
/ O
on O
##cology O
unit O
when O
: O
th O
##urs O
##day O
[ O
* O
* O
219 O
##8 O
- O
5 O
- O
3 O
* O
* O
] O
at O
9 O
: O
30 O
am O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
44 O
##7 O
* O
* O
] O
building O
: O
f O
##d O
[ O
* O
* O
hospital O
ward O
name O
1826 O
* O
* O
] O
building O
( O
[ O
* O
* O
hospital O
ward O
name O
1826 O
* O
* O
] O
/ O
[ O
* O
* O
hospital O
ward O
name O
1827 O
* O
* O
] O
complex O
) O
[ O
* O
* O
location O
( O
un O
) O
39 O
##7 O
##1 O
* O
* O
] O
campus O
: O
east O
best O
parking O
: O
main O
garage O
department O
: O
hem O
##ato O
##logy O
/ O
b O
##m O
##t O
when O
: O
th O
##urs O
##day O
[ O
* O
* O
219 O
##8 O
- O
5 O
- O
3 O
* O
* O
] O
at O
11 O
: O
00 O
am O
with O
: O
[ O
* O
* O
first O
name O
##11 O
( O
name O
pattern O
##1 O
) O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##4 O
) O
77 O
##7 O
##9 O
* O
* O
] O
, O
m O
##d O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
32 O
##41 O
* O
* O
] O
building O
: O
s O
##c O
[ O
* O
* O
hospital O
ward O
name O
23 O
* O
* O
] O
clinical O
c O
##tr O
[ O
* O
* O
location O
( O
un O
) O
* O
* O
] O
campus O
: O
east O
best O
parking O
: O
[ O
* O
* O
hospital O
ward O
name O
23 O
* O
* O
] O
garage O

department O
: O
hem O
##ato O
##logy O
/ O
on O
##cology O
when O
: O
th O
##urs O
##day O
[ O
* O
* O
219 O
##8 O
- O
5 O
- O
3 O
* O
* O
] O
at O
11 O
: O
00 O
am O
with O
: O
n O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
22 O
* O
* O
] O
building O
: O
[ O
* O
* O
hospital O
##6 O
29 O
* O
* O
] O
[ O
* O
* O
location O
( O
un O
) O
24 O
* O
* O
] O
campus O
: O
east O
best O
parking O
: O
[ O
* O
* O
hospital O
ward O
name O
23 O
* O
* O
] O
garage O
completed O
by O
: O
[ O
* O
* O
219 O
##8 O
- O
5 O
- O
2 O
* O
* O
] O

admission O
date O
: O
[ O
* O
* O
213 O
##8 O
- O
8 O
- O
13 O
* O
* O
] O
discharge O
date O
: O
[ O
* O
* O
213 O
##8 O
- O
8 O
- O
16 O
* O
* O
] O
date O
of O
birth O
: O
[ O
* O
* O
207 O
##3 O
- O
3 O
- O
15 O
* O
* O
] O
sex O
: O
m O
service O
: O
surgery O
all O
##er O
##gies O
: O
pen B-DRUG
##ici I-DRUG
##llin I-DRUG
##s I-DRUG
attending O
: O
[ O
* O
* O
first O
name O
##3 O
( O
l O
##f O
) O
69 O
##5 O
* O
* O
] O
chief O
complaint O
: O
abdominal O
pain O
and O
weakness O
major O
surgical O
or O
invasive O
procedure O
: O
none O
history O
of O
present O
illness O
: O
65 O
##m O
with O
history O
of O
h O
##c O
##v O
, O
h O
##cc O
s O
/ O
p O
left O
lateral O
segment O
##ec O
##tom O
##y O
in O
[ O
* O
* O
213 O
##5 O
* O
* O
] O
who O
presents O
now O
with O
1 O
- O
2 O
weeks O
of O
abdominal O
pain O
and O
overall O
weakness O
. O
he O
reports O
that O
~ O
10 O
days O
ago O
he O
had O
a O
few O
days O
of O
nausea O
and O
em O
##esis O
; O
after O
this O
passed O
he O
began O
to O
feel O
very O
weak O
with O
decreased O
energy O
and O
d O
##ys O
##p O
##nea O
on O
ex O
##ert O
##ion O
. O
over O
the O
same O
time O
period O
he O
has O
begun O
to O
have O
sharp O
right B-REA
upper I-REA
q I-REA
##uad I-REA
##rant I-REA
pain I-REA
, I-REA
described O
as O
under O
his O
ribs O
, O
worse O
##ning O
with O
deep O
breaths O
in O
. O
he O
has O
been O
treating O
this O
with O
ad B-DRUG
##vil I-DRUG
, I-DRUG
he O
states O
that O
he O
takes O
three B-DOS
pills B-FOR
( O
un O
##k O
strength O
) O
once B-FRE
a I-FRE
day I-FRE
. I-FRE
he O
also O
end O
##orse O
##s O
in O
##vo O
##lu O
##ntary O
20 O
##l O
##b O
weight O
loss O
over O
the O
past O
month O
. O
he O
denies O
hem O
##ate O
##mes O
##is O
, O
denies O
blood O
in O
his O
stool O
or O
dark O
stool O
##s O
, O
denies O
changes O
in O
u O
##rina O
##ry O
frequency O
/ O
urgency O
or O
color O
. O
he O
denies O
fever O
##s O
or O
chill O
##s O
at O
home O
. O
13 O
point O
review O
of O
systems O
is O
otherwise O
negative O
. O
past O
medical O
history O
: O
pm O
##h O
##x O
: O
per O
##fo O
##rated O
diver O
##tic O
##uli O
##tis O
he O
##pa O
##titis O
c O
, O
diagnosed O
in O
[ O
* O
* O
7 O
- O
/ O
213 O
##5 O
* O
* O
] O
w O
/ O
o O
anti O
##vir O
##al O
therapy O
h O
/ O
o O
alcohol O
abuse O
h O
/ O
o O
tobacco O
abuse O
g O
##lau O
##com O
##a O
cat O
##ara O
##cts O
ps O
##urg O
##h O
##x O
: O
si O
##g O
##mo O
##ide O
##ct O
##omy O
& O
diver O
##ting O
loop O
il O
##eo O
##sto O
##my O
[ O
* O
* O
213 O
##6 O
- O
8 O
- O
21 O
* O
* O
] O
social O
history O
: O
works O
as O
a O
painter O
, O
lives O
alone O
, O
to O
##b O
1 O
pp O
##d O
x O
##40 O
years O
, O
et O
##oh O
one O
pin O
##t O
/ O
day O
vodka O
x O
20 O
years O
, O
a O
##bs O
##tine O
##nce O
since O
[ O
* O
* O
213 O
##6 O
- O
4 O
- O
7 O
* O
* O
] O
, O
remote O
heroin O
use O
, O
current O
occasional O
m O
##j O
use O
. O
family O
history O
: O
non O
- O
contributor O
##y O

physical O
exam O
: O
physical O
exam O
: O
98 O
. O
7 O
95 O
100 O
/ O
61 O
16 O
100 O
% O
g O
##en O
: O
a O
##ao O
##x O
##3 O
, O
comfortable O
, O
na O
##d O
, O
cooperative O
and O
pleasant O
he O
##ent O
: O
per O
##rl O
, O
s O
##cle O
##ra O
an O
##ict O
##eric O
, O
or O
##op O
##har O
##ynx O
clear O
c O
##v O
: O
r O
##rr O
, O
no O
m O
/ O
r O
/ O
g O
pu O
##lm O
: O
c O
##ta O
##b O
a O
##b O
##d O
: O
b O
##s O
( O
+ O
) O
, O
soft O
, O
n O
##d O
, O
mild O
t O
##t O
##p O
at O
r O
##u O
##q O
. O
prior O
surgical O
in O
##cision O
##s O
consistent O
with O
previous O
segment O
##ec O
##tom O
##y O
well O
- O
healed O
, O
non O
- O
in O
##du O
##rated O
, O
non O
- O
er O
##yt O
##hem O
##ato O
##us O
, O
non O
- O
tender O
. O
g O
/ O
u O
: O
def O
##er O
##red O
m O
##sk O
: O
no O
c O
/ O
c O
/ O
e O
per O
##tinent O
results O
: O
[ O
* O
* O
213 O
##8 O
- O
8 O
- O
13 O
* O
* O
] O
04 O
: O
00 O
##pm O
glucose O
- O
122 O
* O
u O
##rea O
n O
- O
19 O
c O
##rea O
##t O
- O
1 O
. O
3 O
* O
sodium O
- O
132 O
* O
potassium O
- O
4 O
. O
6 O
chloride O
- O
97 O
total O
co O
##2 O
- O
25 O
an O
##ion O
gap O
- O
15 O
[ O
* O
* O
213 O
##8 O
- O
8 O
- O
13 O
* O
* O
] O
04 O
: O
00 O
##pm O
al O
##t O
( O
s O
##g O
##pt O
) O
- O
34 O
as O
##t O
( O
s O
##got O
) O
- O
120 O
* O
l O
##d O
( O
l O
##dh O
) O
- O
53 O
##7 O
* O
al O
##k O
p O
##hos O
- O
47 O
##2 O
* O
to O
##t O
bi O
##li O
- O
0 O
. O
9 O
[ O
* O
* O
213 O
##8 O
- O
8 O
- O
13 O
* O
* O
] O
04 O
: O
00 O
##pm O
lip O
##ase O
- O
160 O
* O
[ O
* O
* O
213 O
##8 O
- O
8 O
- O
13 O
* O
* O
] O
04 O
: O
00 O
##pm O
pro O
##b O
##n O
##p O
- O
251 O
* O
[ O
* O
* O
213 O
##8 O
- O
8 O
- O
13 O
* O
* O
] O
04 O
: O
00 O
##pm O
album O
##in O
- O
3 O
. O
5 O
iron O
- O
19 O
* O

brief O
hospital O
course O
: O
m O
##r O
. O
[ O
* O
* O
known O
last O
##name O
* O
* O
] O
was O
admitted O
to O
the O
he O
##pa O
##to O
##bil O
##iary O
surgical O
service O
on O
[ O
* O
* O
213 O
##8 O
- O
8 O
- O
13 O
* O
* O
] O
with O
abdominal O
pain O
and O
weakness O
as O
described O
above O
. O
his O
initial O
labs O
demonstrated O
a O
significant O
an O
##emia O
, O
with O
a O
hem O
##ato O
##c O
##rit O
of O
19 O
. O
7 O
. O
further O
review O
of O
his O
history O
raised O
the O
possibility O
of O
an O
upper B-ADE
g I-ADE
##i I-ADE
bleed I-ADE
, I-ADE
as O
it O
was O
determined O
he O
had O
been O
taking O
high O
doses O
of O
n B-DRUG
##sai I-DRUG
##ds I-DRUG
for O
his O
abdominal B-REA
pain I-REA
, I-REA
and O
had O
unclear O
history O
of O
me O
##lan O
##otic O
stool O
##s O
and O
/ O
or O
blood O
- O
tinged O
em O
##esis O
. O
he O
was O
initially O
admitted O
to O
the O
surgical O
i O
##cu O
, O
where O
he O
was O
stab O
##ilized O
with O
2 B-STR
units I-STR
of O
packed B-DRUG
red I-DRUG
blood I-DRUG
cells I-DRUG
. I-DRUG
his O
hem O
##ato O
##c O
##rit O
then O
rose O
to O
23 O
. O
4 O
, O
at O
which O
time O
he O
was O
trans O
##fused O
an O
additional O
2 O
units O
. O
his O
hem O
##ato O
##c O
##rit O
then O
stab O
##ilized O
at O
28 O
. O
2 O
. O
a O
c O
##t O
of O
his O
abdomen O
performed O
shortly O
after O
admission O
on O
[ O
* O
* O
213 O
##8 O
- O
8 O
- O
13 O
* O
* O
] O
revealed O
the O
following O
: O
1 O
. O
extensive O
he O
##pa O
##tic O
lesions O
( O
presumably O
h O
##cc O
) O
with O
extensive O
me O
##sent O
##eric O
root O
, O
port O
##a O
he O
##pa O
##tis O
l O
##ymph O
##ade O
##no O
##pathy O
, O
and O
media O
##st O
##inal O
l O
##ymph O
##ade O
##no O
##pathy O
as O
well O
as O
me O
##sent O
##eric O
/ O
o O
##mental O
imp O
##lants O
and O
possible O
pan O
##cre O
##atic O
and O
me O
##sent O
##eric O
vein O
invasion O
as O
described O
above O
. O
non O
##hem O
##or O
##r O
##ha O
##gic O
as O
##cite O
##s O
. O
no O
areas O
of O
active O
hem O
##or O
##r O
##hage O
within O
the O
mass O
lesions O
or O
along O
the O
course O
of O
the O
bow O
##el O
are O
present O
. O
2 O
. O
gas O
##tro O
##es O
##op O
##hage O
##al O
var O
##ices O
. O
3 O
. O
non O
##hem O
##or O
##r O
##ha O
##gic O
right O
p O
##le O
##ural O
e O
##ff O
##usion O
with O
associated O
ate O
##lect O
##asis O
. O
new O
bilateral O
pulmonary O
nod O
##ules O
concerning O
for O
meta O
##sta O
##ses O
. O

given O
the O
size O
and O
distribution O
of O
his O
he O
##pa O
##tic O
lesions O
, O
m O
##r O
. O
[ O
* O
* O
known O
last O
##name O
* O
* O
] O
was O
determined O
to O
be O
not O
eligible O
for O
surgical O
re O
##section O
. O
m O
##r O
. O
[ O
* O
* O
known O
last O
##name O
* O
* O
] O
also O
received O
an O
es O
##op O
##ha O
##go O
- O
gas O
##tric O
end O
##os O
##copy O
to O
evaluate O
his O
suspected O
upper O
g O
##i O
bleed O
, O
an O
##emia O
, O
and O
abdominal O
pain O
. O
this O
study O
revealed O
the O
following O
: O
- O
[ O
* O
* O
name O
prefix O
( O
prefix O
##es O
) O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
prefix O
##es O
) O
* O
* O
] O
b O
di O
##stal O
es O
##op O
##ha O
##git O
##is O
, O
2 O
cord O
##s O
of O
small O
es O
##op O
##hage O
##al O
var O
##ices O
without O
red O
whale O
signs O
left O
und O
##ist O
##ur O
##bed O
, O
irregular O
g O
##ej O
with O
2 O
tongues O
of O
salmon O
like O
m O
##uc O
##osa O
left O
und O
##ist O
##ur O
##bed O
. O
- O
di O
##ff O
##use O
mild O
to O
m O
##od O
##ora O
##te O
er O
##yt O
##hem O
##a O
with O
def O
##orm O
##ed O
ant O
##rum O
and O
p O
##yl O
##ori O
##c O
area O
. O
one O
small O
1 O
##c O
##m O
clean O
based O
ul O
##cer O
with O
surrounding O
ed O
##ema O
and O
er O
##yt O
##hem O
##a O
left O
und O
##ist O
##ur O
##bed O
. O
re O
##tro O
##fle O
##x O
view O
revealed O
a O
moderate O
hi O
##ata O
##l O
her O
##nia O
, O
hiatus O
~ O
3 O
##c O
##m O
. O
- O
duo O
##den O
##itis O
and O
one O
small O
< O
1 O
##c O
##m O
superficial O
clean O
based O
ul O
##cer O
in O
the O
duo O
##den O
##al O
bulb O
left O
und O
##ist O
##ur O
##bed O
, O
normal O
second O
portion O
. O
- O
otherwise O
normal O
e O
##g O
##d O
to O
second O
part O
of O
the O
duo O
##den O
##um O
. O
the O
et O
##iology O
of O
his O
an O
##emia O
was O
determined O
to O
be O
a O
combination O
of O
he O
##pa O
##tic O
lesions O
/ O
h O
##cc O
as O
well O
as O
upper B-ADE
g I-ADE
##i I-ADE
bleed I-ADE
, I-ADE
possibly O
secondary O
to O
n B-DRUG
##sai I-DRUG
##d I-DRUG
use O
. O
after O
hem O
##ody O
##nam O
##ic O
and O
card O
##iovascular O
stab O
##ilization O
with O
trans O
##fusion O
##s O
as O
above O
, O
m O
##r O
. O
[ O
* O
* O
known O
last O
##name O
* O
* O
] O
was O
transferred O
out O
of O
the O
sic O
##u O
to O
the O
surgical O
floor O
. O
his O
liver O
lesions O
and O
clinical O
case O
was O
discussed O
during O
a O
multi O
- O
disciplinary O
he O
##pa O
##tic O
tumor O
conference O
. O
it O
was O
determined O
he O
would O
benefit O
from O
bio O
##psy O
of O
his O
lesions O
, O
with O
possible O
systemic O
therapy O
to O
be O
determined O
as O
an O
out O
##patient O
. O
m O
##r O
. O
[ O
* O
* O
known O
last O
##name O
* O
* O
] O
future O
out O
##patient O
care O
was O
coordinated O
with O
the O
hem O
##ato O
##logy O
- O
on O
##cology O
service O
, O
and O
he O
was O
discharged O
on O
[ O
* O
* O
8 O
- O
16 O
* O
* O
] O
, O
[ O
* O
* O
213 O
##7 O
* O
* O
] O
. O
medications O
on O
admission O
: O
occasional O
n B-DRUG
##sai I-DRUG
##d I-DRUG
use O
. O

discharge O
medications O
: O
1 O
. O
pan B-DRUG
##top I-DRUG
##raz I-DRUG
##ole I-DRUG
40 B-STR
mg I-STR
p B-ROU
##o I-ROU
q B-FRE
##12 I-FRE
##h I-FRE
r O
##x O
* O
pan B-DRUG
##top I-DRUG
##raz I-DRUG
##ole I-DRUG
40 B-STR
mg I-STR
1 B-DOS
tablet B-FOR
( I-FOR
s O
) O
by B-ROU
mouth I-ROU
q B-FRE
##12 I-FRE
hours I-FRE
di O
##sp O
# O
* O
60 O
tablet O
re O
##fill O
##s O
: O
* O
2 O
2 O
. O
h B-DRUG
##ydro I-DRUG
##mor I-DRUG
##phone I-DRUG
( O
di B-DRUG
##lau I-DRUG
##di I-DRUG
##d I-DRUG
) I-DRUG
2 B-STR
mg I-STR
p B-ROU
##o I-ROU
q B-FRE
##4 I-FRE
##h I-FRE
: I-FRE
p I-FRE
##rn I-FRE
pain B-REA
r O
##x O
* O
h B-DRUG
##ydro I-DRUG
##mor I-DRUG
##phone I-DRUG
[ O
di B-DRUG
##lau I-DRUG
##di I-DRUG
##d I-DRUG
] I-DRUG
2 B-STR
mg I-STR
[ O
* O
* O
12 O
- O
9 O
* O
* O
] O
tablet B-FOR
( I-FOR
s O
) O
by B-ROU
mouth I-ROU
q B-FRE
4 I-FRE
- I-FRE
6 I-FRE
hours I-FRE
p I-FRE
##rn I-FRE
di O
##sp O
# O
* O
40 O
tablet O
re O
##fill O
##s O
: O
* O
0 O
3 O
. O
do B-DRUG
##cus I-DRUG
##ate I-DRUG
sodium I-DRUG
100 B-STR
mg I-STR
p B-ROU
##o I-ROU
bid B-FRE
r O
##x O
* O
do B-DRUG
##cus I-DRUG
##ate I-DRUG
sodium I-DRUG
100 B-STR
mg I-STR
1 B-DOS
capsule B-FOR
( I-FOR
s O
) O
by B-ROU
mouth I-ROU
[ O
* O
* O
hospital O
##1 O
* O
* O
] O
p B-FRE
##rn I-FRE
di O
##sp O
# O
* O
60 O
capsule O
re O
##fill O
##s O
: O
* O
1 O
discharge O
disposition O
: O
home O
discharge O
diagnosis O
: O
extensive O
liver O
lesions O
( O
presumably O
re O
##current O
he O
##pa O
##to O
##cellular O
car O
##cin O
##oma O
) O
discharge O
condition O
: O
mental O
status O
: O
clear O
and O
coherent O
. O
level O
of O
consciousness O
: O
alert O
and O
interactive O
. O
activity O
status O
: O
am O
##bula O
##tory O
- O
independent O
. O
discharge O
instructions O
: O
please O
call O
d O
##r O
. O
[ O
* O
* O
name O
( O
ni O
) O
136 O
##9 O
* O
* O
] O
office O
at O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
67 O
##3 O
* O
* O
] O
for O
fever O
, O
chill O
##s O
, O
nausea O
, O
vomit O
##ing O
, O
di O
##ar O
##r O
##hea O
, O
con O
##st O
##ip O
##ation O
, O
inability O
to O
tolerate O
food O
, O
fluids O
or O
medications O
. O
you O
will O
be O
following O
up O
with O
the O
on O
##cologist O
d O
##r O
[ O
* O
* O
first O
name O
##4 O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
1852 O
* O
* O
] O
for O
possible O
liver O
bio O
##psy O
and O
treatment O
discussions O
. O
please O
continue O
o B-DRUG
##me I-DRUG
##pra I-DRUG
##zo I-DRUG
##le I-DRUG
2 B-DOS
of O
the O
20 B-STR
mg I-STR
tablets B-FOR
twice B-FRE
a I-FRE
day I-FRE
due O
to O
the O
stomach B-ADE
and I-ADE
small I-ADE
in I-ADE
##test I-ADE
##ine I-ADE
ul I-ADE
##cer I-ADE
##s I-ADE
that O
developed O
most O
likely O
due O
to O
the O
amount O
of O
ad B-DRUG
##vil I-DRUG
( O
i B-DRUG
##bu I-DRUG
##p I-DRUG
##ro I-DRUG
##fen I-DRUG
) I-DRUG
you O
were O
taking O
. O
this O
prescription O
has O
been O
called O
into O
the O
[ O
* O
* O
company O
49 O
##16 O
* O
* O
] O
at O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
84 O
##70 O
##1 O
* O
* O
] O
( O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
84 O
##70 O
##2 O
* O
* O
] O
) O
in O
[ O
* O
* O
location O
( O
un O
) O
66 O
##9 O
* O
* O
] O
. O
it O
should O
be O
covered O
by O
your O
insurance O
. O
please O
take O
2 B-DOS
of O
the O
20 B-STR
mg I-STR
tablets B-FOR
twice B-FRE
a I-FRE
day I-FRE
and O
avoid O
the O
use O
of O
i B-DRUG
##bu I-DRUG
##p I-DRUG
##ro I-DRUG
##fen I-DRUG
( O
ad B-DRUG
##vil I-DRUG
) I-DRUG
, O
as B-DRUG
##pi I-DRUG
##rin I-DRUG
or O
any O
as B-DRUG
##pi I-DRUG
##rin I-DRUG
containing I-DRUG
products I-DRUG
. I-DRUG

please O
see O
d O
##r O
[ O
* O
* O
first O
name O
##4 O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
1852 O
* O
* O
] O
( O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
87 O
##70 O
* O
* O
] O
) O
as O
soon O
as O
possible O
for O
further O
evaluation O
and O
treatment O
options O
. O
no O
driving O
if O
taking O
na B-DRUG
##rc I-DRUG
##otic I-DRUG
pain I-DRUG
medication I-DRUG
. I-DRUG
follow O
##up O
instructions O
: O
[ O
* O
* O
first O
name O
##4 O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
1852 O
* O
* O
] O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
87 O
##70 O
* O
* O
] O
on O
##cologist O
call O
for O
appointment O
as O
soon O
as O
possible O
d O
##r O
. O
[ O
* O
* O
first O
name O
##4 O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
49 O
##7 O
* O
* O
] O
( O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
36 O
##18 O
* O
* O
] O
he O
##pa O
##tology O
. O
call O
to O
schedule O
an O
appointment O
for O
2 O
weeks O
. O
before O
your O
appointment O
, O
you O
will O
go O
to O
the O
lab O
and O
get O
your O
blood O
drawn O
for O
a O
lab O
test O
. O
please O
bring O
the O
lab O
script O
that O
will O
be O
provided O
to O
you O
upon O
discharge O
so O
they O
know O
what O
labs O
to O
draw O
. O
[ O
* O
* O
first O
name O
##11 O
( O
name O
pattern O
##1 O
) O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##4 O
) O
70 O
##7 O
* O
* O
] O
m O
##d O
, O
[ O
* O
* O
m O
##d O
number O
( O
3 O
) O
70 O
##9 O
* O
* O
] O

admission O
date O
: O
[ O
* O
* O
217 O
##5 O
- O
10 O
- O
12 O
* O
* O
] O
discharge O
date O
: O
[ O
* O
* O
217 O
##5 O
- O
10 O
- O
16 O
* O
* O
] O
date O
of O
birth O
: O
[ O
* O
* O
212 O
##8 O
- O
2 O
- O
22 O
* O
* O
] O
sex O
: O
m O
service O
: O
surgery O
all O
##er O
##gies O
: O
vitamin B-DRUG
k I-DRUG
attending O
: O
[ O
* O
* O
first O
name O
##3 O
( O
l O
##f O
) O
66 O
##8 O
* O
* O
] O
chief O
complaint O
: O
leak O
##age O
of O
clear O
fluid O
from O
um O
##bil O
##icus O
. O
major O
surgical O
or O
invasive O
procedure O
: O
no O
repair O
to O
her O
##nia O
re O
##sus O
##citation O
with O
in O
##tub O
##ation O
[ O
* O
* O
217 O
##5 O
- O
10 O
- O
13 O
* O
* O
] O
history O
of O
present O
illness O
: O
47 O
##m O
with O
h O
/ O
o O
es O
##rd O
on O
h O
##d O
, O
es O
##ld O
[ O
* O
* O
2 O
- O
17 O
* O
* O
] O
he O
##pa O
##titis O
c O
, O
alcoholic O
c O
##ir O
##r O
##hos O
##is O
, O
en O
##ce O
##pha O
##lop O
##athy O
who O
presents O
with O
leak O
##age O
of O
clear O
fluid O
from O
his O
um O
##bil O
##icus O
. O
this O
was O
first O
noticed O
last O
evening O
( O
[ O
* O
* O
10 O
- O
11 O
* O
* O
] O
) O
. O
the O
leak O
##age O
soaked O
his O
clothes O
and O
bed O
by O
his O
report O
. O
he O
spoke O
with O
his O
p O
##c O
##p O
, O
[ O
* O
* O
name O
##10 O
( O
name O
##is O
) O
102 O
##3 O
* O
* O
] O
recommended O
he O
go O
to O
the O
ed O
to O
be O
evaluated O
, O
which O
he O
did O
not O
do O
until O
today O
. O
he O
is O
seen O
now O
in O
dial O
##ys O
##is O
. O
the O
leak O
##age O
has O
decreased O
throughout O
today O
. O
he O
notes O
that O
this O
could O
be O
secondary O
to O
his O
belt O
frequently O
rubbing O
on O
his O
large O
um O
##bil O
##ical O
her O
##nia O
. O
he O
denies O
f O
/ O
c O
/ O
n O
/ O
v O
/ O
c O
/ O
d O
. O
he O
reports O
feeling O
generally O
well O
recently O
, O
with O
the O
exception O
of O
this O
new O
complaint O
. O
past O
medical O
history O
: O
# O
c O
##ir O
##r O
##hos O
##is O
- O
he O
##p O
c O
+ O
et O
##oh O
abuse O
- O
c O
/ O
b O
es O
##op O
##hage O
##al O
var O
##ices O
s O
/ O
p O
band O
##ing O
in O
[ O
* O
* O
12 O
- O
26 O
* O
* O
] O
- O
e O
##g O
##d O
[ O
* O
* O
217 O
##5 O
- O
4 O
- O
28 O
* O
* O
] O
: O
4 O
cord O
##s O
of O
grade O
ii O
var O
##ices O
, O
non O
##ble O
##eding O
g O
##e O
j O
##ct O
##n O
ul O
##cer O
- O
has O
not O
been O
treated O
for O
he O
##pa O
##titis O
c O
- O
has O
nod O
##ular O
lesions O
on O
us O
- O
> O
no O
m O
##ri O
to O
e O
##val O
for O
h O
##cc O
, O
a O
##f O
##p O
4 O
. O
3 O
- O
h O
/ O
o O
s O
##b O
##p O
in O
[ O
* O
* O
9 O
- O
21 O
* O
* O
] O
, O
? O
s O
##b O
##p O
during O
last O
hospital O
##ization O
( O
em O
##pi O
##ric O
) O
# O
es O
##rd O
on O
h O
##d O
t O
/ O
th O
/ O
sat O
# O
an O
##emia O
of O
chronic O
disease O
# O
left O
lower O
ex O
##tre O
##mity O
wound O
# O
h O
/ O
o O
major O
depression O
# O
s O
##chi O
##zo O
##ty O
##pal O
personality O
disorder O

social O
history O
: O
lives O
with O
wife O
. O
denies O
tobacco O
, O
et O
##oh O
, O
or O
drug O
use O
currently O
. O
heavy O
et O
##oh O
use O
in O
the O
past O
, O
prior O
i O
##v O
drug O
use O
in O
early O
80s O
( O
last O
[ O
* O
* O
4 O
- O
21 O
* O
* O
] O
) O
. O
family O
history O
: O
maternal O
aunt O
with O
d O
##m O
physical O
exam O
: O
t O
: O
96 O
. O
6 O
88 O
119 O
/ O
67 O
28 O
g O
##en O
: O
na O
##d O
. O
awake O
and O
alert O
. O
pleasant O
. O
he O
##ent O
: O
i O
##cter O
##ic O
s O
##cle O
##ra O
. O
mm O
##m O
. O
op O
clear O
. O
neck O
: O
su O
##pp O
##le O
, O
j O
##v O
##p O
~ O
10 O
cm O
h O
##2 O
##o O
. O
c O
##v O
: O
r O
##rr O
. O
n O
##l O
s O
##1 O
, O
s O
##2 O
. O
no O
m O
##rg O
lungs O
: O
diminished O
b O
##s O
at O
bases O
bilateral O
##ly O
. O
no O
r O
##ales O
or O
r O
##hon O
##chi O
. O
a O
##b O
##d O
: O
+ O
access O
##ory O
muscle O
use O
. O
mild O
work O
of O
breathing O
. O
a O
##b O
##d O
: O
softly O
di O
##sten O
##ded O
. O
large O
um O
##bil O
##ical O
her O
##nia O
. O
very O
small O
drops O
of O
se O
##rous O
fluid O
on O
superior O
aspect O
of O
um O
##bil O
##ical O
her O
##nia O
. O
there O
is O
no O
obvious O
skin O
defect O
where O
the O
leak O
was O
coming O
form O
. O
her O
##nia O
easily O
re O
##ed O
##uc O
##ible O
. O
abdomen O
is O
non O
##tend O
##er O
. O
dull O
##ness O
to O
percussion O
on O
dependent O
flanks O
. O
h O
##y O
##po O
##active O
b O
##s O
. O
otherwise O
soft O
. O
no O
rigid O
##ity O
. O
ex O
##t O
: O
warm O
. O
1 O
+ O
le O
ed O
##ema O
. O
skin O
: O
mild O
j O
##au O
##ndi O
##ce O
. O
no O
spider O
an O
##gio O
##mas O
. O
r O
chest O
e O
##cc O
##hy O
##mos O
##is O
. O
ne O
##uro O
: O
oriented O
x O
##3 O
. O
per O
##tinent O
results O
: O
on O
admission O
: O
[ O
* O
* O
217 O
##5 O
- O
10 O
- O
12 O
* O
* O
] O
w O
##b O
##c O
- O
11 O
. O
3 O
* O
r O
##b O
##c O
- O
2 O
. O
97 O
* O
h O
##g O
##b O
- O
10 O
. O
6 O
* O
h O
##ct O
- O
33 O
. O
7 O
* O
m O
##c O
##v O
- O
114 O
* O
m O
##ch O
- O
35 O
. O
6 O
* O
m O
##ch O
##c O
- O
31 O
. O
4 O
r O
##d O
##w O
- O
19 O
. O
3 O
* O
p O
##lt O
c O
##t O
- O
100 O
* O
p O
##t O
- O
19 O
. O
2 O
* O
p O
##tt O
- O
41 O
. O
9 O
* O
in O
##r O
( O
p O
##t O
) O
- O
1 O
. O
8 O
* O
glucose O
- O
90 O
u O
##rea O
##n O
- O
56 O
* O
c O
##rea O
##t O
- O
7 O
. O
6 O
* O
na O
- O
134 O
k O
- O
5 O
. O
2 O
* O
c O
##l O
- O
99 O
h O
##co O
##3 O
- O
27 O
an O
##ga O
##p O
- O
13 O
al O
##t O
- O
28 O
as O
##t O
- O
60 O
* O
l O
##d O
( O
l O
##dh O
) O
- O
41 O
##8 O
* O
al O
##k O
##ph O
##os O
- O
157 O
* O
am O
##yla O
##se O
- O
92 O
to O
##t O
##bil O
##i O
- O
4 O
. O
0 O
* O
lip O
##ase O
- O
95 O
* O
album O
##in O
- O
2 O
. O
7 O
* O
calcium O
- O
8 O
. O
3 O
* O
p O
##hos O
- O
2 O
. O
9 O
mg O
- O
2 O
. O
5 O
am O
##monia O
- O
65 O
* O

brief O
hospital O
course O
: O
initial O
plan O
for O
patient O
was O
to O
go O
to O
or O
for O
repair O
of O
the O
um O
##bil O
##ical O
her O
##nia O
. O
he O
has O
a O
new O
onset O
of O
as O
##cite O
##s O
and O
there O
is O
concern O
for O
erosion O
of O
her O
##nia O
and O
/ O
or O
infection O
. O
he O
was O
admitted O
following O
hem O
##od O
##ial O
##ys O
##is O
. O
on O
the O
morning O
of O
the O
intended O
surgery O
, O
his O
in O
##r O
was O
1 O
. O
8 O
and O
p O
##tt O
42 O
. O
plan O
was O
to O
give O
vitamin B-DRUG
k I-DRUG
pre O
- O
op O
and O
have O
f B-DRUG
##f I-DRUG
##p I-DRUG
on O
call O
to O
or O
. O
during O
the O
in B-ROU
##fusion I-ROU
of O
the O
vitamin B-DRUG
k I-DRUG
the O
patient O
suffered O
an O
apparent O
an B-ADE
##aph I-ADE
##yla I-ADE
##ctic I-ADE
reaction I-ADE
to O
the O
i B-ROU
##v I-ROU
vitamin B-DRUG
k I-DRUG
and O
he O
required O
re O
##sus O
##citation O
to O
include O
in O
##tub O
##ation O
. O
he O
was O
transferred O
to O
the O
i O
##cu O
where O
he O
was O
stab O
##li O
##zed O
, O
and O
ultimately O
ex O
##tub O
##ated O
. O
he O
was O
transferred O
back O
to O
the O
surgical O
floor O
. O
however O
it O
was O
felt O
that O
the O
risk O
of O
the O
operative O
procedure O
would O
out O
##weight O
the O
benefit O
of O
fixing O
the O
her O
##nia O
, O
so O
it O
was O
determined O
to O
send O
the O
patient O
home O
without O
the O
her O
##nia O
repair O
. O
he O
is O
to O
wear O
an O
abdominal O
bind O
##er O
at O
all O
times O
, O
one O
was O
provided O
to O
the O
patient O
prior O
to O
discharge O
. O
he O
will O
continue O
on O
his O
usual O
home O
medications O
and O
be O
followed O
by O
the O
liver O
team O
as O
he O
has O
been O
prior O
to O
this O
admission O
. O
he O
will O
also O
continue O
his O
hem O
##od O
##ial O
##ys O
##is O
per O
out O
##patient O
schedule O
. O
medications O
on O
admission O
: O
r B-DRUG
##if I-DRUG
##ax I-DRUG
##im I-DRUG
##in I-DRUG
400 B-STR
mg I-STR
p B-ROU
##o I-ROU
t B-FRE
##id I-FRE
, I-FRE
na B-DRUG
##do I-DRUG
##lo I-DRUG
##l I-DRUG
20 B-STR
mg I-STR
daily B-FRE
, I-FRE
la B-DRUG
##ct I-DRUG
##ulos I-DRUG
##e I-DRUG
45 B-DOS
) I-DOS
m I-DOS
##l I-DOS
p B-ROU
##o I-ROU
q B-FRE
##id I-FRE
, I-FRE
th B-DRUG
##iam I-DRUG
##ine I-DRUG
100 B-STR
mg I-STR
daily B-FRE
, I-FRE
f B-DRUG
##olic I-DRUG
acid I-DRUG
1 B-STR
mg I-STR
daily B-FRE
, I-FRE
pro B-DRUG
##ton I-DRUG
##ix I-DRUG
40 B-STR
mg I-STR
once B-FRE
a I-FRE
day I-FRE
, I-FRE
se B-DRUG
##vel I-DRUG
##ame I-DRUG
##r I-DRUG
1600 B-STR
mg I-STR
t B-FRE
##id I-FRE
discharge O
medications O
: O
1 O
. O
r B-DRUG
##if I-DRUG
##ax I-DRUG
##im I-DRUG
##in I-DRUG
200 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
two B-DOS
( I-DOS
2 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
t B-FRE
##id I-FRE
( O
3 O
times O
a O
day O
) O
. O
2 O
. O
na B-DRUG
##do I-DRUG
##lo I-DRUG
##l I-DRUG
20 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( I-FRE
daily I-FRE
) I-FRE
. I-FRE
3 O
. O
la B-DRUG
##ct I-DRUG
##ulos I-DRUG
##e I-DRUG
10 B-STR
g I-STR
/ I-STR
15 I-STR
m I-STR
##l I-STR
syrup B-FOR
si O
##g O
: O
forty B-DOS
five I-DOS
( I-DOS
45 I-DOS
) I-DOS
m I-DOS
##l I-DOS
p B-ROU
##o I-ROU
q B-FRE
##id I-FRE
( O
4 O
times O
a O
day O
) O
. O
4 O
. O
th B-DRUG
##iam I-DRUG
##ine I-DRUG
h I-DRUG
##c I-DRUG
##l I-DRUG
100 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( O
daily O
) O
. O
5 O
. O
f B-DRUG
##olic I-DRUG
acid I-DRUG
1 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( I-FRE
daily I-FRE
) I-FRE
. I-FRE

6 O
. O
se B-DRUG
##vel I-DRUG
##ame I-DRUG
##r I-DRUG
800 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
two B-DOS
( I-DOS
2 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
t B-FRE
##id I-FRE
w I-FRE
/ I-FRE
meals I-FRE
( I-FRE
3 I-FRE
times I-FRE
a I-FRE
day I-FRE
with I-FRE
meals I-FRE
) I-FRE
. I-FRE
7 O
. O
pan B-DRUG
##top I-DRUG
##raz I-DRUG
##ole I-DRUG
40 B-STR
mg I-STR
tablet B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
p B-ROU
##o I-ROU
q B-FRE
##24 I-FRE
##h I-FRE
( I-FRE
every I-FRE
24 I-FRE
hours I-FRE
) I-FRE
. I-FRE
8 O
. O
h B-DRUG
##ydro I-DRUG
##mor I-DRUG
##phone I-DRUG
2 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
0 B-DOS
. I-DOS
5 I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
q B-FRE
##6 I-FRE
##h I-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE
di O
##sp O
: O
* O
20 O
tablet B-FOR
( I-FOR
s I-FOR
) I-FOR
* I-FOR
re O
##fill O
##s O
: O
* O
0 O
* O
discharge O
disposition O
: O
home O
discharge O
diagnosis O
: O
um O
##bil O
##ical O
her O
##nia O
with O
fluid O
leak O
##age O
: O
stable O
discharge O
condition O
: O
fair O
discharge O
instructions O
: O
please O
call O
d O
##r O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
56 O
##22 O
##8 O
* O
* O
] O
office O
at O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
242 O
##2 O
* O
* O
] O
if O
you O
experience O
increased O
abdominal O
pain O
, O
fever O
##s O
> O
101 O
, O
nausea O
, O
vomit O
##ing O
, O
or O
other O
concerning O
symptoms O
. O
continue O
medications O
as O
prescribed O
wear O
the O
abdominal O
bind O
##er O
at O
all O
times O
. O
please O
call O
d O
##r O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
102 O
##8 O
##5 O
* O
* O
] O
if O
you O
feel O
you O
need O
to O
be O
seen O
sooner O
than O
your O
previously O
scheduled O
appointment O
continue O
hem O
##od O
##ial O
##ys O
##is O
schedule O
per O
your O
out O
##patient O
clinic O
schedule O
please O
call O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
67 O
##3 O
* O
* O
] O
and O
ask O
for O
[ O
* O
* O
first O
name O
##8 O
( O
name O
##pa O
##tter O
##n O
##2 O
) O
59 O
##6 O
##9 O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
59 O
##70 O
* O
* O
] O
to O
help O
with O
discussion O
about O
dial O
##ys O
##is O
access O
other O
dial O
##ys O
##is O
clinics O
: O
f O
##res O
##eni O
##us O
, O
dial O
##ys O
##is O
care O
incorporated O
follow O
##up O
instructions O
: O
[ O
* O
* O
name O
##6 O
( O
m O
##d O
) O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##4 O
) O
242 O
##4 O
* O
* O
] O
, O
m O
##d O
phone O
: O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
242 O
##2 O
* O
* O
] O
date O
/ O
time O
: O
[ O
* O
* O
217 O
##6 O
- O
2 O
- O
29 O
* O
* O
] O
11 O
: O
30 O
completed O
by O
: O
[ O
* O
* O
217 O
##5 O
- O
10 O
- O
16 O
* O
* O
] O

admission O
date O
: O
[ O
* O
* O
213 O
##1 O
- O
4 O
- O
12 O
* O
* O
] O
discharge O
date O
: O
[ O
* O
* O
213 O
##1 O
- O
4 O
- O
27 O
* O
* O
] O
date O
of O
birth O
: O
[ O
* O
* O
209 O
##3 O
- O
2 O
- O
10 O
* O
* O
] O
sex O
: O
m O
service O
: O
medicine O
all O
##er O
##gies O
: O
re B-DRUG
##g I-DRUG
##lan I-DRUG
/ O
lid B-DRUG
##oc I-DRUG
##aine I-DRUG
/ O
i B-DRUG
##od I-DRUG
##ine I-DRUG
attending O
: O
[ O
* O
* O
first O
name O
##3 O
( O
l O
##f O
) O
61 O
##3 O
* O
* O
] O
chief O
complaint O
: O
abdominal O
pain O
, O
chest O
pain O
, O
nausea O
+ O
vomit O
##ing O
major O
surgical O
or O
invasive O
procedure O
: O
upper O
end O
##os O
##copy O
do B-DRUG
##but I-DRUG
##amine I-DRUG
stress O
echo O
cardiac O
cat O
##he O
##ter O
##ization O
history O
of O
present O
illness O
: O
38 O
##yo O
man O
with O
type O
i O
d O
##m O
, O
c O
##k O
##d O
( O
base O
##line O
c O
##r O
2 O
. O
2 O
- O
2 O
. O
6 O
, O
s O
##ys O
##to O
##lic O
and O
di O
##ast O
##olic O
ch O
##f O
with O
e O
##f O
50 O
- O
55 O
% O
, O
re O
##fra O
##ctor O
##y O
h O
##t O
##n O
and O
gas O
##tro O
##par O
##esis O
with O
re O
##current O
admissions O
for O
gas O
##tro O
##par O
##esis O
presented O
to O
new O
p O
##c O
##p O
' O
s O
office O
with O
re O
##current O
nausea O
, O
vomit O
##ing O
, O
inability O
to O
take O
p O
##os O
and O
chest O
pain O
radiating O
to O
his O
back O
and O
was O
sent O
to O
ed O
. O
he O
was O
last O
admitted O
2 O
weeks O
ago O
with O
similar O
s O
##x O
other O
than O
chest O
pain O
, O
and O
was O
admitted O
for O
p O
##na O
and O
c O
. O
di O
##ff O
. O
he O
states O
that O
he O
has O
had O
abdominal O
pain O
and O
nausea O
/ O
vomit O
##ing O
over O
last O
week O
similar O
to O
previous O
bouts O
of O
gas O
##tro O
##par O
##esis O
. O
he O
denies O
missing O
any O
insulin B-DRUG
doses O
and O
says O
he O
has O
been O
taking O
10 B-DOS
##u B-FOR
at O
night O
, O
4 B-DOS
##u B-FOR
in O
evening O
with O
sugar O
##s O
< O
200 O
almost O
always O
. O
he O
finished O
[ O
* O
* O
last O
name O
( O
un O
) O
86 O
##9 O
##2 O
* O
* O
] O
flag B-DRUG
##yl I-DRUG
course O
, O
and O
had O
not O
had O
any O
di O
##ar O
##r O
##hea O
other O
than O
1 O
episode O
this O
am O
. O

in O
ed O
, O
initial O
vital O
##s O
were O
significant O
for O
b O
##p O
250 O
/ O
140 O
and O
glucose O
of O
700 O
and O
a O
an O
##ion O
gap O
of O
18 O
when O
corrected O
for O
h O
##yper O
##gly O
##ce O
##mia O
. O
p O
##t O
. O
had O
c O
##t O
without O
contrast O
to O
assess O
for O
di O
##sse O
##ction O
given O
chest O
pain O
radiating O
to O
his O
back O
which O
was O
negative O
. O
no O
le O
##uk O
##oc O
##yt O
##osis O
, O
c O
##x O
##r O
and O
u O
/ O
a O
negative O
, O
blood O
c O
##x O
. O
pending O
. O
he O
was O
placed O
on O
insulin B-DRUG
g B-ROU
##tt I-ROU
and O
received O
40 B-STR
##m I-STR
##g I-STR
lab B-DRUG
##etal I-DRUG
##ol I-DRUG
with O
improvement O
of O
his O
b O
##ps O
and O
resolution O
of O
his O
chest O
pain O
. O
initially O
, O
was O
to O
be O
sent O
to O
i O
##cu O
, O
however O
no O
beds O
available O
. O
as O
his O
sugar O
##s O
improved O
with O
insulin B-DRUG
g B-ROU
##tt I-ROU
and O
his O
his O
a O
##g O
closed O
, O
he O
is O
now O
admitted O
to O
the O
floor O
after O
transition O
##ing O
off O
insulin B-DRUG
g B-ROU
##tt I-ROU
since O
3 O
##am O
. O
he O
received O
6 B-DOS
##u B-FOR
n B-DRUG
##ph I-DRUG
2 O
##h O
prior O
to O
transfer O
and O
was O
actually O
h B-REA
##y I-REA
##po I-REA
##gly I-REA
##ce I-REA
##mic I-REA
ne O
##cess O
##itating O
d B-DRUG
##50 I-DRUG
x O
1 B-DOS
. I-DOS
his O
r O
##os O
is O
significant O
for O
lack O
of O
cough O
. O
+ O
c O
##p O
, O
but O
non O
- O
ex O
##ert O
##ional O
, O
with O
no O
radiation O
and O
associated O
with O
abdominal O
pain O
. O
no O
short O
##ness O
of O
breath O
, O
or O
##th O
##op O
##nea O
, O
p O
##nd O
, O
le O
ed O
##ema O
. O
no O
fever O
##s O
or O
chill O
##s O
, O
though O
currently O
feels O
cold O
. O
past O
medical O
history O
: O
# O
type B-REA
i I-REA
d I-REA
##m I-REA
, I-REA
insulin B-DRUG
- I-DRUG
requiring O
, O
x O
16 O
years O
, O
currently O
seen O
at O
[ O
* O
* O
last O
name O
( O
un O
) O
* O
* O
] O
- O
di O
##abe O
##tic O
gas O
##tro O
##par O
##esis O
( O
per O
patient O
, O
has O
had O
m O
##ot O
##ility O
studies O
at O
o O
##sh O
) O
; O
was O
on O
re B-DRUG
##g I-DRUG
##lan I-DRUG
but O
developed O
e B-ADE
##ps I-ADE
, I-ADE
now O
on O
er B-DRUG
##yt I-DRUG
##hr I-DRUG
##omy I-DRUG
##cin I-DRUG
- O
di O
##abe O
##tic O
ne O
##uro O
##pathy O
and O
re O
##tino O
##pathy O
# O
history O
of O
pan O
##cre O
##ati O
##tis O
# O
h O
##t O
##n O
# O
chronic O
kidney O
disease O
stage O
i O
##v O
, O
recently O
discovered O
# O
th O
##rom O
##bo O
##cy O
##top O
##enia O
no O
##s O
( O
re O
##sol O
##ving O
) O
# O
h O
##x O
of O
es O
##op O
##hage O
##al O
ul O
##cer O
and O
g O
##ib O
# O
s O
##chi O
##zophrenia O
# O
depression O
/ O
su O
##icidal O
idea O
##tion O
# O
ca O
##d O
with O
ch O
##f O
, O
e O
##f O
na O
##dir O
25 O
% O
, O
now O
improved O
to O
50 O
- O
55 O
% O
on O
last O
echo O
in O
[ O
* O
* O
3 O
- O
6 O
* O
* O
] O
. O
social O
history O
: O
recently O
relocated O
from O
n O
##h O
to O
[ O
* O
* O
location O
( O
un O
) O
86 O
* O
* O
] O
, O
where O
he O
is O
living O
with O
his O
brother O
and O
brother O
' O
s O
wife O
. O
denies O
current O
et O
##oh O
use O
; O
admits O
to O
heavy O
drinking O
x O
1 O
year O
about O
age O
27 O
. O
+ O
active O
tobacco O
use O
, O
about O
1 O
##pp O
##d O
+ O
marijuana O
but O
no O
i O
##v O
drug O
use O
. O

family O
history O
: O
+ O
d O
##m O
in O
sister O
, O
brother O
, O
father O
, O
and O
mother O
. O
sister O
: O
died O
from O
di O
##abe O
##tic O
complications O
alcohol O
##ism O
in O
mother O
and O
father O
. O
brother O
diagnosed O
with O
s O
##chi O
##zophrenia O
. O
physical O
exam O
: O
vital O
##s O
: O
t O
97 O
. O
1 O
, O
b O
##p O
144 O
/ O
80 O
in O
r O
, O
148 O
/ O
76 O
in O
l O
. O
h O
##r O
98 O
, O
r O
##r O
16 O
, O
o O
##2 O
sat O
98 O
% O
r O
##a O
general O
: O
pale O
, O
thin O
man O
, O
shivering O
under O
covers O
, O
moaning O
throughout O
exam O
. O
he O
##ent O
: O
per O
##rl O
, O
e O
##omi O
, O
op O
clear O
, O
poor O
den O
##ti O
##tion O
, O
mm O
##m O
c O
##v O
: O
r O
##rr O
, O
no O
m O
##rg O
##s O
, O
no O
re O
##p O
##rod O
##uc O
##ible O
chest O
wall O
tender O
##ness O
chest O
: O
c O
##ta O
##b O
, O
no O
w O
##hee O
##zes O
, O
crack O
##les O
abdomen O
: O
soft O
, O
n O
##d O
, O
very O
mild O
t O
##t O
##p O
, O
to O
left O
of O
um O
##bil O
##icus O
without O
re O
##bound O
or O
guarding O
. O
ex O
##tre O
##mit O
##ies O
: O
2 O
+ O
d O
##ps O
, O
no O
c O
/ O
c O
/ O
e O
ne O
##uro O
: O
c O
##n O
ii O
- O
x O
##ii O
intact O
, O
n O
##l O
strength O
, O
sensation O
to O
l O
##t O
. O
per O
##tinent O
results O
: O
chest O
- O
two O
views O
are O
compared O
with O
the O
recent O
bedside O
study O
, O
dated O
[ O
* O
* O
213 O
##1 O
- O
3 O
- O
16 O
* O
* O
] O
. O
there O
is O
patch O
##y O
and O
somewhat O
nod O
##ular O
airs O
##pace O
op O
##acity O
involving O
the O
right O
upper O
lobe O
, O
predominantly O
its O
anterior O
and O
a O
##pical O
segments O
, O
new O
. O
the O
lungs O
are O
otherwise O
clear O
, O
with O
no O
p O
##le O
##ural O
e O
##ff O
##usion O
. O
the O
card O
##io O
##media O
##st O
##inal O
silhouette O
and O
pulmonary O
vessels O
are O
unchanged O
. O
. O
e O
##c O
##g O
: O
n O
##s O
##r O
with O
s O
##t O
elevations O
~ O
1 O
##mm O
in O
v O
##1 O
- O
v O
##3 O
c O
/ O
w O
early O
re O
##pol O
##ari O
##zation O
changes O
in O
anterior O
leads O
, O
v O
##1 O
similar O
to O
previous O
, O
v O
##2 O
- O
v O
##3 O
, O
s O
##l O
. O
increased O
from O
prior O
##s O
. O
brief O
hospital O
course O
: O
38 O
##yo O
type O
i O
di O
##abe O
##tic O
with O
gas O
##tro O
##par O
##esis O
presents O
with O
chronic O
s O
##x O
. O
and O
d O
##ka O
likely O
[ O
* O
* O
12 O
- O
30 O
* O
* O
] O
medication O
non O
##ad O
##herence O
. O
p O
##t O
c O
/ O
o O
chest O
pain O
and O
found O
to O
have O
significant O
es O
##op O
##ha O
##git O
##is O
. O
then O
with O
acute O
re O
##nal O
failure O
after O
cardiac O
cat O
##he O
##ter O
##ization O
to O
further O
character O
##ize O
chest O
pain O
( O
no O
significant O
ca O
##d O
) O
. O
c O
##r O
returned O
towards O
base O
##line O
. O
compliance O
with O
treatment O
plan O
and O
appointments O
continues O
to O
be O
challenging O
and O
although O
patient O
frustrated O
with O
his O
long O
hospital O
stay O
, O
he O
does O
not O
take O
active O
role O
in O
his O
health O
care O
. O

d O
##ka O
: O
the O
patient O
originally O
presented O
with O
h O
##yper O
##gly O
##ce O
##mia O
. O
no O
evidence O
of O
k O
##eton O
##es O
or O
acid O
##osis O
. O
he O
did O
have O
an O
an O
##ion O
gap O
with O
closed O
quickly O
with O
i B-DRUG
##v I-DRUG
##fs I-DRUG
and O
insulin B-DRUG
g B-ROU
##tt I-ROU
. I-ROU
he O
was O
quickly O
transitioned O
to O
sq B-ROU
insulin B-DRUG
. I-DRUG
there O
was O
no O
evidence O
of O
infection O
. O
his O
blood O
sugar O
##s O
were O
difficult O
to O
control O
throughout O
his O
ho O
##sp O
##ti O
##tal O
stay O
in O
part O
because O
he O
was O
frequently O
n O
##po O
for O
proceed O
##ures O
. O
he O
was O
followed O
by O
the O
[ O
* O
* O
last O
name O
( O
un O
) O
* O
* O
] O
diabetes O
consult O
service O
. O
he O
was O
treated O
with O
n B-DRUG
##ph I-DRUG
and O
a O
gentle O
s B-DRUG
##si I-DRUG
. I-DRUG
disc O
##har O
##ging O
him O
with O
n B-DRUG
##ph I-DRUG
and O
a O
sliding B-DOS
scale I-DOS
was O
discussed O
, O
but O
the O
patient O
noted O
that O
he O
was O
legally O
blind O
and O
only O
able O
to O
read O
his O
inn O
##ole O
##t O
disc O
and O
would O
not O
be O
able O
to O
draw O
up O
s O
##yr O
##inge O
##s O
. O
he O
will O
f O
/ O
u O
with O
[ O
* O
* O
last O
name O
( O
un O
) O
* O
* O
] O
. O
. O
h B-REA
##y I-REA
##po I-REA
##gly I-REA
##ce I-REA
##mia I-REA
/ I-REA
h B-REA
##y I-REA
##pot I-REA
##her I-REA
##mia I-REA
: I-REA
after O
receiving O
full O
insulin B-DRUG
dose O
while O
n O
##po O
and O
undergoing O
stress O
test O
, O
the O
patient O
experienced O
an O
episode O
of O
h O
##y O
##po O
##gly O
##ce O
##mia O
, O
confusion O
, O
di O
##aph O
##ores O
##is O
, O
h O
##y O
##pot O
##her O
##mia O
to O
91 O
. O
9 O
and O
sin O
##us O
bra O
##dy O
##card O
##ia O
. O
he O
was O
transferred O
briefly O
to O
the O
i O
##cu O
for O
monitoring O
, O
but O
once O
his O
glucose O
was O
corrected O
, O
the O
other O
issues O
also O
resolved O
shortly O
thereafter O
. O
he O
was O
transferred O
back O
to O
the O
floor O
the O
following O
day O
. O
. O

n O
/ O
v O
/ O
a O
##b O
##d O
pain O
: O
this O
was O
thought O
secondary O
to O
his O
known O
gas O
##tro O
##par O
##esis O
and O
was O
similar O
in O
nature O
to O
his O
prior O
episodes O
. O
he O
was O
started O
on O
r O
##t O
##c O
anti O
##em O
##etics O
and O
pain O
control O
as O
needed O
. O
he O
was O
transitioned O
from O
i B-ROU
##v I-ROU
to O
p B-ROU
##o I-ROU
di B-DRUG
##lau I-DRUG
##ded I-DRUG
. I-DRUG
it O
was O
difficult O
to O
assess O
his O
a O
##b O
##d O
pain O
as O
it O
was O
both O
l O
##u O
##q O
, O
e O
##pi O
##gas O
##tric O
and O
sub O
##ster O
##nal O
and O
radiated O
to O
the O
left O
shoulder O
. O
c O
##t O
a O
##b O
##d O
in O
the O
ed O
showed O
a O
thick O
##end O
es O
##op O
##ha O
##gus O
. O
he O
was O
evaluated O
with O
an O
e O
##g O
##d O
which O
showed O
severe O
es O
##op O
##ha O
##git O
##is O
, O
gas O
##tri O
##tis O
and O
a O
soft O
food O
be O
##zo O
##ar O
all O
of O
which O
were O
though O
to O
be O
due O
to O
gas O
##tro O
##par O
##esis O
and O
re O
##f O
##lux O
. O
his O
ant O
##ac O
##id O
regime O
##n O
was O
increased O
to O
pp B-DRUG
##i I-DRUG
[ O
* O
* O
hospital O
##1 O
* O
* O
] O
. O
he O
was O
also O
placed O
on O
a O
liquid O
diet O
to O
facilitate O
the O
resolution O
of O
the O
be O
##zo O
##ar O
and O
improve O
his O
gas O
##tro O
##par O
##esis O
. O
h O
. O
p O
##yl O
##ori O
se O
##rol O
##ogy O
was O
negative O
. O
path O
##ology O
showed O
. O
. O
. O
per O
g O
##i O
consult O
re O
##come O
##nda O
##tion O
, O
er B-DRUG
##yt I-DRUG
##hm I-DRUG
##oc I-DRUG
##yi I-DRUG
##n I-DRUG
was O
stopped O
as O
p B-ROU
##o I-ROU
er B-DRUG
##yt I-DRUG
##hr I-DRUG
##omy I-DRUG
##cin I-DRUG
has O
no O
effect O
on O
gas O
##tro O
##par O
##esis O
and O
as O
i B-ROU
##v I-ROU
er B-DRUG
##yt I-DRUG
##hr I-DRUG
##omy I-DRUG
##cin I-DRUG
has O
limited O
effect O
due O
to O
ta O
##chy O
##phy O
##lax O
##is O
. O
in O
addition O
, O
there O
was O
a O
concern O
for O
risk O
of O
prolonged O
q O
##t O
when O
he O
became O
bra O
##dy O
##card O
##ic O
. O
. O

chest O
pain O
: O
in O
the O
ed O
, O
a O
c O
##t O
was O
negative O
for O
di O
##sse O
##ction O
. O
he O
was O
ruled O
out O
by O
cardiac O
enzymes O
. O
he O
was O
seen O
by O
card O
##iology O
on O
the O
floor O
who O
felt O
that O
given O
his O
numerous O
risk O
factors O
he O
should O
have O
a O
stress O
test O
. O
given O
his O
base O
##line O
abnormal O
e O
##k O
##g O
a O
stress O
mi O
##bi O
was O
performed O
, O
during O
which O
he O
had O
chest O
pain O
- O
although O
he O
had O
c O
##p O
prior O
, O
during O
and O
after O
the O
test O
as O
well O
. O
at O
level B-DRUG
of O
exercise O
achieved O
( O
only O
37 O
% O
of O
age O
- O
predicted O
maximum O
) O
, O
there O
were O
no O
my O
##oc O
##ard O
##ial O
per O
##fusion O
defects O
, O
however O
, O
depressed O
l O
##ve O
##f O
( O
38 O
% O
) O
and O
global O
h O
##y O
##po O
##kin O
##esis O
. O
he O
then O
received O
a O
do B-DRUG
##but I-DRUG
##amine I-DRUG
echo O
. O
the O
patient O
received O
in B-ROU
##tra I-ROU
##ven I-ROU
##ous I-ROU
do B-DRUG
##but I-DRUG
##amine I-DRUG
beginning O
at O
15 B-STR
m I-STR
##c I-STR
##g I-STR
/ I-STR
kg I-STR
/ I-STR
min I-STR
. I-STR
the O
blood O
pressure O
response O
to O
stress O
was O
abnormal O
/ O
mildly O
h O
##yper O
##tensive O
. O
resting O
images O
demonstrated O
regional O
left O
vent O
##ric O
##ular O
s O
##ys O
##to O
##lic O
d O
##ys O
##function O
with O
h O
##y O
##po O
##kin O
##esis O
of O
the O
posterior O
wall O
. O
at O
low O
dose O
do B-DRUG
##but I-DRUG
##amine I-DRUG
[ O
15 B-STR
##m I-STR
##c I-STR
##g I-STR
/ I-STR
kg I-STR
/ I-STR
min I-STR
; I-STR
heart O
rate O
68 O
b O
##pm O
, O
blood O
pressure O
210 O
/ O
100 O
mm O
##h O
##g O
) O
, O
there O
was O
global O
h O
##y O
##po O
##kin O
##esis O
and O
no O
reduction O
of O
cavity O
size O
; O
however O
, O
there O
was O
also O
concerning O
l O
##v O
balloon O
##ing O
and O
in O
##du O
##cible O
is O
##hem O
##ia O
. O
because O
of O
these O
results O
, O
he O
was O
thought O
to O
be O
high O
cardiac O
risk O
and O
was O
kept O
in O
house O
for O
card O
##ic O
cat O
##he O
##ter O
##ization O
. O
the O
sign O
##ific O
##iant O
risk O
of O
kidney O
failure O
and O
life O
- O
long O
dial O
##ys O
##is O
was O
discussed O
prior O
to O
cardiac O
cat O
##he O
##ter O
##ization O
. O
the O
patient O
decided O
to O
undergo O
the O
risk O
with O
full O
informed O
consent O
. O
cardiac O
cat O
##he O
##ter O
##ization O
did O
not O
demonstrate O
significant O
co O
##rona O
##ry O
artery O
disease O
. O
he O
was O
medical O
##ly O
managed O
with O
as B-DRUG
##a I-DRUG
, I-DRUG
b B-DRUG
##b I-DRUG
, I-DRUG
[ O
* O
* O
last O
name O
( O
un O
) O
* O
* O
] O
, O
s B-DRUG
##tat I-DRUG
##in I-DRUG
and O
his O
medication O
doses O
were O
adjusted O
as O
indicated O
. O
e O
##g O
##d O
demonstrated O
sign O
##fic O
##iant O
es O
##op O
##ha O
##git O
##is O
and O
this O
was O
thought O
to O
be O
the O
cause O
of O
his O
chest O
pain O
. O
given O
a O
h O
/ O
o O
all O
##er O
##gy O
to O
lid B-DRUG
##oc I-DRUG
##aine I-DRUG
, I-DRUG
he O
did O
not O
receive O
magic B-DRUG
mouth I-DRUG
##wash I-DRUG
and O
was O
started O
on O
su B-DRUG
##c I-DRUG
##ral I-DRUG
##fa I-DRUG
##te I-DRUG
. I-DRUG
he O
will O
f O
/ O
u O
with O
g O
##i O
. O
his O
pp B-DRUG
##i I-DRUG
was O
changed O
to O
ran B-DRUG
##iti I-DRUG
##dine I-DRUG
[ O
* O
* O
12 O
- O
30 O
* O
* O
] O
? O
effect O
on O
his O
acute O
re O
##nal O
failure O
. O
. O

an O
##emia O
: O
he O
has O
a O
base O
##line O
an O
##emia O
due O
to O
c O
##k O
##d O
. O
the O
patient O
reported O
that O
just O
prior O
to O
moving O
his O
care O
to O
[ O
* O
* O
location O
( O
un O
) O
86 O
* O
* O
] O
that O
e O
##po O
shots O
had O
been O
started O
where O
not O
currently O
being O
administered O
. O
two O
days O
after O
e O
##g O
##d O
his O
h O
##ct O
dropped O
from O
32 O
to O
28 O
to O
27 O
. O
his O
h O
##ct O
remained O
stable O
at O
28 O
and O
then O
rose O
again O
. O
he O
was O
g O
##ui O
##ac O
negative O
, O
but O
it O
is O
most O
likely O
that O
he O
had O
some O
mild O
g O
##i O
bleeding O
. O
because O
of O
the O
this O
h O
##ct O
drop O
and O
because O
anti O
##coa O
##gu O
##lants O
are O
given O
during O
cardiac O
cat O
##h O
, O
cardiac O
cat O
##h O
was O
def O
##ered O
until O
his O
h O
##ct O
stab O
##ilized O
. O
p O
##t O
was O
then O
started O
on O
pro B-DRUG
##c I-DRUG
##rit I-DRUG
and O
will O
receive O
weekly B-FRE
injection B-FOR
##s I-FOR
. I-FOR
. O
h B-REA
##t I-REA
##n I-REA
: I-REA
un O
##con O
##tro O
##lled O
while O
hospital O
##ized O
, O
partly O
because O
not O
to O
##ler O
##ating O
all O
of O
his O
p O
##o O
medications O
at O
the O
begin O
##ing O
of O
his O
hospital O
course O
. O
his O
v B-DRUG
##als I-DRUG
##art I-DRUG
##an I-DRUG
and O
b B-DRUG
##b I-DRUG
were O
up O
##ti O
##trate O
##d O
to O
achieve O
better O
control O
but O
v B-DRUG
##als I-DRUG
##art I-DRUG
##an I-DRUG
was O
again O
decreased O
[ O
* O
* O
12 O
- O
30 O
* O
* O
] O
re O
##nal O
failure O
. O
his O
beta B-DRUG
- I-DRUG
block I-DRUG
##er I-DRUG
was O
limited O
by O
bra O
##dy O
##card O
##ia O
in O
the O
i O
##cu O
and O
then O
h O
##r O
60 O
- O
70 O
on O
the O
floor O
. O
c B-DRUG
##lon I-DRUG
##id I-DRUG
##ine I-DRUG
was O
started O
and O
he O
will O
take O
this O
in O
patch B-FOR
form O
. O
. O
acute B-ADE
on I-ADE
chronic I-ADE
re I-ADE
##nal I-ADE
failure I-ADE
: I-ADE
the O
c O
##rea O
##tin O
##ine O
remained O
at O
base O
##line O
2 O
- O
2 O
. O
4 O
throughout O
his O
hospital O
course O
but O
day O
after O
cat O
##he O
##ter O
##ization O
and O
after O
having O
received O
ad O
##qua O
##te O
h O
##yd O
##ration O
, O
sodium B-DRUG
bi I-DRUG
##car I-DRUG
##bon I-DRUG
##ate I-DRUG
and O
m B-DRUG
##uc I-DRUG
##omy I-DRUG
##st I-DRUG
p O
##t O
' O
s O
c O
##rea O
##tin O
##ine O
jumped O
to O
peak O
3 O
. O
3 O
. O
it O
we O
##as O
thought O
to O
be O
secondary O
to O
contrast B-DRUG
##e I-DRUG
dye I-DRUG
versus O
his O
pp B-DRUG
##i I-DRUG
has O
he O
had O
high O
e O
##os O
##ino O
##phi O
##lia O
. O
he O
was O
changed O
back O
to O
ran B-DRUG
##iti I-DRUG
##dine I-DRUG
. I-DRUG
he O
was O
seen O
by O
the O
re O
##nal O
consult O
team O
and O
will O
see O
d O
##r O
. O
[ O
* O
* O
first O
name O
( O
s O
##ti O
##tle O
) O
80 O
##5 O
* O
* O
] O
as O
out O
##patient O
. O

medications O
on O
admission O
: O
as B-DRUG
##pi I-DRUG
##rin I-DRUG
81 B-STR
mg I-STR
daily B-FRE
at B-DRUG
##or I-DRUG
##vas I-DRUG
##tat I-DRUG
##in I-DRUG
10 B-STR
mg I-STR
bed B-FRE
##time I-FRE
v B-DRUG
##als I-DRUG
##art I-DRUG
##an I-DRUG
160 B-STR
mg I-STR
daily B-FRE
met B-DRUG
##op I-DRUG
##rol I-DRUG
##ol I-DRUG
su I-DRUG
##cci I-DRUG
##nate I-DRUG
300 B-STR
mg I-STR
once B-FRE
a I-FRE
day I-FRE
er B-DRUG
##yt I-DRUG
##hr I-DRUG
##omy I-DRUG
##cin I-DRUG
250 B-STR
mg I-STR
q B-FRE
##ida I-FRE
##chs I-FRE
ran B-DRUG
##iti I-DRUG
##dine I-DRUG
h I-DRUG
##c I-DRUG
##l I-DRUG
75 B-STR
mg I-STR
twice B-FRE
a I-FRE
day I-FRE
am B-DRUG
##lo I-DRUG
##di I-DRUG
##pine I-DRUG
10 B-STR
mg I-STR
once B-FRE
a I-FRE
day I-FRE
do B-DRUG
##cus I-DRUG
##ate I-DRUG
sodium I-DRUG
100 B-STR
mg I-STR
[ O
* O
* O
hospital O
##1 O
* O
* O
] O
p B-FRE
##rn I-FRE
se B-DRUG
##nna I-DRUG
[ O
* O
* O
hospital O
##1 O
* O
* O
] O
p B-FRE
##rn I-FRE
on B-DRUG
##dan I-DRUG
##set I-DRUG
##ron I-DRUG
4 B-STR
mg I-STR
q B-FRE
##8 I-FRE
##h I-FRE
p O
##rn O
ch B-DRUG
##roma I-DRUG
##gen I-DRUG
fort I-DRUG
##e I-DRUG
( I-DRUG
w I-DRUG
/ I-DRUG
sum I-DRUG
##ala I-DRUG
##te I-DRUG
) I-DRUG
once B-FRE
a I-FRE
day I-FRE
insulin B-DRUG
n I-DRUG
##ph I-DRUG
10 B-STR
units I-STR
every B-FRE
morning I-FRE
, I-FRE
4 B-DOS
units I-DOS
at B-FRE
bed I-FRE
##time I-FRE
tram B-DRUG
##ado I-DRUG
##l I-DRUG
50 B-STR
mg I-STR
q B-FRE
##6 I-FRE
##h I-FRE
p O
##rn O
h B-DRUG
##ydro I-DRUG
##mor I-DRUG
##phone I-DRUG
2 B-STR
mg I-STR
q B-FRE
##4 I-FRE
##h I-FRE
p O
##rn O
recently O
course O
of O
flag B-DRUG
##yl I-DRUG
for O
c B-REA
. I-REA
di I-REA
##ff I-REA
. I-REA

discharge O
medications O
: O
1 O
. O
as B-DRUG
##pi I-DRUG
##rin I-DRUG
81 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE
2 O
. O
am B-DRUG
##lo I-DRUG
##di I-DRUG
##pine I-DRUG
5 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
two B-DOS
( I-DOS
2 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( O
daily O
) O
. O
[ O
* O
* O
hospital O
##1 O
* O
* O
] O
: O
* O
60 O
tablet O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
2 O
* O
3 O
. O
tram B-DRUG
##ado I-DRUG
##l I-DRUG
50 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
q B-FRE
##6 I-FRE
##h I-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
abdominal B-REA
pain I-REA
. I-REA
4 O
. O
multi B-DRUG
##vi I-DRUG
##tam I-DRUG
##in I-DRUG
, I-DRUG
t I-DRUG
##x I-DRUG
- I-DRUG
minerals I-DRUG
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( O
daily O
) O
. O
5 O
. O
at B-DRUG
##or I-DRUG
##vas I-DRUG
##tat I-DRUG
##in I-DRUG
10 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( O
daily O
) O
. O
6 O
. O
se B-DRUG
##nna I-DRUG
8 B-STR
. I-STR
6 I-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
bid B-FRE
( O
2 O
times O
a O
day O
) O
as O
needed O
for O
con B-REA
##st I-REA
##ip I-REA
##ation I-REA
. I-REA
7 O
. O
do B-DRUG
##cus I-DRUG
##ate I-DRUG
sodium I-DRUG
100 B-STR
mg I-STR
capsule B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
capsule B-FOR
p B-ROU
##o I-ROU
bid B-FRE
( O
2 O
times O
a O
day O
) O
as O
needed O
for O
con B-REA
##st I-REA
##ip I-REA
##ation I-REA
. I-REA
8 O
. O
pro B-DRUG
##c I-DRUG
##rit I-DRUG
10 B-STR
, I-STR
000 I-STR
unit I-STR
/ I-STR
m I-STR
##l I-STR
solution B-FOR
si O
##g O
: O
[ O
* O
* O
n O
##ume O
##ric O
id O
##ent O
##ifier O
96 O
##1 O
* O
* O
] O
( O
[ O
* O
* O
n O
##ume O
##ric O
id O
##ent O
##ifier O
96 O
##1 O
* O
* O
] O
) O
units B-FOR
injection B-ROU
once B-FRE
a I-FRE
week I-FRE
. I-FRE
[ O
* O
* O
n O
##ume O
##ric O
id O
##ent O
##ifier O
* O
* O
] O
: O
* O
30 O
doses O
* O
re O
##fill O
##s O
: O
* O
2 O
* O
9 O
. O
su B-DRUG
##c I-DRUG
##ral I-DRUG
##fa I-DRUG
##te I-DRUG
1 B-STR
gram I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
bid B-FRE
( O
2 O
times O
a O
day O
) O
. O
[ O
* O
* O
n O
##ume O
##ric O
id O
##ent O
##ifier O
* O
* O
] O
: O
* O
60 O
tablet O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
2 O
* O
10 O
. O
ran B-DRUG
##iti I-DRUG
##dine I-DRUG
h I-DRUG
##c I-DRUG
##l I-DRUG
150 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( O
daily O
) O
. O
[ O
* O
* O
n O
##ume O
##ric O
id O
##ent O
##ifier O
* O
* O
] O
: O
* O
30 O
tablet O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
2 O
* O
11 O
. O
v B-DRUG
##als I-DRUG
##art I-DRUG
##an I-DRUG
80 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( O
daily O
) O
. O
[ O
* O
* O
n O
##ume O
##ric O
id O
##ent O
##ifier O
* O
* O
] O
: O
* O
30 O
tablet O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
2 O
* O
12 O
. O
c B-DRUG
##lon I-DRUG
##id I-DRUG
##ine I-DRUG
0 B-STR
. I-STR
3 I-STR
mg I-STR
/ I-STR
24 B-FOR
h I-FOR
##r I-FOR
patch I-FOR
weekly I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
patch B-FOR
weekly B-FOR
trans B-ROU
##der I-ROU
##mal I-ROU
q B-FRE
##f I-FRE
##ri I-FRE
( O
every O
f O
##rida O
##y O
) O
. O

[ O
* O
* O
n O
##ume O
##ric O
id O
##ent O
##ifier O
* O
* O
] O
: O
* O
12 O
patch O
weekly O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
2 O
* O
13 O
. O
c B-DRUG
##lon I-DRUG
##id I-DRUG
##ine I-DRUG
0 B-STR
. I-STR
1 I-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
bid B-FRE
( O
2 O
times O
a O
day O
) O
for B-DUR
3 I-DUR
doses I-DUR
: I-DUR
take O
one B-DOS
tablet B-FOR
twice B-FRE
a I-FRE
day I-FRE
[ O
* O
* O
4 O
- O
28 O
* O
* O
] O
and O
then O
once O
on O
[ O
* O
* O
4 O
- O
29 O
* O
* O
] O
and O
then O
c B-DRUG
##lon I-DRUG
##id I-DRUG
##ine I-DRUG
patch B-FOR
will O
work O
on O
its O
own O
. O
[ O
* O
* O
month O
/ O
day O
( O
4 O
) O
* O
* O
] O
: O
* O
3 O
tablet O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
0 O
* O
14 O
. O
out O
##patient O
lab O
work O
h O
##ct O
and O
ch O
##em O
7 O
and O
please O
f O
##ax O
to O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
* O
* O
] O
attention O
d O
##r O
. O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
* O
* O
] O
15 O
. O
glucose O
meter O
, O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
* O
* O
] O
& O
strips O
kit O
si O
##g O
: O
one O
( O
1 O
) O
kit O
mi O
##s O
##cell O
##aneous O
once O
a O
day O
. O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
* O
* O
] O
: O
* O
1 O
1 O
* O
re O
##fill O
##s O
: O
* O
2 O
* O
16 O
. O
g O
##lu O
##come O
##ter O
test O
strips O
please O
provide O
g O
##lu O
##come O
##ter O
test O
strips O
for O
the O
patient O
with O
6 O
re O
##fill O
##s O
17 O
. O
no B-DRUG
##vo I-DRUG
##lin I-DRUG
70 B-STR
/ I-STR
30 I-STR
inn I-STR
##ole I-STR
##t I-STR
100 I-STR
unit I-STR
/ I-STR
m I-STR
##l I-STR
( O
70 O
- O
30 O
) O
insulin B-FOR
pen I-FOR
si O
##g O
: O
as O
directed O
sub B-ROU
##cut I-ROU
##aneous I-ROU
twice B-FRE
a I-FRE
day I-FRE
: I-FRE
8 I-FRE
units I-FRE
in I-FRE
the I-FRE
am I-FRE
4 I-FRE
units I-FRE
in I-FRE
the I-FRE
pm I-FRE
. I-FRE
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
* O
* O
] O
: O
* O
q O
##s O
q O
##s O
* O
re O
##fill O
##s O
: O
* O
10 O
* O
18 O
. O
top B-DRUG
##rol I-DRUG
x I-DRUG
##l I-DRUG
50 B-STR
mg I-STR
tablet B-FOR
sustained I-FOR
release I-FOR
24 I-FOR
h I-FOR
##r I-FOR
si O
##g O
: O
three B-DOS
( I-DOS
3 I-DOS
) I-DOS
tablet B-FOR
sustained I-FOR
release I-FOR
24 I-FOR
h I-FOR
##r I-FOR
p B-ROU
##o I-ROU
once B-FRE
a I-FRE
day I-FRE
: I-FRE
150 B-STR
##m I-STR
##g I-STR
daily B-FRE
. I-FRE
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
* O
* O
] O
: O
* O
90 O
tablet O
sustained O
release O
24 O
h O
##r O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
2 O
* O
discharge O
disposition O
: O
home O
with O
service O
facility O
: O
[ O
* O
* O
hospital O
119 O
* O
* O
] O
home O
##care O
discharge O
diagnosis O
: O
primary O
diagnosis O
: O
type O
i O
d O
##m O
d O
##ka O
mild O
g O
##i O
bleeding O
due O
to O
gas O
##tri O
##tis O
h O
##yper O
##tens O
##ion O
gas O
##tro O
##par O
##esis O
es O
##op O
##ha O
##git O
##is O
gas O
##tri O
##tis O
card O
##io O
##my O
##op O
##athy O
discharge O
condition O
: O
stable O
; O
improved O
blood O
sugar O
, O
blood O
pressure O
, O
to O
##ler O
##ating O
p O
##os O
. O

discharge O
instructions O
: O
you O
were O
admitted O
to O
the O
hospital O
with O
nausea O
, O
vomit O
##ing O
and O
abdominal O
pain O
which O
was O
thought O
to O
be O
secondary O
to O
your O
gas O
##tro O
##par O
##esis O
, O
es O
##op O
##ha O
##git O
##is O
and O
gas O
##tri O
##tis O
. O
you O
had O
bio O
##ps O
##ies O
taken O
of O
your O
es O
##op O
##ha O
##gus O
and O
stomach O
. O
it O
is O
important O
that O
you O
see O
a O
gas O
##tro O
##enter O
##ologist O
to O
follow O
up O
on O
these O
results O
. O
we O
increased O
your O
doses O
of O
anti O
- O
acid O
medication O
to O
treat O
the O
es O
##op O
##ha O
##git O
##is O
and O
gas O
##tri O
##tis O
. O
we O
gave O
you O
nausea B-DRUG
medication I-DRUG
and O
pain B-DRUG
medication I-DRUG
and O
your O
symptoms O
improved O
but O
did O
not O
completely O
resolve O
. O
you O
should O
eat O
small O
frequent O
meals O
with O
a O
low O
residual O
diet O
. O
it O
will O
take O
some O
time O
for O
your O
nausea O
and O
pain O
to O
go O
away O
as O
the O
gas O
##tri O
##tis O
resolve O
##s O
. O
. O
you O
also O
had O
chest O
pain O
while O
you O
were O
hospital O
##ized O
. O
your O
blood O
work O
and O
e O
##k O
##g O
' O
s O
were O
normal O
but O
because O
you O
have O
risk O
factors O
for O
heart O
disease O
a O
stress O
test O
was O
performed O
. O
it O
showed O
that O
you O
heart O
has O
a O
decreased O
ability O
to O
pump O
. O
cardiac O
cat O
##he O
##ter O
##ization O
was O
negative O
for O
significant O
disease O
. O
. O
you O
had O
acute B-ADE
kidney I-ADE
failure I-ADE
and O
were O
seen O
by O
the O
kidney O
specialists O
. O
this O
was O
thought O
to O
be O
secondary O
to O
medication O
effect O
( O
pan B-DRUG
##top I-DRUG
##raz I-DRUG
##ole I-DRUG
) I-DRUG
and O
possibly O
the O
cardiac B-DRUG
cat I-DRUG
##he I-DRUG
##ter I-DRUG
##ization I-DRUG
dye I-DRUG
. I-DRUG
. O
some O
medication O
changes O
were O
made O
to O
better O
control O
you O
blood O
sugar O
, O
blood O
pressure O
and O
cardiac O
risk O
factors O
. O
you O
should O
stop O
taking O
er B-DRUG
##yt I-DRUG
##hr I-DRUG
##omy I-DRUG
##cin I-DRUG
. I-DRUG
please O
follow O
the O
medications O
as O
directed O
. O
. O
please O
have O
the O
v O
##na O
draw O
a O
lab O
to O
check O
your O
c O
##rea O
##tin O
##ine O
next O
week O
. O
you O
do O
not O
need O
to O
go O
to O
the O
lab O
unless O
the O
v O
##na O
is O
unable O
to O
draw O
them O
. O
. O
please O
make O
all O
appointments O
scheduled O
for O
you O
. O
you O
have O
many O
medical O
appointments O
to O
follow O
but O
if O
you O
do O
not O
keep O
these O
appointments O
you O
will O
likely O
end O
up O
back O
in O
the O
hospital O
. O
your O
health O
is O
very O
important O
and O
is O
a O
full O
time O
job O
and O
we O
will O
help O
you O
coordinate O
your O
care O
. O
. O
please O
return O
to O
the O
er O
for O
inability O
to O
keep O
food O
down O
, O
chest O
pain O
, O
short O
##ness O
of O
breath O
, O
fever O
##s O
, O
chill O
##s O
, O
or O
high O
blood O
sugar O
##s O
. O
if O
you O
have O
blood O
in O
your O
stool O
or O
vomit O
, O
you O
should O
return O
to O
the O
emergency O
room O
. O
follow O
##up O
instructions O
: O
d O
##r O
. O
[ O
* O
* O
first O
name O
( O
s O
##ti O
##tle O
) O
80 O
##5 O
* O
* O
] O
( O
re O
##nal O
) O
. O
( O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
81 O
##7 O
* O
* O
] O
. O
they O
will O
need O
to O
contact O
you O
or O
you O
contact O
them O
. O
[ O
* O
* O
name O
##2 O
( O
ni O
) O
* O
* O
] O
should O
see O
him O
next O
week O
. O
. O

u O
##rol O
##ogy O
: O
[ O
* O
* O
first O
name O
##11 O
( O
name O
pattern O
##1 O
) O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##4 O
) O
46 O
##53 O
* O
* O
] O
, O
m O
##d O
phone O
: O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
27 O
##4 O
* O
* O
] O
date O
/ O
time O
: O
[ O
* O
* O
213 O
##1 O
- O
4 O
- O
30 O
* O
* O
] O
4 O
: O
10 O
. O
* O
provider O
: O
[ O
* O
* O
name O
##10 O
( O
name O
##is O
) O
* O
* O
] O
[ O
* O
* O
name O
##11 O
( O
name O
##is O
) O
248 O
##9 O
* O
* O
] O
, O
[ O
* O
* O
name O
##12 O
( O
name O
##is O
) O
* O
* O
] O
[ O
* O
* O
hospital O
98 O
##2 O
* O
* O
] O
clinic O
( O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
1748 O
##4 O
* O
* O
] O
[ O
* O
* O
213 O
##1 O
- O
5 O
- O
2 O
* O
* O
] O
( O
wed O
##nes O
##day O
) O
at O
11 O
##am O
. O
provider O
: O
[ O
* O
* O
name O
##10 O
( O
name O
##is O
) O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
247 O
##3 O
* O
* O
] O
, O
gas O
##tro O
##enter O
##ology O
( O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
223 O
##3 O
* O
* O
] O
[ O
* O
* O
213 O
##1 O
- O
5 O
- O
1 O
* O
* O
] O
4 O
: O
00 O
##pm O
[ O
* O
* O
hospital O
ward O
name O
51 O
##6 O
* O
* O
] O
, O
[ O
* O
* O
hospital O
unit O
name O
1825 O
* O
* O
] O
. O
primary O
care O
provider O
: O
( O
d O
##r O
. O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
* O
* O
] O
[ O
* O
* O
name O
( O
s O
##ti O
##tle O
) O
77 O
##32 O
##5 O
* O
* O
] O
schedule O
currently O
not O
available O
) O
d O
##r O
. O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
* O
* O
] O
, O
primary O
care O
, O
[ O
* O
* O
hospital O
ward O
name O
* O
* O
] O
, O
[ O
* O
* O
hospital O
ward O
name O
* O
* O
] O
building O
[ O
* O
* O
location O
( O
un O
) O
* O
* O
] O
, O
th O
##urs O
##day O
[ O
* O
* O
5 O
- O
3 O
* O
* O
] O
at O
2 O
: O
30 O
##pm O
( O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
250 O
* O
* O
] O
) O
. O
provider O
: O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##4 O
) O
* O
* O
] O
. O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
* O
* O
] O
, O
card O
##iology O
( O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
74 O
##37 O
* O
* O
] O
[ O
* O
* O
213 O
##1 O
- O
5 O
- O
21 O
* O
* O
] O
8 O
: O
00 O
##am O
[ O
* O
* O
first O
name O
##5 O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
* O
* O
] O
m O
##d O
[ O
* O
* O
m O
##d O
number O
( O
2 O
) O
61 O
##7 O
* O
* O
] O

admission O
date O
: O
[ O
* O
* O
218 O
##6 O
- O
6 O
- O
14 O
* O
* O
] O
discharge O
date O
: O
[ O
* O
* O
218 O
##6 O
- O
6 O
- O
19 O
* O
* O
] O
date O
of O
birth O
: O
[ O
* O
* O
210 O
##9 O
- O
6 O
- O
19 O
* O
* O
] O
sex O
: O
m O
service O
: O
medicine O
all O
##er O
##gies O
: O
patient O
recorded O
as O
having O
no O
known O
all O
##er O
##gies O
to O
drugs O
attending O
: O
[ O
* O
* O
first O
name O
##3 O
( O
l O
##f O
) O
32 O
##7 O
##6 O
* O
* O
] O
chief O
complaint O
: O
short O
##ness O
of O
breath O
major O
surgical O
or O
invasive O
procedure O
: O
none O
history O
of O
present O
illness O
: O
76 O
yo O
m O
w O
/ O
h O
/ O
o O
d O
##m O
, O
h O
##t O
##n O
, O
h O
##yper O
##cho O
##les O
##tero O
##lem O
##ia O
, O
n O
##s O
##c O
##l O
##c O
s O
/ O
p O
re O
##section O
, O
progressive O
on O
multiple O
ch O
##em O
##o O
regime O
##n O
, O
presents O
to O
the O
ed O
with O
3 O
days O
of O
worse O
##ning O
n O
/ O
v O
/ O
d O
, O
found O
to O
be O
f O
##eve O
##bri O
##le O
, O
h O
##y O
##pot O
##ens O
##ive O
, O
h O
##y O
##pox O
##em O
##ic O
. O
on O
[ O
* O
* O
6 O
- O
8 O
* O
* O
] O
c O
##1 O
##w O
##2 O
of O
tax B-DRUG
##oter I-DRUG
##e I-DRUG
( O
3 B-FRE
##w I-FRE
##ks I-FRE
on I-FRE
1 I-FRE
##w I-FRE
##k I-FRE
off I-FRE
) I-FRE
. O
tolerate O
##d O
well O
until O
3 O
days O
ago O
when O
he O
developed O
non O
- O
bloody O
di B-REA
##ar I-REA
##r I-REA
##hea I-REA
after O
he O
went O
out O
to O
eat O
at O
a O
restaurant O
. O
he O
called O
the O
fellow O
on O
call O
and O
was O
given O
im B-DRUG
##od I-DRUG
##ium I-DRUG
which O
he O
[ O
* O
* O
last O
name O
( O
un O
) O
* O
* O
] O
w O
/ O
o O
significant O
relief O
. O
today O
, O
p O
##t O
' O
s O
wife O
called O
to O
inform O
hem O
##e O
/ O
on O
##c O
fellow O
that O
m O
##r O
. O
[ O
* O
* O
known O
last O
##name O
* O
* O
] O
is O
having O
n O
/ O
v O
, O
and O
now O
unable O
to O
keep O
down O
p O
##o O
fluids O
. O
he O
also O
c O
/ O
o O
chill O
##s O
. O
p O
##t O
was O
referred O
to O
ed O
for O
further O
evaluation O
. O
he O
reports O
4 O
episodes O
of O
non O
- O
bi O
##lio O
##us O
non O
- O
bloody O
vomit O
##ing O
today O
. O
he O
denies O
abdominal O
pain O
. O
+ O
chill O
##s O
. O

in O
the O
ed O
, O
initial O
vs O
t O
102 O
. O
1 O
, O
h O
##r O
102 O
; O
b O
##p O
133 O
/ O
52 O
; O
r O
##r O
20 O
; O
93 O
% O
r O
##a O
. O
he O
then O
became O
h O
##y O
##pox O
##ic O
to O
88 O
% O
( O
base O
##line O
92 O
% O
) O
and O
h O
##y O
##pot O
##ens O
##ive O
with O
s O
##ys O
##to O
##lic O
b O
##p O
in O
upper O
80 O
' O
s O
/ O
low O
90 O
' O
s O
, O
blood O
gas O
concerning O
with O
7 O
. O
37 O
/ O
34 O
/ O
63 O
. O
la O
##ct O
##ate O
1 O
. O
2 O
. O
labs O
remarkable O
for O
k O
5 O
. O
6 O
, O
p O
##t O
was O
given O
ka O
##ye O
##xa O
##late O
. O
w O
##b O
##c O
3 O
. O
9 O
( O
46 O
% O
ne O
##ut O
##rop O
##hil O
##s O
) O
, O
h O
##ct O
35 O
. O
6 O
( O
down O
from O
40 O
. O
2 O
in O
[ O
* O
* O
4 O
- O
1 O
* O
* O
] O
) O
. O
u O
/ O
a O
negative O
, O
b O
##c O
##x O
and O
u O
##c O
##x O
sent O
. O
c O
##x O
##r O
with O
interval O
progression O
of O
n O
##s O
##c O
##l O
##c O
in O
the O
right O
upper O
and O
left O
lower O
lobes O
with O
larger O
more O
dense O
masses O
. O
otherwise O
, O
relatively O
stable O
. O
the O
patient O
was O
given O
c B-DRUG
##ef I-DRUG
##ep I-DRUG
##ime I-DRUG
2 B-STR
g I-STR
##m I-STR
i B-ROU
##v I-ROU
once B-FRE
, I-FRE
z B-DRUG
##of I-DRUG
##ran I-DRUG
, I-DRUG
t B-DRUG
##yle I-DRUG
##no I-DRUG
##l I-DRUG
, I-DRUG
ka B-DRUG
##ye I-DRUG
##xa I-DRUG
##late I-DRUG
, I-DRUG
and O
given O
total O
of O
5 B-DOS
##l B-FOR
n B-DRUG
##s I-DRUG
. I-DRUG
. O
the O
patient O
currently O
is O
as O
##ym O
##pt O
##oma O
##tic O
. O
denies O
any O
trouble O
breathing O
. O
denies O
l O
##h O
or O
di O
##zzi O
##ness O
. O
reports O
normal O
urine O
output O
at O
home O
. O
past O
medical O
history O
: O
- O
n B-REA
##s I-REA
##c I-REA
##l I-REA
##c I-REA
: I-REA
s O
/ O
p O
right O
upper O
and O
middle O
lobe O
##ct O
##omy O
( O
[ O
* O
* O
11 O
- O
27 O
* O
* O
] O
) O
and O
wedge O
re O
##section O
of O
the O
left O
lower O
lobe O
( O
[ O
* O
* O
3 O
- O
30 O
* O
* O
] O
) O
lung O
nod O
##ule O
, O
re O
##current O
[ O
* O
* O
2 O
- O
27 O
* O
* O
] O
, O
s O
/ O
p O
protocol O
with O
nave B-DRUG
##l I-DRUG
##bine I-DRUG
and O
c B-DRUG
##et I-DRUG
##ux I-DRUG
##ima I-DRUG
##b I-DRUG
, I-DRUG
started O
[ O
* O
* O
5 O
- O
30 O
* O
* O
] O
, O
completed O
6 B-DUR
cycles I-DUR
by O
[ O
* O
* O
10 O
- O
30 O
* O
* O
] O
. O
given O
d O
##z O
progression O
started O
on O
ta B-DRUG
##rc I-DRUG
##eva I-DRUG
d O
/ O
c O
' O
d O
in O
[ O
* O
* O
12 O
- O
31 O
* O
* O
] O
due O
to O
further O
d O
##z O
progression O
. O
subsequently O
had O
2 B-DUR
cycles I-DUR
al B-DRUG
##im I-DRUG
##ta I-DRUG
, I-DRUG
o B-DRUG
##xa I-DRUG
##lip I-DRUG
##lat I-DRUG
##in I-DRUG
, I-DRUG
and O
a B-DRUG
##vas I-DRUG
##tin I-DRUG
but O
again O
had O
d O
##z O
progression O
on O
imaging O
. O
e O
##co O
##g O
protocol O
250 O
##1 O
with O
so B-DRUG
##ra I-DRUG
##fen I-DRUG
##ib I-DRUG
started O
03 O
/ O
[ O
* O
* O
218 O
##4 O
* O
* O
] O
. O
- O
diabetes O
me O
##lli O
##tus O
type O
2 O
- O
h O
##yper O
##tens O
##ion O
- O
h O
##yper O
##lip O
##ide O
##mia O

social O
history O
: O
he O
is O
a O
retired O
automotive O
mechanic O
and O
has O
taught O
most O
recently O
automotive O
repair O
. O
he O
is O
married O
with O
one O
child O
. O
he O
is O
a O
50 O
- O
pack O
- O
year O
smoke O
##r O
but O
quit O
approximately O
35 O
years O
ago O
. O
he O
uses O
alcohol O
on O
an O
irregular O
basis O
but O
has O
never O
drunken O
to O
excess O
. O
family O
history O
: O
un O
##rem O
##ark O
##able O
for O
ma O
##li O
##gna O
##ncy O
but O
he O
has O
a O
significant O
history O
of O
c O
##ere O
##bro O
##vas O
##cular O
and O
co O
##rona O
##ry O
artery O
disease O
among O
his O
relatives O
. O
physical O
exam O
: O
vs O
: O
t O
97 O
. O
2 O
; O
b O
##p O
109 O
/ O
52 O
; O
h O
##r O
89 O
; O
r O
##r O
20 O
: O
sat O
89 O
- O
91 O
% O
on O
4 O
##l O
n O
##c O
g O
##en O
- O
alert O
, O
no O
acute O
distress O
, O
breathing O
comfortably O
he O
##ent O
- O
per O
##rl O
, O
extra O
##oc O
##ular O
motions O
intact O
, O
an O
##ict O
##eric O
, O
m O
##uc O
##ous O
membrane O
##s O
slightly O
dry O
, O
no O
lesions O
neck O
- O
no O
j O
##v O
##d O
, O
no O
c O
##er O
##vic O
##al O
l O
##ymph O
##ade O
##no O
##pathy O
chest O
- O
coarse O
b O
##s O
bilateral O
##ly O
, O
r O
##hon O
##chi O
, O
decreased O
b O
##s O
ll O
##b O
, O
+ O
ex O
##pi O
##rator O
##y O
w O
##hee O
##zes O
c O
##v O
- O
regular O
, O
n O
##l O
s O
##1 O
/ O
s O
##2 O
, O
no O
murmurs O
, O
rub O
##s O
, O
or O
gal O
##lops O
a O
##b O
##d O
- O
soft O
, O
o O
##bes O
##e O
, O
non O
##tend O
##er O
, O
non O
##dis O
##tended O
, O
with O
norm O
##oa O
##ctive O
bow O
##el O
sounds O
back O
- O
no O
cost O
##over O
##te O
##bra O
##l O
angle O
tender O
##nes O
ex O
##tr O
- O
no O
club O
##bing O
, O
c O
##yan O
##osis O
, O
or O
ed O
##ema O
. O
2 O
+ O
d O
##p O
pulses O
bilateral O
##ly O
ne O
##uro O
- O
alert O
and O
oriented O
x O
3 O
, O
c O
##rani O
##al O
nerves O
[ O
* O
* O
2 O
- O
6 O
* O
* O
] O
intact O
, O
upper O
and O
lower O
ex O
##tre O
##mity O
strength O
5 O
/ O
5 O
bilateral O
##ly O
, O
sensation O
gross O
##ly O
intact O
skin O
- O
no O
r O
##ash O
re O
##ct O
##al O
- O
brown O
; O
strongly O
g O
##ua O
##iac O
positive O
per O
##tinent O
results O
: O
[ O
* O
* O
218 O
##6 O
- O
6 O
- O
14 O
* O
* O
] O
. O
c O
##ta O
. O
impression O
: O
no O
filling O
defect O
is O
identified O
within O
the O
pulmonary O
art O
##eries O
to O
suggest O
pulmonary O
em O
##bol O
##us O
. O
again O
seen O
are O
multi O
##fo O
##cal O
consolidation O
##s O
throughout O
bilateral O
lungs O
, O
corresponding O
to O
known O
br O
##on O
##chi O
##oa O
##lve O
##olar O
cell O
car O
##cin O
##oma O
. O
compared O
to O
the O
prior O
c O
##t O
from O
[ O
* O
* O
218 O
##6 O
- O
5 O
- O
15 O
* O
* O
] O
, O
there O
is O
dramatic O
increase O
in O
the O
extent O
and O
the O
density O
of O
the O
consolidation O
which O
is O
concerning O
for O
significant O
short O
- O
term O
disease O
progression O
versus O
super O
##im O
##posed O
infection O
. O

brief O
hospital O
course O
: O
in O
summary O
, O
m O
##r O
. O
[ O
* O
* O
known O
last O
##name O
* O
* O
] O
is O
a O
76 O
year O
old O
male O
with O
n O
##s O
##c O
##l O
##c O
who O
was O
admitted O
for O
post O
- O
o O
##bs O
##truct O
##ive O
pneumonia O
and O
de O
##hy O
##dra O
##tion O
secondary O
to O
di O
##ar O
##r O
##hea O
from O
ch O
##em O
##otherapy O
. O
. O
post O
o O
##bs O
##truct O
##ive O
p O
##na O
. O
m O
##r O
. O
[ O
* O
* O
known O
last O
##name O
* O
* O
] O
was O
initially O
treated O
in O
the O
mi O
##cu O
, O
but O
was O
then O
transferred O
to O
o O
##med O
. O
he O
was O
treated O
for O
pneumonia B-REA
with O
un B-DRUG
##as I-DRUG
##yn I-DRUG
in O
the O
hospital O
and O
was O
sent O
home O
on O
au B-DRUG
##gment I-DRUG
##in I-DRUG
. I-DRUG
he O
was O
requiring O
5 B-DOS
##l B-FOR
n B-ROU
##c I-ROU
of O
oxygen B-DRUG
during O
the O
hospital O
##ization O
, O
which O
was O
thought O
to O
be O
due O
to O
lung O
cancer O
, O
pneumonia O
and O
pulmonary O
ed O
##ema O
after O
get O
##ing O
5 B-DOS
##l B-FOR
of O
fluid B-DRUG
in O
the O
mi O
##cu O
. O
his O
oxygen O
re O
##qui O
##rm O
##ents O
improved O
with O
las B-DRUG
##ix I-DRUG
. I-DRUG
by O
discharge O
, O
he O
was O
requiring O
only O
2 B-DOS
##ln B-ROU
##c O
of O
oxygen B-DRUG
. I-DRUG
. O
di O
##ar O
##r O
##hea O
. O
he O
was O
initially O
admitted O
with O
di O
##ar O
##r O
##hea O
, O
thought O
to O
be O
due O
to O
ch B-DRUG
##em I-DRUG
##otherapy I-DRUG
. I-DRUG
he O
was O
treated O
with O
i B-DRUG
##v I-DRUG
##f I-DRUG
in O
the O
mi O
##cu O
. O
his O
di O
##ar O
##r O
##hea O
resolved O
without O
intervention O
. O
. O
in O
addition O
, O
he O
was O
treated O
with O
is B-DRUG
##s I-DRUG
for O
type B-REA
ii I-REA
d I-REA
##m I-REA
, I-REA
h B-DRUG
##ct I-DRUG
##z I-DRUG
, I-DRUG
ve B-DRUG
##rp I-DRUG
##ami I-DRUG
##l I-DRUG
and O
l B-DRUG
##isi I-DRUG
##no I-DRUG
##p I-DRUG
##ril I-DRUG
for O
h B-REA
##t I-REA
##n I-REA
( O
one O
h O
##y O
##pot O
##ens O
##ion O
from O
di O
##ar O
##r O
##hea O
resolved O
) O
, O
and O
lo B-DRUG
##vas I-DRUG
##tat I-DRUG
##in I-DRUG
for O
h B-REA
##yper I-REA
##lip I-REA
##ide I-REA
##mia I-REA
. I-REA

medications O
on O
admission O
: O
g B-DRUG
##lu I-DRUG
##co I-DRUG
##pha I-DRUG
##ge I-DRUG
1000 B-STR
mg I-STR
p B-ROU
##o I-ROU
bid B-FRE
start O
[ O
* O
* O
217 O
##9 O
* O
* O
] O
g B-DRUG
##lip I-DRUG
##iz I-DRUG
##ide I-DRUG
10 B-STR
mg I-STR
p B-ROU
##o I-ROU
bid B-FRE
start O
[ O
* O
* O
217 O
##9 O
* O
* O
] O
act B-DRUG
##os I-DRUG
30 B-STR
##m I-STR
##g I-STR
p B-ROU
##o I-ROU
daily B-FRE
( I-FRE
changed O
by O
his O
p O
##c O
##p O
in O
[ O
* O
* O
month O
( O
only O
) O
* O
* O
] O
from O
15 O
##m O
##g O
) O
ve B-DRUG
##rap I-DRUG
##ami I-DRUG
##l I-DRUG
s I-DRUG
##r I-DRUG
240 B-STR
##m I-STR
##g I-STR
p B-ROU
##o I-ROU
daily B-FRE
start O
[ O
* O
* O
217 O
##3 O
* O
* O
] O
l B-DRUG
##isi I-DRUG
##no I-DRUG
##p I-DRUG
##ril I-DRUG
40 B-STR
mg I-STR
p B-ROU
##o I-ROU
daily B-FRE
lo B-DRUG
##vas I-DRUG
##tin I-DRUG
10 B-STR
##m I-STR
##g I-STR
p B-ROU
##o I-ROU
daily B-FRE
start O
[ O
* O
* O
218 O
##2 O
* O
* O
] O
p B-DRUG
##ril I-DRUG
##ose I-DRUG
##c I-DRUG
20 B-STR
##m I-STR
##g I-STR
p B-ROU
##o I-ROU
daily B-FRE
vitamin B-DRUG
c I-DRUG
100 B-STR
##u I-STR
p B-ROU
##o I-ROU
daily B-FRE
start O
[ O
* O
* O
217 O
##3 O
* O
* O
] O
multi B-DRUG
##vi I-DRUG
##tam I-DRUG
##in I-DRUG
p B-ROU
##o I-ROU
daily B-FRE
start O
[ O
* O
* O
217 O
##3 O
* O
* O
] O
h B-DRUG
##ydro I-DRUG
##ch I-DRUG
##lor I-DRUG
##oth I-DRUG
##ia I-DRUG
##zi I-DRUG
##de I-DRUG
25 B-STR
##m I-STR
##g I-STR
p B-ROU
##o I-ROU
daily B-FRE
re B-DRUG
##g I-DRUG
##lan I-DRUG
for O
nausea B-REA
p O
##rn O
d O
/ O
c O
' O
ed O
[ O
* O
* O
218 O
##6 O
- O
2 O
- O
22 O
* O
* O
] O
im B-DRUG
##mo I-DRUG
##dium I-DRUG
1 B-DOS
- I-DOS
2 I-DOS
ta B-FOR
##bs I-FOR
p B-ROU
##o I-ROU
, I-ROU
p O
##rn O
for O
di B-REA
##ar I-REA
##r I-REA
##hea I-REA
ended O
[ O
* O
* O
218 O
##6 O
- O
3 O
- O
27 O
* O
* O
] O
gas B-DRUG
- I-DRUG
x I-DRUG
40 B-STR
mg I-STR
p B-ROU
##o I-ROU
every B-FRE
6 I-FRE
hours I-FRE
, I-FRE
p O
##rn O
start O
[ O
* O
* O
218 O
##6 O
- O
2 O
- O
22 O
* O
* O
] O
ended O
[ O
* O
* O
218 O
##6 O
- O
3 O
- O
27 O
* O
* O
] O
im B-DRUG
##mo I-DRUG
##dium I-DRUG
with I-DRUG
gas I-DRUG
- I-DRUG
x I-DRUG
1 B-DOS
- I-DOS
2 I-DOS
ta B-FOR
##bs I-FOR
p B-ROU
##o I-ROU
q B-FRE
##id I-FRE
, I-FRE
p O
##rn O
start O
[ O
* O
* O
218 O
##6 O
- O
3 O
- O
28 O
* O
* O
] O
nap B-DRUG
##ro I-DRUG
##xen I-DRUG
1 B-DOS
- I-DOS
2 I-DOS
ta B-FOR
##bs I-FOR
p B-ROU
##o I-ROU
q B-FRE
##id I-FRE
, I-FRE
p O
##rn O
discharge O
medications O
: O
1 O
. O
he B-DRUG
##xa I-DRUG
##vi I-DRUG
##tam I-DRUG
##in I-DRUG
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
cap B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( O
daily O
) O
. O
2 O
. O
h B-DRUG
##ydro I-DRUG
##ch I-DRUG
##lor I-DRUG
##oth I-DRUG
##ia I-DRUG
##zi I-DRUG
##de I-DRUG
25 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( O
daily O
) O
. O
3 O
. O
ve B-DRUG
##rap I-DRUG
##ami I-DRUG
##l I-DRUG
240 B-STR
mg I-STR
tablet B-FOR
sustained I-FOR
release I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
sustained I-FOR
release I-FOR
p B-ROU
##o I-ROU
q B-FRE
##24 I-FRE
##h I-FRE
( O
every O
24 O
hours O
) O
. O
4 O
. O
l B-DRUG
##isi I-DRUG
##no I-DRUG
##p I-DRUG
##ril I-DRUG
10 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( O
daily O
) O
. O

5 O
. O
g B-DRUG
##lip I-DRUG
##iz I-DRUG
##ide I-DRUG
5 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
two B-DOS
( I-DOS
2 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
bid B-FRE
( O
2 O
times O
a O
day O
) O
. O
6 O
. O
met B-DRUG
##form I-DRUG
##in I-DRUG
500 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
two B-DOS
( I-DOS
2 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
bid B-FRE
( O
2 O
times O
a O
day O
) O
. O
7 O
. O
au B-DRUG
##gment I-DRUG
##in I-DRUG
x I-DRUG
##r I-DRUG
1 B-STR
, I-STR
000 I-STR
- I-STR
62 I-STR
. I-STR
5 I-STR
mg I-STR
tablet B-FOR
sustained I-FOR
release I-FOR
12 I-FOR
h I-FOR
##r I-FOR
si O
##g O
: O
two B-DOS
( I-DOS
2 I-DOS
) I-DOS
tablet B-FOR
sustained I-FOR
release I-FOR
12 I-FOR
h I-FOR
##r I-FOR
p B-ROU
##o I-ROU
twice B-FRE
a I-FRE
day I-FRE
for B-DUR
4 I-DUR
days I-DUR
. I-DUR
di O
##sp O
: O
* O
16 O
tablet O
sustained O
release O
12 O
h O
##r O
( O
s O
) O
* O
re O
##fill O
##s O
: O
* O
0 O
* O
8 O
. O
oxygen B-DRUG
home O
oxygen B-DRUG
at O
2 B-DOS
l O
##pm O
continuous O
via O
nasal B-ROU
can I-ROU
##nu I-ROU
##la I-ROU
con O
##ser O
##ving O
device O
for O
port O
##ability O
. O
9 O
. O
ne O
##bul O
##izer O
home O
ne O
##bul O
##izer O
and O
supplies O
. O
10 O
. O
al B-DRUG
##but I-DRUG
##ero I-DRUG
##l I-DRUG
- I-DRUG
i I-DRUG
##pra I-DRUG
##tro I-DRUG
##pi I-DRUG
##um I-DRUG
2 B-STR
. I-STR
5 I-STR
- I-STR
0 I-STR
. I-STR
5 I-STR
mg I-STR
/ I-STR
3 I-STR
m I-STR
##l I-STR
solution B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
in B-ROU
##hala I-ROU
##tion I-ROU
every B-FRE
6 I-FRE
- I-FRE
8 I-FRE
hours I-FRE
as I-FRE
needed I-FRE
for O
short B-REA
##ness I-REA
of I-REA
breath I-REA
or O
w B-REA
##hee I-REA
##zing I-REA
. I-REA
di O
##sp O
: O
* O
60 O
treatments O
* O
re O
##fill O
##s O
: O
* O
0 O
* O
11 O
. O
lo B-DRUG
##vas I-DRUG
##tat I-DRUG
##in I-DRUG
10 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE
12 O
. O
p B-DRUG
##ril I-DRUG
##ose I-DRUG
##c I-DRUG
20 B-STR
mg I-STR
capsule B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
capsule B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
p B-ROU
##o I-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE
discharge O
disposition O
: O
home O
with O
service O
facility O
: O
[ O
* O
* O
location O
( O
un O
) O
65 O
##4 O
##9 O
* O
* O
] O
discharge O
diagnosis O
: O
primary O
: O
- O
non O
small O
cell O
lung O
cancer O
- O
post O
- O
o O
##bs O
##truct O
##ive O
pneumonia O
- O
se O
##psis O
secondary O
: O
- O
diabetes O
me O
##lli O
##tus O
type O
2 O
- O
h O
##yper O
##tens O
##ion O
- O
h O
##yper O
##lip O
##ide O
##mia O
discharge O
condition O
: O
stable O
, O
requiring O
oxygen B-DRUG
by O
nasal B-ROU
can I-ROU
##ula I-ROU
at O
2 B-DOS
liter B-FOR
##s I-FOR
per O
minute O
, O
am O
##bula O
##ting O
discharge O
instructions O
: O
you O
were O
treated O
for O
a O
pneumonia B-REA
. I-REA
please O
continue O
your O
anti B-DRUG
##biotics I-DRUG
, I-DRUG
au B-DRUG
##gment I-DRUG
##in I-DRUG
for B-DUR
four I-DUR
days I-DUR
. I-DUR
please O
measure O
fingers O
##tick O
##s O
twice O
daily O
, O
and O
call O
your O
doctor O
if O
it O
is O
greater O
than O
400 O
. O
you O
should O
contact O
your O
primary O
care O
physician O
about O
restart O
##ing O
your O
act B-DRUG
##os I-DRUG
once O
your O
ed O
##ema O
is O
resolved O
. O
. O
please O
return O
to O
the O
hospital O
or O
see O
your O
primary O
care O
physician O
if O
you O
have O
any O
short O
##ness O
of O
breath O
, O
fever O
##s O
, O
chill O
##s O
or O
any O
other O
concerns O
. O

follow O
##up O
instructions O
: O
[ O
* O
* O
first O
name O
##8 O
( O
name O
##pa O
##tter O
##n O
##2 O
) O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
* O
* O
] O
from O
d O
##r O
. O
[ O
* O
* O
name O
( O
ni O
) O
32 O
##7 O
##9 O
* O
* O
] O
office O
will O
call O
you O
about O
the O
timing O
of O
the O
appointment O
on O
th O
##urs O
##day O
. O
. O
please O
also O
not O
##ify O
your O
primary O
care O
physician O
about O
your O
admission O
to O
the O
hospital O
. O
you O
should O
contact O
your O
primary O
care O
physician O
about O
restart O
##ing O
your O
act B-DRUG
##os I-DRUG
once O
your O
ed O
##ema O
is O
resolved O
. O
[ O
* O
* O
first O
name O
##8 O
( O
name O
##pa O
##tter O
##n O
##2 O
) O
251 O
* O
* O
] O
[ O
* O
* O
name O
##8 O
( O
m O
##d O
) O
* O
* O
] O
m O
##d O
[ O
* O
* O
m O
##d O
number O
( O
1 O
) O
32 O
##8 O
##2 O
* O
* O
] O

name O
: O
[ O
* O
* O
known O
last O
##name O
161 O
##32 O
* O
* O
] O
, O
[ O
* O
* O
known O
first O
##name O
133 O
* O
* O
] O
unit O
no O
: O
[ O
* O
* O
n O
##ume O
##ric O
id O
##ent O
##ifier O
161 O
##33 O
* O
* O
] O
admission O
date O
: O
[ O
* O
* O
218 O
##1 O
- O
6 O
- O
7 O
* O
* O
] O
discharge O
date O
: O
[ O
* O
* O
218 O
##1 O
- O
6 O
- O
19 O
* O
* O
] O
date O
of O
birth O
: O
[ O
* O
* O
210 O
##2 O
- O
11 O
- O
4 O
* O
* O
] O
sex O
: O
m O
service O
: O
medicine O
all O
##er O
##gies O
: O
ace B-DRUG
inhibitor I-DRUG
##s I-DRUG
attending O
: O
[ O
* O
* O
first O
name O
##3 O
( O
l O
##f O
) O
161 O
* O
* O
] O
add O
##end O
##um O
: O
78 O
year O
old O
man O
with O
h O
/ O
o O
stroke O
admitted O
for O
weakness O
, O
course O
complicated O
by O
an O
##gio O
##ede O
##ma O
s O
/ O
p O
in O
##tub O
##ation O
. O
. O
# O
fever O
+ O
le O
##uk O
##oc O
##yt O
##osis O
: O
patient O
de O
##vo O
##lop O
##ed O
low O
grade O
fever O
( O
100 O
. O
4 O
) O
the O
day O
before O
discharge O
. O
he O
has O
no O
local O
##izing O
symptoms O
. O
u O
##a O
and O
c O
##x O
##r O
is O
negative O
. O
blood O
cultures O
are O
pending O
. O
however O
he O
has O
been O
having O
di O
##ar O
##r O
##hea O
during O
this O
time O
. O
stool O
cultures O
and O
c O
##di O
##ff O
panel O
were O
sent O
. O
he O
has O
been O
a O
##fe O
##bri O
##le O
overnight O
and O
this O
morning O
and O
afternoon O
. O
please O
follow O
up O
on O
stool O
and O
c O
##di O
##ff O
cultures O
. O
c O
##di O
##ff O
has O
only O
been O
sent O
once O
so O
it O
will O
have O
to O
be O
sent O
twice O
more O
to O
rule O
out O
infection O
. O
. O
# O
an O
##emia O
: O
norm O
##oc O
##ytic O
an O
##emia O
. O
b O
##12 O
and O
f O
##olate O
normal O
. O
ha O
##pt O
##og O
##lo O
##bin O
likely O
an O
##emia O
of O
chronic O
disease O
: O
iron O
: O
49 O
, O
ca O
##lt O
##ib O
##c O
: O
211 O
, O
f O
##er O
##rit O
##n O
: O
116 O
##9 O
, O
t O
##rf O
: O
162 O
. O
# O
insulin B-REA
resistance I-REA
: I-REA
his O
blood O
sugar O
##s O
has O
been O
elevated O
: O
fingers O
##tick O
##s O
115 O
- O
170 O
. O
he O
should O
follow O
up O
as O
an O
out O
##patient O
. O
he O
may O
benefit O
from O
met B-DRUG
##form I-DRUG
##in I-DRUG
. I-DRUG
. O
# O
as O
##piration O
: O
per O
speech O
and O
swallow O
e O
##val O
by O
video O
: O
he O
continues O
to O
as O
##pi O
##rate O
thin O
liquid O
##s O
which O
may O
be O
his O
base O
##line O
from O
his O
history O
of O
strokes O
. O
he O
is O
currently O
on O
a O
pure O
##ed O
, O
ne O
##ct O
##ar O
pre O
##thi O
##cke O
##ned O
liquid O
##s O
diet O
. O
he O
may O
resume O
a O
thin O
liquid O
diet O
on O
discharge O
if O
he O
chooses O
to O
known O
##ing O
that O
he O
will O
as O
##pi O
##rate O
small O
amounts O
. O
of O
note O
, O
speech O
and O
swallow O
recommend O
##s O
that O
all O
his O
me O
##ds O
be O
crushed O
and O
given O
in O
apple O
sauce O
. O
however O
, O
m O
##r O
. O
[ O
* O
* O
known O
last O
##name O
* O
* O
] O
does O
not O
like O
to O
have O
his O
medications O
crushed O
. O
he O
understands O
that O
he O
has O
risks O
of O
as O
##piration O
that O
might O
result O
in O
pneumonia O
and O
other O
complications O
. O
he O
should O
have O
another O
swallow O
video O
done O
in O
two O
weeks O
. O

discharge O
disposition O
: O
extended O
care O
facility O
: O
[ O
* O
* O
doctor O
last O
name O
321 O
* O
* O
] O
nursing O
& O
rehabilitation O
center O
- O
[ O
* O
* O
location O
( O
un O
) O
322 O
* O
* O
] O
[ O
* O
* O
first O
name O
##11 O
( O
name O
pattern O
##1 O
) O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##4 O
) O
165 O
* O
* O
] O
m O
##d O
[ O
* O
* O
m O
##d O
number O
( O
1 O
) O
166 O
* O
* O
] O
completed O
by O
: O
[ O
* O
* O
218 O
##1 O
- O
6 O
- O
19 O
* O
* O
] O

admission O
date O
: O
[ O
* O
* O
214 O
##0 O
- O
3 O
- O
24 O
* O
* O
] O
discharge O
date O
: O
[ O
* O
* O
214 O
##0 O
- O
4 O
- O
4 O
* O
* O
] O
date O
of O
birth O
: O
[ O
* O
* O
205 O
##6 O
- O
8 O
- O
22 O
* O
* O
] O
sex O
: O
f O
service O
: O
surgery O
all O
##er O
##gies O
: O
dem B-DRUG
##ero I-DRUG
##l I-DRUG
/ O
drop B-DRUG
##eri I-DRUG
##do I-DRUG
##l I-DRUG
/ O
pen B-DRUG
##ici I-DRUG
##lla I-DRUG
##mine I-DRUG
/ O
s B-DRUG
##tre I-DRUG
##pt I-DRUG
##omy I-DRUG
##cin I-DRUG
/ O
am B-DRUG
##pic I-DRUG
##ill I-DRUG
##in I-DRUG
attending O
: O
[ O
* O
* O
first O
name O
##3 O
( O
l O
##f O
) O
1 O
* O
* O
] O
chief O
complaint O
: O
abdominal O
pain O
major O
surgical O
or O
invasive O
procedure O
: O
ex O
##p O
##lora O
##tory O
lap O
##aro O
##tom O
##y O
, O
extensive O
l O
##ys O
##is O
of O
ad O
##hesion O
##s O
, O
small O
bow O
##el O
re O
##section O
with O
re O
##ana O
##sto O
##mos O
##is O
, O
repair O
re O
##current O
ventral O
her O
##nia O
. O
history O
of O
present O
illness O
: O
m O
##rs O
. O
[ O
* O
* O
known O
last O
##name O
104 O
##29 O
##9 O
* O
* O
] O
is O
an O
83 O
##yo O
female O
with O
[ O
* O
* O
hospital O
102 O
##24 O
* O
* O
] O
medical O
and O
surgical O
problems O
. O
she O
has O
a O
known O
h O
/ O
o O
re O
##current O
ventral O
her O
##nia O
. O
she O
presented O
to O
[ O
* O
* O
hospital O
##1 O
18 O
* O
* O
] O
ed O
with O
complaints O
of O
abdominal O
pain O
, O
n O
/ O
v O
x O
3 O
hours O
. O
she O
reported O
the O
pain O
to O
be O
similar O
to O
the O
prior O
pain O
that O
she O
had O
with O
previous O
small O
bow O
##el O
o O
##bs O
##truction O
##s O
. O
she O
last O
reports O
passing O
flat O
##us O
the O
night O
before O
presentation O
to O
the O
ed O
, O
but O
no O
flat O
##us O
since O
. O
she O
was O
admitted O
to O
the O
surgery O
service O
for O
further O
evaluation O
. O
. O
during O
work O
- O
up O
in O
ed O
, O
the O
patient O
was O
found O
to O
have O
a O
prolonged B-REA
q I-REA
##t I-REA
interval I-REA
near O
600 O
. O
of O
note O
, O
patient O
had O
dose O
of O
fl B-DRUG
##eca I-DRUG
##ni I-DRUG
##de I-DRUG
recently O
increased O
. O
she O
was O
also O
h O
##y O
##po O
##kal O
##em O
##ic O
, O
k O
##c O
##l O
down O
to O
2 O
. O
9 O
on O
presentation O

past O
medical O
history O
: O
h O
##yper O
##lip O
##ide O
##mia O
: O
[ O
* O
* O
8 O
- O
/ O
213 O
##9 O
* O
* O
] O
l O
##dl O
114 O
h O
##dl O
73 O
ch O
##ol O
209 O
t O
##g O
108 O
h O
##yper O
##tens O
##ion O
, O
lab O
##ile O
blood O
pressure O
di O
##ast O
##olic O
left O
vent O
##ric O
##ular O
d O
##ys O
##function O
with O
e O
##f O
> O
55 O
% O
re O
##nal O
ins O
##uff O
##iciency O
: O
e O
##g O
##f O
##r O
50 O
stage O
3 O
##a O
( O
most O
likely O
[ O
* O
* O
1 O
- O
25 O
* O
* O
] O
h O
##t O
##n O
) O
chronic O
chest O
pain O
, O
clean O
co O
##rona O
##ry O
art O
##eries O
by O
[ O
* O
* O
212 O
##7 O
* O
* O
] O
cat O
##he O
##ter O
##ization O
par O
##ox O
##ys O
##mal O
a O
##fi O
##b O
es O
##op O
##hage O
##al O
spa O
##sm O
go O
##ut O
gas O
##tro O
##es O
##op O
##hage O
##al O
re O
##f O
##lux O
disease O
status O
ta O
##h O
- O
b O
##so O
in O
[ O
* O
* O
212 O
##1 O
* O
* O
] O
for O
men O
##or O
##r O
##ha O
##gia O
. O
chronic B-REA
v I-REA
##agi I-REA
##nal I-REA
it I-REA
##ching I-REA
, I-REA
now O
on O
pre B-DRUG
##mar I-DRUG
##in I-DRUG
cream B-FOR
. I-FOR
small O
bow O
##el O
o O
##bs O
##truction O
in O
[ O
* O
* O
212 O
##3 O
* O
* O
] O
, O
[ O
* O
* O
212 O
##6 O
* O
* O
] O
and O
[ O
* O
* O
213 O
##8 O
* O
* O
] O
s O
/ O
p O
ad O
##hesion O
l O
##ys O
##is O
in O
[ O
* O
* O
9 O
- O
/ O
213 O
##9 O
* O
* O
] O
mi O
##gra O
##ine O
headache O
##s O
h O
/ O
o O
h O
##yster O
##ec O
##tom O
##y O
( O
abdominal O
) O
h O
/ O
o O
abdominal O
her O
##nia O
with O
repair O
gal O
##lston O
##es O
social O
history O
: O
social O
history O
is O
significant O
for O
the O
absence O
of O
current O
tobacco O
use O
and O
patient O
states O
she O
has O
never O
smoked O
. O
there O
is O
no O
history O
of O
alcohol O
abuse O
or O
illegal O
substance O
use O
. O
patient O
lives O
in O
[ O
* O
* O
location O
58 O
##3 O
* O
* O
] O
, O
ma O
. O
she O
is O
a O
retired O
den O
##tist O
and O
immigrated O
from O
[ O
* O
* O
country O
53 O
##2 O
* O
* O
] O
and O
[ O
* O
* O
location O
( O
un O
) O
315 O
##6 O
* O
* O
] O
in O
the O
[ O
* O
* O
211 O
##0 O
* O
* O
] O
. O
family O
history O
: O
there O
is O
no O
family O
history O
of O
premature O
co O
##rona O
##ry O
artery O
disease O
or O
sudden O
death O
. O
[ O
* O
* O
name O
( O
ni O
) O
* O
* O
] O
mother O
had O
h O
##t O
##n O
. O

physical O
exam O
: O
at O
discharge O
: O
vital O
##s O
: O
g O
##en O
: O
na O
##d O
, O
a O
/ O
o O
##x O
##3 O
c O
##v O
: O
r O
##rr O
, O
no O
m O
/ O
r O
/ O
g O
re O
##sp O
: O
c O
##ta O
##b O
, O
decreased O
bases O
bilateral O
##ly O
. O
no O
w O
/ O
r O
/ O
r O
a O
##b O
##d O
: O
soft O
slightly O
di O
##sten O
##ded O
, O
appropriately O
t O
##t O
##p O
in O
##cision O
: O
mid O
##line O
abdominal O
o O
##ta O
with O
staple O
##s O
, O
mild O
er O
##yt O
##hem O
##a O
at O
staple O
##s O
sites O
with O
scan O
##t O
dry O
blood O
, O
otherwise O
c O
##di O
g O
##i O
/ O
g O
##u O
: O
di O
##aper O
in O
place O
due O
to O
u O
##rina O
##ry O
frequency O
/ O
in O
##con O
##tine O
##nce O
. O
re O
##ct O
##al O
tube O
placed O
on O
[ O
* O
* O
214 O
##0 O
- O
4 O
- O
2 O
* O
* O
] O
for O
frequent O
loose O
brown O
stool O
. O
intact O
. O
no O
re O
##ct O
##al O
irritation O
/ O
ex O
##cor O
##iation O
noted O
skin O
: O
per O
##ine O
##al O
skin O
free O
of O
r O
##ash O
and O
ex O
##cor O
##iation O
ex O
##tre O
##m O
: O
b O
/ O
l O
1 O
+ O
pedal O
ed O
##ema O
. O
+ O
d O
##p O
' O
s O

per O
##tinent O
results O
: O
[ O
* O
* O
214 O
##0 O
- O
3 O
- O
23 O
* O
* O
] O
09 O
: O
05 O
##pm O
blood O
w O
##b O
##c O
- O
8 O
. O
1 O
r O
##b O
##c O
- O
4 O
. O
22 O
h O
##g O
##b O
- O
11 O
. O
8 O
* O
h O
##ct O
- O
34 O
. O
4 O
* O
m O
##c O
##v O
- O
81 O
* O
m O
##ch O
- O
27 O
. O
9 O
m O
##ch O
##c O
- O
34 O
. O
2 O
r O
##d O
##w O
- O
15 O
. O
5 O
p O
##lt O
c O
##t O
- O
201 O
[ O
* O
* O
214 O
##0 O
- O
3 O
- O
25 O
* O
* O
] O
04 O
: O
43 O
##am O
blood O
w O
##b O
##c O
- O
7 O
. O
7 O
r O
##b O
##c O
- O
3 O
. O
74 O
* O
h O
##g O
##b O
- O
10 O
. O
6 O
* O
h O
##ct O
- O
31 O
. O
1 O
* O
m O
##c O
##v O
- O
83 O
m O
##ch O
- O
28 O
. O
3 O
m O
##ch O
##c O
- O
34 O
. O
1 O
r O
##d O
##w O
- O
15 O
. O
9 O
* O
p O
##lt O
c O
##t O
- O
153 O
[ O
* O
* O
214 O
##0 O
- O
3 O
- O
27 O
* O
* O
] O
04 O
: O
11 O
##am O
blood O
w O
##b O
##c O
- O
11 O
. O
2 O
* O
# O
r O
##b O
##c O
- O
3 O
. O
84 O
* O
# O
h O
##g O
##b O
- O
10 O
. O
9 O
* O
# O
h O
##ct O
- O
33 O
. O
2 O
* O
# O
m O
##c O
##v O
- O
87 O
m O
##ch O
- O
28 O
. O
5 O
m O
##ch O
##c O
- O
32 O
. O
9 O
r O
##d O
##w O
- O
15 O
. O
2 O
p O
##lt O
c O
##t O
- O
175 O
[ O
* O
* O
214 O
##0 O
- O
3 O
- O
29 O
* O
* O
] O
02 O
: O
18 O
##am O
blood O
w O
##b O
##c O
- O
8 O
. O
5 O
r O
##b O
##c O
- O
3 O
. O
11 O
* O
h O
##g O
##b O
- O
9 O
. O
0 O
* O
h O
##ct O
- O
27 O
. O
3 O
* O
m O
##c O
##v O
- O
88 O
m O
##ch O
- O
28 O
. O
9 O
m O
##ch O
##c O
- O
32 O
. O
9 O
r O
##d O
##w O
- O
15 O
. O
3 O
p O
##lt O
c O
##t O
- O
175 O
[ O
* O
* O
214 O
##0 O
- O
4 O
- O
1 O
* O
* O
] O
04 O
: O
49 O
##am O
blood O
w O
##b O
##c O
- O
7 O
. O
0 O
r O
##b O
##c O
- O
3 O
. O
13 O
* O
h O
##g O
##b O
- O
8 O
. O
7 O
* O
h O
##ct O
- O
26 O
. O
7 O
* O
m O
##c O
##v O
- O
85 O
m O
##ch O
- O
27 O
. O
6 O
m O
##ch O
##c O
- O
32 O
. O
4 O
r O
##d O
##w O
- O
15 O
. O
3 O
p O
##lt O
c O
##t O
- O
195 O
[ O
* O
* O
214 O
##0 O
- O
4 O
- O
3 O
* O
* O
] O
03 O
: O
34 O
##am O
blood O
w O
##b O
##c O
- O
10 O
. O
2 O
r O
##b O
##c O
- O
3 O
. O
49 O
* O
h O
##g O
##b O
- O
9 O
. O
8 O
* O
h O
##ct O
- O
28 O
. O
6 O
* O
m O
##c O
##v O
- O
82 O
m O
##ch O
- O
28 O
. O
0 O
m O
##ch O
##c O
- O
34 O
. O
2 O
r O
##d O
##w O
- O
15 O
. O
7 O
* O
p O
##lt O
c O
##t O
- O
255 O

[ O
* O
* O
214 O
##0 O
- O
4 O
- O
4 O
* O
* O
] O
05 O
: O
50 O
##am O
blood O
w O
##b O
##c O
- O
12 O
. O
0 O
* O
r O
##b O
##c O
- O
3 O
. O
75 O
* O
h O
##g O
##b O
- O
10 O
. O
2 O
* O
h O
##ct O
- O
30 O
. O
9 O
* O
m O
##c O
##v O
- O
83 O
m O
##ch O
- O
27 O
. O
2 O
m O
##ch O
##c O
- O
33 O
. O
0 O
r O
##d O
##w O
- O
15 O
. O
9 O
* O
p O
##lt O
c O
##t O
- O
31 O
##8 O
[ O
* O
* O
214 O
##0 O
- O
3 O
- O
23 O
* O
* O
] O
09 O
: O
05 O
##pm O
blood O
p O
##t O
- O
32 O
. O
3 O
* O
p O
##tt O
- O
35 O
. O
4 O
* O
in O
##r O
( O
p O
##t O
) O
- O
3 O
. O
4 O
* O
[ O
* O
* O
214 O
##0 O
- O
3 O
- O
25 O
* O
* O
] O
04 O
: O
43 O
##am O
blood O
p O
##t O
- O
42 O
. O
0 O
* O
p O
##tt O
- O
44 O
. O
0 O
* O
in O
##r O
( O
p O
##t O
) O
- O
4 O
. O
6 O
* O
[ O
* O
* O
214 O
##0 O
- O
3 O
- O
26 O
* O
* O
] O
06 O
: O
20 O
##pm O
blood O
p O
##t O
- O
18 O
. O
1 O
* O
p O
##tt O
- O
35 O
. O
0 O
in O
##r O
( O
p O
##t O
) O
- O
1 O
. O
7 O
* O
[ O
* O
* O
214 O
##0 O
- O
3 O
- O
27 O
* O
* O
] O
12 O
: O
40 O
##am O
blood O
p O
##t O
- O
17 O
. O
3 O
* O
p O
##tt O
- O
32 O
. O
7 O
in O
##r O
( O
p O
##t O
) O
- O
1 O
. O
6 O
* O
[ O
* O
* O
214 O
##0 O
- O
3 O
- O
28 O
* O
* O
] O
02 O
: O
03 O
##am O
blood O
p O
##t O
- O
15 O
. O
7 O
* O
p O
##tt O
- O
37 O
. O
3 O
* O
in O
##r O
( O
p O
##t O
) O
- O
1 O
. O
4 O
* O
[ O
* O
* O
214 O
##0 O
- O
3 O
- O
23 O
* O
* O
] O
09 O
: O
05 O
##pm O
blood O
glucose O
- O
109 O
* O
u O
##rea O
##n O
- O
77 O
* O
c O
##rea O
##t O
- O
2 O
. O
1 O
* O
na O
- O
137 O
k O
- O
2 O
. O
9 O
* O
c O
##l O
- O
90 O
* O
h O
##co O
##3 O
- O
33 O
* O
an O
##ga O
##p O
- O
17 O
[ O
* O
* O
214 O
##0 O
- O
3 O
- O
24 O
* O
* O
] O
08 O
: O
51 O
##pm O
blood O
glucose O
- O
118 O
* O
u O
##rea O
##n O
- O
65 O
* O
c O
##rea O
##t O
- O
1 O
. O
6 O
* O
na O
- O
144 O
k O
- O
4 O
. O
0 O
c O
##l O
- O
105 O
h O
##co O
##3 O
- O
28 O
an O
##ga O
##p O
- O
15 O
[ O
* O
* O
214 O
##0 O
- O
3 O
- O
26 O
* O
* O
] O
02 O
: O
25 O
##am O
blood O
glucose O
- O
104 O
u O
##rea O
##n O
- O
41 O
* O
c O
##rea O
##t O
- O
1 O
. O
1 O
na O
- O
150 O
* O
k O
- O
3 O
. O
3 O
c O
##l O
- O
109 O
* O
h O
##co O
##3 O
- O
32 O
an O
##ga O
##p O
- O
12 O

[ O
* O
* O
214 O
##0 O
- O
3 O
- O
28 O
* O
* O
] O
03 O
: O
29 O
##pm O
blood O
glucose O
- O
106 O
* O
u O
##rea O
##n O
- O
31 O
* O
c O
##rea O
##t O
- O
1 O
. O
1 O
na O
- O
152 O
* O
k O
- O
3 O
. O
7 O
c O
##l O
- O
114 O
* O
h O
##co O
##3 O
- O
31 O
an O
##ga O
##p O
- O
11 O
[ O
* O
* O
214 O
##0 O
- O
3 O
- O
29 O
* O
* O
] O
02 O
: O
18 O
##am O
blood O
glucose O
- O
105 O
u O
##rea O
##n O
- O
29 O
* O
c O
##rea O
##t O
- O
1 O
. O
0 O
na O
- O
153 O
* O
k O
- O
3 O
. O
7 O
c O
##l O
- O
116 O
* O
h O
##co O
##3 O
- O
30 O
an O
##ga O
##p O
- O
11 O
[ O
* O
* O
214 O
##0 O
- O
3 O
- O
29 O
* O
* O
] O
12 O
: O
46 O
##pm O
blood O
glucose O
- O
128 O
* O
u O
##rea O
##n O
- O
27 O
* O
c O
##rea O
##t O
- O
0 O
. O
9 O
na O
- O
152 O
* O
k O
- O
3 O
. O
8 O
c O
##l O
- O
116 O
* O
h O
##co O
##3 O
- O
28 O
an O
##ga O
##p O
- O
12 O
[ O
* O
* O
214 O
##0 O
- O
4 O
- O
2 O
* O
* O
] O
04 O
: O
03 O
##am O
blood O
glucose O
- O
94 O
u O
##rea O
##n O
- O
17 O
c O
##rea O
##t O
- O
0 O
. O
8 O
na O
- O
141 O
k O
- O
3 O
. O
5 O
c O
##l O
- O
104 O
h O
##co O
##3 O
- O
29 O
an O
##ga O
##p O
- O
12 O
[ O
* O
* O
214 O
##0 O
- O
4 O
- O
3 O
* O
* O
] O
06 O
: O
53 O
##am O
blood O
glucose O
- O
80 O
u O
##rea O
##n O
- O
16 O
c O
##rea O
##t O
- O
0 O
. O
7 O
na O
- O
141 O
k O
- O
3 O
. O
5 O
c O
##l O
- O
103 O
h O
##co O
##3 O
- O
30 O
an O
##ga O
##p O
- O
12 O
[ O
* O
* O
214 O
##0 O
- O
4 O
- O
4 O
* O
* O
] O
05 O
: O
50 O
##am O
blood O
glucose O
- O
101 O
u O
##rea O
##n O
- O
12 O
c O
##rea O
##t O
- O
0 O
. O
8 O
na O
- O
140 O
k O
- O
4 O
. O
2 O
c O
##l O
- O
104 O
h O
##co O
##3 O
- O
28 O
an O
##ga O
##p O
- O
12 O
[ O
* O
* O
214 O
##0 O
- O
3 O
- O
23 O
* O
* O
] O
09 O
: O
05 O
##pm O
blood O
album O
##in O
- O
4 O
. O
1 O
[ O
* O
* O
214 O
##0 O
- O
3 O
- O
24 O
* O
* O
] O
04 O
: O
30 O
##am O
blood O
calcium O
- O
8 O
. O
5 O
p O
##hos O
- O
6 O
. O
2 O
* O
# O
mg O
- O
2 O
. O
4 O
[ O
* O
* O
214 O
##0 O
- O
3 O
- O
24 O
* O
* O
] O
08 O
: O
51 O
##pm O
blood O
calcium O
- O
8 O
. O
1 O
* O
p O
##hos O
- O
4 O
. O
7 O
* O
mg O
- O
3 O
. O
2 O
* O
[ O
* O
* O
214 O
##0 O
- O
3 O
- O
27 O
* O
* O
] O
12 O
: O
13 O
##pm O
blood O
calcium O
- O
8 O
. O
5 O
p O
##hos O
- O
2 O
. O
6 O
* O
mg O
- O
2 O
. O
1 O
[ O
* O
* O
214 O
##0 O
- O
3 O
- O
28 O
* O
* O
] O
02 O
: O
03 O
##am O
blood O
calcium O
- O
8 O
. O
4 O
p O
##hos O
- O
3 O
. O
9 O
mg O
- O
2 O
. O
4 O

[ O
* O
* O
214 O
##0 O
- O
3 O
- O
28 O
* O
* O
] O
03 O
: O
29 O
##pm O
blood O
calcium O
- O
8 O
. O
3 O
* O
p O
##hos O
- O
4 O
. O
2 O
mg O
- O
2 O
. O
5 O
[ O
* O
* O
214 O
##0 O
- O
4 O
- O
2 O
* O
* O
] O
04 O
: O
03 O
##am O
blood O
calcium O
- O
7 O
. O
8 O
* O
p O
##hos O
- O
2 O
. O
9 O
mg O
- O
2 O
. O
0 O
[ O
* O
* O
214 O
##0 O
- O
4 O
- O
3 O
* O
* O
] O
06 O
: O
53 O
##am O
blood O
calcium O
- O
7 O
. O
7 O
* O
p O
##hos O
- O
3 O
. O
4 O
mg O
- O
1 O
. O
8 O
[ O
* O
* O
214 O
##0 O
- O
4 O
- O
4 O
* O
* O
] O
05 O
: O
50 O
##am O
blood O
calcium O
- O
7 O
. O
9 O
* O
p O
##hos O
- O
3 O
. O
8 O
mg O
- O
2 O
. O
2 O
. O
c O
##di O
##ff O
culture O
negative O
x O
2 O
on O
[ O
* O
* O
4 O
- O
3 O
* O
* O
] O
& O
[ O
* O
* O
214 O
##0 O
- O
4 O
- O
4 O
* O
* O
] O
. O
m O
##rsa O
culture O
negative O
x O
2 O
on O
[ O
* O
* O
3 O
- O
24 O
* O
* O
] O
& O
[ O
* O
* O
214 O
##0 O
- O
3 O
- O
26 O
* O
* O
] O
. O
urine O
culture O
negative O
on O
[ O
* O
* O
214 O
##0 O
- O
3 O
- O
23 O
* O
* O
] O
. O
c O
##t O
abdomen O
w O
/ O
o O
contrast B-DRUG
study O
date O
of O
[ O
* O
* O
214 O
##0 O
- O
3 O
- O
24 O
* O
* O
] O
12 O
: O
43 O
am O
impression O
: O
1 O
. O
findings O
consistent O
with O
small O
bow O
##el O
o O
##bs O
##truction O
at O
the O
level O
of O
the O
ventral O
abdominal O
wall O
out O
##po O
##uchi O
##ng O
( O
likely O
at O
##ten O
##uation O
of O
per O
##ito O
##ne O
##um O
rather O
than O
true O
her O
##nia O
) O
, O
with O
di O
##stal O
de O
##com O
##press O
##ion O
. O
no O
per O
##fo O
##ration O
. O
2 O
. O
ch O
##ole O
##lit O
##hia O
##sis O
without O
ch O
##ole O
##cy O
##st O
##itis O
. O
3 O
. O
at O
##her O
##os O
##cle O
##rot O
##ic O
ca O
##l O
##ci O
##fication O
. O
. O
path O
##ology O
examination O
procedure O
date O
[ O
* O
* O
214 O
##0 O
- O
3 O
- O
26 O
* O
* O
] O
diagnosis O
: O
small O
bow O
##el O
, O
segment O
##al O
re O
##section O
: O
segment O
of O
small O
bow O
##el O
with O
fi O
##bro O
##us O
ad O
##hesion O
##s O
, O
one O
incorporating O
synthetic O
mesh O
material O
, O
and O
focus O
of O
is O
##che O
##mic O
ne O
##c O
##rosis O
. O
tissue O
at O
margins O
appears O
viable O
. O
clinical O
: O
bow O
##el O
o O
##bs O
##truction O
. O
. O
chest O
( O
p O
##a O
& O
la O
##t O
) O
study O
date O
of O
[ O
* O
* O
214 O
##0 O
- O
3 O
- O
31 O
* O
* O
] O
4 O
: O
16 O
pm O
impression O
: O
new O
left O
per O
##ih O
##ila O
##r O
region O
faint O
ground O
- O
glass O
op O
##acity O
concerning O
for O
as O
##piration O
. O
persistent O
bi O
##bas O
##ila O
##r O
ate O
##lect O
##asis O
with O
bilateral O
p O
##le O
##ural O
e O
##ff O
##usions O
. O
. O
[ O
* O
* O
214 O
##0 O
- O
4 O
- O
1 O
* O
* O
] O
- O
video O
swallow O
completed O
via O
c O
##t O
scan O

brief O
hospital O
course O
: O
m O
##rs O
. O
[ O
* O
* O
known O
last O
##name O
104 O
##29 O
##9 O
* O
* O
] O
was O
underwent O
a O
c O
##t O
scan O
in O
the O
ed O
for O
c O
/ O
o O
abdominal O
pain O
. O
her O
c O
##t O
scan O
revealed O
a O
small O
bow O
##el O
o O
##bs O
##truction O
near O
her O
known O
ventral O
her O
##nia O
which O
was O
red O
##uc O
##ible O
at O
the O
beside O
. O
general O
surgery O
was O
consulted O
, O
and O
she O
was O
admitted O
to O
the O
i O
##cu O
found O
to O
have O
junction O
##al O
bra O
##dy O
rhythm O
with O
prolonged B-REA
q I-REA
##t I-REA
( O
q O
##t O
##c O
near O
600 O
) O
in O
context O
of O
recent O
increase O
in O
fl B-DRUG
##eca I-DRUG
##ini I-DRUG
##de I-DRUG
dose O
per O
p O
##c O
##p O
. O
[ O
* O
* O
name O
##10 O
( O
name O
##is O
) O
* O
* O
] O
was O
monitored O
in O
the O
i O
##cu O
for O
a O
few O
days O
. O
card O
##iology O
was O
consulted O
, O
and O
recommended O
holding O
beta B-DRUG
block I-DRUG
##er I-DRUG
, I-DRUG
and O
fl B-DRUG
##eca I-DRUG
##ni I-DRUG
##de I-DRUG
. I-DRUG
co B-DRUG
##uma I-DRUG
##din I-DRUG
was O
also O
held O
in O
case O
of O
need O
for O
surgical O
intervention O
. O
in O
addition O
, O
her O
potassium O
of O
2 O
. O
9 O
and O
ma O
##gnesium O
were O
aggressively O
re O
##ple O
##ted O
. O
her O
cardiac O
status O
stab O
##ilized O
after O
undergoing O
di B-REA
##ures I-REA
##is I-REA
with O
di B-DRUG
##amo I-DRUG
##x I-DRUG
, I-DRUG
however O
, O
her O
abdominal O
exam O
worse O
##ned O
over O
the O
following O
48 O
hours O
after O
a O
few O
days O
of O
conservative O
management O
with O
n O
##po O
/ O
ng O
##t O
for O
de O
##com O
##press O
##ion O
and O
i B-ROU
##v I-ROU
anti B-DRUG
##biotics I-DRUG
. I-DRUG
. O
she O
was O
taken O
to O
the O
or O
, O
and O
underwent O
l O
##ys O
##is O
of O
ad O
##hesion O
##s O
and O
small O
bow O
##el O
re O
##section O
. O
her O
operative O
course O
was O
un O
##com O
##plicate O
##d O
, O
routinely O
observed O
in O
the O
p O
##ac O
##u O
, O
and O
transferred O
back O
to O
[ O
* O
* O
hospital O
unit O
name O
153 O
* O
* O
] O
where O
cardiac O
monitoring O
and O
electro O
##ly O
##te O
correction O
occurred O
. O
she O
was O
trans O
##fused O
post O
/ O
op O
with O
2 B-DOS
u I-DOS
p B-DRUG
##rb I-DRUG
##c I-DRUG
. I-DRUG
h O
##cts O
remained O
stable O
thereafter O
. O
she O
was O
ex O
##tub O
##ated O
and O
we O
##an O
off O
press B-DRUG
##ors I-DRUG
, I-DRUG
and O
transferred O
to O
stone O
5 O
. O
. O

physical O
therapy O
was O
consulted O
upon O
transfer O
to O
stone O
5 O
for O
expected O
discharge O
to O
re O
##hab O
due O
to O
physical O
de O
##con O
##dition O
##ing O
. O
remained O
n O
##po O
until O
bow O
##el O
function O
resumed O
. O
electro O
##ly O
##tes O
checked O
and O
re O
##ple O
##ted O
daily O
. O
h O
##y O
##po O
##nat O
##rem O
##ia O
resolved O
gradually O
. O
started O
on O
sip O
##s O
of O
water O
, O
advanced O
to O
clear O
liquid O
##s O
. O
noted O
to O
have O
difficulty O
swallowing O
and O
clearing O
secret O
##ions O
. O
bedside O
swallow O
study O
conducted O
. O
she O
was O
taken O
for O
video O
swallow O
, O
and O
cleared O
for O
regular O
diet O
with O
thick O
liquid O
##s O
, O
and O
whole O
pills O
in O
pure O
##e O
. O
patient O
reported O
passing O
flat O
##us O
, O
and O
in O
##continent O
of O
loose O
, O
brown O
stool O
##s O
. O
re O
##ct O
##al O
tube O
inserted O
on O
[ O
* O
* O
214 O
##0 O
- O
4 O
- O
2 O
* O
* O
] O
due O
to O
f O
##re O
##quence O
##y O
of O
bow O
##el O
movements O
, O
and O
risk O
for O
compromise O
of O
per O
##ine O
##al O
skin O
. O
re O
##ct O
##al O
tube O
should O
be O
removed O
by O
f O
##rida O
##y O
[ O
* O
* O
214 O
##0 O
- O
4 O
- O
8 O
* O
* O
] O
to O
prevent O
re O
##ct O
##al O
breakdown O
. O
diet O
advanced O
to O
regular O
food O
. O
reported O
intermittent O
nausea O
and O
lack O
of O
appetite O
which O
has O
persisted O
throughout O
post O
- O
op O
recovery O
. O
f O
##ole O
##y O
was O
removed O
. O
she O
was O
able O
to O
u O
##rina O
##te O
, O
in O
##continent O
of O
urine O
. O
u O
##a O
and O
urine O
cultures O
negative O
. O
. O
mobility O
compromised O
. O
she O
requires O
[ O
* O
* O
1 O
- O
26 O
* O
* O
] O
people O
for O
am O
##bula O
##tion O
and O
transfer O
. O
requires O
aggressive O
physical O
re O
##hab O
, O
and O
monitoring O
of O
nutrition O
##al O
, O
bow O
##el O
, O
and O
cardiac O
status O
. O
she O
should O
follow O
- O
up O
with O
p O
##c O
##p O
( O
d O
##r O
. O
[ O
* O
* O
first O
name O
##8 O
( O
name O
##pa O
##tter O
##n O
##2 O
) O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
245 O
##0 O
* O
* O
] O
) O
, O
and O
card O
##iology O
to O
address O
cardiac O
events O
( O
prolonged O
q O
##t O
interval O
) O
during O
this O
admission O
. O
[ O
* O
* O
hospital O
197 O
* O
* O
] O
clinic O
at O
[ O
* O
* O
hospital O
##1 O
18 O
* O
* O
] O
manages O
the O
patients O
co B-DRUG
##uma I-DRUG
##din I-DRUG
dos O
##ing O
for O
p B-REA
##af I-REA
. I-REA
co B-DRUG
##uma I-DRUG
##din I-DRUG
2 B-STR
##m I-STR
##g I-STR
p B-ROU
##o I-ROU
given O
at O
[ O
* O
* O
214 O
##0 O
- O
4 O
- O
4 O
* O
* O
] O
. O
in O
##r O
should O
be O
checked O
on O
[ O
* O
* O
214 O
##0 O
- O
4 O
- O
5 O
* O
* O
] O
, O
and O
daily O
until O
therapeutic O
. O
goal O
in O
##r O
[ O
* O
* O
1 O
- O
26 O
* O
* O
] O
. O
. O
she O
will O
require O
to O
have O
the O
in O
##cision O
##al O
staple O
##s O
removed O
in O
another O
week O
. O
this O
can O
be O
done O
per O
re O
##hab O
facility O
after O
authorization O
per O
d O
##r O
. O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
* O
* O
] O
( O
surgeon O
) O
. O

medications O
on O
admission O
: O
all B-DRUG
##op I-DRUG
##uri I-DRUG
##no I-DRUG
##l I-DRUG
100 B-STR
' I-STR
, I-STR
lip B-DRUG
##itor I-DRUG
20 B-STR
' I-STR
, I-STR
co B-DRUG
##l I-DRUG
##chi I-DRUG
##cine I-DRUG
p B-FRE
##rn I-FRE
, I-FRE
di B-DRUG
##lts I-DRUG
##r I-DRUG
240 B-STR
' I-STR
, I-STR
fl B-DRUG
##ona I-DRUG
##se I-DRUG
50 B-STR
" I-STR
, O
las B-DRUG
##ix I-DRUG
80 B-STR
" I-STR
, I-STR
di B-DRUG
##az I-DRUG
##ep I-DRUG
##am I-DRUG
5 B-STR
p B-FRE
##rn I-FRE
, I-FRE
g B-DRUG
##aba I-DRUG
##pent I-DRUG
##in I-DRUG
600 B-STR
##hs B-FRE
/ I-FRE
300 B-STR
##am B-FRE
/ I-FRE
300 B-STR
##pm B-FRE
h B-DRUG
##yd I-DRUG
##ral I-DRUG
##azi I-DRUG
##ne I-DRUG
50 B-STR
t B-FRE
##id I-FRE
, I-FRE
top B-DRUG
##rol I-DRUG
##x I-DRUG
##l I-DRUG
100 B-STR
daily B-FRE
, I-FRE
ni B-DRUG
##tro I-DRUG
##gly I-DRUG
##cer I-DRUG
##in I-DRUG
p B-FRE
##rn I-FRE
, I-FRE
p B-DRUG
##ril I-DRUG
##ose I-DRUG
##c I-DRUG
40 B-STR
daily B-FRE
, I-FRE
z B-DRUG
##olo I-DRUG
##ft I-DRUG
100 B-STR
' I-STR
, O
s B-DRUG
##pi I-DRUG
##ron I-DRUG
##ola I-DRUG
##cton I-DRUG
##e I-DRUG
25 B-STR
' I-STR
, I-STR
as B-DRUG
##a I-DRUG
81 B-STR
' I-STR
, I-STR
co B-DRUG
##uma I-DRUG
##din I-DRUG
1 B-STR
##m I-STR
##g I-STR
##m B-FRE
##w I-FRE
##f I-FRE
2 B-STR
##m I-STR
##g I-STR
other B-FRE
days I-FRE

discharge O
medications O
: O
1 O
. O
as B-DRUG
##pi I-DRUG
##rin I-DRUG
81 B-STR
mg I-STR
tablet B-FOR
, I-FOR
ch I-FOR
##ew I-FOR
##able I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
, I-FOR
ch I-FOR
##ew I-FOR
##able I-FOR
p B-ROU
##o I-ROU
daily B-FRE
( I-FRE
daily I-FRE
) I-FRE
. I-FRE
2 O
. O
calcium B-DRUG
carbon I-DRUG
##ate I-DRUG
500 B-STR
mg I-STR
tablet B-FOR
, I-FOR
ch I-FOR
##ew I-FOR
##able I-FOR
si O
##g O
: O
two B-DOS
( I-DOS
2 I-DOS
) I-DOS
tablet B-FOR
, I-FOR
ch I-FOR
##ew I-FOR
##able I-FOR
p B-ROU
##o I-ROU
q B-FRE
12 I-FRE
##h I-FRE
( I-FRE
every I-FRE
12 I-FRE
hours I-FRE
) I-FRE
. I-FRE
3 O
. O
h B-DRUG
##ydro I-DRUG
##mor I-DRUG
##phone I-DRUG
2 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
1 B-DOS
- I-DOS
2 I-DOS
tablets B-FOR
p B-ROU
##o I-ROU
q B-FRE
##4 I-FRE
##h I-FRE
( I-FRE
every I-FRE
4 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
breakthrough B-REA
for B-DUR
2 I-DUR
weeks I-DUR
. I-DUR
4 O
. O
at B-DRUG
##or I-DRUG
##vas I-DRUG
##tat I-DRUG
##in I-DRUG
20 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( I-FRE
daily I-FRE
) I-FRE
. I-FRE
5 O
. O
all B-DRUG
##op I-DRUG
##uri I-DRUG
##no I-DRUG
##l I-DRUG
100 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( I-FRE
daily I-FRE
) I-FRE
. I-FRE
6 O
. O
co B-DRUG
##l I-DRUG
##chi I-DRUG
##cine I-DRUG
0 B-STR
. I-STR
6 I-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( I-FRE
daily I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
go B-REA
##ut I-REA
flare I-REA
/ I-REA
pain I-REA
. I-REA
7 O
. O
di B-DRUG
##lt I-DRUG
##ia I-DRUG
##ze I-DRUG
##m I-DRUG
h I-DRUG
##c I-DRUG
##l I-DRUG
240 B-STR
mg I-STR
capsule B-FOR
, I-FOR
sustained I-FOR
release I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
capsule B-FOR
, I-FOR
sustained I-FOR
release I-FOR
p B-ROU
##o I-ROU
daily B-FRE
( I-FRE
daily I-FRE
) I-FRE
. I-FRE
8 O
. O
flu B-DRUG
##tica I-DRUG
##son I-DRUG
##e I-DRUG
50 B-STR
m I-STR
##c I-STR
##g I-STR
/ I-STR
act I-STR
##uation I-STR
spray B-FOR
, I-FOR
suspension I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
spray B-FOR
nasal B-ROU
[ O
* O
* O
hospital O
##1 O
* O
* O
] O
( O
2 B-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. O
9 O
. O
fur B-DRUG
##ose I-DRUG
##mi I-DRUG
##de I-DRUG
80 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
bid B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE
10 O
. O
di B-DRUG
##az I-DRUG
##ep I-DRUG
##am I-DRUG
5 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
q B-FRE
##6 I-FRE
##h I-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
anxiety B-REA
. I-REA
11 O
. O
g B-DRUG
##aba I-DRUG
##pent I-DRUG
##in I-DRUG
300 B-STR
mg I-STR
capsule B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
capsule B-FOR
p B-ROU
##o I-ROU
q B-FRE
##12 I-FRE
##h I-FRE
( I-FRE
every I-FRE
12 I-FRE
hours I-FRE
) I-FRE
. I-FRE
12 O
. O
g B-DRUG
##aba I-DRUG
##pent I-DRUG
##in I-DRUG
300 B-STR
mg I-STR
capsule B-FOR
si O
##g O
: O
two B-DOS
( I-DOS
2 I-DOS
) I-DOS
capsule B-FOR
p B-ROU
##o I-ROU
h B-FRE
##s I-FRE
( I-FRE
at I-FRE
bed I-FRE
##time I-FRE
) I-FRE
. I-FRE
13 O
. O
h B-DRUG
##yd I-DRUG
##ral I-DRUG
##azi I-DRUG
##ne I-DRUG
50 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
t B-FRE
##id I-FRE
( I-FRE
3 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE
14 O
. O
met B-DRUG
##op I-DRUG
##rol I-DRUG
##ol I-DRUG
su I-DRUG
##cci I-DRUG
##nate I-DRUG
100 B-STR
mg I-STR
tablet B-FOR
sustained I-FOR
release I-FOR
24 I-FOR
h I-FOR
##r I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
sustained I-FOR
release I-FOR
24 I-FOR
h I-FOR
##r I-FOR
p B-ROU
##o I-ROU
daily B-FRE
( I-FRE
daily I-FRE
) I-FRE
. I-FRE
15 O
. O
o B-DRUG
##me I-DRUG
##pra I-DRUG
##zo I-DRUG
##le I-DRUG
20 B-STR
mg I-STR
capsule B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
si O
##g O
: O
two B-DOS
( I-DOS
2 I-DOS
) I-DOS
capsule B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
p B-ROU
##o I-ROU
daily B-FRE
( I-FRE
daily I-FRE
) I-FRE
. I-FRE
16 O
. O
se B-DRUG
##rt I-DRUG
##ral I-DRUG
##ine I-DRUG
100 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( I-FRE
daily I-FRE
) I-FRE
. I-FRE

17 O
. O
s B-DRUG
##pi I-DRUG
##ron I-DRUG
##ola I-DRUG
##cton I-DRUG
##e I-DRUG
25 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( I-FRE
daily I-FRE
) I-FRE
. I-FRE
18 O
. O
ace B-DRUG
##tam I-DRUG
##ino I-DRUG
##phe I-DRUG
##n I-DRUG
325 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
two B-DOS
( I-DOS
2 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
q B-FRE
##6 I-FRE
##h I-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
fever B-REA
or O
pain B-REA
for B-DUR
2 I-DUR
weeks I-DUR
: I-DUR
do O
not O
exceed O
4000 O
##m O
##g O
in O
24 O
##hr O
##s O
. O
19 O
. O
co B-DRUG
##uma I-DRUG
##din I-DRUG
1 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
t O
##it O
##rate O
dose O
per O
in O
##r O
tablet B-FOR
p B-ROU
##o I-ROU
once B-FRE
a I-FRE
day I-FRE
: I-FRE
goal O
in O
##r O
[ O
* O
* O
1 O
- O
26 O
* O
* O
] O
. O
usual O
dos O
##ing O
m B-FRE
##w I-FRE
##f I-FRE
- I-FRE
1 B-STR
##m I-STR
##g I-STR
, I-STR
other B-FRE
days I-FRE
2 B-STR
##m I-STR
##g I-STR
. I-STR
20 O
. O
metro B-DRUG
##ni I-DRUG
##da I-DRUG
##zo I-DRUG
##le I-DRUG
500 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
q B-FRE
##8 I-FRE
##h I-FRE
( I-FRE
every I-FRE
8 I-FRE
hours I-FRE
) I-FRE
for B-DUR
5 I-DUR
days I-DUR
. I-DUR
21 O
. O
z B-DRUG
##of I-DRUG
##ran I-DRUG
2 B-STR
mg I-STR
/ I-STR
m I-STR
##l I-STR
solution B-FOR
si O
##g O
: O
two B-DOS
( I-DOS
2 I-DOS
) I-DOS
in B-ROU
##tra I-ROU
##ven I-ROU
##ous I-ROU
every B-FRE
eight I-FRE
( I-FRE
8 I-FRE
) I-FRE
hours I-FRE
as I-FRE
needed I-FRE
for O
nausea B-REA
for B-DUR
1 I-DUR
weeks I-DUR
. I-DUR
discharge O
disposition O
: O
extended O
care O
facility O
: O
[ O
* O
* O
hospital O
##6 O
45 O
##9 O
* O
* O
] O
for O
the O
aged O
- O
[ O
* O
* O
location O
( O
un O
) O
550 O
* O
* O
] O
discharge O
diagnosis O
: O
primary O
: O
pre O
/ O
op O
prolonged O
q O
##t O
interval O
- O
managed O
in O
i O
##cu O
& O
card O
##iology O
consulted O
re O
##current O
in O
##cision O
##al O
her O
##nia O
reduced O
in O
##test O
##ine O
post O
- O
op O
d O
##ys O
##pha O
##gia O
- O
evaluated O
per O
speech O
& O
swallow O
specialist O
post O
- O
op O
blood O
loss O
an O
##emia O
. O
secondary O
: O
h O
##x O
of O
s O
##box O
##3 O
, O
h O
##cho O
##l O
, O
h O
##t O
##n O
, O
lab O
##ile O
blood O
pressure O
, O
[ O
* O
* O
last O
name O
( O
un O
) O
60 O
##43 O
* O
* O
] O
l O
##v O
d O
##ys O
##f O
##n O
, O
c O
##ri O
, O
chronic O
chest O
pain O
, O
par O
##ox O
##ys O
##mal O
a O
##fi O
##b O
, O
es O
##op O
##h O
spa O
##sm O
, O
go O
##ut O
, O
g O
##erd O
, O
mi O
##gra O
##ines O
, O
gal O
##l O
stones O
discharge O
condition O
: O
stable O
to O
##ler O
##ating O
a O
regular O
diet O
with O
ensure O
supplement O
##s O
. O
to O
##ler O
##ating O
oral O
medications O
, O
whole O
, O
if O
pure O
##es O
. O
adequate O
pain O
control O
with O
oral O
medication O
. O
discharge O
instructions O
: O
for O
re O
##hab O
: O
weigh O
patient O
every O
morning O
, O
[ O
* O
* O
name O
##8 O
( O
m O
##d O
) O
138 O
* O
* O
] O
m O
##d O
if O
weight O
> O
3 O
lbs O
. O
ad O
##here O
to O
2 O
g O
##m O
sodium O
diet O
fluid O
restriction O
: O
none O
. O
contact O
p O
##c O
##p O
, O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##4 O
) O
* O
* O
] O
. O
[ O
* O
* O
first O
name O
##8 O
( O
name O
##pa O
##tter O
##n O
##2 O
) O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
245 O
##0 O
* O
* O
] O
, O
with O
any O
concerns O
. O
. O

please O
call O
d O
##r O
. O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
* O
* O
] O
or O
return O
to O
the O
er O
for O
any O
of O
the O
following O
: O
* O
you O
experience O
new O
chest O
pain O
, O
pressure O
, O
squeezing O
or O
tight O
##ness O
. O
* O
new O
or O
worse O
##ning O
cough O
or O
w O
##hee O
##zing O
. O
* O
if O
you O
are O
vomit O
##ing O
and O
cannot O
keep O
in O
fluids O
or O
your O
medications O
. O
* O
you O
are O
getting O
de O
##hy O
##dra O
##ted O
due O
to O
continued O
vomit O
##ing O
, O
di O
##ar O
##r O
##hea O
or O
other O
reasons O
. O
signs O
of O
de O
##hy O
##dra O
##tion O
include O
dry O
mouth O
, O
rapid O
heartbeat O
or O
feeling O
dizzy O
or O
faint O
when O
standing O
. O
* O
you O
see O
blood O
or O
dark O
/ O
black O
material O
when O
you O
vomit O
or O
have O
a O
bow O
##el O
movement O
. O
* O
your O
pain O
is O
not O
improving O
within O
8 O
- O
12 O
hours O
or O
not O
gone O
within O
24 O
hours O
. O
call O
or O
return O
immediately O
if O
your O
pain O
is O
getting O
worse O
or O
is O
changing O
location O
or O
moving O
to O
your O
chest O
or O
back O
. O
* O
avoid O
lifting O
objects O
> O
5 O
##l O
##bs O
until O
your O
follow O
- O
up O
appointment O
with O
the O
surgeon O
. O
* O
avoid O
driving O
or O
operating O
heavy O
machinery O
while O
taking O
pain O
medications O
. O
* O
you O
have O
shaking O
chill O
##s O
, O
or O
a O
fever O
greater O
than O
101 O
. O
5 O
( O
f O
) O
degrees O
or O
38 O
( O
c O
) O
degrees O
. O
* O
any O
serious O
change O
in O
your O
symptoms O
, O
or O
any O
new O
symptoms O
that O
concern O
you O
. O
* O
continue O
to O
am O
##bula O
##te O
several O
times O
per O
day O
. O
. O
in O
##cision O
care O
: O
- O
your O
staple O
##s O
will O
be O
removed O
at O
your O
follow O
- O
up O
appointment O
with O
d O
##r O
. O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
* O
* O
] O
. O
staple O
##s O
may O
be O
removed O
at O
re O
##hab O
f O
##ac O
##ili O
##t O
. O
please O
contact O
d O
##r O
. O
[ O
* O
* O
name O
( O
ni O
) O
109 O
##46 O
* O
* O
] O
office O
to O
author O
##ize O
removal O
. O
s O
##ter O
##i O
strips O
will O
be O
applied O
. O
- O
your O
s O
##ter O
##i O
- O
strips O
will O
fall O
off O
on O
their O
own O
. O
please O
remove O
any O
remaining O
strips O
7 O
- O
10 O
days O
after O
surgery O
. O
- O
you O
may O
shower O
, O
and O
wash O
surgical O
in O
##cision O
##s O
. O
- O
avoid O
swimming O
and O
baths O
until O
your O
follow O
- O
up O
appointment O
. O
- O
please O
call O
the O
doctor O
if O
you O
have O
increased O
pain O
, O
swelling O
, O
red O
##ness O
, O
or O
drainage O
from O
the O
in O
##cision O
sites O
. O
. O
medications O
: O
1 O
. O
co B-DRUG
##uma I-DRUG
##din I-DRUG
: I-DRUG
continue O
to O
dose O
patient O
daily O
according O
to O
in O
##r O
level O
. O
goal O
in O
##r O
[ O
* O
* O
1 O
- O
26 O
* O
* O
] O
. O
usual O
home O
dos O
##ing O
is O
1 B-STR
mg I-STR
m B-FRE
##w I-FRE
##f I-FRE
, I-FRE
and O
2 B-STR
##m I-STR
##g I-STR
other B-FRE
days I-FRE
of I-FRE
week I-FRE
. I-FRE
patient O
is O
followed O
per O
[ O
* O
* O
hospital O
18 O
* O
* O
] O
[ O
* O
* O
hospital O
197 O
* O
* O
] O
clinic O
. O

follow O
##up O
instructions O
: O
1 O
. O
please O
follow O
- O
up O
with O
d O
##r O
. O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
* O
* O
] O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
9 O
* O
* O
] O
in O
[ O
* O
* O
12 O
- O
25 O
* O
* O
] O
weeks O
for O
removal O
of O
staple O
##s O
. O
2 O
. O
follow O
- O
up O
with O
p O
##c O
##p O
, O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##4 O
) O
* O
* O
] O
. O
[ O
* O
* O
first O
name O
##8 O
( O
name O
##pa O
##tter O
##n O
##2 O
) O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
245 O
##0 O
* O
* O
] O
, O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
250 O
* O
* O
] O
, O
1 O
- O
2 O
weeks O
after O
discharge O
from O
re O
##hab O
. O
3 O
. O
follow O
- O
up O
with O
[ O
* O
* O
hospital O
197 O
* O
* O
] O
clinic O
( O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
108 O
##44 O
* O
* O
] O
- O
[ O
* O
* O
hospital O
##1 O
18 O
* O
* O
] O
[ O
* O
* O
location O
( O
un O
) O
86 O
* O
* O
] O
- O
after O
discharge O
from O
re O
##hab O
for O
continued O
management O
of O
co B-DRUG
##uma I-DRUG
##din I-DRUG
. I-DRUG
. O
previous O
appointments O
: O
1 O
. O
provider O
: O
[ O
* O
* O
name O
initial O
( O
name O
##is O
) O
70 O
##3 O
* O
* O
] O
( O
h O
##3 O
) O
general O
2 O
[ O
* O
* O
name O
initial O
( O
name O
##is O
) O
70 O
##6 O
* O
* O
] O
phone O
: O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
32 O
##7 O
* O
* O
] O
date O
/ O
time O
: O
[ O
* O
* O
214 O
##0 O
- O
4 O
- O
5 O
* O
* O
] O
9 O
: O
30 O
2 O
. O
provider O
: O
[ O
* O
* O
name O
##10 O
( O
name O
##is O
) O
70 O
##6 O
* O
* O
] O
phone O
: O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
32 O
##7 O
* O
* O
] O
date O
/ O
time O
: O
[ O
* O
* O
214 O
##0 O
- O
4 O
- O
7 O
* O
* O
] O
8 O
: O
00 O
3 O
. O
provider O
: O
[ O
* O
* O
name O
##10 O
( O
name O
##is O
) O
70 O
##6 O
* O
* O
] O
phone O
: O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
32 O
##7 O
* O
* O
] O
date O
/ O
time O
: O
[ O
* O
* O
214 O
##0 O
- O
4 O
- O
7 O
* O
* O
] O
8 O
: O
15 O
completed O
by O
: O
[ O
* O
* O
214 O
##0 O
- O
4 O
- O
4 O
* O
* O
] O

admission O
date O
: O
[ O
* O
* O
211 O
##6 O
- O
7 O
- O
25 O
* O
* O
] O
discharge O
date O
: O
[ O
* O
* O
211 O
##6 O
- O
7 O
- O
28 O
* O
* O
] O
date O
of O
birth O
: O
[ O
* O
* O
207 O
##7 O
- O
2 O
- O
1 O
* O
* O
] O
sex O
: O
f O
service O
: O
medicine O
all O
##er O
##gies O
: O
pen B-DRUG
##tos I-DRUG
##tat I-DRUG
##in I-DRUG
/ O
i B-DRUG
##od I-DRUG
##ine I-DRUG
; I-DRUG
i B-DRUG
##od I-DRUG
##ine I-DRUG
containing I-DRUG
/ O
line B-DRUG
##zo I-DRUG
##lid I-DRUG
attending O
: O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
43 O
##7 O
##7 O
* O
* O
] O
chief O
complaint O
: O
h O
##y O
##pot O
##ens O
##ion O
, O
fever O
major O
surgical O
or O
invasive O
procedure O
: O
none O
history O
of O
present O
illness O
: O
m O
##s O
. O
[ O
* O
* O
known O
last O
##name O
92 O
##19 O
##1 O
* O
* O
] O
is O
a O
39 O
year O
- O
old O
female O
with O
a O
history O
of O
n O
##hl O
t O
- O
cell O
status O
post O
mini O
- O
all O
##o O
- O
mud O
b O
##m O
##t O
in O
[ O
* O
* O
12 O
/ O
211 O
##4 O
* O
* O
] O
complicated O
by O
grade O
1 O
skin O
g O
##v O
##h O
##d O
now O
in O
re O
##mission O
, O
off O
c O
##sa O
since O
[ O
* O
* O
6 O
- O
/ O
211 O
##5 O
* O
* O
] O
, O
pre B-DRUG
##dn I-DRUG
##ison I-DRUG
##e I-DRUG
[ O
* O
* O
2 O
- O
/ O
211 O
##6 O
* O
* O
] O
, O
and O
cell B-DRUG
##ce I-DRUG
##pt I-DRUG
[ O
* O
* O
4 O
- O
/ O
211 O
##6 O
* O
* O
] O
, O
who O
presents O
from O
the O
ed O
with O
h O
##y O
##pot O
##ens O
##ion O
, O
and O
fever O
. O
* O

she O
was O
recently O
evaluated O
in O
the O
hem O
/ O
[ O
* O
* O
hospital O
* O
* O
] O
clinic O
and O
a O
rest O
##aging O
pet O
scan O
was O
w O
##or O
##ris O
##ome O
for O
two O
new O
bilateral O
f O
##oc O
##i O
of O
increased O
f O
##d O
##g O
up O
##take O
in O
the O
neck O
raising O
suspicion O
for O
re O
##current O
f O
##d O
##g O
- O
avid O
l O
##ymph O
##oma O
. O
she O
was O
therefore O
scheduled O
for O
a O
c O
##t O
neck O
with O
contrast B-DRUG
today O
for O
further O
evaluation O
. O
she O
press O
##ented O
for O
her O
c O
##t O
scan O
to O
[ O
* O
* O
hospital O
##1 O
18 O
* O
* O
] O
, O
and O
underwent O
the O
study O
uneven O
##t O
##fully O
. O
following O
the O
procedure O
, O
she O
ate O
a O
ha O
##mb O
##urger O
with O
may O
##on O
##nai O
##se O
from O
the O
cafeteria O
, O
and O
walked O
home O
. O
when O
she O
arrived O
, O
she O
developed O
vague O
di O
##ff O
##use O
abdominal O
pain O
, O
then O
water O
##y O
di O
##ar O
##r O
##hea O
x O
3 O
- O
4 O
times O
. O
she O
also O
end O
##orse O
##s O
n O
/ O
v O
, O
with O
em O
##esis O
x O
multiple O
times O
. O
around O
the O
same O
time O
, O
she O
also O
noted O
a O
new O
p O
##ru O
##ritic O
r O
##ash O
inside O
both O
her O
ankles O
, O
which O
su O
##s O
##bs O
##e O
##quent O
##ly O
resolved O
. O
she O
called O
em O
##s O
, O
who O
came O
to O
her O
house O
, O
but O
for O
an O
unclear O
reason O
felt O
that O
she O
did O
not O
require O
further O
care O
. O
she O
subsequently O
presented O
to O
the O
ed O
for O
further O
evaluation O
. O
+ O
chill O
##s O
and O
subjective O
fever O
, O
+ O
flush O
##ing O
. O
mild O
dry O
cough O
over O
past O
few O
days O
. O
she O
reports O
a O
[ O
* O
* O
12 O
- O
20 O
* O
* O
] O
- O
week O
history O
of O
u O
##rina O
##ry O
frequency O
, O
no O
d O
##ys O
##uria O
. O
? O
cloud O
##y O
urine O
in O
past O
week O
, O
with O
right O
- O
sided O
back O
pain O
. O
urine O
culture O
from O
[ O
* O
* O
7 O
- O
22 O
* O
* O
] O
( O
hem O
/ O
on O
##c O
clinic O
) O
contaminated O
. O
no O
recent O
travel O
, O
no O
other O
unusual O
food O
. O
she O
lives O
in O
a O
boarding O
home O
, O
may O
have O
been O
in O
contact O
with O
other O
sick O
people O
. O
* O
in O
the O
ed O
, O
her O
initial O
vital O
##s O
were O
t O
104 O
. O
2 O
, O
h O
##r O
147 O
, O
b O
##p O
91 O
/ O
39 O
, O
r O
##r O
18 O
, O
sat O
98 O
% O
r O
##a O
. O
she O
was O
h B-REA
##yd I-REA
##rated I-REA
with O
6 B-DOS
. I-DOS
5 I-DOS
l I-DOS
n B-DRUG
##s I-DRUG
, I-DRUG
and O
given O
van B-DRUG
##com I-DRUG
##y I-DRUG
##cin I-DRUG
1 B-STR
##g I-STR
##m I-STR
, I-STR
le B-DRUG
##vo I-DRUG
##f I-DRUG
##lo I-DRUG
##xa I-DRUG
##cin I-DRUG
500 B-STR
mg I-STR
i B-ROU
##v I-ROU
, I-ROU
and O
c B-DRUG
##ef I-DRUG
##ep I-DRUG
##ime I-DRUG
2 B-STR
##g I-STR
##m I-STR
i B-ROU
##v I-ROU
. I-ROU
she O
was O
also O
given O
h B-DRUG
##c I-DRUG
100 B-STR
mg I-STR
i B-ROU
##v I-ROU
, I-ROU
and O
ben B-DRUG
##ad I-DRUG
##ryl I-DRUG
25 B-STR
mg I-STR
i B-ROU
##v I-ROU
. I-ROU
her O
blood O
pressure O
improved O
with O
the O
above O
therapy O
. O
a O
right O
i O
##j O
triple O
l O
##ume O
##n O
was O
placed O
in O
s O
##ter O
##ile O
conditions O
. O
she O
is O
being O
admitted O
for O
further O
care O
. O

past O
medical O
history O
: O
1 O
. O
non B-REA
- I-REA
ho I-REA
##d I-REA
##g I-REA
##kin I-REA
' I-REA
s I-REA
t I-REA
cell I-REA
l I-REA
##ymph I-REA
##oma I-REA
, I-REA
diagnosed O
in O
[ O
* O
* O
1 O
- O
/ O
211 O
##3 O
* O
* O
] O
, O
s O
/ O
p O
r B-DRUG
##it I-DRUG
##ux I-DRUG
##ima I-DRUG
##b I-DRUG
with O
disease O
progression O
, O
s O
/ O
p O
ch O
##op O
with O
evidence O
of O
progression O
after O
3rd O
cycle O
, O
s O
/ O
p O
pen B-DRUG
##tos I-DRUG
##tat I-DRUG
##in I-DRUG
, I-DRUG
r B-DRUG
##it I-DRUG
##ux I-DRUG
##an I-DRUG
c O
/ O
b O
t O
##t O
##p O
, O
s O
/ O
p O
mini O
- O
all O
##o O
- O
mud O
b O
##m O
##t O
in O
[ O
* O
* O
12 O
/ O
211 O
##4 O
* O
* O
] O
complicated O
by O
grade B-REA
1 I-REA
skin I-REA
g I-REA
##v I-REA
##h I-REA
##d I-REA
, I-REA
off O
c B-DRUG
##sa I-DRUG
since O
[ O
* O
* O
6 O
- O
/ O
211 O
##5 O
* O
* O
] O
, O
pre B-DRUG
##dn I-DRUG
##ison I-DRUG
##e I-DRUG
since O
[ O
* O
* O
2 O
- O
/ O
211 O
##6 O
* O
* O
] O
, O
cell B-DRUG
##ce I-DRUG
##pt I-DRUG
06 O
/ O
[ O
* O
* O
211 O
##5 O
* O
* O
] O
. O
2 O
. O
history O
of O
re B-ADE
##nal I-ADE
failure I-ADE
requiring O
h O
##d O
secondary O
to O
c B-DRUG
##sa I-DRUG
and O
l O
##ymph O
##oma O
##to O
##us O
in O
##fi O
##ltration O
. O
3 O
. O
h O
##yper O
##cho O
##les O
##tero O
##lem O
##ia O
4 O
. O
depression O
5 O
. O
con O
##gen O
##ital O
abnormal O
##ities O
of O
the O
fingers O
, O
status O
post O
2 O
surgical O
interventions O
. O
6 O
. O
generalized O
art O
##hra O
##l O
##gia O
##s O
, O
followed O
by O
r O
##he O
##uma O
##tology O
, O
? O
fi O
##bro O
##my O
##al O
##gia O
7 O
. O
g O
##lau O
##com O
##a O
8 O
. O
history O
of O
v O
##re O
u O
##ti O
. O
social O
history O
: O
she O
lives O
in O
a O
boarding O
home O
, O
with O
40 O
other O
co O
- O
residents O
. O
they O
share O
a O
kitchen O
and O
bathroom O
. O
she O
is O
a O
non O
- O
smoke O
##r O
. O
she O
currently O
lives O
in O
the O
apartments O
. O
she O
denied O
use O
of O
tobacco O
or O
ill O
##icit O
drugs O
. O
she O
no O
longer O
drinks O
alcohol O
but O
formerly O
used O
socially O
. O
family O
history O
: O
her O
sister O
died O
at O
the O
age O
of O
22 O
of O
l O
##ymph O
##oma O
##to O
##id O
g O
##ran O
##ulo O
##mat O
##osis O
. O
she O
also O
had O
c O
##ns O
l O
##ymph O
##oma O
. O
her O
father O
died O
of O
c O
##ll O
after O
ma O
##rrow O
transplant O
##ation O
for O
a O
##p O
##lastic O
an O
##emia O
at O
62 O
. O
her O
mother O
died O
of O
stroke O
at O
the O
age O
of O
65 O
. O

physical O
exam O
: O
vital O
##s O
: O
t O
98 O
. O
9 O
, O
b O
##p O
88 O
/ O
53 O
, O
h O
##r O
94 O
, O
r O
##r O
16 O
, O
sat O
99 O
% O
on O
2 O
##l O
. O
c O
##v O
##p O
10 O
. O
last O
s O
##vo O
##2 O
84 O
% O
. O
g O
##en O
: O
in O
na O
##d O
. O
he O
##ent O
: O
mm O
##m O
. O
an O
##ict O
##eric O
. O
per O
##rl O
. O
mild O
bilateral O
tons O
##illa O
##r O
en O
##lar O
##gement O
, O
with O
? O
food O
residue O
versus O
ex O
##uda O
##te O
on O
right O
. O
or O
##op O
##har O
##ynx O
otherwise O
un O
##rem O
##ark O
##able O
. O
neck O
: O
no O
p O
##al O
##pable O
c O
##er O
##vic O
##al O
, O
a O
##xi O
##llar O
##y O
l O
##ymph O
##ade O
##no O
##pathy O
. O
re O
##sp O
: O
c O
##ta O
##b O
, O
without O
advent O
##iti O
##ous O
sounds O
. O
c O
##v O
##s O
: O
r O
##rr O
. O
normal O
s O
##1 O
, O
s O
##2 O
. O
no O
s O
##3 O
, O
s O
##4 O
. O
no O
murmur O
or O
rub O
. O
g O
##i O
: O
o O
##bes O
##e O
abdomen O
. O
b O
##s O
na O
. O
abdomen O
soft O
, O
non O
- O
tender O
. O
mild O
right O
c O
##va O
tender O
##ness O
. O
ex O
##t O
: O
without O
ed O
##ema O
. O
in O
##te O
##gum O
##ent O
: O
no O
r O
##ash O
. O
no O
flush O
##ing O
. O

per O
##tinent O
results O
: O
[ O
* O
* O
211 O
##6 O
- O
7 O
- O
24 O
* O
* O
] O
08 O
: O
30 O
##pm O
w O
##b O
##c O
- O
7 O
. O
5 O
r O
##b O
##c O
- O
3 O
. O
66 O
* O
h O
##g O
##b O
- O
12 O
. O
7 O
h O
##ct O
- O
36 O
. O
2 O
m O
##c O
##v O
- O
99 O
* O
m O
##ch O
- O
34 O
. O
6 O
* O
m O
##ch O
##c O
- O
35 O
. O
1 O
* O
r O
##d O
##w O
- O
13 O
. O
7 O
[ O
* O
* O
211 O
##6 O
- O
7 O
- O
24 O
* O
* O
] O
08 O
: O
30 O
##pm O
ne O
##uts O
- O
50 O
bands O
- O
48 O
* O
l O
##ymph O
##s O
- O
1 O
* O
mon O
##os O
- O
1 O
* O
e O
##os O
- O
0 O
b O
##as O
##os O
- O
0 O
at O
##y O
##ps O
- O
0 O
meta O
##s O
- O
0 O
my O
##elo O
##s O
- O
0 O
[ O
* O
* O
211 O
##6 O
- O
7 O
- O
24 O
* O
* O
] O
08 O
: O
30 O
##pm O
p O
##lt O
count O
- O
248 O
[ O
* O
* O
211 O
##6 O
- O
7 O
- O
24 O
* O
* O
] O
08 O
: O
30 O
##pm O
co O
##rt O
##is O
##ol O
- O
35 O
. O
0 O
* O
[ O
* O
* O
211 O
##6 O
- O
7 O
- O
24 O
* O
* O
] O
08 O
: O
30 O
##pm O
ha O
##pt O
##og O
##lo O
##b O
- O
147 O
[ O
* O
* O
211 O
##6 O
- O
7 O
- O
24 O
* O
* O
] O
08 O
: O
30 O
##pm O
calcium O
- O
9 O
. O
2 O
phosphate O
- O
1 O
. O
6 O
* O
# O
ma O
##gnesium O
- O
1 O
. O
5 O
* O
[ O
* O
* O
211 O
##6 O
- O
7 O
- O
24 O
* O
* O
] O
08 O
: O
30 O
##pm O
lip O
##ase O
- O
65 O
* O
[ O
* O
* O
211 O
##6 O
- O
7 O
- O
24 O
* O
* O
] O
08 O
: O
30 O
##pm O
al O
##t O
( O
s O
##g O
##pt O
) O
- O
29 O
as O
##t O
( O
s O
##got O
) O
- O
22 O
l O
##d O
( O
l O
##dh O
) O
- O
152 O
al O
##k O
p O
##hos O
- O
129 O
* O
am O
##yla O
##se O
- O
91 O
to O
##t O
bi O
##li O
- O
0 O
. O
2 O
[ O
* O
* O
211 O
##6 O
- O
7 O
- O
24 O
* O
* O
] O
08 O
: O
30 O
##pm O
glucose O
- O
118 O
* O
u O
##rea O
n O
- O
18 O
c O
##rea O
##t O
- O
1 O
. O
4 O
* O
sodium O
- O
140 O
potassium O
- O
3 O
. O
6 O
chloride O
- O
103 O
total O
co O
##2 O
- O
23 O
an O
##ion O
gap O
- O
18 O
[ O
* O
* O
211 O
##6 O
- O
7 O
- O
24 O
* O
* O
] O
08 O
: O
48 O
##pm O
la O
##ct O
##ate O
- O
4 O
. O
0 O
* O
[ O
* O
* O
211 O
##6 O
- O
7 O
- O
24 O
* O
* O
] O
09 O
: O
30 O
##pm O
fi O
##bri O
##no O
##ge O
- O
340 O
[ O
* O
* O
211 O
##6 O
- O
7 O
- O
24 O
* O
* O
] O
09 O
: O
30 O
##pm O
p O
##t O
- O
11 O
. O
6 O
p O
##tt O
- O
21 O
. O
6 O
* O
in O
##r O
( O
p O
##t O
) O
- O
1 O
. O
0 O
* O

e O
##k O
##g O
in O
ed O
: O
sin O
##us O
ta O
##chy O
##card O
##ia O
, O
rate O
129 O
b O
##pm O
, O
in O
##det O
##er O
##minate O
axis O
, O
old O
q O
##s O
in O
ii O
##i O
, O
a O
##v O
##f O
, O
t O
##w O
flat O
##ten O
##ing O
in O
v O
##2 O
- O
6 O
, O
no O
change O
versus O
prior O
. O
* O
relevant O
imaging O
data O
: O
[ O
* O
* O
211 O
##6 O
- O
7 O
- O
24 O
* O
* O
] O
c O
##x O
##r O
portable O
: O
again O
noted O
are O
staple O
##s O
from O
prior O
lung O
wedge O
re O
##section O
on O
the O
right O
. O
there O
are O
very O
low O
lung O
volumes O
. O
no O
definite O
consolidation O
##s O
are O
seen O
. O
there O
is O
plate O
##like O
ate O
##lect O
##asis O
at O
the O
left O
lung O
base O
. O
the O
heart O
size O
is O
normal O
given O
technique O
. O
no O
layer O
##ing O
p O
##le O
##ural O
e O
##ff O
##usions O
are O
seen O
. O
* O
[ O
* O
* O
211 O
##6 O
- O
7 O
- O
24 O
* O
* O
] O
c O
##t O
neck O
w O
/ O
contrast B-DRUG
: I-DRUG
no O
abnormal O
##ly O
enlarged O
nodes O
in O
the O
neck O
. O
the O
areas O
of O
increased O
up O
##take O
noted O
on O
pet O
scan O
could O
correspond O
to O
the O
region O
of O
the O
tons O
##ils O
, O
which O
appear O
un O
##rem O
##ark O
##able O
on O
the O
c O
##t O
scan O
. O
however O
, O
any O
interval O
change O
in O
their O
size O
could O
not O
be O
assessed O
due O
to O
lack O
of O
prior O
comparable O
studies O
. O
* O
[ O
* O
* O
211 O
##6 O
- O
7 O
- O
17 O
* O
* O
] O
pet O
scan O
: O
two O
new O
bilateral O
f O
##oc O
##i O
of O
increased O
f O
##d O
##g O
up O
##take O
in O
neck O
raising O
raising O
suspicion O
for O
re O
##current O
f O
##d O
##g O
- O
avid O
l O
##ymph O
##oma O
. O
other O
considerations O
would O
include O
g O
##ran O
##ulo O
##mat O
##ous O
processes O
and O
reactive O
l O
##ymph O
##ade O
##no O
##pathy O
. O
the O
intensity O
is O
greater O
than O
usually O
seen O
but O
does O
not O
exclude O
reactive O
nodes O
. O
recommend O
correlation O
with O
history O
of O
any O
recent O
infectious O
symptoms O
. O
brief O
hospital O
course O
: O
assessment O
and O
plan O
: O
39 O
yo O
female O
with O
history O
of O
t O
- O
cell O
n O
##hl O
in O
re O
##mission O
with O
recent O
abnormal O
pet O
scan O
findings O
under O
further O
investigation O
, O
with O
fever O
, O
h B-REA
##y I-REA
##pot I-REA
##ens I-REA
##ion I-REA
of O
12 O
- O
hour O
duration O
, O
re O
##sp O
##ons O
##ive O
to O
i B-DRUG
##v I-DRUG
##f I-DRUG
. I-DRUG
* O

1 O
) O
fever O
, O
h O
##y O
##pot O
##ens O
##ion O
: O
resolved O
after O
one O
night O
. O
although O
her O
presentation O
most O
suggest O
##ive O
of O
severe O
se O
##psis O
, O
with O
elevated O
la O
##ct O
##ate O
and O
h B-REA
##y I-REA
##pot I-REA
##ens I-REA
##ion I-REA
re O
##sp O
##ons O
##ive O
to O
i B-DRUG
##v I-DRUG
##f I-DRUG
re O
##sus O
##citation O
, O
the O
rapid O
resolution O
was O
more O
consistent O
with O
an O
an B-ADE
##aph I-ADE
##yla I-ADE
##ctic I-ADE
reaction I-ADE
to O
i B-ROU
##v I-ROU
contrast B-DRUG
from O
the O
c O
##t O
. O
d O
##r O
. O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
410 O
* O
* O
] O
has O
reported O
a O
similar O
admission O
where O
the O
patient O
presented O
with O
a O
se O
##ptic O
picture O
which O
subsequently O
resolved O
without O
local O
##izing O
a O
source O
. O
s O
##be O
was O
treated O
with O
the O
se B-REA
##psis I-REA
protocol I-REA
and O
broad B-DRUG
- I-DRUG
spectrum I-DRUG
anti I-DRUG
##biotic I-DRUG
coverage O
with O
c B-DRUG
##ef I-DRUG
##ep I-DRUG
##ime I-DRUG
and O
le B-DRUG
##vo I-DRUG
##f I-DRUG
##lo I-DRUG
##xa I-DRUG
##cin I-DRUG
. I-DRUG
h B-DRUG
##ydro I-DRUG
##cor I-DRUG
##tis I-DRUG
##one I-DRUG
was O
given O
in O
the O
emergency O
room O
, O
so O
[ O
* O
* O
initials O
( O
name O
##pa O
##tter O
##n O
##4 O
) O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##4 O
) O
104 O
* O
* O
] O
s O
##ti O
##m O
test O
would O
have O
been O
useless O
. O
* O
2 O
) O
t O
- O
cell O
n O
##hl O
in O
re O
##mission O
: O
recent O
pet O
findings O
were O
concerning O
for O
disease O
re O
##cu O
##rrence O
, O
although O
c O
##t O
neck O
without O
l O
##ymph O
##ade O
##no O
##pathy O
. O
her O
a B-DRUG
##cy I-DRUG
##c I-DRUG
##lov I-DRUG
##ir I-DRUG
and O
b B-DRUG
##act I-DRUG
##rim I-DRUG
prop B-REA
##hyl I-REA
##ax I-REA
##is I-REA
were O
both O
continued O
. O
there O
were O
no O
active O
hem O
##e O
/ O
on O
##c O
issues O
during O
this O
admission O
. O
* O
3 O
) O
a O
##rf O
: O
c O
##rea O
##tin O
##ine O
up O
to O
1 O
. O
4 O
on O
admission O
, O
decreased O
to O
normal O
, O
suspect O
pre O
- O
re O
##nal O
physiology O
given O
elevated O
specific O
gravity O
and O
improvement O
with O
h O
##yd O
##ration O
. O
medications O
on O
admission O
: O
a B-DRUG
##cy I-DRUG
##c I-DRUG
##lov I-DRUG
##ir I-DRUG
400 B-STR
mg I-STR
p B-ROU
##o I-ROU
t B-FRE
##id I-FRE
b B-DRUG
##act I-DRUG
##rim I-DRUG
d I-DRUG
##s I-DRUG
1 B-DOS
ta B-FOR
##b I-FOR
p B-ROU
##o I-ROU
q B-FRE
##d I-FRE
3 I-FRE
##x I-FRE
/ I-FRE
week I-FRE
pro B-DRUG
##ton I-DRUG
##ix I-DRUG
40 B-STR
mg I-STR
p B-ROU
##o I-ROU
q B-FRE
##d I-FRE
f B-DRUG
##olic I-DRUG
acid I-DRUG
1 B-STR
mg I-STR
p B-ROU
##o I-ROU
q B-FRE
##d I-FRE
c B-DRUG
##ele I-DRUG
##xa I-DRUG
40 B-STR
mg I-STR
p B-ROU
##o I-ROU
q B-FRE
##d I-FRE

discharge O
medications O
: O
1 O
. O
a B-DRUG
##cy I-DRUG
##c I-DRUG
##lov I-DRUG
##ir I-DRUG
200 B-STR
mg I-STR
capsule B-FOR
si O
##g O
: O
two B-DOS
( I-DOS
2 I-DOS
) I-DOS
capsule B-FOR
p B-ROU
##o I-ROU
q B-FRE
##8 I-FRE
##h I-FRE
( I-FRE
every I-FRE
8 I-FRE
hours I-FRE
) I-FRE
. I-FRE
2 O
. O
trim B-DRUG
##eth I-DRUG
##op I-DRUG
##rim I-DRUG
- I-DRUG
su I-DRUG
##lf I-DRUG
##ame I-DRUG
##th I-DRUG
##ox I-DRUG
##az I-DRUG
##ole I-DRUG
160 B-STR
- I-STR
800 I-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
3 B-FRE
##x I-FRE
/ I-FRE
week I-FRE
( I-FRE
m I-FRE
##o I-FRE
, I-FRE
we I-FRE
, I-FRE
f I-FRE
##r I-FRE
) I-FRE
. I-FRE
3 O
. O
pan B-DRUG
##top I-DRUG
##raz I-DRUG
##ole I-DRUG
40 B-STR
mg I-STR
tablet B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
p B-ROU
##o I-ROU
q B-FRE
##24 I-FRE
##h I-FRE
( I-FRE
every I-FRE
24 I-FRE
hours I-FRE
) I-FRE
. I-FRE
tablet B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
e I-FOR
. I-FOR
c I-FOR
. I-FOR
) I-FOR
( I-FOR
s O
) O
4 O
. O
c B-DRUG
##ital I-DRUG
##op I-DRUG
##ram I-DRUG
20 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
two B-DOS
( I-DOS
2 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( I-FRE
daily I-FRE
) I-FRE
. I-FRE
5 O
. O
f B-DRUG
##olic I-DRUG
acid I-DRUG
1 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( I-FRE
daily I-FRE
) I-FRE
. I-FRE
6 O
. O
z B-DRUG
##ant I-DRUG
##ac I-DRUG
150 B-STR
mg I-STR
capsule B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
capsule B-FOR
p B-ROU
##o I-ROU
every B-FRE
six I-FRE
( I-FRE
6 I-FRE
) I-FRE
hours I-FRE
for B-DUR
3 I-DUR
days I-DUR
. I-DUR
di O
##sp O
: O
* O
12 O
capsule B-FOR
( I-FOR
s I-FOR
) I-FOR
* I-FOR
re O
##fill O
##s O
: O
* O
0 O
* O
7 O
. O
dip B-DRUG
##hen I-DRUG
##hy I-DRUG
##dra I-DRUG
##mine I-DRUG
h I-DRUG
##c I-DRUG
##l I-DRUG
25 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
every B-FRE
six I-FRE
( I-FRE
6 I-FRE
) I-FRE
hours I-FRE
for B-DUR
3 I-DUR
days I-DUR
. I-DUR
di O
##sp O
: O
* O
12 O
tablet B-FOR
( I-FOR
s I-FOR
) I-FOR
* I-FOR
re O
##fill O
##s O
: O
* O
0 O
* O
discharge O
disposition O
: O
home O
discharge O
diagnosis O
: O
primary O
: O
likely O
an B-ADE
##aph I-ADE
##yla I-ADE
##ctic I-ADE
reaction I-ADE
to O
contrast B-DRUG
secondary O
: O
t O
- O
cell O
l O
##ymph O
##oma O
discharge O
condition O
: O
stable O
, O
a O
##fe O
##bri O
##le O
. O
discharge O
instructions O
: O
please O
take O
all O
of O
your O
medications O
as O
prescribed O
. O
if O
you O
experience O
any O
di O
##zzi O
##ness O
, O
fever O
, O
headache O
, O
nausea O
, O
vomit O
##ing O
, O
r O
##ash O
, O
or O
other O
concerning O
symptoms O
, O
please O
seek O
medical O
attention O
immediately O
. O
you O
have O
been O
prescribed O
ben B-DRUG
##ad I-DRUG
##ryl I-DRUG
and O
z B-DRUG
##ant I-DRUG
##ac I-DRUG
to O
take O
every B-FRE
6 I-FRE
hours I-FRE
until O
your O
appointment O
with O
d O
##r O
. O
[ O
* O
* O
first O
name O
( O
s O
##ti O
##tle O
) O
* O
* O
] O
. O
follow O
##up O
instructions O
: O
please O
follow O
up O
with O
d O
##r O
. O
[ O
* O
* O
first O
name O
( O
s O
##ti O
##tle O
) O
* O
* O
] O
on O
th O
##urs O
##day O
[ O
* O
* O
7 O
- O
30 O
* O
* O
] O
. O

admission O
date O
: O
[ O
* O
* O
211 O
##4 O
- O
12 O
- O
18 O
* O
* O
] O
discharge O
date O
: O
[ O
* O
* O
211 O
##5 O
- O
1 O
- O
2 O
* O
* O
] O
date O
of O
birth O
: O
[ O
* O
* O
204 O
##5 O
- O
12 O
- O
15 O
* O
* O
] O
sex O
: O
f O
service O
: O
medicine O
all O
##er O
##gies O
: O
code B-DRUG
##ine I-DRUG
attending O
: O
[ O
* O
* O
first O
name O
##3 O
( O
l O
##f O
) O
42 O
##8 O
##2 O
* O
* O
] O
chief O
complaint O
: O
fatigue O
major O
surgical O
or O
invasive O
procedure O
: O
none O
history O
of O
present O
illness O
: O
hp O
##i O
: O
the O
patient O
is O
a O
69 O
yo O
woman O
with O
h O
/ O
o O
recently O
diagnosed O
m O
##ds O
( O
[ O
* O
* O
4 O
- O
9 O
* O
* O
] O
) O
, O
a B-DRUG
##zac I-DRUG
##yt I-DRUG
##od I-DRUG
##ine I-DRUG
ch I-DRUG
##em I-DRUG
##otherapy I-DRUG
, I-DRUG
day O
15 O
presently O
cycle O
5 O
. O
presented O
to O
clinic O
for O
scheduled O
n O
##p O
follow O
up O
visit O
s O
/ O
p O
c O
##5 O
a B-DRUG
##zac I-DRUG
##iti I-DRUG
##dine I-DRUG
; I-DRUG
arrived O
feeling O
extremely O
weak O
, O
quite O
pale O
, O
shivering O
; O
describes O
4 O
days O
of O
these O
s O
##x O
, O
including O
di O
##ar O
##r O
##hea O
; O
no O
n O
/ O
v O
, O
states O
taking O
large O
amounts O
of O
p O
##o O
fluids O
, O
non O
productive O
cough O
with O
fever O
to O
102 O
. O
she O
had O
received O
3 B-DOS
##u I-DOS
p B-DRUG
##rb I-DRUG
##c I-DRUG
prior O
to O
a O
3 O
week O
trip O
in O
me O
##dit O
##er O
##rane O
##an O
. O
presented O
to O
clinic O
fatigue O
##d O
, O
with O
non O
- O
productive O
cough O
, O
but O
has O
been O
a O
##fe O
##bri O
##le O
, O
without O
evidence O
of O
respiratory O
distress O
. O
. O
past O
medical O
history O
: O
past O
on O
##co O
##log O
##ic O
history O
: O
- O
- O
presented O
to O
er O
in O
[ O
* O
* O
211 O
##4 O
- O
1 O
- O
1 O
* O
* O
] O
with O
short O
##ness O
of O
breath O
and O
fever O
secondary O
to O
pneumonia O
. O
hem O
##og O
##lo O
##bin O
and O
hem O
##ato O
##c O
##rit O
levels O
were O
4 O
. O
9 O
mg O
/ O
d O
##l O
and O
14 O
. O
2 O
% O
, O
respectively O
, O
with O
m O
##c O
##v O
= O
122 O
at O
the O
time O
. O
required O
several O
red O
cell O
trans O
##fusion O
##s O
between O
[ O
* O
* O
1 O
- O
8 O
* O
* O
] O
and O
[ O
* O
* O
4 O
- O
9 O
* O
* O
] O
. O
- O
- O
bone O
ma O
##rrow O
bio O
##psy O
on O
[ O
* O
* O
211 O
##4 O
- O
4 O
- O
26 O
* O
* O
] O
showed O
" O
h O
##yper O
##cellular O
er O
##yt O
##hr O
##oid O

dominant O
bone O
ma O
##rrow O
with O
d O
##ys O
##ery O
##throp O
##oi O
##esis O
and O
ring O
##ed O
side O
##ro O
##blast O
consistent O
with O
my O
##elo O
##dy O
##sp O
##lastic O
syndrome O
best O
classified O
as O
r O
##ars O
. O
c O
##yt O
##ogen O
##etics O
revealed O
t O
##ris O
##omy O
8 O
. O
i O
##ps O
##s O
intermediate O
- O
1 O
risk O
score O
. O
- O
- O
began O
pro B-DRUG
##c I-DRUG
##rit I-DRUG
40 B-DOS
, I-DOS
000 I-DOS
units I-DOS
weekly B-FRE
[ O
* O
* O
211 O
##4 O
- O
5 O
- O
1 O
* O
* O
] O
with O
increase O
of O
dose O
to O
60 B-DOS
, I-DOS
000 I-DOS
units I-DOS
weekly B-FRE
with O
no O
improvement O
in O
her O
red O
cell O
trans O
##fusion O
requirement O
. O
- O
- O
received O
cycle O
1 B-DOS
a B-DRUG
##zac I-DRUG
##iti I-DRUG
##dine I-DRUG
ch I-DRUG
##em I-DRUG
##otherapy I-DRUG
[ O
* O
* O
211 O
##4 O
- O
7 O
- O
9 O
* O
* O
] O
through O
[ O
* O
* O
211 O
##4 O
- O
7 O
- O
13 O
* O
* O
] O
. O
cycle O
2 O
administered O
[ O
* O
* O
date O
range O
( O
1 O
) O
97 O
##9 O
##86 O
* O
* O
] O
; O
delayed O
by O
one O
week O
due O
to O
ne B-ADE
##ut I-ADE
##rop I-ADE
##enia I-ADE
. I-ADE
cycle O
3 O
administered O
[ O
* O
* O
date O
range O
( O
1 O
) O
97 O
##9 O
##8 O
##7 O
* O
* O
] O
; O
again O
delayed O
by O
one O
week O
due O
to O
ne O
##ut O
##rop O
##enia O
. O
cycle O
4 O
administered O
. O
past O
medical O
history O
: O
s O
/ O
p O
per O
##ica O
##rdi O
##tis O
4 O
years O
ago O
bilateral O
[ O
* O
* O
hospital O
##1 O
153 O
##0 O
##9 O
* O
* O
] O
ne O
##uro O
##ma O
h O
/ O
o O
mi O
##gra O
##ines O
that O
resolved O
2 O
years O
ago O
s O
/ O
p O
plant O
##ar O
f O
##as O
##ci O
##itis O
l O
foot O
s O
/ O
p O
s O
##hing O
##les O
s O
/ O
p O
multiple O
skin O
cancer O
##s O
removed O
by O
either O
der O
##mat O
##ologists O
, O
d O
##r O
. O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
* O
* O
] O
, O
or O
d O
##r O
. O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
223 O
##42 O
* O
* O
] O
s O
/ O
p O
tons O
##ille O
##ct O
##omy O
. O
per O
##ica O
##rdi O
##tis O
social O
history O
: O
lives O
alone O
by O
herself O
in O
co O
##lli O
##dge O
corner O
in O
a O
condom O
##ini O
##um O
. O
no O
known O
family O
members O
. O
[ O
* O
* O
name O
( O
ni O
) O
* O
* O
] O
lots O
of O
friends O
who O
live O
nearby O
. O
1 O
pack O
c O
##ig O
per O
day O
active O
smoke O
##r O
for O
approx O
50 O
years O
. O
family O
history O
: O
father O
passed O
away O
of O
p O
##na O
. O
physical O
exam O
: O
physical O
exam O
: O
vs O
: O
t O
##c O
: O
98 O
. O
7 O
h O
##r O
: O
100 O
b O
##p O
: O
106 O
/ O
51 O
. O
general O
: O
comfortable O
. O
skin O
: O
very O
pale O
, O
warm O
, O
dry O
, O
without O
e O
##cc O
##hy O
##mos O
##is O
, O
er O
##yt O
##hem O
##a O
, O
pet O
##ech O
##iae O
or O
r O
##ash O
. O
he O
##ent O
: O
s O
##cle O
##ra O
an O
##ict O
##eric O
, O
con O
##junct O
##iva O
very O
pale O
. O
or O
##op O
##har O
##ynx O
pale O
pink O
, O
moist O
, O
without O
m O
##uc O
##os O
##itis O
, O
er O
##yt O
##hem O
##a O
or O
th O
##rush O
. O
lungs O
: O
breathing O
easily O
with O
occasional O
dry O
cough O
, O
able O
to O
talk O
in O
full O
sentences O
; O
dull O
##ness O
to O
percussion O
at O
l O
base O
; O
diminished O

coarse O
breath O
sounds O
at O
r O
base O
with O
ins O
##pi O
##rator O
##y O
and O
ex O
##pi O
##rator O
##y O
crack O
##les O
. O
remainder O
of O
lung O
fields O
clear O
. O
cardiac O
: O
heart O
rate O
regular O
in O
rate O
and O
rhythm O
, O
without O
murmur O
, O
rub O
or O
gal O
##lop O
. O
ex O
##tre O
##mit O
##ies O
: O
symmetrical O
, O
trace O
ed O
##ema O
bilateral O
##ly O
from O
feet O
to O
mid O
- O
calf O
bilateral O
##ly O
. O
no O
er O
##yt O
##hem O
##a O
or O
tender O
##ness O
. O
per O
##tinent O
results O
: O
[ O
* O
* O
211 O
##4 O
- O
12 O
- O
18 O
* O
* O
] O
09 O
: O
00 O
##pm O
h O
##bs O
##ag O
- O
negative O
h O
##bs O
a O
##b O
- O
negative O
h O
##b O
##c O
a O
##b O
- O
negative O
i O
##g O
##m O
ha O
##v O
- O
negative O
[ O
* O
* O
211 O
##4 O
- O
12 O
- O
18 O
* O
* O
] O
09 O
: O
00 O
##pm O
smooth O
- O
negative O
[ O
* O
* O
211 O
##4 O
- O
12 O
- O
18 O
* O
* O
] O
09 O
: O
00 O
##pm O
[ O
* O
* O
doctor O
first O
name O
* O
* O
] O
- O
positive O
* O
[ O
* O
* O
211 O
##4 O
- O
12 O
- O
18 O
* O
* O
] O
09 O
: O
00 O
##pm O
h O
##c O
##v O
a O
##b O
- O
negative O
[ O
* O
* O
211 O
##4 O
- O
12 O
- O
18 O
* O
* O
] O
08 O
: O
50 O
##am O
u O
##rea O
n O
- O
22 O
* O
c O
##rea O
##t O
- O
1 O
. O
1 O
sodium O
- O
130 O
* O
potassium O
- O
3 O
. O
7 O
chloride O
- O
97 O
total O
co O
##2 O
- O
21 O
* O
an O
##ion O
gap O
- O
16 O
[ O
* O
* O
211 O
##4 O
- O
12 O
- O
18 O
* O
* O
] O
08 O
: O
50 O
##am O
al O
##t O
( O
s O
##g O
##pt O
) O
- O
191 O
* O
as O
##t O
( O
s O
##got O
) O
- O
230 O
* O
l O
##d O
( O
l O
##dh O
) O
- O
34 O
##3 O
* O
al O
##k O
p O
##hos O
- O
89 O
to O
##t O
bi O
##li O
- O
0 O
. O
7 O
[ O
* O
* O
211 O
##4 O
- O
12 O
- O
18 O
* O
* O
] O
08 O
: O
50 O
##am O
ha O
##pt O
##og O
##lo O
##b O
- O
176 O
[ O
* O
* O
211 O
##4 O
- O
12 O
- O
18 O
* O
* O
] O
08 O
: O
50 O
##am O
w O
##b O
##c O
- O
0 O
. O
8 O
* O
# O
r O
##b O
##c O
- O
1 O
. O
53 O
* O
# O
h O
##g O
##b O
- O
4 O
. O
5 O
* O
# O
h O
##ct O
- O
13 O
. O
6 O
* O
# O
m O
##c O
##v O
- O
89 O
m O
##ch O
- O
29 O
. O
4 O
m O
##ch O
##c O
- O
33 O
. O
1 O
r O
##d O
##w O
- O
21 O
. O
4 O
* O
[ O
* O
* O
211 O
##4 O
- O
12 O
- O
18 O
* O
* O
] O
08 O
: O
50 O
##am O
ne O
##uts O
- O
42 O
. O
8 O
* O
l O
##ymph O
##s O
- O
53 O
. O
5 O
* O
mon O
##os O
- O
1 O
. O
5 O
* O
e O
##os O
- O
0 O
. O
9 O
b O
##as O
##os O
- O
1 O
. O
3 O
[ O
* O
* O
211 O
##4 O
- O
12 O
- O
18 O
* O
* O
] O
08 O
: O
50 O
##am O
p O
##lt O
s O
##m O
##r O
- O
very O
low O
p O
##lt O
count O
- O
74 O
* O
# O
[ O
* O
* O
211 O
##4 O
- O
12 O
- O
18 O
* O
* O
] O
08 O
: O
50 O
##am O
re O
##t O
au O
##t O
- O
2 O
. O
5 O
. O

micro O
: O
direct O
in O
##fluenza O
a O
anti O
##gen O
test O
( O
final O
[ O
* O
* O
211 O
##4 O
- O
12 O
- O
19 O
* O
* O
] O
) O
: O
negative O
for O
in O
##fluenza O
a O
. O
direct O
in O
##fluenza O
b O
anti O
##gen O
test O
( O
final O
[ O
* O
* O
211 O
##4 O
- O
12 O
- O
19 O
* O
* O
] O
) O
: O
negative O
for O
in O
##fluenza O
b O
. O
[ O
* O
* O
211 O
##4 O
- O
12 O
- O
19 O
* O
* O
] O
: O
liver O
us O
. O
. O
impression O
: O
1 O
. O
no O
in O
##tra O
- O
or O
extra O
- O
he O
##pa O
##tic O
bi O
##lia O
##ry O
duct O
di O
##lat O
##ation O
. O
2 O
. O
small O
amount O
of O
free O
per O
##ih O
##ep O
##atic O
fluid O
. O
3 O
. O
collapsed O
gal O
##l O
##bla O
##dder O
with O
wall O
ed O
##ema O
and O
small O
amount O
of O
per O
##ich O
##ole O
##cy O
##stic O
fluid O
. O
these O
findings O
could O
be O
due O
to O
a O
var O
##ier O
##y O
of O
chronic O
conditions O
including O
h O
##y O
##po O
##al O
##bu O
##mine O
##mia O
, O
ch O
##f O
, O
or O
can O
be O
seen O
in O
he O
##pa O
##titis O
. O
there O
is O
no O
evidence O
to O
suggest O
acute O
inflammation O
. O
. O
c O
##x O
##r O
: O
[ O
* O
* O
211 O
##4 O
- O
12 O
- O
18 O
* O
* O
] O
very O
severe O
he O
##tero O
##gene O
##ous O
op O
##ac O
##ification O
has O
developed O
in O
the O
left O
upper O
lobe O
. O
left O
lower O
lobe O
was O
collapsed O
in O
[ O
* O
* O
month O
( O
only O
) O
109 O
##6 O
* O
* O
] O
, O
now O
re O
##ex O
##pan O
##ded O
and O
densely O
consolidated O
. O
there O
may O
be O
left O
hi O
##lar O
ad O
##eno O
##pathy O
and O
small O
left O
p O
##le O
##ural O
e O
##ff O
##usion O
. O
overall O
, O
findings O
are O
consistent O
with O
extensive O
pneumonia O
though O
under O
the O
appropriate O
clinical O
circumstances O
, O
this O
could O
be O
in O
##fi O
##lt O
##rated O
ma O
##li O
##gna O
##ncy O
. O
small O
region O
of O
ground O
- O
glass O
op O
##acity O
in O
the O
right O
apex O
per O
##sist O
##s O
since O
the O
chest O
c O
##t O
done O
on O
[ O
* O
* O
211 O
##4 O
- O
1 O
- O
13 O
* O
* O
] O
. O
mild O
- O
to O
- O
moderate O
card O
##io O
##me O
##gal O
##y O
is O
long O
##standing O
and O
right O
lung O
shows O
some O
mild O
vascular O
red O
##ist O
##ri O
##but O
##ion O
but O
i O
do O
not O
believe O
pulmonary O
ed O
##ema O
is O
playing O
any O
role O
. O
. O

- O
[ O
* O
* O
211 O
##4 O
- O
12 O
- O
21 O
* O
* O
] O
t O
##te O
: O
the O
left O
at O
##rium O
is O
mildly O
di O
##lated O
. O
left O
vent O
##ric O
##ular O
wall O
thickness O
##is O
is O
normal O
. O
there O
is O
normal O
cavity O
size O
and O
regional O
/ O
global O
s O
##ys O
##to O
##lic O
function O
( O
l O
##ve O
##f O
> O
55 O
% O
) O
. O
the O
estimated O
cardiac O
index O
is O
normal O
( O
> O
= O
2 O
. O
5 O
##l O
/ O
min O
/ O
m O
##2 O
) O
. O
do O
##pp O
##ler O
parameters O
are O
most O
consistent O
with O
grade O
ii O
( O
moderate O
) O
left O
vent O
##ric O
##ular O
di O
##ast O
##olic O
d O
##ys O
##function O
. O
the O
right O
vent O
##ric O
##ular O
cavity O
is O
mildly O
di O
##lated O
with O
normal O
free O
wall O
contract O
##ility O
. O
the O
a O
##ort O
##ic O
valve O
leaf O
##lets O
( O
3 O
) O
are O
mildly O
thick O
##ened O
but O
a O
##ort O
##ic O
s O
##ten O
##osis O
is O
not O
present O
. O
no O
a O
##ort O
##ic O
re O
##gu O
##rg O
##itation O
is O
seen O
. O
the O
mit O
##ral O
valve O
leaf O
##lets O
are O
mildly O
thick O
##ened O
. O
there O
is O
no O
mit O
##ral O
valve O
pro O
##lap O
##se O
. O
moderate O
( O
2 O
+ O
) O
mit O
##ral O
re O
##gu O
##rg O
##itation O
is O
seen O
. O
there O
is O
moderate O
pulmonary O
artery O
s O
##ys O
##to O
##lic O
h O
##yper O
##tens O
##ion O
. O
there O
is O
no O
per O
##ica O
##rdi O
##al O
e O
##ff O
##usion O
. O
- O
[ O
* O
* O
211 O
##4 O
- O
12 O
- O
24 O
* O
* O
] O
c O
##t O
chest O
: O
1 O
. O
multi O
##fo O
##cal O
pneumonia O
, O
comparable O
in O
extent O
to O
the O
appearance O
on O
the O
chest O
radio O
##graph O
, O
[ O
* O
* O
12 O
- O
23 O
* O
* O
] O
, O
which O
has O
progressed O
since O
[ O
* O
* O
12 O
- O
18 O
* O
* O
] O
. O
small O
bilateral O
p O
##le O
##ural O
e O
##ff O
##usions O
are O
also O
comparable O
and O
not O
of O
sufficient O
size O
to O
suggest O
em O
##py O
##ema O
. O
there O
are O
no O
characteristics O
of O
the O
widespread O
pulmonary O
infection O
, O
to O
permit O
disc O
##rim O
##inating O
among O
possible O
causes O
: O
virus O
, O
bacteria O
, O
or O
fungus O
. O
2 O
. O
minimal O
increase O
in O
size O
and O
number O
of O
media O
##st O
##inal O
l O
##ymph O
nodes O
, O
presumably O
reactive O
. O
more O
substantial O
left O
hi O
##lar O
ad O
##eno O
##pathy O
cannot O
be O
excluded O
, O
but O
if O
present O
, O
is O
not O
o O
##bs O
##truct O
##ive O
, O
and O
is O
equally O
likely O
to O
be O
reactive O
. O
3 O
. O
new O
tiny O
right O
middle O
lobe O
lung O
nod O
##ule O
. O
4 O
. O
small O
p O
##le O
##ural O
and O
per O
##ica O
##rdi O
##al O
e O
##ff O
##usions O
could O
be O
sympathetic O
to O
infection O
, O
or O
residual O
from O
prior O
card O
##io O
##genic O
ed O
##ema O
- O
[ O
* O
* O
211 O
##4 O
- O
12 O
- O
27 O
* O
* O
] O
c O
##t O
head O
no O
acute O
in O
##tra O
##c O
##rani O
##al O
hem O
##or O
##r O
##hage O
. O
no O
acute O
in O
##tra O
##c O
##rani O
##al O
process O

- O
[ O
* O
* O
211 O
##4 O
- O
12 O
- O
30 O
* O
* O
] O
m O
##ri O
/ O
m O
##ra O
multiple O
areas O
of O
restricted O
diffusion O
are O
seen O
in O
both O
cerebral O
hemisphere O
##s O
involving O
frontal O
, O
par O
##iet O
##al O
and O
o O
##cci O
##pit O
##al O
lobes O
. O
no O
focal O
acute O
in O
##far O
##cts O
are O
seen O
within O
the O
posterior O
f O
##ossa O
. O
the O
distribution O
is O
in O
the O
watershed O
region O
in O
the O
left O
frontal O
lobe O
, O
but O
otherwise O
, O
it O
is O
in O
the O
co O
##rt O
##ical O
and O
sub O
##cor O
##tical O
region O
of O
both O
cerebral O
hemisphere O
##s O
. O
there O
is O
no O
acute O
hem O
##or O
##r O
##hage O
identified O
. O
there O
is O
no O
mass O
effect O
, O
mid O
##line O
shift O
or O
h O
##ydro O
##ce O
##pha O
##lus O
. O
mild O
- O
to O
- O
moderate O
brain O
at O
##rop O
##hy O
is O
seen O
. O
impression O
: O
1 O
. O
multiple O
small O
acute O
co O
##rt O
##ical O
and O
sub O
##cor O
##tical O
in O
##far O
##cts O
including O
in O
##far O
##ct O
in O
the O
left O
frontal O
watershed O
distribution O
as O
described O
above O
. O
mild O
di O
##ff O
##use O
decreased O
signal O
within O
the O
bony O
structures O
of O
the O
head O
could O
be O
due O
to O
ma O
##rrow O
h O
##yper O
##p O
##lasia O
or O
in O
##fi O
##ltration O
and O
clinical O
correlation O
recommended O
. O
m O
##ra O
of O
the O
neck O
: O
neck O
m O
##ra O
shows O
normal O
flow O
in O
car O
##ot O
##id O
and O
ve O
##rte O
##bra O
##l O
art O
##eries O
without O
s O
##ten O
##osis O
or O
o O
##cc O
##lusion O
. O
impression O
: O
normal O
m O
##ra O
of O
the O
neck O
. O
m O
##ra O
head O
: O
head O
m O
##ra O
demonstrates O
normal O
flow O
in O
the O
art O
##eries O
of O
anterior O
and O
posterior O
circulation O
. O
impression O
: O
normal O
m O
##ra O
of O
the O
head O
- O
[ O
* O
* O
211 O
##5 O
- O
1 O
- O
1 O
* O
* O
] O
t O
##te O
bubble O
study O
: O
no O
at O
##rial O
se O
##pta O
##l O
defect O
or O
patent O
for O
##ame O
##n O
oval O
##e O
is O
seen O
by O
2d O
, O
color O
do O
##pp O
##ler O
or O
sa O
##line O
contrast O
with O
maneuvers O
- O
[ O
* O
* O
211 O
##5 O
- O
1 O
- O
1 O
* O
* O
] O
c O
##s O
##f O
: O
w O
##b O
##c O
: O
2 O
( O
x O
##2 O
tubes O
) O
t O
##p O
28 O
g O
##lu O
##c O
51 O
l O
##dh O
31 O
- O
[ O
* O
* O
211 O
##5 O
- O
1 O
- O
2 O
* O
* O
] O
e O
##eg O
: O
pending O
at O
time O
of O
discharge O
labs O
on O
day O
of O
discharge O
: O
w O
##b O
##c O
4 O
. O
4 O
h O
##ct O
21 O
. O
9 O
p O
##lt O
221 O
na O
138 O
k O
4 O
. O
3 O
c O
##l O
109 O
h O
##co O
##3 O
26 O
b O
##un O
16 O
c O
##rea O
##t O
0 O
. O
7 O
g O
##lu O
##c O
73 O
al O
##t O
37 O
as O
##t O
81 O
a O
##p O
158 O
t O
##bil O
0 O
. O
2 O
al O
##b O
2 O
. O
0 O
brief O
hospital O
course O
: O
69 O
yo O
with O
my O
##elo O
##dy O
##sp O
##lastic O
syndrome O
( O
r O
##ars O
) O
, O
presently O
d O
##15 O
##c O
##5 O
a B-DRUG
##zac I-DRUG
##iti I-DRUG
##dine I-DRUG
presenting O
with O
fever O
, O
ne B-ADE
##ut I-ADE
##rop I-ADE
##enia I-ADE
, I-ADE
profound B-REA
an I-REA
##emia I-REA
, I-REA
di B-ADE
##ar I-ADE
##r I-ADE
##hea I-ADE
and O
cough O
with O
fever O
, O
lung O
exam O
concerning O
for O
p O
##na O
. O
. O

respiratory O
distress O
: O
patient O
presented O
with O
profound O
an O
##emia O
likely O
secondary O
to O
her O
m O
##ds O
. O
she O
received O
5 B-DOS
up B-DRUG
##rb I-DRUG
##c I-DRUG
with O
improvement O
of O
her O
h O
##ct O
from O
13 O
. O
6 O
on O
admission O
to O
23 O
. O
2 O
. O
she O
developed O
re O
##sp O
##it O
##rator O
##y O
distress O
likely O
secondary O
to O
combined O
insult O
of O
her O
pneumonia O
and O
volume O
over O
##load O
for O
which O
she O
triggered O
. O
she O
was O
found O
to O
be O
in O
flash O
pulmonary O
ed O
##ema O
. O
she O
received O
supportive O
therapy O
. O
her O
respiratory O
status O
improved O
and O
she O
was O
transferred O
to O
the O
floor O
. O
she O
was O
started O
on O
al B-DRUG
##but I-DRUG
##ero I-DRUG
##l I-DRUG
ne B-FOR
##bul I-FOR
##izer I-FOR
treat O
##ement O
for O
possible O
br B-REA
##on I-REA
##cho I-REA
##sp I-REA
##as I-REA
##m I-REA
, I-REA
but O
this O
may O
not O
need O
to O
be O
continued O
at O
the O
rehabilitation O
facility O
. O
. O
p O
##na O
/ O
re O
##current O
fever O
##s O
: O
she O
had O
presented O
to O
clinic O
where O
she O
was O
found O
to O
be O
f O
##eb O
##ril O
##e O
to O
102 O
and O
ne O
##ut O
##rop O
##eni O
##c O
. O
a O
c O
##x O
##r O
showed O
a O
left B-REA
lower I-REA
lobe I-REA
pneumonia I-REA
. I-REA
she O
was O
started O
on O
van B-DRUG
##com I-DRUG
##y I-DRUG
##cin I-DRUG
and O
c B-DRUG
##ef I-DRUG
##ep I-DRUG
##ime I-DRUG
. I-DRUG
a O
d O
##fa O
was O
negative O
. O
blood O
cultures O
were O
negative O
. O
in O
the O
interim O
, O
the O
patient O
was O
managed O
with O
me B-DRUG
##rop I-DRUG
##ene I-DRUG
##m I-DRUG
, I-DRUG
v B-DRUG
##ori I-DRUG
##cona I-DRUG
##zo I-DRUG
##le I-DRUG
, I-DRUG
a B-DRUG
##zi I-DRUG
##th I-DRUG
##rom I-DRUG
##y I-DRUG
##cin I-DRUG
, I-DRUG
and O
van B-DRUG
##com I-DRUG
##cy I-DRUG
##in I-DRUG
in O
the O
setting O
of O
re B-REA
##current I-REA
fever I-REA
##s I-REA
and O
night B-REA
sweat I-REA
##s I-REA
. I-REA
she O
was O
discharged O
after O
being O
a O
##fe O
##bri O
##le O
for O
1 O
- O
2 O
days O
, O
with O
a O
short O
course O
of O
me B-DRUG
##rop I-DRUG
##ene I-DRUG
##m I-DRUG
to O
be O
completed O
. O
. O
m B-REA
##ds I-REA
/ I-REA
an B-REA
##emia I-REA
: I-REA
she O
has O
a O
history O
of O
side B-REA
##ro I-REA
##blast I-REA
##ic I-REA
an I-REA
##emia I-REA
for O
which O
she O
is O
on O
a B-DRUG
##zac I-DRUG
##iti I-DRUG
##dine I-DRUG
. I-DRUG
she O
received O
5 B-DOS
units I-DOS
of O
p B-DRUG
##rb I-DRUG
##c I-DRUG
over O
the B-DUR
first I-DUR
2 I-DUR
days I-DUR
of O
her O
hospital O
##ization O
. O
there O
was O
a O
consideration O
, O
given O
the O
re O
##current O
fever O
##s O
and O
night O
sweat O
##s O
, O
that O
the O
patient O
had O
a O
hem O
##ato O
##log O
##ic O
et O
##iology O
, O
perhaps O
transformation O
to O
am O
##l O
. O
a O
s O
##me O
##ar O
was O
obtained O
and O
was O
un O
##rem O
##ark O
##able O
, O
so O
bone O
ma O
##rrow O
bio O
##psy O
was O
def O
##er O
##red O
. O
she O
received O
a B-DOS
unit I-DOS
of O
p B-DRUG
##rb I-DRUG
##c I-DRUG
on O
the O
day O
of O
discharge O
, O
which O
she O
completed O
prior O
to O
transfer O
to O
rehabilitation O
. O
. O

altered O
mental O
status O
/ O
right O
hand O
- O
wrist O
weakness O
: O
the O
patient O
developed O
right O
hand O
/ O
wrist O
weakness O
on O
[ O
* O
* O
12 O
- O
26 O
* O
* O
] O
. O
the O
patient O
also O
developed O
attention O
/ O
cognitive O
deficit O
##s O
. O
an O
m O
##r O
head O
was O
obtained O
which O
showed O
a O
likely O
watershed O
in O
##far O
##ct O
in O
the O
left O
frontal O
cortex O
, O
with O
multiple O
focal O
lesions O
in O
both O
hemisphere O
##s O
. O
l O
##p O
was O
negative O
for O
men O
##ing O
##itis O
. O
t O
##te O
bubble O
study O
was O
negative O
for O
p O
##fo O
or O
as O
##d O
. O
e O
##eg O
was O
performed O
with O
results O
pending O
at O
time O
of O
discharge O
. O
her O
mental O
status O
improved O
considerably O
and O
she O
had O
a O
clear O
thought O
process O
, O
and O
was O
consistently O
oriented O
to O
her O
name O
, O
the O
name O
of O
her O
hospital O
, O
and O
the O
month O
/ O
year O
. O
. O
l O
##ft O
elevation O
: O
he O
##pa O
##titis O
se O
##rol O
##ogies O
were O
negative O
, O
as O
were O
smooth O
antibodies O
. O
she O
did O
have O
a O
positive O
[ O
* O
* O
doctor O
first O
name O
* O
* O
] O
with O
t O
##iter O
pending O
. O
he O
##pa O
##tic O
us O
showed O
small O
amount O
of O
free O
per O
##ih O
##ep O
##atic O
fluid O
, O
collapsed O
gal O
##l O
##bla O
##dder O
with O
wall O
ed O
##ema O
, O
and O
small O
amount O
of O
per O
##ich O
##ole O
##cy O
##stic O
fluid O
. O
l O
##fts O
were O
improved O
by O
day O
of O
discharge O
. O
. O
ne B-ADE
##ut I-ADE
##rop I-ADE
##eni I-ADE
##c I-ADE
fever I-ADE
: I-ADE
her O
ne B-ADE
##ut I-ADE
##rop I-ADE
##enia I-ADE
was O
likely O
secondary O
to O
her O
ch B-DRUG
##em I-DRUG
##otherapy I-DRUG
. I-DRUG
she O
was O
placed O
on O
ne O
##ut O
##rop O
##eni O
##c O
pre O
##ca O
##ution O
##s O
and O
her O
an O
##c O
was O
trend O
##ed O
. O
her O
ne B-REA
##ut I-REA
##rop I-REA
##enia I-REA
resolved O
with O
periodic O
dos O
##ing O
of O
ne B-DRUG
##up I-DRUG
##ogen I-DRUG
. I-DRUG
she O
had O
had O
no O
fever O
##s O
for O
1 O
- O
2 O
days O
prior O
to O
discharge O
. O
per O
id O
recommendations O
, O
she O
was O
discharged O
on O
me B-DRUG
##rop I-DRUG
##ene I-DRUG
##m I-DRUG
, I-DRUG
to O
be O
continued O
for B-DUR
six I-DUR
days I-DUR
following O
discharge O
. O
. O
prop O
##hyl O
##ax O
##is O
: O
she O
did O
not O
receive O
he B-DRUG
##par I-DRUG
##in I-DRUG
sq B-ROU
prop O
##hyl O
##actic O
##ally O
given O
the O
con O
##tra O
##ind O
##ica O
##tion O
posed O
by O
her O
a B-DRUG
##zac I-DRUG
##iti I-DRUG
##dine I-DRUG
therapy O
. O
as O
her O
plate O
##let O
count O
remained O
normal O
, O
and O
there O
was O
no O
evidence O
of O
in O
##tra O
##c O
##rani O
##al O
hem O
##or O
##r O
##hage O
on O
imaging O
, O
s B-ROU
##c I-ROU
he B-DRUG
##par I-DRUG
##in I-DRUG
was O
given O
for O
d B-REA
##v I-REA
##t I-REA
prop I-REA
##hyl I-REA
##ax I-REA
##is I-REA
. I-REA
medications O
on O
admission O
: O
pro B-DRUG
##ch I-DRUG
##lor I-DRUG
##per I-DRUG
##azi I-DRUG
##ne I-DRUG
male I-DRUG
##ate I-DRUG
- O
10 B-STR
mg I-STR
tablet B-FOR
- O
1 B-DOS
tablet B-FOR
( I-FOR
s I-FOR
) I-FOR
by B-ROU
mouth I-ROU
every B-FRE
6 I-FRE
hours I-FRE
as I-FRE
needed I-FRE
for O
nausea B-REA
z B-DRUG
##olm I-DRUG
##it I-DRUG
##rip I-DRUG
##tan I-DRUG
[ I-DRUG
z I-DRUG
##omi I-DRUG
##g I-DRUG
] I-DRUG
- O
( O
prescribed O
by O
other O
provider O
) O
- O
dos O
##age O
uncertain O

medications O
- O
o O
##t O
##c O
as B-DRUG
##pi I-DRUG
##rin I-DRUG
[ I-DRUG
as I-DRUG
##pi I-DRUG
##rin I-DRUG
[ I-DRUG
* I-DRUG
* I-DRUG
hospital I-DRUG
##1 I-DRUG
* I-DRUG
* I-DRUG
] I-DRUG
] I-DRUG
- O
( O
prescribed O
by O
other O
provider O
; O
o O
##t O
##c O
) O
- O
81 B-STR
mg I-STR
tablet B-FOR
, I-FOR
ch I-FOR
##ew I-FOR
##able I-FOR
- O
one B-DOS
tablet B-FOR
( I-FOR
s I-FOR
) I-FOR
by B-ROU
mouth I-ROU
once B-FRE
a I-FRE
day I-FRE
er B-DRUG
##go I-DRUG
##cal I-DRUG
##ci I-DRUG
##fer I-DRUG
##ol I-DRUG
( I-DRUG
vitamin I-DRUG
d I-DRUG
##2 I-DRUG
) I-DRUG
[ I-DRUG
vitamin I-DRUG
d I-DRUG
] I-DRUG
- O
( O
prescribed O
by O
other O
provider O
) O
- O
1 B-STR
, I-STR
000 I-STR
unit I-STR
tablet B-FOR
- O
1 B-DOS
tablet B-FOR
( I-FOR
s I-FOR
) I-FOR
by B-ROU
mouth I-ROU
once B-FRE
a I-FRE
day I-FRE
multi B-DRUG
##vi I-DRUG
##tam I-DRUG
##in I-DRUG
- O
( O
prescribed O
by O
other O
provider O
) O
- O
capsule B-FOR
- O
1 B-DOS
##cap B-FOR
capsule B-FOR
( I-FOR
s I-FOR
) I-FOR
by B-ROU
mouth I-ROU
once B-FRE
daily I-FRE
o B-DRUG
##me I-DRUG
##ga I-DRUG
- I-DRUG
3 I-DRUG
fatty I-DRUG
acids I-DRUG
[ I-DRUG
fish I-DRUG
oil I-DRUG
] I-DRUG
- O
( O
prescribed O
by O
other O
provider O
) O
- O
dos O
##age O
uncertain O
vitamin B-DRUG
e I-DRUG
- O
( O
prescribed O
by O
other O
provider O
) O
- O
dos O
##age O
uncertain O
. O
all O
##er O
##gies O
: O
code B-DRUG
##ine I-DRUG

discharge O
medications O
: O
1 O
. O
as B-DRUG
##pi I-DRUG
##rin I-DRUG
81 B-STR
mg I-STR
tablet B-FOR
, I-FOR
ch I-FOR
##ew I-FOR
##able I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
, I-FOR
ch I-FOR
##ew I-FOR
##able I-FOR
p B-ROU
##o I-ROU
daily B-FRE
( I-FRE
daily I-FRE
) I-FRE
. I-FRE
2 O
. O
pro B-DRUG
##ch I-DRUG
##lor I-DRUG
##per I-DRUG
##azi I-DRUG
##ne I-DRUG
male I-DRUG
##ate I-DRUG
10 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
q B-FRE
##6 I-FRE
##h I-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
nausea B-REA
. O
3 O
. O
g B-DRUG
##ua I-DRUG
##ife I-DRUG
##nes I-DRUG
##in I-DRUG
100 B-STR
mg I-STR
/ I-STR
5 I-STR
m I-STR
##l I-STR
syrup B-FOR
si O
##g O
: O
5 B-DOS
- I-DOS
10 I-DOS
m I-DOS
##ls I-DOS
p B-ROU
##o I-ROU
q B-FRE
##6 I-FRE
##h I-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
cough B-REA
. I-REA
4 O
. O
ben B-DRUG
##zon I-DRUG
##ata I-DRUG
##te I-DRUG
100 B-STR
mg I-STR
capsule B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
capsule B-FOR
p B-ROU
##o I-ROU
t B-FRE
##id I-FRE
( I-FRE
3 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
cough B-REA
. I-REA
5 O
. O
me B-DRUG
##rop I-DRUG
##ene I-DRUG
##m I-DRUG
500 B-STR
mg I-STR
re B-FOR
##con I-FOR
so I-FOR
##ln I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
dose I-DOS
in B-ROU
##tra I-ROU
##ven I-ROU
##ous I-ROU
every B-FRE
six I-FRE
( I-FRE
6 I-FRE
) I-FRE
hours I-FRE
for B-DUR
6 I-DUR
days I-DUR
: I-DUR
last O
doses O
on O
[ O
* O
* O
211 O
##5 O
- O
1 O
- O
8 O
* O
* O
] O
. O
6 O
. O
al B-DRUG
##but I-DRUG
##ero I-DRUG
##l I-DRUG
su I-DRUG
##lf I-DRUG
##ate I-DRUG
2 B-STR
. I-STR
5 I-STR
mg I-STR
/ I-STR
3 I-STR
m I-STR
##l I-STR
( I-STR
0 I-STR
. I-STR
08 I-STR
##3 I-STR
% I-STR
) I-STR
solution B-FOR
for I-FOR
ne I-FOR
##bul I-FOR
##ization I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
treatment B-ROU
in I-ROU
##hala I-ROU
##tion I-ROU
every B-FRE
four I-FRE
( I-FRE
4 I-FRE
) I-FRE
hours I-FRE
as I-FRE
needed I-FRE
for O
sob B-REA
/ I-REA
w B-REA
##hee I-REA
##ze I-REA
. I-REA
7 O
. O
ace B-DRUG
##tam I-DRUG
##ino I-DRUG
##phe I-DRUG
##n I-DRUG
325 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
1 B-DOS
- I-DOS
2 I-DOS
tablets B-FOR
p B-ROU
##o I-ROU
q B-FRE
##8 I-FRE
##h I-FRE
( I-FRE
every I-FRE
8 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for I-FRE
p I-FRE
##rn I-FRE
fever B-REA
. I-REA
8 O
. O
ch B-DRUG
##ole I-DRUG
##cal I-DRUG
##ci I-DRUG
##fer I-DRUG
##ol I-DRUG
( I-DRUG
vitamin I-DRUG
d I-DRUG
##3 I-DRUG
) I-DRUG
1 B-STR
, I-STR
000 I-STR
unit I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE
9 O
. O
o B-DRUG
##me I-DRUG
##ga I-DRUG
- I-DRUG
3 I-DRUG
fish I-DRUG
oil I-DRUG
1 B-STR
, I-STR
000 I-STR
- I-STR
5 I-STR
mg I-STR
- I-STR
unit I-STR
capsule B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
capsule B-FOR
p B-ROU
##o I-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE
10 O
. O
vitamin B-DRUG
e I-DRUG
400 B-STR
unit I-STR
capsule B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
capsule B-FOR
p B-ROU
##o I-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE
discharge O
disposition O
: O
extended O
care O
facility O
: O
[ O
* O
* O
hospital O
##6 O
45 O
##9 O
* O
* O
] O
for O
the O
aged O
- O
mac O
##u O
discharge O
diagnosis O
: O
primary O
multi O
##fo O
##cal O
pneumonia O
f O
##eb O
##ril O
##e O
ne O
##ut O
##rop O
##enia O
left O
frontal O
watershed O
cerebral O
in O
##far O
##ct O
my O
##elo O
##dy O
##sp O
##lastic O
syndrome O

secondary O
s O
/ O
p O
per O
##ica O
##rdi O
##tis O
4 O
years O
ago O
bilateral O
[ O
* O
* O
hospital O
##1 O
153 O
##0 O
##9 O
* O
* O
] O
ne O
##uro O
##ma O
h O
/ O
o O
mi O
##gra O
##ines O
that O
resolved O
2 O
years O
ago O
s O
/ O
p O
plant O
##ar O
f O
##as O
##ci O
##itis O
l O
foot O
s O
/ O
p O
s O
##hing O
##les O
s O
/ O
p O
multiple O
skin O
cancer O
##s O
removed O
by O
either O
der O
##mat O
##ologists O
, O
d O
##r O
. O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
* O
* O
] O
, O
or O
d O
##r O
. O
[ O
* O
* O
last O
name O
( O
s O
##ti O
##tle O
) O
223 O
##42 O
* O
* O
] O
s O
/ O
p O
tons O
##ille O
##ct O
##omy O
. O
per O
##ica O
##rdi O
##tis O
discharge O
condition O
: O
medical O
##ly O
stable O
for O
discharge O
to O
rehabilitation O
facility O
. O
discharge O
instructions O
: O
you O
were O
admitted O
to O
the O
hospital O
because O
you O
were O
fatigue O
##d O
and O
having O
fever O
##s O
. O
you O
were O
found O
to O
have O
a O
pneumonia B-REA
treated O
with O
anti B-DRUG
##biotics I-DRUG
. I-DRUG
you O
also O
received O
blood B-DRUG
trans B-FOR
##fusion I-FOR
##s I-FOR
. I-FOR
your O
breathing O
initially O
improved O
, O
however O
your O
lungs O
became O
over O
##loaded O
with O
fluid O
and O
you O
went O
to O
the O
intensive O
care O
unit O
. O
your O
breathing O
improved O
and O
you O
came O
back O
to O
the O
regular O
floor O
. O
. O
you O
con O
##in O
##ued O
to O
have O
difficulty O
with O
your O
breathing O
and O
continued O
to O
have O
fever O
##s O
so O
procedures O
were O
done O
to O
sample O
your O
lung O
fluid O
to O
culture O
and O
remove O
some O
of O
the O
fluid O
, O
which O
did O
not O
show O
obvious O
infection O
. O
your O
p B-REA
##nu I-REA
##emon I-REA
##ia I-REA
was O
treated O
with O
anti B-DRUG
##biotics I-DRUG
. I-DRUG
you O
also O
developed O
some O
mild O
confusion O
and O
right O
hand O
weakness O
, O
due O
to O
a O
stroke O
, O
which O
was O
seen O
on O
m O
##ri O
. O
a O
l O
##umba O
##r O
pu O
##nc O
##ture O
did O
not O
show O
any O
infection O
of O
your O
c O
##ere O
##bro O
##sp O
##inal O
fluid O
. O
you O
had O
an O
e O
##eg O
exam O
to O
look O
for O
seizure O
activity O
, O
the O
final O
results O
of O
which O
were O
pending O
at O
the O
time O
of O
discharge O
. O
. O

the O
following O
changes O
were O
made O
to O
your O
medications O
: O
- O
you O
were O
started O
on O
me B-DRUG
##rop I-DRUG
##ene I-DRUG
##m I-DRUG
, I-DRUG
an O
in B-ROU
##tra I-ROU
##ven I-ROU
##ous I-ROU
anti B-DRUG
##biotic I-DRUG
. I-DRUG
you O
will O
have O
an O
i O
##v O
line O
placed O
at O
the O
rehabilitation O
facility O
to O
receive O
this O
medication O
. O
you O
will O
continue O
to O
take O
this O
for B-DUR
six I-DUR
days I-DUR
post O
- O
discharge O
, O
with O
your O
last O
doses O
on O
[ O
* O
* O
211 O
##5 O
- O
1 O
- O
8 O
* O
* O
] O
. O
- O
added O
g B-DRUG
##ua I-DRUG
##ife I-DRUG
##nes I-DRUG
##in I-DRUG
100 B-STR
mg I-STR
/ I-STR
5 I-STR
m I-STR
##l I-STR
syrup B-FOR
si O
##g O
: O
5 B-DOS
- I-DOS
10 I-DOS
m I-DOS
##ls I-DOS
p B-ROU
##o I-ROU
q B-FRE
##6 I-FRE
##h I-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
cough B-REA
. I-REA
- O
added O
ben B-DRUG
##zon I-DRUG
##ata I-DRUG
##te I-DRUG
100 B-STR
mg I-STR
capsule B-FOR
, I-FOR
one B-DOS
capsule B-FOR
by B-ROU
mouth I-ROU
3 B-FRE
times I-FRE
a I-FRE
day I-FRE
- O
added O
ace B-DRUG
##tam I-DRUG
##ino I-DRUG
##phe I-DRUG
##n I-DRUG
325 B-STR
- I-STR
650 I-STR
mg I-STR
by B-ROU
mouth I-ROU
every B-FRE
eight I-FRE
hours I-FRE
as I-FRE
needed I-FRE
for O
fever B-REA
; I-REA
please O
do O
not O
exceed O
2000 O
##m O
##g O
/ O
day O
- O
added O
al B-DRUG
##but I-DRUG
##ero I-DRUG
##l I-DRUG
0 B-STR
. I-STR
08 I-STR
##3 I-STR
% I-STR
ne B-FOR
##bul I-FOR
##izer I-FOR
to O
be O
inhaled B-ROU
every B-FRE
four I-FRE
hours I-FRE
, I-FRE
as I-FRE
needed I-FRE
for O
short B-REA
##ness I-REA
of I-REA
breath I-REA
or O
w B-REA
##hee I-REA
##ze I-REA
. O
please O
return O
to O
the O
hospital O
or O
call O
your O
doctor O
if O
you O
feel O
faint O
, O
light O
headed O
, O
experience O
nausea O
, O
vomit O
##ing O
, O
con O
##st O
##ip O
##ation O
, O
headache O
, O
blur O
##ry O
vision O
, O
weight O
loss O
, O
night O
sweat O
##s O
, O
chest O
pain O
, O
abdominal O
pain O
, O
short O
##ness O
of O
breath O
, O
muscle O
ache O
##s O
, O
joint O
ache O
##s O
, O
fever O
, O
blood O
in O
your O
stool O
or O
urine O
, O
or O
any O
other O
symptoms O
that O
are O
concerning O
to O
you O
. O
follow O
##up O
instructions O
: O
[ O
* O
* O
first O
name O
##8 O
( O
name O
##pa O
##tter O
##n O
##2 O
) O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
301 O
##4 O
* O
* O
] O
, O
r O
##n O
& O
[ O
* O
* O
first O
name O
##11 O
( O
name O
pattern O
##1 O
) O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##4 O
) O
64 O
##7 O
* O
* O
] O
, O
m O
##d O
phone O
: O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
22 O
* O
* O
] O
date O
/ O
time O
: O
[ O
* O
* O
211 O
##5 O
- O
1 O
- O
10 O
* O
* O
] O
1 O
: O
30 O

admission O
date O
: O
[ O
* O
* O
216 O
##0 O
- O
11 O
- O
16 O
* O
* O
] O
discharge O
date O
: O
[ O
* O
* O
216 O
##0 O
- O
11 O
- O
19 O
* O
* O
] O
date O
of O
birth O
: O
[ O
* O
* O
208 O
##5 O
- O
8 O
- O
22 O
* O
* O
] O
sex O
: O
m O
service O
: O
medicine O
all O
##er O
##gies O
: O
as B-DRUG
##pi I-DRUG
##rin I-DRUG
/ O
in B-DRUG
##dom I-DRUG
##eth I-DRUG
##ac I-DRUG
##in I-DRUG
/ O
c B-DRUG
##ip I-DRUG
##ro I-DRUG
##f I-DRUG
##lo I-DRUG
##xa I-DRUG
##cin I-DRUG
/ O
probe B-DRUG
##ne I-DRUG
##cid I-DRUG
/ O
all B-DRUG
##op I-DRUG
##uri I-DRUG
##no I-DRUG
##l I-DRUG
and O
derivatives O
/ O
p B-DRUG
##hen I-DRUG
##yt I-DRUG
##oi I-DRUG
##n I-DRUG
/ O
k B-DRUG
##ef I-DRUG
##lex I-DRUG
attending O
: O
[ O
* O
* O
first O
name O
##3 O
( O
l O
##f O
) O
202 O
##4 O
* O
* O
] O
chief O
complaint O
: O
h O
##y O
##pot O
##ens O
##ion O
major O
surgical O
or O
invasive O
procedure O
: O
none O
history O
of O
present O
illness O
: O
75 O
year O
old O
gentleman O
with O
a O
pm O
##h O
significant O
for O
h O
##c O
##v O
c O
##ir O
##r O
##hos O
##is O
c O
/ O
b O
h O
##cc O
s O
/ O
p O
lobe O
re O
##section O
in O
[ O
* O
* O
215 O
##6 O
* O
* O
] O
, O
pod O
12 O
from O
c O
##rani O
##oto O
##my O
for O
s O
##dh O
now O
admitted O
to O
the O
[ O
* O
* O
hospital O
unit O
name O
153 O
* O
* O
] O
for O
fever O
, O
r O
##ash O
, O
and O
h O
##y O
##pot O
##ens O
##ion O
. O
the O
patient O
was O
noted O
at O
re O
##hab O
to O
be O
f O
##eb O
##ril O
##e O
to O
103 O
today O
, O
and O
was O
also O
complaining O
of O
a O
" O
total O
body O
it O
##chin O
##ess O
" O
and O
was O
noted O
both O
at O
re O
##hab O
and O
by O
the O
ed O
attending O
to O
have O
trunk O
and O
arm O
er O
##yt O
##hem O
##a O
. O
he O
was O
started O
on O
k B-DRUG
##ef I-DRUG
##lex I-DRUG
yesterday O
for O
possible O
superficial B-REA
p I-REA
##hl I-REA
##eb I-REA
##itis I-REA
at O
an O
old O
p O
##iv O
site O
, O
and O
denies O
any O
local O
##izing O
symptoms O
including O
ha O
, O
men O
##igi O
##smus O
, O
cough O
, O
short O
##ness O
of O
breath O
, O
d O
##ys O
##uria O
, O
n O
/ O
v O
/ O
d O
. O
. O
of O
note O
, O
the O
patient O
was O
admitted O
to O
[ O
* O
* O
hospital O
##1 O
18 O
* O
* O
] O
under O
the O
ne O
##uro O
##su O
##rg O
##ical O
service O
from O
[ O
* O
* O
date O
range O
( O
1 O
) O
308 O
##44 O
* O
* O
] O
after O
a O
fall O
with O
bilateral O
s O
##dh O
, O
and O
underwent O
right O
c O
##rani O
##oto O
##my O
on O
[ O
* O
* O
11 O
- O
5 O
* O
* O
] O
, O
and O
ultimately O
was O
discharged O
to O
re O
##hab O
on O
di B-DRUG
##lant I-DRUG
##in I-DRUG
for O
seizure B-REA
prop I-REA
##hyl I-REA
##ax I-REA
##is I-REA
. I-REA
in O
addition O
, O
he O
was O
started O
on O
k B-DRUG
##ef I-DRUG
##lex I-DRUG
the O
day O
prior O
to O
admission O
for O
question O
of O
cell B-REA
##uli I-REA
##tis I-REA
on O
his O
left O
forearm O
at O
the O
location O
of O
a O
prior O
p O
##iv O
site O
. O
. O

in O
the O
[ O
* O
* O
hospital O
##1 O
18 O
* O
* O
] O
ed O
, O
initial O
vs O
99 O
68 O
78 O
/ O
60 O
18 O
94 O
% O
r O
##a O
. O
the O
patient O
had O
a O
negative O
c O
##x O
##r O
and O
u O
##a O
, O
an O
i O
+ O
/ O
- O
c O
##th O
that O
was O
read O
as O
unchanged O
from O
most O
recent O
post O
- O
operative O
study O
, O
and O
ne O
##uro O
##su O
##rger O
##y O
was O
consulted O
with O
low O
suspicion O
for O
c O
##ns O
infection O
. O
the O
patient O
received O
10 B-STR
mg I-STR
i B-ROU
##v I-ROU
de B-DRUG
##xa I-DRUG
##met I-DRUG
##has I-DRUG
##one I-DRUG
, I-DRUG
5 B-DOS
l I-DOS
i B-DRUG
##v I-DRUG
##f I-DRUG
, I-DRUG
van B-DRUG
##com I-DRUG
##y I-DRUG
##cin I-DRUG
, I-DRUG
and O
le B-DRUG
##vo I-DRUG
##f I-DRUG
##lo I-DRUG
##xa I-DRUG
##cin I-DRUG
, I-DRUG
and O
was O
admitted O
to O
the O
[ O
* O
* O
hospital O
unit O
name O
153 O
* O
* O
] O
for O
further O
management O
. O
. O
currently O
, O
the O
patient O
is O
resting O
comfortably O
without O
complaints O
. O
continues O
to O
deny O
any O
c O
##p O
/ O
sob O
, O
f O
/ O
c O
/ O
s O
, O
n O
/ O
v O
/ O
d O
, O
a O
##b O
##d O
pain O
, O
ha O
, O
p O
##al O
##pit O
##ations O
, O
d O
##ys O
##uria O
. O
past O
medical O
history O
: O
1 O
. O
h O
##yper O
##tens O
##ion O
2 O
. O
h O
##y O
##pot O
##hy O
##roid O
##ism O
3 O
. O
go O
##ut O
4 O
. O
g O
##erd O
5 O
. O
b O
##ph O
6 O
. O
he O
##pa O
##titis O
c O
7 O
. O
he O
##pa O
##to O
##cellular O
car O
##cin O
##oma O
social O
history O
: O
single O
. O
no O
children O
. O
cousin O
and O
friends O
are O
support O
system O
. O
retired O
from O
[ O
* O
* O
location O
( O
un O
) O
66 O
##9 O
##2 O
* O
* O
] O
airport O
working O
for O
united O
on O
ramp O
service O
. O
quit O
smoking O
and O
drinking O
in O
the O
[ O
* O
* O
213 O
##9 O
* O
* O
] O
. O
family O
history O
: O
mother O
: O
breast O
cancer O
, O
died O
at O
69 O
sister O
: O
bi O
##pol O
##ar O
disorder O
aunt O
: O
breast O
cancer O
, O
died O
in O
80s O
. O
physical O
exam O
: O
admission O
exam O
: O
. O
vs O
: O
t O
: O
98 O
. O
5 O
, O
h O
##r O
: O
72 O
, O
b O
##p O
: O
106 O
/ O
69 O
, O
r O
##r O
: O
22 O
, O
so O
##2 O
: O
94 O
% O
r O
##a O
g O
##en O
: O
na O
##d O
he O
##ent O
: O
per O
##rl O
, O
e O
##omi O
, O
s O
##cle O
##rae O
an O
##ict O
##eric O
. O
mm O
dry O
. O
op O
clear O
without O
lesions O
, O
ex O
##uda O
##te O
, O
or O
er O
##yt O
##hem O
##a O
. O
c O
##v O
: O
n O
##l O
s O
##1 O
+ O
s O
##2 O
pu O
##lm O
: O
c O
##ta O
##b O
a O
##b O
##d O
: O
s O
/ O
n O
##t O
+ O
b O
##s O
, O
? O
as O
##cite O
##s O
on O
exam O
. O
ex O
##t O
: O
no O
c O
/ O
c O
/ O
e O
. O
ne O
##uro O
: O
a O
##o O
x O
##3 O
, O
c O
##n O
ii O
- O
x O
##ii O
intact O
. O
skin O
: O
staple O
##d O
surgical O
site O
on O
c O
##rani O
##um O
without O
surround O
er O
##yt O
##hem O
##a O
. O

physical O
exam O
: O
vs O
: O
t O
##max O
97 O
. O
7 O
t O
##c O
96 O
. O
0 O
h O
##r O
52 O
( O
52 O
- O
73 O
) O
b O
##p O
119 O
/ O
68 O
( O
106 O
- O
130 O
/ O
60 O
- O
82 O
) O
r O
##r O
16 O
o O
##2 O
sat O
99 O
% O
on O
r O
##a O
i O
/ O
o O
24 O
##h O
312 O
##0 O
- O
97 O
##5 O
. O
g O
##en O
: O
a O
##ox O
##3 O
, O
na O
##d O
he O
##ent O
: O
per O
##rl O
##a O
. O
e O
##omi O
. O
bi O
##l O
ex O
##op O
##ht O
##hal O
##mus O
( O
this O
is O
a O
feature O
from O
childhood O
and O
runs O
in O
the O
family O
per O
patient O
) O
. O
surgical O
sight O
on O
c O
##rani O
##um O
w O
/ O
o O
er O
##yt O
##hea O
/ O
swelling O
/ O
tender O
##ness O
. O
mm O
##m O
. O
no O
lad O
. O
no O
j O
##v O
##d O
. O
neck O
su O
##pp O
##le O
. O
right O
thy O
##roid O
full O
##ness O
/ O
nod O
##ule O
? O
cards O
: O
r O
##rr O
s O
##1 O
/ O
s O
##2 O
normal O
. O
no O
murmurs O
/ O
gal O
##lops O
/ O
rub O
##s O
. O
pu O
##lm O
: O
c O
##ta O
a O
##b O
##d O
: O
soft O
, O
n O
##t O
, O
di O
##sten O
##ded O
, O
+ O
b O
##s O
. O
no O
re O
##bound O
/ O
guarding O
. O
ex O
##tre O
##mit O
##ies O
: O
w O
##w O
##p O
, O
no O
ed O
##ema O
. O
d O
##ps O
, O
p O
##ts O
2 O
+ O
. O
skin O
: O
no O
r O
##ash O
##es O
. O
ne O
##uro O
/ O
ps O
##ych O
: O
c O
##ns O
ii O
- O
x O
##ii O
intact O
. O
no O
gross O
deficit O
per O
##tinent O
results O
: O
admission O
results O
: O
. O

[ O
* O
* O
216 O
##0 O
- O
11 O
- O
16 O
* O
* O
] O
01 O
: O
08 O
##pm O
blood O
w O
##b O
##c O
- O
6 O
. O
9 O
r O
##b O
##c O
- O
3 O
. O
43 O
* O
h O
##g O
##b O
- O
10 O
. O
8 O
* O
h O
##ct O
- O
32 O
. O
9 O
* O
m O
##c O
##v O
- O
96 O
m O
##ch O
- O
31 O
. O
5 O
m O
##ch O
##c O
- O
32 O
. O
8 O
r O
##d O
##w O
- O
16 O
. O
1 O
* O
p O
##lt O
c O
##t O
- O
224 O
# O
[ O
* O
* O
216 O
##0 O
- O
11 O
- O
16 O
* O
* O
] O
01 O
: O
08 O
##pm O
blood O
ne O
##uts O
- O
84 O
. O
3 O
* O
l O
##ymph O
##s O
- O
10 O
. O
0 O
* O
mon O
##os O
- O
1 O
. O
6 O
* O
e O
##os O
- O
3 O
. O
9 O
b O
##as O
##o O
- O
0 O
. O
2 O
[ O
* O
* O
216 O
##0 O
- O
11 O
- O
16 O
* O
* O
] O
01 O
: O
08 O
##pm O
blood O
p O
##t O
- O
14 O
. O
9 O
* O
p O
##tt O
- O
31 O
. O
6 O
in O
##r O
( O
p O
##t O
) O
- O
1 O
. O
3 O
* O
[ O
* O
* O
216 O
##0 O
- O
11 O
- O
16 O
* O
* O
] O
01 O
: O
08 O
##pm O
blood O
glucose O
- O
154 O
* O
u O
##rea O
##n O
- O
19 O
c O
##rea O
##t O
- O
1 O
. O
3 O
* O
na O
- O
133 O
k O
- O
4 O
. O
6 O
c O
##l O
- O
103 O
h O
##co O
##3 O
- O
17 O
* O
an O
##ga O
##p O
- O
18 O
[ O
* O
* O
216 O
##0 O
- O
11 O
- O
16 O
* O
* O
] O
01 O
: O
08 O
##pm O
blood O
al O
##t O
- O
52 O
* O
as O
##t O
- O
110 O
* O
al O
##k O
##ph O
##os O
- O
350 O
* O
to O
##t O
##bil O
##i O
- O
2 O
. O
2 O
* O
dir O
##bil O
##i O
- O
1 O
. O
1 O
* O
in O
##d O
##bil O
##i O
- O
1 O
. O
1 O
[ O
* O
* O
216 O
##0 O
- O
11 O
- O
16 O
* O
* O
] O
01 O
: O
08 O
##pm O
blood O
calcium O
- O
8 O
. O
0 O
* O
p O
##hos O
- O
2 O
. O
9 O
mg O
- O
1 O
. O
6 O
[ O
* O
* O
216 O
##0 O
- O
11 O
- O
16 O
* O
* O
] O
01 O
: O
13 O
##pm O
blood O
la O
##ct O
##ate O
- O
3 O
. O
1 O
* O
k O
- O
4 O
. O
4 O
. O
c O
##x O
##r O
( O
[ O
* O
* O
216 O
##0 O
- O
11 O
- O
16 O
* O
* O
] O
) O
: O
no O
acute O
card O
##io O
##pu O
##lm O
##ona O
##ry O
process O
. O
. O
c O
##t O
head O
with O
and O
without O
contrast O
( O
[ O
* O
* O
216 O
##0 O
- O
11 O
- O
16 O
* O
* O
] O
) O
: O
stable O
appearance O
of O
evolving O
bilateral O
sub O
##du O
##ral O
hem O
##ato O
##mas O
and O
interval O
re O
##sor O
##ption O
of O
post O
##oper O
##ative O
p O
##ne O
##um O
##oc O
##ep O
##hal O
##us O
, O
with O
no O
concerning O
enhance O
##ment O
. O
. O
interval O
results O
: O
. O

right O
upper O
q O
##uad O
##rant O
ultra O
##sound O
( O
[ O
* O
* O
216 O
##0 O
- O
11 O
- O
17 O
* O
* O
] O
) O
: O
* O
* O
dictated O
, O
final O
pending O
* O
* O
1 O
. O
he O
##tero O
##gene O
##ous O
liver O
with O
lesions O
consistent O
with O
multi O
##fo O
##cal O
he O
##pa O
##to O
##cellular O
car O
##cin O
##oma O
. O
2 O
. O
patent O
portal O
veins O
. O
3 O
. O
patent O
he O
##pa O
##tic O
veins O
and O
artery O
. O
4 O
. O
moderate O
amount O
of O
as O
##cia O
##tes O
. O
. O
. O
. O
last O
updated O
on O
[ O
* O
* O
216 O
##0 O
- O
11 O
- O
17 O
* O
* O
] O
brief O
hospital O
course O
: O
75 O
year O
old O
gentleman O
with O
a O
pm O
##h O
significant O
for O
h O
##c O
##v O
c O
##ir O
##r O
##hos O
##is O
complicated O
by O
h O
##cc O
s O
/ O
p O
lobe O
re O
##section O
in O
[ O
* O
* O
215 O
##6 O
* O
* O
] O
, O
who O
presented O
on O
post O
- O
operative O
day O
12 O
from O
c O
##rani O
##oto O
##my O
for O
a O
sub O
##du O
##ral O
hem O
##ato O
##ma O
with O
fever O
, O
r O
##ash O
, O
and O
h O
##y O
##pot O
##ens O
##ion O
. O
. O

# O
. O
h O
##y O
##pot O
##ens O
##ion O
and O
fever O
: O
there O
was O
immediate O
concern O
for O
se O
##psis O
on O
presentation O
to O
the O
ed O
, O
although O
no O
apparent O
source O
was O
isolated O
and O
no O
significant O
fever O
was O
recorded O
in O
the O
hospital O
( O
had O
100 O
. O
4 O
on O
admission O
to O
the O
ed O
) O
. O
se O
##psis O
work O
##up O
was O
negative O
including O
c O
##x O
##r O
, O
u O
##a O
, O
urine O
and O
blood O
cultures O
. O
final O
blood O
cut O
##lu O
##re O
results O
are O
still O
pending O
. O
given O
recent O
c O
##rani O
##oto O
##my O
the O
ne O
##uro O
##su O
##rger O
##y O
service O
was O
consulted O
and O
was O
not O
concerned O
for O
c O
##ns O
infection O
. O
a O
r O
##u O
##q O
ultra O
##ou O
##nd O
was O
performed O
that O
confirmed O
a O
moderate O
amount O
of O
as O
##cite O
##s O
and O
pat O
##ency O
of O
the O
he O
##pa O
##tic O
vessels O
, O
but O
the O
abdomen O
was O
not O
tender O
and O
the O
suspicion O
for O
s O
##b O
##p O
was O
low O
. O
ad O
##rena O
##l O
ins O
##uf O
##iciency O
was O
ruled O
out O
per O
co B-DRUG
##sy I-DRUG
##nt I-DRUG
##rop I-DRUG
##in I-DRUG
test B-REA
. I-REA
the O
patient O
did O
receive O
a O
dose O
of O
van B-DRUG
##com I-DRUG
##y I-DRUG
##cin I-DRUG
and O
le B-DRUG
##vo I-DRUG
##f I-DRUG
##lo I-DRUG
##xa I-DRUG
##cin I-DRUG
in O
the O
ed O
but O
none O
were O
continued O
in O
the O
i O
##cu O
as O
the O
patient O
remained O
a O
##fe O
##bri O
##le O
and O
the O
i O
##cu O
team O
' O
s O
suspicion O
for O
infectious O
process O
was O
low O
. O
the O
patient O
re O
##cie O
##ved O
a O
dose O
of O
i B-ROU
##v I-ROU
s B-DRUG
##tero I-DRUG
##ids I-DRUG
in O
the O
ed O
and O
subsequently O
re O
##cie O
##ved O
a O
3 B-DUR
day I-DUR
course O
of O
pre B-DRUG
##dn I-DRUG
##ison I-DRUG
##e I-DRUG
60 B-STR
##m I-STR
##g I-STR
. I-STR
di B-DRUG
##lant I-DRUG
##in I-DRUG
was O
considered O
as O
a O
possible O
et O
##iology O
for O
his O
presentation O
, O
especially O
given O
the O
acute B-ADE
re I-ADE
##nal I-ADE
failure I-ADE
and O
associated O
m B-ADE
##or I-ADE
##bill I-ADE
##iform I-ADE
r I-ADE
##ash I-ADE
, I-ADE
as O
a O
type O
i O
##v O
drug B-ADE
reaction I-ADE
, I-ADE
including O
dress O
, O
though O
no O
e O
##os O
##ino O
##phi O
##lia O
was O
noted O
on O
differential O
. O
ad O
##itt O
##ional O
##ly O
patient O
had O
recently O
been O
started O
on O
k B-DRUG
##ef I-DRUG
##lex I-DRUG
so O
an B-ADE
##aph I-ADE
##yla I-ADE
##ctic I-ADE
shock I-ADE
due O
to O
all O
##er O
##gy O
to O
c B-DRUG
##ep I-DRUG
##hal I-DRUG
##os I-DRUG
##por I-DRUG
##ins I-DRUG
is O
another O
possibility O
. O
both O
di B-DRUG
##lant I-DRUG
##in I-DRUG
and O
k B-DRUG
##ef I-DRUG
##lex I-DRUG
were O
discontinued O
and O
should O
be O
avoided O
in O
the O
future O
. O
the O
patient O
remained O
a O
##fe O
##bri O
##le O
and O
norm O
##ote O
##ns O
##ive O
during O
his O
i O
##cu O
stay O
and O
the O
day O
after O
admission O
was O
transferred O
to O
the O
on O
##cology O
service O
. O
he O
remained O
stable O
on O
the O
on O
##cology O
floor O
and O
is O
now O
discharged O
back O
to O
re O
##hab O
facility O
. O
. O
# O
. O
acute O
re O
##nal O
failure O
: O
patient O
was O
admitted O
with O
a O
serum O
c O
##rea O
##tin O
##ine O
of O
1 O
. O
2 O
, O
up O
from O
a O
known O
base O
##line O
of O
0 O
. O
9 O
to O
1 O
likely O
pre O
- O
re O
##nal O
failure O
in O
the O
setting O
of O
h O
##y O
##pot O
##ens O
##ion O
. O
his O
c O
##r O
. O
on O
discharge O
was O
0 O
. O
9 O
. O
re O
##nal O
functions O
and O
electro O
##ly O
##tes O
should O
be O
followed O
in O
the O
out O
##patient O
setting O
. O
. O

# O
. O
elevated O
liver O
enzymes O
: O
2 O
/ O
2 O
##o O
he B-REA
##pa I-REA
##titis I-REA
c I-REA
c I-REA
##ir I-REA
##r I-REA
##hos I-REA
##is I-REA
and O
he B-REA
##pa I-REA
##to I-REA
##cellular I-REA
car I-REA
##cin I-REA
##oma I-REA
: I-REA
patient O
failed O
inter B-DRUG
##fer I-DRUG
##on I-DRUG
and O
rib B-DRUG
##avi I-DRUG
##rin I-DRUG
in O
the O
past O
. O
patient O
with O
known O
multi O
##fo O
##cal O
h O
##cc O
re O
##cu O
##rrence O
re O
- O
confirmed O
per O
r O
##u O
##q O
ultra O
##sound O
on O
this O
admission O
. O
. O
# O
metabolic O
acid O
##osis O
: O
initially O
norm O
##och O
##lore O
##mic O
with O
slightly O
elevated O
a O
##g O
, O
then O
h O
##yper O
##ch O
##lore O
##mic O
with O
normal O
an O
##ion O
gap O
. O
likely O
initially O
[ O
* O
* O
1 O
- O
15 O
* O
* O
] O
to O
tissue O
h O
##y O
##pop O
##er O
##fusion O
given O
the O
elevated O
la O
##ct O
##ate O
on O
admission O
. O
la O
##ct O
##ate O
was O
3 O
. O
1 O
on O
admission O
and O
decreased O
to O
1 O
. O
3 O
. O
also O
contributed O
to O
by O
re O
##nal O
failure O
. O
bi O
##car O
##bon O
##ate O
trend O
##ing O
up O
on O
discharge O
. O
. O
# O
an O
##emia O
: O
at O
base O
##line O
of O
30 O
- O
35 O
. O
had O
initial O
drop O
of O
h O
##ct O
secondary O
to O
re O
##hy O
##dra O
##tion O
and O
resolution O
of O
hem O
##mo O
##con O
##cent O
##ration O
, O
h O
##ct O
back O
to O
base O
##line O
at O
discharge O
. O
. O
# O
. O
h O
##yper O
##tens O
##ion O
: O
anti B-DRUG
- I-DRUG
h I-DRUG
##yper I-DRUG
##tensive I-DRUG
##s I-DRUG
were O
held O
in O
the O
setting O
of O
h O
##y O
##pot O
##ens O
##ion O
. O
ta B-DRUG
##ms I-DRUG
##ulos I-DRUG
##in I-DRUG
0 B-STR
. I-STR
4 I-STR
mg I-STR
was O
restart O
##ed O
on O
discharge O
. O
am B-DRUG
##lo I-DRUG
##di I-DRUG
##pine I-DRUG
continues O
to O
be O
held O
on O
discharge O
. O
# O
. O
h B-REA
##y I-REA
##pot I-REA
##hy I-REA
##roid I-REA
: I-REA
patient O
was O
continued O
on O
le B-DRUG
##vo I-DRUG
##thy I-DRUG
##ro I-DRUG
##xin I-DRUG
##e I-DRUG
without O
event O
. O
of O
note O
patient O
found O
to O
have O
increased O
p O
##al O
##pable O
right O
lower O
thy O
##roid O
lobe O
. O
further O
work O
##up O
of O
this O
finding O
may O
be O
considered O
in O
the O
out O
patient O
setting O
. O
. O
# O
code O
status O
during O
this O
admission O
: O
full O
medications O
on O
admission O
: O
1 O
. O
am B-DRUG
##lo I-DRUG
##di I-DRUG
##pine I-DRUG
5 B-STR
mg I-STR
daily B-FRE
2 O
. O
ta B-DRUG
##ms I-DRUG
##ulos I-DRUG
##in I-DRUG
0 B-STR
. I-STR
4 I-STR
mg I-STR
h B-FRE
##s I-FRE
3 O
. O
o B-DRUG
##xy I-DRUG
##co I-DRUG
##don I-DRUG
##e I-DRUG
5 B-STR
mg I-STR
q B-FRE
##4 I-FRE
##h I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
. I-REA
4 O
. O
multi B-DRUG
##vi I-DRUG
##tam I-DRUG
##in I-DRUG
5 O
. O
ch B-DRUG
##ole I-DRUG
##cal I-DRUG
##ci I-DRUG
##fer I-DRUG
##ol I-DRUG
( O
vitamin B-DRUG
d I-DRUG
##3 I-DRUG
) I-DRUG
400 B-STR
units I-STR
daily B-FRE
6 O
. O
vitamin B-DRUG
e I-DRUG
400 B-STR
units I-STR
daily B-FRE
7 O
. O
le B-DRUG
##vo I-DRUG
##thy I-DRUG
##ro I-DRUG
##xin I-DRUG
##e I-DRUG
75 B-STR
m I-STR
##c I-STR
##g I-STR
daily B-FRE
8 O
. O
do B-DRUG
##cus I-DRUG
##ate I-DRUG
sodium I-DRUG
100 B-STR
mg I-STR
[ O
* O
* O
hospital O
##1 O
* O
* O
] O
9 O
. O
p B-DRUG
##hen I-DRUG
##yt I-DRUG
##oi I-DRUG
##n I-DRUG
sodium I-DRUG
extended I-DRUG
100 B-STR
mg I-STR
t B-FRE
##id I-FRE
10 O
. O
k B-DRUG
##ef I-DRUG
##lex I-DRUG

discharge O
medications O
: O
1 O
. O
ta B-DRUG
##ms I-DRUG
##ulos I-DRUG
##in I-DRUG
0 B-STR
. I-STR
4 I-STR
mg I-STR
capsule B-FOR
, I-FOR
su I-FOR
##st I-FOR
. I-FOR
release I-FOR
24 I-FOR
h I-FOR
##r I-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
capsule B-FOR
, I-FOR
su I-FOR
##st I-FOR
. I-FOR
release I-FOR
24 I-FOR
h I-FOR
##r I-FOR
p B-ROU
##o I-ROU
at O
bed B-FRE
##time I-FRE
. I-FRE
2 O
. O
o B-DRUG
##xy I-DRUG
##co I-DRUG
##don I-DRUG
##e I-DRUG
5 B-STR
mg I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
every B-FRE
four I-FRE
( I-FRE
4 I-FRE
) I-FRE
hours I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
. I-REA
3 O
. O
multi B-DRUG
##vi I-DRUG
##tam I-DRUG
##in I-DRUG
tablet B-FOR
oral B-ROU
4 O
. O
ch B-DRUG
##ole I-DRUG
##cal I-DRUG
##ci I-DRUG
##fer I-DRUG
##ol I-DRUG
( O
vitamin B-DRUG
d I-DRUG
##3 I-DRUG
) I-DRUG
400 B-STR
unit I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE
5 O
. O
le B-DRUG
##vo I-DRUG
##thy I-DRUG
##ro I-DRUG
##xin I-DRUG
##e I-DRUG
75 B-STR
m I-STR
##c I-STR
##g I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
daily B-FRE
( O
daily O
) O
. O
6 O
. O
do B-DRUG
##cus I-DRUG
##ate I-DRUG
sodium I-DRUG
100 B-STR
mg I-STR
capsule B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
capsule B-FOR
p B-ROU
##o I-ROU
bid B-FRE
( O
2 O
times O
a O
day O
) O
. O
7 O
. O
vitamin B-DRUG
e I-DRUG
400 B-STR
unit I-STR
tablet B-FOR
si O
##g O
: O
one B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
p B-ROU
##o I-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE
discharge O
disposition O
: O
extended O
care O
facility O
: O
[ O
* O
* O
location O
( O
un O
) O
230 O
##9 O
##5 O
* O
* O
] O
discharge O
diagnosis O
: O
suspected O
drug O
reaction O
/ O
an O
##aph O
##yla O
##xi O
##s O
cave O
p B-DRUG
##hen I-DRUG
##yt I-DRUG
##oi I-DRUG
##n I-DRUG
cave O
c B-DRUG
##ep I-DRUG
##hale I-DRUG
##xin I-DRUG
s O
/ O
p O
c O
##rani O
##oto O
##my O
for O
bilateral O
acute O
on O
chronic O
sub O
du O
##ral O
hem O
##mor O
##ah O
##ge O
he O
##pa O
##titis O
c O
c O
##ir O
##r O
##hos O
##is O
he O
##pa O
##to O
##cel O
##ular O
car O
##cin O
##oma O
discharge O
condition O
: O
mental O
status O
: O
clear O
and O
coherent O
. O
level O
of O
consciousness O
: O
alert O
and O
interactive O
. O
activity O
status O
: O
am O
##bula O
##tory O
- O
requires O
assistance O
or O
aid O
( O
walk O
##er O
or O
cane O
) O
. O
discharge O
instructions O
: O
you O
were O
admitted O
because O
of O
r B-ADE
##ash I-ADE
and O
low B-ADE
blood I-ADE
pressure I-ADE
. I-ADE
you O
were O
treated O
with O
in B-ROU
##tra I-ROU
##ven I-ROU
##ous I-ROU
fluids B-DRUG
and O
s B-DRUG
##tero I-DRUG
##ids I-DRUG
and O
your O
condition O
quickly O
improved O
. O
we O
believe O
this O
event O
may O
have O
been O
due O
to O
reaction B-ADE
or O
all B-ADE
##er I-ADE
##gy I-ADE
to O
medications O
you O
were O
taking O
either O
di B-DRUG
##lant I-DRUG
##in I-DRUG
( O
p B-DRUG
##hen I-DRUG
##yt I-DRUG
##oi I-DRUG
##n I-DRUG
) I-DRUG
or O
k B-DRUG
##ef I-DRUG
##lex I-DRUG
( O
c B-DRUG
##ep I-DRUG
##hale I-DRUG
##xin I-DRUG
) I-DRUG
. O
please O
avoid O
these O
medications O
in O
the O
future O
. O
. O
the O
following O
changes O
were O
made O
to O
your O
medications O
: O
- O
stop O
di B-DRUG
##lant I-DRUG
##in I-DRUG
- O
stop O
k B-DRUG
##ef I-DRUG
##lex I-DRUG
- O
am B-DRUG
##lo I-DRUG
##di I-DRUG
##pin I-DRUG
was O
stopped O
, O
please O
consult O
your O
treating O
physician O
about O
restart O
##ing O
this O
medication O
. O
please O
continue O
to O
take O
your O
home O
medications O
without O
change O
. O
. O
please O
discussed O
imaging O
of O
your O
thy O
##roid O
g O
##land O
with O
your O
primary O
care O
provider O
. O
follow O
##up O
instructions O
: O
please O
keep O
the O
following O
appointments O
: O
. O

department O
: O
radio O
##logy O
when O
: O
t O
##ues O
##day O
[ O
* O
* O
216 O
##0 O
- O
12 O
- O
9 O
* O
* O
] O
at O
10 O
: O
00 O
am O
with O
: O
cat O
scan O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
32 O
##7 O
* O
* O
] O
building O
: O
cc O
clinical O
center O
[ O
* O
* O
location O
( O
un O
) O
* O
* O
] O
campus O
: O
west O
best O
parking O
: O
[ O
* O
* O
street O
address O
( O
1 O
) O
59 O
##2 O
* O
* O
] O
garage O
department O
: O
ne O
##uro O
##su O
##rger O
##y O
when O
: O
t O
##ues O
##day O
[ O
* O
* O
216 O
##0 O
- O
12 O
- O
9 O
* O
* O
] O
at O
10 O
: O
30 O
am O
with O
: O
[ O
* O
* O
name O
##6 O
( O
m O
##d O
) O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##4 O
) O
91 O
##51 O
* O
* O
] O
, O
m O
##d O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
166 O
##9 O
* O
* O
] O
building O
: O
l O
##m O
[ O
* O
* O
hospital O
unit O
name O
* O
* O
] O
[ O
* O
* O
location O
( O
un O
) O
* O
* O
] O
campus O
: O
west O
best O
parking O
: O
[ O
* O
* O
hospital O
ward O
name O
* O
* O
] O
garage O
department O
: O
hem O
##ato O
##logy O
/ O
on O
##cology O
when O
: O
mon O
##day O
[ O
* O
* O
216 O
##0 O
- O
12 O
- O
22 O
* O
* O
] O
at O
3 O
: O
30 O
pm O
with O
: O
[ O
* O
* O
first O
name O
##4 O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
* O
* O
] O
[ O
* O
* O
last O
name O
( O
name O
##pa O
##tter O
##n O
##1 O
) O
250 O
##2 O
* O
* O
] O
, O
m O
##d O
[ O
* O
* O
telephone O
/ O
f O
##ax O
( O
1 O
) O
22 O
* O
* O
] O
building O
: O
s O
##c O
[ O
* O
* O
hospital O
ward O
name O
23 O
* O
* O
] O
clinical O
c O
##tr O
[ O
* O
* O
location O
( O
un O
) O
24 O
* O
* O
] O
campus O
: O
east O
best O
parking O
: O
[ O
* O
* O
hospital O
ward O
name O
23 O
* O
* O
] O
garage O
completed O
by O
: O
[ O
* O
* O
216 O
##0 O
- O
11 O
- O
20 O
* O
* O
] O

Our O
patient O
was O
a O
72-year O
- O
old O
man O
with O
advanced O
Parkinson O
's O
disease O
( O
PD O
) O
who O
received O
levodopa B-DRUG
and O
anti O
- O
cholinergic O
drugs O
and O
whose O
head O
had O
become O
almost O
completely B-ADE
bald I-ADE
. O

Syncope B-ADE
in O
a O
65-year O
- O
old O
woman O
after O
nitrate B-DRUG
ingestion O
. O

Pravastatin B-DRUG
is O
associated O
with O
myotonia B-ADE
in O
animals O
. O

Although O
his O
renal O
function O
recovered O
completely O
with O
high O
- O
dose O
leucovorin O
, O
hemodialysis O
, O
charcoal O
hemoperfusion O
, O
and O
carboxypeptidase O
G2 O
, O
we O
present O
this O
case O
to O
emphasize O
that O
signs O
of O
renal B-ADE
toxicity I-ADE
may O
be O
present O
as O
early O
as O
2 O
hours O
after O
the O
completion O
of O
a O
4-hour O
MTX B-DRUG
infusion O
, O
and O
to O
suggest O
that O
monitoring O
for O
MTX O
toxicity O
should O
perhaps O
begin O
within O
a O
few O
hours O
after O
the O
completion O
of O
4-hour O
MTX O
infusion O
. O

Thalidomide B-DRUG
neuropathy B-ADE
is O
often O
associated O
with O
proximal B-ADE
weakness I-ADE
and O
may O
progress O
even O
after O
discontinuation O
of O
treatment O
, O
in O
the O
phenomenon O
of O
' O
coasting O
' O
. O

Chlorambucil B-DRUG
- O
induced O
chromosome B-ADE
damage I-ADE
to O
human O
lymphocytes O
is O
dose O
- O
dependent O
and O
cumulative O
. O

The O
authors O
describe O
a O
patient O
with O
hemiparesis O
who O
developed O
the O
syndrome O
of O
irreversible O
lithium B-DRUG
- O
effectuated O
neurotoxicity B-ADE
( O
SILENT O
) O
while O
being O
treated O
with O
lithium O
for O
a O
manic O
episode O
. O

Hepatitis B-ADE
following O
cimetidine B-DRUG
administration O
. O

A O
case O
report O
of O
the O
hypersensitivity B-ADE
syndrome I-ADE
occurring O
in O
a O
patient O
being O
treated O
with O
dapsone B-DRUG
for O
a O
brown O
recluse O
spider O
bite O
is O
presented O
. O

A O
57-year O
- O
old O
woman O
with O
right O
bundle O
branch O
block O
+ O
LPH O
and O
ventricular O
premature O
contractions O
developed O
complete B-ADE
heart I-ADE
block I-ADE
( O
CHB B-ADE
) O
following O
administration O
of O
disopyramide B-DRUG
phosphate I-DRUG
( O
Norpace B-DRUG
) O
. O

Thrombolytic O
therapy O
with O
tissue B-DRUG
plasminogen I-DRUG
activator I-DRUG
( O
tPA B-DRUG
) O
for O
acute O
myocardial O
infarction O
may O
result O
in O
major O
bleeding O
complications O
such O
as O
gastrointestinal B-ADE
or I-ADE
intracranial I-ADE
bleeding I-ADE
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
fatal B-ADE
hyperkalemia I-ADE
owing O
to O
succinylcholine B-DRUG
administration O
in O
a O
patient O
with O
mucositis O
secondary O
to O
chemotherapy O
. O

While O
for O
ribavirin O
antidepressant O
effects O
are O
not O
known O
, O
we O
suppose O
that O
antidepressants O
may O
prevent O
changes B-ADE
in I-ADE
serotonergic I-ADE
or I-ADE
noradrenergic I-ADE
neurotransmission I-ADE
caused O
by O
IFN B-DRUG
- I-DRUG
alpha I-DRUG
. O

Use O
of O
the O
Naranjo O
adverse O
drug O
reaction O
probability O
scale O
indicated O
a O
probable O
relationship O
( O
score O
of O
5 O
) O
between O
the O
patient O
's O
development O
of O
hepatotoxicity B-ADE
and O
the O
TMP B-DRUG
- I-DRUG
SMX I-DRUG
therapy O
. O

A O
complex O
pattern O
of O
melanonychia B-ADE
and O
onycholysis B-ADE
after O
treatment O
with O
pemetrexed B-DRUG
for O
lung O
cancer O
. O

Fixed B-ADE
drug I-ADE
eruption I-ADE
of I-ADE
the I-ADE
scrotum I-ADE
due O
to O
methylphenidate B-DRUG
. O

She O
continued O
to O
receive O
regular O
insulin B-DRUG
4 O
times O
per O
day O
over O
the O
following O
3 O
years O
with O
only O
occasional O
hives B-ADE
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
a O
diffuse B-ADE
papular I-ADE
eruption I-ADE
following O
treatment O
of O
psoriasis O
with O
methotrexate B-DRUG
injections O
. O

Attenuation O
of O
asparaginase B-DRUG
- O
induced O
hyperglycemia B-ADE
after O
substitution O
of O
the O
Erwinia O
carotovora O
for O
the O
Escherichia O
coli O
enzyme O
preparation O
. O

Niflumic B-DRUG
acid I-DRUG
- O
induced O
skeletal B-ADE
fluorosis I-ADE
: O
iatrogenic O
disease O
or O
therapeutic O
perspective O
for O
osteoporosis O
? O

A O
52-year O
- O
old O
Black O
woman O
on O
phenytoin B-DRUG
therapy O
for O
post O
- O
traumatic O
epilepsy O
developed O
transient B-ADE
hemiparesis I-ADE
contralateral O
to O
the O
injury O
. O

After O
seven O
months O
' O
continuous O
treatment O
for O
suspected O
tuberculosis O
with O
rifampicin O
and O
ethambutol B-DRUG
a O
nine O
- O
year O
- O
old O
boy O
developed O
polyarthritis B-ADE
, O
rash B-ADE
and O
hepatitis B-ADE
in O
association O
with O
anti B-ADE
- I-ADE
native I-ADE
DNA I-ADE
antibodies I-ADE
and O
positive O
antinuclear O
factor O
. O

Posthypoglycemic B-ADE
hyperglycemia I-ADE
( O
rebound B-ADE
hyperglycemia I-ADE
) O
after O
overdosing O
of O
insulin B-DRUG
was O
diagnosed O
in O
6 O
cats O
with O
diabetes O
mellitus O
. O

Diagnosis O
of O
hypothyroidism B-ADE
during O
treatment O
can O
be O
difficult O
because O
of O
the O
common O
side O
effects O
of O
alpha B-DRUG
interferon I-DRUG
. O

Physicians O
who O
use O
sulfasalazine O
to O
treat O
patients O
with O
inflammatory O
bowel O
disease O
should O
be O
aware O
of O
the O
signs O
of O
sulfasalazine B-DRUG
- O
induced O
lupus B-ADE
syndrome I-ADE
. O

DIAGNOSIS O
: O
Sustained B-ADE
ventricular I-ADE
tachycardia I-ADE
possibly O
owing O
to O
thalidomide B-DRUG
treatment O
. O

Mesalamine B-DRUG
may O
cause O
hypersensitivity B-ADE
pneumonitis I-ADE
in O
patients O
with O
Crohn O
's O
disease O
. O

After O
treatment O
with O
a O
beta O
- O
sympathomimetic O
drug O
( O
Partusisten B-DRUG
) O
one O
fetus O
developed O
supraventricular B-ADE
tachycardia I-ADE
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
cutaneous B-ADE
and I-ADE
hematologic I-ADE
toxicity I-ADE
in O
a O
patient O
treated O
with O
IL-2 B-DRUG
. O

The O
pharmacology O
and O
toxicology O
of O
chloral B-DRUG
hydrate I-DRUG
are O
discussed O
with O
particular O
reference O
to O
the O
cardiac B-ADE
arrhythmias I-ADE
that O
are O
seen O
with O
overdosage O
. O

Propranolol B-DRUG
: O
an O
unrecognized O
cause O
of O
central B-ADE
nervous I-ADE
system I-ADE
dysfunction I-ADE
in O
patients O
undergoing O
cardiopulmonary O
bypass O
. O

Chlorambucil B-DRUG
central B-ADE
nervous I-ADE
toxicity I-ADE
: O
a O
significant O
side O
effect O
of O
chlorambucil O
therapy O
in O
childhood O
nephrotic O
syndrome O
. O

She O
had O
just O
finished O
a O
3-week O
course O
of O
intravenous O
tobramycin B-DRUG
for O
bronchiectasis O
and O
had O
an O
elevated O
serum O
tobramycin O
trough O
level O
1 O
week O
before O
the O
onset O
of O
tetany B-ADE
. O

However O
, O
cyclosporine B-DRUG
dependency O
is O
associated O
with O
the O
risk O
of O
nephrotoxicity B-ADE
. O

This O
article O
describes O
two O
cases O
of O
aplastic B-ADE
anemia I-ADE
, O
at O
least O
one O
of O
which O
was O
almost O
certainly O
induced O
by O
the O
use O
of O
methazolamide B-DRUG
, O
and O
one O
case O
of O
agranulocytosis B-ADE
related O
to O
the O
use O
of O
methazolamide B-DRUG
. O

Bone B-ADE
marrow I-ADE
aplasia I-ADE
and O
severe B-ADE
skin I-ADE
rash I-ADE
after O
a O
single O
low O
dose O
of O
methotrexate B-DRUG
. O

The O
polycystic B-ADE
changes I-ADE
disappeared O
from O
the O
ovaries O
in O
2 O
of O
the O
women O
after O
valproate B-DRUG
therapy O
was O
discontinued O
, O
and O
the O
2 O
women O
who O
had O
gained B-ADE
weight I-ADE
and O
developed O
amenorrhea B-ADE
while O
being O
treated O
with O
valproate B-DRUG
lost O
weight O
and O
resumed O
menstruating O
after O
the O
change O
in O
medication O
. O

Improved O
awareness O
of O
and O
further O
investigation O
into O
the O
neurotoxic B-ADE
effects I-ADE
of O
ofloxacin B-DRUG
may O
enhance O
its O
safe O
use O
. O

Hepatotoxic B-ADE
effects I-ADE
in O
a O
child O
receiving O
valproate B-DRUG
and O
carnitine B-DRUG
. O

We O
consider O
asterixis B-ADE
to O
be O
an O
easily O
overlooked O
sign O
of O
neurotoxicity B-ADE
, O
which O
may O
occur O
even O
at O
low O
or O
moderate O
dosage O
levels O
, O
if O
certain O
drugs O
as O
lithium B-DRUG
or O
clozapine B-DRUG
are O
used O
in O
combination O
with O
CBZ B-DRUG
. O

Several O
possible O
explanations O
of O
the O
mechanism O
of O
renal B-ADE
failure I-ADE
associated O
with O
the O
use O
of O
dextran-40 B-DRUG
are O
discussed O
. O

Isoniazid B-DRUG
and O
ethambutol B-DRUG
as O
a O
cause O
of O
optic B-ADE
neuropathy I-ADE
. O

INTRODUCTION O
: O
Although O
gefitinib B-DRUG
used O
for O
the O
treatment O
of O
non O
- O
small O
- O
cell O
lung O
cancer O
is O
a O
well O
- O
known O
cause O
of O
interstitial B-ADE
lung I-ADE
disease I-ADE
( O
ILD B-ADE
) O
, O
few O
case O
reports O
on O
erlotinib B-DRUG
- O
induced O
ILD B-ADE
have O
been O
issued O
. O

Gliclazide B-DRUG
- O
induced O
acute B-ADE
hepatitis I-ADE
. O

Capecitabine B-DRUG
- O
induced O
multifocal B-ADE
leukoencephalopathy I-ADE
: O
a O
report O
of O
five O
cases O
. O

In O
this O
article O
, O
we O
describe O
a O
Japanese O
patient O
with O
severe B-ADE
interstitial I-ADE
pneumonia I-ADE
probably O
caused O
by O
sorafenib B-DRUG
treatment O
for O
metastatic O
renal O
cell O
carcinoma O
. O

Hemodynamic B-ADE
collapse I-ADE
following O
labetalol B-DRUG
administration O
in O
preeclampsia O
. O

Severe B-ADE
acidosis I-ADE
in O
patients O
taking O
metformin B-DRUG
-- O
rapid O
reversal O
and O
survival O
despite O
high O
APACHE O
score O
. O

Severe O
serotonin B-ADE
syndrome I-ADE
induced O
by O
mirtazapine B-DRUG
monotherapy O
. O

Recognizing O
early O
signs O
of O
HMSN O
, O
such O
as O
areflexia O
and O
pes O
cavus O
deformity O
, O
can O
prevent O
severe B-ADE
neurotoxicity I-ADE
of O
polychemotherapy O
by O
avoiding O
vincristine B-DRUG
. O

OBJECTIVE O
: O
To O
describe O
onset O
of O
syndrome B-ADE
of I-ADE
inappropriate I-ADE
antidiuretic I-ADE
hormone I-ADE
( O
SIADH B-ADE
) O
associated O
with O
vinorelbine B-DRUG
therapy O
for O
advanced O
breast O
cancer O
. O

Although O
adverse O
reactions O
to O
protamine O
are O
reported O
infrequently O
and O
are O
usually O
mild O
, O
we O
recently O
observed O
the O
first O
fatal O
case O
of O
type B-ADE
I I-ADE
anaphylaxis I-ADE
resulting O
from O
protamine B-DRUG
. O

We O
describe O
the O
development O
of O
cutaneous B-ADE
scleroderma I-ADE
in O
3 O
patients O
coincident O
with O
the O
use O
of O
bleomycin B-DRUG
in O
low O
cumulative O
doses O
of O
less O
than O
100 O
U O
. O

Delayed B-ADE
pseudocyst I-ADE
of I-ADE
the I-ADE
pancreas I-ADE
can O
be O
a O
complication O
of O
intramuscular O
L B-DRUG
- I-DRUG
asparaginase I-DRUG
. O

A O
case O
of O
clozapine B-DRUG
- O
induced O
tonic B-ADE
- I-ADE
clonic I-ADE
seizures I-ADE
managed O
with O
valproate O
: O
implications O
for O
clinical O
care O
. O

Drug O
- O
induced O
psychosis B-ADE
resulted O
from O
the O
administration O
of O
quinacrine B-DRUG
hydrochloride I-DRUG
at O
a O
dosage O
of O
100 O
mg O
twice O
daily O
for O
the O
treatment O
of O
discoid O
lupus O
. O

We O
postulate O
that O
the O
bolus O
of O
sulprostone B-DRUG
resulted O
in O
possible O
coronary B-ADE
spasm I-ADE
that O
resulted O
in O
cardiac B-ADE
arrest I-ADE
. O

It O
was O
hypothesized O
that O
valproic B-DRUG
acid I-DRUG
may O
interfere O
with O
glucuronidation O
of O
lamotrigine B-DRUG
, O
leading O
to O
increased B-ADE
serum I-ADE
lamotrigine I-ADE
levels I-ADE
, O
or O
perhaps O
alter O
the O
drug O
's O
metabolism O
, O
resulting O
in O
accumulation B-ADE
of I-ADE
a I-ADE
toxic I-ADE
intermediate I-ADE
metabolite I-ADE
. O

Barbiturate B-DRUG
- O
induced O
submassive B-ADE
hepatic I-ADE
necrosis I-ADE
. O

Since O
elevated O
cortisol O
levels O
in O
Cushing O
's O
disease O
poses O
a O
threat O
for O
pancreatitis O
, O
there O
is O
a O
possibility O
that O
patients O
with O
Cushing O
's O
disease O
might O
be O
more O
prone O
to O
acute B-ADE
pancreatitis I-ADE
following O
propofol B-DRUG
administration O
. O

In O
the O
third O
child O
, O
the O
tics B-ADE
ceased O
after O
CBZ B-DRUG
discontinuation O
. O

CONCLUSIONS O
: O
Sustained O
- O
release O
verapamil B-DRUG
is O
thought O
to O
be O
the O
cause O
of O
the O
asthma B-ADE
attack I-ADE
in O
this O
patient O
because O
she O
was O
not O
taking O
any O
other O
preparations O
; O
the O
symptoms O
started O
with O
the O
administration O
of O
sustained O
- O
release O
verapamil B-DRUG
and O
were O
relieved O
after O
its O
discontinuation O
. O

One O
of O
these O
was O
clofazimine B-DRUG
, O
an O
aniline O
aposafranine O
derivative O
known O
to O
produce O
a O
ceroid B-ADE
- I-ADE
like I-ADE
pigment I-ADE
in O
the O
tissues O
of O
patients O
treated O
with O
this O
drug O
or O
lepromatous O
leprosy O
. O

CONCLUSIONS O
: O
These O
results O
suggest O
that O
clozapine B-DRUG
may O
cause O
TD B-ADE
; O
however O
, O
the O
prevalence O
is O
low O
and O
the O
severity O
is O
relatively O
mild O
, O
with O
no O
or O
mild O
self O
- O
reported O
discomfort B-ADE
. O

We O
report O
on O
a O
child O
with O
fatal B-ADE
valproate B-DRUG
- O
related O
hepatotoxic B-ADE
effects I-ADE
despite O
this O
supplementation O
. O

Amphotericin B-DRUG
B I-DRUG
nephrotoxicity B-ADE
in O
humans O
decreased O
by O
salt O
repletion O
. O

Pancreatitis O
has O
been O
associated O
with O
the O
tetracycline O
class O
of O
antibiotics O
and O
concerns O
about O
tigecycline B-DRUG
- O
induced O
acute B-ADE
pancreatitis I-ADE
have O
recently O
been O
raised O
. O

Drug B-ADE
rash I-ADE
with I-ADE
eosinophilia I-ADE
and I-ADE
systemic I-ADE
symptoms I-ADE
after O
chlorambucil B-DRUG
treatment O
in O
chronic O
lymphocytic O
leukaemia O
. O

The O
possibility O
of O
phenytoin B-DRUG
hypersensitivity B-ADE
reactions I-ADE
should O
be O
considered O
when O
patients O
receiving O
phenytoin B-DRUG
have O
unusual O
symptoms O
, O
particularly O
fever B-ADE
, O
rash B-ADE
, O
and O
lymphadenopathy B-ADE
. O

METHODS O
: O
We O
report O
two O
cases O
of O
pseudoporphyria B-ADE
caused O
by O
naproxen B-DRUG
and O
oxaprozin B-DRUG
. O

We O
report O
a O
43-year O
- O
old O
woman O
who O
developed O
sore B-ADE
throat I-ADE
, O
swelling B-ADE
of I-ADE
the I-ADE
lips I-ADE
and I-ADE
oral I-ADE
cavity I-ADE
and O
dysphagia B-ADE
, O
2 O
weeks O
after O
the O
use O
of O
budesonide B-DRUG
spray O
( O
Budefat B-DRUG
) O
for O
treatment O
of O
bronchial O
asthma O
. O

Tardive B-ADE
dyskinesia I-ADE
in O
2 O
patients O
treated O
with O
ziprasidone B-DRUG
. O

To O
our O
knowledge O
, O
this O
is O
the O
first O
case O
of O
griseofulvin B-DRUG
- O
exacerbated O
lupus B-ADE
in O
which O
nephrotic B-ADE
syndrome I-ADE
has O
been O
observed O
. O

Levofloxacin B-DRUG
induced O
polymorphic B-ADE
ventricular I-ADE
tachycardia I-ADE
with O
normal O
QT O
interval O
. O

Diagnosis O
of O
sclerosing B-ADE
glomerulonephritis I-ADE
occurred O
in O
this O
patient O
during O
anastrozole B-DRUG
use O
, O
suggesting O
a O
newly O
defined O
side O
effect O
of O
anastrozole O
. O

A O
case O
of O
contact B-ADE
dermatitis I-ADE
due O
to O
sodium B-DRUG
bisulfite I-DRUG
in O
an O
ophthalmic O
solution O
. O

Gemcitabine B-DRUG
- O
induced O
rectus B-ADE
abdominus I-ADE
radiation I-ADE
recall I-ADE
. O

Protamine B-ADE
allergy I-ADE
as O
a O
complication O
of O
insulin B-DRUG
hypersensitivity O
: O
A O
case O
report O
. O

METHODS O
: O
A O
retrospective O
report O
of O
the O
first O
case O
of O
gemcitabine B-DRUG
- O
related O
HUS B-ADE
, O
in O
a O
patient O
with O
metastatic O
pancreatic O
adenocarcinoma O
, O
treated O
with O
a O
variety O
of O
standard O
therapies O
in O
addition O
to O
rituximab O
is O
presented O
. O

Anaphylaxis B-ADE
to O
calcitonin B-DRUG
. O

As O
linezolid B-DRUG
has O
been O
shown O
to O
have O
hematologic B-ADE
side I-ADE
effects I-ADE
, O
blood O
count O
monitoring O
is O
recommended O
in O
patients O
receiving O
this O
drug O
for O
long O
- O
term O
therapy O
. O

The O
patient O
was O
initially O
treated O
with O
hydration O
and O
furosemide B-DRUG
but O
developed O
congestive B-ADE
heart I-ADE
failure I-ADE
. O

RESULTS O
: O
A O
44-year O
- O
old O
man O
taking O
naproxen B-DRUG
for O
chronic O
low O
back O
pain O
and O
a O
20-year O
- O
old O
woman O
on O
oxaprozin B-DRUG
for O
rheumatoid O
arthritis O
presented O
with O
tense B-ADE
bullae I-ADE
and O
cutaneous B-ADE
fragility I-ADE
on O
the O
face O
and O
the O
back O
of O
the O
hands O
. O

Propoxyphene B-DRUG
- O
induced O
wide B-ADE
complex I-ADE
dysrhythmia I-ADE
responsive O
to O
sodium O
bicarbonate O
therapy O
has O
not O
been O
previously O
reported O
in O
the O
literature O
. O

We O
present O
a O
case O
of O
HUS B-ADE
in O
an O
advanced O
ovarian O
cancer O
patient O
treated O
with O
carboplatin B-DRUG
and O
gemcitabine B-DRUG
, O
and O
described O
its O
favorable O
outcome O
after O
chemotherapy O
interruption O
and O
supportive O
care O
with O
a O
1 O
year O
follow O
- O
up O
. O

There O
are O
now O
reports O
of O
liver B-ADE
failure I-ADE
following O
treatment O
of O
childhood O
cancers O
with O
AMD B-DRUG
. O

It O
also O
highlights O
a O
current O
major O
etiologic O
question O
, O
that O
is O
, O
whether O
and O
to O
what O
degree O
lead B-DRUG
exposure O
contributes O
to O
the O
development O
of O
hypertension B-ADE
, O
and O
raises O
the O
issue O
of O
whether O
lead B-DRUG
- I-ADE
induced I-ADE
hypertension I-ADE
constitutes O
a O
subset O
of O
hypertension O
that O
is O
especially O
amenable O
to O
therapy O
with O
dietary O
calcium O
. O

Acute B-ADE
lung I-ADE
injury I-ADE
associated O
with O
5-fluorouracil B-DRUG
and O
oxaliplatinum B-DRUG
combined O
chemotherapy O
. O

Encephalopathy B-ADE
and O
seizures B-ADE
induced O
by O
intravesical O
alum B-DRUG
irrigations O
. O

Progressive B-ADE
anemia I-ADE
following O
combination O
therapy O
with O
interferon B-DRUG
- I-DRUG
alpha I-DRUG
and O
interleukin-2 B-DRUG
in O
a O
patient O
with O
metastatic O
renal O
cell O
carcinoma O
. O

Two O
patients O
with O
extrinsic O
asthma O
and O
coexistent O
insulin O
- O
dependent O
diabetes O
mellitus O
sustained O
an O
anaphylactoid B-ADE
reaction I-ADE
after O
the O
intravenous O
administration O
of O
50 O
% O
solution O
of O
dextrose B-DRUG
. O

We O
report O
a O
patient O
who O
developed O
spontaneous B-ADE
splenic I-ADE
infarction I-ADE
after O
the O
use O
of O
sumatriptan B-DRUG
for O
the O
treatment O
of O
migraine O
headache O
. O

We O
report O
in O
detail O
an O
unusual O
adverse O
reaction O
to O
infliximab B-DRUG
therapy O
, O
a O
drug O
- O
induced O
lupus B-ADE
- I-ADE
like I-ADE
clinical I-ADE
syndrome I-ADE
. O

A O
patient O
is O
described O
who O
developed O
a O
rapid O
onset O
of O
pulmonary B-ADE
fibrosis I-ADE
following O
treatment O
with O
a O
new O
non O
- O
steroidal O
anti O
- O
inflammatory O
drug O
, O
nabumetone B-DRUG
. O

It O
was O
postulated O
that O
the O
allergic B-ADE
reaction I-ADE
was O
most O
likely O
caused O
by O
capecitabine B-DRUG
or O
the O
intermediate O
metabolites O
based O
on O
the O
immediate O
reappearance O
of O
symptoms O
from O
the O
rechallenge O
, O
pharmacokinetic O
data O
, O
and O
well O
- O
tolerance O
of O
fluorouracil O
. O

Additionally O
, O
danazol B-DRUG
produces O
hepatocellular B-ADE
damage I-ADE
in O
approximately O
10 O
% O
of O
women O
. O

This O
report O
describes O
a O
case O
of O
neuroleptic B-ADE
malignant I-ADE
syndrome I-ADE
due O
to O
risperidone B-DRUG
in O
a O
child O
with O
Joubert O
syndrome O
. O

Risperidone B-DRUG
- O
induced O
tardive B-ADE
dyskinesia I-ADE
. O

Can O
ketamine B-DRUG
prescribed O
for O
pain O
cause O
damage B-ADE
to I-ADE
the I-ADE
urinary I-ADE
tract I-ADE
? O

The O
interval O
between O
initiating O
treatment O
with O
interferon B-DRUG
alfa I-DRUG
and O
onset O
of O
anterior B-ADE
ischemic I-ADE
optic I-ADE
neuropathy I-ADE
was O
similar O
to O
that O
of O
interferon B-DRUG
- O
associated O
vascular B-ADE
retinopathy I-ADE
. O

The O
authors O
suggest O
that O
in O
the O
absence O
of O
any O
proven O
benefit O
of O
itraconazole B-DRUG
prophylaxis O
, O
and O
given O
the O
interaction O
of O
this O
drug O
with O
vincristine B-DRUG
leading O
to O
severe O
and O
even O
potentially O
fatal B-ADE
toxicities I-ADE
, O
the O
combination O
use O
of O
these O
drugs O
should O
be O
avoided O
. O

CONCLUSIONS O
: O
The O
observation O
that O
neurotoxicity B-ADE
developed O
with O
a O
delay O
of O
24 O
to O
48 O
hours O
after O
acyclovir B-DRUG
peak O
serum O
concentrations O
could O
explain O
the O
wide O
range O
of O
acyclovir B-DRUG
levels O
reported O
in O
similar O
cases O
. O

Hypogammaglobulinemia B-ADE
associated O
with O
gold B-DRUG
therapy O
: O
evidence O
for O
a O
partial O
maturation O
blockade O
of O
B O
cells O
. O

A O
40-year O
- O
old O
man O
with O
relapsing O
- O
remitting O
multiple O
sclerosis O
( O
MS O
) O
developed O
primary B-ADE
central I-ADE
nervous I-ADE
system I-ADE
lymphoma I-ADE
( O
PCNSL B-ADE
) O
after O
having O
received O
21 O
doses O
of O
natalizumab B-DRUG
monotherapy O
. O

We O
report O
a O
case O
of O
AILD B-ADE
in O
an O
80-year O
- O
old O
male O
who O
presented O
with O
a O
generalized B-ADE
pruritic I-ADE
maculopapular I-ADE
eruption I-ADE
and O
fever B-ADE
following O
doxycycline B-DRUG
administration O
. O

Visual B-ADE
changes I-ADE
secondary O
to O
initiation O
of O
amiodarone B-DRUG
: O
a O
case O
report O
and O
review O
involving O
ocular O
management O
in O
cardiac O
polypharmacy O
. O

Life O
- O
threatening O
hyponatremia B-ADE
caused O
by O
vinblastine B-DRUG
. O

The O
treatment O
for O
acidosis O
and O
hyperkalaemia O
should O
be O
started O
as O
soon O
as O
RTA B-ADE
is O
diagnosed O
, O
and O
the O
dosage O
of O
FK506 B-DRUG
should O
also O
be O
reduced O
if O
possible O
. O

We O
highlight O
two O
instances O
of O
systemic B-ADE
allergic I-ADE
reaction I-ADE
, O
and O
discuss O
the O
potential O
side O
effects O
of O
local O
aprotinin B-DRUG
injections O
in O
the O
orthopaedic O
setting O
as O
well O
as O
the O
evidence O
base O
for O
its O
use O
. O

Thymic B-ADE
enlargement I-ADE
in O
a O
patient O
with O
juvenile O
idiopathic O
arthritis O
during O
etanercept B-DRUG
therapy O
. O

Oxcarbazepine B-DRUG
- O
associated O
angioedema B-ADE
manifested O
by O
swelling O
of O
the O
face O
, O
eyes O
, O
lips O
, O
or O
tongue O
or O
difficulty O
swallowing O
or O
breathing O
( O
or O
both O
) O
is O
a O
rare O
but O
potentially O
life O
- O
threatening O
reaction O
for O
which O
early O
recognition O
and O
management O
are O
vital O
. O

Calcification B-ADE
and O
ossification B-ADE
of I-ADE
the I-ADE
spinal I-ADE
arachnoid I-ADE
after O
intrathecal O
administration O
of O
Depo B-DRUG
- I-DRUG
Medrol I-DRUG
. O

Life O
- O
threatening O
cranial B-ADE
dystonia I-ADE
following O
trihexyphenidyl B-DRUG
withdrawal O
. O

The O
authors O
report O
2 O
cases O
of O
renal B-ADE
damage I-ADE
associated O
with O
lithium B-DRUG
carbonate I-DRUG
treatment O
. O

When O
the O
disease O
recurred O
conventional O
amphotericin B-DRUG
B I-DRUG
was O
used O
again O
, O
but O
had O
to O
be O
stopped O
because O
of O
severe B-ADE
side I-ADE
effects I-ADE
. O

Cutaneous B-ADE
rashes I-ADE
and O
eruptions B-ADE
can O
be O
caused O
by O
many O
medications O
, O
including O
carbamazepine B-DRUG
. O

Common O
adverse O
events O
( O
frequency O
10 O
% O
) O
of O
lacosamide B-DRUG
doses O
up O
to O
600 O
mg O
/ O
day O
include O
nonspecific O
central O
nervous O
system O
effects O
( O
e.g. O
, O
dizziness B-ADE
, O
ataxia B-ADE
, O
diplopia B-ADE
, O
and O
somnolence B-ADE
) O
. O

A O
potential O
role O
for O
renal O
and O
hepatic O
impairment O
in O
the O
observed O
protracted O
course O
of O
amiodarone B-DRUG
- O
induced O
thyrotoxicosis B-ADE
is O
suggested O
. O

Quinapril B-DRUG
is O
an O
angiotensin O
- O
converting O
enzyme O
inhibitor O
( O
ACE O
- O
inhibitor O
) O
and O
overdose O
can O
lead O
to O
prolonged B-ADE
hypotension I-ADE
and O
, O
less O
frequently O
, O
transient B-ADE
renal I-ADE
impairment I-ADE
. O

Only O
one O
case O
of O
severe B-ADE
symptomatic I-ADE
hepatitis I-ADE
occurring O
after O
pulse O
therapy O
with O
itraconazole B-DRUG
for O
onychomycosis O
and O
requiring O
transplantation O
has O
been O
reported O
previously O
. O

Cardiac B-ADE
toxicity I-ADE
related O
to O
BCNU B-DRUG
has O
not O
been O
described O
well O
. O

Erythromycin B-DRUG
is O
a O
macrolide O
antibiotic O
that O
may O
increase O
the O
risk O
of O
lovastatin B-DRUG
- O
induced O
rhabdomyolysis B-ADE
. O

Post O
marketing O
studies O
of O
Interferon B-DRUG
- I-DRUG
beta I-DRUG
( O
IFN B-DRUG
beta I-DRUG
) O
therapy O
in O
multiple O
sclerosis O
( O
MS O
) O
have O
demonstrated O
surprisingly O
high O
rates O
of O
hepatotoxicity B-ADE
. O

The O
case O
histories O
are O
presented O
of O
two O
patients O
who O
developed O
lung B-ADE
disease I-ADE
associated O
with O
the O
use O
of O
nitrofurantoin B-DRUG
with O
histological O
features O
of O
bronchiolitis B-ADE
obliterans I-ADE
organising I-ADE
pneumonia I-ADE
( O
BOOP B-ADE
) O
, O
a O
rare O
but O
recognised O
form O
of O
drug O
induced O
injury O
. O

It O
has O
been O
suggested O
that O
PPE B-ADE
caused O
by O
cytarabine B-DRUG
does O
not O
recur O
with O
subsequent O
cytarabine O
re O
- O
challenge O
. O

Hypersensitivity B-ADE
to O
carboplatin B-DRUG
has O
been O
reported O
in O
up O
to O
44 O
% O
of O
patients O
receiving O
this O
antineoplastic O
agent O
, O
usually O
occurring O
after O
several O
courses O
of O
treatment O
. O

Allergic B-ADE
contact I-ADE
dermatitis I-ADE
from O
4-chloro-7-nitrobenzofurazan B-DRUG
. O

Ulcerating B-ADE
enteritis I-ADE
associated O
with O
flucytosine B-DRUG
therapy O
. O

It O
was O
restarted O
6 O
weeks O
later O
, O
and O
10 O
weeks O
after O
that O
, O
the O
patient O
presented O
with O
fulminant B-ADE
hepatic I-ADE
failure I-ADE
, O
which O
resolved O
rapidly O
after O
cessation O
of O
nicotinic B-DRUG
acid I-DRUG
therapy O
. O

A O
60-year O
- O
old O
woman O
with O
diabetes O
mellitus O
( O
type O
2 O
) O
developed O
an O
acute B-ADE
icteric I-ADE
hepatitis I-ADE
- I-ADE
like I-ADE
illness I-ADE
6 O
weeks O
after O
the O
initiation O
of O
gliclazide B-DRUG
therapy O
. O

Prolonged O
responses O
were O
achieved O
with O
low O
doses O
of O
HU B-DRUG
( O
3 O
- O
10 O
mg O
/ O
kg O
/ O
day O
) O
and O
higher O
doses O
were O
associated O
with O
mild B-ADE
reversible I-ADE
hematologic I-ADE
or O
hepatic B-ADE
toxicity I-ADE
and O
no O
further O
increases O
in O
Hb O
. O

Flaccid B-ADE
quadriparesis I-ADE
was O
noted O
after O
discontinuation O
of O
vecuronium B-DRUG
. O

Treatment O
of O
amiodarone B-DRUG
- O
induced O
thyrotoxicosis B-ADE
( O
AIT O
) O
with O
thionamide O
, O
lithium O
or O
radioactive O
iodine O
is O
ineffective O
. O

Neurophysiological O
mechanisms O
which O
aid O
in O
elucidating O
the O
role O
of O
disulfiram B-DRUG
in O
the O
etiology O
of O
catatonia B-ADE
are O
discussed O
. O

The O
association O
of O
central B-ADE
diabetes I-ADE
insipidus I-ADE
( O
CDI B-ADE
) O
with O
lithium B-DRUG
use O
is O
rare O
. O

During O
her O
third O
cycle O
, O
she O
again O
received O
cisplatin B-DRUG
100 B-ADE
mg I-ADE
/ I-ADE
m2 I-ADE
over O
30 O
minutes O
and O
developed O
palmar B-ADE
pruritus I-ADE
, O
urticaria B-ADE
, O
and O
edema B-ADE
. O

Two O
65-year O
- O
old O
white O
men O
with O
coronary O
heart O
disease O
, O
given O
niacin B-DRUG
therapy O
for O
dyslipidemia O
for O
5 O
months O
, O
developed O
intense B-ADE
dental I-ADE
and I-ADE
gingival I-ADE
pain I-ADE
that O
was O
associated O
with O
increases O
in O
dose O
and O
that O
was O
relieved O
with O
discontinuance O
of O
niacin B-DRUG
treatment O
. O

Lithium B-DRUG
is O
known O
to O
cause O
acute B-ADE
renal I-ADE
failure I-ADE
and O
tubulo B-ADE
- I-ADE
interstitial I-ADE
disease I-ADE
, O
but O
the O
recently O
described O
association O
with O
proteinuria B-ADE
or O
nephrotic B-ADE
syndrome I-ADE
is O
little O
recognized O
. O

There O
have O
been O
only O
two O
reports O
of O
cimetidine B-DRUG
- O
induced O
hepatitis B-ADE
. O

The O
mechanism O
of O
anaphylactoid B-ADE
reaction I-ADE
to O
zomepirac B-DRUG
in O
this O
case O
, O
therefore O
, O
remains O
unclear O
. O

Lower O
extremity O
arterial B-ADE
insufficiency I-ADE
after O
long O
- O
term O
methysergide B-DRUG
maleate I-DRUG
therapy O
. O

The O
pulmonary B-ADE
toxicity I-ADE
of O
gold B-DRUG
salts O
is O
an O
uncommon O
cause O
of O
life O
- O
threatening O
respiratory B-ADE
failure I-ADE
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
rapidly O
occurring O
hyperglycemia B-ADE
that O
occurred O
in O
a O
geriatric O
patient O
3 O
days O
after O
treatment O
with O
olanzapine B-DRUG
. O

Although O
its O
side O
effects O
are O
few O
, O
tamoxifen B-DRUG
increases O
the O
incidence O
of O
proliferative B-ADE
lesions I-ADE
of I-ADE
the I-ADE
endometrium I-ADE
, O
which O
theoretically O
should O
be O
preventable O
with O
progestational O
agents O
. O

Procainamide B-DRUG
- O
induced O
incessant B-ADE
supraventricular I-ADE
tachycardia I-ADE
in O
the O
Wolff O
- O
Parkinson O
- O
White O
syndrome O
. O

While O
on O
a O
maximal O
dose O
of O
phenylephrine B-DRUG
she O
developed O
prominent O
positive B-ADE
U I-ADE
waves I-ADE
, O
which O
disappeared O
with O
the O
cessation O
of O
the O
drug O
. O

Esophageal B-ADE
candidiasis I-ADE
was O
diagnosed O
at O
endoscopy O
in O
two O
patients O
receiving O
omeprazole B-DRUG
therapy O
. O

Antacid O
and O
sucralfate B-DRUG
- O
induced O
hypophosphatemic B-ADE
osteomalacia I-ADE
: O
a O
case O
report O
and O
review O
of O
the O
literature O
. O

Awareness O
of O
this O
route O
of O
intoxication O
might O
be O
important O
in O
patients O
in O
whom O
neurologic O
or O
psychiatric B-ADE
symptoms I-ADE
develop O
while O
large O
amounts O
of O
lidocaine B-DRUG
cream O
are O
being O
used O
. O

She O
was O
administered O
metoclopramide B-DRUG
because O
of O
nausea O
and O
, O
within O
2 O
hours O
, O
developed O
agitation B-ADE
, O
dysarthria B-ADE
, O
diaphoresis B-ADE
, O
and O
a O
movement B-ADE
disorder I-ADE
. O

Warfarin B-DRUG
- O
associated O
bleeding B-ADE
generally O
is O
considered O
deleterious O
; O
however O
, O
in O
our O
patient O
it O
unmasked O
an O
early O
stage O
of O
colon O
cancer O
and O
thus O
may O
have O
saved O
the O
patient O
's O
life O
. O

CONCLUSIONS O
: O
In O
our O
reported O
case O
, O
a O
local O
hyperproduction B-ADE
of I-ADE
TNF I-ADE
- I-ADE
alpha I-ADE
from O
macrophages O
that O
was O
induced O
by O
the O
injected O
insulin B-DRUG
could O
explain O
the O
dedifferentiation B-ADE
of I-ADE
the I-ADE
adipocytes I-ADE
of O
the O
subcutaneous O
tissue O
and O
the O
reversion O
that O
was O
induced O
by O
the O
local O
injection O
of O
dexamethasone O
. O

Pulmonary B-ADE
edema I-ADE
as O
a O
delayed O
complication O
of O
ritodrine B-DRUG
therapy O
. O

Toxicity B-ADE
related O
to O
chloroquine B-DRUG
treatment O
of O
resistant O
vivax O
malaria O
. O

Elevated B-ADE
serum I-ADE
triglycerides I-ADE
with O
clozapine B-DRUG
resolved O
with O
risperidone O
in O
four O
patients O
. O

Exfoliative B-ADE
dermatitis I-ADE
secondary O
to O
tobramycin B-DRUG
sulfate I-DRUG
. O

Theophylline B-DRUG
intoxication I-ADE
mimicking O
diabetic O
ketoacidosis O
in O
a O
child O
. O

Following O
are O
two O
clinical O
case O
reports O
demonstrating O
profound O
cerebral B-ADE
edema I-ADE
associated O
with O
implantation O
of O
Gliadel B-DRUG
wafers O
. O

Severe B-ADE
visual I-ADE
loss I-ADE
after O
a O
single O
dose O
of O
vincristine B-DRUG
in O
a O
patient O
with O
spinal O
cord O
astrocytoma O
. O

The O
patient O
's O
previous O
rash B-ADE
and O
the O
temporal O
relation O
of O
this O
event O
and O
the O
ingestion O
of O
phenolphthalein B-DRUG
, O
as O
well O
as O
the O
similarity O
of O
this O
case O
to O
other O
reports O
, O
point O
to O
phenolphthalein B-DRUG
as O
the O
cause O
of O
TEN B-ADE
in O
this O
patient O
. O

Metabolic O
balance O
studies O
and O
rechallenge O
with O
hydrochlorothiazide B-DRUG
were O
undertaken O
to O
investigate O
the O
mechanism O
of O
the O
thiazide O
- O
induced O
hyponatremia B-ADE
. O

Thus O
any O
case O
of O
severe B-ADE
neutropenia I-ADE
occurring O
in O
a O
patient O
receiving O
olanzapine B-DRUG
is O
alarming O
to O
clinicians O
. O

We O
report O
a O
case O
of O
acute O
hyperphosphatemia B-ADE
secondary O
to O
rectal O
administration O
of O
sodium B-DRUG
phosphate I-DRUG
and O
sodium B-DRUG
biphosphate I-DRUG
( O
Fleet O
enema O
) O
. O

There O
is O
documentation O
of O
ocular B-ADE
toxicity I-ADE
with O
ethambutol B-DRUG
when O
administered O
at O
dosages O
generally O
pronounced O
as O
being O
safe O
. O

A O
case O
of O
phenytoin B-DRUG
- O
induced O
hepatitis B-ADE
with O
mononucleosis B-ADE
is O
reported O
, O
and O
syndromes O
associated O
with O
phenytoin B-DRUG
hypersensitivity B-ADE
reactions I-ADE
are O
discussed O
. O

Goiter B-ADE
and O
hypothyroidism B-ADE
during O
re O
- O
treatment O
with O
amiodarone B-DRUG
in O
a O
patient O
who O
previously O
experienced O
amiodarone B-DRUG
- O
induced O
thyrotoxicosis B-ADE
. O

A O
selective O
association O
between O
fluoxetine B-DRUG
and O
extensive O
, O
prominent O
eye B-ADE
movements I-ADE
in I-ADE
nonrapid I-ADE
eye I-ADE
movement I-ADE
( I-ADE
NREM I-ADE
) I-ADE
sleep I-ADE
was O
detected O
, O
utilizing O
Fisher O
's O
exact O
one O
- O
tailed O
statistic O
( O
p O
less O
than O
0.00001 O
for O
each O
comparison O
) O
. O

She O
was O
diagnosed O
with O
Epstein B-ADE
- I-ADE
Barr I-ADE
virus I-ADE
- I-ADE
associated I-ADE
polymorphic I-ADE
lymphoproliferative I-ADE
disorder I-ADE
( O
LPD B-ADE
) O
due O
to O
immunodeficiency B-ADE
caused O
by O
MTX B-DRUG
administration O
. O

These O
findings O
suggest O
that O
clozapine B-DRUG
- O
induced O
seizures B-ADE
can O
be O
successfully O
treated O
, O
that O
gradual O
dose O
titration O
can O
reduce O
the O
likelihood O
of O
further O
episodes O
of O
seizures O
and O
that O
concomitant O
use O
of O
a O
suitable O
mood O
stabilizer O
/ O
anti O
- O
epileptic O
medication O
can O
improve O
the O
outcome O
of O
treatment O
- O
resistant O
schizophrenia O
. O

We O
report O
a O
case O
of O
an O
infant O
with O
complex O
congenital O
heart O
disease O
who O
was O
placed O
on O
captopril B-DRUG
for O
afterload O
reduction O
following O
cardiac O
surgery O
and O
subsequently O
developed O
pulmonary B-ADE
infiltrates I-ADE
with I-ADE
eosinophilia I-ADE
. O

However O
, O
in O
the O
mid O
- O
to O
- O
late O
1980s O
, O
a O
series O
of O
letters O
to O
the O
editor O
and O
case O
reports O
announced O
an O
association O
between O
tamoxifen B-DRUG
therapy O
in O
women O
with O
breast O
cancer O
and O
the O
development O
of O
endometrial B-ADE
carcinoma I-ADE
. O

We O
report O
a O
case O
of O
torsade B-ADE
de I-ADE
pointes I-ADE
following O
a O
single O
oral O
dose O
of O
amiodarone B-DRUG
( O
1400 O
mg O
or O
30 O
mg O
kg-1 O
) O
administered O
after O
short O
intravenous O
loading O
for O
prevention O
of O
paroxysmal O
atrial O
flutter O
. O

However O
, O
the O
occurrence O
and O
management O
of O
akathisia B-ADE
induced O
by O
fluvoxamine B-DRUG
have O
not O
been O
described O
. O

CONCLUSIONS O
: O
Clarithromycin B-DRUG
may O
be O
a O
cause O
of O
fulminant B-ADE
liver I-ADE
failure I-ADE
either O
alone O
or O
by O
inhibiting O
the O
metabolism O
of O
other O
drugs O
. O

Eighty O
- O
two O
patients O
with O
various O
malignancies O
who O
received O
imipenem B-DRUG
/ O
cilastatin B-DRUG
143 O
times O
for O
neutropenic B-ADE
fever I-ADE
between O
March O
1994 O
and O
October O
1999 O
in O
Department O
of O
Pediatric O
Oncology O
, O
Gazi O
University O
, O
were O
identified O
. O

A O
68-year O
- O
old O
female O
patient O
with O
advanced O
ovarian O
carcinoma O
collapsed B-ADE
whilst O
receiving O
a O
carboplatin B-DRUG
and O
cyclophosphamide B-DRUG
infusion O
. O

Upper B-ADE
tract I-ADE
urothelial I-ADE
malignancy I-ADE
after O
cyclophosphamide B-DRUG
therapy O
: O
a O
case O
report O
and O
literature O
review O
. O

Imidazoline B-DRUG
intoxication I-ADE
due O
to O
overdose O
or O
accidental O
ingestion O
but O
also O
after O
normal O
therapeutic O
usage O
is O
frequent O
in O
children O
. O

A O
case O
of O
severe B-ADE
visual I-ADE
loss I-ADE
following O
a O
single O
dose O
of O
vincristine B-DRUG
is O
described O
. O

In O
this O
healthy O
population O
, O
the O
relative O
risk O
of O
developing O
endometrial B-ADE
carcinoma I-ADE
in O
the O
tamoxifen B-DRUG
arm O
was O
2.54 O
, O
although O
when O
stratified O
by O
age O
, O
in O
women O
over O
50 O
, O
the O
risk O
grew O
to O
4.01 O
. O

We O
describe O
a O
patient O
who O
developed O
NEH B-ADE
on O
three O
separate O
occasions O
provoked O
by O
two O
different O
chemotherapeutic O
agents O
-- O
cytarabine B-DRUG
and O
mitoxantrone B-DRUG
. O

Six O
of O
13 O
outpatients O
with O
schizophrenia O
who O
participated O
in O
a O
ten O
- O
week O
open O
trial O
of O
risperidone B-DRUG
had O
an O
initial O
good O
response O
to O
the O
medication O
followed O
by O
development O
of O
intolerable B-ADE
affect I-ADE
, O
including O
feelings B-ADE
of I-ADE
agitation I-ADE
and O
depression B-ADE
and O
periods B-ADE
of I-ADE
crying I-ADE
and O
insomnia B-ADE
. O

We O
describe O
a O
patient O
with O
transitional O
cell O
carcinoma O
of O
the O
renal O
pelvis O
who O
developed O
respiratory B-ADE
dysfunction I-ADE
and O
an O
abnormal B-ADE
chest I-ADE
x I-ADE
- I-ADE
ray I-ADE
with I-ADE
diffuse I-ADE
interstitial I-ADE
opacities I-ADE
while O
on O
chemotherapy O
with O
piritrexim B-DRUG
, O
a O
methotrexate O
analog O
. O

Hydrocortisone O
may O
decrease O
the O
incidence O
of O
mortality B-ADE
associated O
with O
cardiac B-ADE
arrhythmias I-ADE
in O
children O
receiving O
amphotericin B-DRUG
B I-DRUG
overdoses O
. O

We O
present O
three O
cases O
from O
the O
Provincial O
Toxicology O
Center O
of O
British O
Columbia O
, O
Canada O
in O
which O
suicidal B-ADE
overdose I-ADE
deaths I-ADE
were O
associated O
with O
quetiapine B-DRUG
. O

Although O
taxol B-DRUG
has O
shown O
significant O
activity O
in O
advanced O
ovarian O
cancer O
, O
peripheral B-ADE
neuropathy I-ADE
is O
likely O
to O
become O
the O
major O
dose O
- O
limiting O
toxicity O
. O

In O
four O
patients O
, O
thrombosis B-ADE
occurred O
2 O
- O
45 O
days O
after O
severe O
hepatic B-ADE
veno I-ADE
- I-ADE
occlusive I-ADE
disease I-ADE
( O
HVOD B-ADE
) O
secondary O
to O
intensive O
chemotherapy O
containing O
busulfan B-DRUG
. O

The O
occurrence O
of O
BMTN B-ADE
in O
two O
children O
treated O
with O
RA B-DRUG
in O
our O
unit O
is O
unlikely O
to O
be O
coincidental O
. O

Multiple B-ADE
pulmonary I-ADE
nodules I-ADE
: O
an O
unusual O
presentation O
of O
fludarabine B-DRUG
pulmonary B-ADE
toxicity I-ADE
: O
case O
report O
and O
review O
of O
literature O
. O

These O
findings O
are O
consistent O
with O
an O
immune O
- O
complex O
form O
of O
glomerulopathy O
in O
which O
gold O
is O
neither O
the O
antigen O
nor O
a O
hapten O
in O
the O
glomerular O
deposits O
, O
and O
they O
suggest O
the O
hypothesis O
that O
antibodies O
to O
tubular O
epithelial O
antigens O
induced O
by O
gold B-DRUG
therapy O
may O
be O
a O
causative O
factor O
in O
the O
renal B-ADE
disease I-ADE
associated O
with O
gold B-DRUG
therapy O
in O
rheumatoid O
arthritis O
. O

It O
was O
concluded O
that O
ANCA B-ADE
is O
closely O
related O
to O
the O
pathogenesis O
of O
crescentic O
glomerulonephritis O
and O
that O
treatment O
with O
PTU B-DRUG
appeared O
to O
induce O
ANCA B-ADE
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
marked O
elevation B-ADE
of I-ADE
serum I-ADE
creatine I-ADE
kinase I-ADE
( O
CK O
) O
associated O
with O
olanzapine B-DRUG
therapy O
. O

CASE O
PRESENTATION O
: O
Three O
cases O
of O
Leishmania B-ADE
infantum I-ADE
leishmaniasis I-ADE
in O
corticosteroid B-DRUG
( O
CS O
) O
- O
treated O
patients O
are O
reported O
: O
an O
isolated O
lingual B-ADE
leishmaniasis I-ADE
in O
a O
farmer O
treated O
with O
CS B-DRUG
for O
asthma O
, O
a O
severe O
visceral O
leishmaniasis O
associated O
with O
cutaneous O
lesions O
in O
a O
woman O
with O
myasthenia O
gravis O
, O
and O
a O
visceral O
involvement O
after O
cutaneous B-ADE
leishmaniasis I-ADE
in O
a O
man O
receiving O
CS B-DRUG
. O

OBJECTIVES O
: O
A O
delayed O
stroke B-ADE
- I-ADE
like I-ADE
leukoencephalopathy I-ADE
has O
been O
observed O
in O
patients O
receiving O
methotrexate B-DRUG
( O
MTX B-DRUG
) O
for O
childhood O
leukemia O
. O

Nitrendipine B-DRUG
- O
induced O
gingival B-ADE
hyperplasia I-ADE
. O

CONCLUSIONS O
: O
Although O
budesonide B-DRUG
may O
be O
beneficial O
because O
of O
its O
anti O
- O
inflammatory O
effects O
, O
clinicians O
should O
be O
alert O
to O
its O
potential O
for O
causing O
contact B-ADE
dermatitis I-ADE
. O

Acute B-ADE
generalized I-ADE
exanthematous I-ADE
pustulosis I-ADE
induced O
by O
salazosulfapyridine B-DRUG
in O
a O
patient O
with O
ulcerative O
colitis O
. O

A O
36-y O
- O
o O
patient O
with O
schizophrenia O
, O
who O
had O
consumed O
gradually O
increasing O
quantities O
of O
oolong B-DRUG
tea I-DRUG
that O
eventually O
reached O
15 O
L O
each O
day O
, O
became O
delirious B-ADE
and O
was O
admitted O
to O
a O
psychiatric O
hospital O
. O

Long O
lasting O
respiratory B-ADE
depression I-ADE
induced O
by O
morphine-6-glucuronide B-DRUG
? O

Graves B-ADE
' I-ADE
hyperthyroidism I-ADE
following O
transient B-ADE
thyrotoxicosis I-ADE
during O
interferon B-DRUG
therapy O
for O
chronic O
hepatitis O
type O
C O
. O

The O
patient O
was O
found O
to O
have O
no B-ADE
motile I-ADE
sperm I-ADE
with O
a O
normal O
sperm O
count O
, O
while O
taking O
a O
dose O
of O
400 O
mg O
/ O
day O
of O
carbamazepine B-DRUG
. O

A O
44-year O
- O
old O
woman O
is O
described O
in O
whom O
amiodarone B-DRUG
, O
disopyramide B-DRUG
, O
and O
quinidine B-DRUG
, O
administered O
alone O
separately O
, O
induced O
atypical B-ADE
ventricular I-ADE
tachycardia I-ADE
( O
AVT B-ADE
, O
torsade B-ADE
de I-ADE
pointes I-ADE
) O
. O

Symptoms O
and O
endoscopic B-ADE
lesions I-ADE
quickly O
regressed O
within O
1 O
week O
of O
meloxicam B-DRUG
withdrawal O
. O

This O
panic B-ADE
anxiety I-ADE
was O
not O
relieved O
by O
taking O
etizolam O
and O
flunitrazepam O
again O
, O
but O
subsided O
rapidly O
by O
the O
re O
- O
administration O
of O
mianserin B-DRUG
30 O
mg O
/ O
day O
, O
and O
because O
of O
that O
the O
depressive O
symptom O
also O
disappeared O
. O

A O
58-yr O
- O
old O
male O
patient O
with O
essential O
thrombocythaemia O
( O
ET O
) O
developed O
chronic B-ADE
myeloid I-ADE
leukaemia I-ADE
( O
CML B-ADE
) O
after O
continuous O
uneventful O
treatment O
with O
hydroxyurea B-DRUG
for O
18 O
yr O
. O

Upon O
discontinuation O
of O
MTX B-DRUG
, O
her O
ascites B-ADE
resolved O
, O
and O
her O
arthritis O
became O
more O
active O
. O

We O
report O
a O
4-year O
- O
old O
girl O
who O
presented O
with O
acute B-ADE
bilateral I-ADE
blindness I-ADE
, O
a O
focal B-ADE
seizure I-ADE
and O
hypertension B-ADE
10 O
days O
after O
commencing O
oxybutynin B-DRUG
to O
treat O
enuresis O
. O

Four O
Chinese O
female O
patients O
who O
suffered O
from O
manic O
- O
depressive O
disorder O
and O
underlying O
autoimmune O
thyroiditis O
developed O
transient O
episodes O
of O
thyrotoxicosis B-ADE
during O
maintenance O
lithium B-DRUG
therapy O
. O

There O
are O
no O
previous O
reports O
in O
the O
literature O
about O
the O
emergence O
of O
CML B-ADE
during O
treatment O
with O
hydroxyurea B-DRUG
. O

METHODS O
: O
We O
queried O
35 O
rheumatologists O
at O
the O
Robert O
Breck O
Brigham O
Arthritis O
Center O
to O
determine O
if O
weight B-ADE
loss I-ADE
had O
occurred O
as O
an O
adverse O
event O
in O
patients O
treated O
with O
leflunomide B-DRUG
between O
November O
1998 O
and O
January O
2000 O
. O

Extrapyramidal B-ADE
symptoms I-ADE
are O
well O
- O
documented O
complications O
of O
therapy O
with O
haloperidol B-DRUG
, O
even O
when O
small O
doses O
are O
used O
. O

Glaucoma B-ADE
secondary O
to O
epithelial O
downgrowth O
and O
5-fluorouracil B-DRUG
. O

CASE O
REPORT O
: O
We O
describe O
here O
a O
case O
of O
a O
60 O
year O
old O
female O
that O
experienced O
a O
relapse O
of O
symptomatic B-ADE
hyperlactatemia I-ADE
after O
being O
switched O
from O
stavudine B-DRUG
to O
zidovudine B-DRUG
and O
how O
the O
case O
was O
managed O
at O
the O
Infectious O
Diseases O
Institute O
, O
Kampala O
, O
Uganda O
. O

Other O
thiazolidinediones O
currently O
in O
clinical O
trials O
may O
be O
able O
to O
provide O
the O
therapeutic O
benefits O
of O
troglitazone B-DRUG
without O
significant O
hepatotoxicity B-ADE
. O

Carbamazepine B-DRUG
toxicity I-ADE
induced O
by O
clarithromycin B-DRUG
coadministration O
in O
psychiatric O
patients O
. O

A O
61 O
year O
- O
old O
male O
patient O
developed O
gynecomastia B-ADE
after O
starting O
theophylline B-DRUG
. O

It O
is O
suggested O
that O
the O
fatal B-ADE
stroke I-ADE
may O
have O
resulted O
from O
arterial B-ADE
spasm I-ADE
caused O
by O
ergotamine B-DRUG
overdosage O
and O
possibly O
complicated O
by O
thrombosis O
. O

Adenosine B-DRUG
- O
induced O
ventricular B-ADE
fibrillation I-ADE
. O

Dermatitis B-ADE
to O
captopril B-DRUG
. O

Case O
report O
: O
life B-ADE
- I-ADE
threatening I-ADE
hypoglycaemia I-ADE
associated O
with O
sulfadoxine B-DRUG
- I-DRUG
pyrimethamine I-DRUG
, O
a O
commonly O
used O
antimalarial O
drug O
. O

PVT B-ADE
during O
chemotherapy O
in O
children O
is O
a O
rare O
event O
and O
appears O
to O
be O
closely O
related O
to O
intensive O
chemotherapy O
containing O
busulfan B-DRUG
and O
to O
be O
associated O
with O
HVOD B-ADE
. O

Possible O
linkage O
of O
amprenavir B-DRUG
with O
intracranial B-ADE
bleeding I-ADE
in O
an O
HIV O
- O
infected O
hemophiliac O
. O

Pulmonary B-ADE
fibrosis I-ADE
is O
a O
complication O
of O
paclitaxel B-DRUG
therapy O
that O
may O
occur O
despite O
treatments O
with O
corticosteroids O
. O

Intraventricular O
nafcillin B-DRUG
- O
induced O
seizures B-ADE
in O
a O
neonate O
. O

We O
report O
four O
cases O
of O
sensorimotor B-ADE
axonal I-ADE
neuropathy I-ADE
in O
children O
aged O
10 O
- O
15 O
years O
, O
treated O
with O
thalidomide B-DRUG
for O
myxopapillary O
ependymoma O
, O
Crohn O
's O
disease O
and O
recurrent O
giant O
aphthous O
ulceration O
. O

The O
9 O
other O
reported O
cases O
of O
D B-DRUG
- I-DRUG
penicillamine I-DRUG
induced O
rapidly B-ADE
progressive I-ADE
glomerulonephritis I-ADE
have O
been O
reviewed O
. O

Ciprofloxacin B-DRUG
- O
induced O
hemorrhagic B-ADE
vasculitis I-ADE
is O
a O
rare O
side O
effect O
. O

The O
purpose O
of O
this O
report O
is O
to O
document O
a O
new O
case O
of O
in O
utero O
CP B-DRUG
exposure O
with O
multiple B-ADE
congenital I-ADE
anomalies I-ADE
and O
to O
establish O
an O
apparent O
CP B-DRUG
embryopathy B-ADE
phenotype O
. O

Linear B-ADE
immunoglobulin I-ADE
A I-ADE
bullous I-ADE
dermatosis I-ADE
induced O
by O
gemcitabine B-DRUG
. O

The O
authors O
report O
a O
further O
case O
of O
methimazole B-DRUG
- O
associated O
liver B-ADE
damage I-ADE
and O
present O
a O
brief O
review O
of O
eleven O
previous O
cases O
found O
in O
the O
literature O
. O

CONCLUSIONS O
: O
The O
piloerection B-ADE
observed O
after O
the O
replacement O
of O
fluvoxamine B-DRUG
with O
milnacipran B-DRUG
in O
this O
patient O
appears O
to O
have O
been O
due O
to O
an O
increase O
in O
the O
alpha(1 O
) O
- O
adrenoceptor O
occupancy O
by O
endogenous O
norepinephrine O
induced O
by O
milnacipran O
. O

Ulcer B-ADE
became I-ADE
worse I-ADE
after O
tobramycin B-DRUG
and O
gentamycin B-DRUG
treatment O
for O
2 O
days O
. O

Pigmentary B-ADE
disorders I-ADE
are O
recognized O
adverse O
effects O
of O
the O
semi O
- O
synthetic O
tetracycline O
derivative O
antibiotic O
, O
minocycline B-DRUG
. O

The O
patient O
described O
in O
this O
paper O
was O
a O
78-year O
- O
old O
diabetic O
man O
who O
developed O
oral B-ADE
lesions I-ADE
of I-ADE
PV I-ADE
following O
institution O
of O
glibenclamide B-DRUG
therapy O
. O

We O
recommend O
the O
cautious O
use O
of O
ketorolac B-DRUG
in O
patients O
with O
underlying O
illnesses O
where O
NSAID O
- O
induced O
ototoxicity B-ADE
could O
result O
in O
adverse O
otologic O
consequences O
. O

Herpes B-ADE
simplex I-ADE
esophagitis I-ADE
in O
a O
renal O
transplant O
patient O
treated O
with O
cyclosporine B-DRUG
A I-DRUG
: O
a O
case O
report O
. O

We O
describe O
a O
patient O
with O
idiopathic O
RLS O
who O
developed O
augmentation B-ADE
after O
8 O
months O
of O
levodopa B-DRUG
treatment O
. O

Renal B-ADE
failure I-ADE
associated O
with O
acetazolamide B-DRUG
therapy O
for O
glaucoma O
. O

A O
case O
of O
acute B-ADE
subdural I-ADE
haematoma I-ADE
originating O
spontaneously O
from O
an O
angiomatous O
meningioma O
in O
a O
patient O
receiving O
prophylactic O
aspirin B-DRUG
therapy O
is O
presented O
. O

Protease O
inhibitor O
- O
induced O
carbamazepine B-DRUG
toxicity I-ADE
. O

After O
5 O
weeks O
of O
therapy O
, O
she O
stopped O
taking O
pantoprazole B-DRUG
due O
to O
general B-ADE
malaise I-ADE
. O

Severe B-ADE
hepatitis I-ADE
caused O
by O
cyproterone B-DRUG
acetate I-DRUG
. O

We O
report O
a O
case O
of O
a O
child O
with O
neurodevelopmental O
delay O
with O
chronic O
constipation O
and O
a O
history O
of O
chronic O
mineral B-DRUG
oil I-DRUG
ingestion O
presenting O
as O
asymptomatic O
exogenous B-ADE
lipoid I-ADE
pneumonia I-ADE
( O
ELP B-ADE
) O
. O

Our O
case O
is O
the O
second O
one O
in O
which O
hemorrhage B-ADE
from O
a O
meningioma O
may O
have O
been O
induced O
by O
aspirin B-DRUG
prophylaxis O
. O

Anaphylaxis B-ADE
to O
cisplatin B-DRUG
is O
an O
infrequent O
life O
- O
threatening O
complication O
which O
may O
occur O
even O
in O
patients O
who O
have O
received O
prior O
treatment O
with O
cisplatin O
. O

Papilloedema B-ADE
and O
hepatic B-ADE
dysfunction I-ADE
apparently O
induced O
by O
perhexiline B-DRUG
maleate I-DRUG
( O
Pexid B-DRUG
) O
. O

We O
report O
a O
case O
of O
fulminant O
neuroleptic B-ADE
malignant I-ADE
syndrome I-ADE
in O
a O
man O
aged O
70 O
developing O
within O
12 O
hours O
of O
starting O
six O
- O
hourly O
intravenous O
metoclopramide B-DRUG
. O

We O
report O
a O
cae O
of O
paranoid B-ADE
psychosis I-ADE
following O
use O
of O
a O
decongestant O
containing O
PPA B-DRUG
and O
summarize O
the O
case O
report O
literature O
of O
psychiatric B-ADE
adverse I-ADE
effects I-ADE
to O
PPA B-DRUG
in O
which O
doses O
were O
known O
and O
stated O
to O
be O
within O
recommended O
guidelines O
. O

Retinal B-ADE
abnormalities I-ADE
, O
including O
retinal B-ADE
hemorrhage I-ADE
and O
" B-ADE
cotton I-ADE
- I-ADE
wool I-ADE
" I-ADE
spots I-ADE
, O
often O
occur O
within O
the O
first O
8 O
weeks O
in O
the O
course O
of O
interferon B-DRUG
therapy O
in O
patients O
with O
chronic O
hepatitis O
C O
. O

Onset O
of O
male O
gynaecomastia B-ADE
in O
a O
patient O
treated O
with O
sunitinib B-DRUG
for O
metastatic O
renal O
cell O
carcinoma O
. O

An O
infertile O
patient O
with O
amenorrhea O
- O
galactorrhea O
syndrome O
lost B-ADE
vision I-ADE
during O
a O
pregnancy O
occurring O
after O
Bromocryptine B-DRUG
treatment O
. O

Two O
patients O
with O
osteomyelitis O
who O
developed O
reversible B-ADE
cholestatic I-ADE
jaundice I-ADE
during O
treatment O
with O
oxacillin B-DRUG
derivatives O
are O
described O
. O

An O
immediate O
hemolytic B-ADE
reaction I-ADE
induced O
by O
repeated O
administration O
of O
oxaliplatin B-DRUG
. O

Only O
one O
report O
links O
phenylpropanolamine B-DRUG
consumption O
to O
an O
intracerebral B-ADE
hemorrhage I-ADE
in O
a O
patient O
with O
an O
AVM O
. O

Diarrhoea B-ADE
, O
T B-ADE
- I-ADE
CD4 I-ADE
+ I-ADE
lymphopenia I-ADE
and O
bilateral B-ADE
patchy I-ADE
pulmonary I-ADE
infiltrates I-ADE
developed O
in O
a O
male O
60 O
yrs O
of O
age O
, O
who O
was O
treated O
with O
oxaliplatinum B-DRUG
and O
5-fluorouracil B-DRUG
for O
unresectable O
rectum O
carcinoma O
. O

Acute O
severe O
intoxication O
with O
carbamazepine B-DRUG
is O
associated O
with O
seizures B-ADE
, O
coma B-ADE
and O
respiratory B-ADE
depression I-ADE
. O

Gangrene B-ADE
of O
the O
fingertips O
after O
bleomycin B-DRUG
and O
methotrexate B-DRUG
. O

Drug O
- O
induced O
fever B-ADE
due O
to O
diltiazem B-DRUG
. O

We O
describe O
3 O
AS O
patients O
treated O
with O
etanercept B-DRUG
for O
active O
AS O
who O
developed O
new O
onset O
of O
CD B-ADE
while O
AS O
related O
symptoms O
responded O
well O
to O
etanercept O
. O

We O
describe O
a O
case O
of O
significant O
elevation B-ADE
of I-ADE
serum I-ADE
transaminases I-ADE
in O
a O
patient O
treated O
with O
6-TG B-DRUG
for O
a O
flare O
of O
Crohn O
's O
disease O
. O

Olanzapine B-DRUG
- O
induced O
hyperglycaemic B-ADE
coma I-ADE
and O
neuroleptic B-ADE
malignant I-ADE
syndrome I-ADE
: O
case O
report O
and O
review O
of O
literature O
. O

We O
report O
5 O
patients O
( O
3 O
patients O
with O
chronic O
hepatitis O
C O
treated O
with O
pegylated B-DRUG
interferon I-DRUG
alfa-2b I-DRUG
in O
association O
with O
oral O
ribavirin B-DRUG
and O
two O
patients O
with O
chronic O
myelocytic O
leukemia O
) O
who O
developed O
local B-ADE
cutaneous I-ADE
reactions I-ADE
at O
sites O
of O
injection O
after O
the O
administration O
of O
weekly O
subcutaneous O
injections O
of O
pegylated B-DRUG
interferon I-DRUG
alfa-2b I-DRUG
at O
different O
doses O
. O

Flucloxacillin B-DRUG
- O
induced O
aplastic B-ADE
anaemia I-ADE
and O
liver B-ADE
failure I-ADE
. O

A O
case O
of O
mania B-ADE
associated O
with O
fluoxetine B-DRUG
. O

The O
development O
of O
cutaneous B-ADE
ecchymosis I-ADE
associated O
with O
a O
sudden B-ADE
fall I-ADE
in I-ADE
hemoglobin I-ADE
after O
the O
administration O
of O
alteplase B-DRUG
should O
strongly O
suggest O
the O
possibility O
of O
diffuse B-ADE
subfascial I-ADE
hematoma I-ADE
. O

Lansoprazole B-DRUG
- O
induced O
thrombocytopenia B-ADE
. O

OBJECTIVE O
: O
To O
describe O
a O
probable O
case O
of O
transient B-ADE
global I-ADE
amnesia I-ADE
caused O
by O
propafenone B-DRUG
. O

Electro O
- O
oculography O
, O
electroretinography O
, O
visual O
evoked O
potentials O
, O
and O
multifocal O
electroretinography O
in O
patients O
with O
vigabatrin B-DRUG
- O
attributed O
visual B-ADE
field I-ADE
constriction I-ADE
. O

This O
clinical O
course O
suggests O
that O
the O
sensorimotor B-ADE
polyneuropathy I-ADE
may O
have O
been O
caused O
by O
5-ASA B-DRUG
. O

In O
all O
cases O
, O
seizures B-ADE
were O
controlled O
by O
withdrawal O
of O
phenytoin B-DRUG
and O
reduction O
of O
drug O
levels O
. O

Vanishing B-ADE
bile I-ADE
duct I-ADE
and O
Stevens B-ADE
- I-ADE
Johnson I-ADE
syndrome I-ADE
associated O
with O
ciprofloxacin B-DRUG
treated O
with O
tacrolimus O
. O

The O
course O
of O
delirium B-ADE
due O
to O
lithium B-DRUG
intoxication O
. O

Severe B-ADE
neurotoxicity I-ADE
with O
methyl B-DRUG
G I-DRUG
: I-DRUG
CALGB I-DRUG
experience O
. O

RESULTS O
: O
A O
52-year O
- O
old O
woman O
with O
Parkinson O
disease O
who O
had O
taken O
amantadine B-DRUG
for O
6 O
years O
had O
bilateral B-ADE
corneal I-ADE
edema I-ADE
for O
2 O
months O
at O
baseline O
. O

Spontaneous O
bacterial B-ADE
peritonitis I-ADE
induced O
by O
intraarterial O
vasopressin B-DRUG
therapy O
. O

The O
case O
history O
confirms O
that O
gold B-DRUG
treatment O
, O
even O
in O
the O
same O
patient O
, O
can O
give O
rise O
to O
a O
wide O
range O
of O
skin B-ADE
disturbances I-ADE
, O
which O
in O
many O
cases O
do O
not O
break O
out O
until O
long O
after O
the O
drug O
has O
been O
withdrawn O
. O

A O
young O
patient O
experienced O
marked O
sinus B-ADE
tachycardia I-ADE
while O
smoking O
marijuana O
and O
receiving O
therapeutic O
doses O
of O
nortriptyline B-DRUG
. O

A O
severe O
form O
of O
exophthalmos B-ADE
resulting O
from O
lithium B-DRUG
therapy O
has O
not O
been O
described O
in O
the O
literature O
. O

A O
21-year O
- O
old O
patient O
developed O
rhabdomyolysis B-ADE
during O
his O
nineteenth O
week O
of O
treatment O
with O
clozapine B-DRUG
for O
drug O
- O
resistant O
schizophrenia O
. O

Edema B-ADE
associated O
with O
ibuprofen B-DRUG
therapy O
. O

Recombinant O
VIIa O
concentrate O
in O
the O
management O
of O
bleeding O
following O
prothrombin B-DRUG
complex I-DRUG
concentrate I-DRUG
- O
related O
myocardial B-ADE
infarction I-ADE
in O
patients O
with O
haemophilia O
and O
inhibitors O
. O

Acyclovir B-DRUG
neurotoxicity B-ADE
: O
clinical O
experience O
and O
review O
of O
the O
literature O
. O

Bulbar B-ADE
and O
pseudobulbar B-ADE
palsy I-ADE
complicating O
therapy O
with O
high O
- O
dose O
cytosine B-DRUG
arabinoside I-DRUG
in O
children O
with O
leukemia O
. O

We O
report O
a O
case O
of O
unintentional O
overdose O
of O
oral O
pilocarpine B-DRUG
tablets O
that O
resulted O
in O
bradycardia B-ADE
, O
mild B-ADE
hypotension I-ADE
, O
and O
muscarinic B-ADE
symptoms I-ADE
in O
a O
patient O
with O
Sjogren O
's O
syndrome O
. O

In O
some O
cases O
this O
seems O
to O
happen O
because O
spironolactone B-DRUG
causes O
diarrhoea B-ADE
. O

The O
authors O
report O
one O
case O
of O
incomplete B-ADE
posterior I-ADE
hyaloid I-ADE
detachment I-ADE
( O
PHD O
) O
following O
intravitreal O
pegaptanib B-DRUG
to O
treat O
DME O
. O

Circulating O
anticoagulant O
in O
the O
procainamide B-DRUG
- O
induced O
lupus B-ADE
syndrome I-ADE
. O

After O
a O
two O
- O
month O
interruption O
of O
interferon O
administration O
, O
natural O
interferon B-DRUG
alpha I-DRUG
was O
given O
but O
followed O
by O
another O
episode O
of O
the O
same O
neurological B-ADE
manifestations I-ADE
. O

We O
describe O
a O
41 O
yr O
old O
leprosy O
patient O
treated O
for O
10 O
yrs O
with O
clofazimine B-DRUG
who O
underwent O
laparotomy O
for O
severe O
abdominal B-ADE
pain I-ADE
. O

OBJECTIVE O
: O
To O
our O
knowledge O
, O
this O
is O
the O
first O
published O
case O
report O
of O
an O
adolescent O
girl O
with O
a O
mitochondrial O
disorder O
and O
depression O
who O
displayed O
both O
new O
- O
onset O
psychotic O
and O
increased B-ADE
mood I-ADE
symptoms I-ADE
during O
treatment O
with O
risperidone B-DRUG
. O

Several O
cases O
of O
lithium B-DRUG
- O
induced O
Creutzfeldt B-ADE
- I-ADE
Jakob I-ADE
syndrome I-ADE
have O
been O
reported O
to O
date O
; O
all O
of O
them O
were O
elderly O
patients O
and O
a O
half O
had O
" O
therapeutic O
" O
lithium B-DRUG
serum O
levels O
. O

L B-DRUG
- I-DRUG
DOPA I-DRUG
- O
induced O
excessive O
daytime B-ADE
sleepiness I-ADE
in O
PD O
: O
a O
placebo O
- O
controlled O
case O
with O
MSLT O
assessment O
. O

Methemoglobinemia B-ADE
after O
axillary O
block O
with O
bupivacaine B-DRUG
and O
additional O
injection O
of O
lidocaine B-DRUG
in O
the O
operative O
field O
. O

Benzocaine B-DRUG
, O
an O
ester O
- O
type O
local O
anesthetic O
, O
was O
believed O
responsible O
for O
apparent O
methemoglobinemia B-ADE
in O
a O
cat O
. O

Managing O
cardiovascular B-ADE
collapse I-ADE
in O
severe O
flecainide B-DRUG
overdose O
without O
recourse O
to O
extracorporeal O
therapy O
. O

Tamoxifen B-DRUG
is O
suggested O
to O
be O
carcinogenic B-ADE
both O
through O
direct O
genotoxic O
and O
epigenetic O
mechanisms O
. O

Gabapentin B-DRUG
withdrawal O
presenting O
as O
status B-ADE
epilepticus I-ADE
. O

We O
report O
a O
case O
of O
NEH B-ADE
masquerading O
as O
cutaneous O
vasculitis O
in O
a O
woman O
receiving O
cyclophosphamide B-DRUG
for O
lupus O
nephritis O
. O

Their O
parkinsonism B-ADE
improved O
on O
discontinuation O
of O
metoclopramide B-DRUG
therapy O
. O

In O
summary O
, O
we O
report O
herein O
the O
first O
case O
of O
SIADH B-ADE
believed O
to O
be O
an O
adverse O
effect O
of O
mizoribin B-DRUG
, O
which O
may O
therefore O
needed O
to O
be O
added O
to O
the O
list O
of O
drugs O
which O
can O
induce O
SIADH B-ADE
. O

We O
report O
the O
first O
case O
of O
acute B-ADE
renal I-ADE
failure I-ADE
with O
hyperkalemia B-ADE
associated O
with O
the O
recently O
marketed O
direct O
renin O
inhibitor O
aliskiren B-DRUG
. O

Nine O
azotemic O
patients O
who O
developed O
a O
coagulopathy B-ADE
associated O
with O
the O
use O
of O
either O
cephalosporin B-DRUG
or O
moxalactam B-DRUG
antibiotics O
are O
reported O
. O

During O
the O
first O
days O
of O
arsenic B-DRUG
trioxide I-DRUG
treatment O
a O
rapid O
decrease B-ADE
in I-ADE
the I-ADE
D I-ADE
- I-ADE
dimers I-ADE
was O
seen O
( O
normal O
values O
reached O
until O
day O
7 O
) O
, O
together O
with O
a O
slight B-ADE
decrease I-ADE
in I-ADE
peripheral I-ADE
blood I-ADE
leukocytes I-ADE
. O

Two O
patients O
treated O
with O
alprazolam B-DRUG
had O
histories O
suggestive O
of O
a O
bipolar O
disorder O
and O
developed O
lithium O
- O
responsive O
manic B-ADE
episodes I-ADE
. O

OBJECTIVE O
: O
To O
report O
on O
the O
possible O
development O
of O
serotonin B-ADE
syndrome I-ADE
in O
a O
patient O
receiving O
clomipramine B-DRUG
after O
clozapine B-DRUG
was O
withdrawn O
from O
the O
treatment O
regimen O
. O

These O
nail B-ADE
changes I-ADE
gradually O
disappeared O
when O
the O
dose O
of O
clofazimine B-DRUG
was O
reduced O
. O

Acute B-ADE
dystonia I-ADE
with O
thalamic B-ADE
and I-ADE
brainstem I-ADE
lesions I-ADE
after O
initial O
penicillamine B-DRUG
treatment O
in O
Wilson O
's O
disease O
. O

Paradoxical B-ADE
precipitation I-ADE
of I-ADE
tonic I-ADE
seizures I-ADE
by O
lorazepam B-DRUG
in O
a O
child O
with O
atypical O
absence O
seizures O
. O

We O
report O
two O
cases O
of O
tenofovir B-DRUG
( O
TDF B-DRUG
) O
- O
associated O
nephrotoxicity B-ADE
in O
perinatally O
HIV O
- O
infected O
adolescents O
. O

We O
describe O
a O
patient O
with O
androgen O
- O
independent O
prostate O
cancer O
in O
whom O
PSA B-ADE
continued I-ADE
to I-ADE
decrease I-ADE
for O
a O
period O
of O
15 O
months O
after O
flutamide B-DRUG
withdrawal O
. O

In O
two O
patients O
clozapine B-DRUG
was O
reinstated O
after O
risperidone O
was O
discontinued O
; O
serum B-ADE
triglyceride I-ADE
levels I-ADE
increased I-ADE
. O

We O
report O
a O
case O
of O
fatal B-ADE
fulminant I-ADE
hepatitis I-ADE
caused O
by O
the O
use O
of O
disulfiram B-DRUG
in O
a O
man O
with O
previously O
normal O
hepatocellular O
function O
. O

RESULTS O
: O
Similar O
to O
previous O
findings O
of O
drug O
- O
induced O
vortex B-ADE
keratopathy I-ADE
, O
atovaquone B-DRUG
vortex B-ADE
keratopathy I-ADE
is O
presumably O
caused O
by O
its O
lipophilic O
properties O
. O

46-year O
- O
old O
woman O
developed O
painful B-ADE
ulcers I-ADE
over O
her O
lower O
abdomen O
in O
the O
form O
of O
reticulate B-ADE
erythema I-ADE
after O
injecting O
interferon B-DRUG
beta-1b I-DRUG
subcutaneously O
for O
multiple O
sclerosis O
. O

To O
date O
, O
only O
three O
cases O
of O
seizures B-ADE
associated O
with O
amphotericin B-DRUG
B I-DRUG
have O
been O
reported O
in O
the O
literature O
, O
but O
healthcare O
providers O
should O
be O
aware O
of O
the O
potential O
for O
this O
rare O
adverse O
effect O
. O

We O
report O
a O
case O
of O
SJS B-ADE
in O
a O
14-year O
- O
old O
male O
with O
nephrotic O
syndrome O
, O
who O
was O
treated O
with O
oral O
prednisolone B-DRUG
for O
6 O
weeks O
. O

Therefore O
, O
although O
garenoxacin B-DRUG
reportedly O
causes O
fewer O
adverse O
reactions O
for O
cardiac B-ADE
rhythms I-ADE
than O
third O
- O
generation O
quinolone O
antibiotics O
, O
one O
must O
be O
cautious O
of O
the O
interference O
of O
other O
drugs O
during O
hypokalemia B-ADE
in O
order O
to O
prevent O
TdP O
. O

A O
patient O
with O
generalized O
MG O
was O
effectively O
managed O
with O
MM B-DRUG
but O
developed O
CNS B-ADE
lymphoma I-ADE
after O
3 O
years O
of O
treatment O
. O

Colchicine B-DRUG
- O
induced O
myopathy B-ADE
in O
renal O
failure O
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
serotonin B-ADE
syndrome I-ADE
associated O
with O
interaction O
between O
fentanyl B-DRUG
and O
citalopram B-DRUG
, O
as O
evidenced O
by O
medication O
history O
, O
clinical O
features O
and O
reversal O
following O
discontinuation O
of O
fentanyl B-DRUG
. O

High O
- O
dose O
intravenous O
mannitol B-DRUG
infusion O
in O
various O
clinical O
settings O
may O
result O
in O
acute B-ADE
renal I-ADE
failure I-ADE
( O
ARF B-ADE
) O
. O

Zolpidem B-DRUG
( O
Ambien B-DRUG
) O
, O
a O
relatively O
new O
nonbenzodiazepine O
sedative O
- O
hypnotic O
, O
was O
involved O
in O
the O
death B-ADE
of O
a O
39-year O
- O
old O
obese O
male O
who O
was O
being O
treated O
for O
depression O
and O
insomnia O
. O

Captopril B-DRUG
- O
induced O
pulmonary B-ADE
infiltrates I-ADE
with I-ADE
eosinophilia I-ADE
in O
an O
infant O
with O
congenital O
heart O
disease O
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
calcineurin B-DRUG
- O
induced O
pain B-ADE
syndrome I-ADE
( O
CIPS O
) O
in O
a O
child O
undergoing O
his O
second O
hematopoietic O
stem O
cell O
transplant O
( O
HSCT O
) O
. O

A O
sixty O
- O
year O
- O
old O
woman O
with O
advanced O
breast O
cancer O
, O
previously O
treated O
with O
cisplatin O
, O
developed O
an O
irreversible B-ADE
lethal I-ADE
renal I-ADE
failure I-ADE
with O
anuria B-ADE
, O
the O
day O
after O
5 O
g O
/ O
m2 O
bolus O
ifosfamide B-DRUG
. O

A O
case O
is O
reported O
of O
theophylline B-DRUG
intoxication I-ADE
due O
to O
a O
dramatic O
decrease B-ADE
in I-ADE
theophylline I-ADE
clearance I-ADE
following O
concomitant O
administration O
of O
viloxazine B-DRUG
. O

Methotrexate B-DRUG
may O
rarely O
provoke O
serositis B-ADE
, O
even O
with O
low O
doses O
and O
after O
just O
a O
few O
weeks O
of O
therapy O
. O

Clearance O
rates O
of O
cerivastatin O
metabolites O
in O
a O
patient O
with O
cerivastatin B-DRUG
- O
induced O
rhabdomyolysis B-ADE
. O

Reduction O
of O
methylprednisolone B-DRUG
dosage O
rather O
than O
insulin O
therapy O
resulted O
in O
better O
control O
of O
glycemia B-ADE
. O

A O
62-year O
- O
old O
woman O
who O
was O
being O
treated O
for O
squamous O
cell O
carcinoma O
of O
the O
head O
and O
neck O
developed O
a O
chemotherapy O
- O
related O
hemolytic B-ADE
- I-ADE
uremic I-ADE
syndrome I-ADE
during O
the O
second O
cycle O
of O
neoadjuvant O
chemotherapy O
consisting O
of O
cisplatin B-DRUG
, O
bleomycin B-DRUG
, O
and O
methotrexate B-DRUG
. O

The O
cause O
of O
his O
bleeding O
was O
a O
severe B-ADE
thrombocytopoaenia I-ADE
, O
induced O
by O
chronic O
ingestion O
of O
quinine B-DRUG
. O

Nifedipine B-DRUG
may O
induce O
, O
or O
aggravate O
, O
pre O
- O
existing O
, O
gastro B-ADE
- I-ADE
oesophageal I-ADE
reflux I-ADE
. O

The O
authors O
report O
a O
case O
of O
acute O
pancreatitis B-ADE
( O
AP O
) O
occurring O
in O
a O
patient O
under O
treatment O
with O
carbamazepine B-DRUG
( O
CBZ B-DRUG
) O
for O
post O
- O
traumatic O
petit O
mal O
epilepsy O
, O
and O
review O
the O
current O
literature O
of O
drug O
- O
induced O
AP O
. O

A O
few O
recent O
individual O
case O
reports O
have O
suggested O
that O
a O
myasthenic B-ADE
syndrome I-ADE
may O
be O
associated O
with O
statin B-DRUG
treatment O
, O
but O
this O
association O
is O
not O
well O
described O
. O

Acute B-ADE
syphilitic I-ADE
posterior I-ADE
placoid I-ADE
chorioretinitis I-ADE
following O
intravitreal O
triamcinolone B-DRUG
acetonide I-DRUG
injection O
. O

Data O
have O
been O
published O
regarding O
the O
possibility O
that O
tamoxifen B-DRUG
may O
be O
responsible O
for O
the O
subsequent O
development O
of O
carcinoma B-ADE
of I-ADE
the I-ADE
corpus I-ADE
uteri I-ADE
in O
these O
patients O
. O

Myotonia B-ADE
associated O
with O
sarcoidosis O
: O
marked O
exacerbation O
with O
pravastatin B-DRUG
. O

We O
describe O
two O
patients O
with O
rheumatoid O
factor O
- O
positive O
, O
polyarticular O
- O
onset O
juvenile O
rheumatoid O
arthritis O
in O
whom O
accelerated B-ADE
nodulosis I-ADE
developed O
during O
methotrexate B-DRUG
therapy O
. O

This O
progressed O
to O
tracheal B-ADE
compression I-ADE
with O
stridor O
after O
he O
had O
taken O
some O
aspirin B-DRUG
for O
relief O
of O
the O
neck O
pain O
. O

In O
this O
report O
, O
two O
cases O
of O
ET O
which O
evolved O
into O
AL B-ADE
without O
prior O
exposure O
to O
radiation O
or O
alkylating O
agents O
, O
and O
which O
were O
treated O
with O
long O
- O
term O
hydroxyurea B-DRUG
therapy O
, O
are O
described O
. O

Reflex B-ADE
sympathetic I-ADE
dystrophy I-ADE
syndrome I-ADE
in O
renal O
transplanted O
patients O
under O
immunosuppression O
with O
tacrolimus B-DRUG
. O

Brugada B-ADE
type I-ADE
electrocardiographic I-ADE
changes I-ADE
induced O
by O
concomitant O
use O
of O
lithium B-DRUG
and O
propafenone B-DRUG
in O
patient O
with O
Wolff O
- O
Parkinson O
- O
White O
syndrome O
. O

CONCLUSIONS O
: O
There O
was O
a O
temporal O
relationship O
between O
the O
onset O
of O
nonconvulsive B-ADE
status I-ADE
epilepticus I-ADE
and O
initiation O
of O
ifosfamide B-DRUG
infusion O
. O

Suxamethonium B-DRUG
apnoea B-ADE
terminated O
with O
commercial O
serumcholinesterase O
. O

The O
purpose O
of O
this O
study O
was O
to O
examine O
the O
incidence O
and O
cause O
of O
Clostridium B-ADE
difficile I-ADE
colitis I-ADE
occurring O
after O
cisplatin B-DRUG
- O
based O
combination O
chemotherapy O
in O
ovarian O
cancer O
patients O
. O

Linezolid B-DRUG
- O
induced O
dyserythropoiesis B-ADE
: O
chloramphenicol O
toxicity O
revisited O
. O

Rifampin B-DRUG
- O
induced O
hypothyroidism B-ADE
without O
underlying O
thyroid O
disease O
. O

CONCLUSIONS O
: O
Clinicians O
should O
be O
aware O
that O
Crohn B-ADE
's I-ADE
disease I-ADE
is O
a O
potential O
novel O
adverse O
drug O
effect O
of O
Copaxone B-DRUG
. O

Severe B-ADE
acidosis I-ADE
from O
acetazolamide B-DRUG
in O
a O
diabetic O
patient O
. O

Gold B-DRUG
- I-DRUG
salt I-DRUG
therapy O
may O
result O
in O
damage B-ADE
to I-ADE
proximal I-ADE
tubules I-ADE
that O
leak O
renal O
tubular O
antigens O
, O
which O
in O
turn O
complex O
with O
autoantibody O
and O
produce O
an O
autoimmune O
membranous O
nephropathy O
. O

In O
the O
present O
paper O
, O
we O
describe O
two O
patients O
with O
active O
UC O
who O
developed O
a O
severe B-ADE
systemic I-ADE
CMV I-ADE
infection I-ADE
during O
a O
treatment O
with O
an O
oral O
microemulsion O
form O
of O
cyclosporine B-DRUG
. O

L B-DRUG
- I-DRUG
asparaginase I-DRUG
- O
induced O
posterior B-ADE
reversible I-ADE
encephalopathy I-ADE
syndrome O
during O
acute O
lymphoblastic O
leukemia O
treatment O
in O
children O
. O

Gold B-DRUG
nephropathy I-ADE
due O
to O
auranofin B-DRUG
obscured O
by O
tolmetin B-DRUG
pseudoproteinuria B-ADE
. O

Herein O
, O
we O
present O
a O
patient O
with O
severe O
and O
prolonged B-ADE
hypoglycemia I-ADE
after O
long O
- O
acting O
octreotide B-DRUG
treatment O
. O

A O
major O
limitation O
in O
the O
use O
of O
amphotericin B-DRUG
B I-DRUG
is O
its O
potential O
to O
cause O
nephrotoxicity B-ADE
. O

Tegaserod B-DRUG
- O
associated O
ischemic B-ADE
colitis I-ADE
. O

Agranulocytosis B-ADE
is O
a O
rare O
adverse O
effect O
associated O
with O
prolonged O
vancomycin B-DRUG
therapy O
, O
and O
is O
potentially O
serious O
, O
especially O
in O
end O
stage O
renal O
disease O
( O
ESRD O
) O
patients O
. O

A O
58-year O
- O
old O
woman O
with O
rheumatoid O
arthritis O
( O
RA O
) O
developed O
fever B-ADE
, O
skin B-ADE
eruptions I-ADE
, O
leukocytopenia B-ADE
, O
and O
thrombocytopenia B-ADE
, O
3 O
weeks O
after O
treatment O
with O
sulfasalazine B-DRUG
. O

Two O
cases O
of O
sirolimus B-DRUG
- O
associated O
pneumonitis B-ADE
have O
been O
reported O
after O
cardiac O
transplantation O
. O

Seizures B-ADE
and O
transient B-ADE
blindness I-ADE
following O
intravenous O
pulse O
methylprednisolone B-DRUG
in O
children O
with O
primary O
glomerulonephritis O
. O

In O
addition O
, O
ethambutol B-DRUG
rarely O
causes O
visual B-ADE
loss I-ADE
during O
the O
early O
period O
or O
when O
given O
at O
lower O
doses O
. O

When O
the O
acute O
manic O
state O
is O
characterized O
by O
marked O
psychotic B-ADE
symptoms I-ADE
and O
intense B-ADE
anxiety I-ADE
, O
it O
may O
be O
associated O
with O
increased O
vulnerability O
to O
the O
development O
of O
severe O
lithium B-DRUG
neurotoxicity B-ADE
. O

CONCLUSION O
: O
Although O
a O
definite O
association O
has O
not O
been O
proven O
, O
clinicians O
should O
be O
aware O
of O
the O
possibility O
of O
agranulocytosis B-ADE
while O
using O
quetiapine B-DRUG
. O

We O
report O
a O
45-year O
- O
old O
psoriasis O
patient O
who O
developed O
eruptive B-ADE
mollusca I-ADE
contagiosa I-ADE
during O
an O
antipsoriatic O
treatment O
with O
efalizumab B-DRUG
. O

After O
receiving O
3 O
doses O
of O
ifosfamide B-DRUG
/ O
mesna B-DRUG
, O
she O
was O
found O
to O
be O
unresponsive B-ADE
. O

We O
report O
a O
case O
of O
chronic O
use O
of O
HCQ B-DRUG
associated O
with O
torsade B-ADE
de I-ADE
pointes I-ADE
. O

CONCLUSION O
: O
Severe O
and O
sustained B-ADE
ocular I-ADE
hypertension I-ADE
may O
occur O
after O
intravitreal O
ranibizumab B-DRUG
. O

Cushing B-ADE
's I-ADE
syndrome I-ADE
persisted O
more O
than O
6 O
months O
while O
TCA B-DRUG
concentrations O
remained O
detectable O
for O
at O
least O
80 O
days O
. O

Secondary B-ADE
hyperparathyroidism I-ADE
in O
certain O
patients O
with O
lithium B-DRUG
nephrotoxicity B-ADE
is O
also O
possible O
. O

Hepatolithiasis B-ADE
( O
intrahepatic O
stone O
) O
during O
octreotide B-DRUG
therapy O
for O
acromegaly O
: O
a O
case O
report O
. O

We O
report O
on O
a O
patient O
with O
an O
embryonal O
teratocarcinoma O
of O
the O
testicle O
who O
had O
the O
syndrome O
of O
inappropriate B-ADE
secretion I-ADE
of I-ADE
antidiuretic I-ADE
hormone I-ADE
after O
receiving O
a O
high O
dose O
of O
vinblastine B-DRUG
. O

We O
describe O
a O
73-year O
- O
old O
woman O
who O
developed O
serious O
systemic B-ADE
vasculitis I-ADE
with O
associated O
thrombocytopenia B-ADE
in O
the O
course O
of O
treatment O
with O
cladribine B-DRUG
. O

A O
54-year O
- O
old O
man O
developed O
TEN B-ADE
4 O
weeks O
after O
beginning O
lamotrigine B-DRUG
for O
complex O
partial O
seizures O
related O
to O
a O
glioblastoma O
multiforme O
brain O
tumor O
. O

Two O
patients O
with O
bipolar O
affective O
disorder O
and O
a O
history O
of O
bronchospastic O
phenomena O
experienced O
tremor B-ADE
during O
lithium B-DRUG
carbonate I-DRUG
therapy O
. O

These O
cases O
were O
considered O
unusual O
in O
light O
of O
the O
short O
delay O
of O
their O
onset O
after O
initiation O
of O
immunosuppressive O
therapy O
and O
their O
fulminant O
course O
: O
3 O
of O
these O
patients O
died B-ADE
of O
PCP O
occurring O
during O
the O
first O
month O
of O
treatment O
with O
prednisone B-DRUG
. O

Two O
days O
after O
administration O
of O
Kalimate B-DRUG
enema O
, O
he O
had O
profuse B-ADE
hematochezia I-ADE
, O
and O
a O
sigmoidoscopy O
showed O
diffuse O
colonic B-ADE
mucosal I-ADE
necrosis I-ADE
in I-ADE
the I-ADE
rectum I-ADE
and O
sigmoid O
colon O
. O

Colchicine B-DRUG
- O
induced O
rhabdomyolysis B-ADE
. O

Acute B-ADE
pancreatitis I-ADE
associated O
with O
danazol B-DRUG
treatment O
for O
endometriosis O
. O

Nevertheless O
, O
the O
coagulopathy B-ADE
seemed O
to O
be O
most O
closely O
associated O
with O
the O
administration O
of O
the O
cephalosporin B-DRUG
. O

Favorable O
outcome O
of O
de O
novo O
hepatitis B-ADE
B I-ADE
infection I-ADE
after O
liver O
transplantation O
with O
lamivudine B-DRUG
and O
adefovir B-DRUG
therapy O
. O

Although O
visual O
hallucinations O
have O
not O
been O
reported O
as O
an O
adverse O
effect O
of O
this O
agent O
, O
we O
describe O
three O
patients O
who O
experienced O
complex O
visual B-ADE
hallucinations I-ADE
and O
altered B-ADE
mental I-ADE
status I-ADE
after O
zonisamide B-DRUG
treatment O
was O
begun O
or O
its O
dosage O
increased O
. O

Transient B-ADE
hemiparesis I-ADE
caused O
by O
phenytoin B-DRUG
toxicity O
. O

RESULTS O
: O
Both O
patients O
experienced O
a O
previously O
unreported O
side O
effect O
-- O
falling B-ADE
backward I-ADE
-- O
associated O
with O
bupropion B-DRUG
use O
. O

Rhabdomyolysis B-ADE
caused O
by O
tocolysis O
with O
oral O
ritodrine B-DRUG
hydrochloride I-DRUG
in O
a O
pregnant O
patient O
with O
myotonic O
dystrophy O
. O

RESULTS O
: O
A O
34-year O
- O
old O
man O
acquired O
visual B-ADE
field I-ADE
defects I-ADE
and O
severe B-ADE
vision I-ADE
loss I-ADE
in O
both O
eyes O
after O
intravitreal O
injection O
of O
triamcinolone B-DRUG
for O
diabetic O
macular O
edema O
. O

We O
review O
the O
literature O
on O
previously O
reported O
cases O
of O
cutaneous B-ADE
necrosis I-ADE
after O
injection O
of O
standard O
interferon B-DRUG
alfa I-DRUG
or O
pegylated B-DRUG
interferon I-DRUG
alfa-2b I-DRUG
and O
discuss O
the O
different O
pathophysiologic O
mechanisms O
that O
might O
be O
involved O
. O

We O
report O
a O
case O
of O
glaucoma B-ADE
induced O
by O
doxetaxel B-DRUG
therapy O
for O
metastatic O
breast O
cancer O
. O

A O
patient O
receiving O
vancomycin B-DRUG
for O
a O
serious O
staphylococcal O
infection O
had O
a O
lupus B-ADE
- I-ADE
like I-ADE
syndrome I-ADE
characterized O
by O
a O
malar B-ADE
rash I-ADE
, O
pain B-ADE
and O
erythema B-ADE
of I-ADE
the I-ADE
cartilage I-ADE
of I-ADE
both I-ADE
ears I-ADE
, O
and O
tender B-ADE
erythematous I-ADE
and O
hemorrhagic B-ADE
lesions I-ADE
of I-ADE
the I-ADE
finger I-ADE
tips I-ADE
. O

We O
present O
a O
pediatric O
patient O
with O
leukemia O
and O
a O
severe O
, O
L B-DRUG
- I-DRUG
asparaginase I-DRUG
- O
induced O
necrotizing B-ADE
pancreatitis I-ADE
, O
treated O
successfully O
with O
percutaneous O
drainage O
used O
to O
flush O
the O
infected O
necrotic O
parts O
. O

Lithium B-DRUG
therapy O
was O
discontinued O
because O
of O
poor O
compliance O
to O
the O
medication O
and O
intolerable O
polyuria B-ADE
. O

Until O
additional O
data O
are O
available O
, O
if O
intravenous O
acyclovir B-DRUG
is O
administered O
concurrently O
with O
lithium O
, O
we O
recommend O
closely O
monitoring O
patients O
for O
signs O
of O
lithium B-DRUG
toxicity I-ADE
and O
measuring O
serum O
lithium O
levels O
every O
second O
or O
third O
day O
. O

We O
have O
safely O
used O
recombinant O
factor O
VIIa O
to O
treat O
bleeding O
in O
the O
immediate O
and O
long O
- O
term O
period O
following O
PCC B-DRUG
- O
related O
MI B-ADE
. O

A O
combination O
of O
behavioural O
and O
cognitive O
adverse O
effects O
is O
illustrated O
in O
this O
case O
report O
of O
a O
recurrent O
triazolam B-DRUG
- O
induced O
eating B-ADE
disorder I-ADE
. O

We O
report O
a O
patient O
with O
inoperable O
pancreatic O
cancer O
who O
developed O
gastrointestinal B-ADE
bleeding I-ADE
secondary O
to O
radiation B-ADE
- I-ADE
recall I-ADE
related O
to O
gemcitabine B-DRUG
and O
review O
literature O
. O

We O
evaluated O
a O
patient O
who O
developed O
a O
psychotic B-ADE
disorder I-ADE
after O
4 O
months O
of O
isoniazid B-DRUG
prophylaxis O
for O
a O
positive O
tuberculosis O
tine O
test O
. O

There O
have O
been O
several O
reported O
cases O
of O
omeprazole B-DRUG
- O
induced O
AIN B-ADE
. O

Extra O
caution O
should O
be O
taken O
in O
using O
octreotide B-DRUG
or O
its O
long O
- O
acting O
analog O
in O
patients O
otherwise O
predisposed O
to O
intrahepatic B-ADE
bile I-ADE
stasis I-ADE
. O

A O
child O
in O
whom O
a O
phenobarbital B-DRUG
hypersensitivity B-ADE
drug O
reaction O
developed O
which O
consisted O
of O
fever B-ADE
, O
a B-ADE
pruritic I-ADE
desquamating I-ADE
erythrodermic I-ADE
rash I-ADE
, O
alopecia B-ADE
, O
icterus B-ADE
, O
protein B-ADE
- I-ADE
losing I-ADE
enteropathy I-ADE
, O
myositis B-ADE
, O
and O
nephritis B-ADE
, O
is O
described O
. O

Vision B-ADE
declined I-ADE
after O
treatment O
with O
methylprednisolone B-DRUG
, O
after O
which O
fundus O
examination O
became O
consistent O
with O
progressive O
outer O
retinal O
necrosis O
. O

Horner B-ADE
's I-ADE
syndrome I-ADE
and O
demyelinating B-ADE
peripheral I-ADE
neuropathy I-ADE
caused O
by O
high O
- O
dose O
cytosine B-DRUG
arabinoside I-DRUG
. O

Although O
they O
had O
complex O
medical O
problems O
, O
the O
high O
serum O
concentrations O
of O
ampicillin B-DRUG
at O
the O
time O
of O
seizures O
without O
their O
recurrence O
after O
discontinuing O
the O
antibiotic O
suggest O
that O
the O
seizures B-ADE
were O
related O
to O
the O
ampicillin B-DRUG
therapy O
. O

A O
56-year O
- O
old O
Caucasian O
man O
who O
received O
concomitant O
chemotherapy O
and O
radiation O
for O
head O
and O
neck O
cancer O
developed O
fever B-ADE
concurrent O
with O
the O
administration O
of O
amifostine B-DRUG
. O

We O
report O
a O
case O
of O
Sweet B-ADE
's I-ADE
syndrome I-ADE
in O
association O
with O
sargramostim B-DRUG
treatment O
following O
chemotherapy O
for O
acute O
myelogenous O
leukemia O
. O

Life O
- O
threatening O
hyperkalemia B-ADE
induced O
by O
arginine B-DRUG
. O

Risperidone B-DRUG
- O
induced O
obsessive B-ADE
- I-ADE
compulsive I-ADE
symptoms I-ADE
in O
two O
children O
. O

Doxycycline B-DRUG
- O
induced O
hypoglycemia B-ADE
in O
a O
nondiabetic O
young O
man O
. O

We O
conclude O
that O
MB O
is O
an O
effective O
treatment O
for O
ifosfamide B-DRUG
- I-ADE
induced I-ADE
encephalopathy I-ADE
. O

Stroke B-ADE
- I-ADE
like I-ADE
syndrome I-ADE
after O
gold B-DRUG
sodium I-DRUG
thiomalate I-DRUG
induced O
vasomotor B-ADE
reaction I-ADE
. O

To O
our O
knowledge O
, O
these O
cases O
are O
the O
first O
published O
reports O
of O
lovastatin B-DRUG
- O
induced O
rhabdomyolysis B-ADE
associated O
with O
azithromycin B-DRUG
and O
clarithromycin B-DRUG
. O

METHODS O
: O
A O
case O
is O
presented O
of O
a O
45-year O
- O
old O
woman O
on O
prolonged O
gemcitabine B-DRUG
treatment O
for O
ovarian O
cancer O
who O
developed O
HUS B-ADE
and O
recovered O
after O
drug O
discontinuation O
. O

The O
failure O
of O
therapy O
with O
disopyramide O
and O
mexiletine O
to O
reproduce O
this O
observation O
suggests O
either O
a O
previously O
unreported O
electrophysiologic B-ADE
effect I-ADE
of O
, O
or O
idiosyncratic O
response O
to O
, O
procainamide B-DRUG
. O

Scleroderma B-ADE
- I-ADE
like I-ADE
reaction I-ADE
induced O
by O
uracil B-DRUG
- I-DRUG
tegafur I-DRUG
( O
UFT B-DRUG
) O
, O
a O
second O
- O
generation O
anticancer O
agent O
. O

OBJECTIVE O
: O
We O
report O
a O
case O
of O
cutaneous B-ADE
KS I-ADE
lesions I-ADE
in O
a O
patient O
affected O
by O
CML O
treated O
with O
imatinib B-DRUG
. O

Torsade B-ADE
de I-ADE
pointes I-ADE
represents O
a O
potential O
complication O
of O
chronic O
amiodarone B-DRUG
therapy O
. O

Tetany B-ADE
in O
a O
child O
with O
AIDS O
receiving O
intravenous O
tobramycin B-DRUG
. O

A O
patient O
with O
chronic O
myelomonocytic O
leukemia O
developed O
drug O
- O
induced O
pulmonary B-ADE
toxicity I-ADE
after O
using O
low O
dose O
oral O
etoposide B-DRUG
. O

In O
2 O
of O
the O
3 O
cases O
the O
patients O
were O
also O
taking O
lithium B-DRUG
carbonate I-DRUG
and O
beta O
- O
blockers O
, O
both O
of O
which O
could O
have O
contributed O
to O
the O
incontinence B-ADE
. O

Calcipotriol B-DRUG
( O
Daivonex O
R O
; O
Leo O
Pharmaceuticals O
, O
Zurich O
, O
Switzerland O
) O
may O
cause O
irritation B-ADE
of I-ADE
the I-ADE
skin I-ADE
, O
whereas O
allergic B-ADE
reactions I-ADE
are O
less O
common O
. O

Two O
children O
, O
1 O
with O
idiopathic O
nephrotic O
syndrome O
and O
1 O
with O
endo O
- O
extracapillary O
glomerulonephritis O
, O
presented O
an O
episode O
of O
seizures B-ADE
and O
transient B-ADE
blindness I-ADE
at O
different O
times O
after O
i.v O
. O
pulse O
methylprednisolone B-DRUG
( O
IVPMP O
) O
treatment O
. O

A O
case O
of O
SIADH B-ADE
associated O
with O
desipramine B-DRUG
treatment O
in O
an O
elderly O
depressed O
woman O
is O
described O
. O

Leiomyosarcoma B-ADE
in O
urinary O
bladder O
after O
cyclophosphamide B-DRUG
therapy O
for O
retinoblastoma O
and O
review O
of O
bladder O
sarcomas O
. O

CONCLUSION O
: O
Patients O
with O
insulin B-DRUG
allergy O
may O
not O
have O
complete O
resolution O
of O
their O
symptoms O
after O
standard O
desensitization O
, O
particularly O
those O
patients O
with O
concomitant O
protamine B-ADE
allergy I-ADE
. O

Animals O
treated O
with O
HAL B-DRUG
showed O
a O
highly O
significant B-ADE
32%-46 I-ADE
% I-ADE
loss I-ADE
of I-ADE
tyrosine I-ADE
hydroxylase I-ADE
( I-ADE
TH I-ADE
) I-ADE
immunoreactive I-ADE
neurons I-ADE
in O
the O
substantia O
nigra O
, O
and O
20 O
% O
contraction O
of O
the O
TH O
stained O
dendritic O
arbour O
. O

Possible O
heart B-ADE
failure I-ADE
exacerbation I-ADE
associated O
with O
rosiglitazone B-DRUG
: O
case O
report O
and O
literature O
review O
. O

Keratitis B-ADE
in O
methamphetamine B-DRUG
abusers O
. O

In O
deciding O
if O
tamoxifen B-DRUG
therapy O
is O
warranted O
, O
all O
potentially O
life O
- O
threatening O
adverse O
events O
associated O
with O
tamoxifen B-DRUG
should O
be O
considered O
, O
including O
endometrial B-ADE
adenocarcinoma I-ADE
or O
uterine B-ADE
sarcoma I-ADE
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
toxin B-ADE
- I-ADE
positive I-ADE
Clostridium I-ADE
difficile I-ADE
- I-ADE
induced I-ADE
colitis I-ADE
( O
CDIC O
) O
after O
use O
of O
clindamycin B-DRUG
phosphate I-DRUG
vaginal O
cream O
. O

We O
report O
3 O
cases O
of O
HIV-1 O
infected O
patients O
who O
experienced O
symptomatic O
angiolipomas B-ADE
shortly O
after O
starting O
antiretroviral O
therapy O
including O
the O
protease O
inhibitor O
indinavir B-DRUG
. O

We O
present O
the O
case O
of O
an O
adult O
Crohn O
's O
disease O
patient O
with O
a O
parvovirus O
B19 O
infection O
and O
leukopenia B-ADE
during O
long O
- O
term O
AZA B-DRUG
therapy O
. O

Our O
patient O
was O
a O
72-year O
- O
old O
man O
with O
advanced O
Parkinson O
's O
disease O
( O
PD O
) O
who O
received O
levodopa B-DRUG
and O
anti O
- O
cholinergic O
drugs O
and O
whose O
head O
had O
become O
almost O
completely B-ADE
bald I-ADE
. O

Syncope B-ADE
in O
a O
65-year O
- O
old O
woman O
after O
nitrate B-DRUG
ingestion O
. O

Pravastatin B-DRUG
is O
associated O
with O
myotonia B-ADE
in O
animals O
. O

Although O
his O
renal O
function O
recovered O
completely O
with O
high O
- O
dose O
leucovorin O
, O
hemodialysis O
, O
charcoal O
hemoperfusion O
, O
and O
carboxypeptidase O
G2 O
, O
we O
present O
this O
case O
to O
emphasize O
that O
signs O
of O
renal B-ADE
toxicity I-ADE
may O
be O
present O
as O
early O
as O
2 O
hours O
after O
the O
completion O
of O
a O
4-hour O
MTX B-DRUG
infusion O
, O
and O
to O
suggest O
that O
monitoring O
for O
MTX O
toxicity O
should O
perhaps O
begin O
within O
a O
few O
hours O
after O
the O
completion O
of O
4-hour O
MTX O
infusion O
. O

Thalidomide B-DRUG
neuropathy B-ADE
is O
often O
associated O
with O
proximal B-ADE
weakness I-ADE
and O
may O
progress O
even O
after O
discontinuation O
of O
treatment O
, O
in O
the O
phenomenon O
of O
' O
coasting O
' O
. O

Chlorambucil B-DRUG
- O
induced O
chromosome B-ADE
damage I-ADE
to O
human O
lymphocytes O
is O
dose O
- O
dependent O
and O
cumulative O
. O

The O
authors O
describe O
a O
patient O
with O
hemiparesis O
who O
developed O
the O
syndrome O
of O
irreversible O
lithium B-DRUG
- O
effectuated O
neurotoxicity B-ADE
( O
SILENT O
) O
while O
being O
treated O
with O
lithium O
for O
a O
manic O
episode O
. O

Hepatitis B-ADE
following O
cimetidine B-DRUG
administration O
. O

A O
case O
report O
of O
the O
hypersensitivity B-ADE
syndrome I-ADE
occurring O
in O
a O
patient O
being O
treated O
with O
dapsone B-DRUG
for O
a O
brown O
recluse O
spider O
bite O
is O
presented O
. O

A O
57-year O
- O
old O
woman O
with O
right O
bundle O
branch O
block O
+ O
LPH O
and O
ventricular O
premature O
contractions O
developed O
complete B-ADE
heart I-ADE
block I-ADE
( O
CHB B-ADE
) O
following O
administration O
of O
disopyramide B-DRUG
phosphate I-DRUG
( O
Norpace B-DRUG
) O
. O

Thrombolytic O
therapy O
with O
tissue B-DRUG
plasminogen I-DRUG
activator I-DRUG
( O
tPA B-DRUG
) O
for O
acute O
myocardial O
infarction O
may O
result O
in O
major O
bleeding O
complications O
such O
as O
gastrointestinal B-ADE
or I-ADE
intracranial I-ADE
bleeding I-ADE
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
fatal B-ADE
hyperkalemia I-ADE
owing O
to O
succinylcholine B-DRUG
administration O
in O
a O
patient O
with O
mucositis O
secondary O
to O
chemotherapy O
. O

While O
for O
ribavirin O
antidepressant O
effects O
are O
not O
known O
, O
we O
suppose O
that O
antidepressants O
may O
prevent O
changes B-ADE
in I-ADE
serotonergic I-ADE
or I-ADE
noradrenergic I-ADE
neurotransmission I-ADE
caused O
by O
IFN B-DRUG
- I-DRUG
alpha I-DRUG
. O

Use O
of O
the O
Naranjo O
adverse O
drug O
reaction O
probability O
scale O
indicated O
a O
probable O
relationship O
( O
score O
of O
5 O
) O
between O
the O
patient O
's O
development O
of O
hepatotoxicity B-ADE
and O
the O
TMP B-DRUG
- I-DRUG
SMX I-DRUG
therapy O
. O

A O
complex O
pattern O
of O
melanonychia B-ADE
and O
onycholysis B-ADE
after O
treatment O
with O
pemetrexed B-DRUG
for O
lung O
cancer O
. O

Fixed B-ADE
drug I-ADE
eruption I-ADE
of I-ADE
the I-ADE
scrotum I-ADE
due O
to O
methylphenidate B-DRUG
. O

She O
continued O
to O
receive O
regular O
insulin B-DRUG
4 O
times O
per O
day O
over O
the O
following O
3 O
years O
with O
only O
occasional O
hives B-ADE
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
a O
diffuse B-ADE
papular I-ADE
eruption I-ADE
following O
treatment O
of O
psoriasis O
with O
methotrexate B-DRUG
injections O
. O

Attenuation O
of O
asparaginase B-DRUG
- O
induced O
hyperglycemia B-ADE
after O
substitution O
of O
the O
Erwinia O
carotovora O
for O
the O
Escherichia O
coli O
enzyme O
preparation O
. O

Niflumic B-DRUG
acid I-DRUG
- O
induced O
skeletal B-ADE
fluorosis I-ADE
: O
iatrogenic O
disease O
or O
therapeutic O
perspective O
for O
osteoporosis O
? O

A O
52-year O
- O
old O
Black O
woman O
on O
phenytoin B-DRUG
therapy O
for O
post O
- O
traumatic O
epilepsy O
developed O
transient B-ADE
hemiparesis I-ADE
contralateral O
to O
the O
injury O
. O

After O
seven O
months O
' O
continuous O
treatment O
for O
suspected O
tuberculosis O
with O
rifampicin O
and O
ethambutol B-DRUG
a O
nine O
- O
year O
- O
old O
boy O
developed O
polyarthritis B-ADE
, O
rash B-ADE
and O
hepatitis B-ADE
in O
association O
with O
anti B-ADE
- I-ADE
native I-ADE
DNA I-ADE
antibodies I-ADE
and O
positive O
antinuclear O
factor O
. O

Posthypoglycemic B-ADE
hyperglycemia I-ADE
( O
rebound B-ADE
hyperglycemia I-ADE
) O
after O
overdosing O
of O
insulin B-DRUG
was O
diagnosed O
in O
6 O
cats O
with O
diabetes O
mellitus O
. O

Diagnosis O
of O
hypothyroidism B-ADE
during O
treatment O
can O
be O
difficult O
because O
of O
the O
common O
side O
effects O
of O
alpha B-DRUG
interferon I-DRUG
. O

Physicians O
who O
use O
sulfasalazine O
to O
treat O
patients O
with O
inflammatory O
bowel O
disease O
should O
be O
aware O
of O
the O
signs O
of O
sulfasalazine B-DRUG
- O
induced O
lupus B-ADE
syndrome I-ADE
. O

DIAGNOSIS O
: O
Sustained B-ADE
ventricular I-ADE
tachycardia I-ADE
possibly O
owing O
to O
thalidomide B-DRUG
treatment O
. O

Mesalamine B-DRUG
may O
cause O
hypersensitivity B-ADE
pneumonitis I-ADE
in O
patients O
with O
Crohn O
's O
disease O
. O

After O
treatment O
with O
a O
beta O
- O
sympathomimetic O
drug O
( O
Partusisten B-DRUG
) O
one O
fetus O
developed O
supraventricular B-ADE
tachycardia I-ADE
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
cutaneous B-ADE
and I-ADE
hematologic I-ADE
toxicity I-ADE
in O
a O
patient O
treated O
with O
IL-2 B-DRUG
. O

The O
pharmacology O
and O
toxicology O
of O
chloral B-DRUG
hydrate I-DRUG
are O
discussed O
with O
particular O
reference O
to O
the O
cardiac B-ADE
arrhythmias I-ADE
that O
are O
seen O
with O
overdosage O
. O

Propranolol B-DRUG
: O
an O
unrecognized O
cause O
of O
central B-ADE
nervous I-ADE
system I-ADE
dysfunction I-ADE
in O
patients O
undergoing O
cardiopulmonary O
bypass O
. O

Chlorambucil B-DRUG
central B-ADE
nervous I-ADE
toxicity I-ADE
: O
a O
significant O
side O
effect O
of O
chlorambucil O
therapy O
in O
childhood O
nephrotic O
syndrome O
. O

She O
had O
just O
finished O
a O
3-week O
course O
of O
intravenous O
tobramycin B-DRUG
for O
bronchiectasis O
and O
had O
an O
elevated O
serum O
tobramycin O
trough O
level O
1 O
week O
before O
the O
onset O
of O
tetany B-ADE
. O

However O
, O
cyclosporine B-DRUG
dependency O
is O
associated O
with O
the O
risk O
of O
nephrotoxicity B-ADE
. O

This O
article O
describes O
two O
cases O
of O
aplastic B-ADE
anemia I-ADE
, O
at O
least O
one O
of O
which O
was O
almost O
certainly O
induced O
by O
the O
use O
of O
methazolamide B-DRUG
, O
and O
one O
case O
of O
agranulocytosis B-ADE
related O
to O
the O
use O
of O
methazolamide B-DRUG
. O

Bone B-ADE
marrow I-ADE
aplasia I-ADE
and O
severe B-ADE
skin I-ADE
rash I-ADE
after O
a O
single O
low O
dose O
of O
methotrexate B-DRUG
. O

The O
polycystic B-ADE
changes I-ADE
disappeared O
from O
the O
ovaries O
in O
2 O
of O
the O
women O
after O
valproate B-DRUG
therapy O
was O
discontinued O
, O
and O
the O
2 O
women O
who O
had O
gained B-ADE
weight I-ADE
and O
developed O
amenorrhea B-ADE
while O
being O
treated O
with O
valproate B-DRUG
lost O
weight O
and O
resumed O
menstruating O
after O
the O
change O
in O
medication O
. O

Improved O
awareness O
of O
and O
further O
investigation O
into O
the O
neurotoxic B-ADE
effects I-ADE
of O
ofloxacin B-DRUG
may O
enhance O
its O
safe O
use O
. O

Hepatotoxic B-ADE
effects I-ADE
in O
a O
child O
receiving O
valproate B-DRUG
and O
carnitine B-DRUG
. O

We O
consider O
asterixis B-ADE
to O
be O
an O
easily O
overlooked O
sign O
of O
neurotoxicity B-ADE
, O
which O
may O
occur O
even O
at O
low O
or O
moderate O
dosage O
levels O
, O
if O
certain O
drugs O
as O
lithium B-DRUG
or O
clozapine B-DRUG
are O
used O
in O
combination O
with O
CBZ B-DRUG
. O

Several O
possible O
explanations O
of O
the O
mechanism O
of O
renal B-ADE
failure I-ADE
associated O
with O
the O
use O
of O
dextran-40 B-DRUG
are O
discussed O
. O

Isoniazid B-DRUG
and O
ethambutol B-DRUG
as O
a O
cause O
of O
optic B-ADE
neuropathy I-ADE
. O

INTRODUCTION O
: O
Although O
gefitinib B-DRUG
used O
for O
the O
treatment O
of O
non O
- O
small O
- O
cell O
lung O
cancer O
is O
a O
well O
- O
known O
cause O
of O
interstitial B-ADE
lung I-ADE
disease I-ADE
( O
ILD B-ADE
) O
, O
few O
case O
reports O
on O
erlotinib B-DRUG
- O
induced O
ILD B-ADE
have O
been O
issued O
. O

Gliclazide B-DRUG
- O
induced O
acute B-ADE
hepatitis I-ADE
. O

Capecitabine B-DRUG
- O
induced O
multifocal B-ADE
leukoencephalopathy I-ADE
: O
a O
report O
of O
five O
cases O
. O

In O
this O
article O
, O
we O
describe O
a O
Japanese O
patient O
with O
severe B-ADE
interstitial I-ADE
pneumonia I-ADE
probably O
caused O
by O
sorafenib B-DRUG
treatment O
for O
metastatic O
renal O
cell O
carcinoma O
. O

Hemodynamic B-ADE
collapse I-ADE
following O
labetalol B-DRUG
administration O
in O
preeclampsia O
. O

Severe B-ADE
acidosis I-ADE
in O
patients O
taking O
metformin B-DRUG
-- O
rapid O
reversal O
and O
survival O
despite O
high O
APACHE O
score O
. O

Severe O
serotonin B-ADE
syndrome I-ADE
induced O
by O
mirtazapine B-DRUG
monotherapy O
. O

Recognizing O
early O
signs O
of O
HMSN O
, O
such O
as O
areflexia O
and O
pes O
cavus O
deformity O
, O
can O
prevent O
severe B-ADE
neurotoxicity I-ADE
of O
polychemotherapy O
by O
avoiding O
vincristine B-DRUG
. O

OBJECTIVE O
: O
To O
describe O
onset O
of O
syndrome B-ADE
of I-ADE
inappropriate I-ADE
antidiuretic I-ADE
hormone I-ADE
( O
SIADH B-ADE
) O
associated O
with O
vinorelbine B-DRUG
therapy O
for O
advanced O
breast O
cancer O
. O

Although O
adverse O
reactions O
to O
protamine O
are O
reported O
infrequently O
and O
are O
usually O
mild O
, O
we O
recently O
observed O
the O
first O
fatal O
case O
of O
type B-ADE
I I-ADE
anaphylaxis I-ADE
resulting O
from O
protamine B-DRUG
. O

We O
describe O
the O
development O
of O
cutaneous B-ADE
scleroderma I-ADE
in O
3 O
patients O
coincident O
with O
the O
use O
of O
bleomycin B-DRUG
in O
low O
cumulative O
doses O
of O
less O
than O
100 O
U O
. O

Delayed B-ADE
pseudocyst I-ADE
of I-ADE
the I-ADE
pancreas I-ADE
can O
be O
a O
complication O
of O
intramuscular O
L B-DRUG
- I-DRUG
asparaginase I-DRUG
. O

A O
case O
of O
clozapine B-DRUG
- O
induced O
tonic B-ADE
- I-ADE
clonic I-ADE
seizures I-ADE
managed O
with O
valproate O
: O
implications O
for O
clinical O
care O
. O

Drug O
- O
induced O
psychosis B-ADE
resulted O
from O
the O
administration O
of O
quinacrine B-DRUG
hydrochloride I-DRUG
at O
a O
dosage O
of O
100 O
mg O
twice O
daily O
for O
the O
treatment O
of O
discoid O
lupus O
. O

We O
postulate O
that O
the O
bolus O
of O
sulprostone B-DRUG
resulted O
in O
possible O
coronary B-ADE
spasm I-ADE
that O
resulted O
in O
cardiac B-ADE
arrest I-ADE
. O

It O
was O
hypothesized O
that O
valproic B-DRUG
acid I-DRUG
may O
interfere O
with O
glucuronidation O
of O
lamotrigine B-DRUG
, O
leading O
to O
increased B-ADE
serum I-ADE
lamotrigine I-ADE
levels I-ADE
, O
or O
perhaps O
alter O
the O
drug O
's O
metabolism O
, O
resulting O
in O
accumulation B-ADE
of I-ADE
a I-ADE
toxic I-ADE
intermediate I-ADE
metabolite I-ADE
. O

Barbiturate B-DRUG
- O
induced O
submassive B-ADE
hepatic I-ADE
necrosis I-ADE
. O

Since O
elevated O
cortisol O
levels O
in O
Cushing O
's O
disease O
poses O
a O
threat O
for O
pancreatitis O
, O
there O
is O
a O
possibility O
that O
patients O
with O
Cushing O
's O
disease O
might O
be O
more O
prone O
to O
acute B-ADE
pancreatitis I-ADE
following O
propofol B-DRUG
administration O
. O

In O
the O
third O
child O
, O
the O
tics B-ADE
ceased O
after O
CBZ B-DRUG
discontinuation O
. O

CONCLUSIONS O
: O
Sustained O
- O
release O
verapamil B-DRUG
is O
thought O
to O
be O
the O
cause O
of O
the O
asthma B-ADE
attack I-ADE
in O
this O
patient O
because O
she O
was O
not O
taking O
any O
other O
preparations O
; O
the O
symptoms O
started O
with O
the O
administration O
of O
sustained O
- O
release O
verapamil B-DRUG
and O
were O
relieved O
after O
its O
discontinuation O
. O

One O
of O
these O
was O
clofazimine B-DRUG
, O
an O
aniline O
aposafranine O
derivative O
known O
to O
produce O
a O
ceroid B-ADE
- I-ADE
like I-ADE
pigment I-ADE
in O
the O
tissues O
of O
patients O
treated O
with O
this O
drug O
or O
lepromatous O
leprosy O
. O

CONCLUSIONS O
: O
These O
results O
suggest O
that O
clozapine B-DRUG
may O
cause O
TD B-ADE
; O
however O
, O
the O
prevalence O
is O
low O
and O
the O
severity O
is O
relatively O
mild O
, O
with O
no O
or O
mild O
self O
- O
reported O
discomfort B-ADE
. O

We O
report O
on O
a O
child O
with O
fatal B-ADE
valproate B-DRUG
- O
related O
hepatotoxic B-ADE
effects I-ADE
despite O
this O
supplementation O
. O

Amphotericin B-DRUG
B I-DRUG
nephrotoxicity B-ADE
in O
humans O
decreased O
by O
salt O
repletion O
. O

Pancreatitis O
has O
been O
associated O
with O
the O
tetracycline O
class O
of O
antibiotics O
and O
concerns O
about O
tigecycline B-DRUG
- O
induced O
acute B-ADE
pancreatitis I-ADE
have O
recently O
been O
raised O
. O

Drug B-ADE
rash I-ADE
with I-ADE
eosinophilia I-ADE
and I-ADE
systemic I-ADE
symptoms I-ADE
after O
chlorambucil B-DRUG
treatment O
in O
chronic O
lymphocytic O
leukaemia O
. O

The O
possibility O
of O
phenytoin B-DRUG
hypersensitivity B-ADE
reactions I-ADE
should O
be O
considered O
when O
patients O
receiving O
phenytoin B-DRUG
have O
unusual O
symptoms O
, O
particularly O
fever B-ADE
, O
rash B-ADE
, O
and O
lymphadenopathy B-ADE
. O

METHODS O
: O
We O
report O
two O
cases O
of O
pseudoporphyria B-ADE
caused O
by O
naproxen B-DRUG
and O
oxaprozin B-DRUG
. O

We O
report O
a O
43-year O
- O
old O
woman O
who O
developed O
sore B-ADE
throat I-ADE
, O
swelling B-ADE
of I-ADE
the I-ADE
lips I-ADE
and I-ADE
oral I-ADE
cavity I-ADE
and O
dysphagia B-ADE
, O
2 O
weeks O
after O
the O
use O
of O
budesonide B-DRUG
spray O
( O
Budefat B-DRUG
) O
for O
treatment O
of O
bronchial O
asthma O
. O

Tardive B-ADE
dyskinesia I-ADE
in O
2 O
patients O
treated O
with O
ziprasidone B-DRUG
. O

To O
our O
knowledge O
, O
this O
is O
the O
first O
case O
of O
griseofulvin B-DRUG
- O
exacerbated O
lupus B-ADE
in O
which O
nephrotic B-ADE
syndrome I-ADE
has O
been O
observed O
. O

Levofloxacin B-DRUG
induced O
polymorphic B-ADE
ventricular I-ADE
tachycardia I-ADE
with O
normal O
QT O
interval O
. O

Diagnosis O
of O
sclerosing B-ADE
glomerulonephritis I-ADE
occurred O
in O
this O
patient O
during O
anastrozole B-DRUG
use O
, O
suggesting O
a O
newly O
defined O
side O
effect O
of O
anastrozole O
. O

A O
case O
of O
contact B-ADE
dermatitis I-ADE
due O
to O
sodium B-DRUG
bisulfite I-DRUG
in O
an O
ophthalmic O
solution O
. O

Gemcitabine B-DRUG
- O
induced O
rectus B-ADE
abdominus I-ADE
radiation I-ADE
recall I-ADE
. O

Protamine B-ADE
allergy I-ADE
as O
a O
complication O
of O
insulin B-DRUG
hypersensitivity O
: O
A O
case O
report O
. O

METHODS O
: O
A O
retrospective O
report O
of O
the O
first O
case O
of O
gemcitabine B-DRUG
- O
related O
HUS B-ADE
, O
in O
a O
patient O
with O
metastatic O
pancreatic O
adenocarcinoma O
, O
treated O
with O
a O
variety O
of O
standard O
therapies O
in O
addition O
to O
rituximab O
is O
presented O
. O

Anaphylaxis B-ADE
to O
calcitonin B-DRUG
. O

As O
linezolid B-DRUG
has O
been O
shown O
to O
have O
hematologic B-ADE
side I-ADE
effects I-ADE
, O
blood O
count O
monitoring O
is O
recommended O
in O
patients O
receiving O
this O
drug O
for O
long O
- O
term O
therapy O
. O

The O
patient O
was O
initially O
treated O
with O
hydration O
and O
furosemide B-DRUG
but O
developed O
congestive B-ADE
heart I-ADE
failure I-ADE
. O

RESULTS O
: O
A O
44-year O
- O
old O
man O
taking O
naproxen B-DRUG
for O
chronic O
low O
back O
pain O
and O
a O
20-year O
- O
old O
woman O
on O
oxaprozin B-DRUG
for O
rheumatoid O
arthritis O
presented O
with O
tense B-ADE
bullae I-ADE
and O
cutaneous B-ADE
fragility I-ADE
on O
the O
face O
and O
the O
back O
of O
the O
hands O
. O

Propoxyphene B-DRUG
- O
induced O
wide B-ADE
complex I-ADE
dysrhythmia I-ADE
responsive O
to O
sodium O
bicarbonate O
therapy O
has O
not O
been O
previously O
reported O
in O
the O
literature O
. O

We O
present O
a O
case O
of O
HUS B-ADE
in O
an O
advanced O
ovarian O
cancer O
patient O
treated O
with O
carboplatin B-DRUG
and O
gemcitabine B-DRUG
, O
and O
described O
its O
favorable O
outcome O
after O
chemotherapy O
interruption O
and O
supportive O
care O
with O
a O
1 O
year O
follow O
- O
up O
. O

There O
are O
now O
reports O
of O
liver B-ADE
failure I-ADE
following O
treatment O
of O
childhood O
cancers O
with O
AMD B-DRUG
. O

It O
also O
highlights O
a O
current O
major O
etiologic O
question O
, O
that O
is O
, O
whether O
and O
to O
what O
degree O
lead B-DRUG
exposure O
contributes O
to O
the O
development O
of O
hypertension B-ADE
, O
and O
raises O
the O
issue O
of O
whether O
lead B-DRUG
- I-ADE
induced I-ADE
hypertension I-ADE
constitutes O
a O
subset O
of O
hypertension O
that O
is O
especially O
amenable O
to O
therapy O
with O
dietary O
calcium O
. O

Acute B-ADE
lung I-ADE
injury I-ADE
associated O
with O
5-fluorouracil B-DRUG
and O
oxaliplatinum B-DRUG
combined O
chemotherapy O
. O

Encephalopathy B-ADE
and O
seizures B-ADE
induced O
by O
intravesical O
alum B-DRUG
irrigations O
. O

Progressive B-ADE
anemia I-ADE
following O
combination O
therapy O
with O
interferon B-DRUG
- I-DRUG
alpha I-DRUG
and O
interleukin-2 B-DRUG
in O
a O
patient O
with O
metastatic O
renal O
cell O
carcinoma O
. O

Two O
patients O
with O
extrinsic O
asthma O
and O
coexistent O
insulin O
- O
dependent O
diabetes O
mellitus O
sustained O
an O
anaphylactoid B-ADE
reaction I-ADE
after O
the O
intravenous O
administration O
of O
50 O
% O
solution O
of O
dextrose B-DRUG
. O

We O
report O
a O
patient O
who O
developed O
spontaneous B-ADE
splenic I-ADE
infarction I-ADE
after O
the O
use O
of O
sumatriptan B-DRUG
for O
the O
treatment O
of O
migraine O
headache O
. O

We O
report O
in O
detail O
an O
unusual O
adverse O
reaction O
to O
infliximab B-DRUG
therapy O
, O
a O
drug O
- O
induced O
lupus B-ADE
- I-ADE
like I-ADE
clinical I-ADE
syndrome I-ADE
. O

A O
patient O
is O
described O
who O
developed O
a O
rapid O
onset O
of O
pulmonary B-ADE
fibrosis I-ADE
following O
treatment O
with O
a O
new O
non O
- O
steroidal O
anti O
- O
inflammatory O
drug O
, O
nabumetone B-DRUG
. O

It O
was O
postulated O
that O
the O
allergic B-ADE
reaction I-ADE
was O
most O
likely O
caused O
by O
capecitabine B-DRUG
or O
the O
intermediate O
metabolites O
based O
on O
the O
immediate O
reappearance O
of O
symptoms O
from O
the O
rechallenge O
, O
pharmacokinetic O
data O
, O
and O
well O
- O
tolerance O
of O
fluorouracil O
. O

Additionally O
, O
danazol B-DRUG
produces O
hepatocellular B-ADE
damage I-ADE
in O
approximately O
10 O
% O
of O
women O
. O

This O
report O
describes O
a O
case O
of O
neuroleptic B-ADE
malignant I-ADE
syndrome I-ADE
due O
to O
risperidone B-DRUG
in O
a O
child O
with O
Joubert O
syndrome O
. O

Risperidone B-DRUG
- O
induced O
tardive B-ADE
dyskinesia I-ADE
. O

Can O
ketamine B-DRUG
prescribed O
for O
pain O
cause O
damage B-ADE
to I-ADE
the I-ADE
urinary I-ADE
tract I-ADE
? O

The O
interval O
between O
initiating O
treatment O
with O
interferon B-DRUG
alfa I-DRUG
and O
onset O
of O
anterior B-ADE
ischemic I-ADE
optic I-ADE
neuropathy I-ADE
was O
similar O
to O
that O
of O
interferon B-DRUG
- O
associated O
vascular B-ADE
retinopathy I-ADE
. O

The O
authors O
suggest O
that O
in O
the O
absence O
of O
any O
proven O
benefit O
of O
itraconazole B-DRUG
prophylaxis O
, O
and O
given O
the O
interaction O
of O
this O
drug O
with O
vincristine B-DRUG
leading O
to O
severe O
and O
even O
potentially O
fatal B-ADE
toxicities I-ADE
, O
the O
combination O
use O
of O
these O
drugs O
should O
be O
avoided O
. O

CONCLUSIONS O
: O
The O
observation O
that O
neurotoxicity B-ADE
developed O
with O
a O
delay O
of O
24 O
to O
48 O
hours O
after O
acyclovir B-DRUG
peak O
serum O
concentrations O
could O
explain O
the O
wide O
range O
of O
acyclovir B-DRUG
levels O
reported O
in O
similar O
cases O
. O

Hypogammaglobulinemia B-ADE
associated O
with O
gold B-DRUG
therapy O
: O
evidence O
for O
a O
partial O
maturation O
blockade O
of O
B O
cells O
. O

A O
40-year O
- O
old O
man O
with O
relapsing O
- O
remitting O
multiple O
sclerosis O
( O
MS O
) O
developed O
primary B-ADE
central I-ADE
nervous I-ADE
system I-ADE
lymphoma I-ADE
( O
PCNSL B-ADE
) O
after O
having O
received O
21 O
doses O
of O
natalizumab B-DRUG
monotherapy O
. O

We O
report O
a O
case O
of O
AILD B-ADE
in O
an O
80-year O
- O
old O
male O
who O
presented O
with O
a O
generalized B-ADE
pruritic I-ADE
maculopapular I-ADE
eruption I-ADE
and O
fever B-ADE
following O
doxycycline B-DRUG
administration O
. O

Visual B-ADE
changes I-ADE
secondary O
to O
initiation O
of O
amiodarone B-DRUG
: O
a O
case O
report O
and O
review O
involving O
ocular O
management O
in O
cardiac O
polypharmacy O
. O

Life O
- O
threatening O
hyponatremia B-ADE
caused O
by O
vinblastine B-DRUG
. O

The O
treatment O
for O
acidosis O
and O
hyperkalaemia O
should O
be O
started O
as O
soon O
as O
RTA B-ADE
is O
diagnosed O
, O
and O
the O
dosage O
of O
FK506 B-DRUG
should O
also O
be O
reduced O
if O
possible O
. O

We O
highlight O
two O
instances O
of O
systemic B-ADE
allergic I-ADE
reaction I-ADE
, O
and O
discuss O
the O
potential O
side O
effects O
of O
local O
aprotinin B-DRUG
injections O
in O
the O
orthopaedic O
setting O
as O
well O
as O
the O
evidence O
base O
for O
its O
use O
. O

Thymic B-ADE
enlargement I-ADE
in O
a O
patient O
with O
juvenile O
idiopathic O
arthritis O
during O
etanercept B-DRUG
therapy O
. O

Oxcarbazepine B-DRUG
- O
associated O
angioedema B-ADE
manifested O
by O
swelling O
of O
the O
face O
, O
eyes O
, O
lips O
, O
or O
tongue O
or O
difficulty O
swallowing O
or O
breathing O
( O
or O
both O
) O
is O
a O
rare O
but O
potentially O
life O
- O
threatening O
reaction O
for O
which O
early O
recognition O
and O
management O
are O
vital O
. O

Calcification B-ADE
and O
ossification B-ADE
of I-ADE
the I-ADE
spinal I-ADE
arachnoid I-ADE
after O
intrathecal O
administration O
of O
Depo B-DRUG
- I-DRUG
Medrol I-DRUG
. O

Life O
- O
threatening O
cranial B-ADE
dystonia I-ADE
following O
trihexyphenidyl B-DRUG
withdrawal O
. O

The O
authors O
report O
2 O
cases O
of O
renal B-ADE
damage I-ADE
associated O
with O
lithium B-DRUG
carbonate I-DRUG
treatment O
. O

When O
the O
disease O
recurred O
conventional O
amphotericin B-DRUG
B I-DRUG
was O
used O
again O
, O
but O
had O
to O
be O
stopped O
because O
of O
severe B-ADE
side I-ADE
effects I-ADE
. O

Cutaneous B-ADE
rashes I-ADE
and O
eruptions B-ADE
can O
be O
caused O
by O
many O
medications O
, O
including O
carbamazepine B-DRUG
. O

Common O
adverse O
events O
( O
frequency O
10 O
% O
) O
of O
lacosamide B-DRUG
doses O
up O
to O
600 O
mg O
/ O
day O
include O
nonspecific O
central O
nervous O
system O
effects O
( O
e.g. O
, O
dizziness B-ADE
, O
ataxia B-ADE
, O
diplopia B-ADE
, O
and O
somnolence B-ADE
) O
. O

A O
potential O
role O
for O
renal O
and O
hepatic O
impairment O
in O
the O
observed O
protracted O
course O
of O
amiodarone B-DRUG
- O
induced O
thyrotoxicosis B-ADE
is O
suggested O
. O

Quinapril B-DRUG
is O
an O
angiotensin O
- O
converting O
enzyme O
inhibitor O
( O
ACE O
- O
inhibitor O
) O
and O
overdose O
can O
lead O
to O
prolonged B-ADE
hypotension I-ADE
and O
, O
less O
frequently O
, O
transient B-ADE
renal I-ADE
impairment I-ADE
. O

Only O
one O
case O
of O
severe B-ADE
symptomatic I-ADE
hepatitis I-ADE
occurring O
after O
pulse O
therapy O
with O
itraconazole B-DRUG
for O
onychomycosis O
and O
requiring O
transplantation O
has O
been O
reported O
previously O
. O

Cardiac B-ADE
toxicity I-ADE
related O
to O
BCNU B-DRUG
has O
not O
been O
described O
well O
. O

Erythromycin B-DRUG
is O
a O
macrolide O
antibiotic O
that O
may O
increase O
the O
risk O
of O
lovastatin B-DRUG
- O
induced O
rhabdomyolysis B-ADE
. O

Post O
marketing O
studies O
of O
Interferon B-DRUG
- I-DRUG
beta I-DRUG
( O
IFN B-DRUG
beta I-DRUG
) O
therapy O
in O
multiple O
sclerosis O
( O
MS O
) O
have O
demonstrated O
surprisingly O
high O
rates O
of O
hepatotoxicity B-ADE
. O

The O
case O
histories O
are O
presented O
of O
two O
patients O
who O
developed O
lung B-ADE
disease I-ADE
associated O
with O
the O
use O
of O
nitrofurantoin B-DRUG
with O
histological O
features O
of O
bronchiolitis B-ADE
obliterans I-ADE
organising I-ADE
pneumonia I-ADE
( O
BOOP B-ADE
) O
, O
a O
rare O
but O
recognised O
form O
of O
drug O
induced O
injury O
. O

It O
has O
been O
suggested O
that O
PPE B-ADE
caused O
by O
cytarabine B-DRUG
does O
not O
recur O
with O
subsequent O
cytarabine O
re O
- O
challenge O
. O

Hypersensitivity B-ADE
to O
carboplatin B-DRUG
has O
been O
reported O
in O
up O
to O
44 O
% O
of O
patients O
receiving O
this O
antineoplastic O
agent O
, O
usually O
occurring O
after O
several O
courses O
of O
treatment O
. O

Allergic B-ADE
contact I-ADE
dermatitis I-ADE
from O
4-chloro-7-nitrobenzofurazan B-DRUG
. O

Ulcerating B-ADE
enteritis I-ADE
associated O
with O
flucytosine B-DRUG
therapy O
. O

It O
was O
restarted O
6 O
weeks O
later O
, O
and O
10 O
weeks O
after O
that O
, O
the O
patient O
presented O
with O
fulminant B-ADE
hepatic I-ADE
failure I-ADE
, O
which O
resolved O
rapidly O
after O
cessation O
of O
nicotinic B-DRUG
acid I-DRUG
therapy O
. O

A O
60-year O
- O
old O
woman O
with O
diabetes O
mellitus O
( O
type O
2 O
) O
developed O
an O
acute B-ADE
icteric I-ADE
hepatitis I-ADE
- I-ADE
like I-ADE
illness I-ADE
6 O
weeks O
after O
the O
initiation O
of O
gliclazide B-DRUG
therapy O
. O

Prolonged O
responses O
were O
achieved O
with O
low O
doses O
of O
HU B-DRUG
( O
3 O
- O
10 O
mg O
/ O
kg O
/ O
day O
) O
and O
higher O
doses O
were O
associated O
with O
mild B-ADE
reversible I-ADE
hematologic I-ADE
or O
hepatic B-ADE
toxicity I-ADE
and O
no O
further O
increases O
in O
Hb O
. O

Flaccid B-ADE
quadriparesis I-ADE
was O
noted O
after O
discontinuation O
of O
vecuronium B-DRUG
. O

Treatment O
of O
amiodarone B-DRUG
- O
induced O
thyrotoxicosis B-ADE
( O
AIT O
) O
with O
thionamide O
, O
lithium O
or O
radioactive O
iodine O
is O
ineffective O
. O

Neurophysiological O
mechanisms O
which O
aid O
in O
elucidating O
the O
role O
of O
disulfiram B-DRUG
in O
the O
etiology O
of O
catatonia B-ADE
are O
discussed O
. O

The O
association O
of O
central B-ADE
diabetes I-ADE
insipidus I-ADE
( O
CDI B-ADE
) O
with O
lithium B-DRUG
use O
is O
rare O
. O

During O
her O
third O
cycle O
, O
she O
again O
received O
cisplatin B-DRUG
100 B-ADE
mg I-ADE
/ I-ADE
m2 I-ADE
over O
30 O
minutes O
and O
developed O
palmar B-ADE
pruritus I-ADE
, O
urticaria B-ADE
, O
and O
edema B-ADE
. O

Two O
65-year O
- O
old O
white O
men O
with O
coronary O
heart O
disease O
, O
given O
niacin B-DRUG
therapy O
for O
dyslipidemia O
for O
5 O
months O
, O
developed O
intense B-ADE
dental I-ADE
and I-ADE
gingival I-ADE
pain I-ADE
that O
was O
associated O
with O
increases O
in O
dose O
and O
that O
was O
relieved O
with O
discontinuance O
of O
niacin B-DRUG
treatment O
. O

Lithium B-DRUG
is O
known O
to O
cause O
acute B-ADE
renal I-ADE
failure I-ADE
and O
tubulo B-ADE
- I-ADE
interstitial I-ADE
disease I-ADE
, O
but O
the O
recently O
described O
association O
with O
proteinuria B-ADE
or O
nephrotic B-ADE
syndrome I-ADE
is O
little O
recognized O
. O

There O
have O
been O
only O
two O
reports O
of O
cimetidine B-DRUG
- O
induced O
hepatitis B-ADE
. O

The O
mechanism O
of O
anaphylactoid B-ADE
reaction I-ADE
to O
zomepirac B-DRUG
in O
this O
case O
, O
therefore O
, O
remains O
unclear O
. O

Lower O
extremity O
arterial B-ADE
insufficiency I-ADE
after O
long O
- O
term O
methysergide B-DRUG
maleate I-DRUG
therapy O
. O

The O
pulmonary B-ADE
toxicity I-ADE
of O
gold B-DRUG
salts O
is O
an O
uncommon O
cause O
of O
life O
- O
threatening O
respiratory B-ADE
failure I-ADE
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
rapidly O
occurring O
hyperglycemia B-ADE
that O
occurred O
in O
a O
geriatric O
patient O
3 O
days O
after O
treatment O
with O
olanzapine B-DRUG
. O

Although O
its O
side O
effects O
are O
few O
, O
tamoxifen B-DRUG
increases O
the O
incidence O
of O
proliferative B-ADE
lesions I-ADE
of I-ADE
the I-ADE
endometrium I-ADE
, O
which O
theoretically O
should O
be O
preventable O
with O
progestational O
agents O
. O

Procainamide B-DRUG
- O
induced O
incessant B-ADE
supraventricular I-ADE
tachycardia I-ADE
in O
the O
Wolff O
- O
Parkinson O
- O
White O
syndrome O
. O

While O
on O
a O
maximal O
dose O
of O
phenylephrine B-DRUG
she O
developed O
prominent O
positive B-ADE
U I-ADE
waves I-ADE
, O
which O
disappeared O
with O
the O
cessation O
of O
the O
drug O
. O

Esophageal B-ADE
candidiasis I-ADE
was O
diagnosed O
at O
endoscopy O
in O
two O
patients O
receiving O
omeprazole B-DRUG
therapy O
. O

Antacid O
and O
sucralfate B-DRUG
- O
induced O
hypophosphatemic B-ADE
osteomalacia I-ADE
: O
a O
case O
report O
and O
review O
of O
the O
literature O
. O

Awareness O
of O
this O
route O
of O
intoxication O
might O
be O
important O
in O
patients O
in O
whom O
neurologic O
or O
psychiatric B-ADE
symptoms I-ADE
develop O
while O
large O
amounts O
of O
lidocaine B-DRUG
cream O
are O
being O
used O
. O

She O
was O
administered O
metoclopramide B-DRUG
because O
of O
nausea O
and O
, O
within O
2 O
hours O
, O
developed O
agitation B-ADE
, O
dysarthria B-ADE
, O
diaphoresis B-ADE
, O
and O
a O
movement B-ADE
disorder I-ADE
. O

Warfarin B-DRUG
- O
associated O
bleeding B-ADE
generally O
is O
considered O
deleterious O
; O
however O
, O
in O
our O
patient O
it O
unmasked O
an O
early O
stage O
of O
colon O
cancer O
and O
thus O
may O
have O
saved O
the O
patient O
's O
life O
. O

CONCLUSIONS O
: O
In O
our O
reported O
case O
, O
a O
local O
hyperproduction B-ADE
of I-ADE
TNF I-ADE
- I-ADE
alpha I-ADE
from O
macrophages O
that O
was O
induced O
by O
the O
injected O
insulin B-DRUG
could O
explain O
the O
dedifferentiation B-ADE
of I-ADE
the I-ADE
adipocytes I-ADE
of O
the O
subcutaneous O
tissue O
and O
the O
reversion O
that O
was O
induced O
by O
the O
local O
injection O
of O
dexamethasone O
. O

Pulmonary B-ADE
edema I-ADE
as O
a O
delayed O
complication O
of O
ritodrine B-DRUG
therapy O
. O

Toxicity B-ADE
related O
to O
chloroquine B-DRUG
treatment O
of O
resistant O
vivax O
malaria O
. O

Elevated B-ADE
serum I-ADE
triglycerides I-ADE
with O
clozapine B-DRUG
resolved O
with O
risperidone O
in O
four O
patients O
. O

Exfoliative B-ADE
dermatitis I-ADE
secondary O
to O
tobramycin B-DRUG
sulfate I-DRUG
. O

Theophylline B-DRUG
intoxication I-ADE
mimicking O
diabetic O
ketoacidosis O
in O
a O
child O
. O

Following O
are O
two O
clinical O
case O
reports O
demonstrating O
profound O
cerebral B-ADE
edema I-ADE
associated O
with O
implantation O
of O
Gliadel B-DRUG
wafers O
. O

Severe B-ADE
visual I-ADE
loss I-ADE
after O
a O
single O
dose O
of O
vincristine B-DRUG
in O
a O
patient O
with O
spinal O
cord O
astrocytoma O
. O

The O
patient O
's O
previous O
rash B-ADE
and O
the O
temporal O
relation O
of O
this O
event O
and O
the O
ingestion O
of O
phenolphthalein B-DRUG
, O
as O
well O
as O
the O
similarity O
of O
this O
case O
to O
other O
reports O
, O
point O
to O
phenolphthalein B-DRUG
as O
the O
cause O
of O
TEN B-ADE
in O
this O
patient O
. O

Metabolic O
balance O
studies O
and O
rechallenge O
with O
hydrochlorothiazide B-DRUG
were O
undertaken O
to O
investigate O
the O
mechanism O
of O
the O
thiazide O
- O
induced O
hyponatremia B-ADE
. O

Thus O
any O
case O
of O
severe B-ADE
neutropenia I-ADE
occurring O
in O
a O
patient O
receiving O
olanzapine B-DRUG
is O
alarming O
to O
clinicians O
. O

We O
report O
a O
case O
of O
acute O
hyperphosphatemia B-ADE
secondary O
to O
rectal O
administration O
of O
sodium B-DRUG
phosphate I-DRUG
and O
sodium B-DRUG
biphosphate I-DRUG
( O
Fleet O
enema O
) O
. O

There O
is O
documentation O
of O
ocular B-ADE
toxicity I-ADE
with O
ethambutol B-DRUG
when O
administered O
at O
dosages O
generally O
pronounced O
as O
being O
safe O
. O

A O
case O
of O
phenytoin B-DRUG
- O
induced O
hepatitis B-ADE
with O
mononucleosis B-ADE
is O
reported O
, O
and O
syndromes O
associated O
with O
phenytoin B-DRUG
hypersensitivity B-ADE
reactions I-ADE
are O
discussed O
. O

Goiter B-ADE
and O
hypothyroidism B-ADE
during O
re O
- O
treatment O
with O
amiodarone B-DRUG
in O
a O
patient O
who O
previously O
experienced O
amiodarone B-DRUG
- O
induced O
thyrotoxicosis B-ADE
. O

A O
selective O
association O
between O
fluoxetine B-DRUG
and O
extensive O
, O
prominent O
eye B-ADE
movements I-ADE
in I-ADE
nonrapid I-ADE
eye I-ADE
movement I-ADE
( I-ADE
NREM I-ADE
) I-ADE
sleep I-ADE
was O
detected O
, O
utilizing O
Fisher O
's O
exact O
one O
- O
tailed O
statistic O
( O
p O
less O
than O
0.00001 O
for O
each O
comparison O
) O
. O

She O
was O
diagnosed O
with O
Epstein B-ADE
- I-ADE
Barr I-ADE
virus I-ADE
- I-ADE
associated I-ADE
polymorphic I-ADE
lymphoproliferative I-ADE
disorder I-ADE
( O
LPD B-ADE
) O
due O
to O
immunodeficiency B-ADE
caused O
by O
MTX B-DRUG
administration O
. O

These O
findings O
suggest O
that O
clozapine B-DRUG
- O
induced O
seizures B-ADE
can O
be O
successfully O
treated O
, O
that O
gradual O
dose O
titration O
can O
reduce O
the O
likelihood O
of O
further O
episodes O
of O
seizures O
and O
that O
concomitant O
use O
of O
a O
suitable O
mood O
stabilizer O
/ O
anti O
- O
epileptic O
medication O
can O
improve O
the O
outcome O
of O
treatment O
- O
resistant O
schizophrenia O
. O

We O
report O
a O
case O
of O
an O
infant O
with O
complex O
congenital O
heart O
disease O
who O
was O
placed O
on O
captopril B-DRUG
for O
afterload O
reduction O
following O
cardiac O
surgery O
and O
subsequently O
developed O
pulmonary B-ADE
infiltrates I-ADE
with I-ADE
eosinophilia I-ADE
. O

However O
, O
in O
the O
mid O
- O
to O
- O
late O
1980s O
, O
a O
series O
of O
letters O
to O
the O
editor O
and O
case O
reports O
announced O
an O
association O
between O
tamoxifen B-DRUG
therapy O
in O
women O
with O
breast O
cancer O
and O
the O
development O
of O
endometrial B-ADE
carcinoma I-ADE
. O

We O
report O
a O
case O
of O
torsade B-ADE
de I-ADE
pointes I-ADE
following O
a O
single O
oral O
dose O
of O
amiodarone B-DRUG
( O
1400 O
mg O
or O
30 O
mg O
kg-1 O
) O
administered O
after O
short O
intravenous O
loading O
for O
prevention O
of O
paroxysmal O
atrial O
flutter O
. O

However O
, O
the O
occurrence O
and O
management O
of O
akathisia B-ADE
induced O
by O
fluvoxamine B-DRUG
have O
not O
been O
described O
. O

CONCLUSIONS O
: O
Clarithromycin B-DRUG
may O
be O
a O
cause O
of O
fulminant B-ADE
liver I-ADE
failure I-ADE
either O
alone O
or O
by O
inhibiting O
the O
metabolism O
of O
other O
drugs O
. O

Eighty O
- O
two O
patients O
with O
various O
malignancies O
who O
received O
imipenem B-DRUG
/ O
cilastatin B-DRUG
143 O
times O
for O
neutropenic B-ADE
fever I-ADE
between O
March O
1994 O
and O
October O
1999 O
in O
Department O
of O
Pediatric O
Oncology O
, O
Gazi O
University O
, O
were O
identified O
. O

A O
68-year O
- O
old O
female O
patient O
with O
advanced O
ovarian O
carcinoma O
collapsed B-ADE
whilst O
receiving O
a O
carboplatin B-DRUG
and O
cyclophosphamide B-DRUG
infusion O
. O

Upper B-ADE
tract I-ADE
urothelial I-ADE
malignancy I-ADE
after O
cyclophosphamide B-DRUG
therapy O
: O
a O
case O
report O
and O
literature O
review O
. O

Imidazoline B-DRUG
intoxication I-ADE
due O
to O
overdose O
or O
accidental O
ingestion O
but O
also O
after O
normal O
therapeutic O
usage O
is O
frequent O
in O
children O
. O

A O
case O
of O
severe B-ADE
visual I-ADE
loss I-ADE
following O
a O
single O
dose O
of O
vincristine B-DRUG
is O
described O
. O

In O
this O
healthy O
population O
, O
the O
relative O
risk O
of O
developing O
endometrial B-ADE
carcinoma I-ADE
in O
the O
tamoxifen B-DRUG
arm O
was O
2.54 O
, O
although O
when O
stratified O
by O
age O
, O
in O
women O
over O
50 O
, O
the O
risk O
grew O
to O
4.01 O
. O

We O
describe O
a O
patient O
who O
developed O
NEH B-ADE
on O
three O
separate O
occasions O
provoked O
by O
two O
different O
chemotherapeutic O
agents O
-- O
cytarabine B-DRUG
and O
mitoxantrone B-DRUG
. O

Six O
of O
13 O
outpatients O
with O
schizophrenia O
who O
participated O
in O
a O
ten O
- O
week O
open O
trial O
of O
risperidone B-DRUG
had O
an O
initial O
good O
response O
to O
the O
medication O
followed O
by O
development O
of O
intolerable B-ADE
affect I-ADE
, O
including O
feelings B-ADE
of I-ADE
agitation I-ADE
and O
depression B-ADE
and O
periods B-ADE
of I-ADE
crying I-ADE
and O
insomnia B-ADE
. O

We O
describe O
a O
patient O
with O
transitional O
cell O
carcinoma O
of O
the O
renal O
pelvis O
who O
developed O
respiratory B-ADE
dysfunction I-ADE
and O
an O
abnormal B-ADE
chest I-ADE
x I-ADE
- I-ADE
ray I-ADE
with I-ADE
diffuse I-ADE
interstitial I-ADE
opacities I-ADE
while O
on O
chemotherapy O
with O
piritrexim B-DRUG
, O
a O
methotrexate O
analog O
. O

Hydrocortisone O
may O
decrease O
the O
incidence O
of O
mortality B-ADE
associated O
with O
cardiac B-ADE
arrhythmias I-ADE
in O
children O
receiving O
amphotericin B-DRUG
B I-DRUG
overdoses O
. O

We O
present O
three O
cases O
from O
the O
Provincial O
Toxicology O
Center O
of O
British O
Columbia O
, O
Canada O
in O
which O
suicidal B-ADE
overdose I-ADE
deaths I-ADE
were O
associated O
with O
quetiapine B-DRUG
. O

Although O
taxol B-DRUG
has O
shown O
significant O
activity O
in O
advanced O
ovarian O
cancer O
, O
peripheral B-ADE
neuropathy I-ADE
is O
likely O
to O
become O
the O
major O
dose O
- O
limiting O
toxicity O
. O

In O
four O
patients O
, O
thrombosis B-ADE
occurred O
2 O
- O
45 O
days O
after O
severe O
hepatic B-ADE
veno I-ADE
- I-ADE
occlusive I-ADE
disease I-ADE
( O
HVOD B-ADE
) O
secondary O
to O
intensive O
chemotherapy O
containing O
busulfan B-DRUG
. O

The O
occurrence O
of O
BMTN B-ADE
in O
two O
children O
treated O
with O
RA B-DRUG
in O
our O
unit O
is O
unlikely O
to O
be O
coincidental O
. O

Multiple B-ADE
pulmonary I-ADE
nodules I-ADE
: O
an O
unusual O
presentation O
of O
fludarabine B-DRUG
pulmonary B-ADE
toxicity I-ADE
: O
case O
report O
and O
review O
of O
literature O
. O

These O
findings O
are O
consistent O
with O
an O
immune O
- O
complex O
form O
of O
glomerulopathy O
in O
which O
gold O
is O
neither O
the O
antigen O
nor O
a O
hapten O
in O
the O
glomerular O
deposits O
, O
and O
they O
suggest O
the O
hypothesis O
that O
antibodies O
to O
tubular O
epithelial O
antigens O
induced O
by O
gold B-DRUG
therapy O
may O
be O
a O
causative O
factor O
in O
the O
renal B-ADE
disease I-ADE
associated O
with O
gold B-DRUG
therapy O
in O
rheumatoid O
arthritis O
. O

It O
was O
concluded O
that O
ANCA B-ADE
is O
closely O
related O
to O
the O
pathogenesis O
of O
crescentic O
glomerulonephritis O
and O
that O
treatment O
with O
PTU B-DRUG
appeared O
to O
induce O
ANCA B-ADE
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
marked O
elevation B-ADE
of I-ADE
serum I-ADE
creatine I-ADE
kinase I-ADE
( O
CK O
) O
associated O
with O
olanzapine B-DRUG
therapy O
. O

CASE O
PRESENTATION O
: O
Three O
cases O
of O
Leishmania B-ADE
infantum I-ADE
leishmaniasis I-ADE
in O
corticosteroid B-DRUG
( O
CS O
) O
- O
treated O
patients O
are O
reported O
: O
an O
isolated O
lingual B-ADE
leishmaniasis I-ADE
in O
a O
farmer O
treated O
with O
CS B-DRUG
for O
asthma O
, O
a O
severe O
visceral O
leishmaniasis O
associated O
with O
cutaneous O
lesions O
in O
a O
woman O
with O
myasthenia O
gravis O
, O
and O
a O
visceral O
involvement O
after O
cutaneous B-ADE
leishmaniasis I-ADE
in O
a O
man O
receiving O
CS B-DRUG
. O

OBJECTIVES O
: O
A O
delayed O
stroke B-ADE
- I-ADE
like I-ADE
leukoencephalopathy I-ADE
has O
been O
observed O
in O
patients O
receiving O
methotrexate B-DRUG
( O
MTX B-DRUG
) O
for O
childhood O
leukemia O
. O

Nitrendipine B-DRUG
- O
induced O
gingival B-ADE
hyperplasia I-ADE
. O

CONCLUSIONS O
: O
Although O
budesonide B-DRUG
may O
be O
beneficial O
because O
of O
its O
anti O
- O
inflammatory O
effects O
, O
clinicians O
should O
be O
alert O
to O
its O
potential O
for O
causing O
contact B-ADE
dermatitis I-ADE
. O

Acute B-ADE
generalized I-ADE
exanthematous I-ADE
pustulosis I-ADE
induced O
by O
salazosulfapyridine B-DRUG
in O
a O
patient O
with O
ulcerative O
colitis O
. O

A O
36-y O
- O
o O
patient O
with O
schizophrenia O
, O
who O
had O
consumed O
gradually O
increasing O
quantities O
of O
oolong B-DRUG
tea I-DRUG
that O
eventually O
reached O
15 O
L O
each O
day O
, O
became O
delirious B-ADE
and O
was O
admitted O
to O
a O
psychiatric O
hospital O
. O

Long O
lasting O
respiratory B-ADE
depression I-ADE
induced O
by O
morphine-6-glucuronide B-DRUG
? O

Graves B-ADE
' I-ADE
hyperthyroidism I-ADE
following O
transient B-ADE
thyrotoxicosis I-ADE
during O
interferon B-DRUG
therapy O
for O
chronic O
hepatitis O
type O
C O
. O

The O
patient O
was O
found O
to O
have O
no B-ADE
motile I-ADE
sperm I-ADE
with O
a O
normal O
sperm O
count O
, O
while O
taking O
a O
dose O
of O
400 O
mg O
/ O
day O
of O
carbamazepine B-DRUG
. O

A O
44-year O
- O
old O
woman O
is O
described O
in O
whom O
amiodarone B-DRUG
, O
disopyramide B-DRUG
, O
and O
quinidine B-DRUG
, O
administered O
alone O
separately O
, O
induced O
atypical B-ADE
ventricular I-ADE
tachycardia I-ADE
( O
AVT B-ADE
, O
torsade B-ADE
de I-ADE
pointes I-ADE
) O
. O

Symptoms O
and O
endoscopic B-ADE
lesions I-ADE
quickly O
regressed O
within O
1 O
week O
of O
meloxicam B-DRUG
withdrawal O
. O

This O
panic B-ADE
anxiety I-ADE
was O
not O
relieved O
by O
taking O
etizolam O
and O
flunitrazepam O
again O
, O
but O
subsided O
rapidly O
by O
the O
re O
- O
administration O
of O
mianserin B-DRUG
30 O
mg O
/ O
day O
, O
and O
because O
of O
that O
the O
depressive O
symptom O
also O
disappeared O
. O

A O
58-yr O
- O
old O
male O
patient O
with O
essential O
thrombocythaemia O
( O
ET O
) O
developed O
chronic B-ADE
myeloid I-ADE
leukaemia I-ADE
( O
CML B-ADE
) O
after O
continuous O
uneventful O
treatment O
with O
hydroxyurea B-DRUG
for O
18 O
yr O
. O

Upon O
discontinuation O
of O
MTX B-DRUG
, O
her O
ascites B-ADE
resolved O
, O
and O
her O
arthritis O
became O
more O
active O
. O

We O
report O
a O
4-year O
- O
old O
girl O
who O
presented O
with O
acute B-ADE
bilateral I-ADE
blindness I-ADE
, O
a O
focal B-ADE
seizure I-ADE
and O
hypertension B-ADE
10 O
days O
after O
commencing O
oxybutynin B-DRUG
to O
treat O
enuresis O
. O

Four O
Chinese O
female O
patients O
who O
suffered O
from O
manic O
- O
depressive O
disorder O
and O
underlying O
autoimmune O
thyroiditis O
developed O
transient O
episodes O
of O
thyrotoxicosis B-ADE
during O
maintenance O
lithium B-DRUG
therapy O
. O

There O
are O
no O
previous O
reports O
in O
the O
literature O
about O
the O
emergence O
of O
CML B-ADE
during O
treatment O
with O
hydroxyurea B-DRUG
. O

METHODS O
: O
We O
queried O
35 O
rheumatologists O
at O
the O
Robert O
Breck O
Brigham O
Arthritis O
Center O
to O
determine O
if O
weight B-ADE
loss I-ADE
had O
occurred O
as O
an O
adverse O
event O
in O
patients O
treated O
with O
leflunomide B-DRUG
between O
November O
1998 O
and O
January O
2000 O
. O

Extrapyramidal B-ADE
symptoms I-ADE
are O
well O
- O
documented O
complications O
of O
therapy O
with O
haloperidol B-DRUG
, O
even O
when O
small O
doses O
are O
used O
. O

Glaucoma B-ADE
secondary O
to O
epithelial O
downgrowth O
and O
5-fluorouracil B-DRUG
. O

CASE O
REPORT O
: O
We O
describe O
here O
a O
case O
of O
a O
60 O
year O
old O
female O
that O
experienced O
a O
relapse O
of O
symptomatic B-ADE
hyperlactatemia I-ADE
after O
being O
switched O
from O
stavudine B-DRUG
to O
zidovudine B-DRUG
and O
how O
the O
case O
was O
managed O
at O
the O
Infectious O
Diseases O
Institute O
, O
Kampala O
, O
Uganda O
. O

Other O
thiazolidinediones O
currently O
in O
clinical O
trials O
may O
be O
able O
to O
provide O
the O
therapeutic O
benefits O
of O
troglitazone B-DRUG
without O
significant O
hepatotoxicity B-ADE
. O

Carbamazepine B-DRUG
toxicity I-ADE
induced O
by O
clarithromycin B-DRUG
coadministration O
in O
psychiatric O
patients O
. O

A O
61 O
year O
- O
old O
male O
patient O
developed O
gynecomastia B-ADE
after O
starting O
theophylline B-DRUG
. O

It O
is O
suggested O
that O
the O
fatal B-ADE
stroke I-ADE
may O
have O
resulted O
from O
arterial B-ADE
spasm I-ADE
caused O
by O
ergotamine B-DRUG
overdosage O
and O
possibly O
complicated O
by O
thrombosis O
. O

Adenosine B-DRUG
- O
induced O
ventricular B-ADE
fibrillation I-ADE
. O

Dermatitis B-ADE
to O
captopril B-DRUG
. O

Case O
report O
: O
life B-ADE
- I-ADE
threatening I-ADE
hypoglycaemia I-ADE
associated O
with O
sulfadoxine B-DRUG
- I-DRUG
pyrimethamine I-DRUG
, O
a O
commonly O
used O
antimalarial O
drug O
. O

PVT B-ADE
during O
chemotherapy O
in O
children O
is O
a O
rare O
event O
and O
appears O
to O
be O
closely O
related O
to O
intensive O
chemotherapy O
containing O
busulfan B-DRUG
and O
to O
be O
associated O
with O
HVOD B-ADE
. O

Possible O
linkage O
of O
amprenavir B-DRUG
with O
intracranial B-ADE
bleeding I-ADE
in O
an O
HIV O
- O
infected O
hemophiliac O
. O

Pulmonary B-ADE
fibrosis I-ADE
is O
a O
complication O
of O
paclitaxel B-DRUG
therapy O
that O
may O
occur O
despite O
treatments O
with O
corticosteroids O
. O

Intraventricular O
nafcillin B-DRUG
- O
induced O
seizures B-ADE
in O
a O
neonate O
. O

We O
report O
four O
cases O
of O
sensorimotor B-ADE
axonal I-ADE
neuropathy I-ADE
in O
children O
aged O
10 O
- O
15 O
years O
, O
treated O
with O
thalidomide B-DRUG
for O
myxopapillary O
ependymoma O
, O
Crohn O
's O
disease O
and O
recurrent O
giant O
aphthous O
ulceration O
. O

The O
9 O
other O
reported O
cases O
of O
D B-DRUG
- I-DRUG
penicillamine I-DRUG
induced O
rapidly B-ADE
progressive I-ADE
glomerulonephritis I-ADE
have O
been O
reviewed O
. O

Ciprofloxacin B-DRUG
- O
induced O
hemorrhagic B-ADE
vasculitis I-ADE
is O
a O
rare O
side O
effect O
. O

The O
purpose O
of O
this O
report O
is O
to O
document O
a O
new O
case O
of O
in O
utero O
CP B-DRUG
exposure O
with O
multiple B-ADE
congenital I-ADE
anomalies I-ADE
and O
to O
establish O
an O
apparent O
CP B-DRUG
embryopathy B-ADE
phenotype O
. O

Linear B-ADE
immunoglobulin I-ADE
A I-ADE
bullous I-ADE
dermatosis I-ADE
induced O
by O
gemcitabine B-DRUG
. O

The O
authors O
report O
a O
further O
case O
of O
methimazole B-DRUG
- O
associated O
liver B-ADE
damage I-ADE
and O
present O
a O
brief O
review O
of O
eleven O
previous O
cases O
found O
in O
the O
literature O
. O

CONCLUSIONS O
: O
The O
piloerection B-ADE
observed O
after O
the O
replacement O
of O
fluvoxamine B-DRUG
with O
milnacipran B-DRUG
in O
this O
patient O
appears O
to O
have O
been O
due O
to O
an O
increase O
in O
the O
alpha(1 O
) O
- O
adrenoceptor O
occupancy O
by O
endogenous O
norepinephrine O
induced O
by O
milnacipran O
. O

Ulcer B-ADE
became I-ADE
worse I-ADE
after O
tobramycin B-DRUG
and O
gentamycin B-DRUG
treatment O
for O
2 O
days O
. O

Pigmentary B-ADE
disorders I-ADE
are O
recognized O
adverse O
effects O
of O
the O
semi O
- O
synthetic O
tetracycline O
derivative O
antibiotic O
, O
minocycline B-DRUG
. O

The O
patient O
described O
in O
this O
paper O
was O
a O
78-year O
- O
old O
diabetic O
man O
who O
developed O
oral B-ADE
lesions I-ADE
of I-ADE
PV I-ADE
following O
institution O
of O
glibenclamide B-DRUG
therapy O
. O

We O
recommend O
the O
cautious O
use O
of O
ketorolac B-DRUG
in O
patients O
with O
underlying O
illnesses O
where O
NSAID O
- O
induced O
ototoxicity B-ADE
could O
result O
in O
adverse O
otologic O
consequences O
. O

Herpes B-ADE
simplex I-ADE
esophagitis I-ADE
in O
a O
renal O
transplant O
patient O
treated O
with O
cyclosporine B-DRUG
A I-DRUG
: O
a O
case O
report O
. O

We O
describe O
a O
patient O
with O
idiopathic O
RLS O
who O
developed O
augmentation B-ADE
after O
8 O
months O
of O
levodopa B-DRUG
treatment O
. O

Renal B-ADE
failure I-ADE
associated O
with O
acetazolamide B-DRUG
therapy O
for O
glaucoma O
. O

A O
case O
of O
acute B-ADE
subdural I-ADE
haematoma I-ADE
originating O
spontaneously O
from O
an O
angiomatous O
meningioma O
in O
a O
patient O
receiving O
prophylactic O
aspirin B-DRUG
therapy O
is O
presented O
. O

Protease O
inhibitor O
- O
induced O
carbamazepine B-DRUG
toxicity I-ADE
. O

After O
5 O
weeks O
of O
therapy O
, O
she O
stopped O
taking O
pantoprazole B-DRUG
due O
to O
general B-ADE
malaise I-ADE
. O

Severe B-ADE
hepatitis I-ADE
caused O
by O
cyproterone B-DRUG
acetate I-DRUG
. O

We O
report O
a O
case O
of O
a O
child O
with O
neurodevelopmental O
delay O
with O
chronic O
constipation O
and O
a O
history O
of O
chronic O
mineral B-DRUG
oil I-DRUG
ingestion O
presenting O
as O
asymptomatic O
exogenous B-ADE
lipoid I-ADE
pneumonia I-ADE
( O
ELP B-ADE
) O
. O

Our O
case O
is O
the O
second O
one O
in O
which O
hemorrhage B-ADE
from O
a O
meningioma O
may O
have O
been O
induced O
by O
aspirin B-DRUG
prophylaxis O
. O

Anaphylaxis B-ADE
to O
cisplatin B-DRUG
is O
an O
infrequent O
life O
- O
threatening O
complication O
which O
may O
occur O
even O
in O
patients O
who O
have O
received O
prior O
treatment O
with O
cisplatin O
. O

Papilloedema B-ADE
and O
hepatic B-ADE
dysfunction I-ADE
apparently O
induced O
by O
perhexiline B-DRUG
maleate I-DRUG
( O
Pexid B-DRUG
) O
. O

We O
report O
a O
case O
of O
fulminant O
neuroleptic B-ADE
malignant I-ADE
syndrome I-ADE
in O
a O
man O
aged O
70 O
developing O
within O
12 O
hours O
of O
starting O
six O
- O
hourly O
intravenous O
metoclopramide B-DRUG
. O

We O
report O
a O
cae O
of O
paranoid B-ADE
psychosis I-ADE
following O
use O
of O
a O
decongestant O
containing O
PPA B-DRUG
and O
summarize O
the O
case O
report O
literature O
of O
psychiatric B-ADE
adverse I-ADE
effects I-ADE
to O
PPA B-DRUG
in O
which O
doses O
were O
known O
and O
stated O
to O
be O
within O
recommended O
guidelines O
. O

Retinal B-ADE
abnormalities I-ADE
, O
including O
retinal B-ADE
hemorrhage I-ADE
and O
" B-ADE
cotton I-ADE
- I-ADE
wool I-ADE
" I-ADE
spots I-ADE
, O
often O
occur O
within O
the O
first O
8 O
weeks O
in O
the O
course O
of O
interferon B-DRUG
therapy O
in O
patients O
with O
chronic O
hepatitis O
C O
. O

Onset O
of O
male O
gynaecomastia B-ADE
in O
a O
patient O
treated O
with O
sunitinib B-DRUG
for O
metastatic O
renal O
cell O
carcinoma O
. O

An O
infertile O
patient O
with O
amenorrhea O
- O
galactorrhea O
syndrome O
lost B-ADE
vision I-ADE
during O
a O
pregnancy O
occurring O
after O
Bromocryptine B-DRUG
treatment O
. O

Two O
patients O
with O
osteomyelitis O
who O
developed O
reversible B-ADE
cholestatic I-ADE
jaundice I-ADE
during O
treatment O
with O
oxacillin B-DRUG
derivatives O
are O
described O
. O

An O
immediate O
hemolytic B-ADE
reaction I-ADE
induced O
by O
repeated O
administration O
of O
oxaliplatin B-DRUG
. O

Only O
one O
report O
links O
phenylpropanolamine B-DRUG
consumption O
to O
an O
intracerebral B-ADE
hemorrhage I-ADE
in O
a O
patient O
with O
an O
AVM O
. O

Diarrhoea B-ADE
, O
T B-ADE
- I-ADE
CD4 I-ADE
+ I-ADE
lymphopenia I-ADE
and O
bilateral B-ADE
patchy I-ADE
pulmonary I-ADE
infiltrates I-ADE
developed O
in O
a O
male O
60 O
yrs O
of O
age O
, O
who O
was O
treated O
with O
oxaliplatinum B-DRUG
and O
5-fluorouracil B-DRUG
for O
unresectable O
rectum O
carcinoma O
. O

Acute O
severe O
intoxication O
with O
carbamazepine B-DRUG
is O
associated O
with O
seizures B-ADE
, O
coma B-ADE
and O
respiratory B-ADE
depression I-ADE
. O

Gangrene B-ADE
of O
the O
fingertips O
after O
bleomycin B-DRUG
and O
methotrexate B-DRUG
. O

Drug O
- O
induced O
fever B-ADE
due O
to O
diltiazem B-DRUG
. O

We O
describe O
3 O
AS O
patients O
treated O
with O
etanercept B-DRUG
for O
active O
AS O
who O
developed O
new O
onset O
of O
CD B-ADE
while O
AS O
related O
symptoms O
responded O
well O
to O
etanercept O
. O

We O
describe O
a O
case O
of O
significant O
elevation B-ADE
of I-ADE
serum I-ADE
transaminases I-ADE
in O
a O
patient O
treated O
with O
6-TG B-DRUG
for O
a O
flare O
of O
Crohn O
's O
disease O
. O

Olanzapine B-DRUG
- O
induced O
hyperglycaemic B-ADE
coma I-ADE
and O
neuroleptic B-ADE
malignant I-ADE
syndrome I-ADE
: O
case O
report O
and O
review O
of O
literature O
. O

We O
report O
5 O
patients O
( O
3 O
patients O
with O
chronic O
hepatitis O
C O
treated O
with O
pegylated B-DRUG
interferon I-DRUG
alfa-2b I-DRUG
in O
association O
with O
oral O
ribavirin B-DRUG
and O
two O
patients O
with O
chronic O
myelocytic O
leukemia O
) O
who O
developed O
local B-ADE
cutaneous I-ADE
reactions I-ADE
at O
sites O
of O
injection O
after O
the O
administration O
of O
weekly O
subcutaneous O
injections O
of O
pegylated B-DRUG
interferon I-DRUG
alfa-2b I-DRUG
at O
different O
doses O
. O

Flucloxacillin B-DRUG
- O
induced O
aplastic B-ADE
anaemia I-ADE
and O
liver B-ADE
failure I-ADE
. O

A O
case O
of O
mania B-ADE
associated O
with O
fluoxetine B-DRUG
. O

The O
development O
of O
cutaneous B-ADE
ecchymosis I-ADE
associated O
with O
a O
sudden B-ADE
fall I-ADE
in I-ADE
hemoglobin I-ADE
after O
the O
administration O
of O
alteplase B-DRUG
should O
strongly O
suggest O
the O
possibility O
of O
diffuse B-ADE
subfascial I-ADE
hematoma I-ADE
. O

Lansoprazole B-DRUG
- O
induced O
thrombocytopenia B-ADE
. O

OBJECTIVE O
: O
To O
describe O
a O
probable O
case O
of O
transient B-ADE
global I-ADE
amnesia I-ADE
caused O
by O
propafenone B-DRUG
. O

Electro O
- O
oculography O
, O
electroretinography O
, O
visual O
evoked O
potentials O
, O
and O
multifocal O
electroretinography O
in O
patients O
with O
vigabatrin B-DRUG
- O
attributed O
visual B-ADE
field I-ADE
constriction I-ADE
. O

This O
clinical O
course O
suggests O
that O
the O
sensorimotor B-ADE
polyneuropathy I-ADE
may O
have O
been O
caused O
by O
5-ASA B-DRUG
. O

In O
all O
cases O
, O
seizures B-ADE
were O
controlled O
by O
withdrawal O
of O
phenytoin B-DRUG
and O
reduction O
of O
drug O
levels O
. O

Vanishing B-ADE
bile I-ADE
duct I-ADE
and O
Stevens B-ADE
- I-ADE
Johnson I-ADE
syndrome I-ADE
associated O
with O
ciprofloxacin B-DRUG
treated O
with O
tacrolimus O
. O

The O
course O
of O
delirium B-ADE
due O
to O
lithium B-DRUG
intoxication O
. O

Severe B-ADE
neurotoxicity I-ADE
with O
methyl B-DRUG
G I-DRUG
: I-DRUG
CALGB I-DRUG
experience O
. O

RESULTS O
: O
A O
52-year O
- O
old O
woman O
with O
Parkinson O
disease O
who O
had O
taken O
amantadine B-DRUG
for O
6 O
years O
had O
bilateral B-ADE
corneal I-ADE
edema I-ADE
for O
2 O
months O
at O
baseline O
. O

Spontaneous O
bacterial B-ADE
peritonitis I-ADE
induced O
by O
intraarterial O
vasopressin B-DRUG
therapy O
. O

The O
case O
history O
confirms O
that O
gold B-DRUG
treatment O
, O
even O
in O
the O
same O
patient O
, O
can O
give O
rise O
to O
a O
wide O
range O
of O
skin B-ADE
disturbances I-ADE
, O
which O
in O
many O
cases O
do O
not O
break O
out O
until O
long O
after O
the O
drug O
has O
been O
withdrawn O
. O

A O
young O
patient O
experienced O
marked O
sinus B-ADE
tachycardia I-ADE
while O
smoking O
marijuana O
and O
receiving O
therapeutic O
doses O
of O
nortriptyline B-DRUG
. O

A O
severe O
form O
of O
exophthalmos B-ADE
resulting O
from O
lithium B-DRUG
therapy O
has O
not O
been O
described O
in O
the O
literature O
. O

A O
21-year O
- O
old O
patient O
developed O
rhabdomyolysis B-ADE
during O
his O
nineteenth O
week O
of O
treatment O
with O
clozapine B-DRUG
for O
drug O
- O
resistant O
schizophrenia O
. O

Edema B-ADE
associated O
with O
ibuprofen B-DRUG
therapy O
. O

Recombinant O
VIIa O
concentrate O
in O
the O
management O
of O
bleeding O
following O
prothrombin B-DRUG
complex I-DRUG
concentrate I-DRUG
- O
related O
myocardial B-ADE
infarction I-ADE
in O
patients O
with O
haemophilia O
and O
inhibitors O
. O

Acyclovir B-DRUG
neurotoxicity B-ADE
: O
clinical O
experience O
and O
review O
of O
the O
literature O
. O

Bulbar B-ADE
and O
pseudobulbar B-ADE
palsy I-ADE
complicating O
therapy O
with O
high O
- O
dose O
cytosine B-DRUG
arabinoside I-DRUG
in O
children O
with O
leukemia O
. O

We O
report O
a O
case O
of O
unintentional O
overdose O
of O
oral O
pilocarpine B-DRUG
tablets O
that O
resulted O
in O
bradycardia B-ADE
, O
mild B-ADE
hypotension I-ADE
, O
and O
muscarinic B-ADE
symptoms I-ADE
in O
a O
patient O
with O
Sjogren O
's O
syndrome O
. O

In O
some O
cases O
this O
seems O
to O
happen O
because O
spironolactone B-DRUG
causes O
diarrhoea B-ADE
. O

The O
authors O
report O
one O
case O
of O
incomplete B-ADE
posterior I-ADE
hyaloid I-ADE
detachment I-ADE
( O
PHD O
) O
following O
intravitreal O
pegaptanib B-DRUG
to O
treat O
DME O
. O

Circulating O
anticoagulant O
in O
the O
procainamide B-DRUG
- O
induced O
lupus B-ADE
syndrome I-ADE
. O

After O
a O
two O
- O
month O
interruption O
of O
interferon O
administration O
, O
natural O
interferon B-DRUG
alpha I-DRUG
was O
given O
but O
followed O
by O
another O
episode O
of O
the O
same O
neurological B-ADE
manifestations I-ADE
. O

We O
describe O
a O
41 O
yr O
old O
leprosy O
patient O
treated O
for O
10 O
yrs O
with O
clofazimine B-DRUG
who O
underwent O
laparotomy O
for O
severe O
abdominal B-ADE
pain I-ADE
. O

OBJECTIVE O
: O
To O
our O
knowledge O
, O
this O
is O
the O
first O
published O
case O
report O
of O
an O
adolescent O
girl O
with O
a O
mitochondrial O
disorder O
and O
depression O
who O
displayed O
both O
new O
- O
onset O
psychotic O
and O
increased B-ADE
mood I-ADE
symptoms I-ADE
during O
treatment O
with O
risperidone B-DRUG
. O

Several O
cases O
of O
lithium B-DRUG
- O
induced O
Creutzfeldt B-ADE
- I-ADE
Jakob I-ADE
syndrome I-ADE
have O
been O
reported O
to O
date O
; O
all O
of O
them O
were O
elderly O
patients O
and O
a O
half O
had O
" O
therapeutic O
" O
lithium B-DRUG
serum O
levels O
. O

L B-DRUG
- I-DRUG
DOPA I-DRUG
- O
induced O
excessive O
daytime B-ADE
sleepiness I-ADE
in O
PD O
: O
a O
placebo O
- O
controlled O
case O
with O
MSLT O
assessment O
. O

Methemoglobinemia B-ADE
after O
axillary O
block O
with O
bupivacaine B-DRUG
and O
additional O
injection O
of O
lidocaine B-DRUG
in O
the O
operative O
field O
. O

Benzocaine B-DRUG
, O
an O
ester O
- O
type O
local O
anesthetic O
, O
was O
believed O
responsible O
for O
apparent O
methemoglobinemia B-ADE
in O
a O
cat O
. O

Managing O
cardiovascular B-ADE
collapse I-ADE
in O
severe O
flecainide B-DRUG
overdose O
without O
recourse O
to O
extracorporeal O
therapy O
. O

Tamoxifen B-DRUG
is O
suggested O
to O
be O
carcinogenic B-ADE
both O
through O
direct O
genotoxic O
and O
epigenetic O
mechanisms O
. O

Gabapentin B-DRUG
withdrawal O
presenting O
as O
status B-ADE
epilepticus I-ADE
. O

We O
report O
a O
case O
of O
NEH B-ADE
masquerading O
as O
cutaneous O
vasculitis O
in O
a O
woman O
receiving O
cyclophosphamide B-DRUG
for O
lupus O
nephritis O
. O

Their O
parkinsonism B-ADE
improved O
on O
discontinuation O
of O
metoclopramide B-DRUG
therapy O
. O

In O
summary O
, O
we O
report O
herein O
the O
first O
case O
of O
SIADH B-ADE
believed O
to O
be O
an O
adverse O
effect O
of O
mizoribin B-DRUG
, O
which O
may O
therefore O
needed O
to O
be O
added O
to O
the O
list O
of O
drugs O
which O
can O
induce O
SIADH B-ADE
. O

We O
report O
the O
first O
case O
of O
acute B-ADE
renal I-ADE
failure I-ADE
with O
hyperkalemia B-ADE
associated O
with O
the O
recently O
marketed O
direct O
renin O
inhibitor O
aliskiren B-DRUG
. O

Nine O
azotemic O
patients O
who O
developed O
a O
coagulopathy B-ADE
associated O
with O
the O
use O
of O
either O
cephalosporin B-DRUG
or O
moxalactam B-DRUG
antibiotics O
are O
reported O
. O

During O
the O
first O
days O
of O
arsenic B-DRUG
trioxide I-DRUG
treatment O
a O
rapid O
decrease B-ADE
in I-ADE
the I-ADE
D I-ADE
- I-ADE
dimers I-ADE
was O
seen O
( O
normal O
values O
reached O
until O
day O
7 O
) O
, O
together O
with O
a O
slight B-ADE
decrease I-ADE
in I-ADE
peripheral I-ADE
blood I-ADE
leukocytes I-ADE
. O

Two O
patients O
treated O
with O
alprazolam B-DRUG
had O
histories O
suggestive O
of O
a O
bipolar O
disorder O
and O
developed O
lithium O
- O
responsive O
manic B-ADE
episodes I-ADE
. O

OBJECTIVE O
: O
To O
report O
on O
the O
possible O
development O
of O
serotonin B-ADE
syndrome I-ADE
in O
a O
patient O
receiving O
clomipramine B-DRUG
after O
clozapine B-DRUG
was O
withdrawn O
from O
the O
treatment O
regimen O
. O

These O
nail B-ADE
changes I-ADE
gradually O
disappeared O
when O
the O
dose O
of O
clofazimine B-DRUG
was O
reduced O
. O

Acute B-ADE
dystonia I-ADE
with O
thalamic B-ADE
and I-ADE
brainstem I-ADE
lesions I-ADE
after O
initial O
penicillamine B-DRUG
treatment O
in O
Wilson O
's O
disease O
. O

Paradoxical B-ADE
precipitation I-ADE
of I-ADE
tonic I-ADE
seizures I-ADE
by O
lorazepam B-DRUG
in O
a O
child O
with O
atypical O
absence O
seizures O
. O

We O
report O
two O
cases O
of O
tenofovir B-DRUG
( O
TDF B-DRUG
) O
- O
associated O
nephrotoxicity B-ADE
in O
perinatally O
HIV O
- O
infected O
adolescents O
. O

We O
describe O
a O
patient O
with O
androgen O
- O
independent O
prostate O
cancer O
in O
whom O
PSA B-ADE
continued I-ADE
to I-ADE
decrease I-ADE
for O
a O
period O
of O
15 O
months O
after O
flutamide B-DRUG
withdrawal O
. O

In O
two O
patients O
clozapine B-DRUG
was O
reinstated O
after O
risperidone O
was O
discontinued O
; O
serum B-ADE
triglyceride I-ADE
levels I-ADE
increased I-ADE
. O

We O
report O
a O
case O
of O
fatal B-ADE
fulminant I-ADE
hepatitis I-ADE
caused O
by O
the O
use O
of O
disulfiram B-DRUG
in O
a O
man O
with O
previously O
normal O
hepatocellular O
function O
. O

RESULTS O
: O
Similar O
to O
previous O
findings O
of O
drug O
- O
induced O
vortex B-ADE
keratopathy I-ADE
, O
atovaquone B-DRUG
vortex B-ADE
keratopathy I-ADE
is O
presumably O
caused O
by O
its O
lipophilic O
properties O
. O

46-year O
- O
old O
woman O
developed O
painful B-ADE
ulcers I-ADE
over O
her O
lower O
abdomen O
in O
the O
form O
of O
reticulate B-ADE
erythema I-ADE
after O
injecting O
interferon B-DRUG
beta-1b I-DRUG
subcutaneously O
for O
multiple O
sclerosis O
. O

To O
date O
, O
only O
three O
cases O
of O
seizures B-ADE
associated O
with O
amphotericin B-DRUG
B I-DRUG
have O
been O
reported O
in O
the O
literature O
, O
but O
healthcare O
providers O
should O
be O
aware O
of O
the O
potential O
for O
this O
rare O
adverse O
effect O
. O

We O
report O
a O
case O
of O
SJS B-ADE
in O
a O
14-year O
- O
old O
male O
with O
nephrotic O
syndrome O
, O
who O
was O
treated O
with O
oral O
prednisolone B-DRUG
for O
6 O
weeks O
. O

Therefore O
, O
although O
garenoxacin B-DRUG
reportedly O
causes O
fewer O
adverse O
reactions O
for O
cardiac B-ADE
rhythms I-ADE
than O
third O
- O
generation O
quinolone O
antibiotics O
, O
one O
must O
be O
cautious O
of O
the O
interference O
of O
other O
drugs O
during O
hypokalemia B-ADE
in O
order O
to O
prevent O
TdP O
. O

A O
patient O
with O
generalized O
MG O
was O
effectively O
managed O
with O
MM B-DRUG
but O
developed O
CNS B-ADE
lymphoma I-ADE
after O
3 O
years O
of O
treatment O
. O

Colchicine B-DRUG
- O
induced O
myopathy B-ADE
in O
renal O
failure O
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
serotonin B-ADE
syndrome I-ADE
associated O
with O
interaction O
between O
fentanyl B-DRUG
and O
citalopram B-DRUG
, O
as O
evidenced O
by O
medication O
history O
, O
clinical O
features O
and O
reversal O
following O
discontinuation O
of O
fentanyl B-DRUG
. O

High O
- O
dose O
intravenous O
mannitol B-DRUG
infusion O
in O
various O
clinical O
settings O
may O
result O
in O
acute B-ADE
renal I-ADE
failure I-ADE
( O
ARF B-ADE
) O
. O

Zolpidem B-DRUG
( O
Ambien B-DRUG
) O
, O
a O
relatively O
new O
nonbenzodiazepine O
sedative O
- O
hypnotic O
, O
was O
involved O
in O
the O
death B-ADE
of O
a O
39-year O
- O
old O
obese O
male O
who O
was O
being O
treated O
for O
depression O
and O
insomnia O
. O

Captopril B-DRUG
- O
induced O
pulmonary B-ADE
infiltrates I-ADE
with I-ADE
eosinophilia I-ADE
in O
an O
infant O
with O
congenital O
heart O
disease O
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
calcineurin B-DRUG
- O
induced O
pain B-ADE
syndrome I-ADE
( O
CIPS O
) O
in O
a O
child O
undergoing O
his O
second O
hematopoietic O
stem O
cell O
transplant O
( O
HSCT O
) O
. O

A O
sixty O
- O
year O
- O
old O
woman O
with O
advanced O
breast O
cancer O
, O
previously O
treated O
with O
cisplatin O
, O
developed O
an O
irreversible B-ADE
lethal I-ADE
renal I-ADE
failure I-ADE
with O
anuria B-ADE
, O
the O
day O
after O
5 O
g O
/ O
m2 O
bolus O
ifosfamide B-DRUG
. O

A O
case O
is O
reported O
of O
theophylline B-DRUG
intoxication I-ADE
due O
to O
a O
dramatic O
decrease B-ADE
in I-ADE
theophylline I-ADE
clearance I-ADE
following O
concomitant O
administration O
of O
viloxazine B-DRUG
. O

Methotrexate B-DRUG
may O
rarely O
provoke O
serositis B-ADE
, O
even O
with O
low O
doses O
and O
after O
just O
a O
few O
weeks O
of O
therapy O
. O

Clearance O
rates O
of O
cerivastatin O
metabolites O
in O
a O
patient O
with O
cerivastatin B-DRUG
- O
induced O
rhabdomyolysis B-ADE
. O

Reduction O
of O
methylprednisolone B-DRUG
dosage O
rather O
than O
insulin O
therapy O
resulted O
in O
better O
control O
of O
glycemia B-ADE
. O

A O
62-year O
- O
old O
woman O
who O
was O
being O
treated O
for O
squamous O
cell O
carcinoma O
of O
the O
head O
and O
neck O
developed O
a O
chemotherapy O
- O
related O
hemolytic B-ADE
- I-ADE
uremic I-ADE
syndrome I-ADE
during O
the O
second O
cycle O
of O
neoadjuvant O
chemotherapy O
consisting O
of O
cisplatin B-DRUG
, O
bleomycin B-DRUG
, O
and O
methotrexate B-DRUG
. O

The O
cause O
of O
his O
bleeding O
was O
a O
severe B-ADE
thrombocytopoaenia I-ADE
, O
induced O
by O
chronic O
ingestion O
of O
quinine B-DRUG
. O

Nifedipine B-DRUG
may O
induce O
, O
or O
aggravate O
, O
pre O
- O
existing O
, O
gastro B-ADE
- I-ADE
oesophageal I-ADE
reflux I-ADE
. O

The O
authors O
report O
a O
case O
of O
acute O
pancreatitis B-ADE
( O
AP O
) O
occurring O
in O
a O
patient O
under O
treatment O
with O
carbamazepine B-DRUG
( O
CBZ B-DRUG
) O
for O
post O
- O
traumatic O
petit O
mal O
epilepsy O
, O
and O
review O
the O
current O
literature O
of O
drug O
- O
induced O
AP O
. O

A O
few O
recent O
individual O
case O
reports O
have O
suggested O
that O
a O
myasthenic B-ADE
syndrome I-ADE
may O
be O
associated O
with O
statin B-DRUG
treatment O
, O
but O
this O
association O
is O
not O
well O
described O
. O

Acute B-ADE
syphilitic I-ADE
posterior I-ADE
placoid I-ADE
chorioretinitis I-ADE
following O
intravitreal O
triamcinolone B-DRUG
acetonide I-DRUG
injection O
. O

Data O
have O
been O
published O
regarding O
the O
possibility O
that O
tamoxifen B-DRUG
may O
be O
responsible O
for O
the O
subsequent O
development O
of O
carcinoma B-ADE
of I-ADE
the I-ADE
corpus I-ADE
uteri I-ADE
in O
these O
patients O
. O

Myotonia B-ADE
associated O
with O
sarcoidosis O
: O
marked O
exacerbation O
with O
pravastatin B-DRUG
. O

We O
describe O
two O
patients O
with O
rheumatoid O
factor O
- O
positive O
, O
polyarticular O
- O
onset O
juvenile O
rheumatoid O
arthritis O
in O
whom O
accelerated B-ADE
nodulosis I-ADE
developed O
during O
methotrexate B-DRUG
therapy O
. O

This O
progressed O
to O
tracheal B-ADE
compression I-ADE
with O
stridor O
after O
he O
had O
taken O
some O
aspirin B-DRUG
for O
relief O
of O
the O
neck O
pain O
. O

In O
this O
report O
, O
two O
cases O
of O
ET O
which O
evolved O
into O
AL B-ADE
without O
prior O
exposure O
to O
radiation O
or O
alkylating O
agents O
, O
and O
which O
were O
treated O
with O
long O
- O
term O
hydroxyurea B-DRUG
therapy O
, O
are O
described O
. O

Reflex B-ADE
sympathetic I-ADE
dystrophy I-ADE
syndrome I-ADE
in O
renal O
transplanted O
patients O
under O
immunosuppression O
with O
tacrolimus B-DRUG
. O

Brugada B-ADE
type I-ADE
electrocardiographic I-ADE
changes I-ADE
induced O
by O
concomitant O
use O
of O
lithium B-DRUG
and O
propafenone B-DRUG
in O
patient O
with O
Wolff O
- O
Parkinson O
- O
White O
syndrome O
. O

CONCLUSIONS O
: O
There O
was O
a O
temporal O
relationship O
between O
the O
onset O
of O
nonconvulsive B-ADE
status I-ADE
epilepticus I-ADE
and O
initiation O
of O
ifosfamide B-DRUG
infusion O
. O

Suxamethonium B-DRUG
apnoea B-ADE
terminated O
with O
commercial O
serumcholinesterase O
. O

The O
purpose O
of O
this O
study O
was O
to O
examine O
the O
incidence O
and O
cause O
of O
Clostridium B-ADE
difficile I-ADE
colitis I-ADE
occurring O
after O
cisplatin B-DRUG
- O
based O
combination O
chemotherapy O
in O
ovarian O
cancer O
patients O
. O

Linezolid B-DRUG
- O
induced O
dyserythropoiesis B-ADE
: O
chloramphenicol O
toxicity O
revisited O
. O

Rifampin B-DRUG
- O
induced O
hypothyroidism B-ADE
without O
underlying O
thyroid O
disease O
. O

CONCLUSIONS O
: O
Clinicians O
should O
be O
aware O
that O
Crohn B-ADE
's I-ADE
disease I-ADE
is O
a O
potential O
novel O
adverse O
drug O
effect O
of O
Copaxone B-DRUG
. O

Severe B-ADE
acidosis I-ADE
from O
acetazolamide B-DRUG
in O
a O
diabetic O
patient O
. O

Gold B-DRUG
- I-DRUG
salt I-DRUG
therapy O
may O
result O
in O
damage B-ADE
to I-ADE
proximal I-ADE
tubules I-ADE
that O
leak O
renal O
tubular O
antigens O
, O
which O
in O
turn O
complex O
with O
autoantibody O
and O
produce O
an O
autoimmune O
membranous O
nephropathy O
. O

In O
the O
present O
paper O
, O
we O
describe O
two O
patients O
with O
active O
UC O
who O
developed O
a O
severe B-ADE
systemic I-ADE
CMV I-ADE
infection I-ADE
during O
a O
treatment O
with O
an O
oral O
microemulsion O
form O
of O
cyclosporine B-DRUG
. O

L B-DRUG
- I-DRUG
asparaginase I-DRUG
- O
induced O
posterior B-ADE
reversible I-ADE
encephalopathy I-ADE
syndrome O
during O
acute O
lymphoblastic O
leukemia O
treatment O
in O
children O
. O

Gold B-DRUG
nephropathy I-ADE
due O
to O
auranofin B-DRUG
obscured O
by O
tolmetin B-DRUG
pseudoproteinuria B-ADE
. O

Herein O
, O
we O
present O
a O
patient O
with O
severe O
and O
prolonged B-ADE
hypoglycemia I-ADE
after O
long O
- O
acting O
octreotide B-DRUG
treatment O
. O

A O
major O
limitation O
in O
the O
use O
of O
amphotericin B-DRUG
B I-DRUG
is O
its O
potential O
to O
cause O
nephrotoxicity B-ADE
. O

Tegaserod B-DRUG
- O
associated O
ischemic B-ADE
colitis I-ADE
. O

Agranulocytosis B-ADE
is O
a O
rare O
adverse O
effect O
associated O
with O
prolonged O
vancomycin B-DRUG
therapy O
, O
and O
is O
potentially O
serious O
, O
especially O
in O
end O
stage O
renal O
disease O
( O
ESRD O
) O
patients O
. O

A O
58-year O
- O
old O
woman O
with O
rheumatoid O
arthritis O
( O
RA O
) O
developed O
fever B-ADE
, O
skin B-ADE
eruptions I-ADE
, O
leukocytopenia B-ADE
, O
and O
thrombocytopenia B-ADE
, O
3 O
weeks O
after O
treatment O
with O
sulfasalazine B-DRUG
. O

Two O
cases O
of O
sirolimus B-DRUG
- O
associated O
pneumonitis B-ADE
have O
been O
reported O
after O
cardiac O
transplantation O
. O

Seizures B-ADE
and O
transient B-ADE
blindness I-ADE
following O
intravenous O
pulse O
methylprednisolone B-DRUG
in O
children O
with O
primary O
glomerulonephritis O
. O

In O
addition O
, O
ethambutol B-DRUG
rarely O
causes O
visual B-ADE
loss I-ADE
during O
the O
early O
period O
or O
when O
given O
at O
lower O
doses O
. O

When O
the O
acute O
manic O
state O
is O
characterized O
by O
marked O
psychotic B-ADE
symptoms I-ADE
and O
intense B-ADE
anxiety I-ADE
, O
it O
may O
be O
associated O
with O
increased O
vulnerability O
to O
the O
development O
of O
severe O
lithium B-DRUG
neurotoxicity B-ADE
. O

CONCLUSION O
: O
Although O
a O
definite O
association O
has O
not O
been O
proven O
, O
clinicians O
should O
be O
aware O
of O
the O
possibility O
of O
agranulocytosis B-ADE
while O
using O
quetiapine B-DRUG
. O

We O
report O
a O
45-year O
- O
old O
psoriasis O
patient O
who O
developed O
eruptive B-ADE
mollusca I-ADE
contagiosa I-ADE
during O
an O
antipsoriatic O
treatment O
with O
efalizumab B-DRUG
. O

After O
receiving O
3 O
doses O
of O
ifosfamide B-DRUG
/ O
mesna B-DRUG
, O
she O
was O
found O
to O
be O
unresponsive B-ADE
. O

We O
report O
a O
case O
of O
chronic O
use O
of O
HCQ B-DRUG
associated O
with O
torsade B-ADE
de I-ADE
pointes I-ADE
. O

CONCLUSION O
: O
Severe O
and O
sustained B-ADE
ocular I-ADE
hypertension I-ADE
may O
occur O
after O
intravitreal O
ranibizumab B-DRUG
. O

Cushing B-ADE
's I-ADE
syndrome I-ADE
persisted O
more O
than O
6 O
months O
while O
TCA B-DRUG
concentrations O
remained O
detectable O
for O
at O
least O
80 O
days O
. O

Secondary B-ADE
hyperparathyroidism I-ADE
in O
certain O
patients O
with O
lithium B-DRUG
nephrotoxicity B-ADE
is O
also O
possible O
. O

Hepatolithiasis B-ADE
( O
intrahepatic O
stone O
) O
during O
octreotide B-DRUG
therapy O
for O
acromegaly O
: O
a O
case O
report O
. O

We O
report O
on O
a O
patient O
with O
an O
embryonal O
teratocarcinoma O
of O
the O
testicle O
who O
had O
the O
syndrome O
of O
inappropriate B-ADE
secretion I-ADE
of I-ADE
antidiuretic I-ADE
hormone I-ADE
after O
receiving O
a O
high O
dose O
of O
vinblastine B-DRUG
. O

We O
describe O
a O
73-year O
- O
old O
woman O
who O
developed O
serious O
systemic B-ADE
vasculitis I-ADE
with O
associated O
thrombocytopenia B-ADE
in O
the O
course O
of O
treatment O
with O
cladribine B-DRUG
. O

A O
54-year O
- O
old O
man O
developed O
TEN B-ADE
4 O
weeks O
after O
beginning O
lamotrigine B-DRUG
for O
complex O
partial O
seizures O
related O
to O
a O
glioblastoma O
multiforme O
brain O
tumor O
. O

Two O
patients O
with O
bipolar O
affective O
disorder O
and O
a O
history O
of O
bronchospastic O
phenomena O
experienced O
tremor B-ADE
during O
lithium B-DRUG
carbonate I-DRUG
therapy O
. O

These O
cases O
were O
considered O
unusual O
in O
light O
of O
the O
short O
delay O
of O
their O
onset O
after O
initiation O
of O
immunosuppressive O
therapy O
and O
their O
fulminant O
course O
: O
3 O
of O
these O
patients O
died B-ADE
of O
PCP O
occurring O
during O
the O
first O
month O
of O
treatment O
with O
prednisone B-DRUG
. O

Two O
days O
after O
administration O
of O
Kalimate B-DRUG
enema O
, O
he O
had O
profuse B-ADE
hematochezia I-ADE
, O
and O
a O
sigmoidoscopy O
showed O
diffuse O
colonic B-ADE
mucosal I-ADE
necrosis I-ADE
in I-ADE
the I-ADE
rectum I-ADE
and O
sigmoid O
colon O
. O

Colchicine B-DRUG
- O
induced O
rhabdomyolysis B-ADE
. O

Acute B-ADE
pancreatitis I-ADE
associated O
with O
danazol B-DRUG
treatment O
for O
endometriosis O
. O

Nevertheless O
, O
the O
coagulopathy B-ADE
seemed O
to O
be O
most O
closely O
associated O
with O
the O
administration O
of O
the O
cephalosporin B-DRUG
. O

Favorable O
outcome O
of O
de O
novo O
hepatitis B-ADE
B I-ADE
infection I-ADE
after O
liver O
transplantation O
with O
lamivudine B-DRUG
and O
adefovir B-DRUG
therapy O
. O

Although O
visual O
hallucinations O
have O
not O
been O
reported O
as O
an O
adverse O
effect O
of O
this O
agent O
, O
we O
describe O
three O
patients O
who O
experienced O
complex O
visual B-ADE
hallucinations I-ADE
and O
altered B-ADE
mental I-ADE
status I-ADE
after O
zonisamide B-DRUG
treatment O
was O
begun O
or O
its O
dosage O
increased O
. O

Transient B-ADE
hemiparesis I-ADE
caused O
by O
phenytoin B-DRUG
toxicity O
. O

RESULTS O
: O
Both O
patients O
experienced O
a O
previously O
unreported O
side O
effect O
-- O
falling B-ADE
backward I-ADE
-- O
associated O
with O
bupropion B-DRUG
use O
. O

Rhabdomyolysis B-ADE
caused O
by O
tocolysis O
with O
oral O
ritodrine B-DRUG
hydrochloride I-DRUG
in O
a O
pregnant O
patient O
with O
myotonic O
dystrophy O
. O

RESULTS O
: O
A O
34-year O
- O
old O
man O
acquired O
visual B-ADE
field I-ADE
defects I-ADE
and O
severe B-ADE
vision I-ADE
loss I-ADE
in O
both O
eyes O
after O
intravitreal O
injection O
of O
triamcinolone B-DRUG
for O
diabetic O
macular O
edema O
. O

We O
review O
the O
literature O
on O
previously O
reported O
cases O
of O
cutaneous B-ADE
necrosis I-ADE
after O
injection O
of O
standard O
interferon B-DRUG
alfa I-DRUG
or O
pegylated B-DRUG
interferon I-DRUG
alfa-2b I-DRUG
and O
discuss O
the O
different O
pathophysiologic O
mechanisms O
that O
might O
be O
involved O
. O

We O
report O
a O
case O
of O
glaucoma B-ADE
induced O
by O
doxetaxel B-DRUG
therapy O
for O
metastatic O
breast O
cancer O
. O

A O
patient O
receiving O
vancomycin B-DRUG
for O
a O
serious O
staphylococcal O
infection O
had O
a O
lupus B-ADE
- I-ADE
like I-ADE
syndrome I-ADE
characterized O
by O
a O
malar B-ADE
rash I-ADE
, O
pain B-ADE
and O
erythema B-ADE
of I-ADE
the I-ADE
cartilage I-ADE
of I-ADE
both I-ADE
ears I-ADE
, O
and O
tender B-ADE
erythematous I-ADE
and O
hemorrhagic B-ADE
lesions I-ADE
of I-ADE
the I-ADE
finger I-ADE
tips I-ADE
. O

We O
present O
a O
pediatric O
patient O
with O
leukemia O
and O
a O
severe O
, O
L B-DRUG
- I-DRUG
asparaginase I-DRUG
- O
induced O
necrotizing B-ADE
pancreatitis I-ADE
, O
treated O
successfully O
with O
percutaneous O
drainage O
used O
to O
flush O
the O
infected O
necrotic O
parts O
. O

Lithium B-DRUG
therapy O
was O
discontinued O
because O
of O
poor O
compliance O
to O
the O
medication O
and O
intolerable O
polyuria B-ADE
. O

Until O
additional O
data O
are O
available O
, O
if O
intravenous O
acyclovir B-DRUG
is O
administered O
concurrently O
with O
lithium O
, O
we O
recommend O
closely O
monitoring O
patients O
for O
signs O
of O
lithium B-DRUG
toxicity I-ADE
and O
measuring O
serum O
lithium O
levels O
every O
second O
or O
third O
day O
. O

We O
have O
safely O
used O
recombinant O
factor O
VIIa O
to O
treat O
bleeding O
in O
the O
immediate O
and O
long O
- O
term O
period O
following O
PCC B-DRUG
- O
related O
MI B-ADE
. O

A O
combination O
of O
behavioural O
and O
cognitive O
adverse O
effects O
is O
illustrated O
in O
this O
case O
report O
of O
a O
recurrent O
triazolam B-DRUG
- O
induced O
eating B-ADE
disorder I-ADE
. O

We O
report O
a O
patient O
with O
inoperable O
pancreatic O
cancer O
who O
developed O
gastrointestinal B-ADE
bleeding I-ADE
secondary O
to O
radiation B-ADE
- I-ADE
recall I-ADE
related O
to O
gemcitabine B-DRUG
and O
review O
literature O
. O

We O
evaluated O
a O
patient O
who O
developed O
a O
psychotic B-ADE
disorder I-ADE
after O
4 O
months O
of O
isoniazid B-DRUG
prophylaxis O
for O
a O
positive O
tuberculosis O
tine O
test O
. O

There O
have O
been O
several O
reported O
cases O
of O
omeprazole B-DRUG
- O
induced O
AIN B-ADE
. O

Extra O
caution O
should O
be O
taken O
in O
using O
octreotide B-DRUG
or O
its O
long O
- O
acting O
analog O
in O
patients O
otherwise O
predisposed O
to O
intrahepatic B-ADE
bile I-ADE
stasis I-ADE
. O

A O
child O
in O
whom O
a O
phenobarbital B-DRUG
hypersensitivity B-ADE
drug O
reaction O
developed O
which O
consisted O
of O
fever B-ADE
, O
a B-ADE
pruritic I-ADE
desquamating I-ADE
erythrodermic I-ADE
rash I-ADE
, O
alopecia B-ADE
, O
icterus B-ADE
, O
protein B-ADE
- I-ADE
losing I-ADE
enteropathy I-ADE
, O
myositis B-ADE
, O
and O
nephritis B-ADE
, O
is O
described O
. O

Vision B-ADE
declined I-ADE
after O
treatment O
with O
methylprednisolone B-DRUG
, O
after O
which O
fundus O
examination O
became O
consistent O
with O
progressive O
outer O
retinal O
necrosis O
. O

Horner B-ADE
's I-ADE
syndrome I-ADE
and O
demyelinating B-ADE
peripheral I-ADE
neuropathy I-ADE
caused O
by O
high O
- O
dose O
cytosine B-DRUG
arabinoside I-DRUG
. O

Although O
they O
had O
complex O
medical O
problems O
, O
the O
high O
serum O
concentrations O
of O
ampicillin B-DRUG
at O
the O
time O
of O
seizures O
without O
their O
recurrence O
after O
discontinuing O
the O
antibiotic O
suggest O
that O
the O
seizures B-ADE
were O
related O
to O
the O
ampicillin B-DRUG
therapy O
. O

A O
56-year O
- O
old O
Caucasian O
man O
who O
received O
concomitant O
chemotherapy O
and O
radiation O
for O
head O
and O
neck O
cancer O
developed O
fever B-ADE
concurrent O
with O
the O
administration O
of O
amifostine B-DRUG
. O

We O
report O
a O
case O
of O
Sweet B-ADE
's I-ADE
syndrome I-ADE
in O
association O
with O
sargramostim B-DRUG
treatment O
following O
chemotherapy O
for O
acute O
myelogenous O
leukemia O
. O

Life O
- O
threatening O
hyperkalemia B-ADE
induced O
by O
arginine B-DRUG
. O

Risperidone B-DRUG
- O
induced O
obsessive B-ADE
- I-ADE
compulsive I-ADE
symptoms I-ADE
in O
two O
children O
. O

Doxycycline B-DRUG
- O
induced O
hypoglycemia B-ADE
in O
a O
nondiabetic O
young O
man O
. O

We O
conclude O
that O
MB O
is O
an O
effective O
treatment O
for O
ifosfamide B-DRUG
- I-ADE
induced I-ADE
encephalopathy I-ADE
. O

Stroke B-ADE
- I-ADE
like I-ADE
syndrome I-ADE
after O
gold B-DRUG
sodium I-DRUG
thiomalate I-DRUG
induced O
vasomotor B-ADE
reaction I-ADE
. O

To O
our O
knowledge O
, O
these O
cases O
are O
the O
first O
published O
reports O
of O
lovastatin B-DRUG
- O
induced O
rhabdomyolysis B-ADE
associated O
with O
azithromycin B-DRUG
and O
clarithromycin B-DRUG
. O

METHODS O
: O
A O
case O
is O
presented O
of O
a O
45-year O
- O
old O
woman O
on O
prolonged O
gemcitabine B-DRUG
treatment O
for O
ovarian O
cancer O
who O
developed O
HUS B-ADE
and O
recovered O
after O
drug O
discontinuation O
. O

The O
failure O
of O
therapy O
with O
disopyramide O
and O
mexiletine O
to O
reproduce O
this O
observation O
suggests O
either O
a O
previously O
unreported O
electrophysiologic B-ADE
effect I-ADE
of O
, O
or O
idiosyncratic O
response O
to O
, O
procainamide B-DRUG
. O

Scleroderma B-ADE
- I-ADE
like I-ADE
reaction I-ADE
induced O
by O
uracil B-DRUG
- I-DRUG
tegafur I-DRUG
( O
UFT B-DRUG
) O
, O
a O
second O
- O
generation O
anticancer O
agent O
. O

OBJECTIVE O
: O
We O
report O
a O
case O
of O
cutaneous B-ADE
KS I-ADE
lesions I-ADE
in O
a O
patient O
affected O
by O
CML O
treated O
with O
imatinib B-DRUG
. O

Torsade B-ADE
de I-ADE
pointes I-ADE
represents O
a O
potential O
complication O
of O
chronic O
amiodarone B-DRUG
therapy O
. O

Tetany B-ADE
in O
a O
child O
with O
AIDS O
receiving O
intravenous O
tobramycin B-DRUG
. O

A O
patient O
with O
chronic O
myelomonocytic O
leukemia O
developed O
drug O
- O
induced O
pulmonary B-ADE
toxicity I-ADE
after O
using O
low O
dose O
oral O
etoposide B-DRUG
. O

In O
2 O
of O
the O
3 O
cases O
the O
patients O
were O
also O
taking O
lithium B-DRUG
carbonate I-DRUG
and O
beta O
- O
blockers O
, O
both O
of O
which O
could O
have O
contributed O
to O
the O
incontinence B-ADE
. O

Calcipotriol B-DRUG
( O
Daivonex O
R O
; O
Leo O
Pharmaceuticals O
, O
Zurich O
, O
Switzerland O
) O
may O
cause O
irritation B-ADE
of I-ADE
the I-ADE
skin I-ADE
, O
whereas O
allergic B-ADE
reactions I-ADE
are O
less O
common O
. O

Two O
children O
, O
1 O
with O
idiopathic O
nephrotic O
syndrome O
and O
1 O
with O
endo O
- O
extracapillary O
glomerulonephritis O
, O
presented O
an O
episode O
of O
seizures B-ADE
and O
transient B-ADE
blindness I-ADE
at O
different O
times O
after O
i.v O
. O
pulse O
methylprednisolone B-DRUG
( O
IVPMP O
) O
treatment O
. O

A O
case O
of O
SIADH B-ADE
associated O
with O
desipramine B-DRUG
treatment O
in O
an O
elderly O
depressed O
woman O
is O
described O
. O

Leiomyosarcoma B-ADE
in O
urinary O
bladder O
after O
cyclophosphamide B-DRUG
therapy O
for O
retinoblastoma O
and O
review O
of O
bladder O
sarcomas O
. O

CONCLUSION O
: O
Patients O
with O
insulin B-DRUG
allergy O
may O
not O
have O
complete O
resolution O
of O
their O
symptoms O
after O
standard O
desensitization O
, O
particularly O
those O
patients O
with O
concomitant O
protamine B-ADE
allergy I-ADE
. O

Animals O
treated O
with O
HAL B-DRUG
showed O
a O
highly O
significant B-ADE
32%-46 I-ADE
% I-ADE
loss I-ADE
of I-ADE
tyrosine I-ADE
hydroxylase I-ADE
( I-ADE
TH I-ADE
) I-ADE
immunoreactive I-ADE
neurons I-ADE
in O
the O
substantia O
nigra O
, O
and O
20 O
% O
contraction O
of O
the O
TH O
stained O
dendritic O
arbour O
. O

Possible O
heart B-ADE
failure I-ADE
exacerbation I-ADE
associated O
with O
rosiglitazone B-DRUG
: O
case O
report O
and O
literature O
review O
. O

Keratitis B-ADE
in O
methamphetamine B-DRUG
abusers O
. O

In O
deciding O
if O
tamoxifen B-DRUG
therapy O
is O
warranted O
, O
all O
potentially O
life O
- O
threatening O
adverse O
events O
associated O
with O
tamoxifen B-DRUG
should O
be O
considered O
, O
including O
endometrial B-ADE
adenocarcinoma I-ADE
or O
uterine B-ADE
sarcoma I-ADE
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
toxin B-ADE
- I-ADE
positive I-ADE
Clostridium I-ADE
difficile I-ADE
- I-ADE
induced I-ADE
colitis I-ADE
( O
CDIC O
) O
after O
use O
of O
clindamycin B-DRUG
phosphate I-DRUG
vaginal O
cream O
. O

We O
report O
3 O
cases O
of O
HIV-1 O
infected O
patients O
who O
experienced O
symptomatic O
angiolipomas B-ADE
shortly O
after O
starting O
antiretroviral O
therapy O
including O
the O
protease O
inhibitor O
indinavir B-DRUG
. O

We O
conclude O
that O
( O
a O
) O
cyclophosphamide B-DRUG
is O
a O
human B-ADE
teratogen I-ADE
, O
( O
b O
) O
a O
distinct O
phenotype O
exists O
, O
and O
( O
c O
) O
the O
safety O
of O
CP O
in O
pregnancy O
is O
in O
serious O
question O
. O

Lethal B-ADE
anuria I-ADE
complicating O
high O
dose O
ifosfamide B-DRUG
chemotherapy O
in O
a O
breast O
cancer O
patient O
with O
an O
impaired O
renal O
function O
. O

A O
34-year O
- O
old O
lady O
developed O
a O
constellation B-ADE
of I-ADE
dermatitis I-ADE
, O
fever B-ADE
, O
lymphadenopathy B-ADE
and O
hepatitis B-ADE
, O
beginning O
on O
the O
17th O
day O
of O
a O
course O
of O
oral O
sulphasalazine B-DRUG
for O
sero O
- O
negative O
rheumatoid O
arthritis O
. O

Gemcitabine B-DRUG
- O
induced O
pulmonary B-ADE
toxicity I-ADE
is O
usually O
a O
dramatic O
condition O
. O

These O
findings O
support O
previous O
studies O
that O
showed O
that O
the O
use O
of O
aspirin B-DRUG
during O
the O
antecedent O
illness O
may O
be O
a O
risk O
factor O
for O
the O
development O
of O
RS B-ADE
. O

In O
this O
article O
, O
we O
describe O
another O
case O
of O
subcutaneous B-ADE
changes I-ADE
following O
repeated O
glatiramer B-DRUG
acetate I-DRUG
injection O
, O
presented O
as O
localized B-ADE
panniculitis I-ADE
in O
the O
area O
around O
the O
injection O
sites O
, O
in O
a O
46-year O
- O
old O
female O
patient O
who O
was O
treated O
with O
glatiramer B-DRUG
acetate I-DRUG
for O
18 O
months O
. O

A O
patient O
with O
alcoholic O
cerebellar O
degeneration O
had O
periodic B-ADE
alternating I-ADE
nystagmus I-ADE
during O
a O
period O
of O
phenytoin B-DRUG
intoxication O
. O

We O
present O
the O
management O
of O
agranulocytosis B-ADE
and O
neutropenic B-ADE
sepsis I-ADE
secondary O
to O
carbimazole B-DRUG
with O
recombinant O
human O
granulocyte O
colony O
stimulating O
factor O
( O
G O
- O
CSF O
) O
. O

Peripheral B-ADE
neuropathy I-ADE
associated O
with O
capecitabine B-DRUG
. O

Duodenal B-ADE
ulceration I-ADE
: O
a O
complication O
of O
tolazoline B-DRUG
therapy O
. O

According O
to O
the O
literature O
, O
chlorambucil B-DRUG
central B-ADE
nervous I-ADE
toxicity I-ADE
is O
found O
almost O
exclusively O
in O
childhood O
nephrotic O
syndrome O
. O

Captopril B-DRUG
- O
induced O
bone B-ADE
marrow I-ADE
suppression I-ADE
in O
two O
cardiac O
patients O
with O
trisomy O
21 O
. O

Two O
cases O
of O
mequitazine B-DRUG
- O
induced O
photosensitivity B-ADE
reactions I-ADE
. O

Severe O
bleomycin B-DRUG
lung B-ADE
toxicity I-ADE
: O
reversal O
with O
high O
dose O
corticosteroids O
. O

Poorly O
controlled O
hypertension O
in O
a O
painter O
with O
chronic O
lead B-DRUG
toxicity I-ADE
. O

Additive B-ADE
pulmonary I-ADE
toxicity I-ADE
with O
melphalan B-DRUG
and O
busulfan B-DRUG
therapy O
. O

A O
55-yr O
- O
old O
man O
developed O
prolonged B-ADE
jaundice I-ADE
and O
sicca B-ADE
complex I-ADE
after O
a O
course O
of O
thiabendazole B-DRUG
therapy O
. O

Rapid O
onset O
of O
muscle B-ADE
weakness I-ADE
( O
rhabdomyolysis B-ADE
) O
associated O
with O
the O
combined O
use O
of O
simvastatin B-DRUG
and O
colchicine B-DRUG
. O

Extensive O
immunological O
investigations O
were O
performed O
in O
a O
patient O
with O
definite O
seronegative O
rheumatoid O
arthritis O
who O
developed O
hypogammaglobulinemia B-ADE
in O
the O
course O
of O
gold B-DRUG
therapy O
. O

In O
case O
1 O
, O
a O
total O
daily O
dose O
of O
25 O
mg O
sertraline B-DRUG
, O
with O
nondetectable O
sertraline B-DRUG
and O
desmethylsertraline B-DRUG
blood O
levels O
, O
resulted O
in O
a O
doubling B-ADE
of I-ADE
the I-ADE
lamotrigine B-DRUG
blood I-ADE
level I-ADE
with O
symptoms B-ADE
of I-ADE
toxicity I-ADE
. O

Metamizole B-DRUG
, O
a O
nonsteroidal O
antiinflammatory O
agent O
, O
is O
prohibited O
in O
the O
United O
States O
because O
of O
the O
risk O
of O
agranulocytosis B-ADE
but O
is O
widely O
used O
in O
Mexico O
and O
other O
countries O
. O

Our O
patient O
had O
headache B-ADE
, O
mild B-ADE
fever I-ADE
, O
nausea B-ADE
, O
vomiting B-ADE
, O
rash B-ADE
, O
and O
eosinophilia B-ADE
after O
3 O
weeks O
of O
disulfiram B-DRUG
therapy O
. O

An O
unusual O
presentation O
of O
spontaneous O
sub B-ADE
- I-ADE
conjunctival I-ADE
haematoma I-ADE
in O
a O
patient O
receiving O
warfarin B-DRUG
. O

It O
carries O
a O
well O
- O
known O
risk O
of O
neutropenia B-ADE
and O
agranulocytosis B-ADE
, O
which O
necessitates O
the O
immediate O
discontinuation O
of O
clozapine B-DRUG
. O

Ciprofloxacin B-DRUG
is O
one O
drug O
that O
has O
been O
reported O
to O
cause O
interstitial B-ADE
nephritis I-ADE
. O

Although O
both O
the O
spontaneous O
occurrence O
of O
SLE B-ADE
and O
the O
psychosis O
as O
a O
sign O
of O
CNS O
involvement O
of O
SLE B-ADE
can O
not O
be O
excluded O
, O
SLE B-ADE
could O
be O
considered O
as O
an O
adverse O
effect O
of O
carbamazepine B-DRUG
. O

A O
17-year O
- O
old O
female O
patient O
who O
had O
been O
taking O
oral O
minocycline B-DRUG
( O
50 O
mg O
twice O
daily O
) O
for O
3 O
weeks O
for O
acne O
developed O
an O
eruption B-ADE
that O
progressed O
to O
an O
exfoliative B-ADE
dermatitis I-ADE
. O

Though O
they O
are O
generally O
considered O
safe O
, O
there O
have O
been O
a O
few O
reports O
of O
myocardial B-ADE
infarction I-ADE
and O
stroke B-ADE
associated O
with O
triptan B-DRUG
use O
. O

A O
35-year O
- O
old O
female O
with O
borderline O
lepromatous O
( O
BL O
) O
leprosy O
who O
suffered O
from O
dapsone B-DRUG
- O
induced O
erythroderma B-ADE
is O
reported O
. O

We O
describe O
the O
side O
effects O
of O
5-FU B-DRUG
in O
a O
colon O
cancer O
patient O
who O
suffered O
severe B-ADE
mucositis I-ADE
, O
desquamating O
dermatitis O
, O
prolonged B-ADE
myelosuppression I-ADE
, O
and O
neurologic B-ADE
toxicity I-ADE
that O
required O
admission O
to O
the O
intensive O
care O
unit O
. O

Two O
patients O
with O
rheumatoid O
arthritis O
developed O
evidence O
of O
hepatotoxicity B-ADE
while O
receiving O
D B-DRUG
- I-DRUG
penicillamine I-DRUG
. O

Gold B-DRUG
- O
induced O
pneumonitis B-ADE
is O
a O
rare O
complication O
of O
gold O
salt O
therapy O
. O

Gemcitabine B-DRUG
- O
associated O
hemolytic B-ADE
- I-ADE
uremic I-ADE
syndrome I-ADE
. O

Massive B-ADE
subfascial I-ADE
hematoma I-ADE
after O
alteplase B-DRUG
therapy O
for O
acute O
myocardial O
infarction O
. O

She O
was O
admitted O
following O
a O
fall O
and O
, O
after O
being O
given O
metoclopramide B-DRUG
, O
developed O
movement B-ADE
disorder I-ADE
and O
a O
period O
of O
unresponsiveness B-ADE
. O

PURPOSE O
: O
The O
case O
of O
a O
patient O
who O
developed O
aseptic B-ADE
meningitis I-ADE
, O
hemolytic B-ADE
anemia I-ADE
, O
hepatitis B-ADE
, O
and O
orthostatic B-ADE
hypotension I-ADE
simultaneously O
during O
treatment O
with O
trimethoprim B-DRUG
- O
sulfamethoxazole B-DRUG
is O
described O
. O

To O
our O
knowledge O
this O
is O
the O
first O
report O
that O
demonstrates O
histological B-ADE
abnormalities I-ADE
of I-ADE
the I-ADE
glomerulus I-ADE
associated O
with O
postoperative O
IFN B-DRUG
- I-DRUG
beta I-DRUG
therapy O
for O
the O
malignant O
melanoma O
. O

Several O
hypersensitivity B-ADE
reactions O
to O
cloxacillin B-DRUG
have O
been O
reported O
, O
although O
IgE B-ADE
- I-ADE
mediated I-ADE
allergic I-ADE
reactions I-ADE
to O
the O
drug O
are O
rare O
and O
there O
is O
little O
information O
about O
possible O
tolerance O
to O
other O
semisynthetic O
penicillins O
or O
cephalosporins O
in O
patients O
with O
cloxacillin O
allergy O
. O

OBJECTIVE O
: O
To O
test O
the O
hypothesis O
that O
tumor O
necrosis O
factor O
( O
TNF O
) O
- O
alpha O
may O
mediate O
the O
loss O
and O
the O
dedifferentiation O
of O
subcutaneous O
fat O
tissue O
in O
the O
insulin B-DRUG
- O
induced O
lipoatrophies B-ADE
of O
a O
diabetic O
patient O
who O
presented O
extensive O
lesions O
. O

The O
most O
common O
complication O
of O
warfarin B-DRUG
use O
is O
adverse O
bleeding B-ADE
. O

It O
was O
highly O
suspected O
that O
finasteride B-DRUG
was O
associated O
with O
the O
anterior B-ADE
subcapsular I-ADE
opacity I-ADE
on I-ADE
the I-ADE
lens I-ADE
, O
and O
the O
patient O
therefore O
discontinued O
use O
of O
finasteride B-DRUG
. O

Pulmonary B-ADE
toxicity I-ADE
with O
mefloquine B-DRUG
. O

Methylphenidate B-DRUG
( O
Ritalin B-DRUG
) O
- O
associated O
cataract B-ADE
and O
glaucoma B-ADE
. O

In O
the O
absence O
of O
mucositis O
or O
diarrhea O
, O
severe B-ADE
dermatologic I-ADE
toxicity I-ADE
following O
a O
single O
low O
dose O
of O
the O
drug O
suggests O
an O
' O
allergic O
' O
or O
acute B-ADE
hypersensitivity I-ADE
reaction I-ADE
to O
MTX B-DRUG
in O
this O
patient O
. O

A O
literature O
review O
revealed O
83 O
other O
reported O
cases O
of O
rifampicin B-DRUG
- O
induced O
renal B-ADE
insufficiency I-ADE
. O

We O
report O
the O
occurrence O
of O
spontaneous O
intracranial B-ADE
bleeding I-ADE
in O
an O
human O
immunodeficiency O
virus O
( O
HIV O
) O
- O
infected O
adolescent O
with O
hemophilia O
A O
who O
was O
receiving O
amprenavir B-DRUG
( O
APV O
) O
. O

The O
multiple B-ADE
comedones I-ADE
and O
ruptured B-ADE
epidermoid I-ADE
cysts I-ADE
are O
newly O
reported O
adverse O
effects O
of O
imiquimod B-DRUG
therapy O
. O

Amiodarone B-DRUG
- O
induced O
dysthyroidism B-ADE
. O

Multiple O
mechanisms O
for O
ciprofloxacin B-DRUG
- O
induced O
nephrotoxicity B-ADE
have O
been O
proposed O
. O

Here O
, O
we O
describe O
levofloxacin B-DRUG
- O
induced O
delirium B-ADE
with I-ADE
psychotic I-ADE
features I-ADE
in O
a O
relatively O
young O
, O
otherwise O
healthy O
female O
. O

Possible O
induction O
of O
diabetes B-ADE
by O
treatment O
of O
hypertension O
with O
indapamide B-DRUG
( O
with O
four O
case O
reports O
) O
. O

There O
are O
major O
side O
effects O
of O
anastrozole B-DRUG
including O
decrease B-ADE
in I-ADE
both I-ADE
lumbar I-ADE
spine I-ADE
and O
total O
hip O
bone O
mineral O
density O
, O
increase B-ADE
in I-ADE
the I-ADE
incidence I-ADE
of I-ADE
all I-ADE
bone I-ADE
fractures I-ADE
( O
especially O
fractures O
of O
spine O
, O
hip O
and O
wrist O
) O
, O
joint B-ADE
disorders I-ADE
and O
increase B-ADE
in I-ADE
the I-ADE
cholesterol I-ADE
level I-ADE
. O

CASE O
SUMMARY O
: O
An O
80-year O
- O
old O
white O
female O
, O
followed O
up O
at O
the O
Memory O
Clinic O
for O
mild B-ADE
cognitive I-ADE
impairment I-ADE
, O
had O
been O
taking O
propafenone B-DRUG
900 O
mg O
/ O
d O
for O
> O
10 O
years O
for O
paroxysmal O
atrial O
fibrillation O
without O
adverse O
effects O
. O

We O
present O
a O
20-year O
- O
old O
woman O
with O
Basedow O
- O
Graves O
' O
disease O
who O
developed O
PTU B-DRUG
- O
induced O
fulminant B-ADE
hepatitis I-ADE
, O
which O
progressed O
to O
acute O
hepatic O
failure O
with O
grade O
III O
hepatic O
encephalopathy O
. O

The O
knowledge O
concerning O
VGB B-DRUG
- O
associated O
visual B-ADE
dysfunction I-ADE
in O
pediatric O
patients O
, O
particularly O
in O
those O
who O
have O
been O
exposed O
to O
VGB O
in O
utero O
is O
limited O
. O

In O
addition O
, O
loading O
with O
one O
low O
oral O
dose O
of O
serine B-DRUG
produced O
psychotic B-ADE
symptoms I-ADE
5 O
h O
later O
which O
lasted O
3 O
- O
6 O
h O
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
ciprofloxacin B-DRUG
- O
induced O
psychosis B-ADE
and O
to O
discuss O
occurrence O
rates O
, O
risk O
factors O
, O
possible O
etiologies O
, O
preventive O
measures O
, O
and O
treatment O
courses O
for O
this O
adverse O
reaction O
. O

Pamidronate O
therapy O
should O
be O
considered O
in O
patients O
with O
hypercalcemia B-ADE
secondary O
to O
acute B-ADE
vitamin B-DRUG
D I-DRUG
poisoning I-ADE
. O

One O
of O
the O
side O
- O
effects O
of O
intravitreal O
triamcinolone B-DRUG
is O
the O
development O
of O
cataract B-ADE
, O
and O
it O
is O
known O
that O
cataract O
extraction O
can O
exacerbate O
macular O
degeneration O
. O

PURPOSE O
: O
To O
present O
a O
case O
of O
respiratory B-ADE
depression I-ADE
following O
the O
administration O
of O
nebulised O
morphine B-DRUG
. O

Cutaneous B-ADE
necrosis I-ADE
after O
injection O
of O
polyethylene O
glycol O
- O
modified O
interferon B-DRUG
alfa I-DRUG
. O

Well O
- O
known O
signs O
of O
methotrexate B-ADE
toxicity I-ADE
include O
bone B-ADE
marrow I-ADE
suppression I-ADE
and O
oral B-ADE
and I-ADE
gastrointestinal I-ADE
ulceration I-ADE
. O

Fulminant O
metoclopramide B-DRUG
induced O
neuroleptic B-ADE
malignant I-ADE
syndrome I-ADE
rapidly O
responsive O
to O
intravenous O
dantrolene O
. O

A O
25-year O
- O
old O
woman O
sought O
medical O
attention O
because O
of O
iliocaval O
manifestations O
of O
retroperitoneal B-ADE
fibrosis I-ADE
while O
she O
was O
taking O
methysergide B-DRUG
. O

Bronchiolitis B-ADE
obliterans I-ADE
with I-ADE
organizing I-ADE
pneumonia I-ADE
after O
rituximab B-DRUG
therapy O
for O
non O
- O
Hodgkin O
's O
lymphoma O
. O

Potential O
causes O
of O
methamphetamine B-DRUG
- O
related O
keratitis B-ADE
can O
be O
divided O
into O
four O
categories O
resulting O
from O
( O
a O
) O
direct O
pharmacologic O
and O
physical O
effects O
of O
methamphetamine O
; O
( O
b O
) O
the O
toxic B-ADE
effects I-ADE
of O
diluting O
or O
" O
cutting O
" O
agents O
such O
as O
lidocaine B-DRUG
and O
quinine B-DRUG
; O
( O
c O
) O
effects O
related O
to O
the O
route O
of O
drug O
administration O
( O
intravenous O
, O
inhalation O
, O
smoking O
) O
; O
and O
( O
d O
) O
manufacture O
- O
related O
effects O
of O
exposure O
to O
unintentional O
caustic O
contaminants O
in O
the O
final O
product O
. O

We O
report O
a O
case O
of O
senna B-DRUG
- O
induced O
cholestatic B-ADE
hepatitis I-ADE
which O
was O
not O
diagnosed O
at O
presentation O
. O

Primary O
CNS B-ADE
lymphoma I-ADE
complicating O
treatment O
of O
myasthenia O
gravis O
with O
mycophenolate B-DRUG
mofetil I-DRUG
. O

Cutaneous B-ADE
vasculitis I-ADE
secondary O
to O
ramipril B-DRUG
. O

We O
report O
a O
case O
of O
successful O
surgical O
management O
of O
arterial B-ADE
thrombosis I-ADE
after O
percutaneous O
thrombin B-DRUG
injection O
of O
a O
femoral O
artery O
pseudoaneurysm O
in O
a O
69-year O
- O
old O
woman O
. O

Acute B-ADE
vision I-ADE
loss I-ADE
after O
intravitreal O
injection O
of O
bevacizumab B-DRUG
( O
avastin B-DRUG
) O
associated O
with O
ocular B-ADE
ischemic I-ADE
syndrome I-ADE
. O

Hypoxemia O
improved O
during O
continuous O
tolazoline B-DRUG
infusion O
, O
but O
gastrointestinal B-ADE
bleeding I-ADE
occurred O
. O

CONCLUSIONS O
: O
This O
case O
suggests O
that O
losartan B-DRUG
can O
induce O
late O
- O
onset O
angioedema B-ADE
in O
patients O
with O
normal O
renal O
function O
and O
that O
the O
reaction O
can O
recur O
after O
initial O
resolution O
of O
the O
symptoms O
. O

We O
present O
the O
first O
case O
of O
WES B-ADE
in O
an O
infant O
born O
to O
a O
mother O
taking O
haloperidol B-DRUG
during O
her O
pregnancy O
. O

Studies O
performed O
10 O
years O
ago O
on O
25 O
patients O
with O
MTX B-DRUG
- O
induced O
liver B-ADE
cirrhosis I-ADE
indicated O
that O
this O
type O
of O
cirrhosis B-ADE
was O
not O
of O
an O
aggressive O
nature O
. O

A O
case O
of O
congestive B-ADE
heart I-ADE
failure I-ADE
in O
a O
child O
with O
Wilms O
' O
tumor O
treated O
Adriamycin B-DRUG
is O
presented O
and O
discussed O
. O

A O
47 O
year O
- O
old O
woman O
who O
had O
a O
4-year O
history O
of O
intramuscular O
pentazocine B-DRUG
injections O
in O
the O
lower O
extremities O
, O
developed O
gradual B-ADE
stiffness I-ADE
and O
weakness B-ADE
of I-ADE
the I-ADE
lower I-ADE
extremities I-ADE
. O

Gynecomastia B-ADE
associated O
with O
theophylline B-DRUG
. O

Conversely O
, O
diffuse B-ADE
interstitial I-ADE
pulmonary I-ADE
fibrosis I-ADE
should O
be O
considered O
in O
the O
differential O
diagnosis O
of O
patients O
receiving O
methotrexate B-DRUG
who O
develop O
bilateral B-ADE
pulmonary I-ADE
infiltrates I-ADE
seen O
on O
chest O
roentgenograms O
. O

Captopril B-DRUG
is O
known O
to O
be O
associated O
with O
dermatologic B-ADE
, I-ADE
hematologic I-ADE
, I-ADE
and I-ADE
pulmonary I-ADE
adverse I-ADE
effects I-ADE
. O

We O
conclude O
that O
while O
thrombocytopenia B-ADE
and O
schistocytosis B-ADE
can O
be O
seen O
in O
quinine B-DRUG
- O
associated O
TTP B-ADE
/ I-ADE
HUS I-ADE
, O
the O
pathophysiology O
seems O
to O
be O
distinct O
from O
that O
seen O
in O
most O
cases O
of O
idiopathic O
TTP O
( O
i.e. O
, O
severely O
decreased O
ADAMTS13 O
with O
an O
inhibitor O
) O
. O

2-CdA B-DRUG
typically O
causes O
a O
long O
- O
lasting O
state O
of O
immunodeficiency B-ADE
and O
the O
profound O
influence O
of O
this O
drug O
on O
the O
immune O
system O
has O
raised O
questions O
concerning O
the O
emergence O
of O
secondary B-ADE
neoplasms I-ADE
after O
its O
use O
. O

Tubulointerstitial B-ADE
nephritis I-ADE
induced O
by O
the O
leukotriene O
receptor O
antagonist O
pranlukast B-DRUG
. O

Large B-ADE
cerebral I-ADE
infarction I-ADE
during O
praziquantel B-DRUG
therapy O
in O
neurocysticercosis O
. O

Significant O
clinical O
improvement O
of O
the O
porphyria B-ADE
followed O
withdrawal O
of O
the O
diphenylhydantoin B-DRUG
. O

The O
temporal O
sequence O
of O
the O
respiratory B-ADE
insufficiency I-ADE
and O
the O
histopathology O
, O
when O
compared O
to O
the O
previous O
examples O
in O
the O
literature O
, O
suggest O
that O
cyclophosphamide B-DRUG
was O
aetiologically O
responsible O
for O
the O
lung B-ADE
disease I-ADE
. O

Transient O
trazodone B-DRUG
- O
induced O
hypomanic B-ADE
symptoms I-ADE
occurred O
in O
three O
depressed O
patients O
. O

The O
dose O
- O
limiting O
toxicity O
of O
KW-2149 B-DRUG
is O
pulmonary B-ADE
toxicity I-ADE
. O

CONCLUSIONS O
: O
Priapism B-ADE
is O
an O
uncommon O
but O
potentially O
serious O
adverse O
effect O
of O
zuclopenthixol B-DRUG
that O
practitioners O
, O
as O
with O
many O
other O
antipsychotics O
, O
should O
be O
aware O
of O
. O

Successful O
desensitization O
to O
high O
- O
dose O
methotrexate B-DRUG
after O
systemic B-ADE
anaphylaxis I-ADE
. O

Hence O
, O
hyperthyroidism B-ADE
induced O
by O
IFN B-DRUG
- I-DRUG
alpha I-DRUG
could O
correspond O
to O
the O
first O
phase O
of O
silent O
thyroiditis O
, O
to O
Graves O
' O
disease O
or O
to O
the O
succession O
of O
both O
. O

He O
had O
also O
developed O
elevated B-ADE
serum I-ADE
ammonia I-ADE
levels I-ADE
while O
on O
valproic B-DRUG
acid I-DRUG
. O

Heparin B-DRUG
- O
associated O
thrombocytopenia B-ADE
and O
thrombosis B-ADE
is O
a O
severe O
complication O
of O
systemic O
heparin B-DRUG
therapy O
. O

Tacrolimus B-DRUG
- O
induced O
HUS B-ADE
: O
an O
unusual O
cause O
of O
acute B-ADE
renal I-ADE
failure I-ADE
in O
nephrotic O
syndrome O
. O

The O
major O
side O
effect O
of O
infliximab B-DRUG
is O
infection B-ADE
. O

Clinical B-ADE
, I-ADE
spectroscopic I-ADE
, I-ADE
and I-ADE
imaging I-ADE
abnormalities I-ADE
resolved O
with O
discontinuation O
of O
metronidazole B-DRUG
. O

SLE B-ADE
receded O
after O
withdrawal O
of O
carbamazepine B-DRUG
and O
treatment O
with O
anti O
- O
inflammatory O
drugs O
. O

Heparin B-DRUG
- O
associated O
thrombocytopenia B-ADE
: O
successful O
therapy O
with O
the O
heparinoid O
Org O
10172 O
in O
a O
patient O
showing O
cross O
- O
reaction O
to O
LMW O
heparins O
. O

Alternating B-ADE
sinus I-ADE
rhythm I-ADE
and O
intermittent B-ADE
sinoatrial I-ADE
block I-ADE
induced O
by O
propranolol B-DRUG
. O

PURPOSE O
: O
To O
report O
a O
case O
of O
traumatic B-ADE
flap I-ADE
dehiscence I-ADE
and O
Enterobacter B-ADE
keratitis I-ADE
34 O
months O
after O
LASIK B-DRUG
. O

A O
67-year O
- O
old O
man O
developed O
diarrhea B-ADE
shortly O
after O
a O
10-day O
course O
of O
oral O
ampicillin B-DRUG
. O

However O
here O
we O
reported O
two O
patients O
, O
presenting O
with O
PD B-ADE
during O
high O
dose O
colchicine B-DRUG
treatment O
for O
familiar O
mediterranean O
fever O
( O
FMF O
) O
. O

A O
51-year O
- O
old O
man O
developed O
type B-ADE
1 I-ADE
diabetes I-ADE
mellitus I-ADE
following O
24 O
weeks O
of O
treatment O
with O
recombinant O
alpha-2b B-DRUG
peginterferon I-DRUG
plus O
ribavirin B-DRUG
for O
chronic O
hepatitis O
C O
. O

Native O
arterial B-ADE
thrombosis I-ADE
, O
though O
recognized O
as O
a O
severe O
complication O
of O
thrombin B-DRUG
injection O
, O
has O
not O
been O
well O
described O
in O
the O
literature O
. O

Recurrent O
septicemia B-ADE
with O
lethal B-ADE
outcome O
during O
and O
after O
cyclosporine B-DRUG
therapy O
in O
severe O
ulcerative O
colitis O
. O

Despite O
the O
low O
dosage O
of O
warfarin B-DRUG
, O
international O
normalized O
ratio O
( O
INR O
) O
was O
markedly O
elevated O
from O
1.15 O
to O
11.28 O
for O
only O
4 O
days O
, O
and O
bleeding B-ADE
symptoms I-ADE
concurrently O
developed O
. O

Nephrotic B-ADE
syndrome I-ADE
associated O
with O
interferon B-DRUG
- I-DRUG
beta-1b I-DRUG
therapy O
for O
multiple O
sclerosis O
. O

Fatal B-ADE
acute I-ADE
tubular I-ADE
necrosis I-ADE
occurred O
in O
1 O
patient O
in O
whom O
intravesical O
formalin B-DRUG
was O
used O
to O
control O
massive O
persistent O
hemorrhage O
from O
radiation O
cystitis O
. O

Digestive B-ADE
hemorrhage I-ADE
caused O
by O
a O
Meckel O
's O
diverticulum O
in O
a O
metformin B-DRUG
- O
treated O
patient O
: O
is O
there O
any O
connection O
? O

Increased B-ADE
ocular I-ADE
pressure I-ADE
in O
two O
patients O
with O
narrow O
angle O
glaucoma O
treated O
with O
venlafaxine B-DRUG
. O

A O
53-year O
- O
old O
male O
, O
without O
any O
prior O
history O
of O
psychosis O
, O
developed O
schizophrenia B-ADE
4 O
days O
after O
starting O
low O
- O
dose O
bromocriptine B-DRUG
therapy O
for O
a O
macroprolactinoma O
. O

We O
reviewed O
the O
literature O
in O
an O
attempt O
to O
characterize O
the O
pattern O
and O
predictors O
of O
TMP B-DRUG
/ O
SMX B-DRUG
- O
induced O
aseptic B-ADE
meningitis I-ADE
. O

CASE O
SUMMARY O
: O
A O
45-year O
- O
old O
HIV O
- O
positive O
man O
( O
CD4 O
+ O
count O
450 O
cells O
/ O
mm(3 O
) O
and O
history O
of O
AIDS O
- O
defining O
illness O
) O
presented O
with O
JHR B-ADE
after O
an O
initial O
intravenous O
dose O
of O
penicillin B-DRUG
G I-DRUG
for O
presumed O
neurosyphilis O
. O

A O
5-month O
- O
old O
infant O
became O
lethargic B-ADE
and O
poorly B-ADE
responsive I-ADE
after O
receiving O
1 O
drop O
of O
brimonidine B-DRUG
in O
each O
eye O
. O

Drug O
- O
induced O
mammary B-ADE
hyperplasias I-ADE
have O
been O
reported O
as O
rare O
complications O
of O
D B-DRUG
- I-DRUG
penicillamine I-DRUG
and O
Neothetazone B-DRUG
. O

Neuropathy B-ADE
is O
a O
significant O
side O
effect O
of O
thalidomide B-DRUG
therapy O
, O
which O
may O
limit O
its O
clinical O
use O
. O

After O
taking O
cholestyramine B-DRUG
II I-DRUG
sachets O
twice O
daily O
for O
two O
months O
she O
presented O
with O
lethargy B-ADE
, O
confusion B-ADE
and O
drowsiness B-ADE
. O

Hypoglycemia B-ADE
can O
be O
a O
serious O
side O
effect O
of O
etanercept B-DRUG
in O
patients O
already O
on O
antidiabetic O
medications O
known O
to O
cause O
hypoglycemia B-ADE
, O
such O
as O
sulfonylureas B-DRUG
, O
meglitinides B-DRUG
, O
and O
insulin B-DRUG
. O

The O
hepatic B-ADE
enzyme I-ADE
disturbances I-ADE
normalized O
after O
discontinuation O
of O
pegvisomant B-DRUG
. O

Despite O
these O
antithrombotic O
effects O
, O
the O
patient O
developed O
repeated O
venous B-ADE
thromboembolism I-ADE
during O
treatment O
with O
low O
- O
molecular O
- O
weight O
heparin B-DRUG
. O

According O
to O
the O
Naranjo O
adverse O
drug O
reaction O
probability O
scale O
, O
the O
likelihood O
that O
temozolomide B-DRUG
was O
responsible O
for O
the O
adverse O
drug O
reaction O
of O
fever B-ADE
was O
probable O
( O
score O
of O
6 O
) O
. O

We O
report O
the O
case O
of O
a O
woman O
who O
developed O
photo B-ADE
- I-ADE
onycholysis I-ADE
on O
multiple O
nails O
after O
uptake O
of O
olanzapine B-DRUG
. O

Spectral O
- O
domain O
optical O
coherence O
tomography O
and O
adaptive O
optics O
may O
detect O
hydroxychloroquine B-DRUG
retinal B-ADE
toxicity I-ADE
before O
symptomatic O
vision O
loss O
. O

The O
day O
after O
methotrexate B-DRUG
administration O
, O
the O
patient O
complained O
of O
severe B-ADE
back I-ADE
pain I-ADE
and O
urinary B-ADE
retention I-ADE
. O

Neurologic B-ADE
symptoms I-ADE
resolved O
after O
stopping O
CAP B-DRUG
for O
4 O
weeks O
in O
Patient O
A O
, O
with O
no O
recurrence O
after O
reinitiating O
CAP B-DRUG
alone O
at O
2000 O
mg O
/ O
m2 O
. O

Reversible O
methotrexate B-DRUG
- O
associated O
lymphoproliferative B-ADE
disorder I-ADE
resembling O
advanced O
gastric O
cancer O
in O
a O
patient O
with O
rheumatoid O
arthritis O
. O

We O
report O
a O
patient O
with O
advanced O
colonic O
carcinoma O
who O
was O
treated O
with O
concomitant O
chemoirradiation O
with O
oxaliplatin B-DRUG
and O
developed O
a O
peculiar O
dermnatitis B-ADE
in O
the O
irradiated O
field O
after O
being O
exposed O
to O
subsequent O
chemotherapy O
with O
oxaliplatin O
. O

Disseminated B-ADE
tuberculous I-ADE
lesions I-ADE
post O
intravesical O
BCG B-DRUG
therapy O
are O
rare O
but O
need O
to O
be O
identified O
and O
treated O
quickly O
. O

Three O
patients O
, O
in O
whom O
tumour O
overkill O
by O
cytotoxic O
treatment O
, O
including O
high O
dose O
methotrexate B-DRUG
with O
folinic B-DRUG
acid I-DRUG
rescue O
, O
resulted O
in O
the O
' O
phosphate B-ADE
shower I-ADE
syndrome I-ADE
' O
( O
hyper B-ADE
- I-ADE
uricaemia I-ADE
, O
hyperkalaemia B-ADE
and O
hyperphosphataemia B-ADE
with O
hypocalcaemia B-ADE
and O
tetany B-ADE
, O
with O
metabolic B-ADE
acidosis I-ADE
and O
acute B-ADE
renal I-ADE
impairment I-ADE
) O
are O
described O
. O

Methimazole B-DRUG
- O
associated O
cholestatic B-ADE
liver I-ADE
injury I-ADE
: O
case O
report O
and O
brief O
literature O
review O
. O

Usefulness O
of O
antiplatelet O
drugs O
in O
the O
management O
of O
heparin B-DRUG
- O
associated O
thrombocytopenia B-ADE
and O
thrombosis B-ADE
. O

We O
report O
an O
unusually O
short O
lived O
and O
asymptomatic O
episode O
of O
severe O
cisplatin B-DRUG
- O
induced O
renal B-ADE
tubular I-ADE
salt I-ADE
wasting I-ADE
in O
a O
fit O
41-year O
- O
old O
patient O
with O
malignant O
teratoma O
. O

We O
report O
an O
unusual O
case O
of O
massive O
fluoxetine B-DRUG
ingestion O
resulting O
in O
neurological B-ADE
and I-ADE
cardiovascular I-ADE
toxicity I-ADE
resulting O
in O
death B-ADE
. O

A O
62-year O
- O
old O
woman O
treated O
with O
pranlukast B-DRUG
for O
2 O
months O
developed O
interstitial B-ADE
pneumonitis I-ADE
with O
a O
high B-ADE
fever I-ADE
. O

Amiodarone B-DRUG
induced O
torsades B-ADE
de I-ADE
pointe I-ADE
. O

We O
conclude O
that O
the O
presence O
of O
this O
metabolic O
defect O
combined O
with O
topical O
5-FU B-DRUG
( O
a O
drug O
demonstrating O
a O
narrow O
therapeutic O
index O
) O
results O
in O
the O
unusual O
presentation O
of O
life B-ADE
- I-ADE
threatening I-ADE
toxicity I-ADE
after O
treatment O
with O
a O
topical O
drug O
. O

Acute B-ADE
unilateral I-ADE
total I-ADE
visual I-ADE
loss I-ADE
after O
retrogasserian O
phenol B-DRUG
injection O
for O
the O
treatment O
of O
trigeminal O
neuralgia O
: O
a O
case O
report O
. O

When O
cyanamide B-DRUG
- O
treated O
alcoholics O
relapse O
into O
drinking O
, O
more O
severe O
inflammation B-ADE
develops O
in O
the O
liver O
. O

Unexpected O
severe O
reversible O
cyclosporine B-DRUG
A I-DRUG
- O
induced O
nephrotoxicity B-ADE
in O
a O
patient O
with O
systemic O
lupus O
erythematosus O
and O
tubulointerstitial O
renal O
disease O
. O

Corneal B-ADE
endothelial I-ADE
deposits I-ADE
associated O
with O
rifabutin B-DRUG
use O
. O

Fulminant B-ADE
hepatitis I-ADE
with O
severe B-ADE
lactate I-ADE
acidosis I-ADE
in O
HIV O
- O
infected O
patients O
on O
didanosine B-DRUG
therapy O
. O

The O
gynecomastia B-ADE
regressed O
when O
the O
theophylline B-DRUG
was O
discontinued O
. O

We O
wish O
to O
call O
for O
cautious O
approach O
at O
time O
of O
cessation O
of O
prolonged O
ACTH B-DRUG
therapy O
because O
of O
possible O
unexpected O
and O
only O
partially O
understood O
hazardous O
side O
effects O
such O
as O
hyperkalemia B-ADE
. O

Treatment O
of O
lithium B-DRUG
- O
induced O
diabetes B-ADE
insipidus I-ADE
with O
amiloride O
. O

Adult B-ADE
respiratory I-ADE
distress I-ADE
syndrome I-ADE
after O
treatment O
with O
pegylated B-DRUG
interferon I-DRUG
alpha-2a I-DRUG
and O
ribavirin B-DRUG
. O

Of O
371 O
patients O
treated O
with O
8MOP B-DRUG
, O
three O
( O
0.8 O
% O
) O
developed O
an O
acute B-ADE
dermatitis I-ADE
in O
the O
PUVA O
- O
treated O
areas O
. O

A O
57-year O
- O
old O
woman O
presented O
with O
a O
3-week O
history O
of O
dysphagia B-ADE
for I-ADE
solids I-ADE
, O
6 O
months O
after O
starting O
treatment O
with O
nifedipine B-DRUG
. O

We O
describe O
a O
63 O
year O
old O
woman O
with O
a O
suppurative O
mediastinitis O
, O
treated O
with O
continuous O
PI B-DRUG
irrigation O
who O
developed O
an O
acute B-ADE
oliguric I-ADE
renal I-ADE
failure I-ADE
. O

Phenolphthalein B-DRUG
- O
induced O
toxic B-ADE
epidermal I-ADE
necrolysis I-ADE
. O

PATIENTS O
: O
Three O
patients O
developed O
a O
reproductive B-ADE
endocrine I-ADE
disorder I-ADE
during O
treatment O
with O
valproate B-DRUG
. O

Terbinafine B-DRUG
- O
induced O
cholestatic B-ADE
liver I-ADE
disease I-ADE
. O

This O
report O
describes O
a O
13-year O
- O
old O
female O
with O
a O
right O
frontal O
high O
- O
grade O
glioma O
and O
complex O
partial O
seizures O
who O
developed O
localized B-ADE
purpura I-ADE
after O
23 O
months O
of O
lamotrigine B-DRUG
monotherapy O
. O

A O
macrophage B-ADE
activation I-ADE
syndrome I-ADE
, O
possibly O
related O
to O
methotrexate B-ADE
toxicity I-ADE
, O
developed O
in O
a O
boy O
with O
systemic O
juvenile O
rheumatoid O
arthritis O
. O

Although O
neurotoxicity B-ADE
is O
a O
frequent O
complication O
of O
methotrexate B-DRUG
therapy O
, O
fatal B-ADE
acute I-ADE
neurotoxicity I-ADE
is O
extremely O
uncommon O
, O
especially O
in O
adults O
. O

We O
report O
a O
case O
of O
Thrombotic B-ADE
Thrombocytopenic I-ADE
Purpura I-ADE
occurring O
as O
an O
allergic O
response O
to O
trimethoprim B-DRUG
- O
sulfamethoxazole B-DRUG
therapy O
( O
Bactrim O
, O
Septra O
) O
in O
a O
Jehovah O
's O
Witness O
patient O
. O

Sertraline B-DRUG
- O
induced O
rhabdomyolysis B-ADE
in O
an O
elderly O
patient O
with O
dementia O
and O
comorbidities O
. O

BACKGROUND O
: O
Gemcitabine B-DRUG
has O
mild O
renal B-ADE
toxicity I-ADE
, O
but O
cases O
of O
gemcitabine B-DRUG
- O
associated O
hemolytic B-ADE
- I-ADE
uremic I-ADE
syndrome I-ADE
( O
HUS B-ADE
) O
have O
been O
reported O
. O

Acute B-ADE
coronary I-ADE
syndromes I-ADE
can O
be O
associated O
with O
the O
infusion O
of O
rituximab B-DRUG
. O

Cephalosporin B-DRUG
- O
induced O
leukopenia B-ADE
following O
rechallenge O
with O
cefoxitin O
. O

PURPOSE O
: O
To O
report O
two O
cases O
in O
which O
topical O
brimonidine B-DRUG
resulted O
in O
apparent O
central B-ADE
nervous I-ADE
system I-ADE
depression I-ADE
and O
unresponsiveness O
in O
an O
infant O
. O

Clinical O
course O
of O
macular B-ADE
edema I-ADE
in O
two O
cases O
of O
interferon B-DRUG
- O
associated O
retinopathy B-ADE
observed O
by O
optical O
coherence O
tomography O
. O

Celiprolol B-DRUG
pneumonitis B-ADE
. O

Methotrexate B-DRUG
- O
induced O
diffuse B-ADE
interstitial I-ADE
pulmonary I-ADE
fibrosis I-ADE
. O

Rofecoxib B-DRUG
, O
used O
for O
dysmenorrhea O
, O
caused O
a O
herpetiform B-ADE
fixed I-ADE
drug I-ADE
eruption I-ADE
predominantly O
involving O
the O
lips O
with O
classic O
clinical O
and O
histological O
findings O
in O
a O
red B-ADE
- I-ADE
brown I-ADE
lesion I-ADE
on O
the O
dorsal O
hand O
. O

The O
fluorine O
contained O
in O
niflumic B-DRUG
acid I-DRUG
induced O
a O
marked O
densification B-ADE
of I-ADE
trabecular I-ADE
bone I-ADE
in O
all O
3 O
cases O
. O

We O
discuss O
our O
observations O
in O
the O
cases O
of O
two O
patients O
with O
acyclovir B-DRUG
neurotoxicity B-ADE
and O
review O
the O
findings O
of O
all O
previous O
reports O
in O
the O
English O
language O
literature O
. O

The O
fever B-ADE
abated O
promptly O
following O
discontinuation O
of O
acyclovir B-DRUG
, O
and O
radiographic O
abnormalities O
resolved O
over O
ten O
days O
. O

Serotonin B-ADE
syndrome I-ADE
caused O
by O
selective O
serotonin O
reuptake O
- O
inhibitors O
- O
metoclopramide B-DRUG
interaction O
. O

A O
patient O
with O
monocular O
open O
- O
angle O
glaucoma O
had O
trichiasis B-ADE
, O
a O
condition O
associated O
with O
the O
use O
of O
a O
prostaglandin B-DRUG
analog O
. O

Sirolimus B-ADE
- I-ADE
eluting I-ADE
stent I-ADE
thrombosis I-ADE
several O
years O
after O
clopidogrel B-DRUG
discontinuation O
. O

CONCLUSIONS O
: O
This O
patient O
's O
rhabdomyolysis B-ADE
was O
probably O
induced O
by O
sertraline B-DRUG
therapy O
. O

Type B-ADE
1 I-ADE
diabetes I-ADE
mellitus I-ADE
provoked O
by O
peginterferon B-DRUG
alpha-2b I-DRUG
plus O
ribavirin B-DRUG
treatment O
for O
chronic O
hepatitis O
C O
. O

Although O
dyspnea B-ADE
associated O
with O
verapamil B-DRUG
administration O
has O
been O
reported O
, O
this O
is O
the O
first O
report O
of O
an O
elderly O
asymptomatic O
asthmatic O
patient O
with O
hypertension O
who O
developed O
an O
acute B-ADE
asthma I-ADE
attack O
following O
sustained O
- O
release O
verapamil B-DRUG
administration O
. O

Warfarin B-DRUG
- O
associated O
bleeding B-ADE
complication O
saved O
life O
. O

We O
report O
a O
case O
of O
Zidovudine B-DRUG
induced O
anaemia B-ADE
and O
bone B-ADE
marrow I-ADE
aplasia I-ADE
in O
a O
patient O
infected O
with O
HIV O
. O

Anterior B-ADE
lumbosacral I-ADE
radiculopathy I-ADE
after O
intrathecal O
methotrexate B-DRUG
treatment O
. O

Interferon B-DRUG
- I-DRUG
alpha I-DRUG
( O
IFN B-DRUG
- I-DRUG
alpha I-DRUG
) O
may O
precipitate O
or O
exacerbate O
the O
occurrence O
of O
MPGN B-ADE
. O

During O
and O
after O
IFN B-DRUG
therapy O
we O
should O
consider O
the O
possibility O
of O
occurrence O
of O
IDDM B-ADE
as O
well O
as O
other O
autoimmune O
diseases O
and O
observe O
the O
clinical O
course O
carefully O
. O

Transient B-ADE
global I-ADE
amnesia I-ADE
after O
clioquinol B-DRUG
: O
five O
personal O
observations O
from O
outside O
Japan O
. O

The O
sulfonamides B-DRUG
are O
the O
best O
verified O
drug O
- O
trigger O
for O
erythema B-ADE
multiforme I-ADE
and O
Stevens B-ADE
- I-ADE
Johnson I-ADE
syndrome I-ADE
. O

This O
case O
highlights O
the O
need O
to O
monitor O
liver O
enzymes O
in O
patients O
treated O
with O
6-TG O
and O
identifies O
the O
need O
for O
additional O
research O
focused O
on O
the O
mechanism O
of O
thiopurine B-DRUG
- O
induced O
hepatic B-ADE
injury I-ADE
. O

Apparent O
central B-ADE
nervous I-ADE
system I-ADE
depression I-ADE
in O
infants O
after O
the O
use O
of O
topical O
brimonidine B-DRUG
. O

An O
elderly O
man O
with O
procainamide B-DRUG
hydrochloride I-DRUG
- O
induced O
lupus B-ADE
syndrome I-ADE
had O
a O
circulating O
anticoagulant O
against O
factor O
XI O
and O
a O
biologic O
false O
- O
positive O
( O
BFP O
) O
test O
result O
for O
syphilis O
. O

We O
describe O
a O
patient O
with O
metastatic O
prostate O
cancer O
who O
developed O
nonoliguric B-ADE
renal I-ADE
failure I-ADE
during O
treatment O
with O
suramin B-DRUG
. O

Although O
it O
would O
be O
expected O
that O
, O
like O
other O
type O
IA O
toxicities O
, O
diphenhydramine B-DRUG
- O
induced O
cardiotoxicity B-ADE
could O
be O
responsive O
to O
hypertonic O
sodium O
bicarbonate O
, O
this O
finding O
is O
largely O
unappreciated O
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
significant O
hepatic B-ADE
and I-ADE
renal I-ADE
failure I-ADE
with O
the O
use O
of O
argatroban B-DRUG
in O
a O
patient O
with O
heparin B-DRUG
- O
induced O
thrombocytopenia B-ADE
( O
HIT O
) O
requiring O
continuous O
veno O
- O
veno O
hemodialysis O
( O
CVVHD O
) O
. O

Amebic B-ADE
abscess I-ADE
of I-ADE
the I-ADE
spleen I-ADE
complicated O
by O
metronidazole B-DRUG
- O
induced O
neurotoxicity B-ADE
: O
case O
report O
. O

The O
clinical O
aspect O
closely O
resembled O
classical O
transient B-ADE
global I-ADE
amnesia I-ADE
but O
the O
episode O
after O
clioquinol B-DRUG
lasted O
longer O
( O
24 O
hours O
to O
three O
days O
) O
and O
a O
more O
or O
less O
extensive O
retrograde B-ADE
amnesia I-ADE
persisted O
permanently O
. O

Valproate B-DRUG
- O
induced O
hyperammonemia B-ADE
as O
a O
cause O
of O
altered B-ADE
mental I-ADE
status I-ADE
. O

RESULTS O
: O
The O
patient O
, O
a O
27-year O
- O
old O
married O
Japanese O
woman O
with O
borderline O
personality O
disorder O
, O
developed O
an O
increased B-ADE
libido I-ADE
with O
the O
administration O
of O
fluvoxamine B-DRUG
. O

Loperamide B-DRUG
poisoning I-ADE
in O
the O
dog O
. O

The O
field B-ADE
defects I-ADE
and O
some O
electrophysiological O
abnormalities O
persist O
when O
vigabatrin B-DRUG
therapy O
is O
withdrawn O
. O

Case O
report O
: O
mannitol B-DRUG
nephrotoxicity B-ADE
syndrome I-ADE
: O
role O
of O
hemodialysis O
and O
postulate O
of O
mechanisms O
. O

Ten O
to O
15 O
% O
of O
patients O
treated O
with O
ifosfamide B-DRUG
develop O
an O
encephalopathy B-ADE
. O

Primary O
CNS B-ADE
lymphoma I-ADE
regressed O
on O
withdrawal O
of O
MM B-DRUG
. O

CONCLUSIONS O
: O
We O
report O
a O
typical O
symptoms O
of O
Charles B-ADE
- I-ADE
Bonnet I-ADE
syndrome I-ADE
( O
CBS B-ADE
) O
in O
patients O
with O
severe O
AMD O
after O
intravitreal O
Avastin B-DRUG
- O
injections O
. O

We O
report O
two O
young O
patients O
with O
cystic O
fibrosis O
who O
presented O
with O
acute B-ADE
renal I-ADE
insufficiency I-ADE
after O
2 O
- O
3 O
weeks O
of O
oral O
ciprofloxacin B-DRUG
therapy O
. O

A O
71-year O
- O
old O
man O
, O
who O
had O
a O
history O
of O
a O
previous O
bullous B-ADE
drug I-ADE
reaction I-ADE
to O
a O
sulfonamide B-DRUG
, O
began O
receiving O
an O
ophthalmic O
preparation O
that O
contained O
sulfacetamide O
sodium O
. O

OBJECTIVE O
: O
The O
purpose O
of O
this O
study O
was O
to O
report O
the O
concomitant O
occurrence O
of O
multiple B-ADE
squamous I-ADE
cell I-ADE
carcinomas I-ADE
and O
diffuse B-ADE
nail I-ADE
hyperpigmentation I-ADE
associated O
with O
hydroxyurea B-DRUG
treatment O
, O
and O
to O
describe O
a O
successful O
therapeutic O
approach O
using O
imiquimod O
5 O
% O
. O

A O
56-year O
- O
old O
white O
woman O
with O
a O
diagnosis O
of O
reactive O
depression O
developed O
severe O
UI B-ADE
after O
a O
30 O
days O
' O
treatment O
with O
venlafaxine B-DRUG
75 O
mg O
/ O
day O
. O

The O
vomiting B-ADE
occurred O
on O
switching O
to O
different O
pancreatic O
enzymes O
preparations O
, O
ie O
, O
Creon B-DRUG
10 I-DRUG
, O
Viokase B-DRUG
, O
and O
Pancrease B-DRUG
MT I-DRUG
16 I-DRUG
. O

We O
report O
the O
case O
of O
a O
51-year O
- O
old O
man O
in O
whom O
IFN B-DRUG
- I-DRUG
alpha I-DRUG
treatment O
was O
followed O
by O
recurrence O
of O
Graves B-ADE
' I-ADE
disease I-ADE
10 O
years O
after O
thyroidectomy O
was O
performed O
and O
the O
patient O
was O
declared O
cured O
. O

CONCLUSION O
: O
A O
26-year O
- O
old O
man O
with O
bipolar O
disorder O
developed O
hyperammonemia B-ADE
three O
weeks O
after O
initiating O
carbamazepine B-DRUG
therapy O
. O

The O
authors O
describe O
a O
case O
of O
interstitial B-ADE
granulomatous I-ADE
dermatitis I-ADE
associated O
with O
darifenacin B-DRUG
. O

A O
lupus B-ADE
- I-ADE
like I-ADE
syndrome I-ADE
associated O
with O
infliximab B-DRUG
therapy O
. O

During O
analysis O
of O
28 O
patients O
receiving O
CAP B-DRUG
with O
concomitant O
radiation O
( O
XRT O
) O
for O
pancreatic O
cancer O
( O
resected O
or O
locally O
advanced O
) O
, O
two O
patients O
developed O
signs O
and O
symptoms O
consistent O
with O
peripheral B-ADE
neuropathy I-ADE
. O

Liver B-ADE
disease I-ADE
induced O
by O
perhexiline B-DRUG
maleate I-DRUG
. O

Both O
patients O
developed O
hypoadrenalism B-ADE
while O
on O
o B-DRUG
, I-DRUG
p'-DDD I-DRUG
and O
apparently O
adequate O
dexamethasone O
replacement O
therapy O
. O

Dental B-ADE
and I-ADE
gingival I-ADE
pain I-ADE
as O
side O
effects O
of O
niacin B-DRUG
therapy O
. O

Intrathecal O
methotrexate B-DRUG
- O
induced O
acute B-ADE
cerebellar I-ADE
syndrome I-ADE
. O

Disseminated B-ADE
eruptive I-ADE
giant I-ADE
mollusca I-ADE
contagiosa I-ADE
in O
an O
adult O
psoriasis O
patient O
during O
efalizumab B-DRUG
therapy O
. O

As O
these O
cases O
revealed O
, O
close O
monitoring O
of O
blood O
chemistry O
is O
mandatory O
after O
starting O
spironolactone O
, O
and O
patients O
should O
be O
advised O
to O
stop O
spironolactone B-DRUG
immediately O
if O
diarrhoea B-ADE
develops O
. O

The O
ulcer B-ADE
did O
not O
respond O
to O
antibiotic O
treatment O
and O
healed O
shortly O
after O
withholding O
ATRA B-DRUG
. O

CONCLUSION O
: O
We O
report O
a O
case O
of O
the O
use O
of O
pamidronate O
for O
significant O
hypercalcemia B-ADE
secondary O
to O
acute B-ADE
vitamin B-DRUG
D I-DRUG
poisoning I-ADE
. O

We O
propose O
a O
mechanism O
of O
vancomycin B-DRUG
- O
induced O
mast O
cell O
degranulation O
and O
subsequent O
release O
of O
eosinophil O
chemotactic O
factor O
as O
a O
cause O
of O
CSFE B-ADE
. O

The O
purpose O
of O
this O
article O
is O
to O
present O
the O
first O
case O
- O
series O
of O
posterior B-ADE
reversible I-ADE
encephalopathy I-ADE
syndrome I-ADE
( O
PRES B-ADE
) O
associated O
with O
L B-DRUG
- I-DRUG
asparaginase I-DRUG
treatment O
. O

This O
article O
describes O
a O
patient O
with O
suspected O
ciprofloxacin B-DRUG
- O
induced O
interstitial B-ADE
nephritis I-ADE
. O

Hemolytic B-ADE
uremic I-ADE
syndrome I-ADE
in O
a O
patient O
on O
cis B-DRUG
- I-DRUG
platinum I-DRUG
, O
vinblastine B-DRUG
and O
bleomycin B-DRUG
. O

Acute B-ADE
ischaemia I-ADE
of I-ADE
the I-ADE
leg I-ADE
following O
accidental O
intra O
- O
arterial O
injection O
of O
dissolved O
flunitrazepam B-DRUG
tablets O
. O

Only O
one O
case O
of O
a O
generalized B-ADE
maculopapular I-ADE
rash I-ADE
with O
enoxaparin B-DRUG
has O
been O
reported O
in O
Europe O
. O

Infectious B-ADE
toxicity I-ADE
of O
dexamethasone B-DRUG
during O
all O
remission O
- O
induction O
chemotherapy O
: O
report O
of O
two O
cases O
and O
literature O
review O
. O

STUDY O
DESIGN O
: O
Case O
reports O
are O
presented O
of O
three O
premature O
infants O
( O
mean O
gestational O
age O
27 O
weeks O
) O
cared O
for O
in O
the O
intensive O
care O
nursery O
in O
whom O
clinically O
significant O
septal B-ADE
hypertrophy I-ADE
and O
left B-ADE
ventricular I-ADE
outflow I-ADE
tract I-ADE
obstruction I-ADE
developed O
during O
dexamethasone B-DRUG
treatment O
for O
bronchopulmonary O
dysplasia O
. O

Potential O
mechanisms O
regarding O
the O
pathophysiology O
of O
lithium B-DRUG
- O
associated O
CDI B-ADE
are O
discussed O
. O

We O
believe O
this O
is O
the O
first O
report O
of O
intrathecal O
diamorphine B-DRUG
causing O
anaphylaxis B-ADE
. O

Acute B-ADE
pulmonary I-ADE
reactions I-ADE
to O
nitrofurantoin B-DRUG
are O
an O
uncommon O
side O
effect O
of O
therapy O
and O
can O
cause O
minor O
or O
life O
- O
threatening O
pulmonary B-ADE
dysfunction I-ADE
. O

Perinatal O
vasoconstrictive O
renal B-ADE
insufficiency I-ADE
associated O
with O
maternal O
nimesulide B-DRUG
use O
. O

CONCLUSIONS O
: O
Cicatrization O
in O
the O
substantia O
propria O
of O
the O
conjunctiva O
by O
excessive O
lymphocytic O
infiltration O
after O
topically O
administered O
antiglaucoma O
drugs O
including O
dipivefrin B-DRUG
is O
a O
possible O
mechanism O
of O
action O
for O
entropion B-ADE
. O

Except O
hypothyroidism B-ADE
after O
radioiodine B-DRUG
treatment O
( O
euthyroid O
under O
substitutional O
therapy O
) O
, O
she O
suffered O
from O
no O
other O
diseases O
. O

The O
intramuscular O
challenge O
test O
with O
25 O
UI O
of O
Miacalcic B-DRUG
was O
positive O
with O
an O
immediate O
anaphylactic B-ADE
reaction I-ADE
. O

A O
syndrome B-ADE
of I-ADE
increased I-ADE
affect I-ADE
in O
response O
to O
risperidone B-DRUG
among O
patients O
with O
schizophrenia O
. O

D B-DRUG
- I-DRUG
penicillamine I-DRUG
induced O
crescentic B-ADE
glomerulonephritis I-ADE
: O
report O
and O
review O
of O
the O
literature O
. O

Heat B-ADE
stroke I-ADE
- I-ADE
like I-ADE
episode I-ADE
in O
a O
child O
caused O
by O
zonisamide B-DRUG
. O

Phenytoin B-DRUG
- O
induced O
hypersensitivity B-ADE
reactions I-ADE
. O

Disopyramide B-DRUG
( O
Norpace B-DRUG
) O
- O
induced O
hypoglycemia B-ADE
. O

Cutaneous B-ADE
eruptions I-ADE
occur O
in O
3 O
% O
of O
individuals O
administered O
carbamazepine B-DRUG
. O

Ten O
years O
of O
behavioral O
data O
are O
presented O
to O
support O
the O
hypothesis O
that O
phenobarbital B-DRUG
was O
exacerbating O
maladaptive B-ADE
behaviors I-ADE
. O

Severe B-ADE
akathisia I-ADE
during O
olanzapine B-DRUG
treatment O
of O
acute O
schizophrenia O
. O

Venlafaxine B-DRUG
- O
induced O
urinary B-ADE
incontinence I-ADE
resolved O
after O
switching O
to O
sertraline O
. O

Fatal B-ADE
venous I-ADE
thrombembolism I-ADE
complicating O
imatinib B-DRUG
therapy O
in O
a O
patient O
with O
metastatic O
gastrointestinal O
stromal O
tumor O
. O

Systemic B-ADE
allergic I-ADE
contact I-ADE
dermatitis I-ADE
to O
8-methoxypsoralen B-DRUG
( O
8-MOP B-DRUG
) O
. O

Minimal B-ADE
change I-ADE
nephrotic I-ADE
syndrome I-ADE
developing O
during O
postoperative O
interferon B-DRUG
- I-DRUG
beta I-DRUG
therapy O
for O
malignant O
melanoma O
. O

CONCLUSIONS O
: O
We O
conclude O
that O
a O
high O
dose O
combined O
with O
a O
short O
infusion O
time O
increases O
the O
risk O
of O
anaphylactoid B-ADE
reactions I-ADE
with O
the O
administration O
of O
intraperitoneal O
cisplatin B-DRUG
. O

Overdose O
of O
magnesium B-DRUG
sulfate I-DRUG
in O
combination O
with O
renal O
insufficiency O
, O
hypocalcemia O
, O
or O
compromise O
of O
intestinal O
integrity O
may O
predispose O
horses O
to O
magnesium B-DRUG
toxicosis I-ADE
. O

A O
previous O
study O
of O
patients O
with O
" O
quinine B-DRUG
- O
associated O
TTP B-ADE
/ I-ADE
HUS I-ADE
" O
found O
that O
ADAMTS13 O
activities O
were O
not O
abnormal O
in O
12/12 O
patients O
. O

A O
74-year O
- O
old O
hypercholestrerolaemic O
woman O
taking O
cerivastatin B-DRUG
( O
0.15 O
mg O
/ O
day O
) O
for O
22 O
days O
complained O
of O
general O
muscle B-ADE
weakness I-ADE
and O
muscle B-ADE
pain I-ADE
. O

Drug O
- O
induced O
fever B-ADE
should O
be O
considered O
in O
patients O
who O
have O
unexplained O
high O
temperatures O
during O
diltiazem B-DRUG
therapy O
. O

The O
introduction O
of O
para B-DRUG
- I-DRUG
aminosalicylic I-DRUG
acid I-DRUG
( O
PAS B-DRUG
) O
led O
to O
hypoglycaemic B-ADE
coma I-ADE
. O

We O
stress O
the O
potential O
of O
benzarone B-DRUG
to O
cause O
hepatotoxicity B-ADE
, O
which O
usually O
resembles O
severe B-ADE
chronic I-ADE
active I-ADE
hepatitis I-ADE
. O

CONCLUSIONS O
: O
We O
report O
the O
first O
case O
of O
gemcitabine B-DRUG
- O
induced O
LABD B-ADE
. O

After O
induction O
of O
general O
anesthesia O
and O
administration O
of O
a O
standard O
dose O
of O
intravenous O
esmolol B-DRUG
hydrochloride I-DRUG
, O
her O
cardiac O
rhythm O
progressed O
to O
asystole B-ADE
. O

Drug O
induced O
liver B-ADE
injury I-ADE
secondary O
to O
interferon B-DRUG
- I-DRUG
beta I-DRUG
( O
IFN B-DRUG
- I-DRUG
beta I-DRUG
) O
in O
multiple O
sclerosis O
. O

Subglottic B-ADE
stenosis I-ADE
in O
Wegener O
's O
granulomatosis O
: O
development O
during O
cyclophosphamide B-DRUG
treatment O
with O
response O
to O
carbon O
dioxide O
laser O
therapy O
. O

After O
therapy O
with O
parenteral O
amiodarone B-DRUG
( O
2300 O
mg O
in O
3 O
days O
) O
and O
other O
measures O
, O
signs O
of O
congestive O
heart O
failure O
disappeared O
; O
subsequently O
the O
patient O
developed O
jaundice B-ADE
, O
marked B-ADE
increase I-ADE
in I-ADE
serum I-ADE
transaminase I-ADE
levels I-ADE
and O
fall B-ADE
in I-ADE
prothrombin I-ADE
time I-ADE
, O
and O
histologic O
changes O
of O
severe B-ADE
centrilobular I-ADE
necrosis I-ADE
were O
observed O
in O
hepatic O
biopsy O
. O

Acute B-ADE
eosinophilic I-ADE
pneumonia I-ADE
caused O
by O
calcium B-DRUG
stearate I-DRUG
, O
an O
additive O
agent O
for O
an O
oral O
antihistaminic O
medication O
. O

A O
case O
of O
the O
Rett O
syndrome O
with O
acute B-ADE
encephalopathy I-ADE
induced O
during O
calcium B-DRUG
hopantenate I-DRUG
treatment O
. O

Flecainide B-DRUG
is O
a O
rare O
cause O
of O
hypersensitivity B-ADE
pneumonitis I-ADE
, O
and O
few O
cases O
have O
been O
reported O
. O

This O
case O
demonstrates O
the O
value O
of O
DWI O
in O
evaluation O
and O
diagnosis O
of O
sub B-ADE
- I-ADE
acute I-ADE
toxic I-ADE
leukoencephalopathy I-ADE
in O
patients O
being O
treated O
with O
methotrexate B-DRUG
. O

Since O
1979 O
, O
over O
30 O
published O
case O
reports O
have O
documented O
the O
relationship O
between O
phenylpropanolamine B-DRUG
and O
stroke B-ADE
. O

Evidence O
obtained O
indicated O
that O
the O
Reye B-ADE
- I-ADE
like I-ADE
syndrome I-ADE
might O
be O
caused O
by O
calcium B-DRUG
hopantenate I-DRUG
possibly O
due O
to O
the O
induction O
of O
pantothenic B-ADE
acid I-ADE
deficiency I-ADE
. O

Ticlopidine B-DRUG
- O
induced O
interstitial B-ADE
pulmonary I-ADE
disease I-ADE
: O
a O
case O
report O
. O

Stroke B-ADE
is O
an O
infrequent O
but O
recognized O
complication O
of O
heroin B-DRUG
addiction O
. O

Four O
cases O
of O
adverse B-ADE
experiences I-ADE
with O
clonidine B-DRUG
are O
described O
. O

Acute B-ADE
coronary I-ADE
syndromes I-ADE
complicating O
the O
first O
infusion O
of O
rituximab B-DRUG
. O

Cyanamide B-DRUG
- O
induced O
liver B-ADE
dysfunction I-ADE
after O
abstinence O
in O
alcoholics O
: O
a O
long O
- O
term O
follow O
- O
up O
study O
on O
four O
cases O
. O

Eosinophilia B-ADE
caused O
by O
clozapine B-DRUG
was O
observed O
in O
challenge O
, O
preceded O
by O
a O
faster O
neutrophil O
production O
and O
consecutive O
decrease O
( O
z O
= O
2.27 O
, O
p O
= O
0.01 O
) O
. O

Diphenhydramine B-DRUG
- O
induced O
wide O
complex O
dysrhythmia B-ADE
responds O
to O
treatment O
with O
sodium O
bicarbonate O
. O

Sulfasalazine B-DRUG
- O
induced O
lung B-ADE
disorder I-ADE
is O
an O
extremely O
rare O
entity O
which O
must O
be O
considered O
in O
all O
ulcerative B-ADE
colitis I-ADE
patients O
while O
on O
sulfasalazine B-DRUG
therapy O
, O
despite O
the O
absence O
of O
pulmonary O
symptomatology O
. O

Ampicillin B-DRUG
increased O
the O
preexisting O
electrical B-ADE
decrement I-ADE
in O
three O
rabbits O
with O
experimental O
autoimmune O
myasthenia O
gravis O
while O
the O
drug O
had O
no O
deleterious O
effects O
in O
less O
affected O
or O
normal O
animals O
. O

Generalized B-ADE
pustular I-ADE
psoriasis I-ADE
precipitated O
by O
trazodone B-DRUG
in O
the O
treatment O
of O
depression O
. O

We O
describe O
in O
detail O
the O
first O
U.S. O
case O
report O
, O
of O
a O
4(1/2 O
) O
- O
year O
- O
old O
boy O
who O
experienced O
angioedema B-ADE
during O
treatment O
with O
oxcarbazepine B-DRUG
. O

In O
our O
patient O
, O
an O
objective O
causality O
scale O
showed O
that O
therapeutic O
doses O
of O
colchicine B-DRUG
for O
FMF O
were O
the O
definite O
cause O
of O
myopathy B-ADE
, O
even O
though O
his O
renal O
and O
hepatic O
function O
were O
normal O
. O

A O
generalized B-ADE
tonic I-ADE
- I-ADE
clonic I-ADE
seizure I-ADE
occurred O
a O
few O
minutes O
after O
injection O
of O
the O
morphine O
antagonist O
naloxone B-DRUG
. O

Although O
no O
coagulation O
study O
was O
done O
and O
the O
Meckel O
's O
diverticulum O
is O
normally O
associated O
with O
bleeding O
, O
the O
particular O
intensity O
of O
the O
following O
hemorrhage B-ADE
may O
have O
been O
favored O
by O
metformin B-DRUG
. O

Minocycline B-DRUG
- O
induced O
autoimmune B-ADE
hepatitis I-ADE
is O
usually O
identical O
to O
sporadic O
autoimmune O
hepatitis O
. O

Fenclofenac B-DRUG
- O
induced O
selective O
IgA B-ADE
deficiency I-ADE
in O
rheumatoid O
arthritis O
. O

Massive B-ADE
pulmonary I-ADE
embolism I-ADE
complicating O
streptokinase B-DRUG
treatment O
for O
deep O
vein O
thrombosis O
. O

An O
adult O
male O
presented O
with O
central B-ADE
blindness I-ADE
after O
ingesting O
methanol B-DRUG
. O

Valvular B-ADE
heart I-ADE
disease I-ADE
in O
a O
patient O
taking O
benfluorex B-DRUG
. O

We O
report O
for O
the O
first O
time O
the O
development O
of O
symptomatic B-ADE
methemoglobinemia I-ADE
after O
an O
acute O
ingestion O
of O
divalproex B-DRUG
sodium I-DRUG
( O
Depakote B-DRUG
) O
, O
resulting O
in O
serum O
concentrations O
10 O
times O
greater O
than O
the O
therapeutic O
range O
. O

Marked B-ADE
hyperkalemia I-ADE
was O
observed O
during O
and O
immediately O
after O
an O
infusion O
of O
arginine B-DRUG
monohydrochloride I-DRUG
in O
two O
patients O
with O
severe O
hepatic O
disease O
and O
moderate O
renal O
insufficiency O
. O

CONCLUSION O
: O
Marked O
visual B-ADE
field I-ADE
constriction I-ADE
appears O
to O
be O
associated O
with O
vigabatrin B-DRUG
therapy O
. O

Erythema B-ADE
multiforme I-ADE
associated O
with O
phenytoin B-DRUG
and O
cranial O
radiation O
therapy O
: O
a O
report O
of O
three O
patients O
and O
review O
of O
the O
literature O
. O

We O
report O
two O
cases O
of O
fulminant B-ADE
hepatic I-ADE
failure I-ADE
in O
HIV-1-infected O
patients O
treated O
with O
didanosine B-DRUG
( O
ddI B-DRUG
) O
. O

Mucosal B-ADE
pigmentation I-ADE
after O
oral O
lichen O
planus O
treatment O
with O
topical O
tacrolimus B-DRUG
. O

Divalproex B-DRUG
sodium I-DRUG
- O
induced O
eosinophilic B-ADE
pleural I-ADE
effusion I-ADE
. O

The O
observation O
of O
cutaneous B-ADE
vasculitis I-ADE
during O
administration O
of O
propylthiouracil B-DRUG
suggested O
that O
clinical O
awareness O
of O
this O
complication O
should O
be O
of O
considerable O
importance O
. O

We O
propose O
that O
cyclophosphamide B-DRUG
be O
added O
to O
the O
list O
of O
exposures O
potentially O
associated O
with O
hepatic B-ADE
angiosarcoma I-ADE
. O

CONCLUSIONS O
: O
It O
is O
probable O
that O
foscarnet B-DRUG
contributed O
to O
the O
electrolyte B-ADE
disorders I-ADE
and O
symptomatology O
in O
this O
patient O
. O

Four O
weeks O
earlier O
she O
had O
developed O
hepatopathy B-ADE
during O
a O
regimen O
of O
carbamazepine B-DRUG
, O
lynestrenol B-DRUG
and O
sodium B-DRUG
valproate I-DRUG
. O

The O
occurrence O
of O
a O
myocardial B-ADE
infarction I-ADE
is O
reported O
after O
chemotherapy O
containing O
etoposide B-DRUG
, O
in O
a O
man O
with O
no O
risk O
factors O
for O
coronary O
heart O
disease O
. O

We O
presented O
the O
case O
of O
a O
patient O
who O
developed O
a O
cutaneous B-ADE
reaction I-ADE
induced O
by O
captopril B-DRUG
with O
positive O
patch O
test O
. O

An O
acute B-ADE
ischaemic I-ADE
event I-ADE
associated O
with O
the O
use O
of O
venlafaxine B-DRUG
: O
a O
case O
report O
and O
proposed O
pathophysiological O
mechanisms O
. O

This O
case O
and O
a O
review O
of O
the O
literature O
show O
the O
severe O
and O
unpredictable O
nature O
of O
ethambutol B-DRUG
toxicity I-ADE
and O
its O
potential O
for O
irreversible O
vision B-ADE
loss I-ADE
despite O
careful O
ophthalmologic O
monitoring O
. O

Neutrophilic B-ADE
dermatoses I-ADE
in O
two O
children O
with O
idiopathic O
neutropenia O
: O
association O
with O
granulocyte B-DRUG
colony I-DRUG
- I-DRUG
stimulating I-DRUG
factor I-DRUG
( O
G B-DRUG
- I-DRUG
CSF I-DRUG
) O
therapy O
. O

Prazosin B-DRUG
- O
induced O
first O
- O
dose O
phenomenon O
possibly O
associated O
with O
hemorrhagic B-ADE
stroke I-ADE
: O
a O
report O
of O
three O
cases O
. O

Spinal B-ADE
cord I-ADE
infarction I-ADE
during O
use O
of O
zolmitriptan B-DRUG
: O
a O
case O
report O
. O

An O
episode O
of O
subacute O
encephalopathy B-ADE
after O
the O
infusion O
of O
a O
moderate O
dose O
of O
methotrexate B-DRUG
( O
1500 O
mg O
/ O
m2 O
) O
( O
MTX O
) O
is O
reported O
in O
a O
young O
adult O
with O
metastastic O
gastric O
cancer O
. O

Nitrendipine B-DRUG
is O
an O
experimental O
calcium O
channel O
blocking O
agent O
that O
also O
appears O
to O
cause O
the O
side O
effect O
of O
drug O
- O
induced O
gingival B-ADE
hyperplasia I-ADE
. O

The O
clinical O
findings O
and O
laboratory O
studies O
suggested O
an O
autoimmune B-ADE
cell I-ADE
- I-ADE
mediated I-ADE
hypersensitivity I-ADE
reaction O
triggered O
by O
phenobarbital B-DRUG
. O

They O
seemed O
to O
involve O
multiple O
aetiological O
factors O
, O
such O
as O
autoimmune O
thyroid O
disease O
, O
the O
toxic B-ADE
and I-ADE
immunomodulatory I-ADE
roles I-ADE
of O
lithium B-DRUG
and O
perhaps O
genetic O
and O
dietary O
factors O
. O

Carbamazepine B-DRUG
hypersensitivity B-ADE
syndrome I-ADE
is O
a O
rare O
, O
life O
- O
threatening O
condition O
. O

Hyperkalemia B-ADE
as O
a O
late O
side O
effect O
of O
prolonged O
adrenocorticotropic B-DRUG
hormone I-DRUG
therapy O
for O
infantile O
spasms O
. O

Bilateral B-ADE
acoustic I-ADE
( I-ADE
VIII I-ADE
) I-ADE
nerve I-ADE
palsy I-ADE
in O
this O
patient O
was O
most O
likely O
a O
manifestation O
of O
vincristine B-DRUG
neurotoxicity B-ADE
. O

Acute B-ADE
hepatic I-ADE
failure I-ADE
is O
a O
rare O
and O
potentially O
lethal O
complication O
of O
propylthiouracil B-DRUG
( O
PTU B-DRUG
) O
use O
for O
hyperthyroidism O
. O

A O
patient O
with O
a O
large O
hydatid O
cyst O
of O
the O
left O
lobe O
of O
the O
liver O
developed O
metabolic B-ADE
acidosis I-ADE
following O
rather O
liberal O
use O
of O
cetrimide B-DRUG
- O
chlorhexidine B-DRUG
solution O
as O
a O
scolicidal O
agent O
. O

To O
our O
knowledge O
, O
this O
is O
the O
first O
report O
of O
an O
angio B-ADE
- I-ADE
oedema I-ADE
associated O
with O
VRC B-DRUG
. O

Anaphylactoid B-ADE
reactions I-ADE
with O
intraperitoneal O
cisplatin B-DRUG
. O

This O
severe B-ADE
illness I-ADE
was O
likely O
caused O
by O
minocycline B-DRUG
, O
and O
we O
speculate O
that O
minocycline B-DRUG
may O
have O
acted O
as O
a O
superantigen O
, O
causing O
lymphocyte B-ADE
over I-ADE
- I-ADE
activation I-ADE
and O
massive B-ADE
cytokine I-ADE
release I-ADE
. O

We O
present O
four O
cases O
in O
which O
the O
use O
of O
heparin B-DRUG
was O
associated O
with O
hyperkalemia B-ADE
and O
discuss O
the O
pathophysiology O
. O

Azathioprine B-DRUG
- O
induced O
myelosuppression B-ADE
due O
to O
thiopurine O
methyltransferase O
deficiency O
in O
a O
patient O
with O
autoimmune O
hepatitis O
. O

However O
, O
to O
our O
knowledge O
, O
in O
newborns O
there O
have O
been O
no O
reported O
cases O
to O
date O
of O
thrombocytosis B-ADE
induced O
by O
enoxaparin B-DRUG
. O

DESIGN O
: O
We O
reviewed O
the O
medical O
records O
of O
four O
patients O
, O
who O
were O
seen O
by O
us O
between O
July O
2000 O
and O
February O
2004 O
for O
sudden O
onset O
of O
a O
central B-ADE
neurological I-ADE
syndrome I-ADE
within O
days O
of O
intrathecal O
MTX B-DRUG
. O

The O
potential O
for O
progressive O
brain B-ADE
injury I-ADE
and O
subsequent O
disability B-ADE
related O
to O
intraventricular O
IL-2 B-DRUG
therapy O
is O
discussed O
. O

CONCLUSIONS O
: O
Peripheral O
administration O
of O
low O
- O
dose O
vasopressin B-DRUG
for O
septic O
shock O
should O
be O
discouraged O
because O
of O
the O
risk O
of O
ischemic B-ADE
skin I-ADE
complications I-ADE
. O

DATA O
SYNTHESIS O
: O
Genetic O
deficiencies O
in O
DPD O
, O
the O
rate O
- O
limiting O
enzyme O
responsible O
for O
5-FU B-DRUG
catabolism O
, O
may O
occur O
in O
3 O
% O
or O
more O
of O
patients O
with O
cancer O
putting O
them O
at O
increased O
risk O
for O
unusually O
severe O
adverse O
reactions O
( O
e.g. O
, O
diarrhea B-ADE
, O
stomatitis B-ADE
, O
mucositis B-ADE
, O
myelosuppression B-ADE
, O
neurotoxicity B-ADE
) O
to O
standard O
doses O
of O
5-FU B-DRUG
. O

Although O
it O
is O
difficult O
to O
solely O
attribute O
intratumoral B-ADE
hemorrhage I-ADE
to O
aspirin B-DRUG
, O
we O
have O
to O
be O
careful O
when O
prescribing O
aspirin O
for O
patients O
who O
have O
asymptomatic O
meningioma O
. O

He O
had O
hypokalemia B-ADE
( O
K O
2.3 O
mmol O
/ O
L O
) O
induced O
by O
licorice B-DRUG
and O
also O
had O
received O
disopyramide O
for O
arrhythmia O
, O
bicalutamide O
for O
prostate O
cancer O
, O
and O
silodosin O
for O
prostate O
hypertrophy O
. O

Administration O
of O
sumatriptan B-DRUG
in O
subarachnoid O
haemorrhage O
( O
SAH O
) O
patients O
, O
misdiagnosed O
as O
migraine O
patients O
, O
may O
induce O
symptomatic B-ADE
cerebral I-ADE
vasospasm I-ADE
with O
potentially O
dangerous O
consequences O
. O

We O
report O
a O
16-year O
- O
old O
male O
who O
developed O
nephrotic B-ADE
syndrome I-ADE
related O
to O
membranous O
glomerulopathy O
with O
clinical O
and O
serological O
evidence O
of O
systemic B-ADE
lupus I-ADE
erythematosus I-ADE
after O
treatment O
with O
griseofulvin B-DRUG
. O

This O
report O
describes O
two O
patients O
who O
developed O
acute B-ADE
myelocytic I-ADE
leukemia I-ADE
only O
after O
exposure O
to O
cyclophosphamide B-DRUG
, O
methotrexate B-DRUG
, O
and O
5-fluorouracil B-DRUG
adjuvant O
therapy O
. O

We O
report O
one O
case O
of O
non B-ADE
- I-ADE
Hodgkin I-ADE
lymphoma I-ADE
in O
a O
patient O
, O
with O
a O
30-year O
history O
of O
rheumatoid O
arthritis O
, O
taking O
low O
dose O
methotrexate B-DRUG
weekly O
over O
a O
10-month O
period O
. O

Hyponatraemia B-ADE
during O
low O
- O
dose O
carbamazepine B-DRUG
therapy O
. O

A O
65-year O
- O
old O
woman O
with O
angina O
pectoris O
presented O
with O
syncope B-ADE
after O
sublingual O
ingestion O
of O
isosorbide B-DRUG
dinitrate I-DRUG
( O
5 O
mg O
) O
. O

PURPOSE O
: O
To O
describe O
the O
clinical O
and O
electrophysiological O
findings O
in O
a O
young O
boy O
with O
decreased B-ADE
vision I-ADE
possibly O
due O
to O
retinal B-ADE
damage I-ADE
by O
rifabutin B-DRUG
. O

After O
the O
first O
oral O
dose O
of O
propranolol B-DRUG
, O
syncope B-ADE
developed O
together O
with O
atrioventricular B-ADE
block I-ADE
. O

Neurotoxicity B-ADE
of O
intrathecal O
methotrexate B-DRUG
: O
MR O
imaging O
findings O
. O

RESULTS O
: O
A O
patient O
developed O
a O
bilaterally B-ADE
symmetric I-ADE
bull's I-ADE
- I-ADE
eye I-ADE
maculopathy I-ADE
45 O
years O
after O
taking O
quinacrine B-DRUG
for O
18 O
months O
as O
prophylaxis O
against O
malaria O
. O

ADR O
induced O
by O
drug O
treatment O
can O
be O
a O
side O
effect O
of O
treatment O
with O
antipsychotic O
drugs O
and O
other O
drugs O
; O
however O
, O
there O
have O
been O
no O
reports O
of O
lamivudine B-DRUG
- O
induced O
ADR B-ADE
in O
the O
English O
literature O
. O

Monoclonal B-ADE
gammopathy I-ADE
and O
subsequent O
multiple B-ADE
myeloma I-ADE
in O
a O
patient O
on O
chronic O
diphenylhydantoin B-DRUG
therapy O
. O

Acute B-ADE
coronary I-ADE
events I-ADE
following O
cisplatin B-DRUG
- O
based O
chemotherapy O
. O

Ifosfamide B-DRUG
- O
associated O
neurotoxicity B-ADE
was O
noted O
within O
hours O
of O
drug O
administration O
and O
improved O
rapidly O
following O
hemodialysis O
. O

Successful O
treatment O
with O
carbimazole O
of O
a O
hyperthyroid O
pregnancy O
with O
hepatic B-ADE
impairment I-ADE
after O
propylthiouracil B-DRUG
administration O
: O
a O
case O
report O
. O

Two O
other O
patients O
who O
did O
not O
receive O
prochlorperazine O
, O
developed O
retinal B-ADE
problems I-ADE
which O
later O
improved O
, O
one O
after O
only O
15 O
g O
of O
desferrioxamine B-DRUG
. O

Central O
nervous O
system O
effects O
secondary O
to O
ciprofloxacin B-DRUG
treatment O
are O
uncommon O
and O
usually O
consist O
only O
of O
minor B-ADE
dizziness I-ADE
or O
mild B-ADE
headache I-ADE
, O
although O
rare O
occurrences O
of O
seizures B-ADE
and O
hallucinations B-ADE
have O
been O
reported O
. O

Five O
patients O
receiving O
fluoxetine B-DRUG
for O
the O
treatment O
of O
obsessive O
compulsive O
disorder O
or O
major O
depression O
developed O
akathisia B-ADE
. O

This O
is O
a O
report O
of O
a O
renal O
transplant O
patient O
with O
Pneumocystis O
pneumonia O
who O
developed O
chemical B-ADE
cellulitis I-ADE
and O
ulceration B-ADE
following O
the O
extravasation O
of O
intravenous O
pentamidine B-DRUG
into O
the O
soft O
tissues O
of O
the O
left O
hand O
and O
forearm O
. O

Painful B-ADE
erosion I-ADE
of I-ADE
psoriatic I-ADE
plaques I-ADE
is O
a O
less O
common O
sign O
of O
methotrexate B-ADE
toxicity I-ADE
that O
may O
precede O
evidence O
of O
bone B-ADE
marrow I-ADE
suppression I-ADE
. O

Severe B-ADE
aphthous I-ADE
stomatitis I-ADE
associated O
with O
oral O
calcineurin B-DRUG
and O
mTOR O
inhibitors O
. O

We O
report O
a O
case O
of O
reversible O
encephalopathy B-ADE
syndrome I-ADE
in O
a O
16-year O
- O
old O
girl O
with O
acute O
myelogenous O
leukemia O
( O
AML O
) O
, O
who O
is O
undergoing O
during O
consolidation O
chemotherapy O
composed O
of O
BH B-DRUG
- I-DRUG
AC I-DRUG
( O
N4-behenoyl-1-beta O
- O
D O
- O
arabinofuranosyl O
cytosine O
) O
and O
idarubicin B-DRUG
. O

We O
describe O
a O
patient O
with O
M4 O
AML O
treated O
with O
standard O
chemotherapy O
followed O
by O
G B-DRUG
- I-DRUG
CSF I-DRUG
who O
developed O
marked O
monocytosis B-ADE
on O
day O
8 O
of O
G B-DRUG
- I-DRUG
CSF I-DRUG
therapy O
. O

Concomitant O
irradiation O
apparently O
enhanced O
the O
skin B-ADE
toxicity I-ADE
of O
aminoglutethimide B-DRUG
or O
possibly O
aminoglutethimide O
had O
a O
radiosensitizing O
role O
in O
this O
patient O
. O

Comparable O
adverse O
effects O
, O
such O
as O
disorientation B-ADE
and O
temporary B-ADE
amnesia I-ADE
, O
have O
been O
reported O
in O
patients O
in O
the O
analogous O
agent O
, O
propranolol B-DRUG
. O

An O
apparent O
link O
is O
described O
between O
the O
use O
of O
MMF B-DRUG
with O
prednisone B-DRUG
to O
treat O
pemphigus O
vulgaris O
and O
the O
development O
of O
red B-ADE
blood I-ADE
cell I-ADE
anemia I-ADE
. O

BACKGROUND O
: O
Fluoxetine B-DRUG
, O
a O
highly O
specific O
serotonin O
reuptake O
inhibitor O
, O
has O
been O
reported O
to O
cause O
sexual B-ADE
dysfunction I-ADE
in O
a O
minority O
of O
patients O
. O

Didanosine B-DRUG
also O
has O
a O
potential O
for O
inducing O
seizures B-ADE
. O

Antithyroid O
treatment O
with O
propylthiouracil B-DRUG
( O
PTU B-DRUG
) O
resulted O
in O
elevated B-ADE
hepatic I-ADE
enzymes I-ADE
and O
after O
the O
12th O
week O
of O
pregnancy O
treatment O
was O
changed O
to O
carbimazole O
( O
CBZ O
) O
. O

Penicillin B-DRUG
- O
induced O
Jarisch B-ADE
- I-ADE
Herxheimer I-ADE
reaction I-ADE
. O

Argatroban O
for O
heparin B-DRUG
- O
induced O
thrombocytopenia B-ADE
in O
hepato O
- O
renal O
failure O
and O
CVVHD O
. O

Relapse B-ADE
in I-ADE
the I-ADE
external I-ADE
auditory I-ADE
canal I-ADE
of I-ADE
acute I-ADE
promyelocytic I-ADE
leukemia I-ADE
after O
treatment O
with O
all B-DRUG
- I-DRUG
trans I-DRUG
retinoic I-DRUG
acid I-DRUG
. O

She O
continued O
taking O
verapamil O
for O
6 O
months O
, O
then O
, O
on O
her O
own O
, O
stopped O
all O
medications O
including O
the O
sustained O
- O
release O
verapamil B-DRUG
, O
and O
her O
asthma B-ADE
symptoms O
disappeared O
. O

Radiologic O
recognition O
of O
adriamycin B-DRUG
cardiotoxicity B-ADE
. O

Danazol B-DRUG
induced O
thrombocytopenia B-ADE
. O

We O
report O
a O
case O
with O
chronic O
hepatitis O
C O
( O
CHC O
) O
who O
developed O
sarcoidosis B-ADE
after O
the O
treatment O
by O
interferon B-DRUG
alpha I-DRUG
and O
ribavirin B-DRUG
. O

Supravenous B-ADE
hyperpigmentation I-ADE
in O
association O
with O
CHOP B-DRUG
chemotherapy O
of O
a O
CD30 O
( O
Ki-1 O
) O
- O
positive O
anaplastic O
large O
- O
cell O
lymphoma O
. O

However O
, O
we O
have O
recently O
had O
four O
cases O
of O
clofibrate B-DRUG
- O
induced O
myopathy B-ADE
in O
patients O
with O
diabetes O
insipidus O
due O
to O
hypothalamic O
lesions O
. O

Hypersensitivity B-ADE
reactions I-ADE
to O
cisplatin B-DRUG
following O
multiple O
uncomplicated O
courses O
: O
a O
report O
on O
two O
cases O
. O

No O
other O
endogenous O
or O
exogenous O
cause O
for O
the O
gynecomastia B-ADE
could O
be O
found O
except O
for O
the O
theophylline B-DRUG
. O

To O
our O
knowledge O
, O
this O
is O
the O
first O
report O
of O
insulin B-DRUG
- O
induced O
lipohypertrophy B-ADE
with O
detailed O
histological O
examinations O
. O

Spontaneous B-ADE
nasal I-ADE
septal I-ADE
perforation I-ADE
with O
antiangiogenic O
bevacizumab B-DRUG
therapy O
. O

Treatment O
of O
chronic O
hepatitis O
C O
with O
interferon B-DRUG
alpha I-DRUG
( O
IFN B-DRUG
- I-DRUG
alpha I-DRUG
) O
is O
relatively O
contraindicated O
in O
patients O
with O
psychiatric O
disorders O
because O
of O
possible O
severe O
psychiatric B-ADE
side I-ADE
effects I-ADE
. O

Acute B-ADE
dystonia I-ADE
during O
pegylated B-DRUG
interferon I-DRUG
alpha I-DRUG
therapy O
in O
a O
case O
with O
chronic O
hepatitis O
B O
infection O
. O

Flucytosine B-DRUG
- O
associated O
diarrhea B-ADE
has O
been O
previously O
described O
in O
6%-10 O
% O
of O
patients O
receiving O
the O
drug O
. O

We O
describe O
a O
heroin O
abuser O
in O
whom O
clinical O
and O
laboratory O
manifestations O
of O
acute B-ADE
hepatitis I-ADE
B I-ADE
and I-ADE
C I-ADE
appeared O
a O
few O
days O
after O
the O
insertion O
of O
a O
subcutaneous O
naltrexone B-DRUG
implant O
. O

Anhedonic B-ADE
ejaculation I-ADE
with O
desipramine B-DRUG
. O

Olanzapine B-DRUG
- O
associated O
neuroleptic B-ADE
malignant I-ADE
syndrome I-ADE
. O

Reversal O
of O
severe O
methanol B-DRUG
- O
induced O
visual B-ADE
impairment I-ADE
: O
no O
evidence O
of O
retinal O
toxicity O
due O
to O
fomepizole O
. O

Clofibrate B-DRUG
- O
induced O
myopathy B-ADE
in O
patients O
with O
diabetes O
insipidus O
. O

Dilated B-ADE
cardiomyopathy I-ADE
associated O
with O
chronic O
overuse O
of O
an O
adrenaline B-DRUG
inhaler O
. O

CONCLUSIONS O
: O
Hypersensitivity B-ADE
reactions I-ADE
to O
cyclosporine B-DRUG
are O
due O
to O
Cremophor B-DRUG
EL I-DRUG
. O

This O
is O
the O
first O
report O
of O
a O
possible O
association O
between O
an O
acute B-ADE
cardiovascular I-ADE
event I-ADE
and O
venlafaxine B-DRUG
. O

Temporary B-ADE
neurologic I-ADE
abnormalities I-ADE
were O
observed O
in O
one O
out O
of O
23 O
patients O
undergoing O
chemotherapy O
with O
high O
- O
dose O
methotrexate B-DRUG
( O
HD O
- O
MTX O
) O
for O
osteogenic O
sarcoma O
. O

Insulin B-DRUG
- O
induced O
lipohypertrophy B-ADE
: O
report O
of O
a O
case O
with O
histopathology O
. O

Anaphylaxis B-ADE
after O
the O
injection O
of O
chymopapain B-DRUG
occurs O
in O
about O
1 O
% O
of O
such O
cases O
. O

Salicylate O
intoxication B-ADE
was O
excluded O
, O
and O
theophylline B-DRUG
was O
finally O
incriminated O
. O

Less O
common O
adverse O
events O
to O
dapsone B-DRUG
include O
the O
idiosyncratic O
reactions O
of O
leukopenia B-ADE
and O
agranulocytosis B-ADE
, O
cutaneous B-ADE
eruptions I-ADE
, O
peripheral B-ADE
neuropathy I-ADE
, O
psychosis B-ADE
, O
toxic B-ADE
hepatitis I-ADE
, O
cholestatic B-ADE
jaundice I-ADE
, O
nephrotic B-ADE
syndrome I-ADE
, O
renal B-ADE
papillary I-ADE
necrosis I-ADE
, O
severe B-ADE
hypoalbuminemia I-ADE
without I-ADE
proteinuria I-ADE
, O
an B-ADE
infectious I-ADE
mononucleosis I-ADE
- I-ADE
like I-ADE
syndrome I-ADE
, O
and O
minor B-ADE
neurological I-ADE
and I-ADE
gastrointestinal I-ADE
complaints I-ADE
. O

CONCLUSION O
: O
This O
rare O
case O
of O
PTU B-DRUG
- O
induced O
ANCA B-ADE
- I-ADE
associated I-ADE
vasculitis I-ADE
manifested O
with O
ototoxicity B-ADE
in O
combination O
with O
systemic O
involvement O
. O

Upper B-ADE
gastrointestinal I-ADE
haemorrhage I-ADE
is O
a O
serious O
complication O
of O
aspirin B-DRUG
and O
clopidogrel B-DRUG
( O
dual O
) O
anti O
- O
platelet O
therapy O
with O
a O
high O
morbidity O
and O
mortality O
. O

Peculiar O
nail B-ADE
- I-ADE
changes I-ADE
in O
a O
70-year O
- O
old O
woman O
with O
rheumatoid O
arthritis O
occurring O
after O
approximately O
1 O
year O
of O
penicillamine B-DRUG
treatment O
are O
described O
. O

We O
describe O
a O
case O
of O
an O
NHL O
patient O
who O
received O
rituximab B-DRUG
and O
developed O
symptomatic O
, O
biopsy O
- O
proven O
multinodular O
bronchiolitis B-ADE
obliterans I-ADE
with I-ADE
organizing I-ADE
pneumonia I-ADE
( O
BOOP O
) O
. O

This O
is O
a O
report O
of O
a O
case O
of O
anuric B-ADE
ARF I-ADE
after O
high O
- O
dose O
mannitol B-DRUG
infusion O
for O
treatment O
of O
narrow O
- O
angle O
glaucoma O
that O
readily O
responded O
to O
acute O
hemodialysis O
. O

The O
toxic O
effects O
of O
methotrexate B-DRUG
included O
elevated B-ADE
liver I-ADE
transaminases I-ADE
( O
3/4 O
) O
, O
nausea B-ADE
( O
2/4 O
) O
, O
abdominal B-ADE
pain I-ADE
( O
2/4 O
) O
, O
bone B-ADE
pain I-ADE
( O
2/4 O
) O
, O
mild B-ADE
neutropenia I-ADE
( O
1/4 O
) O
, O
and O
mild B-ADE
pruritus I-ADE
( O
1/4 O
) O
. O

However O
, O
in O
1993 O
, O
a O
clinical O
study O
involving O
400 O
patients O
on O
the O
Thai O
- O
Burmese O
border O
revealed O
cardiac B-ADE
effects I-ADE
of O
antimalarial O
treatment O
with O
halofantrine B-DRUG
, O
including O
one O
sudden B-ADE
death I-ADE
after O
the O
treatment O
. O

OBJECTIVE O
: O
To O
report O
2 O
cases O
of O
serotonin B-ADE
syndrome I-ADE
with O
serious O
extrapyramidal B-ADE
movement I-ADE
disorders I-ADE
occurring O
when O
metoclopramide B-DRUG
was O
coadministered O
with O
sertraline B-DRUG
or O
venlafaxine B-DRUG
. O

Lithium B-DRUG
treatment O
was O
terminated O
in O
1975 O
because O
of O
lithium B-ADE
intoxication I-ADE
with O
a O
diabetes B-ADE
insipidus I-ADE
- I-ADE
like I-ADE
syndrome I-ADE
. O

We O
describe O
a O
patient O
who O
experienced O
a O
lichenoid B-ADE
eruption I-ADE
after O
the O
initiation O
of O
salsalate B-DRUG
for O
relief O
of O
arthritic O
pain O
. O

Splenic B-ADE
hemorrhage I-ADE
: O
a O
complication O
of O
tissue B-DRUG
plasminogen I-DRUG
activator I-DRUG
treatment O
. O

The O
risk O
of O
cardiac B-ADE
decompensation I-ADE
in O
infants O
with O
supraventricular O
tachycardia O
and O
congestive O
cardiac O
failure O
should O
be O
kept O
in O
mind O
prior O
to O
administration O
of O
verapamil B-DRUG
. O

We O
describe O
a O
patient O
who O
developed O
acute B-ADE
cerebellar I-ADE
syndrome I-ADE
after O
prophylactic O
intrathecal O
methotrexate B-DRUG
administration O
and O
recovered O
spontaneously O
. O

Parenteral O
- O
verapamil B-DRUG
- O
induced O
sustained B-ADE
hypotension I-ADE
. O

Transient B-ADE
neurological I-ADE
disturbances I-ADE
induced O
by O
the O
chemotherapy O
of O
high O
- O
dose O
methotrexate B-DRUG
for O
osteogenic O
sarcoma O
. O

Late O
lethal O
hepatitis B-ADE
B I-ADE
virus I-ADE
reactivation I-ADE
after O
rituximab B-DRUG
treatment O
of O
low O
- O
grade O
cutaneous O
B O
- O
cell O
lymphoma O
. O

A O
52 O
year O
- O
old O
male O
patient O
diagnosed O
of O
ankylosing O
spondylitis O
presented O
with O
an O
iron B-ADE
deficiency I-ADE
anemia I-ADE
after O
a O
ten O
- O
month O
treatment O
of O
methotrexate B-DRUG
. O

This O
case O
report O
illustrates O
the O
use O
of O
continuous O
high O
- O
dose O
intracoronary O
nitroglycerin O
infusion O
through O
a O
6 O
French O
coronary O
guiding O
catheter O
in O
the O
treatment O
of O
a O
patient O
with O
cocaine B-DRUG
- O
induced O
refractory B-ADE
coronary I-ADE
vasospasm I-ADE
. O

While O
most O
physicians O
are O
aware O
of O
heparin B-DRUG
- O
induced O
thrombocytopenia B-ADE
and O
skin B-ADE
necrosis I-ADE
, O
the O
association O
of O
heparin B-DRUG
and O
hyperkalemia B-ADE
is O
less O
well O
recognized O
. O

Although O
heparin O
- O
dependent O
antibodies O
( O
HDAs O
) O
typically O
manifest O
with O
thrombocytopenia O
as O
in O
heparin B-DRUG
- O
induced O
thrombocytopenia B-ADE
( O
HIT O
) O
, O
they O
may O
also O
manifest O
with O
preserved O
platelet O
counts O
. O

Antibiotic O
- O
associated O
colitis B-ADE
( O
pseudomembranous B-ADE
colitis I-ADE
) O
developed O
in O
four O
patients O
with O
spinal O
cord O
injury O
and O
taking O
oral O
trimethoprim B-DRUG
- O
sulfamethoxazole B-DRUG
. O

The O
fourth O
patient O
showed O
RLS B-ADE
symptoms I-ADE
that O
were O
initially O
caused O
by O
a O
20-mg O
daily O
olanzapine B-DRUG
dosage O
and O
were O
later O
mitigated O
when O
olanzapine O
was O
reduced O
and O
ropinirole O
was O
administered O
. O

We O
describe O
a O
patient O
with O
a O
liver B-ADE
abscess I-ADE
due O
to O
Entamoeba O
histolytica O
, O
in O
whom O
metronidazole B-DRUG
therapy O
( O
total O
dose O
, O
21 O
g O
over O
14 O
days O
) O
was O
complicated O
by O
reversible B-ADE
deafness I-ADE
, O
tinnitus B-ADE
, O
and O
ataxia B-ADE
and O
who O
relapsed O
5 O
months O
later O
with O
a O
splenic B-ADE
abscess I-ADE
. O

Patients O
treated O
with O
L B-DRUG
- I-DRUG
asparaginase I-DRUG
may O
present O
with O
hemorrhagic B-ADE
and O
thrombotic B-ADE
cerebrovascular I-ADE
events I-ADE
. O

In O
one O
patient O
the O
vasculitis B-ADE
resolved O
after O
termination O
of O
the O
ciprofloxacin B-DRUG
therapy O
; O
in O
the O
other O
patient O
the O
ciprofloxacin B-DRUG
- O
induced O
hemorrhagic B-ADE
vasculitis I-ADE
was O
superimposed O
on O
a O
severe B-ADE
forefoot I-ADE
infection I-ADE
, O
leading O
to O
progressive B-ADE
gangrene I-ADE
and O
a O
below B-ADE
- I-ADE
knee I-ADE
amputation I-ADE
. O

Development O
of O
essential O
thrombocythemia B-ADE
in O
a O
patient O
treated O
with O
interferon B-DRUG
alfa I-DRUG
and O
pentostatin B-DRUG
for O
hairy O
cell O
leukemia O
. O

Cataracts B-ADE
induced O
by O
intermittent O
Decadron B-DRUG
used O
as O
an O
antiemetic O
. O

Physicians O
should O
therefore O
be O
aware O
of O
its O
occurrence O
and O
carefully O
monitor O
serum O
levels O
of O
CPK O
, O
GOT O
and O
GPT O
during O
the O
treatment O
of O
diabetes O
insipidus O
with O
clofibrate B-DRUG
, O
especially O
in O
patients O
with O
associated O
hypothyroidism O
, O
latent O
or O
overt O
, O
which O
possibly O
favors O
the O
development O
of O
myopathy B-ADE
. O

Two O
patients O
who O
developed O
decreased B-ADE
visual I-ADE
acuity I-ADE
after O
several O
months O
of O
ethambutol B-DRUG
treatment O
for O
Mycobacterium O
avium O
- O
intracellulare O
infection O
had O
bitemporal B-ADE
visual I-ADE
field I-ADE
defects I-ADE
that O
suggested O
optic O
chiasm O
damage O
. O

Therefore O
, O
we O
diagnosed O
her O
eruption B-ADE
as O
contact B-ADE
dermatitis I-ADE
due O
to O
sodium B-DRUG
bisulfite I-DRUG
. O

There O
is O
evidence O
that O
the O
angiotensin O
II O
receptor O
antagonist O
, O
losartan B-DRUG
, O
increases B-ADE
urate I-ADE
excretion I-ADE
by O
reducing O
reabsorption O
of O
urate O
in O
the O
renal O
proximal O
tubule O
. O

A O
65-year O
- O
old O
woman O
with O
bipolar O
disorder O
and O
complicated O
cardiovascular O
disease O
who O
was O
on O
maintenance O
lithium B-DRUG
therapy O
developed O
a O
movement B-ADE
disorder I-ADE
following O
high O
doses O
of O
trazodone B-DRUG
for O
treatment O
of O
an O
acute O
depression O
. O

Fortunately O
, O
a O
hypersensitivity B-ADE
reaction I-ADE
to O
one O
formulation O
of O
cyclosporine B-DRUG
does O
not O
preclude O
use O
of O
a O
different O
formulation O
. O

Chronic B-ADE
photosensitivity I-ADE
associated O
with O
hydrochlorothiazide B-DRUG
ingestion O
occurred O
in O
four O
patients O
. O

Five O
patients O
are O
described O
in O
whom O
only O
gentamicin B-DRUG
sulfate I-DRUG
appeared O
responsible O
for O
acute B-ADE
renal I-ADE
failure I-ADE
. O

Cholestyramine B-DRUG
induced O
hyperchloremic B-ADE
metabolic I-ADE
acidosis I-ADE
. O

Agranulocytosis B-ADE
associated O
with O
ticlopidine B-DRUG
: O
a O
possible O
benefit O
with O
filgastim O
. O

This O
is O
a O
case O
report O
of O
fatal O
cryptococcal B-ADE
meningitis I-ADE
in O
a O
child O
with O
systemic O
lupus O
erythematosus O
being O
treated O
with O
prednisolone B-DRUG
and O
azathioprine B-DRUG
. O

This O
confirmed O
the O
history O
of O
captopril B-DRUG
- O
related O
asthma B-ADE
. O

Carbamazepine B-DRUG
- O
induced O
systemic B-ADE
lupus I-ADE
erythematosus I-ADE
- I-ADE
like I-ADE
disease I-ADE
. O

The O
patient O
continued O
to O
have O
fever B-ADE
and O
autonomic B-ADE
instability I-ADE
without O
evidence O
of O
infection O
which O
entirely O
resolved O
within O
24 O
hours O
of O
reinstitution O
of O
full O
preadmission O
dosing O
of O
oral O
baclofen B-DRUG
. O

Patients O
with O
lymphoblastic O
lymphoma O
who O
had O
treatment O
with O
L B-DRUG
- I-DRUG
asparaginase I-DRUG
and O
steroid O
are O
predisposed O
to O
the O
development O
of O
cortical B-ADE
venous I-ADE
thrombosis I-ADE
and O
may O
have O
this O
syndrome O
in O
addition O
to O
a O
dural B-ADE
puncture I-ADE
headache I-ADE
. O

Six O
days O
after O
starting O
acyclovir B-DRUG
she O
exhibited O
signs O
of O
lithium B-DRUG
toxicity I-ADE
. O

These O
observations O
indicate O
that O
submassive B-ADE
hepatic I-ADE
necrosis I-ADE
may O
result O
from O
treatment O
with O
propylthiouracil B-DRUG
and O
are O
consistent O
with O
the O
notion O
that O
sensitization O
mechanisms O
may O
be O
responsible O
for O
the O
hepatic B-ADE
injury I-ADE
induced O
by O
this O
drug O
. O

This O
case O
underscores O
problems O
in O
clinical O
management O
with O
sulfadiazine B-DRUG
hypersensitivity B-ADE
, O
potential O
immunosuppression O
from O
corticosteroids O
and O
selection O
of O
medications O
for O
recurrences O
of O
toxoplasmic O
chorioretinitis O
. O

PURPOSE O
: O
To O
report O
a O
case O
of O
bilateral B-ADE
anterior I-ADE
uveitis I-ADE
associated O
with O
ovulation O
induction O
therapy O
using O
clomiphene B-DRUG
citrate I-DRUG
. O

Severe O
erythroderma B-ADE
as O
a O
complication O
of O
continuous O
epoprostenol B-DRUG
therapy O
. O

We O
describe O
a O
patient O
who O
developed O
granulocytopenia B-ADE
and O
fever O
after O
taking O
dipyrone B-DRUG
and O
discuss O
the O
available O
literature O
. O

Acute B-ADE
abdomen I-ADE
due O
to O
endometriosis B-ADE
in O
a O
premenopausal O
woman O
taking O
tamoxifen B-DRUG
. O

Obsessive B-ADE
- I-ADE
compulsive I-ADE
symptoms I-ADE
suddenly O
emerged O
10 O
days O
after O
starting O
risperidone B-DRUG
and O
resolved O
within O
3 O
days O
of O
discontinuation O
. O

Reversal O
of O
ergotamine B-DRUG
- O
induced O
arteriospasm B-ADE
by O
mechanical O
intra O
- O
arterial O
dilatation O
. O

To O
our O
knowledge O
this O
is O
the O
first O
report O
of O
pancytopenia B-ADE
due O
to O
MMI B-DRUG
, O
where O
the O
usual O
hypoplasia O
found O
is O
replaced O
by O
massive B-ADE
plasmocytosis I-ADE
. O

We O
report O
a O
case O
of O
fulminant B-ADE
hepatic I-ADE
failure I-ADE
associated O
with O
didanosine B-DRUG
and O
masquerading O
as O
a O
surgical O
abdomen O
and O
compare O
the O
clinical O
, O
biologic O
, O
histologic O
, O
and O
ultrastructural O
findings O
with O
reports O
described O
previously O
. O

Depressive B-ADE
symptoms I-ADE
disappeared O
after O
interferon B-DRUG
therapy O
was O
stopped O
. O

A O
case O
of O
a O
53-year O
- O
old O
man O
who O
developed O
acute B-ADE
pneumonitis I-ADE
after O
bleomycin B-DRUG
and O
moderate O
oxygen B-DRUG
administration O
is O
presented O
. O

Systemic O
corticosteroids O
in O
the O
phenytoin B-DRUG
hypersensitivity I-ADE
syndrome I-ADE
. O

Pathogenesis O
of O
methotrexate B-DRUG
- O
induced O
papular B-ADE
eruption I-ADE
in O
psoriasis O
may O
involve O
immune O
mechanisms O
other O
than O
those O
of O
methotrexate B-DRUG
- O
induced O
cutaneous B-ADE
vasculitis I-ADE
in O
collagen O
vascular O
disease O
. O

Two O
of O
the O
five O
patients O
who O
worsened B-ADE
motorically I-ADE
also O
developed O
encephalopathy B-ADE
during O
risperidone B-DRUG
treatment O
; O
the O
encephalopathy O
resolved O
when O
the O
patients O
were O
switched O
to O
clozapine O
treatment O
. O

In O
this O
case O
senna B-DRUG
was O
likely O
the O
cause O
of O
a O
subacute B-ADE
cholestatic I-ADE
hepatitis I-ADE
exemplifying O
again O
the O
potential O
role O
of O
herbal O
related O
liver B-ADE
injury I-ADE
. O

We O
assume O
that O
rIFN B-DRUG
- I-DRUG
gamma I-DRUG
induced O
the O
de O
novo O
development O
of O
SLE B-ADE
in O
our O
patient O
. O

We O
present O
a O
case O
of O
an O
elderly O
woman O
with O
a O
pre O
- O
existing O
history O
of O
ischaemic O
heart O
disease O
, O
who O
was O
treated O
with O
venlafaxine B-DRUG
, O
and O
developed O
acute B-ADE
myocardial I-ADE
ischaemia I-ADE
within O
the O
first O
week O
of O
treatment O
. O

A O
60 O
year O
- O
old O
woman O
with O
chronic O
renal O
failure O
developed O
acute O
proximal B-ADE
muscle I-ADE
weakness I-ADE
after O
receiving O
a O
regular O
dosage O
of O
colchicine B-DRUG
. O

Acute O
interstitial B-ADE
pneumonia I-ADE
induced O
by O
ONO-1078 B-DRUG
( O
pranlukast B-DRUG
) O
, O
a O
leukotriene O
receptor O
antagonist O
. O

Hypernatraemia B-ADE
induced O
by O
sodium B-DRUG
polystyrene I-DRUG
sulphonate I-DRUG
( O
Kayexalate B-DRUG
) O
in O
two O
extremely O
low O
birth O
weight O
newborns O
. O

Eruptive B-ADE
epidermoid I-ADE
cysts I-ADE
resulting O
from O
treatment O
with O
imiquimod B-DRUG
. O

We O
describe O
a O
case O
of O
pneumonitis B-ADE
following O
local O
administration O
of O
methotrexate B-DRUG
for O
nonsurgical O
termination O
of O
an O
ectopic O
pregnancy O
. O

Rifampicin B-DRUG
- O
induced O
adrenal B-ADE
insufficiency I-ADE
in O
the O
acquired O
immunodeficiency O
syndrome O
: O
difficulties O
in O
diagnosis O
and O
treatment O
. O

Physicians O
should O
be O
aware O
of O
the O
possible O
association O
between O
the O
use O
of O
alteplase B-DRUG
and O
the O
development O
of O
subfascial B-ADE
hemorrhage I-ADE
. O

Postoperative O
hypocalcemic B-ADE
tetany I-ADE
caused O
by O
fleet B-DRUG
phospho I-DRUG
- I-DRUG
soda I-DRUG
preparation O
in O
a O
patient O
taking O
alendronate B-DRUG
sodium I-DRUG
: O
report O
of O
a O
case O
. O

The O
authors O
caution O
that O
treatment O
with O
alprazolam B-DRUG
may O
be O
complicated O
by O
the O
induction O
of O
mania B-ADE
. O

A O
45-year O
- O
old O
woman O
with O
steroid O
- O
dependent O
Crohn O
's O
colitis O
, O
successfully O
managed O
with O
maintenance O
infliximab B-DRUG
infusions O
and O
methotrexate B-DRUG
, O
developed O
a O
lupus B-ADE
- I-ADE
like I-ADE
syndrome I-ADE
eight O
months O
after O
her O
initial O
infusion O
. O

Oxcarbazepine B-DRUG
- O
induced O
Drug B-ADE
Reaction I-ADE
with I-ADE
Eosinophilia I-ADE
and I-ADE
Systemic I-ADE
Symptoms I-ADE
( O
DRESS B-ADE
) O
. O

Intraventricular O
vancomycin B-DRUG
- O
induced O
cerebrospinal B-ADE
fluid I-ADE
eosinophilia I-ADE
: O
report O
of O
two O
patients O
. O

Acute B-ADE
ocular I-ADE
ischemic I-ADE
change I-ADE
may O
be O
associated O
with O
intravitreal O
injection O
of O
bevacizumab B-DRUG
in O
patients O
with O
vascular O
compromised O
diabetic O
retinopathy O
and/or O
underlying O
stenosis O
of O
the O
carotid O
artery O
. O

Progressive B-ADE
hypokalemia I-ADE
developed O
during O
phosphate B-DRUG
treatment O
. O

We O
report O
a O
patient O
with O
recurrent O
, O
increasingly O
severe O
episodes O
of O
PPE B-ADE
, O
ultimately O
complicated O
by O
a O
severe O
bullous B-ADE
eruption I-ADE
, O
following O
successive O
cycles O
of O
high O
- O
dose O
cytarabine B-DRUG
for O
the O
treatment O
of O
acute O
lymphoblastic O
leukaemia O
. O

Thrombocytosis B-ADE
induced O
by O
enoxaparin B-DRUG
has O
been O
reported O
as O
a O
rare O
adverse O
effect O
of O
this O
medication O
in O
adults O
. O

Sirolimus B-DRUG
- O
associated O
hepatotoxicity B-ADE
in O
the O
kidney O
graft O
recipient O
. O

Development O
of O
an O
extensive B-ADE
skin I-ADE
rash I-ADE
following O
a O
single O
dose O
of O
MTX B-DRUG
may O
be O
an O
early O
warning O
sign O
for O
life O
- O
threatening O
bone O
marrow O
aplasia O
. O

OBJECTIVE O
: O
To O
report O
a O
fatal O
case O
of O
toxic B-ADE
epidermal I-ADE
necrolysis I-ADE
in O
a O
man O
who O
was O
treated O
with O
oral O
ofloxacin B-DRUG
for O
epididymitis O
. O

Localized B-ADE
purpura I-ADE
associated O
with O
lamotrigine B-DRUG
. O

Our O
findings O
suggest O
that O
hyperkalemia B-ADE
can O
develop O
with O
the O
use O
of O
low O
- O
dose O
heparin B-DRUG
, O
within O
seven O
days O
of O
initiating O
heparin B-DRUG
therapy O
, O
and O
that O
patients O
with O
diabetes O
mellitus O
or O
chronic O
renal O
insufficiency O
are O
especially O
predisposed O
to O
this O
complication O
. O

Neurotoxicity B-ADE
of O
intrathecal O
administration O
of O
amphotericin B-DRUG
B I-DRUG
. O

Fibrosis B-ADE
of I-ADE
corpus I-ADE
cavernosum I-ADE
after O
intracavernous O
injection O
of O
phentolamine B-DRUG
/ O
papaverine B-DRUG
. O

Sustained B-ADE
monomorphic I-ADE
ventricular I-ADE
tachycardia I-ADE
after O
adenosine B-DRUG
infusion O
. O

A O
small O
initial O
dose O
of O
prazosin B-DRUG
ranging O
from O
0.5 O
to O
1 O
mg O
has O
been O
recommended O
to O
avoid O
the O
first O
- O
dose O
phenomenon O
characterized O
by O
a O
sudden O
and O
severe B-ADE
drop I-ADE
in I-ADE
blood I-ADE
pressure I-ADE
after O
the O
administration O
of O
the O
first O
dose O
of O
prazosin B-DRUG
. O

Dural B-ADE
sinus I-ADE
thrombosis I-ADE
developed O
in O
two O
children O
with O
acute O
lymphoblastic O
leukemia O
during O
induction O
treatment O
with O
vincristine B-DRUG
sulfate I-DRUG
, O
prednisone B-DRUG
, O
and O
asparaginase B-DRUG
. O

Although O
a O
lot O
of O
amiodarone B-DRUG
- O
induced O
torsades B-ADE
de I-ADE
pointe I-ADE
have O
been O
published O
, O
a O
review O
of O
all O
these O
cases O
and O
the O
underlying O
risk O
- O
factors O
has O
never O
been O
made O
. O

Rituximab B-DRUG
- I-DRUG
CHOP I-DRUG
induced O
interstitial B-ADE
pneumonitis I-ADE
in O
patients O
with O
disseminated O
extranodal O
marginal O
zone O
B O
cell O
lymphoma O
. O

Transient O
phenytoin B-DRUG
induced O
IgA B-ADE
deficiency I-ADE
and O
permanent O
IgE B-ADE
increase I-ADE
. O

The O
patient O
expired O
after O
seven O
cycles O
of O
treatment O
had O
been O
completed O
because O
of O
pulmonary B-ADE
fibrosis I-ADE
and O
the O
drug O
toxicity O
of O
bleomycin B-DRUG
. O

Progressive B-ADE
hypoxemia I-ADE
mandated O
endotracheal O
intubation O
1 O
week O
after O
rituximab B-DRUG
administration O
and O
led O
to O
death O
4 O
weeks O
after O
admission O
. O

Thus O
, O
we O
confirm O
that O
desensitization O
may O
be O
a O
safe O
procedure O
in O
patients O
with O
cancer O
who O
experience O
methotrexate B-DRUG
- O
induced O
anaphylaxis B-ADE
. O

Chronic O
myelogenous O
leukemia O
( O
CML O
) O
, O
hepatitis O
C O
, O
and O
interferon B-DRUG
alpha I-DRUG
( O
IFNalpha B-DRUG
) O
have O
all O
been O
associated O
with O
renal B-ADE
dysfunction I-ADE
. O

Serotonin B-ADE
syndrome I-ADE
induced O
by O
transitioning O
from O
phenelzine B-DRUG
to O
venlafaxine B-DRUG
: O
four O
patient O
reports O
. O

A O
patient O
, O
while O
on O
intravenous O
ritodrine B-DRUG
therapy O
for O
preterm O
labor O
, O
experienced O
an O
episode O
of O
acute B-ADE
chest I-ADE
pain I-ADE
. O

We O
report O
a O
case O
of O
amiodarone B-DRUG
- O
induced O
thyrotoxicosis B-ADE
of O
protracted O
duration O
, O
unresponsive O
to O
conventional O
thionamide O
therapy O
, O
with O
therapy O
limited O
by O
severe O
adverse O
drug O
reactions O
. O

HUS B-ADE
has O
been O
reported O
after O
several O
anticancer O
chemotherapies O
and O
most O
often O
after O
mitomycin B-DRUG
C I-DRUG
- O
based O
chemotherapy O
regimens O
. O

To O
treat O
hepatitis O
B O
, O
interferon B-DRUG
alpha I-DRUG
was O
administered O
until O
the O
proximal O
muscle B-ADE
weakness I-ADE
developed O
. O

Severe B-ADE
hepatocellular I-ADE
dysfunction I-ADE
following O
cyproterone B-DRUG
acetate I-DRUG
therapy O
. O

We O
present O
the O
first O
case O
( O
to O
our O
knowledge O
) O
of O
a O
potentially O
serious O
drug B-ADE
- I-ADE
drug I-ADE
interaction I-ADE
between O
zafirlukast B-DRUG
and O
theophylline B-DRUG
. O

However O
, O
follow O
- O
up O
revealed O
that O
gestational B-ADE
diabetes I-ADE
when O
associated O
with O
norethisterone B-DRUG
had O
a O
lesser O
risk O
of O
emerging O
diabetes B-ADE
mellitus I-ADE
and O
impaired B-ADE
glucose I-ADE
tolerance I-ADE
. O

The O
ampicillin B-DRUG
rash I-ADE
occurring O
in O
cases O
of O
infectious O
mononucleosis O
is O
well O
documented O
. O

Eleven O
patients O
developed O
infection B-ADE
requiring O
hospitalization O
while O
taking O
leflunomide B-DRUG
including O
: O
lower B-ADE
respiratory I-ADE
tract I-ADE
infections I-ADE
( O
3 O
) O
, O
cellulitis B-ADE
( O
2 O
) O
, O
disseminated B-ADE
herpes I-ADE
zoster I-ADE
( O
2 O
) O
, O
probable O
TB B-ADE
liver I-ADE
( O
1 O
) O
, O
abdominal B-ADE
sepsis I-ADE
( O
1 O
) O
, O
mycotic B-ADE
aneurysm I-ADE
( O
1 O
) O
and O
gastroenteritis B-ADE
( O
1 O
) O
. O

Aggressive B-ADE
endometrial I-ADE
carcinoma I-ADE
in O
a O
breast O
cancer O
patient O
treated O
with O
tamoxifen B-DRUG
with O
normal O
transvaginal O
ultrasonography O
. O

Mefloquine B-DRUG
- O
associated O
hypoglycaemia B-ADE
in O
a O
cachectic O
AIDS O
patient O
. O

This O
is O
the O
first O
report O
of O
non B-ADE
- I-ADE
convulsive I-ADE
status I-ADE
epilepticus I-ADE
provoked O
by O
tiagabine B-DRUG
in O
adolescent O
patients O
. O

A O
48-year O
- O
old O
woman O
who O
was O
treated O
for O
thyrotoxicosis O
with O
methimazole B-DRUG
developed O
agranulocytosis B-ADE
. O

She O
was O
receiving O
phenytoin B-DRUG
sodium I-DRUG
300 O
mg O
/ O
day O
; O
carbamazepine B-DRUG
200 O
mg O
four O
times O
daily O
had O
been O
discontinued O
four O
days O
before O
admission O
because O
of O
leukopenia B-ADE
. O

After O
administration O
of O
Oxybutynin B-DRUG
concomitantly O
with O
an O
increase O
in O
the O
dose O
of O
Dantrolene B-DRUG
, O
she O
presented O
the O
clinical O
symptoms O
and O
laboratory O
finding O
of O
Carbamazepine B-DRUG
intoxication I-ADE
. O

This O
eruption B-ADE
appears O
to O
be O
a O
distinct O
cutaneous O
toxicity O
of O
PLD B-DRUG
. O

Deepening B-ADE
of I-ADE
lid I-ADE
sulcus I-ADE
from O
topical O
bimatoprost B-DRUG
therapy O
. O

Although O
various O
manifestations O
of O
pentamidine B-DRUG
- O
induced O
cardiotoxicity B-ADE
have O
been O
reported O
, O
to O
our O
knowledge O
, O
second B-ADE
- I-ADE
degree I-ADE
heart I-ADE
block I-ADE
associated O
with O
this O
agent O
has O
not O
been O
described O
. O

Ten O
days O
after O
itraconazole B-DRUG
was O
started O
, O
he O
developed O
paralytic B-ADE
ileus I-ADE
, O
neurogenic B-ADE
bladder I-ADE
, O
mild B-ADE
left I-ADE
ptosis I-ADE
, O
and O
absence B-ADE
of I-ADE
deep I-ADE
reflexes I-ADE
, O
with O
severe B-ADE
paralysis I-ADE
of I-ADE
the I-ADE
lower I-ADE
extremities I-ADE
and O
mild B-ADE
weakness I-ADE
of I-ADE
the I-ADE
upper I-ADE
extremities I-ADE
. O

A O
dapsone B-DRUG
hypersensitivity B-ADE
syndrome I-ADE
, O
consisting O
of O
fever B-ADE
, O
headache B-ADE
, O
nausea B-ADE
, O
vomiting B-ADE
, O
lymphadenopathy B-ADE
, O
hepatitis B-ADE
, O
hemolysis B-ADE
, O
leukopenia B-ADE
, O
and O
mononucleosis B-ADE
, O
has O
been O
described O
in O
patients O
treated O
with O
the O
drug O
for O
leprosy O
. O

Progressive B-ADE
pulmonary I-ADE
fibrosis I-ADE
complicating O
cyclophosphamide B-DRUG
therapy O
. O

The O
evidence O
of O
high O
plasmatic O
levels O
of O
CBZ B-DRUG
and O
the O
absence O
of O
other O
aetiologic O
factors O
lead O
the O
authors O
to O
conclude O
that O
the O
overdose O
of O
CBZ B-DRUG
could O
have O
represented O
the O
precipitating O
of O
the O
episode O
of O
acute B-ADE
pancreatitis I-ADE
. O

We O
report O
an O
unusual O
pattern O
of O
supravenous B-ADE
hyperpigmentation I-ADE
occurring O
after O
CHOP B-DRUG
chemotherapy O
. O

We O
hypothesize O
that O
decreased O
renal O
elimination O
of O
MTX B-DRUG
induced O
by O
the O
COX-2 O
inhibitor O
resulted O
in O
enhanced O
hematopoietic B-ADE
toxicity I-ADE
and O
immunosuppression B-ADE
causing O
the O
EBV B-ADE
- I-ADE
associated I-ADE
lymphoproliferative I-ADE
disease I-ADE
. O

Hydroxyurea B-DRUG
- O
induced O
acute B-ADE
interstitial I-ADE
pneumonitis I-ADE
in O
a O
patient O
with O
essential O
thrombocythemia O
. O

Cardiac O
glycosides O
are O
thought O
to O
prevent O
doxorubicin B-DRUG
cardiomyopathy B-ADE
by O
competitively O
inhibiting O
doxorubicin O
at O
its O
receptor O
sites O
, O
but O
ouabain O
has O
a O
much O
shorter O
half O
life O
than O
doxorubicin O
and O
its O
metabolites O
and O
so O
is O
less O
effective O
than O
digoxin O
. O

Erosion B-ADE
of I-ADE
psoriatic I-ADE
plaques I-ADE
: O
an O
early O
sign O
of O
methotrexate B-ADE
toxicity I-ADE
. O

Rapid O
resolution O
of O
topiramate B-DRUG
- O
induced O
angle B-ADE
- I-ADE
closure I-ADE
glaucoma I-ADE
with O
methylprednisolone B-DRUG
and O
mannitol B-DRUG
. O

After O
nine O
previous O
uncomplicated O
cycles O
she O
developed O
severe O
anaphylaxis B-ADE
to O
cisplatin B-DRUG
. O

Case O
report O
: O
acute B-ADE
renal I-ADE
failure I-ADE
after O
administering O
intravenous O
immunoglobulin B-DRUG
. O

L B-DRUG
- I-DRUG
asparaginase I-DRUG
- O
induced O
pancreatitis B-ADE
has O
been O
reported O
during O
or O
closely O
following O
administration O
of O
the O
drug O
. O

Two O
cases O
are O
reported O
of O
patients O
who O
developed O
a O
hematologic B-ADE
malignancy I-ADE
several O
years O
after O
intravesical O
chemotherapy O
of O
superficial O
bladder O
cancer O
with O
etoglucid B-DRUG
, O
doxorubicin B-DRUG
, O
and O
mitomycin B-DRUG
C I-DRUG
. O

We O
report O
a O
case O
of O
codeine B-DRUG
intoxication I-ADE
in O
the O
neonate O
, O
in O
which O
the O
drug O
was O
prescribed O
for O
cough O
control O
during O
an O
emergency O
department O
visit O
. O

The O
authors O
conclude O
that O
among O
patients O
taking O
high O
doses O
of O
oral O
niacin B-DRUG
only O
those O
who O
experience O
visual B-ADE
symptoms I-ADE
need O
to O
be O
ophthalmologically O
evaluated O
. O

The O
fetal B-ADE
valproate I-ADE
syndrome I-ADE
( O
FVS B-ADE
) O
is O
characterized O
by O
distinctive B-ADE
facial I-ADE
appearance I-ADE
, O
major B-ADE
and I-ADE
minor I-ADE
malformations I-ADE
, O
and O
developmental B-ADE
delay I-ADE
. O

Early O
- O
onset O
acute B-ADE
transverse I-ADE
myelitis I-ADE
following O
hepatitis B-DRUG
B I-DRUG
vaccination I-DRUG
and O
respiratory O
infection O
: O
case O
report O
. O

A O
case O
is O
presented O
which O
illustrates O
a O
probably O
fatal B-ADE
interaction I-ADE
between O
minoxidil B-DRUG
and O
a O
coagulation O
disorder O
. O

We O
diagnosed O
this O
case O
as O
danazol B-DRUG
induced O
thrombocytopenia B-ADE
. O

A O
10-year O
- O
old O
girl O
with O
Lennox O
- O
Gastaut O
syndrome O
who O
received O
intravenous O
lorazepam B-DRUG
for O
atypical O
absence O
status O
seizures B-ADE
is O
reported O
. O

Although O
differential O
diagnostic O
alternatives O
can O
be O
considered O
in O
all O
described O
cases O
it O
is O
very O
likely O
that O
vincristine B-DRUG
does O
cause O
severe B-ADE
visual I-ADE
loss I-ADE
in O
a O
small O
number O
of O
patients O
. O

This O
patient O
rapidly O
progressed O
from O
mild B-ADE
neurotoxicity I-ADE
to O
fatal B-ADE
encephalopathy I-ADE
after O
one O
dose O
of O
intrathecal O
methotrexate B-DRUG
during O
his O
third O
cycle O
of O
chemotherapy O
. O

His O
impaired B-ADE
memory I-ADE
was O
found O
to O
be O
due O
to O
the O
atenolol B-DRUG
he O
was O
on O
and O
he O
made O
a O
complete O
recovery O
on O
withdrawing O
the O
beta O
- O
blocker O
. O

She O
died O
within O
six O
weeks O
of O
developing O
congestive B-ADE
heart I-ADE
failure I-ADE
coupled O
with O
liver B-ADE
failure I-ADE
due O
to O
haemosiderosis B-ADE
despite O
regular O
use O
of O
desferrioxamine B-DRUG
. O

Bleomycin B-DRUG
induced O
hyperpigmentation B-ADE
with O
yolk O
sac O
tumor O
. O

Two O
children O
with O
rheumatic O
fever O
developed O
anicteric B-ADE
hepatitis I-ADE
while O
on O
high O
- O
dose O
aspirin B-DRUG
therapy O
. O

Aliskiren B-DRUG
- O
associated O
acute B-ADE
renal I-ADE
failure I-ADE
with O
hyperkalemia O
. O

Dyspnea B-ADE
possibly O
associated O
with O
controlled O
- O
release O
morphine B-DRUG
sulfate I-DRUG
tablets O
. O

Atypical O
neuroleptic B-ADE
malignant I-ADE
syndrome I-ADE
associated O
with O
olanzapine B-DRUG
. O

We O
report O
5 O
cases O
of O
acute B-ADE
reversible I-ADE
renal I-ADE
failure I-ADE
coinciding O
with O
the O
onset O
of O
treatment O
with O
captopril B-DRUG
in O
patients O
with O
severe O
drug O
- O
resistant O
hypertension O
. O

Graft B-ADE
versus I-ADE
host I-ADE
- I-ADE
like I-ADE
illness I-ADE
in O
a O
child O
with O
phenobarbital B-DRUG
hypersensitivity B-ADE
. O

Although O
there O
have O
been O
numerous O
reports O
of O
effusions O
, O
none O
have O
provided O
complete O
pleural O
fluid O
analysis O
; O
therefore O
, O
we O
report O
2 O
patients O
with O
dasatinib B-DRUG
- O
induced O
pleural B-ADE
effusion I-ADE
with O
complete O
pleural O
fluid O
analysis O
. O

A O
second O
patient O
with O
a O
similar O
glucose O
tolerance O
test O
result O
showed O
postprandial B-ADE
hyperglycemia I-ADE
when O
treated O
similarly O
with O
betamethasone B-DRUG
valerate I-DRUG
cream O
0.1 O
% O
. O

Colchicine B-DRUG
- O
induced O
myopathy B-ADE
in O
a O
teenager O
with O
familial O
Mediterranean O
fever O
. O

We O
describe O
the O
clinical O
and O
liver O
biopsy O
morphologic O
features O
for O
4 O
patients O
with O
minocycline B-DRUG
- O
induced O
autoimmune B-ADE
hepatitis I-ADE
( O
group O
1 O
) O
. O

The O
majority O
of O
radiation B-ADE
recall I-ADE
reactions I-ADE
attributed O
to O
gemcitabine B-DRUG
are O
reported O
to O
affect O
internal O
tissue O
or O
organs O
. O

Ciprofloxacin B-DRUG
- O
induced O
renal B-ADE
insufficiency I-ADE
in O
cystic O
fibrosis O
. O

Fixed O
drug O
eruption B-ADE
in O
hands O
caused O
by O
omeprazole B-DRUG
. O

Minimal B-ADE
change I-ADE
disease I-ADE
in O
a O
patient O
receiving O
IFN B-DRUG
- I-DRUG
alpha I-DRUG
therapy O
for O
chronic O
hepatitis O
C O
virus O
infection O
. O

Factors O
that O
suggested O
an O
association O
between O
the O
severe B-ADE
angioedematous I-ADE
reaction I-ADE
and O
BP B-DRUG
topical O
application O
include O
the O
strong O
reaction O
to O
BP O
in O
the O
patch O
- O
test O
, O
the O
temporal O
relationship O
, O
the O
complete O
resolution O
of O
symptoms O
after O
the O
drug O
was O
withdrawn O
and O
the O
absence O
of O
other O
identified O
explanations O
. O

Lansoprazole B-DRUG
- O
associated O
collagenous B-ADE
colitis I-ADE
: O
a O
case O
report O
. O

Acute B-ADE
kidney I-ADE
injury I-ADE
caused O
by O
zonisamide B-DRUG
- O
induced O
hypersensitivity B-ADE
syndrome I-ADE
. O

Myoclonus B-ADE
associated O
with O
continuous O
dobutamine B-DRUG
infusion O
in O
a O
patient O
with O
end O
- O
stage O
renal O
disease O
. O

We O
report O
the O
case O
histories O
of O
identical O
twin O
brothers O
who O
developed O
concordant O
acute O
lymphoblastic O
leukemia O
at O
the O
age O
of O
4 O
years O
and O
who O
later O
developed O
leukoencephalopathy B-ADE
and O
hydrocephalus B-ADE
related O
to O
central O
nervous O
system O
prophylaxis O
by O
, O
in O
the O
first O
case O
intrathecally O
administered O
methotrexate B-DRUG
and O
, O
in O
the O
second O
by O
intrathecally O
administered O
methotrexate B-DRUG
and O
cranial O
irradiation O
. O

We O
report O
the O
syndrome O
of O
inappropriate O
antidiuresis B-ADE
as O
a O
much O
earlier O
side O
- O
effect O
of O
carbamazepine B-DRUG
administration O
in O
a O
29-year O
Nigerian O
female O
patient O
with O
generalized O
tonic O
- O
elonic O
seizures O
. O

The O
renal O
consequences O
of O
indinavir B-DRUG
- O
associated O
nephrotoxicity B-ADE
are O
uncertain O
. O

Radiation B-ADE
recall I-ADE
related O
to O
gemcitabine B-DRUG
has O
been O
reported O
in O
lung O
and O
breast O
cancer O
. O

Caution O
is O
, O
therefore O
, O
needed O
to O
prevent O
undesired O
accumulation O
of O
TCA B-DRUG
that O
may O
lead O
to O
protracted O
Cushing B-ADE
's I-ADE
syndrome I-ADE
. O

Without O
other O
causes O
for O
the O
hyponatremia B-ADE
, O
she O
was O
diagnosed O
with O
the O
syndrome B-ADE
of I-ADE
inappropriate I-ADE
antidiuretic I-ADE
hormone I-ADE
, O
presumably O
caused O
by O
desmopressin B-DRUG
. O

OBJECTIVE O
: O
To O
describe O
two O
cases O
of O
rhabdomyolysis B-ADE
in O
patients O
taking O
lovastatin B-DRUG
that O
were O
precipitated O
by O
the O
use O
of O
the O
newer O
macrolide O
antibiotics O
clarithromycin B-DRUG
and O
azithromycin B-DRUG
. O

In O
a O
postoperative O
patient O
with O
pre O
- O
existent O
myasthenia O
gravis O
, O
oral O
verapamil B-DRUG
caused O
a O
marked O
exacerbation B-ADE
in I-ADE
myasthenic I-ADE
weakness I-ADE
. O

Neutropenia B-ADE
and O
agranulocytosis B-ADE
are O
risks O
known O
to O
occur O
with O
phenothiazines B-DRUG
and O
clozapine B-DRUG
. O

A O
53 O
year O
old O
Greenlandic O
male O
was O
admitted O
twice O
over O
a O
period O
of O
4 O
years O
with O
a O
new O
complete O
right B-ADE
bundle I-ADE
branch I-ADE
block I-ADE
after O
ingestion O
of O
10 O
g O
and O
4 O
g O
of O
carbamazepine B-DRUG
respectively O
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
neuroleptic B-ADE
malignant I-ADE
syndrome I-ADE
( O
NMS B-ADE
) O
associated O
with O
fluphenazine B-DRUG
in O
a O
schizophrenic O
patient O
and O
review O
the O
literature O
related O
to O
this O
condition O
. O

The O
authors O
postulate O
that O
two O
types O
of O
combined O
lithium O
- O
neuroleptic O
toxicity O
occur O
: O
a O
neuroleptic B-ADE
malignant I-ADE
extrapyramidal I-ADE
syndrome I-ADE
and O
a O
lithium B-DRUG
toxicity I-ADE
that O
occurs O
in O
combination O
with O
phenothiazines O
, O
primarily O
thioridazine B-DRUG
. O

Enalapril B-DRUG
- O
induced O
anemia B-ADE
in O
two O
kidney O
transplant O
recipients O
. O

Milk B-ADE
- I-ADE
alkali I-ADE
syndrome I-ADE
induced O
by O
1,25(OH)2D B-DRUG
in O
a O
patient O
with O
hypoparathyroidism O
. O

Clozapine B-DRUG
- O
induced O
eosinophilia B-ADE
and O
switch O
to O
quetiapine O
in O
a O
patient O
with O
chronic O
schizophrenia O
with O
suicidal O
tendencies O
. O

This O
experience O
supports O
the O
hypothesis O
that O
heparin O
can O
be O
readministered O
early O
to O
patients O
with O
heparin B-DRUG
- O
associated O
thrombocytopenia B-ADE
and O
thrombosis B-ADE
, O
provided O
antiplatelet O
therapy O
is O
given O
. O

Reversible B-ADE
cardiomyopathy I-ADE
caused O
by O
administration O
of O
interferon B-DRUG
alpha I-DRUG
. O

Retinopathy B-ADE
in O
hepatitis O
C O
patients O
due O
to O
combination O
therapy O
with O
pegylated B-DRUG
interferon I-DRUG
and O
ribavirin B-DRUG
. O

We O
present O
a O
fatal B-ADE
case O
of O
subacute O
methanol B-ADE
toxicity I-ADE
with O
associated O
diffuse B-ADE
brain I-ADE
involvement I-ADE
, O
including O
bilateral B-ADE
putaminal I-ADE
necrosis I-ADE
and O
cerebral B-ADE
edema I-ADE
with O
ventricular B-ADE
compression I-ADE
. O

Abrupt O
, O
accidental O
withdrawal O
of O
trihexyphenidyl B-DRUG
triggered O
severe O
exacerbation O
of O
the O
cranial B-ADE
dystonia I-ADE
associated O
with O
inspiratory B-ADE
stridor I-ADE
and O
acute B-ADE
respiratory I-ADE
difficulties I-ADE
, O
prompting O
emergency O
admission O
. O

The O
frequency O
and O
relationship O
of O
granulocytopenia B-ADE
caused O
by O
sustained O
- O
release O
procainamide B-DRUG
in O
patients O
with O
tachyarrhythmias O
are O
briefly O
discussed O
, O
and O
prior O
reported O
cases O
are O
reviewed O
. O

To O
our O
knowledge O
, O
this O
is O
the O
first O
report O
of O
significant O
hypotension B-ADE
associated O
with O
intravenous O
valproate B-DRUG
in O
the O
treatment O
of O
status O
epilepticus O
in O
the O
pediatric O
population O
. O

Ibopamine B-DRUG
- O
induced O
reversible O
leukopenia B-ADE
during O
treatment O
for O
congestive O
heart O
failure O
. O

In O
contrast O
to O
chronic O
or O
subacute B-ADE
thyroiditis I-ADE
, O
Graves B-ADE
' I-ADE
disease I-ADE
rarely O
complicates O
IFN B-DRUG
- I-DRUG
alpha I-DRUG
therapy O
for O
chronic O
viral O
C O
hepatitis O
. O

Cardiopulmonary B-ADE
arrest I-ADE
following O
intravenous O
phenytoin B-DRUG
loading O
. O

Induction O
of O
systemic B-ADE
lupus I-ADE
erythematosus I-ADE
by O
interferon B-DRUG
- I-DRUG
gamma I-DRUG
in O
a O
patient O
with O
rheumatoid O
arthritis O
. O

We O
also O
describe O
a O
case O
of O
timolol B-DRUG
- O
induced O
ocular B-ADE
pemphigoid I-ADE
. O

Ciprofloxacin B-DRUG
- O
induced O
hemorrhagic B-ADE
vasculitis I-ADE
. O

Heparin B-DRUG
- O
induced O
thrombocytopenia B-ADE
is O
a O
rare O
and O
serious O
complication O
of O
anticoagulation O
therapy O
. O

We O
report O
the O
case O
of O
a O
female O
acromegalic O
patient O
in O
whom O
multiple O
hepatic B-ADE
adenomas I-ADE
appeared O
soon O
after O
danazol B-DRUG
treatment O
for O
uterine O
fibromatosis O
. O

Focal B-ADE
renal I-ADE
cortical I-ADE
necrosis I-ADE
associated O
with O
zomepirac B-DRUG
. O

RESULTS O
: O
Evidence O
of O
neurological O
improvement O
and O
rehabilitation O
potential O
after O
severe B-ADE
myelopathy I-ADE
due O
to O
intrathecal O
injection O
of O
doxorubicin B-DRUG
. O

A O
patient O
developed O
transient O
, O
acute B-ADE
myopia I-ADE
while O
on O
isotretinoin B-DRUG
( O
Accutane B-DRUG
) O
therapy O
for O
acne O
. O

Hyperkalaemia B-ADE
with O
renal B-ADE
tubular I-ADE
dysfunction I-ADE
by O
sulfamethoxazole B-DRUG
- I-DRUG
trimethoprim I-DRUG
for O
Pneumocystis O
carinii O
pneumonia O
in O
patients O
with O
lymphoid O
malignancy O
. O

Isotretinoin B-DRUG
teratogenicity B-ADE
. O

We O
report O
the O
case O
of O
a O
43-year O
- O
old O
man O
with O
ITP O
refractory O
to O
steroids O
and O
intravenous O
immunoglobulin O
who O
developed O
acute B-ADE
respiratory I-ADE
distress I-ADE
syndrome I-ADE
( O
ARDS B-ADE
) O
after O
a O
single O
infusion O
of O
rituximab B-DRUG
. O

Type O
II O
heparin B-DRUG
- O
induced O
thrombocytopenia B-ADE
( O
HIT O
) O
is O
an O
immunological O
disorder O
characterized O
by O
antibodies O
to O
heparin O
- O
platelet O
factor O
4 O
complexes O
and O
a O
high O
risk O
of O
thrombotic O
complications O
. O

A O
patient O
developed O
papilloedema B-ADE
and O
hepatic B-ADE
dysfunction I-ADE
while O
being O
treated O
with O
perhexiline B-DRUG
maleate I-DRUG
. O

OBJECTIVE O
: O
The O
purpose O
of O
this O
study O
was O
to O
determine O
whether O
desensitization O
to O
NPH B-DRUG
insulin I-DRUG
, O
as O
well O
as O
standard O
insulin B-DRUG
desensitization O
, O
could O
control O
allergic B-ADE
symptoms I-ADE
in O
a O
patient O
allergic O
to O
both O
NPH O
and O
regular O
insulin O
. O

We O
report O
a O
case O
of O
a O
previously O
healthy O
, O
postmenopausal O
woman O
who O
developed O
anticonvulsant B-ADE
hypersensitivity I-ADE
syndrome I-ADE
while O
taking O
Bellamine B-DRUG
S I-DRUG
( O
belladonna B-DRUG
alkaloids I-DRUG
; O
ergotamine B-DRUG
; O
phenobarbital B-DRUG
) O
for O
hot O
flashes O
. O

This O
latest O
( O
third O
) O
report O
suggests O
that O
the O
safety O
profile O
should O
be O
reexamined O
and O
at O
least O
raises O
the O
question O
of O
potential O
renal B-ADE
toxicity I-ADE
of O
interferons B-DRUG
in O
MS O
. O

Acute O
aluminum B-ADE
toxicity I-ADE
after O
continuous O
intravesical O
alum B-DRUG
irrigation O
for O
hemorrhagic O
cystitis O
. O

CONCLUSIONS O
: O
We O
have O
seen O
an O
increased O
incidence O
of O
acute O
INH B-DRUG
neurotoxicity B-ADE
because O
of O
the O
resurgence O
of O
TB O
in O
New O
York O
City O
. O

Amphotericin B-DRUG
B I-DRUG
( O
AmB B-DRUG
) O
is O
effective O
, O
but O
its O
use O
is O
limited O
by O
toxicity O
: O
renal B-ADE
impairment I-ADE
, O
anaemia B-ADE
, O
fever B-ADE
, O
malaise B-ADE
, O
and O
hypokalaemia B-ADE
are O
common O
. O

Transient O
leucopenia B-ADE
and O
thrombocytopenia B-ADE
associated O
with O
sodium B-DRUG
nitroprusside I-DRUG
infusion O
. O

A O
65-year O
- O
old O
female O
patient O
presented O
with O
jaundice B-ADE
followed O
2 O
days O
later O
by O
severe B-ADE
dyspnea I-ADE
and O
tachypnea B-ADE
which O
worsened O
when O
patient O
was O
lying O
flat O
, O
1 O
week O
after O
the O
fourth O
dose O
of O
adalimumab B-DRUG
. O

The O
patient O
's O
clinical O
presentation O
, O
histologic O
features O
on O
liver O
biopsy O
and O
favorable O
course O
after O
stopping O
the O
drug O
suggest O
that O
barbiturates B-DRUG
can O
be O
added O
to O
the O
list O
of O
agents O
which O
can O
cause O
submassive B-ADE
hepatic I-ADE
necrosis I-ADE
. O

A O
case O
of O
colchicine B-DRUG
- O
induced O
rhabdomyolysis B-ADE
is O
reported O
. O

A O
case O
of O
skeletal B-ADE
fluorosis I-ADE
induced O
by O
prolonged O
treatment O
with O
niflumic B-DRUG
acid I-DRUG
, O
a O
fast O
- O
acting O
non O
- O
steroid O
antiinflammatory O
agent O
, O
is O
reported O
in O
a O
35-year O
- O
old O
woman O
suffering O
from O
rheumatoid O
arthritis O
and O
treated O
, O
in O
addition O
, O
with O
corticosteroids O
. O

The O
concomitant O
use O
, O
however O
, O
of O
colchicine B-DRUG
and O
statin B-DRUG
has O
been O
associated O
with O
the O
rapid O
onset O
of O
muscle B-ADE
weakness I-ADE
. O

Immobilization O
, O
while O
Paget O
's O
bone O
disease O
was O
present O
, O
and O
perhaps O
enhanced O
activation O
of O
dihydrotachysterol B-DRUG
by O
rifampicin O
, O
could O
have O
led O
to O
increased B-ADE
calcium I-ADE
- I-ADE
release I-ADE
into O
the O
circulation O
. O

Such O
a O
case O
induced O
by O
hypothyroidism B-ADE
complicating O
long O
- O
term O
therapy O
with O
amiodarone B-DRUG
in O
a O
45 O
year O
old O
woman O
with O
pre O
- O
excitation O
is O
presented O
. O

We O
describe O
a O
patient O
with O
rheumatoid O
arthritis O
treated O
with O
gold B-DRUG
salts O
, O
who O
developed O
bilateral B-ADE
interstitial I-ADE
pulmonary I-ADE
abnormalities I-ADE
and O
showed O
a O
dramatic O
response O
on O
corticosteroid O
therapy O
. O

A O
diagnosis O
of O
trastuzumab B-DRUG
- O
induced O
pneumonitis B-ADE
was O
made O
. O

Occurrence O
of O
IDDM B-ADE
during O
interferon B-DRUG
therapy O
for O
chronic O
viral O
hepatitis O
. O

A O
retrospective O
epidemiological O
study O
of O
deaths O
from O
hepatic B-ADE
angiosarcoma I-ADE
( O
HAS O
) O
in O
the O
U.S. O
showed O
that O
during O
1964 O
- O
-74 O
there O
were O
168 O
such O
cases O
, O
of O
which O
37 O
( O
22 O
% O
) O
were O
associated O
with O
previously O
known O
causes O
( O
vinyl B-DRUG
chloride I-DRUG
, O
' O
Thorotrast B-DRUG
' O
, O
and O
inorganic B-DRUG
arsenic I-DRUG
) O
and O
4 O
( O
3.1 O
% O
) O
of O
the O
remaining O
131 O
cases O
with O
the O
use O
of O
androgenic O
- O
anabolic O
steroids O
. O

We O
describe O
the O
case O
of O
acute B-ADE
hepatitis I-ADE
induced O
by O
gliclazide B-DRUG
, O
a O
second O
generation O
sulfonylurea O
. O

However O
, O
EO B-DRUG
- O
induced O
noncardiogenic B-ADE
pulmonary I-ADE
edema I-ADE
has O
not O
been O
reported O
in O
human O
. O

MTX B-DRUG
- O
induced O
hepatic B-ADE
injury I-ADE
and O
liver B-ADE
enzyme I-ADE
elevations I-ADE
have O
been O
demonstrated O
after O
treatment O
of O
leukemia O
, O
gestational O
disease O
and O
during O
treatment O
of O
psoriasis O
and O
rheumatoid O
arthritis O
. O

Only O
a O
few O
reports O
of O
overt O
jaundice B-ADE
are O
associated O
with O
streptokinase B-DRUG
. O

The O
possibility O
can O
be O
raised O
that O
M B-DRUG
- I-DRUG
CSF I-DRUG
accelerated O
the O
underlying O
renal B-ADE
disease I-ADE
in O
this O
case O
through O
enhancing O
macrophage O
accumulation O
into O
the O
glomerulus O
, O
leading O
to O
the O
development O
of O
nephrotic B-ADE
syndrome I-ADE
. O

Portal B-ADE
vein I-ADE
thrombosis I-ADE
in O
a O
patient O
with O
severe O
haemophilia O
A O
and O
F O
V O
G1691A O
mutation O
during O
continuous O
infusion O
of O
F B-DRUG
VIII I-DRUG
after O
intramural O
jejunal O
bleeding O
-- O
successful O
thrombolysis O
under O
heparin O
therapy O
. O

Sensory B-ADE
neuropathy I-ADE
revealing O
necrotizing B-ADE
vasculitis I-ADE
during O
infliximab B-DRUG
therapy O
for O
rheumatoid O
arthritis O
. O

A O
64-year O
- O
old O
man O
presented O
with O
proteinuria B-ADE
during O
postoperative O
interferon B-DRUG
( I-DRUG
IFN I-DRUG
) I-DRUG
- I-DRUG
beta I-DRUG
therapy O
against O
malignant O
melanoma O
. O

Paralytic B-ADE
ileus I-ADE
in O
patients O
undergoing O
bortezomib B-DRUG
treatment O
has O
been O
reported O
, O
although O
a O
definite O
attribution O
to O
bortezomib O
administration O
has O
not O
been O
established O
. O

A O
case O
is O
reported O
of O
a O
child O
with O
fatal B-ADE
pulmonary I-ADE
fibrosis I-ADE
following O
BCNU B-DRUG
therapy O
. O

This O
case O
suggests O
that O
sarcoidosis O
and O
pravastatin B-DRUG
, O
two O
entities O
not O
frequently O
associated O
with O
myotonia O
, O
may O
interact O
in O
a O
synergistic O
manner O
to O
produce O
severe O
clinical O
myotonia B-ADE
in O
humans O
. O

Pregabalin B-DRUG
- O
induced O
cortical B-ADE
negative I-ADE
myoclonus I-ADE
in O
a O
patient O
with O
neuropathic O
pain O
. O

We O
herein O
described O
an O
additional O
patient O
with O
BCR O
- O
ABL O
( O
ela2 O
) O
positive O
acute O
lymphoblastic O
leukemia O
who O
developed O
tumor B-ADE
lysis I-ADE
syndrome I-ADE
after O
10-day O
treatment O
with O
imatinib B-DRUG
. O

METHODS O
: O
Growth B-ADE
retardation I-ADE
was O
observed O
in O
six O
severely O
asthmatic O
children O
after O
introduction O
of O
high O
- O
dose O
fluticasone B-DRUG
propionate I-DRUG
treatment O
( O
dry O
powder O
) O
. O

Restless B-ADE
legs I-ADE
syndrome I-ADE
may O
thus O
be O
an O
adverse O
effect O
of O
IFN B-DRUG
alpha I-DRUG
treatment O
. O

Acyclovir B-DRUG
produces O
neurologic B-ADE
symptoms I-ADE
that O
resemble O
extension O
of O
viral O
infection O
into O
the O
central O
nervous O
system O
. O

We O
present O
two O
cases O
of O
anaphylaxis B-ADE
under O
anaesthesia O
where O
return O
of O
spontaneous O
circulation O
was O
refractory O
to O
epinephrine O
, O
but O
occurred O
following O
the O
administration O
of O
the O
alpha O
- O
agonist O
metaraminol B-DRUG
. O

To O
develop O
information O
on O
the O
relative O
rarity O
or O
frequency O
of O
neurologic B-ADE
worsening I-ADE
with O
the O
initiation O
of O
penicillamine B-DRUG
therapy O
, O
we O
conducted O
a O
retrospective O
survey O
of O
25 O
additional O
patients O
with O
Wilson O
's O
disease O
who O
met O
the O
criteria O
of O
presenting O
with O
neurologic B-ADE
disease I-ADE
and O
having O
been O
treated O
with O
penicillamine B-DRUG
. O

A O
patient O
that O
received O
methadone B-DRUG
for O
cancer O
- O
associated O
pain O
developed O
myoclonus B-ADE
as O
a O
side O
effect O
. O

In O
this O
case O
, O
discontinuing O
piroxicam B-DRUG
, O
a O
nonsteroidal O
anti O
- O
inflammatory O
drug O
, O
and O
starting O
a O
palliative O
treatment O
plan O
helped O
resolve O
a O
patient O
's O
ulcers B-ADE
. O

In O
a O
postural O
challenge O
test O
after O
administration O
of O
isosorbide B-DRUG
dinitrate I-DRUG
( O
5 O
mg O
) O
, O
blood B-ADE
pressure I-ADE
decreased I-ADE
from O
120/67 O
to O
65/35 O
mmHg O
, O
followed O
by O
syncope B-ADE
with O
a O
sudden B-ADE
decrease I-ADE
in I-ADE
pulse I-ADE
rate I-ADE
from O
85 O
to O
60 O
beats O
/ O
min O
. O

In O
association O
with O
this O
tocolysis O
, O
urinary B-ADE
calculus I-ADE
of O
magnesium B-DRUG
ammonium I-DRUG
phosphate I-DRUG
occurred O
at O
34 O
weeks O
gestation O
. O

The O
induction O
of O
hypoglycaemia B-ADE
with O
PAS B-DRUG
in O
this O
patient O
suggests O
a O
potential O
role O
for O
PAS O
in O
the O
treatment O
of O
diabetes O
mellitus O
. O

Fatal B-ADE
interstitial I-ADE
pneumonitis I-ADE
following O
high O
- O
dose O
intermittent O
chlorambucil B-DRUG
therapy O
for O
chronic O
lymphocyte O
leukemia O
. O

The O
responsibility O
of O
CCNU B-DRUG
in O
the O
pathogenesis O
of O
pulmonary B-ADE
fibrosis I-ADE
seems O
very O
likely O
. O

Cessation O
of O
D B-DRUG
- I-DRUG
Pen I-DRUG
and O
the O
start O
of O
corticosteroid O
therapy O
were O
followed O
by O
recovery O
from O
bicytopenia B-ADE
. O

CONCLUSION O
: O
Atovaquone B-DRUG
should O
be O
added O
to O
the O
list O
of O
agents O
causing O
vortex B-ADE
keratopathy I-ADE
involving O
the O
corneal O
epithelium O
. O

After O
having O
received O
gemcitabine B-DRUG
on O
day O
1 O
of O
the O
second O
course O
, O
the O
patient O
developed O
dry B-ADE
cough I-ADE
, O
subfebrile B-ADE
temperatures I-ADE
and O
dyspnea B-ADE
within O
48 O
h O
. O

A O
further O
case O
of O
anaphylactoid B-ADE
reaction I-ADE
to O
methylprednisolone B-DRUG
is O
reported O
. O

Fever B-ADE
, O
lymphadenopathy B-ADE
, O
eosinophilia B-ADE
, O
lymphocytosis B-ADE
, O
hepatitis B-ADE
, O
and O
dermatitis B-ADE
: O
a O
severe O
adverse O
reaction O
to O
minocycline B-DRUG
. O

Indolent O
aspergillus B-ADE
arthritis I-ADE
complicating O
fludarabine B-DRUG
- O
based O
non O
- O
myeloablative O
stem O
cell O
transplantation O
. O

Alprazolam B-DRUG
withdrawal O
delirium B-ADE
unresponsive O
to O
diazepam O
: O
case O
report O
. O

Electrical B-ADE
proarrhythmia I-ADE
with O
procainamide B-DRUG
: O
a O
new O
ICD O
- O
drug O
interaction O
. O

A O
case O
of O
Erythema B-ADE
Multiforme I-ADE
Bullosum I-ADE
in O
patient O
of O
lepromatous O
leprosy O
with O
pulmonary O
tuberculosis O
due O
to O
Rifampicin B-DRUG
is O
described O
. O

Bull's B-ADE
- I-ADE
eye I-ADE
maculopathy I-ADE
associated O
with O
quinacrine B-DRUG
therapy O
for O
malaria O
. O

This O
article O
presents O
a O
patient O
with O
hypoparathyroidism O
who O
was O
treated O
with O
calcium B-DRUG
carbonate I-DRUG
and O
calcitriol B-DRUG
resulting O
in O
two O
admissions O
to O
the O
hospital O
for O
milk B-ADE
- I-ADE
alkali I-ADE
syndrome I-ADE
. O

We O
report O
on O
a O
37-year O
- O
old O
female O
who O
complained O
of O
moderate O
hair B-ADE
loss I-ADE
during O
paroxetine B-DRUG
treatment O
. O

STUDY O
DESIGN O
: O
Case O
report O
of O
a O
31-year O
- O
old O
woman O
who O
presented O
with O
toxic B-ADE
myelopathy I-ADE
due O
to O
intrathecal O
administration O
of O
doxorubicin B-DRUG
. O

Anaphylactic B-ADE
reaction I-ADE
to O
oral O
prednisone B-DRUG
: O
a O
case O
report O
and O
review O
of O
the O
literature O
. O

After O
a O
second O
dose O
of O
metoclopramide B-DRUG
, O
these O
symptoms O
recurred O
and O
were O
associated O
with O
confusion B-ADE
, O
agitation B-ADE
, O
fever B-ADE
, O
diaphoresis B-ADE
, O
tachypnea B-ADE
, O
tachycardia B-ADE
, O
and O
hypertension B-ADE
. O

Posterior B-ADE
reversible I-ADE
encephalopathy I-ADE
syndrome I-ADE
associated O
with O
methotrexate B-DRUG
neurotoxicity O
: O
conventional O
magnetic O
resonance O
and O
diffusion O
- O
weighted O
imaging O
findings O
. O

Recovery O
of O
the O
tubular B-ADE
dysfunction I-ADE
took O
15 O
days O
following O
cessation O
of O
the O
offending O
drug O
, O
Amikacin B-DRUG
. O

OBJECTIVE O
: O
To O
report O
the O
occurrence O
of O
anaphylactoid B-ADE
reactions I-ADE
to O
intraperitoneal O
cisplatin B-DRUG
in O
3 O
patients O
. O

A O
case O
of O
polymyositis B-ADE
with O
dilated B-ADE
cardiomyopathy I-ADE
associated O
with O
interferon B-DRUG
alpha I-DRUG
treatment O
for O
hepatitis O
B O
. O

We O
observed O
ventricular B-ADE
fibrillation I-ADE
in O
2 O
patients O
who O
presented O
to O
the O
emergency O
department O
with O
pre O
- O
excited O
atrial O
fibrillation O
and O
were O
given O
12 O
mg O
of O
adenosine B-DRUG
. O

These O
novel O
findings O
may O
offer O
specific O
therapeutic O
targets O
in O
the O
treatment O
of O
BCNU B-DRUG
- O
associated O
pulmonary B-ADE
fibrosis I-ADE
. O

Focal B-ADE
glomerulonephritis I-ADE
and O
interstitial B-ADE
nephritis I-ADE
in O
methicillin B-DRUG
- O
treated O
, O
heroin O
- O
related O
infective O
endocarditis O
. O

Alprazolam B-DRUG
- O
induced O
mania B-ADE
: O
two O
clinical O
cases O
. O

In O
two O
patients O
, O
apomorphine B-DRUG
remained O
effective O
in O
the O
morning O
, O
but O
increased O
the O
intensity O
of O
the O
dyskinesias B-ADE
in O
the O
afternoon O
. O

We O
describe O
two O
women O
who O
developed O
HUS B-ADE
after O
MMC B-DRUG
therapy O
and O
presented O
massive B-ADE
pulmonary I-ADE
bleeding I-ADE
. O

On O
the O
3rd O
day O
, O
an O
inferior O
vena O
cava O
( O
IVC O
) O
filter O
was O
placed O
with O
a O
heparin B-DRUG
flush O
, O
after O
which O
massive O
IVC B-ADE
thrombosis I-ADE
developed O
. O

Management O
of O
hypophosphatemia O
induced O
by O
high O
- O
flux O
hemodiafiltration O
for O
the O
treatment O
of O
vancomycin B-DRUG
toxicity I-ADE
: O
intravenous O
phosphorus O
therapy O
versus O
use O
of O
a O
phosphorus O
- O
enriched O
dialysate O
. O

Although O
this O
combination O
agent O
has O
been O
associated O
with O
a O
hypersensitivity B-ADE
syndrome I-ADE
involving O
cutaneous B-ADE
skin I-ADE
eruptions I-ADE
, O
pediatric O
cases O
of O
TMP B-DRUG
- I-DRUG
SMX I-DRUG
- O
induced O
hepatotoxicity B-ADE
are O
rare O
. O

We O
report O
the O
case O
of O
a O
40-year O
- O
old O
woman O
who O
developed O
fulminant B-ADE
hepatic I-ADE
failure I-ADE
and O
aplastic B-ADE
anaemia I-ADE
following O
a O
course O
of O
oral O
flucloxacillin B-DRUG
. O

Basilar B-ADE
invagination I-ADE
and O
mid B-ADE
- I-ADE
line I-ADE
skeletal I-ADE
abnormalities I-ADE
due O
to O
in O
utero O
exposure O
to O
phenytoin B-DRUG
. O

Fulminant B-ADE
hepatitis I-ADE
and O
lymphocyte O
sensitization O
due O
to O
propylthiouracil B-DRUG
. O

A O
37-year O
- O
old O
woman O
with O
relapsing O
invasive O
vertebral O
aspergillosis O
received O
intravenous O
VRC B-DRUG
and O
developed O
angio B-ADE
- I-ADE
oedema I-ADE
10 O
days O
after O
starting O
therapy O
. O

Codeine B-DRUG
intoxication I-ADE
in O
the O
neonate O
. O

The O
hospital O
course O
of O
the O
acute O
renal O
failure O
is O
presented O
with O
a O
review O
of O
the O
literature O
on O
cases O
of O
acute B-ADE
renal I-ADE
failure I-ADE
after O
IVIG B-DRUG
. O

Quetiapine B-DRUG
- O
induced O
leucopenia B-ADE
and O
thrombocytopenia B-ADE
. O

CONCLUSIONS O
: O
Colchicine B-DRUG
- O
induced O
myopathy B-ADE
should O
be O
excluded O
in O
patients O
with O
FMF O
who O
present O
with O
generalized O
muscle O
weakness O
. O

Theophylline B-DRUG
intoxication I-ADE
following O
viloxazine B-DRUG
induced O
decrease B-ADE
in I-ADE
clearance I-ADE
. O

Oncologists O
supervising O
future O
clinical O
trials O
for O
lung O
cancer O
should O
be O
alert O
to O
the O
fact O
that O
sorafenib B-DRUG
can O
potentially O
induce O
serious O
interstitial B-ADE
lung I-ADE
disease I-ADE
, O
although O
this O
might O
depend O
on O
racial O
differences O
. O

Because O
of O
a O
hypersensitivity B-ADE
reaction I-ADE
, O
initial O
therapy O
with O
penicillin B-DRUG
G I-DRUG
and O
gentamicin B-DRUG
was O
stopped O
and O
substituted O
with O
cefazolin O
. O

Colchicine B-DRUG
- O
induced O
rhabdomyolysis B-ADE
is O
a O
rare O
complication O
, O
and O
the O
postulated O
mechanisms O
and O
risk O
factors O
for O
this O
severe O
complication O
are O
discussed O
. O

This O
report O
suggests O
that O
bleomycin B-DRUG
lung B-ADE
toxicity I-ADE
may O
be O
reversible O
if O
treated O
aggressively O
. O

The O
authors O
describe O
a O
case O
of O
neuroleptic B-ADE
malignant I-ADE
syndrome I-ADE
that O
occurred O
in O
a O
patient O
on O
amitriptyline B-DRUG
and O
lithium B-DRUG
carbonate I-DRUG
. O

The O
following O
is O
a O
report O
of O
2 O
cases O
of O
rifampicin B-DRUG
- O
induced O
renal B-ADE
insufficiency I-ADE
. O

The O
addition O
of O
intrathecal O
methotrexate B-DRUG
to O
treatment O
protocols O
has O
increased O
survival O
rates O
in O
children O
with O
acute O
lymphoblastic O
leukemia O
but O
is O
also O
associated O
with O
varying O
degrees O
of O
neurotoxicity B-ADE
. O

A O
23-year O
- O
old O
woman O
with O
systemic O
lupus O
erythematosus O
had O
a O
severe B-ADE
hypersensitivity I-ADE
reaction I-ADE
to O
the O
drug O
ibuprofen B-DRUG
. O

A O
teenage O
girl O
with O
crescentic O
glomerulonephritis O
had O
antineutrophil B-ADE
cytoplasmic I-ADE
antibody I-ADE
( O
ANCA O
) O
detected O
after O
she O
had O
received O
propylthiouracil B-DRUG
( O
PTU B-DRUG
) O
for O
hyperthyroidism O
without O
cutaneous O
vasculitis O
. O

Abnormal B-ADE
retinal I-ADE
function I-ADE
associated O
with O
isotretinoin B-DRUG
therapy O
for O
acne O
. O

Can O
propofol B-DRUG
precipitate O
pancreatitis B-ADE
in O
patients O
with O
Cushing O
's O
syndrome O
? O

Although O
useful O
in O
the O
management O
of O
chronic O
alcoholism O
, O
disulfiram B-DRUG
is O
being O
increasingly O
associated O
with O
a O
wide O
spectrum O
of O
side O
effects O
and O
untoward O
medical O
sequelae O
, O
which O
now O
include O
catatonia B-ADE
. O

Because O
the O
combination O
of O
bleomycin B-DRUG
and O
vinca O
alkaloids O
is O
commonly O
used O
for O
the O
treatment O
of O
AIDS O
- O
related O
Kaposi O
's O
sarcoma O
, O
clinicians O
should O
be O
aware O
of O
the O
risk O
of O
provoking O
acral B-ADE
necrosis I-ADE
in O
patients O
who O
develop O
Raynaud B-ADE
's I-ADE
phenomenon I-ADE
under O
chemotherapy O
. O

Three O
days O
after O
intravitreal O
injection O
of O
bevacizumab B-DRUG
, O
acute B-ADE
ocular I-ADE
ischemic I-ADE
syndrome I-ADE
occurred O
. O

High O
- O
dose O
methotrexate B-DRUG
- O
associated O
acute B-ADE
renal I-ADE
failure I-ADE
may O
be O
an O
avoidable O
complication O
. O

Telescoped B-ADE
digits I-ADE
of I-ADE
the I-ADE
hands I-ADE
and I-ADE
feet I-ADE
developed O
in O
a O
69-year O
- O
old O
male O
with O
severe O
chronic O
tophaceous O
gout O
during O
allopurinol B-DRUG
treatment O
. O

CONCLUSIONS O
: O
Fixed B-ADE
drug I-ADE
rash I-ADE
induced O
by O
methylphenidate B-DRUG
is O
a O
possible O
but O
rare O
phenomenon O
. O

Sulindac B-DRUG
( O
Clinoril B-DRUG
) O
, O
a O
nonsteroidal O
anti O
- O
inflammatory O
agent O
, O
has O
few O
reported O
neurologic B-ADE
toxic I-ADE
effects I-ADE
, O
all O
of O
which O
have O
been O
associated O
with O
systemic O
disease O
. O

CONCLUSIONS O
: O
There O
is O
very O
little O
published O
information O
regarding O
ofloxacin B-DRUG
- O
induced O
toxic B-ADE
epidermal I-ADE
necrolysis I-ADE
. O

PURPOSE O
: O
To O
report O
two O
cases O
of O
acute B-ADE
endophthalmitis I-ADE
following O
intravitreal O
bevacizumab B-DRUG
injection O
. O

We O
report O
a O
case O
of O
a O
young O
woman O
with O
SLE O
and O
thrombocytopenia O
, O
who O
developed O
severe B-ADE
perspiration I-ADE
, O
headache B-ADE
, O
and O
seizure B-ADE
after O
receiving O
cyclosporine B-DRUG
. O

Mycophenolate B-DRUG
mofetil I-DRUG
- O
induced O
neutropenia B-ADE
in O
liver O
transplantation O
. O

A O
64 O
year O
old O
woman O
with O
previous O
history O
of O
coronary O
stenting O
five O
days O
before O
was O
admitted O
in O
our O
institution O
for O
intracranial B-ADE
bleeding I-ADE
while O
receiving O
aspirin B-DRUG
and O
clopidogrel B-DRUG
. O

An O
insulin O
- O
dependent O
diabetic O
patient O
with O
nephropathy O
developed O
severe B-ADE
acidosis I-ADE
after O
treatment O
with O
acetazolamide B-DRUG
for O
glaucoma O
. O

This O
case O
demonstrates O
the O
association O
of O
selective O
IgA B-ADE
deficiency I-ADE
with O
remission O
in O
rheumatoid O
arthritis O
induced O
by O
fenclofenac B-DRUG
as O
well O
as O
aurothiomalate B-DRUG
and O
sulphasalazine B-DRUG
. O

CONCLUSIONS O
: O
Amphotericin B-DRUG
B I-DRUG
seems O
to O
be O
the O
probable O
cause O
of O
the O
seizures B-ADE
. O

We O
report O
here O
on O
a O
heretofore O
undescribed O
respiratory B-ADE
syncytial I-ADE
virus I-ADE
( I-ADE
RSV I-ADE
) I-ADE
infection I-ADE
in O
a O
patient O
with O
a O
long O
- O
standing O
history O
of O
refractory O
CLL O
that O
was O
treated O
with O
fludarabine B-DRUG
phosphate I-DRUG
. O

Allergic B-ADE
contact I-ADE
dermatitis I-ADE
to O
compound O
tincture O
of O
benzoin B-DRUG
. O

The O
visual B-ADE
loss I-ADE
in O
this O
patient O
seems O
to O
result O
from O
phenol B-DRUG
neurotoxicity B-ADE
rather O
than O
mechanical O
compression O
of O
the O
intraorbital O
optic O
nerve O
. O

We O
report O
a O
case O
of O
hyponatremia B-ADE
associated O
with O
a O
grand B-ADE
mal I-ADE
seizure I-ADE
in O
a O
28 O
month O
- O
old O
child O
after O
intra O
- O
nasal O
desmopressin B-DRUG
administration O
for O
high O
fluid O
intake O
with O
nocturnal O
enuresis O
. O

Acute B-ADE
myocardial I-ADE
infarction I-ADE
due O
to O
coronary B-ADE
spasm I-ADE
associated O
with O
L B-DRUG
- I-DRUG
thyroxine I-DRUG
therapy O
. O

Although O
other O
nitrites O
induce O
methemoglobinemia B-ADE
, O
exposure O
to O
methyl B-DRUG
nitrite I-DRUG
during O
phenylpropanolamine O
production O
appears O
to O
be O
a O
new O
cause O
of O
occupational O
methemoglobinemia B-ADE
. O

We O
describe O
a O
case O
of O
disseminated O
muscular O
cysticercosis O
followed O
by O
myositis B-ADE
( O
fever B-ADE
, O
diffuse B-ADE
myalgia I-ADE
, O
weakness B-ADE
of I-ADE
the I-ADE
lower I-ADE
limbs I-ADE
, O
and O
inflammatory B-ADE
reaction I-ADE
around I-ADE
dying I-ADE
cysticerci I-ADE
) O
induced O
by O
praziquantel B-DRUG
therapy O
, O
an O
event O
not O
described O
previously O
. O

The O
reported O
cases O
of O
in O
utero O
exposure O
to O
cyclosposphamide B-DRUG
shared O
the O
following O
manifestations O
with O
our O
patient O
: O
growth O
deficiency O
, O
developmental B-ADE
delay I-ADE
, O
craniosynostosis B-ADE
, O
blepharophimosis B-ADE
, O
flat B-ADE
nasal I-ADE
bridge I-ADE
, O
abnormal O
ears O
, O
and O
distal B-ADE
limb I-ADE
defects I-ADE
including O
hypoplastic B-ADE
thumbs I-ADE
and O
oligodactyly B-ADE
. O

The O
authors O
present O
an O
elderly O
patient O
with O
mixed O
dementia O
who O
developed O
TD B-ADE
at O
multiple O
sites O
, O
( O
including O
respiratory B-ADE
dyskinesia I-ADE
[ O
RD B-ADE
] O
, O
limb B-ADE
dyskinesia I-ADE
, O
and O
orofacial B-ADE
dyskinesia I-ADE
) O
following O
abrupt O
withdrawal O
of O
risperidone B-DRUG
therapy O
. O

A O
paradoxical B-ADE
ocular I-ADE
effect I-ADE
of O
brimonidine B-DRUG
. O

Administration O
of O
intrathecal O
Ara B-DRUG
- I-DRUG
C I-DRUG
in O
the O
same O
dose O
over O
longer O
intervals O
within O
3 O
- O
5 O
days O
between O
consecutive O
doses O
resulted O
in O
mild O
, O
transient O
neurological O
symptoms O
( O
paresthesias B-ADE
) O
in O
only O
one O
of O
30 O
patients O
so O
treated O
. O

While O
undergoing O
treatment O
with O
albendazole B-DRUG
, O
he O
developed O
worsening B-ADE
diarrhea I-ADE
with O
abdominal B-ADE
pain I-ADE
and O
fever B-ADE
. O

We O
report O
an O
additional O
case O
of O
isotretinoin B-DRUG
teratogenicity B-ADE
in O
which O
the O
patient O
had O
agenesis B-ADE
of I-ADE
the I-ADE
cerebellar I-ADE
vermis I-ADE
, O
multiple B-ADE
leptomeningeal I-ADE
neuroglial I-ADE
heterotopias I-ADE
, O
hydrocephalus B-ADE
, O
and O
abnormalities B-ADE
of I-ADE
the I-ADE
corticospinal I-ADE
tracts I-ADE
. O

Rupture B-ADE
of I-ADE
a I-ADE
cerebral I-ADE
aneurysm I-ADE
associated O
with O
nifedipine B-DRUG
treatment O
. O

Hepatotoxicity B-ADE
of O
paracetamol B-DRUG
enhanced O
by O
ingestion O
of O
alcohol O
: O
report O
of O
two O
cases O
. O

CASE O
SUMMARY O
: O
A O
61-year O
- O
old O
woman O
with O
no O
apparent O
risk O
factors O
for O
liver O
injury O
developed O
acute B-ADE
hepatitis I-ADE
one O
week O
after O
the O
final O
dose O
of O
a O
long O
- O
term O
course O
of O
pulse O
itraconazole B-DRUG
therapy O
( O
200 O
mg O
orally O
twice O
daily O
, O
1 O
wk O
on O
, O
3 O
wk O
off O
, O
for O
24 O
wk O
) O
for O
onychomycosis O
. O

Escape O
atrial O
complexes O
, O
which O
occurred O
following O
junctional O
premature O
complexes O
, O
failed O
to O
initiate O
tachycardia O
in O
the O
control O
state O
but O
tachycardia B-ADE
was O
always O
reinitiated O
by O
an O
identical O
escape O
sequence O
after O
procainamide B-DRUG
. O

An O
8-year O
- O
old O
girl O
, O
who O
had O
been O
vaccinated O
with O
BCG B-DRUG
without O
subsequent O
regional O
reactions O
, O
developed O
osteomyelitis B-ADE
in I-ADE
the I-ADE
left I-ADE
calcaneus I-ADE
7 O
months O
later O
. O

In O
a O
female O
with O
acute O
lymphoblastic O
leukemia O
, O
inadvertent O
doxorubicin B-DRUG
administration O
intrathecally O
caused O
severe O
, O
life O
- O
threatening O
, O
acute B-ADE
encephalopathy I-ADE
with O
high B-ADE
- I-ADE
pressure I-ADE
hydrocephalus I-ADE
. O

We O
report O
an O
unusual O
case O
of O
simultaneous O
transitional B-ADE
cell I-ADE
carcinoma I-ADE
of I-ADE
the I-ADE
renal I-ADE
pelvis I-ADE
and O
distal B-ADE
ureter I-ADE
without I-ADE
transitional I-ADE
cell I-ADE
carcinoma I-ADE
of I-ADE
the I-ADE
bladder I-ADE
occurring O
after O
chronic O
cyclophosphamide B-DRUG
therapy O
for O
nonHodgkin O
's O
lymphoma O
. O

Recognition O
of O
a O
potential O
drug O
- O
induced O
Fanconi B-ADE
syndrome I-ADE
is O
important O
when O
managing O
pediatric O
oncology O
patients O
previously O
treated O
with O
ifosfamide B-DRUG
. O

Livedo B-ADE
reticularis I-ADE
associated O
with O
interferon B-DRUG
alpha I-DRUG
therapy O
in O
two O
melanoma O
patients O
. O

Phantom B-ADE
limb I-ADE
pain I-ADE
as O
a O
manifestation O
of O
paclitaxel B-DRUG
neurotoxicity B-ADE
. O

We O
conjectured O
that O
the O
side O
effects O
of O
insulin B-DRUG
, O
such O
as O
anti B-ADE
- I-ADE
natriuresis I-ADE
and O
increased B-ADE
vascular I-ADE
permeability I-ADE
, O
might O
be O
pronounced O
in O
the O
presence O
of O
the O
hepatic O
dysfunction O
that O
accompanies O
insulin B-ADE
insensitivity I-ADE
, O
hyperinsulinaemia B-ADE
and O
hypoalbuminaemia B-ADE
. O

This O
is O
the O
first O
report O
of O
pulmonary B-ADE
hypertension I-ADE
in O
an O
adult O
patient O
during O
lithium B-DRUG
therapy O
. O

Early O
overanticoagulation B-ADE
with O
acenocoumarol B-DRUG
due O
to O
a O
genetic O
polymorphism O
of O
cytochrome O
P450 O
CYP2C9 O
. O

METHODS O
: O
A O
55-year O
- O
old O
woman O
became O
stuporous B-ADE
after O
overdose O
with O
lamotrigine B-DRUG
( O
LTG B-DRUG
) O
and O
valproic B-DRUG
acid I-DRUG
( O
VPA B-DRUG
) O
tablets O
. O

We O
present O
two O
cases O
in O
which O
both O
patients O
suffered O
with O
CLS B-ADE
, O
which O
we O
believe O
was O
caused O
following O
administration O
of O
granulocyte B-DRUG
colony I-DRUG
- I-DRUG
stimulating I-DRUG
factor I-DRUG
, O
to O
our O
knowledge O
not O
described O
in O
the O
intensive O
care O
patient O
previously O
. O

Typically O
, O
drug O
- O
induced O
neutropenia B-ADE
occurs O
in O
a O
patient O
receiving O
a O
semisynthetic O
penicillin B-DRUG
for O
two O
weeks O
or O
more O
. O

In O
conclusion O
, O
this O
case O
strongly O
suggests O
that O
gliclazide B-DRUG
can O
induce O
acute B-ADE
icteric I-ADE
liver I-ADE
necro I-ADE
- I-ADE
inflammation I-ADE
which O
may O
be O
misdiagnosed O
clinically O
as O
acute O
viral O
hepatitis O
. O

We O
experienced O
a O
case O
of O
chronic O
renal O
failure O
in O
a O
patient O
suffering O
from O
acute B-ADE
hemorrhagic I-ADE
gastritis I-ADE
associated O
with O
AZ B-ADE
intoxication I-ADE
. O

The O
patient O
's O
other O
comorbidities O
and O
medications O
have O
not O
been O
suggested O
as O
possible O
interactions O
with O
sertraline B-DRUG
that O
can O
cause O
rhabdomyolysis B-ADE
. O

To O
the O
best O
of O
the O
authors O
' O
knowledge O
, O
this O
is O
the O
first O
reported O
case O
of O
Propecia B-DRUG
- O
associated O
cataract B-ADE
. O

Similar O
to O
reports O
in O
patients O
receiving O
gefitinib O
, O
those O
with O
pathologic O
findings O
of O
UIP O
on O
resected O
lung O
specimens O
or O
known O
pulmonary B-ADE
fibrosis I-ADE
may O
be O
at O
particular O
risk O
for O
erlotinib B-DRUG
pulmonary B-ADE
toxicity I-ADE
. O

We O
report O
a O
case O
of O
reversible O
DKA B-ADE
and O
new O
- O
onset O
DM B-ADE
that O
developed O
in O
a O
demented O
patient O
who O
was O
treated O
with O
quetiapine B-DRUG
for O
14 O
days O
. O

The O
association O
of O
phenothiazine B-DRUG
overdose O
and O
respiratory B-ADE
distress I-ADE
syndrome I-ADE
merits O
consideration O
. O

FINDINGS O
: O
Six O
children O
with O
growth B-ADE
retardation I-ADE
noted O
after O
treatment O
with O
high O
- O
dose O
fluticasone B-DRUG
propionate I-DRUG
were O
found O
to O
have O
adrenal B-ADE
suppression I-ADE
. O

Interstitial B-ADE
lung I-ADE
disease I-ADE
( O
ILD B-ADE
) O
related O
to O
therapy O
with O
the O
drug O
gefitinib B-DRUG
has O
been O
well O
reported O
. O

Severe O
dapsone B-DRUG
hypersensitivity B-ADE
syndrome I-ADE
. O

Capecitabine B-DRUG
- O
induced O
headache B-ADE
responding O
to O
diltiazem O
. O

Here O
, O
we O
report O
a O
case O
of O
angio B-ADE
- I-ADE
oedema I-ADE
associated O
with O
VRC B-DRUG
therapy O
. O

Methimazole B-DRUG
- O
induced O
aplastic B-ADE
anemia I-ADE
in O
third O
exposure O
: O
successful O
treatment O
with O
recombinant O
human O
granulocyte O
colony O
- O
stimulating O
factor O
. O

The O
more O
common O
grade O
3 O
or O
4 O
adverse O
effects O
of O
sunitinib B-DRUG
include O
hypertension B-ADE
, O
fatigue B-ADE
, O
hand B-ADE
- I-ADE
foot I-ADE
syndrome I-ADE
, O
elevated B-ADE
lipase I-ADE
and O
lymphopenia B-ADE
. O

We O
report O
the O
case O
histories O
of O
two O
patients O
with O
histologically O
confirmed O
adenocarcinoma O
of O
the O
prostate O
, O
both O
of O
whom O
had O
been O
treated O
with O
steroidal O
anti O
- O
androgen O
therapy O
in O
the O
form O
of O
cyproterone B-DRUG
acetate I-DRUG
prior O
to O
radical O
or O
palliative O
pelvic O
irradiation O
, O
and O
who O
subsequently O
developed O
femoral B-ADE
head I-ADE
avascular I-ADE
necrosis I-ADE
. O

Assessment O
of O
cortisol O
response O
was O
by O
insulin B-DRUG
- O
induced O
hypoglycaemia B-ADE
in O
three O
cases O
, O
by O
short O
tetracosactrin O
test O
in O
two O
, O
and O
by O
low O
- O
dose O
tetracosactrin O
and O
24-hour O
urinary O
cortisol O
/ O
creatinine O
ratio O
in O
one O
. O

Papillary B-ADE
necrosis I-ADE
associated O
with O
the O
HIV O
protease O
inhibitor O
indinavir B-DRUG
. O

A O
case O
of O
anaphylactoid B-ADE
reaction I-ADE
due O
solely O
to O
the O
use O
of O
Gelofusine B-DRUG
in O
a O
patient O
with O
non O
- O
haemorrhagic O
hypovolaemia O
is O
presented O
, O
with O
a O
discussion O
on O
the O
management O
and O
the O
use O
of O
allergy O
identification O
jewellery O
. O

Renal B-ADE
toxicities I-ADE
have O
been O
reported O
in O
less O
than O
one O
percent O
of O
the O
patients O
receiving O
ciprofloxacin B-DRUG
therapy O
. O

Use O
of O
the O
Naranjo O
probability O
scale O
indicated O
a O
highly O
probable O
relationship O
between O
the O
observed O
cardiac B-ADE
toxicity I-ADE
and O
amphotericin B-DRUG
B I-DRUG
deoxycholate I-DRUG
therapy O
in O
this O
patient O
. O

We O
report O
a O
case O
of O
Graves B-ADE
' I-ADE
hyperthyroidism I-ADE
induced O
by O
long O
- O
term O
interferon B-DRUG
( O
IFN B-DRUG
) O
therapy O
. O

Here O
we O
describe O
another O
case O
of O
VOD B-ADE
occurring O
after O
LT O
, O
but O
in O
which O
the O
causative O
role O
was O
played O
by O
azathioprine B-DRUG
. O

We O
describe O
a O
case O
of O
ulcerative B-ADE
proctitis I-ADE
after O
ibuprofen B-DRUG
treatment O
in O
a O
girl O
with O
juvenile O
systemic O
lupus O
erythematosus O
. O

Severe O
vancomycin B-DRUG
- O
induced O
anaphylactic B-ADE
reaction I-ADE
. O

Ampicillin B-DRUG
- O
induced O
interstitial B-ADE
nephritis I-ADE
with O
generalised B-ADE
exfoliative I-ADE
dermatitis I-ADE
. O

CONCLUSIONS O
: O
This O
study O
confirmed O
that O
in O
most O
patients O
MTX B-DRUG
- O
induced O
liver B-ADE
cirrhosis I-ADE
is O
not O
aggressive O
. O

The O
newborn O
manifested O
a O
four O
day O
course O
of O
lethargy B-ADE
with O
unexplained O
high O
lithium B-DRUG
levels O
in O
the O
adult O
toxic O
range O
. O

We O
experienced O
2 O
cases O
of O
mequitazine B-DRUG
- O
induced O
photosensitivity B-ADE
reaction I-ADE
in O
patients O
who O
took O
mequitazine B-DRUG
for O
their O
dermatologic O
problems O
. O

OBJECTIVE O
: O
To O
study O
therapy O
with O
indapamide B-DRUG
impairing B-ADE
carbohydrate I-ADE
metabolism I-ADE
in O
essential O
hypertension O
patients O
and O
achieve O
earlier O
prevention O
, O
diagnoses O
and O
treatment O
of O
diabetes B-ADE
induced O
by O
indapamide B-DRUG
. O

Thus O
, O
the O
possible O
in O
vivo O
effects O
of O
insulin O
on O
adipocytes O
were O
clearly O
observed O
in O
this O
case O
of O
insulin B-DRUG
- O
induced O
lipohypertrophy B-ADE
. O

Niacin B-DRUG
maculopathy B-ADE
. O

Arthritis B-ADE
and O
bursitis B-ADE
in O
multiple O
sclerosis O
patients O
treated O
with O
interferon B-DRUG
- I-DRUG
beta I-DRUG
. O

Myoglobinuria B-ADE
and O
acute B-ADE
renal I-ADE
failure I-ADE
were O
observed O
in O
two O
patients O
with O
vasopressin B-DRUG
- O
treated O
gastrointestinal O
hemorrhage O
. O

The O
principle O
treatment O
for O
DPD O
- O
deficient O
patients O
with O
severe B-ADE
acute I-ADE
5-FU I-ADE
reactions I-ADE
is O
supportive O
care O
; O
however O
, O
the O
administration O
of O
thymidine O
potentially O
may O
reverse O
severe O
5-FU B-DRUG
- O
induced O
neurologic B-ADE
symptoms I-ADE
such O
as O
encephalopathy B-ADE
and O
coma B-ADE
. O

Acute B-ADE
pancreatitis I-ADE
is O
a O
known O
, O
although O
rare O
, O
complication O
of O
mesalamine B-DRUG
treatment O
. O

Fulminant B-ADE
hepatic I-ADE
failure I-ADE
associated O
with O
bicalutamide B-DRUG
. O

DISCUSSION O
: O
The O
occurrence O
of O
priapism B-ADE
in O
our O
patient O
was O
related O
to O
zuclopenthixol B-DRUG
. O

OBJECTIVE O
: O
To O
report O
the O
safe O
use O
of O
fluorouracil O
in O
a O
patient O
with O
breast O
cancer O
who O
had O
allergic B-ADE
reactions I-ADE
to O
capecitabine B-DRUG
. O

Risperidone B-DRUG
is O
a O
frequently O
used O
member O
of O
a O
new O
class O
of O
atypical O
antipsychotics O
- O
the O
serotonin O
- O
dopamine O
antagonists O
( O
SDAs O
) O
- O
due O
to O
its O
comparatively O
high O
efficacy O
and O
low O
D2/5HT2 O
binding O
ratio O
, O
which O
results O
in O
a O
low O
incidence O
of O
extrapyramidal O
side O
effects O
including O
tardive B-ADE
dyskinesia I-ADE
( O
TD B-ADE
) O
. O

Clonidine B-DRUG
- O
induced O
bradycardia B-ADE
in O
patients O
with O
spinal O
cord O
injury O
. O

Since O
tamoxifen B-DRUG
therapy O
can O
induce O
endometrial B-ADE
disorders I-ADE
, O
surveillance O
schemes O
of O
women O
taking O
tamoxifen B-DRUG
have O
been O
recommended O
. O

Although O
this O
type O
of O
hyperpigmentation B-ADE
has O
been O
previously O
seen O
in O
patients O
with O
cancer O
who O
are O
receiving O
bleomycin B-DRUG
, O
this O
is O
, O
to O
our O
knowledge O
, O
the O
first O
reported O
case O
of O
bleomycin B-DRUG
- O
induced O
hyperpigmentation B-ADE
in O
an O
AIDS O
patient O
and O
should O
be O
added O
to O
the O
growing O
list O
of O
cutaneous O
eruptions O
seen O
in O
these O
patients O
. O

Anisocoria B-ADE
from O
transdermal O
scopolamine B-DRUG
. O

METHODS O
: O
The O
patient O
required O
insulin B-DRUG
desensitization O
for O
severe B-ADE
urticaria I-ADE
, O
angioedema B-ADE
, O
and O
occasional O
wheezing B-ADE
resulting O
from O
her O
insulin B-DRUG
dose O
. O

CONCLUSION O
: O
Fixed O
drug O
eruption B-ADE
is O
associated O
with O
many O
drugs O
but O
this O
is O
the O
first O
such O
report O
with O
omeprazole B-DRUG
. O

The O
patient O
was O
enrolled O
in O
a O
weight O
- O
loss O
clinic O
, O
and O
his O
diabetes O
medications O
were O
adjusted O
. O
Subsequently O
, O
olanzapine B-DRUG
was O
discontinued O
because O
of O
weight B-ADE
gain I-ADE
and O
uncontrolled B-ADE
diabetes I-ADE
. O

Mean O
time O
between O
initiation O
of O
gemcitabine B-DRUG
therapy O
and O
onset O
of O
HUS B-ADE
was O
7.4 O
+ O
/- O
3.5 O
months O
, O
or O
21.9 O
+ O
/- O
10.9 O
doses O
of O
gemcitabine B-DRUG
. O

Acute B-ADE
coronary I-ADE
syndrome I-ADE
induced O
by O
capecitabine B-DRUG
therapy O
. O

Neurointensive O
care O
management O
of O
raised B-ADE
intracranial I-ADE
pressure I-ADE
caused O
by O
severe O
valproic B-DRUG
acid I-DRUG
intoxication O
. O

Acute O
isoniazid B-DRUG
neurotoxicity B-ADE
in O
an O
urban O
hospital O
. O

Tuberculous B-ADE
uveitis I-ADE
after O
treatment O
with O
etanercept B-DRUG
. O

Valproic B-DRUG
acid I-DRUG
induced O
coma B-ADE
is O
presented O
in O
an O
adult O
patient O
without O
a O
history O
of O
metabolic O
disease O
. O

We O
report O
a O
59-year O
- O
old O
patient O
with O
chronic O
myeloid O
leukemia O
, O
who O
developed O
severe B-ADE
interstitial I-ADE
lung I-ADE
fibrosis I-ADE
after O
short O
term O
and O
sequential O
treatment O
with O
melphalan B-DRUG
and O
busulfan B-DRUG
. O

Pulmonary B-ADE
infiltrates I-ADE
and O
skin B-ADE
pigmentation I-ADE
associated O
with O
sulfasalazine B-DRUG
. O

We O
report O
two O
patients O
with O
infectious B-ADE
mononucleosis I-ADE
- I-ADE
like I-ADE
syndrome I-ADE
induced O
by O
salazosulfapyridine B-DRUG
( O
SASP B-DRUG
) O
. O

Lymphoma B-ADE
developing O
in O
a O
patient O
with O
rheumatoid O
arthritis O
taking O
methotrexate B-DRUG
. O

Amphotericin B-DRUG
B I-DRUG
overdose O
in O
pediatric O
patients O
with O
associated O
cardiac B-ADE
arrest I-ADE
. O

Priapism B-ADE
associated O
with O
olanzapine B-DRUG
. O

Naproxen B-DRUG
is O
a O
commonly O
used O
nonsteroidal O
anti O
- O
inflammatory O
drug O
( O
NSAID O
) O
whose O
side O
effects O
include O
tinnitus B-ADE
and O
transient B-ADE
hearing I-ADE
loss I-ADE
. O

We O
present O
a O
case O
report O
of O
a O
patient O
with O
alveolar O
hydatid O
disease O
, O
whose O
treatment O
with O
mebendazole B-DRUG
was O
brief O
due O
to O
side O
effects O
of O
alopecia B-ADE
and O
granulocytopenia B-ADE
; O
and O
review O
the O
features O
of O
this O
disease O
which O
, O
with O
increasing O
international O
migration O
, O
may O
be O
encountered O
more O
frequently O
in O
Australia O
. O

A O
53-year O
- O
old O
man O
developed O
NMS B-ADE
without O
rigidity O
while O
taking O
olanzapine B-DRUG
. O

Cystoid B-ADE
macular I-ADE
edema I-ADE
in O
a O
low O
- O
risk O
patient O
after O
switching O
from O
latanoprost B-DRUG
to O
bimatoprost B-DRUG
. O

FSGS B-ADE
induced O
by O
Adriamycin B-DRUG
( O
Pharmacia O
& O
Upjohn O
, O
Columbus O
, O
OH O
) O
has O
been O
observed O
experimentally O
in O
rats O
. O

We O
describe O
2 O
male O
patients O
, O
a O
49-year O
- O
old O
with O
psoriatic O
arthritis O
and O
impaired O
renal O
function O
and O
a O
43-year O
- O
old O
renal O
transplant O
recipient O
, O
who O
both O
sustained O
a O
marked O
decline B-ADE
in I-ADE
glomerular I-ADE
filtration I-ADE
rate I-ADE
in O
conjunction O
with O
a O
selective O
inhibitor O
of O
cyclooxygenase-2 O
( O
COX-2 O
) O
, O
rofecoxib B-DRUG
. O

CASE O
SUMMARY O
: O
A O
65-year O
- O
old O
patient O
chronically O
treated O
with O
the O
selective O
serotonin O
reuptake O
inhibitor O
( O
SSRI O
) O
citalopram B-DRUG
developed O
confusion B-ADE
, O
agitation B-ADE
, O
tachycardia B-ADE
, O
tremors B-ADE
, O
myoclonic B-ADE
jerks I-ADE
and O
unsteady B-ADE
gait I-ADE
, O
consistent O
with O
serotonin B-ADE
syndrome I-ADE
, O
following O
initiation O
of O
fentanyl B-DRUG
, O
and O
all O
symptoms O
and O
signs O
resolved O
following O
discontinuation O
of O
fentanyl B-DRUG
. O

Isoniazid B-DRUG
causing O
breast B-ADE
tissue I-ADE
enlargement I-ADE
has O
been O
very O
rarely O
reported O
. O

Accordingly O
, O
camptocormia B-ADE
is O
a O
dose O
- O
dependent O
side O
effect O
of O
valproate B-DRUG
. O

We O
describe O
a O
patient O
who O
experienced O
chronic B-ADE
nausea I-ADE
and O
an O
episode O
of O
confusion B-ADE
while O
treated O
with O
a O
small O
, O
stable O
dose O
of O
oral O
morphine B-DRUG
in O
the O
setting O
of O
mild O
renal O
insufficiency O
. O

Pulmonary B-ADE
leukostasis I-ADE
secondary O
to O
all B-DRUG
- I-DRUG
trans I-DRUG
retinoic I-DRUG
acid I-DRUG
in O
the O
treatment O
of O
acute O
promyelocytic O
leukemia O
in O
first O
relapse O
. O

Pneumonitis B-ADE
, O
bilateral B-ADE
pleural I-ADE
effusions I-ADE
, O
echocardiographic O
evidence O
of O
cardiac B-ADE
tamponade I-ADE
, O
and O
positive B-ADE
autoantibodies I-ADE
developed O
in O
a O
43-year O
- O
old O
man O
, O
who O
was O
receiving O
long O
- O
term O
sulfasalazine B-DRUG
therapy O
for O
chronic O
ulcerative O
colitis O
. O

An O
association O
of O
granulocytopenia B-ADE
, O
eosinophilia B-ADE
, O
skin B-ADE
reaction I-ADE
and O
hepatitis B-ADE
during O
propylthiouracil B-DRUG
( O
PTU B-DRUG
) O
therapy O
for O
thyrotoxicosis O
in O
a O
47 O
year O
old O
black O
female O
is O
reported O
. O

The O
authors O
report O
five O
cases O
of O
tremor B-ADE
related O
to O
itraconazole B-DRUG
therapy O
, O
which O
occurred O
within O
1 O
- O
12 O
months O
of O
initiating O
treatment O
and O
resolved O
gradually O
following O
itraconazole B-DRUG
withdrawal O
. O

Four O
patients O
in O
whom O
pulmonary B-ADE
oedema I-ADE
developed O
during O
tocolysis O
with O
hexoprenaline B-DRUG
are O
described O
and O
the O
aetiological O
factors O
and O
pathogenesis O
of O
this O
potentially O
lethal O
complication O
discussed O
. O

Inappropriate B-ADE
antidiuretic I-ADE
hormone I-ADE
following O
adenine B-DRUG
arabinoside I-DRUG
administration O
. O

We O
present O
a O
case O
of O
a O
diabetic O
patient O
taking O
glyburide B-DRUG
who O
was O
prescribed O
ciprofloxacin B-DRUG
and O
developed O
prolonged B-ADE
hypoglycemia I-ADE
, O
which O
persisted O
for O
over O
24 O
hours O
. O

We O
reviewed O
the O
records O
of O
3 O
patients O
with O
lymphoproliferative O
disorders O
who O
experienced O
acute B-ADE
coronary I-ADE
syndromes I-ADE
associated O
with O
their O
initial O
infusion O
of O
rituximab B-DRUG
. O

These O
cases O
indicate O
that O
sulpiride B-DRUG
can O
cause O
tardive B-ADE
dyskinesia I-ADE
and O
that O
this O
drug O
should O
be O
administered O
with O
caution O
. O

She O
received O
an O
accidental O
450-mg O
bolus O
injection O
of O
morphine B-DRUG
intrathecally O
and O
developed O
hypertension B-ADE
, O
status B-ADE
epilepticus I-ADE
, O
intracerebral B-ADE
hemorrhage I-ADE
, O
and O
respiratory B-ADE
failure I-ADE
. O

The O
patient O
, O
a O
28-year O
- O
old O
man O
suffering O
from O
panic O
disorder O
, O
developed O
several O
first B-ADE
- I-ADE
rank I-ADE
symptoms I-ADE
during O
fluvoxamine B-DRUG
administration O
. O

We O
report O
a O
patient O
who O
experienced O
LABD B-ADE
shortly O
after O
starting O
carbamazepine B-DRUG
therapy O
. O

A O
case O
of O
normotensive B-ADE
scleroderma I-ADE
renal I-ADE
crisis I-ADE
after O
high O
- O
dose O
methylprednisolone B-DRUG
treatment O
. O

Rhabdomyolysis B-ADE
has O
been O
recognized O
as O
a O
complication O
of O
tocolytic O
therapy O
with O
ritodrine B-DRUG
hydrochloride I-DRUG
. O

We O
describe O
2 O
patients O
with O
cutaneous O
lupus O
erythematosus O
who O
developed O
severe O
dapsone B-DRUG
reaction I-ADE
after O
low O
dose O
therapy O
, O
with O
a O
fatal B-ADE
outcome O
in O
one O
. O

Intravenous O
cytarabine B-DRUG
and O
methotrexate B-DRUG
appear O
to O
act O
synergistically O
to O
enhance O
the O
potential O
for O
central B-ADE
nervous I-ADE
system I-ADE
toxicity I-ADE
. O

We O
present O
the O
cases O
of O
two O
female O
patients O
diagnosed O
with O
relapsing O
- O
remitting O
multiple O
sclerosis O
( O
RRMS O
) O
who O
developed O
inflammatory B-ADE
musculoskeletal I-ADE
manifestations I-ADE
, O
following O
IFN B-DRUG
- I-DRUG
beta I-DRUG
therapy O
. O

I O
report O
a O
35-year O
- O
old O
woman O
with O
occult O
coronary O
artery O
disease O
who O
experienced O
cardiac B-ADE
arrest I-ADE
within O
minutes O
after O
receiving O
a O
first O
- O
time O
dose O
of O
subcutaneous O
sumatriptan B-DRUG
for O
migraine O
. O

Cardiac B-ADE
arrest I-ADE
following O
use O
of O
sumatriptan B-DRUG
. O

CASE O
PRESENTATION O
: O
We O
report O
a O
patient O
with O
CF O
who O
developed O
recurrent B-ADE
eosinophilia I-ADE
and O
severe B-ADE
persistent I-ADE
bronchospasm I-ADE
following O
repeated O
administration O
of O
preservative O
- O
free O
tobramycin B-DRUG
by O
inhalation O
, O
beginning O
at O
16 O
months O
of O
age O
. O

Ibuprofen B-DRUG
- O
induced O
meningitis B-ADE
: O
detection O
of O
intrathecal O
IgG O
synthesis O
and O
immune O
complexes O
. O

Traumatic B-ADE
late I-ADE
flap I-ADE
dehiscence I-ADE
and O
Enterobacter B-ADE
keratitis I-ADE
following O
LASIK B-DRUG
. O

Despite O
a O
hematologic O
response O
in O
all O
3 O
patients O
, O
none O
of O
them O
achieved O
cytogenetic O
remission O
, O
and O
all O
progressed O
to O
blast B-ADE
crisis I-ADE
at O
7 O
to O
10 O
months O
of O
imatinib B-DRUG
therapy O
. O

CONCLUSIONS O
: O
The O
fundus O
picture O
shown O
in O
these O
cases O
may O
be O
typical O
of O
ASPPC B-ADE
after O
IVTA B-DRUG
injection O
. O

CONCLUSION O
: O
While O
thrombosis B-ADE
has O
been O
reported O
with O
GnRH B-DRUG
- I-DRUG
a I-DRUG
therapy O
in O
men O
with O
prostate O
cancer O
, O
its O
association O
with O
treatment O
in O
this O
benign O
case O
may O
have O
been O
a O
consequence O
of O
the O
massive O
tumor O
size O
. O

One O
week O
after O
the O
initial O
- O
dose O
of O
adalimumab B-DRUG
( O
160 O
mg O
) O
, O
which O
was O
initiated O
due O
to O
an O
acute O
exacerbation O
of O
Crohn O
's O
disease O
, O
the O
patient O
developed O
a O
fulminant B-ADE
cardiomyopathy I-ADE
. O

PATIENT O
AND O
METHOD O
: O
A O
34-year O
- O
old O
woman O
with O
chronic O
hepatitis O
C O
, O
genotype O
3 O
, O
receiving O
pegylated B-DRUG
interferon I-DRUG
alpha-2a I-DRUG
and O
ribavirin B-DRUG
for O
6 O
months O
, O
developed O
progressive B-ADE
malaise I-ADE
and O
anemia B-ADE
6 O
months O
after O
the O
end O
of O
treatment O
. O

We O
observed O
5 O
reactions O
in O
3 O
patients O
that O
appear O
to O
be O
related O
to O
a O
high O
dose O
- O
infusion O
time O
ratio O
, O
indicating O
that O
dose O
and O
rate O
of O
infusion O
may O
be O
important O
factors O
in O
precipitating O
anaphylactoid B-ADE
reactions I-ADE
with O
cisplatin B-DRUG
. O

Ofloxacin B-DRUG
: O
a O
probable O
cause O
of O
toxic B-ADE
epidermal I-ADE
necrolysis I-ADE
. O

Skin B-ADE
rash I-ADE
and O
splinter B-ADE
hemorrhages I-ADE
from O
ganciclovir B-DRUG
. O

Rosaceiform B-ADE
eruption I-ADE
induced O
by O
erlotinib B-DRUG
. O

over O
the O
past O
3 O
years O
there O
have O
been O
several O
reports O
of O
uveitis B-ADE
associated O
with O
rifabutin B-DRUG
therapy O
. O

However O
, O
continued O
low O
- O
dose O
MTX B-DRUG
led O
, O
in O
spite O
of O
normal O
liver O
tests O
, O
8 O
years O
after O
the O
last O
biopsy O
to O
liver B-ADE
failure I-ADE
and O
death B-ADE
in O
1 O
of O
our O
patients O
. O

Premature B-ADE
closure I-ADE
of I-ADE
the I-ADE
ductus I-ADE
arteriosus I-ADE
: O
variable O
response O
among O
monozygotic O
twins O
after O
in O
utero O
exposure O
to O
indomethacin B-DRUG
. O

Ziprasidone B-DRUG
is O
an O
atypical O
antipsychotic O
drug O
that O
is O
believed O
to O
have O
a O
low O
propensity O
for O
inducing O
extrapyramidal B-ADE
symptoms I-ADE
, O
including O
tardive B-ADE
dyskinesia I-ADE
( O
TD B-ADE
) O
. O

Spindle B-ADE
coma I-ADE
in O
benzodiazepine B-DRUG
toxicity O
: O
case O
report O
. O

Priapism B-ADE
as O
a O
complication O
of O
heparin B-DRUG
therapy O
. O

Bisphosphonate B-DRUG
induced O
osteochemonecrosis B-ADE
of I-ADE
the I-ADE
jaw I-ADE
mimicking O
a O
tumour O
. O

Posterior B-ADE
leukoencephalopathy I-ADE
following O
cisplatin B-DRUG
, O
bleomycin B-DRUG
and O
vinblastine B-DRUG
therapy O
for O
germ O
cell O
tumor O
of O
the O
ovary O
. O

Colonic B-ADE
mucosal I-ADE
necrosis I-ADE
following O
administration O
of O
calcium B-DRUG
polystryrene I-DRUG
sulfonate I-DRUG
( O
Kalimate B-DRUG
) O
in O
a O
uremic O
patient O
. O

Coadministration O
of O
antidepressant O
agents O
such O
as O
nefazodone B-DRUG
, O
or O
any O
other O
drug O
that O
inhibits O
the O
CYP3A4 O
isoenzyme O
subfamily O
, O
should O
be O
anticipated O
to O
interfere B-ADE
with I-ADE
tacrolimus B-DRUG
metabolism I-ADE
. O

CONCLUSIONS O
: O
LTG B-DRUG
overdose O
may O
result O
in O
a O
severe O
but O
reversible O
encephalopathy B-ADE
, O
a O
previously O
undescribed O
phenomenon O
. O

Methemoglobinemia B-ADE
associated O
with O
dermal O
application O
of O
benzocaine B-DRUG
cream O
in O
a O
cat O
. O

OBSERVATIONS O
: O
A O
48-year O
- O
old O
woman O
presented O
with O
disfiguring B-ADE
facial I-ADE
edema I-ADE
10 O
weeks O
after O
she O
began O
antiviral O
therapy O
with O
peginterferon B-DRUG
alfa-2a I-DRUG
and O
ribavirin B-DRUG
for O
chronic O
hepatitis O
C O
infection O
. O

Two O
patients O
are O
described O
in O
whom O
subtle O
cognitive B-ADE
impairments I-ADE
are O
associated O
with O
therapeutic O
doses O
of O
amoxapine B-DRUG
. O

Arrhythmias B-ADE
and O
cardiac B-ADE
arrest I-ADE
have O
been O
reported O
during O
amphotericin B-DRUG
B I-DRUG
administration O
but O
no O
effective O
technique O
has O
been O
described O
to O
prevent O
them O
. O

Thus O
, O
tardive B-ADE
seizures I-ADE
in O
our O
cases O
are O
thought O
to O
be O
related O
to O
piperacillin B-DRUG
and O
cefotiam B-DRUG
. O

Paradoxical B-ADE
pulmonary I-ADE
vasoconstriction I-ADE
induced O
by O
nitroglycerin B-DRUG
in O
idiopathic O
pulmonary O
hypertension O
. O

Although O
this O
G B-DRUG
- I-DRUG
CSF I-DRUG
- O
driven O
leucocytosis B-ADE
was O
alarming O
it O
did O
not O
appear O
to O
have O
adversely O
affected O
the O
patient O
's O
prognosis O
. O

A O
case O
report O
is O
presented O
concerning O
the O
administration O
of O
ketanserin O
in O
the O
treatment O
of O
pulmonary B-ADE
vasoconstriction I-ADE
and O
right B-ADE
ventricular I-ADE
failure I-ADE
following O
the O
infusion O
of O
protamine B-DRUG
in O
a O
patient O
undergoing O
coronary O
artery O
bypass O
surgery O
and O
mitral O
valve O
replacement O
. O

However O
, O
recurrent O
staphylococcus B-ADE
aureus I-ADE
sepsis I-ADE
developed O
during O
CyA B-DRUG
therapy O
. O

A O
49-year O
- O
old O
man O
with O
Crohn O
's O
disease O
treated O
with O
prednisone B-DRUG
and O
mesalamine B-DRUG
( O
5-ASA B-DRUG
) O
developed O
worsening B-ADE
respiratory I-ADE
distress I-ADE
and O
fever B-ADE
. O

When O
vague B-ADE
symptoms I-ADE
develop O
during O
desmopressin B-DRUG
therapy O
, O
hyponatremia B-ADE
must O
be O
considered O
as O
part O
of O
the O
differential O
diagnosis O
. O

Noncardiogenic B-ADE
pulmonary I-ADE
edema I-ADE
during O
intrabiliary O
infusion O
of O
mono B-DRUG
- I-DRUG
octanoin I-DRUG
. O

Sodium B-DRUG
phenylbutyrate I-DRUG
was O
added O
to O
treatment O
with O
HU B-DRUG
in O
two O
patients O
, O
but O
failed O
to O
produce O
an O
increase O
in O
total O
Hb O
despite O
increasing B-ADE
Hb I-ADE
F I-ADE
levels O
. O

Massive B-ADE
pulmonary I-ADE
embolism I-ADE
due O
to O
late O
- O
onset O
heparin B-DRUG
- O
induced O
thrombocytopenia B-ADE
following O
coronary O
artery O
bypass O
graft O
surgery O
: O
successful O
treatment O
with O
lepirudin O
. O

This O
case O
report O
illustrates O
the O
neurotoxicity B-ADE
unique O
to O
HDARAC B-DRUG
. O

Secondary B-ADE
leukemia I-ADE
in O
a O
child O
with O
neuroblastoma O
while O
on O
oral O
etoposide B-DRUG
: O
what O
is O
the O
cause O
? O

We O
describe O
the O
first O
case O
of O
de O
novo O
asthma B-ADE
following O
treatment O
with O
the O
angiotensin O
converting O
enzyme O
( O
ACE O
) O
inhibitor O
captopril B-DRUG
. O

Because O
sumatriptan B-DRUG
can O
cause O
coronary B-ADE
artery I-ADE
vasospasm I-ADE
, O
patients O
with O
significant O
risk O
factors O
for O
coronary O
artery O
disease O
should O
be O
carefully O
evaluated O
for O
cardiovascular O
disease O
prior O
to O
the O
use O
of O
sumatriptan O
. O

The O
patient O
's O
arthritis B-ADE
flared O
after O
the O
second O
infusion O
of O
infliximab B-DRUG
, O
which O
was O
discontinued O
. O

Methemoglobinemia B-ADE
is O
another O
common O
finding O
among O
patients O
receiving O
dapsone B-DRUG
therapy O
, O
but O
rarely O
does O
it O
result O
in O
prominent O
symptoms O
other O
than O
transient O
pallor O
. O

A O
51-yr O
- O
old O
nonsmoking O
male O
patient O
without O
any O
history O
of O
previous O
allergies O
, O
asthma O
, O
hay O
fever O
, O
or O
urticaria O
developed O
attacks B-ADE
of I-ADE
asthma I-ADE
when O
captopril B-DRUG
was O
added O
to O
the O
nadolol B-DRUG
and O
dyazide B-DRUG
treatment O
for O
his O
high O
blood O
pressure O
. O

Drug O
- O
induced O
hepatitis B-ADE
in O
an O
acromegalic O
patient O
during O
combined O
treatment O
with O
pegvisomant B-DRUG
and O
octreotide B-DRUG
long O
- O
acting O
repeatable O
attributed O
to O
the O
use O
of O
pegvisomant B-DRUG
. O

Several O
such O
HBV B-ADE
reactivations I-ADE
were O
reported O
after O
combined O
rituximab B-DRUG
and O
multiagent O
chemotherapy O
for O
B O
- O
cell O
lymphomas O
. O

Three O
patients O
with O
niacin B-DRUG
- O
induced O
visual B-ADE
symptoms I-ADE
had O
cystoid B-ADE
maculopathy I-ADE
without O
leakage O
on O
fluorescein O
angiography O
, O
and O
a O
fourth O
patient O
with O
no O
fundus O
abnormality O
experienced O
cessation O
of O
visual B-ADE
symptoms I-ADE
upon O
discontinuation O
of O
niacin B-DRUG
. O

MATERIALS O
AND O
METHODS O
: O
We O
present O
two O
cases O
of O
significant O
morbidity O
related O
to O
primary B-ADE
and I-ADE
secondary I-ADE
perforation I-ADE
of I-ADE
the I-ADE
bladder I-ADE
following O
two O
instillations O
of O
epirubicin B-DRUG
. O

Three O
cases O
of O
gold B-DRUG
- O
related O
neuropathy B-ADE
are O
reported O
. O

Therefore O
, O
parenteral O
amiodarone B-DRUG
was O
implicated O
as O
the O
cause O
of O
acute B-ADE
hepatitis I-ADE
in O
this O
patient O
. O

Early O
ritonavir B-DRUG
- O
induced O
maculopapular B-ADE
eruption I-ADE
. O

Transtentorial B-ADE
herniation I-ADE
caused O
by O
an O
intracranial B-ADE
mass I-ADE
lesion I-ADE
following O
high O
- O
dose O
methotrexate B-DRUG
. O

The O
other O
patient O
developed O
transient B-ADE
intraoperative I-ADE
hypertension I-ADE
immediately O
after O
inadvertent O
submucosal O
injection O
of O
concentrated O
epinephrine B-DRUG
. O

BACKGROUND O
: O
Reproductive B-ADE
endocrine I-ADE
disorders I-ADE
characterized O
by O
menstrual B-ADE
disorders I-ADE
, O
polycystic B-ADE
ovaries I-ADE
, O
and O
hyperandrogenism B-ADE
seem O
to O
be O
common O
among O
women O
treated O
with O
sodium B-DRUG
valproate I-DRUG
for O
epilepsy O
. O

Ticlopidine B-DRUG
- O
induced O
aplastic B-ADE
anemia I-ADE
( O
TIAA B-ADE
) O
is O
considered O
very O
uncommon O
. O

Carbamazepine B-DRUG
- O
induced O
systemic B-ADE
lupus I-ADE
erythematosus I-ADE
. O

Although O
the O
existence O
of O
an O
acute O
pericarditis O
or O
an O
acute O
myocarditis O
as O
possible O
causes O
of O
the O
ST O
elevation O
can O
not O
be O
fully O
ruled O
out O
, O
the O
sudden O
onset O
, O
prominent O
magnitude O
, O
and O
brief O
duration O
of O
the O
ST O
elevation O
are O
perhaps O
more O
indicative O
of O
an O
acute O
ischemic O
event O
, O
possibly O
related O
to O
a O
transient O
coronary B-ADE
vasoconstriction I-ADE
induced O
by O
the O
dopamine B-DRUG
infusion O
. O

Sustained B-ADE
ventricular I-ADE
tachycardia I-ADE
in O
a O
thalidomide B-DRUG
- O
treated O
patient O
with O
primary O
plasma O
- O
cell O
leukemia O
. O

The O
present O
report O
illustrates O
a O
rare O
case O
of O
refractory O
akathisia B-ADE
after O
interferon B-DRUG
- I-DRUG
alpha I-DRUG
treatment O
and O
also O
that O
levodopa O
treatment O
would O
be O
theoretically O
and O
practically O
useful O
in O
reducing O
the O
neurotoxicity B-ADE
associated O
with O
interferon B-DRUG
- I-DRUG
alpha I-DRUG
. O

Methotrexate B-DRUG
- O
induced O
hepatic B-ADE
necrosis I-ADE
requiring O
liver O
transplantation O
in O
a O
patient O
with O
rheumatoid O
arthritis O
. O

A O
78-year O
- O
old O
man O
with O
a O
transvenous O
cardioverter O
defibrillator O
system O
developed O
frequent O
shocks B-ADE
during O
oral O
procainamide B-DRUG
therapy O
. O

CONCLUSIONS O
: O
Because O
of O
its O
structural O
similarity O
to O
the O
other O
vinca O
alkaloids O
, O
vinorelbine B-DRUG
is O
believed O
to O
be O
responsible O
for O
SIADH B-ADE
in O
our O
patient O
. O

An O
objective O
causality O
assessment O
by O
use O
of O
the O
Naranjo O
probability O
scale O
revealed O
that O
NCSE B-ADE
due O
to O
ifosfamide B-DRUG
was O
probable O
. O

Propranolol B-DRUG
- O
induced O
hypertension B-ADE
in O
treatment O
of O
cocaine O
intoxication O
. O

A O
patient O
with O
acute O
esophageal O
variceal O
bleeding O
developed O
fatal B-ADE
rhabdomyolysis I-ADE
during O
treatment O
with O
a O
continuous O
intravenous O
infusion O
of O
vasopressin B-DRUG
. O

When O
the O
trazodone B-DRUG
was O
reduced O
, O
the O
involuntary B-ADE
movements I-ADE
promptly O
ceased O
. O

CONCLUSIONS O
: O
SD O
- O
OCT O
and O
AO O
detected O
abnormalities O
that O
correlate O
topographically O
with O
visual B-ADE
field I-ADE
loss I-ADE
from O
hydroxychloroquine B-DRUG
toxicity O
as O
demonstrated O
by O
HVF O
10 O
- O
2 O
and O
may O
be O
useful O
in O
the O
detection O
of O
subclinical O
abnormalities O
that O
precede O
symptoms O
or O
objective B-ADE
visual I-ADE
field I-ADE
loss I-ADE
. O

Serotonin B-ADE
syndrome I-ADE
caused O
by O
interaction O
between O
citalopram B-DRUG
and O
fentanyl B-DRUG
. O

Neuroleptic B-ADE
malignant I-ADE
syndrome I-ADE
due O
to O
risperidone B-DRUG
treatment O
in O
a O
child O
with O
Joubert O
syndrome O
. O

After O
an O
extensive O
review O
of O
the O
literature O
, O
we O
believe O
that O
this O
is O
the O
first O
communication O
of O
the O
successful O
use O
of O
amiodarone O
to O
control O
hyperthyroidism O
in O
a O
patient O
with O
PTU B-DRUG
- O
induced O
fulminant B-ADE
hepatitis I-ADE
. O

A O
22-year O
- O
old O
drug O
- O
abuser O
injected O
flunitrazepam B-DRUG
tablets O
dissolved O
in O
tap O
water O
into O
her O
left O
femoral O
artery O
and O
presented O
with O
clinical O
signs O
of O
acute B-ADE
ischaemia I-ADE
of I-ADE
the I-ADE
left I-ADE
leg I-ADE
. O

Hepatotoxicity B-ADE
after O
high O
- O
dose O
methylprednisolone B-DRUG
for O
demyelinating O
disease O
. O

INTERVENTIONS O
AND O
RESULTS O
: O
Cardiac B-ADE
complications I-ADE
were O
observed O
in O
five O
pediatric O
patients O
who O
received O
between O
4.6 O
and O
40.8 O
mg O
/ O
kg O
/ O
d O
of O
amphotericin B-DRUG
B I-DRUG
. O

A O
56-year O
- O
old O
woman O
with O
scleroderma O
developed O
rapidly B-ADE
progressive I-ADE
glomerulonephritis I-ADE
with O
epithelial B-ADE
crescents I-ADE
associated O
with O
hemoptysis B-ADE
after O
27 O
months O
of O
D B-DRUG
- I-DRUG
penicillamine I-DRUG
therapy O
and O
a O
cumulative O
dose O
of O
1,200 O
g O
. O

Akathisia B-ADE
appeared O
to O
be O
a O
common O
side O
effect O
of O
fluoxetine B-DRUG
and O
generally O
responded O
well O
to O
treatment O
with O
the O
beta O
- O
adrenergic O
antagonist O
propranolol O
, O
dose O
reduction O
, O
or O
both O
. O

Our O
patient O
developed O
both O
nephrogenic B-ADE
diabetes I-ADE
insipidus I-ADE
and O
renal B-ADE
tubular I-ADE
acidosis I-ADE
with O
a O
temporal O
pattern O
that O
demonstrated O
a O
link O
between O
foscarnet B-DRUG
therapy O
and O
these O
abnormalities O
. O

Dystonia B-ADE
associated O
with O
carbamazepine B-DRUG
administration O
: O
experience O
in O
brain O
- O
damaged O
children O
. O

There O
have O
been O
numerous O
case O
reports O
of O
hyperglycemia B-ADE
with O
olanzapine B-DRUG
in O
the O
literature O
, O
but O
none O
reported O
hyperglycemia O
within O
days O
of O
initiation O
of O
the O
medication O
. O

Salicylate B-DRUG
- O
induced O
hepatotoxicity B-ADE
is O
reviewed O
. O

Ticlopidine B-DRUG
- O
induced O
marrow B-ADE
aplasia I-ADE
treated O
with O
cyclosporine O
. O

The O
incidence O
of O
angioedema B-ADE
secondary O
to O
losartan B-DRUG
, O
an O
angiotensin O
II O
receptor O
antagonist O
, O
is O
unknown O
. O

We O
report O
two O
new O
cases O
of O
sarcoidosis B-ADE
in O
two O
patients O
with O
hepatitis O
C O
virus O
infection O
treated O
with O
interferon B-DRUG
alfa I-DRUG
and O
ribavirin B-DRUG
. O

Interferon B-DRUG
- O
based O
treatments O
have O
the O
potential O
to O
decrease O
the O
burden O
of O
disease O
, O
but O
are O
complicated O
by O
side O
effects O
, O
including O
neuropsychiatric B-ADE
symptoms I-ADE
. O

Despite O
a O
response O
of O
the O
meningeal O
tumor O
the O
patient O
developed O
in O
the O
third O
week O
of O
MTX B-DRUG
treatment O
a O
progressive B-ADE
visual I-ADE
loss I-ADE
and O
loss B-ADE
of I-ADE
consciousness I-ADE
which O
worsened O
during O
subsequent O
Ara B-DRUG
- I-DRUG
C I-DRUG
treatment O
and O
led O
to O
death B-ADE
within O
3 O
weeks O
. O

In O
this O
case O
, O
unlike O
those O
previously O
reported O
, O
hyponatremia B-ADE
recurred O
5 O
months O
after O
switching O
from O
citalopram B-DRUG
to O
mirtazapine B-DRUG
, O
which O
is O
believed O
to O
be O
a O
safe O
antidepressant O
. O

Vogt B-ADE
- I-ADE
Koyanagi I-ADE
- I-ADE
Harada I-ADE
disease I-ADE
occurring O
during O
interferon B-DRUG
alpha I-DRUG
therapy O
for O
chronic O
hepatitis O
C O
. O

Anaphylaxis B-ADE
to O
intrathecal O
diamorphine B-DRUG
. O

Anastrozole B-DRUG
- O
associated O
sclerosing B-ADE
glomerulonephritis I-ADE
in O
a O
patient O
with O
breast O
cancer O
. O

Priapism B-ADE
associated O
with O
trazodone B-DRUG
therapy O
: O
case O
report O
. O

Methyldopa B-DRUG
- O
induced O
liver B-ADE
injury I-ADE
. O

We O
also O
describe O
a O
new O
, O
noninvasive O
method O
to O
assess O
magnesium B-DRUG
- O
induced O
neuromuscular B-ADE
block I-ADE
when O
curariform O
muscle O
relaxant O
was O
given O
simultaneously O
. O

To O
our O
knowledge O
, O
drug O
- O
induced O
fever B-ADE
has O
not O
been O
reported O
with O
the O
use O
of O
diltiazem B-DRUG
hydrochloride I-DRUG
, O
a O
commonly O
prescribed O
calcium O
channel O
blocker O
. O

Diclofenac B-DRUG
- O
associated O
hepatitis B-ADE
. O

Acute B-ADE
renal I-ADE
insufficiency I-ADE
is O
known O
to O
occur O
in O
patients O
who O
are O
taking O
ciprofloxacin B-DRUG
, O
particularly O
the O
elderly O
. O

Acetazolamide B-DRUG
- O
accelerated O
anticonvulsant O
osteomalacia B-ADE
. O

An O
unusual O
case O
of O
Ecstasy B-DRUG
poisoning I-ADE
. O

Severe B-ADE
osteomalacia I-ADE
was O
present O
in O
two O
epileptic O
patients O
who O
were O
under O
long O
- O
term O
treatment O
with O
congeners O
of O
phenytoin B-DRUG
, O
phenobarbital B-DRUG
, O
and O
acetazolamide B-DRUG
. O

BACKGROUND O
: O
Methotrexate B-DRUG
( O
MTX B-DRUG
) O
may O
induce O
liver B-ADE
damage I-ADE
, O
which O
in O
some O
psoriatics O
will O
lead O
to O
fibrosis B-ADE
or O
cirrhosis B-ADE
. O

A O
case O
report O
of O
a O
patient O
with O
probable O
cisplatin B-DRUG
and O
bleomycin B-DRUG
- O
induced O
TMA B-ADE
is O
presented O
. O

Cephalexin B-DRUG
rash I-ADE
in O
infectious O
mononucleosis O
. O

We O
report O
a O
45-year O
- O
old O
Chinese O
man O
with O
CML O
and O
chronic O
hepatitis O
B O
virus O
infection O
, O
on O
imatinib B-DRUG
treatment O
, O
presenting O
with O
herpetic B-ADE
rash I-ADE
and O
acute B-ADE
liver I-ADE
failure I-ADE
. O

We O
describe O
longitudinal O
diffusion O
- O
weighted O
MRI O
findings O
of O
sub B-ADE
- I-ADE
acute I-ADE
leukoencephalopathy I-ADE
following O
methotrexate B-DRUG
therapy O
in O
a O
24-year O
- O
old O
man O
diagnosed O
with O
pre O
- O
B O
- O
cell O
acute O
lymphoblastic O
leukemia O
( O
ALL O
) O
, O
presenting O
with O
right O
- O
sided O
paralysis O
and O
aphasia O
after O
second O
consolidation O
with O
intrathecal O
triple O
- O
drug O
therapy O
given O
intrathecally O
. O

Electrocardiographic O
findings O
and O
laboratory O
data O
indicated O
a O
diagnosis O
of O
acute B-ADE
myocardial I-ADE
infarction I-ADE
due O
to O
the O
L B-DRUG
- I-DRUG
thyroxine I-DRUG
therapy O
. O

Scleritis B-ADE
complicating O
zoledronic B-DRUG
acid I-DRUG
infusion O
. O

In O
a O
phase O
II O
study O
of O
hycanthone B-DRUG
in O
patients O
with O
breast O
cancer O
we O
have O
recently O
observed O
severe B-ADE
hepatotoxicity I-ADE
, O
even O
at O
lower O
doses O
, O
which O
resulted O
in O
two O
drug O
- O
related O
deaths O
. O

This O
patient O
developed O
sequential O
symptoms O
including O
alternative O
hemiparesis B-ADE
, O
dysarthria B-ADE
and O
altered B-ADE
consciousness I-ADE
5 O
days O
after O
the O
second O
course O
of O
HD B-DRUG
- I-DRUG
MTX I-DRUG
( O
8 O
gm O
/ O
m2 O
by O
6 O
h O
continuous O
infusion O
) O
with O
leucovorin O
rescue O
. O

Following O
discontinuation O
of O
clozapine B-DRUG
, O
she O
was O
rechallenged O
and O
again O
was O
observed O
to O
have O
seizures B-ADE
. O

Moxalactam B-DRUG
is O
more O
likely O
to O
be O
associated O
with O
platelet B-ADE
dysfunction I-ADE
. O

Physicians O
using O
this O
" O
new O
" O
drug O
must O
be O
aware O
of O
the O
potential O
danger O
of O
sulfonamide B-DRUG
- O
induced O
injury B-ADE
to I-ADE
the I-ADE
urinary I-ADE
tract I-ADE
. O

OBJECTIVE O
: O
To O
report O
the O
case O
of O
a O
young O
woman O
with O
Graves O
' O
disease O
in O
whom O
ototoxicity B-ADE
developed O
because O
of O
propylthiouracil B-DRUG
( O
PTU B-DRUG
) O
- O
induced O
antineutrophil B-ADE
cytoplasmic I-ADE
antibody I-ADE
( I-ADE
ANCA I-ADE
) I-ADE
- I-ADE
associated I-ADE
vasculitis I-ADE
. O

Thrombocytosis B-ADE
under O
ciprofloxacin B-DRUG
and O
tazobactam B-DRUG
/ O
piperacillin B-DRUG
. O

We O
report O
the O
case O
of O
an O
adult O
patient O
with O
acute O
lymphoblastic O
leukemia O
who O
presented O
with O
repeated O
transient B-ADE
ischemic I-ADE
attacks I-ADE
followed O
by O
a O
seizure B-ADE
during O
consolidation O
treatment O
with O
L B-DRUG
- I-DRUG
asparaginase I-DRUG
. O

Inhaled O
tobramycin B-DRUG
solution O
- O
associated O
recurrent B-ADE
eosinophilia I-ADE
and O
severe B-ADE
persistent I-ADE
bronchospasm I-ADE
in O
a O
patient O
with O
cystic O
fibrosis O
: O
a O
case O
report O
. O

We O
report O
on O
a O
patient O
who O
developed O
acute B-ADE
rhabdomyolysis I-ADE
after O
taking O
cerivastatin B-DRUG
. O

Since O
the O
bronchospasm B-ADE
was O
relieved O
with O
discontinuation O
of O
propranolol B-DRUG
and O
supportive O
bronchodilator O
therapy O
, O
the O
bronchospasm B-ADE
was O
believed O
to O
be O
caused O
by O
propranolol B-DRUG
. O

We O
describe O
the O
case O
of O
a O
nonatopic O
17-year O
- O
old O
girl O
with O
bronchial O
asthma O
and O
aspirin O
intolerance O
who O
developed O
a O
dramatic O
anaphylactic B-ADE
reaction I-ADE
to O
oral O
prednisone B-DRUG
. O

RESULTS O
: O
Our O
patient O
developed O
Crohn B-ADE
's I-ADE
disease I-ADE
while O
on O
Copaxone B-DRUG
treatment O
as O
a O
consequence O
of O
long B-ADE
- I-ADE
term I-ADE
immunosuppression I-ADE
. O

One O
patient O
with O
systemic O
lupus O
erythematosus O
developed O
erythema B-ADE
multiforme I-ADE
after O
taking O
griseofulvin B-DRUG
. O

Soon O
after O
its O
introduction O
in O
1952 O
, O
chlorpromazine B-DRUG
was O
noted O
to O
induce O
symptoms B-ADE
resembling I-ADE
Parkinson I-ADE
's I-ADE
disease I-ADE
. O

MR O
findings O
in O
methotrexate B-DRUG
- O
induced O
CNS B-ADE
abnormalities I-ADE
. O

Because O
there O
were O
no O
other O
obvious O
causes O
of O
renal O
failure O
in O
either O
patient O
, O
we O
propose O
that O
skeletal B-ADE
muscle I-ADE
ischemia I-ADE
developed O
during O
vasopressin B-DRUG
infusion O
, O
followed O
by O
release O
of O
myoglobin O
and O
renal B-ADE
damage I-ADE
. O

The O
authors O
describe O
a O
case O
of O
valvular B-ADE
heart I-ADE
disease I-ADE
in O
a O
48-year O
- O
old O
woman O
receiving O
benfluorex B-DRUG
( O
150 O
mg O
t.i.d O
. O
for O
8 O
years O
) O
and O
leading O
to O
surgical O
mitral O
valve O
replacement O
. O

Scleroderma B-ADE
in O
association O
with O
the O
use O
of O
bleomycin B-DRUG
: O
a O
report O
of O
3 O
cases O
. O

We O
report O
a O
case O
of O
drug O
- O
induced O
Kaposi B-ADE
's I-ADE
sarcoma I-ADE
( O
KS O
) O
on O
the O
sole O
of O
the O
right O
foot O
in O
a O
71-year O
- O
old O
man O
, O
treated O
for O
6 O
months O
with O
corticosteroid O
therapy O
( O
prednisolone B-DRUG
25 O
mg O
/ O
day O
) O
for O
pericardial O
effusion O
. O

A O
young O
woman O
with O
epilepsy O
had O
tonic B-ADE
- I-ADE
clonic I-ADE
seizures I-ADE
during O
antineoplastic O
therapy O
with O
adriamycin B-DRUG
and O
cisplatin B-DRUG
. O

Acute B-ADE
myeloid I-ADE
leukemia I-ADE
and O
lung B-ADE
cancer I-ADE
occurring O
in O
a O
chronic O
lymphocytic O
leukemia O
patient O
treated O
with O
fludarabine B-DRUG
and O
autologous O
peripheral O
blood O
stem O
- O
cell O
transplantation O
. O

Idiosyncratic O
factors O
involving O
vasopressin O
receptor O
affinity O
and O
distribution O
, O
vasopressin B-DRUG
- O
associated O
vasodilation B-ADE
in O
some O
vascular O
beds O
, O
and O
the O
effect O
of O
vasopressin B-DRUG
on O
the O
renin O
- O
angiotensin O
system O
may O
further O
contribute O
to O
impaired B-ADE
tissue I-ADE
perfusion I-ADE
. O

We O
describe O
six O
patients O
who O
developed O
tardive B-ADE
dyskinesia I-ADE
after O
treatment O
with O
sulpiride B-DRUG
for O
depression O
or O
gastrointestinal O
symptoms O
. O

Skin B-ADE
necrosis I-ADE
secondary O
to O
low B-DRUG
- I-DRUG
molecular I-DRUG
weight I-DRUG
heparin I-DRUG
in O
a O
patient O
with O
antiphospholipid O
antibody O
syndrome O
. O

The O
development O
of O
systemic B-ADE
lupus I-ADE
erythematosus I-ADE
( O
SLE B-ADE
) O
after O
38 O
months O
of O
therapy O
with O
recombinant B-DRUG
human I-DRUG
interferon I-DRUG
gamma I-DRUG
( O
rIFN B-DRUG
- I-DRUG
gamma I-DRUG
) O
was O
observed O
in O
a O
patient O
with O
rheumatoid O
arthritis O
. O

Accelerated B-ADE
nodulosis I-ADE
during O
methotrexate B-DRUG
therapy O
for O
juvenile O
rheumatoid O
arthritis O
. O

Acute B-ADE
non I-ADE
- I-ADE
lymphocytic I-ADE
leukemia I-ADE
occurred O
in O
eight O
women O
following O
long O
- O
term O
treatment O
with O
Treosulfan B-DRUG
(= O
dihydroxybusulfan B-DRUG
) O
for O
ovarian O
carcinoma O
. O

Transient B-ADE
left I-ADE
homonymous I-ADE
hemianopsia I-ADE
and O
encephalopathy B-ADE
following O
treatment O
of O
testicular O
carcinoma O
with O
cisplatinum B-DRUG
, O
vinblastine B-DRUG
, O
and O
bleomycin B-DRUG
. O

CD20-negative B-ADE
T I-ADE
- I-ADE
cell I-ADE
- I-ADE
rich I-ADE
B I-ADE
- I-ADE
cell I-ADE
lymphoma I-ADE
as O
a O
progression O
of O
a O
nodular O
lymphocyte O
- O
predominant O
Hodgkin O
's O
lymphoma O
treated O
with O
rituximab B-DRUG
: O
a O
molecular O
analysis O
using O
laser O
capture O
microdissection O
. O

We O
present O
the O
case O
of O
a O
postictal O
patient O
with O
lethargy B-ADE
, O
hyperammonemia B-ADE
, O
otherwise O
normal O
liver O
function O
tests O
, O
and O
a O
therapeutic O
valproic B-DRUG
acid I-DRUG
level O
. O

Nonoliguric B-ADE
acute I-ADE
renal I-ADE
failure I-ADE
after O
captopril B-DRUG
therapy O
. O

Listeria B-ADE
brain I-ADE
abscess I-ADE
, O
Pneumocystis B-ADE
pneumonia I-ADE
and O
Kaposi B-ADE
's I-ADE
sarcoma I-ADE
after O
temozolomide B-DRUG
. O

RESULTS O
: O
After O
4- O
to O
14-month O
period O
of O
therapy O
with O
the O
combination O
of O
indapamide B-DRUG
( O
2.5 O
mg O
/ O
day O
) O
and O
fosinopril B-DRUG
( O
10 O
mg O
/ O
day O
) O
in O
three O
patients O
and O
6-month O
period O
of O
monotherapy O
with O
indapamide B-DRUG
( O
2.5 O
mg O
/ O
day O
) O
in O
one O
patient O
, O
glucose O
levels O
of O
all O
patients O
increased O
and O
achieve O
criteria O
of O
diabetes B-ADE
diagnoses O
. O

In O
these O
patients O
, O
long O
- O
acting O
octreotide B-DRUG
may O
trigger O
serious B-ADE
hypoglycemia I-ADE
. O

Albuterol B-DRUG
- O
induced O
hypokalemia B-ADE
and O
its O
potential O
cardiac B-ADE
toxicity I-ADE
are O
discussed O
briefly O
. O

OBJECTIVE O
: O
1 O
) O
To O
describe O
a O
patient O
with O
rheumatoid O
arthritis O
receiving O
adalimumab B-DRUG
who O
developed O
fever B-ADE
, O
pancytopenia B-ADE
, O
splenomegaly B-ADE
, O
and O
extreme B-ADE
hyperferritinemia I-ADE
. O

In O
two O
patients O
with O
mycosis O
fungoides O
, O
a O
squamous B-ADE
cell I-ADE
carcinoma I-ADE
developed O
during O
therapy O
with O
psoralens B-DRUG
plus O
long O
- O
wave O
ultraviolet O
radiation O
( O
PUVA O
) O
. O

Transfusion B-ADE
haemosiderosis I-ADE
inspite O
of O
regular O
use O
of O
desferrioxamine B-DRUG
: O
case O
report O
. O

CONCLUSIONS O
: O
Infectious B-ADE
endophthalmitis I-ADE
is O
a O
potential O
complication O
of O
intravitreal O
bevacizumab B-DRUG
injection O
. O

Discontinuation O
of O
simvastatin B-DRUG
and O
cyclosporine B-DRUG
resulted O
in O
resolution O
of O
rhabdomyolysis B-ADE
and O
normalization O
of O
renal O
function O
. O

Captopril B-DRUG
- O
induced O
acute B-ADE
reversible I-ADE
renal I-ADE
failure I-ADE
. O

Gastro B-ADE
- I-ADE
oesophageal I-ADE
reflux I-ADE
associated O
with O
nifedipine B-DRUG
. O

Pirmenol B-DRUG
hydrochloride I-DRUG
- O
induced O
QT B-ADE
prolongation I-ADE
and O
T B-ADE
wave I-ADE
inversion I-ADE
on O
electrocardiogram O
during O
treatment O
for O
symptomatic O
atrial O
fibrillation O
. O

Isoniazid B-DRUG
associated O
, O
painful O
, O
bilateral B-ADE
gynaecomastia I-ADE
. O

Voriconazole B-DRUG
( O
VRC B-DRUG
) O
has O
not O
previously O
been O
reported O
to O
cause O
angio B-ADE
- I-ADE
oedema I-ADE
. O

Fatal B-ADE
agranulocytosis I-ADE
in O
an O
Indian O
male O
receiving O
100 O
mg O
of O
dapsone B-DRUG
daily O
, O
hospitalized O
for O
mid O
- O
borderline O
leprosy O
in O
type O
I O
reaction O
with O
triple O
nerve O
paralysis O
is O
reported O
. O

Within O
3 O
weeks O
of O
beginning O
continuous O
daily O
isoniazid B-DRUG
and O
rifampin B-DRUG
therapy O
for O
pulmonary O
tuberculosis O
, O
a O
patient O
developed O
acute B-ADE
renal I-ADE
failure I-ADE
. O

Reported O
are O
three O
children O
who O
developed O
progressive B-ADE
paraparesis I-ADE
after O
intrathecal O
methotrexate B-DRUG
administration O
followed O
by O
complete O
or O
partial O
recovery O
. O

These O
case O
reports O
provide O
evidence O
that O
5-aminosalicylic B-DRUG
acid I-DRUG
may O
induce O
acute B-ADE
pancreatitis I-ADE
after O
long O
term O
treatment O
. O

Torsades B-ADE
de I-ADE
Pointes I-ADE
induced O
by O
a O
combination O
of O
garenoxacin B-DRUG
and O
disopyramide B-DRUG
and O
other O
cytochrome O
P450 O
, O
family O
3 O
, O
subfamily O
A O
polypeptide-4-influencing O
drugs O
during O
hypokalemia O
due O
to O
licorice O
. O

A O
65-year O
- O
old O
man O
on O
warfarin B-DRUG
therapy O
with O
a O
sudden O
spontaneous O
onset O
of O
sub B-ADE
- I-ADE
conjunctival I-ADE
haematoma I-ADE
associated O
with O
bloody B-ADE
tears I-ADE
was O
assessed O
in O
the O
clinic O
following O
a O
referral O
from O
an O
optometrist O
. O

Sunburn B-ADE
may O
sometimes O
be O
a O
major O
injury O
in O
psoralen B-DRUG
users O
because O
high O
doses O
or O
inappropriate O
use O
of O
the O
drug O
may O
render O
the O
skin B-ADE
extremely I-ADE
sensitive I-ADE
. O

In O
this O
report O
, O
we O
describe O
a O
fatal O
gemcitabine B-DRUG
- O
induced O
pulmonary B-ADE
toxicity I-ADE
in O
a O
patient O
with O
gallbladder O
metastatic O
adenocarcinoma O
. O

Severe B-ADE
Raynaud I-ADE
's I-ADE
phenomenon I-ADE
with O
yohimbine B-DRUG
therapy O
for O
erectile O
dysfunction O
. O

This O
concerns O
2 O
male O
patients O
who O
experienced O
incontinence B-ADE
while O
taking O
venlafaxine B-DRUG
. O

We O
suggest O
that O
meloxicam B-DRUG
might O
have O
intestinal B-ADE
toxic I-ADE
effects I-ADE
when O
taken O
in O
high O
doses O
, O
because O
of O
reduced O
COX-2 O
selectivity O
. O

A O
52-year O
- O
old O
, O
white O
female O
developed O
low B-ADE
- I-ADE
grade I-ADE
fever I-ADE
, O
cough B-ADE
, O
and O
dyspnea B-ADE
after O
8 O
weeks O
treatment O
with O
sodium B-DRUG
aurothiomalate I-DRUG
for O
rheumatoid O
arthritis O
. O

Destructive O
thyrotoxicosis B-ADE
appeared O
4 O
- O
6 O
months O
after O
starting O
IFN B-DRUG
- I-DRUG
alpha I-DRUG
, O
followed O
by O
Graves B-ADE
' I-ADE
hyperthyroidism I-ADE
within O
8 O
to O
11 O
months O
. O

Two O
heroin O
addicts O
, O
aged O
34 O
and O
19 O
years O
, O
developed O
ballistic B-ADE
movements I-ADE
after O
intravenous O
heroin B-DRUG
overdose O
. O

Five O
days O
after O
the O
fourth O
dose O
of O
vincristine B-DRUG
, O
she O
presented O
with O
bilateral B-ADE
ptosis I-ADE
. O

We O
describe O
the O
clinical O
response O
, O
as O
determined O
by O
increases B-ADE
in I-ADE
total I-ADE
Hb I-ADE
and O
decreased O
transfusion O
needs O
, O
in O
five O
patients O
with O
thalassemia O
intermedia O
treated O
with O
HU B-DRUG
alone O
or O
in O
combination O
with O
SPB B-DRUG
. O

Patient O
B O
developed O
perioral B-ADE
and I-ADE
upper I-ADE
extremity I-ADE
paresthesias I-ADE
during O
the O
fourth O
cycle O
of O
CAP B-DRUG
alone O
( O
2500 O
mg O
/ O
m2 O
) O
. O

Clozapine B-DRUG
is O
speculated O
to O
cause O
rhabdomyolysis B-ADE
in O
patients O
with O
defective O
calcium O
- O
activated O
K+ O
channels O
. O

Severe B-ADE
systemic I-ADE
hypersensitivity I-ADE
reaction I-ADE
to O
ibuprofen B-DRUG
occurring O
after O
prolonged O
therapy O
. O

Dexamethasone O
treatment O
of O
amiodarone B-DRUG
- O
induced O
thyrotoxicosis B-ADE
( O
AIT O
) O
with O
or O
without O
persistent O
administration O
of O
the O
drug O
. O

The O
fifth O
patient O
exhibited O
paraesthesia B-ADE
and O
agitation B-ADE
caused O
by O
olanzapine B-DRUG
that O
was O
misdiagnosed O
as O
psychotic O
agitation O
. O

We O
report O
2 O
cases O
of O
maculopapular B-ADE
eruption I-ADE
and O
fever B-ADE
in O
patients O
infected O
with O
human O
immunodeficiency O
virus O
( O
HIV O
) O
on O
the O
2nd O
day O
of O
first O
administration O
of O
ritonavir B-DRUG
, O
a O
protease O
inhibitor O
. O

Gallstones B-ADE
and O
bile B-ADE
sludge I-ADE
are O
common O
side O
effects O
of O
octreotide B-DRUG
therapy O
but O
rarely O
become O
symptomatic O
or O
require O
treatment O
. O

One O
patient O
had O
severe B-ADE
temporary I-ADE
weakness I-ADE
after O
an O
ampicillin B-DRUG
sodium I-DRUG
challenge O
. O

Proliferation B-ADE
of I-ADE
abnormal I-ADE
bone I-ADE
marrow I-ADE
histiocytes I-ADE
, O
an O
undesired O
effect O
of O
granulocyte B-DRUG
macrophage I-DRUG
- I-DRUG
colony I-DRUG
- I-DRUG
stimulating I-DRUG
factor I-DRUG
therapy O
in O
a O
patient O
with O
Hurler O
's O
syndrome O
undergoing O
bone O
marrow O
transplantation O
. O

Generalised B-ADE
pustular I-ADE
psoriasis I-ADE
induced O
by O
cyclosporin B-DRUG
a I-DRUG
withdrawal O
responding O
to O
the O
tumour O
necrosis O
factor O
alpha O
inhibitor O
etanercept O
. O

In O
a O
series O
of O
104 O
cases O
of O
intentional O
or O
inadvertent O
use O
of O
zidovudine B-DRUG
at O
differing O
gestations O
in O
pregnancy O
, O
there O
were O
eight O
spontaneous O
first B-ADE
trimester I-ADE
abortions I-ADE
, O
eight O
therapeutic O
terminations O
, O
and O
eight O
cases O
of O
fetal B-ADE
abnormality I-ADE
occurring O
among O
a O
total O
of O
88 O
cases O
where O
the O
pregnancy O
progressed O
. O

Clozapine B-DRUG
- O
induced O
tardive B-ADE
dyskinesia I-ADE
in O
schizophrenic O
patients O
taking O
clozapine O
as O
a O
first O
- O
line O
antipsychotic O
drug O
. O

We O
concluded O
that O
the O
colonic B-ADE
ulcer I-ADE
and O
the O
sigmoidovesical B-ADE
fistula I-ADE
had O
been O
caused O
by O
the O
administration O
of O
calcium B-DRUG
polystyrene I-DRUG
sulfonate I-DRUG
and O
sorbitol B-DRUG
. O

Interstitial B-ADE
pneumonitis I-ADE
and O
alveolar B-ADE
hemorrhage I-ADE
complicating O
use O
of O
rituximab B-DRUG
: O
case O
report O
and O
review O
of O
the O
literature O
. O

Recurrent O
palmar B-ADE
- I-ADE
plantar I-ADE
erythrodysaesthesia I-ADE
following O
high O
- O
dose O
cytarabine B-DRUG
treatment O
for O
acute O
lymphoblastic O
leukemia O
. O

This O
case O
suggests O
that O
acyclovir B-DRUG
when O
given O
intravenously O
in O
doses O
of O
10 O
mg O
/ O
kg O
may O
result O
in O
increased B-ADE
serum I-ADE
lithium B-DRUG
concentrations O
. O

However O
, O
repeated O
intracameral O
tPA B-DRUG
injections O
may O
cause O
unwanted O
complications O
such O
as O
vitreous B-ADE
hemorrhage I-ADE
. O

Carbamazepine B-DRUG
- O
induced O
hyperammonemia B-ADE
. O

The O
authors O
present O
a O
case O
study O
of O
a O
mentally O
healthy O
man O
who O
repeatedly O
experienced O
short O
- O
lived O
, O
obsessional B-ADE
- I-ADE
like I-ADE
suicidal I-ADE
ideas I-ADE
and I-ADE
images I-ADE
after O
ingestion O
of O
the O
anti O
- O
fungal O
drug O
ketoconazole B-DRUG
. O

Reversible O
findings O
of O
restricted O
diffusion O
in O
5-fluorouracil B-DRUG
neurotoxicity B-ADE
. O

CONCLUSIONS O
: O
This O
report O
indicates O
clindamycin B-DRUG
phosphate I-DRUG
vaginal O
cream O
as O
the O
most O
probable O
cause O
of O
CDIC B-ADE
due O
to O
the O
temporal O
relationship O
between O
the O
occurrence O
of O
diarrhea B-ADE
and O
clindamycin B-DRUG
administration O
, O
lack O
of O
concomitant O
medications O
, O
and O
documentation O
of O
C. B-ADE
difficile I-ADE
toxin I-ADE
. O

Oculomotor B-ADE
disturbances I-ADE
associated O
with O
5-fluorouracil B-DRUG
chemotherapy O
. O

Renal B-ADE
tubular I-ADE
acidosis I-ADE
secondary O
to O
FK506 B-DRUG
in O
living O
donor O
liver O
transplantation O
: O
a O
case O
report O
. O

Acute B-ADE
delirium I-ADE
resulting O
from O
levofloxacin B-DRUG
therapy O
is O
an O
exceedingly O
rare O
complication O
that O
has O
been O
thought O
to O
occur O
more O
commonly O
in O
elderly O
patients O
. O

When O
the O
data O
of O
the O
57 O
patients O
are O
evaluated O
, O
a O
reversible O
direct O
cytotoxic B-ADE
effect I-ADE
of O
ticlopidine B-DRUG
on O
the O
pluripotent O
/ O
bipotent O
hematopoietic O
progenitor O
stem O
cell O
is O
proposed O
. O

Seizures B-ADE
associated O
with O
fluoxetine B-DRUG
therapy O
. O

Thrombotic B-ADE
thrombocytopenic I-ADE
purpura I-ADE
during O
penicillamine B-DRUG
therapy O
in O
rheumatoid O
arthritis O
. O

Skin B-ADE
necrosis I-ADE
after O
extravasation O
of O
low O
- O
dose O
vasopressin B-DRUG
administered O
for O
septic O
shock O
. O

The O
hyperpigmentation O
was O
diffuse O
scattered O
, O
flagellate O
like O
and O
linear O
streaking O
which O
was O
thought O
to O
be O
mainly O
related O
to O
the O
skin B-ADE
toxicity I-ADE
of O
bleomycin B-DRUG
. O

Arterial B-ADE
hypertension I-ADE
associated O
with O
topical O
ocular O
use O
of O
phenylephrine B-DRUG
in O
dogs O
. O

Histological O
examination O
of O
the O
dacryolith B-ADE
suggested O
its O
derivation O
from O
breakdown O
products O
of O
adrenaline B-DRUG
. O

The O
administration O
of O
" O
sweet B-DRUG
spirits I-DRUG
of I-DRUG
nitre I-DRUG
" O
( O
4 B-DRUG
% I-DRUG
ethyl I-DRUG
nitrite I-DRUG
CH3CH2ONO I-DRUG
in I-DRUG
70 I-DRUG
% I-DRUG
ethyl I-DRUG
alcohol I-DRUG
) O
was O
followed O
by O
acute B-ADE
methemoglobinemia I-ADE
and O
severe B-ADE
anoxic I-ADE
metabolic I-ADE
acidosis I-ADE
in O
infant O
twins O
, O
Methylene O
blue O
administration O
reversed O
methemoglobinemia O
in O
both O
, O
but O
one O
twin O
died B-ADE
from O
the O
consequences O
of O
hypoxemia B-ADE
. O

Severe B-ADE
respiratory I-ADE
syncytial I-ADE
virus I-ADE
pulmonary I-ADE
infection I-ADE
in O
a O
patient O
treated O
with O
fludarabine B-DRUG
for O
chronic O
lymphocytic O
leukemia O
. O

Piloerection B-ADE
induced O
by O
replacing O
fluvoxamine B-DRUG
with O
milnacipran B-DRUG
. O

A O
50-year O
- O
old O
diabetic O
and O
hypertensive O
male O
patient O
is O
reported O
who O
had O
ticlopidine B-DRUG
- O
induced O
marrow B-ADE
aplasia I-ADE
partially O
responsive O
to O
colony O
- O
stimulating O
factors O
and O
corticosteroids O
, O
but O
experienced O
complete O
recovery O
with O
cyclosporine O
. O

Tigecycline B-DRUG
- O
induced O
acute B-ADE
pancreatitis I-ADE
: O
case O
report O
and O
literature O
review O
. O

Oral O
25-hydroxyvitain B-DRUG
D3 I-DRUG
in O
treatment O
of O
osteomalacia O
associated O
with O
ileal B-ADE
resection I-ADE
and O
cholestyramine O
therapy O
. O

OBJECTIVE O
: O
This O
case O
report O
outlines O
a O
significant O
type O
of O
morbidity O
due O
to O
continued O
use O
of O
gabapentin B-DRUG
during O
an O
episode O
of O
acute B-ADE
renal I-ADE
failure I-ADE
. O

Fatal O
gemcitabine B-DRUG
- O
induced O
pulmonary B-ADE
toxicity I-ADE
in O
metastatic O
gallbladder O
adenocarcinoma O
. O

Massive B-ADE
plasmocytosis I-ADE
due O
to O
methimazole B-DRUG
- O
induced O
bone B-ADE
marrow I-ADE
toxicity I-ADE
. O

Isoniazid B-DRUG
inhibits O
the O
conversion O
of O
tryptophan O
to O
niacin O
and O
may O
induce O
pellagra B-ADE
, O
particularly O
in O
poorly O
nourished O
patients O
. O

Acute B-ADE
respiratory I-ADE
depression I-ADE
as O
a O
complication O
of O
nebulised O
morphine B-DRUG
. O

Sideroblastic B-ADE
anemia I-ADE
due O
to O
linezolid B-DRUG
in O
a O
patient O
with O
a O
left O
ventricular O
assist O
device O
. O

Use O
of O
the O
Naranjo O
probability O
scale O
determined O
the O
association O
between O
cephalosporin B-DRUG
use O
and O
leukopenia B-ADE
to O
be O
probable O
. O

A O
58-year O
- O
old O
man O
with O
rheumatoid O
arthritis O
developed O
lichen B-ADE
planus I-ADE
during O
treatment O
with O
gold B-DRUG
. O

Allergic O
and O
irritant B-ADE
contact I-ADE
dermatitis I-ADE
to O
calcipotriol B-DRUG
. O

CASE O
SUMMARY O
: O
A O
46-year O
- O
old O
African O
- O
American O
man O
experienced O
recurrent O
grand B-ADE
mal I-ADE
seizures I-ADE
during O
intravenous O
infusion O
of O
amphotericin B-DRUG
B I-DRUG
, O
then O
petit O
mal O
seizures O
as O
the O
infusion O
was O
stopped O
and O
the O
drug O
concentrations O
decreased O
with O
time O
. O

We O
present O
an O
AIDS O
patient O
with O
severe O
and O
prolonged O
lactic B-ADE
acidosis I-ADE
on O
stavudine B-DRUG
and O
lamivudine B-DRUG
. O

We O
report O
here O
a O
case O
of O
cardiovascular O
and O
neurological B-ADE
depression I-ADE
induced O
by O
oxymetalzoline B-DRUG
in O
a O
toddler O
. O

Our O
cases O
constitute O
the O
most O
severe O
cases O
of O
benzarone B-DRUG
hepatotoxicity B-ADE
reported O
so O
far O
, O
and O
comprise O
the O
first O
cases O
of O
( B-ADE
sub)fulminant I-ADE
hepatitis I-ADE
and O
cirrhosis B-ADE
related O
to O
benzarone B-DRUG
. O

A O
35-year O
- O
old O
nephrotic O
man O
developed O
acute B-ADE
renal I-ADE
failure I-ADE
with O
serum O
creatinine O
to O
1543 O
micromol O
/ O
l O
after O
a O
month O
of O
therapy O
with O
enalapril B-DRUG
. O

Moreover O
, O
these O
findings O
suggest O
that O
the O
incidence O
of O
BOOP B-ADE
following O
rituximab B-DRUG
therapy O
may O
be O
higher O
than O
has O
been O
previously O
appreciated O
. O

RESULTS O
: O
Budesonide B-DRUG
use O
can O
cause O
contact B-ADE
dermatitis I-ADE
. O

Case O
studies O
in O
heparin B-DRUG
- O
induced O
thrombocytopenia B-ADE
. O

Dihydropyrimidine O
dehydrogenase O
deficiency O
: O
a O
pharmacogenetic O
defect O
causing O
severe B-ADE
adverse I-ADE
reactions I-ADE
to O
5-fluorouracil B-DRUG
- O
based O
chemotherapy O
. O

Establishment O
of O
diuresis O
with O
fluids O
and O
IV O
administration O
of O
calcium O
may O
provide O
successful O
treatment O
of O
magnesium B-DRUG
toxicosis I-ADE
in O
horses O
. O

Does O
acyclovir B-DRUG
increase B-ADE
serum I-ADE
lithium I-ADE
levels I-ADE
? O

Even O
after O
a O
strict O
warning O
, O
he O
took O
another O
quinine B-DRUG
tablet O
that O
evening O
, O
which O
triggered O
his O
fifth O
episode O
of O
severe O
thrombocytopenia B-ADE
, O
and O
confirmed O
the O
etiology O
of O
quinine B-DRUG
- O
induced O
thrombocytopenia B-ADE
. O

Itraconazole B-DRUG
- O
related O
increased O
vincristine B-DRUG
neurotoxicity I-ADE
: O
case O
report O
and O
review O
of O
literature O
. O

The O
diagnosis O
was O
based O
on O
the O
rapid O
onset O
of O
renal B-ADE
failure I-ADE
, O
presence O
of O
eosinophilia B-ADE
, O
skin B-ADE
rash I-ADE
, O
and O
characteristic O
renal O
biopsy O
finding O
, O
following O
the O
administration O
of O
ampicillin B-DRUG
. O

CONCLUSIONS O
: O
Amantadine B-DRUG
can O
cause O
reversible B-ADE
corneal I-ADE
edema I-ADE
but O
can O
irreversibly O
reduce O
the O
density O
of O
endothelial O
cells O
. O

The O
bleeding B-ADE
resolved O
on O
discontinuation O
of O
APV B-DRUG
. O

Thrombotic B-ADE
stroke I-ADE
associated O
with O
the O
use O
of O
porcine B-DRUG
factor I-DRUG
VIII I-DRUG
in O
a O
patient O
with O
acquired O
haemophilia O
. O

This O
compound O
, O
used O
by O
adults O
in O
the O
child O
's O
home O
, O
had O
caused O
accidental O
theophylline B-DRUG
poisoning I-ADE
, O
mimicking O
diabetic O
ketoacidosis O
. O

Failure O
of O
plasmapheresis O
, O
corticosteroids O
and O
thionamides O
to O
ameliorate O
a O
case O
of O
protracted O
amiodarone B-DRUG
- O
induced O
thyroiditis B-ADE
. O

Pulmonary B-ADE
fibrosis I-ADE
associated O
with O
nabumetone B-DRUG
. O

An O
asymptomatic O
HIV O
- O
infected O
woman O
experienced O
right O
- O
sided O
renal B-ADE
colicky I-ADE
pain I-ADE
during O
treatment O
with O
indinavir B-DRUG
. O

Heat B-ADE
stroke I-ADE
in O
schizophrenia O
during O
clozapine B-DRUG
treatment O
: O
rapid O
recognition O
and O
management O
. O

Idiosyncratic B-ADE
pulmonary I-ADE
reactions I-ADE
to O
nitrofurantoin B-DRUG
are O
not O
unusual O
, O
often O
presenting O
as O
eosinophilic B-ADE
pneumonia I-ADE
. O

We O
believe O
that O
mucositis O
was O
a O
contributing O
factor O
to O
this O
case O
of O
fatal B-ADE
hyperkalemia I-ADE
after O
administration O
of O
succinylcholine B-DRUG
, O
with O
a O
mechanism O
similar O
to O
that O
reported O
with O
thermal O
injury O
. O

A O
chronic O
reaction O
associated O
with O
long O
- O
term O
treatment O
with O
nitrofurantoin B-DRUG
has O
also O
been O
reported O
and O
causes O
irreversible O
pulmonary B-ADE
fibrosis I-ADE
. O

Ceftriaxone B-DRUG
- O
induced O
fixed B-ADE
drug I-ADE
eruption I-ADE
: O
first O
report O
. O

A O
32-year O
- O
old O
man O
with O
a O
family O
history O
of O
type O
2 O
diabetes O
mellitus O
presented O
with O
circulatory B-ADE
collapse I-ADE
and O
deep B-ADE
coma I-ADE
after O
9 O
days O
of O
treatment O
with O
perospirone B-DRUG
hydrochloride I-DRUG
, O
a O
recently O
developed O
atypical O
antipsychotic O
agent O
available O
only O
in O
Japan O
. O

The O
findings O
were O
judged O
to O
be O
consistent O
with O
soft B-ADE
- I-ADE
tissue I-ADE
injury I-ADE
associated O
with O
intravenous O
administration O
of O
phenytoin B-DRUG
, O
also O
termed O
purple B-ADE
glove I-ADE
syndrome I-ADE
. O

Our O
report O
suggested O
that O
CBDCA B-DRUG
hypersensitivity B-ADE
was O
correlated O
with O
the O
total O
dose O
of O
previously O
administered O
platinum O
agents O
and O
that O
CBDCA O
should O
be O
excluded O
in O
patients O
who O
have O
received O
multiple O
platinum O
- O
based O
chemotherapy O
, O
even O
in O
platinum O
- O
sensitive O
cases O
, O
because O
CBDCA B-DRUG
hypersensitivity B-ADE
can O
occur O
even O
with O
low O
- O
dose O
CBDCA B-DRUG
administration O
. O

Restless B-ADE
legs I-ADE
syndrome I-ADE
due O
to O
interferon B-DRUG
- I-DRUG
alpha I-DRUG
. O

We O
describe O
a O
patient O
who O
presented O
with O
bloody B-ADE
diarrhoea I-ADE
after O
15 O
mg O
meloxicam B-DRUG
daily O
for O
10 O
days O
for O
osteoarthritis O
. O

In O
eight O
patients O
, O
a O
mean O
decrease B-ADE
in I-ADE
serum I-ADE
Na+ I-ADE
of O
8.25 O
+ O
/- O
3.2 O
mEq O
/ O
L O
was O
observed O
after O
a O
single O
200 O
mg O
intravenous O
dose O
of O
lorcainide B-DRUG
. O

DISCUSSION O
: O
A O
review O
of O
the O
cases O
of O
SS B-ADE
with O
implication O
of O
mirtazapine B-DRUG
as O
the O
cause O
was O
performed O
. O

Antineutrophil B-ADE
cytoplasmic I-ADE
antibody I-ADE
- I-ADE
positive I-ADE
crescentic I-ADE
glomerulonephritis I-ADE
associated O
with O
propylthiouracil B-DRUG
therapy O
. O

Since O
early O
symptoms O
of O
the O
toxic O
effects O
of O
theophylline B-DRUG
can O
mimic O
peptic B-ADE
ulcer I-ADE
disease I-ADE
, O
cimetidine O
might O
be O
prescribed O
for O
the O
gastrointestinal O
symptoms O
with O
subsequent O
worsening O
of O
theophylline O
poisoning O
. O

Cutaneous B-ADE
reactions I-ADE
to O
propylthiouracil B-DRUG
and O
methimazole B-DRUG
occur O
in O
3%-5 O
% O
of O
adults O
. O

Both O
6-MP B-DRUG
and O
AZA B-DRUG
are O
widely O
used O
and O
are O
known O
to O
cause O
hepatotoxicity B-ADE
in O
a O
proportion O
of O
patients O
. O

Monitoring O
of O
liver O
function O
tests O
should O
be O
mandatory O
in O
patients O
receiving O
high O
doses O
of O
cyproterone B-DRUG
acetate I-DRUG
; O
the O
drug O
should O
be O
withdrawn O
immediately O
if O
abnormal B-ADE
liver I-ADE
function I-ADE
tests I-ADE
are O
found O
. O

There O
remains O
a O
paucity O
of O
information O
pertaining O
to O
alternative O
anticoagulation O
strategies O
for O
use O
during O
cardiopulmonary O
bypass O
concomitant O
with O
heparin B-DRUG
- O
induced O
thrombocytopenia B-ADE
, O
especially O
in O
children O
. O

Renal B-ADE
failure I-ADE
is O
a O
rare O
complication O
associated O
with O
the O
use O
of O
rifampicin B-DRUG
for O
the O
treatment O
of O
tuberculosis O
, O
usually O
occurring O
well O
into O
the O
course O
of O
therapy O
. O

Clinicians O
should O
be O
aware O
of O
the O
signs O
and O
symptoms O
of O
neurotoxicity B-ADE
during O
treatment O
, O
as O
well O
as O
predisposing O
factors O
that O
put O
patients O
receiving O
methotrexate B-DRUG
at O
risk O
for O
neurotoxic O
effects O
. O

We O
report O
a O
31-year O
- O
old O
women O
with O
recurrent O
Hodgkin O
's O
lymphoma O
and O
unrecognized O
HMSN-1 O
who O
developed O
severe B-ADE
motor I-ADE
neuropathy I-ADE
3 O
weeks O
after O
the O
first O
cycle O
of O
treatment O
including O
2 O
mg O
of O
vincristine B-DRUG
. O

Four O
cases O
of O
oesophageal B-ADE
damage I-ADE
associated O
with O
ingestion O
of O
the O
urinary O
anti O
- O
spasmodic O
agent O
emepronium B-DRUG
bromide I-DRUG
are O
described O
. O

Up O
to O
four O
percent O
of O
patients O
treated O
with O
imatinib B-DRUG
may O
develop O
hepatotoxicity B-ADE
, O
which O
usually O
resolves O
with O
discontinuation O
of O
the O
drug O
. O

Sixteen O
hours O
after O
the O
first O
administration O
of O
IFN O
, O
IFN B-DRUG
was O
suspended O
by O
the O
symptoms O
of O
congestive B-ADE
heart I-ADE
failure I-ADE
( O
CHF B-ADE
) O
. O

Sagittal B-ADE
sinus I-ADE
thrombosis I-ADE
associated O
with O
transient B-ADE
free I-ADE
protein I-ADE
S I-ADE
deficiency I-ADE
after O
L B-DRUG
- I-DRUG
asparaginase I-DRUG
treatment O
: O
case O
report O
and O
review O
of O
the O
literature O
. O

In O
this O
case O
report O
, O
we O
have O
described O
a O
patient O
with O
Crohn O
's O
disease O
who O
developed O
subfulminant B-ADE
hepatitis I-ADE
B I-ADE
after O
the O
fourth O
infusion O
of O
infliximab B-DRUG
due O
to O
an O
unrecognized O
HBs O
- O
antigen O
carrier O
state O
. O

Chronic O
hydroxychloroquine B-DRUG
use O
associated O
with O
QT B-ADE
prolongation I-ADE
and O
refractory B-ADE
ventricular I-ADE
arrhythmia I-ADE
. O

Hepatotoxicity B-ADE
resolved O
once O
erlotinib B-DRUG
was O
discontinued O
and O
serum O
transaminases O
returned O
to O
baseline O
normal O
values O
. O

This O
case O
describes O
a O
52-year O
- O
old O
white O
woman O
who O
developed O
a O
spontaneous B-ADE
nasal I-ADE
septal I-ADE
perforation I-ADE
after O
given O
the O
antiangiogenic O
drug O
, O
bevacizumab B-DRUG
, O
for O
metastatic O
ovarian O
cancer O
treatment O
. O

We O
report O
the O
case O
of O
a O
20-year O
- O
old O
woman O
originally O
from O
Cameroon O
who O
was O
infected O
by O
the O
L. O
loa O
parasite O
and O
developed O
severe B-ADE
hepatitis I-ADE
, O
identified O
1 O
month O
after O
a O
single O
dose O
of O
ivermectin B-DRUG
. O

The O
risk O
of O
developing O
sAML B-ADE
is O
estimated O
to O
be O
between O
1 O
% O
and O
5 O
% O
, O
2 O
- O
20 O
years O
after O
exposure O
to O
etoposide B-DRUG
but O
may O
also O
be O
related O
to O
cumulative O
drug O
doses O
, O
treatment O
schedules O
, O
host O
factors O
and O
co O
- O
administration O
of O
other O
antineoplastic O
agents O
. O

In O
this O
report O
, O
a O
patient O
who O
had O
undergone O
a O
renal O
transplantation O
as O
a O
result O
of O
malignant O
hypertension O
, O
and O
who O
was O
on O
immunosuppressive O
therapy O
consisting O
of O
cyclosporin B-DRUG
, O
prednisone B-DRUG
and O
azathioprine B-DRUG
, O
developed O
thrombosis B-ADE
of O
the O
central O
retinal O
vein O
5 O
years O
following O
the O
transplantation O
. O

We O
report O
a O
case O
of O
radiotherapy O
- O
enhanced O
aminoglutethimide B-DRUG
skin B-ADE
toxicity I-ADE
in O
a O
patient O
with O
metastatic O
breast O
cancer O
. O

A O
33-year O
- O
old O
man O
with O
a O
history O
of O
recreational O
benztropine B-DRUG
abuse O
presented O
to O
the O
emergency O
department O
with O
confusion B-ADE
, O
abdominal B-ADE
pain I-ADE
, O
and O
distention B-ADE
. O

DISCUSSION O
: O
Amphotericin B-DRUG
B I-DRUG
deoxycholate I-DRUG
has O
been O
reported O
to O
produce O
significant O
cardiac B-ADE
toxicity I-ADE
, O
with O
ventricular B-ADE
arrhythmias I-ADE
and O
bradycardia B-ADE
reported O
in O
overdoses O
in O
children O
and O
in O
adults O
with O
preexisting O
cardiac O
disease O
, O
even O
when O
administered O
in O
conventional O
dosages O
and O
infusion O
rates O
. O

Comeoscleral B-ADE
perforation I-ADE
after O
pterygium O
excision O
and O
intraoperative O
mitomycin B-DRUG
C I-DRUG
. O

DIAGNOSIS O
: O
Interferon B-DRUG
alpha-2b I-DRUG
- O
induced O
cardiomyopathy B-ADE
. O

A O
case O
of O
heatstroke B-ADE
is O
reported O
in O
a O
32-year O
- O
old O
man O
diagnosed O
with O
schizophrenia O
and O
on O
clozapine B-DRUG
monotherapy O
. O

A O
lethal B-ADE
complication I-ADE
of O
peripheral O
vein O
vasopressin B-DRUG
infusion O
. O

The O
temporal O
relationship O
suggests O
that O
the O
spinal B-ADE
cord I-ADE
infarction I-ADE
may O
be O
related O
to O
the O
use O
of O
zolmitriptan B-DRUG
. O

FK506 B-DRUG
, O
which O
began O
to O
be O
administered O
12 O
days O
earlier O
, O
rose O
to O
a O
level O
of O
44 O
ng O
/ O
mL O
( O
normal O
range O
, O
10 O
- O
20 O
ng O
/ O
mL O
) O
1 O
day O
before O
neurologic B-ADE
abnormalities I-ADE
began O
. O

Rapamycin B-DRUG
/ O
sirolimus B-DRUG
( O
SR B-DRUG
) O
, O
trade O
named O
Rapammune B-DRUG
( O
Wyeth O
- O
Ayerst O
, O
Sydney O
, O
Australia O
) O
, O
is O
a O
potent O
immunosuppressive O
drug O
associated O
with O
myelosuppression B-ADE
, O
hypertension B-ADE
, O
hyperlipidemia B-ADE
, O
and O
infection B-ADE
. O

Ketanserin O
in O
the O
treatment O
of O
protamine B-DRUG
- O
induced O
pulmonary B-ADE
hypertension I-ADE
. O

Several O
case O
reports O
of O
aplastic B-ADE
anemia I-ADE
with O
use O
of O
acetazolamide B-DRUG
, O
and O
two O
cases O
with O
use O
of O
methazolamide B-DRUG
, O
have O
appeared O
in O
the O
literature O
. O

To O
date O
, O
there O
have O
been O
few O
reports O
of O
visual B-ADE
disturbances I-ADE
associated O
with O
BTX B-DRUG
- I-DRUG
B I-DRUG
use O
. O

This O
is O
the O
first O
report O
of O
a O
fluoxetine B-DRUG
- O
related O
death B-ADE
in O
a O
child O
with O
a O
confirmed O
genetic O
polymorphism O
of O
the O
CYP2D6 O
gene O
that O
results O
in O
impaired O
drug O
metabolism O
. O

Six O
patients O
developed O
peripheral B-ADE
neuropathy I-ADE
and O
five O
patients O
bone B-ADE
marrow I-ADE
depression I-ADE
, O
blood O
transfusions O
were O
given O
to O
three O
patients O
and O
in O
all O
five O
patients O
bone O
marrow O
function O
normalized O
after O
cessation O
of O
linezolid B-DRUG
. O

Of O
the O
four O
patients O
who O
responded O
to O
HU B-DRUG
with O
an O
increase B-ADE
in I-ADE
total I-ADE
Hb I-ADE
, O
all O
reported O
symptomatic O
improvement O
and O
three O
have O
not O
required O
further O
transfusions O
. O

Case O
study O
: O
adverse B-ADE
response I-ADE
to O
clonidine B-DRUG
. O

Diphenylhydantoin B-DRUG
apparently O
adversely O
affected O
both O
the O
clinical O
and O
biochemical O
parameters O
of O
the O
acute B-ADE
intermittent I-ADE
porphyria I-ADE
. O

Ifosfamide B-DRUG
is O
a O
known O
nephrotoxic O
drug O
with O
demonstrated O
tubulopathies B-ADE
. O

Due O
to O
discomfort B-ADE
, O
diplopia B-ADE
and O
lagophthalmos B-ADE
, O
the O
haematoma B-ADE
necessitated O
suspension O
of O
warfarin B-DRUG
therapy O
and O
a O
surgical O
evacuation O
. O

Exacerbation O
of O
schizophrenia B-ADE
associated O
with O
amantadine B-DRUG
. O

The O
main O
clinical O
features O
of O
this O
58-year O
- O
old O
female O
patient O
were O
laboratory O
evidence O
of O
leucopenia B-ADE
and O
cholestasis B-ADE
, O
and O
biopsy O
features O
of O
fatty B-ADE
liver I-ADE
parenchyma I-ADE
degeneration I-ADE
with O
granulocytic B-ADE
portal I-ADE
infiltration I-ADE
and O
bile B-ADE
stasis I-ADE
, O
demonstrated O
20 O
days O
after O
the O
initiation O
of O
antithyroid O
therapy O
with O
20 O
mg O
methimazole B-DRUG
daily O
. O

This O
report O
describes O
a O
probable O
case O
of O
infliximab B-DRUG
- O
induced O
membranous B-ADE
nephropathy I-ADE
. O

It O
is O
increasingly O
recognized O
that O
dose O
adjustment O
of O
oral O
valacyclovir B-DRUG
in O
renal O
failure O
is O
necessary O
to O
avoid O
neurotoxicity B-ADE
. O

We O
describe O
two O
cases O
of O
acute B-ADE
pancreatitis I-ADE
that O
occurred O
after O
long O
term O
mesalamine B-DRUG
therapy O
for O
ulcerative O
colitis O
. O

Hepatotoxicity B-ADE
associated O
with O
6-thioguanine B-DRUG
therapy O
for O
Crohn O
's O
disease O
. O

Bradycardia B-ADE
and O
congestive B-ADE
heart I-ADE
failure I-ADE
associated O
with O
ocular O
timolol B-DRUG
maleate I-DRUG
. O

Long O
- O
term O
follow O
- O
up O
after O
neoplastic B-ADE
seeding I-ADE
complicating O
percutaneous O
ethanol B-DRUG
injection O
for O
treatment O
of O
hepatocellular O
carcinoma O
. O

The O
case O
of O
a O
4-year O
- O
old O
girl O
with O
valproate B-DRUG
- O
induced O
stupor B-ADE
and O
electroencephalographic O
pattern O
of O
increased O
fast O
activity O
is O
reported O
. O

We O
report O
here O
a O
rare O
case O
of O
pleuropericarditis B-ADE
due O
to O
methotrexate B-DRUG
. O

We O
report O
four O
cases O
of O
hemodynamically O
significant O
pericardial B-ADE
effusion I-ADE
in O
patients O
with O
refractory O
lymphoma O
who O
were O
receiving O
gemcitabine B-DRUG
, O
all O
of O
whom O
had O
a O
history O
of O
mediastinal O
radiation O
without O
subcarinal O
blocking O
. O

One O
patient O
developed O
severe B-ADE
hyponatremia I-ADE
with O
serum O
Na+ O
of O
108 O
mEq O
/ O
L O
when O
hydrochlorothiazide B-DRUG
was O
given O
to O
control O
hypertension O
. O

Although O
moderate O
myelosuppression O
is O
not O
uncommonly O
seen O
in O
patients O
treated O
with O
lenalidomide B-DRUG
, O
aplastic B-ADE
anemia I-ADE
has O
not O
previously O
been O
reported O
to O
be O
associated O
with O
this O
agent O
. O

Allergic O
reaction O
to O
gemfibrozil B-DRUG
manifesting O
as O
eosinophilic B-ADE
gastroenteritis I-ADE
. O

Inadvertent O
and O
accidental O
epinephrine B-DRUG
overdose O
might O
result O
in O
potentially O
lethal B-ADE
complications I-ADE
. O

Metabolic B-ADE
acidosis I-ADE
induced O
by O
acetazolamide B-DRUG
. O

The O
first O
patient O
developed O
a O
monoarthritis B-ADE
2 O
weeks O
after O
initiation O
of O
IFN B-DRUG
- I-DRUG
beta I-DRUG
, O
which O
persisted O
during O
the O
14 O
months O
of O
therapy O
and O
resolved O
with O
discontinuation O
of O
the O
medication O
. O

Atypical B-ADE
ventricular I-ADE
tachycardia I-ADE
( O
torsade B-ADE
de I-ADE
pointes I-ADE
) O
induced O
by O
amiodarone B-DRUG
: O
arrhythmia B-ADE
previously O
induced O
by O
quinidine B-DRUG
and O
disopyramide B-DRUG
. O

Administration O
of O
lamotrigine B-DRUG
, O
especially O
in O
combination O
with O
valproic B-DRUG
acid I-DRUG
, O
may O
lead O
to O
the O
development O
of O
TEN B-ADE
. O

The O
present O
observation O
suggests O
, O
that O
a O
batch O
of O
different O
testing O
doses O
, O
including O
lower O
testing O
doses O
may O
help O
to O
differentiate O
between O
an O
allergic O
type O
of O
contact O
dermatitis O
and O
an O
irritant B-ADE
type I-ADE
of I-ADE
reaction I-ADE
after O
treatment O
with O
calcipotriol B-DRUG
. O

Progressive B-ADE
interstitial I-ADE
lung I-ADE
disease I-ADE
from O
prolonged O
methotrexate B-DRUG
therapy O
. O

Reversible B-ADE
heart I-ADE
failure I-ADE
in O
a O
patient O
receiving O
etanercept B-DRUG
for O
ankylosing O
spondylitis O
. O

OBJECTIVE O
: O
To O
describe O
a O
case O
of O
sertraline B-DRUG
- O
induced O
rhabdomyolysis B-ADE
in O
an O
elderly O
patient O
with O
dementia O
and O
comorbidities O
. O

We O
report O
a O
fatal O
case O
of O
toxic B-ADE
epidermal I-ADE
necrolysis I-ADE
( O
TEN B-ADE
) O
resulting O
from O
a O
high O
dose O
of O
cytosine B-DRUG
arabinoside I-DRUG
( O
ARA B-DRUG
- I-DRUG
C I-DRUG
) O
. O

Para B-DRUG
- I-DRUG
aminosalicylic I-DRUG
acid I-DRUG
- O
induced O
hypoglycaemia B-ADE
in O
a O
patient O
with O
diabetic O
nephropathy O
. O

Ulcerative B-ADE
proctitis I-ADE
in O
juvenile O
systemic O
lupus O
erythematosus O
after O
ibuprofen B-DRUG
treatment O
. O

Imidazoline B-DRUG
intoxication I-ADE
in O
children O
. O

Fatal B-ADE
eosinophilia I-ADE
myalgia I-ADE
syndrome I-ADE
in O
a O
marrow O
transplant O
patient O
attributed O
to O
total O
parenteral O
nutrition O
with O
a O
solution O
containing O
tryptophan B-DRUG
. O

The O
disease O
- O
modifying O
drugs O
he O
was O
taking O
, O
cyclosporin B-DRUG
and O
methotrexate B-DRUG
, O
were O
stopped O
, O
and O
the O
lymphoma B-ADE
resolved O
spontaneously O
without O
the O
use O
of O
chemotherapy O
. O

We O
report O
the O
first O
case O
of O
a O
patient O
in O
a O
promethazine B-DRUG
- O
induced O
coma B-ADE
responding O
to O
treatment O
with O
flumazenil O
. O

A O
64 O
year O
old O
man O
with O
recurrent O
metastatic O
squamous O
cell O
carcinoma O
of O
the O
head O
and O
neck O
developed O
severe B-ADE
skin I-ADE
rash I-ADE
and O
bone B-ADE
marrow I-ADE
aplasia I-ADE
4 O
and O
7 O
days O
, O
respectively O
, O
following O
a O
single O
dose O
of O
40 O
mg O
/ O
m2 O
methotrexate B-DRUG
( O
MTX B-DRUG
) O
. O

A O
patient O
developed O
cholestatic B-ADE
hepatitis I-ADE
while O
being O
treated O
with O
nitrofurantoin B-DRUG
. O

Gold B-DRUG
- O
induced O
pneumonitis B-ADE
. O

Diagnosis O
: O
practolol B-DRUG
induced O
sclerosing B-ADE
peritonitis I-ADE
. O

Dorzolamide B-DRUG
- O
induced O
choroidal B-ADE
detachment I-ADE
in O
a O
surgically O
untreated O
eye O
. O

Herein O
is O
reported O
an O
unusual O
case O
of O
coexistent O
warfarin B-DRUG
- O
induced O
skin B-ADE
necrosis I-ADE
and O
heparin B-DRUG
- O
induced O
thrombocytopenia B-ADE
following O
mitral O
valve O
replacement O
for O
thromboembolic O
phenomena O
associated O
with O
marantic O
endocarditis O
and O
bronchial O
adenocarcinoma O
. O

Carbamazepine B-DRUG
- O
induced O
tics B-ADE
. O

We O
describe O
four O
patients O
who O
had O
seizures B-ADE
while O
receiving O
ofloxacin B-DRUG
; O
no O
other O
causes O
were O
evident O
. O

Mineral B-DRUG
oil I-DRUG
, O
a O
hydrocarbon O
, O
may O
not O
elicit O
a O
normal O
protective O
cough O
reflex O
and O
may O
impair B-ADE
mucociliary I-ADE
transport I-ADE
. O

Priapism B-ADE
associated O
with O
zuclopenthixol B-DRUG
. O

Extensive B-ADE
forearm I-ADE
deep I-ADE
venous I-ADE
thrombosis I-ADE
following O
a O
severe O
infliximab B-DRUG
infusion O
reaction O
. O

Temozolomide B-DRUG
- O
induced O
desquamative B-ADE
skin I-ADE
rash I-ADE
in O
a O
patient O
with O
metastatic O
melanoma O
. O

Mitomycin B-DRUG
C I-DRUG
- O
related O
hemolytic B-ADE
uremic I-ADE
syndrome I-ADE
in O
cancer O
patients O
. O

Case O
2 O
demonstrated O
after O
40 O
months O
on O
chlorambucil B-DRUG
the O
presence O
of O
a O
balanced B-ADE
translocation I-ADE
, O
t O
( O
1;5 O
) O
( O
p36;q31 O
) O
in O
90 O
% O
of O
the O
cells O
. O

The O
results O
clearly O
demonstrate O
that O
CPH82 B-DRUG
was O
associated O
with O
suppression B-ADE
of I-ADE
the I-ADE
endogeneous I-ADE
production I-ADE
of I-ADE
ACTH I-ADE
and I-ADE
cortisol I-ADE
with O
a O
concomitant O
paradoxical O
picture O
of O
clinical O
hypercortisolism B-ADE
. O

We O
believe O
that O
this O
is O
the O
first O
report O
of O
secretory B-ADE
carcinoma I-ADE
of I-ADE
the I-ADE
endometrium I-ADE
associated O
with O
tamoxifen B-DRUG
use O
. O

We O
report O
a O
third O
case O
of O
a O
6-week O
- O
old O
infant O
with O
Escherichia O
coli O
sepsis O
who O
received O
ampicillin B-DRUG
and O
other O
antibiotics O
and O
subsequently O
developed O
TEN B-ADE
. O

A O
35-year O
- O
old O
woman O
presented O
with O
neurotoxicity B-ADE
correlated O
to O
an O
i.v O
. O
regimen O
of O
5-fluorouracil B-DRUG
as O
episodes O
of O
acute B-ADE
confusional I-ADE
state I-ADE
and O
abnormalities O
of O
symmetrically O
restricted O
diffusion O
in O
the O
periventricular O
white O
matter O
and O
corpus O
callosum O
. O

Syncope B-ADE
induced O
by O
propranolol B-DRUG
in O
hypertrophic O
cardiomyopathy O
. O

We O
report O
3 O
children O
with O
epilepsy O
who O
developed O
facial B-ADE
motor I-ADE
tics I-ADE
after O
initiation O
of O
CBZ B-DRUG
for O
complex O
partial O
seizures O
. O

We O
report O
a O
case O
of O
biopsy O
proven O
myositis B-ADE
whose O
symptoms O
began O
within O
10 O
days O
of O
receiving O
leuprolide B-DRUG
acetate I-DRUG
therapy O
for O
prostate O
cancer O
. O

This O
represents O
the O
first O
report O
of O
nonconvulsive B-ADE
status I-ADE
epilepticus I-ADE
induced O
by O
ifosfamide B-DRUG
. O

This O
report O
suggests O
that O
anemia B-ADE
can O
occur O
due O
to O
MMF B-DRUG
, O
in O
particular O
when O
it O
is O
given O
with O
prednisone B-DRUG
, O
a O
side O
effect O
well O
documented O
in O
the O
transplantation O
literature O
when O
the O
triple O
combination O
of O
MMF B-DRUG
, O
cyclosporine B-DRUG
and O
prednisone B-DRUG
is O
used O
. O

This O
paper O
reports O
an O
autopsy O
case O
of O
a O
78-year O
- O
old O
male O
with O
multiple B-ADE
nodules I-ADE
in I-ADE
the I-ADE
liver I-ADE
developed O
after O
long O
- O
termed O
administration O
of O
phosphate B-DRUG
diethylstilbestrol I-DRUG
( O
PDES B-DRUG
) O
for O
prostatic O
cancer O
. O

Osteonecrosis B-ADE
is O
a O
serious O
side O
effect O
of O
antiemetic O
treatment O
with O
dexamethasone B-DRUG
and O
this O
serious O
complication O
should O
be O
incorporated O
in O
the O
current O
guidelines O
. O

Prolonged O
severe O
5-fluorouracil B-DRUG
- O
associated O
neurotoxicity B-ADE
in O
a O
patient O
with O
dihydropyrimidine O
dehydrogenase O
deficiency O
. O

FDE B-ADE
from O
cephalosporins B-DRUG
has O
been O
rarely O
reported O
, O
and O
to O
the O
best O
of O
our O
knowledge O
there O
is O
no O
published O
report O
of O
ceftriaxone B-DRUG
- O
induced O
FDE B-ADE
in O
the O
literature O
. O

A O
patient O
with O
acute O
changes O
suggesting O
acute B-ADE
hepatitis I-ADE
after O
parenteral O
amiodarone B-DRUG
administration O
is O
described O
. O

Reversible B-ADE
leukopenia I-ADE
was O
documented O
in O
an O
81-year O
- O
old O
woman O
treated O
with O
adjunctive O
ibopamine B-DRUG
100 O
mg O
t.i.d O
. O
for O
chronic O
congestive O
heart O
failure O
. O

L B-DRUG
- I-DRUG
Thyroxine I-DRUG
- O
induced O
leukopenia B-ADE
in O
a O
patient O
with O
Hashimoto O
's O
disease O
: O
involvement O
of O
suppressor O
- O
cytotoxic O
T O
cells O
. O

The O
possibility O
of O
severe O
rhabdomyolysis B-ADE
should O
be O
considered O
in O
a O
patient O
with O
water B-ADE
intoxication I-ADE
due O
to O
massive O
ingestion O
of O
caffeine B-DRUG
- O
containing O
beverages O
. O

Prolonged O
severe B-ADE
cholestasis I-ADE
induced O
by O
oxacillin B-DRUG
derivatives O
. O

A O
58-year O
old O
patient O
is O
reported O
who O
developed O
an O
ischaemic B-ADE
cerebrovascular I-ADE
accident I-ADE
22 O
hours O
after O
successful O
thrombolysis O
with O
streptokinase B-DRUG
for O
life O
- O
threatening O
pulmonary O
emboli O
. O

Cardiomyopathy B-ADE
after O
widely O
separated O
courses O
of O
adriamycin B-DRUG
exacerbated O
by O
actinomycin B-DRUG
- I-DRUG
D I-DRUG
and O
mithramycin B-DRUG
. O

We O
present O
a O
case O
of O
sotalol B-DRUG
- O
induced O
bradycardia B-ADE
reversed O
by O
glucagon O
. O

Angioedema B-ADE
and O
maculopapular B-ADE
eruptions I-ADE
associated O
with O
carbamazepine B-DRUG
administration O
. O

Hepatotoxicity B-ADE
of O
hycanthone B-DRUG
in O
patients O
with O
metastatic O
breast O
cancer O
. O

Case O
report O
: O
lack O
of O
control O
of O
diabetes B-ADE
and O
weight B-ADE
gain I-ADE
in O
a O
patient O
on O
initiation O
and O
rechallenge O
of O
therapy O
with O
olanzapine B-DRUG
. O

We O
describe O
a O
43-year O
- O
old O
man O
who O
developed O
signs O
and O
symptoms O
of O
bilateral B-ADE
optic I-ADE
neuropathy I-ADE
during O
treatment O
with O
ethambutol B-DRUG
. O

It O
should O
be O
recognized O
that O
ibuprofen B-DRUG
may O
be O
associated O
with O
salt B-ADE
and I-ADE
water I-ADE
retention I-ADE
in O
the O
same O
fashion O
as O
previously O
described O
with O
phenylbutazone B-DRUG
and O
indomethacin B-DRUG
. O

Possible O
serotonin B-ADE
syndrome I-ADE
associated O
with O
clomipramine B-DRUG
after O
withdrawal O
of O
clozapine B-DRUG
. O

The O
second O
patient O
developed O
both O
autoimmune B-ADE
thyroid I-ADE
disease I-ADE
and O
a O
refractory B-ADE
pre I-ADE
- I-ADE
patellar I-ADE
bursitis I-ADE
after O
50 O
months O
of O
IFN B-DRUG
- I-DRUG
beta I-DRUG
therapy O
. O

Hyperammonemia B-ADE
has O
been O
described O
as O
a O
complication O
of O
valproic B-DRUG
acid I-DRUG
therapy O
but O
may O
often O
be O
overlooked O
as O
a O
cause O
of O
lethargy B-ADE
in O
the O
postictal O
patient O
who O
presents O
to O
the O
emergency O
department O
. O

CASE O
REPORT O
: O
We O
report O
the O
case O
of O
a O
58 O
year O
old O
patient O
who O
, O
after O
2 O
days O
of O
treatment O
with O
roxithromycin B-DRUG
and O
betamethasone B-DRUG
, O
manifested O
acute B-ADE
pancreatitis I-ADE
. O

Cutaneous B-ADE
necrosis I-ADE
as O
a O
result O
of O
interferon B-DRUG
alfa I-DRUG
is O
an O
infrequent O
complication O
with O
unknown O
pathogenesis O
, O
in O
which O
a O
cutaneous O
local O
immune O
- O
mediated O
inflammatory O
process O
might O
be O
involved O
. O

However O
, O
peripheral B-ADE
neuropathy I-ADE
and O
bone B-ADE
marrow I-ADE
depression I-ADE
led O
to O
linezolid B-DRUG
withdrawal O
in O
seven O
patients O
, O
and O
neuropathy B-ADE
may O
not O
be O
fully O
reversible O
in O
all O
patients O
. O

Despite O
administration O
of O
phenytoin O
and O
lorazepam O
, O
the O
seizures B-ADE
persisted O
and O
occurred O
only O
during O
amphotercin B-DRUG
B I-DRUG
administration O
. O

A O
2-year O
- O
old O
mentally O
retarded O
boy O
with O
frontal O
lobe O
epilepsy O
presented O
with O
an O
episode O
that O
resembled O
heat B-ADE
stroke I-ADE
during O
the O
administration O
of O
zonisamide B-DRUG
. O

Disulfiram B-DRUG
encephalopathy B-ADE
as O
a O
cause O
of O
the O
catatonia B-ADE
syndrome I-ADE
. O

To O
our O
knowledge O
, O
four O
cases O
of O
interstitial B-ADE
pneumonitis I-ADE
associated O
with O
fludarabine B-DRUG
have O
been O
reported O
in O
medical O
literature O
. O

In O
both O
patients O
the O
rippling B-ADE
phenomena I-ADE
worsened I-ADE
with O
pyridostigmine B-DRUG
treatment O
but O
markedly O
improved O
after O
immunosuppression O
with O
azathioprine O
. O

A O
43-year O
- O
old O
white O
man O
developed O
a O
shallow O
erosion B-ADE
of I-ADE
a I-ADE
psoriatic I-ADE
plaque I-ADE
after O
chronic O
administration O
of O
methotrexate B-DRUG
. O

She O
developed O
a O
generalized B-ADE
rash I-ADE
and O
itching B-ADE
, O
sore B-ADE
throat I-ADE
, O
and O
dizziness B-ADE
approximately O
4 O
hours O
after O
the O
first O
dose O
of O
capecitabine B-DRUG
. O

Although O
retinoic B-DRUG
acid I-DRUG
is O
well O
tolerated O
by O
the O
majority O
of O
patients O
with O
this O
disease O
, O
a O
potentially O
fatal B-ADE
complication I-ADE
of O
this O
kind O
of O
treatment O
has O
been O
reported O
: O
" O
the O
retinoic B-ADE
acid I-ADE
syndrome I-ADE
" O
. O

We O
described O
the O
occurrence O
of O
L B-DRUG
- I-DRUG
dopa I-DRUG
- O
induced O
myoclonus B-ADE
and O
seizures B-ADE
in O
a O
case O
of O
parkinsonism O
with O
its O
SEPs O
findings O
. O

To O
our O
knowledge O
, O
we O
describe O
the O
first O
reported O
case O
of O
isolated B-ADE
paresthesia I-ADE
and O
peripheral B-ADE
neuropathy I-ADE
, O
without O
systemic O
involvement O
, O
secondary O
to O
sulindac B-DRUG
administration O
. O

Two O
patients O
who O
were O
receiving O
Tolazoline B-DRUG
by O
infusion O
developed O
duodenal B-ADE
ulceration I-ADE
and O
subsequent O
intestinal B-ADE
perforation I-ADE
. O

Here O
, O
we O
report O
a O
case O
of O
RFP B-DRUG
- O
induced O
hypothyroidism B-ADE
without O
underlying O
thyroid O
disease O
. O

Because O
nephrotic B-ADE
syndrome I-ADE
may O
be O
induced O
by O
IFN B-DRUG
therapy O
, O
the O
IFN B-DRUG
was O
stopped O
. O

We O
report O
the O
first O
case O
of O
tuberculous B-ADE
uveitis I-ADE
due O
to O
etanercept B-DRUG
. O

We O
report O
a O
case O
of O
a O
60-year O
- O
old O
woman O
affected O
by O
squamous O
lung O
carcinoma O
, O
who O
developed O
paroxysmal B-ADE
supraventricular I-ADE
tachycardia I-ADE
during O
cisplatin B-DRUG
and O
etoposide B-DRUG
combination O
chemotherapy O
. O

Preliminary O
results O
suggest O
that O
the O
higher O
concentrations O
of O
dextrose B-DRUG
induce O
increased B-ADE
histamine I-ADE
release I-ADE
from O
blood O
cells O
, O
and O
that O
this O
phenomenon O
is O
more O
marked O
in O
diabetic O
, O
and O
particularly O
diabetic O
- O
allergic O
, O
individuals O
. O

A O
patient O
developed O
restless B-ADE
legs I-ADE
symptoms I-ADE
paralleling O
the O
course O
of O
interferon B-DRUG
- I-DRUG
alpha I-DRUG
( O
IFN B-DRUG
alpha I-DRUG
) O
therapy O
for O
chronic O
hepatitis O
C O
. O

Erythema B-ADE
multiforme I-ADE
bullosum I-ADE
due O
to O
rifampicin B-DRUG
. O

Naproxen B-DRUG
, O
the O
most O
common O
offender O
, O
has O
been O
associated O
with O
a O
dimorphic O
clinical O
pattern O
: O
a O
PCT O
- O
like O
presentation O
and O
one O
simulating O
erythropoietic B-ADE
protoporphyria I-ADE
in O
the O
pediatric O
population O
. O

We O
report O
a O
case O
of O
noncardiogenic B-ADE
pulmonary I-ADE
edema I-ADE
developed O
after O
therapeutic O
trial O
of O
EO B-DRUG
as O
sclerosing O
agent O
for O
esophageal O
varix O
. O

Vancomycin B-DRUG
is O
widely O
used O
against O
methicillin O
- O
resistant O
Staphylococcus O
aureus O
infections O
, O
but O
it O
is O
associated O
with O
many O
adverse O
effects O
such O
as O
nephrotoxicity B-ADE
, O
ototoxicity B-ADE
, O
gastrointestinal B-ADE
disturbances I-ADE
, O
blood B-ADE
disorders I-ADE
, O
and O
two O
types O
of O
hypersensitivity B-ADE
reactions I-ADE
- O
an O
anaphylactoid B-ADE
reaction O
known O
as O
" O
red B-ADE
man I-ADE
syndrome I-ADE
" O
and O
anaphylaxis B-ADE
. O

Docetaxel B-DRUG
induced O
Meibomian B-ADE
duct I-ADE
inflammation I-ADE
and I-ADE
blockage I-ADE
is O
the O
likely O
cause O
of O
this O
presentation O
in O
a O
patient O
with O
no O
history O
of O
eyelid O
masses O
in O
the O
past O
. O

Five O
months O
after O
initiating O
mirtazapine B-DRUG
therapy O
, O
she O
developed O
symptomatic B-ADE
hyponatremia I-ADE
. O

Eye B-ADE
movement I-ADE
disorders I-ADE
in O
bone O
marrow O
transplant O
patients O
on O
cyclosporin B-DRUG
and O
ganciclovir B-DRUG
. O

We O
report O
two O
adults O
who O
received O
gabapentin B-DRUG
( O
GBP B-DRUG
) O
and O
subsequently O
developed O
behavioural B-ADE
side I-ADE
effects I-ADE
. O

A O
66-year O
- O
old O
mand O
suffering O
from O
severe O
coronary O
heart O
disease O
took O
digoxin B-DRUG
with O
suicidal O
intent O
an O
was O
treated O
for O
the O
ensuing O
complete B-ADE
atrioventricular I-ADE
block I-ADE
with O
digoxin O
- O
specific O
antibody O
fragments O
. O

Generalized B-ADE
maculopapular I-ADE
and I-ADE
papular I-ADE
purpuric I-ADE
eruptions I-ADE
are O
perhaps O
the O
most O
common O
thionamide B-DRUG
- O
induced O
reactions O
. O

There O
have O
been O
more O
than O
20 O
observations O
of O
the O
appearance O
or O
aggravation O
of O
this O
granulomatosis B-ADE
with O
interferon B-DRUG
alfa I-DRUG
and O
more O
recently O
with O
the O
combination O
of O
interferon B-DRUG
alfa I-DRUG
plus O
ribavirin B-DRUG
. O

Fatal B-ADE
toxic I-ADE
epidermal I-ADE
necrolysis I-ADE
related O
to O
lamotrigine B-DRUG
administration O
. O

We O
present O
a O
case O
of O
stroke B-ADE
after O
PPA B-DRUG
ingestion O
that O
occurred O
4 O
months O
after O
the O
recall O
in O
an O
8-year O
- O
old O
boy O
on O
chronic O
peritoneal O
dialysis O
. O

Decreased B-ADE
plasma I-ADE
cortisol I-ADE
level I-ADE
during O
alprazolam B-DRUG
treatment O
of O
panic O
disorder O
: O
a O
case O
report O
. O

In O
the O
other O
patient O
, O
a O
78-year O
- O
old O
woman O
, O
Neisseria B-ADE
mucosa I-ADE
knee I-ADE
arthritis I-ADE
occurred O
after O
a O
single O
sodium B-DRUG
hyaluronate I-DRUG
injection O
. O

PURPOSE O
: O
A O
case O
of O
carbamazepine B-DRUG
- O
induced O
hyperammonemia B-ADE
is O
presented O
. O

Neurological O
improvement O
and O
rehabilitation O
potential O
following O
toxic B-ADE
myelopathy I-ADE
due O
to O
intrathecal O
injection O
of O
doxorubicin B-DRUG
. O

Parenteral O
pyridoxine O
, O
the O
specific O
antidote O
for O
INH B-DRUG
- O
induced O
refractory B-ADE
seizures I-ADE
, O
should O
be O
readily O
available O
in O
every O
emergency O
department O
in O
the O
areas O
similarly O
experiencing O
increasing O
trends O
of O
TB O
. O

From O
1996 O
to O
2002 O
several O
medications O
were O
changed O
due O
to O
their O
adverse O
effects O
: O
indinavir B-DRUG
( O
renal B-ADE
colic I-ADE
and O
fever B-ADE
) O
, O
nelfinavir B-DRUG
( O
cutaneous B-ADE
rash I-ADE
) O
, O
and O
efavirenz B-DRUG
( O
nausea B-ADE
and O
temporary B-ADE
memory I-ADE
loss I-ADE
) O
. O

DISCUSSION O
: O
Rhabdomyolysis O
is O
a O
clinical O
syndrome O
resulting O
from O
the O
destruction O
of O
skeletal O
muscle O
that O
may O
progress O
to O
renal O
failure O
Several O
drugs O
have O
been O
associated O
with O
rhabdomyolysis B-ADE
, O
including O
lovastatin B-DRUG
, O
a O
hydroxymethylglutaryl O
- O
coenzyme O
A O
reductase O
inhibitor O
. O

Acute O
hyperphosphatemia B-ADE
caused O
by O
sodium B-DRUG
phosphate I-DRUG
enema O
in O
a O
patient O
with O
liver O
dysfunction O
and O
chronic O
renal O
failure O
. O

BACKGROUND O
: O
We O
describe O
the O
ophthalmic O
features O
and O
clinical O
course O
of O
two O
cases O
of O
acute B-ADE
syphilitic I-ADE
posterior I-ADE
placoid I-ADE
chorioretinitis I-ADE
( O
ASPPC B-ADE
) O
that O
developed O
after O
intravitreal O
triamcinolone B-DRUG
acetonide I-DRUG
( O
IVTA B-DRUG
) O
injection O
. O

Persistent B-ADE
hypoglycemia I-ADE
in O
a O
patient O
with O
diabetes O
taking O
etanercept B-DRUG
for O
the O
treatment O
of O
psoriasis O
. O

Metoclopramide B-DRUG
- O
induced O
parkinsonism B-ADE
is O
not O
rare O
, O
and O
appropriate O
dose O
reduction O
in O
patients O
with O
renal O
failure O
will O
help O
reduce O
the O
incidence O
of O
this O
morbidity O
. O

This O
case O
illustrates O
the O
potential O
decoupling B-ADE
of I-ADE
PSA I-ADE
response I-ADE
from O
disease O
status O
in O
flutamide B-DRUG
withdrawal O
. O

Although O
the O
literature O
on O
the O
use O
of O
risperidone B-DRUG
in O
elderly O
patients O
with O
dementia O
consists O
largely O
of O
uncontrolled O
trials O
, O
case O
reports O
, O
and O
chart O
reviews O
, O
it O
appears O
that O
this O
agent O
is O
effective O
for O
managing O
agitation O
in O
this O
population O
and O
does O
so O
with O
a O
low O
frequency O
of O
extrapyramidal B-ADE
symptoms I-ADE
( O
EPS B-ADE
) O
. O

One O
case O
of O
tacrolimus B-DRUG
- O
induced O
hepatic B-ADE
VOD I-ADE
developing O
after O
lung O
transplantation O
( O
LT O
) O
has O
been O
recently O
reported O
. O

Amiodarone B-DRUG
hydrochloride I-DRUG
, O
a O
new O
antiarrhythmic O
agent O
, O
has O
been O
associated O
with O
pulmonary B-ADE
toxicity I-ADE
characterized O
by O
cough B-ADE
, O
dyspnea B-ADE
and O
diffuse B-ADE
pulmonary I-ADE
infiltrates I-ADE
. O

An O
unusual O
cause O
of O
burn B-DRUG
injury I-DRUG
: O
unsupervised O
use O
of O
drugs O
that O
contain O
psoralens B-ADE
. O

Fracture B-ADE
of I-ADE
the I-ADE
femoral I-ADE
neck I-ADE
occurred O
in O
one O
patient O
during O
PSL B-DRUG
therapy O
, O
although O
the O
relationship O
between O
the O
fracture O
and O
PSL O
therapy O
was O
uncertain O
. O

The O
patient O
experienced O
hallucinations B-ADE
, O
agitation B-ADE
, O
vomiting B-ADE
, O
tachycardia B-ADE
and O
seizures B-ADE
after O
ingestion O
of O
1050 O
( O
48 O
mg O
/ O
kg O
) O
of O
extended O
- O
release O
bupropion B-DRUG
. O

The O
literature O
is O
also O
reviewed O
for O
ARF B-ADE
associated O
with O
mannitol B-DRUG
infusion O
in O
patients O
who O
received O
dialysis O
and O
those O
who O
did O
not O
receive O
dialysis O
; O
and O
the O
possible O
mechanism(s O
) O
of O
mannitol B-DRUG
nephrotoxicity B-ADE
are O
discussed O
. O

We O
describe O
a O
case O
of O
intraoperative O
gelatine B-DRUG
- O
induced O
anaphylaxis B-ADE
whose O
diagnosis O
was O
delayed O
as O
the O
use O
of O
gelatine B-DRUG
during O
surgical O
procedures O
was O
omitted O
for O
two O
times O
in O
patient O
's O
medical O
records O
. O

A O
new O
case O
of O
Creutzfeldt B-ADE
- I-ADE
Jakob I-ADE
disease I-ADE
associated O
with O
human B-DRUG
growth I-DRUG
hormone I-DRUG
therapy O
in O
New O
Zealand O
. O

In O
this O
report O
we O
described O
a O
case O
of O
juvenile O
idiopathic O
arthritis O
patient O
who O
developed O
thymic B-ADE
enlargement I-ADE
( O
true O
thymic B-ADE
hyperplasia I-ADE
) O
, O
mediastinal B-ADE
lymphadenopathy I-ADE
and O
pleurisy B-ADE
associated O
with O
systemic O
symptoms O
under O
Etanercept B-DRUG
treatment O
. O

Methotrexate B-DRUG
( O
MTX B-DRUG
) O
is O
a O
commonly O
used O
second O
line O
agent O
for O
RA O
, O
and O
there O
have O
been O
several O
recent O
reports O
of O
Epstein B-ADE
- I-ADE
Barr I-ADE
virus I-ADE
( I-ADE
EBV I-ADE
) I-ADE
- I-ADE
associated I-ADE
polyclonal I-ADE
B I-ADE
cell I-ADE
lymphoproliferative I-ADE
disorder I-ADE
in O
MTX B-DRUG
- O
treated O
RA O
patients O
. O

The O
photosensitivity B-ADE
is O
still O
present O
3 O
years O
after O
the O
withdrawal O
of O
quinine B-DRUG
. O

Prominent B-ADE
eye I-ADE
movements I-ADE
during I-ADE
NREM I-ADE
sleep I-ADE
and O
REM B-ADE
sleep I-ADE
behavior I-ADE
disorder I-ADE
associated O
with O
fluoxetine B-DRUG
treatment O
of O
depression O
and O
obsessive O
- O
compulsive O
disorder O
. O

Two O
cases O
of O
widespread O
cutaneous B-ADE
vasculitis I-ADE
are O
described O
in O
association O
with O
diltiazem B-DRUG
, O
a O
recently O
introduced O
calcium O
antagonist O
. O

CONCLUSION O
: O
A O
patient O
with O
CHF O
and O
ESRD O
developed O
myoclonic B-ADE
muscle I-ADE
spasms I-ADE
after O
receiving O
dobutamine B-DRUG
by O
continuous O
i.v O
. O
infusion O
. O

The O
authors O
describe O
a O
case O
of O
combined O
lithium B-DRUG
and O
haloperidol B-DRUG
toxicity O
characterized O
by O
hyperpyrexia B-ADE
, O
severe B-ADE
rigidity I-ADE
, O
mutism B-ADE
, O
and O
development O
of O
irreversible B-ADE
tardive I-ADE
dyskinesia I-ADE
. O

Despite O
a O
postulated O
dopaminergic O
mechanism O
, O
there O
seems O
to O
have O
been O
only O
one O
previous O
report O
of O
amantadine B-DRUG
's O
precipitating B-ADE
psychosis I-ADE
in O
a O
schizophrenic O
patient O
. O

BACKGROUND O
: O
reports O
on O
delated B-ADE
cutaneous I-ADE
reactions I-ADE
to O
captopril B-DRUG
have O
been O
seldom O
reported O
. O

Intravenous O
haloperidol B-DRUG
is O
generally O
well O
tolerated O
, O
but O
multiform B-ADE
ventricular I-ADE
tachycardia I-ADE
has O
been O
reported O
. O

INTRODUCTION O
: O
We O
describe O
the O
neurointensive O
care O
( O
NIC O
) O
management O
of O
a O
patient O
with O
severe B-ADE
cerebral I-ADE
swelling I-ADE
and O
raised B-ADE
intracranial I-ADE
pressure I-ADE
( O
ICP O
) O
after O
severe O
sodium B-DRUG
valproic I-DRUG
acid I-DRUG
( O
VPA B-DRUG
) O
intoxication O
. O

Sensorimotor B-ADE
polyneuropathy I-ADE
with O
5-aminosalicylic B-DRUG
acid I-DRUG
: O
a O
case O
report O
. O

Severe B-ADE
leukopenia I-ADE
associated O
with O
mild B-ADE
hepatotoxicity I-ADE
in O
an O
HIV O
carrier O
treated O
with O
nevirapine B-DRUG
. O

Methotrexate B-DRUG
- O
induced O
leukoencephalopathy B-ADE
is O
treatable O
with O
high O
- O
dose O
folinic O
acid O
: O
a O
case O
report O
and O
analysis O
of O
the O
literature O
. O

We O
describe O
a O
patient O
with O
Wilson O
's O
disease O
who O
presented O
with O
neurologic O
disease O
, O
was O
treated O
with O
D B-DRUG
- I-DRUG
penicillamine I-DRUG
, O
and O
suffered O
sudden O
neurologic B-ADE
deterioration I-ADE
coincident O
with O
therapy O
. O

Based O
upon O
the O
observed O
fall B-ADE
of I-ADE
the I-ADE
filtration I-ADE
fraction I-ADE
, O
the O
rise B-ADE
in I-ADE
the I-ADE
relative I-ADE
clearance I-ADE
of I-ADE
99Tc I-ADE
- I-ADE
dimercaptosuccinic I-ADE
acid I-ADE
and O
the O
increase B-ADE
in I-ADE
proteinuria I-ADE
, O
we O
suggest O
that O
in O
this O
case O
the O
tubules O
and/or O
interstitium O
are O
the O
main O
targets O
for O
cyclosporine B-DRUG
A I-DRUG
nephrotoxicity B-ADE
. O

However O
, O
the O
use O
of O
lithium B-DRUG
should O
be O
avoided O
with O
any O
patient O
who O
is O
purging O
, O
since O
it O
may O
exacerbate O
the O
loss B-ADE
of I-ADE
intracellular I-ADE
potassium I-ADE
, O
thereby O
increasing O
the O
risk O
of O
cardiac B-ADE
toxicity I-ADE
. O

We O
report O
a O
child O
with O
yolk O
sac O
tumor O
who O
developed O
localized B-ADE
pigmentation I-ADE
after O
the O
first O
course O
of O
chemotherapy O
regimen O
that O
included O
cisplatin B-DRUG
, O
etoposide B-DRUG
and O
bleomycin B-DRUG
. O

In O
patients O
with O
chronic O
heart O
failure O
, O
spironolactone B-DRUG
added O
to O
conventional O
treatment O
may O
lead O
to O
serious B-ADE
and I-ADE
, I-ADE
occasionally I-ADE
, I-ADE
fatal I-ADE
hyperkalaemia I-ADE
. O

The O
authors O
describe O
valproate B-DRUG
- O
induced O
hyperammonemia B-ADE
and O
mental B-ADE
status I-ADE
changes I-ADE
in O
an O
88-year O
- O
old O
man O
, O
the O
first O
known O
reported O
case O
in O
an O
elderly O
patient O
. O

A O
case O
of O
recall B-ADE
pneumonitis I-ADE
induced O
by O
gemcitabine B-DRUG
is O
reported O
. O

To O
our O
knowledge O
, O
this O
is O
the O
first O
reported O
case O
of O
bromide B-ADE
intoxication I-ADE
due O
to O
pyridostigmine B-DRUG
bromide I-DRUG
administration O
. O

The O
biochemistry O
of O
paracetamol B-DRUG
hepatotoxicity B-ADE
is O
outlined O
and O
the O
increased O
susceptibility O
of O
alcoholic O
patients O
to O
the O
hepatotoxic B-ADE
effects I-ADE
of O
paracetamol B-DRUG
is O
remarked O
upon O
. O

We O
report O
a O
case O
of O
hyperpigmentation B-ADE
due O
to O
bleomycin B-DRUG
treatment O
in O
a O
patient O
with O
acquired O
immune O
deficiency O
syndrome O
( O
AIDS O
) O
. O

We O
report O
a O
case O
of O
an O
11-year O
- O
old O
boy O
who O
experienced O
an O
anaphylactic B-ADE
reaction I-ADE
after O
administration O
of O
bacitracin B-DRUG
ointment O
. O

The O
Naranjo O
probability O
scale O
suggests O
a O
highly O
probable O
relationship O
between O
AIN B-ADE
and O
pantoprazole B-DRUG
therapy O
in O
this O
patient O
. O

Suspected O
ciprofloxacin B-DRUG
- O
induced O
interstitial B-ADE
nephritis I-ADE
. O

One O
patient O
had O
a O
lower B-ADE
average I-ADE
heart I-ADE
rate I-ADE
and O
two O
patients O
had O
lower B-ADE
average I-ADE
mean I-ADE
blood I-ADE
pressure I-ADE
values O
during O
propranolol B-DRUG
treatment O
, O
none O
of O
which O
was O
clinically O
significant O
. O

These O
cases O
and O
a O
review O
of O
the O
literature O
suggested O
that O
hepatotoxicity B-ADE
, O
though O
rare O
, O
should O
be O
added O
to O
the O
list O
of O
adverse O
reactions O
to O
D B-DRUG
- I-DRUG
penicillamine I-DRUG
. O

Four O
years O
after O
the O
beginning O
of O
IFN B-DRUG
therapy O
, O
he O
acutely O
developed O
moderate B-ADE
hyperglycemia I-ADE
and O
severe B-ADE
ketonuria I-ADE
with O
positive O
islet O
cell O
antibody O
, O
and O
then O
28 O
units O
/ O
day O
of O
insulin O
injection O
was O
started O
. O

Adverse O
reaction O
in O
a O
patient O
with O
aspirin B-DRUG
- O
induced O
asthma B-ADE
treated O
with O
zafirlukast O
. O

When O
DSCG B-DRUG
was O
withdrawn O
, O
urticaria B-ADE
vanished O
and O
the O
child O
remained O
symptom O
- O
free O
. O

Lithium B-DRUG
- O
induced O
Creutzfeldt B-ADE
- I-ADE
Jakob I-ADE
syndrome I-ADE
. O

Growth B-ADE
and I-ADE
adrenal I-ADE
suppression I-ADE
in O
asthmatic O
children O
treated O
with O
high O
- O
dose O
fluticasone B-DRUG
propionate I-DRUG
. O

After O
initiation O
of O
topical O
vitamin B-DRUG
D3 I-DRUG
ointment O
( O
20 O
micro O
g O
/ O
g O
of O
tacalcitol O
) O
10 O
g O
/ O
day O
for O
the O
skin O
lesions O
, O
both O
the O
serum B-ADE
level I-ADE
of I-ADE
calcium I-ADE
and I-ADE
urinary I-ADE
excretion I-ADE
of I-ADE
calcium I-ADE
increased I-ADE
gradually O
. O

We O
report O
the O
development O
of O
squamous B-ADE
- I-ADE
cell I-ADE
carcinoma I-ADE
within O
a O
basal O
- O
cell O
epithelioma O
that O
was O
treated O
with O
intralesional O
injections O
of O
5-FU B-DRUG
. O

When O
tuberculosis O
patients O
on O
isoniazid B-DRUG
eat O
certain O
varieties O
of O
fish O
they O
may O
develop O
a O
histamine B-ADE
reaction I-ADE
. O

These O
two O
cases O
highlight O
the O
importance O
of O
considering O
lopinavir B-DRUG
/ O
ritonavir B-DRUG
induced O
arrhythmias B-ADE
when O
dealing O
with O
HIV O
- O
positive O
individuals O
. O

A O
patient O
presented O
with O
a O
painful B-ADE
, I-ADE
oedematous I-ADE
, I-ADE
cyanosed I-ADE
hand I-ADE
having O
injected O
a O
solution O
of O
diamorphine B-DRUG
and O
methylphenidate B-DRUG
into O
his O
radial O
artery O
. O

The O
clinical O
picture O
was O
identical O
to O
that O
of O
chloroquine B-DRUG
and O
hydroxychloroquine B-DRUG
maculopathy B-ADE
. O

We O
report O
a O
78-year O
- O
old O
man O
who O
had O
acute B-ADE
unilateral I-ADE
total I-ADE
visual I-ADE
loss I-ADE
after O
retrogasserian O
phenol B-DRUG
injection O
for O
the O
treatment O
of O
trigeminal O
neuralgia O
. O

Alternating B-ADE
sinus I-ADE
rhythm I-ADE
and O
intermittent B-ADE
sinoatrial I-ADE
( I-ADE
S I-ADE
- I-ADE
A I-ADE
) I-ADE
block I-ADE
was O
observed O
in O
a O
57-year O
- O
old O
woman O
, O
under O
treatment O
for O
angina O
with O
80 O
mg O
propranolol B-DRUG
daily O
. O

Delayed O
neurotoxicity B-ADE
of O
intraventricular O
interleukin-2 B-DRUG
: O
a O
case O
report O
. O

We O
report O
on O
three O
patients O
who O
developed O
acute O
liver B-ADE
damage I-ADE
during O
therapy O
with O
itraconazole B-DRUG
, O
and O
in O
whom O
liver O
biopsy O
specimens O
were O
obtained O
. O

Nitrofurantoin B-DRUG
- O
induced O
acute B-ADE
liver I-ADE
damage I-ADE
in O
pregnancy O
. O

Unusual O
hypersensitivity B-ADE
to O
warfarin B-DRUG
in O
a O
critically O
ill O
patient O
. O

Fatal B-ADE
complication I-ADE
of O
intravesical O
formalin B-DRUG
during O
control O
of O
intractable O
hemorrhage O
from O
radiation O
cystitis O
. O

We O
report O
a O
case O
of O
vitiligo B-ADE
that O
occurred O
during O
the O
second O
month O
of O
interferon B-DRUG
alpha I-DRUG
2a I-DRUG
therapy O
for O
chronic O
active O
hepatitis O
C O
. O

We O
report O
the O
case O
of O
a O
young O
man O
, O
affected O
by O
rheumatoid O
arthritis O
who O
developed O
a O
rapid O
- O
onset O
short B-ADE
- I-ADE
of I-ADE
- I-ADE
breath I-ADE
, O
hemoptysis B-ADE
, O
and O
severe B-ADE
weakness I-ADE
, O
about O
2 O
weeks O
after O
the O
administration O
of O
leflunomide B-DRUG
. O

Although O
fluoxetine B-DRUG
- O
induced O
headache B-ADE
occurred O
in O
one O
patient O
, O
the O
other O
five O
reported O
no O
side O
effects O
at O
the O
doses O
used O
. O

While O
the O
mechanism O
of O
dextran B-DRUG
- O
associated O
renal B-ADE
failure I-ADE
remains O
unsolved O
, O
plasma O
exchange O
seems O
to O
be O
effective O
therapy O
. O

Cerebral B-ADE
infarcts I-ADE
in O
a O
pediatric O
patient O
secondary O
to O
phenylpropanolamine B-DRUG
, O
a O
recalled O
medication O
. O

The O
site O
of O
thrombosis O
and O
the O
chronological O
relationship O
with O
the O
IIR B-ADE
implicates O
a O
hypersensitivity B-ADE
to O
infliximab B-DRUG
in O
the O
causation O
of O
the O
venous B-ADE
thrombosis I-ADE
in O
this O
case O
. O

Life O
- O
threatening O
interstitial B-ADE
lung I-ADE
disease I-ADE
associated O
with O
trastuzumab B-DRUG
: O
case O
report O
. O

Inadvertent O
subsequent O
rechallenge O
with O
celiprolol B-DRUG
led O
to O
recurrence O
of O
the O
pneumonitis B-ADE
, O
10 O
weeks O
after O
drug O
readministration O
. O

The O
use O
of O
methotrexate B-DRUG
( O
MTX B-DRUG
) O
has O
been O
contraindicated O
for O
treatment O
of O
severe O
psoriasis O
in O
HIV O
infection O
on O
the O
basis O
of O
six O
previously O
reported O
cases O
in O
which O
MTX B-DRUG
appeared O
to O
potentiate O
opportunistic O
infections O
and O
accelerate B-ADE
HIV I-ADE
disease I-ADE
. O

Verapamil B-DRUG
is O
widely O
used O
for O
the O
termination O
of O
paroxysmal O
supraventricular O
tachycardia O
( O
PSVT O
) O
with O
little O
proarrhythmic B-ADE
effect I-ADE
. O

Combining O
methylephedrine B-DRUG
and O
Chinese O
herbal O
drugs O
might O
carry O
a O
risk O
of O
stroke B-ADE
. O

Cyclophosphamide B-DRUG
can O
rarely O
cause O
interstitial B-ADE
pneumonitis I-ADE
and O
fibrosis B-ADE
. O

We O
report O
a O
case O
of O
exfoliative B-ADE
dermatitis I-ADE
clearly O
linked O
to O
intravenous O
and O
intraperitoneal O
administration O
of O
tobramycin B-DRUG
. O

A O
74-year O
- O
old O
man O
received O
oral O
administration O
of O
pilsicainide B-DRUG
, O
a O
pure O
sodium O
channel O
blocker O
with O
slow O
recovery O
kinetics O
, O
to O
convert O
paroxysmal O
atrial O
fibrillation O
to O
sinus O
rhythm O
and O
developed O
loss B-ADE
of I-ADE
consciousness I-ADE
two O
days O
later O
. O

Development O
of O
Crohn B-ADE
's I-ADE
disease I-ADE
in O
a O
patient O
with O
multiple O
sclerosis O
treated O
with O
copaxone B-DRUG
. O

On O
the O
other O
hand O
, O
MTX B-DRUG
- O
induced O
pneumonitis B-ADE
seems O
to O
be O
very O
rare O
in O
psoriatic O
arthritis O
( O
PsA O
) O
. O

CONCLUSIONS O
: O
This O
is O
the O
first O
report O
of O
a O
possible O
interaction O
between O
propafenone B-DRUG
and O
citalopram B-DRUG
, O
which O
caused O
propafenone O
adverse O
effects O
( O
eg O
, O
dizziness B-ADE
, O
falls B-ADE
) O
and O
mimicked O
coronary B-ADE
artery I-ADE
disease I-ADE
. O

We O
described O
a O
very O
atypical O
case O
of O
a O
high O
stage O
, O
high O
grade O
endometrial B-ADE
cancer I-ADE
associated O
with O
tamoxifen B-DRUG
in O
a O
64-year O
- O
old O
woman O
with O
a O
past O
history O
of O
breast O
cancer O
. O

We O
report O
the O
case O
of O
a O
patient O
with O
multiple O
myeloma O
who O
developed O
acute O
life B-ADE
- I-ADE
threatening I-ADE
water I-ADE
intoxication I-ADE
following O
treatment O
with O
oral O
indomethacin B-DRUG
and O
low O
dose O
intravenous O
cyclophosphamide B-DRUG
. O

Myoglobinuria B-ADE
and O
acute B-ADE
renal I-ADE
failure I-ADE
associated O
with O
intravenous O
vasopressin B-DRUG
infusion O
. O

Acute B-ADE
bilateral I-ADE
phrenic I-ADE
neuropathy I-ADE
following O
treatment O
with O
adalimumab B-DRUG
. O

Ectropion B-ADE
secondary O
to O
bolus O
injection O
of O
5-fluorouracil B-DRUG
. O

DISCUSSION O
: O
Phenolphthalein B-DRUG
is O
the O
active O
ingredient O
in O
several O
over O
- O
the O
- O
counter O
laxative O
preparations O
and O
has O
only O
rarely O
been O
reported O
to O
cause O
TEN B-ADE
. O

DISCUSSION O
: O
No O
published O
clinical O
studies O
in O
patients O
receiving O
clindamycin B-DRUG
vaginal O
cream O
for O
bacterial O
vaginosis O
have O
documented O
C. B-ADE
difficile I-ADE
toxin I-ADE
in I-ADE
stool I-ADE
samples O
of O
patients O
with O
diarrhea B-ADE
. O

Ampicillin B-DRUG
may O
aggravate O
clinical O
and O
experimental O
myasthenia B-ADE
gravis I-ADE
. O

Within O
24 O
hours O
of O
fluid O
restriction O
and O
cessation O
of O
desmopressin B-DRUG
, O
her O
symptoms O
and O
hyponatremia B-ADE
resolved O
. O

Carbamazepine B-DRUG
- O
related O
hyponatremia B-ADE
following O
cardiopulmonary O
bypass O
. O

Vasomotor B-ADE
reactions I-ADE
after O
gold B-DRUG
sodium I-DRUG
thiomalate I-DRUG
are O
well O
recognized O
. O

Second O
, O
we O
report O
a O
case O
of O
neutropenia B-ADE
, O
which O
proved O
to O
be O
fatal O
in O
a O
schizophrenia O
patient O
receiving O
olanzapine B-DRUG
and O
thiazide B-DRUG
. O

This O
is O
the O
first O
report O
of O
acute B-ADE
kidney I-ADE
injury I-ADE
due O
to O
zonisamide B-DRUG
- O
induced O
DRESS B-ADE
/ O
DIHS B-ADE
. O

Physicians O
should O
be O
aware O
of O
the O
potentially O
lethal B-ADE
side O
effects O
of O
dapsone B-DRUG
. O

The O
authors O
describe O
three O
families O
in O
whom O
the O
occurrence O
of O
FVS B-ADE
in O
all O
the O
siblings O
strongly O
suggests O
hereditary O
susceptibility O
to O
valproic B-DRUG
acid I-DRUG
- O
induced O
adverse O
outcome O
. O

We O
report O
the O
case O
of O
a O
60-year O
- O
old O
woman O
who O
developed O
erythema B-ADE
and O
erosions B-ADE
in I-ADE
the I-ADE
axilla I-ADE
and I-ADE
groin I-ADE
while O
on O
PLD B-DRUG
for O
breast O
cancer O
. O

A O
young O
woman O
developed O
galactorrhea B-ADE
during O
treatment O
with O
a O
new O
dibenzoxazepine B-DRUG
antidepressant O
, O
amoxapine B-DRUG
. O

A O
73-year O
- O
old O
woman O
presented O
with O
fever B-ADE
and O
cough B-ADE
2 O
weeks O
after O
completing O
the O
third O
cycle O
of O
fludarabine B-DRUG
for O
chronic O
lymphocytic O
leukemia O
( O
CLL O
) O
. O

Intracranial B-ADE
haemorrhage I-ADE
from O
a O
meningioma O
in O
a O
patient O
receiving O
aspirin B-DRUG
prophylaxis O
: O
a O
case O
report O
. O

Intrahepatic B-ADE
cholestasis I-ADE
and O
cutaneous B-ADE
bullae I-ADE
associated O
with O
glibenclamide B-DRUG
therapy O
. O

Based O
on O
the O
Naranjo O
algorithm O
, O
the O
adverse O
reaction O
observed O
was O
probably O
related O
to O
the O
hydroxyurea O
treatment O
( O
score O
= O
6 O
) O
; O
however O
, O
the O
hydroxyurea B-DRUG
chemotherapy O
could O
not O
be O
discontinued O
because O
of O
the O
myeloproliferative B-ADE
disorder I-ADE
. O

Rifampin B-DRUG
can O
be O
associated O
with O
severe O
adverse O
effects O
such O
as O
hepatitis B-ADE
, O
acute B-ADE
renal I-ADE
failure I-ADE
, O
hemolytic B-ADE
anemia I-ADE
, O
and O
thrombocytopenia B-ADE
. O

In O
addition O
to O
its O
known O
effect O
on O
gallbladder B-ADE
stasis I-ADE
, O
octreotide B-DRUG
alters B-ADE
bile I-ADE
acid I-ADE
composition I-ADE
and O
may O
thus O
hasten B-ADE
intrahepatic I-ADE
sludge I-ADE
and O
stone B-ADE
formation I-ADE
. O

This O
selective O
closure O
of O
the O
ductus O
arteriosus O
suggests O
that O
the O
affected O
twin O
was O
predisposed O
to O
hypoxia B-ADE
and O
thus O
was O
more O
susceptible O
to O
ductal B-ADE
closure I-ADE
in O
response O
to O
indomethacin B-DRUG
exposure O
. O

The O
results O
of O
the O
ultrasound O
examination O
combined O
with O
clinical O
anamnesis O
allowed O
diagnosis O
of O
gastric B-ADE
mucosa I-ADE
foveolar I-ADE
hyperplasia I-ADE
due O
to O
prolonged O
PGE1 B-DRUG
therapy O
. O

Amphotericin B-DRUG
B I-DRUG
- O
induced O
seizures B-ADE
in O
a O
patient O
with O
AIDS O
. O

We O
observed O
3 O
diabetic O
patients O
with O
intolerable B-ADE
dizziness I-ADE
followed O
by O
nausea B-ADE
and O
vomiting B-ADE
immediately O
after O
an O
initial O
administration O
of O
the O
alpha O
- O
glucosidase O
inhibitor O
, O
voglibose B-DRUG
. O

Hepatitis B-ADE
with O
bridging B-ADE
fibrosis I-ADE
and O
reversible B-ADE
hepatic I-ADE
insufficiency I-ADE
in O
a O
woman O
with O
rheumatoid O
arthritis O
taking O
methotrexate B-DRUG
. O

To O
date O
, O
eight O
cases O
of O
TEN B-ADE
and O
one O
of O
SJS B-ADE
related O
to O
lamotrigine B-DRUG
administration O
have O
been O
reported O
in O
the O
literature O
. O

DISCUSSION O
: O
Patients O
with O
5-FU B-DRUG
- O
induced O
ectropion B-ADE
experience O
tender B-ADE
, I-ADE
red I-ADE
, I-ADE
scaled I-ADE
lids I-ADE
, O
making O
contact O
lens O
wear O
difficult O
. O

Patients O
treated O
with O
captopril B-DRUG
who O
develop O
" O
atypical B-ADE
cholangitis I-ADE
" O
should O
be O
suspected O
of O
having O
captopril B-DRUG
- O
associated O
liver B-ADE
damage I-ADE
. O

The O
allopurinol B-DRUG
hypersensitivity B-ADE
syndrome I-ADE
is O
a O
rare O
adverse O
drug O
reaction O
. O

This O
eruption B-ADE
emerged O
after O
1 O
month O
of O
therapy O
with O
salsalate B-DRUG
, O
persisted O
for O
as O
long O
as O
salsalate O
was O
administered O
, O
and O
cleared O
within O
3 O
weeks O
of O
discontinuing O
the O
medication O
. O

The O
increased B-ADE
libido I-ADE
disappeared O
after O
fluvoxamine B-DRUG
was O
discontinued O
. O

The O
use O
of O
pamidronate O
for O
hypercalcemia O
secondary O
to O
acute O
vitamin B-DRUG
D I-DRUG
intoxication I-ADE
. O

Trazodone B-DRUG
- O
induced O
transient B-ADE
hypomanic I-ADE
symptoms I-ADE
and O
their O
management O
. O

Early O
recognition O
of O
hereditary O
motor O
and O
sensory O
neuropathy O
type O
1 O
can O
avoid O
life B-ADE
- I-ADE
threatening I-ADE
vincristine B-DRUG
neurotoxicity I-ADE
. O

When O
thrombosis B-ADE
develops O
during O
heparin B-DRUG
treatment O
, O
it O
is O
important O
to O
suspect O
HITTs O
and O
to O
assay O
for O
the O
associated O
antibodies O
, O
regardless O
of O
the O
actual O
platelet O
count O
. O

Widespread O
cutaneous B-ADE
vasculitis I-ADE
associated O
with O
diltiazem B-DRUG
. O

He O
developed O
fever B-ADE
, O
nausea B-ADE
, O
diarrhea B-ADE
, O
and O
malaise B-ADE
and O
stopped O
taking O
on O
the O
third O
day O
after O
commencing O
Pentasa B-DRUG
. O

It O
is O
likely O
that O
RA B-DRUG
contributed O
to O
the O
deterioration B-ADE
in I-ADE
renal I-ADE
function I-ADE
in O
these O
patients O
. O

Pneumonitis B-ADE
with O
pleural B-ADE
and I-ADE
pericardial I-ADE
effusion I-ADE
and O
neuropathy B-ADE
during O
amiodarone B-DRUG
therapy O
. O

Fatal B-ADE
hepatitis I-ADE
after O
long O
- O
term O
pulse O
itraconazole B-DRUG
treatment O
for O
onychomycosis O
. O

This O
is O
a O
rare O
case O
of O
ARDS B-ADE
associated O
with O
lithium B-DRUG
intoxication O
. O

Probable O
enoxaparin B-DRUG
- O
induced O
hepatotoxicity B-ADE
. O

Both O
patients O
suddenly O
became O
hypotensive B-ADE
after O
injection O
of O
chymopapain B-DRUG
into O
a O
disk O
. O

Hypersensitivity B-ADE
reactions I-ADE
due O
to O
chloramphenicol B-DRUG
are O
rarely O
reported O
in O
the O
literature O
. O

Some O
patients O
develop O
hypersensitivity B-ADE
rash I-ADE
in O
response O
to O
HCQ B-DRUG
. O

A O
45-year O
- O
old O
woman O
with O
thyrotoxicosis O
developed O
agranulocytosis B-ADE
after O
treatment O
with O
propylthiouracil B-DRUG
. O

However O
, O
the O
amount O
of O
prednisone B-DRUG
required O
to O
maintain O
normotension O
resulted O
in O
Cushingoid B-ADE
features I-ADE
and O
has O
been O
discontinued O
. O

PURPOSE O
: O
A O
case O
of O
probable O
enoxaparin B-DRUG
- O
induced O
hepatotoxicity B-ADE
is O
described O
. O

The O
potential O
role O
of O
propranolol B-DRUG
in O
inducing O
central B-ADE
nervous I-ADE
system I-ADE
disturbances I-ADE
is O
emphasized O
, O
and O
the O
literature O
on O
the O
subject O
is O
reviewed O
. O

Ischaemia B-ADE
following O
selfadministered O
intra O
- O
arterial O
injection O
of O
methylphenidate B-DRUG
and O
diamorphine B-DRUG
. O

It O
is O
tempting O
to O
speculate O
that O
interferon B-DRUG
alpha I-DRUG
may O
be O
involved O
in O
the O
pathogenesis O
of O
lichen B-ADE
nitidus I-ADE
. O

Thiopurine O
methyltransferase O
deficiency O
occurs O
at O
a O
frequency O
of O
one O
in O
300 O
and O
is O
associated O
with O
profound O
myelosuppression B-ADE
after O
a O
short O
course O
of O
azathioprine B-DRUG
. O

PURPOSE O
: O
We O
report O
an O
unusual O
paradoxical B-ADE
effect I-ADE
of O
brimonidine B-DRUG
. O

The O
authors O
' O
results O
suggest O
that O
L B-DRUG
- I-DRUG
dopa I-DRUG
may O
cause O
daytime B-ADE
somnolence I-ADE
in O
some O
patients O
with O
Parkinson O
's O
disease O
. O

Amiodarone B-DRUG
was O
discontinued O
, O
and O
thyrotoxicosis B-ADE
gradually O
abated O
. O

To O
our O
knowledge O
, O
this O
is O
the O
first O
case O
reported O
in O
the O
English O
literature O
of O
a O
generalized B-ADE
exanthem I-ADE
due O
to O
subcutaneous O
injection O
of O
enoxaparin B-DRUG
. O

We O
present O
the O
case O
of O
a O
5-year O
- O
old O
girl O
who O
developed O
bilateral B-ADE
vocal I-ADE
cord I-ADE
paralysis I-ADE
following O
preoperative O
peritonsillar O
bupivacaine B-DRUG
infiltration O
. O

Despite O
minimal O
short O
- O
term O
side O
effects O
and O
apparent O
efficacy O
, O
chronic O
treatment O
of O
MG O
with O
MM B-DRUG
may O
be O
associated O
with O
increased O
risk O
of O
lymphoproliferative B-ADE
disorders I-ADE
. O

The O
most O
likely O
cause O
of O
such O
hyponatremic B-ADE
episode I-ADE
is O
vinblastine B-DRUG
. O

Although O
there O
is O
one O
case O
report O
of O
cholesterol B-ADE
crystal I-ADE
embolization I-ADE
following O
t B-DRUG
- I-DRUG
PA I-DRUG
therapy O
with O
only O
extrarenal B-ADE
manifestations I-ADE
( O
N O
Engl O
J O
Med O
321:1270 O
, O
1989 O
) O
, O
this O
is O
the O
first O
reported O
case O
of O
atheroembolic B-ADE
acute I-ADE
renal I-ADE
failure I-ADE
following O
t B-DRUG
- I-DRUG
PA I-DRUG
therapy O
. O

Possible O
recurrence O
of O
amiodarone B-DRUG
pulmonary B-ADE
toxicity I-ADE
following O
corticosteroid O
therapy O
. O

Minor B-ADE
electrocardiographical I-ADE
changes I-ADE
were O
noted O
in O
five O
out O
of O
six O
patients O
who O
were O
not O
receiving O
a O
cardiac O
glycoside O
and O
four O
out O
of O
six O
who O
were O
receiving O
ouabain B-DRUG
, O
and O
none O
of O
the O
16 O
who O
were O
receiving O
digoxin O
. O

Myoclonus B-ADE
and O
seizures B-ADE
disappeared O
after O
discontinuation O
of O
L B-DRUG
- I-DRUG
dopa I-DRUG
and O
the O
introduction O
of O
valproate O
sodium O
( O
VPA O
) O
. O

We O
report O
the O
first O
case O
of O
an O
acute O
flare O
of O
eosinophilic B-ADE
cystitis I-ADE
in O
a O
51-year O
- O
old O
woman O
after O
bladder O
instillation O
with O
dimethyl B-DRUG
sulfoxide I-DRUG
( O
DMSO B-DRUG
) O
for O
presumed O
interstitial O
cystitis O
. O

Therefore O
, O
we O
concluded O
that O
this O
patient O
's O
pulmonary B-ADE
disease I-ADE
was O
caused O
by O
calcium B-DRUG
stearate I-DRUG
, O
an O
additive O
for O
an O
antihistaminic O
drug O
. O

DATA O
SYNTHESIS O
: O
A O
49-year O
- O
old O
man O
developed O
symptoms O
of O
severe B-ADE
psychosis I-ADE
concomitant O
with O
ciprofloxacin B-DRUG
( O
250 O
mg O
bid O
) O
treatment O
. O

Charcoal O
haemoperfusion O
and O
cysteamine O
therapy O
led O
to O
the O
rapid O
removal O
of O
the O
paracetamol B-DRUG
from O
the O
body O
and O
consequently O
prevented O
the O
development O
of O
severe B-ADE
hepatic I-ADE
necrosis I-ADE
. O

AIM O
: O
To O
report O
a O
patient O
with O
diabetic O
rubeosis O
who O
suffered O
from O
acute B-ADE
retinal I-ADE
ischemic I-ADE
change I-ADE
and O
stroke B-ADE
after O
intravitreal O
injection O
of O
bevacizumab B-DRUG
. O

Clinical O
and O
morphological O
features O
of O
gold B-DRUG
neuropathy B-ADE
. O

In O
keeping O
with O
findings O
in O
the O
literature O
, O
the O
aortic B-ADE
wall I-ADE
in I-ADE
this I-ADE
case I-ADE
was I-ADE
damaged I-ADE
by O
secondary O
changes O
following O
irradiation O
and O
Bleomycin B-DRUG
treatment O
. O

We O
describe O
the O
development O
of O
ischemic B-ADE
colitis I-ADE
in O
a O
woman O
who O
was O
treated O
with O
tegaserod B-DRUG
and O
review O
the O
relationship O
among O
ischemic B-ADE
colitis I-ADE
, O
tegaserod B-DRUG
use O
, O
and O
irritable B-ADE
bowel I-ADE
syndrome I-ADE
. O

We O
present O
a O
patient O
with O
human O
immunodeficiency O
virus O
infection O
under O
treatment O
with O
foscarnet B-DRUG
for O
CMV O
retinitis O
who O
complained O
of O
thirst B-ADE
and O
polyuria B-ADE
. O

A O
7-year O
- O
old O
girl O
developed O
diabetes B-ADE
mellitus I-ADE
and O
exocrine B-ADE
pancreatic I-ADE
insufficiency I-ADE
after O
3.5 O
years O
of O
almost O
continuous O
treatment O
with O
azathioprine B-DRUG
and/or O
prednisone B-DRUG
for O
idiopathic O
auto O
- O
immune O
haemolytic O
anaemia O
. O

Cefoxitin B-DRUG
therapy O
for O
Mycobacterium O
fortuitum O
bacteremia O
with O
associated O
granulomatous B-ADE
hepatitis I-ADE
. O

We O
report O
the O
case O
of O
a O
21-year O
- O
old O
female O
patient O
with O
dapsone B-DRUG
hypersensitivity B-ADE
syndrome I-ADE
. O

Unaccountable O
severe O
hypercalcemia B-ADE
in O
a O
patient O
treated O
for O
hypoparathyroidism O
with O
dihydrotachysterol B-DRUG
. O

CASE O
DESCRIPTION O
: O
A O
59-year O
- O
old O
man O
with O
known O
neurocysticercosis O
developed O
a O
large B-ADE
cerebral I-ADE
infarction I-ADE
during O
praziquantel B-DRUG
therapy O
. O

Seven O
of O
the O
eight O
cases O
of O
acute B-ADE
leukemia I-ADE
occurred O
in O
a O
series O
of O
553 O
patients O
treated O
with O
Treosulfan B-DRUG
for O
ovarian O
cancer O
in O
the O
period O
from O
1970 O
to O
1977 O
and O
followed O
closely O
for O
a O
total O
of O
1159 O
patient O
- O
years O
up O
to O
February O
1978 O
. O

This O
is O
a O
case O
report O
of O
possible O
association O
of O
methylphenidate B-DRUG
and O
enuresis B-ADE
in O
an O
11-year O
- O
old O
boy O
with O
attention O
deficit O
hyperactivity O
disorder O
. O

In O
addition O
, O
while O
cases O
of O
loop O
diuretic O
- O
induced O
pancreatitis B-ADE
, O
including O
furosemide B-DRUG
, O
have O
been O
published O
, O
the O
allergic O
manifestations O
with O
both O
sulfonamide O
antibiotics O
and O
non O
- O
antibiotics O
in O
our O
patient O
suggest O
possible O
cross O
- O
reactivity O
between O
these O
2 O
drug O
classes O
. O

Acceleration B-ADE
of I-ADE
ventricular I-ADE
response I-ADE
to O
atrial O
flutter O
after O
intravenous O
adenosine B-DRUG
. O

Pulmonary B-ADE
toxicity I-ADE
associated O
with O
erlotinib B-DRUG
. O

We O
report O
the O
occurrence O
of O
renal B-ADE
failure I-ADE
due O
to O
cholesterol B-ADE
crystal I-ADE
embolization I-ADE
following O
thrombolytic O
therapy O
with O
intravenous O
recombinant B-DRUG
tissue I-DRUG
- I-DRUG
type I-DRUG
plasminogen I-DRUG
activator I-DRUG
( O
t B-DRUG
- I-DRUG
PA I-DRUG
) O
. O

We O
present O
a O
case O
of O
hypereosinophilia B-ADE
related O
to O
zafirlukast B-DRUG
therapy O
. O

Fatal B-ADE
interstitial I-ADE
lung I-ADE
disease I-ADE
after O
erlotinib B-DRUG
administration O
in O
a O
patient O
with O
radiation O
fibrosis O
. O

The O
aim O
of O
this O
study O
was O
to O
describe O
the O
occurrence O
of O
acute B-ADE
coronary I-ADE
syndromes I-ADE
in O
3 O
cases O
of O
rituximab B-DRUG
infusions O
. O

It O
remains O
to O
be O
seen O
whether O
the O
hepatotoxicity B-ADE
associated O
with O
troglitazone B-DRUG
is O
a O
drug O
- O
class O
effect O
or O
specific O
to O
troglitazone B-DRUG
. O

Nitrofurantoin B-DRUG
- O
induced O
lung B-ADE
disease I-ADE
: O
two O
cases O
demonstrating O
resolution O
of O
apparently O
irreversible O
CT O
abnormalities O
. O

Despite O
a O
very O
low O
complication O
rate O
, O
several O
severe B-ADE
arterial I-ADE
thrombotic I-ADE
events I-ADE
have O
been O
reported O
following O
thrombin B-DRUG
injection O
of O
pseudoaneurysms O
. O

ARDS B-ADE
is O
rarely O
associated O
with O
rituximab B-DRUG
infusion O
for O
lympho O
- O
proliferative O
disorders O
, O
but O
it O
should O
be O
considered O
by O
those O
administering O
rituximab B-DRUG
, O
especially O
when O
a O
patient O
develops O
severe B-ADE
pulmonary I-ADE
symptoms I-ADE
soon O
after O
infusion O
. O

Methylene O
blue O
in O
the O
treatment O
and O
prevention O
of O
ifosfamide B-DRUG
- I-ADE
induced I-ADE
encephalopathy I-ADE
: O
report O
of O
12 O
cases O
and O
a O
review O
of O
the O
literature O
. O

We O
report O
a O
case O
of O
cough B-ADE
following O
the O
administration O
of O
quinapril B-DRUG
, O
with O
complete O
resolution O
after O
changing O
to O
the O
alternative O
ACE O
inhibitor O
fosinopril O
in O
a O
patient O
with O
essential O
hypertension O
. O

Central B-ADE
pontine I-ADE
myelinolysis I-ADE
manifested O
by O
temporary B-ADE
blindness I-ADE
: O
a O
possible O
complication O
of O
lithium B-DRUG
toxicity O
. O

We O
report O
the O
case O
of O
a O
patient O
with O
increased B-ADE
cerebral I-ADE
cortical I-ADE
excitability I-ADE
following O
intoxication O
with O
flupirtine B-DRUG
, O
a O
centrally O
acting O
analgesic O
and O
antispastic O
drug O
. O

A O
10-year O
- O
old O
asthmatic O
boy O
began O
to O
suffer O
from O
urticarial B-ADE
rash I-ADE
and O
moderately B-ADE
severe I-ADE
bronchospasm I-ADE
after O
8 O
weeks O
' O
treatment O
with O
disodium B-DRUG
cromoglycate I-DRUG
. O

A O
61-year O
- O
old O
man O
developed O
clinical B-ADE
lupus I-ADE
syndrome I-ADE
with O
positive O
antinuclear O
antibody O
, O
positive O
lupus B-ADE
erythematosus I-ADE
( O
LE O
) O
cell O
preparation O
, O
and O
diffuse B-ADE
proliferative I-ADE
glomerulonephritis I-ADE
following O
26 O
months O
of O
procainamide B-DRUG
therapy O
. O

A O
64-year O
- O
old O
man O
with O
schizophrenia O
developed O
myoclonic B-ADE
jerks I-ADE
when O
given O
higher O
doses O
of O
quetiapine B-DRUG
. O

During O
dose O
- O
finding O
studies O
for O
intravenous O
proton O
pump O
inhibitors O
omeprazole O
and O
pantoprazole O
, O
three O
of O
six O
young O
female O
volunteers O
receiving O
omeprazole B-DRUG
and O
two O
young O
female O
volunteers O
receiving O
pantoprazole B-DRUG
developed O
peripheral B-ADE
edema I-ADE
within O
8 O
hr O
when O
high O
doses O
of O
the O
proton O
pump O
inhibitors O
were O
applied O
by O
continuous O
infusion O
together O
with O
large O
volumes O
of O
fluid O
. O

We O
report O
a O
fatal B-ADE
case I-ADE
of I-ADE
acute I-ADE
interstitial I-ADE
pneumonitis I-ADE
in O
a O
patient O
treated O
with O
carmustine B-DRUG
( O
BCNU B-DRUG
) O
for O
a O
brain O
tumor O
. O

Lithium B-DRUG
- O
associated O
transient B-ADE
thyrotoxicosis I-ADE
in O
4 O
Chinese O
women O
with O
autoimmune O
thyroiditis O
. O

In O
the O
first O
patient O
, O
two O
episodes O
of O
ventricular B-ADE
tachycardia I-ADE
requiring O
cardioversion O
occurred O
in O
close O
temporal O
sequence O
with O
administering O
bretylium B-DRUG
. O

These O
data O
indicated O
that O
infliximab B-DRUG
possibly O
triggered O
production B-ADE
of I-ADE
granulocyte I-ADE
and I-ADE
neutrophil I-ADE
autoantibodies I-ADE
with O
resultant O
autoimmune B-ADE
agranulocytosis I-ADE
. O

Allopurinol B-DRUG
- O
associated O
hand B-ADE
and I-ADE
foot I-ADE
deformities I-ADE
in O
chronic O
tophaceous O
gout O
. O

The O
literature O
search O
found O
12 O
cases O
of O
radiation B-ADE
recall I-ADE
caused O
by O
gemcitabine B-DRUG
. O

Two O
patients O
on O
long O
- O
term O
lithium B-DRUG
therapy O
developed O
the O
nephrotic B-ADE
syndrome I-ADE
. O

Flare O
of O
Kaposi B-ADE
's I-ADE
sarcoma I-ADE
( O
KS B-ADE
) O
is O
well O
described O
in O
immunosuppressed O
patients O
treated O
with O
corticosteroids O
and O
rituximab B-DRUG
, O
but O
has O
not O
yet O
been O
reported O
during O
treatment O
with O
imatinib O
. O

This O
is O
a O
case O
of O
pseudoephedrine B-DRUG
- O
induced O
intracerebral B-ADE
hemorrhage I-ADE
in O
a O
patient O
with O
an O
underlying O
vascular O
malformation O
. O

Renal B-ADE
damage I-ADE
associated O
with O
long O
term O
use O
of O
lithium B-DRUG
carbonate I-DRUG
. O

Atypical O
endometriosis O
may O
act O
as O
a O
precancerous O
lesion O
in O
the O
process O
of O
tamoxifen B-DRUG
- O
induced O
malignant B-ADE
transformation I-ADE
of I-ADE
endometriosis I-ADE
. O

Severe B-ADE
hepatotoxicity I-ADE
from O
phenobarbital B-DRUG
occurred O
in O
an O
infant O
boy O
who O
had O
a O
complicated O
illness O
with O
chronic O
bilateral O
subdural O
hematomas O
and O
sepsis O
. O

Visceral B-ADE
herpesvirus I-ADE
infections I-ADE
in O
leukemic O
patients O
receiving O
cytarabine B-DRUG
. O

Acute B-ADE
renal I-ADE
failure I-ADE
is O
a O
rare O
complication O
following O
the O
administration O
of O
intravenous O
immunoglobulin B-DRUG
( O
IVIG O
) O
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
multiple O
episodes O
of O
seizure B-ADE
activity O
in O
an O
AIDS O
patent O
following O
amphotericin B-DRUG
B I-DRUG
infusion O
. O

We O
present O
a O
case O
of O
acute O
epinephrine B-DRUG
toxicity O
resulting O
in O
acute B-ADE
myocardial I-ADE
ischemia I-ADE
in O
a O
young O
boy O
with O
combined O
variable O
immunodeficiency O
syndrome O
who O
developed O
severe B-ADE
allergic I-ADE
reaction I-ADE
to O
intravenous O
immunoglobulin O
, O
and O
was O
subsequently O
given O
epinephrine B-DRUG
by O
mistake O
intravenously O
rather O
than O
subcutaneously O
. O

A O
drug O
addict O
with O
staphylococcal O
endocarditis O
treated O
with O
methicillin B-DRUG
, O
who O
developed O
massive B-ADE
proteinuria I-ADE
and O
acute B-ADE
nephritic I-ADE
syndrome I-ADE
is O
described O
. O

This O
report O
describes O
a O
case O
of O
flucytosine B-DRUG
- O
associated O
ulcerating B-ADE
enteritis I-ADE
in O
which O
the O
small O
bowel O
x O
- O
ray O
demonstrated O
severe B-ADE
luminal I-ADE
narrowing I-ADE
, O
ulceration B-ADE
, O
and O
marked B-ADE
separation I-ADE
of I-ADE
loops I-ADE
of I-ADE
bowel I-ADE
. O

We O
report O
a O
case O
of O
Ritalin B-DRUG
- O
associated O
cataract B-ADE
and O
glaucoma B-ADE
. O

The O
main O
side O
- O
effects O
of O
Lp B-DRUG
- I-DRUG
TAE I-DRUG
combined O
with O
HT O
were O
low B-ADE
- I-ADE
grade I-ADE
fever I-ADE
, O
localized B-ADE
pain I-ADE
, O
myelo B-ADE
- I-ADE
suppression I-ADE
and O
liver B-ADE
dysfunction I-ADE
, O
but O
these O
were O
transient O
and O
eventually O
disappeared O
. O

CASE O
SUMMARY O
: O
A O
10-year O
- O
old O
white O
girl O
with O
bilateral O
optic O
glioma O
developed O
a O
hypersensitivity B-ADE
reaction O
to O
carboplatin B-DRUG
after O
nine O
courses O
. O

We O
report O
the O
case O
of O
a O
young O
healthy O
woman O
who O
presented O
an O
early O
overanticoagulation B-ADE
when O
receiving O
acenocoumarol B-DRUG
for O
a O
first O
thromboembolic O
episode O
. O

Mechanisms O
and O
triggering O
factors O
of O
hypoglycaemia B-ADE
induced O
by O
mefloquine B-DRUG
and O
some O
other O
anti O
- O
malarial O
quinine O
analogues O
are O
discussed O
. O

Nitrofurantoin B-DRUG
- O
induced O
pulmonary B-ADE
toxicity I-ADE
during O
pregnancy O
: O
a O
report O
of O
a O
case O
and O
review O
of O
the O
literature O
. O

Knowledge O
regarding O
potential O
adverse O
effects O
of O
CAP B-DRUG
is O
paramount O
and O
dose O
modification O
is O
indicated O
with O
development O
of O
neurotoxicity B-ADE
. O

The O
presence O
of O
a O
lymphocyte O
alveolitis O
with O
a O
predominance O
of O
CD4 O
+ O
T O
cells O
in O
3 O
RA O
patients O
and O
CD8 O
+ O
T O
cells O
with O
a O
concomitant O
increase O
in O
neutrophils O
in O
another O
case O
suggests O
that O
immunologically O
mediated O
reactions O
may O
be O
one O
damage O
mechanism O
in O
MTX B-DRUG
- O
induced O
pneumonitis B-ADE
. O

To O
the O
best O
of O
our O
knowledge O
, O
this O
is O
the O
first O
case O
of O
lithium B-DRUG
- O
associated O
CDI B-ADE
and O
NDI B-ADE
presenting O
concurrently O
. O

We O
report O
on O
three O
patients O
with O
acute O
schizophrenia O
, O
who O
developed O
severe B-ADE
akathisia I-ADE
during O
treatment O
with O
olanzapine B-DRUG
( O
20 O
- O
25 O
mg O
/ O
d O
) O
. O

PURPOSE O
: O
The O
occurrence O
of O
myoclonus B-ADE
associated O
with O
continuous O
i.v O
. O
infusion O
of O
dobutamine B-DRUG
in O
a O
patient O
with O
end O
- O
stage O
renal O
disease O
( O
ESRD O
) O
is O
described O
. O

It O
is O
concluded O
that O
simultaneous O
administration O
of O
ciprofloxacin B-DRUG
and O
tazobactam B-DRUG
/ O
piperacillin B-DRUG
may O
cause O
marked O
thrombocytosis B-ADE
. O

Bowel B-ADE
perforation I-ADE
associated O
with O
intraperitoneal O
chromic B-DRUG
phosphate I-DRUG
instillation O
. O

Skin B-ADE
manifestations I-ADE
of O
a O
case O
of O
phenylbutazone B-DRUG
- O
induced O
serum B-ADE
sickness I-ADE
- I-ADE
like I-ADE
reactions I-ADE
. O

Co B-DRUG
- I-DRUG
trimoxazole I-DRUG
red B-ADE
cell I-ADE
aplasia I-ADE
in O
leukaemia O
. O

Fulminant B-ADE
hepatic I-ADE
failure I-ADE
is O
a O
rare O
complication O
of O
disulfiram B-DRUG
treatment O
for O
alcoholism O
. O

We O
conclude O
that O
vincristine B-DRUG
and O
actinomycin B-DRUG
D I-DRUG
were O
the O
cause O
of O
this O
rare O
from O
of O
hepatotoxicity B-ADE
and O
that O
chemotherapy O
for O
the O
underlying O
malignant O
disease O
could O
be O
given O
safely O
after O
clinical O
recovery O
. O

Beginning O
ductopenia B-ADE
was O
present O
in O
two O
, O
suggesting O
that O
itraconazole B-DRUG
might O
be O
responsible O
for O
the O
occurrence O
of O
prolonged O
drug O
- O
induced O
cholangiopathy B-ADE
. O

Severe B-ADE
hemolytic I-ADE
uremic I-ADE
syndrome I-ADE
in O
an O
advanced O
ovarian O
cancer O
patient O
treated O
with O
carboplatin B-DRUG
and O
gemcitabine B-DRUG
. O

Here O
, O
we O
describe O
a O
case O
of O
Vogt B-ADE
- I-ADE
Koyanagi I-ADE
- I-ADE
Harada I-ADE
disease I-ADE
occurring O
4 O
months O
after O
the O
start O
of O
interferon B-DRUG
alpha I-DRUG
treatment O
, O
probably O
induced O
by O
the O
immunomodulatory O
effects O
of O
interferon B-DRUG
. O

Transient B-ADE
anuria I-ADE
following O
administration O
of O
angiotensin O
I O
- O
converting O
enzyme O
inhibitor O
( O
SQ B-DRUG
14225 I-DRUG
) O
in O
a O
patient O
with O
renal O
artery O
stenosis O
of O
the O
solitary O
kidney O
successfully O
treated O
with O
renal O
autotransplantation O
. O

Acute B-ADE
renal I-ADE
failure I-ADE
following O
intravenous O
immunoglobulin B-DRUG
therapy O
in O
a O
HIV O
- O
infected O
patient O
. O

Sporadic B-ADE
rippling I-ADE
muscle I-ADE
disease I-ADE
unmasked O
by O
simvastatin B-DRUG
. O

Flutamide B-ADE
withdrawal I-ADE
syndrome I-ADE
is O
characterized O
by O
a O
decrease B-ADE
in I-ADE
prostate I-ADE
- I-ADE
specific I-ADE
antigen I-ADE
( O
PSA O
) O
after O
flutamide B-DRUG
withdrawal O
in O
a O
subset O
of O
patients O
with O
progressing O
metastatic O
carcinoma O
of O
the O
prostate O
. O

The O
uncomplicated O
long O
- O
term O
use O
of O
adequately O
- O
dosed O
AZA B-DRUG
and O
stable O
non O
- O
toxic O
metabolite O
levels O
could O
not O
acknowledge O
TPMT O
deficiency O
as O
a O
primary O
cause O
of O
the O
leukopenia B-ADE
. O

However O
, O
a O
large O
case O
- O
control O
study O
included O
three O
cases O
of O
either O
Stevens B-ADE
- I-ADE
Johnson I-ADE
syndrome I-ADE
or O
toxic B-ADE
epidermal I-ADE
necrolysis I-ADE
associated O
with O
ofloxacin B-DRUG
use O
, O
but O
no O
details O
of O
the O
cases O
were O
given O
. O

Restless B-ADE
legs I-ADE
syndrome I-ADE
and O
periodic B-ADE
limb I-ADE
movements I-ADE
during I-ADE
sleep I-ADE
probably O
associated O
with O
olanzapine B-DRUG
. O

Acute B-ADE
interstitial I-ADE
nephritis I-ADE
due O
to O
pantoprazole B-DRUG
. O

Multiple B-ADE
syncopal I-ADE
episodes I-ADE
started O
to O
occur O
during O
thalidomide B-DRUG
treatment O
, O
and O
a O
Holter O
electrocardiogram O
showed O
multiple O
abnormalities O
, O
with O
an O
episode O
of O
sustained B-ADE
ventricular I-ADE
tachycardia I-ADE
. O

Hyperkalaemia B-ADE
with O
renal B-ADE
tubular I-ADE
dysfunction I-ADE
by O
oral O
therapy O
of O
sulfamethoxazole B-DRUG
- I-DRUG
trimethoprim I-DRUG
( O
co B-DRUG
- I-DRUG
trimoxazole I-DRUG
) O
is O
described O
in O
2 O
elderly O
Japanese O
patients O
with O
lymphoid O
malignancy O
, O
who O
developed O
Pneumocystis O
carinii O
pneumonia O
and O
improved O
. O

The O
present O
report O
describes O
the O
first O
case O
of O
acute B-ADE
pancreatitis I-ADE
associated O
with O
danazol B-DRUG
treatment O
of O
endometriosis O
. O

Hepatotoxicity B-ADE
related O
to O
itraconazole B-DRUG
: O
report O
of O
three O
cases O
. O

Clinicians O
should O
be O
aware O
of O
fasting B-ADE
hypoglycemia I-ADE
as O
an O
unusual O
but O
potentially O
serious O
complication O
of O
disopyramide B-DRUG
therapy O
. O

Reversible O
valproic B-DRUG
acid I-DRUG
- O
induced O
dementia B-ADE
: O
a O
case O
report O
. O

I O
saw O
two O
patients O
with O
kala O
- O
azar O
resistant O
to O
sodium O
stibogluconate O
who O
developed O
cardiac B-ADE
arrest I-ADE
after O
amphotericin B-DRUG
infusion O
( O
in O
spite O
of O
tolerating O
a O
test O
dose O
) O
. O

Recurrent B-ADE
hypotension I-ADE
immediately O
after O
seizures B-ADE
in O
nortriptyline B-DRUG
overdose O
. O

Septic B-ADE
knee I-ADE
arthritis I-ADE
after O
intra O
- O
articular O
hyaluronate B-DRUG
injection O
. O

Multiple B-ADE
sclerosis I-ADE
- I-ADE
like I-ADE
disease I-ADE
secondary O
to O
alpha B-DRUG
interferon I-DRUG
. O

All O
patients O
had O
taken O
phenytoin B-DRUG
for O
variable O
time O
periods O
( O
range O
16 O
- O
80 O
days O
; O
mean O
: O
40 O
) O
and O
were O
on O
the O
medication O
when O
the O
skin B-ADE
lesions I-ADE
first O
appeared O
. O

We O
report O
a O
case O
of O
long O
lasting O
respiratory B-ADE
depression I-ADE
after O
intravenous O
administration O
of O
morphine B-DRUG
to O
a O
7 O
year O
old O
girl O
with O
haemolytic O
uraemic O
syndrome O
. O

Cardiac B-ADE
arrest I-ADE
after O
esmolol B-DRUG
administration O
: O
a O
review O
of O
acute O
beta O
- O
blocker O
toxicity O
. O

Polyarthritis B-ADE
, O
hepatitis B-ADE
and O
anti B-ADE
- I-ADE
native I-ADE
DNA I-ADE
antibodies I-ADE
after O
treatment O
with O
ethambutol B-DRUG
and O
rifampicin B-DRUG
. O

OBJECTIVE O
: O
To O
report O
the O
finding O
of O
squamous B-ADE
metaplasia I-ADE
within I-ADE
endometrial I-ADE
glands I-ADE
occurring O
as O
a O
result O
of O
progestin B-DRUG
therapy O
of O
hyperplasia O
. O

Nephrogenic B-ADE
diabetes I-ADE
insipidus I-ADE
and O
renal B-ADE
tubular I-ADE
acidosis I-ADE
secondary O
to O
foscarnet B-DRUG
therapy O
. O

The O
nephrotic B-ADE
syndrome I-ADE
developed O
in O
a O
patient O
receiving O
therapy O
with O
gold B-DRUG
for O
rheumatoid O
arthritis O
. O

A O
75-year O
- O
old O
man O
developed O
bilateral B-ADE
lower I-ADE
leg I-ADE
edema I-ADE
6 O
months O
after O
switching O
from O
troglitazone O
to O
pioglitazone B-DRUG
. O

Early O
- O
onset O
pentamidine B-DRUG
- O
associated O
second B-ADE
- I-ADE
degree I-ADE
heart I-ADE
block I-ADE
and O
sinus B-ADE
bradycardia I-ADE
: O
case O
report O
and O
review O
of O
the O
literature O
. O

Nephropathy B-ADE
caused O
by O
methicillin B-DRUG
therapy O
for O
staphylococcal O
septicemia O
. O

The O
pro B-ADE
- I-ADE
arrhythmic I-ADE
effects I-ADE
of O
procainamide B-DRUG
may O
be O
explained O
on O
the O
basis O
of O
both O
its O
vagolytic O
action O
on O
the O
atrioventricular O
node O
as O
well O
as O
by O
prolongation O
of O
refractoriness O
in O
the O
accessory O
pathway O
. O

Incidence O
of O
seizures B-ADE
in O
pediatric O
cancer O
patients O
treated O
with O
imipenem B-DRUG
/ O
cilastatin B-DRUG
. O

Severe B-ADE
hypo I-ADE
- I-ADE
alpha I-ADE
- I-ADE
lipoproteinemia I-ADE
during O
treatment O
with O
rosiglitazone B-DRUG
. O

NCSE B-ADE
, O
an O
epileptic O
disorder O
in O
which O
typical O
convulsive O
activity O
is O
absent O
, O
has O
previously O
been O
reported O
in O
only O
4 O
patients O
receiving O
ifosfamide B-DRUG
. O

Fixed B-ADE
drug I-ADE
eruption I-ADE
to O
rofecoxib B-DRUG
. O

Emergence O
of O
Philadelphia B-ADE
positive I-ADE
chronic I-ADE
myeloid I-ADE
leukaemia I-ADE
during O
treatment O
with O
hydroxyurea B-DRUG
for O
Philadelphia O
negative O
essential O
thrombocythaemia O
. O

We O
report O
here O
a O
case O
of O
TEN B-ADE
after O
administration O
of O
ciprofloxacin B-DRUG
. O

The O
reported O
case O
represents O
an O
unusual O
association O
between O
medication O
with O
the O
proton O
pump O
inhibitor O
lansoprazole B-DRUG
and O
the O
development O
of O
collagenous B-ADE
colitis I-ADE
suggesting O
the O
importance O
of O
evaluation O
of O
drug O
use O
in O
patients O
with O
microscopic O
colitis O
. O

The O
patient O
experienced O
muscle B-ADE
twitches I-ADE
, O
tremulousness B-ADE
, O
and O
anxiety B-ADE
on O
day O
17 O
of O
foscarnet B-DRUG
therapy O
. O

Refractory B-ADE
hypoglycemia I-ADE
from O
ciprofloxacin B-DRUG
and O
glyburide B-DRUG
interaction O
. O

Further O
studies O
are O
necessary O
to O
evaluate O
whether O
the O
study O
of O
HLA O
antigens O
may O
be O
a O
very O
useful O
tool O
to O
detect O
the O
patients O
with O
a O
predisposition O
to O
develop O
autoimmune B-ADE
thyroiditis I-ADE
, O
in O
order O
to O
make O
a O
early O
diagnosis O
of O
thyroid B-ADE
disorders I-ADE
during O
the O
IFN B-DRUG
- I-DRUG
alpha I-DRUG
treatment O
. O

A O
young O
diamond O
dealer O
developed O
visual B-ADE
impairment I-ADE
attributed O
to O
bilateral B-ADE
posterior I-ADE
subcapsular I-ADE
cataracts I-ADE
following O
only O
four O
courses O
of O
intermittent O
Decadron B-DRUG
used O
as O
part O
of O
a O
five O
- O
drug O
antiemetic O
regimen O
for O
cisplatin B-DRUG
- O
associated O
nausea B-ADE
. O

Scrotal B-ADE
ulceration I-ADE
induced O
by O
all O
- O
trans O
retinoic B-DRUG
acid I-DRUG
in O
a O
patient O
with O
acute O
promyelocytic O
leukemia O
. O

We O
believe O
that O
these O
skin B-ADE
eruptions I-ADE
belong O
to O
a O
spectrum O
of O
neutrophilic B-ADE
dermatoses I-ADE
that O
can O
be O
induced O
or O
aggravated O
by O
G B-DRUG
- I-DRUG
CSF I-DRUG
therapy O
. O

A O
patient O
with O
an O
allergy O
to O
a O
macrolide O
antibiotic O
was O
given O
tacrolimus B-DRUG
and O
developed O
a O
sudden B-ADE
cutaneous I-ADE
reaction I-ADE
. O

He O
had O
an O
immediate O
hypersensitivity B-ADE
reaction I-ADE
during O
the O
initiation O
of O
the O
MTX B-DRUG
infusion O
with O
diffuse B-ADE
urticaria I-ADE
, O
facial B-ADE
swelling I-ADE
, O
cough B-ADE
, O
and O
chest B-ADE
tightness I-ADE
. O

The O
literature O
of O
vincristine B-DRUG
optic B-ADE
nerve I-ADE
toxicity I-ADE
is O
reviewed O
. O

Vitiligo B-ADE
associated O
with O
alpha B-DRUG
- I-DRUG
interferon I-DRUG
in O
a O
patient O
with O
chronic O
active O
hepatitis O
C O
. O

All B-DRUG
- I-DRUG
trans I-DRUG
retinoic I-DRUG
acid I-DRUG
- O
induced O
focal B-ADE
myositis I-ADE
, O
synovitis B-ADE
, O
and O
mononeuritis B-ADE
. O

Dapsone B-DRUG
- O
induced O
erythroderma B-ADE
with O
Beau O
's O
lines O
. O

Pancytopenia B-ADE
associated O
with O
5-aminosalicylic B-DRUG
acid I-DRUG
use O
in O
a O
patient O
with O
Crohn O
's O
disease O
. O

DISCUSSION O
: O
Anaphylactoid B-ADE
reactions I-ADE
have O
been O
described O
previously O
with O
cisplatin B-DRUG
administration O
. O

Delayed B-ADE
hypersensitivity I-ADE
to O
flurbiprofen B-DRUG
. O

A O
62-year O
- O
old O
Indian O
with O
diabetic O
nephropathy O
controlled O
with O
metformin B-DRUG
, O
developed O
miliary B-ADE
tuberculosis I-ADE
for O
which O
he O
was O
treated O
with O
rifampicin O
, O
isoniazid O
and O
ethambutol O
. O

CONCLUSION O
: O
We O
believe O
this O
to O
be O
the O
first O
reported O
case O
of O
rhGH B-DRUG
- O
induced O
hypercalcemia B-ADE
in O
an O
HIV O
- O
infected O
patient O
. O

Theoretical O
basal O
ganglia O
toxicologic O
mechanisms O
of O
methanol B-DRUG
poisoning I-ADE
are O
reviewed O
, O
and O
the O
role O
of O
brain O
imaging O
studies O
will O
regard O
to O
diagnosis O
, O
prognosis O
and O
impact O
on O
management O
is O
discussed O
. O

However O
, O
there O
are O
few O
reports O
in O
the O
literature O
of O
ampicillin B-DRUG
as O
a O
cause O
of O
acute B-ADE
interstitial I-ADE
nephritis I-ADE
. O

Subcutaneous O
IL-2 B-DRUG
is O
safe O
and O
well O
tolerated O
, O
with O
a O
mortality B-ADE
rate I-ADE
<3 I-ADE
% O
. O

An O
intertrigo B-ADE
- I-ADE
like I-ADE
eruption I-ADE
from O
pegylated O
liposomal O
doxorubicin B-DRUG
. O

However O
, O
in O
order O
to O
avoid O
neuropathic B-ADE
side I-ADE
effects I-ADE
, O
patients O
under O
thalidomide B-DRUG
therapy O
should O
be O
monitored O
every O
6 O
months O
with O
nerve O
conduction O
studies O
while O
taking O
the O
drug O
. O

The O
authors O
report O
the O
first O
case O
of O
bucillamine B-DRUG
- O
induced O
giant B-ADE
mammary I-ADE
hyperplasia I-ADE
. O

Among O
12 O
thyrotoxic O
patients O
, O
a O
patient O
with O
arrhythmogenic O
right O
ventricular O
dysplasia O
, O
who O
had O
been O
taking O
amiodarone B-DRUG
for O
4 O
years O
, O
developed O
thyrotoxicosis B-ADE
with O
subacute O
onset O
, O
accompanied O
by O
transiently B-ADE
positive I-ADE
thyrotropin I-ADE
( I-ADE
TSH I-ADE
) I-ADE
receptor I-ADE
antibody I-ADE
( O
TRAb O
) O
, O
or O
thyrotropin B-ADE
- I-ADE
binding I-ADE
inhibiting I-ADE
immunoglobulin I-ADE
( O
TBII O
) O
. O

IFNalpha B-DRUG
- O
induced O
recurrence O
of O
Graves B-ADE
' I-ADE
disease I-ADE
ten O
years O
after O
thyroidectomy O
in O
chronic O
viral O
hepatitis O
C O
. O

Acute B-ADE
myeloid I-ADE
leukemia I-ADE
evolving O
from O
essential O
thrombocythemia O
in O
two O
patients O
treated O
with O
hydroxyurea B-DRUG
. O

The O
cause O
of O
these O
previously O
unreported O
side O
effects O
of O
niacin B-DRUG
therapy O
is O
uncertain O
but O
may O
be O
related O
to O
prostaglandin B-ADE
- I-ADE
mediated I-ADE
vasodilatation I-ADE
, O
hyperalgesia B-ADE
of I-ADE
sensory I-ADE
nerve I-ADE
receptors I-ADE
, O
and O
potentiation B-ADE
of I-ADE
inflammation I-ADE
in I-ADE
the I-ADE
gingiva I-ADE
with O
referral O
of O
pain B-ADE
to I-ADE
the I-ADE
teeth I-ADE
. O

Two O
patients O
had O
ampicillin B-DRUG
- O
associated O
seizures B-ADE
. O

a O
67-year O
- O
old O
man O
with O
bipolar O
disorder O
developed O
a O
Creutzfeldt B-ADE
- I-ADE
Jakob I-ADE
like I-ADE
syndrome I-ADE
during O
lithium B-DRUG
carbonate I-DRUG
treatment O
. O

This O
is O
the O
first O
case O
of O
HBV B-ADE
reactivation I-ADE
occurring O
during O
the O
year O
following O
rituximab B-DRUG
monotherapy O
in O
the O
absence O
of O
any O
other O
immunosuppressive O
factor O
. O

Pheripheral B-ADE
edema I-ADE
was O
observed O
in O
five O
female O
patients O
after O
taking O
proton O
pump O
inhibitors O
omeprazole B-DRUG
, O
lansoprazole B-DRUG
, O
or O
pantoprazole B-DRUG
for O
7 O
- O
15 O
days O
for O
peptic O
acid O
diseases O
in O
recommended O
standard O
doses O
. O

CONCLUSIONS O
: O
Prolonged O
exposure O
to O
itraconazole B-DRUG
, O
administered O
either O
continuously O
or O
intermittently O
, O
may O
precipitate O
severe B-ADE
and I-ADE
irreversible I-ADE
hepatotoxic I-ADE
events I-ADE
. O

Recent O
reports O
have O
shown O
that O
Decadron O
( O
dexamethasone O
; O
Merck O
Sharp O
& O
Dohme O
, O
West O
Point O
, O
Pa O
) O
has O
a O
significant O
antiemetic O
effect O
on O
cisplatin B-DRUG
- O
induced O
vomiting B-ADE
. O

Angioimmunoblastic B-ADE
lymphadenopathy I-ADE
with I-ADE
dysproteinemia I-ADE
following O
doxycycline B-DRUG
administration O
. O

We O
describe O
a O
case O
of O
subcutaneous B-ADE
metastasis I-ADE
along O
the O
needle O
track O
after O
percutaneous O
ethanol B-DRUG
injection O
( O
PEI O
) O
for O
treatment O
of O
hepatocellular O
carcinoma O
. O

We O
reported O
a O
case O
of O
disulfiram B-DRUG
- O
induced O
hepatitis B-ADE
with O
unique O
clinical O
features O
and O
compared O
our O
case O
with O
others O
in O
the O
literature O
. O

We O
report O
a O
case O
of O
IDDM B-ADE
which O
occurred O
during O
interferon B-DRUG
therapy O
for O
chronic O
hepatitis O
. O

When O
pilsicainide B-DRUG
is O
prescribed O
in O
patients O
with O
coronary O
artery O
disease O
or O
renal O
dysfunction O
, O
close O
attention O
must O
be O
paid O
to O
avoid O
life B-ADE
- I-ADE
threatening I-ADE
arrhythmias I-ADE
due O
to O
high O
plasma O
concentrations O
of O
the O
drug O
. O

Severe O
autoimmune B-ADE
hemolytic I-ADE
anemia I-ADE
following O
rituximab B-DRUG
therapy O
in O
a O
patient O
with O
a O
lymphoproliferative O
disorder O
. O

Esophageal B-ADE
spasm I-ADE
following O
propranolol B-DRUG
overdose O
relieved O
by O
glucagon O
. O

Methadone B-DRUG
- O
induced O
myoclonus B-ADE
in O
advanced O
cancer O
. O

Central B-ADE
nervous I-ADE
system I-ADE
toxicity I-ADE
associated O
with O
meperidine B-DRUG
use O
in O
hepatic O
disease O
. O

This O
report O
describes O
an O
unexpected O
drug O
- O
induced O
hepatitis B-ADE
in O
a O
previously O
healthy O
young O
woman O
exposed O
to O
2 O
doses O
of O
amodiaquine B-DRUG
and O
artesunate B-DRUG
. O

We O
report O
a O
case O
of O
severe O
hypotension B-ADE
associated O
with O
intravenous O
valproate B-DRUG
used O
to O
treat O
status O
epilepticus O
in O
an O
11-year O
- O
old O
girl O
. O

There O
is O
no O
consensus O
on O
the O
treatment O
of O
ticlopidine B-DRUG
- O
induced O
marrow B-ADE
aplasia I-ADE
. O

A O
patient O
with O
Wegener O
's O
granulomatosis O
rapidly O
developed O
a O
circumferential B-ADE
subglottic I-ADE
stenosis I-ADE
while O
on O
a O
cyclophosphamide B-DRUG
regimen O
that O
had O
caused O
resolution O
of O
systemic O
symptoms O
and O
pulmonary O
infiltrates O
. O

We O
report O
a O
case O
of O
biopsy O
- O
proven O
acute B-ADE
tubulointerstitial I-ADE
nephritis I-ADE
associated O
with O
a O
second O
course O
of O
flurbiprofen B-DRUG
, O
a O
nonsteroidal O
anti O
- O
inflammatory O
drug O
of O
the O
propionic O
acid O
class O
. O

Drug O
- O
induced O
agranulocytosis B-ADE
during O
treatment O
with O
infliximab B-DRUG
in O
enteropathic O
spondyloarthropathy O
. O

Acute O
esmolol B-DRUG
toxicity I-ADE
may O
be O
self O
- O
limiting O
because O
of O
its O
extremely O
short O
half O
- O
life O
. O

We O
present O
a O
surprising O
case O
of O
a O
woman O
schizophrenic O
patient O
treated O
with O
clozapine B-DRUG
suffering O
from O
EPS B-ADE
. O

Enoxaparin B-DRUG
- O
induced O
generalized B-ADE
exanthem I-ADE
. O

The O
patient O
's O
defects O
may O
be O
due O
to O
methimazole B-DRUG
teratogenicity B-ADE
or O
could O
represent O
a O
previously O
undescribed O
syndrome O
affecting O
ectodermal O
structures O
. O

One O
other O
patient O
on O
digoxin B-DRUG
stopped O
taking O
it O
and O
developed O
cardiomyopathy B-ADE
. O

This O
paper O
reports O
on O
a O
6.9-year O
- O
old O
autistic O
male O
who O
developed O
repeated O
episodes O
of O
acute B-ADE
dystonic I-ADE
reactions I-ADE
associated O
with O
pimozide B-DRUG
administration O
at O
the O
doses O
of O
0.096 O
mg O
/ O
kg O
/ O
day O
and O
0.032 O
mg O
/ O
kg O
/ O
day O
and O
32 O
hours O
following O
pimozide B-DRUG
withdrawal O
, O
as O
well O
as O
during O
subsequent O
thioridazine B-DRUG
administration O
. O

This O
is O
the O
first O
description O
, O
to O
our O
knowledge O
, O
of O
ductopenia B-ADE
apparently O
caused O
by O
clindamycin B-DRUG
. O

Incomplete B-ADE
posterior I-ADE
hyaloid I-ADE
detachment I-ADE
after O
intravitreal O
pegaptanib B-DRUG
injection O
in O
diabetic O
macular O
edema O
. O

Hypotension B-ADE
and O
sinus B-ADE
arrest I-ADE
with O
nifedipine B-DRUG
in O
pulmonary O
hypertension O
. O

We O
suggest O
that O
nicotinic B-DRUG
acid I-DRUG
was O
the O
cause O
of O
his O
liver B-ADE
disease I-ADE
, O
that O
this O
case O
is O
of O
particular O
note O
because O
of O
the O
rather O
short O
period O
of O
therapy O
before O
the O
onset O
of O
liver O
injury O
and O
the O
severity O
of O
the O
hepatic O
failure O
, O
and O
that O
the O
probable O
increased O
use O
of O
nicotinic B-DRUG
acid I-DRUG
for O
serum O
cholesterol O
control O
makes O
it O
especially O
important O
for O
physicians O
and O
their O
patients O
to O
be O
alert O
to O
the O
signs O
of O
hepatotoxicity B-ADE
. O

In O
each O
of O
the O
three O
reported O
patients O
, O
alteration B-ADE
of I-ADE
eyelid I-ADE
appearance I-ADE
with O
deepening B-ADE
of I-ADE
the I-ADE
lid I-ADE
sulcus I-ADE
was O
evident O
as O
the O
result O
of O
topical O
bimatoprost B-DRUG
therapy O
. O

Severe B-ADE
corneal I-ADE
toxicity I-ADE
after O
topical O
fluoroquinolone B-DRUG
therapy O
: O
report O
of O
two O
cases O
. O

There O
was O
a O
clear O
relationship O
between O
restarting O
the O
Accutane B-DRUG
and O
recurrence O
of O
the O
transient B-ADE
myopia I-ADE
. O

Postoperatively O
, O
the O
first O
two O
patients O
treated O
with O
1 O
to O
2 O
cc O
of O
thrombin B-DRUG
were O
slow B-ADE
to I-ADE
awaken I-ADE
; O
one O
had O
evidence O
of O
vasospasm B-ADE
by O
transcranial O
Doppler O
ultrasound O
studies O
and O
multiple B-ADE
infarcts I-ADE
on O
cranial O
computerized O
tomography O
, O
while O
the O
other O
had O
a O
moderate O
- O
sized O
frontal O
hematoma O
with O
intracranial O
hypertension O
. O

The O
toxicity B-ADE
and O
plasma O
concentrations O
of O
ifosfamide B-DRUG
, O
chloroacetaldehyde B-DRUG
, O
and O
4-hydroxyifosfamide B-DRUG
were O
then O
determined O
over O
24 O
h O
after O
a O
single O
1.6 O
g O
/ O
m2 O
dose O
of O
ifosfamide B-DRUG
. O

Paradoxical B-ADE
cerebral I-ADE
cortical I-ADE
hyperexcitability I-ADE
following O
flupirtine B-DRUG
overdose O
. O

A O
22-year O
- O
old O
black O
man O
developed O
fever B-ADE
, O
chills B-ADE
, O
fatigue B-ADE
, O
night B-ADE
sweats I-ADE
, O
tender O
lymphadenopathy O
, O
and O
a O
generalized B-ADE
, I-ADE
pruritic I-ADE
, I-ADE
macular I-ADE
eruption I-ADE
3 O
weeks O
after O
starting O
minocycline B-DRUG
therapy O
for O
acne O
. O

It O
was O
concluded O
that O
potassium B-ADE
loss I-ADE
occurred O
by O
a O
non O
- O
renal O
( O
intestinal O
) O
route O
in O
phosphate B-DRUG
- O
induced O
hypokalemia B-ADE
. O

OBJECTIVE O
: O
To O
evaluate O
the O
efficacy O
of O
the O
administration O
of O
insulin O
by O
a O
jet O
- O
injector O
device O
in O
stopping O
and O
reversing O
severe O
human B-DRUG
insulin I-DRUG
- O
induced O
lipoatrophy B-ADE
. O

To O
our O
knowledge O
, O
this O
case O
is O
the O
first O
published O
report O
of O
levofloxacin B-DRUG
- O
induced O
TEN B-ADE
. O

Cutaneous B-ADE
sarcoidosis I-ADE
during O
interferon B-DRUG
alfa I-DRUG
and O
ribavirin B-DRUG
treatment O
of O
hepatitis O
C O
virus O
infection O
: O
two O
cases O
. O

To O
our O
knowledge O
, O
this O
is O
the O
first O
granulomatous B-ADE
reaction I-ADE
described O
after O
calcium B-DRUG
hydroxylapatite I-DRUG
injection O
. O

This O
report O
details O
the O
pulmonary O
pathologic O
findings O
in O
four O
patients O
with O
rheumatoid O
arthritis O
, O
who O
developed O
new O
onset O
of O
pulmonary B-ADE
signs I-ADE
and I-ADE
symptoms I-ADE
with I-ADE
alveolar I-ADE
infiltrates I-ADE
temporally O
related O
to O
the O
institution O
of O
etanercept B-DRUG
therapy O
. O

Adrenaline B-DRUG
dacryolith B-ADE
: O
detection O
by O
ultrasound O
examination O
of O
the O
nasolacrimal O
duct O
. O

Metformin B-DRUG
- O
associated O
lactic B-ADE
acidosis I-ADE
precipitated O
by O
diarrhea O
. O

Amoxapine B-DRUG
- O
induced O
cognitive B-ADE
impairment I-ADE
in O
two O
patients O
. O

AIM O
: O
To O
report O
three O
cases O
of O
extensive O
skin B-ADE
necrosis I-ADE
in O
cirrhotic O
patients O
treated O
with O
the O
vasoconstrictor O
agent O
terlipressin B-DRUG
( O
Glypressin B-DRUG
) O
. O

Excluding O
other O
causes O
, O
Pentasa B-DRUG
- O
associated O
pancytopenia B-ADE
was O
considered O
. O

Gestational B-ADE
diabetes I-ADE
was O
no O
less O
severe O
( O
degree O
of O
hyperglycaemia O
, O
need O
for O
insulin O
therapy O
) O
when O
associated O
with O
norethisterone B-DRUG
. O

Tumor B-ADE
- I-ADE
volume I-ADE
increase I-ADE
at O
beginning O
of O
primary O
treatment O
with O
topical O
interferon B-DRUG
alpha I-DRUG
2-beta I-DRUG
in O
a O
case O
of O
conjunctiva O
- O
cornea O
intraepithelial O
neoplasia O
. O

Gabapentin B-DRUG
toxicity O
in O
renal B-ADE
failure I-ADE
: O
the O
importance O
of O
dose O
adjustment O
. O

During O
clarithromycin B-DRUG
coadministration O
, O
four O
out O
of O
the O
seven O
patients O
developed O
moderate O
- O
to O
- O
severe O
toxic B-ADE
symptoms I-ADE
of O
carbamazepine B-DRUG
, O
such O
as O
drowsiness B-ADE
, O
dizziness B-ADE
, O
and O
ataxia B-ADE
, O
which O
resolved O
within O
5 O
days O
after O
clarithromycin B-DRUG
discontinuation O
. O

Uveitis B-ADE
during O
treatment O
of O
disseminated O
Mycobacterium O
avium O
- O
intracellulare O
complex O
infection O
with O
the O
combination O
of O
rifabutin B-DRUG
, O
clarithromycin B-DRUG
and O
ethambutol B-DRUG
. O

The O
authors O
intend O
to O
carry O
out O
a O
case O
- O
control O
study O
on O
patients O
treated O
with O
tamoxifen B-DRUG
for O
breast O
carcinoma O
to O
reveal O
the O
possible O
presence O
of O
endometrial B-ADE
carcinoma I-ADE
. O

Biomicroscopy O
revealed O
amiodarone B-DRUG
corneal B-ADE
deposits I-ADE
. O

We O
describe O
the O
clinical O
course O
of O
2 O
patients O
with O
Crohn O
's O
disease O
( O
CD O
) O
in O
whom O
lymphoma B-ADE
was O
diagnosed O
after O
treatment O
with O
infliximab B-DRUG
. O

Following O
several O
of O
these O
courses O
of O
therapy O
, O
respiratory B-ADE
distress I-ADE
occurred O
9 O
to O
12 O
days O
after O
the O
chlorambucil B-DRUG
was O
given O
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
chronic O
, O
nonproductive O
cough B-ADE
secondary O
to O
the O
angiotensin O
- O
converting O
enzyme O
( O
ACE O
) O
inhibitor O
quinapril B-DRUG
, O
with O
complete O
resolution O
after O
switching O
to O
another O
ACE O
inhibitor O
, O
fosinopril O
. O

Sodium B-DRUG
valproate I-DRUG
and O
carbamazepine B-DRUG
, O
antiepileptic O
drugs O
that O
are O
associated O
with O
a O
relatively O
low O
rate O
of O
adverse O
cutaneous O
reactions O
, O
should O
be O
added O
to O
the O
growing O
list O
of O
drugs O
that O
produce O
psoriasiform B-ADE
eruptions I-ADE
. O

CCBs O
should O
be O
considered O
in O
the O
treatment O
of O
5-FU B-DRUG
or O
capecitabine B-DRUG
- O
induced O
headaches B-ADE
. O

Prick O
tests O
and O
intradermal O
tests O
with O
a O
series O
of O
dilutions O
of O
carboplatin O
and O
cisplatin O
were O
performed O
on O
three O
patients O
who O
had O
exhibited O
medium O
and O
severe B-ADE
hypersensitivity I-ADE
reactions O
to O
carboplatin B-DRUG
. O

Fatal B-ADE
pulmonary I-ADE
fibrosis I-ADE
associated O
with O
BCNU B-DRUG
: O
the O
relative O
role O
of O
platelet O
- O
derived O
growth O
factor O
- O
B O
, O
insulin O
- O
like O
growth O
factor O
I O
, O
transforming O
growth O
factor O
- O
beta1 O
and O
cyclooxygenase-2 O
. O

She O
developed O
a O
severe B-ADE
urticarial I-ADE
rash I-ADE
3 O
weeks O
following O
initiation O
of O
therapy O
with O
Enoxaparin B-DRUG
. O

Tardive B-ADE
oculogyric I-ADE
crisis I-ADE
during O
treatment O
with O
clozapine B-DRUG
: O
report O
of O
three O
cases O
. O

Following O
7 O
days O
of O
tigecycline B-DRUG
she O
developed O
severe B-ADE
abdominal I-ADE
pain I-ADE
and O
elevated B-ADE
pancreatic I-ADE
enzymes I-ADE
suggesting O
acute B-ADE
pancreatitis I-ADE
. O

We O
present O
a O
case O
of O
ethylenediamine B-DRUG
- O
induced O
delayed B-ADE
hypersensitivity I-ADE
reaction I-ADE
in O
a O
46-year O
- O
old O
woman O
who O
received O
parenteral O
aminophylline B-DRUG
for O
an O
acute O
asthma O
exacerbation O
. O

Albendazole B-DRUG
- O
induced O
pseudomembranous B-ADE
colitis I-ADE
. O

Since O
its O
FDA O
approval O
in O
2002 O
, O
there O
are O
no O
known O
citations O
of O
ezetimibe B-DRUG
- O
induced O
pancreatitis B-ADE
. O

A O
brief O
review O
of O
reported O
cases O
of O
chloramphenicol B-DRUG
hypersensitivity B-ADE
in O
the O
English O
- O
language O
literature O
, O
as O
well O
as O
possible O
alternative O
explanations O
in O
this O
case O
, O
are O
provided O
. O

Three O
months O
after O
starting O
citalopram B-DRUG
, O
she O
experienced O
episodes O
of O
chest B-ADE
tightness I-ADE
and O
dizziness B-ADE
. O

First O
case O
of O
ivermectin B-DRUG
- O
induced O
severe B-ADE
hepatitis I-ADE
. O

Intravenous O
valproate B-DRUG
associated O
with O
significant O
hypotension B-ADE
in O
the O
treatment O
of O
status O
epilepticus O
. O

Interstitial B-ADE
pneumonia I-ADE
probably O
associated O
with O
sorafenib B-DRUG
treatment O
: O
An O
alert O
of O
an O
adverse O
event O
. O

The O
occurrence O
of O
neuromuscular B-ADE
blockade I-ADE
and O
the O
resulting O
potentiation B-ADE
of I-ADE
muscle I-ADE
relaxants I-ADE
during O
magnesium B-DRUG
sulfate I-DRUG
( O
MgSO4 B-DRUG
) O
administration O
is O
well O
known O
. O

Anterior B-ADE
spinal I-ADE
artery I-ADE
syndrome I-ADE
-- O
a O
complication O
of O
cervical O
intrathecal O
phenol B-DRUG
injection O
. O

Pericardial B-ADE
hemorrhage I-ADE
due O
to O
acetylsalicylic B-DRUG
acid I-DRUG
in O
a O
patient O
with O
essential O
thrombocythemia O
. O

Thirty O
patients O
with O
hepatic B-ADE
reactions I-ADE
to O
cyclofenil B-DRUG
, O
a O
non O
- O
steroidal O
drug O
with O
a O
stimulating O
effect O
on O
ovulation O
, O
are O
reviewed O
. O

Lichen B-ADE
planus I-ADE
induced O
by O
hepatitis B-DRUG
B I-DRUG
vaccination I-DRUG
: O
a O
new O
case O
and O
review O
of O
the O
literature O
. O

This O
entity O
is O
probably O
related O
to O
a O
combination O
of O
high O
doses O
of O
corticosteroids O
, O
vecuronium B-DRUG
administration O
and O
metabolic O
abnormalities O
associated O
with O
respiratory B-ADE
failure I-ADE
. O

A O
17-year O
- O
old O
boy O
with O
refractory O
psoriatic O
arthritis O
and O
alpha-1 O
antitrypsin O
deficiency O
who O
developed O
a O
syringotropic B-ADE
hypersensitivity I-ADE
reaction I-ADE
after O
9 O
months O
of O
therapy O
with O
infliximab B-DRUG
and O
leflunomide B-DRUG
is O
described O
. O

Three O
cases O
of O
acute B-ADE
renal I-ADE
toxicity I-ADE
in O
patients O
receiving O
long O
- O
term O
therapy O
with O
mitomycin B-DRUG
C I-DRUG
and O
5-fluorouracil B-DRUG
are O
reported O
. O

We O
report O
the O
development O
of O
scrotal B-ADE
ulcer I-ADE
in O
a O
patient O
with O
acute O
promyleocytic O
leukemia O
( O
APL O
) O
within O
10 O
days O
of O
treatment O
with O
ATRA B-DRUG
at O
a O
dose O
of O
40 O
mg O
orally O
twice O
daily O
. O

We O
describe O
two O
patients O
in O
whom O
painful B-ADE
erosions I-ADE
of I-ADE
their I-ADE
psoriasis I-ADE
developed O
as O
the O
presenting O
sign O
of O
methotrexate B-DRUG
toxicity I-ADE
and O
review O
the O
literature O
, O
emphasizing O
the O
risk O
factors O
associated O
with O
this O
manifestation O
. O

Ramipril B-DRUG
- O
induced O
cutaneous B-ADE
vasculitis I-ADE
is O
particularly O
rare O
and O
our O
case O
was O
atypical O
because O
the O
patient O
had O
tolerated O
lisinopril O
before O
. O

Only O
two O
case O
reports O
of O
adults O
with O
allergic O
contact O
dermatitis O
to O
this O
chemical O
exist O
in O
the O
literature O
, O
and O
we O
describe O
three O
more O
cases O
of O
children O
with O
recalcitrant O
atopic O
dermatitis O
found O
to O
have O
potential O
allergic B-ADE
contact I-ADE
dermatitis I-ADE
to O
bisabolol B-DRUG
- O
a O
component O
of O
the O
Aquaphor O
emollient O
they O
were O
using O
to O
treat O
their O
atopic O
dermatitis O
. O

This O
report O
presents O
a O
case O
of O
colon B-ADE
perforation I-ADE
which O
occurred O
4 O
months O
after O
treatment O
with O
intraperitoneal O
chromic B-DRUG
phosphate I-DRUG
for O
stage O
IB O
ovarian O
papillary O
serous O
cystadenocarcinoma O
. O

He O
developed O
a O
late O
secondary B-ADE
infection I-ADE
in O
some O
sites O
treated O
with O
imiquimod B-DRUG
. O

Thrombo B-ADE
- I-ADE
embolic I-ADE
complication I-ADE
after O
streptokinase B-DRUG
therapy O
of O
pulmonary O
emboli O
. O

We O
believe O
that O
this O
represents O
an O
unusual O
case O
of O
moderate O
- O
dose O
MTX B-DRUG
- O
induced O
neurotoxicity B-ADE
in O
a O
patient O
with O
gastric O
cancer O
, O
which O
has O
not O
previously O
been O
reported O
. O

Detection O
of O
activated O
eosinophils O
in O
nasal O
polyps O
of O
an O
aspirin B-DRUG
- O
induced O
asthma B-ADE
patient O
. O

We O
have O
described O
three O
patients O
with O
hepatitis O
C O
for O
whom O
IFN B-DRUG
- I-DRUG
alpha I-DRUG
and O
ribavirin B-DRUG
were O
prescribed O
and O
who O
developed O
two O
successive O
phases O
of O
silent O
thyroiditis B-ADE
followed O
by O
hyperthryroidism B-ADE
relapse O
due O
to O
Graves O
' O
disease O
. O

Phenytoin O
was O
discontinued O
after O
admission O
; O
however O
, O
phenytoin B-DRUG
1 O
g O
i.v O
. O
was O
given O
for O
a O
tonic O
- O
clonic O
seizure O
two O
days O
after O
admission O
, O
after O
which O
swelling B-ADE
of I-ADE
the I-ADE
face I-ADE
and I-ADE
legs I-ADE
and O
pruritus B-ADE
developed O
. O

Toxic B-ADE
epidermal I-ADE
necrolysis I-ADE
resulted O
after O
19 O
days O
of O
treatment O
with O
5-fluorocytosine B-DRUG
and O
amphotericin B-DRUG
B I-DRUG
. O

Development O
of O
persistent B-ADE
late I-ADE
onset I-ADE
asthma I-ADE
following O
treatment O
with O
captopril B-DRUG
. O

In O
this O
paper O
, O
we O
report O
a O
case O
of O
3 O
years O
- O
old O
boy O
who O
developed O
acute B-ADE
onset I-ADE
tetraparesia I-ADE
following O
a O
viral O
respiratory O
infecction O
and O
hepatitis B-DRUG
B I-DRUG
vaccination I-DRUG
. O

We O
report O
a O
patient O
with O
pulmonary O
adenocarcinoma O
complicated O
by O
the O
syndrome B-ADE
of I-ADE
inappropriate I-ADE
secretion I-ADE
of I-ADE
antidiuretic I-ADE
hormone I-ADE
( O
SIADH B-ADE
) O
following O
systemic O
chemotherapy O
with O
cisplatin B-DRUG
( O
CDDP B-DRUG
) O
and O
vindesine B-DRUG
( O
VDS B-DRUG
) O
. O

Therefore O
, O
clinicians O
should O
pay O
close O
attention O
to O
possible O
onset O
of O
RD B-ADE
in O
patients O
with O
multiple O
risk O
factors O
for O
TD O
, O
even O
when O
SDA B-DRUG
therapy O
is O
used O
. O

We O
describe O
a O
case O
of O
life O
- O
threatening O
hyponatremia B-ADE
associated O
with O
sibutramine B-DRUG
use O
in O
an O
obese O
woman O
. O

It O
is O
concluded O
that O
' O
cerebral B-ADE
atrophy I-ADE
' O
on O
CT O
scans O
may O
represent O
an O
accumulative O
effect O
of O
ACTH B-DRUG
and O
that O
ACTH O
should O
be O
given O
with O
the O
utmost O
discretion O
, O
and O
in O
as O
low O
a O
dose O
as O
possible O
. O

We O
describe O
a O
patient O
who O
, O
after O
receiving O
his O
first O
dose O
of O
pregabalin B-DRUG
to O
relieve O
neuropathic O
pain O
, O
presented O
with O
a O
negative B-ADE
myoclonus I-ADE
. O

Ovarian B-ADE
endometrioid I-ADE
carcinoma I-ADE
and O
endometriosis B-ADE
developing O
in O
a O
postmenopausal O
breast O
cancer O
patient O
during O
tamoxifen B-DRUG
therapy O
: O
a O
case O
report O
and O
review O
of O
the O
literature O
. O

We O
describe O
a O
patient O
who O
developed O
HUS B-ADE
after O
treatment O
with O
mitomycin B-DRUG
C I-DRUG
( O
total O
dose O
144 O
mg O
/ O
m2 O
) O
due O
to O
a O
carcinoma O
of O
the O
ascending O
colon O
. O

We O
describe O
a O
patient O
who O
had O
a O
systemic B-ADE
allergic I-ADE
contact I-ADE
dermatitis I-ADE
to O
8-MOP B-DRUG
develop O
during O
her O
second O
course O
of O
PUVA O
treatment O
for O
psoriasis O
. O

Dipyrone B-DRUG
, O
also O
known O
as O
metamizole B-DRUG
, O
is O
an O
analgesic O
and O
antipyretic O
drug O
that O
was O
banned O
by O
the O
United O
States O
Food O
and O
Drug O
Administration O
because O
of O
its O
association O
with O
agranulocytosis B-ADE
. O

Torsade B-ADE
de I-ADE
pointes I-ADE
during O
loading O
with O
amiodarone B-DRUG
. O

Liver O
transplantation O
for O
fulminant B-ADE
hepatitis I-ADE
related O
to O
nevirapine B-DRUG
therapy O
. O

In O
two O
of O
these O
cases O
akathisia B-ADE
resolved O
after O
withdrawal O
of O
olanzapine B-DRUG
and O
substitution O
by O
a O
classical O
or O
an O
atypical O
neuroleptic O
agent O
, O
respectively O
. O

In O
patients O
with O
swallowing B-ADE
dysfunction I-ADE
and O
pneumonia B-ADE
, O
a O
history O
of O
mineral B-DRUG
oil I-DRUG
use O
should O
be O
obtained O
and O
a O
diagnosis O
of O
ELP B-ADE
should O
be O
considered O
in O
the O
differential O
diagnoses O
if O
mineral B-DRUG
oil I-DRUG
use O
has O
occurred O
. O

PURPOSE O
: O
To O
report O
a O
case O
of O
nodular B-ADE
scleritis I-ADE
following O
alendronate B-DRUG
sodium I-DRUG
. O

Pulmonary B-ADE
eosinophilia I-ADE
or O
granulomas B-ADE
, O
classically O
seen O
in O
previously O
reported O
cases O
of O
methotrexate B-DRUG
pneumonitis B-ADE
, O
were O
not O
observed O
. O

Tiagabine B-DRUG
overdose O
causes O
an O
unusual B-ADE
array I-ADE
of I-ADE
neurological I-ADE
symptoms I-ADE
, O
many O
similar O
to O
reported O
adverse O
effects O
during O
therapeutic O
use O
. O

However O
, O
as O
the O
use O
of O
hepatitis B-DRUG
B I-DRUG
vaccination I-DRUG
is O
growing O
, O
adverse O
side O
effects O
, O
including O
mental B-ADE
nerve I-ADE
neuropathy I-ADE
, O
should O
be O
observed O
with O
an O
increased O
frequency O
. O

Toxic B-ADE
hepatitis I-ADE
due O
to O
combination O
therapy O
with O
methotrexate B-DRUG
and O
etretinate B-DRUG
in O
psoriasis O
. O

CONCLUSION O
: O
Significant O
ocular B-ADE
complications I-ADE
such O
as O
an O
irreversible B-ADE
decrease I-ADE
of I-ADE
visual I-ADE
acuity I-ADE
may O
develop O
in O
patients O
treated O
with O
pegylated B-DRUG
interferon I-DRUG
. O

Although O
the O
movement B-ADE
disorder I-ADE
could O
not O
with O
certainty O
be O
attributed O
to O
trazodone B-DRUG
alone O
, O
the O
drug O
at O
least O
acted O
as O
an O
eliciting O
agent O
. O

Severe O
steroid B-DRUG
- O
induced O
glaucoma B-ADE
following O
intravitreal O
injection O
of O
triamcinolone B-DRUG
acetonide I-DRUG
. O

Acute B-ADE
sensorineural I-ADE
hearing I-ADE
loss I-ADE
following O
intravenous O
ketoralac B-DRUG
administration O
. O

Catatonia B-ADE
associated O
with O
disulfiram B-DRUG
therapy O
. O

Nine O
eyes O
from O
6 O
patients O
, O
74 O
years O
to O
90 O
years O
of O
age O
, O
referred O
by O
ophthalmologists O
for O
repair O
of O
cicatricial B-ADE
entropion I-ADE
after O
at O
least O
2 O
years O
of O
twice O
- O
a O
- O
day O
application O
of O
dipivefrin B-DRUG
. O

Contact B-ADE
dermatitis I-ADE
due O
to O
budesonide B-DRUG
: O
report O
of O
five O
cases O
and O
review O
of O
the O
Japanese O
literature O
. O

Risperidone B-DRUG
- O
induced O
psychosis B-ADE
and O
depression B-ADE
in O
a O
child O
with O
a O
mitochondrial O
disorder O
. O

Children O
with O
acute O
lymphoblastic O
leukemia O
( O
ALL O
) O
, O
treated O
with O
L B-DRUG
- I-DRUG
asparaginase I-DRUG
are O
at O
risk O
for O
cerebral B-ADE
thrombosis I-ADE
or O
hemorrhage B-ADE
because O
of O
coagulation B-ADE
protein I-ADE
deficiencies I-ADE
. O

We O
report O
the O
case O
of O
a O
patient O
with O
chronic O
lymphocytic O
leukemia O
( O
CLL O
) O
who O
developed O
fatal B-ADE
intravascular I-ADE
autoimmune I-ADE
hemolytic I-ADE
anemia I-ADE
( O
AIHA B-ADE
) O
after O
fludarabine B-DRUG
treatment O
. O

Succinylcholine B-DRUG
- O
induced O
hyperkalemia B-ADE
in O
a O
patient O
with O
mucositis O
secondary O
to O
chemotherapy O
. O

The O
former O
patient O
had O
complained O
once O
that O
his O
visual B-ADE
acuity I-ADE
had I-ADE
decreased I-ADE
after O
the O
termination O
of O
IFN B-DRUG
therapy O
, O
and O
the O
latter O
patient O
complained O
twice O
during O
IFN B-DRUG
therapy O
that O
his O
visual B-ADE
acuity I-ADE
had I-ADE
decreased I-ADE
. O

Severe O
abdominal B-ADE
pain I-ADE
in O
low O
dosage O
clofazimine B-DRUG
. O

We O
describe O
two O
ELBW O
infants O
affected O
by O
hyperkalaemia O
, O
treated O
with O
Kayexalate B-DRUG
, O
who O
developed O
serious O
hypernatraemia B-ADE
, O
that O
has O
never O
been O
reported O
before O
in O
preterm O
infants O
. O

A O
short O
review O
on O
imatinib B-DRUG
- O
related O
hepatotoxicity B-ADE
is O
also O
presented O
. O

Potential O
mechanisms O
involved O
in O
the O
occurrence O
of O
ischemic B-ADE
colitis I-ADE
in O
patients O
receiving O
tegaserod B-DRUG
are O
also O
discussed O
. O

DISCUSSION O
: O
Central B-ADE
nervous I-ADE
system I-ADE
( I-ADE
CNS I-ADE
) I-ADE
toxicity I-ADE
has O
been O
described O
with O
ifosfamide B-DRUG
, O
with O
most O
cases O
reported O
in O
the O
pediatric O
population O
. O

We O
suggest O
that O
itraconazole B-DRUG
should O
be O
added O
to O
the O
list O
of O
drugs O
that O
may O
be O
responsible O
for O
a O
drug O
- O
induced O
vanishing B-ADE
bile I-ADE
duct I-ADE
syndrome I-ADE
. O

Stevens B-ADE
- I-ADE
Johnson I-ADE
syndrome I-ADE
in O
a O
boy O
with O
nephrotic O
syndrome O
during O
prednisolone B-DRUG
therapy O
. O

OBJECTIVE O
: O
To O
document O
a O
case O
of O
serotonin B-ADE
syndrome I-ADE
( O
SS B-ADE
) O
associated O
with O
mirtazapine B-DRUG
monotherapy O
, O
review O
the O
previously O
reported O
cases O
of O
SS O
associated O
with O
this O
tetracyclic O
antidepressant O
, O
and O
discuss O
the O
possible O
pathogenic O
mechanisms O
leading O
to O
this O
serious O
adverse O
drug O
reaction O
. O

AIM O
: O
Report O
of O
a O
case O
of O
a O
woman O
patient O
who O
developed O
celiac B-ADE
disease I-ADE
after O
pegylated B-DRUG
interferon I-DRUG
alpha-2a I-DRUG
and O
ribavirin B-DRUG
use O
for O
chronic O
hepatitis O
C O
. O

CONCLUSION O
: O
To O
the O
best O
of O
our O
knowledge O
, O
this O
is O
the O
first O
time O
colchicine B-DRUG
intoxication I-ADE
in O
this O
age O
group O
has O
been O
described O
in O
the O
English O
literature O
. O

Methotrexate B-DRUG
- O
associated O
nephropathy B-ADE
is O
a O
rare O
complication O
in O
pediatric O
oncology O
, O
and O
a O
review O
of O
the O
literature O
suggests O
that O
exposure O
to O
nephrotoxic O
agents O
may O
be O
a O
significant O
but O
perhaps O
underrecognized O
risk O
factor O
for O
its O
development O
. O

CASE O
SUMMARY O
: O
A O
39-year O
- O
old O
white O
Jewish O
schizophrenic O
man O
treated O
with O
olanzapine B-DRUG
developed O
an O
elevated B-ADE
serum I-ADE
CK I-ADE
concentration I-ADE
with O
a O
peak O
concentration O
of O
4000 O
IU O
/ O
L O
( O
normal O
< O
230 O
) O
. O

A O
60-year O
- O
old O
white O
man O
with O
chronic O
bronchitis O
was O
noted O
to O
develop O
acute B-ADE
respiratory I-ADE
failure I-ADE
and O
metabolic B-ADE
acidosis I-ADE
four O
days O
after O
being O
started O
on O
methazolamide B-DRUG
( O
Neptazane B-DRUG
) O
for O
an O
ophthalmologic O
problem O
. O

A O
mentally O
retarded O
23-year O
- O
old O
woman O
with O
myoclonic O
astatic O
epilepsy O
developed O
an O
abnormal B-ADE
posture I-ADE
of I-ADE
extreme I-ADE
forward I-ADE
flexion I-ADE
, O
called O
camptocormia B-ADE
, O
during O
valproate B-DRUG
monotherapy O
. O

Interaction B-ADE
between O
tacrolimus B-DRUG
and O
nefazodone B-DRUG
in O
a O
stable O
renal O
transplant O
recipient O
. O

A O
variety O
of O
movement B-ADE
disorders I-ADE
are O
known O
to O
occur O
in O
association O
with O
carbamazepine B-DRUG
( O
CBZ B-DRUG
) O
therapy O
in O
adults O
and O
children O
, O
but O
development O
of O
tics B-ADE
has O
been O
described O
infrequently O
and O
only O
in O
patients O
with O
underlying O
Tourette O
's O
syndrome O
or O
other O
movement O
disorders O
. O

Acyclovir B-DRUG
- O
induced O
neurotoxicity B-ADE
: O
concentration O
- O
side O
effect O
relationship O
in O
acyclovir O
overdose O
. O

We O
report O
on O
a O
young O
adolescent O
with O
benign B-ADE
intracranial I-ADE
hypertension I-ADE
which O
we O
attribute O
to O
the O
use O
of O
minocycline B-DRUG
for O
acne O
. O

Ischaemic B-ADE
colitis I-ADE
in O
a O
patient O
taking O
meloxicam B-DRUG
. O

This O
case O
demonstrates O
an O
occupational O
activity O
( O
construction O
) O
that O
has O
now O
become O
the O
dominant O
source O
of O
lead O
exposure O
for O
U.S. O
adults O
, O
the O
importance O
of O
a O
good O
occupational O
history O
to O
suspecting O
and O
making O
a O
diagnosis O
, O
the O
possible O
outcomes O
of O
chronic O
lead B-DRUG
toxicity I-ADE
, O
and O
the O
importance O
of O
preventing O
further O
exposure O
and O
using O
proper O
methods O
to O
treat O
acute O
toxicity O
. O

Increased B-ADE
lash I-ADE
length I-ADE
, O
thickness O
, O
and O
pigmentation B-ADE
are O
well O
- O
documented O
side O
effects O
of O
prostaglandin B-DRUG
analog O
glaucoma O
drops O
. O

We O
describe O
a O
relatively O
healthy O
, O
9-year O
- O
old O
boy O
who O
developed O
a O
CA O
- O
MRSA O
skin O
and O
soft B-ADE
tissue I-ADE
infection I-ADE
and O
was O
treated O
with O
TMP B-DRUG
- I-DRUG
SMX I-DRUG
. O

Initial O
treatment O
with O
heparin B-DRUG
was O
substituted O
with O
thrombolysis O
, O
which O
resulted O
in O
clinical O
improvement O
and O
dissolution O
of O
right O
heart O
thrombus O
but O
was O
followed O
by O
fatal B-ADE
intracerebral I-ADE
haemorrhage I-ADE
. O

In O
this O
paper O
, O
we O
report O
a O
case O
of O
severe B-ADE
hypercalcemia I-ADE
of O
immobilization O
in O
a O
40-year O
- O
old O
hemodialyzed O
woman O
treated O
by O
cinacalcet B-DRUG
HCl I-DRUG
for O
a O
severe O
HPTH O
- O
II O
( O
PTH>1,000 O
pg O
/ O
mL O
) O
. O

METHODS O
: O
A O
76-year O
- O
old O
woman O
with O
primary O
open O
- O
angle O
glaucoma O
and O
no O
history O
of O
ocular O
surgery O
developed O
a O
choroidal B-ADE
detachment I-ADE
12 O
hours O
after O
initiation O
of O
therapy O
with O
dorzolamide B-DRUG
eye O
drops O
. O

CD4 B-ADE
T I-ADE
- I-ADE
lymphocyte I-ADE
depletion I-ADE
, O
myelosuppression B-ADE
, O
and O
subsequent O
severe B-ADE
infections I-ADE
are O
the O
major O
side O
effects O
of O
fludarabine B-DRUG
phosphate I-DRUG
therapy O
. O

We O
describe O
a O
case O
of O
advanced O
ovarian O
carcinoma O
who O
developed O
difficulty B-ADE
walking I-ADE
because O
of O
marked B-ADE
pain I-ADE
in O
the O
lower O
extremities O
and O
loss B-ADE
of I-ADE
proprioception I-ADE
25 O
days O
after O
treatment O
with O
weekly O
taxol B-DRUG
( O
80 O
mg O
/ O
m(2)x3 O
) O
. O

A O
14-year O
- O
old O
girl O
with O
newly O
diagnosed O
SLE O
developed O
a O
pruritic B-ADE
bullous I-ADE
eruption I-ADE
while O
on O
prednisone B-DRUG
. O

Although O
combinations O
of O
belladonna B-DRUG
, O
ergotamine B-DRUG
, O
and O
phenobarbital B-DRUG
have O
been O
used O
for O
medical O
treatment O
of O
menopausal O
symptoms O
since O
the O
1960s O
, O
this O
is O
the O
first O
known O
case O
report O
of O
its O
association O
with O
anticonvulsant B-ADE
hypersensitivity I-ADE
syndrome I-ADE
. O

A O
case O
of O
severe B-ADE
aplastic I-ADE
anemia I-ADE
secondary O
to O
treatment O
with O
lenalidomide B-DRUG
for O
multiple O
myeloma O
. O

CONCLUSION O
: O
Alendronate B-DRUG
led O
to O
nodular B-ADE
scleritis I-ADE
and O
rechallenge O
caused O
recurrence O
of O
scleritis B-ADE
. O

CONCLUSION O
: O
Tamoxifen B-DRUG
may O
cause O
malignant B-ADE
transformation I-ADE
of I-ADE
endometriosis I-ADE
through O
atypical O
endometriosis O
even O
in O
the O
postmenopausal O
state O
. O

Nine O
delirious B-ADE
patients O
suffering O
from O
lithium B-DRUG
intoxication O
were O
examined O
with O
the O
Mini O
- O
Mental O
State O
Exam O
( O
MMS O
) O
to O
describe O
the O
clinical O
course O
of O
the O
disorder O
. O

We O
have O
reported O
six O
cases O
of O
metoclopramide B-DRUG
- O
induced O
parkinsonism B-ADE
seen O
in O
consultation O
over O
a O
two O
- O
year O
period O
. O

METHOD O
: O
We O
describe O
two O
patients O
who O
presented O
with O
diabetic B-ADE
ketoacidosis I-ADE
after O
treatment O
with O
quetiapine B-DRUG
and O
risperidone B-DRUG
, O
respectively O
. O

Severe B-ADE
apnea I-ADE
in O
an O
infant O
exposed O
to O
lamotrigine B-DRUG
in O
breast O
milk O
. O

Propylthiouracil B-DRUG
- O
induced O
cutaneous B-ADE
vasculitis I-ADE
. O

We O
describe O
two O
cases O
of O
PSVT O
that O
changed O
to O
non B-ADE
- I-ADE
sustained I-ADE
polymorphic I-ADE
ventricular I-ADE
tachycardia I-ADE
after O
administration O
of O
verapamil B-DRUG
. O

Halothane B-DRUG
hepatitis B-ADE
and O
prompt O
resolution O
with O
methionine O
therapy O
: O
case O
report O
. O

We O
report O
here O
two O
cases O
of O
dyserythropoietic B-ADE
anaemia I-ADE
associated O
with O
long O
- O
term O
linezolid B-DRUG
use O
that O
share O
striking O
similarities O
to O
chloramphenicol B-DRUG
- O
associated O
myelotoxicity B-ADE
. O

Diabetes B-ADE
Mellitus I-ADE
was O
observed O
in O
a O
patient O
given O
carbamazepine B-DRUG
. O

CASE O
SUMMARY O
: O
We O
report O
the O
case O
of O
a O
31-year O
- O
old O
patient O
hospitalized O
due O
to O
behavioral O
alterations O
and O
treated O
with O
oral O
zuclopenthixol B-DRUG
, O
an O
antipsychotic O
from O
the O
thioxanthene O
family O
, O
who O
developed O
an O
acute O
, O
painful B-ADE
erection I-ADE
. O

Administration O
of O
pyridoxine B-DRUG
to O
an O
infant O
after O
a O
long O
period O
of O
convulsions O
was O
followed O
by O
acute B-ADE
hypotonia I-ADE
. O

We O
are O
concerned O
that O
the O
macular B-ADE
lesion I-ADE
was O
a O
retinal O
toxic O
effect O
of O
gentamicin B-DRUG
because O
of O
the O
recent O
description O
of O
similar O
lesions O
occurring O
after O
the O
inadvertent O
intraocular O
injection O
of O
massive O
doses O
of O
this O
drug O
. O

These O
findings O
suggest O
that O
bicytopenia B-ADE
in O
this O
patient O
was O
caused O
by O
D B-DRUG
- I-DRUG
Pen I-DRUG
and O
may O
be O
due O
to O
different O
sensitivities O
in O
the O
hematopoietic O
lineage O
. O

To O
the O
best O
of O
our O
knowledge O
, O
corneoscleral B-ADE
melting I-ADE
in O
the O
first O
postoperative O
week O
after O
a O
single O
intraoperative O
application O
of O
mitomycin B-DRUG
C I-DRUG
has O
not O
been O
reported O
. O

Allergic B-ADE
contact I-ADE
angioedema I-ADE
to O
benzoyl B-DRUG
peroxide I-DRUG
. O

Morphea B-ADE
after O
bromocriptine B-DRUG
therapy O
. O

Gastric B-ADE
tumor I-ADE
, O
endometrial B-ADE
carcinoma I-ADE
and O
cervical B-ADE
adenocarcinoma I-ADE
in O
situ O
were O
detected O
after O
treatment O
with O
tamoxifen B-DRUG
for O
breast O
cancer O
. O

We O
recommend O
that O
a O
TMA O
in O
association O
with O
quinine O
be O
consistently O
referred O
to O
as O
quinine B-DRUG
- O
associated O
thrombotic B-ADE
microangiopathy I-ADE
( O
quinine O
- O
TMA O
) O
to O
better O
distinguish O
this O
entity O
from O
idiopathic O
TTP O
. O

A O
patient O
with O
psoriasis O
is O
described O
who O
had O
an O
abnormal O
response O
to O
the O
glucose O
tolerance O
test O
without O
other O
evidence O
of O
diabetes O
and O
then O
developed O
postprandial B-ADE
hyperglycemia I-ADE
and O
glycosuria B-ADE
during O
a O
period O
of O
topical O
administration O
of O
a O
corticosteroid O
cream O
, O
halcinonide B-DRUG
cream O
0.1 O
% O
, O
under O
occlusion O
. O

The O
elicitation O
of O
a O
movement B-ADE
disorder I-ADE
by O
trazodone B-DRUG
: O
case O
report O
. O

In O
four O
patients O
, O
spasm B-ADE
occurred O
spontaneous O
and O
in O
one O
patient O
after O
0.05 O
mg O
of O
ergonovine B-DRUG
. O

There O
is O
a O
dose O
- O
effect O
relationship O
between O
doxorubicin B-DRUG
and O
the O
incidence O
of O
symptomatic B-ADE
cardiac I-ADE
failure I-ADE
. O

Primary B-ADE
central I-ADE
nervous I-ADE
system I-ADE
lymphoma I-ADE
in O
a O
patient O
treated O
with O
natalizumab B-DRUG
. O

Probable O
propafenone B-DRUG
- O
induced O
transient B-ADE
global I-ADE
amnesia I-ADE
. O

Acute B-ADE
myelogenous I-ADE
leukemia I-ADE
in O
patients O
receiving O
chlorambucil B-DRUG
as O
long O
- O
term O
adjuvant O
chemotherapy O
for O
stage O
II O
breast O
cancer O
. O

Intravenous O
sodium O
bicarbonate O
appears O
to O
be O
indicated O
prophylactically O
in O
combating O
the O
associated O
metabolic B-ADE
acidosis I-ADE
due O
to O
absorbed O
formic B-DRUG
acid I-DRUG
. O

We O
describe O
a O
detailed O
case O
of O
fulminant B-ADE
hepatitis I-ADE
induced O
by O
nevirapine B-DRUG
( O
Viramune B-DRUG
) O
and O
treated O
by O
liver O
transplantation O
. O

We O
report O
here O
a O
26-year O
- O
old O
female O
with O
diffuse O
large O
B O
- O
cell O
lymphoma O
who O
died O
of O
severe B-ADE
pulmonary I-ADE
fibrosis I-ADE
81 O
days O
after O
the O
administration O
of O
high O
- O
dose O
BCNU B-DRUG
( O
600 O
mg O
/ O
m2 O
) O
. O

METHODS O
: O
Repeated O
blood O
samples O
were O
drawn O
in O
a O
patient O
with O
severe O
acyclovir B-DRUG
overdose O
who O
developed O
coma B-ADE
and O
nonoliguric B-ADE
renal I-ADE
failure I-ADE
. O

Amphotericin B-DRUG
B I-DRUG
- O
induced O
cutaneous B-ADE
leucocytoclastic I-ADE
vasculitis I-ADE
: O
case O
report O
. O

Nonsustained B-ADE
polymorphous I-ADE
ventricular I-ADE
tachycardia I-ADE
during O
amiodarone B-DRUG
therapy O
for O
atrial O
fibrillation O
complicating O
cardiomyopathy O
. O

Deposits B-ADE
of I-ADE
plasma I-ADE
proteins I-ADE
in I-ADE
the I-ADE
skin I-ADE
during O
treatment O
with O
carbamazepine B-DRUG
and O
diphenylhydantoin B-DRUG
. O

Methotrexate B-DRUG
- O
induced O
papular B-ADE
eruption I-ADE
following O
treatment O
of O
psoriasis O
. O

Myelodysplasia B-ADE
terminating O
in O
acute B-ADE
myeloid I-ADE
leukemia I-ADE
in O
a O
hairy O
cell O
leukemia O
patient O
treated O
with O
2-deoxycoformycin B-DRUG
. O

OBJECTIVE O
: O
To O
report O
the O
occurrence O
of O
acute B-ADE
cytolytic I-ADE
hepatitis I-ADE
in O
a O
patient O
exposed O
to O
pulse O
itraconazole B-DRUG
therapy O
for O
24 O
weeks O
and O
provide O
a O
concise O
review O
of O
the O
literature O
on O
cases O
of O
itraconazole B-DRUG
- O
induced O
hepatitis B-ADE
. O

Albeit O
rare O
among O
Western O
patients O
, O
such O
lithium B-DRUG
- O
associated O
thyroid B-ADE
dysfunctions I-ADE
appeared O
to O
be O
more O
likely O
to O
occur O
in O
Hong O
Kong O
Chinese O
. O

Propranolol B-DRUG
- O
related O
bronchospasm B-ADE
in O
patients O
without O
history O
of O
asthma O
. O

CONCLUSION O
: O
This O
is O
, O
to O
our O
knowledge O
, O
the O
first O
report O
of O
severe B-ADE
myelopathy I-ADE
following O
accidental O
intrathecal O
administration O
of O
doxorubicin B-DRUG
. O

On O
day O
7 O
of O
linezolid B-DRUG
treatment O
, O
the O
patient O
developed O
severe B-ADE
pruritus I-ADE
, O
macular B-ADE
rash I-ADE
, O
facial B-ADE
edema I-ADE
, O
eosinophilia B-ADE
, O
marked B-ADE
increase I-ADE
in I-ADE
serum I-ADE
creatinine I-ADE
level I-ADE
, O
and O
mild B-ADE
hepatitis I-ADE
. O

Ampicillin B-DRUG
- O
associated O
seizures B-ADE
. O

Proconvulsive B-ADE
tendency O
of O
imipenem B-DRUG
/ O
cilastatin B-DRUG
is O
one O
of O
its O
well O
- O
known O
side O
effects O
. O

Trimethoprim B-DRUG
- I-DRUG
sulfamethoxazole I-DRUG
- O
induced O
hepatotoxicity B-ADE
in O
a O
pediatric O
patient O
. O

Dapsone B-DRUG
syndrome I-ADE
in O
cutaneous O
lupus O
erythematosus O
. O

The O
chemotherapeutics O
, O
including O
vincristine B-DRUG
, O
actinomycin B-DRUG
D I-DRUG
, O
and O
epirubicin B-DRUG
in O
case O
1 O
and O
vincristine B-DRUG
and O
actinomycin B-DRUG
D I-DRUG
in O
case O
2 O
, O
were O
given O
before O
the O
hepatotoxicity B-ADE
developed O
. O

Hepatoxicity B-ADE
is O
a O
rare O
complication O
of O
SRL B-DRUG
therapy O
and O
may O
be O
connected O
with O
some O
diagnostic O
and/or O
therapeutic O
problems O
. O

This O
case O
report O
describes O
an O
adolescent O
with O
severe B-ADE
lupus I-ADE
erythematosus I-ADE
who O
received O
cyclophosphamide B-DRUG
( O
CY B-DRUG
) O
paired O
with O
taste O
( O
cod O
liver O
oil O
) O
and O
smell O
( O
rose O
perfume O
) O
as O
conditioned O
stimuli O
. O

Hepatic B-ADE
angiosarcoma I-ADE
occurring O
after O
cyclophosphamide B-DRUG
therapy O
: O
case O
report O
and O
review O
of O
the O
literature O
. O

Rebound B-ADE
hyperglycemia I-ADE
was O
observed O
with O
both O
intermediate O
( O
neutral O
protamine B-DRUG
hagedorn I-DRUG
) O
and O
long O
- O
acting O
( O
protamine B-DRUG
zinc I-DRUG
iletin I-DRUG
) O
insulins O
, O
and O
the O
range O
of O
insulin O
doses O
at O
which O
the O
disorder O
developed O
overlapped O
previously O
determined O
therapeutic O
doses O
for O
these O
insulins O
in O
the O
cat O
. O

Fever B-ADE
caused O
by O
the O
use O
of O
furosemide B-DRUG
was O
proved O
; O
the O
fever O
resolved O
after O
discontinuation O
of O
this O
medication O
and O
recurred O
after O
its O
reintroduction O
. O

His O
symptoms O
of O
brain O
stem O
compression O
were O
alleviated O
and O
the O
role O
of O
phenytoin B-DRUG
in O
the O
production O
of O
his O
craniocervical B-ADE
abnormality I-ADE
is O
discussed O
. O

We O
report O
three O
cases O
of O
severe B-ADE
hepatotoxicity I-ADE
related O
to O
benzarone B-DRUG
, O
a O
benzofuran O
derivative O
. O

Nodular B-ADE
scleritis I-ADE
following O
alendronate B-DRUG
therapy O
. O

Symptoms O
and O
signs O
of O
augmentation B-ADE
were O
related O
to O
low O
plasma O
levodopa B-DRUG
levels O
, O
abating O
75 O
minutes O
after O
oral O
levodopa B-DRUG
administration O
and O
reappearing O
after O
3 O
hours O
, O
closely O
mirroring O
the O
rapid O
rise O
and O
fall O
of O
plasma O
levodopa O
concentration O
. O

Two O
infants O
developed O
hyperkalemia B-ADE
shortly O
after O
cessation O
of O
prolonged O
ACTH B-DRUG
therapy O
for O
infantile O
spasms O
. O

CONCLUSIONS O
: O
Amphotericin B-DRUG
B I-DRUG
overdose O
can O
be O
fatal B-ADE
in O
children O
and O
infants O
. O

However O
, O
acute B-ADE
cardiomyopathy I-ADE
and O
pericarditis B-ADE
secondary O
to O
methylphenidate B-DRUG
use O
has O
been O
rarely O
reported O
. O

Acute B-ADE
dystonia I-ADE
induced O
by O
lamivudine B-DRUG
. O

A O
77-year O
- O
old O
woman O
with O
no O
history O
of O
epilepsy O
presented O
a O
probable O
nonconvulsive B-ADE
status I-ADE
epilepticus I-ADE
while O
receiving O
continuous O
intravenous O
morphine B-DRUG
for O
back O
pain O
relating O
to O
vertebral O
metastasis O
of O
a O
malignant O
lymphoma O
. O

With O
the O
negative O
viral O
serologies O
, O
the O
clinical O
picture O
was O
most O
consistent O
with O
an O
infectious O
mononucleosis B-ADE
- I-ADE
like I-ADE
syndrome I-ADE
produced O
by O
the O
minocycline B-DRUG
ingestion O
. O

A O
case O
report O
of O
fatal O
dapsone B-DRUG
- O
induced O
agranulocytosis B-ADE
in O
an O
Indian O
mid O
- O
borderline O
leprosy O
patient O
. O

Seventy O
- O
four O
per O
cent O
of O
patients O
with O
epileptogenic O
disorders O
seen O
at O
the O
Emergency O
Unit O
at O
Groote O
Schuur O
Hospital O
were O
on O
phenytoin B-DRUG
and O
11.6 O
% O
of O
these O
had O
blood B-ADE
levels I-ADE
in I-ADE
the I-ADE
toxic I-ADE
range I-ADE
. O

Warfarin B-DRUG
- O
induced O
skin B-ADE
necrosis I-ADE
and O
heparin B-DRUG
- O
induced O
thrombocytopenia B-ADE
following O
mitral O
valve O
replacement O
for O
marantic O
endocarditis O
. O

The O
second O
had O
acute O
cystitis O
and O
was O
treated O
by O
sulphonamide B-DRUG
and O
the O
third O
developed O
myopia B-ADE
coincident O
with O
metronidazole B-DRUG
treatment O
for O
trichomonas O
vaginalis O
. O

We O
report O
on O
a O
patient O
with O
renal O
artery O
stenosis O
who O
had O
only O
1 O
kidney O
and O
in O
whom O
acute B-ADE
renal I-ADE
impairment I-ADE
developed O
with O
transient B-ADE
anuria I-ADE
after O
the O
administration O
of O
captopril B-DRUG
. O

Interferon B-DRUG
- I-DRUG
alpha I-DRUG
- O
induced O
hyperthyroidism B-ADE
: O
a O
three O
- O
stage O
evolution O
from O
silent O
thyroiditis O
towards O
Graves O
' O
disease O
. O

Sweet B-ADE
's I-ADE
syndrome I-ADE
is O
an O
acute B-ADE
febrile I-ADE
neutrophilic I-ADE
dermatosis I-ADE
that O
is O
a O
known O
complication O
of O
the O
administration O
of O
filgrastim B-DRUG
, O
a O
drug O
that O
causes O
increased O
neutrophil O
proliferation O
and O
differentiation O
. O

We O
report O
three O
cases O
of O
amiodarone B-DRUG
- O
induced O
torsades B-ADE
de I-ADE
pointe I-ADE
. O

L B-DRUG
- I-DRUG
asparaginase I-DRUG
- O
provoked O
seizures B-ADE
as O
singular O
expression O
of O
central B-ADE
nervous I-ADE
toxicity I-ADE
. O

The O
clinical O
course O
suggested O
that O
recombinant B-DRUG
alpha-2b I-DRUG
peginterferon I-DRUG
plus O
ribavirin B-DRUG
provoked O
type B-ADE
1 I-ADE
diabetes I-ADE
mellitus I-ADE
, O
therefore O
, O
in O
patients O
who O
are O
candidates O
for O
interferon O
therapy O
the O
presence O
of O
pancreatic O
autoantibodies O
and O
the O
fasting O
plasma O
glucose O
level O
should O
be O
investigated O
before O
and O
during O
treatment O
. O

PURPOSE O
: O
To O
describe O
spectral O
- O
domain O
optical O
coherence O
tomography O
( O
SD O
- O
OCT O
) O
and O
adaptive O
optics O
( O
AO O
) O
imaging O
in O
hydroxychloroquine B-DRUG
retinal B-ADE
toxicity I-ADE
. O

This O
report O
describes O
an O
individual O
with O
mental O
retardation O
who O
experienced O
behavioral B-ADE
exacerbation I-ADE
associated O
with O
clonazepam B-DRUG
prescribed O
at O
2 O
mg O
/ O
day O
( O
0.02 O
mg O
/ O
kg O
/ O
day O
) O
to O
treat O
aggression O
, O
self O
- O
injurious O
behavior O
, O
property O
destruction O
, O
and O
screaming O
, O
which O
was O
measured O
with O
a O
15-minute O
partial O
interval O
recording O
measurement O
method O
. O

Leishmania B-ADE
infantum I-ADE
leishmaniasis I-ADE
in O
corticosteroid B-DRUG
-- O
treated O
patients O
. O

RESULTS O
: O
Replacing O
valproate B-DRUG
with O
lamotrigine O
resulted O
in O
a O
decrease O
in O
serum B-ADE
testosterone I-ADE
concentrations O
in O
all O
3 O
women O
. O

The O
mild O
immunosuppression O
that O
occurs O
with O
methotrexate B-DRUG
therapy O
probably O
places O
patients O
with O
rheumatoid O
arthritis O
at O
added O
risk O
of O
developing O
lymphoproliferative B-ADE
diseases I-ADE
, O
but O
coincidence O
can O
not O
be O
excluded O
. O

Pulmonary B-ADE
hypertension I-ADE
during O
lithium B-DRUG
therapy O
: O
clinical O
case O
study O
. O

Stupor B-ADE
and O
fast O
activity O
on O
electroencephalography O
in O
a O
child O
treated O
with O
valproate B-DRUG
. O

The O
association O
between O
heparin B-DRUG
and O
priapism B-ADE
is O
often O
recognized O
; O
abnormal B-ADE
platelet I-ADE
aggregation I-ADE
could O
play O
a O
role O
in O
the O
pathogenesis O
of O
this O
side O
effect O
. O

We O
describe O
a O
case O
of O
needle O
- O
track O
cutaneous B-ADE
seeding I-ADE
of O
hepatocellular O
carcinoma O
( O
HCC O
) O
after O
sonographically O
guided O
percutaneous O
ethanol B-DRUG
injection I-DRUG
( O
PEI O
) O
. O

Clinicians O
should O
be O
vigilant O
when O
monitoring O
for O
cardiotoxicity B-ADE
in O
patients O
receiving O
pentamidine B-DRUG
throughout O
the O
duration O
of O
therapy O
. O

Prominent O
positive B-ADE
U I-ADE
waves I-ADE
appearing O
with O
high O
- O
dose O
intravenous O
phenylephrine B-DRUG
. O

Thoracoscopic O
biopsy O
to O
confirm O
metastasis O
revealed O
instead O
fibrotic B-ADE
lesions I-ADE
apparently O
attributable O
to O
bleomycin B-DRUG
or O
cyclophosphamide B-DRUG
. O

DIAGNOSIS O
: O
Severe O
temozolomide B-DRUG
- O
induced O
immunosuppression B-ADE
, O
exacerbated O
by O
corticosteroids O
, O
with O
profound O
T B-ADE
- I-ADE
cell I-ADE
lymphocytopenia I-ADE
and O
simultaneous O
opportunistic O
infections B-ADE
with I-ADE
Pneumocystis I-ADE
jiroveci I-ADE
pneumonia I-ADE
, O
brain B-ADE
abscess I-ADE
with I-ADE
Listeria I-ADE
monocytogenes I-ADE
, O
and O
cutaneous B-ADE
Kaposi I-ADE
's I-ADE
sarcoma I-ADE
. O

Bronchiolitis B-ADE
obliterans I-ADE
organising I-ADE
pneumonia I-ADE
associated O
with O
the O
use O
of O
nitrofurantoin B-DRUG
. O

Many O
clinicians O
appear O
to O
be O
concerned O
about O
the O
potential O
hepatotoxicity B-ADE
of O
the O
opiate O
antagonist O
naltrexone B-DRUG
( O
NTX B-DRUG
) O
and O
this O
may O
be O
one O
reason O
why O
it O
is O
not O
used O
more O
widely O
in O
treating O
both O
heroin O
and O
alcohol O
abusers O
. O

Methemoglobinemia B-ADE
: O
an O
occupational O
hazard O
of O
phenylpropanolamine B-DRUG
production O
. O

Tacrolimus B-DRUG
( O
FK506 B-DRUG
) O
, O
an O
immunosuppressant O
, O
has O
been O
associated O
with O
mutism B-ADE
in O
adults O
after O
liver O
transplant O
. O

We O
now O
present O
four O
cases O
of O
RSDS B-ADE
in O
kidney O
transplant O
recipients O
treated O
with O
tacrolimus B-DRUG
. O

Cerebral B-ADE
edema I-ADE
associated O
with O
Gliadel B-DRUG
wafers O
: O
two O
case O
studies O
. O

This O
sulfonamide O
like O
nephropathy O
should O
be O
differentiated O
from O
acetazolamide B-DRUG
- O
related O
calcium B-ADE
phosphate I-ADE
nephrolithiasis I-ADE
. O

We O
report O
the O
case O
of O
a O
man O
, O
treated O
with O
mesalazine B-DRUG
for O
Crohn O
's O
disease O
who O
developed O
drug O
- O
induced O
pericarditis B-ADE
. O

Provocation O
of O
non B-ADE
- I-ADE
convulsive I-ADE
status I-ADE
epilepticus I-ADE
by O
tiagabine B-DRUG
in O
three O
adolescent O
patients O
. O

Gemcitabine B-DRUG
is O
a O
known O
risk O
factor O
for O
hemolytic B-ADE
uremic I-ADE
syndrome I-ADE
( O
HUS B-ADE
) O
, O
which O
can O
often O
have O
a O
rapidly O
fatal O
clinical O
course O
despite O
intervention O
with O
steroids O
, O
plasmapheresis O
and O
hemodialysis O
. O

An O
adolescent O
male O
developed O
acute B-ADE
pancreatitis I-ADE
and O
pseudocyst B-ADE
of I-ADE
the I-ADE
pancreas I-ADE
16 O
weeks O
after O
cessation O
of O
intramuscular O
L B-DRUG
- I-DRUG
asparaginase I-DRUG
. O

We O
present O
a O
depressive O
patient O
who O
developed O
mild B-ADE
parkinsonian I-ADE
signs I-ADE
and O
camptocormia B-ADE
after O
the O
introduction O
of O
olanzapine B-DRUG
. O

Despite O
the O
underlying O
hepatitis O
C O
, O
this O
case O
represents O
renal B-ADE
abnormalities I-ADE
consistent O
with O
IFNalpha B-DRUG
therapy O
for O
CML O
. O

The O
authors O
presented O
a O
case O
of O
pulmonary B-ADE
hypertension I-ADE
during O
lithium B-DRUG
therapy O
, O
while O
she O
has O
been O
on O
lithium O
for O
6 O
years O
. O

A O
diagnosis O
of O
masked O
theophylline B-DRUG
poisoning I-ADE
should O
be O
considered O
in O
similar O
situations O
involving O
a O
rapid O
decrease O
of O
insulin O
requirements O
. O

Alveolar B-ADE
- I-ADE
interstitial I-ADE
pneumopathy I-ADE
after O
gold B-DRUG
- O
salts O
compounds O
administration O
, O
requiring O
mechanical O
ventilation O
. O

Four O
cases O
of O
fat B-ADE
embolism I-ADE
are O
described O
in O
infants O
receiving O
prolonged O
intravenous O
infusion O
of O
fat O
( O
Intralipid B-DRUG
20 O
% O
) O
. O

Metformin B-DRUG
- O
associated O
lactic B-ADE
acidosis I-ADE
( O
MALA O
) O
is O
a O
serious O
metabolic O
complication O
that O
occurs O
because O
of O
metformin B-DRUG
accumulation O
in O
patients O
who O
become O
dehydrated O
or O
developed O
acute O
renal O
failure O
. O

Neurological B-ADE
side I-ADE
effects I-ADE
in O
two O
patients O
receiving O
gold B-DRUG
injections O
for O
rheumatoid O
arthritis O
. O

Pentazocine B-DRUG
- O
induced O
fibrous B-ADE
myopathy I-ADE
and O
localized O
neuropathy B-ADE
. O

Following O
the O
institution O
of O
intravenous O
therapy O
with O
acyclovir B-DRUG
, O
the O
patient O
developed O
fever B-ADE
, O
hemoptysis B-ADE
, O
and O
a O
pleural B-ADE
friction I-ADE
rub I-ADE
. O

The O
epivodes O
of O
NMS B-ADE
occured O
under O
treatment O
with O
clozapine B-DRUG
, O
risperidone B-DRUG
, O
and O
amisulpride B-DRUG
. O

The O
ocular B-ADE
motor I-ADE
disturbances I-ADE
are O
probably O
an O
expression O
of O
regional O
5-FU B-DRUG
neurotoxicity B-ADE
primarily O
affecting O
the O
brain O
stem O
. O

Central B-ADE
nervous I-ADE
system I-ADE
manifestations I-ADE
of O
an O
ibuprofen B-DRUG
overdose O
reversed O
by O
naloxone O
. O

Increased B-ADE
libido I-ADE
in O
a O
woman O
treated O
with O
fluvoxamine B-DRUG
: O
a O
case O
report O
. O

Occult O
quinine B-DRUG
- O
induced O
thrombocytopenia B-ADE
. O

One O
patient O
who O
received O
clindamycin B-DRUG
had O
liver O
biopsy O
findings O
of O
marked B-ADE
cholestasis I-ADE
, O
portal B-ADE
inflammation I-ADE
, O
bile B-ADE
duct I-ADE
injury I-ADE
and O
bile B-ADE
duct I-ADE
paucity I-ADE
( O
ductopenia B-ADE
) O
. O

A O
rechallenge O
, O
performed O
in O
both O
patients O
, O
confirmed O
the O
diagnosis O
of O
mesalamine B-DRUG
- O
induced O
pancreatitis B-ADE
. O

CONCLUSION O
: O
The O
findings O
in O
these O
two O
patients O
suggest O
that O
colchicine B-DRUG
may O
delay B-ADE
corneal I-ADE
wound I-ADE
healing I-ADE
. O

Both O
the O
longitudinal B-ADE
melanonychia I-ADE
and O
the O
multiple B-ADE
skin I-ADE
cancers I-ADE
first O
appeared O
after O
approximately O
6 O
months O
of O
hydroxyurea B-DRUG
treatment O
. O

We O
describe O
a O
10-year O
- O
old O
boy O
with O
ulcerative O
colitis O
who O
developed O
acute B-ADE
pancreatitis I-ADE
while O
on O
long O
- O
term O
treatment O
with O
5-aminosalicylic B-DRUG
acid I-DRUG
. O

A O
69-year O
- O
old O
man O
developed O
pure B-ADE
red I-ADE
cell I-ADE
aplasia I-ADE
after O
taking O
fenoprofen B-DRUG
for O
ten O
months O
. O

Agranulocytosis B-ADE
induced O
by O
vancomycin B-DRUG
in O
an O
ESRD O
patient O
on O
CAPD O
. O

Recently O
, O
some O
studies O
have O
also O
reported O
association O
between O
patients O
with O
juvenile O
rheumatoid O
arthritis O
( O
JRA O
) O
treated O
with O
Methotrexate B-DRUG
( O
MTX B-DRUG
) O
and O
malignant B-ADE
lymphoma I-ADE
developing O
. O

Atenolol B-DRUG
- O
induced O
pseudolymphoma B-ADE
. O

Nonconvulsive B-ADE
status I-ADE
epilepticus I-ADE
due O
to O
ifosfamide B-DRUG
. O

METHODS O
: O
Double O
- O
blind O
, O
placebo O
- O
controlled O
titrated O
oral O
challenges O
with O
pancreatic O
enzymes O
resulted O
in O
definite O
vomiting B-ADE
within O
1 O
to O
1.5 O
hours O
after O
challenges O
with O
Viokase B-DRUG
and O
Pancrease B-DRUG
MT I-DRUG
16 I-DRUG
, O
but O
not O
with O
placebo O
. O

The O
NZ O
Pharmacovigilance O
Centre O
has O
received O
7 O
additional O
reports O
of O
severe B-ADE
infections I-ADE
in O
patients O
with O
RA O
taking O
leflunomide B-DRUG
. O

Anaphylactoid B-ADE
reaction I-ADE
to O
50 O
% O
solution O
of O
dextrose B-DRUG
. O

Persisent B-ADE
ocular I-ADE
hypertension I-ADE
following O
intravitreal O
ranibizumab B-DRUG
. O

Protamine B-DRUG
- O
induced O
fatal B-ADE
anaphylaxis I-ADE
. O

We O
describe O
a O
premenopausal O
woman O
who O
, O
while O
having O
tamoxifen B-DRUG
due O
to O
a O
diagnosis O
of O
in O
situ O
ductal O
carcinoma O
, O
developed O
endometriosis B-ADE
requiring O
surgery O
. O

Leflunomide B-DRUG
- O
associated O
weight B-ADE
loss I-ADE
in O
rheumatoid O
arthritis O
. O

Cardiac B-ADE
hypersensitivity I-ADE
and O
myopericarditis B-ADE
have O
been O
reported O
during O
long O
- O
term O
treatment O
with O
mesalazine B-DRUG
. O

Acute B-ADE
myocardial I-ADE
necrosis I-ADE
during O
administration O
of O
amsacrine B-DRUG
. O

We O
present O
a O
case O
of O
the O
syndrome B-ADE
of I-ADE
inappropriate I-ADE
antidiuretic I-ADE
hormone I-ADE
( O
SIADH B-ADE
) O
secondary O
to O
cisplatin B-DRUG
therapy O
in O
a O
patient O
with O
advanced O
- O
stage O
large O
cell O
neuroendocrine O
carcinoma O
of O
the O
cervix O
. O

Our O
review O
of O
194 O
RA O
patients O
and O
38 O
PsA O
patients O
receiving O
MTX O
has O
identified O
four O
RA O
patients O
and O
one O
PsA O
patient O
with O
MTX B-DRUG
- O
induced O
pneumonitis B-ADE
, O
giving O
a O
prevalence O
of O
2.1 O
% O
and O
0.03 O
% O
, O
respectively O
. O

Zidovudine B-DRUG
induced O
pure B-ADE
red I-ADE
cell I-ADE
aplasia I-ADE
: O
a O
case O
report O
. O

Flecainide B-DRUG
- O
associated O
pneumonitis B-ADE
with O
acute B-ADE
respiratory I-ADE
failure I-ADE
in O
a O
patient O
with O
the O
LEOPARD O
syndrome O
. O

Rifampin B-DRUG
( O
RFP B-DRUG
) O
increases O
hepatic O
microsomal O
enzyme O
activity O
, O
and O
there O
are O
case O
reports O
of O
RFP O
- O
induced O
hypothyroidism B-ADE
, O
all O
associated O
with O
Hashimoto B-ADE
's I-ADE
thyroiditis I-ADE
. O

Anterior B-ADE
ischemic I-ADE
optic I-ADE
neuropathy I-ADE
secondary O
to O
interferon B-DRUG
alfa I-DRUG
. O

We O
describe O
a O
case O
of O
poisoning B-ADE
with O
3,4-methylenedioxymet B-DRUG
- I-DRUG
amphetamine I-DRUG
Ecstasy I-DRUG
that O
presented O
with O
all O
the O
features O
suggestive O
of O
a O
fatal O
outcome O
, O
including O
a O
creatinine O
phosphokinase O
level O
markedly O
higher O
than O
any O
previously O
reported O
. O

Allopurinol B-DRUG
hypersensitivity B-ADE
. O

According O
to O
the O
Naranjo O
probability O
scale O
, O
the O
relationship O
of O
gemcitabine B-DRUG
treatment O
with O
cutaneous B-ADE
eruption I-ADE
in O
our O
patient O
is O
possible O
. O

New O
onset O
of O
CD B-ADE
may O
be O
considered O
as O
an O
immune B-ADE
- I-ADE
mediated I-ADE
injury I-ADE
induced O
by O
etanercept B-DRUG
. O

Total B-ADE
blindness I-ADE
with I-ADE
a I-ADE
transient I-ADE
tonic I-ADE
pupillary I-ADE
response I-ADE
, O
denervation B-ADE
supersensitivity I-ADE
, O
and O
abnormal B-ADE
visual I-ADE
- I-ADE
evoked I-ADE
potentials I-ADE
developed O
in O
a O
54-year O
- O
old O
man O
after O
the O
use O
of O
quinine B-DRUG
sulfate I-DRUG
for O
leg O
cramps O
. O

Phenobarbital B-DRUG
hepatotoxicity B-ADE
in O
an O
8-month O
- O
old O
infant O
. O

These O
are O
the O
first O
reported O
patients O
to O
show O
mfERG B-ADE
abnormalities I-ADE
that O
correspond O
to O
bitemporal B-ADE
visual I-ADE
field I-ADE
defects I-ADE
and O
add O
to O
the O
growing O
evidence O
that O
ethambutol B-DRUG
damages O
the O
retina O
. O

Interstitial B-ADE
fibrosis I-ADE
of I-ADE
the I-ADE
lung I-ADE
is O
a O
potential O
complication O
of O
methotrexate B-DRUG
therapy O
for O
psoriasis O
. O

This O
case O
describes O
fulminant B-ADE
hepatic I-ADE
failure I-ADE
in O
a O
patient O
taking O
disulfiram B-DRUG
with O
no O
previous O
liver O
disease O
and O
report O
of O
being O
compliant O
with O
alcohol O
abstinence O
. O

Development O
of O
Peyronie B-ADE
's I-ADE
disease I-ADE
during O
long O
- O
term O
colchicine B-DRUG
treatment O
. O

Nineteen O
cases O
of O
allergic B-ADE
contact I-ADE
dermatitis I-ADE
to O
compound O
tincture O
of O
benzoin B-DRUG
are O
described O
. O

We O
report O
a O
case O
of O
contact B-ADE
dermatitis I-ADE
due O
to O
sodium B-DRUG
bisulfite I-DRUG
in O
Tathion O
eye O
drops O
. O

INH B-DRUG
, O
which O
is O
a O
leading O
cause O
of O
drug B-ADE
eruptions I-ADE
in O
the O
above O
group O
of O
drugs O
was O
withdrawn O
. O

A O
79-year O
- O
old O
man O
with O
ischemic O
heart O
disease O
, O
chronic O
atrial O
fibrillation O
, O
chronic O
renal O
failure O
, O
hypothyroidism O
, O
and O
gout O
arthritis O
was O
hospitalized O
because O
of O
fatigue B-ADE
, O
myalgia B-ADE
, O
and O
leg B-ADE
weakness I-ADE
, O
shortly O
after O
starting O
treatment O
with O
colchicine B-DRUG
. O

A O
7-year O
- O
old O
boy O
developed O
a O
severe B-ADE
unilateral I-ADE
grand I-ADE
mal I-ADE
seizure I-ADE
at O
the O
age O
of O
5 O
years O
( O
phenobarbitone B-DRUG
therapy O
) O
; O
1.5 O
years O
later O
valproate B-DRUG
( O
2-propylpentanoic B-DRUG
acid I-DRUG
, O
VPA B-DRUG
) O
was O
added O
to O
the O
therapy O
. O

It O
is O
thought O
that O
the O
clinico O
- O
pathological O
features O
and O
chronology O
of O
this O
case O
bore O
the O
hallmarks O
of O
the O
so O
- O
called O
" O
3-week O
sulphasalazine B-ADE
syndrome I-ADE
" O
, O
a O
rare O
, O
but O
often O
fatal B-ADE
, O
immunoallergic B-ADE
reaction I-ADE
to O
sulphasalazine B-DRUG
. O

This O
case O
extends O
the O
spectrum O
of O
fludarabine B-DRUG
pulmonary B-ADE
toxicity I-ADE
to O
include O
pulmonary B-ADE
nodules I-ADE
. O

CONCLUSIONS O
: O
Life O
- O
threatening O
adrenal B-ADE
suppression I-ADE
, O
requiring O
hydrocortisone O
supplementation O
and O
intensive O
therapy O
, O
was O
observed O
and O
successfully O
treated O
in O
a O
newborn O
, O
whose O
mother O
had O
received O
high O
- O
dose O
methylprednisolone B-DRUG
in O
late O
pregnancy O
. O

Acne B-ADE
provoked O
by O
gold B-DRUG
seems O
not O
to O
have O
been O
described O
elsewhere O
. O

Marked O
sinus B-ADE
tachycardia I-ADE
resulting O
from O
the O
synergistic O
effects O
of O
marijuana O
and O
nortriptyline B-DRUG
. O

A O
case O
of O
oculogyric B-ADE
crisis I-ADE
induced O
by O
metoclopramide B-DRUG
is O
described O
in O
this O
paper O
. O

We O
report O
two O
cases O
of O
cerebrospinal B-ADE
fluid I-ADE
eosinophilia I-ADE
( O
CSFE B-ADE
) O
secondary O
to O
the O
intraventricular O
administration O
of O
vancomycin B-DRUG
. O

Severe O
sulfadiazine B-DRUG
hypersensitivity B-ADE
in O
a O
child O
with O
reactivated O
congenital O
toxoplasmic O
chorioretinitis O
. O

Chlorpropamide B-DRUG
- O
induced O
hemolytic B-ADE
anemia I-ADE
. O

This O
article O
reports O
the O
occurrence O
of O
rifampin B-DRUG
- O
associated O
thrombocytopenia B-ADE
in O
an O
indigent O
patient O
after O
a O
four O
- O
month O
lapse O
in O
therapy O
for O
pulmonary O
tuberculosis O
. O

The O
exophthalmos B-ADE
improved O
dramatically O
within O
72 O
hours O
of O
the O
withdrawal O
of O
lithium B-DRUG
. O

CASE O
: O
We O
report O
a O
case O
of O
a O
woman O
with O
severe O
human B-DRUG
insulin I-DRUG
- O
induced O
lipoatrophy B-ADE
who O
has O
been O
treated O
exclusively O
with O
recombinant B-DRUG
DNA I-DRUG
human I-DRUG
insulin I-DRUG
since O
the O
onset O
of O
IDDM O
. O

Recent O
studies O
have O
shown O
that O
under O
experimental O
conditions O
ferrous B-DRUG
sulfate I-DRUG
may O
reduce B-ADE
the I-ADE
gastrointestinal I-ADE
absorption I-ADE
of I-ADE
orally I-ADE
administered I-ADE
levothyroxine I-ADE
sodium I-ADE
in O
patients O
with O
primary O
hypothyroidism O
. O

We O
conclude O
peripheral B-ADE
neuropathy I-ADE
with O
5-FU B-DRUG
is O
rare O
. O

Musculoskeletal B-ADE
complaints I-ADE
were O
the O
presenting O
symptoms O
in O
four O
of O
44 O
children O
( O
9 O
% O
) O
treated O
for O
relapsed O
Wilms O
' O
tumors O
with O
ifosfamide B-DRUG
, O
a O
derivative O
of O
cyclophosphamide B-DRUG
. O

However O
, O
a O
new O
episode O
of O
neutropenia B-ADE
, O
with O
a O
WBC O
count O
of O
2.8 O
x O
10(3)/mm3 O
and O
ANC O
of O
0.448 O
x O
10(3)/mm3 O
, O
occurred O
11 O
days O
after O
teicoplanin B-DRUG
initiation O
. O

We O
postulate O
that O
cyclosporin B-DRUG
, O
possibly O
together O
with O
ganciclovir B-DRUG
, O
can O
produce O
transient B-ADE
brain I-ADE
stem I-ADE
or I-ADE
neuromuscular I-ADE
dysfunction I-ADE
with O
eye B-ADE
movement I-ADE
abnormality I-ADE
in O
occasional O
patients O
. O

Clofazimine B-DRUG
enteropathy B-ADE
in O
a O
pediatric O
bone O
marrow O
transplant O
recipient O
. O

Neutrophilic B-ADE
eccrine I-ADE
hidradenitis I-ADE
mimicking O
cutaneous O
vasculitis O
in O
a O
lupus O
patient O
: O
a O
complication O
of O
cyclophosphamide B-DRUG
. O

PET O
scintigraphy O
of O
etoposide B-DRUG
- O
induced O
pulmonary B-ADE
toxicity I-ADE
. O

We O
report O
a O
case O
of O
severe B-ADE
anemia I-ADE
, O
which O
responded O
well O
to O
steroid O
therapy O
, O
in O
a O
patient O
receiving O
IL-2 B-DRUG
plus O
IFN B-DRUG
- I-DRUG
alpha I-DRUG
for O
metastatic O
renal O
cell O
carcinoma O
. O

RESULTS O
: O
Quetiapine B-DRUG
was O
associated O
with O
leucopenia B-ADE
in O
two O
patients O
and O
clinically O
apparent O
agranulocytosis B-ADE
in O
one O
patient O
. O

Prenatal B-ADE
cytomegalovirus I-ADE
( I-ADE
CMV I-ADE
) I-ADE
infection I-ADE
associated O
with O
severe O
brain B-ADE
damage I-ADE
was O
detected O
in O
an O
infant O
whose O
mother O
had O
been O
treated O
with O
prednisolone B-DRUG
and O
azathioprine B-DRUG
for O
systemic O
lupus O
erythematosus O
( O
SLE O
) O
. O

Generalized B-ADE
argyria I-ADE
after O
habitual O
use O
of O
AgNO3 B-DRUG
. O

To O
our O
knowledge O
, O
our O
report O
is O
one O
of O
the O
first O
on O
shock B-ADE
and O
angio B-ADE
- I-ADE
oedema I-ADE
from O
irbesartan B-DRUG
. O

Its O
overall O
toxicity B-ADE
is O
considerably O
less O
compared O
to O
standard O
induction O
chemotherapy O
; O
however O
, O
it O
is O
associated O
with O
a O
high O
incidence O
of O
a O
potentially B-ADE
fatal I-ADE
symptom I-ADE
complex O
referred O
to O
as O
" O
retinoic B-ADE
acid I-ADE
syndrome I-ADE
. O
" O
This O
report O
describes O
a O
patient O
with O
APL O
who O
developed O
the O
syndrome O
a O
few O
weeks O
after O
initiating O
induction O
therapy O
with O
ATRA O
despite O
being O
treated O
for O
hyperleukocytosis O
. O

Paraplegia B-ADE
following O
intrathecal O
cytosine B-DRUG
arabinoside I-DRUG
. O

He O
had O
priapism B-ADE
following O
the O
use O
of O
olanzapine B-DRUG
. O

Losartan B-DRUG
- O
induced O
angioedema B-ADE
. O

The O
authors O
report O
a O
case O
of O
Balint B-ADE
syndrome I-ADE
with O
irreversible O
posterior B-ADE
leukoencephalopathy I-ADE
on O
MRI O
following O
intrathecal O
methotrexate B-DRUG
and O
cytarabine B-DRUG
. O

After O
extensive O
neurological O
' O
work O
up O
' O
, O
we O
realized O
that O
the O
anisocoria B-ADE
was O
related O
to O
the O
transdermal O
scopolamine B-DRUG
patch O
that O
we O
had O
prescribed O
for O
weaning O
off O
the O
opioid O
. O

After O
ruling O
out O
a O
hydrotelluric O
source O
of O
fluorine O
, O
the O
patient O
's O
fluorosis B-ADE
was O
linked O
to O
chronic O
use O
of O
niflumic B-DRUG
acid I-DRUG
, O
following O
the O
publication O
in O
1978 O
of O
the O
2 O
previously O
reported O
cases O
affected O
by O
this O
drug O
. O

This O
case O
represents O
the O
third O
example O
of O
erythroid B-ADE
aplasia I-ADE
associated O
with O
an O
anti O
- O
inflammatory O
agent O
and O
the O
first O
instance O
due O
to O
fenoprofen B-DRUG
. O

After O
approximately O
two O
weeks O
of O
sertraline B-DRUG
treatment O
he O
noted O
an O
intense B-ADE
itching I-ADE
sensation I-ADE
in O
his O
scalp O
after O
eating O
a O
piece O
of O
chocolate O
cake O
. O

Sustained O
- O
release O
procainamide B-DRUG
- O
induced O
reversible B-ADE
granulocytopenia I-ADE
after O
myocardial O
infarction O
. O

ARDS B-ADE
has O
been O
associated O
with O
the O
administration O
of O
other O
monoclonal O
antibodies O
, O
such O
as O
infliximab B-DRUG
, O
gemtuzumab B-DRUG
ozogamicin I-DRUG
, O
and O
OKT3 B-DRUG
and O
is O
believed O
to O
be O
directly O
mediated O
by O
release O
of O
proinflammatory O
cytokines O
. O

OBJECTIVE O
: O
To O
report O
the O
late O
development O
of O
immune B-ADE
- I-ADE
mediated I-ADE
diabetes I-ADE
mellitus I-ADE
after O
completion O
of O
alfa B-DRUG
- I-DRUG
interferon I-DRUG
therapy O
for O
hepatitis O
C O
in O
an O
Asian O
patient O
. O

The O
authors O
suggest O
that O
fluoxetine B-DRUG
- O
induced O
akathisia B-ADE
may O
be O
caused O
by O
serotonergically O
mediated O
inhibition O
of O
dopaminergic O
neurotransmission O
and O
that O
the O
pathophysiology O
of O
fluoxetine B-DRUG
- O
induced O
akathisia B-ADE
and O
tricyclic O
antidepressant O
- O
induced O
" O
jitteriness O
" O
may O
be O
identical O
. O

Clostridium B-ADE
difficile I-ADE
toxin I-ADE
- I-ADE
induced I-ADE
colitis I-ADE
after O
use O
of O
clindamycin B-DRUG
phosphate I-DRUG
vaginal O
cream O
. O

After O
several O
unrevealing O
medical O
work O
- O
ups O
, O
he O
was O
found O
to O
have O
a O
high B-ADE
blood I-ADE
lead B-DRUG
level I-ADE
( O
122 O
microg O
/ O
dL O
) O
; O
he O
has O
a O
history O
of O
scraping O
and O
sanding O
lead O
paint O
without O
adequate O
protective O
measures O
. O

In O
a O
61-year O
- O
old O
man O
receiving O
chronic O
low O
- O
dosage O
amiodarone B-DRUG
an O
interstitial B-ADE
pneumopathy I-ADE
was O
observed O
. O

Carbamyl O
phosphate O
synthetase-1 O
deficiency O
discovered O
after O
valproic B-DRUG
acid I-DRUG
- O
induced O
coma B-ADE
. O

The O
authors O
describe O
a O
woman O
with O
chronic O
schizophrenia O
who O
experienced O
delirium B-ADE
, O
grand B-ADE
mal I-ADE
seizure I-ADE
, O
and O
photosensitivity B-ADE
after O
the O
addition O
of O
propranolol B-DRUG
to O
her O
neuroleptic O
regimen O
. O

A O
boy O
with O
chronic O
neutropenia O
and O
recurrent O
inflammatory O
skin O
lesions O
developed O
multiple B-ADE
erythematous I-ADE
nodules I-ADE
following O
administration O
of O
G B-DRUG
- I-DRUG
CSF I-DRUG
. O

Epsilon B-DRUG
- I-DRUG
aminocaproic I-DRUG
acid I-DRUG
and O
renal B-ADE
complications I-ADE
: O
case O
report O
and O
review O
of O
the O
literature O
. O

Hyperglycemia B-ADE
and O
diabetic B-ADE
coma I-ADE
: O
possible O
relationship O
to O
diuretic O
- O
propranolol B-DRUG
therapy O
. O

We O
report O
a O
patient O
in O
whom O
the O
anti O
- O
depressant O
trazodone B-DRUG
hydrochloride I-DRUG
( O
Molipaxin B-DRUG
, O
Roussel O
) O
, O
a O
serotonin O
antagonist O
, O
provoked O
generalized B-ADE
pustular I-ADE
psoriasis I-ADE
( O
GPP B-ADE
) O
. O

Trichiasis B-ADE
associated O
with O
prostaglandin B-DRUG
analog O
use O
. O

Sarcoma B-ADE
complicating O
therapy O
with O
cyclophosphamide B-DRUG
. O

We O
report O
3 O
cases O
of O
children O
with O
acute O
lymphoblastic O
leukemia O
who O
developed O
seizures B-ADE
and O
altered B-ADE
sensorium I-ADE
after O
L B-DRUG
- I-DRUG
asparaginase I-DRUG
therapy O
. O

Various O
case O
reports O
concerning O
dapsone B-DRUG
- O
induced O
agranulocytosis B-ADE
are O
reviewed O
. O

We O
believe O
that O
this O
is O
the O
first O
description O
of O
acute B-ADE
hepatitis I-ADE
caused O
by O
an O
idiosyncratic O
adverse O
reaction O
to O
gliclazide B-DRUG
or O
to O
one O
of O
its O
metabolites O
. O

Disseminated B-ADE
cellulitic I-ADE
cryptococcosis I-ADE
in O
the O
setting O
of O
prednisone B-DRUG
monotherapy O
for O
pemphigus O
vulgaris O
. O

Three O
patients O
with O
no O
history O
of O
asthma O
or O
allergy O
developed O
bronchospasm B-ADE
while O
taking O
propranolol B-DRUG
for O
hypertension O
. O

DISCUSSION O
: O
The O
Naranjo O
probability O
scale O
indicated O
a O
probable O
relationship O
between O
sertraline B-DRUG
treatment O
and O
the O
onset O
of O
rhabdomyolysis B-ADE
. O

This O
case O
suggests O
that O
BH B-DRUG
- I-DRUG
AC I-DRUG
, O
a O
derivative O
of O
cytosine O
arabinoside O
( O
1-beta O
- O
D O
- O
arabinofuranosylcytosine O
) O
could O
be O
a O
cause O
of O
reversible O
encephalopathy B-ADE
syndrome I-ADE
. O

Cardiac B-ADE
arrest I-ADE
associated O
with O
sulprostone B-DRUG
use O
during O
caesarean O
section O
. O

Quinine B-DRUG
- O
induced O
hearing B-ADE
loss I-ADE
. O

The O
second O
is O
a O
29-year O
- O
old O
man O
with O
CD O
in O
whom O
nodular B-ADE
sclerosing I-ADE
Hodgkin I-ADE
's I-ADE
lymphoma I-ADE
was O
diagnosed O
3 O
weeks O
after O
infusion O
with O
infliximab B-DRUG
. O

Given O
that O
discontinuation O
of O
nitrofurantoin O
and O
introduction O
of O
methylprednisolon O
therapy O
significantly O
lowered O
liver O
enzyme O
levels O
, O
restoring O
most O
of O
them O
to O
normal O
, O
we O
concluded O
that O
this O
was O
probably O
the O
case O
of O
toxic B-ADE
liver I-ADE
damage I-ADE
caused O
by O
nitrofurantoin B-DRUG
. O

CONCLUSION O
: O
We O
have O
introduced O
a O
case O
of O
anaphylaxis B-ADE
by O
calcitonin B-DRUG
that O
suggest O
an O
IgE O
mediated O
hypersensitivity O
reaction O
. O

We O
report O
the O
first O
case O
of O
polymorphic B-ADE
ventricular I-ADE
tachycardia I-ADE
with O
normal O
QT O
interval O
associated O
with O
the O
oral O
use O
of O
levofloxacin B-DRUG
in O
the O
absence O
of O
other O
etiologies O
known O
to O
cause O
these O
arrhythmias O
. O

INTRODUCTION O
: O
In O
resource O
limited O
settings O
patients O
on O
antiretroviral O
treatment O
who O
develop O
stavudine B-DRUG
induced O
hyperlactatemia B-ADE
are O
often O
switched O
to O
zidovudine O
on O
the O
basis O
of O
published O
studies O
that O
demonstrate O
that O
this O
agent O
can O
be O
a O
safe O
alternative O
. O

The O
events O
of O
non B-ADE
- I-ADE
convulsive I-ADE
status I-ADE
epilepticus I-ADE
subsided O
following O
reduction O
in O
tiagabine B-DRUG
dosages O
. O

Propafenone B-DRUG
- O
induced O
ataxia B-ADE
: O
report O
of O
three O
cases O
. O

We O
report O
a O
patient O
with O
chronic O
renal O
failure O
and O
ischemic O
heart O
disease O
who O
developed O
clinically O
significant O
methemoglobinemia B-ADE
after O
an O
axillary O
block O
with O
bupivacaine B-DRUG
and O
additional O
injection O
of O
lidocaine B-DRUG
in O
the O
operative O
field O
. O

We O
report O
the O
case O
of O
a O
patient O
who O
developed O
polyserositis B-ADE
( O
pericardial B-ADE
effusion I-ADE
, O
pleural B-ADE
effusion I-ADE
, O
and O
pericarditis B-ADE
) O
after O
being O
started O
on O
clozapine B-DRUG
, O
and O
whose O
symptoms O
remitted O
upon O
discontinuation O
of O
clozapine B-DRUG
. O

Cerebrovascular B-ADE
complications I-ADE
of O
L B-DRUG
- I-DRUG
asparaginase I-DRUG
therapy O
in O
children O
with O
leukemia O
: O
aphasia B-ADE
and O
other O
neuropsychological B-ADE
deficits I-ADE
. O

We O
describe O
a O
case O
of O
prolonged O
terbinafine B-DRUG
- O
induced O
cholestatic B-ADE
liver I-ADE
disease I-ADE
. O

We O
present O
a O
case O
in O
which O
dipyridamole B-DRUG
induced O
high B-ADE
- I-ADE
grade I-ADE
atrioventricular I-ADE
( I-ADE
AV I-ADE
) I-ADE
block I-ADE
that O
responded O
promptly O
to O
intravenous O
aminophylline O
but O
not O
to O
atropine O
. O

Although O
the O
two O
local O
anesthetics O
usually O
do O
not O
cause O
methemoglobinemia O
, O
we O
suspect O
that O
the O
displacement O
of O
lidocaine B-DRUG
from O
protein O
binding O
by O
bupivacaine O
, O
in O
combination O
with O
metabolic O
acidosis O
and O
treatment O
with O
other O
oxidants O
, O
was O
the O
reason O
for O
the O
development O
of O
methemoglobinemia B-ADE
. O

Hepatobiliary B-ADE
disorders I-ADE
associated O
with O
orally O
administered O
terbinafine B-DRUG
have O
rarely O
been O
reported O
. O

A O
14-year O
- O
old O
female O
developed O
systemic B-ADE
lupus I-ADE
erythematosus I-ADE
( I-ADE
SLE I-ADE
) I-ADE
- I-ADE
like I-ADE
symptoms I-ADE
, O
rash B-ADE
, O
fever B-ADE
, O
leukopenia B-ADE
and O
positive B-ADE
anti I-ADE
- I-ADE
nuclear I-ADE
antibody I-ADE
( O
ANA O
) O
two O
weeks O
after O
administration O
of O
carbamazepine B-DRUG
( O
CBZ B-DRUG
; O
Tegretol B-DRUG
) O
used O
against O
benign O
Rolandic O
epilepsy O
. O

Eosinophilia B-ADE
has O
been O
encountered O
from O
0.2 O
to O
61.7 O
% O
in O
clozapine B-DRUG
- O
treated O
patients O
, O
mostly O
with O
a O
transient O
course O
and O
spontaneous O
remission O
. O

Anaphylaxis B-ADE
to O
cisplatin B-DRUG
following O
nine O
previous O
uncomplicated O
cycles O
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
Carbamazepine B-DRUG
toxicity I-ADE
following O
the O
administration O
of O
Oxybutynin B-DRUG
and O
Dantrolene B-DRUG
. O

Aseptic B-ADE
meningitis I-ADE
, O
hemolytic B-ADE
anemia I-ADE
, O
hepatitis B-ADE
, O
and O
orthostatic B-ADE
hypotension I-ADE
in O
a O
patient O
treated O
with O
trimethoprim B-DRUG
- O
sulfamethoxazole B-DRUG
. O

Five O
personal O
observations O
of O
an O
acute B-ADE
amnestic I-ADE
episode I-ADE
in O
younger O
individuals O
after O
intake O
of O
clioquinol B-DRUG
are O
described O
together O
with O
three O
observations O
from O
the O
medical O
literature O
. O

Corneal B-ADE
endothelial I-ADE
dysfunction I-ADE
associated O
with O
amantadine B-DRUG
toxicity O
. O

However O
, O
1 O
eye O
had O
vitreous B-ADE
hemorrhage I-ADE
after O
repeated O
injections O
of O
tPA B-DRUG
. O

Neurotoxicity B-ADE
of O
valacyclovir B-DRUG
in O
peritoneal O
dialysis O
: O
a O
pharmacokinetic O
study O
. O

BACKGROUND O
: O
Hypersensitivity B-ADE
reactions I-ADE
to O
cyclosporine B-DRUG
are O
rare O
. O

Seven O
patients O
with O
hematologic O
malignancies O
who O
were O
treated O
with O
miconazole B-DRUG
for O
either O
suspected O
or O
proven O
fungal O
infections O
developed O
eight O
episodes O
of O
major O
adverse O
cardiorespiratory B-ADE
and I-ADE
anaphylactic I-ADE
reactions I-ADE
. O

Recently O
, O
CD20-negative B-ADE
tumors I-ADE
have O
been O
described O
after O
Rituximab B-DRUG
therapy O
. O

The O
delayed O
encephalopathy B-ADE
developed O
9 O
and O
22 O
months O
respectively O
after O
the O
first O
dose O
of O
intrathecal O
methotrexate B-DRUG
. O

Gold B-DRUG
- O
induced O
aplastic B-ADE
anemia I-ADE
. O

Disseminated O
muscular O
cysticercosis O
with O
myositis B-ADE
induced O
by O
praziquantel B-DRUG
therapy O
. O

Acute B-ADE
intravascular I-ADE
hemolysis I-ADE
developed O
when O
a O
diabetic O
patient O
, O
previously O
treated O
with O
glyburide B-DRUG
, O
was O
started O
on O
another O
oral O
sulfonylurea O
drug O
, O
chlorpropamide B-DRUG
. O

CONCLUSION O
: O
There O
are O
only O
a O
few O
confirmed O
cases O
of O
gemcitabine B-DRUG
- O
associated O
HUS B-ADE
despite O
the O
widespread O
use O
of O
the O
drug O
. O

Tardive B-ADE
dyskinesia I-ADE
induced O
by O
sulpiride B-DRUG
. O

Despite O
the O
known O
pulmonary B-ADE
side I-ADE
effects I-ADE
of O
nitrofurantoin B-DRUG
, O
there O
is O
no O
report O
of O
this O
toxicity O
occurring O
in O
pregnant O
patients O
. O

Ophthalmologists O
should O
be O
aware O
of O
the O
ocular B-ADE
side I-ADE
effects I-ADE
of O
IFN B-DRUG
therapy O
and O
carefully O
monitor O
patients O
for O
the O
possible O
occurrence O
of O
hypoalbuminemia B-ADE
and O
thrombocytopenia B-ADE
. O

Reversible O
nonthrombocytopenic B-ADE
palpable I-ADE
purpura I-ADE
associated O
with O
metoclopramide B-DRUG
. O

Hepatotoxicity B-ADE
associated O
with O
choline B-DRUG
magnesium I-DRUG
trisalicylate I-DRUG
: O
case O
report O
and O
review O
of O
salicylate B-DRUG
- O
induced O
hepatotoxicity B-ADE
. O

OBJECTIVES O
: O
The O
authors O
described O
a O
case O
of O
Hashimoto B-ADE
's I-ADE
disease I-ADE
during O
interferon B-DRUG
- I-DRUG
alpha I-DRUG
( O
IFN B-DRUG
- I-DRUG
alpha I-DRUG
) O
treatment O
for O
chronic O
viral O
C O
hepatitis O
in O
a O
patient O
with O
the O
specific O
genetic O
susceptibility O
associated O
with O
the O
thyroid O
disease O
. O

Successful O
treatment O
of O
visceral O
leishmaniasis O
with O
allopurinol O
plus O
ketoconazole O
in O
an O
infant O
who O
developed O
pancreatitis B-ADE
caused O
by O
meglumine B-DRUG
antimoniate I-DRUG
. O

CONCLUSIONS O
: O
The O
administration O
of O
prostaglandin B-DRUG
E1 I-DRUG
to O
neonates O
can O
cause O
gastric B-ADE
- I-ADE
outlet I-ADE
obstruction I-ADE
due O
to O
antral B-ADE
hyperplasia I-ADE
. O

No O
explanation O
for O
this O
delay O
was O
found O
, O
other O
than O
the O
possibility O
that O
magnesium B-DRUG
sulfate I-DRUG
treatment O
impeded B-ADE
lactogenesis I-ADE
. O

Stuttering B-ADE
priapism I-ADE
complicating O
warfarin B-DRUG
therapy O
in O
a O
patient O
with O
protein O
C O
deficiency O
. O

We O
report O
the O
first O
case O
of O
rhabdomyolysis B-ADE
related O
to O
the O
administration O
of O
clarithromycin B-DRUG
without O
concurrent O
use O
of O
other O
medications O
. O

We O
report O
a O
case O
of O
acute B-ADE
generalized I-ADE
exanthematous I-ADE
pustulosis I-ADE
( O
AGEP O
) O
induced O
by O
salazosulfapyridine B-DRUG
in O
a O
patient O
with O
ulcerative O
colitis O
. O

The O
authors O
describe O
pericardial B-ADE
hemorrhage I-ADE
, O
which O
is O
related O
to O
the O
use O
of O
low O
- O
dose O
acetylsalicylic B-DRUG
acid I-DRUG
in O
a O
patient O
with O
essential O
thrombocythemia O
. O

In O
this O
case O
, O
it O
was O
suspected O
that O
a O
combination O
of O
cigarette O
smoking O
, O
pulmonary O
fibrosis O
, O
and O
low O
- O
dose O
methotrexate B-DRUG
therapy O
might O
have O
promoted O
the O
development O
of O
lung B-ADE
cancer I-ADE
. O

Cutaneous B-ADE
ulceration I-ADE
: O
an O
unusual O
complication O
of O
intravenous O
pentamidine B-DRUG
therapy O
. O

We O
presented O
a O
patient O
with O
status O
asthmaticus O
treated O
with O
a O
combination O
of O
theophylline B-DRUG
and O
prednisone B-DRUG
who O
developed O
a O
perforated B-ADE
gastric I-ADE
ulcer I-ADE
. O

Methylphenidate B-DRUG
and O
dextroamphetamine B-DRUG
- O
induced O
peripheral B-ADE
vasculopathy I-ADE
. O

On O
the O
fifth O
day O
after O
administration O
of O
a O
high O
dose O
of O
ARA B-DRUG
- I-DRUG
C I-DRUG
( O
2 O
g O
/ O
m2 O
intravenously O
every O
12 O
hours O
) O
, O
she O
developed O
bullous B-ADE
lesions I-ADE
on I-ADE
the I-ADE
hands I-ADE
and I-ADE
soles I-ADE
that I-ADE
disseminated I-ADE
, I-ADE
evolving I-ADE
to I-ADE
necrosis I-ADE
, O
sepsis B-ADE
, O
and O
death B-ADE
on O
the O
22nd O
day O
. O

k O
bipolar O
manic O
- O
depressive O
patient O
, O
developed O
while O
on O
lithium B-DRUG
prophylaxis O
, O
akathisia B-ADE
at O
therapeutic O
serum O
lithium O
levels O
and O
subsequently O
bucco B-ADE
- I-ADE
linguo I-ADE
- I-ADE
masticatory I-ADE
dyskinesia I-ADE
. O

Evidence O
is O
shown O
in O
this O
report O
that O
adenosine B-DRUG
was O
associated O
with O
dangerous O
worsening O
of O
arrhythmia B-ADE
in O
patients O
with O
atrial O
flutter O
. O

Hydroxyurea B-DRUG
( O
HU O
) O
and O
sodium B-DRUG
phenylbutyrate I-DRUG
( O
SPB O
) O
have O
been O
shown O
to O
increase B-ADE
fetal I-ADE
hemoglobin I-ADE
( O
Hb O
F O
) O
levels O
in O
patients O
with O
thalassemia O
intermedia O
. O

Pure B-ADE
red I-ADE
cell I-ADE
aplasia I-ADE
associated O
with O
fenoprofen B-DRUG
. O

Herein O
, O
we O
describe O
a O
patient O
with O
AIDS O
who O
presented O
to O
medical O
attention O
with O
pancytopenia B-ADE
48 O
months O
postchemotherapy O
with O
etoposide B-DRUG
, O
prednisone B-DRUG
, O
vincristine B-DRUG
, O
cyclophosphamide B-DRUG
, O
doxorubicin B-DRUG
, O
and O
rituximab B-DRUG
( O
R O
- O
EPOCH O
) O
for O
diffuse O
large O
B O
- O
cell O
lymphoma O
. O

We O
report O
a O
case O
of O
acute B-ADE
generalized I-ADE
exanthematous I-ADE
pustulosis I-ADE
( O
AGEP B-ADE
) O
in O
a O
50-year O
- O
old O
woman O
that O
was O
attributed O
to O
the O
ingestion O
of O
nimesulide B-DRUG
. O

Sulfasalazine B-DRUG
has O
been O
associated O
with O
bronchopulmonary B-ADE
complications I-ADE
of I-ADE
inflammatory I-ADE
bowel I-ADE
disease I-ADE
( O
IBD B-ADE
) O
in O
adults O
. O

The O
second O
was O
an O
82-year O
- O
old O
man O
receiving O
ticlopidine B-DRUG
for O
2 O
years O
when O
, O
during O
a O
febrile O
episode O
, O
he O
was O
found O
neutropenic B-ADE
with O
marrow B-ADE
aplasia I-ADE
. O

The O
renal O
biopsy O
showed O
focal B-ADE
segmental I-ADE
glomerulosclerosis I-ADE
, O
which O
has O
only O
been O
previously O
reported O
in O
two O
cases O
of O
CML O
treated O
with O
IFNalpha B-DRUG
. O

Well O
- O
differentiated O
endometrial B-ADE
adenocarcinoma I-ADE
of I-ADE
the I-ADE
secretory I-ADE
type I-ADE
( O
FIGO O
Grade O
1 O
) O
with O
minimal O
myometrial O
invasion O
occurred O
in O
a O
postmenopausal O
patient O
on O
tamoxifen B-DRUG
therapy O
5 O
years O
after O
mastectomy O
for O
breast O
carcinoma O
. O

CONCLUSION O
: O
This O
case O
illustrates O
a O
potential O
link O
between O
dermatologic B-ADE
and I-ADE
ocular I-ADE
5-FU B-DRUG
toxicities I-ADE
. O

Disulfiram B-DRUG
- O
induced O
hepatitis B-ADE
. O

Zoledronic B-DRUG
acid I-DRUG
- O
induced O
severe B-ADE
hypocalcaemia I-ADE
in O
a O
prostate O
cancer O
patient O
with O
extensive O
osteoblastic O
bone O
metastases O
. O

We O
report O
a O
myeloma O
patient O
who O
developed O
severe B-ADE
paralytic I-ADE
ileus I-ADE
during O
bortezomib B-DRUG
therapy O
, O
which O
presented O
in O
the O
context O
of O
progressive O
constipation O
without O
other O
known O
causes O
and O
which O
regressed O
promptly O
with O
medical O
management O
after O
drug O
cessation O
, O
suggesting O
a O
direct O
causal O
relationship O
. O

The O
most O
commonly O
recognized O
toxic O
effect O
of O
ethambutol B-DRUG
is O
optic B-ADE
neuropathy I-ADE
, O
which O
generally O
is O
considered O
uncommon O
and O
reversible O
in O
medical O
literature O
. O

Here O
we O
report O
ramipril B-DRUG
- O
induced O
cutaneous B-ADE
vasculitis I-ADE
in O
a O
patient O
who O
required O
steroid O
therapy O
to O
control O
it O
. O

Based O
on O
the O
clinical O
status O
of O
the O
patient O
, O
it O
was O
suspected O
that O
several O
conditions O
contributed O
to O
the O
abnormal B-ADE
hypersensitivity I-ADE
to O
warfarin B-DRUG
. O

The O
patient O
described O
feeling B-ADE
cold I-ADE
with O
worsening B-ADE
headache I-ADE
and O
chills B-ADE
approximately O
one O
hour O
after O
infusion O
of O
the O
first O
dose O
of O
penicillin B-DRUG
. O

Visual B-ADE
hallucinations I-ADE
after O
intravitreal O
injection O
of O
bevacizumab B-DRUG
in O
vascular O
age O
- O
related O
macular O
degeneration O
. O

A O
case O
of O
metoclopramide B-DRUG
- O
induced O
oculogyric B-ADE
crisis I-ADE
in O
a O
16-year O
- O
old O
girl O
with O
cystic O
fibrosis O
. O

Thus O
, O
clinical O
recognition O
of O
sleep B-ADE
disordered I-ADE
breathing I-ADE
should O
be O
taken O
into O
account O
when O
rheumatoid O
arthritis O
patients O
are O
to O
be O
treated O
with O
infliximab B-DRUG
. O

The O
use O
of O
beclomethasone B-DRUG
diproprionate I-DRUG
inhaler O
complicated O
by O
the O
development O
of O
an O
eosinophilic B-ADE
pneumonia I-ADE
reaction I-ADE
. O

Hydroxyurea B-DRUG
associated O
with O
concomitant O
occurrence O
of O
diffuse B-ADE
longitudinal I-ADE
melanonychia I-ADE
and O
multiple B-ADE
squamous I-ADE
cell I-ADE
carcinomas I-ADE
in O
an O
elderly O
subject O
. O

CASE O
SUMMARIES O
: O
Two O
patients O
who O
received O
ifosfamide B-DRUG
- O
containing O
chemotherapy O
developed O
NCSE B-ADE
. O

A O
girl O
with O
cystic O
fibrosis O
and O
cyclic O
neutropenia O
developed O
an O
erythematous B-ADE
papular I-ADE
eruption I-ADE
without O
fever O
or O
neutrophilia O
7 O
months O
after O
commencing O
therapy O
with O
G B-DRUG
- I-DRUG
CSF I-DRUG
. O

We O
describe O
a O
case O
of O
severe B-ADE
aplastic I-ADE
anemia I-ADE
( O
AA B-ADE
) O
that O
was O
probably O
induced O
by O
lenalidomide B-DRUG
. O

Review O
of O
this O
and O
previously O
reported O
cases O
indicates O
the O
need O
for O
early O
diagnosis O
of O
amiodarone B-DRUG
pneumonitis B-ADE
, O
immediate O
withdrawal O
of O
amiodarone O
, O
and O
prompt O
but O
continued O
steroid O
therapy O
to O
ensure O
full O
recovery O
. O

De B-ADE
novo I-ADE
absence I-ADE
status I-ADE
of O
late O
onset O
following O
withdrawal O
of O
lorazepam B-DRUG
: O
a O
case O
report O
. O

Intravenous O
diazepam B-DRUG
exacerbated O
the O
seizures B-ADE
. O

The O
capacity O
of O
zuclopenthixol B-DRUG
to O
induce O
priapism B-ADE
is O
thought O
to O
be O
due O
to O
its O
antagonist O
activity O
on O
alpha O
- O
adrenergic O
receptors O
. O

Two O
elderly O
women O
suffered O
an O
acute B-ADE
deterioration I-ADE
of I-ADE
renal I-ADE
function I-ADE
after O
treatment O
with O
cefoxitin B-DRUG
sodium I-DRUG
. O

In O
this O
case O
, O
interferon B-DRUG
alpha I-DRUG
induced O
polymyositis B-ADE
and O
cardiomyopathy B-ADE
is O
diagnosed O
in O
a O
33-yr O
- O
old O
male O
patient O
with O
history O
of O
chronic O
hepatitis O
B O
. O

A O
third O
patient O
experienced O
disabling B-ADE
neurotoxicity I-ADE
in O
the O
extremity O
of O
a O
prior O
ulnar O
nerve O
and O
tendon O
transposition O
after O
receiving O
paclitaxel B-DRUG
. O

A O
73-year O
- O
old O
woman O
with O
non O
- O
Hodgkin O
's O
lymphoma O
had O
two O
episodes O
of O
severe O
, O
bilateral O
, O
sensori B-ADE
- I-ADE
neural I-ADE
hearing I-ADE
loss I-ADE
after O
vincristine B-DRUG
therapy O
. O

Diffusion O
- O
weighted O
MRI O
correlates O
of O
subacute O
methotrexate B-DRUG
- O
related O
neurotoxicity B-ADE
. O

A O
case O
is O
presented O
in O
which O
a O
68-year O
- O
old O
man O
became O
delirious B-ADE
after O
being O
withdrawn O
from O
a O
low O
dosage O
of O
alprazolam B-DRUG
. O

However O
, O
adenosine B-DRUG
shortens O
the O
antegrade O
refractoriness O
of O
accessory O
atrioventricular O
connections O
and O
may O
cause O
acceleration B-ADE
of I-ADE
the I-ADE
ventricular I-ADE
rate I-ADE
during O
atrial O
fibrillation O
. O

CONCLUSIONS O
: O
Symptoms O
and O
pathologic O
changes O
of O
colitis B-ADE
are O
associated O
with O
exposure O
to O
rofecoxib B-DRUG
. O

This O
case O
suggests O
the O
importance O
of O
careful O
observation O
for O
extramedullary B-ADE
relapse I-ADE
in O
patients O
who O
are O
treated O
with O
ATRA B-DRUG
. O

Infliximab B-DRUG
therapy O
may O
cause O
a O
lupus B-ADE
- I-ADE
like I-ADE
syndrome I-ADE
that O
is O
reversible O
upon O
discontinuing O
this O
agent O
. O

Pulmonary B-ADE
oedema I-ADE
after O
hexoprenaline B-DRUG
administration O
in O
preterm O
labour O
. O

Case O
study O
: O
a O
modified O
topical O
treatment O
regimen O
for O
sodium O
warfarin B-DRUG
- O
induced O
necrotizing B-ADE
fasciitis I-ADE
. O

Reye B-ADE
- I-ADE
like I-ADE
syndrome I-ADE
following O
treatment O
with O
the O
pantothenic O
acid O
antagonist O
, O
calcium B-DRUG
hopantenate I-DRUG
. O

We O
describe O
2 O
cases O
of O
SJS B-ADE
related O
to O
nevirapine B-DRUG
use O
and O
review O
the O
literature O
on O
this O
newly O
recognized O
association O
. O

By O
means O
of O
the O
in O
vitro O
heparin O
- O
induced O
platelet O
activation O
( O
HIPA O
) O
assay O
it O
was O
shown O
that O
standard O
heparin B-DRUG
and O
the O
LMW O
heparins O
Fragmin B-DRUG
and O
Fraxiparin B-DRUG
( O
Sanofi O
Labaz O
, O
Munich O
, O
FRG O
) O
, O
as O
well O
as O
the O
enoxaparine O
Clexane B-DRUG
( O
Nattermann O
, O
Cologne O
, O
FRG O
) O
, O
all O
induced O
platelet B-ADE
activation I-ADE
with O
the O
patient O
's O
serum O
. O

The O
authors O
report O
a O
case O
of O
urinary B-ADE
incontinence I-ADE
( O
UI B-ADE
) O
that O
occurred O
in O
a O
woman O
after O
administration O
of O
venlafaxine B-DRUG
. O

DISCUSSION O
: O
This O
case O
shows O
that O
switching O
to O
zidovudine B-DRUG
potentially O
can O
lead O
to O
a O
hyperlactatemia B-ADE
relapse I-ADE
. O

Four O
days O
after O
intravenous O
Zoledronic B-DRUG
acid I-DRUG
, O
the O
patient O
presented O
to O
emergency O
room O
with O
complaints O
of O
carpopedal B-ADE
spasm I-ADE
and O
bronchospasm B-ADE
. O

The O
authors O
describe O
a O
case O
of O
the O
catatonia B-ADE
syndrome I-ADE
associated O
with O
disulfiram B-DRUG
therapy O
. O

Prolonged B-ADE
prostate I-ADE
- I-ADE
specific I-ADE
antigen I-ADE
response I-ADE
in O
flutamide B-DRUG
withdrawal I-ADE
syndrome I-ADE
despite O
disease O
progression O
. O

A O
high O
dose O
of O
cotrimoxazole B-DRUG
induced O
hyperkalaemia B-ADE
with O
the O
elevation B-ADE
of I-ADE
serum I-ADE
creatinine I-ADE
and I-ADE
blood I-ADE
urea I-ADE
, O
and O
increased B-ADE
urinary I-ADE
N I-ADE
- I-ADE
acetyl I-ADE
glucosaminase I-ADE
after O
several O
days O
of O
the O
drug O
administration O
in O
these O
patients O
; O
one B-ADE
patient I-ADE
became I-ADE
unconscious I-ADE
. O

Presented O
is O
a O
case O
of O
acute B-ADE
renal I-ADE
failure I-ADE
induced O
by O
acetazolamide B-DRUG
therapy O
for O
glaucoma O
. O

In O
addition O
, O
there O
is O
a O
report O
on O
prolonged B-ADE
ECT I-ADE
seizure I-ADE
related O
to O
ciprofloxacin B-DRUG
, O
which O
has O
an O
epileptogenic O
property O
with O
a O
similar O
action O
to O
beta O
- O
lactam O
antibiotics O
. O

A O
patient O
with O
disseminated O
herpes O
zoster O
developed O
a O
syndrome B-ADE
of I-ADE
inappropriate I-ADE
antidiuretic I-ADE
hormone I-ADE
and O
profound O
hyponatremia B-ADE
secondary O
to O
the O
administration O
of O
adenine B-DRUG
arabinoside I-DRUG
. O

Anticonvulsant B-ADE
hypersensitivity I-ADE
syndrome I-ADE
associated O
with O
Bellamine B-DRUG
S I-DRUG
, O
a O
therapy O
for O
menopausal O
symptoms O
. O

Life O
- O
threatening O
anaphylactoid B-ADE
reaction I-ADE
to O
amifostine B-DRUG
used O
with O
concurrent O
chemoradiotherapy O
for O
nasopharyngeal O
cancer O
in O
a O
patient O
with O
dermatomyositis O
: O
a O
case O
report O
with O
literature O
review O
. O

Tamoxifen B-DRUG
retinopathy B-ADE
. O

Thyroid B-ADE
dysfunction I-ADE
has O
been O
reported O
in O
patients O
with O
malignant O
disease O
treated O
with O
recombinant B-DRUG
alpha I-DRUG
interferon I-DRUG
. O

Such O
anagen B-ADE
effluvium I-ADE
with O
lichenoid B-ADE
eruption I-ADE
following O
INH B-DRUG
therapy O
has O
not O
been O
observed O
previously O
. O

Aplastic B-ADE
anemia I-ADE
and O
agranulocytosis B-ADE
in O
patients O
using O
methazolamide B-DRUG
for O
glaucoma O
. O

Cicatricial B-ADE
entropion I-ADE
associated O
with O
chronic O
dipivefrin B-DRUG
application O
. O

We O
report O
a O
case O
of O
myoclonus B-ADE
induced O
by O
quetiapine B-DRUG
. O

BACKGROUND O
: O
Accutane B-DRUG
a O
teratogenic B-ADE
prescription O
drug O
licensed O
to O
treat O
severe O
, O
recalcitrant O
nodular O
acne O
. O

CASE O
REPORT O
: O
We O
report O
a O
case O
of O
acute B-ADE
severe I-ADE
hepatitis I-ADE
resulting O
from O
erlotinib B-DRUG
monotherapy O
in O
a O
patient O
with O
locally O
advanced O
pancreatic O
cancer O
. O

Withdrawal B-ADE
emergent I-ADE
syndrome I-ADE
in O
an O
infant O
associated O
with O
maternal O
haloperidol B-DRUG
therapy O
. O

The O
use O
of O
cyclosporin B-DRUG
has O
been O
associated O
with O
the O
development O
of O
cholelithiasis B-ADE
in O
transplant O
recipients O
. O

After O
abstinence O
from O
oolong B-DRUG
tea I-DRUG
his O
delirium B-ADE
resolved O
. O

Four O
patients O
who O
manifested O
symptoms O
of O
the O
antiepileptic O
drug O
( O
AED O
) O
hypersensitivity B-ADE
syndrome I-ADE
during O
therapy O
with O
carbamazepine B-DRUG
are O
reported O
. O

Two O
weeks O
following O
rechallenge O
with O
alendronate B-DRUG
sodium I-DRUG
resulted O
in O
recurrence O
of O
his O
scleritis B-ADE
. O

Ezetimibe B-DRUG
- O
induced O
acute B-ADE
pancreatitis I-ADE
. O

A O
review O
of O
the O
literature O
revealed O
two O
other O
cases O
of O
hepatic B-ADE
angiosarcoma I-ADE
in O
patients O
after O
long O
- O
term O
cyclophosphamide B-DRUG
treatment O
. O

With O
the O
increasing O
use O
of O
Cyclosporine B-DRUG
A I-DRUG
in O
transplant O
patients O
, O
the O
incidence O
of O
herpes B-ADE
esophagitis I-ADE
may O
increase O
. O

CONCLUSION O
: O
These O
cases O
suggest O
that O
moxifloxacin B-DRUG
may O
interfere O
with O
the O
healing O
of O
corneal B-ADE
ulcers I-ADE
. O

To O
the O
best O
of O
our O
knowledge O
only O
two O
previous O
cases O
of O
AML B-ADE
have O
been O
linked O
to O
treatment O
of O
HCL O
with O
purine O
analogs O
, O
both O
with O
2-chlorodeoxyadenosine B-DRUG
. O

The O
patient O
suffered O
a O
life B-ADE
- I-ADE
threatening I-ADE
anaphylactoid I-ADE
reaction I-ADE
to O
amifostine B-DRUG
. O

The O
mean O
time O
from O
starting O
MMF B-DRUG
to O
the O
development O
of O
neutropenia B-ADE
was O
4 O
months O
. O

The O
possible O
effects O
of O
tamoxifen O
upon O
the O
uterus O
are O
discussed O
in O
this O
article O
, O
in O
view O
of O
reports O
of O
tamoxifen B-DRUG
associated O
with O
endometrial B-ADE
carcinoma I-ADE
and O
endometriosis B-ADE
. O

This O
article O
reports O
the O
case O
of O
an O
otherwise O
healthy O
patient O
who O
experienced O
permanent O
sensorineural B-ADE
hearing I-ADE
loss I-ADE
after O
a O
brief O
course O
of O
naproxen B-DRUG
and O
reviews O
the O
literature O
on O
NSAID O
- O
related O
permanent O
sensorineural O
hearing O
loss O
. O

Nonspecific O
but O
significant B-ADE
abnormalities I-ADE
have O
been O
described O
in O
the O
infants O
of O
women O
treated O
with O
disulfiram B-DRUG
in O
the O
first O
trimester O
of O
their O
pregnancies O
. O

In O
this O
report O
we O
present O
four O
patients O
treated O
with O
a O
combination O
of O
different O
psychotropic O
drugs O
, O
in O
whom O
asterixis B-ADE
was O
triggered O
either O
by O
adding O
carbamazepine B-DRUG
( O
CBZ B-DRUG
) O
to O
a O
treatment O
regimen O
, O
or O
by O
increasing O
its O
dosage O
. O

One O
patient O
developed O
large B-ADE
intramural I-ADE
esophageal I-ADE
hematoma I-ADE
as O
a O
complication O
of O
heparin B-DRUG
therapy O
. O

Persistent B-ADE
light I-ADE
reactivity I-ADE
from O
systemic O
quinine B-DRUG
. O

This O
is O
, O
to O
the O
best O
of O
our O
knowledge O
, O
the O
first O
report O
of O
a O
case O
in O
which O
agranulocytosis B-ADE
followed O
treatment O
with O
both O
propylthiouracil B-DRUG
and O
methimazole B-DRUG
in O
the O
same O
patient O
. O

CONCLUSIONS O
: O
Although O
mirtazapine B-DRUG
offers O
clinicians O
a O
combination O
of O
strong O
efficacy O
and O
good O
safety O
, O
we O
suggest O
bearing O
SS B-ADE
in O
mind O
when O
prescribing O
this O
drug O
, O
especially O
in O
frail O
, O
elderly O
patients O
with O
underlying O
chronic O
conditions O
. O

Case O
report O
: O
dapsone B-DRUG
hypersensitivity B-ADE
syndrome I-ADE
associated O
with O
treatment O
of O
the O
bite O
of O
a O
brown O
recluse O
spider O
. O

Used O
injudiciously O
, O
naloxone B-DRUG
can O
lead O
to O
withdrawal B-ADE
syndrome I-ADE
, O
return O
of O
severe B-ADE
pain I-ADE
, O
and O
other O
adverse O
effects O
. O

The O
case O
of O
a O
29-year O
- O
old O
man O
suffering O
from O
falciparum O
malaria O
disease O
who O
got O
a O
reversible B-ADE
hearing I-ADE
loss I-ADE
from O
quinine B-DRUG
therapy O
is O
presented O
. O

The O
patient O
was O
diagnosed O
with O
carbamazepine B-DRUG
toxicity I-ADE
related O
to O
the O
introduction O
of O
ritonavir B-DRUG
. O

Approximately O
15 O
min O
after O
the O
first O
administration O
of O
nebulised O
morphine B-DRUG
the O
patient O
became O
markedly O
bradypneic B-ADE
( O
respiratory O
rate O
: O
4 O
- O
5 O
bpm O
) O
, O
hypotensive B-ADE
( O
BP O
70/40 O
mmHg O
) O
, O
and O
responded O
only O
partially O
to O
command O
. O

Based O
on O
our O
experience O
and O
on O
previously O
published O
data O
, O
serum O
ammonia O
levels O
appear O
to O
be O
indicated O
in O
all O
ED O
patients O
on O
valproic B-DRUG
acid I-DRUG
therapy O
who O
present O
with O
altered B-ADE
mental I-ADE
status I-ADE
. O

Described O
here O
are O
2 O
patients O
who O
developed O
thrombotic B-ADE
microangiopathy I-ADE
of O
the O
kidneys O
after O
receiving O
high O
cumulative O
doses O
of O
the O
new O
anticancer O
drug O
gemcitabine B-DRUG
. O

A O
15-year O
follow O
- O
up O
of O
phenytoin B-DRUG
- O
induced O
unilateral B-ADE
gingival I-ADE
hyperplasia I-ADE
: O
a O
case O
report O
. O

Leflunomide B-DRUG
- O
associated O
infections B-ADE
in O
rheumatoid O
arthritis O
. O

The O
neurotoxicity B-ADE
seen O
with O
HDARAC B-DRUG
is O
dose O
- O
related O
and O
has O
occurred O
in O
up O
to O
60 O
percent O
of O
treated O
patients O
. O

We O
report O
the O
first O
case O
of O
chlorambucil B-DRUG
- O
induced O
DRESS B-ADE
syndrome I-ADE
in O
a O
70-year O
- O
old O
man O
recently O
diagnosed O
with O
chronic O
lymphocytic O
leukaemia O
. O

L B-DRUG
- I-DRUG
asparaginase I-DRUG
- O
induced O
severe B-ADE
necrotizing I-ADE
pancreatitis I-ADE
successfully O
treated O
with O
percutaneous O
drainage O
. O

In O
this O
report O
, O
we O
describe O
a O
patient O
receiving O
lenalidomide B-DRUG
in O
whom O
dyspnea B-ADE
, O
fever B-ADE
, O
hypoxia B-ADE
, O
and O
diffuse B-ADE
pulmonary I-ADE
infiltrates I-ADE
developed O
. O

Three O
senile O
patients O
developed O
fatal B-ADE
acute I-ADE
encephalopathy I-ADE
while O
receiving O
calcium B-DRUG
hopantenate I-DRUG
. O

CONCLUSIONS O
: O
Optic B-ADE
neuritis I-ADE
in O
combination O
with O
other O
neurological B-ADE
signs I-ADE
, O
simulating O
multiple O
sclerosis O
, O
should O
be O
included O
in O
the O
list O
of O
adverse O
effects O
of O
recombinant O
and O
natural O
interferon B-DRUG
alpha I-DRUG
administration O
. O

Experience O
with O
five O
patients O
in O
whom O
impaired B-ADE
renal I-ADE
function I-ADE
developed O
early O
during O
amphotericin B-DRUG
B I-DRUG
therapy O
is O
reported O
. O

Hepatocellular B-ADE
damage I-ADE
following O
therapeutic O
intravenous O
iron B-DRUG
sucrose I-DRUG
infusion O
in O
a O
child O
. O

Case O
3 O
: O
A O
29-year O
- O
old O
female O
alcoholic O
complained O
of O
general O
fatigue B-ADE
and O
a O
slight O
fever B-ADE
after O
1.5 O
years O
of O
abstinence O
with O
cyanamide B-DRUG
treatment O
. O

METHODS O
: O
We O
report O
a O
patient O
who O
had O
an O
anaphylactic B-ADE
reaction I-ADE
during O
the O
intravenous O
infusion O
of O
cyclosporine B-DRUG
. O

Although O
the O
data O
indicate O
an O
immune O
- O
complex O
cause O
for O
gold B-DRUG
- I-DRUG
salt I-DRUG
nephropathy B-ADE
, O
the O
incident O
antigen O
( O
or O
antigens O
) O
and O
mechanism O
of O
action O
remain O
unidentified O
. O

After O
discontinuing O
captopril B-DRUG
and O
starting O
systemic O
steroids O
, O
her O
symptomatology O
rapidly O
improved O
, O
and O
her O
eosinophilia B-ADE
and O
radiographic B-ADE
abnormalities I-ADE
both O
resolved O
. O

PURPOSE O
: O
To O
investigate O
the O
concentration O
- O
side O
effect O
relationship O
in O
a O
patient O
with O
severe O
acyclovir B-DRUG
- O
induced O
neurotoxicity B-ADE
and O
to O
summarize O
the O
information O
available O
in O
the O
literature O
about O
central B-ADE
nervous I-ADE
system I-ADE
side I-ADE
effects I-ADE
due O
to O
acyclovir B-DRUG
. O

Delayed O
bowel B-ADE
injury I-ADE
is O
an O
infrequently O
observed O
complication O
of O
chromic B-DRUG
phosphate I-DRUG
administration O
. O

This O
paper O
reports O
a O
case O
of O
fatal B-ADE
perhexiline B-DRUG
maleate I-DRUG
liver I-ADE
injury I-ADE
. O

We O
describe O
a O
case O
of O
interstitial B-ADE
hypoxaemiant I-ADE
pneumonitis I-ADE
probably O
related O
to O
flecainide B-DRUG
in O
a O
patient O
with O
the O
LEOPARD O
syndrome O
, O
a O
rare O
congenital O
disorder O
. O

A O
possible O
case O
of O
carbamazepine B-DRUG
induced O
pancreatitis B-ADE
. O

Toxicity B-ADE
, O
pharmacokinetics O
, O
and O
in O
vitro O
hemodialysis O
clearance O
of O
ifosfamide B-DRUG
and O
metabolites O
in O
an O
anephric O
pediatric O
patient O
with O
Wilms O
' O
tumor O
. O

Cefuroxime B-DRUG
- O
induced O
immune B-ADE
hemolysis I-ADE
. O

Two O
years O
later O
, O
24 O
hours O
following O
an O
increase O
in O
the O
dose O
of O
disopyramide B-DRUG
from O
300 O
to O
600 O
mg O
/ O
day O
, O
AVT B-ADE
with O
syncope B-ADE
occurred O
; O
isoproterenol O
abolished O
the O
arrhythmia O
instantly O
. O

Proton O
MRS O
examination O
demonstrated O
a O
persistent O
lactate B-ADE
elevation I-ADE
during O
metronidazole B-DRUG
treatment O
. O

We O
report O
a O
5-year O
- O
old O
boy O
with O
CF O
who O
had O
a O
stricture B-ADE
of I-ADE
the I-ADE
hepatic I-ADE
flexure I-ADE
region I-ADE
with I-ADE
associated I-ADE
narrowing I-ADE
due O
to O
submucosal B-ADE
fibrosis I-ADE
of I-ADE
the I-ADE
transverse I-ADE
colon I-ADE
, O
secondary O
to O
high B-DRUG
- I-DRUG
lipase I-DRUG
pancreatin I-DRUG
therapy O
. O

Based O
on O
the O
Naranjo O
probability O
scale O
, O
serotonin B-ADE
syndrome I-ADE
was O
a O
probable O
adverse O
reaction O
associated O
with O
co O
- O
administration O
of O
citalopram B-DRUG
and O
fentanyl B-DRUG
. O

A O
woman O
with O
a O
20-year O
history O
of O
acral O
pustular O
psoriasis O
of O
Hallopeau O
and O
recurrent O
pustular O
lesions O
of O
the O
forearms O
and O
lower O
legs O
, O
developed O
a O
B B-ADE
- I-ADE
cell I-ADE
lymphoma I-ADE
of O
the O
lip O
following O
4 O
1/2 O
years O
of O
treatment O
with O
razoxane B-DRUG
. O

The O
case O
resembles O
two O
previously O
reported O
cases O
of O
optic B-ADE
neuropathy I-ADE
which O
occurred O
in O
patients O
with O
Wilson O
's O
disease O
who O
were O
receiving O
penicillamine B-DRUG
. O

Fatal B-ADE
radiation I-ADE
myelopathy I-ADE
after O
high O
- O
dose O
busulfan B-DRUG
and O
melphalan B-DRUG
chemotherapy O
and O
radiotherapy O
for O
Ewing O
's O
sarcoma O
: O
a O
review O
of O
the O
literature O
and O
implications O
for O
practice O
. O

The O
presented O
patient O
was O
treated O
with O
200 O
mg O
TCA B-DRUG
and O
developed O
Cushing B-ADE
's I-ADE
syndrome I-ADE
6 O
weeks O
later O
( O
cortisol O
and O
ACTH O
concentrations O
were O
below O
limits O
of O
detection O
, O
TCA O
concentrations O
were O
> O
3 O
micrograms O
/ O
l O
) O
. O

This O
finding O
suggests O
that O
fluvoxamine B-DRUG
can O
precipitate O
Schneiderian B-ADE
first I-ADE
- I-ADE
rank I-ADE
symptoms I-ADE
in O
some O
susceptible O
patients O
. O

A O
40-year O
- O
old O
man O
with O
a O
long O
standing O
history O
of O
rheumatoid O
arthritis O
was O
treated O
with O
MTX B-DRUG
over O
a O
6 O
month O
period O
and O
developed O
an O
overwhelming B-ADE
hepatic I-ADE
necrosis I-ADE
. O

We O
report O
a O
13 O
year O
- O
old O
male O
who O
developed O
life O
- O
threatening O
anaphylaxis B-ADE
early O
in O
the O
course O
of O
Increlex B-DRUG
therapy O
. O

The O
case O
concerns O
the O
sudden B-ADE
death I-ADE
of O
a O
29-year O
- O
old O
male O
during O
clozapine B-DRUG
therapy O
started O
2 O
weeks O
before O
. O

PURPOSE O
: O
To O
report O
patients O
who O
presented O
to O
the O
oculoplastics O
department O
for O
repair O
of O
cicatrical B-ADE
entropion I-ADE
after O
topical O
use O
of O
dipivefrin B-DRUG
. O

METHOD O
: O
The O
authors O
followed O
a O
patient O
with O
chronic O
HCV O
who O
received O
interferon B-DRUG
and O
ribavirin B-DRUG
and O
who O
developed O
hallucinations B-ADE
ultimately O
requiring O
psychiatric O
hospitalization O
. O

To O
our O
knowledge O
, O
the O
syndrome O
of O
fever B-ADE
, O
pulmonary B-ADE
infiltrates I-ADE
, O
and O
pleural B-ADE
effusion I-ADE
following O
use O
of O
acyclovir B-DRUG
has O
not O
been O
previously O
reported O
. O

Metoclopramide B-DRUG
- O
induced O
parkinsonism B-ADE
. O

Lamotrigine B-DRUG
toxicity I-ADE
secondary O
to O
sertraline B-DRUG
. O

Intra B-ADE
- I-ADE
neural I-ADE
ceroid I-ADE
- I-ADE
like I-ADE
pigment I-ADE
following O
the O
treatment O
of O
lepromatous O
leprosy O
with O
clofazimine B-DRUG
( O
B663 B-DRUG
; O
Lamprene B-DRUG
) O
. O

In O
the O
present O
paper O
, O
we O
discuss O
the O
first O
Japanese O
vivax O
malaria O
patient O
whose O
QT B-ADE
interval I-ADE
was I-ADE
prolonged I-ADE
after O
treatment O
with O
halofantrine B-DRUG
. O

Psoriasis B-ADE
- I-ADE
like I-ADE
skin I-ADE
reaction I-ADE
in O
a O
patient O
with O
rheumatoid O
arthritis O
after O
sulphasalazine B-DRUG
therapy O
. O

The O
hearing B-ADE
impairment I-ADE
and O
tinnitus B-ADE
were O
gradually O
reduced O
after O
PTU B-DRUG
withdrawal O
and O
corticosteroid O
and O
azathioprine O
treatment O
. O

A O
typical O
case O
of O
dextran-40 B-DRUG
associated O
acute B-ADE
renal I-ADE
failure I-ADE
is O
presented O
. O

A O
twelve O
year O
- O
old O
- O
girl O
with O
idiopathic O
partial O
epilepsy O
with O
secondary O
generalization O
, O
developed O
acute B-ADE
psychosis I-ADE
10 O
days O
after O
the O
administration O
of O
levetiracetam B-DRUG
. O

We O
report O
two O
patients O
who O
developed O
intense O
livedo B-ADE
reticularis I-ADE
clearly O
related O
to O
the O
administration O
of O
interferon B-DRUG
alpha I-DRUG
2b I-DRUG
as O
an O
adjuvant O
therapy O
for O
melanoma O
. O

Mycobacterium B-ADE
marinum I-ADE
infection I-ADE
complicating O
Crohn O
's O
disease O
, O
treated O
with O
infliximab B-DRUG
. O

We O
present O
a O
case O
of O
a O
sustained B-ADE
monomorphic I-ADE
ventricular I-ADE
tachycardia I-ADE
following O
adenosine B-DRUG
infusion O
. O

A O
case O
of O
severe B-ADE
acute I-ADE
hepatitis I-ADE
caused O
by O
cyproterone B-DRUG
acetate I-DRUG
in O
a O
71 O
year O
old O
man O
with O
prostatic O
carcinoma O
is O
reported O
with O
a O
review O
of O
the O
literature O
on O
hepatic O
reactions O
to O
this O
drug O
. O

Severe O
rhabdomyolysis B-ADE
following O
massive O
ingestion O
of O
oolong B-DRUG
tea I-DRUG
: O
caffeine B-DRUG
intoxication I-ADE
with O
coexisting O
hyponatremia O
. O

In O
addition O
to O
disease O
refractoriness O
, O
rare O
instances O
of O
disease O
progression O
from O
chronic O
phase O
to O
blast B-ADE
crisis I-ADE
during O
imatinib B-DRUG
therapy O
have O
recently O
been O
anecdotally O
reported O
. O

Prior O
neurologic O
illness O
or O
CNS O
insult O
of O
any O
kind O
is O
known O
to O
increase O
the O
vulnerability O
to O
neurotoxicity B-ADE
of O
lithium B-DRUG
. O

The O
objective O
of O
this O
report O
is O
to O
describe O
a O
case O
of O
fixed O
drug O
eruption B-ADE
that O
occurred O
during O
omeprazole B-DRUG
treatment O
. O

Quinine B-DRUG
induced O
coagulopathy B-ADE
-- O
a O
near O
fatal O
experience O
. O

It O
is O
suggested O
that O
the O
patient O
had O
sulfasalazine B-DRUG
- O
induced O
lupus B-ADE
, O
which O
manifested O
with O
serositis B-ADE
and O
pulmonary B-ADE
parenchymal I-ADE
involvement I-ADE
in O
the O
absence O
of O
joint O
symptoms O
. O

RESULTS O
: O
In O
a O
22-year O
- O
old O
Thai O
woman O
with O
Graves O
' O
disease O
, O
tinnitus B-ADE
, O
hearing B-ADE
impairment I-ADE
in I-ADE
the I-ADE
left I-ADE
ear I-ADE
( I-ADE
with I-ADE
progression I-ADE
to I-ADE
the I-ADE
right I-ADE
ear I-ADE
) I-ADE
, O
and O
vertigo B-ADE
developed O
after O
3 O
years O
of O
therapy O
with O
PTU B-DRUG
. O

The O
pulmonary B-ADE
toxicity I-ADE
is O
probably O
induced O
by O
piritrexim B-DRUG
. O

Tremor B-ADE
: O
a O
newly O
described O
adverse O
event O
with O
long O
- O
term O
itraconazole B-DRUG
therapy O
. O

We O
report O
2 O
patients O
who O
developed O
polyarteritis B-ADE
nodosa I-ADE
following O
vaccination B-DRUG
against I-DRUG
hepatitis I-DRUG
B I-DRUG
. O

We O
report O
the O
case O
of O
an O
11-year O
- O
old O
female O
treated O
for O
mediastinal O
T O
- O
cell O
lymphoma O
who O
presented O
renal B-ADE
failure I-ADE
following O
the O
second O
cycle O
of O
high O
- O
dose O
methotrexate B-DRUG
( O
HDMTX B-DRUG
) O
. O

This O
is O
the O
first O
report O
on O
the O
histopathological O
findings O
of O
thyroid O
tissue O
from O
a O
patient O
with O
amiodarone B-DRUG
- O
induced O
hypothyroidism B-ADE
. O

Three O
patients O
receiving O
gold B-DRUG
salt O
treatment O
for O
rheumatoid O
arthritis O
developed O
severe O
aplastic B-ADE
anemia I-ADE
. O

The O
changes O
were O
progressive O
regardless O
of O
discontinuation O
of O
cyclophosphamide B-DRUG
and O
led O
to O
severe B-ADE
restrictive I-ADE
ventilatory I-ADE
defect I-ADE
. O

Anaphylactoid B-ADE
shock I-ADE
, O
disseminated B-ADE
intravascular I-ADE
coagulation I-ADE
, O
and O
anuric B-ADE
renal I-ADE
failure I-ADE
requiring O
dialysis O
occurred O
in O
a O
patient O
receiving O
zomepirac B-DRUG
sodium O
for O
toothache O
. O

Ibuprofen B-DRUG
overdose O
is O
usually O
characterized O
by O
GI B-ADE
upset I-ADE
, O
dizziness B-ADE
, O
and O
mild B-ADE
sedation I-ADE
. O

Hemorrhage B-ADE
from O
a O
falx O
meningioma O
after O
internal O
use O
of O
low O
- O
dose O
aspirin B-DRUG
. O

High O
- O
resolution O
computed O
tomography O
scan O
findings O
were O
consistent O
with O
ILD O
, O
which O
was O
sufficient O
to O
diagnose O
as O
erlotinib B-DRUG
- O
induced O
ILD B-ADE
. O

Severe B-ADE
hyperkalemia I-ADE
occurred O
in O
a O
patient O
with O
radiation O
pneumonitis O
and O
glaucoma O
shortly O
after O
beginning O
prednisone B-DRUG
therapy O
. O

Herein O
, O
we O
describe O
2 O
patients O
who O
developed O
unusual O
CD8 B-ADE
+ I-ADE
cutaneous I-ADE
lymphoproliferative I-ADE
disorders I-ADE
after O
treatment O
with O
efalizumab B-DRUG
and O
infliximab B-DRUG
. O

The O
literature O
on O
thiabendazole B-DRUG
- O
induced O
cholestasis B-ADE
and O
its O
association O
with O
sicca B-ADE
complex I-ADE
is O
reviewed O
. O

CONCLUSION O
: O
There O
may O
be O
an O
association O
between O
raloxifene B-DRUG
and O
the O
development O
of O
malignant B-ADE
mixed I-ADE
mesodermal I-ADE
tumor I-ADE
. O

Temozolomide B-DRUG
was O
restarted O
2 O
months O
later O
; O
the O
patient O
again O
developed O
a O
fever B-ADE
. O

CONCLUSION O
: O
Acetic B-DRUG
acid I-DRUG
is O
corrosive O
and O
may O
cause O
vagina B-ADE
bleeding I-ADE
. O

We O
report O
a O
case O
of O
a O
64-year O
- O
old O
man O
with O
secondary O
adrenocortical B-ADE
insufficiency I-ADE
who O
has O
been O
on O
a O
chronic O
transdermal O
fentanyl B-DRUG
treatment O
because O
of O
sciatic O
pain O
syndrome O
. O

A O
57-year O
- O
old O
man O
developed O
chronic B-ADE
, I-ADE
watery I-ADE
diarrhea I-ADE
four O
weeks O
after O
Helicobacter O
pylori O
eradication O
therapy O
including O
lansoprazole B-DRUG
followed O
by O
lansoprazole B-DRUG
monotherapy O
for O
gastroesophageal O
reflux O
disease O
. O

Lethargy B-ADE
in O
a O
newborn O
: O
lithium B-ADE
toxicity I-ADE
or O
lab O
error O
? O

Hypo B-ADE
- I-ADE
oestrogenic I-ADE
and I-ADE
anabolic I-ADE
/ I-ADE
androgenic I-ADE
side I-ADE
- I-ADE
effects I-ADE
of O
danazol B-DRUG
are O
well O
known O
by O
the O
gynaecologist O
and O
some O
of O
them O
are O
present O
in O
> O
50 O
% O
of O
patients O
being O
treated O
for O
endometriosis O
. O

Levofloxacin B-DRUG
- O
induced O
toxic B-ADE
epidermal I-ADE
necrolysis I-ADE
in O
an O
elderly O
patient O
. O

BACKGROUND O
: O
To O
describe O
the O
occurrence O
of O
ocular B-ADE
hypertension I-ADE
in O
four O
patients O
following O
injection O
of O
ranibizumab B-DRUG
intravitreally O
. O

CONCLUSION O
: O
Long O
- O
term O
treatment O
with O
rifabutin B-DRUG
may O
have O
a O
reversible O
and O
previously O
undescribed O
side B-ADE
- I-ADE
effect I-ADE
on I-ADE
retinal I-ADE
function I-ADE
. O

Iatrogenic B-ADE
Cushing I-ADE
syndrome I-ADE
after O
epidural O
triamcinolone B-DRUG
injections O
in O
an O
HIV O
type O
1-infected O
patient O
receiving O
therapy O
with O
ritonavir O
- O
lopinavir O
. O

She O
had O
been O
taking O
nabumetone B-DRUG
for O
6 O
months O
, O
but O
had O
discontinued O
the O
agent O
2 O
weeks O
before O
admission O
due O
to O
progressive O
edema B-ADE
. O

Isotretinoin B-DRUG
, O
a O
drug O
used O
for O
the O
treatment O
of O
acne O
, O
has O
been O
shown O
to O
have O
teratogenic B-ADE
effects I-ADE
. O

We O
describe O
a O
patient O
who O
became O
hypothyroid B-ADE
while O
taking O
ferrous B-DRUG
sulfate I-DRUG
. O

The O
reversal O
of O
heparin O
by O
protamine B-DRUG
may O
cause O
severe B-ADE
hemodynamic I-ADE
deterioration I-ADE
, O
characterized O
by O
systemic B-ADE
hypotension I-ADE
, O
pulmonary B-ADE
hypertension I-ADE
, O
and O
bronchoconstriction B-ADE
. O

MR O
findings O
in O
methotrexate B-DRUG
- O
induced O
CNS B-ADE
abnormalities I-ADE
. O

OBJECTIVE O
: O
Clozapine B-DRUG
causes O
few O
extrapyramidal B-ADE
symptoms I-ADE
and O
is O
recommended O
as O
a O
treatment O
drug O
for O
severe O
tardive O
dyskinesia O
( O
TD O
) O
. O

Patients O
with O
vitamin O
B12 O
deficiency O
are O
exceedingly O
sensitive O
to O
neurologic B-ADE
deterioration I-ADE
following O
nitrous B-DRUG
oxide I-DRUG
anesthesia O
. O

Here O
, O
we O
present O
a O
case O
of O
sirolimus B-DRUG
- O
associated O
interstitial B-ADE
pneumonitis I-ADE
in O
a O
cardiac O
transplant O
recipient O
that O
resolved O
completely O
with O
withdrawal O
of O
the O
drug O
and O
treatment O
with O
corticosteroids O
. O

We O
report O
the O
case O
of O
a O
27-year O
- O
old O
Indian O
woman O
who O
developed O
maculopapular B-ADE
rash I-ADE
and O
angioedema B-ADE
secondary O
to O
carbamazepine B-DRUG
administration O
. O

Malignant B-ADE
mixed I-ADE
mullerian I-ADE
tumor I-ADE
of I-ADE
the I-ADE
uterus I-ADE
in O
a O
patient O
taking O
raloxifene B-DRUG
. O

Renal B-ADE
injury I-ADE
due O
to O
anastrozole B-DRUG
has O
not O
been O
published O
in O
the O
English O
literature O
. O

Hepatopathy B-ADE
subsided O
after O
the O
cessation O
of O
carbamazepine B-DRUG
and O
lynestrenol B-DRUG
. O

Vancomycin B-DRUG
is O
the O
most O
frequently O
implicated O
drug O
, O
but O
other O
agents O
have O
been O
reported O
to O
cause O
LABD B-ADE
. O

The O
present O
study O
describes O
a O
patient O
who O
had O
unusual B-ADE
weight I-ADE
fluctuation I-ADE
under O
corticosteroid O
and O
psychotropic O
treatment O
such O
as O
mianserin B-DRUG
and O
aripiprazole B-DRUG
. O

Administration O
of O
cisplatin O
in O
three O
patients O
with O
carboplatin B-DRUG
hypersensitivity B-ADE
: O
is O
skin O
testing O
useful O
? O

Phenylpropanolamine B-DRUG
- O
induced O
psychosis B-ADE
. O

The O
azathioprine B-DRUG
dose O
was O
low O
( O
1 O
mg O
/ O
kg O
) O
and O
pancytopenia B-ADE
occurred O
after O
56 O
days O
therapy O
. O

Such O
a O
rapid O
and O
relentless O
progression O
of O
methyldopa B-DRUG
- O
induced O
liver B-ADE
injury I-ADE
is O
undoubtedly O
rare O
, O
but O
it O
may O
be O
prevented O
by O
careful O
supervision O
of O
patients O
who O
exhibit O
liver O
function O
abnormalities O
early O
in O
the O
course O
of O
therapy O
. O

Lichen B-ADE
planus I-ADE
and O
acne B-ADE
provoked O
by O
gold B-DRUG
. O

The O
clinical O
symptoms O
of O
gastric B-ADE
mucosa I-ADE
foveolar I-ADE
hyperplasia I-ADE
due O
to O
long O
- O
term O
PGE1 B-DRUG
therapy O
simulate O
hypertrophic O
pyloric O
stenosis O
. O

Glomerulonephritis B-ADE
in O
procainamide B-DRUG
induced O
lupus B-ADE
erythematosus I-ADE
: O
report O
of O
a O
case O
and O
review O
of O
the O
literature O
. O

Osteomyelitis B-ADE
occurring O
during O
infliximab B-DRUG
treatment O
of O
severe O
psoriasis O
. O

We O
report O
a O
patient O
who O
developed O
heparin B-DRUG
associated O
thrombocytopenia B-ADE
during O
continuous O
arteriovenous O
haemofiltration O
and O
discuss O
its O
implications O
and O
alternative O
anticoagulant O
treatment O
. O

Two O
of O
our O
patients O
developed O
TD B-ADE
after O
23 O
months O
and O
34 O
months O
of O
ziprasidone B-DRUG
monotherapy O
, O
respectively O
. O

PURPOSE O
: O
To O
report O
a O
case O
of O
angiographically O
documented O
cystoid B-ADE
macula I-ADE
edema I-ADE
occurring O
after O
switching O
a O
pseudophakic O
patient O
from O
latanoprost B-DRUG
to O
bimatoprost B-DRUG
. O

Large O
dose O
of O
methylphenidate B-DRUG
may O
cause O
cataract B-ADE
and O
glaucoma B-ADE
. O

Occasionally O
, O
despite O
good O
therapeutic O
response O
, O
clozapine B-DRUG
must O
be O
stopped O
due O
to O
dangerous O
side O
effects O
such O
as O
agranulocytosis B-ADE
. O

Ocular B-ADE
ethambutol B-DRUG
toxicity I-ADE
. O

After O
excluding O
other O
causes O
of O
long O
QT O
syndrome O
, O
the O
HCQ B-DRUG
was O
suspected O
as O
the O
cause O
of O
her O
ventricular B-ADE
tachycardia I-ADE
. O

While O
both O
amiodarone B-DRUG
and O
digoxin B-DRUG
can O
cause O
permanent O
visual B-ADE
changes I-ADE
, O
the O
ocular B-ADE
effects I-ADE
are O
often O
reversible O
. O

BACKGROUND O
: O
Cyanamide B-DRUG
, O
an O
aversive O
agent O
widely O
used O
in O
Japan O
, O
is O
known O
to O
induce O
various O
degrees O
of O
hepatic B-ADE
lesion I-ADE
with I-ADE
ground I-ADE
- I-ADE
glass I-ADE
inclusion I-ADE
bodies I-ADE
. O

In O
rare O
cases O
mitomycin B-DRUG
C I-DRUG
( O
MMC B-DRUG
) O
may O
induce O
cancer O
- O
associated O
hemolytic B-ADE
uremic I-ADE
syndrome I-ADE
, O
which O
is O
characterized O
by O
hemolytic B-ADE
anemia I-ADE
, O
thrombocytopenia B-ADE
and O
progressive B-ADE
renal I-ADE
failure I-ADE
. O

5-Fluorouracil B-DRUG
cardiotoxicity B-ADE
complicating O
treatment O
of O
stage O
IIB O
cervical O
cancer O
-- O
case O
report O
. O

A O
fatal B-ADE
massive I-ADE
pulmonary I-ADE
embolus I-ADE
developed O
in O
a O
patient O
treated O
with O
streptokinase B-DRUG
for O
acute O
deep O
vein O
thrombosis O
. O

Although O
they O
had O
only O
a O
few O
nodules B-ADE
at O
diagnosis O
, O
the O
nodules B-ADE
increased O
in O
number O
and O
size O
3 O
to O
4 O
months O
after O
the O
start O
of O
methotrexate B-DRUG
therapy O
in O
both O
patients O
. O

Captopril B-DRUG
- O
induced O
lichen B-ADE
planus I-ADE
pemphigoides I-ADE
with O
pemphigus O
- O
like O
features O
. O

Case O
2 O
: O
A O
43-year O
- O
old O
male O
alcoholic O
remained O
completely O
abstinent O
with O
cyanamide B-DRUG
treatment O
for O
5 O
years O
and O
complained O
of O
general B-ADE
fatigue I-ADE
. O

In O
a O
patient O
suffering O
from O
rheumatoid O
arthritis O
, O
we O
report O
the O
first O
simultaneous O
occurrence O
of O
two O
side O
effects O
of O
low O
- O
dose O
methotrexate B-DRUG
: O
an O
acute B-ADE
megaloblastic I-ADE
anaemia I-ADE
and O
a O
pneumonitis B-ADE
. O

Severe B-ADE
hepatotoxicity I-ADE
related O
to O
benzarone B-DRUG
: O
a O
report O
of O
three O
cases O
with O
two O
fatalities O
. O

A O
74-year O
- O
old O
patient O
with O
idiopathic O
Parkinson O
's O
disease O
was O
evaluated O
for O
unintended B-ADE
sleep I-ADE
episodes I-ADE
that O
occurred O
after O
long O
- O
term O
treatment O
with O
400 O
mg O
/ O
day O
of O
L B-DRUG
- I-DRUG
dopa I-DRUG
. O

Here O
we O
report O
a O
patient O
with O
newly O
diagnosed O
acute O
promyelocytic O
leukemia O
who O
developed O
acute B-ADE
focal I-ADE
myositis I-ADE
, O
synovitis B-ADE
, O
and O
possible B-ADE
vasculitis I-ADE
, O
after O
receiving O
all B-DRUG
- I-DRUG
trans I-DRUG
retinoic I-DRUG
acid I-DRUG
therapy O
. O

Bisphosphonate B-DRUG
- O
related O
osteonecrosis B-ADE
of I-ADE
the I-ADE
jaw I-ADE
( O
BRONJ O
) O
is O
reported O
in O
up O
to O
18.6 O
% O
of O
patients O
treated O
with O
intravenous O
bisphosphonates O
and O
can O
result O
in O
significant O
morbidity O
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
reversible O
nonthrombocytopenic B-ADE
palpable I-ADE
purpura I-ADE
associated O
with O
metoclopramide B-DRUG
. O

Clofazimine B-DRUG
induced O
nail B-ADE
changes I-ADE
. O

Mechanism O
of O
topiramate B-DRUG
- O
induced O
acute B-ADE
- I-ADE
onset I-ADE
myopia I-ADE
and O
angle B-ADE
closure I-ADE
glaucoma I-ADE
. O

Actinomycin B-DRUG
D I-DRUG
associated O
hepatic B-ADE
veno I-ADE
- I-ADE
occlusive I-ADE
disease I-ADE
-- O
a O
report O
of O
2 O
cases O
. O

We O
report O
on O
7 O
patients O
( O
2 O
women O
, O
5 O
men O
) O
with O
chronic O
renal O
failure O
, O
who O
developed O
under O
a O
high O
dosage O
of O
the O
new O
diuretic O
muzolimine B-DRUG
( O
range O
240 O
to O
1440 O
mg O
per O
day O
) O
fatal B-ADE
neuromyeloencephalopathy I-ADE
. O

A O
patient O
developed O
typical O
ECM B-ADE
after O
subcutaneous O
selfinjection O
of O
glatiramer B-DRUG
acetate I-DRUG
for O
multiple O
sclerosis O
. O

Clinicians O
should O
include O
phenolphthalein B-DRUG
in O
their O
list O
of O
possible O
causes O
of O
drug O
- O
induced O
TEN B-ADE
. O

We O
believe O
the O
temporal O
association O
of O
the O
abnormal B-ADE
liver I-ADE
enzymes I-ADE
in O
this O
patient O
, O
in O
the O
absence O
of O
other O
offending O
agents O
, O
argues O
strongly O
in O
favor O
of O
6-TG B-DRUG
as O
a O
cause O
of O
liver B-ADE
enzyme I-ADE
abnormalities I-ADE
. O

CASE O
: O
We O
present O
an O
11-year O
old O
male O
with O
Budd O
- O
Chiari O
syndrome O
who O
experienced O
profound O
worsening B-ADE
of I-ADE
chronic I-ADE
aphthous I-ADE
ulcers I-ADE
after O
immunosuppressive O
therapy O
was O
changed O
from O
tacrolimus B-DRUG
to O
sirolimus B-DRUG
. O

L O
- O
Carnitine O
supplementation O
has O
been O
recommended O
to O
prevent O
the O
fatal B-ADE
hepatotoxic I-ADE
effects I-ADE
associated O
with O
valproic B-DRUG
acid I-DRUG
. O

Mental B-ADE
nerve I-ADE
neuropathy I-ADE
as O
a O
result O
of O
hepatitis B-DRUG
B I-DRUG
vaccination I-DRUG
. O

Though O
hypotension B-ADE
, O
dry B-ADE
mouth I-ADE
, O
and O
constipation B-ADE
are O
well O
- O
documented O
possible O
adverse O
effects O
, O
the O
possibility O
of O
clonidine B-DRUG
- O
induced O
bradycardia B-ADE
is O
less O
well O
recognized O
and O
is O
rare O
. O

The O
authors O
report O
a O
case O
of O
a O
patient O
who O
received O
alteplase B-DRUG
for O
acute O
myocardial O
infarction O
and O
developed O
spontaneous O
subfascial B-ADE
hematoma I-ADE
without O
any O
evidence O
of O
direct O
trauma O
. O

Muzolimine B-DRUG
- O
induced O
severe B-ADE
neuromyeloencephalopathy I-ADE
: O
report O
of O
seven O
cases O
. O

Cutaneous B-ADE
mycobacterial I-ADE
infection I-ADE
post O
intravesical O
BCG B-DRUG
installation O
. O

Atrial B-ADE
fibrillation I-ADE
was O
induced O
by O
diltiazem B-DRUG
in O
two O
patients O
and O
verapamil B-DRUG
induced O
syncope B-ADE
in O
one O
patient O
. O

Thrombocytosis B-ADE
associated O
with O
enoxaparin B-DRUG
: O
A O
very O
rare O
cause O
in O
newborns O
. O

We O
now O
report O
the O
first O
known O
cancer O
patient O
who O
developed O
life B-ADE
- I-ADE
threatening I-ADE
complications I-ADE
after O
treatment O
with O
topical O
5-FU B-DRUG
and O
was O
shown O
subsequently O
to O
have O
profound O
DPD O
deficiency O
. O

Statin B-DRUG
- O
associated O
myasthenia B-ADE
gravis I-ADE
: O
report O
of O
4 O
cases O
and O
review O
of O
the O
literature O
. O

The O
authors O
suggest O
that O
in O
patients O
with O
corneal B-ADE
ulcers I-ADE
refractory I-ADE
to I-ADE
conventional I-ADE
treatment I-ADE
who O
are O
receiving O
colchicine B-DRUG
, O
cessation O
of O
colchicine O
therapy O
should O
be O
considered O
. O

The O
first O
reported O
case O
, O
in O
an O
adult O
, O
of O
cholestyramine B-DRUG
induced O
hyperchloremic B-ADE
metabolic I-ADE
acidosis I-ADE
is O
a O
70 O
year O
old O
female O
with O
a O
two O
year O
history O
of O
primary O
biliary O
cirrhosis O
confirmed O
by O
histologic O
and O
immunologic O
criteria O
. O

An O
amiodarone B-DRUG
optic B-ADE
neuropathy I-ADE
has O
been O
described O
. O

CASES O
: O
" O
A O
" O
was O
an O
8-year O
- O
old O
boy O
with O
attention O
deficit O
and O
chronic O
tic O
disorder O
who O
developed O
obsessive B-ADE
- I-ADE
compulsive I-ADE
symptoms I-ADE
within O
2 O
weeks O
of O
starting O
risperidone B-DRUG
. O

We O
conclude O
that O
neurosurgeons O
and O
neurologists O
should O
be O
aware O
of O
calcium O
antagonist O
-- O
related O
ileus B-ADE
in O
patients O
treated O
with O
nimodipine B-DRUG
. O

This O
is O
the O
first O
reported O
case O
of O
BOOP B-ADE
associated O
with O
single O
- O
agent O
rituximab B-DRUG
, O
and O
along O
with O
two O
other O
patients O
we O
describe O
, O
as O
well O
as O
two O
prior O
reports O
of O
BOOP B-ADE
in O
NHL O
patients O
receiving O
rituximab B-DRUG
- O
based O
combinations O
, O
strengthens O
the O
possibility O
of O
a O
causal O
relationship O
. O

Fever B-ADE
, O
pulmonary B-ADE
infiltrates I-ADE
, O
and O
pleural B-ADE
effusion I-ADE
following O
acyclovir B-DRUG
therapy O
for O
herpes O
zoster O
ophthalmicus O
. O

We O
report O
a O
71-year O
male O
with O
castration O
- O
resistant O
metastatic O
prostate O
cancer O
who O
was O
treated O
with O
weekly O
docetaxel B-DRUG
for O
12 O
weeks O
and O
developed O
significant O
eye B-ADE
irritation I-ADE
and I-ADE
dryness I-ADE
during O
treatment O
. O

The O
case O
of O
an O
adult O
who O
developed O
both O
hepatic B-ADE
dysfunction I-ADE
and O
an O
impaired B-ADE
macrophage I-ADE
migration I-ADE
after O
exposure O
to O
cimetidine B-DRUG
is O
discussed O
. O

This O
case O
is O
remarkable O
since O
1 O
) O
ECM O
developed O
after O
subcutaneous O
and O
not O
after O
intramuscular O
injection O
, O
2 O
) O
the O
injection O
was O
given O
by O
the O
patient O
himself O
, O
and O
3 O
) O
glatiramer B-DRUG
acetate I-DRUG
can O
induce O
skin B-ADE
necrosis I-ADE
as O
a O
side O
effect O
. O

This O
profile O
should O
trigger O
a O
" O
red O
flag O
" O
as O
to O
the O
possibility O
of O
phenobarbital B-DRUG
behavioral B-ADE
side I-ADE
effects I-ADE
or O
exacerbation B-ADE
of I-ADE
preexisting I-ADE
maladaptive I-ADE
behaviors I-ADE
. O

A O
healthy O
, O
30-year O
- O
old O
man O
, O
exposed O
to O
sulindac B-DRUG
on O
two O
separate O
occasions O
, O
had O
an O
incapacitating O
isolated B-ADE
idential I-ADE
sensory I-ADE
neuropathy I-ADE
. O

According O
to O
the O
Naranjo O
et O
al O
. O
adverse O
- O
reaction O
probability O
scale O
, O
enoxaparin B-DRUG
was O
the O
probable O
cause O
of O
hepatotoxicity B-ADE
in O
this O
patient O
. O

OBJECTIVE O
: O
To O
describe O
a O
case O
of O
cefazolin B-DRUG
- O
induced O
leukopenia B-ADE
in O
a O
critically O
ill O
patient O
who O
developed O
this O
adverse O
reaction O
upon O
rechallenge O
with O
cefoxitin O
. O

The O
nodules B-ADE
regressed O
after O
withdrawal O
of O
methotrexate B-DRUG
therapy O
in O
one O
patient O
and O
were O
arrested O
with O
the O
addition O
of O
hydroxychloroquine O
in O
the O
other O
. O

OBJECTIVE O
: O
To O
present O
a O
single O
case O
of O
zuclopenthixol B-DRUG
- O
induced O
priapism B-ADE
and O
a O
literature O
review O
. O

Prior O
to O
surgery O
, O
levodopa B-DRUG
induced O
dyskinesia B-ADE
had O
improved O
( O
< O
or O
= O
50 O
% O
) O
under O
treatment O
with O
amantadine O
( O
400 O
mg O
/ O
day O
, O
po O
) O
in O
all O
three O
patients O
. O

We O
report O
five O
cases O
of O
restless B-ADE
legs I-ADE
syndrome I-ADE
( O
RLS B-ADE
) O
and O
periodic B-ADE
limb I-ADE
movements I-ADE
during I-ADE
sleep I-ADE
( O
PLMS B-ADE
) O
that O
were O
probably O
associated O
with O
olanzapine B-DRUG
. O

Physicians O
should O
be O
aware O
that O
PLP B-ADE
can O
occur O
after O
initiation O
of O
paclitaxel B-DRUG
. O

A O
70-year O
- O
old O
man O
was O
admitted O
to O
our O
hospital O
because O
of O
dyspnea B-ADE
after O
taking O
an O
antihistaminic O
agent O
( O
homochlorcyclizine B-DRUG
hydrochloride I-DRUG
) O
for O
itching O
. O

However O
, O
other O
factors O
or O
drugs O
( O
e.g. O
cresol B-DRUG
) O
are O
thought O
to O
induce O
MH B-ADE
. O

Syndrome B-ADE
of I-ADE
inappropriate I-ADE
antidiuretic I-ADE
hormone I-ADE
associated O
with O
vinorelbine B-DRUG
therapy O
. O

Regression O
of O
thyrotoxic B-ADE
ophthalmopathy I-ADE
following O
lithium B-DRUG
withdrawal O
. O

Azathioprine B-DRUG
can O
cause O
severe O
myelosuppression B-ADE
. O

After O
5-ASA B-DRUG
was O
discontinued O
, O
the O
polyneuropathy B-ADE
symptoms O
recovered O
gradually O
. O

Biopsy O
- O
proven O
acute B-ADE
interstitial I-ADE
nephritis I-ADE
associated O
with O
the O
tyrosine O
kinase O
inhibitor O
sunitinib B-DRUG
: O
a O
class O
effect O
? O

We O
report O
3 O
patients O
with O
severe B-ADE
hepatocellular I-ADE
damage I-ADE
due O
to O
CPA B-DRUG
therapy O
, O
2 O
with O
fatal B-ADE
fulminant I-ADE
hepatitis I-ADE
. O

There O
is O
a O
putative O
role O
of O
liothyronine B-DRUG
administration O
in O
precipitating O
or O
activating O
hyperthyroidism B-ADE
. O

CONCLUSION O
: O
All O
doctors O
need O
to O
be O
aware O
of O
the O
need O
to O
review O
the O
indications O
for O
gabapentin B-DRUG
use O
during O
periods O
of O
acute O
illness O
, O
especially O
with O
regard O
to O
renal B-ADE
impairment I-ADE
. O

Acute B-ADE
pancreatitis I-ADE
after O
long O
- O
term O
5-aminosalicylic B-DRUG
acid I-DRUG
therapy O
. O

CASE O
REPORT O
: O
We O
report O
a O
case O
of O
intracerebral B-ADE
hemorrhage I-ADE
occurring O
in O
a O
middle O
- O
aged O
man O
who O
suffered O
from O
chronic O
sinusitis O
and O
had O
been O
ingesting O
pseudoephedrine B-DRUG
daily O
for O
one O
year O
. O

Foscarnet B-DRUG
- O
induced O
severe B-ADE
hypomagnesemia I-ADE
and O
other O
electrolyte B-ADE
disorders I-ADE
. O

We O
have O
successfully O
overcome O
severe B-ADE
neutropenia I-ADE
in O
an O
RA O
patient O
treated O
with O
gold B-DRUG
salts O
, O
using O
granulocyte O
colony O
- O
stimulating O
factor O
( O
G O
- O
CSF O
) O
, O
reducing O
the O
duration O
of O
neutropenia O
and O
risk O
of O
infection O
. O

The O
successful O
development O
and O
implementation O
of O
this O
protocol O
will O
have O
impact O
on O
patients O
who O
have O
anaphylactic B-ADE
reactions I-ADE
to O
MTX B-DRUG
but O
require O
this O
medication O
for O
specific O
diseases O
. O

The O
patient O
completed O
a O
10-month O
follow O
- O
up O
, O
maintaining O
a O
complete O
resolution O
of O
the O
treated O
skin O
lesions O
; O
however O
, O
the O
development O
of O
a O
painful B-ADE
hand I-ADE
ulcer I-ADE
, O
possibly O
associated O
with O
the O
hydroxyurea B-DRUG
, O
and O
new O
skin B-ADE
cancers I-ADE
were O
observed O
at O
the O
last O
follow O
- O
up O
visit O
. O

Gynaecomastia B-ADE
is O
a O
rarely O
reported O
adverse O
drug O
reaction O
due O
to O
isoniazid B-DRUG
therapy O
. O

Marked B-ADE
QT I-ADE
prolongation I-ADE
and O
torsades B-ADE
de I-ADE
pointes I-ADE
secondary O
to O
acute B-ADE
ischemia I-ADE
in O
an O
elderly O
man O
taking O
dofetilide B-DRUG
for O
atrial O
fibrillation O
: O
a O
cautionary O
tale O
. O

Autopsy O
findings O
were O
consistent O
with O
bleomycin B-DRUG
and O
oxygen B-DRUG
- O
induced O
pulmonary B-ADE
damage I-ADE
. O

The O
goal O
of O
this O
study O
is O
to O
describe O
three O
patients O
diagnosed O
with O
migraine O
and O
epilepsy O
( O
both O
under O
control O
) O
who O
evolved O
into O
status B-ADE
migrainosus I-ADE
after O
the O
introduction O
of O
oxcarbazepine B-DRUG
( O
OXC B-DRUG
) O
, O
as O
part O
of O
a O
switch O
off O
from O
carbamazepine B-DRUG
( O
CBZ B-DRUG
) O
. O

CONCLUSIONS O
: O
Clinicians O
should O
be O
aware O
of O
the O
possible O
association O
of O
thrombocytopenia B-ADE
with O
lansoprazole B-DRUG
and O
discontinue O
the O
drug O
if O
thrombocytopenia O
becomes O
apparent O
. O

CONCLUSION O
: O
Hypersensitivity O
reaction O
should O
be O
considered O
in O
patients O
who O
develop O
recurrent B-ADE
eosinophilia I-ADE
and O
deterioration B-ADE
of I-ADE
pulmonary I-ADE
function I-ADE
following O
the O
use O
of O
tobramycin B-DRUG
by O
inhalation O
or O
by O
intravenous O
administration O
. O

Findings O
on O
discontinuation O
and O
rechallenge O
supported O
the O
assumption O
that O
the O
hair B-ADE
loss I-ADE
was O
a O
side O
effect O
of O
the O
paroxetine B-DRUG
. O

Rapid O
identification O
of O
speech B-ADE
loss I-ADE
linked O
to O
FK506 B-DRUG
may O
be O
important O
because O
reduction O
or O
cessation O
of O
the O
drug O
may O
be O
associated O
with O
reverse O
of O
speech O
loss O
. O

Cimetidine B-DRUG
is O
a O
rare O
cause O
of O
drug O
- O
induced O
fever B-ADE
. O

He O
was O
later O
skin O
tested O
to O
confirm O
allergy B-ADE
to O
MTX B-DRUG
. O

Anaphylactoid B-ADE
reaction I-ADE
to O
methylprednisolone B-DRUG
pulsed O
therapy O
for O
multiple O
sclerosis O
. O

Acute B-ADE
leukaemia I-ADE
during O
tamoxifen B-DRUG
therapy O
. O

BACKGROUND O
: O
To O
assess O
the O
nature O
, O
incidence O
, O
and O
risk O
factors O
of O
retinopathy B-ADE
associated O
with O
pegylated B-DRUG
interferon I-DRUG
and O
ribavirin B-DRUG
combination O
therapy O
in O
chronic O
hepatitis O
C O
patients O
. O

In O
the O
presented O
case O
fluvoxamine B-DRUG
- O
induced O
akathisia B-ADE
in O
an O
OCD O
patient O
was O
partially O
resistant O
to O
the O
anticholinergic O
agent O
biperiden O
, O
and O
was O
successfully O
treated O
with O
the O
5-HT2A/5-HT2C O
antagonist O
mianserin O
. O

Interstitial B-ADE
granulomatous I-ADE
dermatitis I-ADE
associated O
with O
darifenacin B-DRUG
. O

These O
cases O
were O
chosen O
for O
study O
because O
they O
were O
all O
deaths B-ADE
as O
a O
result O
of O
suicidal O
ingestion O
of O
drugs O
in O
which O
quetiapine B-DRUG
was O
considered O
a O
significant O
factor O
. O

She O
was O
treated O
with O
acyclovir B-DRUG
and O
subsequently O
developed O
VZV B-ADE
antigen I-ADE
- I-ADE
positive I-ADE
zoster I-ADE
. O

Although O
risk O
factors O
for O
MTX B-DRUG
- O
induced O
pulmonary B-ADE
toxicity I-ADE
are O
poorly O
understood O
, O
the O
presence O
in O
3 O
out O
of O
5 O
of O
our O
patients O
of O
pre O
- O
existing O
lung O
disease O
, O
represented O
by O
diffuse O
interstitial O
changes O
on O
chest O
X O
- O
ray O
, O
and O
mild O
bronchial O
asthma O
in O
two O
RA O
patients O
and O
by O
pulmonary O
silicosis O
in O
the O
patient O
with O
PsA O
may O
account O
for O
a O
predisposition O
to O
the O
development O
of O
MTX B-DRUG
pneumonitis B-ADE
. O

Replicate O
brain O
magnetic O
resonance O
imaging O
examinations O
after O
six O
weeks O
and O
11 O
months O
of O
penicillamine B-DRUG
therapy O
documented O
the O
development O
of O
new O
brain B-ADE
lesions I-ADE
during O
this O
period O
, O
while O
liver O
biopsy O
specimen O
data O
disclosed O
that O
excellent O
hepatic O
decoppering O
had O
occurred O
. O

NMS B-ADE
is O
a O
drug O
- O
related O
response O
to O
various O
medications O
, O
such O
as O
Haloperidol B-DRUG
, O
which O
the O
patient O
was O
receiving O
. O

Finally O
, O
reserpine B-DRUG
toxicity I-ADE
, O
in O
particular O
central O
nervous O
system O
( O
CNS O
) O
disturbances O
, O
was O
reported O
more O
frequently O
in O
patients O
also O
receiving O
barbiturates O
, O
suggesting O
additive O
CNS O
effects O
. O

Two O
patients O
are O
described O
who O
developed O
testicular B-ADE
swelling I-ADE
and O
pain B-ADE
during O
treatment O
with O
desipramine B-DRUG
. O

Psoriasis B-ADE
triggered O
by O
toll O
- O
like O
receptor O
7 O
agonist O
imiquimod B-DRUG
in O
the O
presence O
of O
dermal O
plasmacytoid O
dendritic O
cell O
precursors O
. O

Ibuprofen B-DRUG
rarely O
causes O
lower O
gastrointestinal B-ADE
adverse I-ADE
reactions I-ADE
but O
has O
been O
implicated O
in O
systemic O
and O
local O
side O
effects O
in O
patients O
with O
lupus O
. O

This O
case O
study O
describes O
an O
atypical O
case O
of O
refractory O
, O
sodium B-DRUG
warfarin I-DRUG
- O
induced O
necrotizing B-ADE
fasciitis I-ADE
and O
myonecrosis B-ADE
. O

RESULTS O
: O
The O
estimated O
number O
of O
Accutane B-DRUG
prescriptions O
for O
reproductive O
- O
aged O
women O
has O
more O
than O
doubled O
in O
the O
past O
10 O
years O
; O
it O
is O
the O
most O
widely O
used O
teratogenic B-ADE
drug O
in O
the O
United O
States O
, O
with O
approximately O
2.5 O
per O
1,000 O
reproductive O
- O
aged O
women O
exposed O
to O
Accutane O
in O
1999 O
. O

Ocular B-ADE
hypertension I-ADE
occurred O
1 O
month O
after O
the O
second O
ranibizumab B-DRUG
injection O
in O
patients O
1 O
and O
3 O
, O
and O
1 O
month O
after O
the O
first O
ranibizumab O
in O
patient O
2 O
. O

Clostridium B-ADE
difficile I-ADE
colitis I-ADE
associated O
with O
cisplatin B-DRUG
- O
based O
chemotherapy O
in O
ovarian O
cancer O
patients O
. O

Since O
ethambutol B-DRUG
is O
actively O
excreted O
via O
the O
renal O
system O
, O
compromise O
of O
renal O
function O
such O
as O
due O
to O
renal O
tuberculosis O
may O
lead O
to O
serum O
concentration O
elevations O
of O
ethambutol O
sufficient O
to O
produce O
optic B-ADE
neuropathy I-ADE
. O

We O
report O
the O
case O
of O
a O
lung O
cancer O
patient O
with O
bronquiloalveolar O
carcinoma O
( O
BAC O
) O
presenting O
with O
BOOP B-ADE
after O
chemotherapy O
with O
docetaxel B-DRUG
and O
gemcitabine B-DRUG
producing O
severe B-ADE
respiratory I-ADE
insufficiency I-ADE
, O
and O
simulating O
a O
progression B-ADE
of I-ADE
the I-ADE
tumor I-ADE
. O

Polysomnographic O
and O
pharmacokinetic O
findings O
in O
levodopa B-DRUG
- O
induced O
augmentation O
of O
restless B-ADE
legs I-ADE
syndrome I-ADE
. O

We O
report O
an O
HIV O
- O
infected O
woman O
who O
developed O
mild O
leukopenia B-ADE
as O
the O
first O
sign O
of O
a O
nevirapine B-DRUG
- O
related O
adverse O
event O
, O
which O
was O
followed O
by O
skin B-ADE
and I-ADE
hepatic I-ADE
toxicity I-ADE
associated O
with O
a O
more O
severe O
leukopenia B-ADE
. O

A O
62-year O
- O
old O
Caucasian O
man O
with O
atrial O
fibrillation O
who O
was O
taking O
warfarin B-DRUG
reported O
an O
episode O
of O
hematochezia B-ADE
; O
his O
international O
normalized O
ratio O
( O
INR O
) O
was O
1.74 O
. O

Acute B-ADE
leukopenia I-ADE
associated O
with O
silver B-DRUG
sulfadiazine I-DRUG
therapy O
. O

Simvastatin B-DRUG
- O
induced O
rhabdomyolysis B-ADE
following O
cyclosporine B-DRUG
treatment O
for O
uveitis O
. O

Four O
patients O
receiving O
high O
- O
dose O
tamoxifen B-DRUG
for O
greater O
than O
1 O
year O
have O
demonstrated O
similar O
retinal B-ADE
changes I-ADE
. O

After O
five O
and O
six O
weeks O
of O
continuous O
oral O
administration O
of O
methylprednisolone B-DRUG
, O
the O
boys O
developed O
steroid B-ADE
diabetes I-ADE
. O

Vortex B-ADE
keratopathy I-ADE
associated O
with O
atovaquone B-DRUG
. O

Trimethoprim B-DRUG
- I-DRUG
sulfamethoxazole I-DRUG
- O
induced O
aseptic B-ADE
meningitis I-ADE
. O

OBSERVATIONS O
: O
We O
observed O
aggravation B-ADE
and I-ADE
spreading I-ADE
of I-ADE
a I-ADE
psoriatic I-ADE
plaque I-ADE
when O
treated O
topically O
with O
the O
toll O
- O
like O
receptor O
( O
TLR O
) O
7 O
agonist O
imiquimod B-DRUG
. O

The O
noted O
increase B-ADE
in I-ADE
the I-ADE
theophylline B-DRUG
level I-ADE
after O
zafirlukast B-DRUG
administration O
is O
in O
contrast O
to O
the O
original O
reports O
by O
the O
manufacturer O
. O

A O
case O
is O
described O
of O
severe B-ADE
splenic I-ADE
hemorrhage I-ADE
and I-ADE
rupture I-ADE
which O
developed O
3 O
h O
after O
completion O
of O
tPA B-DRUG
infusion O
for O
suspected O
acute O
myocardial O
infarction O
. O

Multiple O
complications O
of O
propylthiouracil B-DRUG
treatment O
: O
granulocytopenia B-ADE
, O
eosinophilia B-ADE
, O
skin B-ADE
reaction I-ADE
and O
hepatitis B-ADE
with O
lymphocyte B-ADE
sensitization I-ADE
. O

She O
was O
thus O
diagnosed O
as O
having O
AZ B-DRUG
intoxication I-ADE
. O

In O
addition O
, O
an O
immediate O
erythematous B-ADE
macule I-ADE
was O
observed O
on O
the O
photopatch O
test O
site O
of O
mequitazine B-DRUG
directly O
after O
UV O
exposure O
which O
was O
similar O
to O
the O
immediate B-ADE
erythema I-ADE
noted O
in O
chlorpromazine O
photoallergy O
. O

We O
present O
here O
a O
female O
patient O
who O
developed O
acute B-ADE
bilateral I-ADE
parotitis I-ADE
within O
minutes O
of O
i.v O
. O
enalaprilat B-DRUG
injection O
and O
recovered O
within O
24 O
hours O
of O
stopping O
the O
drug O
and O
with O
symptomatic O
treatment O
. O

Secondary O
acute B-ADE
myeloid I-ADE
leukemia I-ADE
after O
etoposide B-DRUG
therapy O
for O
haemophagocytic O
lymphohistiocytosis O
. O

Polymyoclonus B-ADE
seizure I-ADE
resulting O
from O
accidental O
injection O
of O
tranexamic B-DRUG
acid I-DRUG
in O
spinal O
anesthesia O
. O

Paradoxical O
seizures B-ADE
in O
phenytoin B-DRUG
toxicity O
. O

Pemphigus B-ADE
foliaceus I-ADE
was O
seen O
in O
a O
patient O
with O
pulmonary O
tuberculosis O
during O
rifampicin B-DRUG
therapy O
. O

Pediatric O
heparin B-DRUG
- O
induced O
thrombocytopenia B-ADE
: O
management O
with O
Danaparoid O
( O
orgaran O
) O
. O

We O
report O
a O
case O
of O
sustained B-ADE
hypotension I-ADE
after O
administration O
of O
parenteral O
verapamil B-DRUG
. O

It O
is O
presumed O
that O
her O
hyperchloremic B-ADE
metabolic I-ADE
acidosis I-ADE
was O
secondary O
to O
cholestyramine B-DRUG
because O
of O
the O
similarity O
to O
pediatric O
reports O
; O
the O
rapid O
and O
lasting O
response O
to O
intravenous O
sodium O
bicarbonate O
; O
the O
absence O
of O
another O
etiology O
; O
normal O
serum O
potassium O
, O
chloride O
and O
bicarbonate O
despite O
continued O
spironolactone O
therapy O
after O
recovery O
. O

Exposure O
of O
the O
fetus O
to O
indomethacin B-DRUG
by O
administration O
of O
the O
drug O
to O
the O
mother O
may O
cause O
many O
side O
effects O
, O
including O
premature B-ADE
closure I-ADE
of I-ADE
the I-ADE
ductus I-ADE
arteriosus I-ADE
. O

This O
increase O
when O
clozapine O
was O
switched O
to O
risperidone O
and O
vice O
versa O
is O
consistent O
with O
our O
previous O
report O
of O
elevated B-ADE
serum I-ADE
triglyceride I-ADE
levels I-ADE
in O
clozapine B-DRUG
- O
treated O
patients O
. O

To O
our O
knowledge O
, O
this O
is O
the O
first O
case O
of O
ivermectin B-DRUG
- O
induced O
severe B-ADE
liver I-ADE
disease I-ADE
published O
in O
the O
literature O
. O

A O
77-year O
- O
old O
man O
developed O
ankle B-ADE
, I-ADE
hand I-ADE
, I-ADE
and I-ADE
facial I-ADE
swelling I-ADE
2 O
weeks O
after O
starting O
rosiglitazone B-DRUG
. O

CONCLUSIONS O
: O
Clinicians O
treating O
elderly O
patients O
with O
olanzapine B-DRUG
should O
be O
aware O
of O
the O
potential O
for O
rapidly O
developing O
hyperglycemia B-ADE
and O
monitor O
such O
patients O
accordingly O
. O

A O
case O
of O
allopurinol B-DRUG
hypersensitivity B-ADE
, O
possibly O
the O
first O
in O
a O
black O
African O
, O
is O
reported O
. O

An O
11-year O
- O
old O
boy O
who O
was O
treated O
with O
a O
relatively O
high O
dose O
of O
methotrimeprazine B-DRUG
meleate I-DRUG
( O
Levemepromazine B-DRUG
) O
a O
phenothiazine O
antipsychotic O
drug O
, O
was O
admitted O
to O
the O
pediatric O
intensive O
care O
unit O
suffering O
from O
respiratory B-ADE
distress I-ADE
syndrome I-ADE
. O

We O
describe O
a O
patient O
with O
extranodal O
non O
- O
Hodgkin O
lymphoma O
who O
developed O
systemic B-ADE
candidiasis I-ADE
after O
treatment O
with O
a O
cyclophosphamide B-DRUG
- O
based O
chemotherapy O
regimen O
. O

Mitomycin B-DRUG
C I-DRUG
( O
MMC B-DRUG
) O
is O
an O
alkylating O
agent O
that O
has O
been O
recently O
associated O
with O
the O
hemolytic B-ADE
- I-ADE
uremic I-ADE
syndrome I-ADE
( O
HUS B-ADE
) O
. O

Palpable B-ADE
purpuric I-ADE
skin I-ADE
lesions I-ADE
on O
the O
anterior O
surface O
of O
both O
legs O
appeared O
on O
the O
55th O
day O
of O
amphotericin B-DRUG
B I-DRUG
treatment O
. O

Minocycline B-DRUG
as O
a O
cause O
of O
drug O
- O
induced O
autoimmune B-ADE
hepatitis I-ADE
. O

Hypersensitivity B-ADE
reaction I-ADE
following O
chloramphenicol B-DRUG
administration O
in O
a O
patient O
with O
typhoid O
fever O
. O

Anaphylactic B-ADE
reaction I-ADE
to O
recombinant B-DRUG
insulin I-DRUG
- I-DRUG
like I-DRUG
growth I-DRUG
factor I-DRUG
- I-DRUG
I I-DRUG
. O

Three O
years O
later O
, O
treatment O
with O
ampicillin B-DRUG
caused O
another O
episode O
of O
cholestatic B-ADE
hepatitis I-ADE
with O
cholestasis B-ADE
and O
duct B-ADE
paucity I-ADE
on O
rebiopsy O
. O

This O
case O
emphasizes O
the O
importance O
of O
the O
evaluation O
of O
lithium B-DRUG
- O
associated O
polyuria B-ADE
with O
a O
direct O
measurement O
of O
plasma O
vasopressin O
, O
interpreted O
with O
simultaneous O
plasma O
and O
urine O
osmolality O
to O
secure O
the O
correct O
diagnosis O
and O
ensure O
appropriate O
therapeutic O
management O
. O

Hepatic B-ADE
damage I-ADE
after O
danazol B-DRUG
treatment O
. O

Myoclonus B-ADE
and O
seizures B-ADE
in O
a O
patient O
with O
parkinsonism O
: O
induction O
by O
levodopa B-DRUG
and O
its O
confirmation O
on O
SEPs O
. O

Prolonged O
used O
of O
hydroxyurea B-DRUG
in O
patients O
with O
ET O
may O
lead O
to O
therapy O
- O
associated O
acute B-ADE
leukemia I-ADE
. O

CONCLUSIONS O
: O
Intrathecal O
baclofen B-DRUG
can O
impair B-ADE
sexual I-ADE
function I-ADE
and O
ejaculation O
in O
some O
patients O
. O

RESULTS O
: O
At O
our O
institution O
, O
no O
children O
appeared O
with O
acute O
INH B-DRUG
neurotoxicity B-ADE
in O
the O
period O
1985 O
through O
1990 O
, O
whereas O
seven O
patients O
were O
treated O
from O
1991 O
through O
1993 O
. O

It O
has O
been O
reported O
that O
fluoroquinolone B-DRUG
antimicrobials O
prolong O
the O
corrected O
QT O
interval O
but O
rarely O
cause O
torsade B-ADE
de I-ADE
pointes I-ADE
. O

The O
authors O
present O
a O
case O
report O
of O
a O
granulomatous B-ADE
reaction I-ADE
leading O
to O
urethral B-ADE
prolapse I-ADE
, O
3 O
months O
after O
the O
transurethral O
injection O
of O
calcium B-DRUG
hydroxylapatite I-DRUG
. O

Teicoplanin B-DRUG
- O
induced O
agranulocytosis B-ADE
that O
followed O
vancomycin B-DRUG
- O
induced O
agranulocytosis B-ADE
suggests O
a O
possible O
cross O
- O
reactivity O
between O
the O
2 O
drugs O
. O

A O
7-year O
- O
old O
with O
congenital O
toxoplasmosis O
who O
took O
pyrimethamine B-DRUG
and O
sulfadiazine B-DRUG
for O
reactivated O
chorioretinitis O
developed O
fever B-ADE
, O
severe B-ADE
cutaneous I-ADE
involvement I-ADE
, O
swelling B-ADE
, O
abdominal B-ADE
pain I-ADE
and O
transaminitis B-ADE
, O
persisting O
weeks O
after O
withholding O
medicines O
. O

We O
describe O
a O
case O
of O
infection O
with O
Mycobacterium B-ADE
abscessus I-ADE
in O
a O
67-year O
- O
old O
woman O
receiving O
infliximab B-DRUG
as O
a O
component O
of O
her O
therapy O
for O
RA O
. O

To O
our O
knowledge O
, O
these O
cases O
represent O
the O
first O
reports O
of O
TDF B-DRUG
- O
associated O
irreversible B-ADE
renal I-ADE
failure I-ADE
and O
rickets B-ADE
in O
pediatric O
patients O
. O

Unique O
behavioral B-ADE
change I-ADE
with O
cinepazide B-DRUG
in O
parkinsonism O
. O

Acute O
renal B-ADE
failure I-ADE
should O
be O
recognized O
as O
a O
potential O
complication O
of O
suramin B-DRUG
treatment O
. O

Sulfasalazine B-DRUG
- O
induced O
hypersensitivity B-ADE
syndrome I-ADE
and O
hemophagocytic B-ADE
syndrome I-ADE
associated O
with O
reactivation O
of O
Epstein O
- O
Barr O
virus O
. O

Presently O
, O
treatment O
of O
acute O
ibuprofen B-DRUG
intoxication I-ADE
with O
complications O
requires O
supportive O
therapy O
until O
the O
symptoms O
resolve O
over O
24 O
to O
48 O
hours O
. O

We O
report O
two O
cases O
of O
neutropenia B-ADE
following O
captopril B-DRUG
use O
in O
cardiac O
patients O
with O
trisomy O
21 O
. O

Life O
- O
threatening O
alterations B-ADE
in I-ADE
heart I-ADE
rate I-ADE
after O
the O
use O
of O
adenosine B-DRUG
in O
atrial O
flutter O
. O

Cyclosporin B-DRUG
side O
effects O
included O
hirsutism B-ADE
, O
hypertension B-ADE
, O
increased B-ADE
blood I-ADE
levels I-ADE
of I-ADE
urea I-ADE
and I-ADE
creatinine I-ADE
, O
and O
abnormalities B-ADE
in I-ADE
liver I-ADE
function I-ADE
tests I-ADE
. O

This O
unusual O
pattern O
of O
low B-ADE
- I-ADE
grade I-ADE
endometrial I-ADE
carcinoma I-ADE
adds O
to O
the O
spectrum O
of O
uterine B-ADE
neoplasia I-ADE
associated O
with O
tamoxifen B-DRUG
therapy O
. O

The O
spectrum O
of O
nitrofurantoin B-DRUG
lung B-ADE
injury I-ADE
continues O
to O
widen O
. O

The O
day O
after O
clozapine B-DRUG
was O
stopped O
, O
while O
he O
was O
still O
receiving O
clomipramine B-DRUG
150 O
mg O
/ O
d O
, O
he O
began O
behaving B-ADE
oddly I-ADE
, O
started O
sweating B-ADE
profusely I-ADE
, O
shivering B-ADE
, O
and O
became O
tremulous B-ADE
, O
agitated B-ADE
, O
and O
confused B-ADE
. O

Two O
reports O
of O
spindle B-ADE
coma I-ADE
are O
noted O
with O
alcohol O
and O
imipramine B-DRUG
. O

Iatrogenic O
hypercalcemia B-ADE
due O
to O
vitamin B-DRUG
D3 I-DRUG
ointment O
( O
1,24(OH)2D3 B-DRUG
) O
combined O
with O
thiazide B-DRUG
diuretics O
in O
a O
case O
of O
psoriasis O
. O

Lower O
extremity O
arterial B-ADE
thrombosis I-ADE
following O
sonographically O
guided O
thrombin B-DRUG
injection O
of O
a O
femoral O
pseudoaneurysm O
. O

This O
report O
details O
a O
case O
of O
bilateral B-ADE
avascular I-ADE
necrosis I-ADE
of I-ADE
the I-ADE
femoral I-ADE
heads I-ADE
in O
a O
patient O
receiving O
' O
standard O
' O
doses O
of O
dexamethasone B-DRUG
as O
part O
of O
the O
antiemetic O
regimen O
used O
in O
cisplatin O
- O
based O
combination O
chemotherapy O
. O

This O
therapy O
was O
also O
complicated O
by O
Warfarin B-DRUG
- O
induced O
skin B-ADE
necrosis I-ADE
. O

The O
case O
reported O
here O
is O
of O
a O
child O
given O
a O
large O
dose O
of O
intravenous O
iron B-DRUG
sucrose I-DRUG
( O
16 O
mg O
/ O
kg O
) O
over O
3 O
hours O
, O
who O
subsequently O
developed O
features O
of O
systemic B-ADE
iron I-ADE
toxicity I-ADE
. O

DISCUSSION O
: O
Olanzapine B-DRUG
, O
like O
other O
atypical O
antipsychotic O
drugs O
, O
may O
cause O
muscle B-ADE
injury I-ADE
with I-ADE
concomitant I-ADE
elevations I-ADE
of I-ADE
serum I-ADE
CK I-ADE
of O
muscle O
origin O
. O

A O
patient O
with O
ulcerative O
colitis O
developed O
skin B-ADE
pigmentation I-ADE
and O
diffuse B-ADE
pulmonary I-ADE
shadowing I-ADE
without O
respiratory O
symptomatology O
, O
while O
taking O
sulfasalazine B-DRUG
. O

In O
one O
child O
, O
a O
second O
course O
of O
carbamazepine B-DRUG
resulted O
in O
a O
return O
of O
the O
dystonia B-ADE
. O

The O
international O
literature O
regarding O
opportunistic B-ADE
infections I-ADE
after O
immunosuppressive O
therapy O
with O
alemtuzumab B-DRUG
with O
particular O
attention O
on O
fungal B-ADE
infections I-ADE
has O
also O
been O
reviewed O
. O

A O
59-year O
- O
old O
woman O
with O
myasthenia O
gravis O
who O
received O
a O
large O
dose O
of O
pyridostigmine B-DRUG
bromide I-DRUG
developed O
postoperative B-ADE
psychosis I-ADE
and O
was O
diagnosed O
as O
having O
bromide B-ADE
intoxication I-ADE
. O

A O
case O
of O
liver B-ADE
damage I-ADE
following O
treatment O
with O
Danazol B-DRUG
for O
fibrocystic O
breast O
disease O
is O
reported O
. O

Atrioventricular B-ADE
block I-ADE
complicating O
amiodarone B-DRUG
- O
induced O
hypothyroidism B-ADE
in O
a O
patient O
with O
pre O
- O
excitation O
and O
rate O
- O
dependent O
bilateral O
bundle O
branch O
block O
. O

EEG B-ADE
abnormalities I-ADE
were O
observed O
in O
two O
of O
the O
nine O
children O
during O
chlorambucil B-DRUG
therapy O
. O

A O
9-year O
- O
old O
boy O
developed O
acute B-ADE
renal I-ADE
failure I-ADE
following O
intravenous O
acyclovir B-DRUG
( O
30 O
mg O
/ O
kg O
per O
day O
) O
administered O
for O
6 O
days O
to O
treat O
herpetic O
encephalitis O
. O

An O
83-year O
- O
old O
man O
receiving O
glipizide B-DRUG
10 O
mg O
bid O
developed O
symptomatic B-ADE
hypoglycemia I-ADE
within O
three O
days O
of O
adding O
trimethoprim B-DRUG
/ O
sulfamethoxazole B-DRUG
( O
TMP B-DRUG
/ O
SMX B-DRUG
) O
to O
his O
regimen O
. O

The O
first O
patient O
was O
a O
61-year O
- O
old O
man O
with O
a O
30-year O
history O
of O
fistulizing O
CD O
in O
whom O
B B-ADE
- I-ADE
cell I-ADE
non I-ADE
- I-ADE
Hodgkin I-ADE
's I-ADE
lymphoma I-ADE
was O
diagnosed O
9 O
months O
after O
treatment O
with O
infliximab B-DRUG
. O

Fatal B-ADE
lung I-ADE
fibrosis I-ADE
caused O
by O
paclitaxel B-DRUG
toxicity O
has O
not O
been O
reported O
In O
this O
report O
, O
we O
describe O
the O
case O
of O
a O
62-year O
- O
old O
woman O
who O
received O
six O
cycles O
of O
paclitaxel B-DRUG
and O
carboplatin B-DRUG
as O
combination O
chemotherapy O
for O
advanced O
ovarian O
cancer O
. O

Paradoxical B-ADE
ventricular I-ADE
tachycardia I-ADE
and O
fibrillation B-ADE
after O
intravenous O
bretylium B-DRUG
therapy O
. O

We O
report O
five O
cases O
of O
carboplatin B-DRUG
( O
CBDCA B-DRUG
) O
hypersensitivity B-ADE
after O
weekly O
low O
- O
dose O
paclitaxel B-DRUG
( O
60 O
mg O
/ O
m2)/CBDCA O
( O
area O
under O
the O
concentration O
curve O
= O
2 O
) O
therapy O
in O
patients O
with O
recurrent O
ovarian O
cancer O
receiving O
multiple O
platinum O
- O
based O
chemotherapy O
. O

We O
report O
a O
50-year O
- O
old O
male O
patient O
with O
a O
15-year O
history O
of O
psoriasis O
including O
mutilating O
psoriatic O
arthritis O
, O
in O
whom O
the O
withdrawal O
of O
cyclosporin B-DRUG
A I-DRUG
induced O
a O
generalised B-ADE
pustular I-ADE
exacerbation I-ADE
and O
a O
aggravation B-ADE
of I-ADE
the I-ADE
joint I-ADE
condition I-ADE
. O

These O
in O
vitro O
findings O
and O
clinical O
course O
suggest O
that O
TRAb B-ADE
/ I-ADE
TBII I-ADE
without I-ADE
thyroid I-ADE
- I-ADE
stimulating I-ADE
activity I-ADE
may O
develop O
in O
patients O
with O
amiodarone B-DRUG
- O
induced O
destructive B-ADE
thyroiditis I-ADE
, O
as O
reported O
in O
patients O
with O
destructive B-ADE
thyroiditis I-ADE
, O
such O
as O
subacute O
and O
silent O
thyroiditis B-ADE
. O

The O
authors O
present O
a O
case O
of O
t B-ADE
- I-ADE
AML I-ADE
that O
developed O
in O
a O
child O
with O
metastatic O
neuroblastoma O
18 O
months O
after O
he O
received O
oral O
etoposide B-DRUG
, O
given O
for O
palliation O
purpose O
. O

Insulin B-DRUG
- O
induced O
cardiac B-ADE
failure I-ADE
. O

We O
report O
on O
a O
patient O
with O
acromegaly O
who O
developed O
severe O
drug O
- O
induced O
hepatitis B-ADE
during O
combined O
treatment O
with O
the O
long O
- O
acting O
somatostatin O
- O
analog O
octreotide B-DRUG
and O
the O
GH O
receptor O
antagonist O
pegvisomant B-DRUG
. O

Autopsy O
evidence O
of O
herpesvirus B-ADE
infection I-ADE
was O
found O
in O
visceral O
organs O
of O
four O
leukemic O
patients O
who O
had O
received O
large O
doses O
of O
cytarabine B-DRUG
( O
cytosine B-DRUG
arabinoside I-DRUG
; O
Ara B-DRUG
- I-DRUG
C I-DRUG
) O
shortly O
before O
their O
death O
. O

Renal B-ADE
failure I-ADE
associated O
with O
the O
use O
of O
dextran-40 B-DRUG
. O

Macular B-ADE
infarction I-ADE
after O
endophthalmitis O
treated O
with O
vitrectomy O
and O
intravitreal O
gentamicin B-DRUG
. O

RESULTS O
: O
Two O
patients O
with O
ocular O
inflammation O
of O
unknown O
origin O
developed O
severe B-ADE
chorioretinitis I-ADE
after O
IVTA B-DRUG
injection O
. O

Beneficial O
effect O
of O
low O
- O
dose O
mianserin O
on O
fluvoxamine B-DRUG
- O
induced O
akathisia B-ADE
in O
an O
obsessive O
- O
compulsive O
patient O
. O

Putaminal B-ADE
infarct I-ADE
in O
methanol B-DRUG
intoxication I-ADE
: O
case O
report O
and O
role O
of O
brain O
imaging O
studies O
. O

In O
the O
present O
paper O
the O
authors O
describe O
2 O
female O
patients O
who O
developed O
incontinence B-ADE
secondary O
to O
the O
selective O
serotonin O
reuptake O
inhibitors O
paroxetine B-DRUG
and O
sertraline B-DRUG
, O
as O
well O
as O
a O
third O
who O
developed O
this O
side O
effect O
on O
venlafaxine B-DRUG
. O

Ciprofloxacin B-DRUG
- O
induced O
psychosis B-ADE
. O

Metipranolol B-DRUG
associated O
granulomatous B-ADE
anterior I-ADE
uveitis I-ADE
: O
not O
so O
uncommon O
as O
thought O
. O

We O
describe O
the O
case O
of O
a O
50-year O
- O
old O
woman O
with O
advanced O
non O
- O
small O
cell O
lung O
cancer O
who O
developed O
status B-ADE
epilepticus I-ADE
shortly O
after O
receiving O
cisplatin B-DRUG
and O
gemcitabine B-DRUG
chemotherapy O
. O

We O
report O
three O
patients O
, O
all O
of O
whom O
had O
preexisting O
diabetic O
dyslipidemia O
, O
who O
showed O
a O
profound O
reduction B-ADE
in I-ADE
plasma I-ADE
HDL I-ADE
cholesterol I-ADE
and I-ADE
apolipoprotein I-ADE
AI I-ADE
levels I-ADE
soon O
after O
the O
initiation O
of O
rosiglitazone B-DRUG
therapy O
. O

Ifosfamide B-DRUG
- O
induced O
nonconvulsive B-ADE
status I-ADE
epilepticus I-ADE
. O

CASE O
SUMMARY O
: O
Two O
children O
with O
attention O
deficit O
disorder O
treated O
with O
methylphenidate B-DRUG
as O
a O
simple O
drug O
developed O
fixed B-ADE
drug I-ADE
eruption I-ADE
of I-ADE
the I-ADE
scrotum I-ADE
. O

Flumazenil O
reversal O
of O
benzodiazepine B-DRUG
- O
induced O
sedation B-ADE
for O
a O
patient O
with O
severe O
pre O
- O
ECT O
anxiety O
. O

Linezolid B-DRUG
- O
associated O
acute B-ADE
interstitial I-ADE
nephritis I-ADE
and O
drug B-ADE
rash I-ADE
with I-ADE
eosinophilia I-ADE
and I-ADE
systemic I-ADE
symptoms I-ADE
( O
DRESS B-ADE
) O
syndrome O
. O

Jaundice B-ADE
induced O
by O
streptokinase B-DRUG
. O

The O
authors O
report O
a O
case O
of O
focal B-ADE
myocardial I-ADE
necrosis I-ADE
, O
presenting O
clinically O
as O
an O
acute B-ADE
myocardial I-ADE
infarction I-ADE
during O
the O
administration O
of O
the O
antineoplastic O
drug O
, O
amsacrine B-DRUG
, O
in O
a O
patient O
without O
coronary O
artery O
disease O
. O

The O
clinical O
course O
suggests O
that O
the O
interstitial B-ADE
pneumonitis I-ADE
was O
induced O
by O
hydroxyurea B-DRUG
. O

CONCLUSIONS O
: O
Jet O
- O
injection O
devices O
might O
constitute O
a O
helpful O
method O
to O
treat O
those O
patients O
affected O
by O
severe O
human B-DRUG
insulin I-DRUG
- O
induced O
lipoatrophy B-ADE
. O

We O
report O
marked O
QT B-ADE
prolongation I-ADE
and O
torsades B-ADE
de I-ADE
pointes I-ADE
in O
a O
setting O
of O
flash B-ADE
pulmonary I-ADE
edema I-ADE
resulting O
from O
acute B-ADE
myocardial I-ADE
ischemia I-ADE
in O
a O
patient O
who O
was O
being O
treated O
with O
dofetilide B-DRUG
for O
atrial O
fibrillation O
. O

Aripiprazole B-DRUG
- O
induced O
hiccups B-ADE
: O
a O
case O
report O
. O

Rhabdomyolysis B-ADE
associated O
with O
the O
use O
of O
intravenous O
vasopressin B-DRUG
. O

Investigation O
confirmed O
the O
diagnosis O
of O
rhabdomyolysis O
, O
and O
discontinuation O
of O
colchicine B-DRUG
resulted O
in O
resolution O
of O
clinical O
and O
biochemical O
features O
of O
rhabdomylysis B-ADE
. O

BACKGROUND O
: O
Hydroxyurea B-DRUG
is O
a O
cytostatic O
agent O
used O
to O
treat O
myeloproliferative O
disorders O
and O
long O
- O
term O
treatment O
is O
associated O
with O
mucocutaneous B-ADE
adverse I-ADE
events I-ADE
and O
nail B-ADE
hyperpigmentation I-ADE
. O

A O
57-year O
- O
old O
man O
developed O
morphea B-ADE
while O
taking O
bromocriptine B-DRUG
. O

Choanal B-ADE
atresia I-ADE
and O
athelia B-ADE
: O
methimazole B-DRUG
teratogenicity B-ADE
or O
a O
new O
syndrome O
? O

Immunosuppression O
elicited O
by O
the O
extensive O
administration O
of O
prednisolone B-DRUG
was O
suspected O
for O
the O
initiation O
of O
the O
generalized O
mite B-ADE
infestation I-ADE
. O

5-fluorouracil B-DRUG
( O
5-FU B-DRUG
) O
- O
associated O
peripheral B-ADE
neuropathy I-ADE
is O
an O
uncommon O
event O
. O

Other O
upper B-ADE
tract I-ADE
neoplasms I-ADE
after O
cyclophosphamide B-DRUG
are O
reviewed O
. O

CONCLUSIONS O
: O
Topiramate B-DRUG
may O
be O
associated O
with O
ciliochoroidal B-ADE
effusion I-ADE
with O
forward O
displacement B-ADE
of I-ADE
the I-ADE
lens I-ADE
- I-ADE
iris I-ADE
diaphragm I-ADE
and O
anterior B-ADE
chamber I-ADE
shallowing I-ADE
, O
resulting O
in O
acute B-ADE
myopia I-ADE
and O
angle B-ADE
- I-ADE
closure I-ADE
glaucoma I-ADE
. O

A O
patient O
with O
intracranial O
osteosarcoma O
that O
arose O
16 O
years O
after O
radiation O
therapy O
for O
hereditary O
retinoblastoma O
developed O
fatal B-ADE
cerebral I-ADE
edema I-ADE
and O
brainstem B-ADE
herniation I-ADE
after O
she O
received O
a O
single O
dose O
of O
intravenous O
methotrexate B-DRUG
. O

Erythropoietin O
is O
beneficial O
in O
mitomycin B-DRUG
- O
induced O
hemolytic B-ADE
- I-ADE
uremic I-ADE
syndrome I-ADE
. O

Alopecia B-ADE
, O
nausea B-ADE
, O
and O
vomiting B-ADE
were O
attributed O
to O
the O
cyclophosphamide B-DRUG
component O
of O
the O
therapy O
. O

This O
is O
a O
case O
report O
of O
subtle O
, O
mild O
hypothermia B-ADE
in O
a O
54-year O
old O
female O
patient O
receiving O
risperidone B-DRUG
for O
schizophrenia O
. O

Infliximab B-DRUG
and O
its O
serious O
adverse O
effects O
are O
discussed O
, O
and O
other O
cases O
of O
osteomyelitis B-ADE
with O
infliximab B-DRUG
use O
are O
also O
reviewed O
. O

However O
, O
we O
recently O
saw O
two O
patients O
with O
renal O
tuberculosis O
treated O
with O
ethambutol B-DRUG
in O
whom O
visual B-ADE
loss I-ADE
from O
toxic B-ADE
optic I-ADE
neuropathies I-ADE
was O
severe O
and O
irreversible O
despite O
careful O
ophthalmological O
monitoring O
and O
prompt O
discontinuation O
of O
the O
agent O
at O
the O
first O
sign O
of O
impaired O
visual O
function O
. O

In O
one O
case O
, O
the O
readministration O
of O
riluzole B-DRUG
was O
followed O
by O
the O
relapse O
of O
hepatitis B-ADE
. O

Behavioral O
side O
effects O
associated O
with O
clonazepam B-DRUG
may O
include O
agitation B-ADE
, O
aggression B-ADE
, O
hyperactivity B-ADE
, O
irritability B-ADE
, O
property B-ADE
destruction I-ADE
, O
and O
temper B-ADE
tantrums I-ADE
. O

BACKGROUND O
: O
Aphthous B-ADE
stomatitis I-ADE
, O
a O
common O
mucocutaneous O
disorder O
, O
is O
a O
well O
accepted O
complication O
of O
sirolimus B-DRUG
therapy O
. O

Due O
to O
the O
increasing O
use O
of O
TMP B-DRUG
- I-DRUG
SMX I-DRUG
in O
children O
, O
clinicians O
should O
be O
aware O
of O
this O
potentially O
life O
- O
threatening O
, O
immunemediated B-ADE
hypersensitivity I-ADE
reaction I-ADE
. O

We O
describe O
a O
15-year O
- O
old O
female O
patient O
diagnosed O
with O
acute B-ADE
lymphoblastic I-ADE
leukemia I-ADE
presenting O
with O
status O
epilepticus O
after O
receiving O
intrathecal O
methotrexate B-DRUG
. O

The O
mechanism O
by O
which O
sunitinib B-DRUG
induces O
gynaecomastia B-ADE
is O
thought O
to O
be O
associated O
with O
an O
unknown O
direct O
action O
on O
breast O
hormonal O
receptors O
. O

In O
the O
following O
case O
report O
, O
a O
patient O
developed O
acute B-ADE
interstitial I-ADE
nephritis I-ADE
with O
renal B-ADE
failure I-ADE
and O
exfoliative B-ADE
dermatitis I-ADE
following O
ampicillin B-DRUG
therapy O
. O

We O
report O
a O
patient O
of O
organic O
bipolar O
affective O
disorder O
who O
developed O
hiccups B-ADE
with O
the O
atypical O
antipsychotic O
aripiprazole B-DRUG
. O

We O
report O
four O
cases O
of O
severe B-ADE
corneal I-ADE
ulceration I-ADE
in O
methamphetamine B-DRUG
abusers O
. O

Worsening B-ADE
of I-ADE
neurologic I-ADE
syndrome I-ADE
in O
patients O
with O
Wilson O
's O
disease O
with O
initial O
penicillamine B-DRUG
therapy O
. O

Based O
on O
the O
history O
and O
clinical O
features O
, O
a O
diagnosis O
of O
insulin B-DRUG
- O
induced O
lipohypertrophy B-ADE
was O
made O
. O

We O
report O
a O
case O
of O
generalized B-ADE
cutaneous I-ADE
sclerosis I-ADE
associated O
with O
muscle O
and O
oesophageal O
involvement O
in O
a O
patient O
exposed O
to O
herbicides O
containing O
bromocil B-DRUG
, O
diuron B-DRUG
and O
aminotriazole B-DRUG
. O

OBJECTIVE O
: O
To O
determine O
the O
frequency O
of O
weight B-ADE
loss I-ADE
in O
patients O
treated O
with O
leflunomide B-DRUG
for O
rheumatoid O
arthritis O
at O
an O
arthritis O
referral O
center O
. O

Abdominal B-ADE
wall I-ADE
ulceration I-ADE
and O
mucinosis B-ADE
secondary O
to O
recombinant B-DRUG
human I-DRUG
interferon I-DRUG
- I-DRUG
beta-1b I-DRUG
. O

CONCLUSIONS O
: O
Clinicians O
should O
be O
aware O
of O
a O
risk O
of O
serotonin B-ADE
syndrome I-ADE
with O
serious O
extrapyramidal B-ADE
reactions I-ADE
in O
patients O
receiving O
sertraline B-DRUG
or O
venlafaxine B-DRUG
when O
metoclopramide B-DRUG
is O
coadministered O
even O
in O
a O
single O
, O
conventional O
dose O
. O

This O
is O
a O
unique O
autopsy O
case O
of O
hepatocellular B-ADE
carcinoma I-ADE
closely O
related O
to O
diethylstilbestrol B-DRUG
( O
DES B-DRUG
) O
therapy O
for O
prostatic O
cancer O
. O

We O
present O
a O
neonate O
with O
a O
seizure O
disorder O
who O
acutely O
developed O
pupillary B-ADE
mydriasis I-ADE
secondary O
to O
lidocaine B-DRUG
overdose O
. O

In O
this O
case O
, O
CIPS B-ADE
was O
considered O
to O
be O
probably O
associated O
with O
cyclosporine B-DRUG
according O
to O
the O
Naranjo O
probability O
scale O
. O

This O
is O
the O
first O
histologically O
confirmed O
case O
of O
NASH B-ADE
that O
was O
aggravated O
by O
raloxifene B-DRUG
. O

A O
well O
- O
recognized O
complication O
of O
ethambutol B-DRUG
use O
is O
optic B-ADE
neuropathy I-ADE
, O
but O
the O
potential O
ocular B-ADE
toxicity I-ADE
of O
isoniazid B-DRUG
is O
often O
overlooked O
. O

This O
treatment O
has O
the O
potential O
to O
cause O
severe B-ADE
vision I-ADE
loss I-ADE
as O
a O
result O
of O
intractable O
corticosteroid B-DRUG
- O
induced O
glaucoma B-ADE
. O

CONCLUSIONS O
: O
The O
increasing O
prevalence O
of O
Type O
2 O
diabetes O
and O
its O
treatment O
with O
metformin B-DRUG
might O
result O
in O
more O
cases O
of O
lactic B-ADE
acidosis I-ADE
. O

Isoniazid B-DRUG
induced O
gynaecomastia B-ADE
: O
a O
case O
report O
. O

The O
authors O
report O
two O
cases O
of O
acute B-ADE
dystonic I-ADE
reactions I-ADE
( O
ADRs B-ADE
) O
as O
a O
side O
effect O
of O
lamivudine B-DRUG
. O

A O
case O
of O
toxic B-ADE
hepatitis I-ADE
caused O
by O
combination O
therapy O
with O
methotrexate B-DRUG
and O
etretinate B-DRUG
in O
the O
treatment O
of O
severe O
psoriasis O
is O
presented O
in O
a O
47-year O
- O
old O
woman O
. O

Methotrexate B-DRUG
is O
an O
effective O
but O
potentially B-ADE
toxic I-ADE
treatment O
for O
psoriasis O
. O

A O
52-year O
- O
old O
woman O
developed O
symmetric B-ADE
sensorimotor I-ADE
polyneuropathy I-ADE
and O
cerebellar B-ADE
syndrome I-ADE
after O
24 O
months O
of O
amiodarone B-DRUG
treatment O
. O

When O
SASP O
was O
changed O
to O
5-aminosalicylic B-DRUG
acid I-DRUG
( O
5-ASA B-DRUG
) O
, O
his O
skin O
eruptions O
were O
resolved O
, O
however O
, O
he O
developed O
weakness B-ADE
and O
atrophy B-ADE
in O
his O
right O
arm O
as O
well O
as O
progressive O
worsening B-ADE
of I-ADE
the I-ADE
dysesthesia I-ADE
in O
his O
legs O
and O
gait B-ADE
disturbance I-ADE
. O

These O
findings O
suggest O
that O
the O
corneal B-ADE
and I-ADE
retinal I-ADE
changes I-ADE
are O
the O
result O
of O
a O
toxic O
effect O
of O
tamoxifen B-DRUG
when O
used O
in O
the O
doses O
and O
duration O
described O
. O

This O
was O
accepted O
as O
evidence O
for O
propranolol B-DRUG
being O
the O
cause O
of O
this O
conduction B-ADE
disorder I-ADE
. O

After O
only O
the O
third O
dose O
of O
pentamidine B-DRUG
, O
it O
was O
noted O
that O
the O
patient O
's O
heart B-ADE
rate I-ADE
had I-ADE
decreased I-ADE
to O
48 O
beats O
/ O
minute O
. O

Schneiderian B-ADE
first I-ADE
- I-ADE
rank I-ADE
symptoms I-ADE
associated O
with O
fluvoxamine B-DRUG
treatment O
: O
a O
case O
report O
. O

Akathisia B-ADE
is O
a O
relatively O
rare O
side O
effect O
with O
the O
newer O
atypical O
antipsychotic O
agents O
, O
particularly O
clozapine B-DRUG
, O
and O
is O
easily O
misdiagnosed O
in O
children O
. O

The O
wide O
use O
of O
phenytoin B-DRUG
during O
the O
recent O
tuberculosis O
epidemic O
makes O
it O
imperative O
to O
suspect O
this O
drug O
interaction O
in O
patients O
exhibiting O
clinical O
features O
that O
might O
be O
related O
to O
phenytoin B-DRUG
toxicity I-ADE
. O

The O
aim O
of O
this O
paper O
is O
to O
report O
the O
case O
of O
rosaceiform B-ADE
eruption I-ADE
induced O
by O
erlotinib B-DRUG
in O
an O
81-year O
- O
old O
- O
man O
and O
to O
discuss O
the O
pathogenetic O
role O
of O
Demodex O
folliculorum O
mites O
, O
found O
in O
the O
present O
patient O
, O
using O
skin O
scraping O
. O

A O
case O
of O
high B-ADE
- I-ADE
grade I-ADE
endometrial I-ADE
stromal I-ADE
sarcoma I-ADE
, O
confined O
into O
an O
intrauterine B-ADE
polypoid I-ADE
growth I-ADE
, O
in O
a O
woman O
with O
a O
history O
of O
breast O
cancer O
who O
was O
treated O
with O
adjuvant O
tamoxifen B-DRUG
. O

Toxic B-ADE
epidermal I-ADE
necrolysis I-ADE
after O
the O
use O
of O
high O
- O
dose O
cytosine B-DRUG
arabinoside I-DRUG
. O

Review O
of O
the O
literature O
relating O
to O
methicillin B-DRUG
- O
induced O
nephropathy B-ADE
suggests O
a O
hypersensitivity O
origin O
for O
this O
disorder O
, O
but O
immunologic O
and O
ultrastructural O
investigation O
to O
date O
has O
failed O
to O
elucidate O
pathogenesis O
. O

We O
hypothesize O
that O
caffeine B-DRUG
toxicity I-ADE
injured B-ADE
the I-ADE
muscle I-ADE
cells I-ADE
, O
which O
were O
fragile O
due O
to O
the O
potassium B-ADE
depletion I-ADE
induced O
by O
the O
coexisting B-ADE
hyponatremia I-ADE
, O
to O
result O
in O
unusually O
severe O
rhabdomyolysis B-ADE
. O

Previous O
studies O
have O
demonstrated O
the O
interaction O
of O
MTX B-DRUG
and O
a O
variety O
of O
non O
- O
steroidal O
, O
anti O
- O
inflammatory O
drugs O
( O
NSAIDs O
) O
with O
various O
clinical O
manifestations O
including O
acute B-ADE
renal I-ADE
failure I-ADE
, O
pancytopenia B-ADE
, O
vomiting B-ADE
, O
diarrhea B-ADE
, O
elevated B-ADE
liver I-ADE
transaminases I-ADE
, O
jaundice B-ADE
, O
mucosal B-ADE
ulcerations I-ADE
, O
and O
pyrexia B-ADE
. O

We O
report O
a O
rare O
case O
of O
colonic B-ADE
mucosal I-ADE
necrosis I-ADE
following O
Kalimate B-DRUG
( O
calcium B-DRUG
polystryrene I-DRUG
sulfonate I-DRUG
) O
, O
an O
analogue O
of O
Kayexalate B-DRUG
without O
sorbitol O
in O
a O
34-yr O
- O
old O
man O
. O

We O
present O
a O
case O
of O
respiratory B-ADE
failure I-ADE
occurring O
in O
a O
woman O
at O
16 O
weeks O
' O
gestation O
who O
was O
being O
treated O
with O
nitrofurantoin B-DRUG
for O
a O
urinary O
tract O
infection O
. O

Progression O
of O
chronic O
myeloid O
leukemia O
to O
blast B-ADE
crisis I-ADE
during O
treatment O
with O
imatinib B-DRUG
mesylate I-DRUG
. O

METHODS O
/ O
RESULTS O
: O
This O
paper O
presents O
a O
new O
case O
of O
rifabutin B-DRUG
uveitis B-ADE
and O
a O
review O
of O
the O
various O
published O
reports O
to O
date O
. O

We O
describe O
two O
dark O
- O
skinned O
patients O
who O
developed O
hyperpigmented B-ADE
skin I-ADE
and O
tongue B-ADE
lesions I-ADE
during O
combination O
therapy O
with O
IFN B-DRUG
and O
ribavirin B-DRUG
. O

These O
multiple O
overlapping O
factors O
probably O
lead O
to O
rhabdomyolysis B-ADE
in O
a O
minority O
of O
patients O
receiving O
vasopressin B-DRUG
infusion O
. O

Symptomatic B-ADE
hypoglycemia I-ADE
secondary O
to O
a O
glipizide B-DRUG
- O
trimethoprim B-DRUG
/ O
sulfamethoxazole B-DRUG
drug O
interaction O
. O

Lithium B-ADE
neurotoxicity I-ADE
should O
be O
considered O
in O
Creutzfeldt B-ADE
- I-ADE
Jakob I-ADE
disease I-ADE
differential O
diagnosis O
, O
serial O
electroencephalograms O
being O
the O
most O
valuable O
. O

Treatment O
of O
APL O
in O
pregnancy O
is O
controversial O
as O
the O
use O
of O
ATRA B-DRUG
has O
been O
questioned O
due O
to O
the O
teratogenic B-ADE
effect I-ADE
of O
retinoids O
. O

An O
objective O
causality O
assessment O
indicated O
a O
probable O
relationship O
between O
clotting B-ADE
abnormality I-ADE
and O
warfarin B-DRUG
administration O
, O
although O
the O
degree O
of O
elevation O
of O
the O
INR O
was O
unusual O
in O
the O
light O
of O
the O
daily O
warfarin O
dose O
and O
duration O
of O
its O
exposure O
. O

Peripheral B-ADE
nerve I-ADE
dysfunction I-ADE
is O
a O
potentially O
serious O
complication O
of O
high O
- O
dose O
cytosine B-DRUG
arabinoside I-DRUG
. O

Isonicotinic B-DRUG
acid I-DRUG
hydrazide I-DRUG
induced O
anagen B-ADE
effluvium I-ADE
and O
associated O
lichenoid B-ADE
eruption I-ADE
. O

Vigabatrin B-DRUG
- O
induced O
visual B-ADE
field I-ADE
defects I-ADE
are O
at O
present O
the O
most O
important O
safety O
issue O
in O
the O
use O
of O
the O
drug O
. O

However O
, O
prolongation O
of O
5-FU O
half O
- O
life O
and O
an O
increase B-ADE
in I-ADE
INR I-ADE
have O
been O
reported O
with O
the O
concurrent O
use O
of O
5-FU B-DRUG
and O
warfarin B-DRUG
. O

Bisphosphonate B-DRUG
- O
related O
osteonecrosis B-ADE
of I-ADE
the I-ADE
skull I-ADE
base I-ADE
. O

Six O
patients O
with O
rheumatoid O
arthritis O
developed O
a O
syndrome O
resembling O
lupus B-ADE
erythematosus I-ADE
while O
being O
treated O
with O
penicillamine B-DRUG
. O

Lovastatin B-DRUG
- O
induced O
rhabdomyolysis B-ADE
possibly O
associated O
with O
clarithromycin B-DRUG
and O
azithromycin B-DRUG
. O

Although O
both O
patients O
recovered O
from O
the O
colitis O
after O
the O
administration O
of O
vancomycin O
, O
the O
first O
case O
demonstrated O
a O
relapse O
of O
the O
colitis B-ADE
after O
receiving O
a O
subsequent O
course O
of O
the O
same O
chemotherapy O
with O
cisplatin B-DRUG
. O

The O
occurrence O
of O
acute O
hepatitis B-ADE
is O
best O
known O
for O
ketoconazole B-DRUG
. O

Anaphylaxis B-ADE
from O
isoniazid B-DRUG
is O
a O
possible O
side O
effect O
to O
this O
commonly O
prescribed O
antibiotic O
. O

Effect O
of O
beta O
- O
blockade O
on O
symptomatic O
dexamethasone B-DRUG
- O
induced O
hypertrophic B-ADE
obstructive I-ADE
cardiomyopathy I-ADE
in O
premature O
infants O
: O
three O
case O
reports O
and O
literature O
review O
. O

In O
conclusion O
, O
RSDS B-ADE
is O
a O
relevant O
osteoarticular O
complication O
in O
patients O
receiving O
either O
anticalcineurinic O
drug O
( O
CyA B-DRUG
or O
tacrolimus B-DRUG
) O
, O
even O
under O
monotherapy O
or O
with O
a O
low O
steroid O
dose O
. O

Two O
patients O
with O
imminent O
gangrene B-ADE
of I-ADE
the I-ADE
extremities I-ADE
caused O
by O
ergot B-DRUG
- O
induced O
arteriospasm B-ADE
underwent O
mechanical O
dilatation O
of O
the O
arteries O
when O
conventional O
measures O
such O
as O
anticoagulation O
, O
vasodilation O
, O
and O
sympathetic O
blockade O
produced O
no O
improvement O
. O

Nail B-ADE
staining I-ADE
from O
hydroquinone B-DRUG
cream O
. O

Angio B-ADE
- I-ADE
oedema I-ADE
as O
an O
unusual O
tolerable O
side O
effect O
of O
voriconazole B-DRUG
therapy O
. O

We O
describe O
a O
patient O
with O
acute O
leukemia O
who O
developed O
Horner B-ADE
's I-ADE
syndrome I-ADE
and O
a O
severe B-ADE
demyelinating I-ADE
peripheral I-ADE
neuropathy I-ADE
leading O
to O
death B-ADE
after O
receiving O
high O
- O
dose O
cytosine B-DRUG
arabinoside I-DRUG
. O

Life O
- O
threatening O
acute B-ADE
hyponatraemia I-ADE
induced O
by O
low O
dose O
cyclophosphamide B-DRUG
and O
indomethacin B-DRUG
. O

Patients O
receiving O
amifostine B-DRUG
who O
develop O
only O
fever B-ADE
should O
be O
evaluated O
for O
an O
adverse O
drug O
reaction O
, O
as O
well O
as O
for O
sepsis B-ADE
and O
fevers B-ADE
of I-ADE
neutropenia I-ADE
, O
and O
it O
may O
be O
necessary O
to O
discontinue O
the O
drug O
. O

Delusional B-ADE
parasitosis I-ADE
associated O
with O
phenelzine B-DRUG
. O

Differential O
diagnoses O
included O
ocular O
rosacea O
with O
cicatrizing O
conjunctivitis O
and O
5-FU B-DRUG
- O
induced O
ectropion B-ADE
. O

Acute B-ADE
neutrophilic I-ADE
dermatosis I-ADE
induced O
by O
all B-DRUG
- I-DRUG
trans I-DRUG
- I-DRUG
retinoic I-DRUG
acid I-DRUG
treatment O
for O
acute O
promyelocytic O
leukemia O
. O

Our O
experience O
supports O
hemodialysis O
for O
ESRF O
patients O
with O
atenolol B-DRUG
toxicity I-ADE
. O

This O
case O
study O
is O
the O
second O
report O
of O
localized B-ADE
purpura I-ADE
after O
prolonged O
lamotrigine B-DRUG
treatment O
suggesting O
this O
may O
be O
an O
atypical O
lamotrigine O
- O
induced O
drug O
reaction O
. O

Ticlopidine B-DRUG
is O
an O
oral O
antiplatelet O
agent O
frequently O
utilized O
in O
the O
treatment O
of O
cerebrovascular O
disease O
and O
is O
rarely O
associated O
with O
severe B-ADE
bone I-ADE
marrow I-ADE
suppression I-ADE
, O
typically O
aplastic B-ADE
anemia I-ADE
. O

We O
report O
the O
case O
of O
a O
20-year O
- O
old O
female O
with O
polyarteritis O
nodosa O
( O
PAN O
) O
who O
developed O
bilateral B-ADE
sensorineural I-ADE
hearing I-ADE
loss I-ADE
25 O
minutes O
after O
receiving O
30 O
mg O
of O
intravenous O
ketoralac B-DRUG
. O

We O
report O
a O
case O
of O
penile B-ADE
fibrosis I-ADE
after O
intracavernous O
self O
- O
injection O
of O
a O
combination O
of O
phentolamine B-DRUG
and O
papaverine B-DRUG
. O

We O
report O
the O
case O
of O
a O
child O
with O
metastatic O
osteosarcoma O
, O
who O
experienced O
an O
anaphylactic B-ADE
/ I-ADE
anaphylactoid I-ADE
reaction I-ADE
to O
methotrexate B-DRUG
. O

We O
report O
the O
first O
case O
of O
a O
54-year O
- O
old O
Turkish O
woman O
who O
presented O
with O
ceftriaxone B-DRUG
- O
induced O
FDE B-ADE
. O

Piritrexim B-DRUG
- O
induced O
pulmonary B-ADE
toxicity I-ADE
. O

Nephrotic B-ADE
syndrome I-ADE
associated O
with O
lithium B-DRUG
therapy O
. O

Retrospectively O
, O
bucillamine B-DRUG
was O
believed O
to O
be O
the O
cause O
of O
the O
giant B-ADE
hypertrophy I-ADE
because O
of O
its O
structural O
similarity O
to O
D B-DRUG
- I-DRUG
penicillamine I-DRUG
, O
which O
was O
the O
subject O
of O
an O
abundance O
of O
reports O
of O
mammary B-ADE
hyperplasia I-ADE
. O

It O
is O
hoped O
that O
this O
case O
report O
creates O
awareness O
that O
ofloxacin B-DRUG
- O
induced O
toxic B-ADE
epidermal I-ADE
necrolysis I-ADE
is O
possible O
. O

OBJECTIVES O
: O
To O
describe O
the O
presentation O
and O
treatment O
of O
acute O
isoniazid B-DRUG
( O
INH B-DRUG
) O
neurotoxicity B-ADE
appearing O
at O
an O
inner O
- O
city O
municipal O
hospital O
. O

CASE O
SUMMARIES O
: O
Two O
patients O
with O
stable O
hypothyroidism O
experienced O
symptoms O
of O
hypothyroidism O
with O
increased B-ADE
serum I-ADE
thyroid I-ADE
- I-ADE
stimulating I-ADE
hormone I-ADE
( O
TSH O
) O
concentrations O
after O
switching O
from O
1 O
levothyroxine B-DRUG
product O
to O
another O
. O

An O
11-year O
- O
old O
boy O
developed O
a O
severe B-ADE
enteropathy I-ADE
2 O
years O
after O
initiation O
of O
clofazimine B-DRUG
treatment O
for O
graft O
- O
versus O
- O
host O
disease O
. O

The O
authors O
report O
five O
additional O
cases O
of O
capecitabine B-DRUG
- O
induced O
multifocal B-ADE
leukoencephalopathy I-ADE
. O

There O
are O
, O
however O
, O
case O
studies O
describing O
patients O
experiencing O
recurrences O
of O
tics B-ADE
following O
treatment O
with O
atomoxetine B-DRUG
. O

We O
report O
a O
premature O
infant O
who O
developed O
seizures B-ADE
associated O
with O
intraventricular O
administration O
of O
nafcillin B-DRUG
and O
discuss O
the O
need O
for O
electroencephalographic O
monitoring O
of O
patients O
receiving O
intraventricular O
antibiotics O
. O

We O
report O
a O
case O
of O
baclofen B-DRUG
withdrawal B-ADE
syndrome I-ADE
resulting O
from O
oral O
baclofen B-DRUG
underdosing O
. O

Reversible B-ADE
posterior I-ADE
leukoencephalopathy I-ADE
syndrome I-ADE
in O
systemic O
lupus O
erythematosus O
with O
thrombocytopenia O
treated O
with O
cyclosporine B-DRUG
. O

Pellagra O
should O
be O
suspected O
whenever O
tuberculous O
patients O
under O
treatment O
with O
isoniazid B-DRUG
develop O
mental B-ADE
, I-ADE
neurological I-ADE
or I-ADE
gastrointestinal I-ADE
symptoms I-ADE
, O
even O
in O
the O
absence O
of O
typical O
pellagra O
dermatitis O
. O

The O
patient O
developed O
grade O
3 O
capecitabine B-DRUG
- O
induced O
headache B-ADE
. O

A O
MEDLINE O
search O
identified O
all O
the O
reported O
cases O
of O
hypersensitivity B-ADE
reactions I-ADE
to O
cyclosporine B-DRUG
. O

Chlormadinone B-DRUG
acetate I-DRUG
withdrawal B-ADE
syndrome I-ADE
under O
combined O
androgen O
blockade O
for O
advanced O
prostate O
cancer O
. O

Treatment O
with O
infliximab B-DRUG
is O
known O
to O
produce O
an O
increase B-ADE
of I-ADE
autoantibodies I-ADE
( O
antinuclear B-ADE
antibodies I-ADE
, O
anti B-ADE
- I-ADE
double I-ADE
- I-ADE
stranded I-ADE
DNA I-ADE
) O
, O
but O
not O
clinical O
disease O
. O

We O
report O
a O
case O
of O
a O
23-year O
- O
old O
man O
who O
developed O
a O
vancomycin B-DRUG
- O
induced O
anaphylactic B-ADE
reaction I-ADE
in O
the O
treatment O
of O
methicillin O
- O
resistant O
Staphylococcus O
aureus O
infection O
. O

After O
identification O
of O
the O
index O
patient O
, O
additional O
inquiry O
revealed O
that O
the O
patient O
's O
mother O
was O
hospitalized O
previously O
for O
overwhelming O
sepsis B-ADE
associated O
with O
metamizole B-DRUG
use O
. O

RESULTS O
: O
One O
case O
of O
recurrent O
primary O
peritoneal O
carcinoma O
previously O
treated O
with O
a O
carboplatin B-DRUG
- O
based O
regimen O
, O
developed O
a O
platinum B-ADE
hypersensitivity I-ADE
. O

Torsade B-ADE
de I-ADE
pointes I-ADE
associated O
with O
moxifloxacin B-DRUG
: O
a O
rare O
but O
potentially O
fatal O
adverse O
event O
. O

Pulmonary B-ADE
fibrosis I-ADE
subsequent O
to O
high O
doses O
of O
CCNU B-DRUG
for O
chronic O
myeloid O
leukemia O
. O

The O
association O
with O
prolonged O
unopposed O
estrogen O
- O
like O
stimulation O
with O
tamoxifen B-DRUG
as O
a O
possible O
factor O
in O
the O
development O
of O
ovarian B-ADE
endometrioid I-ADE
carcinoma I-ADE
is O
discussed O
. O

Complications O
of O
chemotherapy O
for O
a O
synovial O
sarcoma O
in O
an O
eight O
- O
year O
old O
boy O
included O
cisplatinum B-DRUG
nephrotoxicity B-ADE
and O
adriamycin B-DRUG
cardiotoxicity B-ADE
. O

Pneumocystis B-ADE
carinii I-ADE
pneumonia I-ADE
as O
a O
complication O
of O
methotrexate B-DRUG
treatment O
of O
asthma O
. O

RTA B-ADE
is O
one O
type O
of O
nephrotoxicity B-ADE
induced O
by O
FK506 B-DRUG
, O
and O
it O
is O
reversible O
in O
mild O
cases O
when O
appropriately O
treated O
. O

The O
mechanism O
of O
RTA B-ADE
induced O
by O
FK506 B-DRUG
has O
not O
yet O
been O
clearly O
elucidated O
. O

Three O
nephrotic O
patients O
who O
had O
reduced O
renal O
function O
and O
active O
renal O
disease O
with O
progressive O
deterioration O
of O
renal O
function O
prior O
to O
the O
use O
of O
MP B-DRUG
developed O
transient B-ADE
renal I-ADE
failure I-ADE
following O
an O
MP B-DRUG
pulse O
therapy O
. O

Hyperammonemia B-ADE
secondary O
to O
valproic B-DRUG
acid I-DRUG
as O
a O
cause O
of O
lethargy B-ADE
in O
a O
postictal O
patient O
. O

Methysergide B-DRUG
- O
induced O
retroperitoneal B-ADE
fibrosis I-ADE
: O
successful O
outcome O
and O
two O
new O
laboratory O
features O
. O

A O
small O
number O
of O
oxaliplatin B-DRUG
- O
related O
hemolytic B-ADE
and/or I-ADE
thrombocytopenic I-ADE
reactions I-ADE
have O
been O
reported O
. O

We O
report O
a O
case O
of O
interstitial B-ADE
pneumonitis I-ADE
induced O
by O
bicalutamide B-DRUG
and/or O
leuprorelin B-DRUG
acetate I-DRUG
given O
as O
therapy O
for O
prostate O
cancer O
, O
in O
which O
the O
pneumonitis O
was O
successfully O
managed O
by O
steroid O
treatment O
. O

This O
case O
report O
describes O
a O
patient O
who O
was O
previously O
prescribed O
alendronate B-DRUG
( O
Fosamax B-DRUG
) O
and O
presented O
with O
postoperative O
hypophosphatemia B-ADE
and O
hypocalcemic B-ADE
tetany I-ADE
after O
bowel O
preparation O
with O
Fleet B-DRUG
Phospho I-DRUG
- I-DRUG
Soda I-DRUG
. O

OBJECTIVE O
: O
To O
describe O
a O
patient O
with O
asymptomatic O
bronchial O
asthma O
and O
hypertension O
who O
developed O
an O
acute B-ADE
asthma I-ADE
attack O
after O
receiving O
sustained O
- O
release O
verapamil B-DRUG
. O

We O
report O
such O
a O
series O
of O
patients O
who O
had O
transient B-ADE
asymptomatic I-ADE
bradycardia I-ADE
after O
being O
treated O
with O
continuous O
infusion O
5-FU B-DRUG
. O

Because O
of O
serious O
side O
effects O
of O
an O
increase B-ADE
in I-ADE
the I-ADE
QT I-ADE
interval I-ADE
causing O
torsades B-ADE
de I-ADE
pointes I-ADE
, O
dofetilide B-DRUG
must O
be O
initiated O
with O
close O
monitoring O
of O
the O
QT O
interval O
in O
an O
inpatient O
setting O
. O

Subfulminant B-ADE
hepatitis I-ADE
B I-ADE
after O
infliximab B-DRUG
in O
Crohn O
's O
disease O
: O
need O
for O
HBV O
- O
screening O
? O

We O
discuss O
a O
patient O
who O
developed O
severe B-ADE
renal I-ADE
tubular I-ADE
dysfunction I-ADE
secondary O
to O
short O
- O
term O
therapy O
with O
Amikacin B-DRUG
, O
resulting O
in O
refractory B-ADE
hypokalemia I-ADE
, O
hypocalcemia B-ADE
, O
hypomagnesemia B-ADE
, O
metabolic B-ADE
alkalosis I-ADE
, O
and O
polyuria B-ADE
. O

A O
second O
possibility O
is O
an O
interaction O
between O
clarithromycin B-DRUG
and O
isradipine B-DRUG
, O
potentially O
increasing B-ADE
the I-ADE
hepatic I-ADE
toxicity I-ADE
of O
isradipine B-DRUG
. O

Three O
male O
patients O
aged O
78 O
- O
83 O
years O
are O
presented O
, O
in O
whom O
severe B-ADE
hepatotoxic I-ADE
reactions I-ADE
emerged O
after O
CPA B-DRUG
administration O
. O

Systemic B-ADE
capillary I-ADE
leak I-ADE
syndrome I-ADE
after O
granulocyte B-DRUG
colony I-DRUG
- I-DRUG
stimulating I-DRUG
factor I-DRUG
( O
G B-DRUG
- I-DRUG
CSF I-DRUG
) O
. O

Markedly O
increased B-ADE
pigmementation I-ADE
of I-ADE
skin I-ADE
immediately O
overlying O
veins O
used O
for O
multiple O
5-fluorouracil B-DRUG
infusions O
was O
noted O
. O

These O
cases O
highlight O
the O
occurrence O
of O
livedo B-ADE
reticularis I-ADE
as O
an O
uncommon O
side O
- O
effect O
of O
interferon B-DRUG
alpha I-DRUG
treatment O
. O

Stevens B-ADE
- I-ADE
Johnson I-ADE
syndrome I-ADE
caused O
by O
the O
antiretroviral O
drug O
nevirapine B-DRUG
. O

Propecia B-DRUG
- O
associated O
bilateral B-ADE
cataract I-ADE
. O

A O
second O
episode O
of O
jaundice B-ADE
followed O
the O
intravaginal O
administration O
of O
a O
mixture O
of O
furazolidone B-DRUG
and O
nifuroxime B-DRUG
. O

Acute B-ADE
asthma I-ADE
associated O
with O
sustained O
- O
release O
verapamil B-DRUG
. O

Relief O
by O
naloxone O
of O
morphine B-DRUG
- O
induced O
spasm B-ADE
of O
the O
sphincter O
of O
Oddi O
in O
a O
post O
- O
cholecystectomy O
patient O
. O

An O
episode O
of O
leukoencephalopathy B-ADE
is O
reported O
in O
a O
13-year O
- O
old O
girl O
who O
, O
after O
standard O
radiotherapy O
for O
a O
posterior O
fossa O
medulloblastoma O
, O
received O
8 O
treatments O
with O
a O
protocol O
containing O
a O
4-hour O
infusion O
of O
500 O
mg O
/ O
m2 O
methotrexate B-DRUG
and O
12 O
mg O
intrathecal O
methotrexate B-DRUG
. O

We O
report O
the O
use O
of O
pamidronate O
for O
acute O
, O
severe B-ADE
hypercalcemia I-ADE
secondary O
to O
iatrogenic O
vitamin B-ADE
D I-ADE
poisoning I-ADE
. O

We O
present O
a O
case O
of O
photo B-ADE
- I-ADE
onycholysis I-ADE
in O
a O
patient O
treated O
with O
doxycycline B-DRUG
for O
acne O
vulgaris O
. O

The O
most O
likely O
cause O
of O
liver B-ADE
failure I-ADE
in O
this O
patient O
was O
, O
therefore O
, O
clarithromycin B-DRUG
, O
which O
undergoes O
hepatic O
metabolism O
and O
has O
been O
reported O
to O
cause O
fulminant B-ADE
hepatic I-ADE
failure I-ADE
. O

Clinical O
signs O
of O
hypermagnesemia B-ADE
are O
an O
uncommon O
complication O
following O
oral O
administration O
of O
magnesium B-DRUG
sulfate I-DRUG
. O

Controversy O
concerning O
the O
nephrotoxicity B-ADE
of O
lithium B-DRUG
is O
discussed O
, O
and O
recommendations O
for O
the O
evaluation O
of O
renal B-ADE
failure I-ADE
during O
lithium B-DRUG
therapy O
are O
provided O
. O

PURPOSE O
: O
To O
describe O
bilateral B-ADE
corneal I-ADE
endothelial I-ADE
dysfunction I-ADE
in O
a O
patient O
with O
Parkinson O
disease O
who O
was O
treated O
with O
long O
- O
term O
amantadine B-DRUG
. O

Three O
distinct O
types O
of O
minocycline B-DRUG
- O
induced O
cutaneous B-ADE
pigmentation I-ADE
have O
been O
described O
. O

A O
21-year O
- O
old O
man O
with O
Tourette O
's O
syndrome O
, O
pedophilia O
, O
Asperger O
's O
syndrome O
, O
and O
multiple O
sclerosis O
experienced O
seizures B-ADE
after O
receiving O
therapy O
with O
interferon B-DRUG
beta-1a I-DRUG
. O

Patients O
from O
endemic O
areas O
referred O
to O
transplant O
centers O
may O
be O
at O
high O
risk O
for O
disseminated B-ADE
histoplasmosis I-ADE
when O
treated O
with O
long O
- O
term O
prednisone B-DRUG
for O
graft O
- O
versus O
- O
host O
disease O
. O

Methotrexate B-DRUG
- O
induced O
pneumonitis B-ADE
in O
patients O
with O
rheumatoid O
arthritis O
and O
psoriatic O
arthritis O
: O
report O
of O
five O
cases O
and O
review O
of O
the O
literature O
. O

Because O
the O
cerebellar B-ADE
toxicity I-ADE
may O
be O
worsened O
by O
continuation O
of O
therapy O
after O
initial O
onset O
of O
symptoms O
, O
prompt O
termination O
of O
HDARAC B-DRUG
is O
recommended O
. O

OBJECTIVE O
: O
The O
authors O
described O
a O
case O
of O
interferon B-DRUG
- O
induced O
psychosis B-ADE
as O
a O
framework O
to O
review O
the O
literature O
and O
discuss O
the O
decision O
to O
pursue O
antiviral O
treatment O
in O
psychiatrically O
ill O
patients O
with O
hepatitis O
C O
. O

Terlipressin B-DRUG
- O
induced O
ventricular B-ADE
arrhythmia I-ADE
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
colchicine B-DRUG
- O
induced O
myopathy B-ADE
in O
a O
teenager O
with O
familial O
Mediterranean O
fever O
( O
FMF O
) O
. O

METHOD O
: O
Case O
analysis O
of O
a O
poly O
- O
drug O
overdose O
( O
venlafaxine B-DRUG
, O
topiramate B-DRUG
, O
divalproex B-DRUG
sodium I-DRUG
, O
risperidone B-DRUG
, O
and O
carbamazepine B-DRUG
) O
presenting O
with O
mixed O
SS B-ADE
/ O
NMS B-ADE
features O
and O
whose O
clinical O
management O
suggests O
a O
practical O
algorithm O
for O
treatment O
of O
undifferentiated O
SS O
/ O
NMS O
in O
critical O
care O
settings O
. O

Docetaxel B-DRUG
- O
induced O
Meibomian B-ADE
duct I-ADE
inflammation I-ADE
and I-ADE
blockage I-ADE
leading O
to O
chalazion B-ADE
formation O
. O

We O
report O
a O
53-year O
- O
old O
- O
man O
who O
developed O
rippling B-ADE
muscle I-ADE
disease I-ADE
( O
RMD B-ADE
) O
2 O
months O
after O
starting O
simvastatin B-DRUG
therapy O
for O
hypercholesterolemia O
. O

Aminophylline B-DRUG
hypersensitivity I-ADE
apparently O
due O
to O
ethylenediamine B-DRUG
. O

To O
our O
knowledge O
, O
this O
is O
the O
first O
case O
of O
spontaneous O
remission O
of O
MTX B-DRUG
- O
associated O
gastric B-ADE
LPD I-ADE
after O
discontinuation O
of O
MTX O
therapy O
. O

Erosion B-ADE
of I-ADE
psoriatic I-ADE
plaques I-ADE
after O
chronic O
methotrexate B-DRUG
administration O
. O

The O
third O
patient O
had O
been O
suffering O
from O
serious O
akathisia B-ADE
while O
on O
risperidone B-DRUG
, O
and O
was O
cured O
after O
switching O
to O
olanzapine B-DRUG
, O
but O
thereafter O
the O
patient O
suffered O
from O
RLS B-ADE
at O
nighttime O
. O

CONCLUSION O
: O
Under O
certain O
circumstances O
topical O
brimonidine B-DRUG
can O
cause O
paradoxical B-ADE
raised I-ADE
IOP I-ADE
necessitating O
vigilance O
in O
follow O
- O
up O
of O
patients O
on O
topical O
brimonidine O
. O

The O
3-week O
sulphasalazine B-DRUG
syndrome I-ADE
strikes O
again O
. O

A O
case O
of O
propranolol B-DRUG
overdose O
complicated O
by O
esophageal B-ADE
spasm I-ADE
preventing O
extrication O
of O
an O
orogastric O
lavage O
tube O
and O
relieved O
by O
intravenous O
glucagon O
is O
presented O
. O

A O
case O
of O
basilar B-ADE
invagination I-ADE
which O
is O
thought O
to O
have O
arisen O
from O
the O
patient O
's O
intrauterine O
exposure O
to O
phenytoin B-DRUG
is O
presented O
. O

CONCLUSION O
: O
Significant O
weight B-ADE
loss I-ADE
is O
a O
potential O
adverse O
event O
in O
patients O
with O
rheumatoid O
arthritis O
treated O
with O
leflunomide B-DRUG
. O

This O
case O
report O
describes O
a O
38-year O
- O
old O
male O
in O
whom O
SIADH B-ADE
was O
strongly O
suspected O
secondary O
to O
Tegretol B-DRUG
therapy O
to O
control O
a O
seizure O
disorder O
. O

Thrombocytopenia B-ADE
with O
or O
without O
microangiopathy O
following O
quinine B-DRUG
is O
often O
referred O
to O
as O
quinine O
" O
hypersensitivity O
. O
" O
When O
schistocytes O
are O
present O
it O
is O
frequently O
termed O
" O
quinine B-DRUG
- O
associated O
TTP B-ADE
/ I-ADE
HUS I-ADE
. O
" O
A O
severe O
deficiency O
of O
the O
vWF O
- O
cleaving O
protease O
, O
ADAMTS13 O
, O
is O
associated O
with O
idiopathic O
TTP O
. O

Dasatinib B-DRUG
- O
induced O
pleural B-ADE
effusions I-ADE
: O
a O
lymphatic O
network O
disorder O
? O

Even O
though O
only O
a O
few O
cases O
of O
this O
adverse O
event O
have O
been O
reported O
in O
the O
literature O
, O
severe O
docetaxel B-DRUG
- O
induced O
pulmonary B-ADE
toxicity I-ADE
needs O
to O
be O
considered O
in O
the O
differential O
diagnosis O
when O
such O
patients O
present O
with O
respiratory O
symptoms O
. O

Rapidly O
developing O
hyperglycemia B-ADE
during O
treatment O
with O
olanzapine B-DRUG
. O

Acute B-ADE
hemorrhagic I-ADE
gastritis I-ADE
associated O
with O
acetazolamide B-DRUG
intoxication I-ADE
in O
a O
patient O
with O
chronic O
renal O
failure O
. O

We O
herein O
report O
this O
rare O
case O
of O
acute O
onset O
of O
nephrotic B-ADE
syndrome I-ADE
during O
interferon B-DRUG
- I-DRUG
alpha I-DRUG
retreatment O
. O

The O
disease O
predisposes O
to O
severe O
vincristine B-DRUG
neurotoxicity I-ADE
. O

The O
present O
report O
suggests O
that O
clarithromycin B-DRUG
coadministration O
induces O
increased B-ADE
plasma I-ADE
carbamazepine I-ADE
concentrations O
, O
which O
may O
result O
in O
carbamazepine B-DRUG
toxicity I-ADE
. O

Clofazimine B-DRUG
enteropathy B-ADE
caused O
by O
crystal O
deposition O
can O
be O
life B-ADE
- I-ADE
threatening I-ADE
. O

Two O
patients O
with O
extrapyramidal B-ADE
side I-ADE
effects I-ADE
after O
the O
use O
of O
fluphenazine B-DRUG
decanoate I-DRUG
were O
evaluated O
by O
means O
of O
IBZM O
- O
SPECT O
. O

The O
development O
of O
an O
IgG B-ADE
lambda I-ADE
- I-ADE
type I-ADE
monoclonal I-ADE
gammopathy I-ADE
and O
subsequent O
multiple B-ADE
myeloma I-ADE
in O
an O
epilepsy O
patient O
on O
diphenylhydantoin B-DRUG
( O
DILANTIN B-DRUG
) O
therapy O
for O
20 O
years O
is O
reported O
. O

A O
search O
of O
the O
United O
States O
Food O
and O
Drug O
Administration O
's O
Adverse O
Event O
Reporting O
System O
identified O
nine O
cases O
of O
oxcarbazepine B-DRUG
- O
associated O
angioedema B-ADE
in O
pediatric O
patients O
aged O
16 O
years O
and O
younger O
. O

Type B-ADE
I I-ADE
second I-ADE
- I-ADE
degree I-ADE
AV I-ADE
block I-ADE
( O
Mobitz B-ADE
type I-ADE
I I-ADE
, O
Wenckebach B-ADE
AV I-ADE
block I-ADE
) O
during O
ritodrine B-DRUG
therapy O
for O
preterm O
labor O
. O

RESULTS O
: O
We O
recently O
experienced O
a O
case O
of O
fatal O
erlotinib B-DRUG
- O
induced O
ILD B-ADE
, O
diagnosed O
based O
on O
clinical O
and O
radiologic O
findings O
, O
which O
occurred O
in O
a O
patient O
with O
radiation O
fibrosis O
. O

Myasthenia B-ADE
gravis I-ADE
during O
low O
- O
dose O
IFN B-DRUG
- I-DRUG
alpha I-DRUG
therapy O
for O
chronic O
hepatitis O
C O
. O

In O
the O
second O
case O
, O
five O
cardiac B-ADE
arrests I-ADE
due O
to O
ventricular B-ADE
tachycardia I-ADE
and O
fibrillation B-ADE
occurred O
during O
several O
hours O
after O
beginning O
a O
trial O
of O
bretylium B-DRUG
maintenance O
therapy O
for O
complex O
ventricular O
ectopy O
. O

In O
all O
three O
cases O
, O
autopsy O
revealed O
gross O
and O
microscopic O
features O
indistinguishable O
from O
those O
seen O
in O
the O
Hamman O
- O
Rich O
syndrome O
, O
and O
methotrexate B-DRUG
hepatotoxicity B-ADE
was O
present O
in O
one O
. O

Metronidazole B-DRUG
neuropathy B-ADE
. O

Interference B-ADE
with I-ADE
the I-ADE
cortisol I-ADE
axis I-ADE
by O
the O
microtubule O
antagonist O
, O
CPH82 B-DRUG
. O

In O
addition O
, O
the O
tachycardia B-ADE
persisted O
and O
was O
repeatedly O
spontaneously O
reinitiated O
for O
prolonged O
periods O
after O
procainamide B-DRUG
. O

PURPOSE O
: O
The O
aim O
of O
this O
study O
was O
to O
report O
on O
the O
possible O
development O
of O
corneal B-ADE
endothelial I-ADE
deposits I-ADE
resulting O
from O
the O
use O
of O
rifabutin B-DRUG
. O

We O
present O
the O
case O
of O
a O
58-year O
- O
old O
woman O
who O
ingested O
more O
than O
35 O
g O
of O
caffeine B-DRUG
in O
a O
suicide B-ADE
attempt I-ADE
. O

His O
fever O
resolved O
, O
but O
he O
developed O
symptoms O
consistent O
with O
those O
of O
chloroquine B-DRUG
toxicity I-ADE
. O

Lupus B-ADE
- I-ADE
like I-ADE
syndrome I-ADE
caused O
by O
5-aminosalicylic B-DRUG
acid I-DRUG
in O
patients O
with O
inflammatory O
bowel O
disease O
. O

Although O
a O
few O
case O
reports O
link O
metronidazole B-DRUG
with O
the O
development O
of O
pseudomembranous B-ADE
colitis I-ADE
, O
albendazole O
has O
not O
been O
associated O
with O
the O
development O
of O
this O
condition O
. O

The O
occurrence O
of O
severe O
AIHA B-ADE
in O
CLL O
patients O
treated O
with O
fludarabine B-DRUG
has O
been O
reported O
by O
several O
authors O
. O

We O
observed O
2 O
cases O
of O
hepatotoxicity B-ADE
after O
a O
high O
- O
dose O
methylprednisolone B-DRUG
treatment O
of O
a O
demyelinating O
disease O
and O
evaluated O
the O
potential O
relationship O
in O
the O
light O
of O
available O
evidence O
. O

We O
present O
a O
case O
of O
a O
58-year O
- O
old O
female O
patient O
with O
Graves O
' O
disease O
who O
developed O
AA B-ADE
in O
the O
third O
exposure O
to O
methimazole B-DRUG
( O
MMI O
) O
. O

Intensive O
high O
- O
flux O
hemodiafiltration O
is O
often O
used O
in O
the O
management O
of O
vancomycin B-DRUG
toxicity I-ADE
. O

We O
report O
a O
case O
of O
acne B-ADE
fulminans I-ADE
occurring O
during O
treatment O
with O
13-cis B-DRUG
- I-DRUG
retinoic I-DRUG
acid I-DRUG
for O
cystic O
acne O
. O

Within O
6 O
months O
of O
pranlukast B-DRUG
withdrawal O
, O
anemia B-ADE
resolved O
and O
urinary O
sediment O
and O
renal O
function O
normalized O
. O

Both O
patients O
were O
then O
treated O
with O
a O
carboplatin O
alternative O
to O
cisplatin B-DRUG
in O
the O
following O
courses O
, O
which O
resulted O
in O
neither O
a O
relapse O
of O
the O
colitis B-ADE
nor O
a O
recurrence O
of O
the O
malignancies O
up O
to O
this O
time O
. O

Amikacin B-DRUG
- O
induced O
type B-ADE
5 I-ADE
Bartter I-ADE
- I-ADE
like I-ADE
syndrome I-ADE
with O
severe B-ADE
hypocalcemia I-ADE
. O

Insulin B-ADE
- I-ADE
dependent I-ADE
diabetes I-ADE
mellitus I-ADE
developed O
in O
a O
young O
woman O
8 O
weeks O
after O
the O
initiation O
of O
danazol B-DRUG
for O
treatment O
of O
pelvic O
endometriosis O
. O

Muscle O
biopsy O
revealed O
variation B-ADE
in I-ADE
muscle I-ADE
fiber I-ADE
size I-ADE
and O
few O
vacuolated B-ADE
fibers I-ADE
which O
were O
features O
of O
colchicine B-DRUG
- O
induced O
myopathy B-ADE
. O

Two O
renal O
transplant O
patients O
developed O
anemia B-ADE
during O
treatment O
of O
hypertension O
with O
enalapril B-DRUG
medication O
. O

Fatal B-ADE
outcome I-ADE
of O
intravesical O
formalin B-DRUG
instillation O
, O
with O
changes O
mimicking O
renal O
tuberculosis O
. O

She O
developed O
neurotoxicity B-ADE
with O
an O
adjustment O
dosage O
of O
valacyclovir B-DRUG
for O
a O
cutaneous O
zoster O
infection O
. O

However O
, O
one O
patient O
exhibited O
severe B-ADE
hypersensitivity I-ADE
reactions I-ADE
including O
cardiac B-ADE
arrest I-ADE
and O
apnea B-ADE
, O
and O
another O
four O
patients O
developed O
eruptions B-ADE
, O
hypotension B-ADE
, O
and O
tachycardia B-ADE
soon O
after O
administration O
of O
CBDCA B-DRUG
. O

A O
case O
of O
phenobarbital B-DRUG
exacerbation B-ADE
of I-ADE
a I-ADE
preexisting I-ADE
maladaptive I-ADE
behavior I-ADE
partially O
suppressed O
by O
chlorpromazine O
and O
misinterpreted O
as O
chlorpromazine O
efficacy O
. O

Successful O
treatment O
of O
hyperthyroidism O
with O
amiodarone O
in O
a O
patient O
with O
propylthiouracil B-DRUG
- O
induced O
acute B-ADE
hepatic I-ADE
failure I-ADE
. O

Thus O
, O
the O
eosinophilia B-ADE
myalgia I-ADE
syndrome I-ADE
can O
be O
associated O
with O
parenteral O
tryptophan B-DRUG
administration O
. O

In O
this O
article O
lithium O
is O
not O
discussed O
, O
although O
there O
are O
a O
number O
of O
concerns O
about O
lithium B-DRUG
's O
potential O
teratogenicity B-ADE
, O
and O
it O
has O
been O
implicated O
in O
Epstein B-ADE
's I-ADE
anomaly I-ADE
, O
a O
congenital O
heart O
defect O
among O
infants O
born O
to O
women O
taking O
lithium B-DRUG
; O
as O
with O
other O
medications O
, O
however O
, O
the O
data O
have O
specific O
limitations O
. O

This O
fourth O
type O
of O
cutaneous O
minocycline B-DRUG
hyperpigmentation B-ADE
may O
be O
a O
variant O
of O
Type O
I O
, O
but O
based O
on O
clinical O
, O
pathological O
and O
microanalytical O
differences O
, O
appears O
to O
be O
a O
new O
entity O
. O

We O
report O
a O
44-year O
- O
old O
woman O
with O
t O
- O
MDS O
( O
refractory B-ADE
anemia I-ADE
with I-ADE
excess I-ADE
blasts I-ADE
) O
following O
treatment O
of O
recurrent O
anaplastic O
astrocytoma O
with O
temozolomide B-DRUG
( O
TMZ B-DRUG
) O
. O

Disulfiram B-DRUG
- O
induced O
fulminant B-ADE
hepatic I-ADE
failure I-ADE
in O
an O
active O
duty O
soldier O
. O

An O
objective O
causality O
assessment O
suggests O
that O
the O
JHR B-ADE
in O
our O
patient O
was O
probably O
related O
to O
penicillin B-DRUG
. O

High O
- O
dose O
phosphate B-DRUG
treatment O
leads O
to O
hypokalemia B-ADE
in O
hypophosphatemic O
osteomalacia O
. O

Possible O
mechanisms O
for O
damage B-ADE
to I-ADE
the I-ADE
urothelium I-ADE
by O
ketamine B-DRUG
are O
suggested O
. O

We O
have O
seen O
a O
case O
of O
terminal O
malignant O
melanoma O
in O
which O
clinical O
manifestations O
, O
indicative O
of O
anterior B-ADE
spinal I-ADE
artery I-ADE
syndrome I-ADE
, O
developed O
following O
the O
injection O
of O
0.3 O
ml O
of O
10 O
% O
phenol B-DRUG
- I-DRUG
glycerine I-DRUG
into O
the O
cervical O
subarachnoid O
space O
at O
the O
C4 O
- O
-C5 O
level O
for O
the O
control O
of O
severe O
right O
arm O
pain O
. O

Doxycycline B-DRUG
- O
induced O
photo B-ADE
- I-ADE
onycholysis I-ADE
. O

Masculinization B-ADE
of I-ADE
a I-ADE
female I-ADE
fetus I-ADE
occurred O
in O
5 O
of O
39 O
( O
12.8 O
% O
) O
exposed O
to O
norethisterone B-DRUG
; O
all O
were O
cases O
of O
clitoral B-ADE
hypertrophy I-ADE
not O
requiring O
surgical O
treatment O
. O

PURPOSE O
: O
To O
report O
a O
case O
of O
severe O
corticosteroid B-DRUG
- O
induced O
glaucoma B-ADE
after O
intravitreal O
injection O
of O
triamcinolone B-DRUG
acetate I-DRUG
in O
a O
34-year O
- O
old O
man O
without O
a O
history O
of O
glaucoma O
. O

A O
patient O
with O
chronic O
myeloid O
leukaemia O
treated O
with O
busulphan B-DRUG
for O
4 O
- O
5 O
years O
, O
developed O
signs O
of O
busulphan O
toxicity O
and O
portal B-ADE
hypertension I-ADE
with O
ascites B-ADE
, O
oesophageal B-ADE
varices I-ADE
and O
jaundice B-ADE
. O

Asterixis B-ADE
induced O
by O
carbamazepine B-DRUG
therapy O
. O

Observations O
in O
our O
patient O
suggest O
that O
the O
leukoencephalopathy B-ADE
that O
developed O
in O
previously O
reported O
patients O
who O
received O
5-fluorouracil B-DRUG
and O
levamisole B-DRUG
may O
have O
been O
caused O
at O
least O
partly O
by O
levamisole B-DRUG
. O

A O
65-year O
- O
old O
woman O
, O
in O
the O
intensive O
care O
unit O
because O
of O
septic O
shock O
and O
acute O
renal O
failure O
, O
had O
a O
small B-ADE
- I-ADE
bowel I-ADE
obstruction I-ADE
due O
to O
Amphojel B-DRUG
concretions O
. O

Fever B-ADE
and O
maculopapular B-ADE
rashes I-ADE
appeared O
at O
10 O
days O
after O
phenytoin B-DRUG
initiation O
, O
and O
then O
the O
drug O
was O
discontinued O
. O

Intrahepatic B-ADE
cholestasis I-ADE
and O
sicca B-ADE
complex I-ADE
after O
thiabendazole B-DRUG
. O

Three O
cases O
of O
pseudocyst B-ADE
of I-ADE
the I-ADE
pancreas I-ADE
in O
two O
women O
and O
one O
man O
have O
previously O
been O
reported O
with O
the O
use O
of O
intravenous O
L B-DRUG
- I-DRUG
asparaginase I-DRUG
. O

Acute B-ADE
pancreatitis I-ADE
in O
a O
child O
with O
idiopathic O
ulcerative O
colitis O
on O
long O
- O
term O
5-aminosalicylic B-DRUG
acid I-DRUG
therapy O
. O

Naproxen B-DRUG
- O
associated O
sudden B-ADE
sensorineural I-ADE
hearing I-ADE
loss I-ADE
. O

We O
report O
the O
successful O
treatment O
of O
heparin B-DRUG
- O
induced O
thrombocytopenia B-ADE
and O
subsequent O
hemorrhagic B-ADE
complications I-ADE
postoperatively O
in O
a O
2-year O
- O
old O
child O
with O
Danaparoid O
( O
orgaran O
) O
. O

Increasing O
the O
olanzapine B-DRUG
dosage O
severely O
aggravated O
the O
symptoms O
of O
RLS B-ADE
. O

A O
patient O
with O
coccidioidal O
meningitis O
was O
treated O
with O
intrathecally O
administered O
amphotericin B-DRUG
B I-DRUG
, O
and O
an O
acute B-ADE
toxic I-ADE
delirium I-ADE
with O
EEG B-ADE
abnormalities I-ADE
developed O
. O

We O
present O
the O
first O
case O
of O
ovarian B-ADE
endometrioid I-ADE
carcinoma I-ADE
and O
endometriosis B-ADE
in O
a O
postmenopausal O
patient O
who O
was O
treated O
with O
tamoxifen B-DRUG
for O
breast O
cancer O
. O

We O
report O
a O
46-yr O
- O
old O
woman O
with O
ovarian O
carcinoma O
who O
developed O
porphyria B-ADE
cutanea I-ADE
tarda I-ADE
while O
undergoing O
treatment O
with O
cisplatin B-DRUG
and O
cyclophosphamide B-DRUG
. O

Interferon B-DRUG
- I-DRUG
alpha I-DRUG
- O
induced O
focal B-ADE
segmental I-ADE
glomerulosclerosis I-ADE
in O
chronic O
myelogenous O
leukemia O
: O
a O
case O
report O
and O
review O
of O
the O
literature O
. O

Hepatotoxicity B-ADE
induced O
by O
cyproterone B-DRUG
acetate I-DRUG
: O
a O
report O
of O
three O
cases O
. O

Caution O
with O
use O
of O
cimetidine B-DRUG
in O
tolazoline B-DRUG
induced O
upper B-ADE
gastrointestinal I-ADE
bleeding I-ADE
. O

CONCLUSION O
: O
In O
some O
abstainers O
who O
take O
cyanamide B-DRUG
for O
several O
years O
, O
thin O
septum B-ADE
- I-ADE
like I-ADE
liver I-ADE
fibrosis I-ADE
progresses O
along O
with O
the O
emergence O
of O
ground B-ADE
- I-ADE
glass I-ADE
hepatocytes I-ADE
. O

When O
measured O
, O
the O
serum B-ADE
lithium B-DRUG
level I-ADE
had I-ADE
increased I-ADE
4-fold O
during O
acyclovir B-DRUG
therapy O
. O

Severe B-ADE
hyperkalemia I-ADE
as O
a O
complication O
of O
timolol B-DRUG
, O
a O
topically O
applied O
beta O
- O
adrenergic O
antagonist O
. O

Clinicians O
should O
be O
cognizant O
of O
this O
possibility O
and O
consider O
a O
diagnosis O
of O
HDAs O
in O
patients O
with O
ongoing O
thrombosis B-ADE
who O
are O
receiving O
heparin B-DRUG
therapy O
. O

METHODS O
: O
A O
68-year O
- O
old O
man O
developed O
intense B-ADE
conjunctival I-ADE
hyperemia I-ADE
and O
cystoid B-ADE
macula I-ADE
edema I-ADE
after O
switching O
from O
latanoprost B-DRUG
to O
bimatoprost B-DRUG
9 O
months O
after O
cataract O
surgery O
in O
an O
eye O
at O
low O
- O
risk O
for O
this O
cystoid B-ADE
macular I-ADE
edema I-ADE
. O

The O
oligohidrosis B-ADE
caused O
by O
zonisamide B-DRUG
was O
reversible O
in O
that O
the O
patient O
regained O
the O
ability O
to O
sweat O
within O
2 O
weeks O
of O
the O
cessation O
of O
drug O
administration O
. O

DISCUSSION O
: O
After O
exclusion O
of O
other O
causes O
, O
the O
onset O
of O
thrombocytopenia B-ADE
after O
administration O
of O
lansoprazole B-DRUG
, O
the O
resolution O
of O
the O
adverse O
reaction O
after O
discontinuation O
of O
the O
drug O
, O
and O
the O
fact O
that O
no O
other O
medicines O
were O
introduced O
during O
this O
time O
frame O
lead O
us O
to O
believe O
that O
this O
was O
most O
likely O
an O
idiosyncratic O
thrombocytopenic B-ADE
response O
to O
lansoprazole B-DRUG
. O

Cardiorespiratory B-ADE
toxicity I-ADE
due O
to O
miconazole B-DRUG
. O

METHODS O
: O
In O
an O
institutional O
practice O
setting O
, O
two O
women O
, O
aged O
25 O
and O
45 O
, O
developed O
acute B-ADE
myopia I-ADE
after O
starting O
topiramate B-DRUG
for O
epilepsy O
. O

Nabumetone B-DRUG
- O
associated O
interstitial B-ADE
nephritis I-ADE
. O

CASE O
REPORT O
: O
Soon O
after O
initiation O
of O
amiodarone B-DRUG
HCl I-DRUG
( O
200 O
mg O
/ O
day O
) O
, O
a O
76-year O
- O
old O
man O
came O
to O
us O
with O
symptoms O
of O
visual B-ADE
" I-ADE
shining I-ADE
, O
" O
glare B-ADE
, O
color B-ADE
vision I-ADE
anomalies I-ADE
, O
and O
gradually O
decreased B-ADE
vision I-ADE
. O

Systemic O
disease O
, O
most O
commonly O
renal O
dysfunction O
, O
preceded O
all O
30 O
reported O
cases O
of O
acyclovir B-DRUG
neurotoxicity B-ADE
. O

Thalidomide B-DRUG
was O
withdrawn O
from O
world O
markets O
in O
1961 O
following O
recognition O
of O
its O
teratogenic B-ADE
effects I-ADE
. O

To O
our O
knowledge O
, O
this O
is O
the O
first O
case O
report O
that O
demonstrates O
the O
occurrence O
of O
fever B-ADE
with O
low O
- O
dose O
amifostine B-DRUG
therapy O
without O
the O
manifestation O
of O
accompanying O
rash O
or O
hypotension O
. O

We O
report O
the O
first O
case O
of O
fulminant O
adult B-ADE
respiratory I-ADE
distress I-ADE
syndrome I-ADE
( O
ARDS B-ADE
) O
associated O
with O
pegylated B-DRUG
interferon I-DRUG
alpha-2a I-DRUG
( O
pegIFNalpha-2a B-DRUG
) O
and O
ribavirin B-DRUG
use O
for O
hepatitis O
C O
, O
complicated O
by O
subsequent O
and O
ultimately O
fatal O
sepsis O
and O
multiorgan O
failure O
. O

Agranulocytosis B-ADE
during O
clozapine B-DRUG
therapy O
. O

Our O
case O
points O
to O
the O
need O
for O
increased O
awareness O
by O
the O
general O
pediatricians O
of O
the O
potential B-ADE
hazards I-ADE
of O
mineral B-DRUG
oil I-DRUG
use O
for O
chronic O
constipation O
. O

CASE O
REPORT O
: O
A O
woman O
of O
80 O
years O
, O
on O
long O
- O
term O
warfarin B-DRUG
therapy O
presented O
with O
an O
acute B-ADE
dissecting I-ADE
thoracic I-ADE
aortic I-ADE
aneurysm I-ADE
; O
on O
investigation O
the O
only O
precipitating O
factor O
found O
was O
an O
international O
normalised O
ratio O
of O
4.8 O
. O

Hemodialysis O
was O
also O
shown O
to O
reverse O
ifosfamide B-DRUG
- O
related O
neurotoxicity B-ADE
. O

Based O
on O
these O
findings O
, O
the O
patient O
was O
diagnosed O
with O
diabetes B-ADE
insipidus I-ADE
secondary O
to O
lithium B-DRUG
therapy O
and O
was O
treated O
successfully O
with O
amiloride O
. O

Human B-DRUG
insulin I-DRUG
- O
induced O
lipoatrophy B-ADE
. O

Hypersensitivity B-ADE
pneumonitis I-ADE
- I-ADE
like I-ADE
syndrome I-ADE
associated O
with O
the O
use O
of O
lenalidomide B-DRUG
. O

This O
case O
and O
other O
published O
evidence O
should O
alert O
physicians O
to O
the O
possibility O
of O
fatal O
erlotinib B-DRUG
- O
induced O
ILD B-ADE
. O

We O
describe O
rupture B-ADE
of I-ADE
a I-ADE
cerebral I-ADE
arterial I-ADE
aneurysm I-ADE
in O
a O
32 O
year O
old O
hypertensive O
woman O
following O
the O
introduction O
of O
nifedipine B-DRUG
treatment O
. O

The O
typical O
fluoxetine B-DRUG
- O
induced O
symptoms O
of O
restlessness B-ADE
, O
constant B-ADE
pacing I-ADE
, O
purposeless B-ADE
movements I-ADE
of I-ADE
the I-ADE
feet I-ADE
and I-ADE
legs I-ADE
, O
and O
marked B-ADE
anxiety I-ADE
were O
indistinguishable O
from O
those O
of O
neuroleptic O
- O
induced O
akathisia O
. O

Argatroban B-DRUG
is O
hepatically O
cleared O
and O
may O
be O
the O
preferred O
direct O
thrombin O
inhibitor O
in O
the O
presence O
of O
significant O
renal O
impairment O
, O
but O
conversely O
has O
prolonged O
effects O
in O
hepatic B-ADE
failure I-ADE
. O

We O
suspect O
that O
nefazodone B-DRUG
inhibits B-ADE
metabolism I-ADE
of I-ADE
tacrolimus B-DRUG
. O

Two O
patients O
with O
ovarian O
cancer O
who O
had O
received O
multiple O
courses O
of O
cisplatin B-DRUG
without O
complications O
experienced O
hypersensitivity B-ADE
reactions I-ADE
to O
cisplatin B-DRUG
: O
one O
, O
involving O
intrahepatic O
artery O
infusion O
, O
manifested O
general B-ADE
erythema I-ADE
, O
dyspnea B-ADE
, O
and O
hypotension B-ADE
; O
the O
other O
, O
involving O
intravenous O
infusion O
, O
manifested O
abdominal B-ADE
pain I-ADE
, O
general B-ADE
erythema I-ADE
, O
and O
fever B-ADE
. O

This O
patient O
, O
who O
had O
a O
history O
of O
osteoarthritis O
, O
had O
severe O
hepatitis B-ADE
5 O
weeks O
after O
being O
started O
on O
diclofenac B-DRUG
for O
increasing O
pain O
in O
the O
joints O
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
phenolphthalein B-DRUG
- O
induced O
toxic B-ADE
epidermal I-ADE
necrolysis I-ADE
( O
TEN B-ADE
) O
in O
a O
patient O
maintained O
on O
several O
other O
medications O
more O
commonly O
known O
to O
be O
associated O
with O
TEN B-ADE
. O

A O
17-year O
- O
old O
boy O
with O
acute O
lymphoblastic O
leukemia O
developed O
acute B-ADE
renal I-ADE
failure I-ADE
within O
48 O
h O
of O
an O
intravenous O
high O
- O
dose O
methotrexate B-DRUG
( O
5 O
g O
/ O
m2 O
) O
infusion O
. O

DISCUSSION O
: O
The O
main O
adverse O
effects O
of O
leflunomide B-DRUG
consist O
of O
diarrhea B-ADE
, O
nausea B-ADE
, O
liver B-ADE
enzyme I-ADE
elevation I-ADE
, O
hypertension B-ADE
, O
alopecia B-ADE
, O
and O
allergic B-ADE
skin I-ADE
reactions I-ADE
. O

We O
present O
the O
first O
case O
of O
a O
patient O
with O
priapism B-ADE
after O
oral O
intake O
of O
the O
phenothiazine O
prothipendylhydrochloride B-DRUG
. O

This O
case O
supports O
the O
view O
that O
in O
gold B-DRUG
- O
induced O
pneumonitis B-ADE
a O
prolonged O
treatment O
with O
corticosteroids O
may O
be O
necessary O
, O
as O
lung O
function O
continued O
to O
improve O
. O

Intracranial B-ADE
hemorrhage I-ADE
and O
focal B-ADE
seizures I-ADE
secondary O
to O
use O
of O
L B-DRUG
- I-DRUG
asparaginase I-DRUG
during O
induction O
therapy O
of O
acute O
lymphocytic O
leukemia O
. O

Although O
gabapentin B-DRUG
withdrawal O
has O
been O
previously O
reported O
and O
usually O
consists O
of O
anxiety B-ADE
, O
diaphoresis B-ADE
, O
and O
palpitations B-ADE
, O
this O
is O
the O
first O
reported O
patient O
with O
generalized B-ADE
seizures I-ADE
and O
status B-ADE
epilepticus I-ADE
secondary O
to O
gabapentin B-DRUG
withdrawal O
. O

In O
patients O
with O
cirrhosis O
, O
the O
metabolism O
of O
meperidine B-DRUG
is O
decreased O
, O
leading O
to O
accumulation B-ADE
of I-ADE
the I-ADE
parent I-ADE
drug I-ADE
and O
possible O
CNS B-ADE
depressive I-ADE
effects I-ADE
similar O
to O
hepatic O
encephalopathy O
. O

METHODS O
: O
A O
patient O
who O
developed O
dramatic O
, O
permanent O
vision B-ADE
loss I-ADE
after O
a O
9-month O
course O
of O
treatment O
with O
ethambutol B-DRUG
and O
isoniazid B-DRUG
for O
pulmonary O
tuberculosis O
is O
presented O
. O

Bleomycin B-DRUG
pneumonitis B-ADE
potentiated O
by O
oxygen O
administration O
. O

Itch B-ADE
and O
skin B-ADE
rash I-ADE
from O
chocolate O
during O
fluoxetine B-DRUG
and O
sertraline B-DRUG
treatment O
: O
case O
report O
. O

Two O
cases O
of O
polymorphic B-ADE
ventricular I-ADE
tachycardia I-ADE
induced O
by O
the O
administration O
of O
verapamil B-DRUG
against O
paroxysmal O
supraventricular O
tachycardia O
. O

The O
medical O
examiner O
's O
report O
indicated O
death B-ADE
caused O
by O
fluoxetine B-ADE
toxicity I-ADE
. O

After O
infliximab B-DRUG
treatment O
, O
additional O
sleep O
studies O
revealed O
an O
increase B-ADE
in I-ADE
the I-ADE
number I-ADE
of I-ADE
apneic I-ADE
events I-ADE
and O
SaO2 B-ADE
dips I-ADE
suggesting O
that O
TNFalpha O
plays O
an O
important O
role O
in O
the O
pathophysiology O
of O
sleep O
apnea O
. O

Allergic O
side O
effects O
of O
AZA B-DRUG
are O
rare O
, O
and O
reported O
allergic B-ADE
skin I-ADE
eruptions I-ADE
from O
AZA B-DRUG
are O
very O
limited O
in O
Japan O
. O

Second B-ADE
cancers I-ADE
including O
various O
types O
of O
hematological B-ADE
malignancy I-ADE
have O
been O
reported O
in O
patients O
with O
hairy O
cell O
leukemia O
treated O
with O
chemotherapy O
or O
interferon B-DRUG
alfa I-DRUG
. O

The O
ototoxicity B-ADE
of O
quinine B-DRUG
can O
accurately O
be O
studied O
with O
ultrahigh O
frequency O
audiometry O
( O
up O
to O
20 O
kHz O
) O
. O

The O
abnormal B-ADE
rhythm I-ADE
disappeared O
with O
the O
withdrawal O
of O
propranolol B-DRUG
and O
when O
the O
drug O
was O
restarted O
a O
2/1 O
S O
- O
A O
block O
was O
seen O
. O

We O
report O
a O
case O
of O
papillary B-ADE
necrosis I-ADE
in O
a O
patient O
treated O
with O
indinavir B-DRUG
. O

In O
all O
the O
patients O
, O
pellagra B-ADE
symptoms O
appeared O
during O
isoniazid B-DRUG
therapy O
. O

A O
case O
of O
prolonged O
suxamethonium B-DRUG
apnoea B-ADE
successfully O
terminated O
by O
the O
infusion O
of O
a O
commercial O
preparation O
of O
serumcholinesterase O
is O
reported O
. O

Fluoxetine B-DRUG
- O
related O
death B-ADE
in O
a O
child O
with O
cytochrome O
P-450 O
2D6 O
genetic O
deficiency O
. O

The O
use O
of O
rituximab B-DRUG
has O
been O
uncommonly O
associated O
with O
delayed B-ADE
pulmonary I-ADE
toxicity I-ADE
. O

Neonatal O
mydriasis B-ADE
: O
intravenous O
lidocaine B-DRUG
adverse O
reaction O
. O

Embolia B-ADE
cutis I-ADE
medicamentosa I-ADE
following O
subcutaneous O
injection O
of O
glatiramer B-DRUG
acetate I-DRUG
. O

Acute O
asymptomatic B-ADE
hepatitis I-ADE
in O
a O
healthy O
normal O
volunteer O
exposed O
to O
2 O
oral O
doses O
of O
amodiaquine B-DRUG
and O
artesunate B-DRUG
. O

This O
is O
the O
second O
report O
of O
lactic B-ADE
acidosis I-ADE
in O
a O
patient O
on O
stavudine B-DRUG
and O
lamivudine B-DRUG
. O

This O
report O
presents O
a O
case O
of O
acute B-ADE
lung I-ADE
injury I-ADE
developing O
within O
hours O
after O
administration O
of O
mefloquine B-DRUG
for O
a O
low O
- O
level O
Plasmodium O
falciparum O
malaria O
, O
which O
was O
persistent O
despite O
halofantrine O
therapy O
. O

The O
most O
serious O
dental O
side O
effect O
of O
bisphosphonate B-DRUG
treatment O
( O
particularly O
when O
it O
is O
administered O
intravenously O
) O
is O
, O
paradoxically O
, O
osteonecrosis B-ADE
of I-ADE
the I-ADE
mandible I-ADE
or O
the O
maxilla O
represented O
by O
exposed O
nonhealing O
bone O
. O

This O
is O
the O
first O
case O
of O
hydroxyurea B-DRUG
- O
induced O
acute B-ADE
interstitial I-ADE
pneumonitis I-ADE
reported O
in O
the O
literature O
. O

Thus O
, O
the O
patient O
's O
clinical O
course O
and O
workup O
strongly O
support O
a O
diagnosis O
of O
lenalidomide B-DRUG
- O
induced O
hypersensitivity B-ADE
pneumonitis I-ADE
- I-ADE
like I-ADE
syndrome I-ADE
. O

We O
present O
two O
children O
with O
acute O
lymphocytic O
leukemia O
who O
developed O
leukoencephalopathy B-ADE
following O
administration O
of O
a O
combination O
of O
intravenous O
ara B-DRUG
= I-DRUG
C I-DRUG
and O
methotrexate B-DRUG
during O
the O
consolidation O
phase O
of O
chemotherapy O
. O

Hypersensitivity B-ADE
to O
carboplatin B-DRUG
is O
a O
rare O
but O
real O
complication O
of O
therapy O
and O
should O
be O
considered O
in O
patients O
presenting O
with O
hyperacute B-ADE
changes I-ADE
on I-ADE
ECG I-ADE
whilst O
receiving O
carboplatin O
therapy O
. O

The O
sub B-ADE
- I-ADE
conjunctival I-ADE
haematoma I-ADE
in O
a O
patient O
receiving O
warfarin B-DRUG
can O
pose O
a O
significant O
management O
challenge O
. O

The O
case O
is O
presented O
of O
a O
72-year O
- O
old O
man O
with O
hormone O
- O
refractory O
prostate O
cancer O
and O
weekly O
administration O
of O
30 O
mg O
/ O
m2 O
docetaxel B-DRUG
who O
developed O
subacute B-ADE
interstitial I-ADE
pneumonitis I-ADE
- I-ADE
related I-ADE
pulmonary I-ADE
fibrosis I-ADE
after O
seven O
doses O
and O
died O
despite O
mechanical O
ventilation O
and O
high O
- O
dose O
corticosteroid O
treatment O
. O

Severe O
C. B-ADE
difficile I-ADE
colitis I-ADE
occurred O
in O
2 O
patients O
( O
6.1 O
% O
) O
after O
receiving O
cisplatin B-DRUG
- O
based O
combination O
chemotherapy O
for O
ovarian O
malignancies O
. O

Acute O
valproate B-DRUG
ingestion O
induces O
symptomatic B-ADE
methemoglobinemia I-ADE
. O

We O
hypothesize O
that O
capecitabine B-DRUG
- O
induced O
headache B-ADE
is O
vascular O
in O
nature O
. O

Although O
lung O
specimens O
were O
lacking O
from O
these O
three O
patients O
, O
it O
is O
suggested O
that O
the O
pulmonary B-ADE
toxicity I-ADE
of O
CCNU B-DRUG
may O
be O
dose O
- O
related O
. O

Massive O
CBZ B-DRUG
OD O
may O
produce O
a O
reversible B-ADE
encephalopathy I-ADE
that O
includes O
cortical B-ADE
hyperexcitability I-ADE
, O
a O
profound B-ADE
burst I-ADE
- I-ADE
suppression I-ADE
EEG I-ADE
pattern I-ADE
, O
and O
cranial B-ADE
nerve I-ADE
areflexia I-ADE
. O

Gemcitabine B-DRUG
therapy O
has O
been O
associated O
with O
radiation B-ADE
recall I-ADE
reactions I-ADE
when O
used O
in O
the O
treatment O
of O
carcinoma O
. O

PATIENTS O
: O
Two O
patients O
, O
ages O
40 O
and O
51 O
years O
, O
undergoing O
treatment O
with O
interferon B-DRUG
alfa I-DRUG
for O
malignant O
neoplasms O
experienced O
sudden B-ADE
bilateral I-ADE
, I-ADE
sequential I-ADE
visual I-ADE
loss I-ADE
with O
disc O
- O
related O
field O
defects O
and O
segmental O
optic O
disc O
edema O
. O

Presentation O
of O
three O
palliative O
care O
patients O
who O
were O
given O
ketamine B-DRUG
as O
an O
analgesic O
and O
subsequently O
developed O
significant O
and O
debilitating O
urological B-ADE
symptoms I-ADE
. O

Here O
we O
describe O
a O
patient O
with O
Crohn O
's O
disease O
who O
developed O
a O
severe B-ADE
infliximab I-ADE
infusion I-ADE
reaction I-ADE
( O
IIR B-ADE
) O
, O
complicated O
1 O
day O
later O
by O
severe B-ADE
swelling I-ADE
of I-ADE
the I-ADE
forearm I-ADE
and I-ADE
hand I-ADE
ipsilateral I-ADE
to O
the O
site O
of O
infliximab B-DRUG
infusion O
. O

Linear B-ADE
IgA I-ADE
bullous I-ADE
dermatosis I-ADE
occurring O
after O
carbamazepine B-DRUG
. O

Progressive B-ADE
interstitial I-ADE
fibrosis I-ADE
with O
roentgenographic O
honeycombing O
developed O
in O
the O
case O
of O
a O
psoriatic O
patient O
who O
had O
been O
on O
a O
regimen O
of O
methotrexate B-DRUG
for O
18 O
years O
. O

The O
occurrence O
of O
symptoms O
that O
could O
be O
ascribed O
to O
an O
acute B-ADE
coronary I-ADE
syndrome I-ADE
should O
always O
be O
taken O
seriously O
during O
the O
first O
rituximab B-DRUG
infusion O
and O
investigated O
aggressively O
. O

Skin B-ADE
necrosis I-ADE
is O
a O
rare O
complication O
of O
subcutaneous O
heparin B-DRUG
therapy O
that O
usually O
occurs O
at O
injection O
sites O
. O

There O
have O
been O
many O
reports O
of O
probable O
lithium B-DRUG
- O
induced O
organic B-ADE
brain I-ADE
syndromes I-ADE
occurring O
when O
serum O
lithium O
levels O
are O
within O
or O
close O
to O
the O
therapeutic O
range O
. O

Hyponatraemia B-ADE
developed O
after O
rechallenge O
with O
controlled O
release O
carbamazepine B-DRUG
. O

OBJECTIVE O
: O
To O
describe O
a O
case O
of O
thrombocytopenia B-ADE
associated O
with O
the O
administration O
of O
lansoprazole B-DRUG
. O

Neurologic B-ADE
toxicity I-ADE
associated O
with O
hepatic O
artery O
infusion O
HAI O
of O
FUdR B-DRUG
. O

Methotrexate B-DRUG
induced O
sprue B-ADE
- I-ADE
like I-ADE
syndrome I-ADE
. O

We O
report O
the O
case O
of O
a O
17-year O
- O
old O
male O
who O
developed O
chest B-ADE
pain I-ADE
, O
elevated B-ADE
cardiac I-ADE
biomarkers I-ADE
, O
and O
acute B-ADE
left I-ADE
ventricular I-ADE
dysfunction I-ADE
following O
a O
single O
dose O
of O
methylphenidate B-DRUG
. O

After O
the O
chlorambucil B-DRUG
was O
discontinued O
, O
the O
wbc O
count O
began O
to O
slowly O
rise O
and O
the O
patient O
developed O
clinical O
AML B-ADE
. O

Papilledema B-ADE
without O
peripheral O
neuropathy O
in O
a O
patient O
taking O
perhexiline B-DRUG
maleate I-DRUG
. O

A O
patient O
with O
the O
Wolff O
- O
Parkinson O
- O
White O
syndrome O
presented O
with O
incessant B-ADE
orthodromic I-ADE
atrioventricular I-ADE
tachycardia I-ADE
following O
initiation O
of O
procainamide B-DRUG
therapy O
. O

Sudden B-ADE
cardiac I-ADE
death I-ADE
due O
to O
hypersensitivity B-ADE
myocarditis I-ADE
during O
clozapine B-DRUG
treatment O
. O

On O
the O
second O
day O
of O
hospitalization O
, O
it O
was O
noted O
that O
the O
patient O
's O
dyspnea B-ADE
and O
sinus B-ADE
bradycardia I-ADE
could O
be O
related O
to O
a O
recent O
increase O
in O
his O
timolol B-DRUG
dosage O
. O

ARA B-DRUG
- I-DRUG
C I-DRUG
is O
frequently O
associated O
with O
dermatologic B-ADE
toxicity I-ADE
, O
but O
this O
is O
only O
the O
second O
case O
of O
toxic B-ADE
epidermal I-ADE
necrolysis I-ADE
described O
in O
connection O
with O
this O
drug O
. O

Special O
care O
should O
be O
taken O
when O
pulmonary B-ADE
symptoms I-ADE
appear O
in O
association O
with O
ticlopidine B-DRUG
treatment O
. O

The O
mechanism O
of O
the O
decrease B-ADE
in I-ADE
plasma I-ADE
potassium I-ADE
induced O
by O
phosphate B-DRUG
treatment O
was O
investigated O
in O
a O
24-year O
- O
old O
hypertensive O
patient O
with O
hypophosphatemic O
osteomalacia O
, O
who O
was O
the O
youngest O
of O
four O
patients O
, O
belonging O
to O
a O
23 O
number O
kindred O
of O
five O
generations O
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
linear B-ADE
immunoglobulin I-ADE
( I-ADE
Ig I-ADE
) I-ADE
A I-ADE
bullous I-ADE
dermatosis I-ADE
( O
LABD B-ADE
) O
induced O
by O
gemcitabine B-DRUG
. O

Desipramine B-DRUG
- O
associated O
SIADH B-ADE
in O
an O
elderly O
woman O
: O
case O
report O
. O

Mitomycin B-DRUG
- I-DRUG
C I-DRUG
induced O
hemolytic B-ADE
uremic I-ADE
syndrome I-ADE
: O
a O
case O
report O
. O

PURPOSE O
/ O
OBJECTIVES O
: O
To O
describe O
the O
pharmacogenetic O
syndrome O
of O
dihydropyrimidine O
dehydrogenase O
( O
DPD O
) O
deficiency O
, O
which O
predisposes O
patients O
with O
cancer O
to O
potentially O
lethal B-ADE
adverse I-ADE
reactions I-ADE
following O
5-fluorouracil B-DRUG
( O
5-FU B-DRUG
) O
- O
based O
chemotherapy O
. O

Visual B-ADE
loss I-ADE
after O
a O
single O
small O
dose O
of O
vincristine B-DRUG
has O
never O
been O
reported O
. O

It O
is O
well O
- O
recognized O
that O
flucloxacillin B-DRUG
may O
occasionally O
result O
in O
fatal B-ADE
hepatic I-ADE
injury I-ADE
. O

The O
Naranjo O
probability O
scale O
indicated O
a O
probable O
relationship O
between O
apnea B-ADE
and O
exposure O
to O
lamotrigine B-DRUG
through O
breast O
- O
feeding O
in O
this O
infant O
. O

In O
both O
cases O
, O
high B-ADE
fever I-ADE
, O
skin B-ADE
rash I-ADE
, O
liver B-ADE
dysfunction I-ADE
and O
atypical B-ADE
lymphocytosis I-ADE
developed O
3 O
weeks O
after O
initiating O
treatment O
with O
SASP B-DRUG
. O

Case O
4 O
: O
A O
61-year O
- O
old O
male O
alcoholic O
who O
remained O
completely O
abstinent O
while O
taking O
cyanamide B-DRUG
for O
3 O
years O
showed O
slight O
elevation B-ADE
of I-ADE
serum I-ADE
transaminases I-ADE
. O

We O
describe O
a O
57-year O
- O
old O
man O
with O
acral O
erythrocyanosis O
progressing O
to O
acute B-ADE
digital I-ADE
ischemia I-ADE
and O
gangrene B-ADE
that O
developed O
after O
combined O
chemotherapy O
( O
bleomycin B-DRUG
and O
methotrexate B-DRUG
) O
used O
to O
treat O
a O
metastatic O
squamous O
cell O
carcinoma O
of O
the O
hypopharynx O
. O

Sulfasalazine B-DRUG
- O
induced O
lupus B-ADE
erythematosus I-ADE
. O

One O
case O
of O
priapism B-ADE
occurred O
during O
heparin B-DRUG
therapy O
for O
a O
previous O
surgical O
operation O
to O
the O
knee O
is O
reported O
. O

A O
10-year O
- O
old O
boy O
with O
osteosarcoma O
and O
normal O
renal O
function O
manifested O
laboratory O
evidence O
of O
impending O
renal B-ADE
toxicity I-ADE
and O
extreme O
elevation B-ADE
of I-ADE
aspartate I-ADE
aminotrasferase I-ADE
and O
alanine O
aminotransferase O
within O
2 O
hours O
after O
the O
completion O
of O
a O
4-hour O
infusion O
of O
high O
- O
dose O
methotrexate B-DRUG
( O
MTX B-DRUG
) O
( O
12 O
g O
/ O
m2 O
) O
, O
and O
went O
on O
to O
develop O
acute B-ADE
renal I-ADE
failure I-ADE
with O
life O
- O
threatening O
hyperkalemia O
29 O
hours O
later O
. O

Heparin B-DRUG
- O
induced O
hyperkalemia B-ADE
. O

Adverse O
effects O
of O
amiodarone B-DRUG
including O
pulmonary B-ADE
toxicity I-ADE
, O
hepatotoxicity B-ADE
, O
aggravation B-ADE
of I-ADE
arrhythmia I-ADE
, O
and O
thyroid B-ADE
diseases I-ADE
are O
well O
understood O
. O

Baclofen B-DRUG
withdrawal B-ADE
syndrome I-ADE
resulting O
from O
underdosing O
of O
oral O
baclofen B-DRUG
should O
be O
considered O
as O
a O
potential O
source O
of O
prolonged O
fever O
in O
the O
intensive O
care O
unit O
. O

Esophageal B-ADE
candidiasis I-ADE
following O
omeprazole B-DRUG
therapy O
: O
a O
report O
of O
two O
cases O
. O

A O
retrospective O
review O
of O
TTP O
patients O
with O
quinine B-DRUG
- O
associated O
thrombotic B-ADE
microangiopathy I-ADE
( O
TMA B-ADE
) O
for O
whom O
ADAMTS13 O
was O
measured O
before O
plasma O
exchange O
was O
performed O
. O

We O
describe O
2 O
patients O
with O
prior O
amputation O
who O
experienced O
phantom B-ADE
limb I-ADE
pain I-ADE
( O
PLP B-ADE
) O
after O
receiving O
paclitaxel B-DRUG
therapy O
. O

Physicians O
should O
be O
aware O
of O
the O
potential O
for O
developing O
a O
gemcitabine B-DRUG
- O
induced O
radiation B-ADE
recall I-ADE
reaction I-ADE
resulting O
in O
hemodynamically O
significant O
pericardial B-ADE
effusion I-ADE
. O

Triiodothyronine B-DRUG
- O
induced O
thyrotoxicosis B-ADE
in O
ophthalmic O
Graves O
disease O
. O

Drug O
- O
induced O
eosinophilia B-ADE
is O
a O
non O
- O
dose O
- O
dependent O
side O
effect O
of O
clozapine B-DRUG
. O

The O
possibility O
of O
deep B-ADE
vein I-ADE
thrombosis I-ADE
caused O
by O
the O
compression O
of O
the O
veins O
by O
necrotic O
tumor O
should O
be O
considered O
in O
patients O
with O
abdominal O
or O
pelvic O
metastases O
of O
GIST O
, O
including O
patients O
treated O
with O
imatinib B-DRUG
. O

It O
may O
cause O
a O
severe O
adverse O
drug O
reaction O
with O
multiorgan O
involvement O
known O
as O
dapsone B-DRUG
hypersensitivity B-ADE
syndrome I-ADE
. O

A O
review O
of O
the O
literature O
showed O
no O
previous O
description O
of O
this O
pattern O
in O
benzodiazepine B-DRUG
coma B-ADE
. O

One O
patient O
required O
nursing O
home O
placement O
and O
a O
feeding B-ADE
gastrostomy I-ADE
as O
a O
result O
of O
the O
worsening B-ADE
parkinsonism I-ADE
during O
risperidone B-DRUG
treatment O
, O
but O
was O
able O
to O
return O
home O
and O
have O
the O
gastrostomy O
removed O
after O
switching O
from O
risperidone B-DRUG
to O
clozapine O
. O

We O
report O
a O
case O
of O
hepatolithiasis B-ADE
( O
intrahepatic O
stone O
) O
complicated O
by O
gram O
- O
negative O
sepsis O
in O
a O
37 O
year O
old O
male O
with O
acromegaly O
being O
treated O
with O
octreotide B-DRUG
. O

We O
report O
the O
specifics O
of O
12 O
cases O
of O
severe B-ADE
hypertension I-ADE
after O
the O
intraoperative O
use O
of O
topical O
phenylephrine B-DRUG
, O
submucosal O
epinephrine B-DRUG
, O
or O
both O
. O

The O
case O
demonstrates O
that O
hypersensitivity B-ADE
reaction I-ADE
to O
pranlukast B-DRUG
and O
resultant O
ATIN B-ADE
is O
possible O
, O
and O
that O
periodic O
urine O
testing O
in O
patients O
receiving O
pranlukast B-DRUG
should O
be O
considered O
. O

Since O
imiquimod B-DRUG
induces O
large B-ADE
amounts I-ADE
of I-ADE
type I-ADE
I I-ADE
interferon I-ADE
production I-ADE
from O
TLR7-expressing O
plasmacytoid O
dendritic O
cell O
precursors O
( O
PDCs O
) O
, O
the O
natural O
interferon O
- O
producing O
cells O
of O
the O
peripheral O
blood O
, O
we O
asked O
whether O
PDCs O
are O
present O
in O
psoriatic O
skin O
. O

As O
this O
relapse O
coincided O
with O
development O
of O
a O
strong O
delayed O
- O
type O
hypersensitivity B-ADE
response I-ADE
to O
tuberculin B-DRUG
and O
improved O
after O
treatment O
with O
the O
anti O
- O
inflammatory O
agent O
oxpentifylline O
, O
it O
was O
probably O
caused O
by O
restoration O
of O
pathogen O
- O
specific O
cellular O
immunity O
. O

After O
5 O
days O
of O
treatment O
with O
IL-2 B-DRUG
, O
the O
patient O
developed O
a O
hemorrhagic B-ADE
lesion I-ADE
that O
progressed O
to O
toxic B-ADE
epidermal I-ADE
necrolysis I-ADE
, O
as O
well O
as O
grade O
4 O
pancytopenia B-ADE
. O

Laryngeal B-ADE
dyspnea I-ADE
in O
relation O
to O
an O
interaction O
between O
acenocoumarol B-DRUG
and O
topical O
econazole B-DRUG
lotion O
. O

OBJECTIVE O
: O
We O
report O
a O
patient O
who O
developed O
neutropenia O
on O
clozapine B-DRUG
, O
but O
behind O
the O
cell O
count O
decrease O
showed O
to O
be O
a O
diurnal B-ADE
variation I-ADE
of I-ADE
the I-ADE
white I-ADE
blood I-ADE
cells I-ADE
( O
WBC O
) O
. O

It O
is O
the O
first O
case O
of O
ciprofloxacin B-DRUG
- O
induced O
VBDS B-ADE
successfully O
treated O
with O
tacrolimus O
. O

This O
case O
highlights O
the O
possible O
development O
of O
acute B-ADE
coronary I-ADE
syndrome I-ADE
as O
a O
side O
effect O
of O
Capecitabine B-DRUG
therapy O
. O

RESULTS O
: O
Three O
patients O
who O
developed O
symptoms O
of O
inflammatory B-ADE
bowel I-ADE
disease I-ADE
( O
IBD B-ADE
) O
during O
rofecoxib B-DRUG
exposure O
are O
described O
along O
with O
pathology O
findings O
. O

We O
report O
a O
case O
of O
secondary O
glaucoma B-ADE
caused O
by O
epithelial O
downgrowth O
in O
which O
filtration O
surgery O
was O
performed O
with O
adjunctive O
use O
of O
subconjunctival O
5-fluorouracil B-DRUG
. O

After O
1 O
week O
of O
nefazodone B-DRUG
therapy O
the O
patient O
experienced O
headache B-ADE
, O
confusion B-ADE
, O
and O
" O
gray B-ADE
areas I-ADE
" O
in O
her O
vision O
, O
without O
abnormal O
ophthalmologic O
findings O
. O

Neuroleptic B-ADE
malignant I-ADE
syndrome I-ADE
in O
an O
adolescent O
receiving O
olanzapine B-DRUG
- O
lithium B-DRUG
combination O
therapy O
. O

Localized B-ADE
panniculitis I-ADE
and O
subsequent O
lipoatrophy B-ADE
with O
subcutaneous O
glatiramer B-DRUG
acetate I-DRUG
( O
Copaxone B-DRUG
) O
injection O
for O
the O
treatment O
of O
multiple O
sclerosis O
. O

This O
prompted O
us O
to O
suspect O
that O
ddI B-DRUG
might O
be O
responsible O
for O
fulminant B-ADE
hepatitis I-ADE
in O
all O
three O
AIDS O
patients O
. O

The O
syndrome O
of O
irreversible O
lithium B-DRUG
- O
effectuated O
neurotoxicity B-ADE
( O
SILENT O
) O
. O

Though O
proteinuria B-ADE
and O
nephrotic B-ADE
syndrome I-ADE
is O
a O
rare O
adverse O
effect O
of O
IFN B-DRUG
- I-DRUG
beta-1b I-DRUG
therapy O
, O
physicians O
treating O
MS O
patients O
with O
this O
agent O
should O
pay O
careful O
attention O
to O
new O
clinical O
symptoms O
and O
laboratory O
findings O
. O

Exacerbation O
of O
5-FU B-DRUG
dermatologic B-ADE
toxicities I-ADE
in O
patients O
with O
preexisting O
conditions O
suggests O
the O
importance O
of O
aggressive O
ocular O
prophylaxis O
, O
using O
frequent O
ocular O
lubrication O
and O
topical O
steroid O
preparations O
with O
concurrent O
medical O
management O
of O
pre O
- O
existing O
dermatologic O
conditions O
. O

These O
results O
indicate O
that O
lithium B-DRUG
may O
cause O
biochemical B-ADE
hyperparathyroidism I-ADE
. O

IV O
propranolol B-DRUG
was O
used O
as O
the O
initial O
treatment O
for O
his O
hyperadrenergic O
state O
, O
resulting O
in O
a O
decrease B-ADE
in I-ADE
heart I-ADE
rate I-ADE
but O
a O
paroxsymal B-ADE
increase I-ADE
in I-ADE
blood I-ADE
pressure I-ADE
. O

We O
report O
a O
case O
of O
intrathecal O
methotrexate B-DRUG
neurotoxicity B-ADE
manifesting O
as O
left B-ADE
arm I-ADE
weakness I-ADE
and O
aphasia B-ADE
. O

Marked O
elevation B-ADE
of I-ADE
serum I-ADE
creatine I-ADE
kinase I-ADE
associated O
with O
olanzapine B-DRUG
therapy O
. O

A O
fatal B-ADE
pancytopenia I-ADE
occurred O
in O
a O
patient O
with O
an O
history O
of O
depression O
with O
hypomanic O
rebounds O
, O
admitted O
for O
a O
manic O
episode O
and O
treated O
with O
levomepromazine B-DRUG
, O
diazepam B-DRUG
and O
lithium B-DRUG
carbonate I-DRUG
. O

The O
currently O
available O
clinical O
and O
neuropharmacologic O
data O
suggest O
that O
carbamazepine B-DRUG
may O
be O
an O
antagonist O
of O
dopamine O
and O
that O
this O
property O
is O
responsible O
for O
the O
production O
of O
dystonia B-ADE
. O

The O
aim O
of O
our O
paper O
was O
to O
describe O
hepatotoxicity B-ADE
of O
sirolimus B-DRUG
( O
SRL O
) O
in O
a O
kidney O
graft O
recipient O
. O

PURPOSE O
: O
We O
evaluated O
the O
in O
vitro O
hemodialysis O
ratio O
and O
subsequent O
toxicity B-DRUG
and O
pharmacokinetics O
of O
ifosfamide B-ADE
in O
an O
anephric O
patient O
with O
Wilms O
' O
tumor O
. O

RESULTS O
: O
Five O
of O
70 O
patients O
who O
had O
begun O
leflunomide B-DRUG
therapy O
had O
significant O
weight B-ADE
loss I-ADE
that O
could O
not O
be O
linked O
to O
other O
identifiable O
etiologies O
. O

Thrombin B-DRUG
is O
highly O
effective O
for O
stopping O
intractable O
arterial O
hemorrhage O
during O
stereotactic O
brain O
biopsy O
; O
however O
, O
it O
is O
a O
vasospastic O
agent O
and O
may O
have O
been O
responsible O
for O
the O
cerebral B-ADE
infarctions I-ADE
in O
one O
patient O
. O

Although O
tardive B-ADE
dyskinesia I-ADE
is O
a O
known O
adverse O
reaction O
of O
sustained O
treatment O
with O
traditional O
neuroleptic O
agents O
, O
it O
was O
only O
rarely O
reported O
in O
association O
with O
sulpiride B-DRUG
, O
a O
selective O
D2-receptor O
antagonist O
. O

Drug B-ADE
eruption I-ADE
caused O
by O
azathioprine B-DRUG
: O
value O
of O
using O
the O
drug O
- O
induced O
lymphocytes O
stimulation O
test O
for O
diagnosis O
. O

The O
patient O
presented O
with O
fulminant B-ADE
microangiopathic I-ADE
hemolytic I-ADE
anemia I-ADE
and O
thrombocytopenia B-ADE
within O
48 O
hr O
of O
initiating O
therapy O
with O
trimethoprim B-DRUG
- O
sulfamethoxazole B-DRUG
. O

Possible O
mechanisms O
by O
which O
clonidine B-DRUG
decreases O
spasticity O
are O
described O
, O
probable O
mechanisms O
of O
induced O
bradycardia B-ADE
are O
reviewed O
, O
and O
specific O
treatment O
recommendations O
for O
the O
use O
of O
clonidine B-DRUG
in O
spinal O
cord O
injured O
patients O
are O
presented O
. O

We O
describe O
children O
and O
adolescents O
with O
chronic O
hematologic O
and O
oncologic O
diseases O
who O
exhibited O
drug B-ADE
- I-ADE
seeking I-ADE
behavior I-ADE
or O
anticholinergic B-ADE
symptoms I-ADE
with O
the O
use O
of O
diphenhydramine B-DRUG
. O

Eleven O
days O
after O
initiation O
of O
therapy O
with O
amiodarone B-DRUG
, O
the O
patient O
experienced O
syncope B-ADE
and O
was O
noted O
to O
have O
recurrent O
episodes O
of O
polymorphous B-ADE
ventricular I-ADE
tachycardia I-ADE
. O

Prior O
neurologic O
illness O
and O
the O
syndrome O
of O
irreversible O
lithium B-DRUG
- O
effectuated O
neurotoxicity B-ADE
( O
SILENT O
) O
. O

A O
new O
type O
of O
minocycline B-DRUG
- O
induced O
cutaneous B-ADE
hyperpigmentation I-ADE
. O

Insulin B-DRUG
- O
induced O
lipoatrophy B-ADE
in O
type O
I O
diabetes O
. O

All O
developed O
mucocutaneous B-ADE
side I-ADE
effects I-ADE
within O
20 O
weeks O
of O
beginning O
i O
m O
gold B-DRUG
therapy O
, O
at O
a O
time O
when O
RA O
had O
improved O
markedly O
compared O
to O
pretreatment O
status O
. O

We O
attribute O
the O
clinical O
and O
radiographic O
findings O
to O
cytotoxic B-ADE
edema I-ADE
secondary O
to O
intrathecal O
methotrexate B-DRUG
. O

We O
present O
three O
patients O
with O
paradoxical O
seizures B-ADE
; O
their O
serum O
phenytoin B-DRUG
levels O
were O
43.5 O
mcg O
/ O
mL O
, O
46.5 O
mcg O
/ O
mL O
and O
38.3 O
mcg O
/ O
mL O
. O

Optic B-ADE
neuropathy I-ADE
in O
ethambutol B-DRUG
- O
treated O
renal O
tuberculosis O
. O

Two O
cases O
of O
lepromatous O
leprosy O
with O
erythema O
nodosum O
leprosum O
who O
were O
on O
high O
doses O
of O
clofazimine B-DRUG
, O
showed O
discoloration B-ADE
of I-ADE
nail I-ADE
plate I-ADE
, O
subungual B-ADE
hyperkeratosis I-ADE
and O
onycholysis B-ADE
. O

CONCLUSION O
: O
Therapy O
with O
indapamide B-DRUG
may O
induce O
diabetes B-ADE
in O
essential O
hypertension O
patients O
. O

PURPOSE O
: O
To O
report O
that O
acute O
lamotrigine B-DRUG
poisoning O
may O
result O
in O
severe O
encephalopathy B-ADE
. O

A O
58-year O
- O
old O
woman O
developed O
unilateral B-ADE
acute I-ADE
angle I-ADE
- I-ADE
closure I-ADE
glaucoma I-ADE
four O
days O
after O
the O
application O
of O
a O
patch O
of O
transdermal O
scopolamine B-DRUG
delivery O
system O
( O
TRANSDERM O
- O
V O
) O
. O

An O
infant O
girl O
with O
choanal B-ADE
atresia I-ADE
, O
athelia B-ADE
, O
minor O
anomalies O
, O
and O
mild O
to O
moderate O
mental B-ADE
retardation I-ADE
was O
born O
to O
a O
woman O
treated O
for O
hyperthyroidism O
throughout O
pregnancy O
with O
methimazole B-DRUG
and O
propranolol B-DRUG
. O

RESULTS O
: O
Extensive O
squamous B-ADE
metaplasia I-ADE
was O
found O
in O
endometrial O
glands O
following O
progestin B-DRUG
therapy O
. O

Adriamycin B-DRUG
- O
induced O
cardiomyopathy B-ADE
aggravated O
by O
cis B-DRUG
- I-DRUG
platinum I-DRUG
nephrotoxicity B-ADE
requiring O
dialysis O
. O

Severe B-ADE
loss I-ADE
of I-ADE
vision I-ADE
after O
removal O
of O
cataract B-ADE
caused O
by O
intravitreal O
triamcinolone B-DRUG
in O
combination O
with O
photodynamic O
therapy O
for O
exudative O
age O
- O
related O
macular O
degeneration O
. O

In O
view O
of O
our O
experience O
in O
the O
present O
case O
, O
it O
should O
be O
stressed O
that O
close O
monitoring O
of O
coagulation O
capacity O
is O
necessary O
in O
critically O
ill O
patients O
in O
order O
to O
avoid O
fatal B-ADE
haemorrhage I-ADE
after O
initiating O
warfarin B-DRUG
therapy O
regardless O
of O
the O
dosage O
. O

Reye B-ADE
syndrome I-ADE
( O
RS B-ADE
) O
is O
believed O
to O
occur O
infrequently O
among O
children O
receiving O
long O
- O
term O
aspirin B-DRUG
therapy O
. O

CONCLUSIONS O
: O
For O
all O
patients O
with O
vancomycin B-DRUG
- O
induced O
neutropenia B-ADE
, O
possible O
cross O
- O
reactivity O
of O
teicoplanin O
should O
be O
monitored O
. O

We O
suggest O
that O
sarcoidosis B-ADE
may O
develop O
in O
chronic O
hepatitis O
C O
patients O
during O
interferon B-DRUG
alpha I-DRUG
and/or O
ribavirin B-DRUG
treatment O
, O
and O
diagnostic O
tests O
for O
this O
adverse O
effect O
should O
be O
performed O
during O
the O
follow O
- O
ups O
. O

Reversible B-ADE
MR I-ADE
imaging I-ADE
and I-ADE
MR I-ADE
spectroscopy I-ADE
abnormalities I-ADE
in O
association O
with O
metronidazole B-DRUG
therapy O
. O

Doxorubicin B-DRUG
cardiotoxicity B-ADE
: O
possible O
role O
of O
digoxin O
in O
its O
prevention O
. O

Reversible B-ADE
corneal I-ADE
keratinization I-ADE
following O
trabeculectomy O
and O
treatment O
with O
5-fluorouracil B-DRUG
. O

In O
patients O
with O
methotrexate B-DRUG
- O
induced O
anaphylaxis B-ADE
, O
discontinuation O
of O
treatment O
may O
increase O
the O
risk O
of O
death O
due O
to O
cancer O
progression O
. O

Reversible O
sclerotic B-ADE
changes I-ADE
of I-ADE
lumbar I-ADE
spine I-ADE
and I-ADE
femur I-ADE
due O
to O
long O
- O
term O
oral O
isotretinoin B-DRUG
therapy O
. O

A O
retrospective O
study O
was O
conducted O
of O
40 O
loperamide B-DRUG
poisoning I-ADE
cases O
recorded O
at O
the O
Centre O
National O
d'Informations O
Toxicologiques O
Veterinaires O
. O

Herein O
we O
report O
four O
patients O
who O
underwent O
liver O
transplantation O
and O
developed O
neutropenia B-ADE
while O
receiving O
MMF B-DRUG
. O

On O
the O
fifth O
day O
of O
tocolysis O
with O
magnesium B-DRUG
sulfate I-DRUG
, O
nifedipine B-DRUG
, O
terbutaline B-DRUG
and O
betamethasone B-DRUG
, O
edema B-ADE
developed O
in O
both O
labia O
. O

We O
report O
the O
case O
of O
an O
87-year O
- O
old O
white O
woman O
with O
myasthenia O
gravis O
who O
presented O
with O
nausea B-ADE
, O
shortness B-ADE
of I-ADE
breath I-ADE
, O
azotemia B-ADE
, O
and O
hyperkalemia B-ADE
shortly O
after O
completing O
a O
course O
of O
intravenous O
immunoglobulin B-DRUG
( O
IVIG B-DRUG
) O
. O

Multiple O
myeloma O
complicated O
by O
congestive B-ADE
heart I-ADE
failure I-ADE
following O
first O
administration O
of O
recombinant B-DRUG
alpha I-DRUG
- I-DRUG
interferon I-DRUG
. O

None O
of O
them O
had O
a O
history O
of O
cardiac O
disease O
, O
and O
with O
the O
possible O
exception O
of O
one O
case O
of O
cardiac B-ADE
arrest I-ADE
, O
where O
the O
patient O
received O
doxorubicin B-DRUG
, O
no O
predisposing O
factors O
could O
be O
found O
. O

Avascular B-ADE
necrosis I-ADE
of I-ADE
the I-ADE
femoral I-ADE
head I-ADE
in O
patients O
with O
prostate O
cancer O
treated O
with O
cyproterone B-DRUG
acetate I-DRUG
and O
radiotherapy O
. O

We O
report O
a O
case O
of O
drug O
- O
induced O
pemphigus B-ADE
caused O
by O
an O
angiotensin O
- O
converting O
enzyme O
inhibitor O
, O
captopril B-DRUG
. O

Reinstitution O
of O
penicillamine O
treatment O
caused O
a O
recurrence O
thus O
proving O
a O
causal O
relationship O
between O
penicillamine B-DRUG
and O
the O
described O
nail B-ADE
- I-ADE
changes I-ADE
. O

Benzocaine B-DRUG
- O
induced O
methemoglobinemia B-ADE
has O
been O
reported O
in O
man O
, O
dogs O
, O
and O
cats O
. O

Paroxysmal B-ADE
supraventricular I-ADE
tachycardia I-ADE
during O
treatment O
with O
cisplatin B-DRUG
and O
etoposide B-DRUG
combination O
. O

The O
latter O
form O
( O
Macrodantin B-DRUG
) O
is O
reported O
to O
engender O
less O
gastrointestinal O
intolerance O
but O
it O
can O
produce O
the O
same O
adverse O
effects O
as O
the O
conventional O
form O
-- O
liver B-ADE
damage I-ADE
, O
acute B-ADE
and I-ADE
chronic I-ADE
pulmonary I-ADE
reactions I-ADE
, O
peripheral B-ADE
neuropathy I-ADE
, O
blood B-ADE
dyscrasias I-ADE
and O
allergic B-ADE
reactions I-ADE
-- O
and O
does O
so O
just O
as O
rapidly O
and O
floridly O
; O
one O
such O
case O
is O
reported O
here O
. O

Fatal B-ADE
acute I-ADE
encephalomyelitis I-ADE
after O
a O
single O
dose O
of O
intrathecal O
methotrexate B-DRUG
. O

BACKGROUND O
: O
The O
risk O
/ O
benefit O
ratio O
of O
warfarin B-DRUG
therapy O
changes O
in O
the O
over O
75s O
, O
when O
haemorrhagic B-ADE
side I-ADE
- I-ADE
effects I-ADE
become O
more O
common O
. O

A O
16-year O
- O
old O
white O
male O
with O
acute O
biphenotypic O
leukemia O
developed O
evidence O
of O
the O
eosinophilia B-ADE
myalgia I-ADE
syndrome I-ADE
associated O
with O
total O
parenteral O
nutritional O
support O
with O
solutions O
containing O
tryptophan B-DRUG
, O
which O
were O
given O
during O
his O
initial O
induction O
chemotherapy O
and O
also O
after O
autologous O
marrow O
transplantation O
. O

OBJECTIVE O
: O
To O
investigate O
the O
mechanisms O
involved O
in O
hypersensitivity B-ADE
reactions I-ADE
to O
cyclosporine B-DRUG
and O
determine O
the O
feasibility O
of O
future O
cyclosporine B-DRUG
use O
. O

Squamous B-ADE
- I-ADE
cell I-ADE
carcinoma I-ADE
arising O
in O
a O
basal O
- O
cell O
epithelioma O
treated O
with O
5-fluorouracil B-DRUG
. O

Bilateral B-ADE
anterior I-ADE
uveitis I-ADE
associated O
with O
clomiphene B-DRUG
citrate I-DRUG
. O

Lichenoid B-ADE
drug I-ADE
eruption I-ADE
to O
salsalate B-DRUG
. O

The O
case O
of O
a O
bipolar O
patient O
who O
developed O
thyrotoxicosis B-ADE
with O
severe B-ADE
exophthalmos I-ADE
while O
on O
lithium B-DRUG
therapy O
is O
described O
. O

Torsemide B-DRUG
appears O
to O
also O
be O
a O
part O
of O
a O
long O
list O
of O
agents O
that O
can O
cause O
pancreatitis B-ADE
. O

Stupor B-ADE
from O
lamotrigine B-DRUG
toxicity O
. O

Acute O
nitrite B-DRUG
toxicity I-ADE
results O
from O
industrial O
exposure O
, O
accidental O
ingestion O
( O
e.g. O
, O
abuse O
of O
organic O
nitrites O
as O
an O
aphrodisiac O
, O
especially O
in O
the O
male O
homosexual O
population O
) O
, O
and O
suicidal O
ingestion O
. O

Uncontrolled O
headache B-ADE
induced O
by O
oxcarbazepine B-DRUG
. O

Polymyositis B-ADE
after O
propylthiouracil B-DRUG
treatment O
for O
hyperthyroidism O
. O

CONCLUSIONS O
: O
Cefazolin B-DRUG
was O
a O
probable O
cause O
of O
this O
patient O
's O
leukopenia B-ADE
. O

OBJECTIVE O
: O
To O
report O
teicoplanin B-DRUG
- O
related O
neutropenia B-ADE
that O
developed O
after O
an O
episode O
of O
neutropenia B-ADE
induced O
by O
vancomycin B-DRUG
therapy O
. O

Risperidone B-DRUG
withdrawal O
- O
related O
respiratory B-ADE
dyskinesia I-ADE
: O
a O
case O
diagnosed O
by O
spirography O
and O
fibroscopy O
. O

Two O
patients O
with O
HLH O
developed O
etoposide B-DRUG
- O
related O
secondary B-ADE
acute I-ADE
myeloid I-ADE
leukemia I-ADE
( O
sAML B-ADE
) O
following O
therapy O
for O
HLH O
. O

After O
rechallenge O
with O
monotherapy O
pegvisomant B-DRUG
, O
however O
, O
the O
hepatic B-ADE
enzyme I-ADE
disturbances I-ADE
reappeared O
within O
a O
few O
weeks O
, O
indicating O
that O
most O
likely O
pegvisomant B-DRUG
alone O
and O
not O
the O
long O
- O
acting O
somatostatin O
analog O
or O
the O
combination O
of O
these O
two O
drugs O
was O
responsible O
for O
this O
case O
of O
drug O
- O
induced O
hepatitis B-ADE
. O

Atrial B-ADE
fibrillation I-ADE
following O
methylprednisolone B-DRUG
pulse O
therapy O
. O

The O
rash B-ADE
seen O
in O
this O
patient O
, O
who O
was O
treated O
with O
cephalexin B-DRUG
, O
may O
be O
similar O
to O
the O
rash B-ADE
seen O
with O
ampicillin B-DRUG
treatment O
of O
patients O
with O
infectious O
mononucleosis O
. O

The O
diagnosis O
was O
supported O
by O
the O
temporal O
course O
of O
renal B-ADE
deterioration I-ADE
during O
exposure O
to O
cefuroxime B-DRUG
and O
improvement O
on O
its O
discontinuation O
; O
the O
pattern O
repeated O
with O
rechallenge O
. O

At O
the O
end O
of O
his O
fifth O
cycle O
of O
sunitinib B-DRUG
therapy O
, O
the O
patient O
complained O
of O
the O
development B-ADE
of I-ADE
abnormally I-ADE
large I-ADE
mammary I-ADE
glands I-ADE
associated O
with O
pain B-ADE
and O
peri B-ADE
- I-ADE
areolar I-ADE
erythema I-ADE
. O

Three O
patients O
are O
reported O
without O
a O
history O
of O
angina O
pectoris O
who O
had O
clinical O
and O
electrocardiographic O
evidence O
of O
myocardial B-ADE
ischemia I-ADE
during O
and O
immediately O
after O
BCNU B-DRUG
infusion O
. O

Induction O
of O
rapid B-ADE
mood I-ADE
cycling I-ADE
during O
L B-DRUG
- I-DRUG
dopa I-DRUG
treatment O
in O
a O
bipolar O
patient O
. O

A O
case O
of O
tuberculosis B-ADE
in O
a O
patient O
on O
Efalizumab B-DRUG
and O
Etanercept B-DRUG
for O
treatment O
of O
refractory O
palmopustular O
psoriasis O
and O
psoriatic O
arthritis O
. O

Clozapine B-DRUG
induced O
polyserositis B-ADE
. O

No O
cases O
of O
renal O
acidosis O
, O
and O
only O
one O
case O
of O
nephrogenic B-ADE
diabetes I-ADE
insipidus I-ADE
, O
has O
been O
previously O
reported O
as O
a O
complication O
of O
foscarnet B-DRUG
treatment O
. O

They O
continued O
to O
rise O
for O
five O
more O
days O
before O
salicylate B-DRUG
hepatotoxicity B-ADE
was O
suspected O
. O

OBJECTIVE O
: O
To O
describe O
a O
patient O
with O
ifosfamide B-DRUG
- O
induced O
nonconvulsive B-ADE
status I-ADE
epilepticus I-ADE
. O

On O
day O
4 O
, O
following O
3 O
doses O
of O
dalteparin B-DRUG
, O
the O
patient O
developed O
acute B-ADE
respiratory I-ADE
distress I-ADE
attributable O
to O
a O
massive O
right O
hemothorax O
confirmed O
by O
computed O
tomography O
pulmonary O
angiography O
( O
CTPA O
) O
and O
intercostal O
drainage O
of O
1500 O
mL O
of O
frank O
blood O
. O

Although O
interferon O
gamma O
has O
been O
implicated O
in O
the O
pathogenesis O
of O
sarcoidosis O
, O
only O
a O
few O
cases O
of O
sarcoidosis B-ADE
associated O
with O
interferon B-DRUG
alpha I-DRUG
therapy O
have O
been O
reported O
. O

Oxygen B-DRUG
potentiation O
of O
bleomycin B-DRUG
- O
induced O
pulmonary B-ADE
toxicity I-ADE
is O
discussed O
. O

We O
report O
on O
three O
observations O
of O
parkinsonian O
patients O
with O
levo B-DRUG
- I-DRUG
dopa I-DRUG
- O
induced O
diphasic B-ADE
dyskinesias I-ADE
, O
who O
received O
subcutaneous O
apomorphine O
to O
reduce O
the O
duration O
of O
abnormal O
movements O
. O

We O
report O
a O
case O
of O
seizure B-ADE
associated O
with O
L B-DRUG
- I-DRUG
asparaginase I-DRUG
therapy O
but O
no O
evidence O
of O
hemorrhagic O
or O
thrombotic O
cerebrovascular O
events O
. O

Intravenous O
azithromycin B-DRUG
- O
induced O
ototoxicity B-ADE
. O

Reports O
of O
colonic B-ADE
perforation I-ADE
as O
a O
result O
of O
the O
administration O
of O
calcium B-DRUG
polystyrene I-DRUG
sulfonate I-DRUG
and O
sorbitol B-DRUG
are O
rare O
. O

CONCLUSIONS O
: O
Patients O
receiving O
intravitreal O
injections O
of O
bevacizumab B-DRUG
should O
be O
evaluated O
for O
potential O
systemic O
risk O
factors O
such O
as O
carotid B-ADE
insufficiency I-ADE
, O
coagulopathy B-ADE
and O
poorly B-ADE
controlled I-ADE
diabetes I-ADE
mellitus I-ADE
. O

A O
cause O
- O
effect O
relationship O
to O
capecitabine O
was O
suggested O
due O
to O
resolution O
of O
headache B-ADE
with O
capecitabine B-DRUG
withdrawal O
and O
reappearance O
with O
capecitabine O
rechallenge O
. O

Development O
of O
nephrotic B-ADE
syndrome I-ADE
in O
a O
patient O
with O
acute O
myeloblastic O
leukemia O
after O
treatment O
with O
macrophage B-DRUG
- I-DRUG
colony I-DRUG
- I-DRUG
stimulating I-DRUG
factor I-DRUG
. O

Cimetidine B-DRUG
- O
induced O
fever B-ADE
. O

We O
present O
a O
case O
report O
of O
a O
patient O
who O
developed O
a O
prolonged B-ADE
QT I-ADE
while O
being O
treated O
with O
oral O
methadone B-DRUG
for O
a O
chronic O
pain O
syndrome O
. O

We O
report O
an O
allogeneic O
bone O
marrow O
transplant O
recipient O
who O
developed O
CMV B-ADE
infection I-ADE
refractory O
to O
sequential O
therapy O
with O
ganciclovir B-DRUG
, O
foscarnet B-DRUG
, O
and O
cidofovir B-DRUG
. O

Thus O
, O
tacrolimus B-DRUG
- O
induced O
HUS B-ADE
is O
a O
rare O
cause O
of O
ARF B-ADE
in O
nephrotic O
syndrome O
. O

Thrombotic B-ADE
microangiopathy I-ADE
with O
renal B-ADE
failure I-ADE
in O
two O
patients O
undergoing O
gemcitabine B-DRUG
chemotherapy O
. O

Evaluation O
revealed O
elevated B-ADE
serum I-ADE
LTG B-DRUG
levels I-ADE
and O
no O
other O
etiology O
for O
encephalopathy O
. O

According O
to O
the O
Naranjo O
probability O
scale O
, O
the O
papular B-ADE
eruption I-ADE
was O
probably O
caused O
by O
methotrexate B-DRUG
. O

The O
first O
patient O
is O
undergoing O
hemodialysis O
and O
, O
though O
responding O
to O
sunitinib B-DRUG
, O
is O
having O
significant O
fatigue B-ADE
and O
hypertension B-ADE
. O

After O
four O
months O
, O
while O
receiving O
RH B-DRUG
, O
he O
developed O
painful O
bilateral B-ADE
gynaecomastia I-ADE
. O

A O
28 O
year O
old O
white O
schizophrenic O
male O
has O
been O
under O
risperidone B-DRUG
monotherapy O
for O
about O
one O
year O
when O
he O
developed O
dyskinetic B-ADE
movements I-ADE
. O

Severe B-ADE
rash I-ADE
, O
including O
the O
Stevens B-ADE
- I-ADE
Johnson I-ADE
syndrome I-ADE
( O
SJS B-ADE
) O
, O
is O
the O
major O
toxicity O
of O
nevirapine B-DRUG
and O
is O
described O
in O
the O
package O
labeling O
with O
a O
prominent O
, O
boxed O
warning O
. O

Subsequently O
, O
he O
developed O
hyperglycemia B-ADE
( O
fasting O
blood O
glucose O
138 O
mg O
/ O
dL O
) O
that O
resolved O
when O
olanzapine B-DRUG
was O
stopped O
and O
recurred O
( O
fasting O
blood O
glucose O
150 O
mg O
/ O
dL O
) O
after O
2 O
days O
of O
rechallenge O
with O
olanzapine O
2.5 O
mg O
twice O
daily O
. O

Allergy B-ADE
to O
cloxacillin B-DRUG
with O
normal O
tolerance O
to O
amoxicillin O
and O
cefuroxime O
. O

This O
communication O
describes O
a O
patient O
who O
developed O
Schneiderian B-ADE
first I-ADE
- I-ADE
rank I-ADE
symptoms I-ADE
in O
the O
course O
of O
treatment O
with O
fluvoxamine B-DRUG
. O

Cerebral B-ADE
demyelinating I-ADE
disease I-ADE
developed O
in O
a O
patient O
during O
adjuvant O
therapy O
with O
levamisole B-DRUG
for O
malignant O
melanoma O
. O

Five O
cases O
of O
clindamycin B-DRUG
- O
associated O
pseudomembranous B-ADE
colitis I-ADE
in O
leukaemic O
patients O
are O
reported O
. O

DISCUSSION O
: O
Methotrexate B-DRUG
- O
induced O
papular B-ADE
eruption I-ADE
is O
rarely O
reported O
shortly O
after O
beginning O
methotrexate O
therapy O
in O
patients O
with O
acute O
exacerbation O
of O
collagen O
vascular O
diseases O
. O

Typical O
symptoms O
of O
active O
CD B-ADE
occurred O
11 O
, O
12 O
, O
and O
26 O
months O
after O
start O
of O
etanercept B-DRUG
therapy O
, O
respectively O
. O

An O
evaluation O
of O
ovarian O
structure O
and O
function O
should O
be O
considered O
in O
women O
of O
reproductive O
age O
being O
treated O
with O
valproate B-DRUG
for O
epilepsy O
, O
especially O
if O
they O
develop O
menstrual B-ADE
cycle I-ADE
disturbances I-ADE
during O
treatment O
. O

We O
explored O
ophthalmic B-ADE
and I-ADE
neurologic I-ADE
findings I-ADE
in O
two O
children O
who O
have O
been O
exposed O
prenatally O
to O
VGB B-DRUG
. O

We O
describe O
two O
cases O
of O
sulfadiazine B-DRUG
- O
induced O
crystalluria B-ADE
and O
renal B-ADE
failure I-ADE
in O
patients O
with O
acquired O
immunodeficiency O
syndrome O
, O
review O
the O
pertinent O
literature O
, O
and O
discuss O
the O
pathogenesis O
. O

Localized B-ADE
dyskeratotic I-ADE
plaque I-ADE
with O
milia B-ADE
associated O
with O
sorafenib B-DRUG
. O

BACKGROUND O
: O
Ovarian B-ADE
cancer I-ADE
arising O
from O
an O
endometriotic O
cyst O
in O
a O
postmenopausal O
woman O
under O
tamoxifen B-DRUG
therapy O
is O
rare O
. O

Acute B-ADE
renal I-ADE
failure I-ADE
most O
likely O
was O
secondary O
to O
the O
nephrotoxic O
effect O
of O
captopril B-DRUG
on O
chronically O
hypoperfused O
kidneys O
. O

Anti O
- O
tuberculous O
drugs O
had O
been O
stopped O
on O
the O
2nd O
day O
of O
therapy O
due O
to O
development O
of O
optic B-ADE
neuritis I-ADE
secondary O
to O
ethambutol B-DRUG
administration O
at O
another O
hospital O
. O

Administration O
of O
steroid O
and O
decreasing O
the O
dose O
of O
PTU B-DRUG
produced O
a O
good O
clinical O
response O
and O
the O
ANCA B-ADE
disappeared O
. O

Ethambutol B-DRUG
toxicity O
manifesting O
as O
acute B-ADE
onset I-ADE
psychosis I-ADE
. O

However O
, O
re O
- O
initiation O
of O
sunitinib B-DRUG
treatment O
was O
followed O
by O
bilateral B-ADE
breast I-ADE
enlargement I-ADE
again O
. O

Prior O
reports O
have O
emphasized O
the O
tubular B-ADE
and I-ADE
interstitial I-ADE
lesions I-ADE
associated O
with O
intermittent O
or O
discontinuous O
rifampin B-DRUG
therapy O
for O
tuberculosis O
. O

The O
patient O
was O
given O
methimazole B-DRUG
instead O
of O
propylthiouracil O
but O
, O
10 O
weeks O
later O
, O
agranulocytosis B-ADE
again O
occurred O
. O

Three O
diabetic O
cases O
of O
acute B-ADE
dizziness I-ADE
due O
to O
initial O
administration O
of O
voglibose B-DRUG
. O

Drug O
induced O
polymyositis B-ADE
secondary O
to O
leuprolide B-DRUG
acetate I-DRUG
( O
Lupron B-DRUG
) O
therapy O
for O
prostate O
carcinoma O
. O

The O
present O
case O
is O
the O
first O
report O
of O
hypercalcemia B-ADE
induced O
by O
vitamin B-DRUG
D3 I-DRUG
ointment O
and O
thiazide B-DRUG
simultaneously O
. O

Clinicians O
should O
be O
aware O
that O
an O
erythematous O
and O
exfoliative B-ADE
rash I-ADE
may O
be O
induced O
by O
temozolomide B-DRUG
, O
and O
be O
familiar O
with O
the O
pharmacologic O
and O
supportive O
measures O
necessary O
for O
its O
treatment O
. O

Anaphylaxis B-ADE
to O
intravenous O
cyclosporine B-DRUG
and O
tolerance O
to O
oral O
cyclosporine O
: O
case O
report O
and O
review O
. O

Hemodialysis O
should O
be O
performed O
for O
rapid O
reversal O
of O
mannitol B-DRUG
- O
induced O
ARF B-ADE
. O

Physicians O
should O
be O
aware O
of O
the O
potential O
for O
the O
development O
of O
RS B-ADE
among O
children O
who O
are O
receiving O
long O
- O
term O
aspirin B-DRUG
therapy O
for O
the O
treatment O
of O
systemic O
inflammatory O
illnesses O
. O

Acute B-ADE
renal I-ADE
failure I-ADE
in O
a O
patient O
treated O
by O
continuous O
povidone B-DRUG
- O
iodine B-DRUG
mediastinal O
irrigation O
. O

Severe O
heparin B-DRUG
associated O
thrombocytopenia B-ADE
is O
a O
rare O
complication O
of O
heparin B-DRUG
therapy O
. O

The O
second O
patient O
, O
who O
developed O
cholestasis B-ADE
after O
receiving O
trimethoprim B-DRUG
- I-DRUG
sulfamethoxazole I-DRUG
, O
had O
marked O
duct B-ADE
paucity I-ADE
in O
the O
liver O
biopsy O
. O

Although O
major O
hazards O
of O
treatment O
of O
hypophosphatemic O
osteomalacia O
with O
phosphate B-DRUG
and O
calcitriol B-DRUG
are O
secondary B-ADE
hyperparathyroidism I-ADE
and O
vitamin B-ADE
D I-ADE
intoxication I-ADE
, O
potassium B-ADE
loss I-ADE
also O
should O
be O
kept O
in O
mind O
. O

After O
39 O
hours O
on O
argatroban B-DRUG
, O
the O
infusion O
was O
stopped O
when O
minor O
bleeding B-ADE
was O
observed O
with O
a O
concurrent O
activated O
partial O
thromboplastin O
time O
( O
aPTT O
) O
of O
100 O
seconds O
. O

The O
possible O
role O
of O
interferon B-DRUG
beta I-DRUG
in O
the O
pathogenesis O
of O
sarcoidosis B-ADE
in O
this O
patient O
is O
discussed O
. O

A O
case O
is O
presented O
of O
a O
patient O
who O
experienced O
benzodiazepine B-ADE
withdrawal I-ADE
symptoms I-ADE
on O
discontinuation O
of O
nefazodone B-DRUG
, O
an O
antidepressant O
that O
inhibits O
the O
cytochrome O
P450 O
3A4 O
isoenzyme O
. O

Presented O
is O
a O
case O
story O
of O
a O
woman O
with O
classical O
rheumatoid O
arthritis O
, O
who O
during O
introduction O
of O
sulphasalazine B-DRUG
( O
SASP B-DRUG
) O
therapy O
developed O
a O
severe O
and O
lasting O
psoriasis B-ADE
- I-ADE
like I-ADE
skin I-ADE
reaction I-ADE
. O

A O
review O
of O
the O
literature O
found O
11 O
children O
and O
2 O
adults O
in O
whom O
intranasal O
desmopressin B-DRUG
was O
associated O
with O
hyponatremia B-ADE
, O
all O
of O
whom O
experienced O
seizures B-ADE
or O
altered B-ADE
mental I-ADE
status I-ADE
. O

Acute B-ADE
endophthalmitis I-ADE
following O
intravitreal O
bevacizumab B-DRUG
( O
Avastin B-DRUG
) O
injection O
. O

We O
describe O
the O
infectious B-ADE
toxicities I-ADE
experienced O
by O
the O
first O
two O
patients O
in O
our O
institution O
treated O
with O
dexamethasone B-DRUG
( O
10 O
mg O
/ O
m(2)/day O
for O
4 O
weeks O
with O
gradual O
tapering O
) O
during O
induction O
according O
to O
the O
dexamethasone O
arm O
of O
BFM O
2000 O
and O
review O
the O
relevant O
literature O
that O
suggests O
an O
increased O
risk O
of O
infectious B-ADE
complications I-ADE
with O
dexamethasone B-DRUG
. O

Trimethoprim B-DRUG
- I-DRUG
sulfamethoxazole I-DRUG
- O
induced O
hypersensitivity B-ADE
syndrome I-ADE
associated O
with O
reactivation O
of O
human O
herpesvirus-6 O
. O

The O
dermatology O
literature O
heretofore O
has O
not O
noted O
that O
anemia B-ADE
is O
a O
side O
effect O
of O
patients O
taking O
MMF B-DRUG
to O
treat O
pemphigus O
. O

We O
describe O
a O
case O
of O
clozapine B-DRUG
- O
induced O
seizures B-ADE
in O
a O
patient O
with O
treatment O
- O
resistant O
schizophrenia O
. O

We O
report O
a O
case O
of O
a O
scleroderma B-ADE
- I-ADE
like I-ADE
reaction I-ADE
induced O
by O
long O
- O
term O
administration O
of O
UFT B-DRUG
. O

Mammary B-ADE
gigantism I-ADE
is O
a O
rare O
complication O
of O
D B-DRUG
- I-DRUG
penicillamine I-DRUG
treatment O
. O

We O
speculate O
that O
platelet O
activation O
induced O
by O
pFVIII B-DRUG
may O
have O
contributed O
to O
thrombosis B-ADE
and O
suggest O
that O
pFVIII O
be O
used O
with O
caution O
in O
elderly O
patients O
with O
pre O
- O
existing O
cardiovascular O
risk O
factors O
. O

Two O
patients O
developed O
diabetic B-ADE
coma I-ADE
when O
taking O
a O
combination O
of O
a O
thiazide B-DRUG
diuretic O
and O
propranolol B-DRUG
. O

We O
strongly O
suspect O
that O
this O
lethal B-ADE
anuria I-ADE
was O
mainly O
due O
to O
ifosfamide B-DRUG
, O
occurring O
in O
a O
patient O
having O
received O
previous O
cisplatin O
chemotherapy O
and O
with O
poor O
kidney O
perfusion O
due O
to O
transient O
hypotension O
. O

Surprisingly O
, O
we O
found O
that O
three O
patients O
appeared O
to O
develop O
tardive B-ADE
OGC I-ADE
while O
taking O
clozapine B-DRUG
. O

Ptosis B-ADE
occurring O
24 O
h O
after O
chloroquine B-DRUG
therapy O
, O
with O
full O
recovery O
48 O
h O
after O
cessation O
of O
chloroquine B-DRUG
, O
has O
not O
been O
described O
previously O
. O

Magnesium B-DRUG
tocolysis O
as O
the O
cause O
of O
urinary B-ADE
calculus I-ADE
during O
pregnancy O
. O

A O
54-year O
- O
old O
man O
, O
treated O
with O
amiodarone B-DRUG
, O
developed O
thyrotoxicosis B-ADE
. O

Ticlopidine B-DRUG
- O
induced O
aplastic B-ADE
anemia I-ADE
: O
two O
new O
case O
reports O
, O
review O
, O
and O
meta O
- O
analysis O
of O
55 O
additional O
cases O
. O

Hemorrhagic B-ADE
cystitis I-ADE
is O
a O
significant O
toxic O
effect O
of O
cyclophosphamide B-DRUG
therapy O
. O

RESULTS O
: O
Both O
cases O
presented O
here O
describe O
corneal B-ADE
ulcers I-ADE
that O
persisted O
and O
showed O
signs O
of O
worsening O
during O
weeks O
of O
frequent O
topical O
dosing O
with O
moxifloxacin B-DRUG
. O

We O
postulate O
that O
gastritis B-ADE
caused O
by O
dexamethasone B-DRUG
, O
mucositis B-ADE
caused O
by O
doxorubicin B-DRUG
, O
and O
the O
unique O
anatomic O
nature O
of O
a O
Meckel O
diverticulum O
may O
have O
contributed O
to O
this O
extremely O
unlikely O
and O
previously O
unreported O
event O
. O

Initiation O
of O
posaconazole B-DRUG
led O
to O
clinical O
improvement O
until O
the O
patient O
's O
demise O
from O
bacteremic O
vancomycin O
- O
resistant O
enterococcal B-ADE
peritonitis I-ADE
. O

CONCLUSIONS O
: O
Metoclopramide B-DRUG
may O
cause O
reversible O
nonthrombocytopenic B-ADE
vascular I-ADE
- I-ADE
type I-ADE
palpable I-ADE
purpura I-ADE
. O

We O
reported O
3 O
patients O
who O
developed O
acute B-ADE
generalized I-ADE
dystonia I-ADE
and O
akinetic B-ADE
rigid I-ADE
syndrome I-ADE
following O
an O
initial O
therapy O
with O
d B-DRUG
- I-DRUG
penicillamine I-DRUG
125 O
- O
500 O
mg O
daily O
. O

So O
far O
, O
few O
cases O
of O
pulmonary B-ADE
side I-ADE
effects I-ADE
caused O
by O
ticlopidine B-DRUG
have O
been O
reported O
. O

This O
report O
highlights O
a O
case O
of O
drug O
- O
induced O
dysphagia B-ADE
in O
a O
patient O
receiving O
haloperidol B-DRUG
for O
obsessive O
nocturnal O
thoughts O
and O
auditory O
disturbances O
. O

However O
, O
several O
case O
reports O
have O
suggested O
that O
clozapine B-DRUG
could O
also O
cause O
TD B-ADE
. O

Fatal B-ADE
pulmonary I-ADE
fibrosis I-ADE
following O
1,3-bis(2-chloroethyl B-DRUG
) I-DRUG
- I-DRUG
1-nitrosourea I-DRUG
( O
BCNU B-DRUG
) O
therapy O
. O

Pleuropulmonary B-ADE
changes I-ADE
during O
treatment O
of O
Parkinson O
's O
disease O
with O
a O
long O
- O
acting O
ergot O
derivative O
, O
cabergoline B-DRUG
. O

Atrial B-ADE
fibrillation I-ADE
occurring O
in O
a O
patient O
taking O
etanercept B-DRUG
plus O
methotrexate B-DRUG
for O
rheumatoid O
arthritis O
. O

Choroidal B-ADE
hemorrhage I-ADE
associated O
with O
systemic O
tissue B-DRUG
plasminogen I-DRUG
activator I-DRUG
. O

Vancomycin B-DRUG
- O
induced O
vasculitis B-ADE
. O

This O
report O
rules O
out O
other O
causes O
of O
toxic B-ADE
epidermal I-ADE
necrolysis I-ADE
and O
implicates O
ofloxacin B-DRUG
in O
what O
appears O
to O
be O
an O
atypical O
presentation O
of O
drug O
- O
induced O
toxic B-ADE
epidermal I-ADE
necrolysis I-ADE
. O

However O
, O
because O
diphenhydramine B-DRUG
also O
exhibits O
type O
IA O
sodium O
channel O
blockade O
, O
cardiac B-ADE
toxicity I-ADE
is O
also O
possible O
. O

Physicians O
should O
be O
aware O
of O
the O
risk O
of O
severe O
AIHA B-ADE
in O
CLL O
patients O
with O
a O
history O
of O
AIHA B-ADE
or O
positivation B-ADE
of I-ADE
the I-ADE
DAT I-ADE
during O
previous O
fludarabine B-DRUG
administration O
, O
or O
in O
case O
of O
secondary O
fixation O
of O
complement O
to O
the O
red O
cell O
membrane O
occurring O
during O
fludarabine B-DRUG
treatment O
. O

CONCLUSION O
: O
The O
present O
findings O
suggest O
that O
fluvoxamine B-DRUG
can O
cause O
increased B-ADE
libido I-ADE
in O
some O
patients O
. O

Hypokalemia B-ADE
after O
normal O
doses O
of O
neubulized O
albuterol B-DRUG
( O
salbutamol B-DRUG
) O
. O

This O
case O
presentation O
is O
of O
a O
patient O
who O
had O
the O
clinical O
appearance O
of O
epiglottitis B-ADE
, O
but O
actually O
had O
an O
oro B-ADE
- I-ADE
pharyngeal I-ADE
dystonic I-ADE
reaction I-ADE
to O
prochlorperazine B-DRUG
. O

We O
describe O
the O
first O
case O
of O
disseminated B-ADE
salmonellosis I-ADE
in O
a O
patient O
treated O
with O
temozolomide B-DRUG
. O

This O
report O
presents O
a O
potential O
case O
of O
risperidone B-DRUG
- O
induced O
tardive B-ADE
dyskinesia I-ADE
. O

We O
report O
a O
girl O
with O
the O
Rett O
syndrome O
who O
had O
acute B-ADE
encephalopathy I-ADE
probably O
induced O
by O
calcium B-DRUG
hopantenate I-DRUG
( O
HOPA B-DRUG
) O
. O

Fulminant B-ADE
hepatitis I-ADE
associated O
with O
disulfiram B-DRUG
. O

We O
observed O
transient O
panhypogammaglobulinaemia B-ADE
in O
a O
patient O
with O
neuropsychiatric O
SLE O
after O
treatment O
with O
prednisolone B-DRUG
and O
cyclophosphamide B-DRUG
. O

Severe B-ADE
acute I-ADE
encephalopathy I-ADE
following O
inadvertent O
intrathecal O
doxorubicin B-DRUG
administration O
. O

Massive O
prolapse B-ADE
of I-ADE
the I-ADE
urethral I-ADE
mucosa I-ADE
following O
periurethral O
injection O
of O
calcium B-DRUG
hydroxylapatite I-DRUG
for O
stress O
urinary O
incontinence O
. O

A O
drug B-ADE
interaction I-ADE
between O
zafirlukast B-DRUG
and O
theophylline B-DRUG
. O

Pulmonary B-ADE
toxicity I-ADE
secondary O
to O
procarbazine B-DRUG
. O

CONCLUSIONS O
: O
This O
observation O
of O
" O
on O
- O
off O
" O
risperidone B-DRUG
treatment O
suggests O
that O
risperidone B-DRUG
may O
have O
worsened O
both O
psychiatric B-ADE
and I-ADE
physical I-ADE
manifestations I-ADE
of O
the O
mitochondrial O
disorder O
in O
this O
adolescent O
. O

Zolpidem B-DRUG
tissue O
concentrations O
in O
a O
multiple O
drug O
related O
death B-ADE
involving O
Ambien B-DRUG
. O

Since O
the O
thrombocyte B-ADE
count I-ADE
started I-ADE
to I-ADE
increase I-ADE
immediately O
after O
initiation O
and O
dropped O
immediately O
after O
discontinuation O
of O
ciprofloxacin B-DRUG
and O
tazobactam B-DRUG
/ O
piperacillin B-DRUG
and O
all O
other O
drugs O
were O
discontinued O
already O
before O
or O
were O
started O
after O
the O
nadir O
of O
the O
thrombocyte O
count O
, O
these O
two O
antibiotics O
were O
regarded O
causative O
. O

New O
onset O
of O
Crohn B-ADE
's I-ADE
disease I-ADE
during O
treatment O
of O
active O
ankylosing O
spondylitis O
with O
etanercept B-DRUG
. O

We O
report O
an O
82-year O
- O
old O
man O
who O
developed O
ventricular B-ADE
tachycardia I-ADE
and O
Torsades B-ADE
de I-ADE
Pointes I-ADE
( O
TdP B-ADE
) O
after O
oral O
administration O
of O
garenoxacin B-DRUG
, O
a O
novel O
quinolone O
antibiotic O
agent O
that O
differs O
from O
the O
third O
- O
generation O
quinolones O
, O
for O
pneumonia O
. O

While O
40 O
mg O
/ O
day O
of O
prednisolone B-DRUG
improved O
hepatic O
dysfunction O
dramatically O
, O
her O
diabetic B-ADE
milieu I-ADE
deteriorated I-ADE
seriously O
. O

The O
potential O
development O
of O
SJS B-ADE
/ O
TEN B-ADE
, O
a O
severe O
life O
- O
threatening O
illness O
, O
emphasizes O
the O
need O
for O
judicious O
use O
of O
TMP B-DRUG
- I-DRUG
Sx I-DRUG
and O
close O
monitoring O
and O
follow O
- O
up O
for O
patients O
who O
were O
given O
TMP O
- O
Sx O
for O
SSTIs O
. O

We O
present O
a O
case O
of O
hemolytic B-ADE
- I-ADE
uremic I-ADE
syndrome I-ADE
that O
developed O
during O
the O
4th O
cycle O
of O
combination O
chemotherapy O
with O
oxaliplatin B-DRUG
, O
5-fluorouracil B-DRUG
and O
leucovorin B-DRUG
. O

Interestingly O
, O
the O
use O
of O
carboplatin O
( O
CBDCA O
) O
and O
VDS O
in O
the O
subsequent O
treatment O
course O
was O
well O
tolerated O
indicating O
that O
the O
SIADH B-ADE
was O
most O
likely O
to O
have O
been O
induced O
by O
administration O
of O
CDDP B-DRUG
. O

We O
present O
two O
cases O
of O
nitrofurantoin B-DRUG
- O
induced O
pulmonary B-ADE
toxicity I-ADE
in O
which O
the O
initial O
HRCT O
showed O
a O
widespread B-ADE
reticular I-ADE
pattern I-ADE
and O
associated O
distortion B-ADE
of I-ADE
the I-ADE
lung I-ADE
parenchyma I-ADE
, O
thought O
to O
represent O
established O
fibrosis B-ADE
. O

Two O
cases O
of O
hypothyroidism B-ADE
in O
patients O
with O
chronic O
hepatitis O
C O
treated O
with O
recombinant B-DRUG
alpha I-DRUG
interferon I-DRUG
are O
reported O
. O

Clinicians O
have O
been O
aware O
of O
lithium B-DRUG
toxicity I-ADE
for O
many O
years O
and O
traditionally O
have O
administered O
thiazide O
diuretics O
for O
lithium B-DRUG
- O
induced O
polyuria B-ADE
and O
nephrogenic B-ADE
diabetes I-ADE
insipidus I-ADE
. O

Mesalamine B-DRUG
- O
induced O
hypersensitivity B-ADE
pneumonitis I-ADE
. O

Psychotic B-ADE
disorder I-ADE
associated O
with O
isoniazid B-DRUG
. O

Dyspnea B-ADE
, O
hypoxemia B-ADE
, O
and O
pleuritic B-ADE
chest I-ADE
pain I-ADE
occurred O
within O
24 O
hours O
of O
rituximab B-DRUG
administration O
, O
and O
there O
was O
no O
other O
apparent O
explanation O
. O

Patient O
1 O
presented O
bilateral B-ADE
ballism I-ADE
1 O
week O
after O
intravenous O
heroin B-DRUG
injection O
. O

Therapy O
with O
IFN B-DRUG
- I-DRUG
alpha I-DRUG
may O
be O
associated O
with O
a O
number O
of O
neuropsychiatric B-ADE
symptoms I-ADE
, O
such O
as O
Parkinsonism B-ADE
, O
akathisia B-ADE
, O
seizure B-ADE
, O
and O
depressive B-ADE
disorders I-ADE
. O

Emphasis O
is O
given O
to O
the O
differentiation O
of O
diphenylhydantoin B-DRUG
induced O
gingival B-ADE
hyperplasia I-ADE
from O
the O
angiomatous O
enlargement O
of O
the O
gingiva O
before O
any O
treatment O
is O
planned O
. O

Camptocormia B-ADE
, O
a O
new O
side O
effect O
of O
sodium B-DRUG
valproate I-DRUG
. O

Toxic B-ADE
hepatitis I-ADE
induced O
by O
disulfiram B-DRUG
in O
a O
non O
- O
alcoholic O
. O

Renal B-ADE
hypophosphatemia I-ADE
in O
this O
patient O
was O
caused O
by O
the O
erroneous O
intake O
of O
1 O
g O
doxycycline B-DRUG
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
angioedema B-ADE
associated O
with O
losartan B-DRUG
administration O
. O

A O
53-year O
- O
old O
man O
developed O
lower B-ADE
leg I-ADE
edema I-ADE
4 O
weeks O
after O
rosiglitazone B-DRUG
was O
increased O
from O
4 O
mg O
once O
/ O
day O
to O
4 O
mg O
twice O
/ O
day O
. O

A O
patient O
developed O
optic B-ADE
neuropathy I-ADE
while O
being O
treated O
with O
isoniazid B-DRUG
and O
ethambutol B-DRUG
. O

It O
occasionally O
accompanies O
the O
heparin B-DRUG
- O
associated O
thrombocytopenia B-ADE
and O
thrombosis B-ADE
syndrome I-ADE
. O

Acute B-ADE
renal I-ADE
failure I-ADE
during O
lisinopril B-DRUG
and O
losartan B-DRUG
therapy O
for O
proteinuria O
. O

After O
therapy O
for O
diabetic O
coma O
with O
insulin B-DRUG
( O
containing O
the O
preservative O
cresol B-DRUG
) O
and O
electrolyte O
solutions O
was O
started O
, O
the O
patient O
complained O
of O
increasing B-ADE
myalgia I-ADE
, O
developed O
a O
high B-ADE
fever I-ADE
and O
respiratory B-ADE
and I-ADE
metabolic I-ADE
acidosis I-ADE
and O
lost B-ADE
consciousness I-ADE
. O

A O
woman O
38-year O
- O
old O
, O
suffering O
for O
about O
ten O
years O
from O
multiple O
sclerosis O
and O
treated O
with O
repeated O
therapy O
cycles O
of O
intrathecal O
Depo B-DRUG
- I-DRUG
Medrol I-DRUG
, O
developed O
a O
spastic B-ADE
paraparesis I-ADE
at I-ADE
the I-ADE
lower I-ADE
limbs I-ADE
. O

Magnesium B-DRUG
toxicosis I-ADE
in O
two O
horses O
. O

A O
50-year O
- O
old O
woman O
with O
a O
history O
of O
migraine O
without O
aura O
, O
predominantly O
occurring O
around O
her O
menstrual O
periods O
, O
developed O
a O
spinal B-ADE
cord I-ADE
lesion I-ADE
following O
the O
use O
of O
zolmitriptan B-DRUG
. O

CASE O
SUMMARY O
: O
A O
68-year O
- O
old O
woman O
developed O
a O
dry O
, O
irritating B-ADE
cough I-ADE
within O
one O
month O
of O
starting O
quinapril B-DRUG
therapy O
for O
the O
treatment O
of O
essential O
hypertension O
. O

RESULTS O
: O
All O
cases O
developed O
corneal B-ADE
endothelial I-ADE
deposits I-ADE
after O
previous O
use O
of O
rifabutin B-DRUG
. O

CONCLUSIONS O
: O
Topical O
brimonidine B-DRUG
may O
be O
associated O
with O
central B-ADE
nervous I-ADE
system I-ADE
depression I-ADE
in O
infants O
. O

The O
authors O
think O
that O
although O
lamivudine B-DRUG
is O
widely O
used O
and O
well O
tolerated O
, O
it O
can O
cause O
ADRs B-ADE
, O
which O
are O
reversible O
after O
drug O
withdrawal O
. O

Most O
cases O
of O
pancreatitis B-ADE
associated O
with O
L B-DRUG
- I-DRUG
asparaginase I-DRUG
toxicity O
are O
self O
- O
limiting O
and O
respond O
favorably O
to O
nasogastric O
decompression O
and O
intravenous O
hyperalimentation O
. O

Hair B-ADE
loss I-ADE
associated O
with O
paroxetine B-DRUG
treatment O
: O
a O
case O
report O
. O

Seizures B-ADE
associated O
with O
ofloxacin B-DRUG
therapy O
. O

Histopathology O
of O
the O
thyroid O
in O
amiodarone B-DRUG
- O
induced O
hypothyroidism B-ADE
. O

We O
present O
the O
case O
of O
a O
patient O
who O
had O
undergone O
cholecystectomy O
previously O
, O
but O
in O
whom O
morphine B-DRUG
given O
in O
the O
Emergency O
Department O
precipitated O
pain B-ADE
consistent O
with O
biliary B-ADE
colic I-ADE
; O
the O
pain O
resolved O
promptly O
after O
administration O
of O
naloxone O
. O

We O
report O
AZA B-DRUG
- O
induced O
drug B-ADE
eruption I-ADE
that O
developed O
in O
two O
cases O
of O
systemic O
scleroderma O
with O
polymyositis O
. O

Fatal B-ADE
pulmonary I-ADE
fibrosis I-ADE
induced O
by O
paclitaxel B-DRUG
: O
a O
case O
report O
and O
review O
of O
the O
literature O
. O

Does O
the O
use O
of O
insulin B-DRUG
in O
a O
patient O
with O
liver O
dysfunction O
increase O
water O
retention O
in O
the O
body O
, O
i.e. O
cause O
insulin O
oedema B-ADE
? O

Three O
patients O
who O
had O
experienced O
neuroleptic O
- O
induced O
akathisia O
in O
the O
past O
reported O
that O
the O
symptoms O
of O
fluoxetine B-DRUG
- O
induced O
akathisia B-ADE
were O
identical O
, O
although O
somewhat O
milder O
. O

Fulminant B-ADE
hepatic I-ADE
failure I-ADE
developed O
in O
a O
24-year O
- O
old O
black O
woman O
who O
had O
been O
treated O
with O
propylthiouracil B-DRUG
and O
propranolol B-DRUG
for O
hyperthyroidism O
. O

This O
article O
describes O
the O
case O
of O
a O
25-year O
- O
old O
man O
found O
dead B-ADE
at O
home O
who O
had O
been O
prescribed O
olanzapine B-DRUG
for O
schizophrenia O
. O

This O
is O
the O
second O
report O
of O
acute B-ADE
lung I-ADE
injury I-ADE
and O
diffuse B-ADE
alveolar I-ADE
damage I-ADE
caused O
by O
mefloquine B-DRUG
. O

We O
present O
a O
case O
of O
significant O
over B-ADE
- I-ADE
anticoagulation I-ADE
temporally O
associated O
with O
a O
bout O
of O
protracted O
diarrhea B-ADE
in O
a O
patient O
on O
warfarin B-DRUG
therapy O
. O

Peripheral B-ADE
nervous I-ADE
system I-ADE
disturbances I-ADE
caused O
by O
cytosine B-DRUG
arabinoside I-DRUG
have O
rarely O
been O
reported O
. O

Shortly O
after O
chemotherapy O
and O
an O
injection O
of O
pegfilgrastim B-DRUG
, O
the O
patient O
developed O
poorly O
defined O
, O
rapidly B-ADE
progressive I-ADE
erythema I-ADE
, O
edema B-ADE
, O
and O
pain B-ADE
in I-ADE
his I-ADE
right I-ADE
forearm I-ADE
. O

Fludarabine B-DRUG
induced O
lung B-ADE
toxicity I-ADE
must O
be O
considered O
in O
all O
patients O
who O
develop O
unexplained O
lung B-ADE
disease I-ADE
while O
receiving O
fludarabine B-DRUG
. O

However O
, O
there O
remain O
questions O
concerning O
whether O
these O
drugs O
, O
especially O
methimazole B-DRUG
( O
MMI B-DRUG
) O
, O
may O
be O
associated O
with O
aplasia B-ADE
cutis I-ADE
congenita I-ADE
( O
ACC B-ADE
) O
and O
how O
best O
to O
avoid O
impairment O
of O
fetal O
thyroid O
function O
during O
their O
use O
. O

Recurrent B-ADE
hyponatremia I-ADE
associated O
with O
citalopram B-DRUG
and O
mirtazapine B-DRUG
. O

Red B-ADE
blood I-ADE
cell I-ADE
anemia I-ADE
in O
a O
patient O
with O
pemphigus O
vulgaris O
induced O
by O
the O
use O
of O
mycophenolate B-DRUG
mofetil I-DRUG
and O
prednisone B-DRUG
. O

Sensorineural B-ADE
hearing I-ADE
loss I-ADE
due O
to O
quinine B-DRUG
therapy O
for O
malaria O
has O
frequently O
been O
mentioned O
in O
the O
literature O
but O
has O
not O
been O
a O
subject O
of O
research O
during O
the O
last O
decades O
. O

Phenylpropanolamine B-DRUG
( O
PPA B-DRUG
) O
recently O
has O
been O
publicly O
implicated O
as O
a O
cause O
of O
stroke B-ADE
and O
other O
neurologic B-ADE
events I-ADE
. O

This O
is O
the O
first O
case O
, O
to O
our O
knowledge O
, O
of O
onset O
of O
prolonged O
infliximab B-DRUG
- O
induced O
lupus B-ADE
. O

Adrenal B-ADE
suppression I-ADE
in I-ADE
a I-ADE
fetus I-ADE
due O
to O
administration O
of O
methylprednisolone B-DRUG
has O
hitherto O
been O
rarely O
published O
. O

Regardless O
of O
a O
negative O
history O
of O
asthma O
, O
therefore O
, O
life O
- O
threatening O
bronchospasm B-ADE
must O
be O
considered O
a O
possible O
complication O
of O
propranolol B-DRUG
therapy O
. O

CONCLUSION O
: O
Healthcare O
professionals O
should O
be O
aware O
of O
the O
possible O
development O
of O
serotonin B-ADE
syndrome I-ADE
as O
a O
complication O
of O
initiation O
of O
fentanyl B-DRUG
and O
other O
phenylpiperidine O
opioids O
in O
patients O
treated O
with O
SSRIs O
. O

Oesophageal B-ADE
ulceration I-ADE
due O
to O
emepronium B-DRUG
bromide I-DRUG
. O

After O
3- O
to O
13-month O
period O
of O
therapy O
without O
indapamide B-DRUG
, O
glucose O
levels O
of O
all O
patients O
decreased O
and O
diabetes B-ADE
disappeared O
. O

Increased O
awareness O
is O
needed O
on O
the O
possible O
occurrence O
of O
LPD B-ADE
resembling O
gastric O
cancer O
in O
rheumatoid O
arthritis O
patients O
treated O
with O
MTX B-DRUG
. O

The O
condition O
should O
be O
suspected O
in O
patients O
who O
develop O
unexplained O
abdominal B-ADE
pain I-ADE
or O
collapse B-ADE
following O
vasopressin B-DRUG
treatment O
. O

It O
is O
very O
likely O
that O
the O
dexamethasone B-DRUG
used O
in O
the O
antiemetic O
drug O
regimen O
contributed O
to O
the O
development O
of O
osteonecrosis B-ADE
in O
these O
patients O
. O

Angioedema B-ADE
, O
a O
rare O
side O
effect O
of O
carbamazepine B-DRUG
, O
involves O
vascular O
leakage O
in O
dermis O
and O
subcutis O
mediated O
by O
immunoglobulin O
E O
and/or O
bradykinins O
. O

We O
describe O
a O
patient O
with O
acute O
myeloblastic O
leukemia O
( O
AML O
) O
who O
developed O
nephrotic B-ADE
syndrome I-ADE
after O
receiving O
several O
courses O
of O
chemotherapy O
, O
including O
macrophage B-DRUG
- I-DRUG
colony I-DRUG
- I-DRUG
stimulating I-DRUG
factor I-DRUG
( O
M B-DRUG
- I-DRUG
CSF I-DRUG
) O
. O

OBJECTIVE O
: O
To O
describe O
a O
case O
of O
exacerbated O
mania B-ADE
potentially O
related O
to O
an O
interaction O
between O
lopinavir B-DRUG
/ O
ritonavir B-DRUG
and O
valproic B-DRUG
acid I-DRUG
( O
VPA B-DRUG
) O
and O
propose O
a O
mechanism O
of O
action O
for O
this O
interaction O
. O

These O
cases O
demonstrate O
that O
CBZ B-DRUG
can O
induce O
simple O
motor B-ADE
tics I-ADE
in O
children O
. O

Cyclophosphamide B-DRUG
pneumonitis B-ADE
. O

This O
report O
describes O
a O
case O
of O
acute O
compromise O
of O
renal O
function O
associated O
with O
hypotension B-ADE
in O
a O
7-year O
- O
old O
boy O
treated O
with O
the O
ACE O
inhibitor O
lisinopril B-DRUG
and O
the O
ARB O
losartan B-DRUG
. O

Pulmonary B-ADE
lymphohistiocytic I-ADE
reactions I-ADE
temporally O
related O
to O
etanercept B-DRUG
therapy O
. O

Pseudomembranous B-ADE
colitis I-ADE
readily O
occurs O
in O
at O
least O
certain O
population O
groups O
receiving O
trimethoprim B-DRUG
- O
sulfamethoxazole B-DRUG
. O

Case O
2 O
, O
a O
29-year O
- O
old O
woman O
, O
developed O
bilateral B-ADE
optic I-ADE
neuritis I-ADE
combined O
with O
numbness B-ADE
of I-ADE
the I-ADE
lower I-ADE
extremities I-ADE
as O
well O
as O
bowel B-ADE
and I-ADE
bladder I-ADE
dysfunction I-ADE
after O
a O
22-month O
use O
of O
recombinant B-DRUG
interferon I-DRUG
alpha-2b I-DRUG
for O
chronic O
myelogenous O
leukemia O
. O

We O
believe O
that O
the O
acute B-ADE
renal I-ADE
failure I-ADE
in O
our O
patient O
was O
associated O
with O
anastrozole B-DRUG
. O

CONCLUSION O
: O
The O
results O
suggest O
that O
olanzapine O
may O
be O
useful O
in O
treating O
patients O
with O
clozapine B-DRUG
- O
induced O
granulocytopenia B-ADE
without O
the O
risk O
of O
recurrence O
of O
hematologic O
side O
effects O
. O

A O
case O
is O
reported O
in O
which O
severe B-ADE
hypocalcemia I-ADE
, O
with O
a O
low B-ADE
plasma I-ADE
parathyroid I-ADE
hormone I-ADE
( O
PTH B-ADE
) O
concentration O
, O
resulted O
from O
the O
therapeutic O
use O
of O
magnesium B-DRUG
sulfate I-DRUG
for O
toxemia O
of O
pregnancy O
. O

Renal B-ADE
failure I-ADE
appeared O
8 O
to O
17 O
days O
after O
beginning O
gentamicin B-DRUG
therapy O
and O
was O
characterized O
by O
creatinine O
clearances O
4 O
to O
10 O
ml O
/ O
min O
, O
urine O
to O
plasma O
creatinine O
ratios O
less O
than O
20 O
, O
urinary O
sodium O
concentrations O
16 O
to O
60 O
mEq O
/ O
liter O
, O
proteinuria O
, O
and O
cylindruria O
. O

Cis B-DRUG
- I-DRUG
retinoic I-DRUG
acid I-DRUG
( O
RA B-DRUG
) O
may O
further O
increase O
the O
risk O
of O
developing O
BMTN B-ADE
. O

CONCLUSION O
: O
Anterior B-ADE
ischemic I-ADE
optic I-ADE
neuropathy I-ADE
may O
complicate O
treatment O
with O
interferon B-DRUG
alfa I-DRUG
. O

Optic B-ADE
neuropathy I-ADE
associated O
with O
penicillamine B-DRUG
therapy O
in O
a O
patient O
with O
rheumatoid O
arthritis O
. O

Multiple B-ADE
seizures I-ADE
after O
bupropion B-DRUG
overdose O
in O
a O
small O
child O
. O

Reversal O
of O
gold B-DRUG
- O
induced O
neutropenia B-ADE
with O
granulocyte O
colony O
- O
stimulating O
factor O
( O
G O
- O
CSF O
) O
. O

The O
electrocardiogram O
( O
ECG O
) O
, O
which O
was O
read O
as O
normal O
prior O
to O
ritodrine B-DRUG
infusion O
, O
demonstrated O
a O
type B-ADE
I I-ADE
second I-ADE
- I-ADE
degree I-ADE
AV I-ADE
block I-ADE
which O
disappeared O
upon O
discontinuation O
of O
ritodrine B-DRUG
therapy O
. O

In O
this O
report O
, O
two O
newborns O
with O
congenital O
heart O
anomalies O
demonstrated O
the O
harlequin B-ADE
color I-ADE
change I-ADE
, O
one O
whose O
skin O
findings O
showed O
a O
course O
related O
to O
the O
dose O
of O
systemic O
prostaglandin B-DRUG
E1 I-DRUG
, O
suggesting O
a O
possible O
association O
. O

Diffuse B-ADE
alveolar I-ADE
hemorrhage I-ADE
after O
leflunomide B-DRUG
therapy O
in O
a O
patient O
with O
rheumatoid O
arthritis O
. O

The O
aim O
of O
this O
report O
is O
to O
describe O
the O
clinical O
and O
electroencephalographic O
findings O
seen O
in O
an O
elderly O
woman O
without O
previous O
history O
of O
seizures O
who O
developed O
a O
nonconvulsive B-ADE
generalized I-ADE
status I-ADE
epilepticus I-ADE
following O
acute O
withdrawal O
of O
lorazepam B-DRUG
. O

Psychosis B-ADE
in O
a O
12-year O
- O
old O
HIV O
- O
positive O
girl O
with O
an O
increased O
serum O
concentration O
of O
efavirenz B-DRUG
. O

A O
case O
of O
SIADH B-ADE
induced O
by O
mizoribin B-DRUG
administration O
. O

After O
three O
weeks O
of O
carbamazepine B-DRUG
therapy O
, O
the O
patient O
arrived O
at O
the O
emergency O
department O
( O
ED O
) O
with O
severe B-ADE
agitation I-ADE
and O
aggressive B-ADE
behavior I-ADE
. O

Thrombotic B-ADE
thrombocytopenic I-ADE
purpura I-ADE
( O
TTP B-ADE
) O
developed O
in O
a O
patient O
with O
seropositive O
rheumatoid O
arthritis O
( O
RA O
) O
after O
2 O
1/2 O
months O
of O
treatment O
with O
penicillamine B-DRUG
. O

Sulfadiazine B-DRUG
crystalluria B-ADE
revisited O
. O

Ritonavir B-DRUG
should O
be O
added O
to O
the O
list O
of O
drugs O
that O
can O
induce O
adverse B-ADE
cutaneous I-ADE
reactions I-ADE
in O
HIV O
patients O
. O

Photo B-ADE
- I-ADE
onycholysis I-ADE
caused O
by O
olanzapine B-DRUG
and O
aripiprazole B-DRUG
. O

The O
first O
patient O
developed O
mild B-ADE
nitritoid I-ADE
symptoms I-ADE
and O
pain B-ADE
in O
a O
band O
- O
like O
distribution O
, O
corresponding O
to O
T10-T12 B-ADE
dermatomes I-ADE
, O
shortly O
after O
gold B-DRUG
sodium I-DRUG
thiomalate I-DRUG
( O
GSTM B-DRUG
) O
injection O
. O

We O
describe O
3 O
cases O
of O
diphenhydramine B-DRUG
- O
induced O
cardiac B-ADE
toxicity I-ADE
that O
were O
responsive O
to O
bicarbonate O
. O

A O
35-year O
- O
old O
man O
with O
seropositive O
rheumatoid O
arthritis O
developed O
selective O
IgA B-ADE
deficiency I-ADE
during O
treatment O
with O
fenclofenac B-DRUG
. O

CONCLUSIONS O
: O
Low O
dosages O
of O
quinacrine B-DRUG
used O
for O
malaria O
prophylaxis O
can O
be O
associated O
with O
a O
delayed O
, O
severe B-ADE
maculopathy I-ADE
indistinguishable O
from O
chloroquine B-DRUG
maculopathy B-ADE
in O
certain O
patients O
. O

Troglitazone B-DRUG
- O
induced O
fulminant B-ADE
hepatic I-ADE
failure I-ADE
. O

Like O
other O
atypical O
neuroleptics O
olanzapine B-DRUG
is O
considered O
to O
show O
a O
reduced O
prevalence O
of O
extrapyramidal B-ADE
side I-ADE
effects I-ADE
when O
compared O
to O
classical O
neuroleptic O
drugs O
. O

Successful O
challenge O
with O
clozapine B-DRUG
in O
a O
history O
of O
eosinophilia B-ADE
. O

We O
report O
the O
case O
of O
an O
11-month O
- O
old O
female O
infant O
with O
a O
depressed B-ADE
level I-ADE
of I-ADE
consciousness I-ADE
after O
ingestion O
of O
ibuprofen B-DRUG
whose O
mental O
status O
markedly O
improved O
with O
administration O
of O
naloxone O
. O

We O
report O
a O
case O
of O
recurrent O
torsades B-ADE
de I-ADE
pointes I-ADE
following O
treatment O
with O
pentavalent O
antimonial O
drugs O
and O
amiodarone B-DRUG
. O

The O
favourable O
outcome O
in O
these O
two O
patients O
contrasts O
with O
the O
fatal B-ADE
outcome I-ADE
of O
the O
two O
other O
reported O
cases O
of O
nitrofurantoin B-ADE
induced I-ADE
BOOP I-ADE
. O

Pemphigus B-ADE
foliaceus I-ADE
induced O
by O
rifampicin B-DRUG
. O

However O
, O
a O
recent O
post O
- O
marketing O
survey O
in O
Japan O
revealed O
that O
interstitial B-ADE
pneumonia I-ADE
occurred O
in O
4 O
among O
approximately O
2 O
000 O
Japanese O
patients O
treated O
with O
sorafenib B-DRUG
. O

We O
report O
a O
case O
of O
RTA B-ADE
secondary O
to O
FK506 B-DRUG
administration O
in O
liver O
transplantation O
. O

RESULTS O
: O
A O
clinical O
diagnosis O
of O
fixed B-ADE
drug I-ADE
eruption I-ADE
owing O
to O
use O
of O
the O
PDE5 O
inhibitor O
tadalafil B-DRUG
( O
Cialis B-DRUG
) O
was O
made O
. O

SUBSEQUENT O
COURSE O
: O
The O
nephrosis B-ADE
resolved O
almost O
completely O
once O
the O
interferon B-DRUG
was O
stopped O
and O
after O
immunosuppressive O
treatment O
. O

OBJECTIVE O
: O
To O
describe O
a O
case O
of O
severe O
skin B-ADE
necrosis I-ADE
resulting O
from O
peripheral O
intravenous O
administration O
of O
low O
- O
dose O
vasopressin B-DRUG
in O
a O
patient O
with O
catecholamine O
- O
resistant O
septic O
shock O
. O

Sudden B-ADE
death I-ADE
in O
an O
infant O
from O
methemoglobinemia O
after O
administration O
of O
" O
sweet B-DRUG
spirits I-DRUG
of I-DRUG
nitre I-DRUG
" O
. O

A O
case O
is O
reported O
of O
an O
elderly O
woman O
who O
developed O
febrile B-ADE
agranulocytosis I-ADE
several O
weeks O
after O
commencing O
ticlopidine B-DRUG
but O
who O
had O
a O
favorable O
outcome O
after O
cessation O
of O
that O
drug O
and O
treatment O
with O
filgastrim O
. O

A O
case O
of O
pyridoxine B-DRUG
- O
dependent O
seizures B-ADE
is O
reported O
. O

Optic B-ADE
neuropathy I-ADE
developed O
in O
a O
patient O
with O
rheumatoid O
arthritis O
who O
had O
been O
receiving O
D B-DRUG
- I-DRUG
penicillamine I-DRUG
for O
about O
1 O
year O
. O

Only O
after O
three O
subsequent O
episodes O
of O
severe O
, O
symptomatic O
thrombocytopenia B-ADE
over O
the O
next O
four O
weeks O
did O
he O
say O
, O
upon O
repeat O
questioning O
, O
that O
he O
had O
continued O
to O
take O
quinine B-DRUG
for O
night O
leg O
cramps O
. O

Three O
patients O
received O
respectively O
190 O
mg O
, O
175 O
mg O
, O
and O
196 O
mg O
of O
methotrexate B-DRUG
and O
developed O
bilateral B-ADE
pulmonary I-ADE
infiltrates I-ADE
without O
evidence O
of O
peripheral O
blood O
eosinophilia O
. O

High O
- O
dose O
methylprednisolone B-DRUG
in O
a O
pregnant O
woman O
with O
Crohn O
's O
disease O
and O
adrenal B-ADE
suppression I-ADE
in O
her O
newborn O
. O

Selective O
estrogen O
receptor O
modulator O
raloxifene B-DRUG
- O
associated O
aggravation B-ADE
of I-ADE
nonalcoholic I-ADE
steatohepatitis I-ADE
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
severe B-ADE
apnea I-ADE
in O
an O
infant O
exposed O
to O
lamotrigine B-DRUG
through O
breast O
- O
feeding O
. O

Severe B-ADE
diffuse I-ADE
interstitial I-ADE
pneumonitis I-ADE
induced O
by O
carmustine B-DRUG
( O
BCNU B-DRUG
) O
. O

According O
to O
the O
Naranjo O
adverse O
drug O
reaction O
probability O
scale O
, O
tigecycline B-DRUG
was O
the O
probable O
cause O
of O
her O
acute B-ADE
pancreatitis I-ADE
. O

Surgeons O
and O
physicians O
should O
therefore O
be O
aware O
of O
the O
potential O
for O
RTA B-ADE
to O
occur O
with O
FK506 B-DRUG
after O
any O
organ O
transplantation O
. O

The O
case O
of O
a O
patient O
with O
infectious O
mononucleosis O
treated O
with O
cephalexin B-DRUG
who O
later O
showed O
a O
rash B-ADE
is O
presented O
and O
the O
previous O
literature O
is O
reviewed O
. O

The O
time O
course O
of O
events O
suggested O
that O
amphotericin B-DRUG
B I-DRUG
was O
the O
cause O
of O
the O
seizures B-ADE
in O
this O
AIDS O
patient O
. O

One O
explanation O
for O
the O
noted O
increase B-ADE
in I-ADE
the I-ADE
theophylline B-DRUG
level I-ADE
is O
that O
metabolism O
occurs O
mainly O
by O
cytochrome O
P450 O
( O
CYP O
1A2 O
) O
, O
an O
enzyme O
that O
is O
known O
to O
be O
inhibited O
with O
high O
concentrations O
of O
zafirlukast B-DRUG
. O

A O
study O
of O
in O
vitro O
reactivity O
to O
L O
- O
T4 O
, O
as O
assessed O
by O
peripheral O
blood O
lymphocyte O
transformation O
, O
was O
carried O
out O
in O
a O
patient O
with O
Hashimoto O
's O
disease O
who O
developed O
leukopenia B-ADE
during O
treatment O
with O
L B-DRUG
- I-DRUG
T4 I-DRUG
. O

We O
report O
the O
case O
of O
intoxication B-ADE
of O
a O
41-year O
- O
old O
female O
patient O
suffering O
from O
major O
depression O
with O
mirtazapine B-DRUG
complicated O
by O
severe O
hypothermia O
. O

These O
evolutional O
changes O
in O
both O
proteinuria O
and O
glomerular O
histology O
suggest O
a O
close O
linkage O
between O
the O
M B-DRUG
- I-DRUG
CSF I-DRUG
treatment O
and O
macrophage B-ADE
- I-ADE
related I-ADE
glomerular I-ADE
injury I-ADE
. O

Asthenozoospermia B-ADE
: O
possible O
association O
with O
long O
- O
term O
exposure O
to O
an O
anti O
- O
epileptic O
drug O
of O
carbamazepine B-DRUG
. O

A O
study O
following O
large O
patient O
groups O
on O
theophylline B-DRUG
and O
a O
combination O
of O
theophylline B-DRUG
and O
steroids O
might O
clarify O
the O
risk O
of O
ulcer B-ADE
formation O
in O
patients O
being O
treated O
with O
these O
medications O
for O
asthma O
. O

An O
adverse O
reaction O
to O
IFN B-DRUG
was O
strongly O
suspected O
as O
the O
cause O
of O
CHF B-ADE
. O

A O
woman O
developed O
delusional B-ADE
parasitosis I-ADE
when O
taking O
phenelzine B-DRUG
. O

A O
55-year O
- O
old O
woman O
developed O
symptoms O
suggestive O
of O
hepatitis B-ADE
12 O
weeks O
after O
first O
receiving O
methyldopa B-DRUG
for O
hypertension O
. O

We O
report O
4 O
patients O
who O
developed O
symptoms O
of O
myasthenia B-ADE
gravis I-ADE
within O
2 O
weeks O
of O
starting O
treatment O
with O
a O
statin B-DRUG
drug O
. O

A O
31-year O
- O
old O
female O
developed O
multiple O
episodes O
of O
grand B-ADE
mal I-ADE
seizures I-ADE
after O
combination O
chemotherapy O
with O
cisplatin B-DRUG
, O
vinblastine B-DRUG
and O
bleomycin B-DRUG
for O
germ O
cell O
ovarian O
cancer O
stage O
Ic O
. O

Toxic B-ADE
epidermal I-ADE
necrolysis I-ADE
associated O
with O
interleukin-2 B-DRUG
. O

A O
57-year O
- O
old O
woman O
developed O
pulmonary B-ADE
sarcoidosis I-ADE
during O
therapy O
with O
interferon B-DRUG
beta I-DRUG
for O
advanced O
renal O
cell O
carcinoma O
metastatic O
to O
mediastinal O
lymph O
nodes O
. O

Both O
PAN B-DRUG
and O
methotrexate B-DRUG
have O
been O
independently O
demonstrated O
to O
cause O
sensorineural B-ADE
hearing I-ADE
loss I-ADE
. O

Acute O
INH B-DRUG
neurotoxicity B-ADE
was O
not O
suspected O
on O
the O
first O
admission O
; O
however O
, O
when O
readmitted O
4 O
weeks O
later O
with O
another O
seizure O
, O
the O
diagnosis O
of O
acute O
INH B-DRUG
neurotoxicity B-ADE
was O
made O
. O

The O
cough B-ADE
continued O
for O
the O
duration O
of O
therapy O
with O
quinapril B-DRUG
. O

Captopril B-DRUG
is O
an O
angiotensin O
- O
converting O
enzyme O
( O
ACE O
) O
inhibitor O
and O
their O
cutaneous B-ADE
side I-ADE
- I-ADE
effects I-ADE
are O
documented O
, O
but O
little O
has O
been O
published O
concerning O
the O
usefulness O
of O
patch O
test O
when O
they O
occur O
. O

Clinicians O
who O
manage O
cachectic O
patients O
, O
particularly O
those O
with O
protracted O
diarrhoea O
and/or O
receiving O
anti O
- O
malarial O
drugs O
including O
mefloquine B-DRUG
, O
should O
be O
aware O
of O
the O
risk O
of O
severe B-ADE
hypoglycaemia I-ADE
. O

This O
is O
the O
first O
reported O
case O
of O
suspected O
DIAN B-ADE
due O
to O
cefuroxime B-DRUG
. O

An O
infant O
who O
developed O
pancreatitis B-ADE
during O
meglumine B-DRUG
antimoniate I-DRUG
treatment O
for O
visceral O
leishmaniasis O
and O
who O
was O
successfully O
treated O
with O
a O
combination O
of O
allopurinol O
and O
ketoconazole O
is O
reported O
. O

Multicentric B-ADE
hepatocellular I-ADE
carcinoma I-ADE
following O
phosphate B-DRUG
diethylstilbestrol I-DRUG
therapy O
for O
prostatic O
cancer O
. O

Protease O
inhibitors O
( O
ritonavir B-DRUG
and O
saquinavir B-DRUG
) O
were O
added O
to O
the O
treatment O
and O
the O
patient O
developed O
progressive B-ADE
ataxia I-ADE
related O
to O
carbamazepine B-DRUG
toxicity I-ADE
. O

Hemolytic B-ADE
uremic I-ADE
syndrome I-ADE
following O
the O
infusion O
of O
oxaliplatin B-DRUG
: O
case O
report O
. O

Anaphylactic B-ADE
reaction I-ADE
to O
bacitracin B-DRUG
ointment O
. O

A O
previous O
review O
described O
data O
on O
15 O
patients O
who O
experienced O
acute B-ADE
hemoglobinemia I-ADE
or O
hemoglobinuria B-ADE
following O
anti B-DRUG
- I-DRUG
D I-DRUG
IGIV I-DRUG
administration O
for O
ITP O
or O
secondary O
thrombocytopenia O
. O

Myoclonus B-ADE
was O
induced O
and O
enhanced O
by O
L B-DRUG
- I-DRUG
dopa I-DRUG
, O
developing O
into O
generalized B-ADE
seizures I-ADE
. O

Propoxyphene B-DRUG
- O
induced O
wide B-ADE
QRS I-ADE
complex I-ADE
dysrhythmia I-ADE
responsive O
to O
sodium O
bicarbonate O
-- O
a O
case O
report O
. O

CONCLUSION O
: O
Gemcitabine B-DRUG
- O
induced O
recall B-ADE
pneumonitis I-ADE
is O
a O
rarely O
reported O
phenomenon O
and O
should O
be O
taken O
into O
account O
even O
after O
extended O
time O
interval O
to O
the O
previous O
radiotherapy O
. O

A O
71-year O
- O
old O
man O
with O
paroxysmal O
atrial O
fibrillation O
who O
had O
a O
previous O
anterior O
myocardial O
infarction O
exhibited O
granulocytopenia B-ADE
8 O
days O
following O
the O
administration O
of O
oral O
sustained O
- O
release O
procainamide B-DRUG
( O
750 O
mg O
/ O
day O
) O
. O

Normalization O
of O
generalized O
retinal O
function O
and O
progression O
of O
maculopathy O
after O
cessation O
of O
therapy O
in O
a O
case O
of O
severe O
hydroxychloroquine B-DRUG
retinopathy B-ADE
with O
19 O
years O
follow O
- O
up O
. O

A O
56-year O
- O
old O
male O
parkinsonian O
patient O
developed O
a O
unique O
behavioral B-ADE
change I-ADE
following O
the O
oral O
administration O
of O
cinepazide B-DRUG
, O
a O
cerebral O
vasodilator O
. O

Dose O
- O
dependent O
olanzapine B-DRUG
- O
associated O
leukopenia B-ADE
: O
three O
case O
reports O
. O

Gigantomastia B-ADE
induced O
by O
bucillamine B-DRUG
. O

CASE O
SUMMARY O
: O
A O
25-year O
- O
old O
postpartum O
white O
woman O
developed O
multiple B-ADE
watery I-ADE
stools I-ADE
and O
abdominal B-ADE
cramping I-ADE
on O
day O
6 O
of O
therapy O
with O
clindamycin B-DRUG
vaginal O
cream O
for O
bacterial O
vaginosis O
. O

The O
case O
history O
and O
toxicological O
findings O
of O
an O
infant O
fatality B-ADE
involving O
pseudoephedrine B-DRUG
, O
brompheniramine B-DRUG
, O
and O
dextromethorphan B-DRUG
are O
presented O
. O

Pleuropulmonary B-ADE
fibrosis I-ADE
after O
long O
- O
term O
treatment O
with O
the O
dopamine O
agonist O
pergolide B-DRUG
for O
Parkinson O
Disease O
. O

In O
addition O
to O
the O
recognized O
arrhythmic O
complications O
, O
the O
authors O
emphasize O
myocardial B-ADE
necrosis I-ADE
as O
a O
possible O
further O
manifestation O
of O
amsacrine B-DRUG
- O
related O
cardiotoxicity B-ADE
. O

A O
58-year O
- O
old O
man O
with O
advanced O
renal O
cell O
carcinoma O
developed O
grade O
3 O
proteinuria B-ADE
( O
8.5 O
g/24 O
h O
) O
without O
microscopic O
hematuria O
or O
renal O
insufficiency O
five O
days O
after O
temsirolimus B-DRUG
infusion O
. O

In O
one O
patient O
, O
treatment O
with O
DCA B-DRUG
was O
associated O
with O
a O
decrease B-ADE
in I-ADE
blood I-ADE
lactate I-ADE
levels I-ADE
from O
11.2 O
mM O
before O
treatment O
to O
0.8 O
mM O
16 O
h O
later O
. O

Ovarian B-ADE
endometrioid I-ADE
adenocarcinoma I-ADE
arising O
from O
an O
endometriotic O
cyst O
in O
a O
postmenopausal O
woman O
under O
tamoxifen B-DRUG
therapy O
for O
breast O
cancer O
: O
a O
case O
report O
. O

Isoniazid B-DRUG
- O
induced O
anaphylaxis B-ADE
. O

A O
patient O
with O
rheumatoid O
arthritis O
developed O
an O
acute O
intrahepatic B-ADE
cholestasis I-ADE
after O
100 O
mg O
of O
sodium B-DRUG
aurothiomalate I-DRUG
. O

CONCLUSIONS O
: O
Clinicians O
should O
be O
aware O
of O
this O
adverse O
reaction O
when O
facing O
similar O
complex O
neurologic B-ADE
symptoms I-ADE
in O
patients O
who O
are O
receiving O
the O
antibiotic O
treatment O
described O
here O
, O
especially O
vancomycin B-DRUG
. O

Pellagra B-ADE
encephalopathy I-ADE
among O
tuberculous O
patients O
: O
its O
relation O
to O
isoniazid B-DRUG
therapy O
. O

Two O
patients O
treated O
for O
chronic O
myeloid O
leukemia O
with O
high O
doses O
of O
CCNU B-DRUG
( O
1100 O
mg O
/ O
m2 O
and O
1240 O
mg O
/ O
m2 O
, O
respectively O
) O
developed O
a O
fatal B-ADE
pulmonary I-ADE
fibrosis I-ADE
. O

We O
describe O
a O
continuous O
ambulatory O
peritoneal O
dialysis O
( O
CAPD O
) O
patient O
that O
developed O
vancomycin B-DRUG
- O
induced O
agranulocytosis B-ADE
during O
treatment O
for O
methicillin O
- O
resistant O
Staphylococcus O
aureus O
( O
MRSA O
) O
- O
associated O
external O
cuff O
infection O
and O
pneumonia O
. O

Eosinophilic B-ADE
cystitis I-ADE
after O
bladder O
instillation O
with O
dimethyl B-DRUG
sulfoxide I-DRUG
. O

However O
, O
as O
illustrated O
by O
these O
and O
other O
cases O
reported O
to O
date O
, O
the O
onset O
of O
troglitazone B-DRUG
- O
induced O
liver B-ADE
injury I-ADE
is O
insidious O
and O
temporally O
variable O
. O

It O
is O
concluded O
that O
the O
aforementioned O
pathological O
manifestations O
were O
due O
to O
chemotherapy O
and O
included O
a O
pulmonary B-ADE
adverse I-ADE
reaction I-ADE
, O
a O
feature O
never O
previously O
associated O
with O
oxaliplatinum B-DRUG
and O
5-fluorouracil B-DRUG
regimens O
. O

Intravenous O
administration O
of O
levodopa O
ameliorated O
a O
refractory O
akathisia B-ADE
case O
induced O
by O
interferon B-DRUG
- I-DRUG
alpha I-DRUG
. O

Generalized B-ADE
lichen I-ADE
nitidus I-ADE
with O
involvement O
of O
the O
palms O
following O
interferon B-DRUG
alpha I-DRUG
treatment O
. O

Cough B-ADE
induced O
by O
quinapril B-DRUG
with O
resolution O
after O
changing O
to O
fosinopril O
. O

This O
is O
the O
first O
case O
of O
TMP B-DRUG
- I-DRUG
SMX I-DRUG
- O
induced O
hypersensitivity B-ADE
syndrome I-ADE
associated O
with O
the O
reactivation O
of O
a O
latent O
viral O
infection O
. O

Rifampicin B-DRUG
- O
induced O
renal B-ADE
failure I-ADE
. O

Systemic B-ADE
lupus I-ADE
erythematosus I-ADE
during O
penicillamine B-DRUG
therapy O
for O
rheumatoid O
arthritis O
. O

PURPOSE O
: O
We O
studied O
a O
case O
of O
vortex B-ADE
keratopathy I-ADE
that O
was O
associated O
with O
the O
use O
of O
atovaquone B-DRUG
. O

Acute B-ADE
myopathy I-ADE
with O
selective O
degeneration B-ADE
of I-ADE
myosin I-ADE
filaments I-ADE
following O
status O
asthmaticus O
treated O
with O
methylprednisolone B-DRUG
and O
vecuronium B-DRUG
. O

High B-ADE
- I-ADE
grade I-ADE
endometrial I-ADE
stromal I-ADE
sarcoma I-ADE
after O
tamoxifen B-DRUG
therapy O
for O
breast O
cancer O
. O

CONCLUSIONS O
: O
Anastrozole B-DRUG
may O
be O
the O
causative O
factor O
in O
patients O
with O
sclerosing B-ADE
glomerulonephritis I-ADE
. O

Thrombotic B-ADE
thrombocytopenic I-ADE
purpura I-ADE
induced O
by O
trimethoprim B-DRUG
- O
sulfamethoxazole B-DRUG
in O
a O
Jehovah O
's O
Witness O
. O

We O
report O
the O
first O
case O
of O
IHA B-ADE
associated O
with O
cefuroxime B-DRUG
administration O
. O

Transient B-ADE
asymptomatic I-ADE
bradycardia I-ADE
in O
patients O
on O
infusional O
5-fluorouracil B-DRUG
. O

The O
HIV O
protease O
inhibitor O
indinavir B-DRUG
may O
cause O
nephrolithiasis B-ADE
and O
interstitial B-ADE
nephritis I-ADE
. O

We O
report O
a O
case O
of O
48-year O
- O
old O
woman O
with O
seizure O
disorder O
on O
divalproex B-DRUG
sodium I-DRUG
( O
Depakote B-DRUG
) O
who O
presented O
with O
dyspnea B-ADE
. O

Two O
fatal B-ADE
cases O
of O
poisoning O
by O
paracetamol B-DRUG
are O
described O
. O

The O
clinical O
course O
suggests O
that O
caffeine B-DRUG
, O
which O
is O
present O
in O
oolong O
tea O
, O
was O
mainly O
responsible O
for O
the O
rhabdomyolysis B-ADE
as O
well O
as O
the O
delirium B-ADE
, O
although O
severe O
hyponatremia B-ADE
has O
been O
reported O
to O
cause O
rhabdomyolysis B-ADE
on O
rare O
occasions O
. O

Easily O
reversible O
hypoxemia B-ADE
and O
hypotension B-ADE
induced O
by O
nimodipine B-DRUG
. O

Children O
receiving O
zonisamide B-DRUG
should O
be O
monitored O
for O
oligohidrosis B-ADE
and O
the O
development O
of O
neurological B-ADE
symptoms I-ADE
associated O
with O
an O
elevation O
of O
body O
temperature O
. O

OBJECTIVE O
: O
To O
report O
2 O
cases O
of O
nonconvulsive B-ADE
status I-ADE
epilepticus I-ADE
( O
NCSE B-ADE
) O
following O
infusion O
of O
ifosfamide B-DRUG
. O

A O
55-year O
- O
old O
woman O
presented O
an O
episode O
of O
acute B-ADE
urticaria I-ADE
and O
labial B-ADE
angioedema I-ADE
60 O
minutes O
after O
ingesting O
500 O
mg O
of O
cloxacillin B-DRUG
for O
a O
skin O
abscess O
. O

A O
27-year O
- O
old O
man O
who O
had O
a O
history O
of O
bronchial O
asthma O
, O
eosinophilic O
enteritis O
, O
and O
eosinophilic O
pneumonia O
presented O
with O
fever B-ADE
, O
skin B-ADE
eruptions I-ADE
, O
cervical B-ADE
lymphadenopathy I-ADE
, O
hepatosplenomegaly B-ADE
, O
atypical B-ADE
lymphocytosis I-ADE
, O
and O
eosinophilia B-ADE
two O
weeks O
after O
receiving O
trimethoprim B-DRUG
( O
TMP B-DRUG
) O
- O
sulfamethoxazole B-DRUG
( O
SMX B-DRUG
) O
treatment O
. O

Slow O
acetylators O
, O
who O
comprise O
roughly O
50 O
% O
of O
the O
South O
African O
population O
, O
are O
likely O
to O
develop O
clinical O
and O
biochemical O
features O
of O
phenytoin B-DRUG
toxicity I-ADE
when O
this O
drug O
is O
given O
together O
with O
antituberculosis O
therapy O
. O

Skin B-ADE
rash I-ADE
began O
after O
2 O
weeks O
of O
treatment O
, O
and O
signs O
of O
hepatocellular B-ADE
failure I-ADE
developed O
3 O
weeks O
after O
phenobarbital B-DRUG
had O
been O
started O
. O

Acute O
onset O
of O
nephrotic B-ADE
syndrome I-ADE
during O
interferon B-DRUG
- I-DRUG
alpha I-DRUG
retreatment O
for O
chronic O
active O
hepatitis O
C O
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
severe B-ADE
chloroquine B-DRUG
toxicity I-ADE
in O
the O
presence O
of O
high O
- O
grade O
chloroquine O
- O
resistant O
Plasmodium O
vivax O
. O

METHODS O
: O
Two O
patients O
with O
exudative O
age B-ADE
- I-ADE
related I-ADE
macular I-ADE
degeneration I-ADE
were O
treated O
sequentially O
with O
an O
intravitreal O
injection O
of O
bevacizumab B-DRUG
and O
developed O
signs O
of O
severe O
but O
painless B-ADE
infectious I-ADE
endophthalmitis I-ADE
2 O
days O
later O
. O

Intranasal O
desmopressin B-DRUG
- O
induced O
hyponatremia B-ADE
. O

For O
patients O
who O
suffer O
from O
osteogenic O
sarcoma O
and O
have O
anaphylactic B-ADE
reactions I-ADE
to O
MTX B-DRUG
, O
this O
desensitization O
protocol O
will O
allow O
these O
patients O
to O
continue O
with O
needed O
therapeutic O
or O
palliative O
chemotherapy O
. O

We O
discuss O
the O
association O
between O
carbamazepine B-DRUG
and O
hyponatremia B-ADE
and O
the O
causes O
of O
hyponatremia O
after O
cardiopulmonary O
bypass O
. O

Twenty O
- O
four O
hours O
after O
the O
administration O
of O
gemcitabine B-DRUG
, O
a O
symmetric B-ADE
, I-ADE
bullous I-ADE
, I-ADE
herpetiform I-ADE
eruption I-ADE
appeared O
on O
his O
trunk O
and O
upper O
limbs O
. O

Subacute B-ADE
cholestatic I-ADE
hepatitis I-ADE
likely O
related O
to O
the O
use O
of O
senna B-DRUG
for O
chronic O
constipation O
. O

Subsequent O
in O
vivo O
/ O
vitro O
studies O
clearly O
demonstrated O
that O
the O
neurological B-ADE
effects I-ADE
were O
due O
to O
a O
synergistic O
action O
of O
desferrioxamine B-DRUG
and O
prochlorperazine B-DRUG
, O
probably O
resulting O
in O
exceptional O
fluxes O
of O
intra O
/ O
extra O
cellular O
iron O
/ O
copper O
disturbing O
noradrenergic O
and O
serotonergic O
systems O
. O

After O
the O
dose O
of O
methylprednisolone B-DRUG
was O
reduced O
from O
40 O
mg O
to O
20 O
mg O
i.v O
. O
q6h O
and O
shifted O
to O
other O
anti O
- O
asthma O
treatment O
by O
procaterol O
metered O
dose O
inhaler O
via O
spacer O
, O
the O
psychotic B-ADE
reaction I-ADE
disappeared O
a O
few O
hours O
later O
. O

RESULTS O
: O
Ethambutol B-DRUG
, O
and O
to O
a O
lesser O
extent O
isoniazid B-DRUG
, O
are O
both O
implicated O
in O
the O
development B-ADE
of I-ADE
visually I-ADE
related I-ADE
side I-ADE
effects I-ADE
. O

A O
12 O
year O
old O
patient O
with O
atrial O
flutter O
is O
presented O
, O
in O
whom O
intravenous O
adenosine B-DRUG
was O
followed O
by O
acceleration B-ADE
of I-ADE
the I-ADE
heart I-ADE
rate I-ADE
to O
a O
potentially O
dangerous O
arrhythmia B-ADE
. O

We O
report O
a O
case O
in O
which O
hemorrhage B-ADE
occurred O
in O
an O
asymptomatic O
falx O
meningioma O
known O
beforehand O
, O
after O
the O
internal O
use O
of O
low O
- O
dose O
aspirin B-DRUG
for O
16 O
months O
. O

Here O
we O
present O
the O
case O
of O
a O
generalized B-ADE
lichen I-ADE
nitidus I-ADE
with O
involvement O
of O
the O
palms O
in O
a O
patient O
with O
hepatitis O
C O
after O
systemic O
treatment O
with O
interferon B-DRUG
alpha I-DRUG
and O
ribavirin B-DRUG
. O

Cutaneous B-ADE
seeding I-ADE
after O
ultrasound O
- O
guided O
percutaneous O
ethanol B-DRUG
injection I-DRUG
for O
treatment O
of O
hepatocellular O
carcinoma O
. O

This O
is O
an O
image O
and O
brief O
case O
report O
of O
a O
13-year O
- O
old O
boy O
who O
presented O
with O
severe B-ADE
rash I-ADE
and O
systemic O
symptoms O
after O
starting O
oxcarbazepine B-DRUG
. O

We O
report O
4 O
patients O
, O
2 O
on O
methylphenidate B-DRUG
and O
2 O
on O
dextroamphetamine B-DRUG
who O
presented O
with O
acral B-ADE
cyanosis I-ADE
, O
livedo B-ADE
reticularis I-ADE
, O
or O
Raynaud B-ADE
phenomenon I-ADE
. O

From O
these O
data O
, O
acute B-ADE
generalized I-ADE
dystonia I-ADE
with O
brainstem B-ADE
and I-ADE
thalamic I-ADE
lesions I-ADE
may O
occur O
in O
WD O
patients O
after O
an O
initial O
d B-DRUG
- I-DRUG
penicillamine I-DRUG
therapy O
. O

Correction O
of O
serum O
electrolyte O
imbalance O
prevents O
cardiac B-ADE
arrhythmia I-ADE
during O
amphotericin B-DRUG
B I-DRUG
administration O
. O

She O
was O
treated O
with O
Pancrease B-DRUG
MT I-DRUG
16 I-DRUG
, O
but O
had O
consistent O
vomiting B-ADE
1 O
to O
2 O
hours O
after O
administration O
of O
enzymes O
. O

Physicians O
should O
be O
aware O
that O
indinavir B-DRUG
nephrolithiasis B-ADE
may O
cause O
papillary B-ADE
necrosis I-ADE
. O

3 O
. O
Thus O
, O
the O
decreased B-ADE
plasma I-ADE
cortisol I-ADE
level I-ADE
during O
alprazolam B-DRUG
treatment O
of O
panic O
disorder O
was O
suggested O
to O
be O
caused O
not O
by O
symptom O
alleviation O
due O
to O
alprazolam O
but O
by O
alprazolam O
administration O
itself O
. O

These O
features O
have O
not O
previously O
been O
reported O
as O
side O
effects O
of O
glibenclamide O
therapy O
, O
but O
intrahepatic B-ADE
cholestasis I-ADE
may O
occur O
with O
chlorpropamide B-DRUG
, O
a O
similar O
sulphonylurea O
agent O
. O

Although O
isradipine B-DRUG
has O
been O
associated O
with O
hepatocellular B-ADE
injury I-ADE
, O
there O
are O
no O
reports O
of O
fulminant O
liver O
failure O
with O
this O
agent O
, O
and O
our O
patient O
had O
been O
treated O
for O
> O
2 O
years O
without O
signs O
of O
toxicity O
. O

Successful O
recovery O
from O
interstitial B-ADE
pneumonitis I-ADE
, O
induced O
by O
bicalutamide B-DRUG
and O
leuprorelin B-DRUG
acetate I-DRUG
given O
as O
treatment O
for O
prostate O
cancer O
. O

Lipoid B-ADE
pneumonia I-ADE
: O
a O
silent O
complication O
of O
mineral B-DRUG
oil I-DRUG
aspiration O
. O

Our O
objective O
is O
to O
present O
a O
retrospective O
analysis O
of O
the O
DWI O
findings O
in O
four O
patients O
who O
suffered O
subacute B-ADE
neurotoxicity I-ADE
after O
intrathecal O
MTX B-DRUG
. O

Corneal B-ADE
edema I-ADE
recurred O
when O
the O
administration O
of O
amantadine B-DRUG
was O
resumed O
. O

Acute B-ADE
myocardial I-ADE
infarction I-ADE
during O
high O
- O
dose O
methylprednisolone B-DRUG
therapy O
for O
Graves O
' O
ophthalmopathy O
. O

Fluphenazine B-DRUG
- O
induced O
neuroleptic B-ADE
malignant I-ADE
syndrome I-ADE
in O
a O
schizophrenic O
patient O
. O

Rituximab O
- O
based O
therapy O
for O
gemcitabine B-DRUG
- O
induced O
hemolytic B-ADE
uremic I-ADE
syndrome I-ADE
in O
a O
patient O
with O
metastatic O
pancreatic O
adenocarcinoma O
: O
a O
case O
report O
. O

The O
cause O
is O
presumed O
to O
be O
secondary O
to O
hypercoagulability O
due O
to O
asparaginase B-DRUG
- O
induced O
antithrombin B-ADE
III I-ADE
deficiency I-ADE
. O

We O
report O
the O
cases O
of O
two O
patients O
who O
developed O
acute O
hepatitis B-ADE
after O
taking O
riluzole B-DRUG
at O
the O
recommended O
dose O
( O
100 O
mg O
daily O
) O
for O
7 O
and O
4 O
weeks O
, O
respectively O
. O

First O
, O
a O
review O
of O
the O
literature O
produced O
41 O
anecdotic O
cases O
of O
neutropenia B-ADE
or O
agranulocytosis B-ADE
during O
treatment O
with O
olanzapine B-DRUG
( O
Zyprexa B-DRUG
) O
reported O
in O
a O
total O
of O
24 O
publications O
. O

This O
article O
presents O
a O
case O
of O
an O
atypical B-ADE
localized I-ADE
cutaneous I-ADE
eruption I-ADE
with O
an O
unusual O
course O
and O
protracted O
resolution O
time O
associated O
with O
sorafenib B-DRUG
therapy O
. O

Cisplatin B-DRUG
- O
induced O
syndrome B-ADE
of I-ADE
inappropriate I-ADE
antidiuretic I-ADE
hormone I-ADE
( O
SIADH B-ADE
) O
in O
a O
patient O
with O
neuroendocrine O
tumor O
of O
the O
cervix O
: O
a O
case O
report O
and O
review O
of O
the O
literature O
. O

OBJECTIVE O
: O
To O
describe O
the O
development O
of O
valproate B-DRUG
- O
related O
reproductive B-ADE
endocrine I-ADE
disorders I-ADE
in O
women O
with O
epilepsy O
. O

Sweet B-ADE
's I-ADE
syndrome I-ADE
associated O
with O
sargramostim B-DRUG
( O
granulocyte O
- O
macrophage O
colony O
stimulating O
factor O
) O
treatment O
. O

Only O
3 O
cases O
of O
imatinib B-DRUG
- O
induced O
tumor B-ADE
lysis I-ADE
syndrome I-ADE
have O
been O
reported O
. O

We O
report O
a O
patient O
receiving O
chronic O
lithium B-DRUG
therapy O
who O
presented O
with O
a O
transient O
CDI B-ADE
occurring O
in O
the O
setting O
of O
underlying O
chronic O
NDI O
. O

A O
patient O
presented O
with O
dilated B-ADE
cardiomyopathy I-ADE
after O
many O
years O
of O
overusing O
an O
adrenaline B-DRUG
inhaler O
. O

Physicians O
treating O
patients O
with O
methotrexate B-DRUG
for O
juvenile O
rheumatoid O
arthritis O
must O
be O
aware O
of O
this O
extraarticular B-ADE
side I-ADE
effect I-ADE
. O

Are O
nasal O
decongestants O
safer O
than O
rhinitis O
? O
A O
case O
of O
oxymetazoline B-DRUG
- O
induced O
syncope B-ADE
. O

Infant O
twins O
sustained O
severe O
circumoral B-ADE
and I-ADE
pharyngeal I-ADE
burns I-ADE
from O
a O
concentrated O
solution O
of O
benzalkonium B-DRUG
( O
Zephiran B-DRUG
) O
chloride O
prescribed O
for O
treatment O
of O
candidiasis O
. O

After O
the O
patient O
discontinued O
rifampicin B-DRUG
, O
the O
skin B-ADE
lesions I-ADE
cleared O
completely O
within O
5 O
weeks O
without O
any O
systemic O
medication O
. O

A O
case O
of O
barbiturate B-DRUG
- O
induced O
submassive B-ADE
hepatic I-ADE
necrosis I-ADE
is O
presented O
and O
the O
literature O
is O
reviewed O
. O

We O
describe O
a O
74-year O
- O
old O
man O
with O
rheumatoid O
arthritis O
( O
RA O
) O
who O
developed O
syndrome B-ADE
of I-ADE
inappropriate I-ADE
secretion I-ADE
of I-ADE
antidiuretic I-ADE
hormone I-ADE
( O
SIADH B-ADE
) O
1.5 O
months O
after O
commencement O
of O
mizoribin B-DRUG
prescription O
when O
his O
arthritis O
was O
improved O
. O

A O
reversible B-ADE
toxic I-ADE
liver I-ADE
damage I-ADE
was O
observed O
in O
a O
non O
- O
alcoholic O
woman O
treated O
with O
disulfiram B-DRUG
. O

Slow O
acetylator O
genotypes O
as O
a O
possible O
risk O
factor O
for O
infectious B-ADE
mononucleosis I-ADE
- I-ADE
like I-ADE
syndrome I-ADE
induced O
by O
salazosulfapyridine B-DRUG
. O

Epstein B-ADE
- I-ADE
Barr I-ADE
virus I-ADE
- I-ADE
associated I-ADE
lymphoproliferative I-ADE
disorder I-ADE
in O
a O
patient O
with O
rheumatoid O
arthritis O
on O
methotrexate B-DRUG
and O
rofecoxib B-DRUG
: O
idiosyncratic O
reaction O
or O
pharmacogenetics O
? O

We O
report O
the O
first O
case O
of O
doxycycline B-DRUG
- O
induced O
hypoglycemia B-ADE
in O
a O
young O
nondiabetic O
man O
. O

Ophthalmologic B-ADE
and I-ADE
neurologic I-ADE
findings I-ADE
in O
two O
children O
exposed O
to O
vigabatrin B-DRUG
in O
utero O
. O

Tenofovir B-DRUG
- O
associated O
nephrotoxicity B-ADE
in O
two O
HIV O
- O
infected O
adolescent O
males O
. O

This O
regimen O
could O
prove O
useful O
for O
other O
patients O
who O
develop O
hypersensitivity B-ADE
reactions O
to O
carboplatin B-DRUG
and O
allow O
therapy O
to O
continue O
. O

We O
describe O
a O
patient O
with O
CREST O
syndrome O
( O
calcinosis O
, O
Raynaud O
's O
phenomenon O
, O
esophageal O
dysfunction O
, O
sclerodactyly O
, O
and O
telangiectasia O
) O
who O
paradoxically O
experienced O
worsening B-ADE
of I-ADE
Raynaud I-ADE
's I-ADE
phenomenon I-ADE
when O
using O
yohimbine B-DRUG
for O
ED O
. O

The O
most O
common O
side O
effects O
associated O
with O
amifostine B-DRUG
are O
nausea B-ADE
, O
vomiting B-ADE
, O
hypotension B-ADE
, O
hypocalcemia B-ADE
and O
allergic B-ADE
reactions I-ADE
. O

After O
stopping O
indapamide B-DRUG
, O
glucose B-ADE
tolerance I-ADE
impairing I-ADE
may O
be O
reversed O
. O

A O
51-year O
old O
physically O
fit O
woman O
experienced O
angio B-ADE
- I-ADE
oedema I-ADE
and O
hypotensive B-ADE
shock I-ADE
after O
irbesartan B-DRUG
ingestion O
requiring O
noradrenaline O
infusion O
. O

The O
exact O
mechanism O
of O
IVIG B-DRUG
- O
associated O
acute B-ADE
renal I-ADE
failure I-ADE
remains O
unclear O
. O

CONCLUSION O
: O
A O
37-year O
- O
old O
African- O
American O
man O
with O
G6PD O
deficiency O
developed O
hemolytic B-ADE
anemia I-ADE
, O
hepatitis B-ADE
, O
orthostatic B-ADE
hypotension I-ADE
, O
and O
aseptic B-ADE
meningitis I-ADE
simultaneously O
after O
using O
trimethoprim B-DRUG
- O
sulfamethoxazole B-DRUG
. O

Due O
to O
the O
severity O
of O
the O
rash B-ADE
, O
temozolomide B-DRUG
was O
permanently O
discontinued O
. O

We O
report O
a O
case O
of O
hypoglycaemia B-ADE
after O
mefloquine B-DRUG
therapy O
( O
1,500 O
mg O
over O
two O
days O
) O
for O
severe O
gastrointestinal O
cryptosporidiasis O
in O
a O
cachectic O
AIDS O
patient O
with O
protracted O
diarrhoea O
. O

Captopril B-DRUG
- O
associated O
" O
pseudocholangitis B-ADE
' O
. O

Our O
findings O
suggest O
that O
significant O
progression B-ADE
of I-ADE
marrow I-ADE
reticulin I-ADE
fibrosis I-ADE
during O
imatinib B-DRUG
therapy O
can O
be O
an O
indicator O
for O
a O
return O
or O
progression O
of O
CML O
and O
, O
in O
some O
patients O
with O
CML O
, O
imatinib O
may O
promote O
cytogenetic O
clonal O
evolution O
, O
resulting O
in O
a O
poor O
response O
to O
treatment O
. O

We O
present O
a O
case O
report O
of O
a O
patient O
with O
typhoid O
fever O
who O
experienced O
a O
hypersensitivity B-ADE
reaction I-ADE
subsequent O
to O
the O
infusion O
of O
chloramphenicol B-DRUG
sodium I-DRUG
succinate I-DRUG
. O

Mitomycin B-DRUG
- I-DRUG
C I-DRUG
is O
used O
widely O
in O
the O
treatment O
of O
malignancies O
and O
is O
associated O
with O
serious O
dose O
related O
adverse O
effects O
including O
the O
occurrence O
of O
hemolytic B-ADE
uremic I-ADE
syndrome I-ADE
. O

A O
patient O
who O
had O
been O
treated O
with O
large O
doses O
of O
thyroid B-DRUG
hormone I-DRUG
for O
several O
years O
developed O
features O
of O
secondary O
hypothyroidism B-ADE
after O
thyroid O
hormone O
withdrawal O
. O

Possible O
interaction O
between O
lopinavir B-DRUG
/ O
ritonavir B-DRUG
and O
valproic B-DRUG
Acid I-DRUG
exacerbates O
bipolar B-ADE
disorder I-ADE
. O

Vincristine B-DRUG
induced O
cranial B-ADE
polyneuropathy I-ADE
. O

This O
report O
describes O
a O
case O
of O
paradoxical B-DRUG
, O
intravenous O
valproic B-DRUG
acid I-DRUG
- O
induced O
seizure B-ADE
exacerbation I-ADE
in O
a O
child O
with O
juvenile O
absence O
epilepsy O
, O
documented O
by O
video O
- O
electroencephalography O
. O

Fulminant B-ADE
liver I-ADE
failure I-ADE
associated O
with O
clarithromycin B-DRUG
. O

Seizures B-ADE
occurred O
in O
two O
patients O
with O
probable O
Alzheimer O
's O
disease O
who O
were O
receiving O
long O
- O
term O
treatment O
with O
metrifonate B-DRUG
, O
an O
irreversible O
acetylcholinesterase O
inhibitor O
. O

Seizures B-ADE
associated O
with O
fluoxetine B-DRUG
therapy O
are O
uncommon O
. O

Transient B-ADE
acute I-ADE
myopia I-ADE
resulting O
from O
isotretinoin B-DRUG
( O
accutane B-DRUG
) O
therapy O
. O

A O
72-year O
- O
old O
woman O
with O
a O
history O
of O
thyrotoxicosis O
presented O
with O
sore B-ADE
throat I-ADE
and O
fever B-ADE
two O
weeks O
after O
starting O
carbimazole B-DRUG
. O

Pancreatitis B-ADE
has O
been O
noted O
to O
be O
a O
complication O
in O
2 O
- O
16 O
% O
of O
patients O
undergoing O
treatment O
with O
L B-DRUG
- I-DRUG
asparaginase I-DRUG
for O
a O
variety O
of O
pediatric O
neoplasms O
. O

Norethisterone B-DRUG
in O
these O
69 O
pregnancies O
accounted O
for O
33.3 O
% O
( O
5 O
of O
15 O
) O
cases O
of O
clitoral B-ADE
hypertrophy I-ADE
diagnosed O
in O
100,756 O
consecutive O
births O
. O

Mannitol B-DRUG
- O
induced O
ARF B-ADE
responds O
promptly O
to O
hemodialysis O
with O
rapid O
resolution O
of O
anuria O
and O
recovery O
of O
renal O
failure O
. O

Spontaneous B-ADE
splenic I-ADE
infarction I-ADE
associated O
with O
sumatriptan B-DRUG
use O
. O

Carbamazepine B-DRUG
toxicity I-ADE
following O
Oxybutynin B-DRUG
and O
Dantrolene B-DRUG
administration O
: O
a O
case O
report O
. O

A O
21-year O
- O
old O
woman O
suffering O
from O
bipolar O
affective O
disorder O
developed O
systemic B-ADE
lupus I-ADE
erythematosus I-ADE
( O
SLE B-ADE
) O
with O
characteristic O
laboratory O
findings O
, O
18 O
months O
after O
starting O
carbamazepine B-DRUG
maintenance O
treatment O
. O

Under O
the O
suspicion O
of O
amiodarone B-DRUG
- O
induced O
acute B-ADE
pancreatitis I-ADE
, O
amiodarone O
was O
substituted O
by O
propafenone O
. O

Sixteen O
of O
33 O
patients O
developed O
significant O
hyponatremia B-ADE
and O
hypoosmolality B-ADE
during O
oral O
treatment O
with O
lorcainide B-DRUG
. O

When O
co B-DRUG
- I-DRUG
trimoxazole I-DRUG
was O
stopped O
the O
red B-ADE
cell I-ADE
aplasia I-ADE
resolved O
. O

Nicotinic B-DRUG
acid I-DRUG
- O
induced O
fulminant B-ADE
hepatic I-ADE
failure I-ADE
. O

RESULTS O
: O
A O
previously O
healthy O
42-year O
- O
old O
woman O
presented O
with O
acute B-ADE
- I-ADE
onset I-ADE
delirium I-ADE
with I-ADE
psychotic I-ADE
features I-ADE
as O
a O
consequence O
of O
levofloxacin B-DRUG
therapy O
. O

In O
a O
patient O
with O
severe O
renovascular O
hypertension O
, O
nonoliguric B-ADE
acute I-ADE
renal I-ADE
failure I-ADE
developed O
after O
she O
received O
captopril B-DRUG
treatment O
. O

Rapamycin B-DRUG
/ O
sirolimus B-DRUG
- O
induced O
pneumonitis B-ADE
has O
been O
described O
previously O
in O
renal O
transplant O
recipients O
, O
and O
this O
report O
describes O
a O
stable O
heart O
- O
lung O
transplant O
recipient O
who O
developed O
a O
pulmonary B-ADE
infiltrate I-ADE
that O
reversed O
after O
ceasing O
SR B-DRUG
therapy O
. O

Nephrotic B-ADE
range I-ADE
pseudoproteinuria I-ADE
in O
a O
tolmetin B-DRUG
- O
treated O
patient O
. O

We O
report O
here O
a O
rare O
case O
of O
ritodrine B-DRUG
- I-DRUG
hydrochloride I-DRUG
- O
induced O
rhabdomyolysis B-ADE
in O
a O
pregnant O
patient O
with O
myotonic O
dystrophy O
. O

We O
report O
the O
case O
of O
a O
14-year O
- O
old O
female O
with O
acute O
promyelocytic O
leukemia O
who O
developed O
symptomatic B-ADE
cardiomyopathy I-ADE
only O
4 O
months O
into O
treatment O
with O
a O
combination O
of O
daunomycin B-DRUG
and O
all B-DRUG
- I-DRUG
trans I-DRUG
retinoic I-DRUG
acid I-DRUG
( O
ATRA B-DRUG
) O
. O

Gemcitabine B-DRUG
- O
induced O
pericardial B-ADE
effusion I-ADE
and O
tamponade B-ADE
after O
unblocked O
cardiac O
irradiation O
. O

Ciprofloxacin B-DRUG
- O
induced O
toxic B-ADE
epidermal I-ADE
necrolysis I-ADE
in O
a O
patient O
with O
systemic O
lupus O
erythematosus O
. O

Although O
the O
t B-ADE
- I-ADE
AML I-ADE
developed O
following O
oral O
etoposide B-DRUG
therapy O
, O
the O
child O
had O
previously O
received O
high O
- O
dose O
, O
multiagent O
chemotherapy O
, O
and O
rearrangement O
of O
the O
MLL O
gene O
was O
not O
demonstrated O
. O

Syndrome B-ADE
of I-ADE
inappropriate I-ADE
secretion I-ADE
of I-ADE
ADH I-ADE
( O
SIADH B-ADE
) O
following O
cisplatin B-DRUG
administration O
in O
a O
pulmonary O
adenocarcinoma O
patient O
with O
a O
malignant O
pleural O
effusion O
. O

Recently O
, O
her O
serum O
theophylline B-DRUG
levels I-ADE
had I-ADE
increased I-ADE
to I-ADE
the I-ADE
toxic I-ADE
range I-ADE
( O
133.2 O
micromol O
/ O
L O
[ O
24 O
microg O
/ O
mL O
] O
) O
shortly O
after O
the O
addition O
of O
zafirlukast B-DRUG
( O
Accolate B-DRUG
, O
Zeneca O
Pharmaceuticals O
, O
Wilmington O
, O
Del O
) O
to O
her O
regimen O
. O

Triazolam B-DRUG
- O
induced O
nocturnal B-ADE
bingeing I-ADE
with O
amnesia B-ADE
. O

Serious O
phenytoin B-DRUG
hypersensitivity B-ADE
reactions I-ADE
may O
appear O
as O
dermatologic B-ADE
, I-ADE
lymphoid I-ADE
, I-ADE
or I-ADE
hepatic I-ADE
syndromes I-ADE
. O

Bromocriptine B-DRUG
- O
induced O
schizophrenia B-ADE
. O

In O
this O
paper O
, O
we O
report O
a O
patient O
with O
primary O
anti O
- O
phospholipid O
syndrome O
treated O
by O
corticosteroid B-DRUG
, O
who O
developed O
disseminated B-ADE
nocardiosis I-ADE
. O

DISCUSSION O
: O
To O
our O
knowledge O
, O
this O
is O
the O
first O
case O
report O
illustrating O
neuralgic B-ADE
amyotrophy I-ADE
triggered O
by O
exposure O
to O
the O
antibiotics O
vancomycin B-DRUG
, O
tobramycin B-DRUG
, O
and O
piperacillin B-DRUG
/ O
tazobactam B-DRUG
. O

A O
wide O
variety O
of O
adverse B-ADE
central I-ADE
nervous I-ADE
system I-ADE
effects I-ADE
have O
been O
reported O
in O
association O
with O
propafenone B-DRUG
; O
dizziness B-ADE
is O
the O
most O
common O
. O

CASE O
REPORT O
: O
We O
hereby O
report O
a O
case O
of O
radiation B-ADE
recall I-ADE
dermatitis I-ADE
and O
myositis B-ADE
occurring O
on O
gemcitabine B-DRUG
monotherapy O
, O
five O
months O
after O
completing O
chemoradiation O
for O
locally O
advanced O
pancreatic O
cancer O
. O

Soon O
after O
introduction O
of O
insulin B-DRUG
therapy O
, O
she O
developed O
severe B-ADE
anasarca I-ADE
, O
including O
marked O
peripheral B-ADE
oedema I-ADE
, O
ascites B-ADE
and O
pleural B-ADE
effusion I-ADE
. O

A O
66-year O
- O
old O
Japanese O
woman O
with O
severe O
scleroderma O
developed O
anemia B-ADE
and O
thrombocytopenia B-ADE
due O
to O
D B-DRUG
- I-DRUG
penicillamine I-DRUG
( O
D B-DRUG
- I-DRUG
Pen I-DRUG
) O
treatment O
, O
although O
the O
leukopenia O
was O
not O
markedly O
severe O
. O

Cardiac B-ADE
decompensation I-ADE
following O
verapamil B-DRUG
therapy O
in O
infants O
with O
supraventricular O
tachycardia O
. O

Haemolytic B-ADE
- I-ADE
uraemic I-ADE
syndrome I-ADE
complicating O
long O
- O
term O
mitomycin B-DRUG
C I-DRUG
and O
5-fluorouracil B-DRUG
therapy O
for O
gastric O
carcinoma O
. O

Zidovudine B-DRUG
use O
in O
pregnancy O
: O
a O
report O
on O
104 O
cases O
and O
the O
occurrence O
of O
birth B-ADE
defects I-ADE
. O

During O
intravenous O
treatment O
with O
terlipressin B-DRUG
for O
recurrent O
gastrointestinal O
( O
GI O
) O
bleeding O
, O
a O
50-year O
- O
old O
male O
with O
no O
history O
of O
heart O
disease O
developed O
a O
newly O
prolonged B-ADE
QT I-ADE
interval I-ADE
and O
torsade B-ADE
de I-ADE
pointes I-ADE
. O

Transtubular B-ADE
potassium I-ADE
gradient I-ADE
( I-ADE
TTKG I-ADE
) I-ADE
also I-ADE
decreased I-ADE
and O
an O
inverse O
correlation O
was O
found O
between O
TTKG O
and O
doses O
of O
phosphate B-DRUG
( O
r O
= O
-0.37 O
; O
p O
< O
0.02 O
; O
N O
= O
38 O
) O
. O

Cytarabine B-DRUG
- O
induced O
cerebellar B-ADE
syndrome I-ADE
: O
case O
report O
and O
literature O
review O
. O

Coagulopathy B-ADE
associated O
with O
the O
use O
of O
cephalosporin B-DRUG
or O
moxalactam B-DRUG
antibiotics O
in O
acute O
and O
chronic O
renal O
failure O
. O

This O
case O
supports O
the O
assessment O
that O
MH O
and O
diabetes O
are O
associated O
diseases O
and O
that O
cresol B-DRUG
could O
possibly O
trigger O
MH B-ADE
. O

The O
ocular B-ADE
toxicity I-ADE
of O
DCF B-DRUG
, O
previously O
described O
as O
conjunctivitis B-ADE
, O
appears O
to O
be O
a O
keratitis B-ADE
of O
moderate O
severity O
which O
requires O
further O
study O
. O

Chloroquine B-DRUG
- O
induced O
bilateral B-ADE
ptosis I-ADE
. O

With O
the O
use O
of O
optical O
coherence O
tomography O
( O
OCT O
) O
, O
two O
patients O
with O
IFN B-DRUG
- O
associated O
retinopathy B-ADE
who O
had O
developed O
macular B-ADE
edema I-ADE
and O
reduced B-ADE
visual I-ADE
acuity I-ADE
during O
the O
clinical O
course O
of O
IFN B-DRUG
therapy O
were O
observed O
. O

This O
is O
the O
third O
report O
of O
reversible O
hepatic B-ADE
decompensation I-ADE
associated O
with O
prolonged O
MTX B-DRUG
therapy O
in O
patients O
with O
rheumatoid O
arthritis O
. O

Three O
patients O
developed O
proteinuria B-ADE
following O
gold B-DRUG
therapy O
for O
rheumatoid O
arthritis O
. O

The O
exacerbation B-ADE
of I-ADE
psoriasis I-ADE
was O
accompanied O
by O
a O
massive O
induction O
of O
lesional O
type O
I O
interferon O
activity O
, O
detected O
by O
MxA O
expression O
after O
imiquimod B-DRUG
therapy O
. O

Ciprofloxacin O
is O
among O
the O
standard O
treatments O
for O
infected O
ischemic O
ulcers O
; O
in O
the O
rare O
case O
of O
ciprofloxacin B-DRUG
- O
induced O
hemorrhagic B-ADE
vasculitis I-ADE
, O
it O
might O
be O
interpreted O
as O
progression O
of O
infection O
, O
instead O
of O
a O
complication O
of O
the O
treatment O
, O
thus O
leading O
to O
faulty O
diagnosis O
and O
treatment O
. O

We O
present O
a O
case O
of O
cutaneous B-ADE
leucocytoclastic I-ADE
vasculitis I-ADE
in O
which O
amphotericin B-DRUG
B I-DRUG
might O
presumably O
be O
the O
aetiological O
factor O
. O

CONCLUSION O
: O
The O
chronic O
use O
of O
HCQ B-DRUG
for O
rheumatic O
diseases O
, O
or O
as O
an O
anti O
- O
malarial O
drug O
, O
should O
be O
balanced O
against O
the O
risk O
of O
developing O
potentially O
lethal O
cardiac B-ADE
arrhythmias I-ADE
. O

Although O
adverse O
effects O
are O
usually O
mild O
, O
the O
author O
reports O
here O
a O
case O
of O
leucocytopenia B-ADE
and O
thrombocytopenia B-ADE
with O
quetiapine B-DRUG
treatment O
that O
required O
its O
discontinuation O
. O

A O
patient O
is O
described O
with O
the O
characteristic O
features O
of O
phenytoin B-ADE
hypersensitivity I-ADE
syndrome I-ADE
( O
PHS O
) O
including O
fever B-ADE
, O
erythroderma B-ADE
, O
tibial B-ADE
and I-ADE
facial I-ADE
oedema I-ADE
, O
pinhead B-ADE
- I-ADE
sized I-ADE
facial I-ADE
pustules I-ADE
and O
abnormal B-ADE
liver I-ADE
function I-ADE
tests I-ADE
. O

Methanol B-ADE
toxicity I-ADE
can O
cause O
severe B-ADE
central I-ADE
nervous I-ADE
system I-ADE
insult I-ADE
in O
which O
a O
characteristic O
pattern O
of O
bilateral B-ADE
putaminal I-ADE
injury I-ADE
is O
noted O
on O
brain O
imaging O
studies O
. O

Our O
literature O
review O
revealed O
an O
additional O
six O
cases O
of O
onset O
of O
inflammatory B-ADE
arthritis I-ADE
in O
MS O
patients O
receiving O
IFN B-DRUG
- I-DRUG
beta I-DRUG
. O

While O
doxorubicin B-DRUG
was O
administered O
, O
the O
patient O
presented O
thoracic B-ADE
pain I-ADE
and O
breathing B-ADE
distress I-ADE
due O
to O
superior O
vena O
cava O
perforation O
by O
the O
central O
catheter O
and O
subsequent O
extravasation O
of O
the O
drug O
into O
the O
mediastinum O
. O

We O
report O
a O
rare O
case O
of O
recurrent O
( O
stuttering B-ADE
) O
priapism B-ADE
in O
a O
patient O
with O
protein O
C O
deficiency O
while O
maintained O
on O
Warfarin B-DRUG
therapy O
. O

That O
review O
suggested O
that O
patients O
receiving O
anti B-DRUG
- I-DRUG
D I-DRUG
IGIV I-DRUG
be O
monitored O
for O
those O
and O
other O
potential O
complications O
of O
hemoglobinemia B-ADE
, O
particularly O
disseminated B-ADE
intravascular I-ADE
coagulation I-ADE
( O
DIC B-ADE
) O
. O

A O
67-year O
- O
old O
patient O
, O
with O
primary O
polymyositis O
and O
without O
previous O
evidence O
of O
liver O
disease O
, O
developed O
clinical O
and O
biochemical O
features O
of O
severe B-ADE
cholestasis I-ADE
3 O
months O
after O
initiation O
of O
azathioprine B-DRUG
therapy O
. O

Retinal B-ADE
dysfunction I-ADE
and O
anterior B-ADE
segment I-ADE
deposits I-ADE
in O
a O
patient O
treated O
with O
rifabutin B-DRUG
. O

RESULTS O
: O
Brimonidine B-DRUG
was O
observed O
to O
cause O
IOP B-ADE
elevation I-ADE
, O
confirmed O
on O
rechallenge O
, O
scoring O
8 O
( O
strong O
probability O
) O
on O
an O
adverse O
drug O
reaction O
probability O
score O
. O

We O
report O
on O
a O
14-year O
- O
old O
boy O
with O
severe O
haemophilia O
A O
who O
developed O
a O
portal B-ADE
vein I-ADE
thrombosis I-ADE
during O
continuous O
infusion O
of O
F B-DRUG
VIII I-DRUG
. O

A O
diagnosis O
of O
infliximab B-DRUG
- O
induced O
lupus B-ADE
was O
made O
and O
the O
drug O
treatment O
was O
withdrawn O
. O

Aggressive O
management O
of O
doxorubicin B-DRUG
- O
induced O
cardiomyopathy B-ADE
associated O
with O
' O
low O
' O
doses O
of O
doxorubicin B-DRUG
. O

Pulmonary B-ADE
hemorrhage I-ADE
is O
an O
uncommon O
feature O
in O
the O
HUS B-ADE
, O
and O
seems O
to O
appear O
especially O
in O
the O
HUS B-ADE
associated O
with O
MMC B-DRUG
therapy O
. O

We O
report O
a O
case O
of O
severe O
respiratory B-ADE
failure I-ADE
due O
to O
gold B-DRUG
salt O
toxicity O
in O
a O
patient O
suffering O
from O
rheumatoid O
arthritis O
requiring O
mechanical O
ventilation O
. O

Pulmonary B-ADE
hemorrhage I-ADE
as O
a O
clinical O
manifestation O
of O
hemolytic B-ADE
- I-ADE
uremic I-ADE
syndrome I-ADE
associated O
with O
mitomycin B-DRUG
C I-DRUG
therapy O
. O

A O
toxic B-ADE
encephalopathy I-ADE
characterized O
by O
depressed B-ADE
level I-ADE
of I-ADE
consciousness I-ADE
, O
marked B-ADE
irritability I-ADE
, O
and O
ataxia B-ADE
developed O
in O
seven O
children O
, O
5 O
years O
of O
age O
and O
younger O
, O
following O
administration O
of O
an O
antiemetic O
combination O
of O
pentobarbital B-DRUG
and O
pyrilamine B-DRUG
maleate I-DRUG
. O

The O
Center O
for O
Disease O
Control O
has O
received O
numerous O
reports O
of O
an O
eosinophilia B-ADE
- I-ADE
myalgia I-ADE
syndrome I-ADE
related O
to O
products O
containing O
L B-DRUG
- I-DRUG
tryptophan I-DRUG
. O

OBJECTIVE O
: O
To O
report O
two O
cases O
of O
fixed B-ADE
drug I-ADE
eruption I-ADE
induced O
by O
methylphenidate B-DRUG
. O

We O
report O
a O
patient O
with O
type O
2 O
diabetes O
mellitus O
who O
, O
while O
treated O
with O
the O
antitumor O
necrosis O
factor O
- O
alpha O
blocking O
agent O
etanercept B-DRUG
for O
severe O
plaque O
psoriasis O
, O
experienced O
persistent B-ADE
hypoglycemia I-ADE
requiring O
the O
lowering O
and O
eventual O
elimination O
of O
his O
previous O
insulin O
regimen O
. O

Asthma B-ADE
and O
urticaria B-ADE
during O
disodium B-DRUG
cromoglycate I-DRUG
treatment O
. O

Careful O
follow O
- O
up O
of O
so O
- O
called O
" O
self O
- O
limited O
" O
insulin B-DRUG
edema B-ADE
is O
encouraged O
, O
and O
the O
early O
institution O
of O
diuretic O
therapy O
is O
advocated O
in O
elderly O
patients O
to O
prevent O
the O
development O
of O
overt O
cardiac O
failure O
. O

CONCLUSIONS O
: O
The O
3 O
cases O
presented O
here O
illustrate O
the O
development O
of O
reproductive B-ADE
endocrine I-ADE
disorders I-ADE
after O
the O
initiation O
of O
valproate B-DRUG
therapy O
in O
women O
with O
epilepsy O
. O

Cefuroxime B-DRUG
- O
induced O
acute B-ADE
renal I-ADE
failure I-ADE
. O

Syringotropic B-ADE
hypersensitivity I-ADE
reaction I-ADE
associated O
with O
infliximab B-DRUG
and O
leflunomide B-DRUG
combination O
therapy O
in O
a O
child O
with O
psoriatic O
arthritis O
. O

The O
authors O
describe O
a O
case O
of O
oral B-ADE
- I-ADE
facial I-ADE
dyskinesia I-ADE
that O
occurred O
after O
discontinuation O
of O
amoxapine B-DRUG
, O
and O
antidepressant O
which O
may O
also O
have O
neuroleptic O
effects O
. O

Imatinib B-DRUG
mesylate I-DRUG
- O
related O
fatal B-ADE
acute I-ADE
hepatic I-ADE
failure I-ADE
in O
a O
patient O
with O
chronic O
myeloid O
leukaemia O
and O
chronic O
hepatitis O
B O
infection O
. O

A O
patient O
is O
described O
who O
developed O
a O
poorly O
differentiated O
sarcoma B-ADE
after O
cyclophosphamide B-DRUG
was O
used O
to O
treat O
his O
rheumatoid O
arthritis O
. O

OBJECTIVE O
: O
To O
describe O
what O
is O
believed O
, O
as O
of O
November O
4 O
, O
2003 O
, O
to O
be O
the O
first O
case O
published O
in O
the O
literature O
of O
acute B-ADE
interstitial I-ADE
nephritis I-ADE
( O
AIN O
) O
due O
to O
pantoprazole B-DRUG
. O

Mequitazine O
seemed O
to O
play O
a O
part O
similar O
to O
chlorpromazine O
, O
and O
absence O
of O
mequitazine B-DRUG
- O
induced O
photosensitivity B-ADE
may O
be O
due O
to O
a O
relatively O
low O
dosage O
of O
the O
drug O
. O

Both O
colchicine B-DRUG
and O
statin B-DRUG
therapy O
may O
be O
associated O
with O
myopathy B-ADE
, O
which O
usually O
occurs O
after O
several O
months O
of O
therapy O
. O

Gelofusine B-DRUG
allergy I-ADE
-- O
the O
need O
for O
identification O
jewellery O
. O

Case O
1 O
, O
a O
62-year O
- O
old O
woman O
, O
developed O
bilateral B-ADE
optic I-ADE
neuritis I-ADE
with O
decreased B-ADE
sensation I-ADE
of I-ADE
vibration I-ADE
and O
increased B-ADE
deep I-ADE
tendon I-ADE
reflex I-ADE
in O
the O
lower O
extremities O
after O
a O
seven O
- O
month O
use O
of O
recombinant B-DRUG
interferon I-DRUG
alpha-2a I-DRUG
for O
chronic O
active O
hepatitis O
C O
. O

After O
gastric B-ADE
- I-ADE
outlet I-ADE
obstruction I-ADE
was O
recognized O
in O
several O
infants O
who O
received O
prostaglandin B-DRUG
E1 I-DRUG
, O
we O
studied O
the O
association O
between O
the O
drug O
and O
this O
complication O
. O

We O
present O
a O
46-year O
- O
old O
African O
- O
American O
man O
with O
AIDS O
who O
was O
admitted O
on O
two O
different O
occasions O
within O
three O
weeks O
for O
signs O
and O
symptoms O
of O
meningitis B-ADE
after O
using O
trimethoprim B-DRUG
/ O
sulfamethoxazole B-DRUG
( O
TMP B-DRUG
/ O
SMX B-DRUG
) O
. O

Hypertension B-ADE
develops O
in O
most O
patients O
after O
transplantation O
when O
immunosuppression O
is O
based O
on O
cyclosporine B-DRUG
and O
prednisone B-DRUG
. O

Gemcitabine B-DRUG
- O
related O
radiation B-ADE
recall I-ADE
preferentially O
involves O
internal O
tissue O
and O
organs O
. O

Gynecomastia B-ADE
developed O
in O
two O
epileptic O
patients O
some O
months O
after O
the O
addition O
of O
oral O
fluoresone B-DRUG
750 O
mg O
daily O
to O
the O
phenobarbital B-DRUG
and O
phenytoin B-DRUG
already O
being O
administered O
. O

However O
, O
each O
infant O
demonstrated O
hemodynamic B-ADE
decompensation I-ADE
shortly O
after O
verapamil B-DRUG
administration O
and O
required O
cardiopulmonary O
resuscitation O
. O

Concomitant O
administration O
of O
lithium B-DRUG
with O
olanzapine B-DRUG
may O
place O
patients O
at O
risk O
for O
NMS B-ADE
. O

We O
describe O
a O
case O
of O
EGE B-ADE
manifested O
as O
an O
allergy O
to O
gemfibrozil B-DRUG
. O

Nephrotic B-ADE
syndrome I-ADE
related O
to O
systemic B-ADE
lupus I-ADE
erythematosus I-ADE
after O
griseofulvin B-DRUG
therapy O
. O

METHODS O
: O
Three O
patients O
with O
apparent O
itraconazole B-DRUG
- O
induced O
liver B-ADE
injury I-ADE
were O
studied O
. O

We O
report O
the O
first O
case O
, O
to O
our O
knowledge O
, O
of O
rituximab B-DRUG
- O
related O
autoimmune B-ADE
hemolytic I-ADE
anemia I-ADE
. O

This O
is O
the O
first O
report O
of O
a O
catatonic B-ADE
syndrome I-ADE
occurring O
in O
a O
patient O
receiving O
disulfiram B-DRUG
treatment O
. O

Cerebral B-ADE
and I-ADE
ocular I-ADE
toxicity I-ADE
induced O
by O
desferrioxamine B-DRUG
. O

Possible O
pathophysiological O
mechanisms O
which O
may O
have O
been O
operative O
in O
this O
case O
include O
: O
a O
direct O
central O
nervous O
system O
( O
CNS O
) O
toxic O
effect O
of O
valproic O
acid O
; O
a O
paradoxical O
epileptogenic O
effect O
secondary O
to O
the O
drug O
; O
and O
an O
indirect O
CNS O
toxic O
effect O
mediated O
through O
valproic B-DRUG
acid I-DRUG
- O
induced O
hyperammonemia B-ADE
. O

The O
relation O
between O
tacrolimus B-DRUG
treatment O
and O
staining O
was O
suggested O
by O
the O
appearance O
of O
pigmentation B-ADE
during O
topical O
tacrolimus B-DRUG
treatment O
and O
its O
clinical O
disappearance O
when O
treatment O
was O
stopped O
. O

Niacin B-DRUG
causes O
a O
reversible B-ADE
toxic I-ADE
cystoid I-ADE
maculopathy I-ADE
that O
occurs O
in O
approximately O
0.67 O
% O
of O
patients O
taking O
high O
doses O
of O
the O
drug O
. O

Clinical O
profile O
of O
oxcarbazepine B-DRUG
- O
related O
angioneurotic B-ADE
edema I-ADE
: O
case O
report O
and O
review O
. O

DLST O
is O
a O
good O
diagnostic O
tool O
for O
AZA B-DRUG
allergy B-ADE
, O
especially O
for O
severe O
drug O
allergy O
cases O
. O

Captopril B-DRUG
- O
related O
( O
and O
-induced O
? O
) O
asthma B-ADE
. O

Colitis B-ADE
as O
a O
manifestation O
of O
infliximab B-DRUG
- O
associated O
disseminated B-ADE
cryptococcosis I-ADE
. O

Gabapentin B-DRUG
- O
induced O
mood B-ADE
changes I-ADE
with O
hypomanic B-ADE
features O
in O
adults O
. O

This O
is O
the O
first O
report O
of O
an O
adverse B-ADE
effect I-ADE
of I-ADE
fetal I-ADE
renal I-ADE
circulation I-ADE
by O
maternal O
ingestion O
of O
nimesulide B-DRUG
. O

Hashimoto B-ADE
's I-ADE
disease I-ADE
during O
interferon B-DRUG
- I-DRUG
alpha I-DRUG
therapy O
in O
a O
patient O
with O
pre O
- O
treatment O
negative O
anti O
- O
thyroid O
autoantibodies O
and O
with O
the O
specific O
genetic O
susceptibility O
to O
the O
thyroid O
disease O
. O

Can O
roxithromycin B-DRUG
and O
betamethasone B-DRUG
induce O
acute B-ADE
pancreatitis I-ADE
? O
A O
case O
report O
. O

In O
all O
cases O
, O
drugs O
in O
addition O
to O
quetiapine O
were O
detected O
, O
but O
in O
cases O
# O
1 O
and O
# O
2 O
, O
the O
cause O
of O
death B-ADE
was O
considered O
to O
be O
a O
quetiapine B-DRUG
overdose O
and O
the O
other O
drugs O
were O
not O
considered O
to O
be O
contributory O
. O

Caution O
in O
longterm O
usage O
and O
early O
recognition O
of O
pentazocine B-ADE
toxicity I-ADE
as O
a O
neuromuscular B-ADE
complication I-ADE
are O
important O
in O
order O
to O
prevent O
irreversible O
drug O
- O
induced O
fibrous B-ADE
myopathy I-ADE
and O
localized O
neuropathy B-ADE
. O

The O
authors O
suggest O
that O
risperidone B-DRUG
may O
increase B-ADE
affect I-ADE
in O
patients O
with O
schizophrenia O
and O
that O
some O
patients O
, O
especially O
those O
with O
anxiety O
, O
may O
have O
difficulty O
managing O
the O
increase O
. O

PURPOSE O
: O
To O
describe O
bilateral B-ADE
optic I-ADE
neuritis I-ADE
that O
occurred O
as O
an O
adverse O
effect O
of O
recombinant O
and O
natural O
interferon B-DRUG
alpha I-DRUG
administration O
. O

We O
report O
a O
patient O
who O
developed O
acute B-ADE
pancreatitis I-ADE
during O
amiodarone B-DRUG
therapy O
. O

Our O
findings O
reveal O
that O
even O
in O
patients O
without O
a O
history O
of O
seizures O
, O
pregabalin B-DRUG
can O
cause O
a O
cortical B-ADE
negative I-ADE
myoclonus I-ADE
. O

The O
hypercalcemia B-ADE
responded O
to O
discontinuation O
of O
rhGH B-DRUG
and O
a O
single O
dose O
of O
intravenous O
pamidronate O
disodium O
and O
has O
not O
recurred O
in O
8 O
months O
of O
follow O
- O
up O
. O

We O
report O
a O
case O
of O
severe B-ADE
AVP I-ADE
three O
weeks O
following O
the O
administration O
of O
infliximab B-DRUG
for O
the O
treatment O
of O
Crohn O
's O
disease O
( O
CD O
) O
. O

Gemcitabine B-DRUG
should O
be O
added O
to O
the O
list O
of O
drugs O
known O
to O
cause O
radiation B-ADE
recall I-ADE
. O

A O
case O
of O
sideroblastic B-ADE
anemia I-ADE
is O
presented O
in O
a O
patient O
with O
a O
left O
ventricular O
assist O
device O
drive O
- O
line O
infection O
who O
was O
receiving O
linezolid B-DRUG
, O
an O
antibiotic O
used O
for O
serious O
infections O
with O
gram O
- O
positive O
organisms O
. O

Disseminated B-ADE
salmonellosis I-ADE
in O
a O
patient O
treated O
with O
temozolomide B-DRUG
. O

After O
the O
addition O
of O
citalopram B-DRUG
, O
a O
desmethylclomipramine B-ADE
plasma I-ADE
level I-ADE
increase I-ADE
and O
an O
8-hydroacy B-ADE
- I-ADE
desmethylclomipramine I-ADE
plasma I-ADE
level I-ADE
decrease I-ADE
were O
observed O
. O

He O
was O
diagnosed O
with O
possible O
serotonin B-ADE
syndrome I-ADE
; O
his O
symptoms O
resolved O
after O
clomipramine B-DRUG
was O
stopped O
but O
before O
clozapine O
was O
restarted O
eight O
days O
later O
. O

Since O
amiodarone O
was O
first O
marketed O
in O
1992 O
in O
Japan O
, O
the O
incidence O
of O
amiodarone B-DRUG
- O
induced O
thyrotoxicosis B-ADE
( O
AIT B-ADE
) O
has O
been O
increasing O
. O

Although O
transient O
increases O
in O
ectopy O
after O
bretylium B-DRUG
therapy O
have O
been O
described O
, O
presumably O
due O
to O
catecholamine O
release O
, O
the O
occurrence O
of O
life O
- O
threatening O
ventricular B-ADE
arrhythmia I-ADE
leading O
to O
cardiac B-ADE
arrest I-ADE
has O
not O
previously O
been O
emphasized O
. O

We O
report O
two O
patients O
with O
anhedonic B-ADE
ejaculation I-ADE
( O
ejaculation B-ADE
without I-ADE
orgasm I-ADE
) O
associated O
with O
initiation O
of O
treatment O
with O
desipramine B-DRUG
. O

We O
report O
on O
a O
patient O
who O
developed O
hypersensitivity B-ADE
pneumonitis I-ADE
during O
treatment O
with O
the O
beta O
- O
blocker O
, O
celiprolol B-DRUG
. O

We O
document O
the O
abrupt O
development O
of O
an O
extensive O
choroidal B-ADE
detachment I-ADE
after O
initiation O
of O
dorzolamide B-DRUG
therapy O
in O
a O
surgically O
untreated O
eye O
with O
primary O
open O
- O
angle O
glaucoma O
. O

A O
40-year O
- O
old O
man O
with O
advanced O
HIV O
infection O
and O
Mycobacterium O
avium O
complex O
infection O
experienced O
rapid B-ADE
cognitive I-ADE
decline I-ADE
after O
commencement O
of O
ethambutol B-DRUG
, O
and O
symptoms O
fully O
resolved O
with O
cessation O
. O

An O
8-year O
- O
old O
child O
with O
familial O
Mediterranean O
fever O
exhibited O
signs O
of O
colchicine B-DRUG
intoxication I-ADE
while O
receiving O
prophylactic O
doses O
of O
the O
drug O
. O

This O
report O
describes O
a O
case O
of O
bilateral B-ADE
ptosis I-ADE
induced O
by O
chloroquine B-DRUG
. O

Nail B-ADE
- I-ADE
changes I-ADE
induced O
by O
penicillamine B-DRUG
. O

He O
was O
started O
on O
digoxin B-DRUG
, O
0.25 O
mg O
daily O
, O
because O
of O
echocardiographically O
demonstrated O
left B-ADE
ventricular I-ADE
dilatation I-ADE
and O
functional B-ADE
impairment I-ADE
; O
he O
died O
of O
ventricular B-ADE
fibrillation I-ADE
15 O
days O
later O
. O

Disseminated B-ADE
intravascular I-ADE
coagulation I-ADE
associated O
with O
acute B-ADE
hemoglobinemia I-ADE
or O
hemoglobinuria B-ADE
following O
Rh(0)(D B-DRUG
) I-DRUG
immune I-DRUG
globulin I-DRUG
intravenous O
administration O
for O
immune O
thrombocytopenic O
purpura O
. O

Disopyramide B-DRUG
- O
induced O
heart B-ADE
block I-ADE
. O

A O
depressed O
woman O
with O
no O
history O
of O
bipolar O
illness O
developed O
a O
manic B-ADE
episode I-ADE
during O
treatment O
with O
fluoxetine B-DRUG
. O

We O
report O
a O
case O
of O
fatal B-ADE
pulmonary I-ADE
toxicity I-ADE
in O
a O
patient O
with O
advanced O
non O
- O
small O
cell O
lung O
cancer O
who O
received O
erlotinib B-DRUG
. O

Symptomatic B-ADE
hypocalcaemia I-ADE
and O
renal B-ADE
impairment I-ADE
associated O
with O
bisphosphonate B-DRUG
treatment O
in O
patients O
with O
multiple O
myeloma O
. O

Sorafenib B-DRUG
induced O
tumor B-ADE
lysis I-ADE
syndrome I-ADE
in O
an O
advanced O
hepatocellular O
carcinoma O
patient O
. O

Pneumocystis B-ADE
pneumonia I-ADE
should O
be O
considered O
in O
asthmatic O
patients O
taking O
methotrexate B-DRUG
who O
present O
with O
fever B-ADE
, O
pulmonary B-ADE
infiltrates I-ADE
, O
and O
hypoxia B-ADE
. O

A O
case O
of O
timolol B-DRUG
- O
associated O
heart B-ADE
failure I-ADE
in O
a O
73-year O
old O
white O
man O
is O
reported O
. O

With O
itraconazole B-DRUG
, O
hepatotoxic B-ADE
reactions O
have O
only O
very O
rarely O
been O
reported O
, O
and O
histologic O
data O
are O
lacking O
. O

The O
cases O
are O
important O
in O
documenting O
that O
drug O
- O
induced O
dystonias O
do O
occur O
in O
patients O
with O
dementia O
, O
that O
risperidone B-DRUG
appears O
to O
have O
contributed O
to O
dystonia B-ADE
among O
elderly O
patients O
, O
and O
that O
the O
categorization O
of O
dystonic O
reactions O
needs O
further O
clarification O
. O

Two O
patients O
treated O
with O
5-fluorouracil B-DRUG
( O
5-FU B-DRUG
) O
for O
disseminated O
adenocarcinoma O
of O
the O
colon O
developed O
cerebellar B-ADE
dysfunction I-ADE
typical O
of O
5-FU B-DRUG
neurotoxicity B-ADE
. O

The O
authors O
also O
determined O
that O
their O
case O
of O
myositis B-ADE
developing O
in O
the O
rectus O
abdominus O
muscle O
of O
a O
patient O
with O
pancreatic O
adenocarcinoma O
was O
the O
manifestation O
of O
radiation B-ADE
recall I-ADE
, O
thereby O
bringing O
the O
number O
of O
patients O
who O
developed O
radiation B-ADE
recall I-ADE
to O
gemcitabine B-DRUG
and O
were O
discussed O
in O
the O
current O
study O
to O
13 O
. O

The O
other O
woman O
had O
rheumatoid O
arthritis O
and O
developed O
acute B-ADE
tubular I-ADE
necrosis I-ADE
after O
treatment O
with O
gentamicin B-DRUG
and O
cefoxitin B-DRUG
. O

Myasthenic O
patients O
receiving O
ampicillin B-DRUG
should O
be O
closely O
monitored O
for O
possible O
acute B-ADE
exacerbations I-ADE
. O

We O
describe O
a O
patient O
with O
the O
antiphospholipid O
syndrome O
who O
had O
skin B-ADE
necrosis I-ADE
develop O
from O
low B-DRUG
- I-DRUG
molecular I-DRUG
weight I-DRUG
heparin I-DRUG
therapy O
at O
sites O
distant O
from O
injection O
sites O
. O

In O
one O
case O
, O
disulfiram B-DRUG
was O
the O
only O
potential O
teratogen B-ADE
exposed O
to O
the O
fetus O
. O

RESULTS O
: O
Including O
our O
own O
patient O
, O
a O
total O
of O
26 O
cases O
of O
gemcitabine B-DRUG
- O
associated O
HUS B-ADE
were O
identified O
. O

Hyperpigmentation B-ADE
during O
interferon B-DRUG
- I-DRUG
alpha I-DRUG
therapy O
for O
chronic O
hepatitis O
C O
virus O
infection O
. O

Primary B-ADE
cutaneous I-ADE
coccidioidomycosis I-ADE
and O
subsequent O
drug B-ADE
eruption I-ADE
to O
itraconazole B-DRUG
in O
a O
dog O
. O

CONCLUSION O
: O
During O
and O
after O
IFN B-DRUG
therapy O
, O
OCT O
is O
a O
useful O
examination O
technique O
for O
revealing O
macular B-ADE
edema I-ADE
in O
patients O
who O
have O
decreased B-ADE
vision I-ADE
. O

Carbamazepine B-DRUG
- O
induced O
Diabetes B-ADE
mellitus I-ADE
. O

When O
the O
patient O
was O
treated O
again O
with O
fludarabine B-DRUG
nine O
months O
later O
, O
the O
DAT B-ADE
became I-ADE
positive I-ADE
with I-ADE
anti I-ADE
- I-ADE
IgG I-ADE
and I-ADE
anti I-ADE
- I-ADE
C3d I-ADE
antiglobulins I-ADE
after O
the O
second O
course O
of O
treatment O
. O

A O
case O
of O
noncardiogenic B-ADE
pulmonary I-ADE
edema I-ADE
by O
ethanolamine B-DRUG
oleate I-DRUG
. O

We O
report O
a O
case O
admitted O
with O
a O
first O
- O
detected O
, O
symptomatic B-ADE
paroxysmal I-ADE
atrial I-ADE
fibrillation I-ADE
in O
a O
healthy O
patient O
after O
self O
- O
medication O
with O
vardenafil B-DRUG
. O

We O
describe O
2 O
patients O
with O
severe O
erosive O
rheumatoid O
arthritis O
and O
rheumatoid O
vasculitis O
, O
respectively O
, O
in O
whom O
infliximab B-DRUG
therapy O
was O
associated O
with O
peripheral B-ADE
neuropathy I-ADE
due O
to O
necrotizing B-ADE
vasculitis I-ADE
in O
one O
patient O
and O
to O
progression B-ADE
of I-ADE
preexisting I-ADE
mononeuritis I-ADE
multiplex I-ADE
in O
the O
other O
. O

Discontinuation O
of O
the O
itraconazole B-DRUG
caused O
resolution O
of O
the O
drug B-ADE
eruption I-ADE
. O

Toxic B-ADE
optic I-ADE
neuropathy I-ADE
associated O
with O
ethambutol B-DRUG
: O
implications O
for O
current O
therapy O
. O

Hepatic B-ADE
reactions I-ADE
to O
cyclofenil B-DRUG
. O

Etoposide B-DRUG
- O
related O
myocardial B-ADE
infarction I-ADE
. O

A O
patient O
suffering O
from O
a O
rare O
enzyme O
deficiency O
developed O
a O
malignant B-ADE
neuroleptic I-ADE
syndrome I-ADE
after O
having O
been O
treated O
with O
one O
single O
dose O
of O
haloperidol B-DRUG
. O

Conventional O
and O
diffusion O
- O
weighted O
MRI O
findings O
of O
methotrexate B-DRUG
related O
sub B-ADE
- I-ADE
acute I-ADE
neurotoxicity I-ADE
. O

Contrary O
to O
previous O
recommendations O
, O
our O
experience O
cautions O
against O
the O
further O
use O
of O
high O
- O
dose O
cytarabine B-DRUG
in O
patients O
who O
develop O
PPE B-ADE
, O
and O
is O
a O
timely O
reminder O
of O
the O
potential O
toxicity O
of O
this O
agent O
, O
which O
is O
now O
increasingly O
being O
used O
as O
first O
- O
line O
treatment O
in O
the O
management O
of O
haematologic O
malignancies O
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
possible O
foscarnet B-DRUG
- O
induced O
severe B-ADE
hypomagnesemia I-ADE
and O
other O
electrolyte B-ADE
disorders I-ADE
. O

A O
case O
of O
aseptic B-ADE
pleuropericarditis I-ADE
in O
a O
patient O
with O
chronic O
plaque O
psoriasis O
under O
methotrexate B-DRUG
therapy O
. O

Hypercalcemia B-ADE
in O
an O
AIDS O
patient O
treated O
with O
growth B-DRUG
hormone I-DRUG
. O

We O
describe O
a O
renal O
transplant O
recipient O
maintained O
on O
cyclosporine B-DRUG
and O
prednisone B-DRUG
developing O
Nocardia B-ADE
Asteroides I-ADE
brain I-ADE
abscess I-ADE
. O

The O
first O
known O
report O
of O
quetiapine B-DRUG
exacerbating B-ADE
OCS I-ADE
in O
a O
43-year O
- O
old O
man O
with O
obsessive O
- O
compulsive O
disorder O
( O
OCD O
) O
, O
trichotillomania O
, O
delusional O
disorder O
and O
bipolar O
II O
disorder O
is O
presented O
. O

We O
introduce O
a O
case O
of O
a O
sixty O
years O
old O
woman O
with O
several O
previous O
episodes O
of O
rhinitis B-ADE
, O
conjunctivitis B-ADE
and O
perspiration B-ADE
immediately O
after O
the O
administration O
of O
salmon O
calcitonin B-DRUG
with O
nasal O
spray O
or O
intramuscular O
administration O
( O
Calsynar B-DRUG
) O
. O

Acute O
drug O
induced O
hepatitis B-ADE
due O
to O
erlotinib B-DRUG
. O

CASE O
SUMMARIES O
: O
While O
conducting O
a O
protocol O
evaluating O
the O
efficacy O
of O
intraperitoneal O
cisplatin B-DRUG
and O
hyperthermia O
in O
the O
treatment O
of O
recurrent O
ovarian O
cancer O
, O
3 O
patients O
were O
noted O
to O
exhibit O
anaphylactoid B-ADE
reactions I-ADE
. O

Leukaemoid B-ADE
monocytosis I-ADE
in O
M4 O
AML O
following O
chemotherapy O
and O
G B-DRUG
- I-DRUG
CSF I-DRUG
. O

Our O
series O
of O
3 O
patients O
supports O
a O
causal O
connection O
between O
bleomycin B-DRUG
and O
scleroderma B-ADE
. O

We O
report O
a O
case O
of O
a O
bullous B-ADE
lichenoid I-ADE
eruption I-ADE
due O
to O
the O
intake O
of O
captopril B-DRUG
. O

Therapy O
with O
IFN B-DRUG
- I-DRUG
beta I-DRUG
has O
rarely O
been O
associated O
with O
the O
development O
of O
autoimmune B-ADE
disorders I-ADE
. O

Ototoxicity B-ADE
as O
a O
result O
of O
cis B-DRUG
- I-DRUG
platinum I-DRUG
administration O
is O
well O
documented O
. O

Visceral B-ADE
leishmaniasis I-ADE
and O
macrophagic B-ADE
activation I-ADE
syndrome I-ADE
in O
a O
patient O
with O
rheumatoid O
arthritis O
under O
treatment O
with O
adalimumab B-DRUG
. O

Panic B-ADE
anxiety I-ADE
after O
abrupt O
discontinuation O
of O
mianserin B-DRUG
. O

ADH B-ADE
hypersecretion I-ADE
in O
relation O
to O
plasma O
osmolality O
was O
reversed O
by O
mizoribin B-DRUG
withdrawal O
, O
suggesting O
that O
bredinin B-DRUG
might O
adversely O
induce O
SIADH B-ADE
. O

Epoprostenol B-DRUG
may O
be O
associated O
rarely O
with O
severe O
erythroderma B-ADE
. O

It O
is O
concluded O
that O
SIADH B-ADE
is O
an O
important O
side O
effect O
of O
lorcainide B-DRUG
therapy O
. O

The O
risk O
of O
new O
- O
onset O
diabetic B-ADE
ketoacidosis I-ADE
in O
patients O
with O
diabetic O
risk O
factors O
who O
are O
taking O
perospirone B-DRUG
hydrochloride I-DRUG
or O
other O
atypical O
antipsychotics O
should O
be O
kept O
in O
mind O
. O

We O
describe O
the O
first O
documented O
case O
of O
azathioprine B-DRUG
- O
induced O
severe O
myelosuppression B-ADE
due O
to O
thiopurine O
methyltransferase O
deficiency O
in O
autoimmune O
liver O
disease O
. O

We O
recommend O
that O
clinicians O
monitor O
patients O
for O
signs O
and O
symptoms O
of O
pancreatitis B-ADE
, O
including O
abdominal B-ADE
pain I-ADE
, O
during O
treatment O
with O
tigecycline B-DRUG
. O

Recombinant B-DRUG
human I-DRUG
interferon I-DRUG
- I-DRUG
alpha I-DRUG
has O
been O
used O
in O
the O
treatment O
of O
several O
cancers O
, O
but O
there O
have O
been O
several O
reports O
that O
it O
may O
exacerbate B-ADE
psoriasis I-ADE
or I-ADE
trigger I-ADE
off I-ADE
its I-ADE
onset I-ADE
. O

We O
report O
a O
case O
of O
a O
patient O
with O
mild B-ADE
chronic I-ADE
renal I-ADE
insufficiency I-ADE
who O
had O
been O
taking O
simvastatin B-DRUG
for O
over O
a O
year O
and O
developed O
acute B-ADE
weakness I-ADE
within O
3 O
weeks O
after O
the O
start O
of O
treatment O
with O
colchicine B-DRUG
for O
acute O
gouty O
bursitis O
. O

He O
developed O
recurrent O
skin B-ADE
rash I-ADE
, O
fever B-ADE
, O
hypereosinophilia B-ADE
, O
and O
acute B-ADE
renal I-ADE
failure I-ADE
after O
rechallenge O
with O
chlorambucil B-DRUG
. O

We O
report O
a O
male O
patient O
with O
advanced O
AIDS O
who O
developed O
hypercalcemia B-ADE
2 O
weeks O
after O
institution O
of O
rhGH B-DRUG
therapy O
. O

One O
patient O
on O
ouabain B-DRUG
also O
developed O
cardiomyopathy B-ADE
. O

CONCLUSION O
: O
Lipoid B-ADE
pneumonia I-ADE
as O
a O
result O
of O
mineral B-DRUG
oil I-DRUG
aspiration O
still O
occurs O
in O
the O
pediatric O
population O
. O

METHOD O
: O
We O
describe O
three O
case O
- O
reports O
concerning O
haematological B-ADE
adverse I-ADE
effects I-ADE
of O
quetiapine B-DRUG
. O

The O
known O
side O
effects O
of O
sibutramine B-DRUG
, O
ie O
, O
hypertension B-ADE
and O
tachycardia B-ADE
, O
depend O
on O
its O
adrenergic O
and O
serotoninergic O
effects O
. O

Systemic B-ADE
vasculitis I-ADE
complicating O
hairy O
cell O
leukaemia O
treatment O
with O
cladribine B-DRUG
. O

CONCLUSIONS O
: O
Among O
the O
many O
presentations O
of O
ifosfamide B-DRUG
neurotoxicity B-ADE
, O
clinicians O
should O
consider O
NCSE O
as O
a O
possible O
explanation O
for O
changes O
in O
consciousness O
in O
a O
patient O
receiving O
this O
agent O
. O

Oral O
intake O
and O
acarbose B-DRUG
were O
withheld O
and O
the O
ileus B-ADE
spontaneously O
resolved O
after O
2 O
days O
. O

One O
of O
the O
subjects O
who O
was O
using O
extemporaneous O
topical O
minoxidil B-DRUG
had O
hypertension B-ADE
and O
arteriosclerotic B-ADE
disease I-ADE
and O
the O
other O
died O
of O
a O
myocardial B-ADE
infarction I-ADE
. O

Cholesterol B-ADE
crystal I-ADE
embolization I-ADE
- O
associated O
renal B-ADE
failure I-ADE
after O
therapy O
with O
recombinant O
tissue B-DRUG
- I-DRUG
type I-DRUG
plasminogen I-DRUG
activator I-DRUG
. O

Kaposi B-ADE
's I-ADE
sarcoma I-ADE
in O
a O
patient O
treated O
with O
imatinib B-DRUG
mesylate I-DRUG
for O
chronic O
myeloid O
leukemia O
. O

Bortezomib B-DRUG
- O
induced O
paralytic B-ADE
ileus I-ADE
is O
a O
potential O
gastrointestinal B-ADE
side I-ADE
effect I-ADE
of O
this O
first O
- O
in O
- O
class O
anticancer O
proteasome O
inhibitor O
. O

Since O
this O
amount O
of O
FAB O
was O
insufficient O
to O
bind O
all O
DGTX O
present O
in O
the O
serum O
, O
cardiac B-ADE
DGTX B-DRUG
toxicity I-ADE
( O
total B-ADE
AV I-ADE
- I-ADE
block I-ADE
) O
persisted O
. O

Sotalol B-DRUG
- O
induced O
bradycardia B-ADE
reversed O
by O
glucagon O
. O

Treatment O
- O
related O
myelodysplastic B-ADE
syndrome I-ADE
after O
temozolomide B-DRUG
for O
recurrent O
high O
- O
grade O
glioma O
. O

Pilocarpine B-DRUG
toxicity I-ADE
and O
the O
treatment O
of O
xerostomia O
. O

Heparin B-DRUG
- O
induced O
thrombocytopenia B-ADE
complicated O
with O
massive B-ADE
thrombosis I-ADE
of I-ADE
the I-ADE
inferior I-ADE
vena I-ADE
cava I-ADE
after O
filter O
placement O
. O

Probable O
early O
acute B-ADE
hepatitis I-ADE
with O
parenteral O
amiodarone B-DRUG
. O

Cholelithiasis B-ADE
and O
thrombosis B-ADE
of I-ADE
the I-ADE
central I-ADE
retinal I-ADE
vein I-ADE
in O
a O
renal O
transplant O
recipient O
treated O
with O
cyclosporin B-DRUG
. O

The O
male O
patient O
was O
treated O
with O
225-mg O
/ O
day O
clozapine B-DRUG
and O
the O
time O
to O
the O
diagnosis O
of O
agranulocytosis B-ADE
was O
6 O
weeks O
. O

Heparin O
- O
dependent O
antibodies O
and O
thrombosis O
without O
heparin B-DRUG
- O
induced O
thrombocytopenia B-ADE
. O

The O
increasing O
prevalence O
of O
methamphetamine B-DRUG
abuse O
and O
the O
severity O
of O
the O
associated O
ulcers B-ADE
should O
alert O
ophthalmologists O
to O
the O
problem O
of O
methamphetamine B-DRUG
- O
related O
keratitis B-ADE
. O

BACKGROUND O
: O
How O
to O
best O
treat O
psychotic O
patients O
who O
have O
had O
past O
clozapine B-DRUG
- O
induced O
agranulocytosis O
or O
granulocytopenia B-ADE
remains O
a O
problem O
. O

A O
patient O
with O
Parkinson O
's O
disease O
, O
initially O
treated O
with O
bromocriptine B-DRUG
and O
subsequently O
with O
cabergoline B-DRUG
, O
developed O
progressive O
pleuropulmonary B-ADE
abnormalities I-ADE
during O
the O
latter O
therapy O
. O

However O
, O
an O
association O
of O
Ritalin B-DRUG
with O
glaucoma B-ADE
has O
been O
reported O
. O

A O
rare O
case O
of O
advanced O
ovarian O
carcinoma O
who O
developed O
difficulty B-ADE
walking I-ADE
25 O
days O
after O
treatment O
with O
weekly O
paclitaxel B-DRUG
. O

It O
should O
be O
emphasized O
that O
the O
recurrence O
of O
nephrotic B-ADE
syndrome I-ADE
was O
observed O
after O
the O
following O
chemotherapy O
, O
including O
M B-DRUG
- I-DRUG
CSF I-DRUG
, O
whereas O
the O
bone O
marrow O
still O
remained O
completely O
remitted O
. O

Quetiapine B-DRUG
- O
induced O
myoclonus B-ADE
. O

We O
describe O
a O
case O
of O
PRES B-ADE
in O
a O
patient O
with O
collapsing O
focal O
glomeruloesclerosis O
( O
collapsing O
FGS O
) O
with O
complete O
recovery O
after O
withdrawal O
of O
cyclosporine B-DRUG
( O
CSA B-DRUG
) O
. O

We O
report O
two O
cases O
that O
developed O
acute B-ADE
myeloid I-ADE
leukaemia I-ADE
( O
AML B-ADE
) O
during O
tamoxifen B-DRUG
therapy O
for O
breast O
cancer O
. O

Sustained B-ADE
hypothyroidism I-ADE
induced O
by O
recombinant B-DRUG
alpha I-DRUG
interferon I-DRUG
in O
patients O
with O
chronic O
hepatitis O
C O
. O

We O
report O
a O
76-year O
- O
old O
man O
who O
developed O
an O
acute B-ADE
blistering I-ADE
eruption I-ADE
following O
high O
- O
dose O
penicillin B-DRUG
treatment O
for O
pneumococcal O
septicaemia O
. O

Secretory B-ADE
endometrial I-ADE
adenocarcinoma I-ADE
in O
a O
patient O
on O
tamoxifen B-DRUG
for O
breast O
cancer O
: O
a O
report O
of O
a O
case O
. O

These O
findings O
mean O
that O
the O
effect O
of O
the O
MP O
pulse O
therapy O
on O
renal O
function O
depends O
on O
the O
clinical O
state O
of O
the O
patient O
and O
that O
renal O
deterioration O
after O
the O
pulse O
therapy O
may O
be O
more O
marked O
in O
patients O
who O
are O
more O
nephrotic O
and O
more O
impaired O
in O
renal O
function O
and O
suggest O
that O
increasing O
sodium O
and O
water O
retention O
during O
an O
MP O
therapy O
and O
the O
associated O
renal O
interstitial O
edema O
, O
proposed O
as O
one O
of O
the O
mechanisms O
of O
acute O
renal O
failure O
occurring O
in O
patients O
with O
minimal O
- O
change O
nephrotic O
syndrome O
, O
may O
be O
responsible O
for O
the O
MP B-DRUG
- O
induced O
transient B-ADE
renal I-ADE
failure I-ADE
. O

Autoimmune B-ADE
thyroid I-ADE
disease I-ADE
is O
a O
common O
side O
- O
effect O
of O
interferon B-DRUG
- I-DRUG
alpha I-DRUG
( O
IFN B-DRUG
- I-DRUG
alpha I-DRUG
) O
treatment O
of O
viral O
hepatitis O
C O
. O

Major O
points O
illustrated O
are O
, O
( O
1 O
) O
occurrence O
of O
HIT B-ADE
with O
any O
dose O
or O
form O
of O
heparin B-DRUG
; O
( O
2 O
) O
misperceptions O
on O
the O
diagnostic O
criteria O
; O
( O
3 O
) O
correct O
( O
thrombin O
inhibitors O
) O
and O
incorrect O
( O
platelet O
transfusions O
and O
warfarin O
) O
management O
; O
( O
4 O
) O
influence O
of O
management O
strategy O
on O
clinical O
outcomes O
; O
( O
5 O
) O
severity O
of O
the O
syndrome O
; O
and O
( O
6 O
) O
potential O
for O
both O
anamnestic O
response O
to O
heparin O
and O
disappearance O
of O
HIT O
antibodies O
over O
time O
. O

It O
is O
believed O
that O
this O
is O
the O
first O
reported O
case O
of O
reversible O
azathioprine B-DRUG
- O
induced O
cholestasis B-ADE
associated O
with O
histological O
evidence O
of O
bile O
duct O
injury O
. O

We O
report O
a O
case O
of O
pediatric O
bupropion B-DRUG
ingestion O
resulting O
in O
multiple B-ADE
seizures I-ADE
. O

Enalaprilat B-DRUG
induced O
acute B-ADE
parotitis I-ADE
. O

A O
noninvasive O
method O
in O
the O
differential O
diagnosis O
of O
vecuronium B-DRUG
- O
induced O
and O
magnesium B-DRUG
- O
induced O
protracted B-ADE
neuromuscular I-ADE
block I-ADE
in O
a O
severely O
preeclamptic O
patient O
. O

Young O
children O
undergoing O
cisplatin B-DRUG
chemotherapy O
are O
known O
to O
be O
at O
risk O
for O
progressive B-ADE
sensorineural I-ADE
hearing I-ADE
loss I-ADE
. O

Tacrolimus B-DRUG
( O
FK506 B-DRUG
) O
- O
induced O
mutism B-ADE
after O
liver O
transplant O
. O

Leukopenia B-ADE
due O
to O
parvovirus O
B19 O
in O
a O
Crohn O
's O
disease O
patient O
using O
azathioprine B-DRUG
. O

METHODS O
: O
Five O
cases O
of O
contact B-ADE
dermatitis I-ADE
due O
to O
budesonide B-DRUG
, O
a O
nonhalogenated O
steroid O
, O
are O
described O
. O

The O
side O
effects O
of O
MMF B-DRUG
, O
such O
as O
bone B-ADE
marrow I-ADE
toxicity I-ADE
, O
have O
been O
reported O
. O

The O
patient O
received O
only O
the O
ophthalmic O
sulfonamide B-DRUG
, O
and O
it O
was O
used O
for O
one O
day O
, O
but O
he O
developed O
Stevens B-ADE
- I-ADE
Johnson I-ADE
syndrome I-ADE
. O

During O
the O
anti O
- O
tuberculous O
therapy O
, O
visual B-ADE
loss I-ADE
can O
be O
related O
to O
ethambutol B-DRUG
toxicity O
or O
the O
tuberculosis O
infection O
itself O
. O

Ceftriaxone O
was O
approved O
in O
1997 O
for O
the O
treatment O
of O
otitis O
media O
despite O
previous O
studies O
that O
documented O
an O
association O
of O
ceftriaxone B-DRUG
with O
elevated B-ADE
hepato I-ADE
- I-ADE
biliary I-ADE
enzymes I-ADE
and O
transient B-ADE
biliary I-ADE
stasis I-ADE
. O

We O
describe O
2 O
children O
with O
cerebral O
palsy O
who O
suffered O
significant O
morbidity B-ADE
immediately O
after O
treatment O
with O
hyperbaric B-DRUG
oxygen I-DRUG
. O

Myoclonic B-ADE
spasms I-ADE
following O
intrathecal O
morphine B-DRUG
. O

We O
describe O
a O
5-year O
- O
old O
girl O
showed O
recovery O
of O
vincristine B-DRUG
induced O
cranial B-ADE
polyneuropathy I-ADE
with O
pyridoxine O
and O
pyridostigmine O
treatment O
. O

Hypoglycemia B-ADE
induced O
by O
long O
- O
acting O
somatostatin B-DRUG
analogues O
in O
a O
patient O
with O
nonfunctional O
neuroendocrine O
tumor O
. O

We O
have O
cared O
for O
three O
children O
in O
whom O
four O
episodes O
of O
dystonia B-ADE
proceeding O
to O
opisthotonus B-ADE
occurred O
in O
association O
with O
carbamazepine B-DRUG
use O
. O

She O
was O
placed O
on O
adjuvant O
Adriamycin B-DRUG
( O
doxorubicin B-DRUG
) O
chemotherapy O
, O
but O
6 O
months O
later O
died B-ADE
of O
Adriamycin B-DRUG
toxicity I-ADE
. O

This O
case O
showed O
sequential O
manifestation O
from O
transient O
thyrotoxicosis O
to O
the O
appearance O
of O
TSH O
- O
receptor O
autoantibodies O
, O
and O
then O
the O
occurrence O
of O
Graves B-ADE
' I-ADE
hyperthyroidism I-ADE
during O
IFN B-DRUG
therapy O
. O

2-CdA B-DRUG
induces O
lymphocytopenia B-ADE
, O
which O
may O
explain O
the O
improvement O
in O
this O
patient O
's O
psoriasis O
. O

Late O
development O
of O
diabetes B-ADE
mellitus I-ADE
after O
interferon B-DRUG
- I-DRUG
alfa I-DRUG
and O
ribavirin B-DRUG
therapy O
for O
chronic O
hepatitis O
C O
: O
a O
case O
report O
. O

Ten O
hours O
after O
the O
second O
methotrexate B-DRUG
injection O
, O
the O
patient O
experienced O
a O
diffuse B-ADE
pruritic I-ADE
papular I-ADE
eruption I-ADE
located O
mainly O
on O
the O
limbs O
. O

We O
report O
three O
cases O
of O
severe B-ADE
hypocalcaemia I-ADE
associated O
with O
i.v O
. O
bisphosphonate B-DRUG
treatment O
in O
patients O
with O
multiple O
myeloma O
. O

We O
report O
four O
patients O
, O
three O
of O
whom O
first O
developed O
psoriasis B-ADE
and O
one O
who O
had O
an O
aggravation O
of O
the O
condition O
during O
treatment O
with O
interferon B-DRUG
- I-DRUG
alpha I-DRUG
. O

Cyclosporine B-DRUG
is O
a O
potent O
inhibitor O
of O
simvastatin O
metabolism O
, O
and O
may O
therefore O
facilitate O
simvastatin B-DRUG
- O
induced O
rhabdomyolysis B-ADE
. O

He O
was O
started O
on O
oral O
lansoprazole B-DRUG
60 O
mg O
twice O
daily O
and O
, O
on O
hospital O
day O
2 O
, O
his O
platelet B-ADE
count I-ADE
decreased I-ADE
to O
102 O
x O
10(3)/mm(3 O
) O
; O
on O
hospital O
day O
3 O
, O
the O
platelet O
count O
was O
36 O
x O
10(3)/mm(3 O
) O
. O

Acute B-ADE
respiratory I-ADE
distress I-ADE
syndrome I-ADE
after O
rituximab B-DRUG
infusion O
. O

Temsirolimus B-DRUG
- O
induced O
glomerulopathy B-ADE
. O

Chromosome B-ADE
abnormalities I-ADE
after O
chlorambucil B-DRUG
therapy O
of O
polycythaemia O
vera O
. O

Development O
of O
tics B-ADE
in O
a O
thirteen O
- O
year O
- O
old O
male O
following O
atomoxetine B-DRUG
use O
. O

The O
authors O
report O
a O
longitudinal O
case O
study O
of O
a O
woman O
with O
a O
history O
of O
bipolar O
affective O
disorder O
in O
which O
L B-DRUG
- I-DRUG
dopa I-DRUG
shortened B-ADE
the I-ADE
manic I-ADE
- I-ADE
depressive I-ADE
cycle I-ADE
length O
when O
administered O
in O
a O
double O
- O
blind O
trial O
. O

This O
review O
presents O
the O
first O
case O
series O
of O
DIC B-ADE
associated O
with O
acute B-ADE
hemoglobinemia I-ADE
or O
hemoglobinuria B-ADE
following O
anti B-DRUG
- I-DRUG
D I-DRUG
IGIV I-DRUG
administration O
for O
ITP O
. O

Psoriasis B-ADE
induced O
by O
interferon B-DRUG
- I-DRUG
alpha I-DRUG
. O

Quinine B-DRUG
and O
its O
isomer O
quinidine B-DRUG
are O
well O
- O
known O
causes O
of O
iatrogenic B-ADE
hypoglycaemia I-ADE
, O
due O
to O
excessive O
insulin O
secretion O
. O

We O
report O
a O
case O
of O
a O
patient O
with O
pulmonary O
hypertension O
and O
undifferentiated O
connective O
tissue O
disease O
who O
, O
after O
2 O
months O
of O
treatment O
with O
epoprostenol B-DRUG
, O
presented O
with O
rapidly B-ADE
progressive I-ADE
erythema I-ADE
, O
scaling B-ADE
, O
nausea B-ADE
and O
vomiting B-ADE
, O
and O
fever B-ADE
. O

CONCLUSIONS O
: O
We O
present O
a O
case O
of O
a O
patient O
with O
CML O
who O
developed O
KS B-ADE
12 O
months O
after O
starting O
treatment O
with O
imatinib B-DRUG
400 O
mg O
/ O
d O
. O

Bromide B-ADE
intoxication I-ADE
secondary O
to O
pyridostigmine B-DRUG
bromide I-DRUG
therapy O
. O

Bleomycin B-DRUG
and O
cyclophosphamide B-DRUG
toxicity O
simulating O
metastatic B-ADE
nodules I-ADE
to O
the O
lungs O
in O
childhood O
cancer O
. O

However O
, O
he O
developed O
acute B-ADE
renal I-ADE
failure I-ADE
, O
hyperkalemia B-ADE
, O
and O
hyperuricemia B-ADE
30 O
d O
after O
receiving O
the O
sorafenib B-DRUG
treatment O
. O

CONCLUSION O
: O
A O
woman O
receiving O
enoxaparin B-DRUG
every O
12 O
hours O
developed O
signs O
and O
symptoms O
of O
hepatotoxicity B-ADE
after O
the O
second O
dose O
. O

Verapamil B-DRUG
in O
effort O
- O
induced O
angina B-ADE
pectoris I-ADE
in O
patients O
with O
normal O
coronary O
arteries O
. O

Here O
we O
present O
the O
case O
of O
a O
woman O
who O
received O
high O
doses O
of O
methylprednisolone B-DRUG
( O
1 O
g O
iv O
daily O
) O
for O
active O
Graves O
' O
ophthalmopathy O
, O
and O
developed O
severe B-ADE
hypertension I-ADE
followed O
by O
myocardial B-ADE
infarction I-ADE
on O
the O
fifth O
day O
of O
treatment O
. O

The O
spectrum O
of O
renal B-ADE
lesions I-ADE
occurring O
during O
antituberculous O
therapy O
, O
particularly O
in O
association O
with O
rifampin B-DRUG
, O
may O
be O
wider O
than O
previously O
suspected O
. O

CONCLUSION O
: O
The O
new O
quinolone O
derivatives O
( O
levofloxacin B-DRUG
, O
sparfloxacin B-DRUG
, O
grepafloxacin B-DRUG
, O
trovafloxacin B-DRUG
, O
gatifloxacin B-DRUG
and O
moxifloxacin B-DRUG
) O
, O
also O
called O
gyrase O
inhibitors O
, O
are O
known O
for O
their O
potential O
to O
cause O
central O
nervous O
system O
- O
related O
adverse O
effects O
, O
including O
headache B-ADE
, O
dizziness B-ADE
and O
insomnia B-ADE
. O

PURPOSE O
: O
Symptomatic O
visual B-ADE
field I-ADE
constriction I-ADE
thought O
to O
be O
associated O
with O
vigabatrin B-DRUG
has O
been O
reported O
. O

The O
probable O
proarrhythmic B-ADE
action O
of O
amiodarone B-DRUG
, O
although O
rare O
, O
is O
reviewed O
along O
with O
a O
discussion O
of O
the O
novel O
use O
of O
intravenous O
magnesium O
sulfate O
therapy O
. O

Acute B-ADE
acoustic I-ADE
nerve I-ADE
palsy I-ADE
associated O
with O
vincristine B-DRUG
therapy O
. O

The O
authors O
report O
two O
cases O
of O
delayed B-ADE
elimination I-ADE
of O
methotrexate B-DRUG
in O
patients O
receiving O
ciprofloxacin B-DRUG
, O
with O
severe O
toxicity B-ADE
. O

Administration O
of O
amantadine B-DRUG
was O
associated O
with O
psychotic B-ADE
decompensations I-ADE
in O
two O
schizophrenic O
patients O
being O
maintained O
on O
concomitant O
neuroleptic O
medication O
. O

Prolongation B-ADE
of I-ADE
the I-ADE
QT I-ADE
interval I-ADE
and O
ventricular B-ADE
tachyarrhymias I-ADE
have O
been O
described O
in O
patients O
on O
amiodarone B-DRUG
therapy O
. O

Carbamazepine B-DRUG
induced O
right B-ADE
bundle I-ADE
branch I-ADE
block I-ADE
in O
a O
Greenlandic O
patient O
. O

A O
transient B-ADE
tonic I-ADE
pupillary I-ADE
response I-ADE
, O
denervation B-ADE
supersensitivity I-ADE
, O
and O
abnormal B-ADE
visual I-ADE
- I-ADE
evoked I-ADE
potentials I-ADE
in O
quinine B-DRUG
toxicity O
, O
to O
our O
knowledge O
, O
have O
not O
been O
previously O
reported O
. O

Acute B-ADE
generalized I-ADE
exanthematous I-ADE
pustulosis I-ADE
induced O
by O
nimesulide B-DRUG
. O

Angioedema B-ADE
and O
dysphagia B-ADE
caused O
by O
contact O
allergy O
to O
inhaled O
budesonide B-DRUG
. O

We O
report O
three O
cases O
of O
IFN B-DRUG
beta I-DRUG
induced O
hepatitis B-ADE
in O
MS O
and O
discuss O
the O
pathology O
findings O
and O
possible O
mechanisms O
of O
drug O
- O
induced O
liver B-ADE
injury I-ADE
. O

Diarrhea B-ADE
- I-ADE
associated I-ADE
over I-ADE
- I-ADE
anticoagulation I-ADE
in O
a O
patient O
taking O
warfarin B-DRUG
: O
therapeutic O
role O
of O
cholestyramine O
. O

The O
pathogenic O
mechanisms O
involved O
in O
the O
development O
of O
adriamycin B-DRUG
cardiomyopathy B-ADE
are O
reviewed O
, O
and O
the O
possible O
synergistic O
effect O
of O
other O
antitumor O
antibiotics O
is O
discussed O
. O

To O
our O
knowledge O
, O
no O
prior O
cases O
of O
penicillamine B-DRUG
- O
induced O
TTP B-ADE
in O
RA O
have O
been O
reported O
. O

Three O
months O
following O
splenectomy O
, O
multiple B-ADE
abscesses I-ADE
occurred O
in O
the O
muscles O
of O
both O
thighs O
while O
the O
patient O
was O
receiving O
the O
third O
course O
of O
the O
CHOP B-DRUG
regimen O
. O

An O
11-day O
- O
old O
infant O
became O
lethargic B-ADE
and O
apneic B-ADE
after O
a O
single O
drop O
of O
brimonidine B-DRUG
. O

Gentamicin B-DRUG
- O
associated O
acute B-ADE
renal I-ADE
failure I-ADE
. O

Patient O
A O
reported O
right B-ADE
leg I-ADE
weakness I-ADE
( O
foot B-ADE
drop I-ADE
) O
during O
week O
4 O
of O
CAP B-DRUG
- I-DRUG
XRT I-DRUG
( O
1600 O
mg O
/ O
m2 O
) O
. O

Cephalosporins B-DRUG
are O
most O
likely O
associated O
with O
Vitamin B-ADE
K I-ADE
deficiency I-ADE
. O

Two O
patients O
are O
described O
who O
developed O
sensory B-ADE
neuropathy I-ADE
after O
the O
ingestion O
of O
30.6 O
and O
114 O
g O
metronidazole B-DRUG
respectively O
. O

A O
33-year O
- O
old O
male O
presented O
with O
brown B-ADE
discolouration I-ADE
of I-ADE
the I-ADE
fingernails I-ADE
following O
the O
application O
of O
4 B-DRUG
% I-DRUG
hydroquinone I-DRUG
in I-DRUG
sorbolene I-DRUG
cream I-DRUG
and O
0.1 B-DRUG
% I-DRUG
tretinoin I-DRUG
cream I-DRUG
to O
the O
face O
intermittently O
for O
9 O
months O
. O

We O
report O
a O
case O
of O
Stevens B-ADE
- I-ADE
Johnson I-ADE
syndrome I-ADE
/ O
toxic B-ADE
epidermal I-ADE
necrolysis I-ADE
( O
SJS B-ADE
/ O
TEN B-ADE
) O
secondary O
to O
trimethoprim B-DRUG
- I-DRUG
sulfamethoxazole I-DRUG
( O
TMP B-DRUG
- I-DRUG
Sx I-DRUG
) O
therapy O
for O
presumed O
community O
- O
associated O
methicillin O
- O
resistant O
Staphylococcus O
aureus O
( O
CA O
- O
MRSA O
) O
infection O
. O

Complications O
associated O
with O
primary B-ADE
and I-ADE
secondary I-ADE
perforation I-ADE
of I-ADE
the I-ADE
bladder I-ADE
following O
immediate O
instillations O
of O
epirubicin B-DRUG
after O
transurethral O
resection O
of O
superficial O
urothelial O
tumours O
. O

One O
should O
therefore O
be O
aware O
of O
possible O
extrapyramidal B-ADE
side I-ADE
effects I-ADE
with O
olanzapine B-DRUG
that O
are O
reduced O
compared O
to O
classical O
neuroleptic O
drugs O
but O
not O
completely O
eliminated O
. O

The O
patient O
whose O
case O
is O
reviewed O
had O
migraine B-ADE
headaches I-ADE
and O
received O
methysergide B-DRUG
maleate O
for O
13 O
years O
. O

CONCLUSIONS O
: O
Acute B-ADE
severe I-ADE
hepatitis I-ADE
though O
rare O
is O
occasionally O
observed O
with O
EGFR O
inhibitors O
gefitinib B-DRUG
or O
erlotinib B-DRUG
. O

Ballistic B-ADE
movements I-ADE
due O
to O
ischemic B-ADE
infarcts I-ADE
after O
intravenous O
heroin B-DRUG
overdose O
: O
report O
of O
two O
cases O
. O

Apparent O
cyclophosphamide B-DRUG
( O
cytoxan O
) O
embryopathy B-ADE
: O
a O
distinct O
phenotype O
? O

We O
report O
a O
case O
of O
MMC B-DRUG
- O
related O
hemolytic B-ADE
uremic I-ADE
syndrome I-ADE
, O
and O
discuss O
the O
etiologic O
parameters O
, O
clinical O
aspects O
, O
prognosis O
and O
treatment O
modalities O
of O
this O
severe O
syndrome O
. O

We O
report O
two O
patients O
with O
acne O
vulgaris O
with O
a O
fourth O
type O
of O
minocycline B-DRUG
- O
induced O
cutaneous B-ADE
pigmentation I-ADE
. O

She O
had O
been O
on O
Copaxone B-DRUG
20 O
mg O
/ O
day O
treatment O
for O
2 O
years O
when O
she O
first O
exhibited O
gastrointestinal B-ADE
symptoms I-ADE
. O

We O
conclude O
that O
low O
- O
dose O
HU B-DRUG
therapy O
in O
patients O
with O
thalassemia O
intermedia O
may O
increase B-ADE
total I-ADE
Hb I-ADE
levels O
sufficiently O
to O
eliminate O
the O
need O
for O
transfusions O
. O

However O
, O
dermatologists O
should O
be O
cautious O
about O
a O
photosensitivity B-ADE
reaction O
induced O
by O
mequitazine B-DRUG
or O
other O
phenothiazine O
- O
derivative O
drugs O
. O

This O
is O
the O
first O
report O
of O
UFT B-DRUG
- I-ADE
induced I-ADE
scleroderma I-ADE
- I-ADE
like I-ADE
reaction I-ADE
. O

Gynecomastia B-ADE
in O
epileptics O
treated O
with O
phenobarbital B-DRUG
, O
phenytoin B-DRUG
and O
fluoresone B-DRUG
: O
two O
case O
reports O
. O

Fatal B-ADE
ventricular I-ADE
fibrillation I-ADE
after O
treatment O
with O
digoxin B-DRUG
in O
a O
27-year O
- O
old O
man O
with O
mitral O
leaflet O
prolapse O
syndrome O
. O

Reversible O
cholestasis B-ADE
with O
bile B-ADE
duct I-ADE
injury I-ADE
following O
azathioprine B-DRUG
therapy O
. O

Tumor B-ADE
lysis I-ADE
syndrome I-ADE
after O
transcatheter O
arterial O
infusion O
of O
cisplatin B-DRUG
and O
embolization O
therapy O
for O
liver O
metastases O
of O
melanoma O
. O

Attempts O
were O
made O
to O
stop O
and O
then O
restart O
the O
theophylline B-DRUG
therapy O
at O
progressively O
lower O
doses O
; O
however O
, O
with O
each O
attempt O
, O
the O
patient O
's O
reaction B-ADE
to I-ADE
the I-ADE
drug I-ADE
became I-ADE
more I-ADE
toxic I-ADE
, O
with O
serum O
theophylline B-DRUG
levels O
ranging O
between O
99.9 O
and O
149.9 O
micromol O
/ O
L O
( O
18 O
and O
27 O
microg O
/ O
mL O
) O
. O

We O
report O
a O
case O
of O
interstitial B-ADE
pulmonary I-ADE
disease I-ADE
that O
occurred O
together O
with O
lymphocytic B-ADE
colitis I-ADE
during O
treatment O
with O
ticlopidine B-DRUG
. O

One O
patient O
had O
MRI B-ADE
T2 I-ADE
abnormalities I-ADE
compatible O
with O
cyclosporin B-DRUG
neurotoxicity B-ADE
. O

OBJECTIVES O
: O
To O
describe O
clinical O
and O
pathologic O
findings O
in O
patients O
noted O
to O
develop O
lower B-ADE
gastrointestinal I-ADE
symptoms I-ADE
when O
exposed O
to O
rofecoxib B-DRUG
. O

Severe B-ADE
cardiomyopathy I-ADE
following O
treatment O
with O
the O
tumour O
necrosis O
factor O
- O
alpha O
inhibitor O
adalimumab B-DRUG
for O
Crohn O
's O
disease O
. O

Phenytoin B-DRUG
toxicity I-ADE
due O
to O
concomitant O
antituberculosis O
therapy O
. O

Development O
of O
sarcoidosis B-ADE
during O
interferon B-DRUG
alpha I-DRUG
2b I-DRUG
and O
ribavirin B-DRUG
combination O
therapy O
for O
chronic O
hepatitis O
C O
-- O
a O
case O
report O
and O
review O
of O
the O
literature O
. O

2-Chloro B-DRUG
- I-DRUG
deoxyadenosine I-DRUG
induces O
durable O
complete O
remission O
in O
Castleman O
's O
disease O
but O
may O
accelerate O
its O
transformation O
to O
non B-ADE
- I-ADE
Hodgkin I-ADE
's I-ADE
lymphoma I-ADE
. O

The O
probability O
of O
developing O
acute B-ADE
leukemia I-ADE
in O
this O
study O
was O
not O
significantly O
correlated O
to O
the O
total O
cumulative O
dosage O
of O
Treosulfan B-DRUG
. O

Nonconvulsive B-ADE
status I-ADE
epilepticus I-ADE
: O
the O
role O
of O
morphine B-DRUG
and O
its O
antagonist O
. O

These O
skin B-ADE
lesions I-ADE
may O
be O
induced O
or O
worsened O
during O
antiviral O
therapy O
with O
interferon B-DRUG
- I-DRUG
alpha I-DRUG
( O
IFN B-DRUG
) O
. O

Two O
case O
reports O
of O
bilateral B-ADE
granulomatous I-ADE
anterior I-ADE
uveitis I-ADE
are O
described O
in O
patients O
with O
open O
angle O
glaucoma O
treated O
with O
metripranolol B-DRUG
0.6 O
% O
eye O
drops O
. O

An O
obese O
patient O
, O
not O
diabetic O
, O
treated O
with O
metformin B-DRUG
for O
some O
weeks O
, O
was O
referred O
to O
us O
with O
severe B-ADE
inferior I-ADE
digestive I-ADE
hemorrhage I-ADE
, O
diagnosed O
with O
Meckel O
's O
diverticulum O
. O

Since O
recent O
studies O
have O
reported O
no O
negative O
interactions O
with O
concurrent O
use O
, O
we O
here O
report O
three O
cases O
( O
one O
case O
of O
a O
prolonged B-ADE
seizure I-ADE
, O
a O
serotonin B-ADE
syndrome I-ADE
and O
a O
focal B-ADE
seizure I-ADE
) O
of O
severe O
lithium B-DRUG
- O
induced O
side O
effects O
while O
patients O
underwent O
ECT O
without O
complications O
and O
lithium O
serum O
levels O
were O
still O
subtherapeutic O
. O

Uveitis B-ADE
associated O
with O
rifabutin B-DRUG
therapy O
: O
a O
clinical O
alert O
. O

A O
61-year O
- O
old O
man O
with O
early O
diffuse O
cutaneous O
scleroderma O
with O
myositis O
and O
progressive O
interstitial O
pneumonia O
developed O
generalized B-ADE
erythema I-ADE
with O
high O
fever O
3 O
weeks O
after O
taking O
sulfamethoxazole B-DRUG
/ O
trimethoprim B-DRUG
. O

An O
encephalopathy B-ADE
and O
cardiomyopathy B-ADE
developed O
in O
a O
seventeen O
- O
year O
- O
old O
girl O
with O
chemotherapy O
- O
induced O
renal O
failure O
while O
receiving O
an O
intravesical O
aluminum B-DRUG
infusion O
for O
hemorrhagic O
cystitis O
. O

The O
possible O
development O
of O
a O
drug O
- O
induced O
vasculitis B-ADE
or O
lupus B-ADE
- I-ADE
like I-ADE
syndrome I-ADE
should O
be O
added O
to O
the O
list O
of O
rare O
toxic O
effects O
of O
vancomycin B-DRUG
. O

Unusual O
pigmentary B-ADE
changes I-ADE
associated O
with O
5-fluorouracil B-DRUG
therapy O
. O

Self B-ADE
- I-ADE
limited I-ADE
edema I-ADE
is O
a O
well O
- O
recognized O
complication O
of O
insulin B-DRUG
therapy O
. O

Celiac B-ADE
disease I-ADE
onset O
after O
pegylated B-DRUG
interferon I-DRUG
and O
ribavirin B-DRUG
treatment O
of O
chronic O
hepatitis O
C O
. O

CONCLUSION O
: O
This O
report O
describes O
a O
case O
of O
a O
probable O
interaction O
between O
topical O
econazole B-DRUG
lotion O
1 O
% O
and O
acenocoumarol B-DRUG
that O
resulted O
in O
overanticoagulation O
and O
a O
life O
- O
threatening O
laryngeal B-ADE
hematoma I-ADE
in O
this O
elderly O
patient O
. O

Although O
it O
is O
difficult O
to O
be O
certain O
of O
the O
direct O
link O
of O
amiodarone O
on O
the O
basis O
of O
a O
single O
case O
, O
it O
is O
reasonable O
to O
presume O
that O
this O
histopathology O
is O
associated O
with O
amiodarone B-DRUG
- O
induced O
hypothyroidism B-ADE
and O
that O
involution O
changes O
represent O
the O
hypofunctional O
status O
of O
this O
drug O
- O
induced O
disorder O
. O

Radiation B-ADE
recall I-ADE
pneumonitis I-ADE
induced O
by O
gemcitabine B-DRUG
. O

A O
patient O
with O
severe B-ADE
cholestatic I-ADE
jaundice I-ADE
induced O
by O
captopril B-DRUG
is O
presented O
. O

Amiodarone B-DRUG
- O
induced O
thyrotoxicosis B-ADE
associated O
with O
thyrotropin B-ADE
receptor I-ADE
antibody I-ADE
. O

After O
treatment O
with O
cimetidine B-DRUG
, O
there O
was O
a O
rapid O
deterioration O
with O
decreased B-ADE
oxygen I-ADE
saturation I-ADE
and I-ADE
arterial I-ADE
PO2 I-ADE
values O
. O

Interstitial B-ADE
pneumonitis I-ADE
associated O
with O
sirolimus B-DRUG
: O
a O
dilemma O
for O
lung O
transplantation O
. O

Videopolysomnographic O
and O
pharmacokinetic O
studies O
with O
monitoring O
of O
plasma O
levodopa B-DRUG
levels O
demonstrated O
marked B-ADE
motor I-ADE
hyperactivity I-ADE
during O
augmentation O
, O
with O
anarchic B-ADE
discharges I-ADE
of I-ADE
motor I-ADE
unit I-ADE
potentials I-ADE
, O
tonic B-ADE
grouped I-ADE
discharges I-ADE
and O
flexor B-ADE
spasms I-ADE
, O
associated O
with O
painful B-ADE
dysesthesia I-ADE
. O

Detection O
of O
antineutrophil O
cytoplasmic O
antibody O
in O
a O
patient O
with O
L B-DRUG
- I-DRUG
tryptophan I-DRUG
induced O
eosinophilia B-ADE
- I-ADE
myalgia I-ADE
syndrome I-ADE
. O

CASE O
SUMMARY O
: O
A O
58-year O
- O
old O
white O
woman O
developed O
fulminant B-ADE
liver I-ADE
failure I-ADE
while O
being O
treated O
with O
the O
macrolide O
antibiotic O
clarithromycin B-DRUG
for O
pneumonia O
. O

CONCLUSION O
: O
The O
present O
findings O
suggest O
that O
: O
( O
i O
) O
amantadine O
probably O
exerts O
its O
anti O
- O
dyskinetic O
effect O
by O
acting O
on O
the O
" O
indirect O
" O
pathway O
; O
( O
ii O
) O
the O
pathophysiological O
mechanisms O
of O
subthalamotomy O
induced O
dyskinesias O
may O
differ O
from O
those O
involved O
in O
L B-DRUG
- I-DRUG
dopa I-DRUG
induced O
dyskinesias B-ADE
; O
( O
iii O
) O
dyskinesias O
induced O
by O
STN O
surgery O
resolve O
spontaneously O
as O
compensatory O
mechanisms O
develop O
. O

Although O
myelosuppression O
is O
mild O
, O
immunosuppression B-ADE
and O
superinfection B-ADE
are O
potential O
hazards O
of O
treatment O
with O
DCF B-DRUG
. O

Thirty O
- O
six O
patients O
with O
AL O
received O
, O
in O
a O
three O
- O
month O
period O
, O
51 O
cycles O
of O
combined O
chemotherapy O
which O
included O
, O
in O
all O
of O
them O
, O
cytosine B-DRUG
arabinoside I-DRUG
( O
ARA B-DRUG
- I-DRUG
C I-DRUG
) O
; O
among O
them O
, O
along O
with O
myelosuppression O
, O
five O
experienced O
fever B-ADE
, O
infectious B-ADE
complications I-ADE
, O
gastrointestinal B-ADE
tract I-ADE
symptoms I-ADE
and O
severe B-ADE
myalgias I-ADE
. O

Peripheral B-ADE
neuropathy I-ADE
and O
cerebellar B-ADE
syndrome I-ADE
associated O
with O
amiodarone B-DRUG
therapy O
. O

Cryptococcus B-ADE
neoformans I-ADE
fatal I-ADE
sepsis I-ADE
in O
a O
chronic O
lymphocytic O
leukemia O
patient O
treated O
with O
alemtuzumab B-DRUG
: O
case O
report O
and O
review O
of O
the O
literature O
. O

Carboplatin B-DRUG
hypersensitivity B-ADE
induced O
by O
low O
- O
dose O
paclitaxel B-DRUG
/ O
carboplatin B-DRUG
in O
multiple O
platinum O
- O
treated O
patients O
with O
recurrent O
ovarian O
cancer O
. O

METHODS O
: O
A O
79-year O
- O
old O
woman O
being O
treated O
with O
imiquimod B-DRUG
5 O
days O
per O
week O
for O
a O
nodular O
basal O
cell O
developed O
a O
verrucous B-ADE
plaque I-ADE
over O
the O
treatment O
area O
after O
7 O
weeks O
of O
therapy O
. O

To O
date O
, O
this O
is O
the O
first O
reported O
case O
of O
what O
appears O
to O
be O
isolated O
thrombocytopenia B-ADE
associated O
with O
lansoprazole B-DRUG
. O

CONCLUSIONS O
: O
The O
pathogenesis O
of O
methotrexate B-DRUG
- O
induced O
papular B-ADE
eruption I-ADE
in O
collagen O
vascular O
diseases O
may O
suggest O
cutaneous O
small O
- O
vessel O
vasculitis O
. O

Therefore O
, O
it O
is O
reasonable O
to O
conclude O
that O
: O
1 O
) O
2-CdA O
can O
induce O
durable O
complete O
remission O
in O
MCD O
patients O
but O
unfortunately O
it O
can O
not O
cure O
the O
disease O
; O
2 O
) O
the O
possibility O
that O
2-CdA B-DRUG
may O
accelerate O
the O
transformation B-ADE
of I-ADE
MCD I-ADE
to I-ADE
NHL I-ADE
can O
not O
be O
ruled O
out O
. O

A O
patient O
with O
seropositive O
rheumatoid O
arthritis O
developed O
ascites B-ADE
while O
taking O
weekly O
doses O
of O
methotrexate B-DRUG
( O
MTX B-DRUG
) O
. O

Methamphetamine B-DRUG
's O
extensive O
physiologic O
effects O
, O
inconsistent O
street O
purity O
, O
and O
multiple O
routes O
of O
administration O
offer O
many O
possibilities O
for O
injury B-ADE
to I-ADE
the I-ADE
cornea I-ADE
. O

He O
had O
been O
taking O
trimethoprim B-DRUG
- O
sulfamethoxazole B-DRUG
for O
approximately O
eight O
days O
when O
he O
revisited O
his O
family O
physician O
, O
complaining O
of O
headaches B-ADE
, O
dizziness B-ADE
, O
difficulty B-ADE
with I-ADE
speech I-ADE
, O
weakness B-ADE
, O
and O
itching B-ADE
on I-ADE
the I-ADE
trunk I-ADE
of O
his O
body O
and O
legs O
, O
where O
a O
maculopapular B-ADE
rash I-ADE
was O
noted O
. O

The O
patient O
developed O
occipital B-ADE
infarcts I-ADE
and O
was O
found O
to O
have O
extremely B-ADE
elevated I-ADE
levels I-ADE
of I-ADE
PPA B-DRUG
in O
his O
blood O
and O
dialysis O
fluid O
. O

We O
describe O
3 O
elderly O
patients O
with O
moderate O
to O
severe O
ataxia B-ADE
that O
occurred O
while O
they O
were O
taking O
propafenone B-DRUG
. O

Aluminum B-DRUG
intoxication I-ADE
, O
along O
with O
other O
factors O
, O
was O
considered O
to O
be O
the O
cause O
of O
TC B-ADE
development O
. O

Acute B-ADE
renal I-ADE
failure I-ADE
in O
a O
patient O
receiving O
treatment O
with O
suramin B-DRUG
. O

Pancreatitis B-ADE
is O
a O
very O
rare O
adverse O
effect O
associated O
with O
the O
use O
of O
amiodarone B-DRUG
, O
and O
only O
four O
cases O
of O
amiodarone B-DRUG
- O
induced O
pancreatitis B-ADE
have O
been O
reported O
in O
literature O
. O

We O
report O
a O
case O
of O
pancytopenia B-ADE
in O
a O
23-year O
- O
old O
man O
with O
Crohn O
's O
disease O
who O
was O
treated O
with O
5-aminosalicylic B-DRUG
acid I-DRUG
( O
Pentasa B-DRUG
; O
Nisshin O
, O
Tokyo O
, O
Japan O
) O
3.0 O
g O
/ O
day O
. O

The O
patient O
had O
recurrence O
of O
urticaria B-ADE
and O
angioedema B-ADE
a O
year O
and O
a O
half O
later O
, O
at O
which O
point O
the O
NPH B-DRUG
was O
stopped O
and O
she O
was O
desensitized O
to O
regular O
insulin B-DRUG
. O

CONCLUSIONS O
: O
In O
these O
3 O
cases O
, O
the O
unique O
positive O
ocular O
finding O
was O
corneal B-ADE
endothelial I-ADE
deposits I-ADE
, O
which O
may O
be O
related O
to O
the O
use O
of O
rifabutin B-DRUG
. O

Exacerbation O
of O
anthracycline B-DRUG
- O
induced O
early B-ADE
chronic I-ADE
cardiomyopathy I-ADE
with O
ATRA O
: O
role O
of O
B O
- O
type O
natriuretic O
peptide O
as O
an O
indicator O
of O
cardiac O
dysfunction O
. O

CASE O
SUMMARY O
: O
A O
57-year O
- O
old O
female O
with O
cardiomyopathy O
and O
" O
sulfa O
" O
( O
trimethoprim O
/ O
sulfamethoxazole O
) O
allergy O
documented O
as O
pancreatitis O
presented O
with O
symptoms O
consistent O
with O
pancreatitis B-ADE
after O
use O
of O
furosemide B-DRUG
. O

A O
case O
of O
priapism B-ADE
associated O
with O
trazodone B-DRUG
is O
described O
. O

Juvenile B-ADE
absence I-ADE
epilepsy I-ADE
exacerbated O
by O
valproic B-DRUG
acid I-DRUG
. O

Hypoxia B-ADE
is O
a O
predisposing O
factor O
for O
premature B-ADE
ductal I-ADE
closure I-ADE
and O
often O
occurs O
after O
maternal O
indomethacin B-DRUG
therapy O
. O

Nephrotic B-ADE
syndrome I-ADE
in O
a O
multiple O
sclerosis O
patient O
treated O
with O
interferon B-DRUG
beta I-DRUG
1a I-DRUG
. O

MI B-ADE
related O
to O
the O
use O
of O
activated O
and O
non O
- O
activated O
PCCs B-DRUG
predominantly O
affects O
young O
patients O
who O
often O
have O
no O
preceding O
history O
of O
, O
or O
risk O
factors O
for O
, O
MI O
and O
tends O
to O
be O
associated O
with O
large O
cumulative O
doses O
of O
concentrate O
. O

This O
report O
describes O
the O
first O
case O
of O
insulin B-DRUG
- O
induced O
cardiac B-ADE
failure I-ADE
in O
a O
patient O
without O
underlying O
heart O
disease O
. O

Flecainide B-DRUG
overdose O
can O
rapidly O
result O
in O
profound O
cardiovascular B-ADE
collapse I-ADE
, O
and O
is O
associated O
with O
a O
relatively O
high O
mortality O
. O

Sexual B-ADE
dysfunction I-ADE
associated O
with O
intrathecal O
baclofen B-DRUG
use O
: O
a O
report O
of O
two O
cases O
. O

Complete O
remission O
of O
the O
nephrosis B-ADE
occurred O
after O
discontinuation O
of O
hydroxychloroquine B-DRUG
therapy O
. O

CONTEXT O
: O
Previous O
investigators O
have O
reported O
discrepancies B-ADE
between I-ADE
hematologic I-ADE
, I-ADE
marrow I-ADE
morphologic I-ADE
, I-ADE
and I-ADE
cytogenetic I-ADE
responses I-ADE
to O
imatinib B-DRUG
mesylate I-DRUG
among O
patients O
with O
chronic O
myeloid O
leukemia O
( O
CML O
) O
. O

The O
three O
reported O
cases O
demonstrate O
that O
troglitazone B-DRUG
is O
an O
idiosyncratic O
hepatotoxin O
that O
can O
lead O
to O
irreversible B-ADE
liver I-ADE
injury I-ADE
. O

Amifostine B-DRUG
- O
induced O
fever B-ADE
: O
case O
report O
and O
review O
of O
the O
literature O
. O

We O
thus O
concluded O
that O
an O
excessive O
dose O
of O
AZ B-DRUG
had O
probably O
destroyed B-ADE
the I-ADE
gastric I-ADE
mucosal I-ADE
barrier I-ADE
or O
thrombocytopenia B-ADE
due I-ADE
to I-ADE
bone I-ADE
marrow I-ADE
disorder I-ADE
and O
thus O
eventually O
led O
to O
the O
development O
of O
hemorrhagic B-ADE
gastritis I-ADE
. O

Carboplatin B-DRUG
hypersensitivity O
presenting O
as O
coronary B-ADE
vasospasm I-ADE
- O
a O
case O
report O
. O

A O
clinically O
atypical O
, O
neuropathologically O
verified O
case O
of O
Creutzfeldt B-ADE
- I-ADE
Jakob I-ADE
disease I-ADE
is O
described O
in O
a O
32-year O
- O
old O
New O
Zealand O
woman O
with O
idiopathic O
hypopituitarism O
who O
had O
been O
treated O
in O
late O
adolescence O
( O
1970 O
to O
1973 O
) O
with O
human B-DRUG
growth I-DRUG
hormone I-DRUG
processed O
from O
pooled O
cadaveric O
pituitary O
glands O
. O

Transient B-ADE
central I-ADE
diabetes I-ADE
insipidus I-ADE
in O
the O
setting O
of O
underlying O
chronic O
nephrogenic O
diabetes O
insipidus O
associated O
with O
lithium B-DRUG
use O
. O

Elderly O
patients O
for O
whom O
nitrate B-DRUG
has O
been O
prescribed O
should O
be O
warned O
of O
the O
occurrence O
of O
hypotension B-ADE
, O
leading O
to O
unconsciousness B-ADE
. O

TREATMENT O
/ O
OUTCOME O
: O
Standard O
anti O
- O
tuberculosis O
therapy O
was O
administered O
but O
was O
complicated O
by O
interaction O
with O
cyclosporine B-DRUG
and O
drug O
- O
induced O
cholestasis B-ADE
. O

RESULTS O
: O
A O
male O
and O
a O
female O
patient O
with O
spasticity O
treated O
with O
intrathecal O
baclofen B-DRUG
were O
recognized O
to O
have O
sexual B-ADE
dysfunction I-ADE
side O
effects O
from O
treatment O
. O

The O
two O
middle O
aged O
women O
presented O
with O
respiratory B-ADE
symptoms I-ADE
after O
prolonged O
treatment O
with O
nitrofurantoin B-DRUG
. O

Prolongation B-ADE
of I-ADE
the I-ADE
QT I-ADE
interval I-ADE
observed O
in O
a O
Japanese O
patient O
with O
vivax O
malaria O
following O
treatment O
with O
halofantrine B-DRUG
. O

The O
diagnosis O
of O
hypothermia B-ADE
was O
delayed O
until O
it O
was O
apparent O
for O
several O
days O
but O
resolved O
with O
the O
discontinuation O
of O
risperidone B-DRUG
and O
continuation O
of O
clozapine O
. O

A O
42 O
year O
old O
man O
, O
treated O
for O
testicular O
carcinoma O
with O
combination O
chemotherapy O
that O
included O
bleomycin B-DRUG
, O
developed O
life O
threatening O
interstitial B-ADE
pneumonitis I-ADE
. O

Quetiapine B-DRUG
and O
obsessive B-ADE
- I-ADE
compulsive I-ADE
symptoms I-ADE
( O
OCS B-ADE
) O
: O
case O
report O
and O
review O
of O
atypical O
antipsychotic O
- O
induced O
OCS B-ADE
. O

Patients O
should O
be O
informed O
about O
the O
risk O
of O
osteonecrosis B-ADE
when O
taking O
dexamethasone B-DRUG
as O
an O
antiemetic O
drug O
. O

Intravenous O
verapamil B-DRUG
therapy O
in O
babies O
may O
cause O
apnea B-ADE
, O
hypotension B-ADE
, O
and O
bradycardia B-ADE
; O
continued O
episodes O
of O
atrial B-ADE
flutter I-ADE
in O
a O
child O
may O
cause O
sudden B-ADE
death I-ADE
; O
quinidine B-DRUG
may O
be O
related O
to O
the O
death B-ADE
; O
children O
with O
" O
familial O
seizure O
disorders O
" O
may O
in O
fact O
have O
the O
long B-ADE
QT I-ADE
interval I-ADE
syndrome I-ADE
. O

Methotrexate B-DRUG
- O
induced O
liver B-ADE
cirrhosis I-ADE
. O

Fatal B-ADE
intravascular I-ADE
autoimmune I-ADE
hemolytic I-ADE
anemia I-ADE
after O
fludarabine B-DRUG
treatment O
for O
chronic O
lymphocytic O
leukemia O
. O

Unintended O
exposure O
to O
acyclovir B-DRUG
early O
in O
pregnancy O
, O
which O
is O
not O
uncommon O
, O
may O
cause O
excessive B-ADE
maternal I-ADE
and I-ADE
physician I-ADE
anxiety I-ADE
. O

We O
suggest O
that O
objective O
evaluation O
of O
retinal O
function O
with O
electrophysiological O
methods O
should O
be O
performed O
in O
patients O
with O
visual B-ADE
disturbance I-ADE
during O
treatment O
with O
rifabutin B-DRUG
. O

CONCLUSION O
: O
The O
administration O
of O
tissue B-DRUG
plasminogen I-DRUG
activator I-DRUG
was O
responsible O
for O
the O
large O
extent O
of O
hemorrhage B-ADE
and O
should O
be O
considered O
in O
the O
differential O
diagnosis O
of O
hemorrhagic B-ADE
choroidal I-ADE
detachment I-ADE
. O

To O
our O
knowledge O
, O
this O
recurrence O
of O
amiodarone B-DRUG
pulmonary B-ADE
toxicity I-ADE
has O
not O
been O
reported O
previously O
. O

Gold B-DRUG
nephropathy B-ADE
: O
tissue O
analysis O
by O
X O
- O
ray O
fluorescent O
spectroscopy O
. O

CASE O
REPORT O
: O
We O
report O
a O
patient O
who O
developed O
a O
DAT B-ADE
- I-ADE
positive I-ADE
hemolytic I-ADE
episode I-ADE
after O
a O
red O
cell O
( O
RBC O
) O
transfusion O
was O
delivered O
during O
the O
infusion O
of O
her O
17th O
cycle O
of O
oxaliplatin B-DRUG
. O

CONCLUSION O
: O
Squamous B-ADE
metaplasia I-ADE
in O
these O
cases O
appears O
to O
be O
a O
consequence O
of O
progestin B-DRUG
therapy O
. O

DISCUSSION O
: O
Electrolyte B-ADE
disorders I-ADE
associated O
with O
foscarnet B-DRUG
are O
reviewed O
. O

We O
report O
the O
case O
of O
a O
patient O
with O
the O
acquired O
immunodeficiency O
syndrome O
treated O
with O
rifampicin B-DRUG
who O
had O
a O
' O
normal O
' O
screening O
test O
for O
adrenal O
insufficiency O
, O
yet O
had O
clinical O
evidence O
of O
adrenal B-ADE
failure I-ADE
. O

Case O
report O
of O
withdrawal O
dyskinesia B-ADE
associated O
with O
amoxapine B-DRUG
. O

Visual B-ADE
system I-ADE
side I-ADE
effects I-ADE
caused O
by O
parasympathetic B-ADE
dysfunction I-ADE
after O
botulinum B-DRUG
toxin I-DRUG
type I-DRUG
B I-DRUG
injections O
. O

We O
describe O
a O
patient O
in O
whom O
noncardiogenic B-ADE
pulmonary I-ADE
edema I-ADE
developed O
during O
intrabiliary O
infusion O
of O
monooctanoin B-DRUG
. O

Myocardial B-ADE
ischemia I-ADE
associated O
with O
high O
- O
dose O
carmustine B-DRUG
infusion O
. O

Severe O
histological O
osteomalacia B-ADE
developed O
in O
a O
woman O
with O
Crohn O
's O
disease O
2 O
years O
after O
ileal O
resection O
and O
the O
start O
of O
cholestyramine B-DRUG
therapy O
. O

Exacerbations B-ADE
of I-ADE
the I-ADE
heart I-ADE
failure I-ADE
were O
temporally O
related O
to O
the O
administration O
of O
the O
antitumor O
antibiotics O
actinomycin B-DRUG
- I-DRUG
D I-DRUG
( O
NSC-3053 B-DRUG
) O
and O
mithramycin B-DRUG
( O
NSC-24559 B-DRUG
) O
. O

Other O
potential O
causes O
of O
renal B-ADE
failure I-ADE
were O
not O
present O
in O
our O
patient O
and O
his O
renal O
function O
gradually O
recovered O
with O
the O
cessation O
of O
suramin B-DRUG
treatment O
. O

Methylphenidate B-DRUG
- O
associated O
enuresis B-ADE
in O
attention O
deficit O
hyperactivity O
disorder O
. O

Patients O
receiving O
neutral B-DRUG
protamine I-DRUG
Hagedorn I-DRUG
( I-DRUG
NPH I-DRUG
) I-DRUG
insulin I-DRUG
are O
at O
increased O
risk O
for O
the O
development O
of O
protamine B-ADE
hypersensitivity I-ADE
. O

We O
report O
a O
case O
of O
a O
women O
in O
whom O
a O
malignant B-ADE
mixed I-ADE
mesodermal I-ADE
tumor I-ADE
was O
diagnosed O
while O
she O
was O
taking O
raloxifene B-DRUG
, O
which O
is O
also O
a O
selective O
estrogen O
receptor O
modulator O
. O

After O
the O
second O
infliximab B-DRUG
infusion O
, O
he O
was O
found O
to O
have O
a O
severe B-ADE
transient I-ADE
neutropenia I-ADE
( O
0.5 O
x O
10(9)/L O
) O
. O

Rapid O
onset O
of O
quetiapine B-DRUG
- O
induced O
diabetic B-ADE
ketoacidosis I-ADE
in O
an O
elderly O
patient O
: O
a O
case O
report O
. O

Pulmonary B-ADE
gold B-DRUG
toxicity I-ADE
. O

OBJECTIVE O
: O
The O
aim O
of O
this O
paper O
is O
to O
describe O
a O
case O
of O
increased B-ADE
libido I-ADE
during O
fluvoxamine B-DRUG
therapy O
. O

Development O
of O
porphyria B-ADE
cutanea I-ADE
tarda I-ADE
after O
treatment O
with O
cyclophosphamide B-DRUG
. O

Cefoxitin B-DRUG
- O
associated O
renal B-ADE
failure I-ADE
. O

Severe B-ADE
symptomatic I-ADE
hyponatremia I-ADE
during O
sibutramine B-DRUG
therapy O
: O
a O
case O
report O
. O

We O
report O
three O
cases O
of O
patients O
who O
developed O
leukopenia B-ADE
during O
olanzapine B-DRUG
treatment O
. O

The O
development O
of O
erythroid O
leukemia O
plus O
carcinoma B-ADE
in O
these O
two O
men O
suggests O
mutagenic O
change O
secondary O
to O
cyclophosphamide B-DRUG
therapy O
. O

Acute B-ADE
reversible I-ADE
ataxo I-ADE
- I-ADE
myoclonic I-ADE
encephalopathy I-ADE
with O
flecainide B-DRUG
therapy O
. O

INTERPRETATION O
: O
When O
high O
doses O
of O
fluticasone B-DRUG
propionate I-DRUG
are O
used O
, O
growth B-ADE
may I-ADE
be I-ADE
retarded I-ADE
and O
adrenal B-ADE
suppression I-ADE
may O
occur O
. O

After O
reviewing O
the O
literature O
we O
suggest O
the O
CPM B-ADE
was O
a O
complication O
of O
lithium B-DRUG
toxicity O
which O
affected O
the O
lateral O
geniculate O
nucleus O
which O
produced O
blindness B-ADE
. O

Thus O
cabergoline B-DRUG
may O
cause O
similar O
pleuropulmonary B-ADE
abnormalities I-ADE
to O
bromocriptine B-DRUG
. O

Scleromyxedema B-ADE
in O
a O
patient O
with O
multiple O
sclerosis O
and O
monoclonal O
gammopathy O
on O
interferon B-DRUG
beta-1a I-DRUG
. O

We O
describe O
a O
life O
threatening O
side O
effect O
of O
acute O
epoprostenol B-DRUG
infusion O
( O
pulmonary B-ADE
edema I-ADE
) O
in O
a O
patient O
with O
pulmonary O
hypertension O
associated O
with O
limited O
scleroderma O
and O
discuss O
its O
management O
and O
potential O
etiology O
. O

OBJECTIVE O
: O
To O
report O
the O
first O
five O
cases O
of O
amphotericin B-DRUG
B I-DRUG
overdose O
with O
secondary O
cardiac B-ADE
complications I-ADE
in O
a O
pediatric O
population O
. O

PURPOSE O
: O
To O
describe O
transient B-ADE
structured I-ADE
visual I-ADE
hallucinations I-ADE
in O
a O
patient O
with O
vascular O
age O
- O
related O
macular O
degeneration O
( O
AMD O
) O
, O
following O
an O
intravitreal O
Avastin B-DRUG
- O
injection O
. O

High B-ADE
- I-ADE
grade I-ADE
atrioventricular I-ADE
block I-ADE
during O
dipyridamole B-DRUG
stress O
testing O
. O

Ataxia B-ADE
caused O
by O
propafenone B-DRUG
has O
been O
reported O
to O
the O
pharmaceutical O
companies O
and O
drug O
monitoring O
agencies O
, O
but O
has O
not O
been O
well O
described O
or O
emphasized O
in O
the O
medical O
literature O
. O

Insulin B-ADE
- I-ADE
dependent I-ADE
diabetes I-ADE
mellitus I-ADE
associated O
with O
danazol B-DRUG
. O

Purple B-ADE
glove I-ADE
syndrome I-ADE
, O
named O
for O
its O
distinctive O
purple B-ADE
discoloration I-ADE
and O
swelling B-ADE
of I-ADE
the I-ADE
hands I-ADE
in O
the O
distribution O
of O
a O
glove O
, O
is O
an O
uncommon O
complication O
of O
intravenous O
phenytoin B-DRUG
administration O
through O
small O
dorsal O
veins O
of O
the O
hands O
. O

The O
pathophysiological O
mechanisms O
remain O
unknown O
, O
although O
the O
drug O
could O
act O
through O
massive B-ADE
cytokines I-ADE
liberation I-ADE
after O
destruction B-ADE
of I-ADE
CD20 I-ADE
positive I-ADE
cells I-ADE
by O
rituximab B-DRUG
. O

CONCLUSIONS O
: O
The O
risk O
of O
drug O
- O
induced O
rhabdomyolysis B-ADE
due O
to O
the O
potential O
interaction O
between O
lovastatin B-DRUG
and O
azithromycin B-DRUG
or O
clarithromycin B-DRUG
should O
be O
considered O
before O
the O
concomitant O
use O
of O
these O
agents O
. O

The O
role O
of O
Adriamycin B-DRUG
in O
the O
production O
of O
cardiotoxicity B-ADE
is O
reviewed O
. O

Four O
days O
after O
the O
initial O
injection O
of O
3.6 O
mg O
of O
goserelin B-DRUG
acetate I-DRUG
, O
severe B-ADE
dyspnea I-ADE
developed O
due O
to O
worsening B-ADE
pleuritis I-ADE
carcinomatosa I-ADE
, O
which O
was O
considered O
as O
a O
flare B-ADE
- I-ADE
up I-ADE
. O

In O
this O
paper O
we O
report O
a O
case O
of O
nimodipine B-DRUG
overdosage O
resulting O
in O
prolonged B-ADE
hypotension I-ADE
and O
hypoxemia B-ADE
, O
which O
was O
successfully O
treated O
with O
calcium O
gluconate O
. O

Acute B-ADE
psychosis I-ADE
associated O
with O
levetiracetam B-DRUG
. O

Metastatic B-ADE
osteomyelitis I-ADE
following O
BCG B-DRUG
vaccination O
. O

Neutropenic B-ADE
colitis I-ADE
during O
standard O
dose O
combination O
chemotherapy O
with O
nedaplatin B-DRUG
and O
irinotecan B-DRUG
for O
testicular O
cancer O
. O

Acute B-ADE
dystonic I-ADE
reaction I-ADE
with O
low O
- O
dose O
pimozide B-DRUG
. O

CONCLUSIONS O
: O
The O
value O
of O
multihormonal O
therapy O
in O
breast O
carcinoma O
is O
not O
established O
, O
and O
the O
addition O
of O
progestogens O
to O
tamoxifen B-DRUG
may O
not O
reduce O
of O
developing O
endometrial B-ADE
lesions I-ADE
, O
including O
carcinoma B-ADE
. O

Six O
patients O
with O
no O
previous O
signs O
or O
symptoms O
suggestive O
of O
coronary O
artery O
disease O
developed O
acute B-ADE
coronary I-ADE
ischemia I-ADE
/ O
infarction B-ADE
shortly O
after O
cis B-DRUG
- I-DRUG
diamine I-DRUG
- I-DRUG
dichloroplatinum I-DRUG
II I-DRUG
( O
cisplatin B-DRUG
) O
-based O
chemotherapy O
. O

We O
report O
the O
first O
case O
of O
herpes B-ADE
esophagitis I-ADE
in O
a O
renal O
transplant O
patient O
treated O
with O
Cyclosporine B-DRUG
A I-DRUG
while O
on O
chronic O
steroid O
therapy O
. O

This O
case O
report O
describes O
the O
development O
of O
asymptomatic O
visual B-ADE
field I-ADE
defects I-ADE
( O
VFDs B-ADE
) O
in O
a O
psychiatric O
patient O
with O
bipolar O
disorder O
receiving O
adjunctive O
tiagabine B-DRUG
treatment O
. O

Interstitial B-ADE
pneumopathy I-ADE
and O
low O
- O
dosage O
amiodarone B-DRUG
. O

Atrial B-ADE
fibrillation I-ADE
after O
vardenafil B-DRUG
therapy O
. O

We O
report O
on O
three O
cases O
wherein O
treatment O
of O
dexmedetomidine B-DRUG
- O
induced O
bradycardia B-ADE
with O
i.v O
. O
glycopyrrolate B-DRUG
( O
5.0 O
microg O
/ O
kg O
) O
not O
only O
resulting O
in O
resolution O
of O
bradycardia O
but O
also O
resulting O
in O
an O
exaggerated B-ADE
increase I-ADE
of I-ADE
arterial I-ADE
blood I-ADE
pressure I-ADE
. O

Because O
psoralens B-DRUG
sensitize O
skin O
to O
ultraviolet O
A O
light O
, O
phototoxic B-ADE
reactions I-ADE
are O
the O
most O
frequent O
adverse O
effect O
of O
this O
treatment O
. O

Occurrence O
of O
withdrawal O
dyskinesia B-ADE
indicates O
that O
the O
neuroleptic O
effects O
of O
amoxapine B-DRUG
may O
be O
clinically O
significant O
. O

Amiodarone B-DRUG
was O
the O
third O
drug O
to O
induce O
AVT B-ADE
in O
this O
patient O
; O
she O
received O
200 O
mg O
/ O
day O
six O
days O
per O
week O
for O
six O
months O
. O

Hyponatremia B-ADE
in O
patients O
treated O
with O
lorcainide B-DRUG
, O
a O
new O
antiarrhythmic O
drug O
. O

A O
26-year O
- O
old O
Japanese O
man O
, O
who O
had O
been O
receiving O
medical O
attention O
for O
ulcerative O
colitis O
for O
one O
year O
, O
presented O
with O
diffuse B-ADE
erythema I-ADE
and O
pustules B-ADE
on O
his O
face O
and O
trunk O
, O
malaise B-ADE
, O
and O
fever B-ADE
up I-ADE
to I-ADE
39 I-ADE
degrees I-ADE
C I-ADE
one O
day O
after O
the O
administration O
of O
salazosulfapyridine B-DRUG
. O

Acute B-ADE
renal I-ADE
failure I-ADE
with O
severe B-ADE
tubulointerstitial I-ADE
changes I-ADE
in O
a O
patient O
with O
minimal O
change O
nephrotic O
syndrome O
treated O
with O
enalapril B-DRUG
. O

DISCUSSION O
: O
To O
our O
knowledge O
this O
is O
the O
first O
reported O
case O
of O
tuberculous B-ADE
uveitis I-ADE
following O
treatment O
with O
etanercept B-DRUG
. O

Paraplegia B-ADE
following O
prophylactic O
intrathecal O
cytosine B-DRUG
arabinoside I-DRUG
( O
Ara B-DRUG
- I-DRUG
C I-DRUG
) O
is O
described O
in O
a O
patient O
with O
acute O
myelogenous O
leukemia O
in O
remission O
who O
received O
doses O
of O
100 O
mg O
/ O
m2/d O
for O
5 O
consecutive O
days O
. O

In O
three O
of O
these O
patients O
the O
infection O
was O
clinically O
unsuspected O
; O
in O
the O
fourth O
, O
cutaneous B-ADE
herpes I-ADE
zoster I-ADE
developed O
after O
administration O
of O
300 O
mg O
of O
cytarabine B-DRUG
daily O
for O
the O
preceding O
five O
days O
. O

Spontaneous B-ADE
hemothorax I-ADE
following O
anticoagulation O
with O
low O
- O
molecular O
- O
weight O
heparin B-DRUG
. O

In O
this O
report O
, O
we O
present O
a O
case O
of O
hypoglycaemic B-ADE
coma I-ADE
associated O
with O
SP B-DRUG
, O
an O
adverse O
reaction O
that O
is O
likely O
to O
be O
underreported O
and O
expected O
to O
occur O
with O
greater O
frequency O
as O
the O
use O
of O
SP B-DRUG
increases O
. O

Phenytoin B-DRUG
toxicity O
: O
an O
easily O
missed O
cause O
of O
cerebellar B-ADE
syndrome I-ADE
. O

Pulmonary B-ADE
fibrosis I-ADE
is O
a O
severe O
complication O
associated O
with O
bis B-DRUG
- I-DRUG
chloronitrosourea I-DRUG
( O
BCNU B-DRUG
) O
therapy O
. O

Three O
days O
after O
receiving O
intravitreal O
injection O
of O
bevacizumab B-DRUG
( O
1.25 O
mg O
in O
0.1 O
ml O
) O
, O
he O
developed O
acute B-ADE
vision I-ADE
loss I-ADE
and O
change B-ADE
of I-ADE
consciousness I-ADE
. O

A O
case O
is O
reported O
of O
a O
40 O
year O
old O
woman O
treated O
with O
intraventricular O
IL-2 B-DRUG
for O
leptomeningeal O
disease O
who O
developed O
progressive O
cognitive B-ADE
dysfunction I-ADE
. O

Radiation B-ADE
recall I-ADE
from O
gemcitabine B-DRUG
is O
rare O
, O
but O
can O
potentially O
arise O
in O
any O
site O
that O
has O
been O
previously O
irradiated O
. O

The O
cases O
of O
CBZ B-DRUG
- O
induced O
SLE B-ADE
reported O
in O
the O
literature O
were O
reviewed O
. O

Two O
of O
these O
patients O
, O
who O
also O
received O
the O
anti O
- O
emetic O
prochlorperazine B-DRUG
, O
lost B-ADE
consciousness I-ADE
for O
48 O
- O
72 O
h O
and O
then O
fully O
recovered O
. O

Three O
of O
50 O
patients O
treated O
with O
isotretinoin B-DRUG
( O
1 O
mg O
/ O
kg O
/ O
day O
) O
for O
cystic O
acne O
complained O
of O
poor B-ADE
night I-ADE
vision I-ADE
and/or O
excessive B-ADE
glare I-ADE
sensitivity I-ADE
. O

Pharmacokinetic O
determinants O
of O
6-mercaptopurine B-DRUG
myelotoxicity B-ADE
and O
therapeutic O
failure O
in O
children O
with O
acute O
lymphoblastic O
leukemia O
. O

L B-DRUG
- I-DRUG
asparaginase I-DRUG
- O
induced O
pancreatitis B-ADE
is O
an O
uncommon O
but O
potential O
lethal B-ADE
complication I-ADE
of O
the O
treatment O
of O
leukemia O
. O

Treatment O
of O
carbimazole B-DRUG
- O
induced O
agranulocytosis B-ADE
and O
sepsis B-ADE
with O
granulocyte O
colony O
stimulating O
factor O
. O

CONCLUSIONS O
: O
This O
case O
report O
showed O
that O
the O
clinical O
appearance O
of O
Hashimoto B-ADE
's I-ADE
disease I-ADE
after O
IFN B-DRUG
- I-DRUG
alpha I-DRUG
therapy O
for O
chronic O
C O
hepatitis O
in O
our O
patient O
was O
associated O
with O
a O
specific O
genetic O
predisposition O
( O
DR5 O
) O
for O
this O
pathology O
. O

We O
report O
the O
first O
histopathologically O
documented O
case O
of O
oral B-ADE
mucosa I-ADE
pigmentation I-ADE
after O
OLP O
treatment O
with O
topical O
tacrolimus B-DRUG
. O

A O
unique O
case O
of O
a O
transient O
, O
nonpigmenting O
fixed B-ADE
drug I-ADE
eruption I-ADE
caused O
by O
the O
radiopaque O
contrast O
medium O
iothalamate B-DRUG
is O
reported O
. O

He O
became O
hyperkalemic B-ADE
on O
rechallenge O
with O
timolol B-DRUG
and O
normokalemic O
following O
its O
withdrawal O
. O

A O
female O
patient O
with O
HER2 O
positive O
, O
metastatic O
breast O
cancer O
presented O
with O
pulmonary B-ADE
infiltrates I-ADE
, O
and O
a O
plural B-ADE
effusion I-ADE
dyspnoea I-ADE
after O
several O
months O
of O
trastuzumab B-DRUG
treatment O
. O

The O
patient O
was O
positive O
for O
antibody O
against O
complexes O
of O
heparin O
and O
platelet O
factor O
4 O
, O
and O
was O
diagnosed O
as O
heparin B-DRUG
- O
induced O
thrombocytopenia B-ADE
with O
thrombosis B-ADE
syndrome I-ADE
( O
HITTS O
) O
. O

A O
case O
of O
halothane B-DRUG
induced O
hepatitis B-ADE
is O
reported O
in O
a O
middle O
aged O
woman O
who O
underwent O
gastric O
surgery O
for O
morbid O
obesity O
. O

Serious B-ADE
adverse I-ADE
events I-ADE
experienced O
by O
patients O
with O
chronic O
heart O
failure O
taking O
spironolactone B-DRUG
. O

Extrapyramidal B-ADE
side I-ADE
effects I-ADE
induced O
by O
some O
selective O
serotonin O
reuptake O
inhibitors O
( O
SSRIs O
) O
, O
i.e. O
fluoxetine B-DRUG
and O
sertraline B-DRUG
, O
have O
been O
previously O
reported O
in O
patients O
with O
depression O
and O
obsessive O
- O
compulsive O
disorder O
( O
OCD O
) O
. O

The O
first O
case O
concerns O
a O
70-year O
- O
old O
man O
who O
developed O
severe O
aplastic B-ADE
anemia I-ADE
7 O
weeks O
after O
treatment O
with O
500 O
mg O
of O
ticlopidine B-DRUG
daily O
. O

On O
the O
other O
hand O
, O
aspirin B-DRUG
may O
have O
promoted O
the O
enlargement B-ADE
of I-ADE
spontaneous I-ADE
hemorrhage I-ADE
from O
meningioma O
. O

This O
supports O
the O
well O
- O
reported O
potential O
of O
bleomycin B-DRUG
to O
trigger O
acral B-ADE
vascular I-ADE
toxicity I-ADE
. O

A O
43-year O
- O
old O
woman O
with O
multiple O
sclerosis O
( O
MS O
) O
had O
nephrotic B-ADE
syndrome I-ADE
21 O
months O
after O
starting O
treatment O
with O
interferon B-DRUG
( I-DRUG
IFN I-DRUG
) I-DRUG
- I-DRUG
beta-1b I-DRUG
( O
subcutaneous O
administration O
) O
. O

This O
pattern O
is O
suggestive O
of O
renal B-ADE
toxicity I-ADE
due O
to O
tobramycin B-DRUG
. O

CONCLUSIONS O
: O
This O
is O
the O
second O
case O
report O
that O
describes O
gemcitabine B-DRUG
- O
induced O
radiation B-ADE
recall I-ADE
in O
rectus O
abdominus O
muscles O
after O
gemcitabine O
- O
based O
radiation O
therapy O
. O

CASE O
REPORT O
: O
A O
six O
- O
year O
- O
old O
boy O
with O
transfusion O
- O
dependent O
beta O
- O
thalassaemia O
developed O
a O
unilateral B-ADE
hearing I-ADE
loss I-ADE
shortly O
after O
commencing O
desferrioxamine B-DRUG
therapy O
. O

Falling B-ADE
backward I-ADE
in O
two O
elderly O
patients O
taking O
bupropion B-DRUG
. O

BACKGROUND O
: O
Interferon B-DRUG
( O
IFN B-DRUG
) O
- O
associated O
retinopathy B-ADE
is O
typically O
characterized O
by O
retinal B-ADE
hemorrhages I-ADE
and O
cotton B-ADE
wool I-ADE
spots I-ADE
at O
the O
posterior O
fundus O
, O
but O
visual O
function O
is O
usually O
maintained O
. O

Although O
the O
essential O
cause O
of O
PV B-ADE
is O
unclear O
, O
its O
onset O
has O
occasionally O
been O
associated O
with O
drug O
therapy O
, O
in O
particular O
penicillamine B-DRUG
. O

We O
report O
a O
case O
of O
a O
patient O
with O
ciprofloxacin B-DRUG
- O
induced O
SJS B-ADE
and O
acute O
onset O
of O
VBDS B-ADE
, O
and O
reviewed O
the O
related O
literature O
. O

With O
the O
first O
cyclosporine B-DRUG
dose O
, O
the O
patient O
complained O
of O
leg B-ADE
pain I-ADE
that O
was O
most O
severe O
during O
the O
cyclosporine B-DRUG
infusion O
. O

Infants O
are O
particularly O
susceptible O
to O
chronic O
nitrate B-DRUG
- O
induced O
methemoglobinemia B-ADE
because O
of O
their O
low O
stomach O
acid O
production O
, O
large O
numbers O
of O
nitrite O
- O
reducing O
bacteria O
, O
and O
the O
relatively O
easy O
oxidation O
of O
fetal O
hemoglobin O
. O

Clinicians O
should O
be O
aware O
of O
the O
possibility O
that O
vinorelbine B-DRUG
may O
cause O
SIADH B-ADE
and O
possibly O
hypokalemia B-ADE
. O

A O
73 O
year O
- O
old O
patient O
with O
Wolff O
- O
Parkinson O
- O
White O
syndrome O
and O
paroxysmic O
supraventricular O
tachycardia O
developed O
an O
acute B-ADE
reversible I-ADE
encephalopathy I-ADE
within O
15 O
days O
of O
initiation O
of O
flecainide B-DRUG
. O

Neutropenia B-ADE
is O
an O
infrequent O
complication O
following O
administration O
of O
the O
angiotensin O
- O
converting O
enzyme O
( O
ACE O
) O
inhibitor O
, O
captopril B-DRUG
. O

Morphine B-DRUG
, O
an O
opium O
alkaloid O
, O
frequently O
causes O
side O
effects O
such O
as O
hyperhidrosis B-ADE
and O
facial B-ADE
flushing I-ADE
, O
but O
serious O
cutaneous O
adverse O
drug O
reactions O
are O
seldom O
observed O
. O

A O
16-year O
- O
old O
boy O
developed O
fever B-ADE
, O
generalized B-ADE
rigidity I-ADE
, O
leukocytosis B-ADE
, O
and O
increased B-ADE
serum I-ADE
transaminase I-ADE
and I-ADE
creatine I-ADE
kinase I-ADE
levels O
while O
receiving O
treatment O
with O
olanzapine B-DRUG
and O
lithium B-DRUG
. O

Cholestatic B-ADE
liver I-ADE
disease I-ADE
with O
ductopenia B-ADE
( O
vanishing B-ADE
bile I-ADE
duct I-ADE
syndrome I-ADE
) O
after O
administration O
of O
clindamycin B-DRUG
and O
trimethoprim B-DRUG
- I-DRUG
sulfamethoxazole I-DRUG
. O

After O
cessation O
of O
amantadine B-DRUG
, O
the O
edema B-ADE
resolved O
, O
and O
the O
endothelial O
cell O
densities O
were O
< O
or=600/mm O
. O

The O
cases O
of O
two O
asthmatic O
patients O
who O
became O
hypokalemic B-ADE
after O
inhalation O
of O
normal O
doses O
of O
albuterol B-DRUG
are O
presented O
. O

CONCLUSION O
: O
Zidovudine B-DRUG
is O
well O
a O
known O
cause O
of O
anaemia B-ADE
and O
thus O
should O
be O
used O
with O
caution O
in O
the O
initiation O
of O
antiretroviral O
therapy O
. O

Colonic B-ADE
necrosis I-ADE
is O
known O
as O
a O
rare O
complication O
following O
the O
administration O
of O
Kayexalate B-DRUG
( O
sodium B-DRUG
polystryrene I-DRUG
sulfonate I-DRUG
) O
in O
sorbitol O
. O

The O
psychotic B-ADE
behavior I-ADE
resolved O
completely O
soon O
after O
the O
discontinuation O
of O
levetiracetam B-DRUG
. O

Early O
recognition O
of O
renal B-ADE
toxicity I-ADE
of O
high O
- O
dose O
methotrexate B-DRUG
therapy O
: O
a O
case O
report O
. O

The O
5 O
patients O
had O
severe O
renovascular O
disease O
which O
might O
thus O
represent O
a O
significant O
risk O
factor O
in O
the O
development O
of O
captopril B-DRUG
- O
induced O
acute B-ADE
renal I-ADE
failure I-ADE
. O

Of O
particular O
interest O
in O
this O
patient O
is O
the O
fluctuation B-ADE
of I-ADE
the I-ADE
QT I-ADE
interval I-ADE
at O
a O
stable O
dose O
of O
methadone B-DRUG
, O
suggesting O
that O
a O
single O
normal O
electrocardiogram O
( O
ECG O
) O
does O
not O
guarantee O
that O
the O
patient O
is O
not O
at O
risk O
of O
ventricular O
arrhythmias O
. O

Two O
cases O
of O
childhood O
- O
onset O
schizophrenia O
associated O
with O
clozapine B-DRUG
- O
induced O
akathisia B-ADE
responsive O
to O
beta O
- O
blocker O
treatment O
are O
described O
. O

Four O
months O
after O
receiving O
an O
orthotopic O
liver O
transplant O
, O
a O
51-year O
- O
old O
man O
was O
admitted O
for O
progressive B-ADE
liver I-ADE
failure I-ADE
and O
severe B-ADE
hepatocellular I-ADE
necrosis I-ADE
thought O
to O
be O
due O
to O
tacrolimus B-DRUG
. O

Motor B-ADE
fluctuations I-ADE
appear O
after O
2 O
- O
3 O
years O
of O
levodopa B-DRUG
treatment O
, O
and O
affect O
at O
least O
50 O
% O
of O
patients O
after O
five O
years O
. O

Renal B-ADE
failure I-ADE
after O
high O
- O
dose O
methotrexate B-DRUG
in O
a O
child O
homozygous O
for O
MTHFR O
C677 O
T O
polymorphism O
. O

Delay B-ADE
of I-ADE
corneal I-ADE
wound I-ADE
healing I-ADE
in O
patients O
treated O
with O
colchicine B-DRUG
. O

The O
second O
patient O
experienced O
mild B-ADE
nitritoid I-ADE
symptoms I-ADE
following O
several O
GSTM B-DRUG
injections O
prior O
experiencing O
a O
cerebrovascular O
accident O
within O
several O
hours O
of O
her O
next O
injection O
. O

Physicians O
should O
keep O
in O
mind O
that O
taxanes O
such O
as O
paclitaxel B-DRUG
have O
the O
potential O
to O
cause O
pneumonitis B-ADE
and O
lung B-ADE
fibrosis I-ADE
. O

In O
this O
article O
, O
we O
present O
the O
case O
of O
a O
vitiligo O
patient O
who O
was O
admitted O
to O
our O
facility O
with O
an O
intense B-ADE
burn I-ADE
after O
the O
topical O
use O
of O
8-methoxypsoralen B-DRUG
solution O
as O
a O
suntanning O
agent O
. O

INTRODUCTION O
- O
The O
aim O
of O
this O
case O
report O
is O
to O
present O
a O
15-year O
follow O
- O
up O
of O
a O
patient O
with O
phenytoin B-DRUG
( O
PHT B-DRUG
) O
intoxication O
with O
unilateral B-ADE
gingival I-ADE
hyperplasia I-ADE
( O
GH O
) O
. O

The O
pharmaceutical O
company O
producing O
Halfan B-DRUG
has O
reported O
8 O
cardiac B-ADE
arrests I-ADE
, O
leading O
to O
6 O
deaths B-ADE
, O
when O
a O
higher O
dose O
than O
recommended O
was O
used O
, O
there O
was O
recent O
or O
concomitant O
treatment O
with O
mefloquine B-DRUG
, O
there O
was O
pre O
- O
existing O
prolongation O
of O
the O
QT O
interval O
or O
the O
patient O
had O
a O
thiamine O
deficiency O
. O

A O
possible O
mechanism O
for O
focal B-ADE
neurological I-ADE
deficit I-ADE
in O
brain O
- O
damaged O
patients O
on O
phenytoin B-DRUG
therapy O
is O
discussed O
. O

Although O
vasculitis B-ADE
has O
been O
reported O
in O
the O
course O
of O
hairy O
cell O
leukaemia O
, O
it O
has O
only O
rarely O
been O
reported O
as O
the O
consequence O
of O
cladribine B-DRUG
treatment O
. O

Acute B-ADE
generalized I-ADE
exanthematous I-ADE
pustulosis I-ADE
caused O
by O
morphine B-DRUG
, O
confirmed O
by O
positive O
patch O
test O
and O
lymphocyte O
transformation O
test O
. O

We O
suggest O
adding O
this O
side O
effect O
to O
the O
list O
of O
untoward O
effects O
of O
lidocaine O
and O
to O
the O
differential O
diagnosis O
of O
fixed O
dilated B-ADE
pupils I-ADE
in O
neonates O
treated O
with O
lidocaine B-DRUG
. O

Levofloxacin B-DRUG
- O
induced O
delirium B-ADE
with I-ADE
psychotic I-ADE
features I-ADE
. O

CONCLUSIONS O
: O
This O
case O
describes O
the O
clinically O
significant O
increase B-ADE
of I-ADE
INR I-ADE
in O
an O
elderly O
patient O
after O
adding O
a O
chemotherapy O
regimen O
of O
levamisole B-DRUG
and O
5-FU B-DRUG
to O
a O
previous O
regimen O
of O
warfarin B-DRUG
alone O
. O

Fatal B-ADE
interstitial I-ADE
pneumonitis I-ADE
associated O
with O
docetaxel B-DRUG
administration O
in O
a O
patient O
with O
hormone O
- O
refractory O
prostate O
cancer O
. O

Thus O
, O
an O
immunological O
mechanism O
might O
be O
involved O
in O
the O
mechanism O
of O
pirmenol B-DRUG
- O
induced O
QT B-ADE
prolongation I-ADE
and O
T B-ADE
wave I-ADE
inversion I-ADE
on O
the O
electrocardiogram O
. O

To O
the O
best O
of O
our O
knowledge O
, O
this O
is O
the O
first O
reported O
patient O
with O
captopril B-DRUG
- O
induced O
pemphigus B-ADE
in O
whom O
no O
new O
lesions O
developed O
after O
subsequent O
treatment O
with O
enalapril O
. O

Aminoglutethimide B-DRUG
was O
discontinued O
until O
completion O
of O
radiotherapy O
, O
and O
the O
rash B-ADE
resolved O
. O

Early O
peritoneal O
dialysis O
has O
not O
previously O
been O
reported O
for O
lisinopril B-DRUG
induced O
multiorgan B-ADE
failure I-ADE
. O

Retinoic B-DRUG
acid I-DRUG
may O
increase O
the O
risk O
of O
bone B-ADE
marrow I-ADE
transplant I-ADE
nephropathy I-ADE
. O

It O
is O
suggested O
therefore O
that O
methotrexate B-DRUG
be O
added O
to O
the O
list O
of O
agents O
capable O
of O
inducing O
diffuse B-ADE
interstitial I-ADE
pulmonary I-ADE
fibrosis I-ADE
. O

Rhabdomyolysis B-ADE
following O
clarithromycin B-DRUG
monotherapy O
. O

Disulfiram B-ADE
- I-ADE
like I-ADE
reactions I-ADE
with O
newer O
cephalosporins O
: O
cefmenoxime B-DRUG
. O

OBJECTIVE O
: O
To O
report O
a O
patient O
developing O
fulminant B-ADE
liver I-ADE
failure I-ADE
while O
being O
treated O
with O
clarithromycin B-DRUG
for O
pneumonia O
. O

We O
suggest O
discontinuing O
gemcitabine B-DRUG
if O
radiation B-ADE
recall I-ADE
is O
observed O
. O

We O
describe O
a O
case O
of O
fibrosing B-ADE
alveolitis I-ADE
, O
diagnosed O
by O
lung O
biopsy O
, O
in O
a O
patient O
receiving O
amiodarone B-DRUG
which O
responded O
to O
corticosteroid O
therapy O
. O

Can O
magnesium B-DRUG
sulfate I-DRUG
therapy O
impact O
lactogenesis B-ADE
? O

In O
this O
study O
, O
we O
report O
on O
three O
individual O
patients O
who O
received O
BTX B-DRUG
- I-DRUG
B I-DRUG
and O
who O
subsequently O
developed O
parasympathetic B-ADE
dysfunction I-ADE
of I-ADE
the I-ADE
visual I-ADE
system I-ADE
after O
injections O
of O
BTX B-DRUG
- I-DRUG
B I-DRUG
at O
remote O
sites O
. O

How O
low O
can O
you O
go O
? O
Use O
of O
very O
low O
dosage O
of O
gold B-DRUG
in O
patients O
with O
mucocutaneous B-ADE
reactions I-ADE
. O

Salicylate B-DRUG
hepato B-ADE
toxicity I-ADE
in O
rheumatic O
fever O
. O

Polymyositis B-ADE
is O
a O
rare O
complication O
of O
interferon B-DRUG
alpha I-DRUG
treatment O
as O
a O
result O
of O
immune O
- O
modulating O
role O
of O
the O
drug O
itself O
. O

We O
conclude O
that O
myocardial B-ADE
infarction I-ADE
may O
develop O
in O
patients O
treated O
with O
high O
- O
dose O
glucocorticoids B-DRUG
for O
Graves O
' O
ophthalmopathy O
, O
and O
increased O
blood O
pressure O
may O
herald O
this O
complication O
. O

A O
case O
history O
of O
a O
15-year O
- O
old O
boy O
who O
developed O
incapacitating O
tardive B-ADE
dyskinesia I-ADE
that O
resolved O
during O
treatment O
with O
deanol B-DRUG
is O
presented O
. O

DISCUSSION O
: O
Colchicine B-DRUG
, O
the O
most O
important O
drug O
in O
treatment O
of O
FMF O
, O
can O
cause O
myopathy B-ADE
in O
patients O
with O
impaired O
renal O
and O
hepatic O
function O
. O

Leflunomide B-DRUG
- O
induced O
toxic B-ADE
epidermal I-ADE
necrolysis I-ADE
in O
a O
patient O
with O
rheumatoid O
arthritis O
. O

Reversible O
valproic B-DRUG
acid I-DRUG
- O
induced O
dementia B-ADE
was O
documented O
in O
a O
21-year O
- O
old O
man O
with O
epilepsy O
who O
had O
a O
3-year O
history O
of O
insidious O
progressive O
decline O
in O
global O
cognitive O
abilities O
documented O
by O
serial O
neuropsychological O
studies O
. O

Fluoxetine B-DRUG
- O
induced O
akathisia B-ADE
: O
clinical O
and O
theoretical O
implications O
. O

Cyclosporine B-DRUG
- O
induced O
pain B-ADE
syndrome I-ADE
in O
a O
child O
undergoing O
hematopoietic O
stem O
cell O
transplant O
. O

One O
type O
of O
SMON B-ADE
is O
associated O
with O
acrodermatitis B-ADE
enteropathica I-ADE
which O
has O
a O
very O
high O
frequency O
of O
occurrence O
in O
association O
with O
administration O
of O
clioquinol B-DRUG
. O

We O
report O
a O
case O
of O
a O
patient O
with O
rheumatoid O
arthritis O
treated O
with O
low O
- O
dose O
methotrexate B-DRUG
( O
15 O
mg O
/ O
week O
) O
who O
developed O
infection B-ADE
with I-ADE
both I-ADE
M. I-ADE
tuberculosis I-ADE
and I-ADE
M. I-ADE
chelonae I-ADE
after O
the O
revision O
of O
a O
prosthetic O
hip O
. O

The O
harlequin B-ADE
color I-ADE
change I-ADE
and O
association O
with O
prostaglandin B-DRUG
E1 I-DRUG
. O

Pemphigus B-ADE
vulgaris I-ADE
precipitated O
by O
glibenclamide B-DRUG
therapy O
. O

Treatment O
of O
ELP B-ADE
in O
children O
is O
generally O
supportive O
, O
with O
the O
symptoms O
and O
roentgenographic B-ADE
abnormalities I-ADE
resolving O
within O
months O
after O
stopping O
the O
use O
of O
mineral B-DRUG
oil I-DRUG
. O

After O
other O
potential O
causes O
of O
liver B-ADE
toxicity I-ADE
were O
excluded O
, O
TMP B-DRUG
- I-DRUG
SMX I-DRUG
was O
determined O
to O
be O
the O
cause O
of O
his O
acute B-ADE
liver I-ADE
toxicity I-ADE
. O

We O
report O
on O
a O
patient O
with O
subarachnoid O
haemorrhage O
who O
developed O
an O
acute O
life O
- O
threatening O
pseudo B-ADE
- I-ADE
obstruction I-ADE
of I-ADE
the I-ADE
colon I-ADE
, O
a O
variant O
of O
adynamic B-ADE
ileus I-ADE
, O
while O
being O
treated O
with O
intravenous O
nimodipine B-DRUG
. O

This O
case O
illustrates O
that O
the O
hemophagocytic B-ADE
syndrome I-ADE
associated O
with O
reactivation O
of O
EBV O
can O
occur O
as O
part O
of O
drug O
hypersensitivity O
reactions O
in O
RA O
patients O
taking O
sulfasalazine B-DRUG
. O

We O
report O
( O
to O
our O
knowledge O
, O
for O
the O
first O
time O
in O
a O
child O
) O
the O
emergence O
of O
psychosis B-ADE
in O
a O
12-year O
old O
white O
girl O
with O
an O
increased O
efavirenz B-DRUG
concentration O
and O
heterozygous O
gene O
polymorphism O
of O
the O
CYP2B6-G516 O
T O
. O

Hypersensitivity O
to O
aspirin B-DRUG
can O
be O
manifested O
as O
acute O
asthma O
, O
urticaria B-ADE
and/or O
angioedema B-ADE
, O
or O
a O
systemic B-ADE
anaphylactoid I-ADE
reaction I-ADE
. O

Reversible O
sirolimus B-DRUG
- O
associated O
pneumonitis B-ADE
after O
heart O
transplantation O
. O

We O
discuss O
a O
variety O
of O
bronchopulmonary O
complications O
of O
IBD B-ADE
and O
their O
association O
with O
sulfasalazine B-DRUG
. O

CONCLUSIONS O
: O
Spontaneous B-ADE
hemothorax I-ADE
is O
a O
rare O
phenomenon O
in O
conjunction O
with O
LMWH B-DRUG
but O
should O
be O
considered O
in O
cases O
of O
acute O
respiratory O
distress O
following O
commencement O
of O
LMWH O
. O

Although O
praziquantel B-DRUG
administration O
may O
have O
been O
effective O
in O
killing O
the O
parasite O
in O
both O
patients O
, O
we O
are O
concerned O
about O
the O
production O
of O
marked O
inflammation B-ADE
as O
a O
result O
of O
treatment O
. O

In O
vitro O
inhibition B-ADE
of I-ADE
hematopoiesis I-ADE
in O
a O
patient O
with O
systemic O
sclerosis O
treated O
with O
D B-DRUG
- I-DRUG
penicillamine I-DRUG
. O

Methotrexate B-DRUG
- O
induced O
papular B-ADE
eruption I-ADE
following O
treatment O
of O
psoriasis O
has O
not O
been O
previously O
reported O
. O

One O
patient O
suffered O
coronary B-ADE
artery I-ADE
vasospasm I-ADE
, O
attributed O
to O
the O
use O
of O
topical O
1:1000 O
epinephrine B-DRUG
during O
surgery O
. O

Flurbiprofen B-DRUG
- O
associated O
acute B-ADE
tubulointerstitial I-ADE
nephritis I-ADE
. O

Management O
and O
successful O
desensitization O
in O
methotrexate B-DRUG
- O
induced O
anaphylaxis B-ADE
. O

Acute B-ADE
erythroid I-ADE
leukemia I-ADE
after O
cyclophosphamide B-DRUG
therapy O
for O
multiple O
myeloma O
: O
report O
of O
two O
cases O
. O

In O
this O
report O
, O
one O
patient O
who O
developed O
gangrene B-ADE
after O
bleomycin B-DRUG
and O
vincristine B-DRUG
/ O
vinblastine B-DRUG
chemotherapy O
for O
AIDS O
- O
related O
Kaposi O
's O
sarcoma O
and O
another O
HIV O
- O
infected O
patient O
who O
exhibited O
symptoms O
of O
severe B-ADE
Raynaud I-ADE
's I-ADE
phenomenon I-ADE
related O
to O
the O
same O
regimen O
are O
presented O
. O

Though O
physicians O
treating O
large O
populations O
of O
patients O
with O
HIV O
are O
well O
aware O
of O
this O
complication O
, O
only O
one O
other O
report O
of O
nevirapine B-DRUG
- O
associated O
SJS B-ADE
has O
been O
documented O
in O
the O
dermatology O
literature O
. O

We O
report O
a O
case O
of O
ibuprofen B-DRUG
- O
induced O
meningitis B-ADE
in O
an O
otherwise O
healthy O
individual O
. O

One O
patient O
was O
an O
80-year O
- O
old O
woman O
who O
was O
admitted O
for O
Staphylococcus B-ADE
aureus I-ADE
knee I-ADE
arthritis I-ADE
after O
several O
intraarticular O
injections O
of O
sodium B-DRUG
hyaluronate I-DRUG
and O
corticosteroids B-DRUG
. O

The O
relationship O
between O
infliximab B-DRUG
treatment O
and O
lymphoma B-ADE
in O
Crohn O
's O
disease O
. O

Taxane B-DRUG
- O
induced O
glaucoma B-ADE
. O

Currently O
the O
use O
of O
zidovudine B-DRUG
is O
one O
of O
the O
few O
specific O
measures O
available O
, O
and O
as O
a O
potentially O
teratogenic B-ADE
and O
fetotoxic B-ADE
agent O
, O
any O
decision O
for O
its O
use O
requires O
evaluation O
of O
the O
potential O
for O
fetal B-ADE
damage I-ADE
. O

Therefore O
, O
amantadine B-DRUG
was O
permanently O
discontinued O
and O
the O
cornea B-ADE
cleared O
again O
. O

Intravitreal O
triamcinolone B-DRUG
may O
have O
had O
an O
influence O
on O
the O
exacerbation B-ADE
of I-ADE
retinochoroiditis I-ADE
in O
the O
posterior O
pole O
of O
the O
patient O
. O

Reactivation B-ADE
of I-ADE
cytomegalovirus I-ADE
probably O
followed O
the O
treatment O
of O
Wegener O
's O
granulomatosis O
with O
corticosteroids O
and O
azathioprine B-DRUG
. O

After O
intravitreal O
injection O
of O
triamcinolone B-DRUG
acetonide I-DRUG
, O
cataract B-ADE
may O
rapidly O
develop O
in O
eyes O
that O
have O
been O
intensively O
treated O
, O
topically O
and O
systemically O
, O
by O
corticosteroids O
for O
several O
years O
. O

Intrahepatic B-ADE
cholestasis I-ADE
and O
cutaneous B-ADE
bullae I-ADE
associated O
with O
glibenclamide B-DRUG
therapy O
are O
described O
in O
a O
61-year O
- O
old O
diabetic O
patient O
who O
presented O
wit O
hypoglycaemic O
coma O
. O

These O
cases O
suggest O
the O
possibility O
that O
, O
in O
some O
patients O
, O
leukopenia B-ADE
or O
agranulocytosis B-ADE
during O
olanzapine B-DRUG
treatment O
might O
be O
dose O
- O
related O
. O

Baclofen B-DRUG
withdrawal O
: O
a O
cause O
of O
prolonged O
fever B-ADE
in O
the O
intensive O
care O
unit O
. O

The O
renal B-ADE
insufficiency I-ADE
of O
three O
patients O
and O
the O
timing O
of O
the O
seizures B-ADE
implicate O
accumulation O
of O
ofloxacin B-DRUG
as O
a O
contributing O
factor O
. O

On O
the O
next O
day O
, O
after O
a O
total O
dose O
of O
only O
600 O
mg O
of O
danazol B-DRUG
, O
gingival B-ADE
bleeding I-ADE
and O
purpura B-ADE
occurred O
. O

In O
addition O
, O
a O
31-year O
- O
old O
man O
with O
obsessive O
- O
compulsive O
disorder O
developed O
RBD B-ADE
soon O
after O
starting O
fluoxetine B-DRUG
therapy O
, O
which O
persisted O
at O
PSG O
study O
19 O
months O
after O
fluoxetine B-DRUG
discontinuation O
. O

Fluorouracil O
for O
allergic B-ADE
reactions I-ADE
to O
capecitabine B-DRUG
. O

Rifampin B-DRUG
- O
associated O
thrombocytopenia B-ADE
secondary O
to O
poor O
compliance O
. O

Severe B-ADE
adenovirus I-ADE
pneumonia I-ADE
( O
AVP B-ADE
) O
following O
infliximab B-DRUG
infusion O
for O
the O
treatment O
of O
Crohn O
's O
disease O
. O

Response O
of O
a O
promethazine B-DRUG
- O
induced O
coma B-ADE
to O
flumazenil O
. O

Multifocal O
electroretinographic O
abnormalities O
in O
ethambutol B-DRUG
- O
induced O
visual B-ADE
loss I-ADE
. O

OBJECTIVE O
: O
To O
report O
the O
occurrence O
of O
anterior B-ADE
ischemic I-ADE
optic I-ADE
neuropathy I-ADE
as O
a O
complication O
of O
treatment O
with O
interferon B-DRUG
alfa I-DRUG
and O
to O
consider O
the O
possible O
underlying O
mechanisms O
for O
this O
association O
. O

Generalised B-ADE
cutaneous I-ADE
rash I-ADE
associated O
with O
ganciclovir B-DRUG
therapy O
has O
rarely O
been O
reported O
in O
literature O
. O

Inappropriate B-ADE
antidiuretic I-ADE
hormone I-ADE
secretion I-ADE
after O
high O
dose O
vinblastine B-DRUG
. O

The O
incidence O
of O
oral O
- O
verapamil B-DRUG
- O
induced O
hypotension B-ADE
in O
the O
presence O
of O
concomitant O
beta O
- O
adrenergic O
blockade O
by O
the O
oral O
route O
is O
quite O
rare O
. O

Chronic O
fentanyl B-DRUG
application O
induces O
adrenocortical B-ADE
insufficiency I-ADE
. O

Grade B-ADE
3 I-ADE
hepatotoxicity I-ADE
( O
AST O
and O
ALT O
> O
5 O
to O
20 O
upper O
limit O
normal O
) O
or O
higher O
has O
been O
observed O
in O
as O
many O
as O
1.4 O
% O
of O
MS O
patients O
on O
IFN B-DRUG
beta I-DRUG
. O

Capecitabine B-DRUG
was O
discontinued O
and O
the O
allergic B-ADE
reactions I-ADE
resolved O
after O
the O
woman O
took O
diphenhydramine O
for O
1 O
week O
. O

A O
patient O
is O
presented O
with O
typical O
hyperthyroidism B-ADE
, O
who O
developed O
a O
severe B-ADE
proximal I-ADE
muscle I-ADE
weakness I-ADE
and O
a O
raised B-ADE
creatine I-ADE
phosphokinase I-ADE
after O
treatment O
for O
hyperthyroidism O
with O
propylthiouracil B-DRUG
( O
100 O
mg O
orally O
, O
three O
times O
a O
day O
) O
. O

Multifocal B-ADE
inflammatory I-ADE
leukoencephalopathy I-ADE
associated O
with O
levamisole B-DRUG
therapy O
. O

The O
autopsy O
findings O
and O
a O
detailed O
medical O
history O
supported O
the O
conclusion O
that O
clozapine B-DRUG
- O
induced O
hypersensitivity B-ADE
myocarditis I-ADE
was O
the O
most O
likely O
cause O
of O
death O
. O

Acetazolamide B-DRUG
may O
have O
accelerated O
the O
development O
of O
osteomalacia B-ADE
by O
several O
mechanisms O
, O
including O
increased O
renal O
calcium O
excretion O
. O

We O
present O
a O
case O
of O
a O
20-year O
- O
old O
woman O
who O
ingested O
900 O
mg O
of O
glyburide B-DRUG
causing O
refractory O
hypoglycemia B-ADE
resistant O
to O
treatment O
with O
intravenous O
dextrose O
, O
glucagon O
, O
and O
diazoxide O
. O

Clozapine B-DRUG
- O
induced O
akathisia B-ADE
in O
children O
with O
schizophrenia O
. O

Rhabdomyolysis B-ADE
associated O
with O
clozapine B-DRUG
treatment O
in O
a O
patient O
with O
decreased O
calcium O
- O
dependent O
potassium O
permeability O
of O
cell O
membranes O
. O

A O
36-year O
- O
old O
man O
being O
treated O
with O
cisplatinum B-DRUG
, O
vinblastine B-DRUG
, O
and O
bleomycin B-DRUG
for O
testicular O
carcinoma O
developed O
a O
dense O
left B-ADE
homonymous I-ADE
hemianopsia I-ADE
, O
encephalopathy B-ADE
, O
and O
a O
partial B-ADE
nondominant I-ADE
parietal I-ADE
lobe I-ADE
syndrome I-ADE
. O

Because O
etoposide B-DRUG
- O
induced O
pulmonary B-ADE
toxicity I-ADE
is O
an O
uncommon O
but O
serious O
adverse O
event O
, O
clinicians O
must O
be O
vigilant O
about O
the O
possibility O
of O
it O
, O
so O
that O
the O
optimal O
treatment O
can O
start O
as O
soon O
as O
possible O
. O

Interferon B-DRUG
- O
induced O
psychosis B-ADE
as O
a O
" O
psychiatric O
contraindication O
" O
to O
hepatitis O
C O
treatment O
: O
a O
review O
and O
case O
- O
based O
discussion O
. O

Most O
cardiac O
surgical O
patients O
have O
had O
previous O
exposure O
to O
heparin O
for O
diagnostic O
or O
therapeutic O
interventions O
and O
hence O
have O
an O
increased O
susceptibility O
to O
developing O
heparin B-DRUG
- O
induced O
thrombocytopenia B-ADE
( O
HIT O
) O
postoperatively O
. O

This O
is O
the O
first O
reported O
case O
of O
hepatolithiasis B-ADE
during O
octreotide B-DRUG
therapy O
. O

Valproate B-DRUG
embryopathy I-ADE
in O
three O
sets O
of O
siblings O
: O
further O
proof O
of O
hereditary O
susceptibility O
. O

The O
literature O
search O
revealed O
22 O
cases O
of O
hypersensitivity B-ADE
reaction I-ADE
to O
cyclosporine B-DRUG
. O

However O
, O
given O
the O
clinically O
significant O
result O
to O
the O
interaction O
between O
tolazoline B-DRUG
and O
cimetidine B-DRUG
we O
report O
, O
the O
use O
of O
cimetidine B-DRUG
in O
tolazoline B-DRUG
induced O
upper B-ADE
gastrointestinal I-ADE
hemorrhage I-ADE
should O
deserve O
more O
attention O
. O

While O
the O
introduction O
of O
carmustine B-DRUG
wafers O
( O
Gliadel B-DRUG
wafers O
) O
into O
the O
tumor O
resection O
cavity O
has O
been O
shown O
to O
be O
a O
beneficial O
therapy O
for O
malignant O
glioma O
, O
it O
is O
recognized O
that O
clinically O
significant O
cerebral B-ADE
edema I-ADE
is O
a O
potential O
adverse O
effect O
. O

Seizure B-ADE
with O
hyponatremia B-ADE
in O
a O
child O
prescribed O
desmopressin B-DRUG
for O
nocturnal O
enuresis O
. O

Although O
high O
- O
dose O
methotrexate B-DRUG
has O
been O
shown O
to O
be O
useful O
in O
the O
treatment O
of O
primary O
osteogenic O
sarcoma O
, O
the O
tumoricidal O
effects O
of O
therapy O
appear O
to O
have O
caused O
a O
fatal B-ADE
rise I-ADE
in I-ADE
intracranial I-ADE
pressure I-ADE
. O

After O
a O
six O
- O
week O
course O
of O
low O
- O
dose O
cyclosporine B-DRUG
A I-DRUG
, O
she O
developed O
a O
severe O
but O
reversible O
loss B-ADE
of I-ADE
glomerular I-ADE
filtration I-ADE
rate I-ADE
and O
effective B-ADE
renal I-ADE
plasma I-ADE
flow I-ADE
despite O
of O
low O
cyclosporine O
A O
plasma O
levels O
. O

A O
30-year O
- O
old O
pharmacist O
suffered O
from O
acute B-ADE
allergic I-ADE
contact I-ADE
dermatitis I-ADE
due O
to O
4-chloro-7-nitrobenzofurazan B-DRUG
( O
NBD B-DRUG
- I-DRUG
Cl I-DRUG
) O
. O

The O
current O
report O
describes O
a O
man O
who O
was O
prescribed O
zonisamide B-DRUG
for O
epilepsy O
and O
subsequently O
developed O
widespread O
skin B-ADE
rash I-ADE
, O
acute B-ADE
kidney I-ADE
injury I-ADE
, O
high B-ADE
- I-ADE
grade I-ADE
fever I-ADE
, O
eosinophilia B-ADE
, O
liver B-ADE
dysfunction I-ADE
, O
lymphadenopathy B-ADE
and O
an B-ADE
increase I-ADE
in I-ADE
antihuman I-ADE
herpesvirus-6 I-ADE
immunoglobulin I-ADE
G I-ADE
titer I-ADE
. O

Rebound O
hyperglycemia B-ADE
following O
overdosing O
of O
insulin B-DRUG
in O
cats O
with O
diabetes O
mellitus O
. O

Pneumonitis B-ADE
is O
emerging O
as O
one O
of O
the O
most O
unpredictable O
and O
potentially O
serious O
, O
adverse O
effects O
of O
treatment O
with O
MTX B-DRUG
. O

Acute B-ADE
renal I-ADE
failure I-ADE
in O
a O
child O
associated O
with O
acyclovir B-DRUG
. O

Five O
cases O
( O
four O
from O
the O
literature O
and O
one O
new O
case O
) O
are O
presented O
in O
which O
patients O
unsuspected O
of O
having O
vitamin O
B12 O
deficiency O
developed O
subacute B-ADE
combined I-ADE
degeneration I-ADE
of I-ADE
the I-ADE
spinal I-ADE
cord I-ADE
following O
nitrous B-DRUG
oxide I-DRUG
anesthesia O
. O

Moreover O
, O
treatment O
with O
immunosuppressive O
drugs O
such O
as O
cyclosporine B-DRUG
, O
cisplatin B-DRUG
, O
tacrolimus B-DRUG
, O
and O
interferon B-DRUG
- I-DRUG
alpha I-DRUG
can O
induce O
a O
condition O
resembling O
RPLS B-ADE
. O

Prothipendylhydrochloride B-DRUG
- O
induced O
priapism B-ADE
: O
case O
report O
. O

In O
case O
no O
. O
2 O
, O
the O
pathogenic O
mechanism O
seemed O
to O
be O
persistent O
light O
reaction O
preceded O
by O
systemic O
photoallergy O
, O
as O
he O
had O
taken O
mequitazine B-DRUG
for O
6 O
months O
, O
and O
there O
were O
strong O
positive O
photopatch O
test O
results O
with O
immediate O
erythema B-ADE
reaction O
, O
cross B-ADE
- I-ADE
reaction I-ADE
to I-ADE
promethazine B-DRUG
, O
decreased B-ADE
MED I-ADE
to I-ADE
both I-ADE
UVA I-ADE
and I-ADE
UVB I-ADE
, O
and O
persistence B-ADE
of I-ADE
the I-ADE
photosensitivity I-ADE
over O
a O
3-year O
follow O
- O
up O
period O
after O
discontinuation O
of O
the O
mequitazine B-DRUG
. O

Although O
an O
association O
between O
exposure O
to O
bleomycin B-DRUG
and O
the O
development O
of O
scleroderma B-ADE
has O
been O
suspected O
, O
few O
cases O
are O
reported O
. O

A O
fatal B-ADE
case I-ADE
of I-ADE
pancytopenia I-ADE
due O
to O
levomepromazine B-DRUG
. O

Abnormalities B-ADE
of I-ADE
the I-ADE
pupil I-ADE
and O
visual O
- O
evoked O
potential O
in O
quinine B-DRUG
amblyopia B-ADE
. O

OBJECTIVES O
: O
To O
describe O
the O
clinicopathologic O
features O
of O
3 O
patients O
with O
CML O
who O
rapidly O
progressed O
from O
chronic O
phase O
to O
blast B-ADE
crisis I-ADE
while O
taking O
imatinib B-DRUG
and O
to O
perform O
a O
review O
of O
the O
literature O
. O

Infections B-ADE
are O
a O
major O
adverse O
effect O
during O
the O
treatment O
with O
anti B-DRUG
- I-DRUG
TNF I-DRUG
- I-DRUG
alpha I-DRUG
. O

CASE O
SUMMARIES O
: O
In O
each O
case O
, O
the O
patients O
were O
treated O
over O
5 O
years O
with O
lovastatin B-DRUG
and O
developed O
rhabdomyolysis B-ADE
that O
coincided O
with O
the O
completion O
of O
a O
prescribed O
regimen O
of O
a O
newer O
macrolide O
antibiotic O
. O

A O
patient O
suffering O
from O
heparin B-DRUG
- O
associated O
thrombocytopenia B-ADE
( O
HAT B-ADE
) O
, O
recurrent B-ADE
arteriothromboses I-ADE
, O
and O
acute B-ADE
renal I-ADE
failure I-ADE
after O
treatment O
with O
standard O
heparin B-DRUG
is O
described O
. O

We O
have O
recently O
encountered O
a O
patient O
with O
acquired O
haemophilia O
who O
developed O
a O
thrombotic B-ADE
left I-ADE
middle I-ADE
cerebral I-ADE
artery I-ADE
distribution I-ADE
stroke I-ADE
while O
being O
treated O
with O
pFVIII B-DRUG
. O

In O
this O
case O
report O
, O
we O
present O
clinical O
and O
laboratory O
findings O
of O
a O
case O
with O
chronic O
hepatitis O
B O
that O
developed O
acute B-ADE
dystonia I-ADE
soon O
after O
the O
first O
dose O
of O
pegylated B-DRUG
interferon I-DRUG
alpha I-DRUG
. O

The O
cause O
of O
death O
was O
determined O
to O
be O
acute B-ADE
intoxication I-ADE
by O
olanzapine B-DRUG
, O
and O
the O
manner O
of O
death O
was O
accidental O
. O

Vocal B-ADE
cord I-ADE
paralysis I-ADE
as O
a O
consequence O
of O
peritonsillar O
infiltration O
with O
bupivacaine B-DRUG
. O

AIMS O
: O
To O
present O
a O
case O
of O
piloerection B-ADE
after O
replacing O
fluvoxamine B-DRUG
maleate I-DRUG
with O
milnacipran B-DRUG
hydrochloride I-DRUG
, O
and O
to O
analyse O
this O
effect O
based O
on O
receptor O
occupancy O
theory O
. O

We O
recommended O
periodic O
examination O
of O
the O
serum O
proteins O
in O
patients O
receiving O
diphenylhydantoin B-DRUG
in O
order O
to O
detect O
development O
of O
monoclonal B-ADE
gammopathy I-ADE
. O

Near B-ADE
fatal I-ADE
acute O
colchicine B-DRUG
intoxication I-ADE
in O
a O
child O
. O

Gemcitabine B-DRUG
- O
related O
radiation B-ADE
recall I-ADE
in O
a O
patient O
with O
pancreatic O
cancer O
. O

Acute B-ADE
non I-ADE
- I-ADE
lymphocytic I-ADE
leukemia I-ADE
in O
patients O
with O
ovarian O
carcinoma O
following O
long O
- O
term O
treatment O
with O
Treosulfan B-DRUG
(= O
dihydroxybusulfan B-DRUG
) O
. O

Painful B-ADE
neutrophilic B-ADE
skin I-ADE
lesions I-ADE
were O
observed O
in O
two O
children O
receiving O
granulocyte B-DRUG
colony I-DRUG
- I-DRUG
stimulating I-DRUG
factor I-DRUG
( O
G B-DRUG
- I-DRUG
CSF I-DRUG
) O
for O
treatment O
of O
idiopathic O
neutropenia O
. O

Granulocytopenia B-ADE
and O
agranulocytosis B-ADE
are O
considered O
among O
the O
most O
dangerous O
adverse O
effects O
of O
clozapine B-DRUG
. O

Fatal B-ADE
digoxin B-DRUG
poisoning I-ADE
: O
an O
unsuccessful O
resuscitation O
with O
use O
of O
digoxin O
- O
immune O
Fab O
. O

The O
incidence O
of O
5-fluorouracil B-DRUG
( O
5-FU B-DRUG
) O
- O
related O
cardiotoxicity B-ADE
seems O
to O
be O
dosage O
and O
schedule O
dependent O
. O

We O
present O
a O
case O
of O
severe B-ADE
unilateral I-ADE
posterior I-ADE
scleritis I-ADE
associated O
with O
zoledronic B-DRUG
acid I-DRUG
administration O
that O
was O
recognized O
and O
treated O
in O
a O
timely O
manner O
. O

CASE O
: O
A O
malignant B-ADE
mixed I-ADE
mesodermal I-ADE
tumor I-ADE
was O
diagnosed O
in O
a O
64-year O
- O
old O
woman O
with O
a O
bicornuate O
uterus O
while O
she O
was O
taking O
raloxifene B-DRUG
for O
osteoporosis O
prevention O
. O

We O
present O
a O
unique O
case O
of O
GTBM B-ADE
in O
a O
patient O
with O
myeloma O
following O
treatment O
with O
Melphalan B-DRUG
. O

Propylthiouracil B-DRUG
- O
induced O
sensorineural B-ADE
hearing I-ADE
loss I-ADE
associated O
with O
antineutrophil B-ADE
cytoplasmic I-ADE
antibodies I-ADE
. O

A O
15-kg B-ADE
weight I-ADE
gain I-ADE
developed O
in O
a O
patient O
during O
the O
third O
week O
of O
ibuprofen B-DRUG
therapy O
. O

We O
describe O
two O
patients O
with O
aspergillus B-ADE
arthritis I-ADE
of I-ADE
the I-ADE
knee I-ADE
joint I-ADE
following O
fludarabine B-DRUG
- O
based O
non O
- O
myeloablative O
stem O
cell O
transplantation O
. O

We O
report O
the O
first O
case O
of O
a O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV-1 O
) O
- O
infected O
individual O
receiving O
combination O
antiretroviral O
therapy O
, O
which O
included O
ritonavir O
, O
who O
developed O
Cushing B-ADE
syndrome I-ADE
with O
profound O
complications O
after O
epidural O
triamcinolone B-DRUG
injections O
. O

We O
believe O
this O
is O
the O
first O
report O
of O
myocardial B-ADE
infarction I-ADE
due O
to O
coronary B-ADE
spasm I-ADE
, O
demonstrated O
by O
angiography O
associated O
with O
L B-DRUG
- I-DRUG
thyroxine I-DRUG
therapy O
. O

Hepatotoxicity B-ADE
associated O
with O
use O
of O
D B-DRUG
- I-DRUG
penicillamine I-DRUG
in O
rheumatoid O
arthritis O
. O

In O
our O
patient O
, O
DIAN B-ADE
possibly O
was O
related O
to O
cefuroxime B-DRUG
, O
but O
the O
patient O
did O
not O
experience O
associated O
allergic O
symptoms O
. O

CONCLUSIONS O
: O
The O
use O
of O
fluorouracil O
treatment O
with O
careful O
monitoring O
can O
be O
considered O
in O
a O
patient O
with O
mild O
allergic B-ADE
reactions I-ADE
to O
capecitabine B-DRUG
. O

Warfarin B-DRUG
- O
associated O
thoracic B-ADE
aortic I-ADE
dissection I-ADE
in O
an O
elderly O
woman O
. O

Both O
had O
impaired B-ADE
lung I-ADE
function I-ADE
and O
abnormal B-ADE
computed I-ADE
tomographic I-ADE
scans I-ADE
, O
and O
their O
condition O
improved O
when O
nitrofurantoin B-DRUG
was O
withdrawn O
and O
corticosteroid O
treatment O
commenced O
. O

We O
describe O
two O
cases O
that O
illustrate O
the O
use O
of O
lithium B-DRUG
in O
the O
treatment O
of O
veterans O
with O
PTSD O
who O
complained O
of O
serious O
problems O
with O
irritability B-ADE
or O
angry B-ADE
outbursts I-ADE
. O

BACKGROUND O
: O
Headaches B-ADE
have O
been O
reported O
as O
a O
potential O
side O
effect O
of O
capecitabine B-DRUG
therapy O
. O

CASE O
REPORT O
: O
We O
present O
a O
case O
of O
a O
28-yr O
- O
old O
male O
who O
developed O
a O
severe O
case O
of O
nephrotic B-ADE
syndrome I-ADE
while O
being O
treated O
for O
relapsing O
/ O
remitting O
Multiple O
Sclerosis O
( O
RRMS O
) O
with O
weekly O
injections O
of O
interferon B-DRUG
beta I-DRUG
1a I-DRUG
. O

Furosemide B-DRUG
- O
associated O
fever B-ADE
. O

CASES O
: O
Two O
postmenopausal O
women O
treated O
with O
tamoxifen B-DRUG
and O
progestational O
agents O
for O
breast O
carcinoma O
developed O
uterine B-ADE
enlargement I-ADE
and O
intermittent B-ADE
spotting I-ADE
. O

We O
suggest O
that O
the O
previous O
classification O
of O
nitrofurantoin B-DRUG
induced I-ADE
lung I-ADE
injury I-ADE
into O
" O
acute O
" O
and O
" O
chronic O
" O
injury O
is O
an O
oversimplification O
in O
view O
of O
the O
wide O
variety O
of O
pathological O
entities O
that O
have O
subsequently O
emerged O
. O

Withdrawal O
of O
Depakote B-DRUG
resulted O
in O
resolution O
of O
the O
effusion B-ADE
. O

Hypersensitivity B-ADE
to O
zonisamide B-DRUG
was O
confirmed O
by O
the O
skin O
patch O
test O
. O

A O
case O
of O
acute B-ADE
respiratory I-ADE
failure I-ADE
due O
to O
diaphragmatic O
weakness O
following O
adalimumab B-DRUG
therapy O
for O
psoriasis O
is O
described O
. O

Indinavir B-DRUG
- O
associated O
nephrolithiasis B-ADE
and O
chronic O
interstitial B-ADE
nephritis I-ADE
were O
the O
only O
possible O
causes O
identified O
in O
this O
patient O
. O

Concurrent B-ADE
acute I-ADE
megaloblastic I-ADE
anaemia I-ADE
and O
pneumonitis B-ADE
: O
a O
severe O
side O
- O
effect O
of O
low O
- O
dose O
methotrexate B-DRUG
therapy O
during O
rheumatoid O
arthritis O
. O

A O
25-year O
- O
old O
man O
with O
a O
history O
of O
mid O
- O
borderline O
( O
BB O
) O
Hansen O
's O
disease O
developing O
a O
reversal B-ADE
reaction I-ADE
after O
starting O
dapsone B-DRUG
and O
rifampin B-DRUG
therapy O
is O
presented O
. O

Nephrogenic B-ADE
diabetes I-ADE
insipidus I-ADE
( O
NDI B-ADE
) O
is O
a O
well O
- O
documented O
complication O
of O
lithium B-DRUG
use O
. O

Agranulocytosis B-ADE
and O
granulocytopenia B-ADE
associated O
with O
quetiapine B-DRUG
. O

Acute B-ADE
myocardial I-ADE
ischemia I-ADE
following O
accidental O
intravenous O
administration O
of O
epinephrine B-DRUG
in O
high O
concentration O
. O

Based O
on O
our O
findings O
, O
it O
is O
thus O
concluded O
that O
cisplatin B-DRUG
may O
cause O
C. B-ADE
difficile I-ADE
colitis I-ADE
. O

Transient B-ADE
cardiac I-ADE
arrhythmias I-ADE
related O
to O
lopinavir B-DRUG
/ O
ritonavir B-DRUG
in O
two O
patients O
with O
HIV O
infection O
. O

Five O
and O
one O
- O
half O
years O
after O
the O
diagnosis O
of O
myeloma O
, O
while O
in O
remission O
on O
cyclophosphamide B-DRUG
therapy O
, O
the O
patient O
experienced O
severe O
abdominal B-ADE
right I-ADE
lower I-ADE
quadrant I-ADE
pain I-ADE
due O
to O
a O
large O
cecal B-ADE
lymphoma I-ADE
. O

The O
observations O
suggest O
that O
testicular B-ADE
swelling I-ADE
and O
pain B-ADE
are O
side O
effects O
of O
desipramine B-DRUG
. O

In O
a O
single O
practice O
during O
the O
21 O
years O
1971 O
- O
1991 O
, O
the O
incidence O
of O
gestational B-ADE
diabetes I-ADE
in O
pregnancies O
in O
which O
norethisterone B-DRUG
was O
prescribed O
was O
32.4 O
% O
( O
22 O
of O
69 O
) O
in O
comparison O
with O
7.1 O
% O
in O
pregnancies O
in O
which O
the O
women O
did O
not O
take O
norethisterone O
( O
137 O
of O
1,684 O
) O
( O
p O
< O
0.001 O
) O
. O

The O
purpose O
of O
this O
review O
is O
to O
increase O
awareness O
among O
physicians O
and O
other O
health O
care O
professionals O
that O
DIC B-ADE
may O
be O
a O
rare O
but O
potentially O
severe O
complication O
of O
anti B-DRUG
- I-DRUG
D I-DRUG
IGIV I-DRUG
treatment O
. O

We O
present O
findings O
from O
three O
patients O
who O
experienced O
a O
psoriasiform B-ADE
eruption I-ADE
apparently O
due O
to O
the O
antiepileptic O
agents O
sodium B-DRUG
valproate I-DRUG
and O
carbamazepine B-DRUG
. O

In O
patients O
with O
a O
known O
access O
to O
INH O
, O
seizures B-ADE
should O
be O
considered O
to O
be O
caused O
by O
INH B-DRUG
toxicity O
unless O
proved O
otherwise O
. O

Administration O
of O
excessive O
insulin B-DRUG
induced O
hypoglycemia B-ADE
within O
4 O
to O
8 O
hours O
, O
followed O
by O
rebound B-ADE
hyperglycemia I-ADE
. O

A O
case O
of O
fluoxetine B-DRUG
induced O
seizures B-ADE
, O
in O
a O
person O
with O
Down O
syndrome O
, O
is O
described O
. O

Hepato B-ADE
- I-ADE
biliary I-ADE
abnormalities I-ADE
secondary O
to O
ceftriaxone B-DRUG
use O
: O
a O
case O
report O
. O

We O
report O
the O
first O
biopsy O
confirmed O
occurrence O
of O
acute B-ADE
interstitial I-ADE
nephritis I-ADE
in O
a O
patient O
receiving O
treatment O
with O
Sunitinib B-DRUG
for O
metastatic O
renal O
cell O
cancer O
. O

OBJECTIVE O
: O
To O
report O
the O
clinical O
course O
of O
a O
woman O
with O
cryptococcal O
meningitis O
and O
no O
previous O
cardiac O
disease O
who O
developed O
a O
fatal B-ADE
cardiac I-ADE
arrhythmia I-ADE
after O
an O
acute O
overdose O
of O
amphotericin B-DRUG
B I-DRUG
and O
to O
review O
its O
toxicity O
. O

Atenolol B-DRUG
induced O
memory B-ADE
impairment I-ADE
: O
a O
case O
report O
. O

PURPOSE O
: O
To O
determine O
the O
cause O
of O
spontaneous B-ADE
choroidal I-ADE
hemorrhage I-ADE
in O
a O
67-year O
- O
old O
man O
after O
a O
myocardial O
infarction O
and O
administration O
of O
tissue B-DRUG
plasminogen I-DRUG
activator I-DRUG
. O

Visual B-ADE
hallucinations I-ADE
associated O
with O
zonisamide B-DRUG
. O

Metabolic B-ADE
acidosis I-ADE
induced O
by O
cetrimide B-DRUG
- O
chlorhexidine B-DRUG
solution O
in O
hydatid O
cyst O
surgery O
. O

Meperidine B-DRUG
- O
associated O
central B-ADE
nervous I-ADE
system I-ADE
( I-ADE
CNS I-ADE
) I-ADE
excitatory I-ADE
toxicities I-ADE
are O
believed O
to O
be O
caused O
by O
accumulation B-ADE
of I-ADE
the I-ADE
active I-ADE
metabolite I-ADE
normeperidine I-ADE
. O

A O
case O
of O
a O
21-year O
- O
old O
woman O
who O
had O
developed O
mild O
hepatotoxicity B-ADE
while O
receiving O
choline B-DRUG
magnesium I-DRUG
trisalicylate I-DRUG
therapy O
is O
described O
. O

1 O
. O
Changes B-ADE
in I-ADE
the I-ADE
plasma I-ADE
cortisol I-ADE
level I-ADE
were O
reported O
in O
a O
male O
patient O
with O
panic O
disorder O
during O
the O
period O
of O
low O
- O
dose O
alprazolam B-DRUG
treatment O
( O
mean O
0.62 O
+ O
/- O
0.15 O
mg O
/ O
day O
) O
compared O
with O
during O
the O
period O
of O
high O
- O
dose O
period O
( O
mean O
1.08 O
+ O
/- O
0.28 O
mg O
/ O
day O
) O
. O

Administration O
of O
intravenous O
nitroglycerin B-DRUG
in O
a O
patient O
with O
idiopathic O
pulmonary O
hypertension O
resulted O
in O
an O
increase B-ADE
in I-ADE
pulmonary I-ADE
artery I-ADE
pressure I-ADE
associated O
with O
a O
decrease B-ADE
in I-ADE
blood I-ADE
flow I-ADE
that O
is O
best O
explained O
by O
an O
increase B-ADE
in I-ADE
pulmonary I-ADE
vascular I-ADE
resistance I-ADE
. O

Dipyrone B-DRUG
- O
induced O
granulocytopenia B-ADE
: O
a O
case O
for O
awareness O
. O

The O
induced O
hyperglycaemia O
could O
not O
be O
controlled O
sufficiently O
, O
despite O
a O
high O
dose O
of O
insulin B-DRUG
( O
> O
110 O
units O
/ O
day O
) O
, O
suggesting O
the O
existence O
of O
insulin B-ADE
insensitivity I-ADE
and O
hyperinsulinaemia B-ADE
. O

We O
report O
on O
a O
56-year O
- O
old O
female O
who O
exhibited O
drug O
refractory O
paroxysmal O
atrial O
fibrillation O
, O
in O
which O
marked O
prolongation B-ADE
of I-ADE
the I-ADE
QT I-ADE
interval I-ADE
and O
T B-ADE
wave I-ADE
inversion I-ADE
on O
electrocardiogram O
was O
demonstrated O
reproducibly O
shortly O
after O
the O
administration O
of O
oral O
pirmenol B-DRUG
therapy O
. O

Gold B-DRUG
nephropathy B-ADE
. O

This O
case O
had O
radiation O
fibrosis O
, O
so O
we O
suggest O
that O
radiation O
fibrosis O
may O
be O
another O
contributor O
of O
the O
occurrence O
of O
ILD B-ADE
in O
patients O
taking O
erlotinib B-DRUG
. O

The O
female O
patient O
received O
clozapine B-DRUG
in O
a O
daily O
dose O
of O
400 O
mg O
, O
which O
induced O
agranulocytosis B-ADE
after O
2 O
months O
. O

We O
further O
used O
immunohistochemistry O
( O
IHC O
) O
to O
examine O
the O
relative O
role O
of O
platelet O
- O
derived O
growth O
factor O
- O
B O
( O
PDGF O
- O
B O
) O
, O
insulin O
- O
like O
growth O
factor O
I O
( O
IGF O
- O
I O
) O
, O
transforming O
growth O
factor O
- O
beta1 O
( O
TGF O
- O
beta1 O
) O
and O
cyclooxygenase-2 O
( O
COX-2 O
) O
in O
the O
pathogenesis O
of O
BCNU B-DRUG
- O
related O
pulmonary B-ADE
fibrosis I-ADE
. O

This O
case O
of O
linezolid B-DRUG
- O
associated O
acute B-ADE
interstitial I-ADE
nephritis I-ADE
within O
the O
context O
of O
a O
drug B-ADE
rash I-ADE
with I-ADE
eosinophilia I-ADE
and I-ADE
systemic I-ADE
symptoms I-ADE
( O
DRESS B-ADE
) O
syndrome O
in O
a O
patient O
treated O
with O
linezolid B-DRUG
raises O
concerns O
about O
the O
presumed O
renal O
safety O
of O
this O
drug O
. O

The O
second O
patient O
exhibited O
sudden O
PLMS B-ADE
following O
olanzapine B-DRUG
injection O
. O

Continuous O
EEG O
monitoring O
is O
helpful O
in O
managing O
seizures B-ADE
that O
occur O
as O
a O
complication O
of O
CBZ B-DRUG
OD O
, O
after O
the O
course O
of O
recovery O
or O
worsening O
, O
and O
in O
providing O
assistance O
with O
prognosis O
. O

In O
one O
instance O
a O
systemic B-ADE
hypoglycemic I-ADE
reaction I-ADE
resulting O
in O
head B-ADE
trauma I-ADE
and O
confusion B-ADE
ended O
in O
an O
emegency O
hospital O
admission O
following O
the O
substitution O
of O
acetohexamide B-DRUG
for O
acetazolamide O
. O

We O
cared O
for O
a O
patient O
with O
progressive O
renal O
impairment O
who O
presented O
with O
blurred B-ADE
vision I-ADE
, O
QRS B-ADE
broadening I-ADE
and O
cardiac B-ADE
failure I-ADE
due O
to O
chronic O
cibenzoline B-ADE
intoxication I-ADE
. O

Bone B-ADE
formation I-ADE
induced O
in O
an O
infant O
by O
systemic O
prostaglandin B-DRUG
- I-DRUG
E2 I-DRUG
administration O
. O

We O
describe O
a O
case O
of O
a O
man O
treated O
with O
an O
EGFR O
- O
inhibitor O
( O
erlotinib B-DRUG
) O
for O
a O
cell O
lung O
cancer O
who O
developed O
skin B-ADE
manifestations I-ADE
localized O
in O
an O
uncommon O
area O
and O
with O
an O
atypical O
evolution O
. O

Pulmonary B-ADE
edema I-ADE
occurred O
24 O
hours O
after O
intravenous O
ritodrine B-DRUG
therapy O
and O
10 O
hours O
after O
subcutaneous O
terbutaline B-DRUG
therapy O
. O

CONCLUSIONS O
: O
Itraconazole B-DRUG
- O
induced O
liver B-ADE
injury I-ADE
presents O
with O
a O
cholestatic B-ADE
pattern I-ADE
of I-ADE
injury I-ADE
with O
damage B-ADE
to I-ADE
the I-ADE
interlobular I-ADE
bile I-ADE
ducts I-ADE
, O
possibly O
leading O
to O
ductopenia B-ADE
. O

Neurologic B-ADE
degeneration I-ADE
associated O
with O
nitrous B-DRUG
oxide I-DRUG
anesthesia O
in O
patients O
with O
vitamin O
B12 O
deficiency O
. O

PURPOSE O
: O
Topiramate B-DRUG
- O
induced O
angle B-ADE
- I-ADE
closure I-ADE
glaucoma I-ADE
( O
TiACG O
) O
is O
believed O
to O
be O
related O
to O
its O
sulfonamide O
moiety O
. O

Introduction O
of O
etanercept B-DRUG
was O
also O
clinically O
effective O
but O
followed O
by O
development O
of O
severe B-ADE
heart I-ADE
failure I-ADE
. O

After O
discontinuation O
of O
danazol B-DRUG
the O
diabetes B-ADE
completely O
resolved O
. O

Seizures B-ADE
and O
extrapyramidal B-ADE
symptoms I-ADE
in O
a O
patient O
with O
Tourette O
's O
syndrome O
, O
Asperger O
's O
syndrome O
, O
and O
multiple O
sclerosis O
treated O
with O
interferon B-DRUG
beta-1a I-DRUG
and O
clomipramine B-DRUG
. O

Posterior B-ADE
reversible I-ADE
encephalopathy I-ADE
syndrome I-ADE
( O
PRES B-DRUG
) O
induced O
by O
cyclosporine B-ADE
use O
in O
a O
patient O
with O
collapsing O
focal O
glomeruloesclerosis O
. O

As O
far O
as O
we O
know O
, O
this O
is O
the O
first O
case O
report O
of O
acute B-ADE
hemorrhagic I-ADE
gastritis I-ADE
associated O
with O
AZ B-ADE
intoxication I-ADE
. O

We O
report O
four O
cases O
of O
encephalopathy B-ADE
coincident O
with O
elevated B-ADE
aluminum I-ADE
levels I-ADE
as O
well O
as O
one O
patient O
who O
developed O
seizures B-ADE
while O
receiving O
continuous O
bladder O
irrigations O
with O
alum B-DRUG
. O

Infliximab B-DRUG
- O
induced O
lupus B-ADE
in O
Crohn O
's O
disease O
: O
a O
case O
report O
. O

BACKGROUND O
: O
Colchicine B-DRUG
has O
a O
known O
adverse B-ADE
effect I-ADE
on I-ADE
wound I-ADE
healing I-ADE
through O
its O
inhibitory O
effect O
on O
tubulin O
- O
dependent O
cell O
functions O
and O
through O
collagenase B-ADE
activation I-ADE
. O

Methotrexate B-DRUG
pneumonitis B-ADE
in O
nonsurgical O
treatment O
of O
ectopic O
pregnancy O
. O

Pseudoephedrine B-DRUG
- O
induced O
hemorrhage B-ADE
associated O
with O
a O
cerebral B-ADE
vascular I-ADE
malformation I-ADE
. O

The O
association O
of O
venlafaxine B-DRUG
treatment O
with O
ischaemic B-ADE
events I-ADE
could O
be O
explained O
by O
its O
unique O
pharmacological O
and O
haemodynamic O
properties O
. O

During O
the O
first O
treatment O
, O
dysarthria B-ADE
and O
ataxia B-ADE
were O
seen O
after O
completion O
of O
the O
patient O
's O
eighth O
and O
final O
dose O
of O
HDARAC B-DRUG
. O

The O
current O
study O
investigated O
the O
visual O
fields O
and O
visual O
electrophysiology O
of O
eight O
patients O
with O
known O
vigabatrin B-DRUG
- O
attributed O
visual B-ADE
field I-ADE
loss I-ADE
, O
three O
of O
whom O
were O
reported O
previously O
. O

Nineteen O
cases O
of O
unusual O
enhanced O
vincristine B-DRUG
neurotoxicity B-ADE
related O
to O
itraconazole B-DRUG
have O
been O
reported O
in O
children O
. O

CONCLUSIONS O
: O
We O
report O
this O
case O
of O
the O
concomitant O
appearance O
of O
multiple B-ADE
skin I-ADE
cancers I-ADE
and O
nail B-ADE
changes I-ADE
associated O
with O
hydroxyurea B-DRUG
use O
. O

We O
experienced O
a O
male O
patient O
with O
psoriasis O
and O
hypertension O
whose O
conditions O
were O
treated O
with O
tacalcitol B-DRUG
ointment O
and O
thiazide B-DRUG
, O
respectively O
, O
resulting O
in O
hypercalciuria B-ADE
and O
hypercalcemia B-ADE
. O

Ritonavir B-DRUG
acted O
as O
a O
CYP3A4 O
inhibitor O
, O
diminishing B-ADE
carbamazepine I-ADE
metabolism I-ADE
and O
provoking O
an O
increase B-ADE
in I-ADE
serum I-ADE
levels I-ADE
and O
clinical B-ADE
toxicity I-ADE
. O

Physicians O
should O
be O
cognizant O
of O
this O
potential O
complication O
in O
patients O
receiving O
thalidomide B-DRUG
or O
thalidomide O
- O
like O
drugs O
who O
present O
with O
fever B-ADE
and O
pulmonary B-ADE
infiltrates I-ADE
and O
fail O
to O
improve O
despite O
treatment O
with O
broad O
- O
spectrum O
antibiotics O
. O

Thalidomide B-DRUG
neuropathy B-ADE
in O
childhood O
. O

A O
case O
of O
acute B-ADE
cardiomyopathy I-ADE
and O
pericarditis B-ADE
associated O
with O
methylphenidate B-DRUG
. O

This O
is O
the O
first O
report O
of O
a O
disulfiram B-ADE
- I-ADE
like I-ADE
reaction I-ADE
with O
cefmenoxime B-DRUG
. O

We O
report O
a O
case O
of O
ST B-ADE
elevation I-ADE
in I-ADE
right I-ADE
precordial I-ADE
leads I-ADE
compatible O
with O
type B-ADE
1 I-ADE
Brugada I-ADE
syndrome I-ADE
following O
administration O
of O
propafenone B-DRUG
in O
a O
patient O
with O
Wolff O
- O
Parkinson O
- O
White O
syndrome O
who O
was O
receiving O
lithium O
at O
concentrations O
within O
therapeutic O
levels O
. O

Treatment O
of O
lithium B-DRUG
tremor B-ADE
with O
metoprolol O
. O

The O
following O
is O
a O
case O
report O
analysis O
intended O
to O
draw O
attention O
to O
the O
need O
for O
better O
care O
coordination O
by O
describing O
the O
observed O
relationship O
of O
olanzapine B-DRUG
to O
metabolic O
changes O
manifested O
as O
uncontrolled B-ADE
diabetes I-ADE
mellitus I-ADE
and O
weight B-ADE
gain I-ADE
. O

Ethambutol B-DRUG
is O
frequently O
used O
in O
the O
treatment O
of O
tuberculosis O
, O
and O
, O
although O
optic B-ADE
neuropathies I-ADE
have O
been O
reported O
with O
the O
use O
of O
ethambutol O
, O
this O
adverse O
side O
effect O
has O
been O
considered O
to O
be O
rare O
and O
generally O
reversible O
with O
discontinuation O
of O
the O
medication O
. O

We O
describe O
the O
exceptional O
development O
of O
AML B-ADE
and O
lung B-ADE
cancer I-ADE
in O
a O
patient O
with O
previously O
diagnosed O
CLL O
in O
minimal O
residual O
disease O
status O
after O
fludarabine B-DRUG
treatment O
followed O
by O
autologous O
peripheral O
blood O
stem O
- O
cell O
transplantation O
. O

Three O
of O
these O
patients O
had O
convulsions B-ADE
attributed O
to O
imipenem B-DRUG
/ O
cilastatin B-DRUG
; O
3.6 O
% O
of O
the O
patients O
had O
seizure B-ADE
, O
or O
2 O
% O
of O
imipenem B-DRUG
/ O
cilastatin B-DRUG
administrations O
was O
followed O
by O
a O
seizure B-ADE
attack O
. O

Diazepam B-DRUG
use O
by O
pregnant O
women O
can O
be O
associated O
with O
a O
later O
presentation O
of O
withdrawal B-ADE
symptoms I-ADE
in O
the O
neonate O
than O
that O
induced O
by O
the O
use O
of O
other O
drugs O
. O

Amiodarone B-DRUG
is O
well O
recognized O
as O
an O
anti O
- O
arrhythmic O
drug O
containing O
a O
high O
dose O
of O
iodine O
with O
considerable O
potential O
to O
cause O
thyroid B-ADE
dysfunction I-ADE
. O

The O
authors O
report O
on O
two O
patients O
with O
corneal B-ADE
ulcers I-ADE
refractory I-ADE
to I-ADE
conventional I-ADE
treatment I-ADE
while O
the O
patients O
were O
undergoing O
oral O
colchicine B-DRUG
therapy O
. O

